Torsade B-Disease +
de I-Disease +
pointes L-Disease +
ventricular B-Disease +
tachycardia L-Disease +
during O +
low O +
dose O +
intermittent O +
dobutamine O +
treatment O +
in O +
a O +
patient O +
with O +
dilated B-Disease +
cardiomyopathy L-Disease +
and O +
congestive B-Disease +
heart I-Disease +
failure L-Disease -
. O -

The O +
authors O +
describe O +
the O +
case O +
of O +
a O +
56-year O -
- O -
old O +
woman O +
with O +
chronic O -
, O +
severe O +
heart B-Disease +
failure L-Disease +
secondary O +
to O +
dilated B-Disease +
cardiomyopathy L-Disease +
and O +
absence O +
of O +
significant O +
ventricular B-Disease +
arrhythmias L-Disease +
who O +
developed O +
QT B-Disease +
prolongation L-Disease +
and O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
ventricular B-Disease +
tachycardia L-Disease +
during O +
one O +
cycle O +
of O +
intermittent O +
low O +
dose O +
( O -
2.5 O +
mcg O -
/ O -
kg O +
per O +
min O -
) O +
dobutamine O -
. O -

This O +
report O +
of O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
ventricular B-Disease +
tachycardia L-Disease +
during O +
intermittent O +
dobutamine O +
supports O +
the O +
hypothesis O +
that O +
unpredictable O +
fatal O +
arrhythmias U-Disease +
may O +
occur O +
even O +
with O +
low O +
doses O +
and O +
in O +
patients O +
with O +
no O +
history O +
of O +
significant O +
rhythm O +
disturbances O -
. O -

The O +
mechanisms O +
of O +
proarrhythmic O +
effects O +
of O +
Dubutamine O +
are O +
discussed O -
. O -

Positive O +
skin O +
tests O +
in O +
late O +
reactions O +
to O +
radiographic O +
contrast O +
media O -
. O -

In O +
the O +
last O +
few O +
years O +
delayed O +
reactions O +
several O +
hours O +
after O +
the O +
injection O +
of O +
radiographic O +
and O +
contrast O +
materials O +
( O -
PRC O -
) O +
have O +
been O +
described O +
with O +
increasing O +
frequency O -
. O -

The O +
authors O +
report O +
two O +
observations O +
on O +
patients O +
with O +
delayed O +
reactions O +
in O +
whom O +
intradermoreactions O +
( O -
IDR O -
) O +
and O +
patch O +
tests O +
to O +
a O +
series O +
of O +
ionic O +
and O +
non O +
ionic O +
PRC O +
were O +
studied O -
. O -

After O +
angiography O +
by O +
the O +
venous O +
route O +
in O +
patient O +
n O +
degree O +
1 O +
a O +
biphasic O +
reaction O +
with O +
an O +
immediate O +
reaction O +
( O -
dyspnea U-Disease -
, O +
loss B-Disease +
of I-Disease +
consciousness L-Disease -
) O +
and O +
delayed O +
macro B-Disease -
- I-Disease -
papular I-Disease +
rash L-Disease +
appeared O -
, O +
whilst O +
patient O +
n O +
degree O +
2 O +
developed O +
a O +
generalised O +
sensation O +
of O +
heat O -
, O +
persistent O +
pain U-Disease +
at O +
the O +
site O +
of O +
injection O +
immediately O +
and O +
a O +
generalised O +
macro O -
- O -
papular O +
reaction O +
after O +
24 O +
hours O -
. O -

The O +
skin O +
tests O +
revealed O +
positive O +
delayed O +
reactions O +
of O +
24 O +
hours O +
and O +
48 O +
hours O +
by O +
IDR O +
and O +
patch O +
tests O +
to O +
only O +
some O +
PRC O +
with O +
common O +
chains O +
in O +
their O +
structures O -
. O -

The O +
positive O +
skin O +
tests O +
are O +
in O +
favour O +
of O +
immunological O +
reactions O +
and O +
may O +
help O +
in O +
diagnosis O +
of O +
allergy U-Disease +
in O +
the O +
patients O -
. O -

Risk O +
of O +
transient O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
in O +
cancer U-Disease +
patients O +
who O +
received O +
continuous O +
infusion O +
of O +
5-fluorouracil O +
with O +
the O +
complication O +
of O +
dehydration U-Disease +
and O +
infection U-Disease -
. O -

From O +
1986 O +
to O +
1998 O -
, O +
29 O +
cancer U-Disease +
patients O +
who O +
had O +
32 O +
episodes O +
of O +
transient O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
related O +
to O +
continuous O +
infusion O +
of O +
5-fluorouracil O +
( O -
5-FU O -
) O +
were O +
identified O -
. O -

None O +
of O +
the O +
patients O +
had O +
decompensated O +
liver B-Disease +
disease L-Disease -
. O -

Onset O +
of O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
varied O +
from O +
0.5 O +
to O +
5 O +
days O +
( O -
mean O -
: O +
2.6 O +
+ O -
/- O -

1.3 O +
days O -
) O +
after O +
the O +
initiation O +
of O +
chemotherapy O -
. O -

Plasma O +
ammonium O +
level O +
ranged O +
from O +
248 O +
to O +
2387 O +
microg% O +
( O -
mean O -
: O +
626 O +
+ O -
/- O -

431 O +
microg% O -
) O -
. O -

Among O +
the O +
32 O +
episodes O -
, O +
26 O +
( O -
81 O -
% O -
) O +
had O +
various O +
degrees O +
of O +
azotemia U-Disease -
, O +
18 O +
( O -
56 O -
% O -
) O +
occurred O +
during O +
bacterial B-Disease +
infections L-Disease +
and O +
14 O +
( O -
44 O -
% O -
) O +
without O +
infection U-Disease +
occurred O +
during O +
periods O +
of O +
dehydration U-Disease -
. O -

Higher O +
plasma O +
ammonium O +
levels O +
and O +
more O +
rapid O +
onset O +
of O +
hyperammonemia U-Disease +
were O +
seen O +
in O +
18 O +
patients O +
with O +
bacterial B-Disease +
infections L-Disease +
( O -
p=0.003 O +
and O +
0.0006 O -
, O +
respectively O -
) O +
and O +
in O +
nine O +
patients O +
receiving O +
high O +
daily O +
doses O +
( O -
2600 O +
or O +
1800 O +
mg O -
/ O -
m2 O -
) O +
of O +
5-FU O +
( O -
p=0.0001 O +
and O +
< O +
0.0001 O -
, O +
respectively O -
) O -
. O -

In O +
25 O +
out O +
of O +
32 O +
episodes O +
( O -
78 O -
% O -
) O -
, O +
plasma O +
ammonium O +
levels O +
and O +
mental O +
status O +
returned O +
to O +
normal O +
within O +
2 O +
days O +
after O +
adequate O +
management O -
. O -

In O +
conclusion O -
, O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
can O +
occur O +
in O +
patients O +
receiving O +
continuous O +
infusion O +
of O +
5-FU O -
. O -

Azotemia U-Disease -
, O +
body O +
fluid O +
insufficiency O +
and O +
bacterial B-Disease +
infections L-Disease +
were O +
frequently O +
found O +
in O +
these O +
patients O -
. O -

It O +
is O +
therefore O +
important O +
to O +
recognize O +
this O +
condition O +
in O +
patients O +
receiving O +
continuous O +
infusion O +
of O +
5-FU O -
. O -

The O +
effects O +
of O +
quinine O +
and O +
4-aminopyridine O +
on O +
conditioned O +
place O +
preference O +
and O +
changes O +
in O +
motor O +
activity O +
induced O +
by O +
morphine O +
in O +
rats O -
. O -

1 O -
. O -

The O +
effects O +
of O +
two O +
unselective O +
potassium O +
( O -
K O -
( O -
+ O -
) O -
- O -
) O +
channel O +
blockers O -
, O +
quinine O +
( O -
12.5 O -
, O +
25 O +
and O +
50 O +
mg O -
/ O -
kg O -
) O +
and O +
4-aminopyridine O +
( O -
1 O +
and O +
2 O +
mg O -
/ O -
kg O -
) O -
, O +
on O +
conditioned O +
place O +
preference O +
and O +
biphasic O +
changes O +
in O +
motor O +
activity O +
induced O +
by O +
morphine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
were O +
tested O +
in O +
Wistar O +
rats O -
. O -

Quinine O +
is O +
known O +
to O +
block O +
voltage- O -
, O +
calcium- O +
and O +
ATP O -
- O -
sensitive O +
K O -
( O -
+ O -
) O -
-channels O +
while O +
4-aminopyridine O +
is O +
known O +
to O +
block O +
voltage O -
- O -
sensitive O +
K O -
( O -
+ O -
) O -
-channels O -
. O -

2 O -
. O -

In O +
the O +
counterbalanced O +
method O -
, O +
quinine O +
attenuated O +
morphine O -
- O -
induced O +
place O +
preference O -
, O +
whereas O +
4-aminopyridine O +
was O +
ineffective O -
. O -

In O +
the O +
motor O +
activity O +
test O +
measured O +
with O +
an O +
Animex O -
- O -
activity O +
meter O +
neither O +
of O +
the O +
K O -
( O -
+ O -
) O -
-channel O +
blockers O +
affected O +
morphine O -
- O -
induced O +
hypoactivity U-Disease -
, O +
but O +
both O +
K O -
( O -
+ O -
) O -
-channel O +
blockers O +
prevented O +
morphine O -
- O -
induced O +
secondary O +
hyperactivity U-Disease -
. O -

3 O -
. O -

These O +
results O +
suggest O +
the O +
involvement O +
of O +
quinine O -
- O -
sensitive O +
but O +
not O +
4-aminopyridine O -
- O -
sensitive O +
K O -
( O -
+ O -
) O -
-channels O +
in O +
morphine O +
reward O -
. O -

It O +
is O +
also O +
suggested O +
that O +
the O +
blockade O +
of O +
K O -
( O -
+ O -
) O -
-channels O +
sensitive O +
to O +
these O +
blockers O +
is O +
not O +
sufficient O +
to O +
prevent O +
morphine O -
- O -
induced O +
hypoactivity U-Disease +
whereas O +
morphine O -
- O -
induced O +
hyperactivity U-Disease +
seems O +
to O +
be O +
connected O +
to O +
both O +
quinine- O +
and O +
4-aminopyridine O -
- O -
sensitive O +
K O -
( O -
+ O -
) O -
-channels O -
. O -

Nociceptin O -
/ O -
orphanin O +
FQ O +
and O +
nocistatin O +
on O +
learning B-Disease +
and I-Disease +
memory I-Disease +
impairment L-Disease +
induced O +
by O +
scopolamine O +
in O +
mice O -
. O -

1 O -
. O +
Nociceptin O -
, O +
also O +
known O +
as O +
orphanin O +
FQ O -
, O +
is O +
an O +
endogenous O +
ligand O +
for O +
the O +
orphan O +
opioid O +
receptor O -
- O -
like O +
receptor O +
1 O +
( O -
ORL1 O -
) O +
and O +
involves O +
in O +
various O +
functions O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O -

On O +
the O +
other O +
hand O -
, O +
nocistatin O +
is O +
recently O +
isolated O +
from O +
the O +
same O +
precursor O +
as O +
nociceptin O +
and O +
blocks O +
nociceptin O -
- O -
induced O +
allodynia U-Disease +
and O +
hyperalgesia U-Disease -
. O -

2 O -
. O -

Although O +
ORL1 O +
receptors O +
which O +
display O +
a O +
high O +
degree O +
of O +
sequence O +
homology O +
with O +
classical O +
opioid O +
receptors O +
are O +
abundant O +
in O +
the O +
hippocampus O -
, O +
little O +
is O +
known O +
regarding O +
their O +
role O +
in O +
learning O +
and O +
memory O -
. O -

3 O -
. O -

The O +
present O +
study O +
was O +
designed O +
to O +
investigate O +
whether O +
nociceptin O -
/ O -
orphanin O +
FQ O +
and O +
nocistatin O +
could O +
modulate O +
impairment B-Disease +
of I-Disease +
learning I-Disease +
and I-Disease +
memory L-Disease +
induced O +
by O +
scopolamine O -
, O +
a O +
muscarinic O +
cholinergic O +
receptor O +
antagonist O -
, O +
using O +
spontaneous O +
alternation O +
of O +
Y O -
- O -
maze O +
and O +
step O -
- O -
down O +
type O +
passive O +
avoidance O +
tasks O +
in O +
mice O -
. O -

4 O -
. O +
While O +
nocistatin O +
( O -
0.5 O -
- O -
5.0 O +
nmol O +
mouse-1 O -
, O +
i.c.v O -
. O -
) O +
administered O +
30 O +
min O +
before O +
spontaneous O +
alternation O +
performance O +
or O +
the O +
training O +
session O +
of O +
the O +
passive O +
avoidance O +
task O -
, O +
had O +
no O +
effect O +
on O +
spontaneous O +
alternation O +
or O +
passive O +
avoidance O +
behaviours O -
, O +
a O +
lower O +
per O +
cent O +
alternation O +
and O +
shorter O +
median O +
step O -
- O -
down O +
latency O +
in O +
the O +
retention O +
test O +
were O +
obtained O +
in O +
nociceptin O +
( O -
1.5 O +
and/or O +
5.0 O +
nmol O +
mouse-1 O -
, O +
i.c.v. O -
) O -
-treated O +
normal O +
mice O -
. O -

5 O -
. O +
Administration O +
of O +
nocistatin O +
( O -
1.5 O +
and/or O +
5.0 O +
nmol O +
mouse-1 O -
, O +
i.c.v O -
. O -
) O +
30 O +
min O +
before O +
spontaneous O +
alternation O +
performance O +
or O +
the O +
training O +
session O +
of O +
the O +
passive O +
avoidance O +
task O -
, O +
attenuated O +
the O +
scopolamine O -
- O -
induced O +
impairment O +
of O +
spontaneous O +
alternation O +
and O +
passive O +
avoidance O +
behaviours O -
. O -

6 O -
. O -

These O +
results O +
indicated O +
that O +
nocistatin O -
, O +
a O +
new O +
biologically O +
active O +
peptide O -
, O +
ameliorates O +
impairments O +
of O +
spontaneous O +
alternation O +
and O +
passive O +
avoidance O +
induced O +
by O +
scopolamine O -
, O +
and O +
suggested O +
that O +
these O +
peptides O +
play O +
opposite O +
roles O +
in O +
learning O +
and O +
memory O -
. O -

Meloxicam O -
- O -
induced O +
liver B-Disease +
toxicity L-Disease -
. O -

We O +
report O +
the O +
case O +
of O +
a O +
female O +
patient O +
with O +
rheumatoid B-Disease +
arthritis L-Disease +
who O +
developed O +
acute O +
cytolytic O +
hepatitis U-Disease +
due O +
to O +
meloxicam O -
. O -

Recently O +
introduced O +
in O +
Belgium O -
, O +
meloxicam O +
is O +
the O +
first O +
nonsteroidal O +
antiinflammatory O +
drug O +
with O +
selective O +
action O +
on O +
the O +
inducible O +
form O +
of O +
cyclooxygenase O +
2 O -
. O -

The O +
acute O +
cytolytic O +
hepatitis U-Disease +
occurred O +
rapidly O +
after O +
meloxicam O +
administration O +
and O +
was O +
associated O +
with O +
the O +
development O +
of O +
antinuclear O +
antibodies O +
suggesting O +
a O +
hypersensitivity U-Disease +
mechanism O -
. O -

This O +
first O +
case O +
of O +
meloxicam O +
related O +
liver B-Disease +
toxicity L-Disease +
demonstrates O +
the O +
potential O +
of O +
this O +
drug O +
to O +
induce O +
hepatic B-Disease +
damage L-Disease -
. O -

Induction O +
of O +
apoptosis O +
by O +
remoxipride O +
metabolites O +
in O +
HL60 O +
and O +
CD34+ O -
/ O -
CD19- O +
human O +
bone O +
marrow O +
progenitor O +
cells O -
: O +
potential O +
relevance O +
to O +
remoxipride O -
- O -
induced O +
aplastic B-Disease +
anemia L-Disease -
. O -

The O +
antipsychotic O +
agent O -
, O +
remoxipride O +
[ O -
( O -
S O -
) O -
- O -
( O -
- O -
) O -
-3-bromo O -
- O -
N- O -
[ O -
( O -
1-ethyl-2-pyrrolidinyl O -
) O -
methyl O -
] O -
-2,6-dimethoxybenz O +
amide O -
] O +
has O +
been O +
associated O +
with O +
acquired O +
aplastic B-Disease +
anemia L-Disease -
. O -

We O +
have O +
examined O +
the O +
ability O +
of O +
remoxipride O -
, O +
three O +
pyrrolidine O +
ring O +
metabolites O +
and O +
five O +
aromatic O +
ring O +
metabolites O +
of O +
the O +
parent O +
compound O +
to O +
induce O +
apoptosis O +
in O +
HL60 O +
cells O +
and O +
human O +
bone O +
marrow O +
progenitor O +
( O -
HBMP O -
) O +
cells O -
. O -

Cells O +
were O +
treated O +
for O +
0 O -
- O -
24 O +
h O +
with O +
each O +
compound O +
( O -
0 O -
- O -
200 O +
microM O -
) O -
. O -

Apoptosis O +
was O +
assessed O +
by O +
fluorescence O +
microscopy O +
in O +
Hoechst O +
33342- O +
and O +
propidium O +
iodide O +
stained O +
cell O +
samples O -
. O -

Results O +
were O +
confirmed O +
by O +
determination O +
of O +
internucleosomal O +
DNA O +
fragmentation O +
using O +
gel O +
electrophoresis O +
for O +
HL60 O +
cell O +
samples O +
and O +
terminal O +
deoxynucleotidyl O +
transferase O +
assay O +
in O +
HBMP O +
cells O -
. O -

The O +
catechol O +
and O +
hydroquinone O +
metabolites O -
, O +
NCQ436 O +
and O +
NCQ344 O -
, O +
induced O +
apoptosis O +
in O +
HL60 O +
and O +
HBMP O +
cells O +
in O +
a O +
time- O +
and O +
concentration O +
dependent O +
manner O -
, O +
while O +
the O +
phenols O -
, O +
NCR181 O -
, O +
FLA873 O -
, O +
and O +
FLA797 O -
, O +
and O +
the O +
derivatives O +
formed O +
by O +
oxidation O +
of O +
the O +
pyrrolidine O +
ring O -
, O +
FLA838 O -
, O +
NCM001 O -
, O +
and O +
NCL118 O -
, O +
had O +
no O +
effect O -
. O -

No O +
necrosis U-Disease +
was O +
observed O +
in O +
cells O +
treated O +
with O +
NCQ436 O +
but O +
NCQ344 O +
had O +
a O +
biphasic O +
effect O +
in O +
both O +
cell O +
types O -
, O +
inducing O +
apoptosis O +
at O +
lower O +
concentrations O +
and O +
necrosis U-Disease +
at O +
higher O +
concentrations O -
. O -

These O +
data O +
show O +
that O +
the O +
catechol O +
and O +
hydroquinone O +
metabolites O +
of O +
remoxipride O +
have O +
direct O +
toxic O +
effects O +
in O +
HL60 O +
and O +
HBMP O +
cells O -
, O +
leading O +
to O +
apoptosis O -
, O +
while O +
the O +
phenol O +
metabolites O +
were O +
inactive O -
. O -

Similarly O -
, O +
benzene O -
- O -
derived O +
catechol O +
and O +
hydroquinone O -
, O +
but O +
not O +
phenol O -
, O +
induce O +
apoptosis O +
in O +
HBMP O +
cells O +
[ O -
Moran O +
et O +
al. O -
, O +
Mol O -
. O -

Pharmacol O -
. O -
, O +
50 O +
( O -
1996 O -
) O +
610 O -
- O -
615 O -
] O -
. O -

We O +
propose O +
that O +
remoxipride O +
and O +
benzene O +
may O +
induce O +
aplastic B-Disease +
anemia L-Disease +
via O +
production O +
of O +
similar O +
reactive O +
metabolites O +
and O +
that O +
the O +
ability O +
of O +
NCQ436 O +
and O +
NCQ344 O +
to O +
induce O +
apoptosis O +
in O +
HBMP O +
cells O +
may O +
contribute O +
to O +
the O +
mechanism O +
underlying O +
acquired O +
aplastic B-Disease +
anemia L-Disease +
that O +
has O +
been O +
associated O +
with O +
remoxipride O -
. O -

Synthesis O +
and O +
preliminary O +
pharmacological O +
investigations O +
of O +
1- O -
( O -
1,2-dihydro-2-acenaphthylenyl O -
) O -
piperazine O +
derivatives O +
as O +
potential O +
atypical O +
antipsychotic O +
agents O +
in O +
mice O -
. O -

In O +
research O +
towards O +
the O +
development O +
of O +
new O +
atypical O +
antipsychotic O +
agents O -
, O +
one O +
strategy O +
is O +
that O +
the O +
dopaminergic O +
system O +
can O +
be O +
modulated O +
through O +
manipulation O +
of O +
the O +
serotonergic O +
system O -
. O -

The O +
synthesis O +
and O +
preliminary O +
pharmacological O +
evaluation O +
of O +
a O +
series O +
of O +
potential O +
atypical O +
antipsychotic O +
agents O +
based O +
on O +
the O +
structure O +
of O +
1- O -
( O -
1,2-dihydro-2-acenaphthylenyl O -
) O -
piperazine O +
( O -
7 O -
) O +
is O +
described O -
. O -

Compound O +
7e O -
, O +
5- O -
{ O -
2- O -
[ O -
4- O -
( O -
1,2-dihydro-2-acenaphthylenyl O -
) O -
piperazinyl O -
] O -
ethyl O -
} O -
-2,3-dihy O +
dro-1H- O +
indol-2-one O -
, O +
from O +
this O +
series O +
showed O +
significant O +
affinities O +
at O +
the O +
5-HT1A O +
and O +
5-HT2A O +
receptors O +
and O +
moderate O +
affinity O +
at O +
the O +
D2 O +
receptor O -
. O -

7e O +
exhibits O +
a O +
high O +
reversal O +
of O +
catalepsy U-Disease +
induced O +
by O +
haloperidol O +
indicating O +
its O +
atypical O +
antipsychotic O +
nature O -
. O -

Sub O -
- O -
chronic O +
inhibition O +
of O +
nitric O -
- O -
oxide O +
synthesis O +
modifies O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease +
and O +
the O +
number O +
of O +
NADPH O -
- O -
diaphorase O +
neurons O +
in O +
mice O -
. O -

RATIONALE O -
: O +
NG O -
- O -
nitro O -
- O -
L O -
- O -
arginine O +
( O -
L O -
- O -
NOARG O -
) O -
, O +
an O +
inhibitor O +
of O +
nitric O -
- O -
oxide O +
synthase O +
( O -
NOS O -
) O -
, O +
induces O +
catalepsy U-Disease +
in O +
mice O -
. O -

This O +
effect O +
undergoes O +
rapid O +
tolerance O -
, O +
showing O +
a O +
significant O +
decrease O +
after O +
2 O +
days O +
of O +
sub O -
- O -
chronic O +
L O -
- O -
NOARG O +
treatment O -
. O -

Nitric O +
oxide O +
( O -
NO O -
) O +
has O +
been O +
shown O +
to O +
influence O +
dopaminergic O +
neurotransmission O +
in O +
the O +
striatum O -
. O -

Neuroleptic O +
drugs O +
such O +
as O +
haloperidol O -
, O +
which O +
block O +
dopamine O +
receptors O -
, O +
also O +
cause O +
catalepsy U-Disease +
in O +
rodents O -
. O -

OBJECTIVES O -
: O +
To O +
investigate O +
the O +
effects O +
of O +
subchronic O +
L O -
- O -
NOARG O +
treatment O +
in O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease +
and O +
the O +
number O +
of O +
NOS O +
neurons O +
in O +
areas O +
related O +
to O +
motor O +
control O -
. O -

METHODS O -
: O +
Male O +
albino O +
Swiss O +
mice O +
were O +
treated O +
sub O -
- O -
chronically O +
( O -
twice O +
a O +
day O +
for O +
4 O +
days O -
) O +
with O +
L O -
- O -
NOARG O +
( O -
40 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
or O +
haloperidol O +
( O -
1 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O -
. O -

Catalepsy U-Disease +
was O +
evaluated O +
at O +
the O +
beginning O +
and O +
the O +
end O +
of O +
the O +
treatments O -
. O -

Reduced O +
nicotinamide O +
adenine O +
dinucleotide O +
phosphate O -
- O -
diaphorase O +
( O -
NADPH O -
- O -
d O -
) O +
histochemistry O +
was O +
also O +
employed O +
to O +
visualize O +
NOS O +
as O +
an O +
index O +
of O +
enzyme O +
expression O +
in O +
mice O +
brain O +
regions O +
related O +
to O +
motor O +
control O -
. O -

RESULTS O -
: O +
L O -
- O -
NOARG O +
sub O -
- O -
chronic O +
administration O +
produced O +
tolerance O +
of O +
L O -
- O -
NOARG O +
and O +
of O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease -
. O -

It O +
also O +
induced O +
an O +
increase O +
in O +
the O +
number O +
of O +
NADPH O -
- O -
d O -
- O -
positive O +
cells O +
in O +
the O +
dorsal O +
part O +
of O +
the O +
caudate O +
and O +
accumbens O +
nuclei O +
compared O +
with O +
haloperidol O +
and O +
in O +
the O +
pedunculopontine O +
tegmental O +
nucleus O +
compared O +
with O +
saline O -
. O -

In O +
contrast O -
, O +
there O +
was O +
a O +
decrease O +
in O +
NADPH O -
- O -
d O +
neuron O +
number O +
in O +
the O +
substantia O +
nigra O -
, O +
pars O +
compacta O +
in O +
both O +
haloperidol O -
- O -
treated O +
and O +
L O -
- O -
NOARG O -
- O -
treated O +
animals O -
. O -

CONCLUSIONS O -
: O +
The O +
results O +
give O +
further O +
support O +
to O +
the O +
hypothesis O +
that O +
NO O +
plays O +
a O +
role O +
in O +
motor O +
behavior O +
control O +
and O +
suggest O +
that O +
it O +
may O +
take O +
part O +
in O +
the O +
synaptic O +
changes O +
produced O +
by O +
antipsychotic O +
treatment O -
. O -

Prolonged O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease +
occurs O +
in O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
after O +
both O +
dobutamine O +
and O +
exercise O +
induced O +
myocardial B-Disease +
ischaemia L-Disease -
. O -

OBJECTIVE O -
: O +
To O +
determine O +
whether O +
pharmacological O +
stress O +
leads O +
to O +
prolonged O +
but O +
reversible O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease +
in O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
, O +
similar O +
to O +
that O +
seen O +
after O +
exercise O -
. O -

DESIGN O -
: O +
A O +
randomised O +
crossover O +
study O +
of O +
recovery O +
time O +
of O +
systolic O +
and O +
diastolic O +
left O +
ventricular O +
function O +
after O +
exercise O +
and O +
dobutamine O +
induced O +
ischaemia U-Disease -
. O -

SUBJECTS O -
: O +
10 O +
patients O +
with O +
stable B-Disease +
angina L-Disease -
, O +
angiographically O +
proven O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
, O +
and O +
normal O +
left O +
ventricular O +
function O -
. O -

INTERVENTIONS O -
: O +
Treadmill O +
exercise O +
and O +
dobutamine O +
stress O +
were O +
performed O +
on O +
different O +
days O -
. O -

Quantitative O +
assessment O +
of O +
systolic O +
and O +
diastolic O +
left O +
ventricular O +
function O +
was O +
performed O +
using O +
transthoracic O +
echocardiography O +
at O +
baseline O +
and O +
at O +
regular O +
intervals O +
after O +
each O +
test O -
. O -

RESULTS O -
: O +
Both O +
forms O +
of O +
stress O +
led O +
to O +
prolonged O +
but O +
reversible O +
systolic O +
and O +
diastolic O +
dysfunction O -
. O -

There O +
was O +
no O +
difference O +
in O +
the O +
maximum O +
double O +
product O +
( O -
p O +
= O +
0.53 O -
) O +
or O +
ST O +
depression U-Disease +
( O -
p O +
= O +
0.63 O -
) O +
with O +
either O +
form O +
of O +
stress O -
. O -

After O +
exercise O -
, O +
ejection O +
fraction O +
was O +
reduced O +
at O +
15 O +
and O +
30 O +
minutes O +
compared O +
with O +
baseline O +
( O -
mean O +
( O -
SEM O -
) O -
, O +
-5.6 O +
( O -
1.5 O -
) O -
% O -
, O +
p O +
< O +
0.05 O -
; O +
and O +
-6.1 O +
( O -
2.2 O -
) O -
% O -
, O +
p O +
< O +
0 O -
. O +
01 O -
) O -
, O +
and O +
at O +
30 O +
and O +
45 O +
minutes O +
after O +
dobutamine O +
( O -
-10.8 O +
( O -
1.8 O -
) O -
% O +
and O +
-5 O -
. O -

5 O +
( O -
1.8 O -
) O -
% O -
, O +
both O +
p O +
< O +
0.01 O -
) O -
. O -

Regional O +
analysis O +
showed O +
a O +
reduction O +
in O +
the O +
worst O +
affected O +
segment O +
15 O +
and O +
30 O +
minutes O +
after O +
exercise O +
( O -
-27.9 O +
( O -
7.2 O -
) O -
% O +
and O +
-28.6 O +
( O -
5.7 O -
) O -
% O -
, O +
both O +
p O +
< O +
0.01 O -
) O -
, O +
and O +
at O +
30 O +
minutes O +
after O +
dobutamine O +
( O -
-32 O +
( O -
5.3 O -
) O -
% O -
, O +
p O +
< O +
0.01 O -
) O -
. O -

The O +
isovolumic O +
relaxation O +
period O +
was O +
prolonged O +
45 O +
minutes O +
after O +
each O +
form O +
of O +
stress O +
( O -
p O +
< O +
0.05 O -
) O -
. O -

CONCLUSIONS O -
: O +
In O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
, O +
dobutamine O +
induced O +
ischaemia U-Disease +
results O +
in O +
prolonged O +
reversible O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease -
, O +
presumed O +
to O +
be O +
myocardial B-Disease +
stunning L-Disease -
, O +
similar O +
to O +
that O +
seen O +
after O +
exercise O -
. O -

Dobutamine O +
induced O +
ischaemia U-Disease +
could O +
therefore O +
be O +
used O +
to O +
study O +
the O +
pathophysiology O +
of O +
this O +
phenomenon O +
further O +
in O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
. O -

Anorexigens O +
and O +
pulmonary B-Disease +
hypertension L-Disease +
in O +
the O +
United O +
States O -
: O +
results O +
from O +
the O +
surveillance O +
of O +
North O +
American O +
pulmonary B-Disease +
hypertension L-Disease -
. O -

BACKGROUND O -
: O +
The O +
use O +
of O +
appetite O +
suppressants O +
in O +
Europe O +
has O +
been O +
associated O +
with O +
the O +
development O +
of O +
primary B-Disease +
pulmonary I-Disease +
hypertension L-Disease +
( O -
PPH U-Disease -
) O -
. O -

Recently O -
, O +
fenfluramine O +
appetite O +
suppressants O +
became O +
widely O +
used O +
in O +
the O +
United O +
States O +
but O +
were O +
withdrawn O +
in O +
September O +
1997 O +
because O +
of O +
concerns O +
over O +
adverse O +
effects O -
. O -

MATERIALS O +
AND O +
METHODS O -
: O +
We O +
conducted O +
a O +
prospective O +
surveillance O +
study O +
on O +
patients O +
diagnosed O +
with O +
pulmonary B-Disease +
hypertension L-Disease +
at O +
12 O +
large O +
referral O +
centers O +
in O +
North O +
America O -
. O -

Data O +
collected O +
on O +
patients O +
seen O +
from O +
September O +
1 O -
, O +
1996 O -
, O +
to O +
December O +
31 O -
, O +
1997 O -
, O +
included O +
the O +
cause O +
of O +
the O +
pulmonary B-Disease +
hypertension L-Disease +
and O +
its O +
severity O -
. O -

Patients O +
with O +
no O +
identifiable O +
cause O +
of O +
pulmonary B-Disease +
hypertension L-Disease +
were O +
classed O +
as O +
PPH U-Disease -
. O -

A O +
history O +
of O +
drug O +
exposure O +
also O +
was O +
taken O +
with O +
special O +
attention O +
on O +
the O +
use O +
of O +
antidepressants O -
, O +
anorexigens O -
, O +
and O +
amphetamines O -
. O -

RESULTS O -
: O +
Five O +
hundred O +
seventy O -
- O -
nine O +
patients O +
were O +
studied O -
, O +
205 O +
with O +
PPH U-Disease +
and O +
374 O +
with O +
pulmonary B-Disease +
hypertension L-Disease +
from O +
other O +
causes O +
( O -
secondary O +
pulmonary B-Disease +
hypertension L-Disease +
[ O -
SPH O -
] O -
) O -
. O -

The O +
use O +
of O +
anorexigens O +
was O +
common O +
in O +
both O +
groups O -
. O -

However O -
, O +
of O +
the O +
medications O +
surveyed O -
, O +
only O +
the O +
fenfluramines O +
had O +
a O +
significant O +
preferential O +
association O +
with O +
PPH U-Disease +
as O +
compared O +
with O +
SPH O +
( O -
adjusted O +
odds O +
ratio O +
for O +
use O +
> O +
6 O +
months O -
, O +
7.5 O -
; O +
95 O -
% O +
confidence O +
interval O -
, O +
1.7 O +
to O +
32.4 O -
) O -
. O -

The O +
association O +
was O +
stronger O +
with O +
longer O +
duration O +
of O +
use O +
when O +
compared O +
to O +
shorter O +
duration O +
of O +
use O +
and O +
was O +
more O +
pronounced O +
in O +
recent O +
users O +
than O +
in O +
remote O +
users O -
. O -

An O +
unexpectedly O +
high O +
( O -
11.4 O -
% O -
) O +
number O +
of O +
patients O +
with O +
SPH O +
had O +
used O +
anorexigens O -
. O -

CONCLUSION O -
: O +
The O +
magnitude O +
of O +
the O +
association O +
with O +
PPH U-Disease -
, O +
the O +
increase O +
of O +
association O +
with O +
increasing O +
duration O +
of O +
use O -
, O +
and O +
the O +
specificity O +
for O +
fenfluramines O +
are O +
consistent O +
with O +
previous O +
studies O +
indicating O +
that O +
fenfluramines O +
are O +
causally O +
related O +
to O +
PPH U-Disease -
. O -

The O +
high O +
prevalence O +
of O +
anorexigen O +
use O +
in O +
patients O +
with O +
SPH O +
also O +
raises O +
the O +
possibility O +
that O +
these O +
drugs O +
precipitate O +
pulmonary B-Disease +
hypertension L-Disease +
in O +
patients O +
with O +
underlying O +
conditions O +
associated O +
with O +
SPH O -
. O -

Clinical O +
aspects O +
of O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease +
and O +
thrombosis U-Disease +
and O +
other O +
side O +
effects O +
of O +
heparin O +
therapy O -
. O -

Heparin O -
, O +
first O +
used O +
to O +
prevent O +
the O +
clotting O +
of O +
blood O +
in O +
vitro O -
, O +
has O +
been O +
clinically O +
used O +
to O +
treat O +
thrombosis U-Disease +
for O +
more O +
than O +
50 O +
years O -
. O -

Although O +
several O +
new O +
anticoagulant O +
drugs O +
are O +
in O +
development O -
, O +
heparin O +
remains O +
the O +
anticoagulant O +
of O +
choice O +
to O +
treat O +
acute O +
thrombotic U-Disease +
episodes O -
. O -

The O +
clinical O +
effects O +
of O +
heparin O +
are O +
meritorious O -
, O +
but O +
side O +
effects O +
do O +
exist O -
. O -

Bleeding U-Disease +
is O +
the O +
primary O +
untoward O +
effect O +
of O +
heparin O -
. O -

Major O +
bleeding U-Disease +
is O +
of O +
primary O +
concern O +
in O +
patients O +
receiving O +
heparin O +
therapy O -
. O -

However O -
, O +
additional O +
important O +
untoward O +
effects O +
of O +
heparin O +
therapy O +
include O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
, O +
heparin O -
- O -
associated O +
osteoporosis U-Disease -
, O +
eosinophilia U-Disease -
, O +
skin B-Disease +
reactions L-Disease -
, O +
allergic B-Disease +
reactions L-Disease +
other O +
than O +
thrombocytopenia U-Disease -
, O +
alopecia U-Disease -
, O +
transaminasemia O -
, O +
hyperkalemia U-Disease -
, O +
hypoaldosteronism U-Disease -
, O +
and O +
priapism U-Disease -
. O -

These O +
side O +
effects O +
are O +
relatively O +
rare O +
in O +
a O +
given O +
individual O -
, O +
but O +
given O +
the O +
extremely O +
widespread O +
use O +
of O +
heparin O -
, O +
some O +
are O +
quite O +
common O -
, O +
particularly O +
HITT U-Disease +
and O +
osteoporosis U-Disease -
. O -

Although O +
reasonable O +
incidences O +
of O +
many O +
of O +
these O +
side O +
effects O +
can O +
be O +
" O -
softly O -
" O +
deduced O +
from O +
current O +
reports O +
dealing O +
with O +
unfractionated O +
heparin O -
, O +
at O +
present O +
the O +
incidences O +
of O +
these O +
side O +
effects O +
with O +
newer O +
low O +
molecular O +
weight O +
heparins O +
appear O +
to O +
be O +
much O +
less O +
common O -
. O -

However O -
, O +
only O +
longer O +
experience O +
will O +
more O +
clearly O +
define O +
the O +
incidence O +
of O +
each O +
side O +
effect O +
with O +
low O +
molecular O +
weight O +
preparations O -
. O -

A O +
case O +
of O +
bilateral O +
optic B-Disease +
neuropathy L-Disease +
in O +
a O +
patient O +
on O +
tacrolimus O +
( O -
FK506 O -
) O +
therapy O +
after O +
liver O +
transplantation O -
. O -

PURPOSE O -
: O +
To O +
report O +
a O +
case O +
of O +
bilateral O +
optic B-Disease +
neuropathy L-Disease +
in O +
a O +
patient O +
receiving O +
tacrolimus O +
( O -
FK O +
506 O -
, O +
Prograf O -
; O +
Fujisawa O +
USA O -
, O +
Inc O -
, O +
Deerfield O -
, O +
Illinois O -
) O +
for O +
immunosuppression O +
after O +
orthotropic O +
liver O +
transplantation O -
. O -

METHOD O -
: O +
Case O +
report O -
. O -

In O +
a O +
58-year O -
- O -
old O +
man O +
receiving O +
tacrolimus O +
after O +
orthotropic O +
liver O +
transplantation O -
, O +
serial O +
neuro O -
- O -
ophthalmologic O +
examinations O +
and O +
laboratory O +
studies O +
were O +
performed O -
. O -

RESULTS O -
: O +
The O +
patient O +
had O +
episodic O +
deterioration O +
of O +
vision O +
in O +
both O +
eyes O -
, O +
with O +
clinical O +
features O +
resembling O +
ischemic B-Disease +
optic I-Disease +
neuropathies L-Disease -
. O -

Deterioration B-Disease +
of I-Disease +
vision L-Disease +
occurred O +
despite O +
discontinuation O +
of O +
the O +
tacrolimus O -
. O -

CONCLUSION O -
: O +
Tacrolimus O +
and O +
other O +
immunosuppressive O +
agents O +
may O +
be O +
associated O +
with O +
optic B-Disease +
nerve I-Disease +
toxicity L-Disease -
. O -

Hypercalcemia U-Disease -
, O +
arrhythmia U-Disease -
, O +
and O +
mood O +
stabilizers O -
. O -

Recent O +
findings O +
in O +
a O +
bipolar U-Disease +
patient O +
receiving O +
maintenance O +
lithium O +
therapy O +
who O +
developed O +
hypercalcemia U-Disease +
and O +
severe O +
bradyarrhythmia U-Disease +
prompted O +
the O +
authors O +
to O +
conduct O +
a O +
retrospective O +
study O +
of O +
bipolar U-Disease +
patients O +
with O +
lithium O -
- O -
associated O +
hypercalcemia U-Disease -
. O -

A O +
printout O +
of O +
all O +
cases O +
of O +
hypercalcemia U-Disease +
that O +
presented O +
during O +
a O +
1-year O +
period O +
was O +
generated O -
. O -

After O +
eliminating O +
spurious O +
hypercalcemias U-Disease +
or O +
those O +
associated O +
with O +
intravenous O +
fluids O -
, O +
the O +
authors O +
identified O +
18 O +
non O -
- O -
lithium O -
- O -
treated O +
patients O +
with O +
hypercalcemias U-Disease +
related O +
to O +
malignancies U-Disease +
and O +
other O +
medical O +
conditions O +
( O -
group O +
A O -
) O +
and O +
12 O +
patients O +
with O +
lithium O -
- O -
associated O +
hypercalcemia U-Disease +
( O -
group O +
B O -
) O -
. O -

Patients O +
in O +
group O +
B O +
were O +
not O +
comparable O +
to O +
those O +
in O +
group O +
A O -
, O +
as O +
the O +
latter O +
were O +
medically O +
compromised O +
and O +
were O +
receiving O +
multiple O +
pharmacotherapies O -
. O -

Thus O -
, O +
two O +
control O +
groups O +
were O +
generated O -
: O +
group O +
C1 O -
, O +
which O +
included O +
age- O +
and O +
sex O -
- O -
comparable O +
lithium O -
- O -
treated O +
bipolar U-Disease +
normocalcemic O +
patients O -
, O +
and O +
group O +
C2 O -
, O +
which O +
included O +
bipolar U-Disease +
normocalcemic O +
patients O +
treated O +
with O +
anticonvulsant O +
mood O +
stabilizers O -
. O -

The O +
electrocardiographic O +
( O -
ECG O -
) O +
findings O +
for O +
patients O +
in O +
group O +
B O +
were O +
compared O +
with O +
those O +
of O +
patients O +
in O +
groups O +
C1 O +
and O +
C2 O -
. O -

It O +
was O +
found O +
that O +
these O +
groups O +
did O +
not O +
differ O +
in O +
their O +
overall O +
frequency O +
of O +
ECG O +
abnormalities O -
; O +
however O -
, O +
there O +
were O +
significant O +
differences O +
in O +
the O +
frequency O +
of O +
conduction O +
defects O -
. O -

Patients O +
with O +
hypercalcemia U-Disease +
resulting O +
from O +
medical O +
diseases O +
and O +
bipolar U-Disease +
patients O +
with O +
lithium O -
- O -
associated O +
hypercalcemia U-Disease +
had O +
significantly O +
higher O +
frequencies O +
of O +
conduction O +
defects O -
. O -

Patients O +
in O +
group O +
A O +
had O +
significant O +
mortality O +
at O +
2-year O +
follow O -
- O -
up O +
( O -
28 O -
% O -
) O -
, O +
in O +
contrast O +
to O +
zero O +
mortality O +
in O +
the O +
other O +
three O +
groups O -
. O -

The O +
clinical O +
implications O +
of O +
these O +
findings O +
are O +
discussed O -
. O -

Attenuation O +
of O +
nephrotoxicity U-Disease +
by O +
a O +
novel O +
lipid O +
nanosphere O +
( O -
NS-718 O -
) O +
incorporating O +
amphotericin O +
B. O +
NS-718 O -
, O +
a O +
lipid O +
nanosphere O +
incorporating O +
amphotericin O +
B O -
, O +
is O +
effective O +
against O +
pathogenic O +
fungi O +
and O +
has O +
low O +
toxicity U-Disease -
. O -

We O +
compared O +
the O +
toxicity U-Disease +
of O +
NS-718 O +
with O +
that O +
of O +
Fungizone O +
( O -
amphotericin O +
B O -
- O -
sodium O +
deoxycholate O -
; O +
D O -
- O -
AmB O -
) O +
in O +
vitro O +
using O +
renal O +
cell O +
cultures O +
and O +
in O +
vivo O +
by O +
biochemical O +
analysis O -
, O +
histopathological O +
study O +
of O +
the O +
kidney O +
and O +
pharmacokinetic O +
study O +
of O +
amphotericin O +
B O +
following O +
intravenous O +
infusion O +
of O +
the O +
formulation O +
in O +
rats O -
. O -

Incubation O +
with O +
NS-718 O +
resulted O +
in O +
significantly O +
less O +
damage O +
of O +
cultured O +
human O +
renal O +
proximal O +
tubular O +
epithelial O +
cells O +
compared O +
with O +
D O -
- O -
AmB. O +
Serum O +
blood O +
urea O +
and O +
creatinine O +
concentrations O +
increased O +
significantly O +
in O +
rats O +
given O +
an O +
iv O +
infusion O +
of O +
D O -
- O -
AmB O +
3 O +
mg O -
/ O -
kg O +
but O +
not O +
in O +
those O +
given O +
the O +
same O +
dose O +
of O +
NS-718 O -
. O -

Histopathological O +
examination O +
of O +
the O +
kidney O +
showed O +
tubular B-Disease +
necrosis L-Disease +
in O +
D O -
- O -
AmB O -
- O -
treated O +
rats O +
but O +
no O +
change O +
in O +
NS-718-treated O +
rats O -
. O -

Amphotericin O +
B O +
concentrations O +
in O +
the O +
kidney O +
in O +
NS-718-treated O +
rats O +
were O +
higher O +
than O +
those O +
in O +
D O -
- O -
AmB O -
- O -
treated O +
rats O -
. O -

Our O +
in O +
vitro O +
and O +
in O +
vivo O +
results O +
suggest O +
that O +
incorporation O +
of O +
amphotericin O +
B O +
into O +
lipid O +
nanospheres O +
of O +
NS-718 O +
attenuates O +
the O +
nephrotoxicity U-Disease +
of O +
amphotericin O +
B. O -

Patterns O +
of O +
sulfadiazine O +
acute B-Disease +
nephrotoxicity L-Disease -
. O -

Sulfadiazine O +
acute B-Disease +
nephrotoxicity L-Disease +
is O +
reviving O +
specially O +
because O +
of O +
its O +
use O +
in O +
toxoplasmosis U-Disease +
in O +
HIV O -
- O -
positive O +
patients O -
. O -

We O +
report O +
4 O +
cases O -
, O +
one O +
of O +
them O +
in O +
a O +
previously O +
healthy O +
person O -
. O -

Under O +
treatment O +
with O +
sulfadiazine O +
they O +
developed O +
oliguria U-Disease -
, O +
abdominal B-Disease +
pain L-Disease -
, O +
renal B-Disease +
failure L-Disease +
and O +
showed O +
multiple O +
radiolucent O +
renal B-Disease +
calculi L-Disease +
in O +
echography O -
. O -

All O +
patients O +
recovered O +
their O +
previous O +
normal O +
renal O +
function O +
after O +
adequate O +
hydration O +
and O +
alcalinization O -
. O -

A O +
nephrostomy O +
tube O +
had O +
to O +
be O +
placed O +
in O +
one O +
of O +
the O +
patients O +
for O +
ureteral B-Disease +
lithiasis L-Disease +
in O +
a O +
single O +
functional O +
kidney O -
. O -

None O +
of O +
them O +
needed O +
dialysis O +
or O +
a O +
renal O +
biopsy O +
because O +
of O +
a O +
typical O +
benign O +
course O -
. O -

Treatment O +
with O +
sulfadiazine O +
requires O +
exquisite O +
control O +
of O +
renal O +
function O -
, O +
an O +
increase O +
in O +
water O +
ingestion O +
and O +
possibly O +
the O +
alcalinization O +
of O +
the O +
urine O -
. O -

We O +
communicate O +
a O +
case O +
in O +
a O +
previously O +
healthy O +
person O -
, O +
a O +
fact O +
not O +
found O +
in O +
the O +
recent O +
literature O -
. O -

Probably O +
many O +
more O +
cases O +
are O +
not O +
detected O -
. O -

We O +
think O +
that O +
a O +
prospective O +
study O +
would O +
be O +
useful O -
. O -

Downbeat B-Disease +
nystagmus L-Disease +
associated O +
with O +
intravenous O +
patient O -
- O -
controlled O +
administration O +
of O +
morphine O -
. O -

IMPLICATIONS O -
: O +
This O +
case O +
documents O +
a O +
patient O +
who O +
developed O +
dizziness U-Disease +
with O +
downbeating B-Disease +
nystagmus L-Disease +
while O +
receiving O +
a O +
relatively O +
large O +
dose O +
of O +
IV O +
patient O -
- O -
controlled O +
analgesia O +
morphine O -
. O -

Although O +
there O +
have O +
been O +
case O +
reports O +
of O +
epidural O +
morphine O +
with O +
these O +
symptoms O +
and O +
signs O -
, O +
this O +
has O +
not O +
been O +
previously O +
documented O +
with O +
IV O +
or O +
patient O -
- O -
controlled O +
analgesia O +
morphine O -
. O -

Hemodynamic O +
and O +
antiadrenergic O +
effects O +
of O +
dronedarone O +
and O +
amiodarone O +
in O +
animals O +
with O +
a O +
healed O +
myocardial B-Disease +
infarction L-Disease -
. O -

The O +
hemodynamic O +
and O +
antiadrenergic O +
effects O +
of O +
dronedarone O -
, O +
a O +
noniodinated O +
compound O +
structurally O +
related O +
to O +
amiodarone O -
, O +
were O +
compared O +
with O +
those O +
of O +
amiodarone O +
after O +
prolonged O +
oral O +
administration O -
, O +
both O +
at O +
rest O +
and O +
during O +
sympathetic O +
stimulation O +
in O +
conscious O +
dogs O +
with O +
a O +
healed O +
myocardial B-Disease +
infarction L-Disease -
. O -

All O +
dogs O +
( O -
n O +
= O +
6 O -
) O +
randomly O +
received O +
orally O +
dronedarone O +
( O -
10 O +
and O +
30 O +
mg O -
/ O -
kg O -
) O -
, O +
amiodarone O +
( O -
10 O +
and O +
30 O +
mg O -
/ O -
kg O -
) O -
, O +
and O +
placebo O +
twice O +
daily O +
for O +
7 O +
days O -
, O +
with O +
a O +
3-week O +
washout O +
between O +
consecutive O +
treatments O -
. O -

Heart O +
rate O +
( O -
HR O -
) O -
, O +
mean O +
arterial O +
pressure O +
( O -
MBP O -
) O -
, O +
positive O +
rate O +
of O +
increase O +
of O +
left O +
ventricular O +
pressure O +
( O -
+ O -
LVdP O -
/ O -
dt O -
) O -
, O +
echocardiographically O +
assessed O +
left O +
ventricular O +
ejection O +
fraction O +
( O -
LVEF O -
) O -
, O +
and O +
fractional O +
shortening O +
( O -
FS O -
) O -
, O +
as O +
well O +
as O +
chronotropic O +
response O +
to O +
isoproterenol O +
and O +
exercise O -
- O -
induced O +
sympathetic O +
stimulation O +
were O +
evaluated O +
under O +
baseline O +
and O +
posttreatment O +
conditions O -
. O -

Resting O +
values O +
of O +
LVEF O -
, O +
FS O -
, O +
+ O -
LVdP O -
/ O -
dt O -
, O +
and O +
MBP O +
remained O +
unchanged O +
whatever O +
the O +
drug O +
and O +
the O +
dosing O +
regimen O -
, O +
whereas O +
resting O +
HR O +
was O +
significantly O +
and O +
dose O -
- O -
dependently O +
lowered O +
after O +
dronedarone O +
and O +
to O +
a O +
lesser O +
extent O +
after O +
amiodarone O -
. O -

Both O +
dronedarone O +
and O +
amiodarone O +
significantly O +
reduced O +
the O +
exercise O -
- O -
induced O +
tachycardia U-Disease +
and O -
, O +
at O +
the O +
highest O +
dose O -
, O +
decreased O +
the O +
isoproterenol O -
- O -
induced O +
tachycardia U-Disease -
. O -

Thus O -
, O +
dronedarone O +
and O +
amiodarone O +
displayed O +
a O +
similar O +
level O +
of O +
antiadrenergic O +
effect O +
and O +
did O +
not O +
impair O +
the O +
resting O +
left O +
ventricular O +
function O -
. O -

Consequently O -
, O +
dronedarone O +
might O +
be O +
particularly O +
suitable O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
various O +
clinical O +
arrhythmias U-Disease -
, O +
without O +
compromising O +
the O +
left O +
ventricular O +
function O -
. O -

Phase O +
2 O +
trial O +
of O +
liposomal O +
doxorubicin O +
( O -
40 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
) O +
in O +
platinum O -
/ O -
paclitaxel O -
- O -
refractory O +
ovarian B-Disease +
and I-Disease +
fallopian I-Disease +
tube I-Disease +
cancers L-Disease +
and O +
primary O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
peritoneum L-Disease -
. O -

BACKGROUND O -
: O +
Several O +
studies O +
have O +
demonstrated O +
liposomal O +
doxorubicin O +
( O -
Doxil O -
) O +
to O +
be O +
an O +
active O +
antineoplastic O +
agent O +
in O +
platinum O -
- O -
resistant O +
ovarian B-Disease +
cancer L-Disease -
, O +
with O +
dose O +
limiting O +
toxicity U-Disease +
of O +
the O +
standard O +
dosing O +
regimen O +
( O -
50 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
q O +
4 O +
weeks O -
) O +
being O +
severe O +
erythrodysesthesia U-Disease +
( O -
" O -
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome L-Disease -
" O -
) O +
and O +
stomatitis U-Disease -
. O -

We O +
wished O +
to O +
develop O +
a O +
more O +
tolerable O +
liposomal O +
doxorubicin O +
treatment O +
regimen O +
and O +
document O +
its O +
level O +
of O +
activity O +
in O +
a O +
well O -
- O -
defined O +
patient O +
population O +
with O +
platinum O -
/ O -
paclitaxel O -
- O -
refractory O +
disease O -
. O -

METHODS O +
AND O +
MATERIALS O -
: O +
Patients O +
with O +
ovarian B-Disease +
or I-Disease +
fallopian I-Disease +
tube I-Disease +
cancers L-Disease +
or O +
primary O +
peritoneal B-Disease +
carcinoma L-Disease +
with O +
platinum O -
/ O -
paclitaxel O -
- O -
refractory O +
disease O +
( O -
stable O +
or O +
progressive O +
disease O +
following O +
treatment O +
with O +
these O +
agents O +
or O +
previous O +
objective O +
response O +
<3 O +
months O +
in O +
duration O -
) O +
were O +
treated O +
with O +
liposomal O +
doxorubicin O +
at O +
a O +
dose O +
of O +
40 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
q O +
4 O +
weeks O -
. O -

RESULTS O -
: O +
A O +
total O +
of O +
49 O +
patients O +
( O -
median O +
age O -
: O +
60 O -
; O +
range O +
41 O -
- O -
81 O -
) O +
entered O +
this O +
phase O +
2 O +
trial O -
. O -

The O +
median O +
number O +
of O +
prior O +
regimens O +
was O +
2 O +
( O -
range O -
: O +
1 O -
- O -
6 O -
) O -
. O -

Six O +
( O -
12 O -
% O -
) O +
and O +
4 O +
( O -
8 O -
% O -
) O +
patients O +
experienced O +
grade O +
2 O +
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome L-Disease +
and O +
stomatitis U-Disease -
, O +
respectively O +
( O -
no O +
episodes O +
of O +
grade O +
3 O -
) O -
. O -

One O +
patient O +
developed O +
grade O +
3 O +
diarrhea U-Disease +
requiring O +
hospitalization O +
for O +
hydration O -
. O -

Six O +
( O -
12 O -
% O -
) O +
individuals O +
required O +
dose O +
reductions O -
. O -

The O +
median O +
number O +
of O +
courses O +
of O +
liposomal O +
doxorubicin O +
administered O +
on O +
this O +
protocol O +
was O +
2 O +
( O -
range O -
: O +
1 O -
- O -
12 O -
) O -
. O -

Four O +
of O +
44 O +
patients O +
( O -
9 O -
% O -
) O +
evaluable O +
for O +
response O +
exhibited O +
objective O +
and O +
subjective O +
evidence O +
of O +
an O +
antineoplastic O +
effect O +
of O +
therapy O -
. O -

CONCLUSION O -
: O +
This O +
modified O +
liposomal O +
doxorubicin O +
regimen O +
results O +
in O +
less O +
toxicity U-Disease +
( O -
stomatitis U-Disease -
, O +
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome L-Disease -
) O +
than O +
the O +
standard O +
FDA O -
- O -
approved O +
dose O +
schedule O -
. O -

Definite O -
, O +
although O +
limited O -
, O +
antineoplastic O +
activity O +
is O +
observed O +
in O +
patients O +
with O +
well O -
- O -
defined O +
platinum- O +
and O +
paclitaxel O -
- O -
refractory O +
ovarian B-Disease +
cancer L-Disease -
. O -

Efficacy O +
of O +
olanzapine O +
in O +
acute O +
bipolar B-Disease +
mania L-Disease -
: O +
a O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
study O -
. O -

The O +
Olanzipine O +
HGGW O +
Study O +
Group O -
. O -

BACKGROUND O -
: O +
We O +
compared O +
the O +
efficacy O +
and O +
safety O +
of O +
olanzapine O +
vs O +
placebo O +
for O +
the O +
treatment O +
of O +
acute O +
bipolar B-Disease +
mania L-Disease -
. O -

METHODS O -
: O +
Four O -
- O -
week O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
parallel O +
study O -
. O -

A O +
total O +
of O +
115 O +
patients O +
with O +
a O +
DSM O -
- O -
IV O +
diagnosis O +
of O +
bipolar B-Disease +
disorder L-Disease -
, O +
manic U-Disease +
or O +
mixed O -
, O +
were O +
randomized O +
to O +
olanzapine O -
, O +
5 O +
to O +
20 O +
mg O -
/ O -
d O +
( O -
n O +
= O +
55 O -
) O -
, O +
or O +
placebo O +
( O -
n O +
= O +
60 O -
) O -
. O -

The O +
primary O +
efficacy O +
measure O +
was O +
the O +
Young O -
- O -
Mania U-Disease +
Rating O +
Scale O +
( O -
Y O -
- O -
MRS O -
) O +
total O +
score O -
. O -

Response O +
and O +
euthymia O +
were O +
defined O -
, O +
a O +
priori O -
, O +
as O +
at O +
least O +
a O +
50 O -
% O +
improvement O +
from O +
baseline O +
to O +
end O +
point O +
and O +
as O +
a O +
score O +
of O +
no O +
less O +
than O +
12 O +
at O +
end O +
point O +
in O +
the O +
Y O -
- O -
MRS O +
total O +
score O -
, O +
respectively O -
. O -

Safety O +
was O +
assessed O +
using O +
adverse O +
events O -
, O +
Extrapyramidal B-Disease +
Symptom L-Disease +
( O -
EPS U-Disease -
) O +
rating O +
scales O -
, O +
laboratory O +
values O -
, O +
electrocardiograms O -
, O +
vital O +
signs O -
, O +
and O +
weight O +
change O -
. O -

RESULTS O -
: O +
Olanzapine O -
- O -
treated O +
patients O +
demonstrated O +
a O +
statistically O +
significant O +
greater O +
mean O +
( O -
+ O -
/- O -

SD O -
) O +
improvement O +
in O +
Y O -
- O -
MRS O +
total O +
score O +
than O +
placebo O -
- O -
treated O +
patients O +
( O -
-14.8 O +
+ O -
/- O -

12.5 O +
and O +
-8.1 O +
+ O -
/- O -

12.7 O -
, O +
respectively O -
; O +
P<.001 O -
) O -
, O +
which O +
was O +
evident O +
at O +
the O +
first O +
postbaseline O +
observation O +
1 O +
week O +
after O +
randomization O +
and O +
was O +
maintained O +
throughout O +
the O +
study O +
( O -
last O +
observation O +
carried O +
forward O -
) O -
. O -

Olanzapine O -
- O -
treated O +
patients O +
demonstrated O +
a O +
higher O +
rate O +
of O +
response O +
( O -
65 O -
% O +
vs O +
43 O -
% O -
, O +
respectively O -
; O +
P O +
= O -
.02 O -
) O +
and O +
euthymia O +
( O -
61 O -
% O +
vs O +
36 O -
% O -
, O +
respectively O -
; O +
P O +
= O -
. O +
01 O -
) O +
than O +
placebo O -
- O -
treated O +
patients O -
. O -

There O +
were O +
no O +
statistically O +
significant O +
differences O +
in O +
EPSs U-Disease +
between O +
groups O -
. O -

However O -
, O +
olanzapine O -
- O -
treated O +
patients O +
had O +
a O +
statistically O +
significant O +
greater O +
mean O +
( O -
+ O -
/- O -

SD O -
) O +
weight B-Disease +
gain L-Disease +
than O +
placebo O -
- O -
treated O +
patients O +
( O -
2.1 O +
+ O -
/- O +
2.8 O +
vs O +
0.45 O +
+ O -
/- O -

2.3 O +
kg O -
, O +
respectively O -
) O +
and O +
also O +
experienced O +
more O +
treatment O -
- O -
emergent O +
somnolence U-Disease +
( O -
21 O +
patients O +
[ O -
38.2 O -
% O -
] O +
vs O +
5 O +
[ O -
8.3 O -
% O +
] O -
, O +
respectively O -
) O -
. O -

CONCLUSION O -
: O +
Olanzapine O +
demonstrated O +
greater O +
efficacy O +
than O +
placebo O +
in O +
the O +
treatment O +
of O +
acute O +
bipolar B-Disease +
mania L-Disease +
and O +
was O +
generally O +
well O +
tolerated O -
. O -

The O +
effect O +
of O +
pupil B-Disease +
dilation L-Disease +
with O +
tropicamide O +
on O +
vision O +
and O +
driving O +
simulator O +
performance O -
. O -

PURPOSE O -
: O +
To O +
assess O +
the O +
effect O +
of O +
pupil B-Disease +
dilation L-Disease +
on O +
vision O +
and O +
driving O +
ability O -
. O -

METHODS O -
: O +
A O +
series O +
of O +
tests O +
on O +
various O +
parameters O +
of O +
visual O +
function O +
and O +
driving O +
simulator O +
performance O +
were O +
performed O +
on O +
12 O +
healthy O +
drivers O -
, O +
before O +
and O +
after O +
pupil B-Disease +
dilation L-Disease +
using O +
guttae O +
tropicamide O +
1 O -
% O -
. O -

A O +
driving O +
simulator O +
( O -
Transport O +
Research O +
Laboratory O -
) O +
was O +
used O +
to O +
measure O +
reaction O +
time O +
( O -
RT O -
) O -
, O +
speed O +
maintenance O +
and O +
steering O +
accuracy O -
. O -

Tests O +
of O +
basic O +
visual O +
function O +
included O +
high- O +
and O +
low O -
- O -
contrast O +
visual O +
acuity O +
( O -
HCVA O +
and O +
LCVA O -
) O -
, O +
Pelli O -
- O -
Robson O +
contrast O +
threshold O +
( O -
CT O -
) O +
and O +
Goldmann O +
perimetry O +
( O -
FIELDS O -
) O -
. O -

Useful O +
Field O +
of O +
View O +
( O -
UFOV O -
-- O -
a O +
test O +
of O +
visual O +
attention O -
) O +
was O +
also O +
undertaken O -
. O -

The O +
mean O +
differences O +
in O +
the O +
pre- O +
and O +
post O -
- O -
dilatation O +
measurements O +
were O +
tested O +
for O +
statistical O +
significance O +
at O +
the O +
95 O -
% O +
level O +
using O +
one O -
- O -
tail O +
paired O +
t O -
- O -
tests O -
. O -

RESULTS O -
: O +
Pupillary B-Disease +
dilation L-Disease +
resulted O +
in O +
a O +
statistically O +
significant O +
deterioration O +
in O +
CT O +
and O +
HCVA O +
only O -
. O -

Five O +
of O +
12 O +
drivers O +
also O +
exhibited O +
deterioration O +
in O +
LCVA O -
, O +
CT O +
and O +
RT O -
. O -

Little O +
evidence O +
emerged O +
for O +
deterioration O +
in O +
FIELDS O +
and O +
UFOV O -
. O -

Also O -
, O +
7 O +
of O +
12 O +
drivers O +
appeared O +
to O +
adjust O +
their O +
driving O +
behaviour O +
by O +
reducing O +
their O +
speed O +
on O +
the O +
driving O +
simulator O -
, O +
leading O +
to O +
improved O +
steering O +
accuracy O -
. O -

CONCLUSIONS O -
: O +
Pupillary B-Disease +
dilation L-Disease +
may O +
lead O +
to O +
a O +
decrease O +
in O +
vision O +
and O +
daylight O +
driving O +
performance O +
in O +
young O +
people O -
. O -

A O +
larger O +
study O -
, O +
including O +
a O +
broader O +
spectrum O +
of O +
subjects O -
, O +
is O +
warranted O +
before O +
guidelines O +
can O +
be O +
recommended O -
. O -

A O +
case O +
of O +
isotretinoin B-Disease +
embryopathy L-Disease +
with O +
bilateral O +
anotia U-Disease +
and O +
Taussig B-Disease -
- I-Disease -
Bing I-Disease +
malformation L-Disease -
. O -

We O +
report O +
a O +
newborn O +
infant O +
with O +
multiple O +
congenital O +
anomalies O +
( O -
anotia U-Disease +
and O +
Taussig B-Disease -
- I-Disease -
Bing I-Disease +
malformation L-Disease -
) O +
due O +
to O +
exposure O +
to O +
isotretinoin O +
within O +
the O +
first O +
trimester O -
. O -

In O +
this O +
paper O +
we O +
aim O +
to O +
draw O +
to O +
the O +
fact O +
that O +
caution O +
is O +
needed O +
when O +
prescribing O +
vitamin O +
A O -
- O -
containing O +
drugs O +
to O +
women O +
of O +
childbearing O +
years O -
. O -

Effect O +
of O +
methoxamine O +
on O +
maximum O +
urethral O +
pressure O +
in O +
women O +
with O +
genuine O +
stress B-Disease +
incontinence L-Disease -
: O +
a O +
placebo O -
- O -
controlled O -
, O +
double O -
- O -
blind O +
crossover O +
study O -
. O -

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
evaluate O +
the O +
potential O +
role O +
for O +
a O +
selective O +
alpha1-adrenoceptor O +
agonist O +
in O +
the O +
treatment O +
of O +
urinary B-Disease +
stress I-Disease +
incontinence L-Disease -
. O -

A O +
randomised O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
crossover O +
study O +
design O +
was O +
employed O -
. O -

Half O +
log O +
incremental O +
doses O +
of O +
intravenous O +
methoxamine O +
or O +
placebo O +
( O -
saline O -
) O +
were O +
administered O +
to O +
a O +
group O +
of O +
women O +
with O +
genuine O +
stress B-Disease +
incontinence L-Disease +
while O +
measuring O +
maximum O +
urethral O +
pressure O +
( O -
MUP O -
) O -
, O +
blood O +
pressure O -
, O +
heart O +
rate O -
, O +
and O +
symptomatic O +
side O +
effects O -
. O -

Methoxamine O +
evoked O +
non O -
- O -
significant O +
increases O +
in O +
MUP O +
and O +
diastolic O +
blood O +
pressure O +
but O +
caused O +
a B-Disease +
significant I-Disease +
rise I-Disease +
in I-Disease +
systolic I-Disease +
blood I-Disease +
pressure L-Disease +
and O +
significant O +
fall O +
in O +
heart O +
rate O +
at O +
maximum O +
dosage O -
. O -

Systemic O +
side O +
effects O +
including O +
piloerection O -
, O +
headache U-Disease -
, O +
and O +
cold O +
extremities O +
were O +
experienced O +
in O +
all O +
subjects O -
. O -

The O +
results O +
indicate O +
that O +
the O +
clinical O +
usefulness O +
of O +
direct O -
, O +
peripherally O +
acting O +
sub O -
- O -
type O -
- O -
selective O +
alpha1-adrenoceptor O +
agonists O +
in O +
the O +
medical O +
treatment O +
of O +
stress B-Disease +
incontinence L-Disease +
may O +
be O +
limited O +
by O +
associated O +
piloerection O +
and O +
cardiovascular O +
side O +
effects O -
. O -

Hyperglycemic U-Disease +
effect O +
of O +
amino O +
compounds O +
structurally O +
related O +
to O +
caproate O +
in O +
rats O -
. O -

The O +
chronic O +
feeding O +
of O +
small O +
amounts O +
( O -
0.3 O -
- O -
3 O -
% O +
of O +
diet O +
weight O -
) O +
of O +
certain O +
amino O +
derivatives O +
of O +
caproate O +
resulted O +
in O +
hyperglycemia U-Disease -
, O +
an O +
elevated O +
glucose O +
tolerance O +
curve O +
and O -
, O +
occasionally O -
, O +
glucosuria U-Disease -
. O -

Effective O +
compounds O +
included O +
norleucine O -
, O +
norvaline O -
, O +
glutamate O -
, O +
epsilon O -
- O -
aminocaproate O -
, O +
methionine O -
, O +
and O +
leucine O -
. O -

Toleration O +
of O +
high O +
doses O +
of O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
in O +
patients O +
with O +
chronic O +
heart B-Disease +
failure L-Disease -
: O +
results O +
from O +
the O +
ATLAS O +
trial O -
. O -

The O +
Assessment O +
of O +
Treatment O +
with O +
Lisinopril O +
and O +
Survival O -
. O -

BACKGROUND O -
: O +
Treatment O +
with O +
angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitors O +
reduces O +
mortality O +
and O +
morbidity O +
in O +
patients O +
with O +
chronic O +
heart B-Disease +
failure L-Disease +
( O -
CHF U-Disease -
) O -
, O +
but O +
most O +
affected O +
patients O +
are O +
not O +
receiving O +
these O +
agents O +
or O +
are O +
being O +
treated O +
with O +
doses O +
lower O +
than O +
those O +
found O +
to O +
be O +
efficacious O +
in O +
trials O -
, O +
primarily O +
because O +
of O +
concerns O +
about O +
the O +
safety O +
and O +
tolerability O +
of O +
these O +
agents O -
, O +
especially O +
at O +
the O +
recommended O +
doses O -
. O -

The O +
present O +
study O +
examines O +
the O +
safety O +
and O +
tolerability O +
of O +
high- O +
compared O +
with O +
low O -
- O -
dose O +
lisinopril O +
in O +
CHF U-Disease -
. O -

METHODS O -
: O +
The O +
Assessment O +
of O +
Lisinopril O +
and O +
Survival O +
study O +
was O +
a O +
multicenter O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
trial O +
in O +
which O +
patients O +
with O +
or O +
without O +
previous O +
ACE O +
inhibitor O +
treatment O +
were O +
stabilized O +
receiving O +
medium O -
- O -
dose O +
lisinopril O +
( O -
12.5 O +
or O +
15.0 O +
mg O +
once O +
daily O +
[ O -
OD O -
] O -
) O +
for O +
2 O +
to O +
4 O +
weeks O +
and O +
then O +
randomized O +
to O +
high- O +
( O -
35.0 O +
or O +
32.5 O +
mg O +
OD O -
) O +
or O +
low O -
- O -
dose O +
( O -
5.0 O +
or O +
2.5 O +
mg O +
OD O -
) O +
groups O -
. O -

Patients O +
with O +
New O +
York O +
Heart O +
Association O +
classes O +
II O +
to O +
IV O +
CHF U-Disease +
and O +
left O +
ventricular O +
ejection O +
fractions O +
of O +
no O +
greater O +
than O +
0.30 O +
( O -
n O +
= O +
3164 O -
) O +
were O +
randomized O +
and O +
followed O +
up O +
for O +
a O +
median O +
of O +
46 O +
months O -
. O -

We O +
examined O +
the O +
occurrence O +
of O +
adverse O +
events O +
and O +
the O +
need O +
for O +
discontinuation O +
and O +
dose O +
reduction O +
during O +
treatment O -
, O +
with O +
a O +
focus O +
on O +
hypotension U-Disease +
and O +
renal B-Disease +
dysfunction L-Disease -
. O -

RESULTS O -
: O +
Of O +
405 O +
patients O +
not O +
previously O +
receiving O +
an O +
ACE O +
inhibitor O -
, O +
doses O +
in O +
only O +
4.2 O -
% O +
could O +
not O +
be O +
titrated O +
to O +
the O +
medium O +
doses O +
required O +
for O +
randomization O +
because O +
of O +
symptoms O +
possibly O +
related O +
to O +
hypotension U-Disease +
( O -
2.0 O -
% O -
) O +
or O +
because O +
of O +
renal B-Disease +
dysfunction L-Disease +
or O +
hyperkalemia U-Disease +
( O -
2.3 O -
% O -
) O -
. O -

Doses O +
in O +
more O +
than O +
90 O -
% O +
of O +
randomized O +
patients O +
in O +
the O +
high- O +
and O +
low O -
- O -
dose O +
groups O +
were O +
titrated O +
to O +
their O +
assigned O +
target O -
, O +
and O +
the O +
mean O +
doses O +
of O +
blinded O +
medication O +
in O +
both O +
groups O +
remained O +
similar O +
throughout O +
the O +
study O -
. O -

Withdrawals O +
occurred O +
in O +
27.1 O -
% O +
of O +
the O +
high- O +
and O +
30.7 O -
% O +
of O +
the O +
low O -
- O -
dose O +
groups O -
. O -

Subgroups O +
presumed O +
to O +
be O +
at O +
higher O +
risk O +
for O +
ACE O +
inhibitor O +
intolerance O +
( O -
blood O +
pressure O -
, O +
< O -
120 O +
mm O +
Hg O -
; O +
creatinine O -
, O +
> O +
or O +
= O -
132.6 O +
micromol O -
/ O -
L O +
[ O -
> O +
or O +
= O -
1.5 O +
mg O -
/ O -
dL O -
] O -
; O +
age O -
, O +
> O +
or O +
= O -
70 O +
years O -
; O +
and O +
patients O +
with O +
diabetes U-Disease -
) O +
generally O +
tolerated O +
the O +
high O -
- O -
dose O +
strategy O -
. O -

CONCLUSIONS O -
: O +
These O +
findings O +
demonstrate O +
that O +
ACE O +
inhibitor O +
therapy O +
in O +
most O +
patients O +
with O +
CHF U-Disease +
can O +
be O +
successfully O +
titrated O +
to O +
and O +
maintained O +
at O +
high O +
doses O -
, O +
and O +
that O +
more O +
aggressive O +
use O +
of O +
these O +
agents O +
is O +
warranted O -
. O -

Cocaine O -
, O +
ethanol O -
, O +
and O +
cocaethylene O +
cardiotoxity U-Disease +
in O +
an O +
animal O +
model O +
of O +
cocaine B-Disease +
and I-Disease +
ethanol I-Disease +
abuse L-Disease -
. O -

OBJECTIVES O -
: O +
Simultaneous O +
abuse B-Disease +
of I-Disease +
cocaine L-Disease +
and B-Disease +
ethanol L-Disease +
affects O +
12 O +
million O +
Americans O +
annually O -
. O -

In O +
combination O -
, O +
these O +
substances O +
are O +
substantially O +
more O +
toxic O +
than O +
either O +
drug O +
alone O -
. O -

Their O +
combined O +
cardiac B-Disease +
toxicity L-Disease +
may O +
be O +
due O +
to O +
independent O +
effects O +
of O +
each O +
drug O -
; O +
however O -
, O +
they O +
may O +
also O +
be O +
due O +
to O +
cocaethylene O +
( O -
CE O -
) O -
, O +
a O +
cocaine O +
metabolite O +
formed O +
only O +
in O +
the O +
presence O +
of O +
ethanol O -
. O -

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
delineate O +
the O +
role O +
of O +
CE O +
in O +
the O +
combined O +
cardiotoxicity U-Disease +
of O +
cocaine O +
and O +
ethanol O +
in O +
a O +
model O +
simulating O +
their O +
abuse O -
. O -

METHODS O -
: O +
Twenty O -
- O -
three O +
dogs O +
were O +
randomized O +
to O +
receive O +
either O +
1 O -
) O +
three O +
intravenous O +
( O -
IV O -
) O +
boluses O +
of O +
cocaine O +
7.5 O +
mg O -
/ O -
kg O +
with O +
ethanol O +
( O -
1 O +
g O -
/ O -
kg O -
) O +
as O +
an O +
IV O +
infusion O +
( O -
C+E O -
, O +
n O +
= O +
8) O -
, O +
2 O -
) O +
three O +
cocaine O +
boluses O +
only O +
( O -
C O -
, O +
n O +
= O +
6 O -
) O -
, O +
3 O -
) O +
ethanol O +
infusion O +
only O +
( O -
E O -
, O +
n O +
= O +
5 O -
) O -
, O +
or O +
4 O -
) O +
placebo O +
boluses O +
and O +
infusion O +
( O -
n O +
= O +
4 O -
) O -
. O -

Hemodynamic O +
measurements O -
, O +
electrocardiograms O -
, O +
and O +
serum O +
drug O +
concentrations O +
were O +
obtained O +
at O +
baseline O -
, O +
and O +
then O +
at O +
fixed O +
time O +
intervals O +
after O +
each O +
drug O +
was O +
administered O -
. O -

RESULTS O -
: O +
Two O +
of O +
eight O +
dogs O +
in O +
the O +
C+E O +
group O +
experienced O +
cardiovascular B-Disease +
collapse L-Disease -
. O -

The O +
most O +
dramatic O +
hemodynamic O +
changes O +
occurred O +
after O +
each O +
cocaine O +
bolus O +
in O +
the O +
C+E O +
and O +
C O +
only O +
groups O -
; O +
however O -
, O +
persistent O +
hemodynamic O +
changes O +
occurred O +
in O +
the O +
C+E O +
group O -
. O -

Peak O +
CE O +
levels O +
were O +
associated O +
with O +
a O +
45 O -
% O +
( O -
SD O +
+ O -
/- O -

22 O -
% O -
, O +
95 O -
% O +
CI O +
= O +
22 O -
% O +
to O +
69 O -
% O -
) O +
decrease B-Disease +
in I-Disease +
cardiac I-Disease +
output L-Disease +
( O -
p O +
< O +
0.05 O -
) O -
, O +
a O +
56 O -
% O +
( O -
SD O +
+ O -
/- O -

23 O -
% O -
, O +
95 O -
% O +
CI O +
= O +
32 O -
% O +
to O +
80 O -
% O -
) O +
decrease O +
in O +
dP O -
/ O -
dt O -
( O -
max O -
) O +
( O -
p O +
< O -
.006 O -
) O -
, O +
and O +
a O +
23 O -
% O +
( O -
SD O +
+ O -
/- O -

15 O -
% O -
, O +
95 O -
% O +
CI O +
= O +
7 O -
% O +
to O +
49 O -
% O -
) O +
decrease O +
in O +
SVO O -
( O -
2 O -
) O +
( O -
p O +
< O +
0.025 O -
) O -
. O -

Ventricular B-Disease +
arrhythmias L-Disease +
were O +
primarily O +
observed O +
in O +
the O +
C+E O +
group O -
, O +
in O +
which O +
four O +
of O +
eight O +
dogs O +
experienced O +
ventricular B-Disease +
tachycardia L-Disease -
. O -

CONCLUSIONS O -
: O +
Cocaine O +
and O +
ethanol O +
in O +
combination O +
were O +
more O +
toxic O +
than O +
either O +
substance O +
alone O -
. O -

Co O -
- O -
administration O +
resulted O +
in O +
prolonged O +
cardiac B-Disease +
toxicity L-Disease +
and O +
was O +
dysrhythmogenic O -
. O -

Peak O +
serum O +
cocaethylene O +
concentrations O +
were O +
associated O +
with O +
prolonged O +
myocardial B-Disease +
depression L-Disease -
. O -

Worsening O +
of O +
Parkinsonism U-Disease +
after O +
the O +
use O +
of O +
veralipride O +
for O +
treatment O +
of O +
menopause O -
: O +
case O +
report O -
. O -

We O +
describe O +
a O +
female O +
patient O +
with O +
stable O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
who O +
has O +
shown O +
a O +
marked O +
worsening O +
of O +
her O +
motor O +
functions O +
following O +
therapy O +
of O +
menopause O +
related O +
symptoms O +
with O +
veralipride O -
, O +
as O +
well O +
as O +
the O +
improvement O +
of O +
her O +
symptoms O +
back O +
to O +
baseline O +
after O +
discontinuation O +
of O +
the O +
drug O -
. O -

We O +
emphasize O +
the O +
anti O -
- O -
dopaminergic O +
effect O +
of O +
veralipride O -
. O -

Viracept O +
and O +
irregular B-Disease +
heartbeat L-Disease +
warning O -
. O -

A O +
group O +
of O +
doctors O +
in O +
Boston O +
warn O +
that O +
the O +
protease O +
inhibitor O +
Viracept O +
may O +
cause O +
an O +
irregular B-Disease +
heart I-Disease +
beat L-Disease -
, O +
known O +
as O +
bradycardia U-Disease -
, O +
in O +
people O +
with O +
HIV O -
. O -

Bradycardia U-Disease +
occurred O +
in O +
a O +
45-year O -
- O -
old O +
male O +
patient O +
who O +
was O +
Viracept O +
in O +
combination O +
with O +
other O +
anti O -
- O -
HIV O +
drugs O -
. O -

The O +
symptoms O +
ceased O +
after O +
switching O +
to O +
another O +
drug O +
combination O -
. O -

Frequency O +
of O +
appearance O +
of O +
myeloperoxidase O -
- O -
antineutrophil O +
cytoplasmic O +
antibody O +
( O -
MPO O -
- O -
ANCA O -
) O +
in O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
patients O +
treated O +
with O +
propylthiouracil O +
and O +
the O +
relationship O +
between O +
MPO O -
- O -
ANCA O +
and O +
clinical O +
manifestations O -
. O -

OBJECTIVE O -
: O +
Myeloperoxidase O +
antineutrophil O +
cytoplasmic O +
antibody O +
( O -
MPO O -
- O -
ANCA O -
) O -
-positive O +
vasculitis U-Disease +
has O +
been O +
reported O +
in O +
patients O +
with O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
who O +
were O +
treated O +
with O +
propylthiouracil O +
( O -
PTU O -
) O -
. O -

The O +
appearance O +
of O +
MPO O -
- O -
ANCA O +
in O +
these O +
cases O +
was O +
suspected O +
of O +
being O +
related O +
to O +
PTU O +
because O +
the O +
titres O +
of O +
MPO O -
- O -
ANCA O +
decreased O +
when O +
PTU O +
was O +
stopped O -
. O -

Nevertheless O -
, O +
there O +
have O +
been O +
no O +
studies O +
on O +
the O +
temporal O +
relationship O +
between O +
the O +
appearance O +
of O +
MPO O -
- O -
ANCA O +
and O +
vasculitis U-Disease +
during O +
PTU O +
therapy O -
, O +
or O +
on O +
the O +
incidence O +
of O +
MPO O -
- O -
ANCA O +
in O +
untreated O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
patients O -
. O -

Therefore O -
, O +
we O +
sought O +
to O +
address O +
these O +
parameters O +
in O +
patients O +
with O +
Graves B-Disease -
' I-Disease +
disease L-Disease -
. O -

PATIENTS O -
: O +
We O +
investigated O +
102 O +
untreated O +
patients O +
with O +
hyperthyroidism U-Disease +
due O +
to O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
for O +
the O +
presence O +
of O +
MPO O -
- O -
ANCA O -
, O +
and O +
for O +
the O +
development O +
vasculitis U-Disease +
after O +
starting O +
PTU O +
therapy O -
. O -

Twenty O -
- O -
nine O +
of O +
them O +
were O +
later O +
excluded O +
because O +
of O +
adverse O +
effects O +
of O +
PTU O +
or O +
because O +
the O +
observation O +
period O +
was O +
less O +
than O +
3 O +
months O -
. O -

The O +
remaining O +
73 O +
patients O +
( O -
55 O +
women O +
and O +
18 O +
men O -
) O -
, O +
all O +
of O +
whom O +
were O +
examined O +
for O +
more O +
than O +
3 O +
months O -
, O +
were O +
adopted O +
as O +
the O +
subjects O +
of O +
the O +
investigation O -
. O -

The O +
median O +
observation O +
period O +
was O +
23.6 O +
months O +
( O -
range O -
: O +
3 O -
- O -
37 O +
months O -
) O -
. O -

MEASUREMENTS O -
: O +
MPO O -
- O -
ANCA O +
was O +
measured O +
at O +
intervals O +
of O +
2 O -
- O -
6 O +
months O -
. O -

RESULTS O -
: O +
Before O +
treatment O -
, O +
the O +
MPO O -
- O -
ANCA O +
titres O +
of O +
all O +
102 O +
untreated O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
patients O +
were O +
within O +
the O +
reference O +
range O +
( O -
below O +
10 O +
U O -
/ O -
ml O -
) O -
. O -

Three O +
( O -
4.1 O -
% O -
) O +
of O +
the O +
73 O +
patients O +
were O +
positive O +
for O +
MPO O -
- O -
ANCA O +
at O +
13 O -
, O +
16 O +
and O +
17 O +
months O -
, O +
respectively O -
, O +
after O +
the O +
start O +
of O +
PTU O +
therapy O -
. O -

In O +
two O +
of O +
them O -
, O +
the O +
MPO O -
- O -
ANCA O +
titres O +
transiently O +
increased O +
to O +
12.8 O +
and O +
15.0 O +
U O -
/ O -
ml O -
, O +
respectively O -
, O +
despite O +
continued O +
PTU O +
therapy O -
, O +
but O +
no O +
vasculitic B-Disease +
disorders L-Disease +
developed O -
. O -

In O +
the O +
third O +
patient O -
, O +
the O +
MPO O -
- O -
ANCA O +
titre O +
increased O +
to O +
204 O +
U O -
/ O -
ml O +
and O +
she O +
developed O +
a O +
higher O +
fever U-Disease -
, O +
oral B-Disease +
ulcers L-Disease +
and O +
polyarthralgia U-Disease -
, O +
but O +
the O +
symptoms O +
resolved O +
2 O +
weeks O +
after O +
stopping O +
PTU O +
therapy O -
, O +
and O +
the O +
MPO O -
- O -
ANCA O +
titre O +
decreased O +
to O +
20.7 O +
U O -
/ O -
ml O +
by O +
4 O +
months O +
after O +
discontinuing O +
PTU O -
. O -

CONCLUSIONS O -
: O +
PTU O +
therapy O +
may O +
be O +
related O +
to O +
the O +
appearance O +
of O +
MPO O -
- O -
ANCA O -
, O +
but O +
MPO O -
- O -
ANCA O +
does O +
not O +
appear O +
to O +
be O +
closely O +
related O +
to O +
vasculitis U-Disease -
. O -

Prevalence O +
of O +
heart B-Disease +
disease L-Disease +
in O +
asymptomatic O +
chronic O +
cocaine O +
users O -
. O -

To O +
determine O +
the O +
prevalence O +
of O +
heart B-Disease +
disease L-Disease +
in O +
outpatient O +
young O +
asymptomatic O +
chronic O +
cocaine O +
users O -
, O +
35 O +
cocaine O +
users O +
and O +
32 O +
age O -
- O -
matched O +
controls O +
underwent O +
resting O +
and O +
exercise O +
electrocardiography O +
( O -
ECG O -
) O +
and O +
Doppler O +
echocardiography O -
. O -

Findings O +
consistent O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
were O +
detected O +
in O +
12 O +
( O -
34 O -
% O -
) O +
patients O +
and O +
3 O +
( O -
9 O -
% O -
) O +
controls O +
( O -
p O +
= O +
0.01 O -
) O -
. O -

Decreased O +
left O +
ventricular O +
systolic O +
function O +
was O +
demonstrated O +
in O +
5 O +
( O -
14 O -
% O -
) O +
patients O -
, O +
but O +
in O +
none O +
of O +
the O +
controls O +
( O -
p O +
= O +
0.055 O -
) O -
. O -

Finally O -
, O +
resting O +
and O +
peak O +
exercise O +
abnormal B-Disease +
left I-Disease +
ventricular I-Disease +
filling L-Disease +
was O +
detected O +
in O +
38 O +
and O +
35 O -
% O +
of O +
patients O +
as O +
compared O +
to O +
19 O +
and O +
9 O -
% O +
of O +
controls O -
, O +
respectively O +
( O -
p O +
= O +
0.11 O +
and O +
0.02 O -
, O +
respectively O -
) O -
. O -

We O +
conclude O +
that O +
coronary B-Disease +
artery I-Disease +
or I-Disease +
myocardial I-Disease +
disease L-Disease +
is O +
common O +
( O -
38 O -
% O -
) O +
in O +
young O +
asymptomatic O +
chronic O +
cocaine O +
users O -
. O -

Therefore O -
, O +
screening O +
ECG O +
and O +
echocardiography O +
may O +
be O +
warranted O +
in O +
these O +
patients O -
. O -

Cardioprotective O +
effects O +
of O +
Picrorrhiza O +
kurroa O +
against O +
isoproterenol O -
- O -
induced O +
myocardial O +
stress O +
in O +
rats O -
. O -

The O +
cardioprotective O +
effect O +
of O +
the O +
ethanol O +
extract O +
of O +
Picrorrhiza O +
kurroa O +
rhizomes O +
and O +
roots O +
( O -
PK O -
) O +
on O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction L-Disease +
in O +
rats O +
with O +
respect O +
to O +
lipid O +
metabolism O +
in O +
serum O +
and O +
heart O +
tissue O +
has O +
been O +
investigated O -
. O -

Oral O +
pre O -
- O -
treatment O +
with O +
PK O +
( O -
80 O +
mg O +
kg O -
( O -
-1 O -
) O +
day O -
( O -
-1 O -
) O +
for O +
15 O +
days O -
) O +
significantly O +
prevented O +
the O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction L-Disease +
and O +
maintained O +
the O +
rats O +
at O +
near O +
normal O +
status O -
. O -

Phase O +
2 O +
early O +
afterdepolarization O +
as O +
a O +
trigger O +
of O +
polymorphic O +
ventricular B-Disease +
tachycardia L-Disease +
in O +
acquired O +
long B-Disease -
- I-Disease -
QT I-Disease +
syndrome L-Disease +
: O +
direct O +
evidence O +
from O +
intracellular O +
recordings O +
in O +
the O +
intact O +
left O +
ventricular O +
wall O -
. O -

BACKGROUND O -
: O +
This O +
study O +
examined O +
the O +
role O +
of O +
phase O +
2 O +
early O +
afterdepolarization O +
( O -
EAD O -
) O +
in O +
producing O +
a O +
trigger O +
to O +
initiate O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
( O -
TdP U-Disease -
) O +
with O +
QT B-Disease +
prolongation L-Disease +
induced O +
by O +
dl O -
- O -
sotalol O +
and O +
azimilide O -
. O -

The O +
contribution O +
of O +
transmural O +
dispersion O +
of O +
repolarization O +
( O -
TDR O -
) O +
to O +
transmural O +
propagation O +
of O +
EAD O +
and O +
the O +
maintenance O +
of O +
TdP U-Disease +
was O +
also O +
evaluated O -
. O -

METHODS O +
AND O +
RESULTS O -
: O +
Transmembrane O +
action O +
potentials O +
from O +
epicardium O -
, O +
midmyocardium O -
, O +
and O +
endocardium O +
were O +
recorded O +
simultaneously O -
, O +
together O +
with O +
a O +
transmural O +
ECG O -
, O +
in O +
arterially O +
perfused O +
canine O +
and O +
rabbit O +
left O +
ventricular O +
preparations O -
. O -

dl O -
- O -
Sotalol O +
preferentially O +
prolonged O +
action O +
potential O +
duration O +
( O -
APD O -
) O +
in O +
M O +
cells O +
dose O -
- O -
dependently O +
( O -
1 O +
to O +
100 O +
micromol O -
/ O -
L O -
) O -
, O +
leading O +
to O +
QT B-Disease +
prolongation L-Disease +
and O +
an O +
increase O +
in O +
TDR O -
. O -

Azimilide O -
, O +
however O -
, O +
significantly O +
prolonged O +
APD O +
and O +
QT O +
interval O +
at O +
concentrations O +
from O +
0.1 O +
to O +
10 O +
micromol O -
/ O -
L O +
but O +
shortened O +
them O +
at O +
30 O +
micromol O -
/ O -
L. O +
Unlike O +
dl O -
- O -
sotalol O -
, O +
azimilide O +
( O -
> O -
3 O +
micromol O -
/ O -
L O -
) O +
increased O +
epicardial O +
APD O +
markedly O -
, O +
causing O +
a O +
diminished O +
TDR O -
. O -

Although O +
both O +
dl O -
- O -
sotalol O +
and O +
azimilide O +
rarely O +
induced O +
EADs O +
in O +
canine O +
left O +
ventricles O -
, O +
they O +
produced O +
frequent O +
EADs O +
in O +
rabbits O -
, O +
in O +
which O +
more O +
pronounced O +
QT B-Disease +
prolongation L-Disease +
was O +
seen O -
. O -

An O +
increase O +
in O +
TDR O +
by O +
dl O -
- O -
sotalol O +
facilitated O +
transmural O +
propagation O +
of O +
EADs O +
that O +
initiated O +
multiple O +
episodes O +
of O +
spontaneous O +
TdP U-Disease +
in O +
3 O +
of O +
6 O +
rabbit O +
left O +
ventricles O -
. O -

Of O +
note O -
, O +
although O +
azimilide O +
( O -
3 O +
to O +
10 O +
micromol O -
/ O -
L O -
) O +
increased O +
APD O +
more O +
than O +
dl O -
- O -
sotalol O -
, O +
its O +
EADs O +
often O +
failed O +
to O +
propagate O +
transmurally O -
, O +
probably O +
because O +
of O +
a O +
diminished O +
TDR O -
. O -

CONCLUSIONS O -
: O +
This O +
study O +
provides O +
the O +
first O +
direct O +
evidence O +
from O +
intracellular O +
action O +
potential O +
recordings O +
that O +
phase O +
2 O +
EAD O +
can O +
be O +
generated O +
from O +
intact O +
ventricular O +
wall O +
and O +
produce O +
a O +
trigger O +
to O +
initiate O +
the O +
onset O +
of O +
TdP U-Disease +
under O +
QT B-Disease +
prolongation L-Disease -
. O -

A O +
pilot O +
study O +
to O +
assess O +
the O +
safety O +
of O +
dobutamine O +
stress O +
echocardiography O +
in O +
the O +
emergency O +
department O +
evaluation O +
of O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
. O -

STUDY O +
OBJECTIVE O -
: O +
Chest B-Disease +
pain L-Disease +
in O +
the O +
setting O +
of O +
cocaine O +
use O +
poses O +
a O +
diagnostic O +
dilemma O -
. O -

Dobutamine O +
stress O +
echocardiography O +
( O -
DSE O -
) O +
is O +
a O +
widely O +
available O +
and O +
sensitive O +
test O +
for O +
evaluating O +
cardiac O +
ischemia U-Disease -
. O -

Because O +
of O +
the O +
theoretical O +
concern O +
regarding O +
administration O +
of O +
dobutamine O +
in O +
the O +
setting O +
of O +
cocaine O +
use O -
, O +
we O +
conducted O +
a O +
pilot O +
study O +
to O +
assess O +
the O +
safety O +
of O +
DSE O +
in O +
emergency O +
department O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
. O -

METHODS O -
: O +
A O +
prospective O +
case O +
series O +
was O +
conducted O +
in O +
the O +
intensive O +
diagnostic O +
and O +
treatment O +
unit O +
in O +
the O +
ED O +
of O +
an O +
urban O +
tertiary O -
- O -
care O +
teaching O +
hospital O -
. O -

Patients O +
were O +
eligible O +
for O +
DSE O +
if O +
they O +
had O +
used O +
cocaine O +
within O +
24 O +
hours O +
preceding O +
the O +
onset O +
of O +
chest B-Disease +
pain L-Disease +
and O +
had O +
a O +
normal O +
ECG O +
and O +
tropinin O +
I O +
level O -
. O -

Patients O +
exhibiting O +
signs O +
of O +
continuing O +
cocaine O +
toxicity U-Disease +
were O +
excluded O +
from O +
the O +
study O -
. O -

All O +
patients O +
were O +
admitted O +
to O +
the O +
hospital O +
for O +
serial O +
testing O +
after O +
the O +
DSE O +
testing O +
in O +
the O +
intensive O +
diagnostic O +
and O +
treatment O +
unit O -
. O -

RESULTS O -
: O +
Twenty O -
- O -
four O +
patients O +
were O +
enrolled O -
. O -

Two O +
patients O +
had O +
inadequate O +
resting O +
images O -
, O +
one O +
DSE O +
was O +
terminated O +
because O +
of O +
inferior O +
hypokinesis U-Disease -
, O +
another O +
DSE O +
was O +
terminated O +
because O +
of O +
a O +
rate O -
- O -
related O +
atrial O +
conduction O +
deficit O -
, O +
and O +
1 O +
patient O +
did O +
not O +
reach O +
the O +
target O +
heart O +
rate O -
. O -

Thus O -
, O +
19 O +
patients O +
completed O +
a O +
DSE O +
and O +
reached O +
their O +
target O +
heart O +
rates O -
. O -

None O +
of O +
the O +
patients O +
experienced O +
signs O +
of O +
exaggerated O +
adrenergic O +
response O -
, O +
which O +
was O +
defined O +
as O +
a O +
systolic O +
blood O +
pressure O +
of O +
greater O +
than O +
200 O +
mm O +
Hg O +
or O +
the O +
occurrence O +
of O +
tachydysrhythmias U-Disease +
( O -
excluding O +
sinus B-Disease +
tachycardia L-Disease -
) O -
. O -

Further O +
suggesting O +
lack O +
of O +
exaggerated O +
adrenergic O +
response O -
, O +
13 O +
( O -
65 O -
% O -
) O +
of O +
20 O +
patients O +
required O +
supplemental O +
atropine O +
to O +
reach O +
their O +
target O +
heart O +
rates O -
. O -

CONCLUSION O -
: O +
No O +
exaggerated O +
adrenergic O +
response O +
was O +
detected O +
when O +
dobutamine O +
was O +
administered O +
to O +
patients O +
with O +
cocaine O -
- O -
related O +
chest B-Disease +
pain L-Disease -
. O -

Prenatal O +
cocaine O +
exposure O +
and O +
cranial O +
sonographic O +
findings O +
in O +
preterm B-Disease +
infants L-Disease -
. O -

PURPOSE O -
: O +
Prenatal O +
cocaine O +
exposure O +
has O +
been O +
linked O +
with O +
subependymal O +
hemorrhage U-Disease +
and O +
the O +
formation O +
of O +
cysts U-Disease +
that O +
are O +
detectable O +
on O +
cranial O +
sonography O +
in O +
neonates O +
born O +
at O +
term O -
. O -

We O +
sought O +
to O +
determine O +
if O +
prenatal O +
cocaine O +
exposure O +
increases O +
the O +
incidence O +
of O +
subependymal B-Disease +
cysts L-Disease +
in O +
preterm B-Disease +
infants L-Disease -
. O -

METHODS O -
: O +
We O +
retrospectively O +
reviewed O +
the O +
medical O +
records O +
and O +
cranial O +
sonograms O +
obtained O +
during O +
a O +
1-year O +
period O +
on O +
122 O +
premature B-Disease +
( I-Disease -
< I-Disease +
36 I-Disease +
weeks I-Disease +
of I-Disease +
gestation I-Disease -
) I-Disease +
infants L-Disease -
. O -

Infants O +
were O +
categorized O +
into O +
1 O +
of O +
2 O +
groups O -
: O +
those O +
exposed O +
to O +
cocaine O +
and O +
those O +
not O +
exposed O +
to O +
cocaine O -
. O -

Infants O +
were O +
assigned O +
to O +
the O +
cocaine O -
- O -
exposed O +
group O +
if O +
there O +
was O +
a O +
maternal O +
history O +
of O +
cocaine B-Disease +
abuse L-Disease +
during O +
pregnancy O +
or O +
if O +
maternal O +
or O +
neonatal O +
urine O +
toxicology O +
results O +
were O +
positive O +
at O +
the O +
time O +
of O +
delivery O -
. O -

RESULTS O -
: O +
Five O +
of O +
the O +
122 O +
infants O +
were O +
excluded O +
from O +
the O +
study O +
because O +
of O +
insufficient O +
medical O +
and O +
drug O +
histories O -
. O -

The O +
incidence O +
of O +
subependymal B-Disease +
cysts L-Disease +
in O +
the O +
117 O +
remaining O +
infants O +
was O +
14 O -
% O +
( O -
16 O +
of O +
117 O -
) O -
. O -

The O +
incidence O +
of O +
subependymal B-Disease +
cysts L-Disease +
in O +
infants O +
exposed O +
to O +
cocaine O +
prenatally O +
was O +
44 O -
% O +
( O -
8 O +
of O +
18 O -
) O +
compared O +
with O +
8 O -
% O +
( O -
8 O +
of O +
99 O -
) O +
in O +
the O +
unexposed O +
group O +
( O -
p O +
< O +
0.01 O -
) O -
. O -

CONCLUSIONS O -
: O +
We O +
found O +
an O +
increased O +
incidence O +
of O +
subependymal B-Disease +
cyst L-Disease +
formation O +
in O +
preterm B-Disease +
infants L-Disease +
who O +
were O +
exposed O +
to O +
cocaine O +
prenatally O -
. O -

This O +
result O +
is O +
consistent O +
with O +
results O +
of O +
similar O +
studies O +
in O +
term O +
infants O -
. O -

Thalidomide O +
neuropathy U-Disease +
in O +
patients O +
treated O +
for O +
metastatic O +
prostate B-Disease +
cancer L-Disease -
. O -

We O +
prospectively O +
evaluated O +
thalidomide O -
- O -
induced O +
neuropathy U-Disease +
using O +
electrodiagnostic O +
studies O -
. O -

Sixty O -
- O -
seven O +
men O +
with O +
metastatic O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer L-Disease +
in O +
an O +
open O -
- O -
label O +
trial O +
of O +
oral O +
thalidomide O +
underwent O +
neurologic O +
examinations O +
and O +
nerve O +
conduction O +
studies O +
( O -
NCS O -
) O +
prior O +
to O +
and O +
at O +
3-month O +
intervals O +
during O +
treatment O -
. O -

NCS O +
included O +
recording O +
of O +
sensory O +
nerve O +
action O +
potentials O +
( O -
SNAPs O -
) O +
from O +
median O -
, O +
radial O -
, O +
ulnar O -
, O +
and O +
sural O +
nerves O -
. O -

SNAP O +
amplitudes O +
for O +
each O +
nerve O +
were O +
expressed O +
as O +
the O +
percentage O +
of O +
its O +
baseline O -
, O +
and O +
the O +
mean O +
of O +
the O +
four O +
was O +
termed O +
the O +
SNAP O +
index O -
. O -

A O +
40 O -
% O +
decline O +
in O +
the O +
SNAP O +
index O +
was O +
considered O +
clinically O +
significant O -
. O -

Thalidomide O +
was O +
discontinued O +
in O +
55 O +
patients O +
for O +
lack O +
of O +
therapeutic O +
response O -
. O -

Of O +
67 O +
patients O +
initially O +
enrolled O -
, O +
24 O +
remained O +
on O +
thalidomide O +
for O +
3 O +
months O -
, O +
8 O +
remained O +
at O +
6 O +
months O -
, O +
and O +
3 O +
remained O +
at O +
9 O +
months O -
. O -

Six O +
patients O +
developed O +
neuropathy U-Disease -
. O -

Clinical O +
symptoms O +
and O +
a O +
decline O +
in O +
the O +
SNAP O +
index O +
occurred O +
concurrently O -
. O -

Older O +
age O +
and O +
cumulative O +
dose O +
were O +
possible O +
contributing O +
factors O -
. O -

Neuropathy U-Disease +
may O +
thus O +
be O +
a O +
common O +
complication O +
of O +
thalidomide O +
in O +
older O +
patients O -
. O -

The O +
SNAP O +
index O +
can O +
be O +
used O +
to O +
monitor O +
peripheral B-Disease +
neuropathy L-Disease -
, O +
but O +
not O +
for O +
early O +
detection O -
. O -

Overexpression O +
of O +
copper O -
/ O -
zinc O -
- O -
superoxide O +
dismutase O +
protects O +
from O +
kanamycin O -
- O -
induced O +
hearing B-Disease +
loss L-Disease -
. O -

The O +
participation O +
of O +
reactive O +
oxygen O +
species O +
in O +
aminoglycoside O -
- O -
induced O +
ototoxicity U-Disease +
has O +
been O +
deduced O +
from O +
observations O +
that O +
aminoglycoside O -
- O -
iron O +
complexes O +
catalyze O +
the O +
formation O +
of O +
superoxide O +
radicals O +
in O +
vitro O +
and O +
that O +
antioxidants O +
attenuate O +
ototoxicity U-Disease +
in O +
vivo O -
. O -

We O +
therefore O +
hypothesized O +
that O +
overexpression O +
of O +
Cu O -
/ O -
Zn O -
- O -
superoxide O +
dismutase O +
( O -
h O -
- O -
SOD1 O -
) O +
should O +
protect O +
transgenic O +
mice O +
from O +
ototoxicity U-Disease -
. O -

Immunocytochemistry O +
confirmed O +
expression O +
of O +
h O -
- O -
SOD1 O +
in O +
inner O +
ear O +
tissues O +
of O +
transgenic O +
C57BL O -
/ O -
6-TgN O -
[ O -
SOD1 O -
] O -
3Cje O +
mice O -
. O -

Transgenic O +
and O +
nontransgenic O +
littermates O +
received O +
kanamycin O +
( O -
400 O +
mg O -
/ O -
kg O +
body O +
weight O -
/ O -
day O -
) O +
for O +
10 O +
days O +
beginning O +
on O +
day O +
10 O +
after O +
birth O -
. O -

Auditory O +
thresholds O +
were O +
tested O +
by O +
evoked O +
auditory O +
brain O +
stem O +
responses O +
at O +
1 O +
month O +
after O +
birth O -
. O -

In O +
nontransgenic O +
animals O -
, O +
the O +
threshold O +
in O +
the O +
kanamycin O -
- O -
treated O +
group O +
was O +
45 O -
- O -
50 O +
dB O +
higher O +
than O +
in O +
saline O -
- O -
injected O +
controls O -
. O -

In O +
the O +
transgenic O +
group O -
, O +
kanamycin O +
increased O +
the O +
threshold O +
by O +
only O +
15 O +
dB O +
over O +
the O +
respective O +
controls O -
. O -

The O +
effects O +
were O +
similar O +
at O +
12 O +
and O +
24 O +
kHz O -
. O -

The O +
protection O +
by O +
overexpression O +
of O +
superoxide O +
dismutase O +
supports O +
the O +
hypothesis O +
that O +
oxidant O +
stress O +
plays O +
a O +
significant O +
role O +
in O +
aminoglycoside O -
- O -
induced O +
ototoxicity U-Disease -
. O -

The O +
results O +
also O +
suggest O +
transgenic O +
animals O +
as O +
suitable O +
models O +
to O +
investigate O +
the O +
underlying O +
mechanisms O +
and O +
possible O +
strategies O +
for O +
prevention O -
. O -

Fatty B-Disease +
liver L-Disease +
induced O +
by O +
tetracycline O +
in O +
the O +
rat O -
. O -

Dose O -
- O -
response O +
relationships O +
and O +
effect O +
of O +
sex O -
. O -

Dose O -
- O -
response O +
relationships O -
, O +
biochemical O +
mechanisms O -
, O +
and O +
sex O +
differences O +
in O +
the O +
experimental O +
fatty B-Disease +
liver L-Disease +
induced O +
by O +
tetracycline O +
were O +
studied O +
in O +
the O +
intact O +
rat O +
and O +
with O +
the O +
isolated O +
perfused O +
rat O +
liver O +
in O +
vitro O -
. O -

In O +
the O +
intact O +
male O +
and O +
female O +
rat O -
, O +
no O +
direct O +
relationship O +
was O +
observed O +
between O +
dose O +
of O +
tetracycline O +
and O +
hepatic O +
accumulation O +
of O +
triglyceride O -
. O -

With O +
provision O +
of O +
adequate O +
oleic O +
acid O +
as O +
a O +
substrate O +
for O +
the O +
isolated O +
perfused O +
liver O -
, O +
a O +
direct O +
relationship O +
was O +
observed O +
between O +
dose O +
of O +
tetracycline O +
and O +
both O +
accumulation O +
of O +
triglyceride O +
in O +
the O +
liver O +
and O +
depression U-Disease +
of O +
output O +
of O +
triglyceride O +
by O +
livers O +
from O +
male O +
and O +
female O +
rats O -
. O -

Marked O +
differences O +
were O +
observed O +
between O +
female O +
and O +
male O +
rats O +
with O +
regard O +
to O +
base O +
line O +
( O -
control O -
) O +
hepatic O +
concentration O +
of O +
triglyceride O +
and O +
output O +
of O +
triglyceride O -
. O -

Accumulation O +
of O +
hepatic O +
triglyceride O -
, O +
as O +
a O +
per O +
cent O +
of O +
control O +
values O -
, O +
in O +
response O +
to O +
graded O +
doses O +
of O +
tetracycline O -
, O +
did O +
not O +
differ O +
significantly O +
between O +
male O -
, O +
female O +
and O +
pregnant O +
rat O +
livers O -
. O -

However O -
, O +
livers O +
from O +
female O -
, O +
and O +
especially O +
pregnant O +
female O +
rats O -
, O +
were O +
strikingly O +
resistant O +
to O +
the O +
effects O +
of O +
tetracycline O +
on O +
depression U-Disease +
of O +
output O +
of O +
triglyceride O +
under O +
these O +
experimental O +
conditions O -
. O -

These O +
differences O +
between O +
the O +
sexes O +
could O +
not O +
be O +
related O +
to O +
altered O +
disposition O +
of O +
tetracycline O +
or O +
altered O +
uptake O +
of O +
oleic O +
acid O -
. O -

Depressed O +
hepatic O +
secretion O +
of O +
triglyceride O +
accounted O +
only O +
for O +
30 O +
to O +
50 O -
% O +
of O +
accumulated O +
hepatic O +
triglyceride O -
, O +
indicating O +
that O +
additional O +
mechanisms O +
must O +
be O +
involved O +
in O +
the O +
production O +
of O +
the O +
triglyceride O -
- O -
rich O +
fatty B-Disease +
liver L-Disease +
in O +
response O +
to O +
tetracycline O -
. O -

Prednisone O +
induces O +
anxiety U-Disease +
and O +
glial O +
cerebral O +
changes O +
in O +
rats O -
. O -

OBJECTIVE O -
: O +
To O +
assess O +
whether O +
prednisone O +
( O -
PDN O -
) O +
produces O +
anxiety U-Disease +
and/or O +
cerebral O +
glial O +
changes O +
in O +
rats O -
. O -

METHODS O -
: O +
Male O +
Wistar O +
rats O +
were O +
studied O +
and O +
3 O +
groups O +
were O +
formed O +
( O -
8 O +
rats O +
per O +
group O -
) O -
. O -

The O +
moderate O -
- O -
dose O +
group O +
received O +
5 O +
mg O -
/ O -
kg O -
/ O -
day O +
PDN O +
released O +
from O +
a O +
subcutaneous O +
implant O -
. O -

In O +
the O +
high O -
- O -
dose O +
group O -
, O +
implants O +
containing O +
PDN O +
equivalent O +
to O +
60 O +
mg O -
/ O -
kg O -
/ O -
day O +
were O +
applied O -
. O -

In O +
the O +
control O +
group O +
implants O +
contained O +
no O +
PDN O -
. O -

Anxiety U-Disease +
was O +
assessed O +
using O +
an O +
open O +
field O +
and O +
elevated O +
plus O -
- O -
maze O +
devices O -
. O -

The O +
number O +
of O +
cells O +
and O +
cytoplasmic O +
transformation O +
of O +
astrocytes O +
and O +
microglia O +
cells O +
were O +
assessed O +
by O +
immunohistochemical O +
analyses O -
. O -

RESULTS O -
: O +
Anxiety U-Disease +
was O +
documented O +
in O +
both O +
groups O +
of O +
PDN O +
treated O +
rats O +
compared O +
with O +
controls O -
. O -

The O +
magnitude O +
of O +
transformation O +
of O +
the O +
microglia O +
assessed O +
by O +
the O +
number O +
of O +
intersections O +
was O +
significantly O +
higher O +
in O +
the O +
PDN O +
groups O +
than O +
in O +
controls O +
in O +
the O +
prefrontal O +
cortex O +
( O -
moderate O -
- O -
dose O -
, O +
24.1 O -
; O +
high O -
- O -
dose O -
, O +
23.6 O -
; O +
controls O +
18.7 O -
; O +
p O +
< O +
0.01 O -
) O +
and O +
striatum O +
( O -
moderate O -
- O -
dose O +
25.6 O -
; O +
high O -
- O -
dose O +
26.3 O -
; O +
controls O +
18.9 O -
; O +
p O +
< O +
0.01 O -
) O -
, O +
but O +
not O +
in O +
hippocampus O -
. O -

The O +
number O +
of O +
stained O +
microglia O +
cells O +
was O +
significantly O +
higher O +
in O +
the O +
PDN O +
treated O +
groups O +
in O +
the O +
prefrontal O +
cortex O +
than O +
in O +
controls O +
( O -
moderate O -
- O -
dose O -
, O +
29.1 O -
; O +
high O -
- O -
dose O -
, O +
28.4 O -
; O +
control O -
, O +
17.7 O +
cells O +
per O +
field O -
; O +
p O +
< O +
0.01 O -
) O -
. O -

Stained O +
microglia O +
cells O +
were O +
significantly O +
more O +
numerous O +
striatum O +
and O +
hippocampus O +
in O +
the O +
high O -
- O -
dose O +
group O +
compared O +
to O +
controls O -
. O -

CONCLUSION O -
: O +
Subacute O +
exposure O +
to O +
PDN O +
induced O +
anxiety U-Disease +
and O +
reactivity O +
of O +
microglia O -
. O -

The O +
relevance O +
of O +
these O +
features O +
for O +
patients O +
using O +
PDN O +
remains O +
to O +
be O +
elucidated O -
. O -

Phase O +
II O +
study O +
of O +
carboplatin O +
and O +
liposomal O +
doxorubicin O +
in O +
patients O +
with O +
recurrent O +
squamous B-Disease +
cell I-Disease +
carcinoma L-Disease +
of B-Disease +
the I-Disease +
cervix L-Disease -
. O -

BACKGROUND O -
: O +
The O +
activity O +
of O +
the O +
combination O +
of O +
carboplatin O +
and O +
liposomal O +
doxorubicin O +
was O +
tested O +
in O +
a O +
Phase O +
II O +
study O +
of O +
patients O +
with O +
recurrent O +
cervical B-Disease +
carcinoma L-Disease -
. O -

METHODS O -
: O +
The O +
combination O +
of O +
carboplatin O +
( O -
area O +
under O +
the O +
concentration O +
curve O +
[ O -
AUC O -
] O -
, O +
5 O -
) O +
and O +
liposomal O +
doxorubicin O +
( O -
Doxil O -
; O +
starting O +
dose O -
, O +
40 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
) O +
was O +
administered O +
intravenously O +
every O +
28 O +
days O +
to O +
37 O +
patients O +
with O +
recurrent O +
squamous B-Disease +
cell I-Disease +
cervical I-Disease +
carcinoma L-Disease +
to O +
determine O +
antitumor O +
activity O +
and O +
toxicity U-Disease +
profile O -
. O -

RESULTS O -
: O +
Twenty O -
- O -
nine O +
patients O +
were O +
assessable O +
for O +
response O -
, O +
and O +
35 O +
patients O +
were O +
assessable O +
for O +
toxicity U-Disease -
. O -

The O +
overall O +
response O +
rate O +
was O +
38 O -
% O -
, O +
the O +
median O +
time O +
to O +
response O +
was O +
10 O +
weeks O -
, O +
the O +
median O +
duration O +
of O +
response O +
was O +
26 O +
weeks O -
, O +
and O +
the O +
median O +
survival O +
was O +
37 O +
weeks O -
. O -

The O +
main O +
toxic O +
effect O +
was O +
myelosuppression U-Disease -
, O +
with O +
Grade O +
3 O +
and O +
4 O +
neutropenia U-Disease +
in O +
16 O +
patients O -
, O +
anemia U-Disease +
in O +
12 O +
patients O -
, O +
thrombocytopenia U-Disease +
in O +
11 O +
patients O -
, O +
and O +
neutropenic U-Disease +
fever U-Disease +
in O +
3 O +
patients O -
. O -

Four O +
patients O +
had O +
five O +
infusion O -
- O -
related O +
reactions O +
during O +
the O +
infusion O +
of O +
liposomal O +
doxorubicin O -
, O +
leading O +
to O +
treatment O +
discontinuation O +
in O +
three O +
patients O -
. O -

Grade O +
> O +
or O +
= O +
2 O +
nonhematologic O +
toxicity U-Disease +
included O +
nausea U-Disease +
in O +
17 O +
patients O -
, O +
emesis U-Disease +
in O +
14 O +
patients O -
, O +
fatigue U-Disease +
in O +
9 O +
patients O -
, O +
mucositis U-Disease +
and/or O +
stomatitis U-Disease +
in O +
8 O +
patients O -
, O +
constipation U-Disease +
in O +
6 O +
patients O -
, O +
weight B-Disease +
loss L-Disease +
in O +
5 O +
patients O -
, O +
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome L-Disease +
in O +
2 O +
patients O -
, O +
and O +
skin B-Disease +
reactions L-Disease +
in O +
3 O +
patients O -
. O -

CONCLUSIONS O -
: O +
The O +
combination O +
of O +
carboplatin O +
and O +
liposomal O +
doxorubicin O +
has O +
modest O +
activity O +
in O +
patients O +
with O +
recurrent O +
cervical B-Disease +
carcinoma L-Disease -
. O -

Antimicrobial O -
- O -
induced O +
mania U-Disease +
( O -
antibiomania U-Disease -
) O -
: O +
a O +
review O +
of O +
spontaneous O +
reports O -
. O -

The O +
authors O +
reviewed O +
reported O +
cases O +
of O +
antibiotic O -
- O -
induced O +
manic U-Disease +
episodes O +
by O +
means O +
of O +
a O +
MEDLINE O +
and O +
PsychLit O +
search O +
for O +
reports O +
of O +
antibiotic O -
- O -
induced O +
mania U-Disease -
. O -

Unpublished O +
reports O +
were O +
requested O +
from O +
the O +
World O +
Health O +
Organization O +
( O -
WHO O -
) O +
and O +
the O +
Food O +
and O +
Drug O +
Administration O +
( O -
FDA O -
) O -
. O -

Twenty O -
- O -
one O +
reports O +
of O +
antimicrobial O -
- O -
induced O +
mania U-Disease +
were O +
found O +
in O +
the O +
literature O -
. O -

There O +
were O +
6 O +
cases O +
implicating O +
clarithromycin O -
, O +
13 O +
implicating O +
isoniazid O -
, O +
and O +
1 O +
case O +
each O +
implicating O +
erythromycin O +
and O +
amoxicillin O -
. O -

The O +
WHO O +
reported O +
82 O +
cases O -
. O -

Of O +
these O -
, O +
clarithromycin O +
was O +
implicated O +
in O +
23 O +
( O -
27.6 O -
% O -
) O +
cases O -
, O +
ciprofloxacin O +
in O +
12 O +
( O -
14.4 O -
% O -
) O +
cases O -
, O +
and O +
ofloxacin O +
in O +
10 O +
( O -
12 O -
% O -
) O +
cases O -
. O -

Cotrimoxazole O -
, O +
metronidazole O -
, O +
and O +
erythromycin O +
were O +
involved O +
in O +
15 O +
reported O +
manic U-Disease +
episodes O -
. O -

Cases O +
reported O +
by O +
the O +
FDA O +
showed O +
clarithromycin O +
and O +
ciprofloxacin O +
to O +
be O +
the O +
most O +
frequently O +
associated O +
with O +
the O +
development O +
of O +
mania U-Disease -
. O -

Statistical O +
analysis O +
of O +
the O +
data O +
would O +
not O +
have O +
demonstrated O +
a O +
significant O +
statistical O +
correlative O +
risk O +
and O +
was O +
therefore O +
not O +
undertaken O -
. O -

Patients O +
have O +
an O +
increased O +
risk O +
of O +
developing O +
mania U-Disease +
while O +
being O +
treated O +
with O +
antimicrobials O -
. O -

Although O +
this O +
is O +
not O +
a O +
statistically O +
significant O +
risk O -
, O +
physicians O +
must O +
be O +
aware O +
of O +
the O +
effect O +
and O +
reversibility O -
. O -

Further O +
research O +
clearly O +
is O +
required O +
to O +
determine O +
the O +
incidence O +
of O +
antimicrobial O -
- O -
induced O +
mania U-Disease -
, O +
the O +
relative O +
risk O +
factors O +
of O +
developing O +
an O +
antimicrobial O -
- O -
induced O +
manic U-Disease +
episode O +
among O +
various O +
demographic O +
populations O -
, O +
and O +
the O +
incidence O +
of O +
patients O +
who O +
continue O +
to O +
have O +
persistent O +
affective O +
disorders O +
once O +
the O +
initial O +
episode O -
, O +
which O +
occurs O +
while O +
the O +
patient O +
is O +
taking O +
antibiotics O -
, O +
subsides O -
. O -

The O +
authors O +
elected O +
to O +
name O +
this O +
syndrome O +
" O -
antibiomania U-Disease -
. O -
" O -

Levodopa O -
- O -
induced O +
ocular B-Disease +
dyskinesias L-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

Levodopa O -
- O -
induced O +
ocular B-Disease +
dyskinesias L-Disease +
are O +
very O +
uncommon O -
. O -

Usually O +
they O +
occur O +
simultaneously O +
with O +
limb O +
peak O -
- O -
dose O +
choreatic B-Disease +
dyskinesias L-Disease -
. O -

We O +
report O +
on O +
a O +
patient O +
with O +
leftward O +
and O +
upward O +
deviations O +
of O +
gaze O +
during O +
the O +
peak O +
effect O +
of O +
levodopa O -
, O +
and O +
hypothesize O +
that O +
a O +
severe O +
dopaminergic O +
denervation O +
in O +
the O +
caudate O +
nucleus O +
is O +
needed O +
for O +
the O +
appearance O +
of O +
these O +
levodopa O -
- O -
induce O +
ocular B-Disease +
dyskinesias L-Disease -
. O -

A O +
comparison O +
of O +
glyceryl O +
trinitrate O +
with O +
diclofenac O +
for O +
the O +
treatment O +
of O +
primary O +
dysmenorrhea U-Disease -
: O +
an O +
open O -
, O +
randomized O -
, O +
cross O -
- O -
over O +
trial O -
. O -

Primary O +
dysmenorrhea U-Disease +
is O +
a O +
syndrome O +
characterized O +
by O +
painful O +
uterine O +
contractility O +
caused O +
by O +
a O +
hypersecretion O +
of O +
endometrial O +
prostaglandins O -
; O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
are O +
the O +
first O +
choice O +
for O +
its O +
treatment O -
. O -

However O -
, O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
have O +
demonstrated O +
that O +
myometrial O +
cells O +
are O +
also O +
targets O +
of O +
the O +
relaxant O +
effects O +
of O +
nitric O +
oxide O +
( O -
NO O -
) O -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
the O +
efficacy O +
of O +
glyceryl O +
trinitrate O +
( O -
GTN O -
) O -
, O +
an O +
NO O +
donor O -
, O +
in O +
the O +
resolution O +
of O +
primary O +
dysmenorrhea U-Disease +
in O +
comparison O +
with O +
diclofenac O +
( O -
DCF O -
) O -
. O -

A O +
total O +
of O +
24 O +
patients O +
with O +
the O +
diagnosis O +
of O +
severe O +
primary O +
dysmenorrhea U-Disease +
were O +
studied O +
during O +
two O +
consecutive O +
menstrual O +
cycles O -
. O -

In O +
an O +
open O -
, O +
cross O -
- O -
over O -
, O +
controlled O +
design O -
, O +
patients O +
were O +
randomized O +
to O +
receive O +
either O +
DCF O +
per O +
os O +
or O +
GTN O +
patches O +
the O +
first O +
days O +
of O +
menses O -
, O +
when O +
menstrual O +
cramps O +
became O +
unendurable O -
. O -

In O +
the O +
subsequent O +
cycle O +
the O +
other O +
treatment O +
was O +
used O -
. O -

Patients O +
received O +
up O +
to O +
3 O +
doses O -
/ O -
day O +
of O +
50 O +
mg O +
DCF O +
or O +
2.5 O +
mg O -
/ O -
24 O +
h O +
transdermal O +
GTN O +
for O +
the O +
first O +
3 O +
days O +
of O +
the O +
cycle O -
, O +
according O +
to O +
their O +
needs O -
. O -

The O +
participants O +
recorded O +
menstrual O +
symptoms O +
and O +
possible O +
side O -
- O -
effects O +
at O +
different O +
times O +
( O -
0 O -
, O +
30 O -
, O +
60 O -
, O +
120 O +
minutes O -
) O +
after O +
the O +
first O +
dose O +
of O +
medication O +
on O +
the O +
first O +
day O +
of O +
the O +
cycle O -
, O +
with O +
both O +
drugs O -
. O -

The O +
difference O +
in O +
pain U-Disease +
intensity O +
score O +
( O -
DPI O -
) O +
was O +
the O +
main O +
outcome O +
variable O -
. O -

Both O +
treatments O +
significantly O +
reduced O +
DPI O +
by O +
the O +
30th O +
minute O +
( O -
GTN O -
, O +
-12.8 O +
+ O -
/- O -

17.9 O -
; O +
DCF O -
, O +
-18.9 O +
+ O -
/- O -

16.6 O -
) O -
. O -

However O -
, O +
DCF O +
continued O +
to O +
be O +
effective O +
in O +
reducing O +
pelvic B-Disease +
pain L-Disease +
for O +
two O +
hours O -
, O +
whereas O +
GTN O +
scores O +
remained O +
more O +
or O +
less O +
stable O +
after O +
30 O +
min O +
and O +
significantly O +
higher O +
than O +
those O +
for O +
DFC O +
( O -
after O +
one O +
hour O -
: O +
GTN O -
, O +
-12.8 O +
+ O -
/- O -

17.9 O -
; O +
DFC O -
, O +
-18.9 O +
+ O -
/- O -

16.6 O +
and O +
after O +
two O +
hours O -
: O +
GTN O -
, O +
-23.7 O +
+ O -
/- O -

20.5 O -
; O +
DFC O -
, O +
-59.7 O +
+ O -
/- O -

17.9 O -
, O +
p O +
= O +
0.0001 O -
) O -
. O -

Low B-Disease +
back I-Disease +
pain L-Disease +
was O +
also O +
relieved O +
by O +
both O +
drugs O -
. O -

Headache U-Disease +
was O +
significantly O +
increased O +
by O +
GTN O +
but O +
not O +
by O +
DCF O -
. O -

Eight O +
patients O +
stopped O +
using O +
GTN O +
because O +
headache U-Disease -
-- O -
attributed O +
to O +
its O +
use O -
-- O -
became O +
intolerable O -
. O -

These O +
findings O +
indicate O +
that O +
GTN O +
has O +
a O +
reduced O +
efficacy O +
and O +
tolerability O +
by O +
comparison O +
with O +
DCF O +
in O +
the O +
treatment O +
of O +
primary O +
dysmenorrhea U-Disease -
. O -

Temocapril O -
, O +
a O +
long O -
- O -
acting O +
non O -
- O -
SH O +
group O +
angiotensin O +
converting O +
enzyme O +
inhibitor O -
, O +
modulates O +
glomerular B-Disease +
injury L-Disease +
in O +
chronic O +
puromycin O +
aminonucleoside O +
nephrosis U-Disease -
. O -

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
whether O +
chronic O +
administration O +
of O +
temocapril O -
, O +
a O +
long O -
- O -
acting O +
non O -
- O -
SH O +
group O +
angiotensin O +
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitor O -
, O +
reduced O +
proteinuria U-Disease -
, O +
inhibited O +
glomerular O +
hypertrophy U-Disease +
and O +
prevented O +
glomerulosclerosis U-Disease +
in O +
chronic O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O +
- O +
induced O +
nephrotic U-Disease +
rats O -
. O -

Nephrosis U-Disease +
was O +
induced O +
by O +
injection O +
of O +
PAN O +
( O -
15mg O -
/ O -
100 O -
g O +
body O +
weight O -
) O +
in O +
male O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O -
. O -

Four O +
groups O +
were O +
used O -
, O +
i O -
) O +
the O +
PAN O +
group O +
( O -
14 O -
) O -
, O +
ii O -
) O +
PAN O -
/ O -
temocapril O +
( O -
13 O -
) O -
, O +
iii O -
) O +
temocapril O +
( O -
14 O -
) O +
and O +
iv O -
) O +
untreated O +
controls O +
( O -
15 O -
) O -
. O -

Temocapril O +
( O -
8 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
was O +
administered O +
to O +
the O +
rats O +
which O +
were O +
killed O +
at O +
weeks O +
4 O -
, O +
14 O +
or O +
20 O -
. O -

At O +
each O +
time O +
point O -
, O +
systolic O +
blood O +
pressure O +
( O -
BP O -
) O -
, O +
urinary O +
protein O +
excretion O +
and O +
renal O +
histopathological O +
findings O +
were O +
evaluated O -
, O +
and O +
morphometric O +
image O +
analysis O +
was O +
done O -
. O -

Systolic O +
BP O +
in O +
the O +
PAN O +
group O +
was O +
significantly O +
high O +
at O +
4 O -
, O +
14 O +
and O +
20 O +
weeks O -
, O +
but O +
was O +
normal O +
in O +
the O +
PAN O -
/ O -
temocapril O +
group O -
. O -

Urinary O +
protein O +
excretion O +
in O +
the O +
PAN O +
group O +
increased O +
significantly O -
, O +
peaking O +
at O +
8 O +
days O -
, O +
then O +
decreased O +
at O +
4 O +
weeks O -
, O +
but O +
rose O +
again O +
significantly O +
at O +
14 O +
and O +
20 O +
weeks O -
. O -

Temocapril O +
did O +
not O +
attenuate O +
proteinuria U-Disease +
at O +
8 O +
days O -
, O +
but O +
it O +
did O +
markedly O +
lower O +
it O +
from O +
weeks O +
4 O +
to O +
20 O -
. O -

The O +
glomerulosclerosis U-Disease +
index O +
( O -
GSI O -
) O +
was O +
6.21 O +
% O +
at O +
4 O +
weeks O +
and O +
respectively O +
25.35 O +
% O +
and O +
30.49 O +
% O +
at O +
14 O +
and O +
20 O +
weeks O +
in O +
the O +
PAN O +
group O -
. O -

There O +
was O +
a O +
significant O +
correlation O +
between O +
urinary O +
protein O +
excretion O +
and O +
GSI O +
( O -
r O +
= O +
0.808 O -
, O +
p O +
< O +
0.0001 O -
) O -
. O -

The O +
ratio O +
of O +
glomerular O +
tuft O +
area O +
to O +
the O +
area O +
of O +
Bowman O -
's O +
capsules O +
( O -
GT O -
/ O -
BC O -
) O +
in O +
the O +
PAN O +
group O +
was O +
significantly O +
increased O -
, O +
but O +
it O +
was O +
significantly O +
lower O +
in O +
the O +
PAN O -
/ O -
temocapril O +
group O -
. O -

It O +
appears O +
that O +
temocapril O +
was O +
effective O +
in O +
retarding O +
renal O +
progression O +
and O +
protected O +
renal O +
function O +
in O +
PAN O +
neprotic U-Disease +
rats O -
. O -

Pulmonary B-Disease +
hypertension L-Disease +
after O +
ibuprofen O +
prophylaxis O +
in O +
very O +
preterm O +
infants O -
. O -

We O +
report O +
three O +
cases O +
of O +
severe O +
hypoxaemia U-Disease +
after O +
ibuprofen O +
administration O +
during O +
a O +
randomised O +
controlled O +
trial O +
of O +
prophylactic O +
treatment O +
of O +
patent B-Disease +
ductus I-Disease +
arteriosus L-Disease +
with O +
ibuprofen O +
in O +
premature O +
infants O +
born O +
at O +
less O +
than O +
28 O +
weeks O +
of O +
gestation O -
. O -

Echocardiography O +
showed O +
severely O +
decreased O +
pulmonary O +
blood O +
flow O -
. O -

Hypoxaemia U-Disease +
resolved O +
quickly O +
on O +
inhaled O +
nitric O +
oxide O +
therapy O -
. O -

We O +
suggest O +
that O +
investigators O +
involved O +
in O +
similar O +
trials O +
pay O +
close O +
attention O +
to O +
pulmonary O +
pressure O +
if O +
hypoxaemia U-Disease +
occurs O +
after O +
prophylactic O +
administration O +
of O +
ibuprofen O -
. O -

Hyponatremia U-Disease +
and O +
syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
anti I-Disease -
- I-Disease -
diuretic I-Disease +
hormone L-Disease +
reported O +
with O +
the O +
use O +
of O +
Vincristine O -
: O +
an O +
over O -
- O -
representation O +
of O +
Asians O -
? O -

PURPOSE O -
: O +
This O +
retrospective O +
study O +
used O +
a O +
pharmaceutical O +
company O -
's O +
global O +
safety O +
database O +
to O +
determine O +
the O +
reporting O +
rate O +
of O +
hyponatremia U-Disease +
and/or O +
syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
secretion I-Disease +
of I-Disease +
anti I-Disease -
- I-Disease -
diuretic I-Disease +
hormone L-Disease +
( O -
SIADH U-Disease -
) O +
among O +
vincristine O -
- O -
treated O +
patients O +
and O +
to O +
explore O +
the O +
possibility O +
of O +
at O -
- O -
risk O +
population O +
subgroups O -
. O -

METHOD O -
: O +
We O +
searched O +
the O +
Eli O +
Lilly O +
and O +
Company O -
's O +
computerized O +
adverse O +
event O +
database O +
for O +
all O +
reported O +
cases O +
of O +
hyponatremia U-Disease +
and/or O +
SIADH U-Disease +
as O +
of O +
1 O +
November O +
1999 O +
that O +
had O +
been O +
reported O +
during O +
the O +
use O +
of O +
vincristine O -
. O -

RESULTS O -
: O +
A O +
total O +
of O +
76 O +
cases O +
of O +
hyponatremia U-Disease +
and/or O +
SIADH U-Disease +
associated O +
with O +
vincristine O +
use O +
were O +
identified O -
. O -

The O +
overall O +
reporting O +
rate O +
was O +
estimated O +
to O +
be O +
1.3 O -
/ O -
100,000 O +
treated O +
patients O -
. O -

The O +
average O +
age O +
of O +
patients O +
was O +
35.6 O +
+ O -
/- O -

28.3 O +
years O -
, O +
and O +
62 O -
% O +
were O +
males O -
. O -

Approximately O +
75 O -
% O +
of O +
the O +
patients O +
were O +
receiving O +
treatment O +
for O +
leukemia U-Disease +
or O +
lymphoma U-Disease -
. O -

Among O +
the O +
39 O +
reports O +
that O +
included O +
information O +
on O +
race O -
, O +
the O +
racial O +
distribution O +
was O -
: O +
1 O +
Black O -
, O +
3 O +
Caucasian O -
, O +
and O +
35 O +
Asian O -
. O -

CONCLUSION O -
: O +
Our O +
data O +
suggest O +
that O +
Asian O +
patients O +
may O +
be O +
at O +
increased O +
risk O +
of O +
hyponatremia U-Disease +
and/or O +
SIADH U-Disease +
associated O +
with O +
vincristine O +
use O -
. O -

Although O +
the O +
overall O +
reported O +
rate O +
of O +
SIADH U-Disease +
associated O +
with O +
vincristine O +
is O +
very O +
low O -
, O +
physicians O +
caring O +
for O +
Asian O +
oncology O +
patients O +
should O +
be O +
aware O +
of O +
this O +
potential O +
serious O +
but O +
reversible O +
adverse O +
event O -
. O -

Delayed O +
toxicity U-Disease +
of O +
cyclophosphamide O +
on O +
the O +
bladder O +
of O +
DBA O -
/ O -
2 O +
and O +
C57BL O -
/ O -
6 O +
female O +
mouse O -
. O -

The O +
present O +
study O +
describes O +
the O +
delayed O +
development O +
of O +
a O +
severe O +
bladder O +
pathology O +
in O +
a O +
susceptible O +
strain O +
of O +
mice O +
( O -
DBA O -
/ O -
2 O -
) O +
but O +
not O +
in O +
a O +
resistant O +
strain O +
( O -
C57BL O -
/ O -
6 O -
) O +
when O +
both O +
were O +
treated O +
with O +
a O +
single O +
300 O +
mg O -
/ O -
kg O +
dose O +
of O +
cyclophosphamide O +
( O -
CY O -
) O -
. O -

Inbred O +
DBA O -
/ O -
2 O +
and O +
C57BL O -
/ O -
6 O +
female O +
mice O +
were O +
injected O +
with O +
CY O -
, O +
and O +
the O +
effect O +
of O +
the O +
drug O +
on O +
the O +
bladder O +
was O +
assessed O +
during O +
100 O +
days O +
by O +
light O +
microscopy O +
using O +
different O +
staining O +
procedures O -
, O +
and O +
after O +
30 O +
days O +
by O +
conventional O +
electron O +
microscopy O -
. O -

Early O +
CY O +
toxicity U-Disease +
caused O +
a O +
typical O +
haemorrhagic U-Disease +
cystitis U-Disease +
in O +
both O +
strains O +
that O +
was O +
completely O +
repaired O +
in O +
about O +
7 O -
- O -
10 O +
days O -
. O -

After O +
30 O +
days O +
of O +
CY O +
injection O +
ulcerous O +
and O +
non O -
- O -
ulcerous O +
forms O +
of O +
chronic O +
cystitis U-Disease +
appeared O +
in O +
86 O -
% O +
of O +
DBA O -
/ O -
2 O +
mice O +
but O +
only O +
in O +
4 O -
% O +
of O +
C57BL O -
/ O -
6 O +
mice O -
. O -

Delayed O +
cystitis U-Disease +
was O +
characterized O +
by O +
infiltration O +
and O +
transepithelial O +
passage O +
into O +
the O +
lumen O +
of O +
inflammatory O +
cells O +
and O +
by O +
frequent O +
exfoliation O +
of O +
the O +
urothelium O -
. O -

Mast O +
cells O +
appeared O +
in O +
the O +
connective O +
and O +
muscular O +
layers O +
of O +
the O +
bladder O +
at O +
a O +
much O +
higher O +
number O +
in O +
DBA O -
/ O -
2 O +
mice O +
than O +
in O +
C57BL O -
/ O -
6 O +
mice O +
or O +
untreated O +
controls O -
. O -

Electron O +
microscopy O +
disclosed O +
the O +
absence O +
of O +
the O +
typical O +
discoidal O +
vesicles O +
normally O +
present O +
in O +
the O +
cytoplasm O +
of O +
surface O +
cells O -
. O -

Instead O -
, O +
numerous O +
abnormal O +
vesicles O +
containing O +
one O +
or O +
several O +
dark O +
granules O +
were O +
observed O +
in O +
the O +
cytoplasm O +
of O +
cells O +
from O +
all O +
the O +
epithelial O +
layers O -
. O -

Delayed O +
cystitis U-Disease +
still O +
persisted O +
in O +
DBA O -
/ O -
2 O +
mice O +
100 O +
days O +
after O +
treatment O -
. O -

These O +
results O +
indicate O +
that O +
delayed O +
toxicity U-Disease +
of O +
CY O +
in O +
female O +
DBA O -
/ O -
2 O +
mice O +
causes O +
a O +
bladder O +
pathology O +
that O +
is O +
not O +
observed O +
in O +
C57BL O -
/ O -
6 O +
mice O -
. O -

This O +
pathology O +
resembles O +
interstitial B-Disease +
cystitis L-Disease +
in O +
humans O +
and O +
could O +
perhaps O +
be O +
used O +
as O +
an O +
animal O +
model O +
for O +
studies O +
on O +
the O +
disease O -
. O -

High O -
- O -
dose O +
5-fluorouracil O +
/ O +
folinic O +
acid O +
in O +
combination O +
with O +
three O -
- O -
weekly O +
mitomycin O +
C O +
in O +
the O +
treatment O +
of O +
advanced O +
gastric B-Disease +
cancer L-Disease -
. O -

A O +
phase O +
II O +
study O -
. O -

BACKGROUND O -
: O +
The O +
24-hour O +
continuous O +
infusion O +
of O +
5-fluorouracil O +
( O -
5-FU O -
) O +
and O +
folinic O +
acid O +
( O -
FA O -
) O +
as O +
part O +
of O +
several O +
new O +
multidrug O +
chemotherapy O +
regimens O +
in O +
advanced O +
gastric B-Disease +
cancer L-Disease +
( O -
AGC U-Disease -
) O +
has O +
shown O +
to O +
be O +
effective O -
, O +
with O +
low O +
toxicity U-Disease -
. O -

In O +
a O +
previous O +
phase O +
II O +
study O +
with O +
3-weekly O +
bolus O +
5-FU O -
, O +
FA O +
and O +
mitomycin O +
C O +
( O -
MMC O -
) O +
we O +
found O +
a O +
low O +
toxicity U-Disease +
rate O +
and O +
response O +
rates O +
comparable O +
to O +
those O +
of O +
regimens O +
such O +
as O +
ELF O -
, O +
FAM O +
or O +
FAMTX O -
, O +
and O +
a O +
promising O +
median O +
overall O +
survival O -
. O -

In O +
order O +
to O +
improve O +
this O +
MMC O -
- O -
dependent O +
schedule O +
we O +
initiated O +
a O +
phase O +
II O +
study O +
with O +
high O -
- O -
dose O +
5-FU O -
/ O -
FA O +
and O +
3-weekly O +
bolus O +
MMC O -
. O -

PATIENTS O +
AND O +
METHODS O -
: O +
From O +
February O -
, O +
1998 O +
to O +
September O -
, O +
2000 O +
we O +
recruited O +
33 O +
patients O +
with O +
AGC U-Disease +
to O +
receive O +
weekly O +
24-hour O +
5-FU O +
2,600 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
preceded O +
by O +
2-hour O +
FA O +
500 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
for O +
6 O +
weeks O -
, O +
followed O +
by O +
a O +
2-week O +
rest O +
period O -
. O -

Bolus O +
MMC O +
10 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
was O +
added O +
in O +
3-weekly O +
intervals O -
. O -

Treatment O +
given O +
on O +
an O +
outpatient O +
basis O -
, O +
using O +
portable O +
pump O +
systems O -
, O +
was O +
repeated O +
on O +
day O +
57 O -
. O -

Patients O -
' O +
characteristics O +
were O -
: O +
male O -
/ O -
female O +
ratio O +
20 O -
/ O -
13 O -
; O +
median O +
age O +
57 O +
( O -
27 O -
- O -
75 O -
) O +
years O -
; O +
median O +
WHO O +
status O +
1 O +
( O -
0 O -
- O -
2 O -
) O -
. O -

18 O +
patients O +
had O +
a O +
primary O +
AGC U-Disease -
, O +
and O +
15 O +
showed O +
a O +
relapsed O +
AGC U-Disease -
. O -

Median O +
follow O -
- O -
up O +
was O +
11.8 O +
months O +
( O -
range O +
of O +
those O +
surviving O -
: O +
2.7 O -
- O -
11.8 O +
months O -
) O -
. O -

RESULTS O -
: O +
32 O +
patients O +
were O +
evaluable O +
for O +
response O +
- O +
complete O +
remission O +
9.1 O -
% O +
( O -
n O +
= O +
3 O -
) O -
, O +
partial O +
remission O +
45.5 O -
% O +
( O -
n O +
= O +
15 O -
) O -
, O +
no O +
change O +
27.3 O -
% O +
( O -
n O +
= O +
9 O -
) O -
, O +
progressive O +
disease O +
15.1 O -
% O +
( O -
n O +
= O +
5 O -
) O -
. O -

Median O +
overall O +
survival O +
time O +
was O +
10.2 O +
months O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O -
: O +
8.7 O -
- O -
11.6 O -
] O -
, O +
and O +
median O +
progression O -
- O -
free O +
survival O +
time O +
was O +
7.6 O +
months O +
( O -
95 O -
% O +
CI O -
: O +
4.4 O -
- O -
10.9 O -
) O -
. O -

The O +
worst O +
toxicities U-Disease +
( O -
% O -
) O +
observed O +
were O +
( O -
CTC O -
- O -
NCI O +
1 O -
/ O -
2 O -
/ O -
3 O -
) O -
: O +
leukopenia U-Disease +
45.5 O -
/ O -
18.2 O -
/ O -
6.1 O -
, O +
thrombocytopenia U-Disease +
33.3 O -
/ O -
9.1 O -
/ O -
6.1 O -
, O +
vomitus U-Disease +
24.2 O -
/ O -
9.1 O -
/ O -
0 O -
, O +
diarrhea U-Disease +
36.4 O -
/ O -
6.1 O -
/ O -
3.0 O -
, O +
stomatitis U-Disease +
18.2 O -
/ O -
9.1 O -
/ O -
0 O -
, O +
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome L-Disease +
12.1 O -
/ O -
0 O -
/ O -
0 O -
. O -

Two O +
patients O +
developed O +
hemolytic B-Disease -
- I-Disease -
uremic I-Disease +
syndrome L-Disease +
( O -
HUS U-Disease -
) O -
. O -

CONCLUSIONS O -
: O +
High O -
- O -
dose O +
5-FU O -
/ O -
FA O -
/ O -
MMC O +
is O +
an O +
effective O +
and O +
well O -
- O -
tolerated O +
outpatient O +
regimen O +
for O +
AGC U-Disease +
( O -
objective O +
response O +
rate O +
54.6 O -
% O -
) O -
. O -

It O +
may O +
serve O +
as O +
an O +
alternative O +
to O +
cisplatin O -
- O -
containing O +
regimens O -
; O +
however O -
, O +
it O +
has O +
to O +
be O +
considered O +
that O +
possibly O +
HUS U-Disease +
may O +
occur O -
. O -

Persistent O +
sterile O +
leukocyturia U-Disease +
is O +
associated O +
with O +
impaired B-Disease +
renal I-Disease +
function L-Disease +
in O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
type I-Disease +
1-infected L-Disease +
children O +
treated O +
with O +
indinavir O -
. O -

BACKGROUND O -
: O +
Prolonged O +
administration O +
of O +
indinavir O +
is O +
associated O +
with O +
the O +
occurrence O +
of O +
a O +
variety O +
of O +
renal O +
complications O +
in O +
adults O -
. O -

These O +
well O -
- O -
documented O +
side O +
effects O +
have O +
restricted O +
the O +
use O +
of O +
this O +
potent O +
protease O +
inhibitor O +
in O +
children O -
. O -

DESIGN O -
: O +
A O +
prospective O +
study O +
to O +
monitor O +
indinavir O -
- O -
related O +
nephrotoxicity U-Disease +
in O +
a O +
cohort O +
of O +
30 O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
type I-Disease +
1-infected L-Disease +
children O +
treated O +
with O +
indinavir O -
. O -

METHODS O -
: O +
Urinary O +
pH O -
, O +
albumin O -
, O +
creatinine O -
, O +
the O +
presence O +
of O +
erythrocytes O -
, O +
leukocytes O -
, O +
bacteria O +
and O +
crystals O -
, O +
and O +
culture O +
were O +
analyzed O +
every O +
3 O +
months O +
for O +
96 O +
weeks O -
. O -

Serum O +
creatinine O +
levels O +
were O +
routinely O +
determined O +
at O +
the O +
same O +
time O +
points O -
. O -

Steady O -
- O -
state O +
pharmacokinetics O +
of O +
indinavir O +
were O +
done O +
at O +
week O +
4 O +
after O +
the O +
initiation O +
of O +
indinavir O -
. O -

RESULTS O -
: O +
The O +
cumulative O +
incidence O +
of O +
persistent O +
sterile O +
leukocyturia U-Disease +
( O -
> O +
or O +
= O -
75 O +
cells O -
/ O +
micro O +
L O +
in O +
at O +
least O +
2 O +
consecutive O +
visits O -
) O +
after O +
96 O +
weeks O +
was O +
53 O -
% O -
. O -

Persistent O +
sterile O +
leukocyturia U-Disease +
was O +
frequently O +
associated O +
with O +
a O +
mild O +
increase O +
in O +
the O +
urine O +
albumin O -
/ O -
creatinine O +
ratio O +
and O +
by O +
microscopic O +
hematuria U-Disease -
. O -

The O +
cumulative O +
incidence O +
of O +
serum O +
creatinine O +
levels O +
> O -
50 O -
% O +
above O +
normal O +
was O +
33 O -
% O +
after O +
96 O +
weeks O -
. O -

Children O +
with O +
persistent O +
sterile O +
leukocyturia U-Disease +
more O +
frequently O +
had O +
serum O +
creatinine O +
levels O +
of O +
50 O -
% O +
above O +
normal O +
than O +
those O +
children O +
without O +
persistent O +
sterile O +
leukocyturia U-Disease -
. O -

In O +
children O +
younger O +
than O +
5.6 O +
years O -
, O +
persistent O +
sterile O +
leukocyturia U-Disease +
was O +
significantly O +
more O +
frequent O +
than O +
in O +
older O +
children O -
. O -

A O +
higher O +
cumulative O +
incidence O +
of O +
persistent O +
leukocyturia U-Disease +
was O +
found O +
in O +
children O +
with O +
an O +
area O +
under O +
the O +
curve O +
> O -
19 O +
mg O -
/ O -
L O +
x O +
h O +
or O +
a O +
peak O +
serum O +
level O +
of O +
indinavir O +
> O -
12 O +
mg O -
/ O -
L. O +
In O +
4 O +
children O -
, O +
indinavir O +
was O +
discontinued O +
because O +
of O +
nephrotoxicity U-Disease -
. O -

Subsequently O -
, O +
the O +
serum O +
creatinine O +
levels O +
decreased O -
, O +
the O +
urine O +
albumin O -
/ O -
creatinine O +
ratios O +
returned O +
to O +
zero O -
, O +
and O +
the O +
leukocyturia U-Disease +
disappeared O +
within O +
3 O +
months O -
. O -

CONCLUSIONS O -
: O +
Children O +
treated O +
with O +
indinavir O +
have O +
a O +
high O +
cumulative O +
incidence O +
of O +
persistent O +
sterile O +
leukocyturia U-Disease -
. O -

Children O +
with O +
persistent O +
sterile O +
leukocyturia U-Disease +
more O +
frequently O +
had O +
an O +
increase O +
in O +
serum O +
creatinine O +
levels O +
of O +
> O -
50 O -
% O +
above O +
normal O -
. O -

Younger O +
children O +
have O +
an O +
additional O +
risk O +
for O +
renal O +
complications O -
. O -

The O +
impairment B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
function L-Disease +
in O +
these O +
children O +
occurred O +
in O +
the O +
absence O +
of O +
clinical O +
symptoms O +
of O +
nephrolithiasis U-Disease -
. O -

Indinavir O -
- O -
associated O +
nephrotoxicity U-Disease +
must O +
be O +
monitored O +
closely O -
, O +
especially O +
in O +
children O +
with O +
risk O +
factors O +
such O +
as O +
persistent O +
sterile O +
leukocyturia U-Disease -
, O +
age O +
< O -
5.6 O +
years O -
, O +
an O +
area O +
under O +
the O +
curve O +
of O +
indinavir O +
> O -
19 O +
mg O -
/ O -
L O +
x O +
h O -
, O +
and O +
a O +
C O -
( O -
max O -
) O +
> O -
12 O +
mg O -
/ O -
L. O -

Utility O +
of O +
troponin O +
I O +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
. O -

Baseline O +
electrocardiogram O +
abnormalities O +
and O +
market O +
elevations O +
not O +
associated O +
with O +
myocardial B-Disease +
necrosis L-Disease +
make O +
accurate O +
diagnosis O +
of O +
myocardial B-Disease +
infarction L-Disease +
( O -
MI U-Disease -
) O +
difficult O +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
. O -

Troponin O +
sampling O +
may O +
offer O +
greater O +
diagnostic O +
utility O +
in O +
these O +
patients O -
. O -

OBJECTIVE O -
: O +
To O +
assess O +
outcomes O +
based O +
on O +
troponin O +
positivity O +
in O +
patients O +
with O +
cocaine O +
chest B-Disease +
pain L-Disease +
admitted O +
for O +
exclusion O +
of O +
MI U-Disease -
. O -

METHODS O -
: O +
Outcomes O +
were O +
examined O +
in O +
patients O +
admitted O +
for O +
possible O +
MI U-Disease +
after O +
cocaine O +
use O -
. O -

All O +
patients O +
underwent O +
a O +
rapid O +
rule O -
- O -
in O +
protocol O +
that O +
included O +
serial O +
sampling O +
of O +
creatine O +
kinase O +
( O -
CK O -
) O -
, O +
CK O -
- O -
MB O -
, O +
and O +
cardiac O +
troponin O +
I O +
( O -
cTnI O -
) O +
over O +
eight O +
hours O -
. O -

Outcomes O +
included O +
CK O -
- O -
MB O +
MI U-Disease +
( O -
CK O -
- O -
MB O +
> O -
or= O +
8 O +
ng O -
/ O -
mL O +
with O +
a O +
relative O +
index O +
[ O -
( O -
CK O -
- O -
MB O +
x O +
100 O -
) O -
/ O -
total O +
CK O -
] O +
> O -
or= O +
4 O -
, O +
cardiac B-Disease +
death L-Disease -
, O +
and O +
significant O +
coronary B-Disease +
disease L-Disease +
( O -
> O -
or=50 O -
% O -
) O -
. O -

RESULTS O -
: O +
Of O +
the O +
246 O +
admitted O +
patients O -
, O +
34 O +
( O -
14 O -
% O -
) O +
met O +
CK O -
- O -
MB O +
criteria O +
for O +
MI U-Disease +
and O +
38 O +
( O -
16 O -
% O -
) O +
had O +
cTnI O +
elevations O -
. O -

Angiography O +
was O +
performed O +
in O +
29 O +
of O +
38 O +
patients O +
who O +
were O +
cTnI O -
- O -
positive O -
, O +
with O +
significant O +
disease O +
present O +
in O +
25 O +
( O -
86 O -
% O -
) O -
. O -

Three O +
of O +
the O +
four O +
patients O +
without O +
significant O +
disease O +
who O +
had O +
cTnI O +
elevations O +
met O +
CK O -
- O -
MB O +
criteria O +
for O +
MI U-Disease -
, O +
and O +
the O +
other O +
had O +
a O +
peak O +
CK O -
- O -
MB O +
level O +
of O +
13 O +
ng O -
/ O -
mL. O +
Sensitivities O -
, O +
specificities O -
, O +
and O +
positive O +
and O +
negative O +
likelihood O +
ratios O +
for O +
predicting O +
cardiac B-Disease +
death L-Disease +
or O +
significant O +
disease O +
were O +
high O +
for O +
both O +
CK O -
- O -
MB O +
MI U-Disease +
and O +
cTnI O +
and O +
were O +
not O +
significantly O +
different O -
. O -

CONCLUSIONS O -
: O +
Most O +
patients O +
with O +
cTnI O +
elevations O +
meet O +
CK O -
- O -
MB O +
criteria O +
for O +
MI U-Disease -
, O +
as O +
well O +
as O +
have O +
a O +
high O +
incidence O +
of O +
underlying O +
significant O +
disease O -
. O -

Troponin O +
appears O +
to O +
have O +
an O +
equivalent O +
diagnostic O +
accuracy O +
compared O +
with O +
CK O -
- O -
MB O +
for O +
diagnosing O +
necrosis U-Disease +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease +
and O +
suspected O +
MI U-Disease -
. O -

Acute O +
interstitial B-Disease +
nephritis L-Disease +
due O +
to O +
nicergoline O +
( O -
Sermion O -
) O -
. O -

We O +
report O +
a O +
case O +
of O +
acute O +
interstitial B-Disease +
nephritis L-Disease +
( O -
AIN U-Disease -
) O +
due O +
to O +
nicergoline O +
( O -
Sermion O -
) O -
. O -

A O +
50-year O -
- O -
old O +
patient O +
admitted O +
to O +
our O +
hospital O +
for O +
fever U-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure L-Disease -
. O -

Before O +
admission O -
, O +
he O +
had O +
been O +
taking O +
nicergoline O +
and O +
bendazac O +
lysine O +
due O +
to O +
retinal B-Disease +
vein I-Disease +
occlusion L-Disease +
at O +
ophthalmologic O +
department O -
. O -

Thereafter O -
, O +
he O +
experienced O +
intermittent O +
fever U-Disease +
and O +
skin B-Disease +
rash L-Disease -
. O -

On O +
admission O -
, O +
clinical O +
symptoms O +
( O -
i.e. O +
arthralgia U-Disease +
and O +
fever U-Disease -
) O +
and O +
laboratory O +
findings O +
( O -
i.e. O +
eosinophilia U-Disease +
and O +
renal B-Disease +
failure L-Disease -
) O +
suggested O +
AIN U-Disease -
, O +
and O +
which O +
was O +
confirmed O +
by O +
pathologic O +
findings O +
on O +
renal O +
biopsy O -
. O -

A O +
lymphocyte O +
transformation O +
test O +
demonstrated O +
a O +
positive O +
result O +
against O +
nicergoline O -
. O -

Treatment O +
was O +
consisted O +
of O +
withdrawal O +
of O +
nicergoline O +
and O +
intravenous O +
methylprednisolone O -
, O +
and O +
his O +
renal O +
function O +
was O +
completely O +
recovered O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
of O +
nicergoline O -
- O -
associated O +
AIN U-Disease -
. O -

Neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
complicated O +
by O +
massive O +
intestinal O +
bleeding U-Disease +
in O +
a O +
patient O +
with O +
chronic B-Disease +
renal I-Disease +
failure L-Disease -
. O -

A O +
patient O +
with O +
chronic B-Disease +
renal I-Disease +
failure L-Disease +
( O -
CRF U-Disease -
) O +
developed O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
( O -
NMS U-Disease -
) O +
after O +
administration O +
of O +
risperidone O +
and O +
levomepromazine O -
. O -

In O +
addition O +
to O +
the O +
typical O +
symptoms O +
of O +
NMS U-Disease -
, O +
massive O +
intestinal O +
bleeding U-Disease +
was O +
observed O +
during O +
the O +
episode O -
. O -

This O +
report O +
suggests O +
that O +
NMS U-Disease +
in O +
a O +
patient O +
with O +
CRF U-Disease +
may O +
be O +
complicated O +
by O +
intestinal O +
bleeding U-Disease +
and O +
needs O +
special O +
caution O +
for O +
this O +
complication O -
. O -

Blood O +
brain O +
barrier O +
in O +
right- O +
and O +
left O -
- O -
pawed O +
female O +
rats O +
assessed O +
by O +
a O +
new O +
staining O +
method O -
. O -

The O +
asymmetrical O +
breakdown O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O +
was O +
studied O +
in O +
female O +
rats O -
. O -

Paw O +
preference O +
was O +
assessed O +
by O +
a O +
food O +
reaching O +
test O -
. O -

Adrenaline O -
- O -
induced O +
hypertension U-Disease +
was O +
used O +
to O +
destroy O +
the O +
BBB O -
, O +
which O +
was O +
evaluated O +
using O +
triphenyltetrazolium O +
( O -
TTC O -
) O +
staining O +
of O +
the O +
brain O +
slices O +
just O +
after O +
giving O +
adrenaline O +
for O +
30 O +
s. O +
In O +
normal O +
rats O -
, O +
the O +
whole O +
brain O +
sections O +
exhibited O +
complete O +
staining O +
with O +
TTC O -
. O -

After O +
adrenaline O +
infusion O +
for O +
30 O +
s O -
, O +
there O +
were O +
large O +
unstained O +
areas O +
in O +
the O +
left O +
brain O +
in O +
right O -
- O -
pawed O +
animals O -
, O +
and O +
vice O +
versa O +
in O +
left O -
- O -
pawed O +
animals O -
. O -

Similar O +
results O +
were O +
obtained O +
in O +
seizure U-Disease -
- O -
induced O +
breakdown O +
of O +
BBB O -
. O -

These O +
results O +
were O +
explained O +
by O +
an O +
asymmetric O +
cerebral O +
blood O +
flow O +
depending O +
upon O +
the O +
paw O +
preference O +
in O +
rats O -
. O -

It O +
was O +
suggested O +
that O +
this O +
new O +
method O +
and O +
the O +
results O +
are O +
consistent O +
with O +
contralateral O +
motor O +
control O +
that O +
may O +
be O +
important O +
in O +
determining O +
the O +
dominant O +
cerebral O +
hemisphere O +
in O +
animals O -
. O -

Carvedilol O +
protects O +
against O +
doxorubicin O -
- O -
induced O +
mitochondrial O +
cardiomyopathy U-Disease -
. O -

Several O +
cytopathic O +
mechanisms O +
have O +
been O +
suggested O +
to O +
mediate O +
the O +
dose O -
- O -
limiting O +
cumulative O +
and O +
irreversible O +
cardiomyopathy U-Disease +
caused O +
by O +
doxorubicin O -
. O -

Recent O +
evidence O +
indicates O +
that O +
oxidative O +
stress O +
and O +
mitochondrial B-Disease +
dysfunction L-Disease +
are O +
key O +
factors O +
in O +
the O +
pathogenic O +
process O -
. O -

The O +
objective O +
of O +
this O +
investigation O +
was O +
to O +
test O +
the O +
hypothesis O +
that O +
carvedilol O -
, O +
a O +
nonselective O +
beta O -
- O -
adrenergic O +
receptor O +
antagonist O +
with O +
potent O +
antioxidant O +
properties O -
, O +
protects O +
against O +
the O +
cardiac O +
and O +
hepatic O +
mitochondrial O +
bioenergetic O +
dysfunction O +
associated O +
with O +
subchronic O +
doxorubicin O +
toxicity U-Disease -
. O -

Heart O +
and O +
liver O +
mitochondria O +
were O +
isolated O +
from O +
rats O +
treated O +
for O +
7 O +
weeks O +
with O +
doxorubicin O +
( O -
2 O +
mg O -
/ O -
kg O +
sc O -
/ O -
week O -
) O -
, O +
carvedilol O +
( O -
1 O +
mg O -
/ O -
kg O +
ip O -
/ O -
week O -
) O -
, O +
or O +
the O +
combination O +
of O +
the O +
two O +
drugs O -
. O -

Heart O +
mitochondria O +
isolated O +
from O +
doxorubicin O -
- O -
treated O +
rats O +
exhibited O +
depressed O +
rates O +
for O +
state O +
3 O +
respiration O +
( O -
336 O +
+ O -
/- O -

26 O +
versus O +
425 O +
+ O -
/- O -

53 O +
natom O +
O O -
/ O -
min O -
/ O -
mg O +
protein O -
) O +
and O +
a O +
lower O +
respiratory O +
control O +
ratio O +
( O -
RCR O -
) O +
( O -
4.3 O +
+ O -
/- O -

0.6 O +
versus O +
5.8 O +
+ O -
/- O -

0.4 O -
) O +
compared O +
with O +
cardiac O +
mitochondria O +
isolated O +
from O +
saline O -
- O -
treated O +
rats O -
. O -

Mitochondrial O +
calcium O -
- O -
loading O +
capacity O +
and O +
the O +
activity O +
of O +
NADH O -
- O -
dehydrogenase O +
were O +
also O +
suppressed O +
in O +
cardiac O +
mitochondria O +
from O +
doxorubicin O -
- O -
treated O +
rats O -
. O -

Doxorubicin O +
treatment O +
also O +
caused O +
a O +
decrease O +
in O +
RCR O +
for O +
liver O +
mitochondria O +
( O -
3.9 O +
+ O -
/- O -

0.9 O +
versus O +
5.6 O +
+ O -
/- O -

0.7 O +
for O +
control O +
rats O -
) O +
and O +
inhibition O +
of O +
hepatic O +
cytochrome O +
oxidase O +
activity O -
. O -

Coadministration O +
of O +
carvedilol O +
decreased O +
the O +
extent O +
of O +
cellular O +
vacuolization O +
in O +
cardiac O +
myocytes O +
and O +
prevented O +
the O +
inhibitory O +
effect O +
of O +
doxorubicin O +
on O +
mitochondrial O +
respiration O +
in O +
both O +
heart O +
and O +
liver O -
. O -

Carvedilol O +
also O +
prevented O +
the O +
decrease O +
in O +
mitochondrial O +
Ca O -
( O -
2 O -
+ O -
) O +
loading O +
capacity O +
and O +
the O +
inhibition O +
of O +
the O +
respiratory O +
complexes O +
of O +
heart O +
mitochondria O +
caused O +
by O +
doxorubicin O -
. O -

Carvedilol O +
by O +
itself O +
did O +
not O +
affect O +
any O +
of O +
the O +
parameters O +
measured O +
for O +
heart O +
or O +
liver O +
mitochondria O -
. O -

It O +
is O +
concluded O +
that O +
this O +
protection O +
by O +
carvedilol O +
against O +
both O +
the O +
structural O +
and O +
functional O +
cardiac O +
tissue O +
damage O +
may O +
afford O +
significant O +
clinical O +
advantage O +
in O +
minimizing O +
the O +
dose O -
- O -
limiting O +
mitochondrial B-Disease +
dysfunction L-Disease +
and O +
cardiomyopathy U-Disease +
that O +
accompanies O +
long O -
- O -
term O +
doxorubicin O +
therapy O +
in O +
cancer U-Disease +
patients O -
. O -

Cocaine O -
- O -
induced O +
hyperactivity U-Disease +
is O +
more O +
influenced O +
by O +
adenosine O +
receptor O +
agonists O +
than O +
amphetamine O -
- O -
induced O +
hyperactivity U-Disease -
. O -

The O +
influence O +
of O +
adenosine O +
receptor O +
agonists O +
and O +
antagonists O +
on O +
cocaine O -
- O -
and O +
amphetamine O -
- O -
induced O +
hyperactivity U-Disease +
was O +
examined O +
in O +
mice O -
. O -

All O +
adenosine O +
receptor O +
agonists O +
significantly O +
decreased B-Disease +
the I-Disease +
locomotor I-Disease +
activity L-Disease +
in O +
mice O -
, O +
and O +
the O +
effects O +
were O +
dose O -
- O -
dependent O -
. O -

It O +
seems O +
that O +
adenosine O +
A1 O +
and O +
A2 O +
receptors O +
might O +
be O +
involved O +
in O +
this O +
reaction O -
. O -

Moreover O -
, O +
all O +
adenosine O +
receptor O +
agonists O -
: O +
2-p- O -
( O -
2-carboxyethyl O -
) O -
phenethylamino-5'-N O -
- O -
ethylcarboxamidoadenosine O +
( O -
CGS O +
21680 O -
) O -
, O +
A2A O +
receptor O +
agonist O -
, O +
N6-cyclopentyladenosine O +
( O -
CPA O -
) O -
, O +
A1 O +
receptor O +
agonist O -
, O +
and O +
5'-N O -
- O -
ethylcarboxamidoadenosine O +
( O -
NECA O -
) O -
, O +
A2 O -
/ O -
A1 O +
receptor O +
agonist O +
significantly O +
and O +
dose O -
- O -
dependently O +
decreased O +
cocaine O -
- O -
induced O +
locomotor O +
activity O -
. O -

CPA O +
reduced O +
cocaine O +
action O +
at O +
the O +
doses O +
which O -
, O +
given O +
alone O -
, O +
did O +
not O +
influence O +
motility O -
, O +
while O +
CGS O +
21680 O +
and O +
NECA O +
decreased O +
the O +
action O +
of O +
cocaine O +
at O +
the O +
doses O +
which O -
, O +
given O +
alone O -
, O +
decreased O +
locomotor O +
activity O +
in O +
animals O -
. O -

These O +
results O +
suggest O +
the O +
involvement O +
of O +
both O +
adenosine O +
receptors O +
in O +
the O +
action O +
of O +
cocaine O +
although O +
agonists O +
of O +
A1 O +
receptors O +
seem O +
to O +
have O +
stronger O +
influence O +
on O +
it O -
. O -

The O +
selective O +
blockade O +
of O +
A2 O +
adenosine O +
receptor O +
by O +
DMPX O +
( O -
3,7-dimethyl-1-propargylxanthine O -
) O +
significantly O +
enhanced O +
cocaine O -
- O -
induced O +
locomotor O +
activity O +
of O +
animals O -
. O -

Caffeine O +
had O +
similar O +
action O +
but O +
the O +
effect O +
was O +
not O +
significant O -
. O -

CPT O +
( O -
8-cyclopentyltheophylline O -
) O -
--A1 O +
receptor O +
antagonist O -
, O +
did O +
not O +
show O +
any O +
influence O +
in O +
this O +
test O -
. O -

Similarly O -
, O +
all O +
adenosine O +
receptor O +
agonists O +
decreased O +
amphetamine O -
- O -
induced O +
hyperactivity U-Disease -
, O +
but O +
at O +
the O +
higher O +
doses O +
than O +
those O +
which O +
were O +
active O +
in O +
cocaine O -
- O -
induced O +
hyperactivity U-Disease -
. O -

The O +
selective O +
blockade O +
of O +
A2 O +
adenosine O +
receptors O +
( O -
DMPX O -
) O +
and O +
non O -
- O -
selective O +
blockade O +
of O +
adenosine O +
receptors O +
( O -
caffeine O -
) O +
significantly O +
increased O +
the O +
action O +
of O +
amphetamine O +
in O +
the O +
locomotor O +
activity O +
test O -
. O -

Our O +
results O +
have O +
shown O +
that O +
all O +
adenosine O +
receptor O +
agonists O +
( O -
A1 O +
and O +
A2 O -
) O +
reduce O +
cocaine- O +
and O +
amphetamine O -
- O -
induced O +
locomotor O +
activity O +
and O +
indicate O +
that O +
cocaine O -
- O -
induced O +
hyperactivity U-Disease +
is O +
more O +
influenced O +
by O +
adenosine O +
receptor O +
agonists O +
( O -
particularly O +
A1 O +
receptors O -
) O +
than O +
amphetamine O -
- O -
induced O +
hyperactivity U-Disease -
. O -

Amiodarone O +
and O +
the O +
risk O +
of O +
bradyarrhythmia U-Disease +
requiring O +
permanent O +
pacemaker O +
in O +
elderly O +
patients O +
with O +
atrial B-Disease +
fibrillation L-Disease +
and O +
prior O +
myocardial B-Disease +
infarction L-Disease -
. O -

OBJECTIVES O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
the O +
use O +
of O +
amiodarone O +
in O +
patients O +
with O +
atrial B-Disease +
fibrillation L-Disease +
( O -
AF U-Disease -
) O +
increases O +
the O +
risk O +
of O +
bradyarrhythmia U-Disease +
requiring O +
a O +
permanent O +
pacemaker O -
. O -

BACKGROUND O -
: O +
Reports O +
of O +
severe O +
bradyarrhythmia U-Disease +
during O +
amiodarone O +
therapy O +
are O +
infrequent O +
and O +
limited O +
to O +
studies O +
assessing O +
the O +
therapy O -
's O +
use O +
in O +
the O +
management O +
of O +
patients O +
with O +
ventricular B-Disease +
arrhythmias L-Disease -
. O -

METHODS O -
: O +
A O +
study O +
cohort O +
of O +
8,770 O +
patients O +
age O +
> O +
or O +
= O -
65 O +
years O +
with O +
a O +
new O +
diagnosis O +
of O +
AF U-Disease +
was O +
identified O +
from O +
a O +
provincewide O +
database O +
of O +
Quebec O +
residents O +
with O +
a O +
myocardial B-Disease +
infarction L-Disease +
( O -
MI U-Disease -
) O +
between O +
1991 O +
and O +
1999 O -
. O -

Using O +
a O +
nested O +
case O -
- O -
control O +
design O -
, O +
477 O +
cases O +
of O +
bradyarrhythmia U-Disease +
requiring O +
a O +
permanent O +
pacemaker O +
were O +
matched O +
( O -
1:4 O -
) O +
to O +
1,908 O +
controls O -
. O -

Multivariable O +
logistic O +
regression O +
was O +
used O +
to O +
estimate O +
the O +
odds O +
ratio O +
( O -
OR O -
) O +
of O +
pacemaker O +
insertion O +
associated O +
with O +
amiodarone O +
use O -
, O +
controlling O +
for O +
baseline O +
risk O +
factors O +
and O +
exposure O +
to O +
sotalol O -
, O +
Class O +
I O +
antiarrhythmic O +
agents O -
, O +
beta O -
- O -
blockers O -
, O +
calcium O +
channel O +
blockers O -
, O +
and O +
digoxin O -
. O -

RESULTS O -
: O +
amiodarone O +
use O +
was O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
pacemaker O +
insertion O +
( O -
OR O -
: O +
2.14 O -
, O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O -
: O +
1.30 O +
to O +
3.54 O -
) O -
. O -

This O +
effect O +
was O +
modified O +
by O +
gender O -
, O +
with O +
a O +
greater O +
risk O +
in O +
women O +
versus O +
men O +
( O -
OR O -
: O +
3.86 O -
, O +
95 O -
% O +
CI O -
: O +
1.70 O +
to O +
8.75 O +
vs. O +
OR O -
: O +
1.52 O -
, O +
95 O -
% O +
CI O -
: O +
0.80 O +
to O +
2.89 O -
) O -
. O -

Digoxin O +
was O +
the O +
only O +
other O +
medication O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
pacemaker O +
insertion O +
( O -
OR O -
: O +
1.78 O -
, O +
95 O -
% O +
CI O -
: O +
1.37 O +
to O +
2.31 O -
) O -
. O -

CONCLUSIONS O -
: O +
This O +
study O +
suggests O +
that O +
the O +
use O +
of O +
amiodarone O +
in O +
elderly O +
patients O +
with O +
AF U-Disease +
and O +
a O +
previous O +
MI U-Disease +
increases O +
the O +
risk O +
of O +
bradyarrhythmia U-Disease +
requiring O +
a O +
permanent O +
pacemaker O -
. O -

The O +
finding O +
of O +
an O +
augmented O +
risk O +
of O +
pacemaker O +
insertion O +
in O +
elderly O +
women O +
receiving O +
amiodarone O +
requires O +
further O +
investigation O -
. O -

Indomethacin O -
- O -
induced O +
morphologic O +
changes O +
in O +
the O +
rat O +
urinary O +
bladder O +
epithelium O -
. O -

OBJECTIVES O -
: O +
To O +
evaluate O +
the O +
morphologic O +
changes O +
in O +
rat O +
urothelium O +
induced O +
by O +
indomethacin O -
. O -

Nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O -
- O -
induced O +
cystitis U-Disease +
is O +
a O +
poorly O +
recognized O +
and O +
under O -
- O -
reported O +
condition O -
. O -

In O +
addition O +
to O +
tiaprofenic O +
acid O -
, O +
indomethacin O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
this O +
condition O -
. O -

METHODS O -
: O +
Three O +
groups O +
were O +
established O -
: O +
a O +
control O +
group O +
( O -
n O +
= O +
10 O -
) O -
, O +
a O +
high O -
- O -
dose O +
group O +
( O -
n O +
= O +
10 O -
) O -
, O +
treated O +
with O +
one O +
intraperitoneal O +
injection O +
of O +
indomethacin O +
20 O +
mg O -
/ O -
kg O -
, O +
and O +
a O +
therapeutic O +
dose O +
group O +
( O -
n O +
= O +
10 O -
) O +
in O +
which O +
oral O +
indomethacin O +
was O +
administered O +
3.25 O +
mg O -
/ O -
kg O +
body O +
weight O +
daily O +
for O +
3 O +
weeks O -
. O -

The O +
animals O +
were O +
then O +
killed O +
and O +
the O +
bladders O +
removed O +
for O +
light O +
and O +
electron O +
microscopic O +
studies O -
. O -

RESULTS O -
: O +
The O +
light O +
microscopic O +
findings O +
showed O +
some O +
focal O +
epithelial O +
degeneration O +
that O +
was O +
more O +
prominent O +
in O +
the O +
high O -
- O -
dose O +
group O -
. O -

When O +
compared O +
with O +
the O +
control O +
group O -
, O +
both O +
indomethacin O +
groups O +
revealed O +
statistically O +
increased O +
numbers O +
of O +
mast O +
cells O +
in O +
the O +
mucosa O +
( O -
P O +
< O -
0.0001 O -
) O +
and O +
penetration O +
of O +
lanthanum O +
nitrate O +
through O +
intercellular O +
areas O +
of O +
the O +
epithelium O -
. O -

Furthermore O -
, O +
the O +
difference O +
in O +
mast O +
cell O +
counts O +
between O +
the O +
high O +
and O +
therapeutic O +
dose O +
groups O +
was O +
also O +
statistically O +
significant O +
( O -
P O +
< O -
0.0001 O -
) O -
. O -

CONCLUSIONS O -
: O +
Indomethacin O +
resulted O +
in O +
histopathologic O +
findings O +
typical O +
of O +
interstitial B-Disease +
cystitis L-Disease -
, O +
such O +
as O +
leaky O +
bladder O +
epithelium O +
and O +
mucosal O +
mastocytosis U-Disease -
. O -

The O +
true O +
incidence O +
of O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O -
- O -
induced O +
cystitis U-Disease +
in O +
humans O +
must O +
be O +
clarified O +
by O +
prospective O +
clinical O +
trials O -
. O -

An O +
open O -
- O -
label O +
phase O +
II O +
study O +
of O +
low O -
- O -
dose O +
thalidomide O +
in O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer L-Disease -
. O -

The O +
antiangiogenic O +
effects O +
of O +
thalidomide O +
have O +
been O +
assessed O +
in O +
clinical O +
trials O +
in O +
patients O +
with O +
various O +
solid O +
and O +
haematological B-Disease +
malignancies L-Disease -
. O -

Thalidomide O +
blocks O +
the O +
activity O +
of O +
angiogenic O +
agents O +
including O +
bFGF O -
, O +
VEGF O +
and O +
IL-6 O -
. O -

We O +
undertook O +
an O +
open O -
- O -
label O +
study O +
using O +
thalidomide O +
100 O +
mg O +
once O +
daily O +
for O +
up O +
to O +
6 O +
months O +
in O +
20 O +
men O +
with O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer L-Disease -
. O -

The O +
mean O +
time O +
of O +
study O +
was O +
109 O +
days O +
( O -
median O +
107 O -
, O +
range O +
4 O -
- O -
184 O +
days O -
) O -
. O -

Patients O +
underwent O +
regular O +
measurement O +
of O +
prostate O -
- O -
specific O +
antigen O +
( O -
PSA O -
) O -
, O +
urea O +
and O +
electrolytes O -
, O +
serum O +
bFGF O +
and O +
VEGF O -
. O -

Three O +
men O +
( O -
15 O -
% O -
) O +
showed O +
a O +
decline O +
in O +
serum O +
PSA O +
of O +
at O +
least O +
50 O -
% O -
, O +
sustained O +
throughout O +
treatment O -
. O -

Of O +
16 O +
men O +
treated O +
for O +
at O +
least O +
2 O +
months O -
, O +
six O +
( O -
37.5 O -
% O -
) O +
showed O +
a O +
fall O +
in O +
absolute O +
PSA O +
by O +
a O +
median O +
of O +
48 O -
% O -
. O -

Increasing O +
levels O +
of O +
serum O +
bFGF O +
and O +
VEGF O +
were O +
associated O +
with O +
progressive O +
disease O -
; O +
five O +
of O +
six O +
men O +
who O +
demonstrated O +
a O +
fall O +
in O +
PSA O +
also O +
showed O +
a O +
decline O +
in O +
bFGF O +
and O +
VEGF O +
levels O -
, O +
and O +
three O +
of O +
four O +
men O +
with O +
a O +
rising O +
PSA O +
showed O +
an O +
increase O +
in O +
both O +
growth O +
factors O -
. O -

Adverse O +
effects O +
included O +
constipation U-Disease -
, O +
morning O +
drowsiness U-Disease -
, O +
dizziness U-Disease +
and O +
rash U-Disease -
, O +
and O +
resulted O +
in O +
withdrawal O +
from O +
the O +
study O +
by O +
three O +
men O -
. O -

Evidence O +
of O +
peripheral B-Disease +
sensory I-Disease +
neuropathy L-Disease +
was O +
found O +
in O +
nine O +
of O +
13 O +
men O +
before O +
treatment O -
. O -

In O +
the O +
seven O +
men O +
who O +
completed O +
six O +
months O +
on O +
thalidomide O -
, O +
subclinical O +
evidence O +
of O +
peripheral B-Disease +
neuropathy L-Disease +
was O +
found O +
in O +
four O +
before O +
treatment O -
, O +
but O +
in O +
all O +
seven O +
at O +
repeat O +
testing O -
. O -

The O +
findings O +
indicate O +
that O +
thalidomide O +
may O +
be O +
an O +
option O +
for O +
patients O +
who O +
have O +
failed O +
other O +
forms O +
of O +
therapy O -
, O +
provided O +
close O +
follow O -
- O -
up O +
is O +
maintained O +
for O +
development O +
of O +
peripheral B-Disease +
neuropathy L-Disease -
. O -

Central B-Disease +
nervous I-Disease +
system I-Disease +
toxicity L-Disease +
following O +
the O +
administration O +
of O +
levobupivacaine O +
for O +
lumbar O +
plexus O +
block O -
: O +
A O +
report O +
of O +
two O +
cases O -
. O -

BACKGROUND O +
AND O +
OBJECTIVES O -
: O +
Central B-Disease +
nervous I-Disease +
system I-Disease +
and I-Disease +
cardiac I-Disease +
toxicity L-Disease +
following O +
the O +
administration O +
of O +
local O +
anesthetics O +
is O +
a O +
recognized O +
complication O +
of O +
regional O +
anesthesia O -
. O -

Levobupivacaine O -
, O +
the O +
pure O +
S O -
( O -
- O -
) O +
enantiomer O +
of O +
bupivacaine O -
, O +
was O +
developed O +
to O +
improve O +
the O +
cardiac O +
safety O +
profile O +
of O +
bupivacaine O -
. O -

We O +
describe O +
2 O +
cases O +
of O +
grand B-Disease +
mal I-Disease +
seizures L-Disease +
following O +
accidental O +
intravascular O +
injection O +
of O +
levobupivacaine O -
. O -

CASE O +
REPORT O -
: O +
Two O +
patients O +
presenting O +
for O +
elective O +
orthopedic O +
surgery O +
of O +
the O +
lower O +
limb O +
underwent O +
blockade O +
of O +
the O +
lumbar O +
plexus O +
via O +
the O +
posterior O +
approach O -
. O -

Immediately O +
after O +
the O +
administration O +
of O +
levobupivacaine O +
0.5 O -
% O +
with O +
epinephrine O +
2.5 O +
microgram O -
/ O -
mL O -
, O +
the O +
patients O +
developed O +
grand B-Disease +
mal I-Disease +
seizures L-Disease -
, O +
despite O +
negative O +
aspiration O +
for O +
blood O +
and O +
no O +
clinical O +
signs O +
of O +
intravenous O +
epinephrine O +
administration O -
. O -

The O +
seizures U-Disease +
were O +
successfully O +
treated O +
with O +
sodium O +
thiopental O +
in O +
addition O +
to O +
succinylcholine O +
in O +
1 O +
patient O -
. O -

Neither O +
patient O +
developed O +
signs O +
of O +
cardiovascular B-Disease +
toxicity L-Disease -
. O -

Both O +
patients O +
were O +
treated O +
preoperatively O +
with O +
beta O -
- O -
adrenergic O +
antagonist O +
medications O -
, O +
which O +
may O +
have O +
masked O +
the O +
cardiovascular O +
signs O +
of O +
the O +
unintentional O +
intravascular O +
administration O +
of O +
levobupivacaine O +
with O +
epinephrine O -
. O -

CONCLUSIONS O -
: O +
Although O +
levobupivacaine O +
may O +
have O +
a O +
safer O +
cardiac B-Disease +
toxicity L-Disease +
profile O +
than O +
racemic O +
bupivacaine O -
, O +
if O +
adequate O +
amounts O +
of O +
levobupivacaine O +
reach O +
the O +
circulation O -
, O +
it O +
will O +
result O +
in O +
convulsions U-Disease -
. O -

Plasma O +
concentrations O +
sufficient O +
to O +
result O +
in O +
central B-Disease +
nervous I-Disease +
system I-Disease +
toxicity L-Disease +
did O +
not O +
produce O +
manifestations O +
of O +
cardiac B-Disease +
toxicity L-Disease +
in O +
these O +
2 O +
patients O -
. O -

Amiodarone O -
- O -
induced O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
during O +
bladder O +
irrigation O -
: O +
an O +
unusual O +
presentation O -
-- O -
a O +
case O +
report O -
. O -

The O +
authors O +
present O +
a O +
case O +
of O +
early O +
( O -
within O +
4 O +
days O -
) O +
development O +
of O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
( O -
TdP U-Disease -
) O +
associated O +
with O +
oral O +
amiodarone O +
therapy O -
. O -

Consistent O +
with O +
other O +
reports O +
this O +
case O +
of O +
TdP U-Disease +
occurred O +
in O +
the O +
context O +
of O +
multiple O +
exacerbating O +
factors O +
including O +
hypokalemia U-Disease +
and O +
digoxin O +
excess O -
. O -

Transient O +
prolongation O +
of O +
the O +
QT O +
during O +
bladder O +
irrigation O +
prompted O +
the O +
episode O +
of O +
TdP. U-Disease +
It O +
is O +
well O +
known O +
that O +
bradycardia U-Disease +
exacerbates O +
acquired O +
TdP. U-Disease +
The O +
authors O +
speculate O +
that O +
the O +
increased O +
vagal O +
tone O +
during O +
bladder O +
irrigation O -
, O +
a O +
vagal O +
maneuver O -
, O +
in O +
the O +
context O +
of O +
amiodarone O +
therapy O +
resulted O +
in O +
amiodarone O -
- O -
induced O +
proarrhythmia U-Disease -
. O -

In O +
the O +
absence O +
of O +
amiodarone O +
therapy O -
, O +
a O +
second O +
bladder O +
irrigation O +
did O +
not O +
induce O +
TdP U-Disease +
despite O +
hypokalemia U-Disease +
and O +
hypomagnesemia U-Disease -
. O -

Anaesthetic O +
complications O +
associated O +
with O +
myotonia B-Disease +
congenita L-Disease -
: O +
case O +
study O +
and O +
comparison O +
with O +
other O +
myotonic B-Disease +
disorders L-Disease -
. O -

Myotonia B-Disease +
congenita L-Disease +
( O -
MC U-Disease -
) O +
is O +
caused O +
by O +
a O +
defect O +
in O +
the O +
skeletal O +
muscle O +
chloride O +
channel O +
function O -
, O +
which O +
may O +
cause O +
sustained B-Disease +
membrane I-Disease +
depolarisation L-Disease -
. O -

We O +
describe O +
a O +
previously O +
healthy O +
32-year O -
- O -
old O +
woman O +
who O +
developed O +
a O +
life O -
- O -
threatening O +
muscle B-Disease +
spasm L-Disease +
and O +
secondary O +
ventilation O +
difficulties O +
following O +
a O +
preoperative O +
injection O +
of O +
suxamethonium O -
. O -

The O +
muscle B-Disease +
spasms L-Disease +
disappeared O +
spontaneously O +
and O +
the O +
surgery O +
proceeded O +
without O +
further O +
problems O -
. O -

When O +
subsequently O +
questioned O -
, O +
she O +
reported O +
minor O +
symptoms O +
suggesting O +
a O +
myotonic B-Disease +
condition L-Disease -
. O -

Myotonia U-Disease +
was O +
found O +
on O +
clinical O +
examination O +
and O +
EMG O -
. O -

The O +
diagnosis O +
MC U-Disease +
was O +
confirmed O +
genetically O -
. O -

Neither O +
the O +
patient O +
nor O +
the O +
anaesthetist O +
were O +
aware O +
of O +
the O +
diagnosis O +
before O +
this O +
potentially O +
lethal O +
complication O +
occurred O -
. O -

We O +
give O +
a O +
brief O +
overview O +
of O +
ion B-Disease +
channel I-Disease +
disorders L-Disease +
including O +
malignant B-Disease +
hyperthermia L-Disease +
and O +
their O +
anaesthetic O +
considerations O -
. O -

Respiratory O +
pattern O +
in O +
a O +
rat O +
model O +
of O +
epilepsy U-Disease -
. O -

PURPOSE O -
: O +
Apnea U-Disease +
is O +
known O +
to O +
occur O +
during O +
seizures U-Disease -
, O +
but O +
systematic O +
studies O +
of O +
ictal O +
respiratory O +
changes O +
in O +
adults O +
are O +
few O -
. O -

Data O +
regarding O +
respiratory O +
pattern O +
defects O +
during O +
interictal O +
periods O +
also O +
are O +
scarce O -
. O -

Here O +
we O +
sought O +
to O +
generate O +
information O +
with O +
regard O +
to O +
the O +
interictal O +
period O +
in O +
animals O +
with O +
pilocarpine O -
- O -
induced O +
epilepsy U-Disease -
. O -

METHODS O -
: O +
Twelve O +
rats O +
( O -
six O +
chronically O +
epileptic U-Disease +
animals O +
and O +
six O +
controls O -
) O +
were O +
anesthetized O -
, O +
given O +
tracheotomies O -
, O +
and O +
subjected O +
to O +
hyperventilation U-Disease +
or O +
hypoventilation O +
conditions O -
. O -

Breathing O +
movements O +
caused O +
changes O +
in O +
thoracic O +
volume O +
and O +
forced O +
air O +
to O +
flow O +
tidally O +
through O +
a O +
pneumotachograph O -
. O -

This O +
flow O +
was O +
measured O +
by O +
using O +
a O +
differential O +
pressure O +
transducer O -
, O +
passed O +
through O +
a O +
polygraph O -
, O +
and O +
from O +
this O +
to O +
a O +
computer O +
with O +
custom O +
software O +
that O +
derived O +
ventilation O +
( O -
VE O -
) O -
, O +
tidal O +
volume O +
( O -
VT O -
) O -
, O +
inspiratory O +
time O +
( O -
TI O -
) O -
, O +
expiratory O +
time O +
( O -
TE O -
) O -
, O +
breathing O +
frequency O +
( O -
f O -
) O -
, O +
and O +
mean O +
inspiratory O +
flow O +
( O -
VT O -
/ O -
TI O -
) O +
on O +
a O +
breath O -
- O -
by O -
- O -
breath O +
basis O -
. O -

RESULTS O -
: O +
The O +
hyperventilation U-Disease +
maneuver O +
caused O +
a O +
decrease O +
in O +
spontaneous O +
ventilation O +
in O +
pilocarpine O -
- O -
treated O +
and O +
control O +
rats O -
. O -

Although O +
VE O +
had O +
a O +
similar O +
decrease O +
in O +
both O +
groups O -
, O +
in O +
the O +
epileptic U-Disease +
group O -
, O +
the O +
decrease O +
in O +
VE O +
was O +
due O +
to O +
a O +
significant O +
( O -
p O +
< O +
0.05 O -
) O +
increase O +
in O +
TE O +
peak O +
in O +
relation O +
to O +
that O +
of O +
the O +
control O +
animals O -
. O -

The O +
hypoventilation O +
maneuver O +
led O +
to O +
an O +
increase O +
in O +
the O +
arterial O +
Paco2 O -
, O +
followed O +
by O +
an O +
increase O +
in O +
VE O -
. O -

In O +
the O +
epileptic U-Disease +
group O -
, O +
the O +
increase O +
in O +
VE O +
was O +
mediated O +
by O +
a O +
significant O +
( O -
p O +
< O +
0.05 O -
) O +
decrease O +
in O +
TE O +
peak O +
compared O +
with O +
the O +
control O +
group O -
. O -

Systemic O +
application O +
of O +
KCN O -
, O +
to O +
evaluate O +
the O +
effects O +
of O +
peripheral O +
chemoreception O +
activation O +
on O +
ventilation O -
, O +
led O +
to O +
a O +
similar O +
increase O +
in O +
VE O +
for O +
both O +
groups O -
. O -

CONCLUSIONS O -
: O +
The O +
data O +
indicate O +
that O +
pilocarpine O -
- O -
treated O +
animals O +
have O +
an O +
altered O +
ability O +
to O +
react O +
to O +
( O -
or O +
compensate O +
for O -
) O +
blood O +
gas O +
changes O +
with O +
changes O +
in O +
ventilation O +
and O +
suggest O +
that O +
it O +
is O +
centrally O +
determined O -
. O -

We O +
speculate O +
on O +
the O +
possible O +
relation O +
of O +
the O +
current O +
findings O +
on O +
treating O +
different O +
epilepsy U-Disease -
- O -
associated O +
conditions O -
. O -

Fatal O +
myeloencephalopathy U-Disease +
due O +
to O +
intrathecal O +
vincristine O +
administration O -
. O -

Vincristine O +
was O +
accidentally O +
given O +
intrathecally O +
to O +
a O +
child O +
with O +
leukaemia U-Disease -
, O +
producing O +
sensory B-Disease +
and I-Disease +
motor I-Disease +
dysfunction L-Disease +
followed O +
by O +
encephalopathy U-Disease +
and O +
death O -
. O -

Separate O +
times O +
for O +
administering O +
vincristine O +
and O +
intrathecal O +
therapy O +
is O +
recommended O -
. O -

Progesterone O +
potentiation O +
of O +
bupivacaine O +
arrhythmogenicity O +
in O +
pentobarbital O -
- O -
anesthetized O +
rats O +
and O +
beating O +
rat O +
heart O +
cell O +
cultures O -
. O -

The O +
effects O +
of O +
progesterone O +
treatment O +
on O +
bupivacaine O +
arrhythmogenicity O +
in O +
beating O +
rat O +
heart O +
myocyte O +
cultures O +
and O +
on O +
anesthetized O +
rats O +
were O +
determined O -
. O -

After O +
determining O +
the O +
bupivacaine O +
AD50 O +
( O -
the O +
concentration O +
of O +
bupivacaine O +
that O +
caused O +
50 O -
% O +
of O +
all O +
beating O +
rat O +
heart O +
myocyte O +
cultures O +
to O +
become O +
arrhythmic U-Disease -
) O -
, O +
we O +
determined O +
the O +
effect O +
of O +
1-hour O +
progesterone O +
HCl O +
exposure O +
on O +
myocyte O +
contractile O +
rhythm O -
. O -

Each O +
concentration O +
of O +
progesterone O +
( O -
6.25 O -
, O +
12.5 O -
, O +
25 O -
, O +
and O +
50 O +
micrograms O -
/ O -
ml O -
) O +
caused O +
a O +
significant O +
and O +
concentration O -
- O -
dependent O +
reduction O +
in O +
the O +
AD50 O +
for O +
bupivacaine O -
. O -

Estradiol O +
treatment O +
also O +
increased O +
the O +
arrhythmogenicity O +
of O +
bupivacaine O +
in O +
myocyte O +
cultures O -
, O +
but O +
was O +
only O +
one O +
fourth O +
as O +
potent O +
as O +
progesterone O -
. O -

Neither O +
progesterone O +
nor O +
estradiol O +
effects O +
on O +
bupivacaine O +
arrhythmogenicity O +
were O +
potentiated O +
by O +
epinephrine O -
. O -

Chronic O +
progesterone O +
pretreatment O +
( O -
5 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
21 O +
days O -
) O +
caused O +
a O +
significant O +
increase O +
in O +
bupivacaine O +
arrhythmogenicity O +
in O +
intact O +
pentobarbital O -
- O -
anesthetized O +
rats O -
. O -

There O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
time O +
to O +
onset O +
of O +
arrhythmia U-Disease +
as O +
compared O +
with O +
control O +
nonprogesterone O -
- O -
treated O +
rats O +
( O -
6.2 O +
+ O -
/- O -

1.3 O +
vs. O +
30.8 O +
+ O -
/- O -

2.5 O +
min O -
, O +
mean O +
+ O -
/- O -

SE O -
) O -
. O -

The O +
results O +
of O +
this O +
study O +
indicate O +
that O +
progesterone O +
can O +
potentiate O +
bupivacaine O +
arrhythmogenicity O +
both O +
in O +
vivo O +
and O +
in O +
vitro O -
. O -

Potentiation O +
of O +
bupivacaine O +
arrhythmia U-Disease +
in O +
myocyte O +
cultures O +
suggests O +
that O +
this O +
effect O +
is O +
at O +
least O +
partly O +
mediated O +
at O +
the O +
myocyte O +
level O -
. O -

Increased O +
serum O +
soluble O +
Fas O +
in O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
due O +
to O +
paracetamol O +
overdose U-Disease -
. O -

BACKGROUND O -
/ O -
AIMS O -
: O +
Experimental O +
studies O +
have O +
suggested O +
that O +
apoptosis O +
via O +
the O +
Fas O -
/ O -
Fas O +
Ligand O +
signaling O +
system O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
development O +
of O +
acute B-Disease +
liver I-Disease +
failure L-Disease -
. O -

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
soluble O +
form O +
of O +
Fas O +
in O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease -
. O -

METHODOLOGY O -
: O +
Serum O +
levels O +
of O +
sFas O +
( O -
soluble O +
Fas O -
) O +
were O +
measured O +
by O +
ELISA O +
in O +
24 O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
and O +
10 O +
normal O +
control O +
subjects O -
. O -

Serum O +
levels O +
of O +
tumor U-Disease +
necrosis U-Disease +
factor O -
- O -
alpha O +
and O +
interferon O -
- O -
gamma O +
were O +
also O +
determined O +
by O +
ELISA O -
. O -

RESULTS O -
: O +
Serum O +
sFas O +
was O +
significantly O +
increased O +
in O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
( O -
median O -
, O +
26.8 O +
U O -
/ O -
mL O -
; O +
range O -
, O +
6.9 O -
- O -
52.7 O +
U O -
/ O -
mL O -
) O +
compared O +
to O +
the O +
normal O +
controls O +
( O -
median O -
, O +
8.6 O +
U O -
/ O -
mL O -
; O +
range O -
, O +
6.5 O -
- O -
12.0 O +
U O -
/ O -
mL O -
, O +
P O +
< O +
0.0001 O -
) O -
. O -

Levels O +
were O +
significantly O +
greater O +
in O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
due O +
to O +
paracetamol O +
overdose U-Disease +
( O -
median O -
, O +
28.7 O +
U O -
/ O -
mL O -
; O +
range O -
, O +
12.8 O -
- O -
52.7 O +
U O -
/ O -
mL O -
, O +
n O +
= O +
17 O -
) O +
than O +
those O +
due O +
to O +
non O -
- O -
A O +
to O +
E O +
hepatitis U-Disease +
( O -
median O -
, O +
12.5 O +
U O -
/ O -
mL O -
; O +
range O -
, O +
6.9 O -
- O -
46.0 O +
U O -
/ O -
mL O -
, O +
n O +
= O +
7 O -
, O +
P O +
< O +
0.01 O -
) O -
. O -

There O +
was O +
no O +
relationship O +
of O +
sFas O +
to O +
eventual O +
outcome O +
in O +
the O +
patients O -
. O -

A O +
significant O +
correlation O +
was O +
observed O +
between O +
serum O +
sFas O +
levels O +
and O +
aspartate O +
aminotransferase O +
( O -
r O +
= O +
0.613 O -
, O +
P O +
< O +
0.01 O -
) O -
. O -

CONCLUSIONS O -
: O +
The O +
increased O +
concentration O +
of O +
sFas O +
in O +
serum O +
of O +
patients O +
with O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
may O +
reflect O +
activation O +
of O +
Fas O -
- O -
mediated O +
apoptosis O +
in O +
the O +
liver O +
and O +
this O +
together O +
with O +
increased O +
tumor U-Disease +
necrosis U-Disease +
factor O -
- O -
alpha O +
may O +
be O +
an O +
important O +
factor O +
in O +
liver O +
cell O +
loss O -
. O -

Bilateral O +
subthalamic O +
nucleus O +
stimulation O +
for O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

High O +
frequency O +
stimulation O +
of O +
the O +
subthalamic O +
nucleus O +
( O -
STN O -
) O +
is O +
known O +
to O +
ameliorate O +
the O +
signs O +
and O +
symptoms O +
of O +
advanced O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

AIM O -
: O +
We O +
studied O +
the O +
effect O +
of O +
high O +
frequency O +
STN O +
stimulation O +
in O +
23 O +
patients O -
. O -

METHOD O -
: O +
Twenty O -
- O -
three O +
patients O +
suffering O +
from O +
severe O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
( O -
Stages O +
III O -
- O -
V O +
on O +
Hoehn O +
and O +
Yahr O +
scale O -
) O +
and O -
, O +
particularly O +
bradykinesia U-Disease -
, O +
rigidity U-Disease -
, O +
and O +
levodopa O -
- O -
induced O +
dyskinesias U-Disease +
underwent O +
bilateral O +
implantation O +
of O +
electrodes O +
in O +
the O +
STN O -
. O -

Preoperative O +
and O +
postoperative O +
assessments O +
of O +
these O +
patients O +
at O +
1 O -
, O +
3 O -
, O +
6 O +
and O +
12 O +
months O +
follow O -
- O -
up O -
, O +
in O +
" O -
on O -
" O +
and O +
" O -
off O -
" O +
drug O +
conditions O -
, O +
was O +
carried O +
out O +
using O +
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease L-Disease +
Rating O +
Scale O -
, O +
Hoehn O +
and O +
Yahr O +
staging O -
, O +
England O +
activities O +
of O +
daily O +
living O +
score O +
and O +
video O +
recordings O -
. O -

RESULTS O -
: O +
After O +
one O +
year O +
of O +
electrical O +
stimulation O +
of O +
the O +
STN O -
, O +
the O +
patients O -
' O +
scores O +
for O +
activities O +
of O +
daily O +
living O +
and O +
motor O +
examination O +
scores O +
( O -
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease L-Disease +
Rating O +
Scale O +
parts O +
II O +
and O +
III O -
) O +
off O +
medication O +
improved O +
by O +
62 O -
% O +
and O +
61 O -
% O +
respectively O +
( O -
p<0.0005 O -
) O -
. O -

The O +
subscores O +
for O +
the O +
akinesia U-Disease -
, O +
rigidity U-Disease -
, O +
tremor U-Disease +
and O +
gait O +
also O +
improved O -
. O -

( O -
p<0.0005 O -
) O -
. O -

The O +
average O +
levodopa O +
dose O +
decreased O +
from O +
813 O +
mg O +
to O +
359 O +
mg O -
. O -

The O +
cognitive O +
functions O +
remained O +
unchanged O -
. O -

Two O +
patients O +
developed O +
device O -
- O -
related O +
complications O +
and O +
two O +
patients O +
experienced O +
abnormal O +
weight O +
gain O -
. O -

CONCLUSION O -
: O +
Bilateral O +
subthalamic O +
nucleus O +
stimulation O +
is O +
an O +
effective O +
treatment O +
for O +
advanced O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

It O +
reduces O +
the O +
severity O +
of O +
" O -
off O -
" O +
phase O +
symptoms O -
, O +
improves O +
the O +
axial O +
symptoms O +
and O +
reduces O +
levodopa O +
requirements O -
. O -

The O +
reduction O +
in O +
the O +
levodopa O +
dose O +
is O +
useful O +
in O +
controlling O +
drug B-Disease -
- I-Disease -
induced I-Disease +
dyskinesias L-Disease -
. O -

Acute B-Disease +
renal I-Disease +
failure L-Disease +
occurring O +
during O +
intravenous O +
desferrioxamine O +
therapy O -
: O +
recovery O +
after O +
haemodialysis O -
. O -

A O +
patient O +
with O +
transfusion O -
- O -
dependent O +
thalassemia U-Disease +
was O +
undergoing O +
home O +
intravenous O +
desferrioxamine O +
( O -
DFX O -
) O +
treatment O +
by O +
means O +
of O +
a O +
totally O +
implanted O +
system O +
because O +
of O +
his O +
poor O +
compliance O +
with O +
the O +
nightly O +
subcutaneous O +
therapy O -
. O -

Due O +
to O +
an O +
accidental O +
malfunctioning O +
of O +
the O +
infusion O +
pump O -
, O +
the O +
patient O +
was O +
inadvertently O +
administered O +
a O +
toxic O +
dosage O +
of O +
the O +
drug O +
which O +
caused O +
renal B-Disease +
insufficiency L-Disease -
. O -

Given O +
the O +
progressive O +
deterioration O +
of O +
the O +
symptoms O +
and O +
of O +
the O +
laboratory O +
values O -
, O +
despite O +
adequate O +
medical O +
treatment O -
, O +
a O +
decision O +
was O +
made O +
to O +
introduce O +
haemodialytical O +
therapy O +
in O +
order O +
to O +
remove O +
the O +
drug O +
and O +
therapy O +
reduce O +
the O +
nephrotoxicity U-Disease -
. O -

From O +
the O +
results O +
obtained O -
, O +
haemodialysis O +
can O +
therefore O +
be O +
suggested O +
as O +
a O +
useful O +
therapy O +
in O +
rare O +
cases O +
of O +
progressive O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
caused O +
by O +
desferrioxamine O -
. O -

Ocular O +
motility O +
changes O +
after O +
subtenon O +
carboplatin O +
chemotherapy O +
for O +
retinoblastoma U-Disease -
. O -

BACKGROUND O -
: O +
Focal O +
subtenon O +
carboplatin O +
injections O +
have O +
recently O +
been O +
used O +
as O +
a O +
presumably O +
toxicity U-Disease -
- O -
free O +
adjunct O +
to O +
systemic O +
chemotherapy O +
for O +
intraocular O +
retinoblastoma U-Disease -
. O -

OBJECTIVE O -
: O +
To O +
report O +
our O +
clinical O +
experience O +
with O +
abnormal B-Disease +
ocular I-Disease +
motility L-Disease +
in O +
patients O +
treated O +
with O +
subtenon O +
carboplatin O +
chemotherapy O -
. O -

METHODS O -
: O +
We O +
noted O +
abnormal B-Disease +
ocular I-Disease +
motility L-Disease +
in O +
10 O +
consecutive O +
patients O +
with O +
retinoblastoma U-Disease +
who O +
had O +
received O +
subtenon O +
carboplatin O -
. O -

During O +
ocular O +
manipulation O +
under O +
general O +
anesthesia O -
, O +
we O +
assessed O +
their O +
eyes O +
by O +
forced O +
duction O +
testing O -
, O +
comparing O +
ocular O +
motility O +
after O +
tumor U-Disease +
control O +
with O +
ocular O +
motility O +
at O +
diagnosis O -
. O -

Eyes O +
subsequently O +
enucleated O +
because O +
of O +
treatment O +
failure O +
( O -
n O +
= O +
4 O -
) O +
were O +
examined O +
histologically O -
. O -

RESULTS O -
: O +
Limitation O +
of O +
ocular O +
motility O +
was O +
detected O +
in O +
all O +
12 O +
eyes O +
of O +
10 O +
patients O +
treated O +
for O +
intraocular O +
retinoblastoma U-Disease +
with O +
1 O +
to O +
6 O +
injections O +
of O +
subtenon O +
carboplatin O +
as O +
part O +
of O +
multimodality O +
therapy O -
. O -

Histopathological O +
examination O +
revealed O +
many O +
lipophages O +
in O +
the O +
periorbital O +
fat O +
surrounding O +
the O +
optic O +
nerve O +
in O +
1 O +
eye O -
, O +
indicative O +
of O +
phagocytosis O +
of O +
previously O +
existing O +
fat O +
cells O +
and O +
suggesting O +
prior O +
fat O +
necrosis U-Disease -
. O -

The O +
enucleations O +
were O +
technically O +
difficult O +
and O +
hazardous O +
for O +
globe O +
rupture U-Disease +
because O +
of O +
extensive O +
orbital O +
soft O +
tissue O +
adhesions O -
. O -

CONCLUSIONS O -
: O +
Subtenon O +
carboplatin O +
chemotherapy O +
is O +
associated O +
with O +
significant O +
fibrosis U-Disease +
of O +
orbital O +
soft O +
tissues O -
, O +
leading O +
to O +
mechanical O +
restriction O +
of O +
eye O +
movements O +
and O +
making O +
subsequent O +
enucleation O +
difficult O -
. O -

Subtenon O +
carboplatin O +
is O +
not O +
free O +
of O +
toxicity U-Disease -
, O +
and O +
its O +
use O +
is O +
best O +
restricted O +
to O +
specific O +
indications O -
. O -

Ethambutol O +
and O +
optic B-Disease +
neuropathy L-Disease -
. O -

PURPOSE O -
: O +
To O +
demonstrate O +
the O +
association O +
between O +
ethambutol O +
and O +
optic B-Disease +
neuropathy L-Disease -
. O -

METHOD O -
: O +
Thirteen O +
patients O +
who O +
developed O +
optic B-Disease +
neuropathy L-Disease +
after O +
being O +
treated O +
with O +
ethambutol O +
for O +
tuberculosis B-Disease +
of I-Disease +
the I-Disease +
lung L-Disease +
or B-Disease +
lymph I-Disease +
node L-Disease +
at O +
Siriraj O +
Hospital O +
between O +
1997 O +
and O +
2001 O +
were O +
retrospectively O +
reviewed O -
. O -

The O +
clinical O +
characteristics O +
and O +
initial O +
and O +
final O +
visual O +
acuity O +
were O +
analyzed O +
to O +
determine O +
visual O +
outcome O -
. O -

RESULTS O -
: O +
All O +
patients O +
had O +
optic B-Disease +
neuropathy L-Disease +
between O +
1 O +
to O +
6 O +
months O +
( O -
mean O +
= O +
2.9 O +
months O -
) O +
after O +
starting O +
ethambutol O +
therapy O +
at O +
a O +
dosage O +
ranging O +
from O +
13 O +
to O +
20 O +
mg O -
/ O -
kg O -
/ O -
day O +
( O -
mean O +
= O +
17 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O -
. O -

Seven O +
( O -
54 O -
% O -
) O +
of O +
the O +
13 O +
patients O +
experienced O +
visual O +
recovery O +
after O +
stopping O +
the O +
drug O -
. O -

Of O +
6 O +
patients O +
with O +
irreversible O +
visual B-Disease +
impairment L-Disease -
, O +
4 O +
patients O +
had O +
diabetes B-Disease +
mellitus L-Disease -
, O +
glaucoma U-Disease +
and O +
a O +
history O +
of O +
heavy O +
smoking O -
. O -

CONCLUSION O -
: O +
Early O +
recognition O +
of O +
optic B-Disease +
neuropathy L-Disease +
should O +
be O +
considered O +
in O +
patients O +
with O +
ethambutol O +
therapy O -
. O -

A O +
low O +
dose O +
and O +
prompt O +
discontinuation O +
of O +
the O +
drug O +
is O +
recommended O +
particularly O +
in O +
individuals O +
with O +
diabetes B-Disease +
mellitus L-Disease -
, O +
glaucoma U-Disease +
or O +
who O +
are O +
heavy O +
smokers O -
. O -

Treatment O +
of O +
compensatory O +
gustatory B-Disease +
hyperhidrosis L-Disease +
with O +
topical O +
glycopyrrolate O -
. O -

Gustatory B-Disease +
hyperhidrosis L-Disease +
is O +
facial O +
sweating U-Disease +
usually O +
associated O +
with O +
the O +
eating O +
of O +
hot O +
spicy O +
food O +
or O +
even O +
smelling O +
this O +
food O -
. O -

Current O +
options O +
of O +
treatment O +
include O +
oral O +
anticholinergic O +
drugs O -
, O +
the O +
topical O +
application O +
of O +
anticholinergics O +
or O +
aluminum O +
chloride O -
, O +
and O +
the O +
injection O +
of O +
botulinum O +
toxin O -
. O -

Thirteen O +
patients O +
have O +
been O +
treated O +
to O +
date O +
with O +
1.5 O -
% O +
or O +
2 O -
% O +
topical O +
glycopyrrolate O -
. O -

All O +
patients O +
had O +
gustatory B-Disease +
hyperhidrosis L-Disease -
, O +
which O +
interfered O +
with O +
their O +
social O +
activities O -
, O +
after O +
transthroacic O +
endoscopic O +
sympathectomy O -
, O +
and O +
which O +
was O +
associated O +
with O +
compensatory O +
focal O +
hyperhidrosis U-Disease -
. O -

After O +
applying O +
topical O +
glycopyrrolate O -
, O +
the O +
subjective O +
effect O +
was O +
excellent O +
( O -
no O +
sweating U-Disease +
after O +
eating O +
hot O +
spicy O +
food O -
) O +
in O +
10 O +
patients O +
( O -
77 O -
% O -
) O -
, O +
and O +
fair O +
( O -
clearly O +
reduced O +
sweating U-Disease -
) O +
in O +
3 O +
patients O +
( O -
23 O -
% O -
) O -
. O -

All O +
had O +
reported O +
incidents O +
of O +
being O +
very O +
embarrassed O +
whilst O +
eating O +
hot O +
spicy O +
foods O -
. O -

Adverse O +
effects O +
included O +
a O +
mildly O +
dry B-Disease +
mouth L-Disease +
and O +
a O +
sore B-Disease +
throat L-Disease +
in O +
2 O +
patients O +
( O -
2 O -
% O +
glycopyrrolate O -
) O -
, O +
a O +
light O +
headache U-Disease +
in O +
1 O +
patient O +
( O -
1.5 O -
% O +
glycopyrrolate O -
) O -
. O -

The O +
topical O +
application O +
of O +
a O +
glycopyrrolate O +
pad O +
appeared O +
to O +
be O +
safe O -
, O +
efficacious O -
, O +
well O +
tolerated O -
, O +
and O +
a O +
convenient O +
method O +
of O +
treatment O +
for O +
moderate O +
to O +
severe O +
symptoms O +
of O +
gustatory B-Disease +
hyperhidrosis L-Disease +
in O +
post O +
transthoracic O +
endoscopic O +
sympathectomy O +
or O +
sympathicotomy O +
patients O -
, O +
with O +
few O +
side O +
effects O -
. O -

Neuroleptic O -
- O -
associated O +
hyperprolactinemia U-Disease -
. O -

Can O +
it O +
be O +
treated O +
with O +
bromocriptine O -
? O -

Six O +
stable O +
psychiatric O +
outpatients O +
with O +
hyperprolactinemia U-Disease +
and O +
amenorrhea U-Disease -
/ O -
oligomenorrhea U-Disease +
associated O +
with O +
their O +
neuroleptic O +
medications O +
were O +
treated O +
with O +
bromocriptine O -
. O -

Daily O +
dosages O +
of O +
5 O -
- O -
10 O +
mg O +
corrected O +
the O +
hyperprolactinemia U-Disease +
and O +
restored O +
menstruation O +
in O +
four O +
of O +
the O +
six O +
patients O -
. O -

One O +
woman O -
, O +
however O -
, O +
developed O +
worsened O +
psychiatric B-Disease +
symptoms L-Disease +
while O +
taking O +
bromocriptine O -
, O +
and O +
it O +
was O +
discontinued O -
. O -

Thus O -
, O +
three O +
of O +
six O +
patients O +
had O +
their O +
menstrual O +
irregularity O +
successfully O +
corrected O +
with O +
bromocriptine O -
. O -

This O +
suggests O +
that O +
bromocriptine O +
should O +
be O +
further O +
evaluated O +
as O +
potential O +
therapy O +
for O +
neuroleptic O -
- O -
associated O +
hyperprolactinemia U-Disease +
and O +
amenorrhea U-Disease -
/ O -
galactorrhea U-Disease -
. O -

Ethacrynic O +
acid O -
- O -
induced O +
convulsions U-Disease +
and O +
brain O +
neurotransmitters O +
in O +
mice O -
. O -

Intracerebroventricular O +
injection O +
of O +
ethacrynic O +
acid O +
( O -
50 O -
% O +
convulsive U-Disease +
dose O -
; O +
50 O +
micrograms O -
/ O -
mouse O -
) O +
accelerated O +
the O +
synthesis O -
/ O -
turnover O +
of O +
5-hydroxytryptamine O +
( O -
5-HT O -
) O +
but O +
suppressed O +
the O +
synthesis O +
of O +
gamma O -
- O -
aminobutyric O +
acid O +
and O +
acetylcholine O +
in O +
mouse O +
brain O -
. O -

These O +
effects O +
were O +
completely O +
antagonized O +
by O +
pretreatment O +
with O +
a O +
glutamate O -
/ O -
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
antagonist O -
, O +
aminophosphonovaleric O +
acid O -
. O -

In O +
ethacrynic O +
acid O -
- O -
induced O +
convulsions U-Disease -
, O +
these O +
neurotransmitter O +
systems O +
may O +
be O +
differentially O +
modulated O -
, O +
probably O +
through O +
activation O +
of O +
glutaminergic O +
neurons O +
in O +
the O +
brain O -
. O -

Pharmacology O +
of O +
gamma O -
- O -
aminobutyric O +
acidA O +
receptor O +
complex O +
after O +
the O +
in O +
vivo O +
administration O +
of O +
the O +
anxioselective O +
and O +
anticonvulsant O +
beta O -
- O -
carboline O +
derivative O +
abecarnil O -
. O -

In O +
rodents O -
, O +
the O +
effect O +
of O +
the O +
beta O -
- O -
carboline O +
derivative O +
isopropyl-6- O +
benzyloxy-4-methoxymethyl O -
- O -
beta O -
- O -
carboline-3-carboxylate O +
( O -
abecarrnil O -
) O -
, O +
a O +
new O +
ligand O +
for O +
benzodiazepine O +
receptors O +
possessing O +
anxiolytic O +
and O +
anticonvulsant O +
properties O -
, O +
was O +
evaluated O +
on O +
the O +
function O +
of O +
central O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
A O +
receptor O +
complex O -
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Added O +
in O +
vitro O +
to O +
rat O +
cortical O +
membrane O +
preparation O -
, O +
abecarnil O +
increased O +
[ O -
3H O -
] O -
GABA O +
binding O -
, O +
enhanced O +
muscimol O -
- O -
stimulated O +
36Cl- O +
uptake O +
and O +
reduced O +
the O +
binding O +
of O +
t- O -
[ O -
35S O -
] O -
butylbicyclophosphorothionate O +
( O -
[ O -
35S O -
] O -
TBPS O -
) O -
. O -

These O +
effects O +
were O +
similar O +
to O +
those O +
induced O +
by O +
diazepam O -
, O +
whereas O +
the O +
partial O +
agonist O +
Ro O +
16 O -
- O -
6028 O +
( O -
tert O -
- O -
butyl- O -
( O -
S O -
) O -
-8-bromo-11,12,13,13a O -
- O -
tetrahydro-9-oxo-9H- O +
imidazo O -
[ O -
1,5-a O -
] O -
-pyrrolo- O -
[ O -
2,1-c O -
] O -
[ O -
1,4 O -
] O -
benzodiazepine-1-carboxylate O -
) O +
showed O +
very O +
weak O +
efficacy O +
in O +
these O +
biochemical O +
tests O -
. O -

After O +
i.p O -
. O -

injection O +
to O +
rats O -
, O +
abecarnil O +
and O +
diazepam O +
decreased O +
in O +
a O +
time O -
- O -
dependent O +
and O +
dose O -
- O -
related O +
( O -
0.25 O -
- O -
20 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
manner O +
[ O -
35S O -
] O -
TBPS O +
binding O +
measured O +
ex O +
vivo O +
in O +
the O +
cerebral O +
cortex O -
. O -

Moreover O -
, O +
both O +
drugs O +
at O +
the O +
dose O +
of O +
0.5 O +
mg O -
/ O -
kg O +
antagonized O +
completely O +
the O +
convulsant O +
activity O +
and O +
the O +
increase O +
of O +
[ O -
35S O -
] O -
TBPS O +
binding O +
induced O +
by O +
isoniazide O +
( O -
350 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
as O +
well O +
as O +
the O +
increase O +
of O +
[ O -
35S O -
] O -
TBPS O +
binding O +
induced O +
by O +
foot O -
- O -
shock O +
stress O -
. O -

To O +
better O +
correlate O +
the O +
biochemical O +
and O +
the O +
pharmacological O +
effects O -
, O +
we O +
studied O +
the O +
action O +
of O +
abecarnil O +
on O +
[ O -
35S O -
] O -
TBPS O +
binding O -
, O +
exploratory O +
motility O +
and O +
on O +
isoniazid O -
- O -
induced O +
biochemical O +
and O +
pharmacological O +
effects O +
in O +
mice O -
. O -

In O +
these O +
animals O -
, O +
abecarnil O +
produced O +
a O +
paralleled O +
dose O -
- O -
dependent O +
( O -
0.05 O -
- O -
1 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
reduction O +
of O +
both O +
motor O +
behavior O +
and O +
cortical O +
[ O -
35S O -
] O -
TBPS O +
binding O -
. O -

Moreover O -
, O +
0.05 O +
mg O -
/ O -
kg O +
of O +
this O +
beta O -
- O -
carboline O +
reduced O +
markedly O +
the O +
increase O +
of O +
[ O -
35S O -
] O -
TBPS O +
binding O +
and O +
the O +
convulsions U-Disease +
induced O +
by O +
isoniazid O +
( O -
200 O +
mg O -
/ O -
kg O +
s.c. O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Recurrent O +
myocardial B-Disease +
infarction L-Disease +
in O +
a O +
postpartum O +
patient O +
receiving O +
bromocriptine O -
. O -

Myocardial B-Disease +
infarction L-Disease +
in O +
puerperium O +
is O +
infrequently O +
reported O -
. O -

Spasm U-Disease -
, O +
coronary O +
dissection O -
, O +
or O +
atheromatous O +
etiology O +
has O +
been O +
described O -
. O -

Bromocriptine O +
has O +
been O +
implicated O +
in O +
several O +
previous O +
case O +
reports O +
of O +
myocardial B-Disease +
infarction L-Disease +
in O +
the O +
puerperium O -
. O -

Our O +
case O +
( O -
including O +
an O +
inadvertent O +
rechallenge O -
) O +
suggests O +
such O +
a O +
relationship O -
. O -

Although O +
generally O +
regarded O +
as O +
" O -
safe O -
, O -
" O +
possible O +
serious O +
cardiac O +
effects O +
of O +
bromocriptine O +
should O +
be O +
acknowledged O -
. O -

Asterixis U-Disease +
induced O +
by O +
carbamazepine O +
therapy O -
. O -

There O +
are O +
very O +
few O +
reports O +
about O +
asterixis U-Disease +
as O +
a O +
side O +
effect O +
of O +
treatment O +
with O +
psychopharmacologic O +
agents O -
. O -

In O +
this O +
report O +
we O +
present O +
four O +
patients O +
treated O +
with O +
a O +
combination O +
of O +
different O +
psychotropic O +
drugs O -
, O +
in O +
whom O +
asterixis U-Disease +
was O +
triggered O +
either O +
by O +
adding O +
carbamazepine O +
( O -
CBZ O -
) O +
to O +
a O +
treatment O +
regimen O -
, O +
or O +
by O +
increasing O +
its O +
dosage O -
. O -

Neither O +
dosage O +
nor O +
serum O +
levels O +
of O +
CBZ O +
were O +
in O +
a O +
higher O +
range O -
. O -

We O +
consider O +
asterixis U-Disease +
to O +
be O +
an O +
easily O +
overlooked O +
sign O +
of O +
neurotoxicity U-Disease -
, O +
which O +
may O +
occur O +
even O +
at O +
low O +
or O +
moderate O +
dosage O +
levels O -
, O +
if O +
certain O +
drugs O +
as O +
lithium O +
or O +
clozapine O +
are O +
used O +
in O +
combination O +
with O +
CBZ O -
. O -

Pharmacodynamics O +
of O +
the O +
hypotensive U-Disease +
effect O +
of O +
levodopa O +
in O +
parkinsonian U-Disease +
patients O -
. O -

Blood O +
pressure O +
effects O +
of O +
i.v O -
. O -

levodopa O +
were O +
examined O +
in O +
parkinsonian U-Disease +
patients O +
with O +
stable O +
and O +
fluctuating O +
responses O +
to O +
levodopa O -
. O -

The O +
magnitude O +
of O +
the O +
hypotensive U-Disease +
effect O +
of O +
levodopa O +
was O +
concentration O +
dependent O +
and O +
was O +
fit O +
to O +
an O +
Emax O +
model O +
in O +
fluctuating O +
responders O -
. O -

Stable O +
responders O +
demonstrated O +
a O +
small O +
hypotensive U-Disease +
response O -
. O -

Baseline O +
blood O +
pressures O +
were O +
higher O +
in O +
fluctuating O +
patients O -
; O +
a O +
higher O +
baseline O +
blood O +
pressure O +
correlated O +
with O +
greater O +
hypotensive U-Disease +
effects O -
. O -

Antiparkinsonian O +
effects O +
of O +
levodopa O +
temporally O +
correlated O +
with O +
blood O +
pressure O +
changes O -
. O -

Phenylalanine O -
, O +
a O +
large O +
neutral O +
amino O +
acid O +
( O -
LNAA O -
) O +
competing O +
with O +
levodopa O +
for O +
transport O +
across O +
the O +
blood O -
- O -
brain O +
barrier O -
, O +
reduced O +
the O +
hypotensive U-Disease +
and O +
antiparkinsonian O +
effects O +
of O +
levodopa O -
. O -

We O +
conclude O +
that O +
levodopa O +
has O +
a O +
central O +
hypotensive U-Disease +
action O +
that O +
parallels O +
the O +
motor O +
effects O +
in O +
fluctuating O +
patients O -
. O -

The O +
hypotensive U-Disease +
effect O +
appears O +
to O +
be O +
related O +
to O +
the O +
higher O +
baseline O +
blood O +
pressure O +
we O +
observed O +
in O +
fluctuating O +
patients O +
relative O +
to O +
stable O +
patients O -
. O -

Syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
secretion I-Disease +
of I-Disease +
antidiuretic I-Disease +
hormone L-Disease +
after O +
infusional O +
vincristine O -
. O -

A O +
77-year O -
- O -
old O +
woman O +
with O +
refractory O +
multiple B-Disease +
myeloma L-Disease +
was O +
treated O +
with O +
a O +
4-day O +
continuous O +
intravenous O +
infusion O +
of O +
vincristine O +
and O +
doxorubicin O +
and O +
4 O +
days O +
of O +
oral O +
dexamethasone O -
. O -

Nine O +
days O +
after O +
her O +
second O +
cycle O +
she O +
presented O +
with O +
lethargy U-Disease +
and O +
weakness U-Disease +
associated O +
with O +
hyponatremia U-Disease -
. O -

Evaluation O +
revealed O +
the O +
syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
secretion I-Disease +
of I-Disease +
antidiuretic I-Disease +
hormone L-Disease -
, O +
which O +
was O +
attributed O +
to O +
the O +
vincristine O +
infusion O -
. O -

After O +
normal O +
serum O +
sodium O +
levels O +
returned O -
, O +
further O +
doxorubicin O +
and O +
dexamethasone O +
chemotherapy O +
without O +
vincristine O +
did O +
not O +
produce O +
this O +
complication O -
. O -

Heart B-Disease +
failure L-Disease -
: O +
to O +
digitalise O +
or O +
not O -
? O -

The O +
view O +
against O -
. O -

Despite O +
extensive O +
clinical O +
experience O +
the O +
role O +
of O +
digoxin O +
is O +
still O +
not O +
well O +
defined O -
. O -

In O +
patients O +
with O +
atrial B-Disease +
fibrillation L-Disease +
digoxin O +
is O +
beneficial O +
for O +
ventricular O +
rate O +
control O -
. O -

For O +
patients O +
in O +
sinus O +
rhythm O +
and O +
heart B-Disease +
failure L-Disease +
the O +
situation O +
is O +
less O +
clear O -
. O -

Digoxin O +
has O +
a O +
narrow O +
therapeutic O -
: O -
toxic O +
ratio O +
and O +
concentrations O +
are O +
affected O +
by O +
a O +
number O +
of O +
drugs O -
. O -

Also O -
, O +
digoxin O +
has O +
undesirable O +
effects O +
such O +
as O +
increasing O +
peripheral O +
resistance O +
and O +
myocardial O +
demands O -
, O +
and O +
causing O +
arrhythmias U-Disease -
. O -

There O +
is O +
a O +
paucity O +
of O +
data O +
from O +
well O -
- O -
designed O +
trials O -
. O -

The O +
trials O +
that O +
are O +
available O +
are O +
generally O +
small O +
with O +
limitations O +
in O +
design O +
and O +
these O +
show O +
variation O +
in O +
patient O +
benefit O -
. O -

More O +
convincing O +
evidence O +
is O +
required O +
showing O +
that O +
digoxin O +
improves O +
symptoms O +
or O +
exercise O +
capacity O -
. O -

Furthermore O -
, O +
no O +
trial O +
has O +
had O +
sufficient O +
power O +
to O +
evaluate O +
mortality O -
. O -

Pooled O +
analysis O +
of O +
the O +
effects O +
of O +
other O +
inotropic O +
drugs O +
shows O +
an O +
excess O +
mortality O +
and O +
there O +
is O +
a O +
possibility O +
that O +
digoxin O +
may O +
increase O +
mortality O +
after O +
myocardial B-Disease +
infarction L-Disease +
( O -
MI U-Disease -
) O -
. O -

Angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitors O +
should O +
be O +
used O +
first O +
as O +
they O +
are O +
safer O -
, O +
do O +
not O +
require O +
blood O +
level O +
monitoring O -
, O +
modify O +
progression O +
of O +
disease O -
, O +
relieve O +
symptoms O -
, O +
improve O +
exercise O +
tolerance O +
and O +
reduce O +
mortality O -
. O -

Caution O +
should O +
be O +
exercised O +
in O +
using O +
digoxin O +
until O +
large O +
mortality O +
trials O +
are O +
completed O +
showing O +
either O +
benefit O +
or O +
harm O -
. O -

Until O +
then O +
digoxin O +
should O +
be O +
considered O +
a O +
third O -
- O -
line O +
therapy O -
. O -

Isradipine O +
treatment O +
for O +
hypertension U-Disease +
in O +
general O +
practice O +
in O +
Hong O +
Kong O -
. O -

A O +
6-week O +
open O +
study O +
of O +
the O +
introduction O +
of O +
isradipine O +
treatment O +
was O +
conducted O +
in O +
general O +
practice O +
in O +
Hong O +
Kong O -
. O -

303 O +
Chinese O +
patients O +
with O +
mild O +
to O +
moderate O +
hypertension U-Disease +
entered O +
the O +
study O -
. O -

Side O +
effects O +
were O +
reported O +
in O +
21 O -
% O +
of O +
patients O +
and O +
caused O +
withdrawal O +
from O +
the O +
study O +
in O +
3 O +
patients O -
. O -

The O +
main O +
side O -
- O -
effects O +
were O +
headache U-Disease -
, O +
dizziness U-Disease -
, O +
palpitation U-Disease +
and O +
flushing U-Disease +
and O +
these O +
were O +
not O +
more O +
frequent O +
than O +
reported O +
in O +
other O +
studies O +
with O +
isradipine O +
or O +
with O +
placebo O -
. O -

Supine O +
blood O +
pressure O +
was O +
reduced O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
from O +
170 O +
+ O -
/- O -

20 O -
/ O -
102 O +
+ O -
/- O -

6 O +
mmHg O +
to O +
153 O +
+ O -
/- O -

19 O -
/ O -
92 O +
+ O -
/- O -

8 O -
, O +
147 O +
+ O -
/- O -

18 O -
/ O -
88 O +
+ O -
/- O -

7 O +
and O +
144 O +
+ O -
/- O -

14 O -
/ O -
87 O +
+ O -
/- O -

6 O +
mmHg O +
at O +
2 O -
, O +
4 O +
and O +
6 O +
weeks O +
respectively O +
in O +
evaluable O +
patients O -
. O -

Similar O +
reductions O +
occurred O +
in O +
standing O +
blood O +
pressure O +
and O +
there O +
was O +
no O +
evidence O +
of O +
postural B-Disease +
hypotension L-Disease -
. O -

Normalization O +
and O +
responder O +
rates O +
at O +
6 O +
weeks O +
were O +
86 O -
% O +
and O +
69 O -
% O +
respectively O -
. O -

Dosage O +
was O +
increased O +
from O +
2.5 O +
mg O +
b.d O -
. O -

to O +
5 O +
mg O +
b.d O -
. O -

at O +
4 O +
weeks O +
in O +
patients O +
with O +
diastolic O +
blood O +
pressure O +
greater O +
than O +
90 O +
mmHg O +
and O +
their O +
further O +
response O +
was O +
greater O +
than O +
those O +
remaining O +
on O +
2.5 O +
mg O +
b.d O -
. O -

Pharmacological O +
characteristics O +
and O +
side O +
effects O +
of O +
a O +
new O +
galenic O +
formulation O +
of O +
propofol O +
without O +
soyabean O +
oil O -
. O -

We O +
compared O +
the O +
pharmacokinetics O -
, O +
pharmacodynamics O +
and O +
safety O +
profile O +
of O +
a O +
new O +
galenic O +
formulation O +
of O +
propofol O +
( O -
AM149 O +
1 O -
% O -
) O -
, O +
which O +
does O +
not O +
contain O +
soyabean O +
oil O -
, O +
with O +
a O +
standard O +
formulation O +
of O +
propofol O +
( O -
Disoprivan O +
1 O -
% O -
) O -
. O -

In O +
a O +
randomised O -
, O +
double O -
- O -
blind O -
, O +
cross O -
- O -
over O +
study O -
, O +
30 O +
healthy O +
volunteers O +
received O +
a O +
single O +
intravenous O +
bolus O +
injection O +
of O +
2.5 O +
mg.kg-1 O +
propofol O -
. O -

Plasma O +
propofol O +
levels O +
were O +
measured O +
for O +
48 O +
h O +
following O +
drug O +
administration O +
and O +
evaluated O +
according O +
to O +
a O +
three O -
- O -
compartment O +
model O -
. O -

The O +
pharmacodynamic O +
parameters O +
assessed O +
included O +
induction O +
and O +
emergence O +
times O -
, O +
respiratory O +
and O +
cardiovascular O +
effects O -
, O +
and O +
pain U-Disease +
on O +
injection O -
. O -

Patients O +
were O +
monitored O +
for O +
side O +
effects O +
over O +
48 O +
h. O +
Owing O +
to O +
a O +
high O +
incidence O +
of O +
thrombophlebitis U-Disease -
, O +
the O +
study O +
was O +
terminated O +
prematurely O +
and O +
only O +
the O +
data O +
of O +
the O +
two O +
parallel O +
treatment O +
groups O +
( O -
15 O +
patients O +
in O +
each O +
group O -
) O +
were O +
analysed O -
. O -

Plasma O +
concentrations O +
did O +
not O +
differ O +
significantly O +
between O +
the O +
two O +
formulations O -
. O -

Anaesthesia O +
induction O +
and O +
emergence O +
times O -
, O +
respiratory O +
and O +
cardiovascular O +
variables O +
showed O +
no O +
significant O +
differences O +
between O +
the O +
two O +
treatment O +
groups O -
. O -

Pain U-Disease +
on O +
injection O +
( O -
80 O +
vs. O +
20 O -
% O -
, O +
p O +
< O +
0.01 O -
) O +
and O +
thrombophlebitis U-Disease +
( O -
93.3 O +
vs. O +
6.6 O -
% O -
, O +
p O +
< O +
0.001 O -
) O +
occurred O +
more O +
frequently O +
with O +
AM149 O +
than O +
with O +
Disoprivan O -
. O -

Although O +
both O +
formulations O +
had O +
similar O +
pharmacokinetic O +
and O +
pharmacodynamic O +
profiles O +
the O +
new O +
formulation O +
is O +
not O +
suitable O +
for O +
clinical O +
use O +
due O +
to O +
the O +
high O +
incidence O +
of O +
thrombophlebitis U-Disease +
produced O -
. O -

Pure B-Disease +
red I-Disease +
cell I-Disease +
aplasia L-Disease -
, O +
toxic B-Disease +
dermatitis L-Disease +
and O +
lymphadenopathy U-Disease +
in O +
a O +
patient O +
taking O +
diphenylhydantoin O -
. O -

A O +
patient O +
taking O +
diphenylhydantoin O +
for O +
3 O +
weeks O +
developed O +
a O +
generalized O +
skin B-Disease +
rash L-Disease -
, O +
lymphadenopathy U-Disease +
and O +
pure B-Disease +
red I-Disease +
cell I-Disease +
aplasia L-Disease -
. O -

After O +
withdrawal O +
of O +
the O +
pharmacon O +
all O +
symptoms O +
disappeared O +
spontaneously O -
. O -

Skin B-Disease +
rash L-Disease +
is O +
a O +
well O -
- O -
known O +
complication O +
of O +
diphenylhydantoin O +
treatment O +
as O +
is O +
benign O +
and O +
malignant O +
lymphadenopathy U-Disease -
. O -

Pure B-Disease +
red I-Disease +
cell I-Disease +
aplasia L-Disease +
associated O +
with O +
diphenylhydantoin O +
medication O +
has O +
been O +
reported O +
in O +
3 O +
patients O -
. O -

The O +
exact O +
mechanism O +
by O +
which O +
diphenylhydantoin O +
exerts O +
its O +
toxic O +
effects O +
is O +
not O +
known O -
. O -

In O +
this O +
patient O +
the O +
time O +
relation O +
between O +
the O +
ingestion O +
of O +
diphenylhydantoin O +
and O +
the O +
occurrence O +
of O +
the O +
skin B-Disease +
rash L-Disease -
, O +
lymphadenopathy U-Disease +
and O +
pure B-Disease +
red I-Disease +
cell I-Disease +
aplasia L-Disease +
is O +
very O +
suggestive O +
of O +
a O +
direct O +
connection O -
. O -

Vinorelbine O -
- O -
related O +
cardiac O +
events O -
: O +
a O +
meta O -
- O -
analysis O +
of O +
randomized O +
clinical O +
trials O -
. O -

Several O +
cases O +
of O +
cardiac O +
adverse O +
reactions O +
related O +
to O +
vinorelbine O +
( O -
VNR O -
) O +
have O +
been O +
reported O +
in O +
the O +
literature O -
. O -

In O +
order O +
to O +
quantify O +
the O +
incidence O +
of O +
these O +
cardiac O +
events O -
, O +
we O +
performed O +
a O +
meta O -
- O -
analysis O +
of O +
clinical O +
trials O +
comparing O +
VNR O +
with O +
other O +
chemotherapeutic O +
agents O +
in O +
the O +
treatment O +
of O +
various O +
malignancies U-Disease -
. O -

Randomized O +
clinical O +
trials O +
comparing O +
VNR O +
with O +
other O +
drugs O +
in O +
the O +
treatment O +
of O +
cancer U-Disease +
were O +
searched O +
in O +
Medline O -
, O +
Embase O -
, O +
Evidence O -
- O -
based O +
Medicine O +
Reviews O +
databases O +
and O +
the O +
Cochrane O +
library O +
from O +
1987 O +
to O +
2002 O -
. O -

Outcomes O +
of O +
interest O +
were O +
severe O +
cardiac O +
events O -
, O +
toxic O +
deaths O +
and O +
cardiac O +
event O -
- O -
related O +
deaths O +
reported O +
in O +
each O +
publication O -
. O -

We O +
found O +
19 O +
trials O -
, O +
involving O +
2441 O +
patients O +
treated O +
by O +
VNR O +
and O +
2050 O +
control O +
patients O -
. O -

The O +
incidence O +
of O +
cardiac O +
events O +
with O +
VNR O +
was O +
1.19 O -
% O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
( O -
0.75 O -
; O +
1.67 O -
) O -
] O -
. O -

There O +
was O +
no O +
difference O +
in O +
the O +
risk O +
of O +
cardiac O +
events O +
between O +
VNR O +
and O +
other O +
drugs O +
[ O -
odds O +
ratio O -
: O +
0.92 O -
, O +
95 O -
% O +
CI O +
( O -
0.54 O -
; O +
1.55 O -
) O -
] O -
. O -

The O +
risk O +
of O +
VNR O +
cardiac O +
events O +
was O +
similar O +
to O +
vindesine O +
( O -
VDS O -
) O +
and O +
other O +
cardiotoxic U-Disease +
drugs O +
[ O -
fluorouracil O -
, O +
anthracyclines O -
, O +
gemcitabine O +
( O -
GEM O -
) O +
em O +
leader O +
] O -
. O -

Even O +
if O +
it O +
did O +
not O +
reach O +
statistical O +
significance O +
because O +
of O +
a O +
few O +
number O +
of O +
cases O -
, O +
the O +
risk O +
was O +
lower O +
in O +
trials O +
excluding O +
patients O +
with O +
cardiac O +
history O -
, O +
and O +
seemed O +
to O +
be O +
higher O +
in O +
trials O +
including O +
patients O +
with O +
pre O -
- O -
existing O +
cardiac B-Disease +
diseases L-Disease -
. O -

Vinorelbine O -
- O -
related O +
cardiac O +
events O +
concern O +
about O +
1 O -
% O +
of O +
treated O +
patients O +
in O +
clinical O +
trials O -
. O -

However O -
, O +
the O +
risk O +
associated O +
with O +
VNR O +
seems O +
to O +
be O +
similar O +
to O +
that O +
of O +
other O +
chemotherapeutic O +
agents O +
in O +
the O +
same O +
indications O -
. O -

MRI O +
findings O +
of O +
hypoxic O +
cortical O +
laminar O +
necrosis U-Disease +
in O +
a O +
child O +
with O +
hemolytic B-Disease +
anemia L-Disease +
crisis O -
. O -

We O +
present O +
magnetic O +
resonance O +
imaging O +
findings O +
of O +
a O +
5-year O -
- O -
old O +
girl O +
who O +
had O +
a O +
rapidly O +
installing O +
hemolytic B-Disease +
anemia L-Disease +
crisis O +
induced O +
by O +
trimethoprim O -
- O -
sulfomethoxazole O -
, O +
resulting O +
in O +
cerebral B-Disease +
anoxia L-Disease +
leading O +
to O +
permanent O +
damage O -
. O -

Magnetic O +
Resonance O +
imaging O +
revealed O +
cortical O +
laminar O +
necrosis U-Disease +
in O +
arterial O +
border O +
zones O +
in O +
both O +
cerebral O +
hemispheres O -
, O +
ischemic O +
changes O +
in O +
subcortical O +
white O +
matter O +
of O +
left O +
cerebral O +
hemisphere O -
, O +
and O +
in O +
the O +
left O +
putamen O -
. O -

Although O +
cortical O +
laminar O +
necrosis U-Disease +
is O +
a O +
classic O +
entity O +
in O +
adulthood O +
related O +
to O +
conditions O +
of O +
energy O +
depletions O -
, O +
there O +
are O +
few O +
reports O +
available O +
in O +
children O -
. O -

A O +
wide O +
review O +
of O +
the O +
literature O +
is O +
also O +
presented O -
. O -

The O +
natural O +
history O +
of O +
Vigabatrin O +
associated O +
visual B-Disease +
field I-Disease +
defects L-Disease +
in O +
patients O +
electing O +
to O +
continue O +
their O +
medication O -
. O -

PURPOSE O -
: O +
To O +
determine O +
the O +
natural O +
history O +
of O +
visual B-Disease +
field I-Disease +
defects L-Disease +
in O +
a O +
group O +
of O +
patients O +
known O +
to O +
have O +
Vigabatrin O -
- O -
associated O +
changes O +
who O +
elected O +
to O +
continue O +
the O +
medication O +
because O +
of O +
good O +
seizure U-Disease +
control O -
. O -

METHODS O -
: O +
All O +
patients O +
taking O +
Vigabatrin O +
alone O +
or O +
in O +
combination O +
with O +
other O +
antiepileptic O +
drugs O +
for O +
at O +
least O +
5 O +
years O +
( O -
range O +
5 O -
- O -
12 O +
years O -
) O +
were O +
entered O +
into O +
a O +
visual O +
surveillance O +
programme O -
. O -

Patients O +
were O +
followed O +
up O +
at O +
6-monthly O +
intervals O +
for O +
not O +
less O +
than O +
18 O +
months O +
( O -
range O +
18 O -
- O -
43 O +
months O -
) O -
. O -

In O +
all O -
, O +
16 O +
patients O +
with O +
unequivocal O +
defects O +
continued O +
the O +
medication O -
. O -

Following O +
already O +
published O +
methodology O +
( O -
Eye O +
2002 O -
; O +
16;567 O -
- O -
571 O -
) O +
monocular O +
mean O +
radial O +
degrees O +
( O -
MRDs O -
) O +
to O +
the O +
I O -
/ O -
4e O +
isopter O +
on O +
Goldmann O +
perimetry O +
was O +
calculated O +
for O +
the O +
right O +
eye O +
at O +
the O +
time O +
of O +
discovery O +
of O +
a O +
visual B-Disease +
field I-Disease +
defect L-Disease +
and O +
again O +
after O +
not O +
less O +
than O +
18 O +
months O +
follow O -
- O -
up O -
. O -

RESULTS O -
: O +
Mean O +
right O +
eye O +
MRD O +
at O +
presentation O +
was O +
36.98 O +
degrees O +
( O -
range O +
22.25 O -
- O -
51.0 O -
) O -
, O +
compared O +
to O +
38.40 O +
degrees O +
( O -
range O +
22.5 O -
- O -
49.75 O -
) O +
after O +
follow O -
- O -
up O -
; O +
P=0.338 O +
unpaired O +
t O -
- O -
test O -
. O -

Only O +
one O +
patient O +
demonstrated O +
a O +
deterioration B-Disease +
in I-Disease +
visual I-Disease +
field L-Disease +
during O +
the O +
study O +
period O +
and O +
discontinued O +
treatment O -
. O -

CONCLUSION O -
: O +
Established O +
visual B-Disease +
field I-Disease +
defects L-Disease +
presumed O +
to O +
be O +
due O +
to O +
Vigabatrin O +
therapy O +
did O +
not O +
usually O +
progress O +
in O +
spite O +
of O +
continuing O +
use O +
of O +
the O +
medication O -
. O -

These O +
data O +
give O +
support O +
to O +
the O +
hypothesis O +
that O +
the O +
pathogenesis O +
of O +
Vigabatrin O -
- O -
associated O +
visual B-Disease +
field I-Disease +
defects L-Disease +
may O +
be O +
an O +
idiosyncratic O +
adverse O +
drug O +
reaction O +
rather O +
than O +
dose O -
- O -
dependent O +
toxicity U-Disease -
. O -

Induction O +
of O +
rosaceiform O +
dermatitis U-Disease +
during O +
treatment O +
of O +
facial B-Disease +
inflammatory I-Disease +
dermatoses L-Disease +
with O +
tacrolimus O +
ointment O -
. O -

BACKGROUND O -
: O +
Tacrolimus O +
ointment O +
is O +
increasingly O +
used O +
for O +
anti O -
- O -
inflammatory O +
treatment O +
of O +
sensitive O +
areas O +
such O +
as O +
the O +
face O -
, O +
and O +
recent O +
observations O +
indicate O +
that O +
the O +
treatment O +
is O +
effective O +
in O +
steroid O -
- O -
aggravated O +
rosacea U-Disease +
and O +
perioral B-Disease +
dermatitis L-Disease -
. O -

We O +
report O +
on O +
rosaceiform O +
dermatitis U-Disease +
as O +
a O +
complication O +
of O +
treatment O +
with O +
tacrolimus O +
ointment O -
. O -

OBSERVATIONS O -
: O +
Six O +
adult O +
patients O +
with O +
inflammatory B-Disease +
facial I-Disease +
dermatoses L-Disease +
were O +
treated O +
with O +
tacrolimus O +
ointment O +
because O +
of O +
the O +
ineffectiveness O +
of O +
standard O +
treatments O -
. O -

Within O +
2 O +
to O +
3 O +
weeks O +
of O +
initially O +
effective O +
and O +
well O -
- O -
tolerated O +
treatment O -
, O +
3 O +
patients O +
with O +
a O +
history O +
of O +
rosacea U-Disease +
and O +
1 O +
with O +
a O +
history O +
of O +
acne U-Disease +
experienced O +
sudden O +
worsening O +
with O +
pustular O +
rosaceiform O +
lesions O -
. O -

Biopsy O +
revealed O +
an O +
abundance O +
of O +
Demodex O +
mites O +
in O +
2 O +
of O +
these O +
patients O -
. O -

In O +
1 O +
patient O +
with O +
eyelid O +
eczema U-Disease -
, O +
rosaceiform O +
periocular B-Disease +
dermatitis L-Disease +
gradually O +
appeared O +
after O +
3 O +
weeks O +
of O +
treatment O -
. O -

In O +
1 O +
patient O +
with O +
atopic B-Disease +
dermatitis L-Disease -
, O +
telangiectatic O +
and O +
papular B-Disease +
rosacea L-Disease +
insidiously O +
appeared O +
after O +
5 O +
months O +
of O +
treatment O -
. O -

CONCLUSIONS O -
: O +
Our O +
observations O +
suggest O +
that O +
the O +
spectrum O +
of O +
rosaceiform O +
dermatitis U-Disease +
as O +
a O +
complication O +
of O +
treatment O +
with O +
tacrolimus O +
ointment O +
is O +
heterogeneous O -
. O -

A O +
variety O +
of O +
factors O -
, O +
such O +
as O +
vasoactive O +
properties O +
of O +
tacrolimus O -
, O +
proliferation O +
of O +
Demodex O +
due O +
to O +
local O +
immunosuppression O -
, O +
and O +
the O +
occlusive O +
properties O +
of O +
the O +
ointment O -
, O +
may O +
be O +
involved O +
in O +
the O +
observed O +
phenomena O -
. O -

Future O +
studies O +
are O +
needed O +
to O +
identify O +
individual O +
risk O +
factors O -
. O -

Intravascular O +
hemolysis U-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
following O +
intermittent O +
rifampin O +
therapy O -
. O -

Renal B-Disease +
failure L-Disease +
is O +
a O +
rare O +
complication O +
associated O +
with O +
the O +
use O +
of O +
rifampin O -
. O -

Intravascular O +
hemolysis U-Disease +
leading O +
to O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
following O +
rifampin O +
therapy O +
is O +
extremely O +
rare O -
. O -

Two O +
patients O +
with O +
leprosy U-Disease +
who O +
developed O +
hemolysis U-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
following O +
rifampin O +
are O +
reported O -
. O -

Structural O +
abnormalities O +
in O +
the O +
brains O +
of O +
human O +
subjects O +
who O +
use O +
methamphetamine O -
. O -

We O +
visualize O -
, O +
for O +
the O +
first O +
time O -
, O +
the O +
profile O +
of O +
structural B-Disease +
deficits I-Disease +
in I-Disease +
the I-Disease +
human I-Disease +
brain L-Disease +
associated O +
with O +
chronic O +
methamphetamine O +
( O -
MA O -
) O +
abuse O -
. O -

Studies O +
of O +
human O +
subjects O +
who O +
have O +
used O +
MA O +
chronically O +
have O +
revealed O +
deficits O +
in O +
dopaminergic O +
and O +
serotonergic O +
systems O +
and O +
cerebral O +
metabolic B-Disease +
abnormalities L-Disease -
. O -

Using O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
and O +
new O +
computational O +
brain O -
- O -
mapping O +
techniques O -
, O +
we O +
determined O +
the O +
pattern O +
of O +
structural O +
brain O +
alterations O +
associated O +
with O +
chronic O +
MA O +
abuse O +
in O +
human O +
subjects O +
and O +
related O +
these O +
deficits O +
to O +
cognitive B-Disease +
impairment L-Disease -
. O -

We O +
used O +
high O -
- O -
resolution O +
MRI O +
and O +
surface O -
- O -
based O +
computational O +
image O +
analyses O +
to O +
map O +
regional O +
abnormalities B-Disease +
in I-Disease +
the I-Disease +
cortex I-Disease -
, I-Disease +
hippocampus I-Disease -
, I-Disease +
white I-Disease +
matter I-Disease -
, I-Disease +
and I-Disease +
ventricles L-Disease +
in O +
22 O +
human O +
subjects O +
who O +
used O +
MA O +
and O +
21 O +
age O -
- O -
matched O -
, O +
healthy O +
controls O -
. O -

Cortical O +
maps O +
revealed O +
severe O +
gray O -
- O -
matter O +
deficits O +
in O +
the O +
cingulate O -
, O +
limbic O -
, O +
and O +
paralimbic O +
cortices O +
of O +
MA O +
abusers O +
( O -
averaging O +
11.3 O -
% O +
below O +
control O -
; O +
p O +
< O +
0.05 O -
) O -
. O -

On O +
average O -
, O +
MA O +
abusers O +
had O +
7.8 O -
% O +
smaller O +
hippocampal O +
volumes O +
than O +
control O +
subjects O +
( O -
p O +
< O +
0.01 O -
; O +
left O -
, O +
p O +
= O +
0.01 O -
; O +
right O -
, O +
p O +
< O +
0.05 O -
) O +
and O +
significant O +
white O -
- O -
matter O +
hypertrophy U-Disease +
( O -
7.0 O -
% O -
; O +
p O +
< O +
0.01 O -
) O -
. O -

Hippocampal O +
deficits O +
were O +
mapped O +
and O +
correlated O +
with O +
memory O +
performance O +
on O +
a O +
word O -
- O -
recall O +
test O +
( O -
p O +
< O +
0.05 O -
) O -
. O -

MRI O -
- O -
based O +
maps O +
suggest O +
that O +
chronic O +
methamphetamine O +
abuse O +
causes O +
a O +
selective O +
pattern O +
of O +
cerebral O +
deterioration O +
that O +
contributes O +
to O +
impaired B-Disease +
memory I-Disease +
performance L-Disease -
. O -

MA O +
may O +
selectively O +
damage O +
the O +
medial O +
temporal O +
lobe O +
and O -
, O +
consistent O +
with O +
metabolic O +
studies O -
, O +
the O +
cingulate O -
- O -
limbic O +
cortex O -
, O +
inducing O +
neuroadaptation O -
, O +
neuropil O +
reduction O -
, O +
or O +
cell O +
death O -
. O -

Prominent O +
white O -
- O -
matter O +
hypertrophy U-Disease +
may O +
result O +
from O +
altered O +
myelination O +
and O +
adaptive O +
glial O +
changes O -
, O +
including O +
gliosis U-Disease +
secondary O +
to O +
neuronal B-Disease +
damage L-Disease -
. O -

These O +
brain O +
substrates O +
may O +
help O +
account O +
for O +
the O +
symptoms O +
of O +
MA O +
abuse O -
, O +
providing O +
therapeutic O +
targets O +
for O +
drug O -
- O -
induced O +
brain B-Disease +
injury L-Disease -
. O -

Disruption O +
of O +
hepatic O +
lipid O +
homeostasis O +
in O +
mice O +
after O +
amiodarone O +
treatment O +
is O +
associated O +
with O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O -
- O -
alpha O +
target O +
gene O +
activation O -
. O -

Amiodarone O -
, O +
an O +
efficacious O +
and O +
widely O +
used O +
antiarrhythmic O +
agent O -
, O +
has O +
been O +
reported O +
to O +
cause O +
hepatotoxicity U-Disease +
in O +
some O +
patients O -
. O -

To O +
gain O +
insight O +
into O +
the O +
mechanism O +
of O +
this O +
unwanted O +
effect O -
, O +
mice O +
were O +
administered O +
various O +
doses O +
of O +
amiodarone O +
and O +
examined O +
for O +
changes O +
in O +
hepatic O +
histology O +
and O +
gene O +
regulation O -
. O -

Amiodarone O +
induced O +
hepatomegaly U-Disease -
, O +
hepatocyte O +
microvesicular O +
lipid O +
accumulation O -
, O +
and O +
a O +
significant O +
decrease O +
in O +
serum O +
triglycerides O +
and O +
glucose O -
. O -

Northern O +
blot O +
analysis O +
of O +
hepatic O +
RNA O +
revealed O +
a O +
dose O -
- O -
dependent O +
increase O +
in O +
the O +
expression O +
of O +
a O +
number O +
of O +
genes O +
critical O +
for O +
fatty O +
acid O +
oxidation O -
, O +
lipoprotein O +
assembly O -
, O +
and O +
lipid O +
transport O -
. O -

Many O +
of O +
these O +
genes O +
are O +
regulated O +
by O +
the O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O -
- O -
alpha O +
( O -
PPARalpha O -
) O -
, O +
a O +
ligand O -
- O -
activated O +
nuclear O +
hormone O +
receptor O +
transcription O +
factor O -
. O -

The O +
absence O +
of O +
induction O +
of O +
these O +
genes O +
as O +
well O +
as O +
hepatomegaly U-Disease +
in O +
PPARalpha O +
knockout O +
[ O -
PPARalpha- O -
/ O -
- O -
] O +
mice O +
indicated O +
that O +
the O +
effects O +
of O +
amiodarone O +
were O +
dependent O +
upon O +
the O +
presence O +
of O +
a O +
functional O +
PPARalpha O +
gene O -
. O -

Compared O +
to O +
wild O -
- O -
type O +
mice O -
, O +
treatment O +
of O +
PPARalpha- O -
/ O -
- O +
mice O +
with O +
amiodarone O +
resulted O +
in O +
an O +
increased O +
rate O +
and O +
extent O +
of O +
total O +
body O +
weight B-Disease +
loss L-Disease -
. O -

The O +
inability O +
of O +
amiodarone O +
to O +
directly O +
activate O +
either O +
human O +
or O +
mouse O +
PPARalpha O +
transiently O +
expressed O +
in O +
human O +
HepG2 O +
hepatoma U-Disease +
cells O +
indicates O +
that O +
the O +
effects O +
of O +
amiodarone O +
on O +
the O +
function O +
of O +
this O +
receptor O +
were O +
indirect O -
. O -

Based O +
upon O +
these O +
results O -
, O +
we O +
conclude O +
that O +
amiodarone O +
disrupts O +
hepatic O +
lipid O +
homeostasis O +
and O +
that O +
the O +
increased O +
expression O +
of O +
PPARalpha O +
target O +
genes O +
is O +
secondary O +
to O +
this O +
toxic O +
effect O -
. O -

These O +
results O +
provide O +
important O +
new O +
mechanistic O +
information O +
regarding O +
the O +
hepatotoxic U-Disease +
effects O +
of O +
amiodarone O +
and O +
indicate O +
that O +
PPARalpha O +
protects O +
against O +
amiodarone O -
- O -
induced O +
hepatotoxicity U-Disease -
. O -

Safety O +
and O +
compliance O +
with O +
once O -
- O -
daily O +
niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O +
as O +
initial O +
therapy O +
in O +
the O +
Impact O +
of O +
Medical O +
Subspecialty O +
on O +
Patient O +
Compliance O +
to O +
Treatment O +
( O -
IMPACT O -
) O +
study O -
. O -

Niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O +
is O +
a O +
new O +
combination O +
product O +
approved O +
for O +
treatment O +
of O +
primary O +
hypercholesterolemia U-Disease +
and O +
mixed O +
dyslipidemia U-Disease -
. O -

This O +
open O -
- O -
labeled O -
, O +
multicenter O +
study O +
evaluated O +
the O +
safety O +
of O +
bedtime O +
niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O +
when O +
dosed O +
as O +
initial O +
therapy O +
and O +
patient O +
compliance O +
to O +
treatment O +
in O +
various O +
clinical O +
practice O +
settings O -
. O -

A O +
total O +
of O +
4,499 O +
patients O +
with O +
dyslipidemia U-Disease +
requiring O +
drug O +
intervention O +
was O +
enrolled O +
at O +
1,081 O +
sites O -
. O -

Patients O +
were O +
treated O +
with O +
1 O +
tablet O +
( O -
500 O +
mg O +
of O +
niacin O +
extended O -
- O -
release O -
/ O -
20 O +
mg O +
of O +
lovastatin O -
) O +
once O +
nightly O +
for O +
4 O +
weeks O +
and O +
then O +
2 O +
tablets O +
for O +
8 O +
weeks O -
. O -

Patients O +
also O +
received O +
dietary O +
counseling O -
, O +
educational O +
materials O -
, O +
and O +
reminders O +
to O +
call O +
a O +
toll O -
- O -
free O +
number O +
that O +
provided O +
further O +
education O +
about O +
dyslipidemia U-Disease +
and O +
niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O -
. O -

Primary O +
end O +
points O +
were O +
study O +
compliance O -
, O +
increases O +
in O +
liver O +
transaminases O +
to O +
> O -
3 O +
times O +
the O +
upper O +
limit O +
of O +
normal O -
, O +
and O +
clinical O +
myopathy U-Disease -
. O -

Final O +
study O +
status O +
was O +
available O +
for O +
4,217 O +
patients O +
( O -
94 O -
% O -
) O -
. O -

Compliance O +
to O +
niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O +
was O +
77 O -
% O -
, O +
with O +
3,245 O +
patients O +
completing O +
the O +
study O -
. O -

Patients O +
in O +
the O +
southeast O +
and O +
those O +
enrolled O +
by O +
endocrinologists O +
had O +
the O +
lowest O +
compliance O +
and O +
highest O +
adverse O +
event O +
rates O -
. O -

Flushing U-Disease +
was O +
the O +
most O +
common O +
adverse O +
event O -
, O +
reported O +
by O +
18 O -
% O +
of O +
patients O +
and O +
leading O +
to O +
discontinuation O +
by O +
6 O -
% O -
. O -

Incidence O +
of O +
increased O +
aspartate O +
aminotransferase O +
and/or O +
alanine O +
aminotransferase O +
> O -
3 O +
times O +
the O +
upper O +
limit O +
of O +
normal O +
was O +
< O -
0.3 O -
% O -
. O -

An O +
increase O +
of O +
creatine O +
phosphokinase O +
to O +
> O -
5 O +
times O +
the O +
upper O +
limit O +
of O +
normal O +
occurred O +
in O +
0.24 O -
% O +
of O +
patients O -
, O +
and O +
no O +
cases O +
of O +
drug O -
- O -
induced O +
myopathy U-Disease +
were O +
observed O -
. O -

Niacin O +
extended O -
- O -
release O -
/ O -
lovastatin O +
1,000 O -
/ O -
40 O +
mg O -
, O +
dosed O +
as O +
initial O +
therapy O -
, O +
was O +
associated O +
with O +
good O +
compliance O +
and O +
safety O +
and O +
had O +
very O +
low O +
incidences O +
of O +
increased O +
liver O +
and O +
muscle O +
enzymes O -
. O -

Protective O +
effect O +
of O +
Terminalia O +
chebula O +
against O +
experimental O +
myocardial B-Disease +
injury L-Disease +
induced O +
by O +
isoproterenol O -
. O -

Cardioprotective O +
effect O +
of O +
ethanolic O +
extract O +
of O +
Terminalia O +
chebula O +
fruits O +
( O -
500 O +
mg O -
/ O -
kg O +
body O +
wt O -
) O +
was O +
examined O +
in O +
isoproterenol O +
( O -
200 O +
mg O -
/ O -
kg O +
body O +
wt O -
) O +
induced O +
myocardial B-Disease +
damage L-Disease +
in O +
rats O -
. O -

In O +
isoproterenol O +
administered O +
rats O -
, O +
the O +
level O +
of O +
lipid O +
peroxides O +
increased O +
significantly O +
in O +
the O +
serum O +
and O +
heart O -
. O -

A O +
significant O +
decrease O +
was O +
observed O +
in O +
the O +
activity O +
of O +
the O +
myocardial O +
marker O +
enzymes O +
with O +
a O +
concomitant O +
increase O +
in O +
their O +
activity O +
in O +
serum O -
. O -

Histopathological O +
examination O +
was O +
carried O +
out O +
to O +
confirm O +
the O +
myocardial O +
necrosis U-Disease -
. O -

T. O +
chebula O +
extract O +
pretreatment O +
was O +
found O +
to O +
ameliorate O +
the O +
effect O +
of O +
isoproterenol O +
on O +
lipid O +
peroxide O +
formation O +
and O +
retained O +
the O +
activities O +
of O +
the O +
diagnostic O +
marker O +
enzymes O -
. O -

A O +
case O +
of O +
postoperative O +
anxiety U-Disease +
due O +
to O +
low O +
dose O +
droperidol O +
used O +
with O +
patient O -
- O -
controlled O +
analgesia O -
. O -

A O +
multiparous O +
woman O +
in O +
good O +
psychological O +
health O +
underwent O +
urgent O +
caesarean O +
section O +
in O +
labour O -
. O -

Postoperatively O -
, O +
she O +
was O +
given O +
a O +
patient O -
- O -
controlled O +
analgesia O +
device O +
delivering O +
boluses O +
of O +
diamorphine O +
0.5 O +
mg O +
and O +
droperidol O +
0.025 O +
mg O -
. O -

Whilst O +
using O +
the O +
device O +
she O +
gradually O +
became O +
anxious O -
, O +
the O +
feeling O +
worsening O +
after O +
each O +
bolus O -
. O -

The O +
diagnosis O +
of O +
droperidol O -
- O -
induced O +
psychological B-Disease +
disturbance L-Disease +
was O +
not O +
made O +
straight O +
away O +
although O +
on O +
subsequent O +
close O +
questioning O +
the O +
patient O +
gave O +
a O +
very O +
clear O +
history O -
. O -

After O +
she O +
had O +
received O +
a O +
total O +
of O +
only O +
0.9 O +
mg O +
droperidol O -
, O +
a O +
syringe O +
containing O +
diamorphine O +
only O +
was O +
substituted O +
and O +
her O +
unease O +
resolved O +
completely O -
. O -

We O +
feel O +
that O -
, O +
although O +
the O +
dramatic O +
extrapyramidal O +
side O +
effects O +
of O +
dopaminergic O +
antiemetics O +
are O +
well O +
known O -
, O +
more O +
subtle O +
manifestations O +
may O +
easily O +
be O +
overlooked O -
. O -

Accurate O +
patient O +
history O +
contributes O +
to O +
differentiating O +
diabetes B-Disease +
insipidus L-Disease -
: O +
a O +
case O +
study O -
. O -

This O +
case O +
study O +
highlights O +
the O +
important O +
contribution O +
of O +
nursing O +
in O +
obtaining O +
an O +
accurate O +
health O +
history O -
. O -

The O +
case O +
discussed O +
herein O +
initially O +
appeared O +
to O +
be O +
neurogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease +
( O -
DI U-Disease -
) O +
secondary O +
to O +
a O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease -
. O -

The O +
nursing O +
staff O -
, O +
by O +
reviewing O +
the O +
patient O -
's O +
health O +
history O +
with O +
his O +
family O -
, O +
discovered O +
a O +
history O +
of O +
polydipsia U-Disease +
and O +
long O -
- O -
standing O +
lithium O +
use O -
. O -

Lithium O +
is O +
implicated O +
in O +
drug O -
- O -
induced O +
nephrogenic B-Disease +
DI L-Disease -
, O +
and O +
because O +
the O +
patient O +
had O +
not O +
received O +
lithium O +
since O +
being O +
admitted O +
to O +
the O +
hospital O -
, O +
his O +
treatment O +
changed O +
to O +
focus O +
on O +
nephrogenic B-Disease +
DI L-Disease -
. O -

By O +
combining O +
information O +
from O +
the O +
patient O +
history O -
, O +
the O +
physical O +
examination O -
, O +
and O +
radiologic O +
and O +
laboratory O +
studies O -
, O +
the O +
critical O +
care O +
team O +
demonstrated O +
that O +
the O +
patient O +
had O +
been O +
self O -
- O -
treating O +
his O +
lithium O -
- O -
induced O +
nephrogenic B-Disease +
DI L-Disease +
and O +
developed O +
neurogenic B-Disease +
DI L-Disease +
secondary O +
to O +
brain B-Disease +
trauma L-Disease -
. O -

Thus O +
successful O +
treatment O +
required O +
that O +
nephrogenic O +
and O +
neurogenic B-Disease +
DI L-Disease +
be O +
treated O +
concomitantly O -
. O -

Factors O +
contributing O +
to O +
ribavirin O -
- O -
induced O +
anemia U-Disease -
. O -

BACKGROUND O +
AND O +
AIM O -
: O +
Interferon O +
and O +
ribavirin O +
combination O +
therapy O +
for O +
chronic B-Disease +
hepatitis I-Disease +
C L-Disease +
produces O +
hemolytic B-Disease +
anemia L-Disease -
. O -

This O +
study O +
was O +
conducted O +
to O +
identify O +
the O +
factors O +
contributing O +
to O +
ribavirin O -
- O -
induced O +
anemia U-Disease -
. O -

METHODS O -
: O +
Eighty O -
- O -
eight O +
patients O +
with O +
chronic B-Disease +
hepatitis I-Disease +
C L-Disease +
who O +
received O +
interferon O -
- O -
alpha-2b O +
at O +
a O +
dose O +
of O +
6 O +
MU O +
administered O +
intramuscularly O +
for O +
24 O +
weeks O +
in O +
combination O +
with O +
ribavirin O +
administered O +
orally O +
at O +
a O +
dose O +
of O +
600 O +
mg O +
or O +
800 O +
mg O +
participated O +
in O +
the O +
study O -
. O -

A O +
hemoglobin O +
concentration O +
of O +
< O -
10 O +
g O -
/ O -
dL O +
was O +
defined O +
as O +
ribavirin O -
- O -
induced O +
anemia U-Disease -
. O -

RESULTS O -
: O +
Ribavirin O -
- O -
induced O +
anemia U-Disease +
occurred O +
in O +
18 O +
( O -
20.5 O -
% O -
) O +
patients O +
during O +
treatment O -
. O -

A O +
2 O +
g O -
/ O -
dL O +
decrease O +
in O +
hemoglobin O +
concentrations O +
in O +
patients O +
with O +
anemia U-Disease +
was O +
observed O +
at O +
week O +
2 O +
after O +
the O +
start O +
of O +
treatment O -
. O -

The O +
hemoglobin O +
concentration O +
in O +
patients O +
with O +
> O +
or O +
= O -
2 O +
g O -
/ O -
dL O +
decrease O +
at O +
week O +
2 O +
was O +
observed O +
to O +
be O +
significantly O +
lower O +
even O +
after O +
week O +
2 O +
than O +
in O +
patients O +
with O +
< O -
2 O +
g O -
/ O -
dL O +
decrease O +
( O -
P O +
< O +
0.01 O -
) O -
. O -

A O +
significant O +
relationship O +
was O +
observed O +
between O +
the O +
rate O +
of O +
reduction O +
of O +
hemoglobin O +
concentrations O +
at O +
week O +
2 O +
and O +
the O +
severity O +
of O +
anemia U-Disease +
( O -
P O +
< O +
0.01 O -
) O -
. O -

Such O +
factors O +
as O +
sex O +
( O -
female O -
) O -
, O +
age O +
( O -
> O +
or O +
= O -
60 O +
years O +
old O -
) O -
, O +
and O +
the O +
ribavirin O +
dose O +
by O +
body O +
weight O +
( O -
12 O +
mg O -
/ O -
kg O +
or O +
more O -
) O +
were O +
significant O +
by O +
univariate O +
analysis O -
. O -

CONCLUSIONS O -
: O +
Careful O +
administration O +
is O +
necessary O +
in O +
patients O +
> O +
or O +
= O -
60 O +
years O +
old O -
, O +
in O +
female O +
patients O -
, O +
and O +
in O +
patients O +
receiving O +
a O +
ribavirin O +
dose O +
of O +
12 O +
mg O -
/ O -
kg O +
or O +
more O -
. O -

Patients O +
who O +
experience O +
a O +
fall O +
in O +
hemoglobin O +
concentrations O +
of O +
2 O +
g O -
/ O -
dL O +
or O +
more O +
at O +
week O +
2 O +
after O +
the O +
start O +
of O +
treatment O +
should O +
be O +
monitored O +
with O +
particular O +
care O -
. O -

Zidovudine O -
- O -
induced O +
hepatitis U-Disease -
. O -

A O +
case O +
of O +
acute O +
hepatitis U-Disease +
induced O +
by O +
zidovudine O +
in O +
a O +
38-year O -
- O -
old O +
patient O +
with O +
AIDS U-Disease +
is O +
presented O -
. O -

The O +
mechanism O +
whereby O +
the O +
hepatitis U-Disease +
was O +
induced O +
is O +
not O +
known O -
. O -

However O -
, O +
the O +
patient O +
tolerated O +
well O +
an O +
alternative O +
reverse O +
transcriptase O +
inhibitor O -
, O +
2'3 O -
' O +
dideoxyinosine O -
. O -

Physicians O +
caring O +
for O +
patients O +
with O +
AIDS U-Disease +
should O +
be O +
aware O +
of O +
this O +
hitherto O +
rarely O +
reported O +
complication O -
. O -

Oxidative O +
damage O +
precedes O +
nitrative O +
damage O +
in O +
adriamycin O -
- O -
induced O +
cardiac O +
mitochondrial B-Disease +
injury L-Disease -
. O -

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
if O +
elevated O +
reactive O +
oxygen O +
( O -
ROS O -
) O -
/ O -
nitrogen O +
species O +
( O -
RNS O -
) O +
reported O +
to O +
be O +
present O +
in O +
adriamycin O +
( O -
ADR O -
) O -
-induced O +
cardiotoxicity U-Disease +
actually O +
resulted O +
in O +
cardiomyocyte O +
oxidative O -
/ O -
nitrative O +
damage O -
, O +
and O +
to O +
quantitatively O +
determine O +
the O +
time O +
course O +
and O +
subcellular O +
localization O +
of O +
these O +
postulated O +
damage O +
products O +
using O +
an O +
in O +
vivo O +
approach O -
. O -

B6C3 O +
mice O +
were O +
treated O +
with O +
a O +
single O +
dose O +
of O +
20 O +
mg O -
/ O -
kg O +
ADR O -
. O -

Ultrastructural O +
damage O +
and O +
levels O +
of O +
4-hydroxy-2-nonenal O +
( O -
4HNE O -
) O -
-protein O +
adducts O +
and O +
3-nitrotyrosine O +
( O -
3NT O -
) O +
were O +
analyzed O -
. O -

Quantitative O +
ultrastructural O +
damage O +
using O +
computerized O +
image O +
techniques O +
showed O +
cardiomyocyte O +
injury O +
as O +
early O +
as O +
3 O +
hours O -
, O +
with O +
mitochondria O +
being O +
the O +
most O +
extensively O +
and O +
progressively O +
injured O +
subcellular O +
organelle O -
. O -

Analysis O +
of O +
4HNE O +
protein O +
adducts O +
by O +
immunogold O +
electron O +
microscopy O +
showed O +
appearance O +
of O +
4HNE O +
protein O +
adducts O +
in O +
mitochondria O +
as O +
early O +
as O +
3 O +
hours O -
, O +
with O +
a O +
peak O +
at O +
6 O +
hours O +
and O +
subsequent O +
decline O +
at O +
24 O +
hours O -
. O -

3NT O +
levels O +
were O +
significantly O +
increased O +
in O +
all O +
subcellular O +
compartments O +
at O +
6 O +
hours O +
and O +
subsequently O +
declined O +
at O +
24 O +
hours O -
. O -

Our O +
data O +
showed O +
ADR O +
induced O +
4HNE O -
- O -
protein O +
adducts O +
in O +
mitochondria O +
at O +
the O +
same O +
time O +
point O +
as O +
when O +
mitochondrial B-Disease +
injury L-Disease +
initially O +
appeared O -
. O -

These O +
results O +
document O +
for O +
the O +
first O +
time O +
in O +
vivo O +
that O +
mitochondrial B-Disease +
oxidative I-Disease +
damage L-Disease +
precedes O +
nitrative O +
damage O -
. O -

The O +
progressive O +
nature O +
of O +
mitochondrial B-Disease +
injury L-Disease +
suggests O +
that O +
mitochondria O -
, O +
not O +
other O +
subcellular O +
organelles O -
, O +
are O +
the O +
major O +
site O +
of O +
intracellular O +
injury O -
. O -

Sotalol O -
- O -
induced O +
coronary B-Disease +
spasm L-Disease +
in O +
a O +
patient O +
with O +
dilated B-Disease +
cardiomyopathy L-Disease +
associated O +
with O +
sustained O +
ventricular B-Disease +
tachycardia L-Disease -
. O -

A O +
54-year O -
- O -
old O +
man O +
with O +
severe O +
left O +
ventricular B-Disease +
dysfunction L-Disease +
due O +
to O +
dilated B-Disease +
cardiomyopathy L-Disease +
was O +
referred O +
to O +
our O +
hospital O +
for O +
symptomatic O +
incessant O +
sustained O +
ventricular B-Disease +
tachycardia L-Disease +
( O -
VT U-Disease -
) O -
. O -

After O +
the O +
administration O +
of O +
nifekalant O +
hydrochloride O -
, O +
sustained O +
VT U-Disease +
was O +
terminated O -
. O -

An O +
alternate O +
class O +
III O +
agent O -
, O +
sotalol O -
, O +
was O +
also O +
effective O +
for O +
the O +
prevention O +
of O +
VT U-Disease -
. O -

However O -
, O +
one O +
month O +
after O +
switching O +
over O +
nifekalant O +
to O +
sotalol O -
, O +
a O +
short O +
duration O +
of O +
ST O +
elevation O +
was O +
documented O +
in O +
ECG O +
monitoring O +
at O +
almost O +
the O +
same O +
time O +
for O +
three O +
consecutive O +
days O -
. O -

ST O +
elevation O +
with O +
chest O +
discomfort O +
disappeared O +
since O +
he O +
began O +
taking O +
long O -
- O -
acting O +
diltiazem O -
. O -

Coronary B-Disease +
vasospasm L-Disease +
may O +
be O +
induced O +
by O +
the O +
non O -
- O -
selective O +
beta O -
- O -
blocking O +
properties O +
of O +
sotalol O -
. O -

Effects O +
of O +
the O +
antidepressant O +
trazodone O -
, O +
a O +
5-HT O +
2A O -
/ O -
2C O +
receptor O +
antagonist O -
, O +
on O +
dopamine O -
- O -
dependent O +
behaviors O +
in O +
rats O -
. O -

RATIONALE O -
: O +
5-Hydroxytryptamine O -
, O +
via O +
stimulation O +
of O +
5-HT O +
2C O +
receptors O -
, O +
exerts O +
a O +
tonic O +
inhibitory O +
influence O +
on O +
dopaminergic O +
neurotransmission O -
, O +
whereas O +
activation O +
of O +
5-HT O +
2A O +
receptors O +
enhances O +
stimulated O +
DAergic O +
neurotransmission O -
. O -

The O +
antidepressant O +
trazodone O +
is O +
a O +
5-HT O +
2A O -
/ O -
2C O +
receptor O +
antagonist O -
. O -

OBJECTIVES O -
: O +
To O +
evaluate O +
the O +
effect O +
of O +
trazodone O +
treatment O +
on O +
behaviors O +
dependent O +
on O +
the O +
functional O +
status O +
of O +
the O +
nigrostriatal O +
DAergic O +
system O -
. O -

METHODS O -
: O +
The O +
effect O +
of O +
pretreatment O +
with O +
trazodone O +
on O +
dexamphetamine- O +
and O +
apomorphine O -
- O -
induced O +
oral B-Disease +
stereotypies L-Disease -
, O +
on O +
catalepsy U-Disease +
induced O +
by O +
haloperidol O +
and O +
apomorphine O +
( O -
0.05 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
, O +
on O +
ergometrine O -
- O -
induced O +
wet O +
dog O +
shake O +
( O -
WDS O -
) O +
behavior O +
and O +
fluoxetine O -
- O -
induced O +
penile O +
erections O +
was O +
studied O +
in O +
rats O -
. O -

We O +
also O +
investigated O +
whether O +
trazodone O +
induces O +
catalepsy U-Disease +
in O +
rats O -
. O -

RESULTS O -
: O +
Trazodone O +
at O +
2.5 O -
- O -
20 O +
mg O -
/ O -
kg O +
i.p O -
. O +
did O +
not O +
induce O +
catalepsy U-Disease -
, O +
and O +
did O +
not O +
antagonize O +
apomorphine O +
( O -
1.5 O +
and O +
3 O +
mg O -
/ O -
kg O -
) O +
stereotypy O +
and O +
apomorphine O +
( O -
0.05 O +
mg O -
/ O -
kg O -
) O -
-induced O +
catalepsy U-Disease -
. O -

However O -
, O +
pretreatment O +
with O +
5 O -
, O +
10 O +
and O +
20 O +
mg O -
/ O -
kg O +
i.p O -
. O -

trazodone O +
enhanced O +
dexamphetamine O +
stereotypy O -
, O +
and O +
antagonized O +
haloperidol O +
catalepsy U-Disease -
, O +
ergometrine O -
- O -
induced O +
WDS O +
behavior O +
and O +
fluoxetine O -
- O -
induced O +
penile O +
erections O -
. O -

Trazodone O +
at O +
30 O -
, O +
40 O +
and O +
50 O +
mg O -
/ O -
kg O +
i.p O -
. O -

induced O +
catalepsy U-Disease +
and O +
antagonized O +
apomorphine O +
and O +
dexamphetamine O +
stereotypies O -
. O -

CONCLUSIONS O -
: O +
Our O +
results O +
indicate O +
that O +
trazodone O +
at O +
2.5 O -
- O -
20 O +
mg O -
/ O -
kg O +
does O +
not O +
block O +
pre- O +
and O +
postsynaptic O +
striatal O +
D2 O +
DA O +
receptors O -
, O +
while O +
at O +
30 O -
, O +
40 O +
and O +
50 O +
mg O -
/ O -
kg O +
it O +
blocks O +
postsynaptic O +
striatal O +
D2 O +
DA O +
receptors O -
. O -

Furthermore O -
, O +
at O +
5 O -
, O +
10 O +
and O +
20 O +
mg O -
/ O -
kg O -
, O +
trazodone O +
blocks O +
5-HT O +
2A O +
and O +
5-HT O +
2C O +
receptors O -
. O -

We O +
suggest O +
that O +
trazodone O +
( O -
5 O -
, O +
10 O +
and O +
20 O +
mg O -
/ O -
kg O -
) O -
, O +
by O +
blocking O +
the O +
5-HT O +
2C O +
receptors O -
, O +
releases O +
the O +
nigrostriatal O +
DAergic O +
neurons O +
from O +
tonic O +
inhibition O +
caused O +
by O +
5-HT O -
, O +
and O +
thereby O +
potentiates O +
dexamphetamine O +
stereotypy O +
and O +
antagonizes O +
haloperidol O +
catalepsy U-Disease -
. O -

Swallowing B-Disease +
abnormalities L-Disease +
and O +
dyskinesia U-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

Gastrointestinal B-Disease +
abnormalities L-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
( O -
PD U-Disease -
) O +
have O +
been O +
known O +
for O +
almost O +
two O +
centuries O -
, O +
but O +
many O +
aspects O +
concerning O +
their O +
pathophysiology O +
have O +
not O +
been O +
completely O +
clarified O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
characterize O +
the O +
oropharyngeal O +
dynamics O +
in O +
PD U-Disease +
patients O +
with O +
and O +
without O +
levodopa O -
- O -
induced O +
dyskinesia U-Disease -
. O -

Fifteen O +
dyskinetic U-Disease -
, O +
12 O +
nondyskinetic O +
patients O -
, O +
and O +
a O +
control O +
group O +
were O +
included O -
. O -

Patients O +
were O +
asked O +
about O +
dysphagia U-Disease +
and O +
evaluated O +
with O +
the O +
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease L-Disease +
Rating O +
Scale O +
Parts O +
II O +
and O +
III O +
and O +
the O +
Hoehn O +
and O +
Yahr O +
scale O -
. O -

Deglutition O +
was O +
assessed O +
using O +
modified O +
barium O +
swallow O +
with O +
videofluoroscopy O -
. O -

Nondyskinetic O +
patients O -
, O +
but O +
not O +
the O +
dyskinetic U-Disease +
ones O -
, O +
showed O +
less O +
oropharyngeal O +
swallowing O +
efficiency O +
( O -
OPSE O -
) O +
for O +
liquid O +
food O +
than O +
controls O +
( O -
Dunnett O -
, O +
P O +
= O +
0.02 O -
) O -
. O -

Dyskinetic U-Disease +
patients O +
tended O +
to O +
have O +
a O +
greater O +
OPSE O +
than O +
nondyskinetic O +
( O -
Dunnett O -
, O +
P O +
= O +
0.06 O -
) O -
. O -

Patients O +
who O +
were O +
using O +
a O +
higher O +
dose O +
of O +
levodopa O +
had O +
a O +
greater O +
OPSE O +
and O +
a O +
trend O +
toward O +
a O +
smaller O +
oral O +
transit O +
time O +
( O -
Pearson O -
's O +
correlation O -
, O +
P O +
= O +
0.01 O +
and O +
0.08 O -
, O +
respectively O -
) O -
. O -

Neither O +
the O +
report O +
of O +
dysphagia U-Disease +
nor O +
any O +
of O +
the O +
PD U-Disease +
severity O +
parameters O +
correlated O +
to O +
the O +
videofluoroscopic O +
variables O -
. O -

In O +
the O +
current O +
study O -
, O +
dyskinetic U-Disease +
patients O +
performed O +
better O +
in O +
swallowing O +
function O -
, O +
which O +
could O +
be O +
explained O +
on O +
the O +
basis O +
of O +
a O +
greater O +
levodopa O +
dose O -
. O -

Our O +
results O +
suggest O +
a O +
role O +
for O +
levodopa O +
in O +
the O +
oral O +
phase O +
of O +
deglutition O +
and O +
confirm O +
that O +
dysphagia U-Disease +
is O +
not O +
a O +
good O +
predictor O +
of O +
deglutition O +
alterations O +
in O +
PD U-Disease -
. O -

Inhibition O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
activation O +
attenuates O +
tubulointerstitial B-Disease +
nephritis L-Disease +
induced O +
by O +
gentamicin O -
. O -

BACKGROUND O -
: O +
Animals O +
treated O +
with O +
gentamicin O +
can O +
show O +
residual O +
areas O +
of O +
interstitial O +
fibrosis U-Disease +
in O +
the O +
renal O +
cortex O -
. O -

This O +
study O +
investigated O +
the O +
expression O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
( O -
NF O -
- O -
kappaB O -
) O -
, O +
mitogen O -
- O -
activated O +
protein O +
( O -
MAP O -
) O +
kinases O +
and O +
macrophages O +
in O +
the O +
renal O +
cortex O +
and O +
structural O +
and O +
functional O +
renal O +
changes O +
of O +
rats O +
treated O +
with O +
gentamicin O +
or O +
gentamicin O +
+ O +
pyrrolidine O +
dithiocarbamate O +
( O -
PDTC O -
) O -
, O +
an O +
NF O -
- O -
kappaB O +
inhibitor O -
. O -

METHODS O -
: O +
38 O +
female O +
Wistar O +
rats O +
were O +
injected O +
with O +
gentamicin O -
, O +
40 O +
mg O -
/ O -
kg O -
, O +
twice O +
a O +
day O +
for O +
9 O +
days O -
, O +
38 O +
with O +
gentamicin O +
+ O +
PDTC O -
, O +
and O +
28 O +
with O +
0.15 O +
M O +
NaCl O +
solution O -
. O -

The O +
animals O +
were O +
killed O +
5 O +
and O +
30 O +
days O +
after O +
these O +
injections O +
and O +
the O +
kidneys O +
were O +
removed O +
for O +
histological O +
and O +
immunohistochemical O +
studies O -
. O -

The O +
results O +
of O +
the O +
immunohistochemical O +
studies O +
were O +
scored O +
according O +
to O +
the O +
extent O +
of O +
staining O -
. O -

The O +
fractional O +
interstitial O +
area O +
was O +
determined O +
by O +
morphometry O -
. O -

RESULTS O -
: O +
Gentamicin O -
- O -
treated O +
rats O +
presented O +
a O +
transitory O +
increase O +
in O +
plasma O +
creatinine O +
levels O -
. O -

Increased O +
ED-1 O -
, O +
MAP O +
kinases O +
and O +
NF O -
- O -
kappaB O +
staining O +
were O +
also O +
observed O +
in O +
the O +
renal O +
cortex O +
from O +
all O +
gentamicin O -
- O -
treated O +
rats O +
compared O +
to O +
control O +
( O -
p O +
< O +
0.05 O -
) O -
. O -

The O +
animals O +
killed O +
on O +
day O +
30 O +
also O +
presented O +
fibrosis U-Disease +
in O +
the O +
renal O +
cortex O +
despite O +
the O +
recovery O +
of O +
renal O +
function O -
. O -

Treatment O +
with O +
PDTC O +
reduced O +
the O +
functional O +
and O +
structural O +
changes O +
induced O +
by O +
gentamicin O -
. O -

CONCLUSIONS O -
: O +
These O +
data O +
show O +
that O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activation O +
attenuates O +
tubulointerstitial B-Disease +
nephritis L-Disease +
induced O +
by O +
gentamicin O -
. O -

Glucose O +
metabolism O +
in O +
patients O +
with O +
schizophrenia U-Disease +
treated O +
with O +
atypical O +
antipsychotic O +
agents O -
: O +
a O +
frequently O +
sampled O +
intravenous O +
glucose O +
tolerance O +
test O +
and O +
minimal O +
model O +
analysis O -
. O -

BACKGROUND O -
: O +
While O +
the O +
incidence O +
of O +
new O -
- O -
onset O +
diabetes B-Disease +
mellitus L-Disease +
may O +
be O +
increasing O +
in O +
patients O +
with O +
schizophrenia U-Disease +
treated O +
with O +
certain O +
atypical O +
antipsychotic O +
agents O -
, O +
it O +
remains O +
unclear O +
whether O +
atypical O +
agents O +
are O +
directly O +
affecting O +
glucose O +
metabolism O +
or O +
simply O +
increasing O +
known O +
risk O +
factors O +
for O +
diabetes U-Disease -
. O -

OBJECTIVE O -
: O +
To O +
study O +
the O +
2 O +
drugs O +
most O +
clearly O +
implicated O +
( O -
clozapine O +
and O +
olanzapine O -
) O +
and O +
risperidone O +
using O +
a O +
frequently O +
sampled O +
intravenous O +
glucose O +
tolerance O +
test O -
. O -

DESIGN O -
: O +
A O +
cross O -
- O -
sectional O +
design O +
in O +
stable O -
, O +
treated O +
patients O +
with O +
schizophrenia U-Disease +
evaluated O +
using O +
a O +
frequently O +
sampled O +
intravenous O +
glucose O +
tolerance O +
test O +
and O +
the O +
Bergman O +
minimal O +
model O +
analysis O -
. O -

SETTING O -
: O +
Subjects O +
were O +
recruited O +
from O +
an O +
urban O +
community O +
mental O +
health O +
clinic O +
and O +
were O +
studied O +
at O +
a O +
general O +
clinical O +
research O +
center O -
. O -

Patients O +
Fifty O +
subjects O +
signed O +
informed O +
consent O +
and O +
41 O +
underwent O +
the O +
frequently O +
sampled O +
intravenous O +
glucose O +
tolerance O +
test O -
. O -

Thirty O -
- O -
six O +
nonobese O +
subjects O +
with O +
schizophrenia U-Disease +
or O +
schizoaffective B-Disease +
disorder L-Disease -
, O +
matched O +
by O +
body O +
mass O +
index O +
and O +
treated O +
with O +
either O +
clozapine O -
, O +
olanzapine O -
, O +
or O +
risperidone O -
, O +
were O +
included O +
in O +
the O +
analysis O -
. O -

MAIN O +
OUTCOME O +
MEASURES O -
: O +
Fasting O +
plasma O +
glucose O +
and O +
fasting O +
serum O +
insulin O +
levels O -
, O +
insulin B-Disease +
sensitivity L-Disease +
index O -
, O +
homeostasis O +
model O +
assessment O +
of O +
insulin B-Disease +
resistance L-Disease -
, O +
and O +
glucose O +
effectiveness O -
. O -

RESULTS O -
: O +
The O +
mean O +
+ O -
/- O -

SD O +
duration O +
of O +
treatment O +
with O +
the O +
identified O +
atypical O +
antipsychotic O +
agent O +
was O +
68.3 O +
+ O -
/- O -

28.9 O +
months O +
( O -
clozapine O -
) O -
, O +
29.5 O +
+ O -
/- O -

17.5 O +
months O +
( O -
olanzapine O -
) O -
, O +
and O +
40.9 O +
+ O -
/- O -

33.7 O +
( O -
risperidone O -
) O -
. O -

Fasting O +
serum O +
insulin O +
concentrations O +
differed O +
among O +
groups O +
( O -
F O -
( O -
33 O -
) O +
= O +
3.35 O -
; O +
P O +
= O +
.047 O -
) O +
( O -
clozapine O -
> O -
olanzapine O -
> O -
risperidone O -
) O +
with O +
significant O +
differences O +
between O +
clozapine O +
and O +
risperidone O +
( O -
t O -
( O -
33 O -
) O +
= O +
2.32 O -
; O +
P O +
= O +
.03 O -
) O +
and O +
olanzapine O +
and O +
risperidone O +
( O -
t O -
( O -
33 O -
) O +
= O +
2.15 O -
; O +
P O +
= O +
.04 O -
) O -
. O -

There O +
was O +
a O +
significant O +
difference O +
in O +
insulin B-Disease +
sensitivity L-Disease +
index O +
among O +
groups O +
( O -
F O -
( O -
33 O -
) O +
= O +
10.66 O -
; O +
P<.001 O -
) O +
( O -
clozapine O -
< O -
olanzapine O -
< O -
risperidone O -
) O -
, O +
with O +
subjects O +
who O +
received O +
clozapine O +
and O +
olanzapine O +
exhibiting O +
significant O +
insulin B-Disease +
resistance L-Disease +
compared O +
with O +
subjects O +
who O +
were O +
treated O +
with O +
risperidone O +
( O -
clozapine O +
vs O +
risperidone O -
, O +
t O -
( O -
33 O -
) O +
= O +
-4.29 O -
; O +
P<.001 O -
; O +
olanzapine O +
vs O +
risperidone O -
, O +
t O -
( O -
33 O -
) O +
= O +
-3.62 O -
; O +
P O +
= O +
.001 O +
[ O -
P<.001 O -
] O -
) O -
. O -

The O +
homeostasis O +
model O +
assessment O +
of O +
insulin B-Disease +
resistance L-Disease +
also O +
differed O +
significantly O +
among O +
groups O +
( O -
F O -
( O -
33 O -
) O +
= O +
4.92 O -
; O +
P O +
= O +
.01 O -
) O +
( O -
clozapine O -
> O -
olanzapine O -
> O -
risperidone O -
) O +
( O -
clozapine O +
vs O +
risperidone O -
, O +
t O -
( O -
33 O -
) O +
= O +
2.94 O -
; O +
P O +
= O +
.006 O -
; O +
olanzapine O +
vs O +
risperidone O -
, O +
t O -
( O -
33 O -
) O +
= O +
2.42 O -
; O +
P O +
= O +
.02 O -
) O -
. O -

There O +
was O +
a O +
significant O +
difference O +
among O +
groups O +
in O +
glucose O +
effectiveness O +
( O -
F O -
( O -
30 O -
) O +
= O +
4.18 O -
; O +
P O +
= O +
.02 O -
) O +
( O -
clozapine O -
< O -
olanzapine O -
< O -
risperidone O -
) O +
with O +
significant O +
differences O +
between O +
clozapine O +
and O +
risperidone O +
( O -
t O -
( O -
30 O -
) O +
= O +
-2.59 O -
; O +
P O +
= O +
.02 O -
) O +
and O +
olanzapine O +
and O +
risperidone O +
( O -
t O -
( O -
30 O -
) O +
= O +
-2.34 O -
, O +
P O +
= O +
.03 O -
) O -
. O -

CONCLUSIONS O -
: O +
Both O +
nonobese O +
clozapine- O +
and O +
olanzapine O -
- O -
treated O +
groups O +
displayed O +
significant O +
insulin B-Disease +
resistance L-Disease +
and O +
impairment O +
of O +
glucose O +
effectiveness O +
compared O +
with O +
risperidone O -
- O -
treated O +
subjects O -
. O -

Patients O +
taking O +
clozapine O +
and O +
olanzapine O +
must O +
be O +
examined O +
for O +
insulin B-Disease +
resistance L-Disease +
and O +
its O +
consequences O -
. O -

Thoracic B-Disease +
hematomyelia L-Disease +
secondary O +
to O +
coumadin O +
anticoagulant O +
therapy O -
: O +
a O +
case O +
report O -
. O -

A O +
case O +
of O +
thoracic B-Disease +
hematomyelia L-Disease +
secondary O +
to O +
anticoagulant O +
therapy O +
is O +
presented O -
. O -

Clinical O +
features O -
, O +
similar O +
to O +
2 O +
other O +
previously O +
reported O +
cases O -
, O +
are O +
discussed O -
. O -

A O +
high O +
index O +
of O +
suspicion O +
may O +
lead O +
to O +
a O +
quick O +
diagnostic O +
procedure O +
and O +
successful O +
decompressive O +
surgery O -
. O -

Mania U-Disease +
associated O +
with O +
fluoxetine O +
treatment O +
in O +
adolescents O -
. O -

Fluoxetine O -
, O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O -
, O +
is O +
gaining O +
increased O +
acceptance O +
in O +
the O +
treatment O +
of O +
adolescent O +
depression U-Disease -
. O -

Generally O +
safe O +
and O +
well O +
tolerated O +
by O +
adults O -
, O +
fluoxetine O +
has O +
been O +
reported O +
to O +
induce O +
mania U-Disease -
. O -

The O +
cases O +
of O +
five O +
depressed U-Disease +
adolescents O -
, O +
14 O -
- O -
16 O +
years O +
of O +
age O -
, O +
who O +
developed O +
mania U-Disease +
during O +
pharmacotherapy O +
with O +
fluoxetine O -
, O +
are O +
reported O +
here O -
. O -

Apparent O +
risk O +
factors O +
for O +
the O +
development O +
of O +
mania U-Disease +
or O +
hypomania U-Disease +
during O +
fluoxetine O +
pharmacotherapy O +
in O +
this O +
population O +
were O +
the O +
combination O +
of O +
attention B-Disease -
- I-Disease -
deficit I-Disease +
hyperactivity I-Disease +
disorder L-Disease +
and O +
affective O +
instability O -
; O +
major O +
depression U-Disease +
with O +
psychotic U-Disease +
features O -
; O +
a O +
family O +
history O +
of O +
affective B-Disease +
disorder L-Disease -
, O +
especially O +
bipolar B-Disease +
disorder L-Disease -
; O +
and O +
a O +
diagnosis O +
of O +
bipolar B-Disease +
disorder L-Disease -
. O -

Further O +
study O +
is O +
needed O +
to O +
determine O +
the O +
optimal O +
dosage O +
and O +
to O +
identify O +
risk O +
factors O +
that O +
increase O +
individual O +
vulnerability O +
to O +
fluoxetine O +
induced O +
mania U-Disease +
in O +
adolescents O -
. O -

Acute B-Disease +
renal I-Disease +
insufficiency L-Disease +
after O +
high O -
- O -
dose O +
melphalan O +
in O +
patients O +
with O +
primary B-Disease +
systemic I-Disease +
amyloidosis L-Disease +
during O +
stem O +
cell O +
transplantation O -
. O -

BACKGROUND O -
: O +
Patients O +
with O +
primary B-Disease +
systemic I-Disease +
amyloidosis L-Disease +
( O -
AL U-Disease -
) O +
have O +
a O +
poor O +
prognosis O -
. O -

Median O +
survival O +
time O +
from O +
standard O +
treatments O +
is O +
only O +
17 O +
months O -
. O -

High O -
- O -
dose O +
intravenous O +
melphalan O +
followed O +
by O +
peripheral O +
blood O +
stem O +
cell O +
transplant O +
( O -
PBSCT O -
) O +
appears O +
to O +
be O +
the O +
most O +
promising O +
therapy O -
, O +
but O +
treatment O +
mortality O +
can O +
be O +
high O -
. O -

The O +
authors O +
have O +
noted O +
the O +
development O +
of O +
acute B-Disease +
renal I-Disease +
insufficiency L-Disease +
immediately O +
after O +
melphalan O +
conditioning O -
. O -

This O +
study O +
was O +
undertaken O +
to O +
further O +
examine O +
its O +
risk O +
factors O +
and O +
impact O +
on O +
posttransplant O +
mortality O -
. O -

METHODS O -
: O +
Consecutive O +
AL U-Disease +
patients O +
who O +
underwent O +
PBSCT O +
were O +
studied O +
retrospectively O -
. O -

Acute B-Disease +
renal I-Disease +
insufficiency L-Disease +
( O -
ARI U-Disease -
) O +
after O +
high O -
- O -
dose O +
melphalan O +
was O +
defined O +
by O +
a O +
minimum O +
increase O +
of O +
0.5 O +
mg O -
/ O -
dL O +
( O -
44 O +
micromol O -
/ O -
L O -
) O +
in O +
the O +
serum O +
creatinine O +
level O +
that O +
is O +
greater O +
than O +
50 O -
% O +
of O +
baseline O +
immediately O +
after O +
conditioning O -
. O -

Urine O +
sediment O +
score O +
was O +
the O +
sum O +
of O +
the O +
individual O +
types O +
of O +
sediment O +
identified O +
on O +
urine O +
microscopy O -
. O -

RESULTS O -
: O +
Of O +
the O +
80 O +
patients O +
studied O -
, O +
ARI U-Disease +
developed O +
in O +
18.8 O -
% O +
of O +
the O +
patients O +
after O +
high O -
- O -
dose O +
melphalan O -
. O -

Univariate O +
analysis O +
identified O +
age O -
, O +
hypoalbuminemia U-Disease -
, O +
heavy O +
proteinuria U-Disease -
, O +
diuretic O +
use O -
, O +
and O +
urine O +
sediment O +
score O +
( O -
> O -
3 O -
) O +
as O +
risk O +
factors O -
. O -

Age O +
and O +
urine O +
sediment O +
score O +
remained O +
independently O +
significant O +
risk O +
factors O +
in O +
the O +
multivariate O +
analysis O -
. O -

Patients O +
who O +
had O +
ARI U-Disease +
after O +
high O -
- O -
dose O +
melphalan O +
underwent O +
dialysis O +
more O +
often O +
( O -
P O +
= O +
0.007 O -
) O -
, O +
and O +
had O +
a O +
worse O +
1-year O +
survival O +
( O -
P O +
= O +
0.03 O -
) O -
. O -

CONCLUSION O -
: O +
The O +
timing O +
of O +
renal B-Disease +
injury L-Disease +
strongly O +
suggests O +
melphalan O +
as O +
the O +
causative O +
agent O -
. O -

Ongoing O +
tubular B-Disease +
injury L-Disease +
may O +
be O +
a O +
prerequisite O +
for O +
renal B-Disease +
injury L-Disease +
by O +
melphalan O +
as O +
evidenced O +
by O +
the O +
active O +
urinary O +
sediment O -
. O -

Development O +
of O +
ARI U-Disease +
adversely O +
affected O +
the O +
outcome O +
after O +
PBSCT O -
. O -

Effective O +
preventive O +
measures O +
may O +
help O +
decrease O +
the O +
treatment O +
mortality O +
of O +
PBSCT O +
in O +
AL U-Disease +
patients O -
. O -

Focal O +
cerebral B-Disease +
ischemia L-Disease +
in O +
rats O -
: O +
effect O +
of O +
phenylephrine O -
- O -
induced O +
hypertension U-Disease +
during O +
reperfusion O -
. O -

After O +
180 O +
min O +
of O +
temporary O +
middle B-Disease +
cerebral I-Disease +
artery I-Disease +
occlusion L-Disease +
in O +
spontaneously O +
hypertensive U-Disease +
rats O -
, O +
the O +
effect O +
of O +
phenylephrine O -
- O -
induced O +
hypertension U-Disease +
on O +
ischemic B-Disease +
brain I-Disease +
injury L-Disease +
and O +
blood O -
- O -
brain O +
barrier O +
permeability O +
was O +
determined O -
. O -

Blood O +
pressure O +
was O +
manipulated O +
by O +
one O +
of O +
the O +
following O +
schedules O +
during O +
120 O +
min O +
of O +
reperfusion O -
: O +
Control O -
, O +
normotensive O +
reperfusion O -
; O +
90 O -
/ O -
hypertension U-Disease +
( O -
90 O -
/ O -
HTN U-Disease -
) O -
, O +
blood O +
pressure O +
was O +
increased O +
by O +
35 O +
mm O +
Hg O +
during O +
the O +
initial O +
90 O +
min O +
of O +
reperfusion O +
only O -
; O +
15 O -
/ O -
hypertension U-Disease +
( O -
15 O -
/ O -
HTN U-Disease -
) O -
, O +
normotensive O +
reperfusion O +
for O +
30 O +
min O +
followed O +
by O +
15 O +
min O +
of O +
hypertension U-Disease +
and O +
75 O +
min O +
of O +
normotension O -
. O -

Part O +
A O -
, O +
for O +
eight O +
rats O +
in O +
each O +
group O +
brain B-Disease +
injury L-Disease +
was O +
evaluated O +
by O +
staining O +
tissue O +
using O +
2,3,5-triphenyltetrazolium O +
chloride O +
and O +
edema U-Disease +
was O +
evaluated O +
by O +
microgravimetry O -
. O -

Part O +
B O -
, O +
for O +
eight O +
different O +
rats O +
in O +
each O +
group O +
blood O -
- O -
brain O +
barrier O +
permeability O +
was O +
evaluated O +
by O +
measuring O +
the O +
amount O +
and O +
extent O +
of O +
extravasation O +
of O +
Evans O +
Blue O +
dye O -
. O -

Brain B-Disease +
injury L-Disease +
( O -
percentage O +
of O +
the O +
ischemic B-Disease +
hemisphere L-Disease -
) O +
was O +
less O +
in O +
the O +
15 O -
/ O -
HTN U-Disease +
group O +
( O -
16 O +
+ O -
/- O -

6 O -
, O +
mean O +
+ O -
/- O -

SD O -
) O +
versus O +
the O +
90 O -
/ O -
HTN U-Disease +
group O +
( O -
30 O +
+ O -
/- O -

6 O -
) O -
, O +
which O +
was O +
in O +
turn O +
less O +
than O +
the O +
control O +
group O +
( O -
42 O +
+ O -
/- O -

5 O -
) O -
. O -

Specific O +
gravity O +
was O +
greater O +
in O +
the O +
15 O -
/ O -
HTN U-Disease +
group O +
( O -
1.043 O +
+ O -
/- O +
0.002 O -
) O +
versus O +
the O +
90 O -
/ O -
HTN U-Disease +
( O -
1.036 O +
+ O -
/- O -

0.003 O -
) O +
and O +
control O +
( O -
1.037 O +
+ O -
/- O -

0.003 O -
) O +
groups O -
. O -

Evans O +
Blue O +
( O -
mug O +
g-1 O +
of O +
brain O +
tissue O -
) O +
was O +
greater O +
in O +
the O +
90 O -
/ O -
HTN U-Disease +
group O +
( O -
24.4 O +
+ O -
/- O -

6.0 O -
) O +
versus O +
the O +
control O +
group O +
( O -
12.3 O +
+ O -
/- O -

4.1 O -
) O -
, O +
which O +
was O +
in O +
turn O +
greater O +
than O +
the O +
15 O -
/ O -
HTN U-Disease +
group O +
( O -
7.3 O +
+ O -
/- O -

3.2 O -
) O -
. O -

This O +
study O +
supports O +
a O +
hypothesis O +
that O +
during O +
reperfusion O -
, O +
a O +
short O +
interval O +
of O +
hypertension U-Disease +
decreases O +
brain B-Disease +
injury L-Disease +
and O +
edema U-Disease -
; O +
and O +
that O +
sustained O +
hypertension U-Disease +
increases O +
the O +
risk O +
of O +
vasogenic B-Disease +
edema L-Disease -
. O -

People O +
aged O +
over O +
75 O +
in O +
atrial B-Disease +
fibrillation L-Disease +
on O +
warfarin O -
: O +
the O +
rate O +
of O +
major O +
hemorrhage U-Disease +
and O +
stroke U-Disease +
in O +
more O +
than O +
500 O +
patient O -
- O -
years O +
of O +
follow O -
- O -
up O -
. O -

OBJECTIVES O -
: O +
To O +
determine O +
the O +
incidence O +
of O +
major O +
hemorrhage U-Disease +
and O +
stroke U-Disease +
in O +
people O +
aged O +
76 O +
and O +
older O +
with O +
atrial B-Disease +
fibrillation L-Disease +
on O +
adjusted O -
- O -
dose O +
warfarin O +
who O +
had O +
been O +
recently O +
been O +
admitted O +
to O +
hospital O -
. O -

DESIGN O -
: O +
A O +
retrospective O +
observational O +
cohort O +
study O -
. O -

SETTING O -
: O +
A O +
major O +
healthcare O +
network O +
involving O +
four O +
tertiary O +
hospitals O -
. O -

PARTICIPANTS O -
: O +
Two O +
hundred O +
thirty O -
- O -
five O +
patients O +
aged O +
76 O +
and O +
older O +
admitted O +
to O +
a O +
major O +
healthcare O +
network O +
between O +
July O +
1 O -
, O +
2001 O -
, O +
and O +
June O +
30 O -
, O +
2002 O -
, O +
with O +
atrial B-Disease +
fibrillation L-Disease +
on O +
warfarin O +
were O +
enrolled O -
. O -

MEASUREMENTS O -
: O +
Information O +
regarding O +
major O +
bleeding U-Disease +
episodes O -
, O +
strokes U-Disease -
, O +
and O +
warfarin O +
use O +
was O +
obtained O +
from O +
patients O -
, O +
relatives O -
, O +
primary O +
physicians O -
, O +
and O +
medical O +
records O -
. O -

RESULTS O -
: O +
Two O +
hundred O +
twenty O -
- O -
eight O +
patients O +
( O -
42 O -
% O +
men O -
) O +
with O +
a O +
mean O +
age O +
of O +
81.1 O +
( O -
range O +
76 O -
- O -
94 O -
) O +
were O +
included O +
in O +
the O +
analysis O -
. O -

Total O +
follow O -
- O -
up O +
on O +
warfarin O +
was O +
530 O +
years O +
( O -
mean O +
28 O +
months O -
) O -
. O -

There O +
were O +
53 O +
major O +
hemorrhages U-Disease -
, O +
for O +
an O +
annual O +
rate O +
of O +
10.0 O -
% O -
, O +
including O +
24 O +
( O -
45.3 O -
% O -
) O +
life O -
- O -
threatening O +
and O +
five O +
( O -
9.4 O -
% O -
) O +
fatal O +
bleeds O -
. O -

The O +
annual O +
stroke U-Disease +
rate O +
after O +
initiation O +
of O +
warfarin O +
was O +
2.6 O -
% O -
. O -

CONCLUSION O -
: O +
The O +
rate O +
of O +
major O +
hemorrhage U-Disease +
was O +
high O +
in O +
this O +
old O -
, O +
frail O +
group O -
, O +
but O +
excluding O +
fatalities O -
, O +
resulted O +
in O +
no O +
long O -
- O -
term O +
sequelae O -
, O +
and O +
the O +
stroke U-Disease +
rate O +
on O +
warfarin O +
was O +
low O -
, O +
demonstrating O +
how O +
effective O +
warfarin O +
treatment O +
is O -
. O -

Safety O +
of O +
celecoxib O +
in O +
patients O +
with O +
adverse O +
skin B-Disease +
reactions L-Disease +
to O +
acetaminophen O +
( O -
paracetamol O -
) O +
and O +
nimesulide O +
associated O +
or O +
not O +
with O +
common O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O -
. O -

BACKGROUND O -
: O +
Acetaminophen O +
( O -
paracetamol O -
-- O -
P O -
) O +
and O +
Nimesulide O +
( O -
N O -
) O +
are O +
widely O +
used O +
analgesic O -
- O -
antipyretic O -
/ O -
anti O -
- O -
inflammatory O +
drugs O -
. O -

The O +
rate O +
of O +
adverse O +
hypersensitivity U-Disease +
reactions O +
to O +
these O +
agents O +
is O +
generally O +
low O -
. O -

On O +
the O +
contrary O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
are O +
commonly O +
involved O +
in O +
such O +
reactions O -
. O -

Celecoxib O +
( O -
CE O -
) O +
is O +
a O +
novel O +
drug O -
, O +
with O +
high O +
selectivity O +
and O +
affinity O +
for O +
COX-2 O +
enzyme O -
. O -

OBJECTIVE O -
: O +
We O +
evaluated O +
the O +
tolerability O +
of O +
CE O +
in O +
a O +
group O +
of O +
patients O +
with O +
documented O +
history O +
of O +
adverse O +
cutaneous B-Disease +
reactions L-Disease +
to O +
P O +
and O +
N O +
associated O +
or O +
not O +
to O +
classic O +
NSAIDs O -
. O -

METHODS O -
: O +
We O +
studied O +
9 O +
patients O +
with O +
hypersensitivity U-Disease +
to O +
P O +
and O +
N O +
with O +
or O +
without O +
associated O +
reactions O +
to O +
classic O +
NSAIDs O -
. O -

The O +
diagnosis O +
of O +
P O +
and O +
N O -
- O -
induced O +
skin B-Disease +
reactions L-Disease +
was O +
based O +
in O +
vivo O +
challenge O -
. O -

The O +
placebo O +
was O +
blindly O +
administered O +
at O +
the O +
beginning O +
of O +
each O +
challenge O -
. O -

After O +
three O +
days O -
, O +
a O +
cumulative O +
dosage O +
of O +
200 O +
mg O +
of O +
CE O +
in O +
refracted O +
doses O +
were O +
given O -
. O -

After O +
2 O -
- O -
3 O +
days O -
, O +
a O +
single O +
dose O +
of O +
200 O +
mg O +
was O +
administered O -
. O -

All O +
patients O +
were O +
observed O +
for O +
6 O +
hours O +
after O +
each O +
challenge O -
, O +
and O +
controlled O +
again O +
after O +
24 O +
hours O +
to O +
exclude O +
delayed O +
reactions O -
. O -

The O +
challenge O +
was O +
considered O +
positive O +
if O +
one O +
or O +
more O +
of O +
the O +
following O +
appeared O -
: O +
erythema U-Disease -
, O +
rush O +
or O +
urticaria U-Disease -
- O -
angioedema U-Disease -
. O -

RESULTS O -
: O +
No O +
reaction O +
was O +
observed O +
with O +
placebo O +
and O +
eight O +
patients O +
( O -
88.8 O -
% O -
) O +
tolerated O +
CE O -
. O -

Only O +
one O +
patient O +
developed O +
a O +
moderate O +
angioedema U-Disease +
of O +
the O +
lips O -
. O -

CONCLUSION O -
: O +
Only O +
one O +
hypersensitivity U-Disease +
reaction O +
to O +
CE O +
was O +
documented O +
among O +
9 O +
P O +
and O +
N O -
- O -
highly O +
NSAIDs O +
intolerant O +
patients O -
. O -

Thus O -
, O +
we O +
conclude O +
that O +
CE O +
is O +
a O +
reasonably O +
safe O +
alternative O +
to O +
be O +
used O +
in O +
subjects O +
who O +
do O +
not O +
tolerate O +
P O +
and O +
N. O -

Case O -
- O -
control O +
study O +
of O +
regular O +
analgesic O +
and O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
use O +
and O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease -
. O -

BACKGROUND O -
: O +
Studies O +
on O +
the O +
association O +
between O +
the O +
long O -
- O -
term O +
use O +
of O +
aspirin O +
and O +
other O +
analgesic O +
and O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
and O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease +
( O -
ESRD U-Disease -
) O +
have O +
given O +
conflicting O +
results O -
. O -

In O +
order O +
to O +
examine O +
this O +
association O -
, O +
a O +
case O -
- O -
control O +
study O +
with O +
incident O +
cases O +
of O +
ESRD U-Disease +
was O +
carried O +
out O -
. O -

METHODS O -
: O +
The O +
cases O +
were O +
all O +
patients O +
entering O +
the O +
local O +
dialysis O +
program O +
because O +
of O +
ESRD U-Disease +
in O +
the O +
study O +
area O +
between O +
June O +
1 O -
, O +
1995 O +
and O +
November O +
30 O -
, O +
1997 O -
. O -

They O +
were O +
classified O +
according O +
to O +
the O +
underlying O +
disease O -
, O +
which O +
had O +
presumably O +
led O +
them O +
to O +
ESRD U-Disease -
. O -

Controls O +
were O +
patients O +
admitted O +
to O +
the O +
same O +
hospitals O +
from O +
where O +
the O +
cases O +
arose O -
, O +
also O +
matched O +
by O +
age O +
and O +
sex O -
. O -

Odds O +
ratios O +
were O +
calculated O +
using O +
a O +
conditional O +
logistic O +
model O -
, O +
including O +
potential O +
confounding O +
factors O -
, O +
both O +
for O +
the O +
whole O +
study O +
population O +
and O +
for O +
the O +
various O +
underlying O +
diseases O -
. O -

RESULTS O -
: O +
Five O +
hundred O +
and O +
eighty O -
- O -
three O +
cases O +
and O +
1190 O +
controls O +
were O +
included O +
in O +
the O +
analysis O -
. O -

Long O -
- O -
term O +
use O +
of O +
any O +
analgesic O +
was O +
associated O +
with O +
an O +
overall O +
odds O +
ratio O +
of O +
1.22 O +
( O -
95 O -
% O +
CI O -
, O +
0.89 O -
- O -
1.66 O -
) O -
. O -

For O +
specific O +
groups O +
of O +
drugs O -
, O +
the O +
risks O +
were O +
1.56 O +
( O -
1.05 O -
- O -
2.30 O -
) O +
for O +
aspirin O -
, O +
1.03 O +
( O -
0.60 O -
- O -
1.76 O -
) O +
for O +
pyrazolones O -
, O +
0.80 O +
( O -
0.39 O -
- O -
1.63 O -
) O +
for O +
paracetamol O -
, O +
and O +
0.94 O +
( O -
0.57 O -
- O -
1.56 O -
) O +
for O +
nonaspirin O +
NSAIDs O -
. O -

The O +
risk O +
of O +
ESRD U-Disease +
associated O +
with O +
aspirin O +
was O +
related O +
to O +
the O +
cumulated O +
dose O +
and O +
duration O +
of O +
use O -
, O +
and O +
it O +
was O +
particularly O +
high O +
among O +
the O +
subset O +
of O +
patients O +
with O +
vascular O +
nephropathy U-Disease +
as O +
underlying O +
disease O +
[ O -
2.35 O +
( O -
1.17 O -
- O -
4.72 O -
) O -
] O -
. O -

CONCLUSION O -
: O +
Our O +
data O +
indicate O +
that O +
long O -
- O -
term O +
use O +
of O +
nonaspirin O +
analgesic O +
drugs O +
and O +
NSAIDs O +
is O +
not O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
ESRD U-Disease -
. O -

However O -
, O +
the O +
chronic O +
use O +
of O +
aspirin O +
may O +
increase O +
the O +
risk O +
of O +
ESRD U-Disease -
. O -

Two O +
cases O +
of O +
amisulpride O +
overdose U-Disease -
: O +
a O +
cause O +
for O +
prolonged B-Disease +
QT I-Disease +
syndrome L-Disease -
. O -

Two O +
cases O +
of O +
deliberate O +
self O -
- O -
poisoning U-Disease +
with O +
5 O +
g O +
and O +
3.6 O +
g O +
of O +
amisulpride O -
, O +
respectively O -
, O +
are O +
reported O -
. O -

In O +
both O +
cases O -
, O +
QT B-Disease +
prolongation L-Disease +
and O +
hypocalcaemia U-Disease +
were O +
noted O -
. O -

The O +
QT B-Disease +
prolongation L-Disease +
appeared O +
to O +
respond O +
to O +
administration O +
of O +
i.v O -
. O -

calcium O +
gluconate O -
. O -

Growth O -
- O -
associated O +
protein O +
43 O +
expression O +
in O +
hippocampal O +
molecular O +
layer O +
of O +
chronic O +
epileptic U-Disease +
rats O +
treated O +
with O +
cycloheximide O -
. O -

PURPOSE O -
: O +
GAP43 O +
has O +
been O +
thought O +
to O +
be O +
linked O +
with O +
mossy O +
fiber O +
sprouting O +
( O -
MFS O -
) O +
in O +
various O +
experimental O +
models O +
of O +
epilepsy U-Disease -
. O -

To O +
investigate O +
how O +
GAP43 O +
expression O +
( O -
GAP43-ir O -
) O +
correlates O +
with O +
MFS O -
, O +
we O +
assessed O +
the O +
intensity O +
( O -
densitometry O -
) O +
and O +
extension O +
( O -
width O -
) O +
of O +
GAP43-ir O +
in O +
the O +
inner O +
molecular O +
layer O +
of O +
the O +
dentate O +
gyrus O +
( O -
IML O -
) O +
of O +
rats O +
subject O +
to O +
status B-Disease +
epilepticus L-Disease +
induced O +
by O +
pilocarpine O +
( O -
Pilo O -
) O -
, O +
previously O +
injected O +
or O +
not O +
with O +
cycloheximide O +
( O -
CHX O -
) O -
, O +
which O +
has O +
been O +
shown O +
to O +
inhibit O +
MFS O -
. O -

METHODS O -
: O +
CHX O +
was O +
injected O +
before O +
the O +
Pilo O +
injection O +
in O +
adult O +
Wistar O +
rats O -
. O -

The O +
Pilo O +
group O +
was O +
injected O +
with O +
the O +
same O +
drugs O -
, O +
except O +
for O +
CHX O -
. O -

Animals O +
were O +
killed O +
between O +
30 O +
and O +
60 O +
days O +
later O -
, O +
and O +
brain O +
sections O +
were O +
processed O +
for O +
GAP43 O +
immunohistochemistry O -
. O -

RESULTS O -
: O +
Densitometry O +
showed O +
no O +
significant O +
difference O +
regarding O +
GAP43-ir O +
in O +
the O +
IML O +
between O +
Pilo O -
, O +
CHX+Pilo O -
, O +
and O +
control O +
groups O -
. O -

However O -
, O +
the O +
results O +
of O +
the O +
width O +
of O +
the O +
GAP43-ir O +
band O +
in O +
the O +
IML O +
showed O +
that O +
CHX+Pilo O +
and O +
control O +
animals O +
had O +
a O +
significantly O +
larger O +
band O +
( O -
p O +
= O +
0.03 O -
) O +
as O +
compared O +
with O +
that O +
in O +
the O +
Pilo O +
group O -
. O -

CONCLUSIONS O -
: O +
Our O +
current O +
finding O +
that O +
animals O +
in O +
the O +
CHX+Pilo O +
group O +
have O +
a O +
GAP43-ir O +
band O +
in O +
the O +
IML O -
, O +
similar O +
to O +
that O +
of O +
controls O -
, O +
reinforces O +
prior O +
data O +
on O +
the O +
blockade O +
of O +
MFS O +
in O +
these O +
animals O -
. O -

The O +
change O +
in O +
GAP43-ir O +
present O +
in O +
Pilo O -
- O -
treated O +
animals O +
was O +
a O +
thinning O +
of O +
the O +
band O +
to O +
a O +
very O +
narrow O +
layer O +
just O +
above O +
the O +
granule O +
cell O +
layer O +
that O +
is O +
likely O +
to O +
be O +
associated O +
with O +
the O +
loss O +
of O +
hilar O +
cell O +
projections O +
that O +
express O +
GAP-43 O -
. O -

Nicotine O +
antagonizes O +
caffeine- O +
but O +
not O +
pentylenetetrazole O -
- O -
induced O +
anxiogenic O +
effect O +
in O +
mice O -
. O -

RATIONALE O -
: O +
Nicotine O +
and O +
caffeine O +
are O +
widely O +
consumed O +
licit O +
psychoactive O +
drugs O +
worldwide O -
. O -

Epidemiological O +
studies O +
showed O +
that O +
they O +
were O +
generally O +
used O +
concurrently O -
. O -

Although O +
some O +
studies O +
in O +
experimental O +
animals O +
indicate O +
clear O +
pharmacological O +
interactions O +
between O +
them O -
, O +
no O +
studies O +
have O +
shown O +
a O +
specific O +
interaction O +
on O +
anxiety U-Disease +
responses O -
. O -

OBJECTIVES O -
: O +
The O +
present O +
study O +
investigates O +
the O +
effects O +
of O +
nicotine O +
on O +
anxiety U-Disease +
induced O +
by O +
caffeine O +
and O +
another O +
anxiogenic O +
drug O -
, O +
pentylenetetrazole O -
, O +
in O +
mice O -
. O -

The O +
elevated O +
plus O -
- O -
maze O +
( O -
EPM O -
) O +
test O +
was O +
used O +
to O +
evaluate O +
the O +
effects O +
of O +
drugs O +
on O +
anxiety U-Disease -
. O -

METHODS O -
: O +
Adult O +
male O +
Swiss O +
Webster O +
mice O +
( O -
25 O -
- O -
32 O +
g O -
) O +
were O +
given O +
nicotine O +
( O -
0.05 O -
- O -
0.25 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
or O +
saline O +
10 O +
min O +
before O +
caffeine O +
( O -
70 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
or O +
pentylenetetrazole O +
( O -
15 O +
and O +
30 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
injections O -
. O -

After O +
15 O +
min O -
, O +
mice O +
were O +
evaluated O +
for O +
their O +
open- O +
and O +
closed O -
- O -
arm O +
time O +
and O +
entries O +
on O +
the O +
EPM O +
for O +
a O +
10-min O +
session O -
. O -

Locomotor O +
activity O +
was O +
recorded O +
for O +
individual O +
groups O +
by O +
using O +
the O +
same O +
treatment O +
protocol O +
with O +
the O +
EPM O +
test O -
. O -

RESULTS O -
: O +
Nicotine O +
( O -
0.05 O -
- O -
0.25 O +
mg O -
/ O -
kg O -
) O +
itself O +
did O +
not O +
produce O +
any O +
significant O +
effect O +
in O +
the O +
EPM O +
test O -
, O +
whereas O +
caffeine O +
( O -
70 O +
mg O -
/ O -
kg O -
) O +
and O +
pentylenetetrazole O +
( O -
30 O +
mg O -
/ O -
kg O -
) O +
produced O +
an O +
anxiogenic O +
effect O -
, O +
apparent O +
with O +
decreases O +
in O +
open O -
- O -
arm O +
time O +
and O +
entry O -
. O -

Nicotine O +
( O -
0.25 O +
mg O -
/ O -
kg O -
) O +
pretreatment O +
blocked O +
the O +
caffeine- O +
but O +
not O +
pentylenetetrazole O -
- O -
induced O +
anxiety U-Disease -
. O -

Administration O +
of O +
each O +
drug O +
and O +
their O +
combinations O +
did O +
not O +
produce O +
any O +
effect O +
on O +
locomotor O +
activity O -
. O -

CONCLUSIONS O -
: O +
Our O +
results O +
suggest O +
that O +
the O +
antagonistic O +
effect O +
of O +
nicotine O +
on O +
caffeine O -
- O -
induced O +
anxiety U-Disease +
is O +
specific O +
to O +
caffeine O -
, O +
instead O +
of O +
a O +
non O -
- O -
specific O +
anxiolytic O +
effect O -
. O -

Thus O -
, O +
it O +
may O +
extend O +
the O +
current O +
findings O +
on O +
the O +
interaction O +
between O +
nicotine O +
and O +
caffeine O -
. O -

Long O +
term O +
hormone O +
therapy O +
for O +
perimenopausal O +
and O +
postmenopausal O +
women O -
. O -

BACKGROUND O -
: O +
Hormone O +
therapy O +
( O -
HT O -
) O +
is O +
widely O +
used O +
for O +
controlling O +
menopausal B-Disease +
symptoms L-Disease -
. O -

It O +
has O +
also O +
been O +
used O +
for O +
the O +
management O +
and O +
prevention O +
of O +
cardiovascular B-Disease +
disease L-Disease -
, O +
osteoporosis U-Disease +
and O +
dementia U-Disease +
in O +
older O +
women O +
but O +
the O +
evidence O +
supporting O +
its O +
use O +
for O +
these O +
indications O +
is O +
largely O +
observational O -
. O -

OBJECTIVES O -
: O +
To O +
assess O +
the O +
effect O +
of O +
long O -
- O -
term O +
HT O +
on O +
mortality O -
, O +
heart B-Disease +
disease L-Disease -
, O +
venous B-Disease +
thromboembolism L-Disease -
, O +
stroke U-Disease -
, O +
transient B-Disease +
ischaemic I-Disease +
attacks L-Disease -
, O +
breast B-Disease +
cancer L-Disease -
, O +
colorectal B-Disease +
cancer L-Disease -
, O +
ovarian B-Disease +
cancer L-Disease -
, O +
endometrial B-Disease +
cancer L-Disease -
, O +
gallbladder B-Disease +
disease L-Disease -
, O +
cognitive O +
function O -
, O +
dementia U-Disease -
, O +
fractures U-Disease +
and O +
quality O +
of O +
life O -
. O -

SEARCH O +
STRATEGY O -
: O +
We O +
searched O +
the O +
following O +
databases O +
up O +
to O +
November O +
2004 O -
: O +
the O +
Cochrane O +
Menstrual O +
Disorders O +
and O +
Subfertility O +
Group O +
Trials O +
Register O -
, O +
Cochrane O +
Central O +
Register O +
of O +
Controlled O +
Trials O +
( O -
CENTRAL O -
) O -
, O +
MEDLINE O -
, O +
EMBASE O -
, O +
Biological O +
Abstracts O -
. O -

Relevant O +
non O -
- O -
indexed O +
journals O +
and O +
conference O +
abstracts O +
were O +
also O +
searched O -
. O -

SELECTION O +
CRITERIA O -
: O +
Randomised O +
double O -
- O -
blind O +
trials O +
of O +
HT O +
( O -
oestrogens O +
with O +
or O +
without O +
progestogens O -
) O +
versus O +
placebo O -
, O +
taken O +
for O +
at O +
least O +
one O +
year O +
by O +
perimenopausal O +
or O +
postmenopausal O +
women O -
. O -

DATA O +
COLLECTION O +
AND O +
ANALYSIS O -
: O -

Fifteen O +
RCTs O +
were O +
included O -
. O -

Trials O +
were O +
assessed O +
for O +
quality O +
and O +
two O +
review O +
authors O +
extracted O +
data O +
independently O -
. O -

They O +
calculated O +
risk O +
ratios O +
for O +
dichotomous O +
outcomes O +
and O +
weighted O +
mean O +
differences O +
for O +
continuous O +
outcomes O -
. O -

Clinical O +
heterogeneity O +
precluded O +
meta O -
- O -
analysis O +
for O +
most O +
outcomes O -
. O -

MAIN O +
RESULTS O -
: O +
All O +
the O +
statistically O +
significant O +
results O +
were O +
derived O +
from O +
the O +
two O +
biggest O +
trials O -
. O -

In O +
relatively O +
healthy O +
women O -
, O +
combined O +
continuous O +
HT O +
significantly O +
increased O +
the O +
risk O +
of O +
venous B-Disease +
thromboembolism L-Disease +
or O +
coronary O +
event O +
( O -
after O +
one O +
year O -
's O +
use O -
) O -
, O +
stroke U-Disease +
( O -
after O +
3 O +
years O -
) O -
, O +
breast B-Disease +
cancer L-Disease +
( O -
after O +
5 O +
years O -
) O +
and O +
gallbladder B-Disease +
disease L-Disease -
. O -

Long O -
- O -
term O +
oestrogen O -
- O -
only O +
HT O +
also O +
significantly O +
increased O +
the O +
risk O +
of O +
stroke U-Disease +
and O +
gallbladder B-Disease +
disease L-Disease -
. O -

Overall O -
, O +
the O +
only O +
statistically O +
significant O +
benefits O +
of O +
HT O +
were O +
a O +
decreased O +
incidence O +
of O +
fractures U-Disease +
and O +
colon B-Disease +
cancer L-Disease +
with O +
long O -
- O -
term O +
use O -
. O -

Among O +
relatively O +
healthy O +
women O +
over O +
65 O +
years O +
taking O +
continuous O +
combined O +
HT O -
, O +
there O +
was O +
a O +
statistically O +
significant O +
increase O +
in O +
the O +
incidence O +
of O +
dementia U-Disease -
. O -

Among O +
women O +
with O +
cardiovascular B-Disease +
disease L-Disease -
, O +
long O -
- O -
term O +
use O +
of O +
combined O +
continuous O +
HT O +
significantly O +
increased O +
the O +
risk O +
of O +
venous B-Disease +
thromboembolism L-Disease -
. O -

No O +
trials O +
focussed O +
specifically O +
on O +
younger O +
women O -
. O -

However O -
, O +
one O +
trial O +
analysed O +
subgroups O +
of O +
2839 O +
relatively O +
healthy O +
50 O +
to O +
59 O +
year O -
- O -
old O +
women O +
taking O +
combined O +
continuous O +
HT O +
and O +
1637 O +
taking O +
oestrogen O -
- O -
only O +
HT O -
, O +
versus O +
similar O -
- O -
sized O +
placebo O +
groups O -
. O -

The O +
only O +
significantly O +
increased O +
risk O +
reported O +
was O +
for O +
venous B-Disease +
thromboembolism L-Disease +
in O +
women O +
taking O +
combined O +
continuous O +
HT O -
; O +
their O +
absolute O +
risk O +
remained O +
very O +
low O -
. O -

AUTHORS O -
' O +
CONCLUSIONS O -
: O +
HT O +
is O +
not O +
indicated O +
for O +
the O +
routine O +
management O +
of O +
chronic B-Disease +
disease L-Disease -
. O -

We O +
need O +
more O +
evidence O +
on O +
the O +
safety O +
of O +
HT O +
for O +
menopausal O +
symptom O +
control O -
, O +
though O +
short O -
- O -
term O +
use O +
appears O +
to O +
be O +
relatively O +
safe O +
for O +
healthy O +
younger O +
women O -
. O -

Drug B-Disease -
- I-Disease -
induced I-Disease +
liver I-Disease +
injury L-Disease -
: O +
an O +
analysis O +
of O +
461 O +
incidences O +
submitted O +
to O +
the O +
Spanish O +
registry O +
over O +
a O +
10-year O +
period O -
. O -

BACKGROUND O +
& O +
AIMS O -
: O +
Progress O +
in O +
the O +
understanding O +
of O +
susceptibility O +
factors O +
to O +
drug B-Disease -
- I-Disease -
induced I-Disease +
liver I-Disease +
injury L-Disease +
( O -
DILI U-Disease -
) O +
and O +
outcome O +
predictability O +
are O +
hampered O +
by O +
the O +
lack O +
of O +
systematic O +
programs O +
to O +
detect O +
bona O +
fide O +
cases O -
. O -

METHODS O -
: O +
A O +
cooperative O +
network O +
was O +
created O +
in O +
1994 O +
in O +
Spain O +
to O +
identify O +
all O +
suspicions O +
of O +
DILI U-Disease +
following O +
a O +
prospective O +
structured O +
report O +
form O -
. O -

The O +
liver B-Disease +
damage L-Disease +
was O +
characterized O +
according O +
to O +
hepatocellular O -
, O +
cholestatic U-Disease -
, O +
and O +
mixed O +
laboratory O +
criteria O +
and O +
to O +
histologic O +
criteria O +
when O +
available O -
. O -

Further O +
evaluation O +
of O +
causality O +
assessment O +
was O +
centrally O +
performed O -
. O -

RESULTS O -
: O +
Since O +
April O +
1994 O +
to O +
August O +
2004 O -
, O +
461 O +
out O +
of O +
570 O +
submitted O +
cases O -
, O +
involving O +
505 O +
drugs O -
, O +
were O +
deemed O +
to O +
be O +
related O +
to O +
DILI U-Disease -
. O -

The O +
antiinfective O +
group O +
of O +
drugs O +
was O +
the O +
more O +
frequently O +
incriminated O -
, O +
amoxicillin O -
- O -
clavulanate O +
accounting O +
for O +
the O +
12.8 O -
% O +
of O +
the O +
whole O +
series O -
. O -

The O +
hepatocellular O +
pattern O +
of O +
damage O +
was O +
the O +
most O +
common O +
( O -
58 O -
% O -
) O -
, O +
was O +
inversely O +
correlated O +
with O +
age O +
( O -
P O +
< O +
.0001 O -
) O -
, O +
and O +
had O +
the O +
worst O +
outcome O +
( O -
Cox O +
regression O -
, O +
P O +
< O +
.034 O -
) O -
. O -

Indeed O -
, O +
the O +
incidence O +
of O +
liver O +
transplantation O +
and O +
death O +
in O +
this O +
group O +
was O +
11.7 O -
% O +
if O +
patients O +
had O +
jaundice U-Disease +
at O +
presentation O -
, O +
whereas O +
the O +
corresponding O +
figure O +
was O +
3.8 O -
% O +
in O +
nonjaundiced O +
patients O +
( O -
P O +
< O +
.04 O -
) O -
. O -

Factors O +
associated O +
with O +
the O +
development O +
of O +
fulminant B-Disease +
hepatic I-Disease +
failure L-Disease +
were O +
female O +
sex O +
( O -
OR O +
= O +
25 O -
; O +
95 O -
% O +
CI O -
: O +
4.1 O -
- O -
151 O -
; O +
P O +
< O +
.0001 O -
) O -
, O +
hepatocellular O +
damage O +
( O -
OR O +
= O +
7.9 O -
; O +
95 O -
% O +
CI O -
: O +
1.6 O -
- O -
37 O -
; O +
P O +
< O +
.009 O -
) O -
, O +
and O +
higher O +
baseline O +
plasma O +
bilirubin O +
value O +
( O -
OR O +
= O +
1.15 O -
; O +
95 O -
% O +
CI O -
: O +
1.09 O -
- O -
1.22 O -
; O +
P O +
< O +
.0001 O -
) O -
. O -

CONCLUSIONS O -
: O +
Patients O +
with O +
drug O -
- O -
induced O +
hepatocellular O +
jaundice U-Disease +
have O +
11.7 O -
% O +
chance O +
of O +
progressing O +
to O +
death O +
or O +
transplantation O -
. O -

Amoxicillin O -
- O -
clavulanate O +
stands O +
out O +
as O +
the O +
most O +
common O +
drug O +
related O +
to O +
DILI U-Disease -
. O -

Morphological O +
evaluation O +
of O +
the O +
effect O +
of O +
d O -
- O -
ribose O +
on O +
adriamycin O -
- O -
evoked O +
cardiotoxicity U-Disease +
in O +
rats O -
. O -

The O +
influence O +
of O +
d O -
- O -
ribose O +
on O +
adriamycin O -
- O -
induced O +
myocardiopathy U-Disease +
in O +
rats O +
was O +
studied O -
. O -

Adriamycin O +
in O +
the O +
cumulative O +
dose O +
of O +
25 O +
mg O -
/ O -
kg O +
evoked O +
fully O +
developed O +
cardiac B-Disease +
toxicity L-Disease -
. O -

D O -
- O -
ribose O +
in O +
the O +
multiple O +
doses O +
of O +
200 O +
mg O -
/ O -
kg O +
did O +
not O +
influence O +
ADR O +
cardiotoxicity U-Disease -
. O -

In O +
vivo O +
evidences O +
suggesting O +
the O +
role O +
of O +
oxidative O +
stress O +
in O +
pathogenesis O +
of O +
vancomycin O -
- O -
induced O +
nephrotoxicity U-Disease -
: O +
protection O +
by O +
erdosteine O -
. O -

The O +
aims O +
of O +
this O +
study O +
were O +
to O +
examine O +
vancomycin O +
( O -
VCM O -
) O -
-induced O +
oxidative O +
stress O +
that O +
promotes O +
production O +
of O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
and O +
to O +
investigate O +
the O +
role O +
of O +
erdosteine O -
, O +
an O +
expectorant O +
agent O -
, O +
which O +
has O +
also O +
antioxidant O +
properties O -
, O +
on O +
kidney O +
tissue O +
against O +
the O +
possible O +
VCM O -
- O -
induced O +
renal B-Disease +
impairment L-Disease +
in O +
rats O -
. O -

Rats O +
were O +
divided O +
into O +
three O +
groups O -
: O +
sham O -
, O +
VCM O +
and O +
VCM O +
plus O +
erdosteine O -
. O -

VCM O +
was O +
administrated O +
intraperitoneally O +
( O -
i.p O -
. O -
) O +
with O +
200mgkg O -
( O -
-1 O -
) O +
twice O +
daily O +
for O +
7 O +
days O -
. O -

Erdosteine O +
was O +
administered O +
orally O -
. O -

VCM O +
administration O +
to O +
control O +
rats O +
significantly O +
increased O +
renal O +
malondialdehyde O +
( O -
MDA O -
) O +
and O +
urinary O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
d O -
- O -
glucosaminidase O +
( O -
NAG O -
, O +
a O +
marker O +
of O +
renal B-Disease +
tubular I-Disease +
injury L-Disease -
) O +
excretion O +
but O +
decreased O +
superoxide O +
dismutase O +
( O -
SOD O -
) O +
and O +
catalase O +
( O -
CAT O -
) O +
activities O -
. O -

Erdosteine O +
administration O +
with O +
VCM O +
injections O +
caused O +
significantly O +
decreased O +
renal O +
MDA O +
and O +
urinary O +
NAG O +
excretion O -
, O +
and O +
increased O +
SOD O +
activity O -
, O +
but O +
not O +
CAT O +
activity O +
in O +
renal O +
tissue O +
when O +
compared O +
with O +
VCM O +
alone O -
. O -

Erdosteine O +
showed O +
histopathological O +
protection O +
against O +
VCM O -
- O -
induced O +
nephrotoxicity U-Disease -
. O -

There O +
were O +
a O +
significant O +
dilatation O +
of O +
tubular O +
lumens O -
, O +
extensive O +
epithelial O +
cell O +
vacuolization O -
, O +
atrophy U-Disease -
, O +
desquamation U-Disease -
, O +
and O +
necrosis U-Disease +
in O +
VCM O -
- O -
treated O +
rats O +
more O +
than O +
those O +
of O +
the O +
control O +
and O +
the O +
erdosteine O +
groups O -
. O -

Erdosteine O +
caused O +
a O +
marked O +
reduction O +
in O +
the O +
extent O +
of O +
tubular O +
damage O -
. O -

It O +
is O +
concluded O +
that O +
oxidative O +
tubular O +
damage O +
plays O +
an O +
important O +
role O +
in O +
the O +
VCM O -
- O -
induced O +
nephrotoxicity U-Disease +
and O +
the O +
modulation O +
of O +
oxidative O +
stress O +
with O +
erdosteine O +
reduces O +
the O +
VCM O -
- O -
induced O +
kidney B-Disease +
damage L-Disease +
both O +
at O +
the O +
biochemical O +
and O +
histological O +
levels O -
. O -

Gemfibrozil O -
- O -
lovastatin O +
therapy O +
for O +
primary O +
hyperlipoproteinemias U-Disease -
. O -

The O +
specific O +
aim O +
of O +
this O +
retrospective O -
, O +
observational O +
study O +
was O +
to O +
assess O +
safety O +
and O +
efficacy O +
of O +
long O -
- O -
term O +
( O -
21 O +
months O -
/ O -
patient O -
) O -
, O +
open O -
- O -
label O -
, O +
gemfibrozil O -
- O -
lovastatin O +
treatment O +
in O +
80 O +
patients O +
with O +
primary O +
mixed O +
hyperlipidemia U-Disease +
( O -
68 O -
% O +
of O +
whom O +
had O +
atherosclerotic B-Disease +
vascular I-Disease +
disease L-Disease -
) O -
. O -

Because O +
ideal O +
lipid O +
targets O +
were O +
not O +
reached O +
( O -
low O -
- O -
density O +
lipoprotein O +
( O -
LDL O -
) O +
cholesterol O +
less O +
than O +
130 O +
mg O -
/ O -
dl O -
, O +
high O -
- O -
density O +
lipoprotein O +
( O -
HDL O -
) O +
cholesterol O +
greater O +
than O +
35 O +
mg O -
/ O -
dl O -
, O +
or O +
total O +
cholesterol O -
/ O -
HDL O +
cholesterol O +
less O +
than O +
4.5 O +
mg O -
/ O -
dl O -
) O +
with O +
diet O +
plus O +
a O +
single O +
drug O -
, O +
gemfibrozil O +
( O -
1.2 O +
g O -
/ O -
day O -
) O -
-lovastatin O +
( O -
primarily O +
20 O +
or O +
40 O +
mg O -
) O +
treatment O +
was O +
given O -
. O -

Follow O -
- O -
up O +
visits O +
were O +
scheduled O +
with O +
2-drug O +
therapy O +
every O +
6 O +
to O +
8 O +
weeks O -
, O +
an O +
average O +
of O +
10.3 O +
visits O +
per O +
patient O -
, O +
with O +
741 O +
batteries O +
of O +
6 O +
liver O +
function O +
tests O +
and O +
714 O +
creatine O +
phosphokinase O +
levels O +
measured O -
. O -

Only O +
1 O +
of O +
the O +
4,446 O +
liver O +
function O +
tests O +
( O -
0.02 O -
% O -
) O -
, O +
a O +
gamma O +
glutamyl O +
transferase O -
, O +
was O +
greater O +
than O +
or O +
equal O +
to O +
3 O +
times O +
the O +
upper O +
normal O +
limit O -
. O -

Of O +
the O +
714 O +
creatine O +
phosphokinase O +
levels O -
, O +
9 O -
% O +
were O +
high O -
; O +
only O +
1 O +
( O -
0.1 O -
% O -
) O +
was O +
greater O +
than O +
or O +
equal O +
to O +
3 O +
times O +
the O +
upper O +
normal O +
limit O -
. O -

With O +
2-drug O +
therapy O -
, O +
mean O +
total O +
cholesterol O +
decreased O +
22 O -
% O +
from O +
255 O +
to O +
200 O +
mg O -
/ O -
dl O -
, O +
triglyceride O +
levels O +
decreased O +
35 O -
% O +
from O +
236 O +
to O +
154 O +
mg O -
/ O -
dl O -
, O +
LDL O +
cholesterol O +
decreased O +
26 O -
% O +
from O +
176 O +
to O +
131 O +
mg O -
/ O -
dl O -
, O +
and O +
the O +
total O +
cholesterol O -
/ O -
HDL O +
cholesterol O +
ratio O +
decreased O +
24 O -
% O +
from O +
7.1 O +
to O +
5.4 O -
, O +
all O +
p O +
less O +
than O +
or O +
equal O +
to O +
0.0001 O -
. O -

Myositis U-Disease -
, O +
attributable O +
to O +
the O +
drug O +
combination O +
and O +
symptomatic O +
enough O +
to O +
discontinue O +
it O -
, O +
occurred O +
in O +
3 O -
% O +
of O +
patients O -
, O +
and O +
in O +
1 O -
% O +
with O +
concurrent O +
high O +
creatine O +
phosphokinase O +
( O -
769 O +
U O -
/ O -
liter O -
) O -
; O +
no O +
patients O +
had O +
rhabdomyolysis U-Disease +
or O +
myoglobinuria. U-Disease -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Does O +
domperidone O +
potentiate O +
mirtazapine O -
- O -
associated O +
restless B-Disease +
legs I-Disease +
syndrome L-Disease -
? O -

There O +
is O +
now O +
evidence O +
to O +
suggest O +
a O +
central O +
role O +
for O +
the O +
dopaminergic O +
system O +
in O +
restless B-Disease +
legs I-Disease +
syndrome L-Disease +
( O -
RLS U-Disease -
) O -
. O -

For O +
example O -
, O +
the O +
symptoms O +
of O +
RLS U-Disease +
can O +
be O +
dramatically O +
improved O +
by O +
levodopa O +
and O +
dopamine O +
agonists O -
, O +
whereas O +
central O +
dopamine O +
D2 O +
receptor O +
antagonists O +
can O +
induce O +
or O +
aggravate O +
RLS U-Disease +
symptoms O -
. O -

To O +
our O +
knowledge O -
, O +
there O +
is O +
no O +
previous O +
report O +
regarding O +
whether O +
domperidone O -
, O +
a O +
peripheral O +
dopamine O +
D2 O +
receptor O +
antagonist O -
, O +
can O +
also O +
induce O +
or O +
aggravate O +
symptoms O +
of O +
RLS U-Disease -
. O -

Mirtazapine O -
, O +
the O +
first O +
noradrenergic O +
and O +
specific O +
serotonergic O +
antidepressant O +
( O -
NaSSA O -
) O -
, O +
has O +
been O +
associated O +
with O +
RLS U-Disease +
in O +
several O +
recent O +
publications O -
. O -

The O +
authors O +
report O +
here O +
a O +
depressed O +
patient O +
comorbid O +
with O +
postprandial B-Disease +
dyspepsia L-Disease +
who O +
developed O +
RLS U-Disease +
after O +
mirtazapine O +
had O +
been O +
added O +
to O +
his O +
domperidone O +
therapy O -
. O -

Our O +
patient O +
started O +
to O +
have O +
symptoms O +
of O +
RLS U-Disease +
only O +
after O +
he O +
had O +
been O +
treated O +
with O +
mirtazapine O -
, O +
and O +
his O +
RLS U-Disease +
symptoms O +
resolved O +
completely O +
upon O +
discontinuation O +
of O +
his O +
mirtazapine O -
. O -

Such O +
a O +
temporal O +
relationship O +
between O +
the O +
use O +
of O +
mirtazapine O +
and O +
the O +
symptoms O +
of O +
RLS U-Disease +
in O +
our O +
patient O +
did O +
not O +
support O +
a O +
potentiating O +
effect O +
of O +
domperione O +
on O +
mirtazapine O -
- O -
associated O +
RLS U-Disease -
. O -

However O -
, O +
physicians O +
should O +
be O +
aware O +
of O +
the O +
possibility O +
that O +
mirtazapine O +
can O +
be O +
associated O +
with O +
RLS U-Disease +
in O +
some O +
individuals O -
, O +
especially O +
those O +
receiving O +
concomitant O +
dopamine O +
D2 O +
receptor O +
antagonists O -
. O -

Antiandrogenic O +
therapy O +
can O +
cause O +
coronary B-Disease +
arterial I-Disease +
disease L-Disease -
. O -

AIM O -
: O +
To O +
study O +
the O +
change O +
of O +
lipid O +
metabolism O +
by O +
antiandrogen O +
therapy O +
in O +
patients O +
with O +
prostate B-Disease +
cancer L-Disease -
. O -

MATERIALS O +
AND O +
METHODS O -
: O +
We O +
studied O +
with O +
a O +
2.5 O +
years O +
follow O -
- O -
up O +
the O +
changes O +
in O +
plasma O +
cholesterols O +
( O -
C O -
) O -
, O +
triglycerides O +
( O -
TG O -
) O -
, O +
lipoproteins O +
( O -
LP O -
) O -
, O +
and O +
apolipoproteins O +
( O -
Apo O -
) O +
B-100 O -
, O +
A O -
- O -
I O -
, O +
and O +
A O -
- O -
II O +
pro O +
fi O +
les O +
in O +
24 O +
patients O +
of O +
mean O +
age O +
60 O +
years O +
with O +
low O +
risk O +
prostate B-Disease +
cancer L-Disease +
( O -
stage O -
: O +
T1cN0M0 O -
, O +
Gleason O +
score O -
: O +
2 O -
- O -
5 O -
) O +
during O +
treatment O +
with O +
cyproterone O +
acetate O +
( O -
CPA O -
) O +
without O +
surgical O +
management O +
or O +
radiation O +
therapy O -
. O -

RESULTS O -
: O +
Significant O +
decreases O +
of O +
HDL O -
- O -
C O -
, O +
Apo O +
A O -
- O -
I O +
and O +
Apo O +
A O -
- O -
II O +
and O +
an O +
increase O +
of O +
triglyceride O +
levels O +
in O +
VLDL O +
were O +
induced O +
by O +
CPA O -
. O -

After O +
a O +
period O +
of O +
2.5 O +
years O +
on O +
CPA O +
treatment O -
, O +
four O +
patients O +
out O +
of O +
twenty O -
- O -
four O +
were O +
found O +
to O +
be O +
affected O +
by O +
coronary B-Disease +
heart I-Disease +
disease L-Disease -
. O -

CONCLUSIONS O -
: O +
Ischaemic O +
coronary B-Disease +
arteriosclerosis L-Disease +
with O +
an O +
incidence O +
rate O +
of O +
16.6 O -
% O +
as O +
caused O +
by O +
prolonged O +
CPA O +
therapy O +
is O +
mediated O +
through O +
changes O +
in O +
HDL O +
cholesterol O -
, O +
Apo O +
A O -
- O -
I O +
and O +
Apo O +
A O -
- O -
II O +
pro O +
fi O +
les O -
, O +
other O +
than O +
the O +
well O -
- O -
known O +
hyperglyceridemic B-Disease +
effect L-Disease +
caused O +
by O +
estrogen O -
. O -

5-Fluorouracil O +
cardiotoxicity U-Disease +
induced O +
by O +
alpha O -
- O -
fluoro O -
- O -
beta O -
- O -
alanine O -
. O -

Cardiotoxicity U-Disease +
is O +
a O +
rare O +
complication O +
occurring O +
during O +
5-fluorouracil O +
( O -
5-FU O -
) O +
treatment O +
for O +
malignancies U-Disease -
. O -

We O +
herein O +
report O +
the O +
case O +
of O +
a O +
70-year O -
- O -
old O +
man O +
with O +
5-FU O -
- O -
induced O +
cardiotoxicity U-Disease -
, O +
in O +
whom O +
a O +
high O +
serum O +
level O +
of O +
alpha O -
- O -
fluoro O -
- O -
beta O -
- O -
alanine O +
( O -
FBAL O -
) O +
was O +
observed O -
. O -

The O +
patient O -
, O +
who O +
had O +
unresectable O +
colon B-Disease +
cancer L-Disease +
metastases O +
to O +
the O +
liver O +
and O +
lung O -
, O +
was O +
referred O +
to O +
us O +
for O +
chemotherapy O +
from O +
an O +
affiliated O +
hospital O -
; O +
he O +
had O +
no O +
cardiac O +
history O -
. O -

After O +
admission O -
, O +
the O +
patient O +
received O +
a O +
continuous O +
intravenous O +
infusion O +
of O +
5-FU O +
( O -
1000 O +
mg O -
/ O -
day O -
) O -
, O +
during O +
which O +
precordial B-Disease +
pain L-Disease +
with O +
right B-Disease +
bundle I-Disease +
branch I-Disease +
block L-Disease +
occurred O +
concomitantly O +
with O +
a O +
high O +
serum O +
FBAL O +
concentration O +
of O +
1955 O +
ng O -
/ O -
ml O -
. O -

Both O +
the O +
precordial B-Disease +
pain L-Disease +
and O +
the O +
electrocardiographic O +
changes O +
disappeared O +
spontaneously O +
after O +
the O +
discontinuation O +
of O +
5-FU O -
. O -

As O +
the O +
precordial B-Disease +
pain L-Disease +
in O +
this O +
patient O +
was O +
considered O +
to O +
have O +
been O +
due O +
to O +
5-FU O -
- O -
induced O +
cardiotoxicity U-Disease -
, O +
the O +
administration O +
of O +
5-FU O +
was O +
abandoned O -
. O -

Instead O -
, O +
oral O +
administration O +
of O +
S-1 O +
( O -
a O +
derivative O +
of O +
5-FU O -
) O -
, O +
at O +
200 O +
mg O -
/ O -
day O +
twice O +
a O +
week O -
, O +
was O +
instituted O -
, O +
because O +
S-1 O +
has O +
a O +
strong O +
inhibitory O +
effect O +
on O +
dihydropyrimidine O +
dehydrogenase O -
, O +
which O +
catalyzes O +
the O +
degradative O +
of O +
5-FU O +
into O +
FBAL O -
. O -

The O +
serum O +
FBAL O +
concentration O +
subsequently O +
decreased O +
to O +
352 O +
ng O -
/ O -
ml O -
, O +
the O +
same O +
as O +
the O +
value O +
measured O +
on O +
the O +
first O +
day O +
of O +
S-1 O +
administration O -
. O -

Thereafter O -
, O +
no O +
cardiac B-Disease +
symptoms L-Disease +
were O +
observed O -
. O -

The O +
patient O +
achieved O +
a O +
partial O +
response O +
6 O +
months O +
after O +
the O +
initiation O +
of O +
the O +
S-1 O +
treatment O -
. O -

The O +
experience O +
of O +
this O +
case O -
, O +
together O +
with O +
a O +
review O +
of O +
the O +
literature O -
, O +
suggests O +
that O +
FBAL O +
is O +
related O +
to O +
5-FU O -
- O -
induced O +
cardiotoxicity U-Disease -
. O -

S-1 O +
may O +
be O +
administered O +
safely O +
to O +
patients O +
with O +
5-FU O -
- O -
induced O +
cardiotoxicity U-Disease -
. O -

Hepatocellular B-Disease +
carcinoma L-Disease +
in O +
Fanconi B-Disease -
's I-Disease +
anemia L-Disease +
treated O +
with O +
androgen O +
and O +
corticosteroid O -
. O -

The O +
case O +
of O +
an O +
11-year O -
- O -
old O +
boy O +
is O +
reported O +
who O +
was O +
known O +
to O +
have O +
Fanconi B-Disease -
's I-Disease +
anemia L-Disease +
for O +
3 O +
years O +
and O +
was O +
treated O +
with O +
androgens O -
, O +
corticosteroids O +
and O +
transfusions O -
. O -

Two O +
weeks O +
before O +
his O +
death O +
he O +
was O +
readmitted O +
because O +
of O +
aplastic O +
crisis O +
with O +
septicemia U-Disease +
and O +
marked O +
abnormalities O +
in O +
liver O +
function O +
and O +
died O +
of O +
hemorrhagic B-Disease +
bronchopneumonia L-Disease -
. O -

At O +
autopsy O +
peliosis U-Disease +
and O +
multiple O +
hepatic B-Disease +
tumors L-Disease +
were O +
found O +
which O +
histologically O +
proved O +
to O +
be O +
well O -
- O -
differentiated O +
hepatocellular B-Disease +
carcinoma L-Disease -
. O -

This O +
case O +
contributes O +
to O +
the O +
previous O +
observations O +
that O +
non O -
- O -
metastasizing O +
hepatic B-Disease +
neoplasms L-Disease +
and O +
peliosis U-Disease +
can O +
develop O +
in O +
patients O +
with O +
androgen- O +
and O +
corticosteroid O -
- O -
treated O +
Fanconi B-Disease -
's I-Disease +
anemia L-Disease -
. O -

The O +
influence O +
of O +
the O +
time O +
interval O +
between O +
monoHER O +
and O +
doxorubicin O +
administration O +
on O +
the O +
protection O +
against O +
doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease +
in O +
mice O -
. O -

PURPOSE O -
: O +
Despite O +
its O +
well O -
- O -
known O +
cardiotoxicity U-Disease -
, O +
the O +
anthracyclin O +
doxorubicin O +
( O -
DOX O -
) O +
continues O +
to O +
be O +
an O +
effective O +
and O +
widely O +
used O +
chemotherapeutic O +
agent O -
. O -

DOX O -
- O -
induced O +
cardiac B-Disease +
damage L-Disease +
presumably O +
results O +
from O +
the O +
formation O +
of O +
free O +
radicals O +
by O +
DOX O -
. O -

Reactive O +
oxygen O +
species O +
particularly O +
affect O +
the O +
cardiac O +
myocytes O +
because O +
these O +
cells O +
seem O +
to O +
have O +
a O +
relatively O +
poor O +
antioxidant O +
defense O +
system O -
. O -

The O +
semisynthetic O +
flavonoid O +
monohydroxyethylrutoside O +
( O -
monoHER O -
) O +
showed O +
cardioprotection O +
against O +
DOX O -
- O -
induced O +
cardiotoxicity U-Disease +
through O +
its O +
radical O +
scavenging O +
and O +
iron O +
chelating O +
properties O -
. O -

Because O +
of O +
the O +
relatively O +
short O +
final O +
half O -
- O -
life O +
of O +
monoHER O +
( O -
about O +
30 O +
min O -
) O -
, O +
it O +
is O +
expected O +
that O +
the O +
time O +
interval O +
between O +
monoHER O +
and O +
DOX O +
might O +
be O +
of O +
influence O +
on O +
the O +
cardioprotective O +
effect O +
of O +
monoHER O -
. O -

Therefore O -
, O +
the O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
this O +
possible O +
effect O -
. O -

METHODS O -
: O +
Six O +
groups O +
of O +
6 O +
BALB O -
/ O -
c O +
mice O +
were O +
treated O +
with O +
saline O -
, O +
DOX O +
alone O +
or O +
DOX O +
( O -
4 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
preceded O +
by O +
monoHER O +
( O -
500 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
with O +
an O +
interval O +
of O +
10 O -
, O +
30 O -
, O +
60 O +
or O +
120 O +
min O -
. O -

After O +
a O +
6-week O +
treatment O +
period O +
and O +
additional O +
observation O +
for O +
2 O +
weeks O -
, O +
the O +
mice O +
were O +
sacrificed O -
. O -

Their O +
cardiac O +
tissues O +
were O +
processed O +
for O +
light O +
microscopy O -
, O +
after O +
which O +
cardiomyocyte B-Disease +
damage L-Disease +
was O +
evaluated O +
according O +
to O +
Billingham O +
( O -
in O +
Cancer U-Disease +
Treat O +
Rep O +
62 O -
( O -
6 O -
) O -
:865 O -
- O -
872 O -
, O +
1978 O -
) O -
. O -

Microscopic O +
evaluation O +
revealed O +
that O +
treatment O +
with O +
DOX O +
alone O +
induced O +
significant O +
cardiac B-Disease +
damage L-Disease +
in O +
comparison O +
to O +
the O +
saline O +
control O +
group O +
( O -
P<0.001 O -
) O -
. O -

RESULTS O -
: O +
The O +
number O +
of O +
damaged O +
cardiomyocytes O +
was O +
9.6-fold O +
( O -
95 O -
% O +
CI O +
4.4 O -
- O -
21.0 O -
) O +
higher O +
in O +
mice O +
treated O +
with O +
DOX O +
alone O +
than O +
that O +
in O +
animals O +
of O +
the O +
control O +
group O -
. O -

The O +
ratio O +
of O +
aberrant O +
cardiomyocytes O +
in O +
mice O +
treated O +
with O +
DOX O +
preceded O +
by O +
monoHER O +
and O +
those O +
in O +
mice O +
treated O +
with O +
saline O +
ranged O +
from O +
1.6 O +
to O +
2.8 O +
( O -
mean O +
2.2 O -
, O +
95 O -
% O +
CI O +
1.2 O -
- O -
4.1 O -
, O +
P=0.019 O -
) O -
. O -

The O +
mean O +
protective O +
effect O +
by O +
adding O +
monoHER O +
before O +
DOX O +
led O +
to O +
a O +
significant O +
4.4-fold O +
reduction O +
( O -
P<0.001 O -
, O +
95 O -
% O +
CI O +
2.3 O -
- O -
8.2 O -
) O +
of O +
abnormal O +
cardiomyocytes O -
. O -

This O +
protective O +
effect O +
did O +
not O +
depend O +
on O +
the O +
time O +
interval O +
between O +
monoHER O +
and O +
DOX O +
administration O +
( O -
P=0.345 O -
) O -
. O -

CONCLUSION O -
: O +
The O +
results O +
indicate O +
that O +
in O +
an O +
outpatient O +
clinical O +
setting O +
monoHER O +
may O +
be O +
administered O +
shortly O +
before O +
DOX O -
. O -

Clinical O +
evaluation O +
of O +
adverse O +
effects O +
during O +
bepridil O +
administration O +
for O +
atrial B-Disease +
fibrillation L-Disease +
and B-Disease +
flutter L-Disease -
. O -

BACKGROUND O -
: O +
Bepridil O +
hydrochloride O +
( O -
Bpd O -
) O +
has O +
attracted O +
attention O +
as O +
an O +
effective O +
drug O +
for O +
atrial B-Disease +
fibrillation L-Disease +
( O -
AF U-Disease -
) O +
and O +
atrial B-Disease +
flutter L-Disease +
( O -
AFL U-Disease -
) O -
. O -

However O -
, O +
serious O +
adverse O +
effects O -
, O +
including O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
( O -
Tdp U-Disease -
) O -
, O +
have O +
been O +
reported O -
. O -

METHODS O +
AND O +
RESULTS O -
: O +
Adverse O +
effects O +
of O +
Bpd O +
requiring O +
discontinuation O +
of O +
treatment O +
were O +
evaluated O -
. O -

Bpd O +
was O +
administered O +
to O +
459 O +
patients O +
( O -
361 O +
males O -
, O +
63+ O -
/ O -
-12 O +
years O +
old O -
) O +
comprising O +
378 O +
AF U-Disease +
and O +
81 O +
AFL U-Disease +
cases O -
. O -

Mean O +
left O +
ventricular O +
ejection O +
fraction O +
and O +
atrial O +
dimension O +
( O -
LAD O -
) O +
were O +
66+ O -
/ O -
-11 O -
% O +
and O +
40+ O -
/ O -
-6 O +
mm O -
, O +
respectively O -
. O -

Adverse O +
effects O +
were O +
observed O +
in O +
19 O +
patients O +
( O -
4 O -
% O -
) O +
during O +
an O +
average O +
follow O -
- O -
up O +
of O +
20 O +
months O -
. O -

There O +
was O +
marked O +
QT B-Disease +
prolongation L-Disease +
greater O +
than O +
0.55 O +
s O +
in O +
13 O +
patients O -
, O +
bradycardia U-Disease +
less O +
than O +
40 O +
beats O -
/ O -
min O +
in O +
6 O +
patients O -
, O +
dizziness U-Disease +
and O +
general O +
fatigue U-Disease +
in O +
1 O +
patient O +
each O -
. O -

In O +
4 O +
of O +
13 O +
patients O +
with O +
QT B-Disease +
prolongation L-Disease -
, O +
Tdp U-Disease +
occurred O -
. O -

The O +
major O +
triggering O +
factors O +
of O +
Tdp U-Disease +
were O +
hypokalemia U-Disease +
and O +
sudden O +
decrease O +
in O +
heart O +
rate O -
. O -

There O +
were O +
no O +
differences O +
in O +
the O +
clinical O +
backgrounds O +
of O +
the O +
patients O +
with O +
and O +
without O +
Tdp U-Disease +
other O +
than O +
LAD O +
and O +
age O -
, O +
which O +
were O +
larger O +
and O +
older O +
in O +
the O +
patients O +
with O +
Tdp U-Disease -
. O -

CONCLUSION O -
: O +
Careful O +
observation O +
of O +
serum O +
potassium O +
concentration O +
and O +
the O +
ECG O +
should O +
always O +
be O +
done O +
during O +
Bpd O +
administration O -
, O +
particularly O +
in O +
elderly O +
patients O -
. O -

Enhanced O +
isoproterenol O -
- O -
induced O +
cardiac B-Disease +
hypertrophy L-Disease +
in O +
transgenic O +
rats O +
with O +
low O +
brain O +
angiotensinogen O -
. O -

We O +
have O +
previously O +
shown O +
that O +
a O +
permanent O +
deficiency O +
in O +
the O +
brain O +
renin O -
- O -
angiotensin O +
system O +
( O -
RAS O -
) O +
may O +
increase O +
the O +
sensitivity O +
of O +
the O +
baroreflex O +
control O +
of O +
heart O +
rate O -
. O -

In O +
this O +
study O +
we O +
aimed O +
at O +
studying O +
the O +
involvement O +
of O +
the O +
brain O +
RAS O +
in O +
the O +
cardiac O +
reactivity O +
to O +
the O +
beta O -
- O -
adrenoceptor O +
( O -
beta O -
- O -
AR O -
) O +
agonist O +
isoproterenol O +
( O -
Iso O -
) O -
. O -

Transgenic O +
rats O +
with O +
low O +
brain O +
angiotensinogen O +
( O -
TGR O -
) O +
were O +
used O -
. O -

In O +
isolated O +
hearts O -
, O +
Iso O +
induced O +
a O +
significantly O +
greater O +
increase O +
in O +
left O +
ventricular O +
( O -
LV O -
) O +
pressure O +
and O +
maximal O +
contraction O +
( O -
+ O -
dP O -
/ O -
dt O -
( O -
max O -
) O -
) O +
in O +
the O +
TGR O +
than O +
in O +
the O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O -
. O -

LV B-Disease +
hypertrophy L-Disease +
induced O +
by O +
Iso O +
treatment O +
was O +
significantly O +
higher O +
in O +
TGR O +
than O +
in O +
SD O +
rats O +
( O -
in O +
g O +
LV O +
wt O -
/ O -
100 O +
g O +
body O +
wt O -
, O +
0.28 O +
+ O -
/- O -

0.004 O +
vs. O +
0.24 O +
+ O -
/- O -

0.004 O -
, O +
respectively O -
) O -
. O -

The O +
greater O +
LV B-Disease +
hypertrophy L-Disease +
in O +
TGR O +
rats O +
was O +
associated O +
with O +
more O +
pronounced O +
downregulation O +
of O +
beta O -
- O -
AR O +
and O +
upregulation O +
of O +
LV O +
beta O -
- O -
AR O +
kinase-1 O +
mRNA O +
levels O +
compared O +
with O +
those O +
in O +
SD O +
rats O -
. O -

The O +
decrease O +
in O +
the O +
heart O +
rate O +
( O -
HR O -
) O +
induced O +
by O +
the O +
beta O -
- O -
AR O +
antagonist O +
metoprolol O +
in O +
conscious O +
rats O +
was O +
significantly O +
attenuated O +
in O +
TGR O +
compared O +
with O +
SD O +
rats O +
( O -
-9.9 O +
+ O -
/- O -

1.7 O -
% O +
vs. O +
-18.1 O +
+ O -
/- O -

1.5 O -
% O -
) O -
, O +
whereas O +
the O +
effect O +
of O +
parasympathetic O +
blockade O +
by O +
atropine O +
on O +
HR O +
was O +
similar O +
in O +
both O +
strains O -
. O -

These O +
results O +
indicate O +
that O +
TGR O +
are O +
more O +
sensitive O +
to O +
beta O -
- O -
AR O +
agonist O -
- O -
induced O +
cardiac B-Disease +
inotropic L-Disease +
response O +
and O +
hypertrophy U-Disease -
, O +
possibly O +
due O +
to O +
chronically O +
low O +
sympathetic O +
outflow O +
directed O +
to O +
the O +
heart O -
. O -

Drug O -
- O -
induced O +
long B-Disease +
QT I-Disease +
syndrome L-Disease +
in O +
injection O +
drug O +
users O +
receiving O +
methadone O -
: O +
high O +
frequency O +
in O +
hospitalized O +
patients O +
and O +
risk O +
factors O -
. O -

BACKGROUND O -
: O +
Drug O -
- O -
induced O +
long B-Disease +
QT I-Disease +
syndrome L-Disease +
is O +
a O +
serious O +
adverse O +
drug O +
reaction O -
. O -

Methadone O +
prolongs O +
the O +
QT O +
interval O +
in O +
vitro O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O -

In O +
the O +
inpatient O +
setting O -
, O +
the O +
frequency O +
of O +
QT B-Disease +
interval I-Disease +
prolongation L-Disease +
with O +
methadone O +
treatment O -
, O +
its O +
dose O +
dependence O -
, O +
and O +
the O +
importance O +
of O +
cofactors O +
such O +
as O +
drug O -
- O -
drug O +
interactions O +
remain O +
unknown O -
. O -

METHODS O -
: O +
We O +
performed O +
a O +
systematic O -
, O +
retrospective O +
study O +
comparing O +
active O +
or O +
former O +
intravenous O +
drug O +
users O +
receiving O +
methadone O +
and O +
those O +
not O +
receiving O +
methadone O +
among O +
all O +
patients O +
hospitalized O +
over O +
a O +
5-year O +
period O +
in O +
a O +
tertiary O +
care O +
hospital O -
. O -

A O +
total O +
of O +
167 O +
patients O +
receiving O +
methadone O +
fulfilled O +
the O +
inclusion O +
criteria O +
and O +
were O +
compared O +
with O +
a O +
control O +
group O +
of O +
80 O +
injection O +
drug O +
users O +
not O +
receiving O +
methadone O -
. O -

In O +
addition O +
to O +
methadone O +
dose O -
, O +
15 O +
demographic O -
, O +
biological O -
, O +
and O +
pharmacological O +
variables O +
were O +
considered O +
as O +
potential O +
risk O +
factors O +
for O +
QT B-Disease +
prolongation L-Disease -
. O -

RESULTS O -
: O +
Among O +
167 O +
methadone O +
maintenance O +
patients O -
, O +
the O +
prevalence O +
of O +
QTc O +
prolongation O +
to O +
0.50 O +
second O -
( O -
( O -
1 O -
/ O -
2 O -
) O -
) O +
or O +
longer O +
was O +
16.2 O -
% O +
compared O +
with O +
0 O -
% O +
in O +
80 O +
control O +
subjects O -
. O -

Six O +
patients O +
( O -
3.6 O -
% O -
) O +
in O +
the O +
methadone O +
group O +
presented O +
torsades B-Disease +
de I-Disease +
pointes L-Disease -
. O -

QTc O +
length O +
was O +
weakly O +
but O +
significantly O +
associated O +
with O +
methadone O +
daily O +
dose O +
( O -
Spearman O +
rank O +
correlation O +
coefficient O -
, O +
0.20 O -
; O +
P<.01 O -
) O -
. O -

Multivariate O +
regression O +
analysis O +
allowed O +
attribution O +
of O +
31.8 O -
% O +
of O +
QTc O +
variability O +
to O +
methadone O +
dose O -
, O +
cytochrome O +
P-450 O +
3A4 O +
drug O -
- O -
drug O +
interactions O -
, O +
hypokalemia U-Disease -
, O +
and O +
altered O +
liver O +
function O -
. O -

CONCLUSIONS O -
: O +
QT B-Disease +
interval I-Disease +
prolongation L-Disease +
in O +
methadone O +
maintenance O +
patients O +
hospitalized O +
in O +
a O +
tertiary O +
care O +
center O +
is O +
a O +
frequent O +
finding O -
. O -

Methadone O +
dose O -
, O +
presence O +
of O +
cytochrome O +
P-450 O +
3A4 O +
inhibitors O -
, O +
potassium O +
level O -
, O +
and O +
liver O +
function O +
contribute O +
to O +
QT B-Disease +
prolongation L-Disease -
. O -

Long B-Disease +
QT I-Disease +
syndrome L-Disease +
can O +
occur O +
with O +
low O +
doses O +
of O +
methadone O -
. O -

Mechanisms O +
of O +
hypertension U-Disease +
induced O +
by O +
nitric O +
oxide O +
( O -
NO O -
) O +
deficiency O -
: O +
focus O +
on O +
venous O +
function O -
. O -

Loss O +
of O +
endothelial O +
cell O -
- O -
derived O +
nitric O +
oxide O +
( O -
NO O -
) O +
in O +
hypertension U-Disease +
is O +
a O +
hallmark O +
of O +
arterial B-Disease +
dysfunction L-Disease -
. O -

Experimental O +
hypertension U-Disease +
created O +
by O +
the O +
removal O +
of O +
NO O -
, O +
however O -
, O +
involves O +
mechanisms O +
in O +
addition O +
to O +
decreased O +
arterial O +
vasodilator O +
activity O -
. O -

These O +
include O +
augmented O +
endothelin-1 O +
( O -
ET-1 O -
) O +
release O -
, O +
increased O +
sympathetic O +
nervous O +
system O +
activity O -
, O +
and O +
elevated O +
tissue O +
oxidative O +
stress O -
. O -

We O +
hypothesized O +
that O +
increased O +
venous O +
smooth O +
muscle O +
( O -
venomotor O -
) O +
tone O +
plays O +
a O +
role O +
in O +
Nomega O -
- O -
nitro O -
- O -
L O -
- O -
arginine O +
( O -
LNNA O -
) O +
hypertension U-Disease +
through O +
these O +
mechanisms O -
. O -

Rats O +
were O +
treated O +
with O +
the O +
NO O +
synthase O +
inhibitor O +
LNNA O +
( O -
0.5 O +
g O -
/ O -
L O +
in O +
drinking O +
water O -
) O +
for O +
2 O +
weeks O -
. O -

Mean O +
arterial O +
pressure O +
of O +
conscious O +
rats O +
was O +
119 O +
+ O -
/- O -

2 O +
mm O +
Hg O +
in O +
control O +
and O +
194 O +
+ O -
/- O -

5 O +
mm O +
Hg O +
in O +
LNNA O +
rats O +
( O -
P<0.05 O -
) O -
. O -

Carotid O +
arteries O +
and O +
vena O +
cava O +
were O +
removed O +
for O +
measurement O +
of O +
isometric O +
contraction O -
. O -

Maximal O +
contraction O +
to O +
norepinephrine O +
was O +
modestly O +
reduced O +
in O +
arteries O +
from O +
LNNA O +
compared O +
with O +
control O +
rats O +
whereas O +
the O +
maximum O +
contraction O +
to O +
ET-1 O +
was O +
significantly O +
reduced O +
( O -
54 O -
% O +
control O -
) O -
. O -

Maximum O +
contraction O +
of O +
vena O +
cava O +
to O +
norepinephrine O +
( O -
37 O -
% O +
control O -
) O +
also O +
was O +
reduced O +
but O +
no O +
change O +
in O +
response O +
to O +
ET-1 O +
was O +
observed O -
. O -

Mean O +
circulatory O +
filling O +
pressure O -
, O +
an O +
in O +
vivo O +
measure O +
of O +
venomotor O +
tone O -
, O +
was O +
not O +
elevated O +
in O +
LNNA O +
hypertension U-Disease +
at O +
1 O +
or O +
2 O +
weeks O +
after O +
LNNA O -
. O -

The O +
superoxide O +
scavenger O +
tempol O +
( O -
30 O -
, O +
100 O -
, O +
and O +
300 O +
micromol O +
kg O -
( O -
-1 O -
) O -
, O +
IV O -
) O +
did O +
not O +
change O +
arterial O +
pressure O +
in O +
control O +
rats O +
but O +
caused O +
a O +
dose O -
- O -
dependent O +
decrease O +
in O +
LNNA O +
rats O +
( O -
-18 O +
+ O -
/- O -

8 O -
, O +
-26 O +
+ O -
/- O -

15 O -
, O +
and O +
-54 O +
+ O -
/- O -

11 O +
mm O +
Hg O -
) O -
. O -

Similarly O -
, O +
ganglionic O +
blockade O +
with O +
hexamethonium O +
caused O +
a O +
significantly O +
greater O +
fall O +
in O +
LNNA O +
hypertensive U-Disease +
rats O +
( O -
76 O +
+ O -
/- O -

9 O +
mm O +
Hg O -
) O +
compared O +
with O +
control O +
rats O +
( O -
35 O +
+ O -
/- O -

10 O +
mm O +
Hg O -
) O -
. O -

Carotid O +
arteries O -
, O +
vena O +
cava O -
, O +
and O +
sympathetic O +
ganglia O +
from O +
LNNA O +
rats O +
had O +
higher O +
basal O +
levels O +
of O +
superoxide O +
compared O +
with O +
those O +
from O +
control O +
rats O -
. O -

These O +
data O +
suggest O +
that O +
while O +
NO O +
deficiency O +
increases O +
oxidative O +
stress O +
and O +
sympathetic O +
activity O +
in O +
both O +
arterial O +
and O +
venous O +
vessels O -
, O +
the O +
impact O +
on O +
veins O +
does O +
not O +
make O +
a O +
major O +
contribution O +
to O +
this O +
form O +
of O +
hypertension U-Disease -
. O -

Association O +
of O +
DRD2 O +
polymorphisms O +
and O +
chlorpromazine O -
- O -
induced O +
extrapyramidal B-Disease +
syndrome L-Disease +
in O +
Chinese O +
schizophrenic U-Disease +
patients O -
. O -

AIM O -
: O +
Extrapyramidal B-Disease +
syndrome L-Disease +
( O -
EPS U-Disease -
) O +
is O +
most O +
commonly O +
affected O +
by O +
typical O +
antipsychotic O +
drugs O +
that O +
have O +
a O +
high O +
affinity O +
with O +
the O +
D2 O +
receptor O -
. O -

Recently O -
, O +
many O +
research O +
groups O +
have O +
reported O +
on O +
the O +
positive O +
relationship O +
between O +
the O +
genetic O +
variations O +
in O +
the O +
DRD2 O +
gene O +
and O +
the O +
therapeutic O +
response O +
in O +
schizophrenia U-Disease +
patients O +
as O +
a O +
result O +
of O +
the O +
role O +
of O +
variations O +
in O +
the O +
receptor O +
in O +
modulating O +
receptor O +
expression O -
. O -

In O +
this O +
study O -
, O +
we O +
evaluate O +
the O +
role O +
DRD2 O +
plays O +
in O +
chlorpromazine O -
- O -
induced O +
EPS U-Disease +
in O +
schizophrenic U-Disease +
patients O -
. O -

METHODS O -
: O +
We O +
identified O +
seven O +
SNP O -
( O -
single O +
nucleotide O +
polymorphism O -
) O +
( O -
-141Cins O -
> O -
del O -
, O +
TaqIB O -
, O +
TaqID O -
, O +
Ser311Cys O -
, O +
rs6275 O -
, O +
rs6277 O +
and O +
TaqIA O -
) O +
in O +
the O +
DRD2 O +
gene O +
in O +
146 O +
schizophrenic U-Disease +
inpatients O +
( O -
59 O +
with O +
EPS U-Disease +
and O +
87 O +
without O +
EPS U-Disease +
according O +
to O +
the O +
Simpson O -
- O -
Angus O +
Scale O -
) O +
treated O +
with O +
chlorpromazine O +
after O +
8 O +
weeks O -
. O -

The O +
alleles O +
of O +
all O +
loci O +
were O +
determined O +
by O +
PCR O +
( O -
polymerase O +
chain O +
reaction O -
) O -
. O -

RESULTS O -
: O +
Polymorphisms O +
TaqID O -
, O +
Ser311Cys O +
and O +
rs6277 O +
were O +
not O +
polymorphic O +
in O +
the O +
population O +
recruited O +
in O +
the O +
present O +
study O -
. O -

No O +
statistical O +
significance O +
was O +
found O +
in O +
the O +
allele O +
distribution O +
of O +
-141Cins O -
> O -
del O -
, O +
TaqIB O -
, O +
rs6275 O +
and O +
TaqIA O +
or O +
in O +
the O +
estimated O +
haplotypes O +
( O -
constituted O +
by O +
TaqIB O -
, O +
rs6275 O +
and O +
TaqIA O -
) O +
in O +
linkage O +
disequilibrium O +
between O +
the O +
two O +
groups O -
. O -

CONCLUSION O -
: O +
Our O +
results O +
did O +
not O +
lend O +
strong O +
support O +
to O +
the O +
view O +
that O +
the O +
genetic O +
variation O +
of O +
the O +
DRD2 O +
gene O +
plays O +
a O +
major O +
role O +
in O +
the O +
individually O +
variable O +
adverse O +
effect O +
induced O +
by O +
chlorpromazine O -
, O +
at O +
least O +
in O +
Chinese O +
patients O +
with O +
schizophrenia U-Disease -
. O -

Our O +
results O +
confirmed O +
a O +
previous O +
study O +
on O +
the O +
relationship O +
between O +
DRD2 O +
and O +
EPS U-Disease +
in O +
Caucasians O -
. O -

Physical O +
training O +
decreases O +
susceptibility O +
to O +
subsequent O +
pilocarpine O -
- O -
induced O +
seizures U-Disease +
in O +
the O +
rat O -
. O -

Regular O +
motor O +
activity O +
has O +
many O +
benefits O +
for O +
mental O +
and O +
physical O +
condition O +
but O +
its O +
implications O +
for O +
epilepsy U-Disease +
are O +
still O +
controversial O -
. O -

In O +
order O +
to O +
elucidate O +
this O +
problem O -
, O +
we O +
have O +
studied O +
the O +
effect O +
of O +
long O -
- O -
term O +
physical O +
activity O +
on O +
susceptibility O +
to O +
subsequent O +
seizures U-Disease -
. O -

Male O +
Wistar O +
rats O +
were O +
subjected O +
to O +
repeated O +
training O +
sessions O +
in O +
a O +
treadmill O +
and O +
swimming O +
pool O -
. O -

Thereafter O -
, O +
seizures U-Disease +
were O +
induced O +
by O +
pilocarpine O +
injections O +
in O +
trained O +
and O +
non O -
- O -
trained O +
control O +
groups O -
. O -

During O +
the O +
acute O +
period O +
of O +
status B-Disease +
epilepticus L-Disease -
, O +
we O +
measured O -
: O +
( O -
1 O -
) O +
the O +
latency O +
of O +
the O +
first O +
motor O +
sign O -
, O +
( O -
2 O -
) O +
the O +
intensity O +
of O +
seizures U-Disease -
, O +
( O -
3 O -
) O +
the O +
time O +
when O +
it O +
occurred O +
within O +
the O +
6-h O +
observation O +
period O -
, O +
and O +
( O -
4 O -
) O +
the O +
time O +
when O +
the O +
acute O +
period O +
ended O -
. O -

All O +
these O +
behavioral O +
parameters O +
showed O +
statistically O +
significant O +
changes O +
suggesting O +
that O +
regular O +
physical O +
exercises O +
decrease O +
susceptibility O +
to O +
subsequently O +
induced O +
seizures U-Disease +
and O +
ameliorate O +
the O +
course O +
of O +
experimentally O +
induced O +
status B-Disease +
epilepticus L-Disease -
. O -

Tonic O +
dopaminergic O +
stimulation O +
impairs B-Disease +
associative I-Disease +
learning L-Disease +
in O +
healthy O +
subjects O -
. O -

Endogenous O +
dopamine O +
plays O +
a O +
central O +
role O +
in O +
salience O +
coding O +
during O +
associative O +
learning O -
. O -

Administration O +
of O +
the O +
dopamine O +
precursor O +
levodopa O +
enhances O +
learning O +
in O +
healthy O +
subjects O +
and O +
stroke U-Disease +
patients O -
. O -

Because O +
levodopa O +
increases O +
both O +
phasic O +
and O +
tonic O +
dopaminergic O +
neurotransmission O -
, O +
the O +
critical O +
mechanism O +
mediating O +
the O +
enhancement O +
of O +
learning O +
is O +
unresolved O -
. O -

We O +
here O +
probed O +
how O +
selective O +
tonic O +
dopaminergic O +
stimulation O +
affects O +
associative O +
learning O -
. O -

Forty O +
healthy O +
subjects O +
were O +
trained O +
in O +
a O +
novel O +
vocabulary O +
of O +
45 O +
concrete O +
nouns O +
over O +
the O +
course O +
of O +
5 O +
consecutive O +
training O +
days O +
in O +
a O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
design O -
. O -

Subjects O +
received O +
the O +
tonically O +
stimulating O +
dopamine O -
- O -
receptor O +
agonist O +
pergolide O +
( O -
0.1 O +
mg O -
) O +
vs O +
placebo O +
120 O +
min O +
before O +
training O +
on O +
each O +
training O +
day O -
. O -

The O +
dopamine O +
agonist O +
significantly O +
impaired B-Disease +
novel I-Disease +
word I-Disease +
learning L-Disease +
compared O +
to O +
placebo O -
. O -

This O +
learning O +
decrement O +
persisted O +
up O +
to O +
the O +
last O +
follow O -
- O -
up O +
4 O +
weeks O +
post O -
- O -
training O -
. O -

Subjects O +
treated O +
with O +
pergolide O +
also O +
showed O +
restricted O +
emotional O +
responses O +
compared O +
to O +
the O +
PLACEBO O +
group O -
. O -

The O +
extent O +
of O +
' O -
flattened O -
' O +
affect O +
with O +
pergolide O +
was O +
related O +
to O +
the O +
degree O +
of O +
learning O +
inhibition O -
. O -

These O +
findings O +
suggest O +
that O +
tonic O +
occupation O +
of O +
dopamine O +
receptors O +
impairs O +
learning O +
by O +
competition O +
with O +
phasic O +
dopamine O +
signals O -
. O -

Thus O -
, O +
phasic O +
signaling O +
seems O +
to O +
be O +
the O +
critical O +
mechanism O +
by O +
which O +
dopamine O +
enhances O +
associative O +
learning O +
in O +
healthy O +
subjects O +
and O +
stroke U-Disease +
patients O -
. O -

Minocycline O -
- O -
induced O +
vasculitis U-Disease +
fulfilling O +
the O +
criteria O +
of O +
polyarteritis B-Disease +
nodosa L-Disease -
. O -

A O +
47-year O -
- O -
old O +
man O +
who O +
had O +
been O +
taking O +
minocycline O +
for O +
palmoplantar B-Disease +
pustulosis L-Disease +
developed O +
fever U-Disease -
, O +
myalgias U-Disease -
, O +
polyneuropathy U-Disease -
, O +
and O +
testicular B-Disease +
pain L-Disease -
, O +
with O +
elevated O +
C O -
- O -
reactive O +
protein O +
( O -
CRP O -
) O -
. O -

Neither O +
myeloperoxidase- O +
nor O +
proteinase-3-antineutrophil O +
cytoplasmic O +
antibody O +
was O +
positive O -
. O -

These O +
manifestations O +
met O +
the O +
American O +
College O +
of O +
Rheumatology O +
1990 O +
criteria O +
for O +
the O +
classification O +
of O +
polyarteritis B-Disease +
nodosa L-Disease -
. O -

Stopping O +
minocycline O +
led O +
to O +
amelioration O +
of O +
symptoms O +
and O +
normalization O +
of O +
CRP O +
level O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
second O +
case O +
of O +
minocycline O -
- O -
induced O +
vasculitis U-Disease +
satisfying O +
the O +
criteria O -
. O -

Differential O +
diagnosis O +
for O +
drug O -
- O -
induced O +
disease O +
is O +
invaluable O +
even O +
for O +
patients O +
with O +
classical O +
polyarteritis B-Disease +
nodosa L-Disease -
. O -

Intramuscular O +
hepatitis B-Disease +
B L-Disease +
immune O +
globulin O +
combined O +
with O +
lamivudine O +
in O +
prevention O +
of O +
hepatitis B-Disease +
B L-Disease +
recurrence O +
after O +
liver O +
transplantation O -
. O -

BACKGROUND O -
: O +
Combined O +
hepatitis B-Disease +
B L-Disease +
immune O +
globulin O +
( O -
HBIg O -
) O +
and O +
lamivudine O +
in O +
prophylaxis O +
of O +
the O +
recurrence O +
of O +
hepatitis B-Disease +
B L-Disease +
after O +
liver O +
transplantation O +
has O +
significantly O +
improved O +
the O +
survival O +
of O +
HBsAg O +
positive O +
patients O -
. O -

This O +
study O +
was O +
undertaken O +
to O +
evaluate O +
the O +
outcomes O +
of O +
liver O +
transplantation O +
for O +
patients O +
with O +
hepatitis B-Disease +
B L-Disease +
virus O +
( O -
HBV O -
) O -
. O -

METHODS O -
: O +
A O +
retrospective O +
chart O +
analysis O +
and O +
a O +
review O +
of O +
the O +
organ O +
transplant O +
database O +
identified O +
51 O +
patients O +
( O -
43 O +
men O +
and O +
8 O +
women O -
) O +
transplanted O +
for O +
benign O +
HBV O -
- O -
related O +
cirrhotic B-Disease +
diseases L-Disease +
between O +
June O +
2002 O +
and O +
December O +
2004 O +
who O +
had O +
survived O +
more O +
than O +
3 O +
months O -
. O -

HBIg O +
was O +
administered O +
intravenously O +
during O +
the O +
first O +
week O +
and O +
intramuscularly O +
thereafter O -
. O -

RESULTS O -
: O +
At O +
a O +
median O +
follow O -
- O -
up O +
of O +
14.1 O +
months O -
, O +
the O +
overall O +
recurrence O +
rate O +
in O +
the O +
51 O +
patients O +
was O +
3.9 O -
% O +
( O -
2 O -
/ O -
51 O -
) O -
. O -

The O +
overall O +
patient O +
survival O +
was O +
88.3 O -
% O -
, O +
and O +
82.4 O -
% O +
after O +
1 O +
and O +
2 O +
years O -
, O +
respectively O -
. O -

A O +
daily O +
oral O +
dose O +
of O +
100 O +
mg O +
lamivudine O +
for O +
2 O +
weeks O +
before O +
transplantation O +
for O +
10 O +
patients O +
enabled O +
57.1 O -
% O +
( O -
4 O -
/ O -
7 O -
) O +
and O +
62.5 O -
% O +
( O -
5 O -
/ O -
8 O -
) O +
of O +
HBV O -
- O -
DNA O +
and O +
HBeAg O +
positive O +
patients O +
respectively O +
to O +
convert O +
to O +
be O +
negative O -
. O -

Intramuscular O +
HBIg O +
was O +
well O +
tolerated O +
in O +
all O +
patients O -
. O -

CONCLUSION O -
: O +
Lamivudine O +
combined O +
with O +
intramuscular O +
HBIg O +
can O +
effectively O +
prevent O +
allograft O +
from O +
the O +
recurrence O +
of O +
HBV O +
after O +
liver O +
transplantation O -
. O -

Anticonvulsant O +
effect O +
of O +
eslicarbazepine O +
acetate O +
( O -
BIA O +
2 O -
- O -
093 O -
) O +
on O +
seizures U-Disease +
induced O +
by O +
microperfusion O +
of O +
picrotoxin O +
in O +
the O +
hippocampus O +
of O +
freely O +
moving O +
rats O -
. O -

Eslicarbazepine O +
acetate O +
( O -
BIA O +
2 O -
- O -
093 O -
, O +
S- O -
( O -
- O -
) O -
-10-acetoxy-10,11-dihydro-5H O -
- O -
dibenzo O -
/ O -
b O -
, O -
f O -
/ O -
azepine-5-carboxamide O -
) O +
is O +
a O +
novel O +
antiepileptic O +
drug O -
, O +
now O +
in O +
Phase O +
III O +
clinical O +
trials O -
, O +
designed O +
with O +
the O +
aim O +
of O +
improving O +
efficacy O +
and O +
safety O +
in O +
comparison O +
with O +
the O +
structurally O +
related O +
drugs O +
carbamazepine O +
( O -
CBZ O -
) O +
and O +
oxcarbazepine O +
( O -
OXC O -
) O -
. O -

We O +
have O +
studied O +
the O +
effects O +
of O +
oral O +
treatment O +
with O +
eslicarbazepine O +
acetate O +
on O +
a O +
whole O -
- O -
animal O +
model O +
in O +
which O +
partial O +
seizures U-Disease +
can O +
be O +
elicited O +
repeatedly O +
on O +
different O +
days O +
without O +
changes O +
in O +
threshold O +
or O +
seizure U-Disease +
patterns O -
. O -

In O +
the O +
animals O +
treated O +
with O +
threshold O +
doses O +
of O +
picrotoxin O -
, O +
the O +
average O +
number O +
of O +
seizures U-Disease +
was O +
2.3+ O -
/ O -
-1.2 O -
, O +
and O +
average O +
seizure U-Disease +
duration O +
was O +
39.5+ O -
/ O -
-8.4s O -
. O -

Pre O -
- O -
treatment O +
with O +
a O +
dose O +
of O +
30 O +
mg O -
/ O -
kg O +
2h O +
before O +
picrotoxin O +
microperfusion O +
prevented O +
seizures U-Disease +
in O +
the O +
75 O -
% O +
of O +
the O +
rats O -
. O -

Lower O +
doses O +
( O -
3 O +
and O +
10mg O -
/ O -
kg O -
) O +
did O +
not O +
suppress O +
seizures U-Disease -
, O +
however O -
, O +
after O +
administration O +
of O +
10mg O -
/ O -
kg O -
, O +
significant O +
reductions O +
in O +
seizures U-Disease +
duration O +
( O -
24.3+ O -
/ O -
-6.8s O -
) O +
and O +
seizure U-Disease +
number O +
( O -
1.6+ O -
/ O -
-0.34 O -
) O +
were O +
found O -
. O -

No O +
adverse O +
effects O +
of O +
eslicarbazepine O +
acetate O +
were O +
observed O +
in O +
the O +
behavioral O -
/ O -
EEG O +
patterns O +
studied O -
, O +
including O +
sleep O -
/ O -
wakefulness O +
cycle O -
, O +
at O +
the O +
doses O +
studied O -
. O -

Acute B-Disease +
renal I-Disease +
failure L-Disease +
associated O +
with O +
prolonged O +
intake O +
of O +
slimming O +
pills O +
containing O +
anthraquinones O -
. O -

Chinese O +
herbal O +
medicine O +
preparations O +
are O +
widely O +
available O +
and O +
often O +
regarded O +
by O +
the O +
public O +
as O +
natural O +
and O +
safe O +
remedies O +
for O +
a O +
variety O +
of O +
medical O +
conditions O -
. O -

Nephropathy U-Disease +
caused O +
by O +
Chinese O +
herbs O +
has O +
previously O +
been O +
reported O -
, O +
usually O +
involving O +
the O +
use O +
of O +
aristolochic O +
acids O -
. O -

We O +
report O +
a O +
23-year O -
- O -
old O +
woman O +
who O +
developed O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
following O +
prolonged O +
use O +
of O +
a O +
proprietary O +
Chinese O +
herbal O +
slimming O +
pill O +
that O +
contained O +
anthraquinone O +
derivatives O -
, O +
extracted O +
from O +
Rhizoma O +
Rhei O +
( O -
rhubarb O -
) O -
. O -

The O +
renal B-Disease +
injury L-Disease +
was O +
probably O +
aggravated O +
by O +
the O +
concomitant O +
intake O +
of O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
, O +
diclofenac O -
. O -

Renal O +
pathology O +
was O +
that O +
of O +
hypocellular O +
interstitial O +
fibrosis U-Disease -
. O -

Spontaneous O +
renal O +
recovery O +
occurred O +
upon O +
cessation O +
of O +
the O +
slimming O +
pills O -
, O +
but O +
mild O +
interstitial O +
fibrosis U-Disease +
and O +
tubular O +
atrophy U-Disease +
was O +
still O +
evident O +
histologically O +
4 O +
months O +
later O -
. O -

Although O +
a O +
causal O +
relationship O +
between O +
the O +
use O +
of O +
an O +
anthraquinone O -
- O -
containing O +
herbal O +
agent O +
and O +
renal B-Disease +
injury L-Disease +
remains O +
to O +
be O +
proven O -
, O +
phytotherapy O -
- O -
associated O +
interstitial O +
nephropathy U-Disease +
should O +
be O +
considered O +
in O +
patients O +
who O +
present O +
with O +
unexplained O +
renal B-Disease +
failure L-Disease -
. O -

Chloroacetaldehyde O +
as O +
a O +
sulfhydryl O +
reagent O -
: O +
the O +
role O +
of O +
critical O +
thiol O +
groups O +
in O +
ifosfamide O +
nephropathy U-Disease -
. O -

Chloroacetaldehyde O +
( O -
CAA O -
) O +
is O +
a O +
metabolite O +
of O +
the O +
alkylating O +
agent O +
ifosfamide O +
( O -
IFO O -
) O +
and O +
putatively O +
responsible O +
for O +
renal B-Disease +
damage L-Disease +
following O +
anti O -
- O -
tumor U-Disease +
therapy O +
with O +
IFO O -
. O -

Depletion O +
of O +
sulfhydryl O +
( O -
SH O -
) O +
groups O +
has O +
been O +
reported O +
from O +
cell O +
culture O -
, O +
animal O +
and O +
clinical O +
studies O -
. O -

In O +
this O +
work O +
the O +
effect O +
of O +
CAA O +
on O +
human O +
proximal O +
tubule O +
cells O +
in O +
primary O +
culture O +
( O -
hRPTEC O -
) O +
was O +
investigated O -
. O -

Toxicity U-Disease +
of O +
CAA O +
was O +
determined O +
by O +
protein O +
content O -
, O +
cell O +
number O -
, O +
LDH O +
release O -
, O +
trypan O +
blue O +
exclusion O +
assay O +
and O +
caspase-3 O +
activity O -
. O -

Free O +
thiols O +
were O +
measured O +
by O +
the O +
method O +
of O +
Ellman O -
. O -

CAA O +
reduced O +
hRPTEC O +
cell O +
number O +
and O +
protein O -
, O +
induced O +
a O +
loss O +
in O +
free O +
intracellular O +
thiols O +
and O +
an O +
increase O +
in O +
necrosis U-Disease +
markers O -
. O -

CAA O +
but O +
not O +
acrolein O +
inhibited O +
the O +
cysteine O +
proteases O +
caspase-3 O -
, O +
caspase-8 O +
and O +
cathepsin O +
B. O +
Caspase O +
activation O +
by O +
cisplatin O +
was O +
inhibited O +
by O +
CAA O -
. O -

In O +
cells O +
stained O +
with O +
fluorescent O +
dyes O +
targeting O +
lysosomes O -
, O +
CAA O +
induced O +
an O +
increase O +
in O +
lysosomal O +
size O +
and O +
lysosomal O +
leakage O -
. O -

The O +
effects O +
of O +
CAA O +
on O +
cysteine O +
protease O +
activities O +
and O +
thiols O +
could O +
be O +
reproduced O +
in O +
cell O +
lysate O -
. O -

Acidification O -
, O +
which O +
slowed O +
the O +
reaction O +
of O +
CAA O +
with O +
thiol O +
donors O -
, O +
could O +
also O +
attenuate O +
effects O +
of O +
CAA O +
on O +
necrosis U-Disease +
markers O -
, O +
thiol O +
depletion O +
and O +
cysteine O +
protease O +
inhibition O +
in O +
living O +
cells O -
. O -

Thus O -
, O +
CAA O +
directly O +
reacts O +
with O +
cellular O +
protein O +
and O +
non O -
- O -
protein O +
thiols O -
, O +
mediating O +
its O +
toxicity U-Disease +
on O +
hRPTEC O -
. O -

This O +
effect O +
can O +
be O +
reduced O +
by O +
acidification O -
. O -

Therefore O -
, O +
urinary O +
acidification O +
could O +
be O +
an O +
option O +
to O +
prevent O +
IFO O +
nephropathy U-Disease +
in O +
patients O -
. O -

Stereological O +
methods O +
reveal O +
the O +
robust O +
size O +
and O +
stability O +
of O +
ectopic O +
hilar O +
granule O +
cells O +
after O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease +
in O +
the O +
adult O +
rat O -
. O -

Following O +
status B-Disease +
epilepticus L-Disease +
in O +
the O +
rat O -
, O +
dentate O +
granule O +
cell O +
neurogenesis O +
increases O +
greatly O -
, O +
and O +
many O +
of O +
the O +
new O +
neurons O +
appear O +
to O +
develop O +
ectopically O -
, O +
in O +
the O +
hilar O +
region O +
of O +
the O +
hippocampal O +
formation O -
. O -

It O +
has O +
been O +
suggested O +
that O +
the O +
ectopic O +
hilar O +
granule O +
cells O +
could O +
contribute O +
to O +
the O +
spontaneous O +
seizures U-Disease +
that O +
ultimately O +
develop O +
after O +
status B-Disease +
epilepticus L-Disease -
. O -

However O -
, O +
the O +
population O +
has O +
never O +
been O +
quantified O -
, O +
so O +
it O +
is O +
unclear O +
whether O +
it O +
is O +
substantial O +
enough O +
to O +
have O +
a O +
strong O +
influence O +
on O +
epileptogenesis O -
. O -

To O +
quantify O +
this O +
population O -
, O +
the O +
total O +
number O +
of O +
ectopic O +
hilar O +
granule O +
cells O +
was O +
estimated O +
using O +
unbiased O +
stereology O +
at O +
different O +
times O +
after O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease -
. O -

The O +
number O +
of O +
hilar O +
neurons O +
immunoreactive O +
for O +
Prox-1 O -
, O +
a O +
granule O -
- O -
cell O -
- O -
specific O +
marker O -
, O +
was O +
estimated O +
using O +
the O +
optical O +
fractionator O +
method O -
. O -

The O +
results O +
indicate O +
that O +
the O +
size O +
of O +
the O +
hilar O +
ectopic O +
granule O +
cell O +
population O +
after O +
status B-Disease +
epilepticus L-Disease +
is O +
substantial O -
, O +
and O +
stable O +
over O +
time O -
. O -

Interestingly O -
, O +
the O +
size O +
of O +
the O +
population O +
appears O +
to O +
be O +
correlated O +
with O +
the O +
frequency O +
of O +
behavioral O +
seizures U-Disease -
, O +
because O +
animals O +
with O +
more O +
ectopic O +
granule O +
cells O +
in O +
the O +
hilus O +
have O +
more O +
frequent O +
behavioral O +
seizures U-Disease -
. O -

The O +
hilar O +
ectopic O +
granule O +
cell O +
population O +
does O +
not O +
appear O +
to O +
vary O +
systematically O +
across O +
the O +
septotemporal O +
axis O -
, O +
although O +
it O +
is O +
associated O +
with O +
an O +
increase O +
in O +
volume O +
of O +
the O +
hilus O -
. O -

The O +
results O +
provide O +
new O +
insight O +
into O +
the O +
potential O +
role O +
of O +
ectopic O +
hilar O +
granule O +
cells O +
in O +
the O +
pilocarpine O +
model O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease -
. O -

A O +
prospective O -
, O +
open O -
- O -
label O +
trial O +
of O +
galantamine O +
in O +
autistic B-Disease +
disorder L-Disease -
. O -

OBJECTIVE O -
: O +
Post O -
- O -
mortem O +
studies O +
have O +
reported O +
abnormalities O +
of O +
the O +
cholinergic O +
system O +
in O +
autism U-Disease -
. O -

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
assess O +
the O +
use O +
of O +
galantamine O -
, O +
an O +
acetylcholinesterase O +
inhibitor O +
and O +
nicotinic O +
receptor O +
modulator O -
, O +
in O +
the O +
treatment O +
of O +
interfering O +
behaviors O +
in O +
children O +
with O +
autism U-Disease -
. O -

METHODS O -
: O +
Thirteen O +
medication O -
- O -
free O +
children O +
with O +
autism U-Disease +
( O -
mean O +
age O -
, O +
8.8 O +
+ O -
/- O -

3.5 O +
years O -
) O +
participated O +
in O +
a O +
12-week O -
, O +
open O -
- O -
label O +
trial O +
of O +
galantamine O -
. O -

Patients O +
were O +
rated O +
monthly O +
by O +
parents O +
on O +
the O +
Aberrant O +
Behavior O +
Checklist O +
( O -
ABC O -
) O +
and O +
the O +
Conners O -
' O +
Parent O +
Rating O +
Scale O -
- O -
Revised O -
, O +
and O +
by O +
a O +
physician O +
using O +
the O +
Children O -
's O +
Psychiatric O +
Rating O +
Scale O +
and O +
the O +
Clinical O +
Global O +
Impressions O +
scale O -
. O -

RESULTS O -
: O +
Patients O +
showed O +
a O +
significant O +
reduction O +
in O +
parent O -
- O -
rated O +
irritability U-Disease +
and O +
social O +
withdrawal O +
on O +
the O +
ABC O +
as O +
well O +
as O +
significant O +
improvements O +
in O +
emotional O +
lability O +
and O +
inattention O +
on O +
the O +
Conners O -
' O +
Parent O +
Rating O +
Scale O -
-- O -
Revised O -
. O -

Similarly O -
, O +
clinician O +
ratings O +
showed O +
reductions O +
in O +
the O +
anger O +
subscale O +
of O +
the O +
Children O -
's O +
Psychiatric O +
Rating O +
Scale O -
. O -

Eight O +
of O +
13 O +
participants O +
were O +
rated O +
as O +
responders O +
on O +
the O +
basis O +
of O +
their O +
improvement O +
scores O +
on O +
the O +
Clinical O +
Global O +
Impressions O +
scale O -
. O -

Overall O -
, O +
galantamine O +
was O +
well O -
- O -
tolerated O -
, O +
with O +
no O +
significant O +
adverse O +
effects O +
apart O +
from O +
headaches U-Disease +
in O +
one O +
patient O -
. O -

CONCLUSION O -
: O +
In O +
this O +
open O +
trial O -
, O +
galantamine O +
was O +
well O -
- O -
tolerated O +
and O +
appeared O +
to O +
be O +
beneficial O +
for O +
the O +
treatment O +
of O +
interfering O +
behaviors O +
in O +
children O +
with O +
autism U-Disease -
, O +
particularly O +
aggression U-Disease -
, O +
behavioral B-Disease +
dyscontrol L-Disease -
, O +
and O +
inattention U-Disease -
. O -

Further O +
controlled O +
trials O +
are O +
warranted O -
. O -

Randomized O +
comparison O +
of O +
olanzapine O +
versus O +
risperidone O +
for O +
the O +
treatment O +
of O +
first O -
- O -
episode O +
schizophrenia U-Disease -
: O +
4-month O +
outcomes O -
. O -

OBJECTIVE O -
: O +
The O +
authors O +
compared O +
4-month O +
treatment O +
outcomes O +
for O +
olanzapine O +
versus O +
risperidone O +
in O +
patients O +
with O +
first O -
- O -
episode O +
schizophrenia U-Disease +
spectrum O +
disorders O -
. O -

METHOD O -
: O +
One O +
hundred O +
twelve O +
subjects O +
( O -
70 O -
% O +
male O -
; O +
mean O +
age=23.3 O +
years O +
[ O -
SD O +
= O +
5.1 O -
] O -
) O +
with O +
first O -
- O -
episode O +
schizophrenia U-Disease +
( O -
75 O -
% O -
) O -
, O +
schizophreniform B-Disease +
disorder L-Disease +
( O -
17 O -
% O -
) O -
, O +
or O +
schizoaffective B-Disease +
disorder L-Disease +
( O -
8 O -
% O -
) O +
were O +
randomly O +
assigned O +
to O +
treatment O +
with O +
olanzapine O +
( O -
2.5 O -
- O -
20 O +
mg O -
/ O -
day O -
) O +
or O +
risperidone O +
( O -
1 O -
- O -
6 O +
mg O -
/ O -
day O -
) O -
. O -

RESULTS O -
: O +
Response O +
rates O +
did O +
not O +
significantly O +
differ O +
between O +
olanzapine O +
( O -
43.7 O -
% O -
, O +
95 O -
% O +
CI=28.8%-58.6 O -
% O -
) O +
and O +
risperidone O +
( O -
54.3 O -
% O -
, O +
95 O -
% O +
CI=39.9%-68.7 O -
% O -
) O -
. O -

Among O +
those O +
responding O +
to O +
treatment O -
, O +
more O +
subjects O +
in O +
the O +
olanzapine O +
group O +
( O -
40.9 O -
% O -
, O +
95 O -
% O +
CI=16.8%-65.0 O -
% O -
) O +
than O +
in O +
the O +
risperidone O +
group O +
( O -
18.9 O -
% O -
, O +
95 O -
% O +
CI=0%-39.2 O -
% O -
) O +
had O +
subsequent O +
ratings O +
not O +
meeting O +
response O +
criteria O -
. O -

Negative O +
symptom O +
outcomes O +
and O +
measures O +
of O +
parkinsonism U-Disease +
and O +
akathisia U-Disease +
did O +
not O +
differ O +
between O +
medications O -
. O -

Extrapyramidal B-Disease +
symptom L-Disease +
severity O +
scores O +
were O +
1.4 O +
( O -
95 O -
% O +
CI=1.2 O -
- O -
1.6 O -
) O +
with O +
risperidone O +
and O +
1.2 O +
( O -
95 O -
% O +
CI=1.0 O -
- O -
1.4 O -
) O +
with O +
olanzapine O -
. O -

Significantly O +
more O +
weight B-Disease +
gain L-Disease +
occurred O +
with O +
olanzapine O +
than O +
with O +
risperidone O -
: O +
the O +
increase O +
in O +
weight O +
at O +
4 O +
months O +
relative O +
to O +
baseline O +
weight O +
was O +
17.3 O -
% O +
( O -
95 O -
% O +
CI=14.2%-20.5 O -
% O -
) O +
with O +
olanzapine O +
and O +
11.3 O -
% O +
( O -
95 O -
% O +
CI=8.4%-14.3 O -
% O -
) O +
with O +
risperidone O -
. O -

Body O +
mass O +
index O +
at O +
baseline O +
and O +
at O +
4 O +
months O +
was O +
24.3 O +
( O -
95 O -
% O +
CI=22.8 O -
- O -
25.7 O -
) O +
versus O +
28.2 O +
( O -
95 O -
% O +
CI=26.7 O -
- O -
29.7 O -
) O +
with O +
olanzapine O +
and O +
23.9 O +
( O -
95 O -
% O +
CI=22.5 O -
- O -
25.3 O -
) O +
versus O +
26.7 O +
( O -
95 O -
% O +
CI=25.2 O -
- O -
28.2 O -
) O +
with O +
risperidone O -
. O -

CONCLUSIONS O -
: O +
Clinical O +
outcomes O +
with O +
risperidone O +
were O +
equal O +
to O +
those O +
with O +
olanzapine O -
, O +
and O +
response O +
may O +
be O +
more O +
stable O -
. O -

Olanzapine O +
may O +
have O +
an O +
advantage O +
for O +
motor O +
side O +
effects O -
. O -

Both O +
medications O +
caused O +
substantial O +
rapid O +
weight B-Disease +
gain L-Disease -
, O +
but O +
weight B-Disease +
gain L-Disease +
was O +
greater O +
with O +
olanzapine O -
. O -

Early O +
paracentral O +
visual B-Disease +
field I-Disease +
loss L-Disease +
in O +
patients O +
taking O +
hydroxychloroquine O -
. O -

OBJECTIVE O -
: O +
To O +
review O +
the O +
natural O +
history O +
and O +
ocular O +
and O +
systemic O +
adverse O +
effects O +
of O +
patients O +
taking O +
hydroxychloroquine O +
sulfate O +
who O +
attended O +
an O +
ophthalmic O +
screening O +
program O -
. O -

DESIGN O -
: O +
Retrospective O +
study O -
. O -

RESULTS O -
: O +
Records O +
of O +
262 O +
patients O +
who O +
were O +
taking O +
hydroxychloroquine O +
and O +
screened O +
in O +
the O +
Department O +
of O +
Ophthalmology O +
were O +
reviewed O -
. O -

Of O +
the O +
262 O +
patients O -
, O +
14 O +
( O -
18 O -
% O -
) O +
of O +
76 O +
who O +
had O +
stopped O +
treatment O +
at O +
the O +
time O +
of O +
the O +
study O +
experienced O +
documented O +
adverse O +
effects O -
. O -

Systemic O +
adverse O +
effects O +
occurred O +
in O +
8 O +
patients O +
( O -
10.5 O -
% O -
) O +
and O +
ocular O +
adverse O +
effects O -
, O +
in O +
5 O +
( O -
6.5 O -
% O -
) O -
. O -

Thirty O -
- O -
five O +
patients O +
( O -
13.4 O -
% O -
) O +
had O +
visual B-Disease +
field I-Disease +
abnormalities L-Disease -
, O +
which O +
were O +
attributed O +
to O +
hydroxychloroquine O +
treatment O +
in O +
4 O +
patients O +
( O -
1.5 O -
% O -
) O -
. O -

Three O +
of O +
the O +
4 O +
patients O +
were O +
taking O +
less O +
than O +
6.5 O +
mg O -
/ O -
kg O +
per O +
day O +
and O +
all O +
patients O +
had O +
normal O +
renal O +
and O +
liver O +
function O +
test O +
results O -
. O -

CONCLUSIONS O -
: O +
The O +
current O +
study O +
used O +
a O +
protocol O +
of O +
visual O +
acuity O +
and O +
color O +
vision O +
assessment O -
, O +
funduscopy O -
, O +
and O +
Humphrey O +
10 O -
- O -
2 O +
visual O +
field O +
testing O +
and O +
shows O +
that O +
visual B-Disease +
field I-Disease +
defects L-Disease +
appeared O +
before O +
any O +
corresponding O +
changes O +
in O +
any O +
other O +
tested O +
clinical O +
parameters O -
; O +
the O +
defects O +
were O +
reproducible O +
and O +
the O +
test O +
parameters O +
were O +
reliable O -
. O -

Patients O +
taking O +
hydroxychloroquine O +
can O +
demonstrate O +
a O +
toxic O +
reaction O +
in O +
the O +
retina O +
despite O +
the O +
absence O +
of O +
known O +
risk O +
factors O -
. O -

Screening O -
, O +
including O +
Humphrey O +
10 O -
- O -
2 O +
visual O +
field O +
assessment O -
, O +
is O +
recommended O +
2 O +
years O +
after O +
the O +
initial O +
baseline O +
and O +
yearly O +
thereafter O -
. O -

Peri O -
- O -
operative O +
atrioventricular B-Disease +
block L-Disease +
as O +
a O +
result O +
of O +
chemotherapy O +
with O +
epirubicin O +
and O +
paclitaxel O -
. O -

A O +
47-year O -
- O -
old O +
woman O +
presented O +
for O +
mastectomy O +
and O +
immediate O +
latissimus O +
dorsi O +
flap O +
reconstruction O +
having O +
been O +
diagnosed O +
with O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
breast L-Disease +
6 O +
months O +
previously O -
. O -

In O +
the O +
preceding O +
months O +
she O +
had O +
received O +
neo O -
- O -
adjuvant O +
chemotherapy O +
with O +
epirubicin O -
, O +
paclitaxel O +
( O -
Taxol O -
) O +
and O +
cyclophosphamide O -
. O -

This O +
had O +
been O +
apparently O +
uncomplicated O +
and O +
she O +
had O +
maintained O +
a O +
remarkably O +
high O +
level O +
of O +
physical O +
activity O -
. O -

She O +
was O +
found O +
to O +
be O +
bradycardic U-Disease +
at O +
pre O -
- O -
operative O +
assessment O +
but O +
had O +
no O +
cardiac O +
symptoms O -
. O -

Second O +
degree O +
Mobitz O +
type O +
II O +
atrioventricular B-Disease +
block L-Disease +
was O +
diagnosed O +
on O +
electrocardiogram O -
, O +
and O +
temporary O +
transvenous O +
ventricular O +
pacing O +
instituted O +
in O +
the O +
peri O -
- O -
operative O +
period O -
. O -

We O +
discuss O +
how O +
evidence O -
- O -
based O +
guidelines O +
would O +
not O +
have O +
been O +
helpful O +
in O +
this O +
case O -
, O +
and O +
how O +
chemotherapy O +
can O +
exhibit O +
substantial O +
cardiotoxicity U-Disease +
that O +
may O +
develop O +
over O +
many O +
years O -
. O -

We O +
suggest O +
that O +
patients O +
who O +
have O +
received O +
chemotherapy O +
at O +
any O +
time O +
should O +
have O +
a O +
pre O -
- O -
operative O +
electrocardiogram O +
even O +
if O +
they O +
are O +
asymptomatic O -
. O -

Risks O +
and O +
benefits O +
of O +
COX-2 O +
inhibitors O +
vs O +
non O -
- O -
selective O +
NSAIDs O -
: O +
does O +
their O +
cardiovascular O +
risk O +
exceed O +
their O +
gastrointestinal O +
benefit O -
? O -

A O +
retrospective O +
cohort O +
study O -
. O -

OBJECTIVES O -
: O +
The O +
risk O +
of O +
acute B-Disease +
myocardial I-Disease +
infarction L-Disease +
( O -
AMI U-Disease -
) O +
with O +
COX-2 O +
inhibitors O +
may O +
offset O +
their O +
gastrointestinal O +
( O -
GI O -
) O +
benefit O +
compared O +
with O +
non O -
- O -
selective O +
( O -
NS O -
) O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
. O -

We O +
aimed O +
to O +
compare O +
the O +
risks O +
of O +
hospitalization O +
for O +
AMI U-Disease +
and O +
GI B-Disease +
bleeding L-Disease +
among O +
elderly O +
patients O +
using O +
COX-2 O +
inhibitors O -
, O +
NS O -
- O -
NSAIDs O +
and O +
acetaminophen O -
. O -

METHODS O -
: O +
We O +
conducted O +
a O +
retrospective O +
cohort O +
study O +
using O +
administrative O +
data O +
of O +
patients O +
> O +
or O +
= O -
65 O +
years O +
of O +
age O +
who O +
filled O +
a O +
prescription O +
for O +
NSAID O +
or O +
acetaminophen O +
during O +
1999 O -
- O -
2002 O -
. O -

Outcomes O +
were O +
compared O +
using O +
Cox O +
regression O +
models O +
with O +
time O -
- O -
dependent O +
exposures O -
. O -

RESULTS O -
: O +
Person O -
- O -
years O +
of O +
exposure O +
among O +
non O -
- O -
users O +
of O +
aspirin O +
were O -
: O +
75,761 O +
to O +
acetaminophen O -
, O +
42,671 O +
to O +
rofecoxib O +
65,860 O +
to O +
celecoxib O -
, O +
and O +
37,495 O +
to O +
NS O -
- O -
NSAIDs O -
. O -

Among O +
users O +
of O +
aspirin O -
, O +
they O +
were O -
: O +
14,671 O +
to O +
rofecoxib O -
, O +
22,875 O +
to O +
celecoxib O -
, O +
9,832 O +
to O +
NS O -
- O -
NSAIDs O +
and O +
38,048 O +
to O +
acetaminophen O -
. O -

Among O +
non O -
- O -
users O +
of O +
aspirin O -
, O +
the O +
adjusted O +
hazard O +
ratios O +
( O -
95 O -
% O +
confidence O +
interval O -
) O +
of O +
hospitalization O +
for O +
AMI U-Disease -
/ O -
GI O +
vs O +
the O +
acetaminophen O +
( O -
with O +
no O +
aspirin O -
) O +
group O +
were O -
: O +
rofecoxib O +
1.27 O +
( O -
1.13 O -
, O +
1.42 O -
) O -
, O +
celecoxib O +
0.93 O +
( O -
0.83 O -
, O +
1.03 O -
) O -
, O +
naproxen O +
1.59 O +
( O -
1.31 O -
, O +
1.93 O -
) O -
, O +
diclofenac O +
1.17 O +
( O -
0.99 O -
, O +
1.38 O -
) O +
and O +
ibuprofen O +
1.05 O +
( O -
0.74 O -
, O +
1.51 O -
) O -
. O -

Among O +
users O +
of O +
aspirin O -
, O +
they O +
were O -
: O +
rofecoxib O +
1.73 O +
( O -
1.52 O -
, O +
1.98 O -
) O -
, O +
celecoxib O +
1.34 O +
( O -
1.19 O -
, O +
1.52 O -
) O -
, O +
ibuprofen O +
1.51 O +
( O -
0.95 O -
, O +
2.41 O -
) O -
, O +
diclofenac O +
1.69 O +
( O -
1.35 O -
, O +
2.10 O -
) O -
, O +
naproxen O +
1.35 O +
( O -
0.97 O -
, O +
1.88 O -
) O +
and O +
acetaminophen O +
1.29 O +
( O -
1.17 O -
, O +
1.42 O -
) O -
. O -

CONCLUSION O -
: O +
Among O +
non O -
- O -
users O +
of O +
aspirin O -
, O +
naproxen O +
seemed O +
to O +
carry O +
the O +
highest O +
risk O +
for O +
AMI U-Disease -
/ O -
GI B-Disease +
bleeding L-Disease -
. O -

The O +
AMI U-Disease -
/ O -
GI O +
toxicity U-Disease +
of O +
celecoxib O +
was O +
similar O +
to O +
that O +
of O +
acetaminophen O +
and O +
seemed O +
to O +
be O +
better O +
than O +
those O +
of O +
rofecoxib O +
and O +
NS O -
- O -
NSAIDs O -
. O -

Among O +
users O +
of O +
aspirin O -
, O +
both O +
celecoxib O +
and O +
naproxen O +
seemed O +
to O +
be O +
the O +
least O +
toxic O -
. O -

Quinine O -
- O -
induced O +
arrhythmia U-Disease +
in O +
a O +
patient O +
with O +
severe B-Disease +
malaria L-Disease -
. O -

It O +
was O +
reported O +
that O +
there O +
was O +
a O +
case O +
of O +
severe B-Disease +
malaria L-Disease +
patient O +
with O +
jaundice U-Disease +
who O +
presented O +
with O +
arrhythmia U-Disease +
( O -
premature B-Disease +
ventricular I-Disease +
contraction L-Disease -
) O +
while O +
getting O +
quinine O +
infusion O +
was O +
reported O -
. O -

A O +
man O -
, O +
25 O +
years O +
old O -
, O +
was O +
admitted O +
to O +
hospital O +
with O +
high O +
fever U-Disease -
, O +
chill U-Disease -
, O +
vomiting U-Disease -
, O +
jaundice U-Disease -
. O -

The O +
patient O +
was O +
fully O +
conscious O -
, O +
blood O +
pressure O +
120 O -
/ O -
80 O +
mmHg O -
, O +
pulse O +
rate O +
100 O +
x O -
/ O -
minute O -
, O +
regular O -
. O -

On O +
admission O -
, O +
laboratory O +
examination O +
showed O +
Plasmodium O +
falciparum O +
( O -
+ O -
+ O -
+ O -
+ O -
) O -
, O +
total O +
bilirubin O +
8.25 O +
mg O -
/ O -
dL O -
, O +
conjugated O +
bilirubin O +
4.36 O +
mg O -
/ O -
dL O -
, O +
unconjugated O +
bilirubin O +
3.89 O +
mg O -
/ O -
dL O -
, O +
potassium O +
3.52 O +
meq O -
/ O -
L O +
Patient O +
was O +
diagnosed O +
as O +
severe B-Disease +
malaria L-Disease +
with O +
jaundice U-Disease +
and O +
got O +
quinine O +
infusion O +
in O +
dextrose O +
5 O -
% O +
500 O +
mg O -
/ O -
8 O +
hour O -
. O -

On O +
the O +
second O +
day O +
the O +
patient O +
had O +
vomitus U-Disease -
, O +
diarrhea U-Disease -
, O +
tinnitus U-Disease -
, O +
loss B-Disease +
of I-Disease +
hearing L-Disease -
. O -

After O +
30 O +
hours O +
of O +
quinine O +
infusion O +
the O +
patient O +
felt O +
palpitation U-Disease +
and O +
electrocardiography O +
( O -
ECG O -
) O +
recording O +
showed O +
premature B-Disease +
ventricular I-Disease +
contraction L-Disease +
( O -
PVC U-Disease -
) O +
> O +
5 O +
x O -
/ O -
minute O -
, O +
trigemini O -
, O +
constant O +
type O -
-- O -
sinoatrial B-Disease +
block L-Disease -
, O +
positive O +
U O +
wave O -
. O -

He O +
was O +
treated O +
with O +
lidocaine O +
50 O +
mg O +
intravenously O +
followed O +
by O +
infusion O +
1500 O +
mg O +
in O +
dextrose O +
5% O -
/ O -
24 O +
hour O +
and O +
potassium O +
aspartate O +
tablet O -
. O -

Quinine O +
infusion O +
was O +
discontinued O +
and O +
changed O +
with O +
sulfate O +
quinine O +
tablets O -
. O -

Three O +
hours O +
later O +
the O +
patient O +
felt O +
better O -
, O +
the O +
frequency O +
of O +
PVC U-Disease +
reduced O +
to O +
4 O +
- O +
5 O +
x O -
/ O -
minute O +
and O +
on O +
the O +
third O +
day O +
ECG O +
was O +
normal O -
, O +
potassium O +
level O +
was O +
3.34 O +
meq O -
/ O -
L. O +
He O +
was O +
discharged O +
on O +
7th O +
day O +
in O +
good O +
condition O -
. O -

Quinine O -
, O +
like O +
quinidine O -
, O +
is O +
a O +
chincona O +
alkaloid O +
that O +
has O +
anti O -
- O -
arrhythmic U-Disease +
property O -
, O +
although O +
it O +
also O +
pro O -
- O -
arrhythmic U-Disease +
that O +
can O +
cause O +
various O +
arrhythmias U-Disease -
, O +
including O +
severe O +
arrhythmia U-Disease +
such O +
as O +
multiple O +
PVC U-Disease -
. O -

Administration O +
of O +
parenteral O +
quinine O +
must O +
be O +
done O +
carefully O +
and O +
with O +
good O +
observation O +
because O +
of O +
its O +
pro O -
- O -
arrhythmic U-Disease +
effect O -
, O +
especially O +
in O +
older O +
patients O +
who O +
have O +
heart B-Disease +
diseases L-Disease +
or O +
patients O +
with O +
electrolyte B-Disease +
disorder L-Disease +
( O -
hypokalemia U-Disease -
) O +
which O +
frequently O +
occurs O +
due O +
to O +
vomiting U-Disease +
and O +
or O +
diarrhea U-Disease +
in O +
malaria U-Disease +
cases O -
. O -

Penicillamine O -
- O -
related O +
lichenoid B-Disease +
dermatitis L-Disease +
and O +
utility O +
of O +
zinc O +
acetate O +
in O +
a O +
Wilson B-Disease +
disease L-Disease +
patient O +
with O +
hepatic O +
presentation O -
, O +
anxiety U-Disease +
and O +
SPECT O +
abnormalities O -
. O -

Wilson B-Disease -
's I-Disease +
disease L-Disease +
is O +
an O +
autosomal O +
recessive O +
disorder O +
of O +
hepatic O +
copper O +
metabolism O +
with O +
consequent O +
copper O +
accumulation O +
and O +
toxicity U-Disease +
in O +
many O +
tissues O +
and O +
consequent O +
hepatic B-Disease -
, I-Disease +
neurologic I-Disease +
and I-Disease +
psychiatric I-Disease +
disorders L-Disease -
. O -

We O +
report O +
a O +
case O +
of O +
Wilson B-Disease -
's I-Disease +
disease L-Disease +
with O +
chronic B-Disease +
liver I-Disease +
disease L-Disease -
; O +
moreover O -
, O +
in O +
our O +
patient O -
, O +
presenting O +
also O +
with O +
high O +
levels O +
of O +
state O +
anxiety U-Disease +
without O +
depression U-Disease -
, O +
99mTc O -
- O -
ECD O -
- O -
SPECT O +
showed O +
cortical O +
hypoperfusion O +
in O +
frontal O +
lobes O -
, O +
more O +
marked O +
on O +
the O +
left O +
frontal O +
lobe O -
. O -

During O +
the O +
follow O -
- O -
up O +
of O +
our O +
patient O -
, O +
penicillamine O +
was O +
interrupted O +
after O +
the O +
appearance O +
of O +
a O +
lichenoid B-Disease +
dermatitis L-Disease -
, O +
and O +
zinc O +
acetate O +
permitted O +
to O +
continue O +
the O +
successful O +
treatment O +
of O +
the O +
patient O +
without O +
side O -
- O -
effects O -
. O -

In O +
our O +
case O +
the O +
therapy O +
with O +
zinc O +
acetate O +
represented O +
an O +
effective O +
treatment O +
for O +
a O +
Wilson B-Disease -
's I-Disease +
disease L-Disease +
patient O +
in O +
which O +
penicillamine O -
- O -
related O +
side O +
effects O +
appeared O -
. O -

The O +
safety O +
of O +
the O +
zinc O +
acetate O +
allowed O +
us O +
to O +
avoid O +
other O +
potentially O +
toxic O +
chelating O +
drugs O -
; O +
this O +
observation O +
is O +
in O +
line O +
with O +
the O +
growing O +
evidence O +
on O +
the O +
efficacy O +
of O +
the O +
drug O +
in O +
the O +
treatment O +
of O +
Wilson B-Disease -
's I-Disease +
disease L-Disease -
. O -

Since O +
most O +
of O +
Wilson B-Disease -
's I-Disease +
disease L-Disease +
penicillamine O -
- O -
treated O +
patients O +
do O +
not O +
seem O +
to O +
develop O +
this O +
skin B-Disease +
lesion L-Disease -
, O +
it O +
could O +
be O +
conceivable O +
that O +
a O +
specific O +
genetic O +
factor O +
is O +
involved O +
in O +
drug O +
response O -
. O -

Further O +
studies O +
are O +
needed O +
for O +
a O +
better O +
clarification O +
of O +
Wilson B-Disease -
's I-Disease +
disease L-Disease +
therapy O -
, O +
and O +
in O +
particular O +
to O +
differentiate O +
specific O +
therapies O +
for O +
different O +
Wilson B-Disease -
's I-Disease +
disease L-Disease +
phenotypes O -
. O -

A O +
dramatic O +
drop B-Disease +
in I-Disease +
blood I-Disease +
pressure L-Disease +
following O +
prehospital O +
GTN O +
administration O -
. O -

A O +
male O +
in O +
his O +
sixties O +
with O +
no O +
history O +
of O +
cardiac O +
chest B-Disease +
pain L-Disease +
awoke O +
with O +
chest B-Disease +
pain L-Disease +
following O +
an O +
afternoon O +
sleep O -
. O -

The O +
patient O +
did O +
not O +
self O +
medicate O -
. O -

The O +
patient O -
's O +
observations O +
were O +
within O +
normal O +
limits O -
, O +
he O +
was O +
administered O +
oxygen O +
via O +
a O +
face O +
mask O +
and O +
glyceryl O +
trinitrate O +
( O -
GTN O -
) O -
. O -

Several O +
minutes O +
after O +
the O +
GTN O +
the O +
patient O +
experienced O +
a O +
sudden O +
drop B-Disease +
in I-Disease +
blood I-Disease +
pressure L-Disease +
and O +
heart O +
rate O -
, O +
this O +
was O +
rectified O +
by O +
atropine O +
sulphate O +
and O +
a O +
fluid O +
challenge O -
. O -

There O +
was O +
no O +
further O +
deterioration O +
in O +
the O +
patient O -
's O +
condition O +
during O +
transport O +
to O +
hospital O -
. O -

There O +
are O +
very O +
few O +
documented O +
case O +
like O +
this O +
in O +
the O +
prehospital O +
scientific O +
literature O -
. O -

The O +
cause O +
appears O +
to O +
be O +
the O +
Bezold O -
- O -
Jarish O +
reflex O -
, O +
stimulation O +
of O +
the O +
ventricular O +
walls O +
which O +
in O +
turn O +
decreases O +
sympathetic O +
outflow O +
from O +
the O +
vasomotor O +
centre O -
. O -

Prehospital O +
care O +
providers O +
who O +
are O +
managing O +
any O +
patient O +
with O +
a O +
syncopal B-Disease +
episode L-Disease +
that O +
fails O +
to O +
recover O +
within O +
a O +
reasonable O +
time O +
frame O +
should O +
consider O +
the O +
Bezold O -
- O -
Jarisch O +
reflex O +
as O +
the O +
cause O +
and O +
manage O +
the O +
patient O +
accordingly O -
. O -

Chronic O +
lesion O +
of O +
rostral O +
ventrolateral O +
medulla O +
in O +
spontaneously O +
hypertensive U-Disease +
rats O -
. O -

We O +
studied O +
the O +
effects O +
of O +
chronic O +
selective O +
neuronal O +
lesion O +
of O +
rostral O +
ventrolateral O +
medulla O +
on O +
mean O +
arterial O +
pressure O -
, O +
heart O +
rate O -
, O +
and O +
neurogenic O +
tone O +
in O +
conscious O -
, O +
unrestrained O +
spontaneously O +
hypertensive U-Disease +
rats O -
. O -

The O +
lesions O +
were O +
placed O +
via O +
bilateral O +
microinjections O +
of O +
30 O +
nmol O -
/ O -
200 O +
nl O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartic O +
acid O -
. O -

The O +
restimulation O +
of O +
this O +
area O +
with O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartic O +
acid O +
15 O +
days O +
postlesion O +
failed O +
to O +
produce O +
a O +
pressor O +
response O -
. O -

One O +
day O +
postlesion O -
, O +
the O +
resting O +
mean O +
arterial O +
pressure O +
was O +
significantly O +
decreased O +
in O +
lesioned O +
rats O +
when O +
compared O +
with O +
sham O +
rats O +
( O -
100 O +
+ O -
/- O -

7 O +
versus O +
173 O +
+ O -
/- O -

4 O +
mm O +
Hg O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
. O -

Fifteen O +
days O +
later O -
, O +
the O +
lesioned O +
group O +
still O +
showed O +
values O +
significantly O +
lower O +
than O +
the O +
sham O +
group O +
( O -
150 O +
+ O -
/- O -

6 O +
versus O +
167 O +
+ O -
/- O -

5 O +
mm O +
Hg O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
. O -

No O +
significant O +
heart O +
rate O +
differences O +
were O +
observed O +
between O +
the O +
sham O +
and O +
lesioned O +
groups O -
. O -

The O +
ganglionic O +
blocker O +
trimethaphan O +
( O -
5 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
caused O +
similar O +
reductions O +
in O +
mean O +
arterial O +
pressure O +
in O +
both O +
lesioned O +
and O +
sham O +
groups O -
. O -

The O +
trimethaphan O -
- O -
induced O +
hypotension U-Disease +
was O +
accompanied O +
by O +
a O +
significant O +
bradycardia U-Disease +
in O +
lesioned O +
rats O +
( O -
-32 O +
+ O -
/- O -

13 O +
beats O +
per O +
minute O -
) O +
but O +
a O +
tachycardia U-Disease +
in O +
sham O +
rats O +
( O -
+ O -
33 O +
+ O -
/- O -

12 O +
beats O +
per O +
minute O -
) O +
1 O +
day O +
postlesion O -
. O -

Therefore O -
, O +
rostral O +
ventrolateral O +
medulla O +
neurons O +
appear O +
to O +
play O +
a O +
significant O +
role O +
in O +
maintaining O +
hypertension U-Disease +
in O +
conscious O +
spontaneously O +
hypertensive U-Disease +
rats O -
. O -

Spinal O +
or O +
suprabulbar O +
structures O +
could O +
be O +
responsible O +
for O +
the O +
gradual O +
recovery O +
of O +
the O +
hypertension U-Disease +
in O +
the O +
lesioned O +
rats O -
. O -

Acute B-Disease +
encephalopathy L-Disease +
and O +
cerebral B-Disease +
vasospasm L-Disease +
after O +
multiagent O +
chemotherapy O +
including O +
PEG O -
- O -
asparaginase O +
and O +
intrathecal O +
cytarabine O +
for O +
the O +
treatment O +
of O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia L-Disease -
. O -

A O +
7-year O -
- O -
old O +
girl O +
with O +
an O +
unusual O +
reaction O +
to O +
induction O +
chemotherapy O +
for O +
precursor O +
B O -
- O -
cell O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia L-Disease +
( O -
ALL U-Disease -
) O +
is O +
described O -
. O -

The O +
patient O +
developed O +
acute B-Disease +
encephalopathy L-Disease +
evidenced O +
by O +
behavioral O +
changes O -
, O +
aphasia U-Disease -
, O +
incontinence U-Disease -
, O +
visual B-Disease +
hallucinations L-Disease -
, O +
and O +
right O -
- O -
sided O +
weakness U-Disease +
with O +
diffuse O +
cerebral B-Disease +
vasospasm L-Disease +
on O +
magnetic O +
resonance O +
angiography O +
after O +
the O +
administration O +
of O +
intrathecal O +
cytarabine O -
. O -

Vincristine O -
, O +
dexamethasone O -
, O +
and O +
polyethylene O +
glycol O -
- O -
asparaginase O +
were O +
also O +
administered O +
before O +
the O +
episode O +
as O +
part O +
of O +
induction O +
therapy O -
. O -

Neurologic O +
status O +
returned O +
to O +
baseline O +
within O +
10 O +
days O +
of O +
the O +
acute O +
event O -
, O +
and O +
magnetic O +
resonance O +
angiography O +
findings O +
returned O +
to O +
normal O +
4 O +
months O +
later O -
. O -

Comparison O +
of O +
valsartan O -
/ O -
hydrochlorothiazide O +
combination O +
therapy O +
at O +
doses O +
up O +
to O +
320 O -
/ O -
25 O +
mg O +
versus O +
monotherapy O -
: O +
a O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
study O +
followed O +
by O +
long O -
- O -
term O +
combination O +
therapy O +
in O +
hypertensive U-Disease +
adults O -
. O -

BACKGROUND O -
: O +
One O +
third O +
of O +
patients O +
treated O +
for O +
hypertension U-Disease +
attain O +
adequate O +
blood O +
pressure O +
( O -
BP O -
) O +
control O -
, O +
and O +
multidrug O +
regimens O +
are O +
often O +
required O -
. O -

Given O +
the O +
lifelong O +
nature O +
of O +
hypertension U-Disease -
, O +
there O +
is O +
a O +
need O +
to O +
evaluate O +
the O +
long O -
- O -
term O +
efficacy O +
and O +
tolerability O +
of O +
higher O +
doses O +
of O +
combination O +
anti O -
- O -
hypertensive U-Disease +
therapies O -
. O -

OBJECTIVE O -
: O +
This O +
study O +
investigated O +
the O +
efficacy O +
and O +
tolerability O +
of O +
valsartan O +
( O -
VAL O -
) O +
or O +
hydrochlorothiazide O +
( O -
HCTZ O -
) O -
-monotherapy O +
and O +
higher O -
- O -
dose O +
combinations O +
in O +
patients O +
with O +
essential B-Disease +
hypertension L-Disease -
. O -

METHODS O -
: O +
The O +
first O +
part O +
of O +
this O +
study O +
was O +
an O +
8-week O -
, O +
multicenter O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O +
controlled O -
, O +
parallel O -
- O -
group O +
trial O -
. O -

Patients O +
with O +
essential B-Disease +
hypertension L-Disease +
( O -
mean O +
sitting O +
diastolic O +
BP O +
[ O -
MSDBP O -
] O -
, O +
> O +
or O +
= O -
95 O +
mm O +
Hg O +
and O +
< O -
110 O +
mm O +
Hg O -
) O +
were O +
randomized O +
to O +
1 O +
of O +
8 O +
treatment O +
groups O -
: O +
VAL O +
160 O +
or O +
320 O +
mg O -
; O +
HCTZ O +
12.5 O +
or O +
25 O +
mg O -
; O +
VAL O -
/ O -
HCTZ O +
160 O -
/ O -
12.5 O -
, O +
320 O -
/ O -
12.5 O -
, O +
or O +
320 O -
/ O -
25 O +
mg O -
; O +
or O +
placebo O -
. O -

Mean O +
changes O +
in O +
MSDBP O +
and O +
mean O +
sitting O +
systolic O +
BP O +
( O -
MSSBP O -
) O +
were O +
analyzed O +
at O +
the O +
8-week O +
core O +
study O +
end O +
point O -
. O -

VAL O -
/ O -
HCTZ O +
320 O -
/ O -
12.5 O +
and O +
320 O -
/ O -
25 O +
mg O +
were O +
further O +
investigated O +
in O +
a O +
54-week O -
, O +
open O -
- O -
label O +
extension O -
. O -

Response O +
was O +
defined O +
as O +
MSDBP O +
< O -
90 O +
mm O +
Hg O +
or O +
a O +
> O +
or O +
= O -
10 O +
mm O +
Hg O +
decrease O +
compared O +
to O +
baseline O -
. O -

Control O +
was O +
defined O +
as O +
MSDBP O +
< O -
90 O +
mm O +
Hg O +
compared O +
with O +
baseline O -
. O -

Tolerability O +
was O +
assessed O +
by O +
monitoring O +
adverse O +
events O +
at O +
randomization O +
and O +
all O +
subsequent O +
study O +
visits O +
and O +
regular O +
evaluation O +
of O +
hematology O +
and O +
blood O +
chemistry O -
. O -

RESULTS O -
: O +
A O +
total O +
of O +
1346 O +
patients O +
were O +
randomized O +
into O +
the O +
8-week O +
core O +
study O +
( O -
734 O +
men O -
, O +
612 O +
women O -
; O +
924 O +
white O -
, O +
291 O +
black O -
, O +
23 O +
Asian O -
, O +
108 O +
other O -
; O +
mean O +
age O -
, O +
52.7 O +
years O -
; O +
mean O +
weight O -
, O +
92.6 O +
kg O -
) O -
. O -

All O +
active O +
treatments O +
were O +
associated O +
with O +
significantly O +
reduced O +
MSSBP O +
and O +
MSDBP O +
during O +
the O +
core O +
8-week O +
study O -
, O +
with O +
each O +
monotherapy O +
significantly O +
contributing O +
to O +
the O +
overall O +
effect O +
of O +
combination O +
therapy O +
( O -
VAL O +
and O +
HCTZ O -
, O +
P O +
< O +
0.001 O -
) O -
. O -

Each O +
combination O +
was O +
associated O +
with O +
significantly O +
greater O +
reductions O +
in O +
MSSBP O +
and O +
MSDBP O +
compared O +
with O +
the O +
monotherapies O +
and O +
placebo O +
( O -
all O -
, O +
P O +
< O +
0.001 O -
) O -
. O -

The O +
mean O +
reduction O +
in O +
MSSBP O -
/ O -
MSDBP O +
with O +
VAL O -
/ O -
HCTZ O +
320 O -
/ O -
25 O +
mg O +
was O +
24.7 O -
/ O -
16.6 O +
mm O +
Hg O -
, O +
compared O +
with O +
5.9 O -
/ O -
7.0 O +
mm O +
Hg O +
with O +
placebo O -
. O -

The O +
reduction O +
in O +
MSSBP O +
was O +
significantly O +
greater O +
with O +
VAL O -
/ O -
HCTZ O +
320 O -
/ O -
25 O +
mg O +
compared O +
with O +
VAL O -
/ O -
HCTZ O +
160 O -
/ O -
12.5 O +
mg O +
( O -
P O +
< O +
0.002 O -
) O -
. O -

Rates O +
of O +
response O +
and O +
BP O +
control O +
were O +
significantly O +
higher O +
in O +
the O +
groups O +
that O +
received O +
combination O +
treatment O +
compared O +
with O +
those O +
that O +
received O +
monotherapy O -
. O -

The O +
incidence O +
of O +
hypokalemia U-Disease +
was O +
lower O +
with O +
VAL O -
/ O -
HCTZ O +
combinations O +
( O -
1.8%-6.1 O -
% O -
) O +
than O +
with O +
HCTZ O +
monotherapies O +
( O -
7.1%-13.3 O -
% O -
) O -
. O -

The O +
majority O +
of O +
adverse O +
events O +
in O +
the O +
core O +
study O +
were O +
of O +
mild O +
to O +
moderate O +
severity O -
. O -

The O +
efficacy O +
and O +
tolerability O +
of O +
VAL O -
/ O -
HCTZ O +
combinations O +
were O +
maintained O +
during O +
the O +
extension O +
( O -
797 O +
patients O -
) O -
. O -

CONCLUSIONS O -
: O +
In O +
this O +
study O +
population O -
, O +
combination O +
therapies O +
with O +
VAL O -
/ O -
HCTZ O +
were O +
associated O +
with O +
significantly O +
greater O +
BP O +
reductions O +
compared O +
with O +
either O +
monotherapy O -
, O +
were O +
well O +
tolerated O -
, O +
and O +
were O +
associated O +
with O +
less O +
hypokalemia U-Disease +
than O +
HCTZ O +
alone O -
. O -

Succimer O +
chelation O +
improves O +
learning O -
, O +
attention O -
, O +
and O +
arousal O +
regulation O +
in O +
lead O -
- O -
exposed O +
rats O +
but O +
produces O +
lasting O +
cognitive B-Disease +
impairment L-Disease +
in O +
the O +
absence O +
of O +
lead O +
exposure O -
. O -

BACKGROUND O -
: O +
There O +
is O +
growing O +
pressure O +
for O +
clinicians O +
to O +
prescribe O +
chelation O +
therapy O +
at O +
only O +
slightly O +
elevated O +
blood O +
lead O +
levels O -
. O -

However O -
, O +
very O +
few O +
studies O +
have O +
evaluated O +
whether O +
chelation O +
improves O +
cognitive O +
outcomes O +
in O +
Pb O -
- O -
exposed O +
children O -
, O +
or O +
whether O +
these O +
agents O +
have O +
adverse O +
effects O +
that O +
may O +
affect O +
brain O +
development O +
in O +
the O +
absence O +
of O +
Pb O +
exposure O -
. O -

OBJECTIVES O -
: O +
The O +
present O +
study O +
was O +
designed O +
to O +
answer O +
these O +
questions O -
, O +
using O +
a O +
rodent O +
model O +
of O +
early O +
childhood O +
Pb O +
exposure O +
and O +
treatment O +
with O +
succimer O -
, O +
a O +
widely O +
used O +
chelating O +
agent O +
for O +
the O +
treatment O +
of O +
Pb B-Disease +
poisoning L-Disease -
. O -

RESULTS O -
: O +
Pb O +
exposure O +
produced O +
lasting O +
impairments B-Disease +
in I-Disease +
learning L-Disease -
, B-Disease +
attention I-Disease -
, I-Disease +
inhibitory I-Disease +
control I-Disease -
, I-Disease +
and I-Disease +
arousal I-Disease +
regulation L-Disease -
, O +
paralleling O +
the O +
areas O +
of O +
dysfunction O +
seen O +
in O +
Pb O -
- O -
exposed O +
children O -
. O -

Succimer O +
treatment O +
of O +
the O +
Pb O -
- O -
exposed O +
rats O +
significantly O +
improved O +
learning O -
, O +
attention O -
, O +
and O +
arousal O +
regulation O -
, O +
although O +
the O +
efficacy O +
of O +
the O +
treatment O +
varied O +
as O +
a O +
function O +
of O +
the O +
Pb O +
exposure O +
level O +
and O +
the O +
specific O +
functional O +
deficit O -
. O -

In O +
contrast O -
, O +
succimer O +
treatment O +
of O +
rats O +
not O +
previously O +
exposed O +
to O +
Pb O +
produced O +
lasting O +
and O +
pervasive O +
cognitive B-Disease +
and I-Disease +
affective I-Disease +
dysfunction L-Disease +
comparable O +
in O +
magnitude O +
to O +
that O +
produced O +
by O +
the O +
higher O +
Pb O +
exposure O +
regimen O -
. O -

CONCLUSIONS O -
: O +
These O +
are O +
the O +
first O +
data O -
, O +
to O +
our O +
knowledge O -
, O +
to O +
show O +
that O +
treatment O +
with O +
any O +
chelating O +
agent O +
can O +
alleviate O +
cognitive B-Disease +
deficits L-Disease +
due O +
to O +
Pb O +
exposure O -
. O -

These O +
findings O +
suggest O +
that O +
it O +
may O +
be O +
possible O +
to O +
identify O +
a O +
succimer O +
treatment O +
protocol O +
that O +
improves O +
cognitive O +
outcomes O +
in O +
Pb O -
- O -
exposed O +
children O -
. O -

However O -
, O +
they O +
also O +
suggest O +
that O +
succimer O +
treatment O +
should O +
be O +
strongly O +
discouraged O +
for O +
children O +
who O +
do O +
not O +
have O +
elevated O +
tissue O +
levels O +
of O +
Pb O +
or O +
other O +
heavy O +
metals O -
. O -

Caffeine O +
challenge O +
test O +
in O +
panic B-Disease +
disorder L-Disease +
and O +
depression U-Disease +
with O +
panic B-Disease +
attacks L-Disease -
. O -

Our O +
aim O +
was O +
to O +
observe O +
if O +
patients O +
with O +
panic B-Disease +
disorder L-Disease +
( O -
PD U-Disease -
) O +
and O +
patients O +
with O +
major B-Disease +
depression L-Disease +
with O +
panic B-Disease +
attacks L-Disease +
( O -
MDP U-Disease -
) O +
( O -
Diagnostic O +
and O +
Statistical O +
Manual O +
of O +
Mental B-Disease +
Disorders L-Disease -
, O +
Fourth O +
Edition O +
criteria O -
) O +
respond O +
in O +
a O +
similar O +
way O +
to O +
the O +
induction O +
of O +
panic B-Disease +
attacks L-Disease +
by O +
an O +
oral O +
caffeine O +
challenge O +
test O -
. O -

We O +
randomly O +
selected O +
29 O +
patients O +
with O +
PD U-Disease -
, O +
27 O +
with O +
MDP U-Disease -
, O +
25 O +
with O +
major B-Disease +
depression L-Disease +
without O +
panic B-Disease +
attacks L-Disease +
( O -
MD U-Disease -
) O -
, O +
and O +
28 O +
healthy O +
volunteers O -
. O -

The O +
patients O +
had O +
no O +
psychotropic O +
drug O +
for O +
at O +
least O +
a O +
4-week O +
period O -
. O -

In O +
a O +
randomized O +
double O -
- O -
blind O +
experiment O +
performed O +
in O +
2 O +
occasions O +
7 O +
days O +
apart O -
, O +
480 O +
mg O +
caffeine O +
and O +
a O +
caffeine O -
- O -
free O +
( O -
placebo O -
) O +
solution O +
were O +
administered O +
in O +
a O +
coffee O +
form O +
and O +
anxiety U-Disease +
scales O +
were O +
applied O +
before O +
and O +
after O +
each O +
test O -
. O -

A O +
total O +
of O +
58.6 O -
% O +
( O -
n O +
= O +
17 O -
) O +
of O +
patients O +
with O +
PD U-Disease -
, O +
44.4 O -
% O +
( O -
n O +
= O +
12 O -
) O +
of O +
patients O +
with O +
MDP U-Disease -
, O +
12.0 O -
% O +
( O -
n O +
= O +
3 O -
) O +
of O +
patients O +
with O +
MD U-Disease -
, O +
and O +
7.1 O -
% O +
( O -
n= O +
2 O -
) O +
of O +
control O +
subjects O +
had O +
a O +
panic B-Disease +
attack L-Disease +
after O +
the O +
480-mg O +
caffeine O +
challenge O +
test O +
( O -
chi O -
( O -
2 O -
) O -
( O -
3 O -
) O +
= O +
16.22 O -
, O +
P O +
= O +
.001 O -
) O -
. O -

The O +
patients O +
with O +
PD U-Disease +
and O +
MDP U-Disease +
were O +
more O +
sensitive O +
to O +
caffeine O +
than O +
were O +
patients O +
with O +
MD U-Disease +
and O +
healthy O +
volunteers O -
. O -

No O +
panic B-Disease +
attack L-Disease +
was O +
observed O +
after O +
the O +
caffeine O -
- O -
free O +
solution O +
intake O -
. O -

The O +
patients O +
with O +
MD U-Disease +
had O +
a O +
lower O +
heart O +
rate O +
response O +
to O +
the O +
test O +
than O +
all O +
the O +
other O +
groups O +
( O -
2-way O +
analysis O +
of O +
variance O -
, O +
group O +
by O +
time O +
interaction O +
with O +
Greenhouse O -
- O -
Geisser O +
correction O -
: O +
F O -
( O -
3,762 O -
) O +
= O +
2.85 O -
, O +
P O +
= O +
.026 O -
) O -
. O -

Our O +
data O +
suggest O +
that O +
there O +
is O +
an O +
association O +
between O +
panic B-Disease +
attacks L-Disease -
, O +
no O +
matter O +
if O +
associated O +
with O +
PD U-Disease +
or O +
MDP U-Disease -
, O +
and O +
hyperreactivity O +
to O +
an O +
oral O +
caffeine O +
challenge O +
test O -
. O -

Mitral O +
annuloplasty O +
as O +
a O +
ventricular O +
restoration O +
method O +
for O +
the O +
failing B-Disease +
left I-Disease +
ventricle L-Disease -
: O +
a O +
pilot O +
study O -
. O -

BACKGROUND O +
AND O +
AIM O +
OF O +
THE O +
STUDY O -
: O +
Undersized O +
mitral O +
annuloplasty O +
( O -
MAP O -
) O +
is O +
effective O +
in O +
patients O +
with O +
dilated B-Disease +
cardiomyopathy L-Disease +
and O +
functional O +
mitral B-Disease +
regurgitation L-Disease +
( O -
MR U-Disease -
) O +
since O -
, O +
as O +
well O +
as O +
addressing O +
the O +
MR U-Disease -
, O +
the O +
MAP O +
may O +
also O +
reshape O +
the O +
dilated O +
left O +
ventricular O +
( O -
LV O -
) O +
base O -
. O -

However O -
, O +
the O +
direct O +
benefits O +
of O +
this O +
possible O +
reshaping O +
on O +
LV O +
function O +
in O +
the O +
absence O +
of O +
underlying O +
MR U-Disease +
remain O +
incompletely O +
understood O -
. O -

The O +
study O +
aim O +
was O +
to O +
identify O +
these O +
benefits O +
in O +
a O +
canine O +
model O +
of O +
acute O +
heart B-Disease +
failure L-Disease -
. O -

METHODS O -
: O +
Six O +
dogs O +
underwent O +
MAP O +
with O +
a O +
prosthetic O +
band O +
on O +
the O +
posterior O +
mitral O +
annulus O -
, O +
using O +
four O +
mattress O +
sutures O -
. O -

The O +
sutures O +
were O +
passed O +
individually O +
through O +
four O +
tourniquets O +
and O +
exteriorized O +
untied O +
via O +
the O +
left O +
atriotomy O -
. O -

Sonomicrometry O +
crystals O +
were O +
implanted O +
around O +
the O +
mitral O +
annulus O +
and O +
left O +
ventricle O +
to O +
measure O +
geometry O +
and O +
regional O +
function O -
. O -

Acute O +
heart B-Disease +
failure L-Disease +
was O +
induced O +
by O +
propranolol O +
and O +
volume O +
loading O +
after O +
weaning O +
from O +
cardiopulmonary O +
bypass O -
; O +
an O +
absence O +
of O +
MR U-Disease +
was O +
confirmed O +
by O +
echocardiography O -
. O -

MAP O +
was O +
accomplished O +
by O +
cinching O +
the O +
tourniquets O -
. O -

Data O +
were O +
acquired O +
at O +
baseline O -
, O +
after O +
induction O +
of O +
acute O +
heart B-Disease +
failure L-Disease -
, O +
and O +
after O +
MAP O -
. O -

RESULTS O -
: O +
MAP O +
decreased O +
mitral O +
annular O +
dimensions O +
in O +
both O +
commissure O -
- O -
commissure O +
and O +
septal O -
- O -
lateral O +
directions O -
. O -

Concomitantly O -
, O +
the O +
diastolic O +
diameter O +
of O +
the O +
LV O +
base O +
and O +
LV O +
sphericity O +
decreased O +
( O -
i.e. O -
, O +
improved O -
) O +
from O +
37.4 O +
+ O -
/- O -

9.3 O +
to O +
35.9 O +
+ O -
/- O -

10 O +
mm O +
( O -
p O +
= O +
0.063 O -
) O -
, O +
and O +
from O +
67.9 O +
+ O -
/- O -

18.6 O -
% O +
to O +
65.3 O +
+ O -
/- O -

18.9 O -
% O +
( O -
p O +
= O +
0.016 O -
) O -
, O +
respectively O -
. O -

Decreases O +
were O +
evident O +
in O +
both O +
LV O +
end O -
- O -
diastolic O +
pressure O +
( O -
from O +
17 O +
+ O -
/- O -

7 O +
to O +
15 O +
+ O -
/- O -

6 O +
mmHg O -
, O +
p O +
= O +
0.0480 O +
and O +
Tau O +
( O -
from O +
48 O +
+ O -
/- O -

8 O +
to O +
45 O +
+ O -
/- O -

8 O +
ms O -
, O +
p O +
< O -
0.01 O -
) O -
, O +
while O +
fractional O +
shortening O +
at O +
the O +
LV O +
base O +
increased O +
from O +
7.7 O +
+ O -
/- O -

4.5 O -
% O +
to O +
9.4 O +
+ O -
/- O -

4.5 O -
% O +
( O -
p O +
= O +
0.045 O -
) O -
. O -

After O +
MAP O -
, O +
increases O +
were O +
identified O +
in O +
both O +
cardiac O +
output O +
( O -
from O +
1.54 O +
+ O -
/- O -

0.57 O +
to O +
1.65 O +
+ O -
/- O -

0.57 O +
1 O -
/ O -
min O -
) O +
and O +
Emax O +
( O -
from O +
1.86 O +
+ O -
/- O -

0.9 O +
to O +
2.41 O +
+ O -
/- O -

1.31 O +
mmHg O -
/ O -
ml O -
) O -
. O -

CONCLUSION O -
: O +
The O +
data O +
acquired O +
suggest O +
that O +
isolated O +
MAP O +
may O +
have O +
certain O +
benefits O +
on O +
LV O +
dimension O -
/ O -
function O +
in O +
acute O +
heart B-Disease +
failure L-Disease -
, O +
even O +
in O +
the O +
absence O +
of O +
MR U-Disease -
. O -

However O -
, O +
further O +
investigations O +
are O +
warranted O +
in O +
a O +
model O +
of O +
chronic O +
heart B-Disease +
failure L-Disease -
. O -

Piperacillin O -
/ O -
tazobactam O -
- O -
induced O +
seizure U-Disease +
rapidly O +
reversed O +
by O +
high O +
flux O +
hemodialysis O +
in O +
a O +
patient O +
on O +
peritoneal O +
dialysis O -
. O -

Despite O +
popular O +
use O +
of O +
piperacillin O -
, O +
the O +
dire O +
neurotoxicity U-Disease +
associated O +
with O +
piperacillin O +
still O +
goes O +
unrecognized O -
, O +
leading O +
to O +
a O +
delay O +
in O +
appropriate O +
management O -
. O -

We O +
report O +
a O +
57-year O -
- O -
old O +
woman O +
with O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease +
receiving O +
continuous O +
ambulatory O +
peritoneal O +
dialysis O +
( O -
CAPD O -
) O -
, O +
who O +
developed O +
slurred O +
speech O -
, O +
tremor U-Disease -
, O +
bizarre O +
behavior O -
, O +
progressive O +
mental O +
confusion U-Disease -
, O +
and O +
2 O +
episodes O +
of O +
generalized O +
tonic B-Disease -
- I-Disease -
clonic I-Disease +
seizure L-Disease +
( O -
GTCS U-Disease -
) O +
after O +
5 O +
doses O +
of O +
piperacillin O -
/ O -
tazobactam O +
( O -
2 O +
g O -
/ O -
250 O +
mg O -
) O +
were O +
given O +
for O +
bronchiectasis U-Disease +
with O +
secondary B-Disease +
infection L-Disease -
. O -

The O +
laboratory O +
data O +
revealed O +
normal O +
plasma O +
electrolyte O +
and O +
ammonia O +
levels O +
but O +
leukocytosis U-Disease -
. O -

Neurologic O +
examinations O +
showed O +
dysarthria U-Disease +
and O +
bilateral O +
Babinski O +
sign O -
. O -

Computed O +
tomography O +
of O +
brain O +
and O +
electroencephalogram O +
were O +
unremarkable O -
. O -

Despite O +
the O +
use O +
of O +
antiepileptic O +
agents O -
, O +
another O +
GTCS U-Disease +
episode O +
recurred O +
after O +
the O +
sixth O +
dose O +
of O +
piperacillin O -
/ O -
tazobactam O -
. O -

Brain O +
magnetic O +
resonance O +
imaging O +
did O +
not O +
demonstrate O +
acute O +
infarction U-Disease +
and O +
organic B-Disease +
brain I-Disease +
lesions L-Disease -
. O -

Initiation O +
of O +
high O -
- O -
flux O +
hemodialysis O +
rapidly O +
reversed O +
the O +
neurologic O +
symptoms O +
within O +
4 O +
hours O -
. O -

Piperacillin O -
- O -
induced O +
encephalopathy U-Disease +
should O +
be O +
considered O +
in O +
any O +
uremic U-Disease +
patients O +
with O +
unexplained O +
neurological O +
manifestations O -
. O -

CAPD O +
is O +
inefficient O +
in O +
removing O +
piperacillin O -
, O +
whereas O +
hemodialysis O +
can O +
rapidly O +
terminate O +
the O +
piperacillin O -
- O -
induced O +
encephalopathy U-Disease -
. O -

Frequency O +
of O +
transient O +
ipsilateral O +
vocal B-Disease +
cord I-Disease +
paralysis L-Disease +
in O +
patients O +
undergoing O +
carotid O +
endarterectomy O +
under O +
local O +
anesthesia O -
. O -

BACKGROUND O -
: O +
Especially O +
because O +
of O +
improvements O +
in O +
clinical O +
neurologic O +
monitoring O -
, O +
carotid O +
endarterectomy O +
done O +
under O +
local O +
anesthesia O +
has O +
become O +
the O +
technique O +
of O +
choice O +
in O +
several O +
centers O -
. O -

Temporary O +
ipsilateral O +
vocal B-Disease +
nerve I-Disease +
palsies L-Disease +
due O +
to O +
local O +
anesthetics O +
have O +
been O +
described O -
, O +
however O -
. O -

Such O +
complications O +
are O +
most O +
important O +
in O +
situations O +
where O +
there O +
is O +
a O +
pre O -
- O -
existing O +
contralateral O +
paralysis U-Disease -
. O -

We O +
therefore O +
examined O +
the O +
effect O +
of O +
local O +
anesthesia O +
on O +
vocal O +
cord O +
function O +
to O +
better O +
understand O +
its O +
possible O +
consequences O -
. O -

METHODS O -
: O +
This O +
prospective O +
study O +
included O +
28 O +
patients O +
undergoing O +
carotid O +
endarterectomy O +
under O +
local O +
anesthesia O -
. O -

Vocal O +
cord O +
function O +
was O +
evaluated O +
before O -
, O +
during O -
, O +
and O +
after O +
surgery O +
( O -
postoperative O +
day O +
1 O -
) O +
using O +
flexible O +
laryngoscopy O -
. O -

Anesthesia O +
was O +
performed O +
by O +
injecting O +
20 O +
to O +
40 O +
mL O +
of O +
a O +
mixture O +
of O +
long O -
- O -
acting O +
( O -
ropivacaine O -
) O +
and O +
short O -
- O -
acting O +
( O -
prilocaine O -
) O +
anesthetic O -
. O -

RESULTS O -
: O +
All O +
patients O +
had O +
normal O +
vocal O +
cord O +
function O +
preoperatively O -
. O -

Twelve O +
patients O +
( O -
43 O -
% O -
) O +
were O +
found O +
to O +
have O +
intraoperative O +
ipsilateral O +
vocal B-Disease +
cord I-Disease +
paralysis L-Disease -
. O -

It O +
resolved O +
in O +
all O +
cases O +
< O +
or O +
= O -
24 O +
hours O -
. O -

There O +
were O +
no O +
significant O +
differences O +
in O +
operating O +
time O +
or O +
volume O +
or O +
frequency O +
of O +
anesthetic O +
administration O +
in O +
patients O +
with O +
temporary O +
vocal B-Disease +
cord I-Disease +
paralysis L-Disease +
compared O +
with O +
those O +
without O -
. O -

CONCLUSION O -
: O +
Local O +
anesthesia O +
led O +
to O +
temporary O +
ipsilateral O +
vocal B-Disease +
cord I-Disease +
paralysis L-Disease +
in O +
almost O +
half O +
of O +
these O +
patients O -
. O -

Because O +
pre O -
- O -
existing O +
paralysis U-Disease +
is O +
of O +
a O +
relevant O +
frequency O +
( O -
up O +
to O +
3 O -
% O -
) O -
, O +
a O +
preoperative O +
evaluation O +
of O +
vocal O +
cord O +
function O +
before O +
carotid O +
endarterectomy O +
under O +
local O +
anesthesia O +
is O +
recommended O +
to O +
avoid O +
intraoperative O +
bilateral O +
paralysis U-Disease -
. O -

In O +
patients O +
with O +
preoperative O +
contralateral O +
vocal B-Disease +
cord I-Disease +
paralysis L-Disease -
, O +
surgery O +
under O +
general O +
anesthesia O +
should O +
be O +
considered O -
. O -

Impaired B-Disease +
fear I-Disease +
recognition L-Disease +
in O +
regular O +
recreational O +
cocaine O +
users O -
. O -

INTRODUCTION O -
: O +
The O +
ability O +
to O +
read O +
facial O +
expressions O +
is O +
essential O +
for O +
normal O +
human O +
social O +
interaction O -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
conduct O +
the O +
first O +
investigation O +
of O +
facial O +
expression O +
recognition O +
performance O +
in O +
recreational O +
cocaine O +
users O -
. O -

MATERIALS O +
AND O +
METHODS O -
: O +
Three O +
groups O -
, O +
comprised O +
of O +
21 O +
cocaine O +
naive O +
participants O +
( O -
CN O -
) O -
, O -
30 O +
occasional O +
cocaine O +
( O -
OC O -
) O -
, O +
and O +
48 O +
regular O +
recreational O +
cocaine O +
( O -
RC O -
) O +
users O -
, O +
were O +
compared O -
. O -

An O +
emotional O +
facial O +
expression O +
( O -
EFE O -
) O +
task O +
consisting O +
of O +
a O +
male O +
and O +
female O +
face O +
expressing O +
six O +
basic O +
emotions O +
( O -
happiness O -
, O +
surprise O -
, O +
sadness O -
, O +
anger O -
, O +
fear O -
, O +
and O +
disgust O -
) O +
was O +
administered O -
. O -

Mean O +
percent O +
accuracy O +
and O +
latencies O +
for O +
correct O +
responses O +
across O +
eight O +
presentations O +
of O +
each O +
basic O +
emotion O +
were O +
derived O -
. O -

Participants O +
were O +
also O +
assessed O +
with O +
the O +
" O -
Eyes O +
task O -
" O +
to O +
investigate O +
their O +
ability O +
to O +
recognize O +
more O +
complex O +
emotional O +
states O +
and O +
the O +
Symptom O +
CheckList-90-Revised O +
to O +
measure O +
psychopathology O -
. O -

RESULTS O -
: O +
There O +
were O +
no O +
group O +
differences O +
in O +
psychopathology O +
or O +
" O -
eyes O +
task O -
" O +
performance O -
, O +
but O +
the O +
RC O +
group O -
, O +
who O +
otherwise O +
had O +
similar O +
illicit O +
substance O +
use O +
histories O +
to O +
the O +
OC O +
group O -
, O +
exhibited O +
impaired B-Disease +
fear I-Disease +
recognition L-Disease +
accuracy O +
compared O +
to O +
the O +
OC O +
and O +
CN O +
groups O -
. O -

The O +
RC O +
group O +
also O +
correctly O +
identified O +
anger O -
, O +
fear O -
, O +
happiness O -
, O +
and O +
surprise O -
, O +
more O +
slowly O +
than O +
CN O -
, O +
but O +
not O +
OC O +
participants O -
. O -

The O +
OC O +
group O +
was O +
slower O +
than O +
CN O +
when O +
correctly O +
identifying O +
disgust O -
. O -

The O +
selective O +
deficit B-Disease +
in I-Disease +
fear I-Disease +
recognition L-Disease +
accuracy O +
manifested O +
by O +
the O +
RC O +
group O +
can O -
not O +
be O +
explained O +
by O +
the O +
subacute O +
effects O +
of O +
cocaine O -
, O +
or O +
ecstasy O -
, O +
because O +
recent O +
and O +
less O +
recent O +
users O +
of O +
these O +
drugs O +
within O +
this O +
group O +
were O +
similarly O +
impaired O -
. O -

Possible O +
parallels O +
between O +
RC O +
users O +
and O +
psychopaths U-Disease +
with O +
respect O +
to O +
impaired B-Disease +
fear I-Disease +
recognition L-Disease -
, O +
amygdala B-Disease +
dysfunction L-Disease -
, O +
and O +
etiology O +
are O +
discussed O -
. O -

Damage B-Disease +
of I-Disease +
substantia I-Disease +
nigra I-Disease +
pars I-Disease +
reticulata L-Disease +
during O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease +
in O +
the O +
rat O -
: O +
immunohistochemical O +
study O +
of O +
neurons O -
, O +
astrocytes O +
and O +
serum O -
- O -
protein O +
extravasation O -
. O -

The O +
substantia O +
nigra O +
has O +
a O +
gating O +
function O +
controlling O +
the O +
spread O +
of O +
epileptic B-Disease +
seizure L-Disease +
activity O -
. O -

Additionally O -
, O +
in O +
models O +
of O +
prolonged B-Disease +
status I-Disease +
epilepticus L-Disease +
the O +
pars O +
reticulata O +
of O +
substantia O +
nigra O +
( O -
SNR O -
) O +
suffers O +
from O +
a O +
massive O +
lesion O +
which O +
may O +
arise O +
from O +
a O +
massive O +
metabolic B-Disease +
derangement L-Disease +
and O +
hyperexcitation O +
developing O +
in O +
the O +
activated O +
SNR O -
. O -

In O +
this O +
study O -
, O +
status B-Disease +
epilepticus L-Disease +
was O +
induced O +
by O +
systemic O +
injection O +
of O +
pilocarpine O +
in O +
rats O -
. O -

The O +
neuropathology O +
of O +
SNR O +
was O +
investigated O +
using O +
immunohistochemical O +
techniques O +
with O +
the O +
major O +
emphasis O +
on O +
the O +
time O -
- O -
course O +
of O +
changes O +
in O +
neurons O +
and O +
astrocytes O -
. O -

Animals O +
surviving O +
20 O -
, O +
30 O -
, O +
40 O -
, O +
60 O +
min O -
, O +
2 O -
, O +
3 O -
, O +
6 O +
hours O -
, O +
1 O -
, O +
2 O -
, O +
and O +
3 O +
days O +
after O +
induction O +
of O +
status B-Disease +
epilepticus L-Disease +
were O +
perfusion O -
- O -
fixed O -
, O +
and O +
brains O +
processed O +
for O +
immunohistochemical O +
staining O +
of O +
SNR O -
. O -

Nissl O -
- O -
staining O +
and O +
antibodies O +
against O +
the O +
neuron O -
- O -
specific O +
calcium O -
- O -
binding O +
protein O -
, O +
parvalbumin O -
, O +
served O +
to O +
detect O +
neuronal B-Disease +
damage L-Disease +
in O +
SNR O -
. O -

Antibodies O +
against O +
the O +
astroglia O -
- O -
specific O +
cytoskeletal O +
protein O -
, O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O -
, O +
and O +
against O +
the O +
glial O +
calcium O -
- O -
binding O +
protein O -
, O +
S-100 O +
protein O -
, O +
were O +
used O +
to O +
assess O +
the O +
status O +
of O +
astrocytes O -
. O -

Immunohistochemical O +
staining O +
for O +
serum O -
- O -
albumin O +
and O +
immunoglobulins O +
in O +
brain O +
tissue O +
was O +
taken O +
as O +
indicator O +
of O +
blood O -
- O -
brain O +
barrier O +
disturbances O +
and O +
vasogenic B-Disease +
edema L-Disease +
formation O -
. O -

Immunohistochemical O +
staining O +
indicated O +
loss O +
of O +
GFAP O -
- O -
staining O +
already O +
at O +
30 O +
min O +
after O +
induction O +
of O +
seizures U-Disease +
in O +
an O +
oval O +
focus O +
situated O +
in O +
the O +
center O +
of O +
SNR O +
while O +
sparing O +
medial O +
and O +
lateral O +
aspects O -
. O -

At O +
1 O +
h O +
there O +
was O +
additional O +
vacuolation O +
in O +
S-100 O +
protein O +
staining O -
. O -

By O +
2 O +
hours O -
, O +
parvalbumin O -
- O -
staining O +
changed O +
in O +
the O +
central O +
SNR O +
indicating O +
neuronal B-Disease +
damage L-Disease -
, O +
and O +
Nissl O -
- O -
staining O +
visualized O +
some O +
neuronal O +
distortion O -
. O -

Staining O +
for O +
serum O -
- O -
proteins O +
occurred O +
in O +
a O +
patchy O +
manner O +
throughout O +
the O +
forebrain O +
during O +
the O +
first O +
hours O -
. O -

By O +
6 O +
h O -
, O +
vasogenic B-Disease +
edema L-Disease +
covered O +
the O +
lesioned B-Disease +
SNR L-Disease -
. O -

By O +
24 O +
h O -
, O +
glial O +
and O +
neuronal O +
markers O +
indicated O +
a O +
massive O +
lesion O +
in O +
the O +
center O +
of O +
SNR O -
. O -

By O +
48 O -
- O -
72 O +
h O -
, O +
astrocytes O +
surrounding O +
the O +
lesion O +
increased O +
in O +
size O -
, O +
and O +
polymorphic O +
phagocytotic O +
cells O +
invaded O +
the O +
damaged O +
area O -
. O -

In O +
a O +
further O +
group O +
of O +
animals O +
surviving O +
1 O +
to O +
5 O +
days O -
, O +
conventional O +
paraffin O -
- O -
sections O +
confirmed O +
the O +
neuronal O +
and O +
glial O +
damage B-Disease +
of I-Disease +
SNR L-Disease -
. O -

Additional O +
pathology O +
of O +
similar O +
quality O +
was O +
found O +
in O +
the O +
globus O +
pallidus O -
. O -

Since O +
astrocytes O +
were O +
always O +
damaged O +
in O +
parallel O +
with O +
neurons O +
in O +
SNR O +
it O +
is O +
proposed O +
that O +
the O +
anatomical O +
and O +
functional O +
interrelationship O +
between O +
neurons O +
and O +
astrocytes O +
is O +
particularly O +
tight O +
in O +
SNR O -
. O -

Both O +
cell O +
elements O +
may O +
suffer O +
in O +
common O +
from O +
metabolic O +
disturbance O +
and O +
neurotransmitter B-Disease +
dysfunction L-Disease +
as O +
occur O +
during O +
massive O +
status B-Disease +
epilepticus L-Disease -
. O -

Neuroprotective O +
effects O +
of O +
melatonin O +
upon O +
the O +
offspring O +
cerebellar O +
cortex O +
in O +
the O +
rat O +
model O +
of O +
BCNU O -
- O -
induced O +
cortical B-Disease +
dysplasia L-Disease -
. O -

Cortical B-Disease +
dysplasia L-Disease +
is O +
a O +
malformation O +
characterized O +
by O +
defects O +
in O +
proliferation O -
, O +
migration O +
and O +
maturation O -
. O -

This O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
alterations O +
in O +
offspring O +
rat O +
cerebellum O +
induced O +
by O +
maternal O +
exposure O +
to O +
carmustine- O -
[ O -
1,3-bis O +
( O -
2-chloroethyl O -
) O -
-1-nitrosoure O -
] O +
( O -
BCNU O -
) O +
and O +
to O +
investigate O +
the O +
effects O +
of O +
exogenous O +
melatonin O +
upon O +
cerebellar O +
BCNU O -
- O -
induced O +
cortical B-Disease +
dysplasia L-Disease -
, O +
using O +
histological O +
and O +
biochemical O +
analyses O -
. O -

Pregnant O +
Wistar O +
rats O +
were O +
assigned O +
to O +
five O +
groups O -
: O +
intact O -
- O -
control O -
, O +
saline O -
- O -
control O -
, O +
melatonin O -
- O -
treated O -
, O +
BCNU O -
- O -
exposed O +
and O +
BCNU O -
- O -
exposed O +
plus O +
melatonin O -
. O -

Rats O +
were O +
exposed O +
to O +
BCNU O +
on O +
embryonic O +
day O +
15 O +
and O +
melatonin O +
was O +
given O +
until O +
delivery O -
. O -

Immuno O -
/ O -
histochemistry O +
and O +
electron O +
microscopy O +
were O +
carried O +
out O +
on O +
the O +
offspring O +
cerebellum O -
, O +
and O +
levels O +
of O +
malondialdehyde O +
and O +
superoxide O +
dismutase O +
were O +
determined O -
. O -

Histopathologically O -
, O +
typical O +
findings O +
were O +
observed O +
in O +
the O +
cerebella O +
from O +
the O +
control O +
groups O -
, O +
but O +
the O +
findings O +
consistent O +
with O +
early O +
embryonic O +
development O +
were O +
noted O +
in O +
BCNU O -
- O -
exposed O +
cortical B-Disease +
dysplasia L-Disease +
group O -
. O -

There O +
was O +
a O +
marked O +
increase O +
in O +
the O +
number O +
of O +
TUNEL O +
positive O +
cells O +
and O +
nestin O +
positive O +
cells O +
in O +
BCNU O -
- O -
exposed O +
group O -
, O +
but O +
a O +
decreased O +
immunoreactivity O +
to O +
glial O +
fibrillary O +
acidic O +
protein O -
, O +
synaptophysin O +
and O +
transforming O +
growth O +
factor O +
beta1 O +
was O +
observed O -
, O +
indicating O +
a O +
delayed O +
maturation O -
, O +
and O +
melatonin O +
significantly O +
reversed O +
these O +
changes O -
. O -

Malondialdehyde O +
level O +
in O +
BCNU O -
- O -
exposed O +
group O +
was O +
higher O +
than O +
those O +
in O +
control O +
groups O +
and O +
melatonin O +
decreased O +
malondialdehyde O +
levels O +
in O +
BCNU O +
group O +
( O -
P<0.01 O -
) O -
, O +
while O +
there O +
were O +
no O +
significant O +
differences O +
in O +
the O +
superoxide O +
dismutase O +
levels O +
between O +
these O +
groups O -
. O -

These O +
data O +
suggest O +
that O +
exposure O +
of O +
animals O +
to O +
BCNU O +
during O +
pregnancy O +
leads O +
to O +
delayed O +
maturation O +
of O +
offspring O +
cerebellum O +
and O +
melatonin O +
protects O +
the O +
cerebellum O +
against O +
the O +
effects O +
of O +
BCNU O -
. O -

Reduced O +
cardiotoxicity U-Disease +
of O +
doxorubicin O +
given O +
in O +
the O +
form O +
of O +
N- O -
( O -
2-hydroxypropyl O -
) O -
methacrylamide O +
conjugates O -
: O +
and O +
experimental O +
study O +
in O +
the O +
rat O -
. O -

A O +
rat O +
model O +
was O +
used O +
to O +
evaluate O +
the O +
general O +
acute O +
toxicity U-Disease +
and O +
the O +
late O +
cardiotoxicity U-Disease +
of O +
4 O +
mg O -
/ O -
kg O +
doxorubicin O +
( O -
DOX O -
) O +
given O +
either O +
as O +
free O +
drug O +
or O +
in O +
the O +
form O +
of O +
three O +
N- O -
( O -
2-hydroxypropyl O -
) O -
methacrylamide O +
( O -
HPMA O -
) O +
copolymer O +
conjugates O -
. O -

In O +
these O +
HPMA O +
copolymers O -
, O +
DOX O +
was O +
covalently O +
bound O +
via O +
peptide O +
linkages O +
that O +
were O +
either O +
non O -
- O -
biodegradable O +
( O -
Gly O -
- O -
Gly O -
) O +
or O +
degradable O +
by O +
lysosomal O +
proteinases O +
( O -
Gly O -
- O -
Phe O -
- O -
Leu O -
- O -
Gly O -
) O -
. O -

In O +
addition O -
, O +
one O +
biodegradable O +
conjugate O +
containing O +
galactosamine O +
was O +
used O -
; O +
this O +
residue O +
was O +
targeted O +
to O +
the O +
liver O -
. O -

Over O +
the O +
first O +
3 O +
weeks O +
after O +
the O +
i.v O -
. O -

administration O +
of O +
free O +
and O +
polymer O -
- O -
bound O +
DOX O -
, O +
all O +
animals O +
showed O +
a O +
transient O +
reduction O +
in O +
body O +
weight O -
. O -

However O -
, O +
the O +
maximal O +
reduction O +
in O +
body O +
weight O +
seen O +
in O +
animals O +
that O +
received O +
polymer O -
- O -
bound O +
DOX O +
( O -
4 O +
mg O -
/ O -
kg O -
) O +
was O +
significantly O +
lower O +
than O +
that O +
observed O +
in O +
those O +
that O +
received O +
free O +
DOX O +
( O -
4 O +
mg O -
/ O -
kg O -
) O +
or O +
a O +
mixture O +
of O +
the O +
unmodified O +
parent O +
HPMA O +
copolymer O +
and O +
free O +
DOX O +
( O -
4 O +
mg O -
/ O -
kg O -
; O +
P O +
less O +
than O +
0.01 O -
) O -
. O -

Throughout O +
the O +
study O +
( O -
20 O +
weeks O -
) O -
, O +
deaths O +
related O +
to O +
cardiotoxicity U-Disease +
were O +
observed O +
only O +
in O +
animals O +
that O +
received O +
either O +
free O +
DOX O +
or O +
the O +
mixture O +
of O +
HPMA O +
copolymer O +
and O +
free O +
DOX O -
; O +
in O +
these O +
cases O -
, O +
histological O +
investigations O +
revealed O +
marked O +
changes O +
in O +
the O +
heart O +
that O +
were O +
consistent O +
with O +
DOX O -
- O -
induced O +
cardiotoxicity U-Disease -
. O -

Sequential O +
measurements O +
of O +
cardiac O +
output O +
in O +
surviving O +
animals O +
that O +
received O +
either O +
free O +
DOX O +
or O +
the O +
mixture O +
of O +
HPMA O +
copolymer O +
and O +
free O +
DOX O +
showed O +
a O +
reduction O +
of O +
approximately O +
30 O -
% O +
in O +
function O +
beginning O +
at O +
the O +
4th O +
week O +
after O +
drug O +
administration O -
. O -

The O +
heart O +
rate O +
in O +
these O +
animals O +
was O +
approximately O +
12 O -
% O +
lower O +
than O +
that O +
measured O +
in O +
age O -
- O -
matched O +
control O +
rats O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

Animals O +
that O +
were O +
given O +
the O +
HPMA O +
copolymer O +
conjugates O +
containing O +
DOX O +
exhibited O +
no O +
significant O +
change O +
in O +
cardiac O +
output O +
throughout O +
the O +
study O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

In O +
addition O -
, O +
no O +
significant O +
histological O +
change O +
was O +
observed O +
in O +
the O +
heart O +
of O +
animals O +
that O +
received O +
DOX O +
in O +
the O +
form O +
of O +
HPMA O +
copolymer O +
conjugates O +
and O +
were O +
killed O +
at O +
the O +
end O +
of O +
the O +
study O -
. O -

However O -
, O +
these O +
animals O +
had O +
shown O +
a O +
significant O +
increase O +
in O +
heart O +
rate O +
beginning O +
at O +
8 O +
weeks O +
after O +
drug O +
administration O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O -
) O -

Corneal B-Disease +
ulcers L-Disease +
associated O +
with O +
aerosolized O +
crack O +
cocaine O +
use O -
. O -

PURPOSE O -
: O +
We O +
report O +
4 O +
cases O +
of O +
corneal B-Disease +
ulcers L-Disease +
associated O +
with O +
drug B-Disease +
abuse L-Disease -
. O -

The O +
pathogenesis O +
of O +
these O +
ulcers U-Disease +
and O +
management O +
of O +
these O +
patients O +
are O +
also O +
reviewed O -
. O -

METHODS O -
: O +
Review O +
of O +
all O +
cases O +
of O +
corneal B-Disease +
ulcers L-Disease +
associated O +
with O +
drug B-Disease +
abuse L-Disease +
seen O +
at O +
our O +
institution O +
from O +
July O +
2006 O +
to O +
December O +
2006 O -
. O -

RESULTS O -
: O +
Four O +
patients O +
with O +
corneal B-Disease +
ulcers L-Disease +
associated O +
with O +
crack O +
cocaine O +
use O +
were O +
reviewed O -
. O -

All O +
corneal B-Disease +
ulcers L-Disease +
were O +
cultured O -
, O +
and O +
the O +
patients O +
were O +
admitted O +
to O +
the O +
hospital O +
for O +
intensive O +
topical O +
antibiotic O +
treatment O -
. O -

Each O +
patient O +
received O +
comprehensive O +
health O +
care O -
, O +
including O +
medical O +
and O +
substance B-Disease +
abuse L-Disease +
consultations O -
. O -

Streptococcal O +
organisms O +
were O +
found O +
in O +
3 O +
cases O +
and O +
Capnocytophaga O +
and O +
Brevibacterium O +
casei O +
in O +
1 O +
patient O -
. O -

The O +
infections U-Disease +
responded O +
to O +
antibiotic O +
treatment O -
. O -

Two O +
patients O +
needed O +
a O +
lateral O +
tarsorrhaphy O +
for O +
persistent O +
epithelial B-Disease +
defects L-Disease -
. O -

CONCLUSIONS O -
: O +
Aerosolized O +
crack O +
cocaine O +
use O +
can O +
be O +
associated O +
with O +
the O +
development O +
of O +
corneal B-Disease +
ulcers L-Disease -
. O -

Drug B-Disease +
abuse L-Disease +
provides O +
additional O +
challenges O +
for O +
management O -
. O -

Not O +
only O +
treatment O +
of O +
their O +
infections U-Disease +
but O +
also O +
the O +
overall O +
poor O +
health O +
of O +
the O +
patients O +
and O +
increased O +
risk O +
of O +
noncompliance O +
need O +
to O +
be O +
addressed O -
. O -

Comprehensive O +
care O +
may O +
provide O +
the O +
patient O +
the O +
opportunity O +
to O +
discontinue O +
their O +
substance B-Disease +
abuse L-Disease -
, O +
improve O +
their O +
overall O +
health O -
, O +
and O +
prevent O +
future O +
corneal O +
complications O -
. O -

Topical O +
0.025 O -
% O +
capsaicin O +
in O +
chronic O +
post B-Disease -
- I-Disease -
herpetic I-Disease +
neuralgia L-Disease -
: O +
efficacy O -
, O +
predictors O +
of O +
response O +
and O +
long O -
- O -
term O +
course O -
. O -

In O +
order O +
to O +
evaluate O +
the O +
efficacy O -
, O +
time O -
- O -
course O +
of O +
action O +
and O +
predictors O +
of O +
response O +
to O +
topical O +
capsaicin O -
, O +
39 O +
patients O +
with O +
chronic O +
post B-Disease -
- I-Disease -
herpetic I-Disease +
neuralgia L-Disease +
( O -
PHN U-Disease -
) O -
, O +
median O +
duration O +
24 O +
months O -
, O +
were O +
treated O +
with O +
0.025 O -
% O +
capsaicin O +
cream O +
for O +
8 O +
weeks O -
. O -

During O +
therapy O +
the O +
patients O +
rated O +
their O +
pain U-Disease +
on O +
a O +
visual O +
analogue O +
scale O +
( O -
VAS O -
) O +
and O +
a O +
verbal O +
outcome O +
scale O -
. O -

A O +
follow O -
- O -
up O +
investigation O +
was O +
performed O +
10 O -
- O -
12 O +
months O +
after O +
study O +
onset O +
on O +
the O +
patients O +
who O +
had O +
improved O -
. O -

Nineteen O +
patients O +
( O -
48.7 O -
% O -
) O +
substantially O +
improved O +
after O +
the O +
8-week O +
trial O -
; O +
5 O +
( O -
12.8 O -
% O -
) O +
discontinued O +
therapy O +
due O +
to O +
side O -
- O -
effects O +
such O +
as O +
intolerable O +
capsaicin O -
- O -
induced O +
burning O +
sensations O +
( O -
4 O -
) O +
or O +
mastitis U-Disease +
( O -
1 O -
) O -
; O +
15 O +
( O -
38.5 O -
% O -
) O +
reported O +
no O +
benefit O -
. O -

The O +
decrease O +
in O +
VAS O +
ratings O +
was O +
significant O +
after O +
2 O +
weeks O +
of O +
continuous O +
application O -
. O -

Of O +
the O +
responders O +
72.2 O -
% O +
were O +
still O +
improved O +
at O +
the O +
follow O -
- O -
up O -
; O +
only O +
one O -
- O -
third O +
of O +
them O +
had O +
continued O +
application O +
irregularly O -
. O -

Treatment O +
effect O +
was O +
not O +
dependent O +
on O +
patient O -
's O +
age O -
, O +
duration O +
or O +
localization O +
of O +
PHN U-Disease +
( O -
trigeminal O +
involvement O +
was O +
excluded O -
) O -
, O +
sensory B-Disease +
disturbance L-Disease +
or O +
pain U-Disease +
character O -
. O -

Treatment O +
response O +
was O +
not O +
correlated O +
with O +
the O +
incidence O -
, O +
time O -
- O -
course O +
or O +
severity O +
of O +
capsaicin O -
- O -
induced O +
burning O -
. O -

If O +
confirmed O +
in O +
controlled O +
trials O -
, O +
the O +
long O -
- O -
term O +
results O +
of O +
this O +
open O -
, O +
non O -
- O -
randomized O +
study O +
might O +
indicate O +
that O +
the O +
analgesic O +
effect O +
of O +
capsaicin O +
in O +
PHN U-Disease +
is O +
mediated O +
by O +
both O +
interference O +
with O +
neuropeptide O +
metabolism O +
and O +
morphological O +
changes O +
( O -
perhaps O +
degeneration O -
) O +
of O +
nociceptive O +
afferents O -
. O -

Myo O -
- O -
inositol-1-phosphate O +
( O -
MIP O -
) O +
synthase O +
inhibition O -
: O +
in O -
- O -
vivo O +
study O +
in O +
rats O -
. O -

Lithium O +
and O +
valproate O +
are O +
the O +
prototypic O +
mood O +
stabilizers O +
and O +
have O +
diverse O +
structures O +
and O +
targets O -
. O -

Both O +
drugs O +
influence O +
inositol O +
metabolism O -
. O -

Lithium O +
inhibits O +
IMPase O +
and O +
valproate O +
inhibits O +
MIP O +
synthase O -
. O -

This O +
study O +
shows O +
that O +
MIP O +
synthase O +
inhibition O +
does O +
not O +
replicate O +
or O +
augment O +
the O +
effects O +
of O +
lithium O +
in O +
the O +
inositol O +
sensitive O +
pilocarpine O -
- O -
induced O +
seizures U-Disease +
model O -
. O -

This O +
lack O +
of O +
effects O +
may O +
stem O +
from O +
the O +
low O +
contribution O +
of O +
de O -
- O -
novo O +
synthesis O +
to O +
cellular O +
inositol O +
supply O +
or O +
to O +
the O +
inhibition O +
of O +
the O +
de O -
- O -
novo O +
synthesis O +
by O +
lithium O +
itself O -
. O -

Non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O -
- O -
associated O +
acute O +
interstitial B-Disease +
nephritis L-Disease +
with O +
granular O +
tubular O +
basement O +
membrane O +
deposits O -
. O -

Acute B-Disease +
tubulo I-Disease -
- I-Disease -
interstitial I-Disease +
nephritis L-Disease +
( O -
ATIN U-Disease -
) O +
is O +
an O +
important O +
cause O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
resulting O +
from O +
a O +
variety O +
of O +
insults O -
, O +
including O +
immune O +
complex O -
- O -
mediated O +
tubulo B-Disease -
- I-Disease -
interstitial I-Disease +
injury L-Disease -
, O +
but O +
drugs O +
such O +
as O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
are O +
a O +
far O +
more O +
frequent O +
cause O -
. O -

Overall O -
, O +
as O +
an O +
entity O -
, O +
ATIN U-Disease +
remains O +
under O -
- O -
diagnosed O -
, O +
as O +
symptoms O +
resolve O +
spontaneously O +
if O +
the O +
medication O +
is O +
stopped O -
. O -

We O +
report O +
on O +
a O +
14-year O -
- O -
old O +
boy O +
who O +
developed O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
2 O +
weeks O +
after O +
aortic O +
valve O +
surgery O -
. O -

He O +
was O +
put O +
on O +
aspirin O +
following O +
surgery O +
and O +
took O +
ibuprofen O +
for O +
fever U-Disease +
for O +
nearly O +
a O +
week O +
prior O +
to O +
presentation O -
. O -

He O +
then O +
presented O +
to O +
the O +
emergency O +
department O +
feeling O +
quite O +
ill O +
and O +
was O +
found O +
to O +
have O +
a O +
blood O +
urea O +
nitrogen O +
( O -
BUN O -
) O +
concentration O +
of O +
of O +
147 O +
mg O -
/ O -
dl O -
, O +
creatinine O +
of O +
15.3 O +
mg O -
/ O -
dl O +
and O +
serum O +
potassium O +
of O +
8.7 O +
mEq O -
/ O -
l O -
. O -

Dialysis O +
was O +
immediately O +
initiated O -
. O -

A O +
kidney O +
biopsy O +
showed O +
inflammatory O +
infiltrate O +
consistent O +
with O +
ATIN U-Disease -
. O -

However O -
, O +
in O +
the O +
tubular O +
basement O +
membrane O +
( O -
TBM O -
) O -
, O +
very O +
intense O +
granular O +
deposits O +
of O +
polyclonal O +
IgG O +
and O +
C3 O +
were O +
noted O -
. O -

He O +
needed O +
dialysis O +
for O +
2 O +
weeks O +
and O +
was O +
treated O +
successfully O +
with O +
steroids O +
for O +
6 O +
months O -
. O -

His O +
renal O +
recovery O +
and O +
disappearance O +
of O +
proteinuria U-Disease +
took O +
a O +
year O -
. O -

In O +
conclusion O -
, O +
this O +
is O +
a O +
first O +
report O +
of O +
NSAIDs O -
- O -
associated O +
ATIN U-Disease -
, O +
showing O +
deposits O +
of O +
granular O +
immune O +
complex O +
present O +
only O +
in O +
the O +
TBM O +
and O +
not O +
in O +
the O +
glomeruli O -
. O -

Rifampicin O -
- O -
associated O +
segmental O +
necrotizing O +
glomerulonephritis U-Disease +
in O +
staphylococcal U-Disease +
endocarditis U-Disease -
. O -

Segmental O +
necrotising O +
glomerulonephritis U-Disease +
has O +
been O +
reported O +
as O +
complication O +
of O +
rifampicin O +
therapy O +
in O +
patients O +
receiving O +
treatment O +
for O +
tuberculosis U-Disease -
. O -

Changing O +
epidemiology O +
of O +
infections U-Disease +
such O +
as O +
infective B-Disease +
endocarditis L-Disease +
( O -
IE U-Disease -
) O +
has O +
led O +
to O +
an O +
increase O +
in O +
the O +
use O +
of O +
rifampicin O +
for O +
Staphylococcal B-Disease +
infections L-Disease -
. O -

We O +
describe O +
a O +
case O +
of O +
a O +
patient O +
with O +
Staphylococcal U-Disease +
IE U-Disease +
who O +
developed O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
secondary O +
to O +
a O +
segmental O +
necrotising O +
glomerulonephritis U-Disease +
while O +
being O +
treated O +
with O +
rifampicin O -
, O +
and O +
review O +
the O +
literature O +
regarding O +
this O +
complication O +
of O +
rifampicin O +
therapy O -
. O -

Rate O +
of O +
YMDD O +
motif O +
mutants O +
in O +
lamivudine O -
- O -
untreated O +
Iranian O +
patients O +
with O +
chronic B-Disease +
hepatitis I-Disease +
B I-Disease +
virus I-Disease +
infection L-Disease -
. O -

BACKGROUND O -
: O +
Lamivudine O +
is O +
used O +
for O +
the O +
treatment O +
of O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
patients O -
. O -

Recent O +
studies O +
show O +
that O +
the O +
YMDD O +
motif O +
mutants O +
( O -
resistant O +
hepatitis B-Disease +
B L-Disease +
virus O -
) O +
occur O +
as O +
natural O +
genome O +
variability O +
in O +
lamivudine O -
- O -
untreated O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
patients O -
. O -

In O +
this O +
study O +
we O +
aimed O +
to O +
determine O +
the O +
rate O +
of O +
YMDD O +
motif O +
mutants O +
in O +
lamivudine O -
- O -
untreated O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
patients O +
in O +
Iran O -
. O -

PATIENTS O +
AND O +
METHODS O -
: O +
A O +
total O +
of O +
77 O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
patients O +
who O +
had O +
not O +
been O +
treated O +
with O +
lamivudine O +
were O +
included O +
in O +
the O +
study O -
. O -

Serum O +
samples O +
from O +
patients O +
were O +
tested O +
by O +
polymerase O +
chain O +
reaction O -
- O -
restriction O +
fragment O +
length O +
polymorphism O +
( O -
PCR O -
- O -
RFLP O -
) O +
for O +
detection O +
of O +
YMDD O +
motif O +
mutants O -
. O -

All O +
patients O +
were O +
also O +
tested O +
for O +
liver O +
enzymes O -
, O +
anti O -
- O -
HCV O -
, O +
HBeAg O -
, O +
and O +
anti O -
- O -
HBe O -
. O -

RESULTS O -
: O +
Of O +
the O +
77 O +
patients O +
enrolled O +
in O +
the O +
study O -
, O +
73 O -
% O +
were O +
male O +
and O +
27 O -
% O +
were O +
female O -
. O -

Mean O +
ALT O +
and O +
AST O +
levels O +
were O +
124.4+ O -
/ O -
-73.4 O +
and O +
103.1+ O -
/ O -
-81 O +
IU O -
/ O -
l O -
, O +
respectively O -
. O -

HBeAg O +
was O +
positive O +
in O +
40 O -
% O +
and O +
anti O -
- O -
HBe O +
in O +
60 O -
% O +
of O +
the O +
patients O -
. O -

Anti O -
- O -
HCV O +
was O +
negative O +
in O +
all O +
of O +
them O -
. O -

YMDD O +
motif O +
mutants O +
were O +
not O +
detected O +
in O +
any O +
of O +
the O +
patients O +
despite O +
the O +
liver O +
enzyme O +
levels O +
and O +
the O +
presence O +
of O +
HBeAg O +
or O +
anti O -
- O -
HBe O -
. O -

CONCLUSION O -
: O +
Although O +
the O +
natural O +
occurrence O +
of O +
YMDD O +
motif O +
mutants O +
in O +
lamivudine O -
- O -
untreated O +
patients O +
with O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
has O +
been O +
reported O -
, O +
these O +
mutants O +
were O +
not O +
detected O +
in O +
Iranian O +
lamivudine O -
- O -
untreated O +
chronic B-Disease +
hepatitis I-Disease +
B L-Disease +
patients O -
. O -

Branch O +
retinal B-Disease +
vein I-Disease +
occlusion L-Disease +
and O +
fluoxetine O -
. O -

A O +
case O +
of O +
branch O +
retinal B-Disease +
vein I-Disease +
occlusion L-Disease +
associated O +
with O +
fluoxetine O -
- O -
induced O +
secondary O +
hypertension U-Disease +
is O +
described O -
. O -

Although O +
an O +
infrequent O +
complication O +
of O +
selective O +
serotonin O +
reuptake O +
inhibitor O +
therapy O -
, O +
it O +
is O +
important O +
that O +
ophthalmologists O +
are O +
aware O +
that O +
these O +
agents O +
can O +
cause O +
hypertension U-Disease +
because O +
this O +
class O +
of O +
drugs O +
is O +
widely O +
prescribed O -
. O -

The O +
differential O +
effects O +
of O +
bupivacaine O +
and O +
lidocaine O +
on O +
prostaglandin O +
E2 O +
release O -
, O +
cyclooxygenase O +
gene O +
expression O +
and O +
pain U-Disease +
in O +
a O +
clinical O +
pain U-Disease +
model O -
. O -

BACKGROUND O -
: O +
In O +
addition O +
to O +
blocking O +
nociceptive O +
input O +
from O +
surgical O +
sites O -
, O +
long O -
- O -
acting O +
local O +
anesthetics O +
might O +
directly O +
modulate O +
inflammation U-Disease -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
describe O +
the O +
proinflammatory O +
effects O +
of O +
bupivacaine O +
on O +
local O +
prostaglandin O +
E2 O +
( O -
PGE2 O -
) O +
production O +
and O +
cyclooxygenase O +
( O -
COX O -
) O +
gene O +
expression O +
that O +
increases O +
postoperative B-Disease +
pain L-Disease +
in O +
human O +
subjects O -
. O -

METHODS O -
: O +
Subjects O +
( O -
n O +
= O +
114 O -
) O +
undergoing O +
extraction O +
of O +
impacted O +
third O +
molars O +
received O +
either O +
2 O -
% O +
lidocaine O +
or O +
0.5 O -
% O +
bupivacaine O +
before O +
surgery O +
and O +
either O +
rofecoxib O +
50 O +
mg O +
or O +
placebo O +
orally O +
90 O +
min O +
before O +
surgery O +
and O +
for O +
the O +
following O +
48 O +
h. O +
Oral O +
mucosal O +
biopsies O +
were O +
taken O +
before O +
surgery O +
and O +
48 O +
h O +
after O +
surgery O -
. O -

After O +
extraction O -
, O +
a O +
microdialysis O +
probe O +
was O +
placed O +
at O +
the O +
surgical O +
site O +
for O +
PGE2 O +
and O +
thromboxane O +
B2 O +
( O -
TXB2 O -
) O +
measurements O -
. O -

RESULTS O -
: O +
The O +
bupivacaine O -
/ O -
rofecoxib O +
group O +
reported O +
significantly O +
less O +
pain U-Disease -
, O +
as O +
assessed O +
by O +
a O +
visual O +
analog O +
scale O -
, O +
compared O +
with O +
the O +
other O +
three O +
treatment O +
groups O +
over O +
the O +
first O +
4 O +
h. O +
However O -
, O +
the O +
bupivacaine O -
/ O -
placebo O +
group O +
reported O +
significantly O +
more O +
pain U-Disease +
at O +
24 O +
h O +
and O +
PGE2 O +
levels O +
during O +
the O +
first O +
4 O +
h O +
were O +
significantly O +
higher O +
than O +
the O +
other O +
three O +
treatment O +
groups O -
. O -

Moreover O -
, O +
bupivacaine O +
significantly O +
increased O +
COX-2 O +
gene O +
expression O +
at O +
48 O +
h O +
as O +
compared O +
with O +
the O +
lidocaine O -
/ O -
placebo O +
group O -
. O -

Thromboxane O +
levels O +
were O +
not O +
significantly O +
affected O +
by O +
any O +
of O +
the O +
treatments O -
, O +
indicating O +
that O +
the O +
effects O +
seen O +
were O +
attributable O +
to O +
inhibition O +
of O +
COX-2 O -
, O +
but O +
not O +
COX-1 O -
. O -

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
bupivacaine O +
stimulates O +
COX-2 O +
gene O +
expression O +
after O +
tissue B-Disease +
injury L-Disease -
, O +
which O +
is O +
associated O +
with O +
higher O +
PGE2 O +
production O +
and O +
pain U-Disease +
after O +
the O +
local O +
anesthetic O +
effect O +
dissipates O -
. O -

p75NTR O +
expression O +
in O +
rat O +
urinary O +
bladder O +
sensory O +
neurons O +
and O +
spinal O +
cord O +
with O +
cyclophosphamide O -
- O -
induced O +
cystitis U-Disease -
. O -

A O +
role O +
for O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O +
in O +
contributing O +
to O +
increased O +
voiding O +
frequency O +
and O +
altered O +
sensation O +
from O +
the O +
urinary O +
bladder O +
has O +
been O +
suggested O -
. O -

Previous O +
studies O +
have O +
examined O +
the O +
expression O +
and O +
regulation O +
of O +
tyrosine O +
kinase O +
receptors O +
( O -
Trks O -
) O +
in O +
micturition O +
reflexes O +
with O +
urinary B-Disease +
bladder I-Disease +
inflammation L-Disease -
. O -

The O +
present O +
studies O +
examine O +
the O +
expression O +
and O +
regulation O +
of O +
another O +
receptor O +
known O +
to O +
bind O +
NGF O -
, O +
p75 O -
( O -
NTR O -
) O -
, O +
after O +
various O +
durations O +
of O +
bladder B-Disease +
inflammation L-Disease +
induced O +
by O +
cyclophosphamide O +
( O -
CYP O -
) O -
. O -

CYP O -
- O -
induced O +
cystitis U-Disease +
increased O +
( O -
P O +
< O +
or O +
= O +
0.001 O -
) O +
p75 O -
( O -
NTR O -
) O +
expression O +
in O +
the O +
superficial O +
lateral O +
and O +
medial O +
dorsal O +
horn O +
in O +
L1-L2 O +
and O +
L6-S1 O +
spinal O +
segments O -
. O -

The O +
number O +
of O +
p75 O -
( O -
NTR O -
) O -
-immunoreactive O +
( O -
-IR O -
) O +
cells O +
in O +
the O +
lumbosacral O +
dorsal O +
root O +
ganglia O +
( O -
DRG O -
) O +
also O +
increased O +
( O -
P O +
< O +
or O +
= O +
0.05 O -
) O +
with O +
CYP O -
- O -
induced O +
cystitis U-Disease +
( O -
acute O -
, O +
intermediate O -
, O +
and O +
chronic O -
) O -
. O -

Quantitative O -
, O +
real O -
- O -
time O +
polymerase O +
chain O +
reaction O +
also O +
demonstrated O +
significant O +
increases O +
( O -
P O +
< O +
or O +
= O +
0.01 O -
) O +
in O +
p75 O -
( O -
NTR O -
) O +
mRNA O +
in O +
DRG O +
with O +
intermediate O +
and O +
chronic O +
CYP O -
- O -
induced O +
cystitis U-Disease -
. O -

Retrograde O +
dye O -
- O -
tracing O +
techniques O +
with O +
Fastblue O +
were O +
used O +
to O +
identify O +
presumptive O +
bladder O +
afferent O +
cells O +
in O +
the O +
lumbosacral O +
DRG O -
. O -

In O +
bladder O +
afferent O +
cells O +
in O +
DRG O -
, O +
p75 O -
( O -
NTR O -
) O -
-IR O +
was O +
also O +
increased O +
( O -
P O +
< O +
or O +
= O +
0.01 O -
) O +
with O +
cystitis U-Disease -
. O -

In O +
addition O +
to O +
increases O +
in O +
p75 O -
( O -
NTR O -
) O -
-IR O +
in O +
DRG O +
cell O +
bodies O -
, O +
increases O +
( O -
P O +
< O +
or O +
= O +
0.001 O -
) O +
in O +
pericellular O +
( O -
encircling O +
DRG O +
cells O -
) O +
p75 O -
( O -
NTR O -
) O -
-IR O +
in O +
DRG O +
also O +
increased O -
. O -

Confocal O +
analyses O +
demonstrated O +
that O +
pericellular O +
p75 O -
( O -
NTR O -
) O -
-IR O +
was O +
not O +
colocalized O +
with O +
the O +
glial O +
marker O -
, O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O -
. O -

These O +
studies O +
demonstrate O +
that O +
p75 O -
( O -
NTR O -
) O +
expression O +
in O +
micturition O +
reflexes O +
is O +
present O +
constitutively O +
and O +
modified O +
by O +
bladder B-Disease +
inflammation L-Disease -
. O -

The O +
functional O +
significance O +
of O +
p75 O -
( O -
NTR O -
) O +
expression O +
in O +
micturition O +
reflexes O +
remains O +
to O +
be O +
determined O -
. O -

Azathioprine O -
- O -
induced O +
suicidal O +
erythrocyte O +
death O -
. O -

BACKGROUND O -
: O +
Azathioprine O +
is O +
widely O +
used O +
as O +
an O +
immunosuppressive O +
drug O -
. O -

The O +
side O +
effects O +
of O +
azathioprine O +
include O +
anemia U-Disease -
, O +
which O +
has O +
been O +
attributed O +
to O +
bone O +
marrow O +
suppression O -
. O -

Alternatively O -
, O +
anemia U-Disease +
could O +
result O +
from O +
accelerated O +
suicidal O +
erythrocyte O +
death O +
or O +
eryptosis O -
, O +
which O +
is O +
characterized O +
by O +
exposure O +
of O +
phosphatidylserine O +
( O -
PS O -
) O +
at O +
the O +
erythrocyte O +
surface O +
and O +
by O +
cell O +
shrinkage O -
. O -

METHODS O -
: O +
The O +
present O +
experiments O +
explored O +
whether O +
azathioprine O +
influences O +
eryptosis O -
. O -

According O +
to O +
annexin O +
V O +
binding O -
, O +
erythrocytes O +
from O +
patients O +
indeed O +
showed O +
a O +
significant O +
increase O +
of O +
PS O +
exposure O +
within O +
1 O +
week O +
of O +
treatment O +
with O +
azathioprine O -
. O -

In O +
a O +
second O +
series O -
, O +
cytosolic O +
Ca2 O -
+ O +
activity O +
( O -
Fluo3 O +
fluorescence O -
) O -
, O +
cell O +
volume O +
( O -
forward O +
scatter O -
) O -
, O +
and O +
PS O -
- O -
exposure O +
( O -
annexin O +
V O +
binding O -
) O +
were O +
determined O +
by O +
FACS O +
analysis O +
in O +
erythrocytes O +
from O +
healthy O +
volunteers O -
. O -

RESULTS O -
: O +
Exposure O +
to O +
azathioprine O +
( O -
> O +
or O +
= O -
2 O +
microg O -
/ O -
mL O -
) O +
for O +
48 O +
hours O +
increased O +
cytosolic O +
Ca2 O -
+ O +
activity O +
and O +
annexin O +
V O +
binding O +
and O +
decreased O +
forward O +
scatter O -
. O -

The O +
effect O +
of O +
azathioprine O +
on O +
both O +
annexin O +
V O +
binding O +
and O +
forward O +
scatter O +
was O +
significantly O +
blunted O +
in O +
the O +
nominal O +
absence O +
of O +
extracellular O +
Ca2 O -
+ O -
. O -

CONCLUSIONS O -
: O +
Azathioprine O +
triggers O +
suicidal O +
erythrocyte O +
death O -
, O +
an O +
effect O +
presumably O +
contributing O +
to O +
azathioprine O -
- O -
induced O +
anemia U-Disease -
. O -

Levetiracetam O +
as O +
an O +
adjunct O +
to O +
phenobarbital O +
treatment O +
in O +
cats O +
with O +
suspected O +
idiopathic B-Disease +
epilepsy L-Disease -
. O -

OBJECTIVE O -
: O +
To O +
assess O +
pharmacokinetics O -
, O +
efficacy O -
, O +
and O +
tolerability O +
of O +
oral O +
levetiracetam O +
administered O +
as O +
an O +
adjunct O +
to O +
phenobarbital O +
treatment O +
in O +
cats O +
with O +
poorly O +
controlled O +
suspected O +
idiopathic B-Disease +
epilepsy L-Disease -
. O -

DESIGN O -
- O -
Open O -
- O -
label O -
, O +
noncomparative O +
clinical O +
trial O -
. O -

ANIMALS O -
: O +
12 O +
cats O +
suspected O +
to O +
have O +
idiopathic B-Disease +
epilepsy L-Disease +
that O +
was O +
poorly O +
controlled O +
with O +
phenobarbital O +
or O +
that O +
had O +
unacceptable O +
adverse O +
effects O +
when O +
treated O +
with O +
phenobarbital O -
. O -

PROCEDURES O -
: O +
Cats O +
were O +
treated O +
with O +
levetiracetam O +
( O -
20 O +
mg O -
/ O -
kg O +
[ O -
9.1 O +
mg O -
/ O -
lb O -
] O -
, O +
PO O -
, O +
q O +
8 O +
h O -
) O -
. O -

After O +
a O +
minimum O +
of O +
1 O +
week O +
of O +
treatment O -
, O +
serum O +
levetiracetam O +
concentrations O +
were O +
measured O +
before O +
and O +
2 O -
, O +
4 O -
, O +
and O +
6 O +
hours O +
after O +
drug O +
administration O -
, O +
and O +
maximum O +
and O +
minimum O +
serum O +
concentrations O +
and O +
elimination O +
half O -
- O -
life O +
were O +
calculated O -
. O -

Seizure U-Disease +
frequencies O +
before O +
and O +
after O +
initiation O +
of O +
levetiracetam O +
treatment O +
were O +
compared O -
, O +
and O +
adverse O +
effects O +
were O +
recorded O -
. O -

RESULTS O -
: O +
Median O +
maximum O +
serum O +
levetiracetam O +
concentration O +
was O +
25.5 O +
microg O -
/ O -
mL O -
, O +
median O +
minimum O +
serum O +
levetiracetam O +
concentration O +
was O +
8.3 O +
microg O -
/ O -
mL O -
, O +
and O +
median O +
elimination O +
half O -
- O -
life O +
was O +
2.9 O +
hours O -
. O -

Median O +
seizure U-Disease +
frequency O +
prior O +
to O +
treatment O +
with O +
levetiracetam O +
( O -
2.1 O +
seizures U-Disease -
/ O -
mo O -
) O +
was O +
significantly O +
higher O +
than O +
median O +
seizure U-Disease +
frequency O +
after O +
initiation O +
of O +
levetiracetam O +
treatment O +
( O -
0.42 O +
seizures U-Disease -
/ O -
mo O -
) O -
, O +
and O +
7 O +
of O +
10 O +
cats O +
were O +
classified O +
as O +
having O +
responded O +
to O +
levetiracetam O +
treatment O +
( O -
ie O -
, O +
reduction O +
in O +
seizure U-Disease +
frequency O +
of O +
> O -
or=50 O -
% O -
) O -
. O -

Two O +
cats O +
had O +
transient O +
lethargy U-Disease +
and O +
inappetence U-Disease -
. O -

CONCLUSIONS O +
AND O +
CLINICAL O +
RELEVANCE O -
: O +
Results O +
suggested O +
that O +
levetiracetam O +
is O +
well O +
tolerated O +
in O +
cats O +
and O +
may O +
be O +
useful O +
as O +
an O +
adjunct O +
to O +
phenobarbital O +
treatment O +
in O +
cats O +
with O +
idiopathic B-Disease +
epilepsy L-Disease -
. O -

Serotonin O +
reuptake O +
inhibitors O -
, O +
paranoia U-Disease -
, O +
and O +
the O +
ventral O +
basal O +
ganglia O -
. O -

Antidepressants O +
have O +
previously O +
been O +
associated O +
with O +
paranoid U-Disease +
reactions O +
in O +
psychiatric O +
patients O -
. O -

Five O +
cases O +
of O +
paranoid U-Disease +
exacerbation O +
with O +
the O +
serotonin O +
reuptake O +
inhibitors O +
fluoxetine O +
and O +
amitriptyline O +
are O +
reported O +
here O -
. O -

Elements O +
common O +
to O +
these O +
cases O +
included O +
a O +
history O +
of O +
paranoid U-Disease +
symptomatology O +
and O +
the O +
concomitant O +
occurrence O +
of O +
depressive B-Disease +
and I-Disease +
psychotic I-Disease +
symptoms L-Disease -
. O -

Complicated O +
depressive B-Disease +
disorders L-Disease +
( O -
including O +
atypicality O +
of O +
course O +
and O +
symptomatology O -
, O +
chronicity O -
, O +
psychosis U-Disease -
, O +
bipolarity O -
, O +
and O +
secondary O +
onset O +
in O +
the O +
course O +
of O +
a O +
primary O +
psychosis U-Disease -
) O +
may O +
present O +
particular O +
vulnerability O +
to O +
paranoid U-Disease +
exacerbations O +
associated O +
with O +
serotonin O +
reuptake O +
inhibitors O -
. O -

Although O +
the O +
pharmacology O +
and O +
neurobiology O +
of O +
paranoia U-Disease +
remain O +
cryptic O -
, O +
several O +
mechanisms O -
, O +
including O +
5HT3 O +
receptor O -
- O -
mediated O +
dopamine O +
release O -
, O +
beta O -
- O -
noradrenergic O +
receptor O +
downregulation O -
, O +
or O +
GABAB O +
receptor O +
upregulation O +
acting O +
in O +
the O +
vicinity O +
of O +
the O +
ventral O +
basal O +
ganglia O +
( O -
possibly O +
in O +
lateral O +
orbitofrontal O +
or O +
anterior O +
cingulate O +
circuits O -
) O -
, O +
might O +
apply O +
to O +
this O +
phenomenon O -
. O -

These O +
cases O +
call O +
attention O +
to O +
possible O +
paranoid U-Disease +
exacerbations O +
with O +
serotonin O +
reuptake O +
blockers O +
in O +
select O +
patients O +
and O +
raise O +
neurobiological O +
considerations O +
regarding O +
paranoia U-Disease -
. O -

Clinical O +
comparison O +
of O +
cardiorespiratory O +
effects O +
during O +
unilateral O +
and O +
conventional O +
spinal O +
anaesthesia O -
. O -

BACKGROUND O -
: O +
Spinal O +
anaesthesia O +
is O +
widely O +
employed O +
in O +
clinical O +
practice O +
but O +
has O +
the O +
main O +
drawback O +
of O +
post O -
- O -
spinal O +
block O +
hypotension U-Disease -
. O -

Efforts O +
must O +
therefore O +
continue O +
to O +
be O +
made O +
to O +
obviate O +
this O +
setback O +
OBJECTIVE O -
: O +
To O +
evaluate O +
the O +
cardiovascular O +
and O +
respiratory O +
changes O +
during O +
unilateral O +
and O +
conventional O +
spinal O +
anaesthesia O -
. O -

METHODS O -
: O +
With O +
ethical O +
approval O -
, O +
we O +
studied O +
74 O +
American O +
Society O +
of O +
Anesthesiologists O +
( O -
ASA O -
) O -
, O +
physical O +
status O +
class O +
1 O +
and O +
2 O +
patients O +
scheduled O +
for O +
elective O +
unilateral O +
lower O +
limb O +
surgery O -
. O -

Patients O +
were O +
randomly O +
allocated O +
into O +
one O +
of O +
two O +
groups O -
: O +
lateral O +
and O +
conventional O +
spinal O +
anaesthesia O +
groups O -
. O -

In O +
the O +
lateral O +
position O +
with O +
operative O +
side O +
down O -
, O +
patients O +
recived O +
10 O +
mg O +
( O -
2mls O -
) O +
of O +
0.5 O -
% O +
hyperbaric O +
bupivacaine O +
through O +
a O +
25-gauge O +
spinal O +
needle O -
. O -

Patients O +
in O +
the O +
unilateral O +
group O +
were O +
maintained O +
in O +
the O +
lateral O +
position O +
for O +
15 O +
minutes O +
following O +
spinal O +
injection O +
while O +
those O +
in O +
the O +
conventional O +
group O +
were O +
turned O +
supine O +
immediately O +
after O +
injection O -
. O -

Blood O +
pressure O -
, O +
heart O +
rate O -
, O +
respiratory O +
rate O +
and O +
oxygen O +
saturation O +
were O +
monitored O +
over O +
1 O +
hour O -
. O -

RESULTS O -
: O +
Three O +
patients O +
( O -
8.1 O -
% O -
) O +
in O +
the O +
unilateral O +
group O +
and O +
5 O +
( O -
13.5 O -
% O -
) O +
in O +
the O +
conventional O +
group O +
developed O +
hypotension U-Disease -
, O +
P= O +
0.71 O -
. O -

Four O +
( O -
10.8 O -
% O -
) O +
patients O +
in O +
the O +
conventional O +
group O +
and O +
1 O +
( O -
2.7 O -
% O -
) O +
in O +
the O +
unilateral O +
group O -
, O +
P= O +
0.17 O +
required O +
epinephrine O +
infusion O +
to O +
treat O +
hypotension U-Disease -
. O -

Patients O +
in O +
the O +
conventional O +
group O +
had O +
statistically O +
significant O +
greater O +
fall O +
in O +
the O +
systolic O +
blood O +
pressures O +
at O +
15 O -
, O +
30 O +
and O +
45 O +
minutes O +
when O +
compared O +
to O +
the O +
baseline O +
( O -
P= O +
0.003 O -
, O +
0.001 O +
and O +
0.004 O -
) O -
. O -

The O +
mean O +
respiratory O +
rate O +
and O +
oxygen O +
saturations O +
in O +
the O +
two O +
groups O +
were O +
similar O -
. O -

CONCLUSION O -
: O +
Compared O +
to O +
conventional O +
spinal O +
anaesthesia O -
, O +
unilateral O +
spinal O +
anaesthesia O +
was O +
associated O +
with O +
fewer O +
cardiovascular O +
perturbations O -
. O -

Also O -
, O +
the O +
type O +
of O +
spinal O +
block O +
instituted O +
affected O +
neither O +
the O +
respiratory O +
rate O +
nor O +
the O +
arterial O +
oxygen O +
saturation O -
. O -

Spectrum O +
of O +
adverse O +
events O +
after O +
generic O +
HAART O +
in O +
southern O +
Indian O +
HIV B-Disease -
- I-Disease -
infected L-Disease +
patients O -
. O -

To O +
determine O +
the O +
incidence O +
of O +
clinically O +
significant O +
adverse O +
events O +
after O +
long O -
- O -
term O -
, O +
fixed O -
- O -
dose O -
, O +
generic O +
highly O +
active O +
antiretroviral O +
therapy O +
( O -
HAART O -
) O +
use O +
among O +
HIV B-Disease -
- I-Disease -
infected L-Disease +
individuals O +
in O +
South O +
India O -
, O +
we O +
examined O +
the O +
experiences O +
of O +
3154 O +
HIV B-Disease -
- I-Disease -
infected L-Disease +
individuals O +
who O +
received O +
a O +
minimum O +
of O +
3 O +
months O +
of O +
generic O +
HAART O +
between O +
February O +
1996 O +
and O +
December O +
2006 O +
at O +
a O +
tertiary O +
HIV O +
care O +
referral O +
center O +
in O +
South O +
India O -
. O -

The O +
most O +
common O +
regimens O +
were O +
3TC O +
+ O +
d4 O -
T O +
+ O +
nevirapine O +
( O -
NVP O -
) O +
( O -
54.8 O -
% O -
) O -
, O +
zidovudine O +
( O -
AZT O -
) O +
+ O +
3TC O +
+ O +
NVP O +
( O -
14.5 O -
% O -
) O -
, O +
3TC O +
+ O +
d4 O -
T O +
+ O +
efavirenz O +
( O -
EFV O -
) O +
( O -
20.1 O -
% O -
) O -
, O +
and O +
AZT O +
+ O +
3TC O +
+ O +
EFV O +
( O -
5.4 O -
% O -
) O -
. O -

The O +
most O +
common O +
adverse O +
events O +
and O +
median O +
CD4 O +
at O +
time O +
of O +
event O +
were O +
rash U-Disease +
( O -
15.2 O -
% O -
; O +
CD4 O -
, O +
285 O +
cells O -
/ O -
microL O -
) O +
and O +
peripheral B-Disease +
neuropathy L-Disease +
( O -
9.0 O -
% O +
and O +
348 O +
cells O -
/ O -
microL O -
) O -
. O -

Clinically O +
significant O +
anemia U-Disease +
( O -
hemoglobin O +
< O -
7 O +
g O -
/ O -
dL O -
) O +
was O +
observed O +
in O +
5.4 O -
% O +
of O +
patients O +
( O -
CD4 O -
, O +
165 O +
cells O -
/ O -
microL O -
) O +
and O +
hepatitis U-Disease +
( O -
clinical O +
jaundice U-Disease +
with O +
alanine O +
aminotransferase O +
> O +
5 O +
times O +
upper O +
limits O +
of O +
normal O -
) O +
in O +
3.5 O -
% O +
of O +
patients O +
( O -
CD4 O -
, O +
260 O +
cells O -
/ O -
microL O -
) O -
. O -

Women O +
were O +
significantly O +
more O +
likely O +
to O +
experience O +
lactic B-Disease +
acidosis L-Disease -
, O +
while O +
men O +
were O +
significantly O +
more O +
likely O +
to O +
experience O +
immune B-Disease +
reconstitution I-Disease +
syndrome L-Disease +
( O -
p O +
< O +
0.05 O -
) O -
. O -

Among O +
the O +
patients O +
with O +
1 O +
year O +
of O +
follow O -
- O -
up O -
, O +
NVP O +
therapy O +
was O +
significantly O +
associated O +
with O +
developing O +
rash U-Disease +
and O +
d4 O -
T O +
therapy O +
with O +
developing O +
peripheral B-Disease +
neuropathy L-Disease +
( O -
p O +
< O +
0.05 O -
) O -
. O -

Anemia U-Disease +
and O +
hepatitis U-Disease +
often O +
occur O +
within O +
12 O +
weeks O +
of O +
initiating O +
generic O +
HAART O -
. O -

Frequent O +
and O +
early O +
monitoring O +
for O +
these O +
toxicities U-Disease +
is O +
warranted O +
in O +
developing O +
countries O +
where O +
generic O +
HAART O +
is O +
increasingly O +
available O -
. O -

Thalidomide O +
and O +
sensory B-Disease +
neurotoxicity L-Disease -
: O +
a O +
neurophysiological O +
study O -
. O -

BACKGROUND O -
: O +
Recent O +
studies O +
confirmed O +
a O +
high O +
incidence O +
of O +
sensory B-Disease +
axonal I-Disease +
neuropathy L-Disease +
in O +
patients O +
treated O +
with O +
different O +
doses O +
of O +
thalidomide O -
. O -

The O +
study O -
's O +
aims O +
were O +
to O +
measure O +
variations O +
in O +
sural O +
nerve O +
sensory O +
action O +
potential O +
( O -
SAP O -
) O +
amplitude O +
in O +
patients O +
with O +
refractory O +
cutaneous B-Disease +
lupus I-Disease +
erythematosus L-Disease +
( O -
CLE U-Disease -
) O +
treated O +
with O +
thalidomide O +
and O +
use O +
these O +
findings O +
to O +
identify O +
the O +
neurotoxic U-Disease +
potential O +
of O +
thalidomide O +
and O +
the O +
recovery O +
capacity O +
of O +
sensory O +
fibres O +
after O +
discontinuation O +
of O +
treatment O -
. O -

PATIENTS O +
AND O +
METHODS O -
: O +
Clinical O +
and O +
electrophysiological O +
data O +
in O +
12 O +
female O +
patients O +
with O +
CLE U-Disease +
during O +
treatment O +
with O +
thalidomide O +
and O +
up O +
to O +
47 O +
months O +
after O +
discontinuation O +
of O +
treatment O +
were O +
analysed O -
. O -

Sural O +
nerve O +
SAP O +
amplitude O +
reduction O +
> O +
or O +
= O -
40 O -
% O +
was O +
the O +
criteria O +
for O +
discontinuing O +
therapy O -
. O -

RESULTS O -
: O +
During O +
treatment O -
, O +
11 O +
patients O +
showed O +
a O +
reduction O +
in O +
sural O +
nerve O +
SAP O +
amplitude O +
compared O +
to O +
baseline O +
values O +
( O -
9 O +
with O +
a O +
reduction O +
> O +
or O +
= O -
50 O -
% O +
and O +
2 O +
< O -
50 O -
% O -
) O -
. O -

One O +
patient O +
showed O +
no O +
changes O +
in O +
SAP O +
amplitude O -
. O -

Five O +
patients O +
complained O +
of O +
paresthesias U-Disease +
and O +
leg O +
cramps U-Disease -
. O -

After O +
thalidomide O +
treatment O -
, O +
sural O +
SAP O +
amplitude O +
recovered O +
in O +
3 O +
patients O -
. O -

At O +
detection O +
of O +
reduction O +
in O +
sural O +
nerve O +
SAP O +
amplitude O -
, O +
the O +
median O +
thalidomide O +
cumulative O +
dose O +
was O +
21.4 O +
g. O +
The O +
threshold O +
neurotoxic U-Disease +
dosage O +
is O +
lower O +
than O +
previously O +
reported O -
. O -

CONCLUSIONS O -
: O +
Sural O +
nerve O +
SAP O +
amplitude O +
reduction O +
is O +
a O +
reliable O +
and O +
sensitive O +
marker O +
of O +
degeneration O +
and O +
recovery O +
of O +
sensory O +
fibres O -
. O -

This O +
electrophysiological O +
parameter O +
provides O +
information O +
about O +
subclinical O +
neurotoxic U-Disease +
potential O +
of O +
thalidomide O +
but O +
is O +
not O +
helpful O +
in O +
predicting O +
the O +
appearance O +
of O +
sensory O +
symptoms O -
. O -

Five O +
cases O +
of O +
encephalitis U-Disease +
during O +
treatment O +
of O +
loiasis U-Disease +
with O +
diethylcarbamazine O -
. O -

Five O +
cases O +
of O +
encephalitis U-Disease +
following O +
treatment O +
with O +
diethylcarbamazine O +
( O -
DEC O -
) O +
were O +
observed O +
in O +
Congolese O +
patients O +
with O +
Loa O +
loa O +
filariasis U-Disease -
. O -

Two O +
cases O +
had O +
a O +
fatal O +
outcome O +
and O +
one O +
resulted O +
in O +
severe O +
sequelae O -
. O -

The O +
notable O +
fact O +
was O +
that O +
this O +
complication O +
occurred O +
in O +
three O +
patients O +
hospitalized O +
before O +
treatment O +
began O -
, O +
with O +
whom O +
particularly O +
strict O +
therapeutic O +
precautions O +
were O +
taken O -
, O +
i.e. O -
, O +
initial O +
dose O +
less O +
than O +
10 O +
mg O +
of O +
DEC O -
, O +
very O +
gradual O +
dose O +
increases O -
, O +
and O +
associated O +
anti O -
- O -
allergic O +
treatment O -
. O -

This O +
type O +
of O +
drug O -
- O -
induced O +
complication O +
may O +
not O +
be O +
that O +
uncommon O +
in O +
highly O +
endemic O +
regions O -
. O -

It O +
occurs O +
primarily O -
, O +
but O +
not O +
exclusively O -
, O +
in O +
subjects O +
presenting O +
with O +
a O +
high O +
microfilarial O +
load O -
. O -

The O +
relationship O +
between O +
the O +
occurrence O +
of O +
encephalitis U-Disease +
and O +
the O +
decrease O +
in O +
microfilaremia U-Disease +
is O +
evident O -
. O -

The O +
pathophysiological O +
mechanisms O +
are O +
discussed O +
in O +
the O +
light O +
of O +
these O +
observations O +
and O +
the O +
few O +
other O +
comments O +
on O +
this O +
subject O +
published O +
in O +
the O +
literature O -
. O -

Amiodarone O -
- O -
related O +
pulmonary B-Disease +
mass L-Disease +
and O +
unique O +
membranous B-Disease +
glomerulonephritis L-Disease +
in O +
a O +
patient O +
with O +
valvular B-Disease +
heart I-Disease +
disease L-Disease -
: O +
Diagnostic O +
pitfall O +
and O +
new O +
findings O -
. O -

Amiodarone O +
is O +
an O +
anti O -
- O -
arrhythmic U-Disease +
drug O +
for O +
life O -
- O -
threatening O +
tachycardia U-Disease -
, O +
but O +
various O +
adverse O +
effects O +
have O +
been O +
reported O -
. O -

Reported O +
herein O +
is O +
an O +
autopsy O +
case O +
of O +
valvular B-Disease +
heart I-Disease +
disease L-Disease -
, O +
in O +
a O +
patient O +
who O +
developed O +
a O +
lung B-Disease +
mass L-Disease +
( O -
1.5 O +
cm O +
in O +
diameter O -
) O +
and O +
proteinuria U-Disease +
( O -
2.76 O +
g O -
/ O -
day O -
) O +
after O +
treatment O +
with O +
amiodarone O +
for O +
a O +
long O +
time O -
. O -

The O +
lung B-Disease +
mass L-Disease +
was O +
highly O +
suspected O +
to O +
be O +
lung B-Disease +
cancer L-Disease +
on O +
CT O +
and O +
positron O +
emission O +
tomography O -
, O +
but O +
histologically O +
the O +
lesion O +
was O +
composed O +
of O +
lymphoplasmacytic O +
infiltrates O +
in O +
alveolar O +
walls O +
and O +
intra O -
- O -
alveolar O +
accumulation O +
of O +
foamy O +
macrophages O +
containing O +
characteristic O +
myelinoid O +
bodies O -
, O +
indicating O +
that O +
it O +
was O +
an O +
amiodarone O -
- O -
related O +
lesion O -
. O -

In O +
addition O -
, O +
the O +
lung O +
tissue O +
had O +
unevenly O +
distributed O +
hemosiderin U-Disease +
deposition O -
, O +
and O +
abnormally O +
tortuous O +
capillaries O +
were O +
seen O +
in O +
the O +
mass O +
and O +
in O +
heavily O +
hemosiderotic U-Disease +
lung O +
portions O +
outside O +
the O +
mass O -
. O -

In O +
the O +
kidneys O -
, O +
glomeruli O +
had O +
membrane O +
spikes O -
, O +
prominent O +
swelling O +
of O +
podocytes O +
and O +
subepithelial O +
deposits O -
, O +
which O +
were O +
sometimes O +
large O +
and O +
hump O -
- O -
like O -
. O -

Autoimmune B-Disease +
diseases L-Disease -
, O +
viral B-Disease +
hepatitis L-Disease -
, O +
malignant O +
neoplasms U-Disease +
or O +
other O +
diseases O +
with O +
a O +
known O +
relationship O +
to O +
membranous B-Disease +
glomerulonephritis L-Disease +
were O +
not O +
found O -
. O -

The O +
present O +
case O +
highlights O +
the O +
possibility O +
that O +
differential O +
diagnosis O +
between O +
an O +
amiodarone O -
- O -
related O +
pulmonary B-Disease +
lesion L-Disease +
and O +
a O +
neoplasm U-Disease +
can O +
be O +
very O +
difficult O +
radiologically O -
, O +
and O +
suggests O +
that O +
membranous B-Disease +
glomerulonephritis L-Disease +
might O +
be O +
another O +
possible O +
complication O +
of O +
amiodarone O +
treatment O -
. O -

Risk O +
of O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
associated O +
with O +
initial O +
sulphonylurea O +
treatment O +
of O +
patients O +
with O +
type B-Disease +
2 I-Disease +
diabetes L-Disease -
: O +
a O +
matched O +
case O -
- O -
control O +
study O -
. O -

AIMS O -
: O +
This O +
study O +
sought O +
to O +
assess O +
the O +
risk O +
of O +
developing O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
( O -
CAD U-Disease -
) O +
associated O +
with O +
initial O +
treatment O +
of O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
with O +
different O +
sulphonylureas O -
. O -

METHODS O -
: O +
In O +
type B-Disease +
2 I-Disease +
diabetic L-Disease +
patients O -
, O +
cases O +
who O +
developed O +
CAD U-Disease +
were O +
compared O +
retrospectively O +
with O +
controls O +
that O +
did O +
not O -
. O -

The O +
20-year O +
risk O +
of O +
CAD U-Disease +
at O +
diagnosis O +
of O +
diabetes U-Disease -
, O +
using O +
the O +
UKPDS O +
risk O +
engine O -
, O +
was O +
used O +
to O +
match O +
cases O +
with O +
controls O -
. O -

RESULTS O -
: O +
The O +
76 O +
cases O +
of O +
CAD U-Disease +
were O +
compared O +
with O +
152 O +
controls O -
. O -

The O +
hazard O +
of O +
developing O +
CAD U-Disease +
( O -
95 O -
% O +
CI O -
) O +
associated O +
with O +
initial O +
treatment O +
increased O +
by O +
2.4-fold O +
( O -
1.3 O -
- O -
4.3 O -
, O +
P=0.004 O -
) O +
with O +
glibenclamide O -
; O +
2-fold O +
( O -
0.9 O -
- O -
4.6 O -
, O +
P=0.099 O -
) O +
with O +
glipizide O -
; O +
2.9-fold O +
( O -
1.6 O -
- O -
5.1 O -
, O +
P=0.000 O -
) O +
with O +
either O -
, O +
and O +
was O +
unchanged O +
with O +
metformin O -
. O -

The O +
hazard O +
decreased O +
0.3-fold O +
( O -
0.7 O -
- O -
1.7 O -
, O +
P=0.385 O -
) O +
with O +
glimepiride O -
, O +
0.4-fold O +
( O -
0.7 O -
- O -
1.3 O -
, O +
P=0.192 O -
) O +
with O +
gliclazide O -
, O +
and O +
0.4-fold O +
( O -
0.7 O -
- O -
1.1 O -
, O +
P=0.09 O -
) O +
with O +
either O -
. O -

CONCLUSIONS O -
: O +
Initiating O +
treatment O +
of O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
with O +
glibenclamide O +
or O +
glipizide O +
is O +
associated O +
with O +
increased O +
risk O +
of O +
CAD U-Disease +
in O +
comparison O +
to O +
gliclazide O +
or O +
glimepiride O -
. O -

If O +
confirmed O -
, O +
this O +
may O +
be O +
important O +
because O +
most O +
Indian O +
patients O +
receive O +
the O +
cheaper O +
older O +
sulphonylureas O -
, O +
and O +
present O +
guidelines O +
do O +
not O +
distinguish O +
between O +
individual O +
agents O -
. O -

Reduced O +
progression O +
of O +
adriamycin O +
nephropathy U-Disease +
in O +
spontaneously O +
hypertensive U-Disease +
rats O +
treated O +
by O +
losartan O -
. O -

BACKGROUND O -
: O +
The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
antihypertensive O +
effects O +
of O +
angiotensin O +
II O +
type-1 O +
receptor O +
blocker O -
, O +
losartan O -
, O +
and O +
its O +
potential O +
in O +
slowing O +
down O +
renal B-Disease +
disease L-Disease +
progression O +
in O +
spontaneously O +
hypertensive U-Disease +
rats O +
( O -
SHR O -
) O +
with O +
adriamycin O +
( O -
ADR O -
) O +
nephropathy U-Disease -
. O -

METHODS O -
: O +
Six O -
- O -
month O -
- O -
old O +
female O +
SHR O +
were O +
randomly O +
selected O +
in O +
six O +
groups O -
. O -

Two O +
control O +
groups O +
( O -
SH O -
( O -
6 O -
) O -
, O +
SH O -
( O -
12 O -
) O -
) O +
received O +
vehicle O -
. O -

Groups O +
ADR O -
( O -
6 O -
) O -
, O +
ADR+LOS O -
( O -
6 O -
) O +
and O +
ADR O -
( O -
12 O -
) O -
, O +
and O +
ADR+LOS O -
( O -
12 O -
) O +
received O +
ADR O +
( O -
2 O +
mg O -
/ O -
kg O -
/ O -
b.w O -
. O -

i.v O -
. O -
) O +
twice O +
in O +
a O +
3-week O +
interval O -
. O -

Group O +
ADR+LOS O -
( O -
6 O -
) O +
received O +
losartan O +
( O -
10 O +
mg O -
/ O -
kg O -
/ O -
b.w. O -
/ O -
day O +
by O +
gavages O -
) O +
for O +
6 O +
weeks O +
and O +
group O +
ADR+LOS O -
( O -
12 O -
) O +
for O +
12 O +
weeks O +
after O +
second O +
injection O +
of O +
ADR O -
. O -

Animals O +
were O +
killed O +
after O +
6 O +
or O +
12 O +
weeks O -
, O +
respectively O -
. O -

Haemodynamic O +
measurements O +
were O +
performed O +
on O +
anaesthetized O +
animals O -
, O +
blood O +
and O +
urine O +
samples O +
were O +
taken O +
for O +
biochemical O +
analysis O +
and O +
the O +
left O +
kidney O +
was O +
processed O +
for O +
morphological O +
studies O -
. O -

RESULTS O -
: O +
Short O -
- O -
term O +
losartan O +
treatment O -
, O +
besides O +
antihypertensive O +
effect O -
, O +
improved O +
glomerular O +
filtration O +
rate O +
and O +
ameliorated O +
glomerulosclerosis U-Disease +
resulting O +
in O +
decreased O +
proteinuria U-Disease -
. O -

Prolonged O +
treatment O +
with O +
losartan O +
showed O +
further O +
reduction O +
of O +
glomerulosclerosis U-Disease +
associated O +
with O +
reduced O +
progression O +
of O +
tubular O +
atrophy U-Disease +
and O +
interstitial B-Disease +
fibrosis L-Disease -
, O +
thus O +
preventing O +
heavy O +
proteinuria U-Disease +
and O +
chronic B-Disease +
renal I-Disease +
failure L-Disease -
. O -

Losartan O +
reduced O +
uraemia U-Disease +
and O +
increased O +
urea O +
clearance O +
in O +
advanced O +
ADR O +
nephropathy U-Disease +
in O +
SHR O -
. O -

Histological O +
examination O +
showed O +
that O +
losartan O +
could O +
prevent O +
tubular O +
atrophy U-Disease -
, O +
interstitial O +
infiltration O +
and O +
fibrosis U-Disease +
in O +
ADR O +
nephropathy U-Disease -
. O -

CONCLUSION O -
: O +
Losartan O +
reduces O +
the O +
rate O +
of O +
progression O +
of O +
ADR O -
- O -
induced O +
focal B-Disease +
segmental I-Disease +
glomerulosclerosis L-Disease +
to O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease +
in O +
SHR O -
. O -

The O +
risks O +
of O +
aprotinin O +
and O +
tranexamic O +
acid O +
in O +
cardiac O +
surgery O -
: O +
a O +
one O -
- O -
year O +
follow O -
- O -
up O +
of O +
1188 O +
consecutive O +
patients O -
. O -

BACKGROUND O -
: O +
Our O +
aim O +
was O +
to O +
investigate O +
postoperative O +
complications O +
and O +
mortality O +
after O +
administration O +
of O +
aprotinin O +
compared O +
to O +
tranexamic O +
acid O +
in O +
an O +
unselected O -
, O +
consecutive O +
cohort O -
. O -

METHODS O -
: O +
Perioperative O +
data O +
from O +
consecutive O +
cardiac O +
surgery O +
patients O +
were O +
prospectively O +
collected O +
between O +
September O +
2005 O +
and O +
June O +
2006 O +
in O +
a O +
university O -
- O -
affiliated O +
clinic O +
( O -
n O +
= O +
1188 O -
) O -
. O -

During O +
the O +
first O +
5 O +
mo O -
, O +
596 O +
patients O +
received O +
aprotinin O +
( O -
Group O +
A O -
) O -
; O +
in O +
the O +
next O +
5 O +
mo O -
, O +
592 O +
patients O +
were O +
treated O +
with O +
tranexamic O +
acid O +
( O -
Group O +
T O -
) O -
. O -

Except O +
for O +
antifibrinolytic O +
therapy O -
, O +
the O +
anesthetic O +
and O +
surgical O +
protocols O +
remained O +
unchanged O -
. O -

RESULTS O -
: O +
The O +
pre- O +
and O +
intraoperative O +
variables O +
were O +
comparable O +
between O +
the O +
treatment O +
groups O -
. O -

Postoperatively O -
, O +
a O +
significantly O +
higher O +
incidence O +
of O +
seizures U-Disease +
was O +
found O +
in O +
Group O +
T O +
( O -
4.6 O -
% O +
vs O +
1.2 O -
% O -
, O +
P O +
< O +
0.001 O -
) O -
. O -

This O +
difference O +
was O +
also O +
significant O +
in O +
the O +
primary O +
valve O +
surgery O +
and O +
the O +
high O +
risk O +
surgery O +
subgroups O +
( O -
7.9 O -
% O +
vs O +
1.2 O -
% O -
, O +
P O +
= O +
0.003 O -
; O +
7.3 O -
% O +
vs O +
2.4 O -
% O -
, O +
P O +
= O +
0.035 O -
, O +
respectively O -
) O -
. O -

Persistent O +
atrial O +
fibrillation O +
( O -
7.9 O -
% O +
vs O +
2.3 O -
% O -
, O +
P O +
= O +
0.020 O -
) O +
and O +
renal B-Disease +
failure L-Disease +
( O -
9.7 O -
% O +
vs O +
1.7 O -
% O -
, O +
P O +
= O +
0.002 O -
) O +
were O +
also O +
more O +
common O +
in O +
Group O +
T O -
, O +
in O +
the O +
primary O +
valve O +
surgery O +
subgroup O -
. O -

On O +
the O +
contrary O -
, O +
among O +
primary O +
coronary O +
artery O +
bypass O +
surgery O +
patients O -
, O +
there O +
were O +
more O +
acute O +
myocardial B-Disease +
infarctions L-Disease +
and O +
renal B-Disease +
dysfunction L-Disease +
in O +
Group O +
A O +
( O -
5.8 O -
% O +
vs O +
2.0 O -
% O -
, O +
P O +
= O +
0.027 O -
; O +
22.5 O -
% O +
vs O +
15.2 O -
% O -
, O +
P O +
= O +
0.036 O -
, O +
respectively O -
) O -
. O -

The O +
1-yr O +
mortality O +
was O +
significantly O +
higher O +
after O +
aprotinin O +
treatment O +
in O +
the O +
high O +
risk O +
surgery O +
group O +
( O -
17.7 O -
% O +
vs O +
9.8 O -
% O -
, O +
P O +
= O +
0.034 O -
) O -
. O -

CONCLUSION O -
: O +
Both O +
antifibrinolytic O +
drugs O +
bear O +
the O +
risk O +
of O +
adverse O +
outcome O +
depending O +
on O +
the O +
type O +
of O +
cardiac O +
surgery O -
. O -

Administration O +
of O +
aprotinin O +
should O +
be O +
avoided O +
in O +
coronary O +
artery O +
bypass O +
graft O +
and O +
high O +
risk O +
patients O -
, O +
whereas O +
administration O +
of O +
tranexamic O +
acid O +
is O +
not O +
recommended O +
in O +
valve O +
surgery O -
. O -

Delirium U-Disease +
in O +
an O +
elderly O +
woman O +
possibly O +
associated O +
with O +
administration O +
of O +
misoprostol O -
. O -

Misoprostol O +
has O +
been O +
associated O +
with O +
adverse O +
reactions O -
, O +
including O +
gastrointestinal O +
symptoms O -
, O +
gynecologic O +
problems O -
, O +
and O +
headache U-Disease -
. O -

Changes O +
in O +
mental O +
status O -
, O +
however O -
, O +
have O +
not O +
been O +
reported O -
. O -

We O +
present O +
a O +
case O +
in O +
which O +
an O +
89-year O -
- O -
old O +
woman O +
in O +
a O +
long O -
- O -
term O +
care O +
facility O +
became O +
confused O +
after O +
the O +
initiation O +
of O +
misoprostol O +
therapy O -
. O -

The O +
patient O -
's O +
change O +
in O +
mental O +
status O +
was O +
first O +
reported O +
nine O +
days O +
after O +
the O +
initiation O +
of O +
therapy O -
. O -

Her O +
delirium U-Disease +
significantly O +
improved O +
after O +
misoprostol O +
was O +
discontinued O +
and O +
her O +
mental O +
status O +
returned O +
to O +
normal O +
within O +
a O +
week O -
. O -

Because O +
no O +
other O +
factors O +
related O +
to O +
this O +
patient O +
changed O +
significantly O -
, O +
the O +
delirium U-Disease +
experienced O +
by O +
this O +
patient O +
possibly O +
resulted O +
from O +
misoprostol O +
therapy O -
. O -

The O +
biological O +
properties O +
of O +
the O +
optical O +
isomers O +
of O +
propranolol O +
and O +
their O +
effects O +
on O +
cardiac B-Disease +
arrhythmias L-Disease -
. O -

1 O -
. O -

The O +
optical O +
isomers O +
of O +
propranolol O +
have O +
been O +
compared O +
for O +
their O +
beta O -
- O -
blocking O +
and O +
antiarrhythmic O +
activities.2 O -
. O -

In O +
blocking O +
the O +
positive O +
inotropic O +
and O +
chronotropic O +
responses O +
to O +
isoprenaline O -
, O +
( O -
+ O -
) O -
-propranolol O +
had O +
less O +
than O +
one O +
hundredth O +
the O +
potency O +
of O +
( O -
- O -
) O -
-propranolol O -
. O -

At O +
dose O +
levels O +
of O +
( O -
+ O -
) O -
-propranolol O +
which O +
attenuated O +
the O +
responses O +
to O +
isoprenaline O -
, O +
there O +
was O +
a O +
significant O +
prolongation O +
of O +
the O +
PR O +
interval O +
of O +
the O +
electrocardiogram.3 O -
. O -

The O +
metabolic O +
responses O +
to O +
isoprenaline O +
in O +
dogs O +
( O -
an O +
increase O +
in O +
circulating O +
glucose O -
, O +
lactate O +
and O +
free O +
fatty O +
acids O -
) O +
were O +
all O +
blocked O +
by O +
( O -
- O -
) O -
-propranolol O -
. O -

( O -
+ O -
) O -
-Propranolol O +
had O +
no O +
effect O +
on O +
fatty O +
acid O +
mobilization O +
but O +
significantly O +
reduced O +
the O +
increments O +
in O +
both O +
lactate O +
and O +
glucose.4 O -
. O -

Both O +
isomers O +
of O +
propranolol O +
possessed O +
similar O +
depressant O +
potency O +
on O +
isolated O +
atrial O +
muscle O +
taken O +
from O +
guinea O -
- O -
pigs.5 O -
. O -

The O +
isomers O +
of O +
propranolol O +
exhibited O +
similar O +
local O +
anaesthetic O +
potencies O +
on O +
an O +
isolated O +
frog O +
nerve O +
preparation O +
at O +
a O +
level O +
approximately O +
three O +
times O +
that O +
of O +
procaine O -
. O -

The O +
racemic O +
compound O +
was O +
significantly O +
less O +
potent O +
than O +
either O +
isomer.6 O -
. O -

Both O +
isomers O +
of O +
propranolol O +
were O +
capable O +
of O +
preventing O +
adrenaline O -
- O -
induced O +
cardiac B-Disease +
arrhythmias L-Disease +
in O +
cats O +
anaesthetized O +
with O +
halothane O -
, O +
but O +
the O +
mean O +
dose O +
of O +
( O -
- O -
) O -
-propranolol O +
was O +
0.09+ O -
/ O -
-0.02 O +
mg O -
/ O -
kg O +
whereas O +
that O +
of O +
( O -
+ O -
) O -
-propranolol O +
was O +
4.2+ O -
/ O -
-1.2 O +
mg O -
/ O -
kg O -
. O -

At O +
the O +
effective O +
dose O +
level O +
of O +
( O -
+ O -
) O -
-propranolol O +
there O +
was O +
a O +
significant O +
prolongation O +
of O +
the O +
PR O +
interval O +
of O +
the O +
electrocardiogram O -
. O -

Blockade O +
of O +
arrhythmias U-Disease +
with O +
both O +
isomers O +
was O +
surmountable O +
by O +
increasing O +
the O +
dose O +
of O +
adrenaline.7 O -
. O -

Both O +
isomers O +
of O +
propranolol O +
were O +
also O +
capable O +
of O +
reversing O +
ventricular B-Disease +
tachycardia L-Disease +
caused O +
by O +
ouabain O +
in O +
anaesthetized O +
cats O +
and O +
dogs O -
. O -

The O +
dose O +
of O +
( O -
- O -
) O -
-propranolol O +
was O +
significantly O +
smaller O +
than O +
that O +
of O +
( O -
+ O -
) O -
-propranolol O +
in O +
both O +
species O +
but O +
much O +
higher O +
than O +
that O +
required O +
to O +
produce O +
evidence O +
of O +
beta O -
- O -
blockade.8 O -
. O -

The O +
implications O +
of O +
these O +
results O +
are O +
discussed O -
. O -

Topotecan O +
in O +
combination O +
with O +
radiotherapy O +
in O +
unresectable O +
glioblastoma U-Disease -
: O +
a O +
phase O +
2 O +
study O -
. O -

Improving O +
glioblastoma B-Disease +
multiforme L-Disease +
( O -
GBM U-Disease -
) O +
treatment O +
with O +
radio O -
- O -
chemotherapy O +
remains O +
a O +
challenge O -
. O -

Topotecan O +
is O +
an O +
attractive O +
option O +
as O +
it O +
exhibits O +
growth O +
inhibition O +
of O +
human O +
glioma U-Disease +
as O +
well O +
as O +
brain O +
penetration O -
. O -

The O +
present O +
study O +
assessed O +
the O +
combination O +
of O +
radiotherapy O +
( O -
60 O +
Gy O -
/ O -
30 O +
fractions O -
/ O -
40 O +
days O -
) O +
and O +
topotecan O +
( O -
0.9 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
/ O -
day O +
on O +
days O +
1 O -
- O -
5 O +
on O +
weeks O +
1 O -
, O +
3 O +
and O +
5 O -
) O +
in O +
50 O +
adults O +
with O +
histologically O +
proven O +
and O +
untreated O +
GBM U-Disease -
. O -

The O +
incidence O +
of O +
non O -
- O -
hematological O +
toxicities U-Disease +
was O +
low O +
and O +
grade O +
3 O -
- O -
4 O +
hematological O +
toxicities U-Disease +
were O +
reported O +
in O +
20 O +
patients O +
( O -
mainly O +
lymphopenia U-Disease +
and O +
neutropenia U-Disease -
) O -
. O -

Partial O +
response O +
and O +
stabilization O +
rates O +
were O +
2 O -
% O +
and O +
32 O -
% O -
, O +
respectively O -
, O +
with O +
an O +
overall O +
time O +
to O +
progression O +
of O +
12 O +
weeks O -
. O -

One O -
- O -
year O +
overall O +
survival O +
( O -
OS O -
) O +
rate O +
was O +
42 O -
% O -
, O +
with O +
a O +
median O +
OS O +
of O +
40 O +
weeks O -
. O -

Topotecan O +
in O +
combination O +
with O +
radiotherapy O +
was O +
well O +
tolerated O -
. O -

However O -
, O +
while O +
response O +
and O +
stabilization O +
concerned O +
one O -
- O -
third O +
of O +
the O +
patients O -
, O +
the O +
study O +
did O +
not O +
show O +
increased O +
benefits O +
in O +
terms O +
of O +
survival O +
in O +
patients O +
with O +
unresectable O +
GBM U-Disease -
. O -

Long O -
- O -
term O +
lithium O +
therapy O +
leading O +
to O +
hyperparathyroidism U-Disease -
: O +
a O +
case O +
report O -
. O -

PURPOSE O -
: O +
This O +
paper O +
reviews O +
the O +
effect O +
of O +
chronic O +
lithium O +
therapy O +
on O +
serum O +
calcium O +
level O +
and O +
parathyroid O +
glands O -
, O +
its O +
pathogenesis O -
, O +
and O +
treatment O +
options O -
. O -

We O +
examined O +
the O +
case O +
of O +
a O +
lithium O -
- O -
treated O +
patient O +
who O +
had O +
recurrent O +
hypercalcemia U-Disease +
to O +
better O +
understand O +
the O +
disease O +
process O -
. O -

CONCLUSION O -
: O +
Primary B-Disease +
hyperparathyroidism L-Disease +
is O +
a O +
rare O +
but O +
potentially O +
life O -
- O -
threatening O +
side O +
effect O +
of O +
long O -
- O -
term O +
lithium O +
therapy O -
. O -

Careful O +
patient O +
selection O +
and O +
long O -
- O -
term O +
follow O -
- O -
up O +
can O +
reduce O +
morbidity O -
. O -

PRACTICAL O +
IMPLICATIONS O -
: O +
As O +
much O +
as O +
15 O -
% O +
of O +
lithium O -
- O -
treated O +
patients O +
become O +
hypercalcemic U-Disease -
. O -

By O +
routinely O +
monitoring O +
serum O +
calcium O +
levels O -
, O +
healthcare O +
providers O +
can O +
improve O +
the O +
quality O +
of O +
life O +
of O +
this O +
patient O +
group O -
. O -

Comparison O +
of O +
laryngeal O +
mask O +
with O +
endotracheal O +
tube O +
for O +
anesthesia O +
in O +
endoscopic O +
sinus O +
surgery O -
. O -

BACKGROUND O -
: O +
The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
compare O +
surgical O +
conditions O -
, O +
including O +
the O +
amount O +
of O +
intraoperative O +
bleeding U-Disease +
as O +
well O +
as O +
intraoperative O +
blood O +
pressure O -
, O +
during O +
functional O +
endoscopic O +
sinus O +
surgery O +
( O -
FESS O -
) O +
using O +
flexible O +
reinforced O +
laryngeal O +
mask O +
airway O +
( O -
FRLMA O -
) O +
versus O +
endotracheal O +
tube O +
( O -
ETT O -
) O +
in O +
maintaining O +
controlled O +
hypotension U-Disease +
anesthesia O +
induced O +
by O +
propofol O -
- O -
remifentanil O +
total O +
i.v O -
. O -

anesthesia O +
( O -
TIVA O -
) O -
. O -

METHODS O -
: O +
Sixty O +
normotensive O +
American O +
Society O +
of O +
Anesthesiologists O +
I O -
- O -
II O +
adult O +
patients O +
undergoing O +
FESS O +
under O +
controlled O +
hypotension U-Disease +
anesthesia O +
caused O +
by O +
propofol O -
- O -
remifentanil O -
- O -
TIVA O +
were O +
randomly O +
assigned O +
into O +
two O +
groups O -
: O +
group O +
I O -
, O +
FRLMA O -
; O +
group O +
II O -
, O +
ETT O -
. O -

Hemorrhage U-Disease +
was O +
measured O +
and O +
the O +
visibility O +
of O +
the O +
operative O +
field O +
was O +
evaluated O +
according O +
to O +
a O +
six O -
- O -
point O +
scale O -
. O -

RESULTS O -
: O +
Controlled O +
hypotension U-Disease +
was O +
achieved O +
within O +
a O +
shorter O +
period O +
using O +
laryngeal O +
mask O +
using O +
lower O +
rates O +
of O +
remifentanil O +
infusion O +
and O +
lower O +
total O +
dose O +
of O +
remifentanil O -
. O -

CONCLUSION O -
: O +
In O +
summary O -
, O +
our O +
results O +
indicate O +
that O +
airway O +
management O +
using O +
FRLMA O +
during O +
controlled O +
hypotension U-Disease +
anesthesia O +
provided O +
better O +
surgical O +
conditions O +
in O +
terms O +
of O +
quality O +
of O +
operative O +
field O +
and O +
blood O +
loss O +
and O +
allowed O +
for O +
convenient O +
induced O +
hypotension U-Disease +
with O +
low O +
doses O +
of O +
remifentanil O +
during O +
TIVA O +
in O +
patients O +
undergoing O +
FESS O -
. O -

Nonalcoholic B-Disease +
fatty I-Disease +
liver I-Disease +
disease L-Disease +
during O +
valproate O +
therapy O -
. O -

Valproic O +
acid O +
( O -
VPA O -
) O +
is O +
effective O +
for O +
the O +
treatment O +
of O +
many O +
types O +
of O +
epilepsy U-Disease -
, O +
but O +
its O +
use O +
can O +
be O +
associated O +
with O +
an O +
increase O +
in O +
body O +
weight O -
. O -

We O +
report O +
a O +
case O +
of O +
nonalcoholic B-Disease +
fatty I-Disease +
liver I-Disease +
disease L-Disease +
( O -
NAFLD U-Disease -
) O +
arising O +
in O +
a O +
child O +
who O +
developed O +
obesity U-Disease +
during O +
VPA O +
treatment O -
. O -

Laboratory O +
data O +
revealed O +
hyperinsulinemia U-Disease +
with O +
insulin B-Disease +
resistance L-Disease -
. O -

After O +
the O +
withdrawal O +
of O +
VPA O +
therapy O -
, O +
our O +
patient O +
showed O +
a O +
significant O +
weight B-Disease +
loss L-Disease -
, O +
a O +
decrease O +
of O +
body O +
mass O +
index O -
, O +
and O +
normalization O +
of O +
metabolic O +
and O +
endocrine O +
parameters O -
; O +
moreover O -
, O +
ultrasound O +
measurements O +
showed O +
a O +
complete O +
normalization O -
. O -

The O +
present O +
case O +
suggests O +
that O +
obesity U-Disease -
, O +
hyperinsulinemia U-Disease -
, O +
insulin B-Disease +
resistance L-Disease -
, O +
and O +
long O -
- O -
term O +
treatment O +
with O +
VPA O +
may O +
be O +
all O +
associated O +
with O +
the O +
development O +
of O +
NAFLD U-Disease -
; O +
this O +
side O +
effect O +
is O +
reversible O +
after O +
VPA O +
withdrawal O -
. O -

Carbimazole O +
induced O +
ANCA B-Disease +
positive I-Disease +
vasculitis L-Disease -
. O -

Anti O -
- O -
thyroid O +
drugs O -
, O +
like O +
carbimazole O +
and O +
propylthiouracil O +
( O -
PTU O -
) O +
are O +
commonly O +
prescribed O +
for O +
the O +
treatment O +
of O +
hyperthyroidism U-Disease -
. O -

One O +
should O +
be O +
aware O +
of O +
the O +
side O +
effects O +
of O +
antithyroid O +
medications O -
. O -

Antineutrophil B-Disease +
cytoplasmic I-Disease +
antibody I-Disease +
( I-Disease -
ANCA I-Disease -
) I-Disease -
--associated I-Disease +
vasculitis L-Disease +
is O +
a O +
potentially O +
life O -
- O -
threatening O +
adverse O +
effect O +
of O +
antithyroidmedications O -
. O -

We O +
report O +
a O +
patient O +
with O +
Graves B-Disease -
' I-Disease +
disease L-Disease +
who O +
developed O +
ANCA O +
positive O +
carbimazole O +
induced O +
vasculitis U-Disease -
. O -

The O +
episode O +
was O +
characterized O +
by O +
a O +
vasculitic U-Disease +
skin B-Disease +
rash L-Disease +
associated O +
with O +
large O +
joint O +
arthritis U-Disease -
, O +
pyrexia U-Disease +
and O +
parotiditis U-Disease +
but O +
no O +
renal O +
or O +
pulmonary O +
involvement O -
. O -

He O +
was O +
referred O +
to O +
us O +
for O +
neurological O +
evaluation O +
because O +
he O +
had O +
difficulty O +
in O +
getting O +
up O +
from O +
squatting O +
position O +
and O +
was O +
suspected O +
to O +
have O +
myositis U-Disease -
. O -

Carbimazole O +
and O +
methimazole O +
have O +
a O +
lower O +
incidence O +
of O +
reported O +
ANCA O +
positive O +
side O +
effects O +
than O +
PUT O -
. O -

To O +
the O +
best O +
of O +
our O +
knowledge O +
this O +
is O +
the O +
first O +
ANCA O +
positive O +
carbimazole O +
induced O +
vasculitis U-Disease +
case O +
reported O +
from O +
India O -
. O -

Aspirin O +
for O +
the O +
primary O +
prevention O +
of O +
cardiovascular O +
events O -
: O +
an O +
update O +
of O +
the O +
evidence O +
for O +
the O +
U.S. O +
Preventive O +
Services O +
Task O +
Force O -
. O -

BACKGROUND O -
: O +
Coronary B-Disease +
heart I-Disease +
disease L-Disease +
and O +
cerebrovascular B-Disease +
disease L-Disease +
are O +
leading O +
causes O +
of O +
death O +
in O +
the O +
United O +
States O -
. O -

In O +
2002 O -
, O +
the O +
U.S. O +
Preventive O +
Services O +
Task O +
Force O +
( O -
USPSTF O -
) O +
strongly O +
recommended O +
that O +
clinicians O +
discuss O +
aspirin O +
with O +
adults O +
who O +
are O +
at O +
increased O +
risk O +
for O +
coronary B-Disease +
heart I-Disease +
disease L-Disease -
. O -

PURPOSE O -
: O +
To O +
determine O +
the O +
benefits O +
and O +
harms O +
of O +
taking O +
aspirin O +
for O +
the O +
primary O +
prevention O +
of O +
myocardial B-Disease +
infarctions L-Disease -
, O +
strokes U-Disease -
, O +
and O +
death O -
. O -

DATA O +
SOURCES O -
: O +
MEDLINE O +
and O +
Cochrane O +
Library O +
( O -
search O +
dates O -
, O +
1 O +
January O +
2001 O +
to O +
28 O +
August O +
2008 O -
) O -
, O +
recent O +
systematic O +
reviews O -
, O +
reference O +
lists O +
of O +
retrieved O +
articles O -
, O +
and O +
suggestions O +
from O +
experts O -
. O -

STUDY O +
SELECTION O -
: O +
English O -
- O -
language O +
randomized O -
, O +
controlled O +
trials O +
( O -
RCTs O -
) O -
; O +
case O -
- O -
control O +
studies O -
; O +
meta O -
- O -
analyses O -
; O +
and O +
systematic O +
reviews O +
of O +
aspirin O +
versus O +
control O +
for O +
the O +
primary O +
prevention O +
of O +
cardiovascular B-Disease +
disease L-Disease +
( O -
CVD U-Disease -
) O +
were O +
selected O +
to O +
answer O +
the O +
following O +
questions O -
: O +
Does O +
aspirin O +
decrease O +
coronary O +
heart O +
events O -
, O +
strokes U-Disease -
, O +
death O +
from O +
coronary O +
heart O +
events O +
or O +
stroke U-Disease -
, O +
or O +
all O -
- O -
cause O +
mortality O +
in O +
adults O +
without O +
known O +
CVD U-Disease -
? O -

Does O +
aspirin O +
increase O +
gastrointestinal B-Disease +
bleeding L-Disease +
or O +
hemorrhagic U-Disease +
strokes U-Disease -
? O -

DATA O +
EXTRACTION O -
: O +
All O +
studies O +
were O +
reviewed O -
, O +
abstracted O -
, O +
and O +
rated O +
for O +
quality O +
by O +
using O +
predefined O +
USPSTF O +
criteria O -
. O -

DATA O +
SYNTHESIS O -
: O +
New O +
evidence O +
from O +
1 O +
good O -
- O -
quality O +
RCT O -
, O +
1 O +
good O -
- O -
quality O +
meta O -
- O -
analysis O -
, O +
and O +
2 O +
fair O -
- O -
quality O +
subanalyses O +
of O +
RCTs O +
demonstrates O +
that O +
aspirin O +
use O +
reduces O +
the O +
number O +
of O +
CVD U-Disease +
events O +
in O +
patients O +
without O +
known O +
CVD U-Disease -
. O -

Men O +
in O +
these O +
studies O +
experienced O +
fewer O +
myocardial B-Disease +
infarctions L-Disease +
and O +
women O +
experienced O +
fewer O +
ischemic O +
strokes U-Disease -
. O -

Aspirin O +
does O +
not O +
seem O +
to O +
affect O +
CVD U-Disease +
mortality O +
or O +
all O -
- O -
cause O +
mortality O +
in O +
either O +
men O +
or O +
women O -
. O -

The O +
use O +
of O +
aspirin O +
for O +
primary O +
prevention O +
increases O +
the O +
risk O +
for O +
major O +
bleeding U-Disease +
events O -
, O +
primarily O +
gastrointestinal B-Disease +
bleeding L-Disease +
events O -
, O +
in O +
both O +
men O +
and O +
women O -
. O -

Men O +
have O +
an O +
increased O +
risk O +
for O +
hemorrhagic U-Disease +
strokes U-Disease +
with O +
aspirin O +
use O -
. O -

A O +
new O +
RCT O +
and O +
meta O -
- O -
analysis O +
suggest O +
that O +
the O +
risk O +
for O +
hemorrhagic U-Disease +
strokes U-Disease +
in O +
women O +
is O +
not O +
statistically O +
significantly O +
increased O -
. O -

LIMITATIONS O -
: O +
New O +
evidence O +
on O +
aspirin O +
for O +
the O +
primary O +
prevention O +
of O +
CVD U-Disease +
is O +
limited O -
. O -

The O +
dose O +
of O +
aspirin O +
used O +
in O +
the O +
RCTs O +
varied O -
, O +
which O +
prevented O +
the O +
estimation O +
of O +
the O +
most O +
appropriate O +
dose O +
for O +
primary O +
prevention O -
. O -

Several O +
of O +
the O +
RCTs O +
were O +
conducted O +
within O +
populations O +
of O +
health O +
professionals O -
, O +
which O +
potentially O +
limits O +
generalizability O -
. O -

CONCLUSION O -
: O +
Aspirin O +
reduces O +
the O +
risk O +
for O +
myocardial B-Disease +
infarction L-Disease +
in O +
men O +
and O +
strokes U-Disease +
in O +
women O -
. O -

Aspirin O +
use O +
increases O +
the O +
risk O +
for O +
serious O +
bleeding U-Disease +
events O -
. O -

Reducing O +
harm O +
associated O +
with O +
anticoagulation O -
: O +
practical O +
considerations O +
of O +
argatroban O +
therapy O +
in O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
. O -

Argatroban O +
is O +
a O +
hepatically O +
metabolized O -
, O +
direct O +
thrombin O +
inhibitor O +
used O +
for O +
prophylaxis O +
or O +
treatment O +
of O +
thrombosis U-Disease +
in O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease +
( O -
HIT U-Disease -
) O +
and O +
for O +
patients O +
with O +
or O +
at O +
risk O +
of O +
HIT U-Disease +
undergoing O +
percutaneous O +
coronary O +
intervention O +
( O -
PCI O -
) O -
. O -

The O +
objective O +
of O +
this O +
review O +
is O +
to O +
summarize O +
practical O +
considerations O +
of O +
argatroban O +
therapy O +
in O +
HIT U-Disease -
. O -

The O +
US O +
FDA O -
- O -
recommended O +
argatroban O +
dose O +
in O +
HIT U-Disease +
is O +
2 O +
microg O -
/ O -
kg O -
/ O -
min O +
( O -
reduced O +
in O +
patients O +
with O +
hepatic B-Disease +
impairment L-Disease +
and O +
in O +
paediatric O +
patients O -
) O -
, O +
adjusted O +
to O +
achieve O +
activated O +
partial O +
thromboplastin O +
times O +
( O -
aPTTs O -
) O +
1.5 O -
- O -
3 O +
times O +
baseline O +
( O -
not O +
> O -
100 O +
seconds O -
) O -
. O -

Contemporary O +
experiences O +
indicate O +
that O +
reduced O +
doses O +
are O +
also O +
needed O +
in O +
patients O +
with O +
conditions O +
associated O +
with O +
hepatic O +
hypoperfusion O -
, O +
e.g. O +
heart B-Disease +
failure L-Disease -
, O +
yet O +
are O +
unnecessary O +
for O +
renal B-Disease +
dysfunction L-Disease -
, O +
adult O +
age O -
, O +
sex O -
, O +
race O -
/ O -
ethnicity O +
or O +
obesity U-Disease -
. O -

Argatroban O +
0.5 O -
- O -
1.2 O +
microg O -
/ O -
kg O -
/ O -
min O +
typically O +
supports O +
therapeutic O +
aPTTs O -
. O -

The O +
FDA O -
- O -
recommended O +
dose O +
during O +
PCI O +
is O +
25 O +
microg O -
/ O -
kg O -
/ O -
min O +
( O -
350 O +
microg O -
/ O -
kg O +
initial O +
bolus O -
) O -
, O +
adjusted O +
to O +
achieve O +
activated O +
clotting O +
times O +
( O -
ACTs O -
) O +
of O +
300 O -
- O -
450 O +
sec. O +
For O +
PCI O -
, O +
argatroban O +
has O +
not O +
been O +
investigated O +
in O +
hepatically O +
impaired O +
patients O -
; O +
dose O +
adjustment O +
is O +
unnecessary O +
for O +
adult O +
age O -
, O +
sex O -
, O +
race O -
/ O -
ethnicity O +
or O +
obesity U-Disease -
, O +
and O +
lesser O +
doses O +
may O +
be O +
adequate O +
with O +
concurrent O +
glycoprotein O +
IIb O -
/ O -
IIIa O +
inhibition O -
. O -

Argatroban O +
prolongs O +
the O +
International O +
Normalized O +
Ratio O -
, O +
and O +
published O +
approaches O +
for O +
monitoring O +
the O +
argatroban O -
- O -
to O -
- O -
warfarin O +
transition O +
should O +
be O +
followed O -
. O -

Major O +
bleeding U-Disease +
with O +
argatroban O +
is O +
0 O -
- O -
10 O -
% O +
in O +
the O +
non O -
- O -
interventional O +
setting O +
and O +
0 O -
- O -
5.8 O -
% O +
periprocedurally O -
. O -

Argatroban O +
has O +
no O +
specific O +
antidote O -
, O +
and O +
if O +
excessive O +
anticoagulation O +
occurs O -
, O +
argatroban O +
infusion O +
should O +
be O +
stopped O +
or O +
reduced O -
. O -

Improved O +
familiarity O +
of O +
healthcare O +
professionals O +
with O +
argatroban O +
therapy O +
in O +
HIT U-Disease -
, O +
including O +
in O +
special O +
populations O +
and O +
during O +
PCI O -
, O +
may O +
facilitate O +
reduction O +
of O +
harm O +
associated O +
with O +
HIT U-Disease +
( O -
e.g. O +
fewer O +
thromboses O -
) O +
or O +
its O +
treatment O +
( O -
e.g. O +
fewer O +
argatroban O +
medication O +
errors O -
) O -
. O -

Rhabdomyolysis U-Disease +
and O +
brain O +
ischemic B-Disease +
stroke L-Disease +
in O +
a O +
heroin O -
- O -
dependent O +
male O +
under O +
methadone O +
maintenance O +
therapy O -
. O -

OBJECTIVE O -
: O +
There O +
are O +
several O +
complications O +
associated O +
with O +
heroin B-Disease +
abuse L-Disease -
, O +
some O +
of O +
which O +
are O +
life O -
- O -
threatening O -
. O -

Methadone O +
may O +
aggravate O +
this O +
problem O -
. O -

METHOD O -
: O +
A O +
clinical O +
case O +
description O -
. O -

RESULTS O -
: O +
A O +
33-year O -
- O -
old O +
man O +
presented O +
with O +
rhabdomyolysis U-Disease +
and O +
cerebral O +
ischemic B-Disease +
stroke L-Disease +
after O +
intravenous O +
heroin O -
. O -

He O +
had O +
used O +
heroin O +
since O +
age O +
20 O -
, O +
and O +
had O +
used O +
150 O +
mg O +
methadone O +
daily O +
for O +
6 O +
months O -
. O -

He O +
was O +
found O +
unconsciousness U-Disease +
at O +
home O +
and O +
was O +
sent O +
to O +
our O +
hospital O -
. O -

In O +
the O +
ER O -
, O +
his O +
opiate O +
level O +
was O +
4497 O +
ng O -
/ O -
ml O -
. O -

In O +
the O +
ICU O -
, O +
we O +
found O +
rhabdomyolysis U-Disease -
, O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
and O +
acute O +
respiratory B-Disease +
failure L-Disease -
. O -

After O +
transfer O +
to O +
an O +
internal O +
ward O -
, O +
we O +
noted O +
aphasia U-Disease +
and O +
weakness U-Disease +
of O +
his O +
left O +
limbs O -
. O -

After O +
MRI O -
, O +
we O +
found O +
cerebral B-Disease +
ischemic I-Disease +
infarction L-Disease -
. O -

CONCLUSION O -
: O +
Those O +
using O +
methadone O +
and O +
heroin O +
simultaneously O +
may O +
increase O +
risk O +
of O +
rhabdomyolysis U-Disease +
and O +
ischemic B-Disease +
stroke L-Disease -
. O -

Patients O +
under O +
methadone O +
maintenance O +
therapy O +
should O +
be O +
warned O +
regarding O +
these O +
serious O +
adverse O +
events O -
. O -

Hypotheses O +
of O +
heroin O -
- O -
related O +
rhabdomyolysis U-Disease +
and O +
stroke U-Disease +
in O +
heroin O +
abusers O +
are O +
discussed O -
. O -

Increased O +
vulnerability O +
to O +
6-hydroxydopamine O +
lesion O +
and O +
reduced O +
development O +
of O +
dyskinesias U-Disease +
in O +
mice O +
lacking O +
CB1 O +
cannabinoid O +
receptors O -
. O -

Motor O +
impairment O -
, O +
dopamine O +
( O -
DA O -
) O +
neuronal O +
activity O +
and O +
proenkephalin O +
( O -
PENK O -
) O +
gene O +
expression O +
in O +
the O +
caudate O -
- O -
putamen O +
( O -
CPu O -
) O +
were O +
measured O +
in O +
6-OHDA O -
- O -
lesioned O +
and O +
treated O +
( O -
L O -
- O -
DOPA+benserazide O -
) O +
CB1 O +
KO O +
and O +
WT O +
mice O -
. O -

A O +
lesion O +
induced O +
by O +
6-OHDA O +
produced O +
more O +
severe O +
motor O +
deterioration O +
in O +
CB1 O +
KO O +
mice O +
accompanied O +
by O +
more O +
loss O +
of O +
DA O +
neurons O +
and O +
increased O +
PENK O +
gene O +
expression O +
in O +
the O +
CPu O -
. O -

Oxidative O -
/ O -
nitrosative O +
and O +
neuroinflammatory O +
parameters O +
were O +
estimated O +
in O +
the O +
CPu O +
and O +
cingulate O +
cortex O +
( O -
Cg O -
) O -
. O -

CB1 O +
KO O +
mice O +
exhibited O +
higher O +
MDA O +
levels O +
and O +
iNOS O +
protein O +
expression O +
in O +
the O +
CPu O +
and O +
Cg O +
compared O +
to O +
WT O +
mice O -
. O -

Treatment O +
with O +
L O -
- O -
DOPA+benserazide O +
( O -
12 O +
weeks O -
) O +
resulted O +
in O +
less O +
severe O +
dyskinesias U-Disease +
in O +
CB1 O +
KO O +
than O +
in O +
WT O +
mice O -
. O -

The O +
results O +
revealed O +
that O +
the O +
lack O +
of O +
cannabinoid O +
CB1 O +
receptors O +
increased O +
the O +
severity O +
of O +
motor O +
impairment O +
and O +
DA O +
lesion O -
, O +
and O +
reduced O +
L O -
- O -
DOPA O -
- O -
induced O +
dyskinesias U-Disease -
. O -

These O +
results O +
suggest O +
that O +
activation O +
of O +
CB1 O +
receptors O +
offers O +
neuroprotection O +
against O +
dopaminergic O +
lesion O +
and O +
the O +
development O +
of O +
L O -
- O -
DOPA O -
- O -
induced O +
dyskinesias U-Disease -
. O -

Hepatocellular O +
oxidant O +
stress O +
following O +
intestinal O +
ischemia U-Disease -
- O -
reperfusion B-Disease +
injury L-Disease -
. O -

Reperfusion O +
of O +
ischemic U-Disease +
intestine O +
results O +
in O +
acute O +
liver B-Disease +
dysfunction L-Disease +
characterized O +
by O +
hepatocellular O +
enzyme O +
release O +
into O +
plasma O -
, O +
reduction O +
in O +
bile O +
flow O +
rate O -
, O +
and O +
neutrophil O +
sequestration O +
within O +
the O +
liver O -
. O -

The O +
pathophysiology O +
underlying O +
this O +
acute O +
hepatic B-Disease +
injury L-Disease +
is O +
unknown O -
. O -

This O +
study O +
was O +
undertaken O +
to O +
determine O +
whether O +
oxidants O +
are O +
associated O +
with O +
the O +
hepatic B-Disease +
injury L-Disease +
and O +
to O +
determine O +
the O +
relative O +
value O +
of O +
several O +
indirect O +
methods O +
of O +
assessing O +
oxidant O +
exposure O +
in O +
vivo O -
. O -

Rats O +
were O +
subjected O +
to O +
a O +
standardized O +
intestinal O +
ischemia U-Disease -
- O -
reperfusion B-Disease +
injury L-Disease -
. O -

Hepatic O +
tissue O +
was O +
assayed O +
for O +
lipid O +
peroxidation O +
products O +
and O +
oxidized O +
and O +
reduced O +
glutathione O -
. O -

There O +
was O +
no O +
change O +
in O +
hepatic O +
tissue O +
total O +
glutathione O +
following O +
intestinal O +
ischemia U-Disease -
- O -
reperfusion B-Disease +
injury L-Disease -
. O -

Oxidized O +
glutathione O +
( O -
GSSG O -
) O +
increased O +
significantly O +
following O +
30 O +
and O +
60 O +
min O +
of O +
reperfusion O -
. O -

There O +
was O +
no O +
increase O +
in O +
any O +
of O +
the O +
products O +
of O +
lipid O +
peroxidation O +
associated O +
with O +
this O +
injury O -
. O -

An O +
increase O +
in O +
GSSG O +
within O +
hepatic O +
tissue O +
during O +
intestinal O +
reperfusion O +
suggests O +
exposure O +
of O +
hepatocytes O +
to O +
an O +
oxidant O +
stress O -
. O -

The O +
lack O +
of O +
a O +
significant O +
increase O +
in O +
products O +
of O +
lipid O +
peroxidation O +
suggests O +
that O +
the O +
oxidant O +
stress O +
is O +
of O +
insufficient O +
magnitude O +
to O +
result O +
in O +
irreversible O +
injury O +
to O +
hepatocyte O +
cell O +
membranes O -
. O -

These O +
data O +
also O +
suggest O +
that O +
the O +
measurement O +
of O +
tissue O +
GSSG O +
may O +
be O +
a O +
more O +
sensitive O +
indicator O +
of O +
oxidant O +
stress O +
than O +
measurement O +
of O +
products O +
of O +
lipid O +
peroxidation O -
. O -

Animal O +
model O +
of O +
mania U-Disease +
induced O +
by O +
ouabain O -
: O +
Evidence O +
of O +
oxidative O +
stress O +
in O +
submitochondrial O +
particles O +
of O +
the O +
rat O +
brain O -
. O -

The O +
intracerebroventricular O +
( O -
ICV O -
) O +
administration O +
of O +
ouabain O +
( O -
a O +
Na O -
( O -
+ O -
) O -
/ O -
K O -
( O -
+ O -
) O -
-ATPase O +
inhibitor O -
) O +
in O +
rats O +
has O +
been O +
suggested O +
to O +
mimic O +
some O +
symptoms O +
of O +
human O +
bipolar B-Disease +
mania L-Disease -
. O -

Clinical O +
studies O +
have O +
shown O +
that O +
bipolar B-Disease +
disorder L-Disease +
may O +
be O +
related O +
to O +
mitochondrial B-Disease +
dysfunction L-Disease -
. O -

Herein O -
, O +
we O +
investigated O +
the O +
behavioral O +
and O +
biochemical O +
effects O +
induced O +
by O +
the O +
ICV O +
administration O +
of O +
ouabain O +
in O +
rats O -
. O -

To O +
achieve O +
this O +
aim O -
, O +
the O +
effects O +
of O +
ouabain O +
injection O +
immediately O +
after O +
and O +
7 O +
days O +
following O +
a O +
single O +
ICV O +
administration O +
( O -
at O +
concentrations O +
of O +
10 O -
( O -
-2 O -
) O +
and O +
10 O -
( O -
-3 O -
) O -
M O -
) O +
on O +
locomotion O +
was O +
measured O +
using O +
the O +
open O -
- O -
field O +
test O -
. O -

Additionally O -
, O +
thiobarbituric O +
acid O +
reactive O +
substances O +
( O -
TBARSs O -
) O +
and O +
superoxide O +
production O +
were O +
measured O +
in O +
submitochondrial O +
particles O +
of O +
the O +
prefrontal O +
cortex O -
, O +
hippocampus O -
, O +
striatum O +
and O +
amygdala O -
. O -

Our O +
findings O +
demonstrated O +
that O +
ouabain O +
at O +
10 O -
( O -
-2 O -
) O +
and O +
10 O -
( O -
-3 O -
) O -
M O +
induced O +
hyperlocomotion U-Disease +
in O +
rats O -
, O +
and O +
this O +
response O +
remained O +
up O +
to O +
7 O +
days O +
following O +
a O +
single O +
ICV O +
injection O -
. O -

In O +
addition O -
, O +
we O +
observed O +
that O +
the O +
persistent O +
increase O +
in O +
the O +
rat O +
spontaneous O +
locomotion O +
is O +
associated O +
with O +
increased O +
TBARS O +
levels O +
and O +
superoxide O +
generation O +
in O +
submitochondrial O +
particles O +
in O +
the O +
prefrontal O +
cortex O -
, O +
striatum O +
and O +
amygdala O -
. O -

In O +
conclusion O -
, O +
ouabain O -
- O -
induced O +
mania U-Disease -
- O -
like O +
behavior O +
may O +
provide O +
a O +
useful O +
animal O +
model O +
to O +
test O +
the O +
hypothesis O +
of O +
the O +
involvement O +
of O +
oxidative O +
stress O +
in O +
bipolar B-Disease +
disorder L-Disease -
. O -

Intraoperative O +
dialysis O +
during O +
liver O +
transplantation O +
with O +
citrate O +
dialysate O -
. O -

Liver O +
transplantation O +
for O +
acutely O +
ill O +
patients O +
with O +
fulminant B-Disease +
liver I-Disease +
failure L-Disease +
carries O +
high O +
intraoperative O +
and O +
immediate O +
postoperative O +
risks O -
. O -

These O +
are O +
increased O +
with O +
the O +
presence O +
of O +
concomitant O +
acute B-Disease +
kidney I-Disease +
injury L-Disease +
( O -
AKI U-Disease -
) O +
and O +
intraoperative O +
dialysis O +
is O +
sometimes O +
required O +
to O +
allow O +
the O +
transplant O +
to O +
proceed O -
. O -

The O +
derangements O +
in O +
the O +
procoagulant O +
and O +
anticoagulant O +
pathways O +
during O +
fulminant B-Disease +
liver I-Disease +
failure L-Disease +
can O +
lead O +
to O +
difficulties O +
with O +
anticoagulation O +
during O +
dialysis O -
, O +
especially O +
when O +
continued O +
in O +
the O +
operating O +
room O -
. O -

Systemic O +
anticoagulation O +
is O +
unsafe O +
and O +
regional O +
citrate O +
anticoagulation O +
in O +
the O +
absence O +
of O +
a O +
functional O +
liver O +
carries O +
the O +
risk O +
of O +
citrate O +
toxicity U-Disease -
. O -

Citrate O +
dialysate O -
, O +
a O +
new O +
dialysate O +
with O +
citric O +
acid O +
can O +
be O +
used O +
for O +
anticoagulation O +
in O +
patients O +
who O +
can O -
not O +
tolerate O +
heparin O +
or O +
regional O +
citrate O -
. O -

We O +
report O +
a O +
case O +
of O +
a O +
40-year O -
- O -
old O +
female O +
with O +
acetaminophen O -
- O -
induced O +
fulminant B-Disease +
liver I-Disease +
failure L-Disease +
with O +
associated O +
AKI U-Disease +
who O +
underwent O +
intraoperative O +
dialytic O +
support O +
during O +
liver O +
transplantation O +
anticoagulated O +
with O +
citrate O +
dialysate O +
during O +
the O +
entire O +
procedure O -
. O -

The O +
patient O +
tolerated O +
the O +
procedure O +
well O +
without O +
any O +
signs O +
of O +
citrate O +
toxicity U-Disease +
and O +
maintained O +
adequate O +
anticoagulation O +
for O +
patency O +
of O +
the O +
dialysis O +
circuit O -
. O -

Citrate O +
dialysate O +
is O +
a O +
safe O +
alternative O +
for O +
intradialytic O +
support O +
of O +
liver O +
transplantation O +
in O +
fulminant B-Disease +
liver I-Disease +
failure L-Disease -
. O -

Delirium U-Disease +
in O +
a O +
patient O +
with O +
toxic O +
flecainide O +
plasma O +
concentrations O -
: O +
the O +
role O +
of O +
a O +
pharmacokinetic O +
drug O +
interaction O +
with O +
paroxetine O -
. O -

OBJECTIVE O -
: O +
To O +
describe O +
a O +
case O +
of O +
flecainide O -
- O -
induced O +
delirium U-Disease +
associated O +
with O +
a O +
pharmacokinetic O +
drug O +
interaction O +
with O +
paroxetine O -
. O -

CASE O +
SUMMARY O -
: O +
A O +
69-year O -
- O -
old O +
white O +
female O +
presented O +
to O +
the O +
emergency O +
department O +
with O +
a O +
history O +
of O +
confusion U-Disease +
and O +
paranoia U-Disease +
over O +
the O +
past O +
several O +
days O -
. O -

On O +
admission O +
the O +
patient O +
was O +
taking O +
carvedilol O +
12 O +
mg O +
twice O +
daily O -
, O +
warfarin O +
2 O +
mg O -
/ O -
day O -
, O +
folic O +
acid O +
1 O +
mg O -
/ O -
day O -
, O +
levothyroxine O +
100 O +
microg O -
/ O -
day O -
, O +
pantoprazole O +
40 O +
mg O -
/ O -
day O -
, O +
paroxetine O +
40 O +
mg O -
/ O -
day O -
, O +
and O +
flecainide O +
100 O +
mg O +
twice O +
daily O -
. O -

Flecainide O +
had O +
been O +
started O +
2 O +
weeks O +
prior O +
for O +
atrial B-Disease +
fibrillation L-Disease -
. O -

Laboratory O +
test O +
findings O +
on O +
admission O +
were O +
notable O +
only O +
for O +
a O +
flecainide O +
plasma O +
concentration O +
of O +
1360 O +
microg O -
/ O -
L O +
( O -
reference O +
range O +
200 O -
- O -
1000 O -
) O -
. O -

A O +
metabolic O +
drug O +
interaction O +
between O +
flecainide O +
and O +
paroxetine O -
, O +
which O +
the O +
patient O +
had O +
been O +
taking O +
for O +
more O +
than O +
5 O +
years O -
, O +
was O +
considered O -
. O -

Paroxetine O +
was O +
discontinued O +
and O +
the O +
dose O +
of O +
flecainide O +
was O +
reduced O +
to O +
50 O +
mg O +
twice O +
daily O -
. O -

Her O +
delirium U-Disease +
resolved O +
3 O +
days O +
later O -
. O -

DISCUSSION O -
: O +
Flecainide O +
and O +
pharmacologically O +
similar O +
agents O +
that O +
interact O +
with O +
sodium O +
channels O +
may O +
cause O +
delirium U-Disease +
in O +
susceptible O +
patients O -
. O -

A O +
MEDLINE O +
search O +
( O -
1966-January O +
2009 O -
) O +
revealed O +
one O +
in O +
vivo O +
pharmacokinetic O +
study O +
on O +
the O +
interaction O +
between O +
flecainide O -
, O +
a O +
CYP2D6 O +
substrate O -
, O +
and O +
paroxetine O -
, O +
a O +
CYP2D6 O +
inhibitor O -
, O +
as O +
well O +
as O +
3 O +
case O +
reports O +
of O +
flecainide O -
- O -
induced O +
delirium U-Disease -
. O -

According O +
to O +
the O +
Naranjo O +
probability O +
scale O -
, O +
flecainide O +
was O +
the O +
probable O +
cause O +
of O +
the O +
patient O -
's O +
delirium U-Disease -
; O +
the O +
Horn O +
Drug O +
Interaction O +
Probability O +
Scale O +
indicates O +
a O +
possible O +
pharmacokinetic O +
drug O +
interaction O +
between O +
flecainide O +
and O +
paroxetine O -
. O -

CONCLUSIONS O -
: O +
Supratherapeutic O +
flecainide O +
plasma O +
concentrations O +
may O +
cause O +
delirium U-Disease -
. O -

Because O +
toxicity U-Disease +
may O +
occur O +
when O +
flecainide O +
is O +
prescribed O +
with O +
paroxetine O +
and O +
other O +
potent O +
CYP2D6 O +
inhibitors O -
, O +
flecainide O +
plasma O +
concentrations O +
should O +
be O +
monitored O +
closely O +
with O +
commencement O +
of O +
CYP2D6 O +
inhibitors O -
. O -

Efficacy O +
of O +
everolimus O +
( O -
RAD001 O -
) O +
in O +
patients O +
with O +
advanced O +
NSCLC U-Disease +
previously O +
treated O +
with O +
chemotherapy O +
alone O +
or O +
with O +
chemotherapy O +
and O +
EGFR O +
inhibitors O -
. O -

BACKGROUND O -
: O +
Treatment O +
options O +
are O +
scarce O +
in O +
pretreated O +
advanced O +
non B-Disease -
- I-Disease -
small I-Disease -
- I-Disease -
cell I-Disease +
lung I-Disease +
cancer L-Disease +
( O -
NSCLC U-Disease -
) O +
patients O -
. O -

RAD001 O -
, O +
an O +
oral O +
inhibitor O +
of O +
the O +
mammalian O +
target O +
of O +
rapamycin O +
( O -
mTOR O -
) O -
, O +
has O +
shown O +
phase O +
I O +
efficacy O +
in O +
NSCLC U-Disease -
. O -

METHODS O -
: O +
Stage O +
IIIb O +
or O +
IV O +
NSCLC U-Disease +
patients O -
, O +
with O +
two O +
or O +
fewer O +
prior O +
chemotherapy O +
regimens O -
, O +
one O +
platinum O +
based O +
( O -
stratum O +
1 O -
) O +
or O +
both O +
chemotherapy O +
and O +
epidermal O +
growth O +
factor O +
receptor O +
tyrosine O +
kinase O +
inhibitors O +
( O -
stratum O +
2 O -
) O -
, O +
received O +
RAD001 O +
10 O +
mg O -
/ O -
day O +
until O +
progression O +
or O +
unacceptable O +
toxicity U-Disease -
. O -

Primary O +
objective O +
was O +
overall O +
response O +
rate O +
( O -
ORR O -
) O -
. O -

Analyses O +
of O +
markers O +
associated O +
with O +
the O +
mTOR O +
pathway O +
were O +
carried O +
out O +
on O +
archival O +
tumor U-Disease +
from O +
a O +
subgroup O +
using O +
immunohistochemistry O +
( O -
IHC O -
) O +
and O +
direct O +
mutation O +
sequencing O -
. O -

RESULTS O -
: O +
Eighty O -
- O -
five O +
patients O +
were O +
enrolled O -
, O +
42 O +
in O +
stratum O +
1 O +
and O +
43 O +
in O +
stratum O -
. O -

ORR O +
was O +
4.7 O -
% O +
( O -
7.1 O -
% O +
stratum O +
1 O -
; O +
2.3 O -
% O +
stratum O +
2 O -
) O -
. O -

Overall O +
disease O +
control O +
rate O +
was O +
47.1 O -
% O -
. O -

Median O +
progression O -
- O -
free O +
survivals O +
( O -
PFSs O -
) O +
were O +
2.6 O +
( O -
stratum O +
1 O -
) O +
and O +
2.7 O +
months O +
( O -
stratum O +
2 O -
) O -
. O -

Common O +
> O +
or O +
= O -
grade O +
3 O +
events O +
were O +
fatigue U-Disease -
, O +
dyspnea U-Disease -
, O +
stomatitis U-Disease -
, O +
anemia U-Disease -
, O +
and O +
thrombocytopenia U-Disease -
. O -

Pneumonitis U-Disease -
, O +
probably O +
or O +
possibly O +
related O -
, O +
mainly O +
grade O +
1 O -
/ O -
2 O -
, O +
occurred O +
in O +
25 O -
% O -
. O -

Cox O +
regression O +
analysis O +
of O +
IHC O +
scores O +
found O +
that O +
only O +
phospho O +
AKT O +
( O -
pAKT O -
) O +
was O +
a O +
significant O +
independent O +
predictor O +
of O +
worse O +
PFS O -
. O -

CONCLUSIONS O -
: O +
RAD001 O +
10 O +
mg O -
/ O -
day O +
was O +
well O +
tolerated O -
, O +
showing O +
modest O +
clinical O +
activity O +
in O +
pretreated O +
NSCLC U-Disease -
. O -

Evaluation O +
of O +
RAD001 O +
plus O +
standard O +
therapy O +
for O +
metastatic O +
NSCLC U-Disease +
continues O -
. O -

Posttransplant O +
anemia U-Disease -
: O +
the O +
role O +
of O +
sirolimus O -
. O -

Posttransplant O +
anemia U-Disease +
is O +
a O +
common O +
problem O +
that O +
may O +
hinder O +
patients O -
' O +
quality O +
of O +
life O -
. O -

It O +
occurs O +
in O +
12 O +
to O +
76 O -
% O +
of O +
patients O -
, O +
and O +
is O +
most O +
common O +
in O +
the O +
immediate O +
posttransplant O +
period O -
. O -

A O +
variety O +
of O +
factors O +
have O +
been O +
identified O +
that O +
increase O +
the O +
risk O +
of O +
posttransplant O +
anemia U-Disease -
, O +
of O +
which O +
the O +
level O +
of O +
renal O +
function O +
is O +
most O +
important O -
. O -

Sirolimus O -
, O +
a O +
mammalian O +
target O +
of O +
rapamycin O +
inhibitor O -
, O +
has O +
been O +
implicated O +
as O +
playing O +
a O +
special O +
role O +
in O +
posttransplant O +
anemia U-Disease -
. O -

This O +
review O +
considers O +
anemia U-Disease +
associated O +
with O +
sirolimus O -
, O +
including O +
its O +
presentation O -
, O +
mechanisms O -
, O +
and O +
management O -
. O -

Coronary O +
computerized O +
tomography O +
angiography O +
for O +
rapid O +
discharge O +
of O +
low O -
- O -
risk O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
. O -

BACKGROUND O -
: O +
Most O +
patients O +
presenting O +
to O +
emergency O +
departments O +
( O -
EDs O -
) O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease +
are O +
admitted O +
for O +
at O +
least O +
12 O +
hours O +
and O +
receive O +
a O +
" O -
rule O +
out O +
acute B-Disease +
coronary I-Disease +
syndrome L-Disease -
" O +
protocol O -
, O +
often O +
with O +
noninvasive O +
testing O +
prior O +
to O +
discharge O -
. O -

In O +
patients O +
without O +
cocaine O +
use O -
, O +
coronary O +
computerized O +
tomography O +
angiography O +
( O -
CTA O -
) O +
has O +
been O +
shown O +
to O +
be O +
useful O +
for O +
identifying O +
a O +
group O +
of O +
patients O +
at O +
low O +
risk O +
for O +
cardiac O +
events O +
who O +
can O +
be O +
safely O +
discharged O -
. O -

It O +
is O +
unclear O +
whether O +
a O +
coronary O +
CTA O +
strategy O +
would O +
be O +
efficacious O +
in O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease -
, O +
as O +
coronary B-Disease +
vasospasm L-Disease +
may O +
account O +
for O +
some O +
of O +
the O +
ischemia U-Disease -
. O -

We O +
studied O +
whether O +
a O +
negative O +
coronary O +
CTA O +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease +
could O +
identify O +
a O +
subset O +
safe O +
for O +
discharge O -
. O -

METHODS O -
: O +
We O +
prospectively O +
evaluated O +
the O +
safety O +
of O +
coronary O +
CTA O +
for O +
low O -
- O -
risk O +
patients O +
who O +
presented O +
to O +
the O +
ED O +
with O +
cocaineassociated O +
chest B-Disease +
pain L-Disease +
( O -
self O -
- O -
reported O +
or O +
positive O +
urine O +
test O -
) O -
. O -

Consecutive O +
patients O +
received O +
either O +
immediate O +
coronary O +
CTA O +
in O +
the O +
ED O +
( O -
without O +
serial O +
markers O -
) O +
or O +
underwent O +
coronary O +
CTA O +
after O +
a O +
brief O +
observation O +
period O +
with O +
serial O +
cardiac O +
marker O +
measurements O -
. O -

Patients O +
with O +
negative O +
coronary O +
CTA O +
( O -
maximal O +
stenosis U-Disease +
less O +
than O +
50 O -
% O -
) O +
were O +
discharged O -
. O -

The O +
main O +
outcome O +
was O +
30-day O +
cardiovascular O +
death O +
or O +
myocardial B-Disease +
infarction L-Disease -
. O -

RESULTS O -
: O +
A O +
total O +
of O +
59 O +
patients O +
with O +
cocaine O -
- O -
associated O +
chest B-Disease +
pain L-Disease +
were O +
evaluated O -
. O -

Patients O +
had O +
a O +
mean O +
age O +
of O +
45.6 O +
+ O -
/- O -

6.6 O +
yrs O +
and O +
were O +
86 O -
% O +
black O -
, O +
66 O -
% O +
male O -
. O -

Seventy O -
- O -
nine O +
percent O +
had O +
a O +
normal O +
or O +
nonspecific O +
ECG O +
and O +
85 O -
% O +
had O +
a O +
TIMI O +
score O +
< O -
2 O -
. O -

Twenty O +
patients O +
received O +
coronary O +
CTA O +
immediately O +
in O +
the O +
ED O -
, O +
18 O +
of O +
whom O +
were O +
discharged O +
following O +
CTA O +
( O -
90 O -
% O -
) O -
. O -

Thirty O -
- O -
nine O +
received O +
coronary O +
CTA O +
after O +
a O +
brief O +
observation O +
period O -
, O +
with O +
37 O +
discharged O +
home O +
following O +
CTA O +
( O -
95 O -
% O -
) O -
. O -

Six O +
patients O +
had O +
coronary B-Disease +
stenosis L-Disease +
> O -
or=50 O -
% O -
. O -

During O +
the O +
30-day O +
follow O -
- O -
up O +
period O -
, O +
no O +
patients O +
died O +
of O +
a O +
cardiovascular O +
event O +
( O -
0 O -
% O -
; O +
95 O -
% O +
CI O -
, O +
0 O -
- O -
6.1 O -
% O -
) O +
and O +
no O +
patient O +
sustained O +
a O +
nonfatal O +
myocardial B-Disease +
infarction L-Disease +
( O -
0 O -
% O -
; O +
95 O -
% O +
CI O -
, O +
0 O -
- O -
6.1 O -
% O -
) O -
. O -

CONCLUSIONS O -
: O +
Although O +
cocaine O -
- O -
associated O +
myocardial B-Disease +
ischemia L-Disease +
can O +
result O +
from O +
coronary O +
vasoconstriction O -
, O +
patients O +
with O +
cocaine O +
associated O +
chest B-Disease +
pain L-Disease -
, O +
a O +
non O -
- O -
ischemic U-Disease +
ECG O -
, O +
and O +
a O +
TIMI O +
risk O +
score O +
< O -
2 O +
may O +
be O +
safely O +
discharged O +
from O +
the O +
ED O +
after O +
a O +
negative O +
coronary O +
CTA O +
with O +
a O +
low O +
risk O +
of O +
30-day O +
adverse O +
events O -
. O -

Bilateral O +
haemorrhagic U-Disease +
infarction B-Disease +
of I-Disease +
the I-Disease +
globus I-Disease +
pallidus L-Disease +
after O +
cocaine O +
and O +
alcohol O +
intoxication O -
. O -

Cocaine O +
is O +
a O +
risk O +
factor O +
for O +
both O +
ischemic B-Disease +
and I-Disease +
haemorrhagic I-Disease +
stroke L-Disease -
. O -

We O +
present O +
the O +
case O +
of O +
a O +
31-year O -
- O -
old O +
man O +
with O +
bilateral O +
ischemia B-Disease +
of I-Disease +
the I-Disease +
globus I-Disease +
pallidus L-Disease +
after O +
excessive O +
alcohol O +
and O +
intranasal O +
cocaine O +
use O -
. O -

Drug O -
- O -
related O +
globus B-Disease +
pallidus I-Disease +
infarctions L-Disease +
are O +
most O +
often O +
associated O +
with O +
heroin O -
. O -

Bilateral O +
basal B-Disease +
ganglia I-Disease +
infarcts L-Disease +
after O +
the O +
use O +
of O +
cocaine O -
, O +
without O +
concurrent O +
heroin O +
use O -
, O +
have O +
never O +
been O +
reported O -
. O -

In O +
our O +
patient O -
, O +
transient O +
cardiac B-Disease +
arrhythmia L-Disease +
or O +
respiratory B-Disease +
dysfunction L-Disease +
related O +
to O +
cocaine O +
and/or O +
ethanol O +
use O +
were O +
the O +
most O +
likely O +
causes O +
of O +
cerebral B-Disease +
hypoperfusion L-Disease -
. O -

Late O +
fulminant O +
posterior B-Disease +
reversible I-Disease +
encephalopathy I-Disease +
syndrome L-Disease +
after O +
liver O +
transplant O -
. O -

OBJECTIVES O -
: O +
Posterior B-Disease +
leukoencephalopathy L-Disease +
due O +
to O +
calcineurin O -
- O -
inhibitor O -
- O -
related O +
neurotoxicity U-Disease +
is O +
a O +
rare O +
but O +
severe O +
complication O +
that O +
results O +
from O +
treatment O +
with O +
immunosuppressive O +
agents O +
( O -
primarily O +
those O +
administered O +
after O +
a O +
liver O +
or O +
kidney O +
transplant O -
) O -
. O -

The O +
pathophysiologic O +
mechanisms O +
of O +
that O +
disorder O +
remain O +
unknown O -
. O -

CASE O -
: O +
We O +
report O +
the O +
case O +
of O +
a O +
46-year O -
- O -
old O +
woman O +
who O +
received O +
a O +
liver O +
transplant O +
in O +
our O +
center O +
as O +
treatment O +
for O +
alcoholic B-Disease +
cirrhosis L-Disease +
and O +
in O +
whom O +
either O +
a O +
fulminant O +
course O +
of O +
posterior B-Disease +
leukoencephalopathy L-Disease +
or O +
posterior B-Disease +
reversible I-Disease +
encephalopathy I-Disease +
syndrome L-Disease +
developed O +
110 O +
days O +
after O +
transplant O -
. O -

After O +
an O +
initially O +
uneventful O +
course O +
after O +
the O +
transplant O -
, O +
the O +
patient O +
rapidly O +
fell O +
into O +
deep O +
coma O -
. O -

RESULTS O -
: O +
Cerebral O +
MRI O +
scan O +
showed O +
typical O +
signs O +
of O +
enhancement O +
in O +
the O +
pontine O +
and O +
posterior O +
regions O -
. O -

Switching O +
the O +
immunosuppressive O +
regimen O +
from O +
tacrolimus O +
to O +
cyclosporine O +
did O +
not O +
improve O +
the O +
clinical O +
situation O -
. O -

The O +
termination O +
of O +
treatment O +
with O +
any O +
calcineurin O +
inhibitor O +
resulted O +
in O +
a O +
complete O +
resolution O +
of O +
that O +
complication O -
. O -

CONCLUSIONS O -
: O +
Posterior B-Disease +
reversible I-Disease +
encephalopathy I-Disease +
syndrome L-Disease +
after O +
liver O +
transplant O +
is O +
rare O -
. O -

We O +
recommend O +
a O +
complete O +
cessation O +
of O +
any O +
calcineurin O +
inhibitor O +
rather O +
than O +
a O +
dose O +
reduction O -
. O -

Prolonged O +
hypothermia U-Disease +
as O +
a O +
bridge O +
to O +
recovery O +
for O +
cerebral B-Disease +
edema L-Disease +
and O +
intracranial B-Disease +
hypertension L-Disease +
associated O +
with O +
fulminant B-Disease +
hepatic I-Disease +
failure L-Disease -
. O -

BACKGROUND O -
: O +
To O +
review O +
evidence O -
- O -
based O +
treatment O +
options O +
in O +
patients O +
with O +
cerebral B-Disease +
edema L-Disease +
complicating O +
fulminant B-Disease +
hepatic I-Disease +
failure L-Disease +
( O -
FHF U-Disease -
) O +
and O +
discuss O +
the O +
potential O +
applications O +
of O +
hypothermia U-Disease -
. O -

METHOD O -
: O +
Case O -
- O -
based O +
observations O +
from O +
a O +
medical O +
intensive O +
care O +
unit O +
( O -
MICU O -
) O +
in O +
a O +
tertiary O +
care O +
facility O +
in O +
a O +
27-year O -
- O -
old O +
female O +
with O +
FHF U-Disease +
from O +
acetaminophen O +
and O +
resultant O +
cerebral B-Disease +
edema L-Disease -
. O -

RESULTS O -
: O +
Our O +
patient O +
was O +
admitted O +
to O +
the O +
MICU O +
after O +
being O +
found O +
unresponsive O +
with O +
presumed O +
toxicity U-Disease +
from O +
acetaminophen O +
which O +
was O +
ingested O +
over O +
a O +
2-day O +
period O -
. O -

The O +
patient O +
had O +
depressed O +
of O +
mental O +
status O +
lasting O +
at O +
least O +
24 O +
h O +
prior O +
to O +
admission O -
. O -

Initial O +
evaluation O +
confirmed O +
FHF U-Disease +
from O +
acetaminophen O +
and O +
cerebral B-Disease +
edema L-Disease -
. O -

The O +
patient O +
was O +
treated O +
with O +
hyperosmolar O +
therapy O -
, O +
hyperventilation U-Disease -
, O +
sedation O -
, O +
and O +
chemical O +
paralysis U-Disease -
. O -

Her O +
intracranial O +
pressure O +
remained O +
elevated O +
despite O +
maximal O +
medical O +
therapy O -
. O -

We O +
then O +
initiated O +
therapeutic O +
hypothermia U-Disease +
which O +
was O +
continued O +
for O +
5 O +
days O -
. O -

At O +
re O -
- O -
warming O -
, O +
patient O +
had O +
resolution O +
of O +
her O +
cerebral B-Disease +
edema L-Disease +
and O +
intracranial B-Disease +
hypertension L-Disease -
. O -

At O +
discharge O -
, O +
she O +
had O +
complete O +
recovery O +
of O +
neurological O +
and O +
hepatic O +
functions O -
. O -

CONCLUSION O -
: O +
In O +
patients O +
with O +
FHF U-Disease +
and O +
cerebral B-Disease +
edema L-Disease +
from O +
acetaminophen O +
overdose U-Disease -
, O +
prolonged O +
therapeutic O +
hypothermia U-Disease +
could O +
potentially O +
be O +
used O +
as O +
a O +
life O +
saving O +
therapy O +
and O +
a O +
bridge O +
to O +
hepatic O +
and O +
neurological O +
recovery O -
. O -

A O +
clinical O +
trial O +
of O +
hypothermia U-Disease +
in O +
patients O +
with O +
this O +
condition O +
is O +
warranted O -
. O -

Binasal B-Disease +
visual I-Disease +
field I-Disease +
defects L-Disease +
are O +
not O +
specific O +
to O +
vigabatrin O -
. O -

This O +
study O +
investigated O +
the O +
visual B-Disease +
defects L-Disease +
associated O +
with O +
the O +
antiepileptic O +
drug O +
vigabatrin O +
( O -
VGB O -
) O -
. O -

Two O +
hundred O +
four O +
people O +
with O +
epilepsy U-Disease +
were O +
grouped O +
on O +
the O +
basis O +
of O +
antiepileptic O +
drug O +
therapy O +
( O -
current O -
, O +
previous O -
, O +
or O +
no O +
exposure O +
to O +
VGB O -
) O -
. O -

Groups O +
were O +
matched O +
with O +
respect O +
to O +
age O -
, O +
gender O -
, O +
and O +
seizure U-Disease +
frequency O -
. O -

All O +
patients O +
underwent O +
objective O +
assessment O +
of O +
electrophysiological O +
function O +
( O -
wide O -
- O -
field O +
multifocal O +
electroretinography O -
) O +
and O +
conventional O +
visual O +
field O +
testing O +
( O -
static O +
perimetry O -
) O -
. O -

Bilateral O +
visual O +
field O +
constriction O +
was O +
observed O +
in O +
59 O -
% O +
of O +
patients O +
currently O +
taking O +
VGB O -
, O +
43 O -
% O +
of O +
patients O +
who O +
previously O +
took O +
VGB O -
, O +
and O +
24 O -
% O +
of O +
patients O +
with O +
no O +
exposure O +
to O +
VGB O -
. O -

Assessment O +
of O +
retinal O +
function O +
revealed O +
abnormal O +
responses O +
in O +
48 O -
% O +
of O +
current O +
VGB O +
users O +
and O +
22 O -
% O +
of O +
prior O +
VGB O +
users O -
, O +
but O +
in O +
none O +
of O +
the O +
patients O +
without O +
previous O +
exposure O +
to O +
VGB O -
. O -

Bilateral B-Disease +
visual I-Disease +
field I-Disease +
abnormalities L-Disease +
are O +
common O +
in O +
the O +
treated O +
epilepsy U-Disease +
population O -
, O +
irrespective O +
of O +
drug O +
history O -
. O -

Assessment O +
by O +
conventional O +
static O +
perimetry O +
may O +
neither O +
be O +
sufficiently O +
sensitive O +
nor O +
specific O +
to O +
reliably O +
identify O +
retinal B-Disease +
toxicity L-Disease +
associated O +
with O +
VGB O -
. O -

Smoking O +
of O +
crack O +
cocaine O +
as O +
a O +
risk O +
factor O +
for O +
HIV B-Disease +
infection L-Disease +
among O +
people O +
who O +
use O +
injection O +
drugs O -
. O -

BACKGROUND O -
: O +
Little O +
is O +
known O +
about O +
the O +
possible O +
role O +
that O +
smoking O +
crack O +
cocaine O +
has O +
on O +
the O +
incidence O +
of O +
HIV B-Disease +
infection L-Disease -
. O -

Given O +
the O +
increasing O +
use O +
of O +
crack O +
cocaine O -
, O +
we O +
sought O +
to O +
examine O +
whether O +
use O +
of O +
this O +
illicit O +
drug O +
has O +
become O +
a O +
risk O +
factor O +
for O +
HIV B-Disease +
infection L-Disease -
. O -

METHODS O -
: O +
We O +
included O +
data O +
from O +
people O +
participating O +
in O +
the O +
Vancouver O +
Injection O +
Drug O +
Users O +
Study O +
who O +
reported O +
injecting O +
illicit O +
drugs O +
at O +
least O +
once O +
in O +
the O +
month O +
before O +
enrolment O -
, O +
lived O +
in O +
the O +
greater O +
Vancouver O +
area O -
, O +
were O +
HIV O -
- O -
negative O +
at O +
enrolment O +
and O +
completed O +
at O +
least O +
1 O +
follow O -
- O -
up O +
study O +
visit O -
. O -

To O +
determine O +
whether O +
the O +
risk O +
of O +
HIV B-Disease +
seroconversion L-Disease +
among O +
daily O +
smokers O +
of O +
crack O +
cocaine O +
changed O +
over O +
time O -
, O +
we O +
used O +
Cox O +
proportional O +
hazards O +
regression O +
and O +
divided O +
the O +
study O +
into O +
3 O +
periods O -
: O +
May O +
1 O -
, O +
1996-Nov O -
. O +
30 O -
, O +
1999 O +
( O -
period O +
1 O -
) O -
, O +
Dec. O +
1 O -
, O +
1999-Nov O -
. O +
30 O -
, O +
2002 O +
( O -
period O +
2 O -
) O -
, O +
and O +
Dec. O +
1 O -
, O +
2002-Dec O -
. O +
30 O -
, O +
2005 O +
( O -
period O +
3 O -
) O -
. O -

RESULTS O -
: O +
Overall O -
, O +
1048 O +
eligible O +
injection O +
drug O +
users O +
were O +
included O +
in O +
our O +
study O -
. O -

Of O +
these O -
, O +
137 O +
acquired O +
HIV B-Disease +
infection L-Disease +
during O +
follow O -
- O -
up O -
. O -

The O +
mean O +
proportion O +
of O +
participants O +
who O +
reported O +
daily O +
smoking O +
of O +
crack O +
cocaine O +
increased O +
from O +
11.6 O -
% O +
in O +
period O +
1 O +
to O +
39.7 O -
% O +
in O +
period O +
3 O -
. O -

After O +
adjusting O +
for O +
potential O +
confounders O -
, O +
we O +
found O +
that O +
the O +
risk O +
of O +
HIV B-Disease +
seroconversion L-Disease +
among O +
participants O +
who O +
were O +
daily O +
smokers O +
of O +
crack O +
cocaine O +
increased O +
over O +
time O +
( O -
period O +
1 O -
: O +
hazard O +
ratio O +
[ O -
HR O -
] O +
1.03 O -
, O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O +
0.57 O -
- O -
1.85 O -
; O +
period O +
2 O -
: O +
HR O +
1.68 O -
, O +
95 O -
% O +
CI O +
1.01 O -
- O -
2.80 O -
; O +
and O +
period O +
3 O -
: O +
HR O +
2.74 O -
, O +
95 O -
% O +
CI O +
1.06 O -
- O -
7.11 O -
) O -
. O -

INTERPRETATION O -
: O +
Smoking O +
of O +
crack O +
cocaine O +
was O +
found O +
to O +
be O +
an O +
independent O +
risk O +
factor O +
for O +
HIV B-Disease +
seroconversion L-Disease +
among O +
people O +
who O +
were O +
injection O +
drug O +
users O -
. O -

This O +
finding O +
points O +
to O +
the O +
urgent O +
need O +
for O +
evidence O -
- O -
based O +
public O +
health O +
initiatives O +
targeted O +
at O +
people O +
who O +
smoke O +
crack O +
cocaine O -
. O -

Fluoxetine O +
improves O +
the O +
memory B-Disease +
deficits L-Disease +
caused O +
by O +
the O +
chemotherapy O +
agent O +
5-fluorouracil O -
. O -

Cancer U-Disease +
patients O +
who O +
have O +
been O +
treated O +
with O +
systemic O +
adjuvant O +
chemotherapy O +
have O +
described O +
experiencing O +
deteriorations O +
in O +
cognition O -
. O -

A O +
widely O +
used O +
chemotherapeutic O +
agent O -
, O +
5-fluorouracil O +
( O -
5-FU O -
) O -
, O +
readily O +
crosses O +
the O +
blood O -
- O -
brain O +
barrier O +
and O +
so O +
could O +
have O +
a O +
direct O +
effect O +
on O +
brain O +
function O -
. O -

In O +
particular O +
this O +
anti O +
mitotic O +
drug O +
could O +
reduce O +
cell O +
proliferation O +
in O +
the O +
neurogenic O +
regions O +
of O +
the O +
adult O +
brain O -
. O -

In O +
contrast O +
reports O +
indicate O +
that O +
hippocampal O +
dependent O +
neurogenesis O +
and O +
cognition O +
are O +
enhanced O +
by O +
the O +
SSRI O +
antidepressant O +
Fluoxetine O -
. O -

In O +
this O +
investigation O +
the O +
behavioural O +
effects O +
of O +
chronic O +
( O -
two O +
week O -
) O +
treatment O +
with O +
5-FU O +
and O +
( O -
three O +
weeks O -
) O +
with O +
Fluoxetine O +
either O +
separately O +
or O +
in O +
combination O +
with O +
5-FU O +
were O +
tested O +
on O +
adult O +
Lister O +
hooded O +
rats O -
. O -

Behavioural O +
effects O +
were O +
tested O +
using O +
a O +
context O +
dependent O +
conditioned O +
emotional O +
response O +
test O +
( O -
CER O -
) O +
which O +
showed O +
that O +
animals O +
treated O +
with O +
5-FU O +
had O +
a O +
significant O +
reduction O +
in O +
freezing O +
time O +
compared O +
to O +
controls O -
. O -

A O +
separate O +
group O +
of O +
animals O +
was O +
tested O +
using O +
a O +
hippocampal O +
dependent O +
spatial O +
working O +
memory O +
test O -
, O +
the O +
object O +
location O +
recognition O +
test O +
( O -
OLR O -
) O -
. O -

Animals O +
treated O +
only O +
with O +
5-FU O +
showed O +
significant O +
deficits O +
in O +
their O +
ability O +
to O +
carry O +
out O +
the O +
OLR O +
task O +
but O +
co O +
administration O +
of O +
Fluoxetine O +
improved O +
their O +
performance O -
. O -

5-FU O +
chemotherapy O +
caused O +
a O +
significant O +
reduction O +
in O +
the O +
number O +
of O +
proliferating O +
cells O +
in O +
the O +
sub O +
granular O +
zone O +
of O +
the O +
dentate O +
gyrus O +
compared O +
to O +
controls O -
. O -

This O +
reduction O +
was O +
eliminated O +
when O +
Fluoxetine O +
was O +
co O +
administered O +
with O +
5-FU O -
. O -

Fluoxetine O +
on O +
its O +
own O +
had O +
no O +
effect O +
on O +
proliferating O +
cell O +
number O +
or O +
behaviour O -
. O -

These O +
findings O +
suggest O +
that O +
5-FU O +
can O +
negatively O +
affect O +
both O +
cell O +
proliferation O +
and O +
hippocampal O +
dependent O +
working O +
memory O +
and O +
that O +
these O +
deficits O +
can O +
be O +
reversed O +
by O +
the O +
simultaneous O +
administration O +
of O +
the O +
antidepressant O +
Fluoxetine O -
. O -

Liver O -
- O -
specific O +
ablation O +
of O +
integrin O -
- O -
linked O +
kinase O +
in O +
mice O +
results O +
in O +
enhanced O +
and O +
prolonged O +
cell O +
proliferation O +
and O +
hepatomegaly U-Disease +
after O +
phenobarbital O +
administration O -
. O -

We O +
have O +
recently O +
demonstrated O +
that O +
disruption O +
of O +
extracellular O +
matrix O +
( O -
ECM O -
) O -
/ O -
integrin O +
signaling O +
via O +
elimination O +
of O +
integrin O -
- O -
linked O +
kinase O +
( O -
ILK O -
) O +
in O +
hepatocytes O +
interferes O +
with O +
signals O +
leading O +
to O +
termination O +
of O +
liver O +
regeneration O -
. O -

This O +
study O +
investigates O +
the O +
role O +
of O +
ILK O +
in O +
liver O +
enlargement O +
induced O +
by O +
phenobarbital O +
( O -
PB O -
) O -
. O -

Wild O -
- O -
type O +
( O -
WT O -
) O +
and O +
ILK O -
: O -
liver- O -
/ O -
- O +
mice O +
were O +
given O +
PB O +
( O -
0.1 O -
% O +
in O +
drinking O +
water O -
) O +
for O +
10 O +
days O -
. O -

Livers O +
were O +
harvested O +
on O +
2 O -
, O +
5 O -
, O +
and O +
10 O +
days O +
during O +
PB O +
administration O -
. O -

In O +
the O +
hepatocyte O -
- O -
specific O +
ILK O -
/ O -
liver- O -
/ O -
- O +
mice O -
, O +
the O +
liver O -
: O -
body O +
weight O +
ratio O +
was O +
more O +
than O +
double O +
as O +
compared O +
to O +
0 O +
h O +
at O +
day O +
2 O +
( O -
2.5 O +
times O -
) O -
, O +
while O +
at O +
days O +
5 O +
and O +
10 O -
, O +
it O +
was O +
enlarged O +
three O +
times O -
. O -

In O +
the O +
WT O +
mice O -
, O +
the O +
increase O +
was O +
as O +
expected O +
from O +
previous O +
literature O +
( O -
1.8 O +
times O -
) O +
and O +
seems O +
to O +
have O +
leveled O +
off O +
after O +
day O +
2 O -
. O -

There O +
were O +
slightly O +
increased O +
proliferating O +
cell O +
nuclear O +
antigen O -
- O -
positive O +
cells O +
in O +
the O +
ILK O -
/ O -
liver- O -
/ O -
- O +
animals O +
at O +
day O +
2 O +
as O +
compared O +
to O +
WT O +
after O +
PB O +
administration O -
. O -

In O +
the O +
WT O +
animals O -
, O +
the O +
proliferative O +
response O +
had O +
come O +
back O +
to O +
normal O +
by O +
days O +
5 O +
and O +
10 O -
. O -

Hepatocytes O +
of O +
the O +
ILK O -
/ O -
liver- O -
/ O -
- O +
mice O +
continued O +
to O +
proliferate O +
up O +
until O +
day O +
10 O -
. O -

ILK O -
/ O -
liver- O -
/ O -
- O +
mice O +
also O +
showed O +
increased O +
expression O +
of O +
key O +
genes O +
involved O +
in O +
hepatocyte O +
proliferation O +
at O +
different O +
time O +
points O +
during O +
PB O +
administration O -
. O -

In O +
summary O -
, O +
ECM O +
proteins O +
communicate O +
with O +
the O +
signaling O +
machinery O +
of O +
dividing O +
cells O +
via O +
ILK O +
to O +
regulate O +
hepatocyte O +
proliferation O +
and O +
termination O +
of O +
the O +
proliferative O +
response O -
. O -

Lack O +
of O +
ILK O +
in O +
the O +
hepatocytes O +
imparts O +
prolonged O +
proliferative O +
response O +
not O +
only O +
to O +
stimuli O +
related O +
to O +
liver O +
regeneration O +
but O +
also O +
to O +
xenobiotic O +
chemical O +
mitogens O -
, O +
such O +
as O +
PB O -
. O -

Decreased O +
Expression O +
of O +
Na O -
/ O -
K O -
- O -
ATPase O -
, O +
NHE3 O -
, O +
NBC1 O -
, O +
AQP1 O +
and O +
OAT O +
in O +
Gentamicin O -
- O -
induced O +
Nephropathy U-Disease -
. O -

The O +
present O +
study O +
was O +
aimed O +
to O +
determine O +
whether O +
there O +
is O +
an O +
altered O +
regulation O +
of O +
tubular O +
transporters O +
in O +
gentamicin O -
- O -
induced O +
nephropathy U-Disease -
. O -

Sprague O -
- O -
Dawley O +
male O +
rats O +
( O -
200~250 O +
g O -
) O +
were O +
subcutaneously O +
injected O +
with O +
gentamicin O +
( O -
100 O +
mg O -
/ O -
kg O +
per O +
day O -
) O +
for O +
7 O +
days O -
, O +
and O +
the O +
expression O +
of O +
tubular O +
transporters O +
was O +
determined O +
by O +
immunoblotting O +
and O +
immunohistochemistry O -
. O -

The O +
mRNA O +
and O +
protein O +
expression O +
of O +
OAT O +
was O +
also O +
determined O -
. O -

Gentamicin O -
- O -
treated O +
rats O +
exhibited O +
significantly O +
decreased O +
creatinine O +
clearance O +
along O +
with O +
increased O +
plasma O +
creatinine O +
levels O -
. O -

Accordingly O -
, O +
the O +
fractional O +
excretion O +
of O +
sodium O +
increased O -
. O -

Urine O +
volume O +
was O +
increased O -
, O +
while O +
urine O +
osmolality O +
and O +
free O +
water O +
reabsorption O +
were O +
decreased O -
. O -

Immunoblotting O +
and O +
immunohistochemistry O +
revealed O +
decreased O +
expression O +
of O +
Na O -
( O -
+ O -
) O -
/ O -
K O -
( O -
+ O -
) O -
-ATPase O -
, O +
NHE3 O -
, O +
NBC1 O -
, O +
and O +
AQP1 O +
in O +
the O +
kidney O +
of O +
gentamicin O -
- O -
treated O +
rats O -
. O -

The O +
expression O +
of O +
OAT1 O +
and O +
OAT3 O +
was O +
also O +
decreased O -
. O -

Gentamicin O -
- O -
induced O +
nephropathy U-Disease +
may O +
at O +
least O +
in O +
part O +
be O +
causally O +
related O +
with O +
a O +
decreased O +
expression O +
of O +
Na O -
( O -
+ O -
) O -
/ O -
K O -
( O -
+ O -
) O -
-ATPase O -
, O +
NHE3 O -
, O +
NBC1 O -
, O +
AQP1 O +
and O +
OAT O -
. O -

Acute B-Disease +
renal I-Disease +
failure L-Disease +
after O +
high O -
- O -
dose O +
methotrexate O +
therapy O +
in O +
a O +
patient O +
with O +
ileostomy O -
. O -

High O -
- O -
dose O +
methotrexate O +
( O -
HD O -
- O -
MTX O -
) O +
is O +
an O +
important O +
treatment O +
for O +
Burkitt B-Disease +
lymphoma L-Disease -
, O +
but O +
can O +
cause O +
hepatic B-Disease +
and I-Disease +
renal I-Disease +
toxicity L-Disease +
when O +
its O +
clearance O +
is O +
delayed O -
. O -

We O +
report O +
a O +
case O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
after O +
HD O -
- O -
MTX O +
therapy O +
in O +
a O +
patient O +
with O +
ileostomy O -
, O +
The O +
patient O +
was O +
a O +
3-year O -
- O -
old O +
boy O +
who O +
had O +
received O +
a O +
living O -
- O -
related O +
liver O +
transplantation O +
for O +
congenital O +
biliary B-Disease +
atresia L-Disease -
. O -

At O +
day O +
833 O +
after O +
the O +
transplantation O -
, O +
he O +
was O +
diagnosed O +
with O +
PTLD U-Disease +
( O -
post B-Disease -
- I-Disease -
transplantation I-Disease +
lymphoproliferative I-Disease +
disorder L-Disease -
, O +
Burkitt B-Disease -
- I-Disease -
type I-Disease +
malignant I-Disease +
lymphoma L-Disease -
) O -
. O -

During O +
induction O +
therapy O -
, O +
he O +
suffered O +
ileal O +
perforation O +
and O +
ileostomy O +
was O +
performed O -
. O -

Subsequent O +
HD O -
- O -
MTX O +
therapy O +
caused O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
that O +
required O +
continuous O +
hemodialysis O -
. O -

We O +
supposed O +
that O +
intravascular O +
hypovolemia U-Disease +
due O +
to O +
substantial O +
drainage O +
from O +
the O +
ileostoma O +
caused O +
acute B-Disease +
prerenal I-Disease +
failure L-Disease -
. O -

After O +
recovery O +
of O +
his O +
renal O +
function O -
, O +
we O +
could O +
safely O +
treat O +
the O +
patient O +
with O +
HD O -
- O -
MTX O +
therapy O +
by O +
controlling O +
drainage O +
from O +
ileostoma O +
with O +
total O +
parenteral O +
nutrition O -
. O -

Longitudinal O +
association O +
of O +
alcohol O +
use O +
with O +
HIV B-Disease +
disease L-Disease +
progression O +
and O +
psychological O +
health O +
of O +
women O +
with O +
HIV O -
. O -

We O +
evaluated O +
the O +
association O +
of O +
alcohol O +
consumption O +
and O +
depression U-Disease -
, O +
and O +
their O +
effects O +
on O +
HIV B-Disease +
disease L-Disease +
progression O +
among O +
women O +
with O +
HIV O -
. O -

The O +
study O +
included O +
871 O +
women O +
with O +
HIV O +
who O +
were O +
recruited O +
from O +
1993 O -
- O -
1995 O +
in O +
four O +
US O +
cities O -
. O -

The O +
participants O +
had O +
physical O +
examination O -
, O +
medical O +
record O +
extraction O -
, O +
and O +
venipuncture O -
, O +
CD4+T O -
- O -
cell O +
counts O +
determination O -
, O +
measurement O +
of O +
depression U-Disease +
symptoms O +
( O -
using O +
the O +
self O -
- O -
report O +
Center O +
for O +
Epidemiological O +
Studies O -
- O -
Depression U-Disease +
Scale O -
) O -
, O +
and O +
alcohol O +
use O +
assessment O +
at O +
enrollment O -
, O +
and O +
semiannually O +
until O +
March O +
2000 O -
. O -

Multilevel O +
random O +
coefficient O +
ordinal O +
models O +
as O +
well O +
as O +
multilevel O +
models O +
with O +
joint O +
responses O +
were O +
used O +
in O +
the O +
analysis O -
. O -

There O +
was O +
no O +
significant O +
association O +
between O +
level O +
of O +
alcohol O +
use O +
and O +
CD4 O -
+ O +
T O -
- O -
cell O +
counts O -
. O -

When O +
participants O +
were O +
stratified O +
by O +
antiretroviral O +
therapy O +
( O -
ART O -
) O +
use O -
, O +
the O +
association O +
between O +
alcohol O +
and O +
CD4 O -
+ O +
T O -
- O -
cell O +
did O +
not O +
reach O +
statistical O +
significance O -
. O -

The O +
association O +
between O +
alcohol O +
consumption O +
and O +
depression U-Disease +
was O +
significant O +
( O -
p<0.001 O -
) O -
. O -

Depression U-Disease +
had O +
a O +
significant O +
negative O +
effect O +
on O +
CD4 O -
+ O +
T O -
- O -
cell O +
counts O +
over O +
time O +
regardless O +
of O +
ART O +
use O -
. O -

Our O +
findings O +
suggest O +
that O +
alcohol O +
consumption O +
has O +
a O +
direct O +
association O +
with O +
depression U-Disease -
. O -

Moreover O -
, O +
depression U-Disease +
is O +
associated O +
with O +
HIV B-Disease +
disease L-Disease +
progression O -
. O -

Our O +
findings O +
have O +
implications O +
for O +
the O +
provision O +
of O +
alcohol O +
use O +
interventions O +
and O +
psychological O +
resources O +
to O +
improve O +
the O +
health O +
of O +
women O +
with O +
HIV O -
. O -

Chemokine O +
CCL2 O +
and O +
its O +
receptor O +
CCR2 O +
are O +
increased O +
in O +
the O +
hippocampus O +
following O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease -
. O -

BACKGROUND O -
: O +
Neuroinflammation U-Disease +
occurs O +
after O +
seizures U-Disease +
and O +
is O +
implicated O +
in O +
epileptogenesis O -
. O -

CCR2 O +
is O +
a O +
chemokine O +
receptor O +
for O +
CCL2 O +
and O +
their O +
interaction O +
mediates O +
monocyte O +
infiltration O +
in O +
the O +
neuroinflammatory U-Disease +
cascade O +
triggered O +
in O +
different O +
brain O +
pathologies O -
. O -

In O +
this O +
work O +
CCR2 O +
and O +
CCL2 O +
expression O +
were O +
examined O +
following O +
status B-Disease +
epilepticus L-Disease +
( O -
SE U-Disease -
) O +
induced O +
by O +
pilocarpine O +
injection O -
. O -

METHODS O -
: O +
SE U-Disease +
was O +
induced O +
by O +
pilocarpine O +
injection O -
. O -

Control O +
rats O +
were O +
injected O +
with O +
saline O +
instead O +
of O +
pilocarpine O -
. O -

Five O +
days O +
after O +
SE U-Disease -
, O +
CCR2 O +
staining O +
in O +
neurons O +
and O +
glial O +
cells O +
was O +
examined O +
using O +
imunohistochemical O +
analyses O -
. O -

The O +
number O +
of O +
CCR2 O +
positive O +
cells O +
was O +
determined O +
using O +
stereology O +
probes O +
in O +
the O +
hippocampus O -
. O -

CCL2 O +
expression O +
in O +
the O +
hippocampus O +
was O +
examined O +
by O +
molecular O +
assay O -
. O -

RESULTS O -
: O +
Increased O +
CCR2 O +
was O +
observed O +
in O +
the O +
hippocampus O +
after O +
SE U-Disease -
. O -

Seizures U-Disease +
also O +
resulted O +
in O +
alterations O +
to O +
the O +
cell O +
types O +
expressing O +
CCR2 O -
. O -

Increased O +
numbers O +
of O +
neurons O +
that O +
expressed O +
CCR2 O +
was O +
observed O +
following O +
SE U-Disease -
. O -

Microglial O +
cells O +
were O +
more O +
closely O +
apposed O +
to O +
the O +
CCR2-labeled O +
cells O +
in O +
SE U-Disease +
rats O -
. O -

In O +
addition O -
, O +
rats O +
that O +
experienced O +
SE U-Disease +
exhibited O +
CCR2-labeling O +
in O +
populations O +
of O +
hypertrophied U-Disease +
astrocytes O -
, O +
especially O +
in O +
CA1 O +
and O +
dentate O +
gyrus O -
. O -

These O +
CCR2 O -
+ O +
astroctytes O +
were O +
not O +
observed O +
in O +
control O +
rats O -
. O -

Examination O +
of O +
CCL2 O +
expression O +
showed O +
that O +
it O +
was O +
elevated O +
in O +
the O +
hippocampus O +
following O +
SE U-Disease -
. O -

CONCLUSION O -
: O +
The O +
data O +
show O +
that O +
CCR2 O +
and O +
CCL2 O +
are O +
up O -
- O -
regulated O +
in O +
the O +
hippocampus O +
after O +
pilocarpine O -
- O -
induced O +
SE U-Disease -
. O -

Seizures U-Disease +
also O +
result O +
in O +
changes O +
to O +
CCR2 O +
receptor O +
expression O +
in O +
neurons O +
and O +
astrocytes O -
. O -

These O +
changes O +
might O +
be O +
involved O +
in O +
detrimental O +
neuroplasticity O +
and O +
neuroinflammatory U-Disease +
changes O +
that O +
occur O +
following O +
seizures U-Disease -
. O -

Metallothionein O +
induction O +
reduces O +
caspase-3 O +
activity O +
and O +
TNFalpha O +
levels O +
with O +
preservation O +
of O +
cognitive O +
function O +
and O +
intact O +
hippocampal O +
neurons O +
in O +
carmustine O -
- O -
treated O +
rats O -
. O -

Hippocampal O +
integrity O +
is O +
essential O +
for O +
cognitive O +
functions O -
. O -

On O +
the O +
other O +
hand O -
, O +
induction O +
of O +
metallothionein O +
( O -
MT O -
) O +
by O +
ZnSO O -
( O -
4 O -
) O +
and O +
its O +
role O +
in O +
neuroprotection O +
has O +
been O +
documented O -
. O -

The O +
present O +
study O +
aimed O +
to O +
explore O +
the O +
effect O +
of O +
MT O +
induction O +
on O +
carmustine O +
( O -
BCNU O -
) O -
-induced O +
hippocampal O +
cognitive B-Disease +
dysfunction L-Disease +
in O +
rats O -
. O -

A O +
total O +
of O +
60 O +
male O +
Wistar O +
albino O +
rats O +
were O +
randomly O +
divided O +
into O +
four O +
groups O +
( O -
15 O -
/ O -
group O -
) O -
: O +
The O +
control O +
group O +
injected O +
with O +
single O +
doses O +
of O +
normal O +
saline O +
( O -
i.c.v O -
) O +
followed O +
24 O +
h O +
later O +
by O +
BCNU O +
solvent O +
( O -
i.v O -
) O -
. O -

The O +
second O +
group O +
administered O +
ZnSO O -
( O -
4 O -
) O +
( O -
0.1 O +
micromol O -
/ O -
10 O +
microl O +
normal O +
saline O -
, O +
i.c.v O -
, O +
once O -
) O +
then O +
BCNU O +
solvent O +
( O -
i.v O -
) O +
after O +
24 O +
h. O +
Third O +
group O +
received O +
BCNU O +
( O -
20 O +
mg O -
/ O -
kg O -
, O +
i.v O -
, O +
once O -
) O +
24 O +
h O +
after O +
injection O +
with O +
normal O +
saline O +
( O -
i.c.v O -
) O -
. O -

Fourth O +
group O +
received O +
a O +
single O +
dose O +
of O +
ZnSO O -
( O -
4 O -
) O +
( O -
0.1 O +
micromol O -
/ O -
10 O +
microl O +
normal O +
saline O -
, O +
i.c.v O -
) O +
then O +
BCNU O +
( O -
20 O +
mg O -
/ O -
kg O -
, O +
i.v O -
, O +
once O -
) O +
after O +
24 O +
h. O +
The O +
obtained O +
data O +
revealed O +
that O +
BCNU O +
administration O +
resulted O +
in O +
deterioration B-Disease +
of I-Disease +
learning L-Disease +
and B-Disease +
short I-Disease -
- I-Disease -
term I-Disease +
memory L-Disease +
( O -
STM O -
) O -
, O +
as O +
measured O +
by O +
using O +
radial O +
arm O +
water O +
maze O -
, O +
accompanied O +
with O +
decreased O +
hippocampal O +
glutathione O +
reductase O +
( O -
GR O -
) O +
activity O +
and O +
reduced O +
glutathione O +
( O -
GSH O -
) O +
content O -
. O -

Also O -
, O +
BCNU O +
administration O +
increased O +
serum O +
tumor U-Disease +
necrosis U-Disease +
factor O -
- O -
alpha O +
( O -
TNFalpha O -
) O -
, O +
hippocampal O +
MT O +
and O +
malondialdehyde O +
( O -
MDA O -
) O +
contents O +
as O +
well O +
as O +
caspase-3 O +
activity O +
in O +
addition O +
to O +
histological O +
alterations O -
. O -

ZnSO O -
( O -
4 O -
) O +
pretreatment O +
counteracted O +
BCNU O -
- O -
induced O +
inhibition O +
of O +
GR O +
and O +
depletion O +
of O +
GSH O +
and O +
resulted O +
in O +
significant O +
reduction O +
in O +
the O +
levels O +
of O +
MDA O +
and O +
TNFalpha O +
as O +
well O +
as O +
the O +
activity O +
of O +
caspase-3 O -
. O -

The O +
histological O +
features O +
were O +
improved O +
in O +
hippocampus O +
of O +
rats O +
treated O +
with O +
ZnSO O -
( O -
4 O -
) O +
+ O +
BCNU O +
compared O +
to O +
only O +
BCNU O -
- O -
treated O +
animals O -
. O -

In O +
conclusion O -
, O +
MT O +
induction O +
halts O +
BCNU O -
- O -
induced O +
hippocampal O +
toxicity U-Disease +
as O +
it O +
prevented O +
GR O +
inhibition O +
and O +
GSH O +
depletion O +
and O +
counteracted O +
the O +
increased O +
levels O +
of O +
TNFalpha O -
, O +
MDA O +
and O +
caspase-3 O +
activity O +
with O +
subsequent O +
preservation O +
of O +
cognition O -
. O -

Fatal O +
carbamazepine O +
induced O +
fulminant B-Disease +
eosinophilic L-Disease +
( O -
hypersensitivity U-Disease -
) O +
myocarditis U-Disease -
: O +
emphasis O +
on O +
anatomical O +
and O +
histological O +
characteristics O -
, O +
mechanisms O +
and O +
genetics O +
of O +
drug B-Disease +
hypersensitivity L-Disease +
and O +
differential O +
diagnosis O -
. O -

The O +
most O +
severe O +
adverse O +
reactions O +
to O +
carbamazepine O +
have O +
been O +
observed O +
in O +
the O +
haemopoietic O +
system O -
, O +
the O +
liver O +
and O +
the O +
cardiovascular O +
system O -
. O -

A O +
frequently O +
fatal O -
, O +
although O +
exceptionally O +
rare O +
side O +
effect O +
of O +
carbamazepine O +
is O +
necrotizing O +
eosinophilic O +
( O -
hypersensitivity U-Disease -
) O +
myocarditis U-Disease -
. O -

We O +
report O +
a O +
case O +
of O +
hypersensitivity U-Disease +
myocarditis U-Disease +
secondary O +
to O +
administration O +
of O +
carbamazepine O -
. O -

Acute O +
hypersensitivity U-Disease +
myocarditis U-Disease +
was O +
not O +
suspected O +
clinically O -
, O +
and O +
the O +
diagnosis O +
was O +
made O +
post O -
- O -
mortem O -
. O -

Histology O +
revealed O +
diffuse O +
infiltration O +
of O +
the O +
myocardium O +
by O +
eosinophils O +
and O +
lymphocytes O +
with O +
myocyte O +
damage O -
. O -

Clinically O -
, O +
death O +
was O +
due O +
to O +
cardiogenic B-Disease +
shock L-Disease -
. O -

To O +
best O +
of O +
our O +
knowledge O +
this O +
is O +
the O +
second O +
case O +
of O +
fatal O +
carbamazepine O +
induced O +
myocarditis U-Disease +
reported O +
in O +
English O +
literature O -
. O -

Neuropsychiatric O +
behaviors O +
in O +
the O +
MPTP O +
marmoset O +
model O +
of O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

OBJECTIVES O -
: O +
Neuropsychiatric O +
symptoms O +
are O +
increasingly O +
recognised O +
as O +
a O +
significant O +
problem O +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
( O -
PD U-Disease -
) O -
. O -

These O +
symptoms O +
may O +
be O +
due O +
to O +
' O -
sensitisation O -
' O +
following O +
repeated O +
levodopa O +
treatment O +
or O +
a O +
direct O +
effect O +
of O +
dopamine O +
on O +
the O +
disease O +
state O -
. O -

The O +
levodopa O -
- O -
treated O +
MPTP O -
- O -
lesioned O +
marmoset O +
was O +
used O +
as O +
a O +
model O +
of O +
neuropsychiatric B-Disease +
symptoms L-Disease +
in O +
PD U-Disease +
patients O -
. O -

Here O +
we O +
compare O +
the O +
time O +
course O +
of O +
levodopa O -
- O -
induced O +
motor O +
fluctuations O +
and O +
neuropsychiatric B-Disease -
- I-Disease -
like I-Disease +
behaviors L-Disease +
to O +
determine O +
the O +
relationship O +
between O +
duration O +
of O +
treatment O +
and O +
onset O +
of O +
symptoms O -
. O -

METHODS O -
: O +
Marmosets O +
were O +
administered O +
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O +
( O -
2.0 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
for O +
five O +
days O -
, O +
resulting O +
in O +
stable O +
parkinsonism U-Disease -
. O -

Levodopa O +
( O -
15 O +
mg O -
/ O -
kg O +
and O +
benserazide O -
, O +
3.75 O +
mg O -
/ O -
kg O -
) O +
p.o O -
. O -

b.i.d O -
, O +
was O +
administered O +
for O +
30 O +
days O -
. O -

Animals O +
were O +
evaluated O +
for O +
parkinsonian B-Disease +
disability L-Disease -
, O +
dyskinesia U-Disease +
and O +
on O -
- O -
time O +
( O -
motor O +
fluctuations O -
) O +
and O +
neuropsychiatric B-Disease -
- I-Disease -
like I-Disease +
behaviors L-Disease +
on O +
Day O +
0 O +
( O -
prior O +
to O +
levodopa O -
) O +
and O +
on O +
Days O +
1 O -
, O +
7 O -
, O +
13 O -
, O +
27 O +
and O +
30 O +
of O +
treatment O +
using O +
post O +
hoc O +
DVD O +
analysis O +
by O +
a O +
trained O +
rater O -
, O +
blind O +
to O +
the O +
treatment O +
day O -
. O -

RESULTS O -
: O +
The O +
neuropsychiatric B-Disease -
- I-Disease -
like I-Disease +
behavior L-Disease +
rating O +
scale O +
demonstrated O +
high O +
interrater O +
reliability O +
between O +
three O +
trained O +
raters O +
of O +
differing O +
professional O +
backgrounds O -
. O -

As O +
anticipated O -
, O +
animals O +
exhibited O +
a O +
progressive O +
increase O +
in O +
levodopa O -
- O -
induced O +
motor O +
fluctuations O -
, O +
dyskinesia U-Disease +
and O +
wearing O -
- O -
off O -
, O +
that O +
correlated O +
with O +
the O +
duration O +
of O +
levodopa O +
therapy O -
. O -

In O +
contrast O -
, O +
levodopa O -
- O -
induced O +
neuropsychiatric B-Disease -
- I-Disease -
like I-Disease +
behaviors L-Disease +
were O +
present O +
on O +
Day O +
1 O +
of O +
levodopa O +
treatment O +
and O +
their O +
severity O +
did O +
not O +
correlate O +
with O +
duration O +
of O +
treatment O -
. O -

CONCLUSIONS O -
: O +
The O +
data O +
suggest O +
that O +
neuropsychiatric B-Disease +
disorders L-Disease +
in O +
PD U-Disease +
are O +
more O +
likely O +
an O +
interaction O +
between O +
levodopa O +
and O +
the O +
disease O +
state O +
than O +
a O +
consequence O +
of O +
sensitisation O +
to O +
repeated O +
dopaminergic O +
therapy O -
. O -

Contrast O +
medium O +
nephrotoxicity U-Disease +
after O +
renal O +
artery O +
and O +
coronary O +
angioplasty O -
. O -

BACKGROUND O -
: O +
Renal B-Disease +
dysfunction L-Disease +
induced O +
by O +
iodinated O +
contrast O +
medium O +
( O -
CM O -
) O +
administration O +
can O +
minimize O +
the O +
benefit O +
of O +
the O +
interventional O +
procedure O +
in O +
patients O +
undergoing O +
renal O +
angioplasty O +
( O -
PTRA O -
) O -
. O -

PURPOSE O -
: O +
To O +
compare O +
the O +
susceptibility O +
to O +
nephrotoxic U-Disease +
effect O +
of O +
CM O +
in O +
patients O +
undergoing O +
PTRA O +
with O +
that O +
of O +
patients O +
submitted O +
to O +
percutaneous O +
coronary O +
intervention O +
( O -
PCI O -
) O -
. O -

MATERIAL O +
AND O +
METHODS O -
: O +
A O +
total O +
of O +
33 O +
patients O +
successfully O +
treated O +
with O +
PTRA O +
( O -
PTRA O +
group O -
, O +
mean O +
age O +
70+ O -
/ O -
-12 O +
years O -
, O +
23 O +
female O -
, O +
basal O +
creatinine O +
1.46+ O -
/ O -
-0.79 O -
, O +
range O +
0.7 O -
- O -
4.9 O +
mg O -
/ O -
dl O -
) O +
were O +
compared O +
with O +
33 O +
patients O +
undergoing O +
successful O +
PCI O +
( O -
PCI O +
group O -
) O -
, O +
matched O +
for O +
basal O +
creatinine O +
( O -
1.44+ O -
/ O -
-0.6 O -
, O +
range O +
0.7 O -
- O -
3.4 O +
mg O -
/ O -
dl O -
) O -
, O +
gender O -
, O +
and O +
age O -
. O -

In O +
both O +
groups O +
postprocedural O +
( O -
48 O +
h O -
) O +
serum O +
creatinine O +
was O +
measured O -
. O -

RESULTS O -
: O +
Postprocedural O +
creatinine O +
level O +
decreased O +
nonsignificantly O +
in O +
the O +
PTRA O +
group O +
( O -
1.46+ O -
/ O -
-0.8 O +
vs. O +
1.34+ O -
/ O -
-0.5 O +
mg O -
/ O -
dl O -
, O +
P O -
= O -
NS O -
) O +
and O +
increased O +
significantly O +
in O +
the O +
PCI O +
group O +
( O -
1.44+ O -
/ O -
-0.6 O +
vs. O +
1.57+ O -
/ O -
-0.7 O +
mg O -
/ O -
dl O -
, O +
P<0.02 O -
) O -
. O -

Changes O +
in O +
serum O +
creatinine O +
after O +
intervention O +
( O -
after O -
- O -
before O -
) O +
were O +
significantly O +
different O +
between O +
the O +
PTRA O +
and O +
PCI O +
groups O +
( O -
-0.12+ O -
/ O -
-0.5 O +
vs. O +
0.13+ O -
/ O -
-0.3 O -
, O +
P=0.014 O -
) O -
. O -

This O +
difference O +
was O +
not O +
related O +
to O +
either O +
a O +
different O +
clinical O +
risk O +
profile O +
or O +
to O +
the O +
volume O +
of O +
CM O +
administered O -
. O -

CONCLUSION O -
: O +
In O +
this O +
preliminary O +
study O +
patients O +
submitted O +
to O +
PTRA O +
showed O +
a O +
lower O +
susceptibility O +
to O +
renal B-Disease +
damage L-Disease +
induced O +
by O +
CM O +
administration O +
than O +
PCI O +
patients O -
. O -

The O +
effectiveness O +
of O +
PTRA O +
on O +
renal O +
function O +
seems O +
to O +
be O +
barely O +
influenced O +
by O +
CM O +
toxicity U-Disease -
. O -

Diphenhydramine O +
prevents O +
the O +
haemodynamic O +
changes O +
of O +
cimetidine O +
in O +
ICU O +
patients O -
. O -

Cimetidine O -
, O +
a O +
histamine O +
2 O +
( O -
H2 O -
) O +
antagonist O -
, O +
produces O +
a O +
decrease O +
in O +
arterial O +
pressure O +
due O +
to O +
vasodilatation O -
, O +
especially O +
in O +
critically O +
ill O +
patients O -
. O -

This O +
may O +
be O +
because O +
cimetidine O +
acts O +
as O +
a O +
histamine O +
agonist O -
. O -

We O -
, O +
therefore O -
, O +
investigated O +
the O +
effects O +
of O +
the O +
histamine O +
1 O -
( O -
H1 O -
) O +
receptor O +
antagonist O -
, O +
diphenhydramine O -
, O +
on O +
the O +
haemodynamic O +
changes O +
observed O +
after O +
cimetidine O +
in O +
ICU O +
patients O -
. O -

Each O +
patient O +
was O +
studied O +
on O +
two O +
separate O +
days O -
. O -

In O +
a O +
random O +
fashion O -
, O +
they O +
received O +
cimetidine O +
200 O +
mg O +
iv O +
on O +
one O +
day O -
, O +
and O +
on O +
the O +
other O -
, O +
a O +
pretreatment O +
of O +
diphenhydramine O +
40 O +
mg O +
iv O +
with O +
cimetidine O +
200 O +
mg O +
iv O -
. O -

In O +
the O +
non O -
- O -
pretreatment O +
group O -
, O +
mean O +
arterial O +
pressure O +
( O -
MAP O -
) O +
decreased O +
from O +
107.4 O +
+ O -
/- O -

8.4 O +
mmHg O +
to O +
86.7 O +
+ O -
/- O -

11.4 O +
mmHg O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
two O +
minutes O +
after O +
cimetidine O -
. O -

Also O -
, O +
systemic O +
vascular O +
resistance O +
( O -
SVR O -
) O +
decreased O +
during O +
the O +
eight O -
- O -
minute O +
observation O +
period O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
. O -

In O +
contrast O -
, O +
in O +
the O +
pretreatment O +
group O -
, O +
little O +
haemodynamic O +
change O +
was O +
seen O -
. O -

We O +
conclude O +
that O +
an O +
H1 O +
antagonist O +
may O +
be O +
useful O +
in O +
preventing O +
hypotension U-Disease +
caused O +
by O +
iv O +
cimetidine O -
, O +
since O +
the O +
vasodilating O +
activity O +
of O +
cimetidine O +
is O +
mediated O -
, O +
in O +
part O -
, O +
through O +
the O +
H1 O +
receptor O -
. O -

Medical O +
and O +
psychiatric O +
outcomes O +
for O +
patients O +
transplanted O +
for O +
acetaminophen O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure L-Disease -
: O +
a O +
case O -
- O -
control O +
study O -
. O -

BACKGROUND O -
: O +
Acetaminophen O -
- O -
induced O +
hepatotoxicity U-Disease +
is O +
the O +
most O +
common O +
cause O +
of O +
acute B-Disease +
liver I-Disease +
failure L-Disease +
( O -
ALF U-Disease -
) O +
in O +
the O +
UK O -
. O -

Patients O +
often O +
consume O +
the O +
drug O +
with O +
suicidal O +
intent O +
or O +
with O +
a O +
background O +
of O +
substance O +
dependence O -
. O -

AIMS O +
AND O +
METHODS O -
: O +
We O +
compared O +
the O +
severity O +
of O +
pretransplant O +
illness O -
, O +
psychiatric O +
co O -
- O -
morbidity O -
, O +
medical O +
and O +
psychosocial O +
outcomes O +
of O +
all O +
patients O +
who O +
had O +
undergone O +
liver O +
transplantation O +
( O -
LT O -
) O +
emergently O +
between O +
1999 O -
- O -
2004 O +
for O +
acetaminophen O -
- O -
induced O +
ALF U-Disease +
( O -
n=36 O -
) O +
with O +
age- O +
and O +
sex O -
- O -
matched O +
patients O +
undergoing O +
emergent O +
LT O +
for O +
non O -
- O -
acetaminophen O -
- O -
induced O +
ALF U-Disease +
( O -
n=35 O -
) O +
and O +
elective O +
LT O +
for O +
chronic B-Disease +
liver I-Disease +
disease L-Disease +
( O -
CLD U-Disease -
, O +
n=34 O -
) O -
. O -

RESULTS O -
: O +
Acetaminophen O -
- O -
induced O +
ALF U-Disease +
patients O +
undergoing O +
LT O +
had O +
a O +
greater O +
severity O +
of O +
pre O -
- O -
LT O +
illness O +
reflected O +
by O +
higher O +
Acute O +
Physiology O +
and O +
Chronic O +
Health O +
Evaluation O +
II O +
scores O +
and O +
requirement O +
for O +
organ O +
support O +
compared O +
with O +
the O +
other O +
two O +
groups O -
. O -

Twenty O +
( O -
56 O -
% O -
) O +
acetaminophen O -
- O -
induced O +
ALF U-Disease +
patients O +
had O +
a O +
formal O +
psychiatric O +
diagnosis O +
before O +
LT O +
( O -
non O -
- O -
acetaminophen O -
- O -
induced O +
ALF=0 U-Disease -
/ O -
35 O -
, O +
CLD=2 U-Disease -
/ O -
34 O -
; O +
P<0.01 O +
for O +
all O -
) O +
and O +
nine O +
( O -
25 O -
% O -
) O +
had O +
a O +
previous O +
suicide O +
attempt O -
. O -

During O +
follow O -
- O -
up O +
( O -
median O +
5 O +
years O -
) O -
, O +
there O +
were O +
no O +
significant O +
differences O +
in O +
rejection O +
( O -
acute O +
and O +
chronic O -
) O -
, O +
graft O +
failure O +
or O +
survival O +
between O +
the O +
groups O +
( O -
acetaminophen O -
- O -
induced O +
ALF U-Disease +
1 O +
year O +
87 O -
% O -
, O +
5 O +
years O +
75 O -
% O -
; O +
non O -
- O -
acetaminophen O -
- O -
induced O +
ALF U-Disease +
88 O -
% O -
, O +
78 O -
% O -
; O +
CLD U-Disease +
93 O -
% O -
, O +
82 O -
% O -
: O +
P>0.6 O +
log O +
rank O -
) O -
. O -

Two O +
acetaminophen O -
- O -
induced O +
ALF U-Disease +
patients O +
reattempted O +
suicide O +
post O -
- O -
LT O +
( O -
one O +
died O +
8 O +
years O +
post O -
- O -
LT O -
) O -
. O -

CONCLUSIONS O -
: O +
Despite O +
a O +
high O +
prevalence O +
of O +
psychiatric O +
disturbance O -
, O +
outcomes O +
for O +
patients O +
transplanted O +
emergently O +
for O +
acetaminophen O -
- O -
induced O +
ALF U-Disease +
were O +
comparable O +
to O +
those O +
transplanted O +
for O +
non O -
- O -
acetaminophen O -
- O -
induced O +
ALF U-Disease +
and O +
electively O +
for O +
CLD U-Disease -
. O -

Multidisciplinary O +
approaches O +
with O +
long O -
- O -
term O +
psychiatric O +
follow O -
- O -
up O +
may O +
contribute O +
to O +
low O +
post O -
- O -
transplant O +
suicide O +
rates O +
seen O +
and O +
low O +
rates O +
of O +
graft O +
loss O +
because O +
of O +
non O -
- O -
compliance O -
. O -

Antithrombotic O +
drug O +
use O -
, O +
cerebral B-Disease +
microbleeds L-Disease -
, O +
and O +
intracerebral B-Disease +
hemorrhage L-Disease -
: O +
a O +
systematic O +
review O +
of O +
published O +
and O +
unpublished O +
studies O -
. O -

BACKGROUND O +
AND O +
PURPOSE O -
: O +
Cerebral B-Disease +
microbleeds L-Disease +
( O -
MB U-Disease -
) O +
are O +
potential O +
risk O +
factors O +
for O +
intracerebral B-Disease +
hemorrhage L-Disease +
( O -
ICH U-Disease -
) O -
, O +
but O +
it O +
is O +
unclear O +
if O +
they O +
are O +
a O +
contraindication O +
to O +
using O +
antithrombotic O +
drugs O -
. O -

Insights O +
could O +
be O +
gained O +
by O +
pooling O +
data O +
on O +
MB U-Disease +
frequency O +
stratified O +
by O +
antithrombotic O +
use O +
in O +
cohorts O +
with O +
ICH U-Disease +
and O +
ischemic B-Disease +
stroke L-Disease +
( O -
IS U-Disease -
) O -
/ O -
transient B-Disease +
ischemic I-Disease +
attack L-Disease +
( O -
TIA U-Disease -
) O -
. O -

METHODS O -
: O +
We O +
performed O +
a O +
systematic O +
review O +
of O +
published O +
and O +
unpublished O +
data O +
from O +
cohorts O +
with O +
stroke U-Disease +
or O +
TIA U-Disease +
to O +
compare O +
the O +
presence O +
of O +
MB U-Disease +
in O -
: O +
( O -
1 O -
) O +
antithrombotic O +
users O +
vs O +
nonantithrombotic O +
users O +
with O +
ICH U-Disease -
; O +
( O -
2 O -
) O +
antithrombotic O +
users O +
vs O +
nonusers O +
with O +
IS U-Disease -
/ O -
TIA U-Disease -
; O +
and O +
( O -
3 O -
) O +
ICH U-Disease +
vs O +
ischemic U-Disease +
events O +
stratified O +
by O +
antithrombotic O +
use O -
. O -

We O +
also O +
analyzed O +
published O +
and O +
unpublished O +
follow O -
- O -
up O +
data O +
to O +
determine O +
the O +
risk O +
of O +
ICH U-Disease +
in O +
antithrombotic O +
users O +
with O +
MB U-Disease -
. O -

RESULTS O -
: O +
In O +
a O +
pooled O +
analysis O +
of O +
1460 O +
ICH U-Disease +
and O +
3817 O +
IS U-Disease -
/ O -
TIA U-Disease -
, O +
MB U-Disease +
were O +
more O +
frequent O +
in O +
ICH U-Disease +
vs O +
IS U-Disease -
/ O -
TIA U-Disease +
in O +
all O +
treatment O +
groups O -
, O +
but O +
the O +
excess O +
increased O +
from O +
2.8 O +
( O -
odds O +
ratio O -
; O +
range O -
, O +
2.3 O -
- O -
3.5 O -
) O +
in O +
nonantithrombotic O +
users O +
to O +
5.7 O +
( O -
range O -
, O +
3.4 O -
- O -
9.7 O -
) O +
in O +
antiplatelet O +
users O +
and O +
8.0 O +
( O -
range O -
, O +
3.5 O -
- O -
17.8 O -
) O +
in O +
warfarin O +
users O +
( O -
P O +
difference=0.01 O -
) O -
. O -

There O +
was O +
also O +
an O +
excess O +
of O +
MB U-Disease +
in O +
warfarin O +
users O +
vs O +
nonusers O +
with O +
ICH U-Disease +
( O -
OR O -
, O +
2.7 O -
; O +
95 O -
% O +
CI O -
, O +
1.6 O -
- O -
4.4 O -
; O +
P<0.001 O -
) O +
but O +
none O +
in O +
warfarin O +
users O +
with O +
IS U-Disease -
/ O -
TIA U-Disease +
( O -
OR O -
, O +
1.3 O -
; O +
95 O -
% O +
CI O -
, O +
0.9 O -
- O -
1.7 O -
; O +
P=0.33 O -
; O +
P O +
difference=0.01 O -
) O -
. O -

There O +
was O +
a O +
smaller O +
excess O +
of O +
MB U-Disease +
in O +
antiplatelet O +
users O +
vs O +
nonusers O +
with O +
ICH U-Disease +
( O -
OR O -
, O +
1.7 O -
; O +
95 O -
% O +
CI O -
, O +
1.3 O -
- O -
2.3 O -
; O +
P<0.001 O -
) O -
, O +
but O +
findings O +
were O +
similar O +
for O +
antiplatelet O +
users O +
with O +
IS U-Disease -
/ O -
TIA U-Disease +
( O -
OR O -
, O +
1.4 O -
; O +
95 O -
% O +
CI O -
, O +
1.2 O -
- O -
1.7 O -
; O +
P<0.001 O -
; O +
P O +
difference=0.25 O -
) O -
. O -

In O +
pooled O +
follow O -
- O -
up O +
data O +
for O +
768 O +
antithrombotic O +
users O -
, O +
presence O +
of O +
MB U-Disease +
at O +
baseline O +
was O +
associated O +
with O +
a O +
substantially O +
increased O +
risk O +
of O +
subsequent O +
ICH U-Disease +
( O -
OR O -
, O +
12.1 O -
; O +
95 O -
% O +
CI O -
, O +
3.4 O -
- O -
42.5 O -
; O +
P<0.001 O -
) O -
. O -

CONCLUSIONS O -
: O +
The O +
excess O +
of O +
MB U-Disease +
in O +
warfarin O +
users O +
with O +
ICH U-Disease +
compared O +
to O +
other O +
groups O +
suggests O +
that O +
MB U-Disease +
increase O +
the O +
risk O +
of O +
warfarin O -
- O -
associated O +
ICH U-Disease -
. O -

Limited O +
prospective O +
data O +
corroborate O +
these O +
findings O -
, O +
but O +
larger O +
prospective O +
studies O +
are O +
urgently O +
required O -
. O -

Studies O +
of O +
synergy O +
between O +
morphine O +
and O +
a O +
novel O +
sodium O +
channel O +
blocker O -
, O +
CNSB002 O -
, O +
in O +
rat O +
models O +
of O +
inflammatory O +
and O +
neuropathic B-Disease +
pain L-Disease -
. O -

OBJECTIVE O -
: O +
This O +
study O +
determined O +
the O +
antihyperalgesic O +
effect O +
of O +
CNSB002 O -
, O +
a O +
sodium O +
channel O +
blocker O +
with O +
antioxidant O +
properties O +
given O +
alone O +
and O +
in O +
combinations O +
with O +
morphine O +
in O +
rat O +
models O +
of O +
inflammatory O +
and O +
neuropathic B-Disease +
pain L-Disease -
. O -

DESIGN O -
: O +
Dose O +
response O +
curves O +
for O +
nonsedating O +
doses O +
of O +
morphine O +
and O +
CNSB002 O +
given O +
intraperitoneally O +
alone O +
and O +
together O +
in O +
combinations O +
were O +
constructed O +
for O +
antihyperalgesic O +
effect O +
using O +
paw O +
withdrawal O +
from O +
noxious O +
heat O +
in O +
two O +
rat O +
pain U-Disease +
models O -
: O +
carrageenan O -
- O -
induced O +
paw O +
inflammation U-Disease +
and O +
streptozotocin O +
( O -
STZ O -
) O -
-induced O +
diabetic B-Disease +
neuropathy L-Disease -
. O -

RESULTS O -
: O +
The O +
maximum O +
nonsedating O +
doses O +
were O -
: O +
morphine O -
, O +
3.2 O +
mg O -
/ O -
kg O -
; O +
CNSB002 O +
10.0 O +
mg O -
/ O -
kg O -
; O +
5.0 O +
mg O -
/ O -
kg O +
CNSB002 O +
with O +
morphine O +
3.2 O +
mg O -
/ O -
kg O +
in O +
combination O -
. O -

The O +
doses O +
calculated O +
to O +
cause O +
50 O -
% O +
reversal O +
of O +
hyperalgesia U-Disease +
( O -
ED50 O -
) O +
were O +
7.54 O +
( O -
1.81 O -
) O +
and O +
4.83 O +
( O -
1.54 O -
) O +
in O +
the O +
carrageenan O +
model O +
and O +
44.18 O +
( O -
1.37 O -
) O +
and O +
9.14 O +
( O -
1.24 O -
) O +
in O +
the O +
STZ O -
- O -
induced O +
neuropathy U-Disease +
model O +
for O +
CNSB002 O +
and O +
morphine O -
, O +
respectively O +
( O -
mg O -
/ O -
kg O -
; O +
mean O -
, O +
SEM O -
) O -
. O -

These O +
values O +
were O +
greater O +
than O +
the O +
maximum O +
nonsedating O +
doses O -
. O -

The O +
ED50 O +
values O +
for O +
morphine O +
when O +
given O +
in O +
combination O +
with O +
CNSB002 O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
were O +
less O +
than O +
the O +
maximum O +
nonsedating O +
dose O -
: O +
0.56 O +
( O -
1.55 O -
) O +
in O +
the O +
carrageenan O +
model O +
and O +
1.37 O +
( O -
1.23 O -
) O +
in O +
the O +
neuropathy U-Disease +
model O +
( O -
mg O -
/ O -
kg O -
; O +
mean O -
, O +
SEM O -
) O -
. O -

The O +
antinociception O +
after O +
morphine O +
( O -
3.2 O +
mg O -
/ O -
kg O -
) O +
was O +
increased O +
by O +
co O -
- O -
administration O +
with O +
CNSB002 O +
from O +
28.0 O +
and O +
31.7 O -
% O +
to O +
114.6 O +
and O +
56.9 O -
% O +
reversal O +
of O +
hyperalgesia U-Disease +
in O +
the O +
inflammatory O +
and O +
neuropathic U-Disease +
models O -
, O +
respectively O +
( O -
P O +
< O +
0.01 O -
; O +
one O -
- O -
way O +
analysis O +
of O +
variance O -
- O -
significantly O +
greater O +
than O +
either O +
drug O +
given O +
alone O -
) O -
. O -

CONCLUSIONS O -
: O +
The O +
maximum O +
antihyperalgesic O +
effect O +
achievable O +
with O +
nonsedating O +
doses O +
of O +
morphine O +
may O +
be O +
increased O +
significantly O +
when O +
the O +
drug O +
is O +
used O +
in O +
combination O +
with O +
CNSB002 O -
. O -

Heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
: O +
a O +
practical O +
review O -
. O -

Heparin O -
- O -
induced O +
thrombocytopenia U-Disease +
( O -
HIT U-Disease -
) O +
remains O +
under O -
- O -
recognized O +
despite O +
its O +
potentially O +
devastating O +
outcomes O -
. O -

It O +
begins O +
when O +
heparin O +
exposure O +
stimulates O +
the O +
formation O +
of O +
heparin O -
- O -
platelet O +
factor O +
4 O +
antibodies O -
, O +
which O +
in O +
turn O +
triggers O +
the O +
release O +
of O +
procoagulant O +
platelet O +
particles O -
. O -

Thrombosis U-Disease +
and O +
thrombocytopenia U-Disease +
that O +
follow O +
comprise O +
the O +
2 O +
hallmark O +
traits O +
of O +
HIT U-Disease -
, O +
with O +
the O +
former O +
largely O +
responsible O +
for O +
significant O +
vascular O +
complications O -
. O -

The O +
prevalence O +
of O +
HIT U-Disease +
varies O +
among O +
several O +
subgroups O -
, O +
with O +
greater O +
incidence O +
in O +
surgical O +
as O +
compared O +
with O +
medical O +
populations O -
. O -

HIT U-Disease +
must O +
be O +
acknowledged O +
for O +
its O +
intense O +
predilection O +
for O +
thrombosis U-Disease +
and O +
suspected O +
whenever O +
thrombosis U-Disease +
occurs O +
after O +
heparin O +
exposure O -
. O -

Early O +
recognition O +
that O +
incorporates O +
the O +
clinical O +
and O +
serologic O +
clues O +
is O +
paramount O +
to O +
timely O +
institution O +
of O +
treatment O -
, O +
as O +
its O +
delay O +
may O +
result O +
in O +
catastrophic O +
outcomes O -
. O -

The O +
treatment O +
of O +
HIT U-Disease +
mandates O +
an O +
immediate O +
cessation O +
of O +
all O +
heparin O +
exposure O +
and O +
the O +
institution O +
of O +
an O +
antithrombotic O +
therapy O -
, O +
most O +
commonly O +
using O +
a O +
direct O +
thrombin O +
inhibitor O -
. O -

Current O +
" O -
diagnostic O -
" O +
tests O -
, O +
which O +
primarily O +
include O +
functional O +
and O +
antigenic O +
assays O -
, O +
have O +
more O +
of O +
a O +
confirmatory O +
than O +
diagnostic O +
role O +
in O +
the O +
management O +
of O +
HIT U-Disease -
. O -

Special O +
attention O +
must O +
be O +
paid O +
to O +
cardiac O +
patients O +
who O +
are O +
often O +
exposed O +
to O +
heparin O +
multiple O +
times O +
during O +
their O +
course O +
of O +
treatment O -
. O -

Direct O +
thrombin O +
inhibitors O +
are O +
appropriate O -
, O +
evidence O -
- O -
based O +
alternatives O +
to O +
heparin O +
in O +
patients O +
with O +
a O +
history O +
of O +
HIT U-Disease -
, O +
who O +
need O +
to O +
undergo O +
percutaneous O +
coronary O +
intervention O -
. O -

As O +
heparin O +
remains O +
one O +
of O +
the O +
most O +
frequently O +
used O +
medications O +
today O +
with O +
potential O +
for O +
HIT U-Disease +
with O +
every O +
heparin O +
exposure O -
, O +
a O +
close O +
vigilance O +
of O +
platelet O +
counts O +
must O +
be O +
practiced O +
whenever O +
heparin O +
is O +
initiated O -
. O -

Abductor O +
paralysis U-Disease +
after O +
botox O +
injection O +
for O +
adductor B-Disease +
spasmodic I-Disease +
dysphonia L-Disease -
. O -

OBJECTIVES O -
/ O -
HYPOTHESIS O -
: O +
Botulinum O +
toxin O +
( O -
Botox O -
) O +
injections O +
into O +
the O +
thyroarytenoid O +
muscles O +
are O +
the O +
current O +
standard O +
of O +
care O +
for O +
adductor B-Disease +
spasmodic I-Disease +
dysphonia L-Disease +
( O -
ADSD U-Disease -
) O -
. O -

Reported O +
adverse O +
effects O +
include O +
a O +
period O +
of O +
breathiness O -
, O +
throat B-Disease +
pain L-Disease -
, O +
and O +
difficulty O +
with O +
swallowing O +
liquids O -
. O -

Here O +
we O +
report O +
multiple O +
cases O +
of O +
bilateral O +
abductor O +
paralysis U-Disease +
following O +
Botox O +
injections O +
for O +
ADSD U-Disease -
, O +
a O +
complication O +
previously O +
unreported O -
. O -

STUDY O +
DESIGN O -
: O +
Retrospective O +
case O +
series O -
. O -

METHODS O -
: O +
Patients O +
that O +
received O +
Botox O +
injections O +
for O +
spasmodic B-Disease +
dysphonia L-Disease +
between O +
January O +
2000 O +
and O +
October O +
2009 O +
were O +
evaluated O -
. O -

Patients O +
with O +
ADSD U-Disease +
were O +
identified O -
. O -

The O +
number O +
of O +
treatments O +
received O +
and O +
adverse O +
effects O +
were O +
noted O -
. O -

For O +
patients O +
with O +
bilateral O +
abductor O +
paralysis U-Disease -
, O +
age O -
, O +
sex O -
, O +
paralytic O +
Botox O +
dose O -
, O +
prior O +
Botox O +
dose O -
, O +
and O +
course O +
following O +
paralysis U-Disease +
were O +
noted O -
. O -

RESULTS O -
: O +
From O +
a O +
database O +
of O +
452 O +
patients O +
receiving O +
Botox O -
, O +
352 O +
patients O +
had O +
been O +
diagnosed O +
with O +
ADSD U-Disease -
. O -

Of O +
these O +
352 O +
patients O -
, O +
eight O +
patients O +
suffered O +
bilateral O +
abductor O +
paralysis U-Disease -
, O +
and O +
two O +
suffered O +
this O +
complication O +
twice O -
. O -

All O +
affected O +
patients O +
were O +
females O +
over O +
the O +
age O +
of O +
50 O +
years O -
. O -

Most O +
patients O +
had O +
received O +
treatments O +
prior O +
to O +
abductor O +
paralysis U-Disease +
and O +
continued O +
receiving O +
after O +
paralysis U-Disease -
. O -

Seven O +
patients O +
recovered O +
after O +
a O +
brief O +
period O +
of O +
activity O +
restrictions O -
, O +
and O +
one O +
underwent O +
a O +
tracheotomy O -
. O -

The O +
incidence O +
of O +
abductor O +
paralysis U-Disease +
after O +
Botox O +
injection O +
for O +
ADSD U-Disease +
was O +
0.34 O -
% O -
. O -

CONCLUSIONS O -
: O +
Bilateral O +
abductor O +
paralysis U-Disease +
is O +
a O +
rare O +
complication O +
of O +
Botox O +
injections O +
for O +
ADSD U-Disease -
, O +
causing O +
difficulty O +
with O +
breathing O +
upon O +
exertion O -
. O -

The O +
likely O +
mechanism O +
of O +
paralysis U-Disease +
is O +
diffusion O +
of O +
Botox O +
around O +
the O +
muscular O +
process O +
of O +
the O +
arytenoid O +
to O +
the O +
posterior O +
cricoarytenoid O +
muscles O -
. O -

The O +
paralysis U-Disease +
is O +
temporary O -
, O +
and O +
watchful O +
waiting O +
with O +
restriction O +
of O +
activity O +
is O +
the O +
recommended O +
management O -
. O -

Mitochondrial B-Disease +
impairment L-Disease +
contributes O +
to O +
cocaine O -
- O -
induced O +
cardiac B-Disease +
dysfunction L-Disease -
: O +
Prevention O +
by O +
the O +
targeted O +
antioxidant O +
MitoQ. O +
The O +
goal O +
of O +
this O +
study O +
was O +
to O +
assess O +
mitochondrial O +
function O +
and O +
ROS O +
production O +
in O +
an O +
experimental O +
model O +
of O +
cocaine O -
- O -
induced O +
cardiac B-Disease +
dysfunction L-Disease -
. O -

We O +
hypothesized O +
that O +
cocaine B-Disease +
abuse L-Disease +
may O +
lead O +
to O +
altered O +
mitochondrial O +
function O +
that O +
in O +
turn O +
may O +
cause O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease -
. O -

Seven O +
days O +
of O +
cocaine O +
administration O +
to O +
rats O +
led O +
to O +
an O +
increased O +
oxygen O +
consumption O +
detected O +
in O +
cardiac O +
fibers O -
, O +
specifically O +
through O +
complex O +
I O +
and O +
complex O +
III O -
. O -

ROS O +
levels O +
were O +
increased O -
, O +
specifically O +
in O +
interfibrillar O +
mitochondria O -
. O -

In O +
parallel O +
there O +
was O +
a O +
decrease O +
in O +
ATP O +
synthesis O -
, O +
whereas O +
no O +
difference O +
was O +
observed O +
in O +
subsarcolemmal O +
mitochondria O -
. O -

This O +
uncoupling O +
effect O +
on O +
oxidative O +
phosphorylation O +
was O +
not O +
detectable O +
after O +
short O -
- O -
term O +
exposure O +
to O +
cocaine O -
, O +
suggesting O +
that O +
these O +
mitochondrial B-Disease +
abnormalities L-Disease +
were O +
a O +
late O +
rather O +
than O +
a O +
primary O +
event O +
in O +
the O +
pathological O +
response O +
to O +
cocaine O -
. O -

MitoQ O -
, O +
a O +
mitochondrial O -
- O -
targeted O +
antioxidant O -
, O +
was O +
shown O +
to O +
completely O +
prevent O +
these O +
mitochondrial B-Disease +
abnormalities L-Disease +
as O +
well O +
as O +
cardiac B-Disease +
dysfunction L-Disease +
characterized O +
here O +
by O +
a O +
diastolic B-Disease +
dysfunction L-Disease +
studied O +
with O +
a O +
conductance O +
catheter O +
to O +
obtain O +
pressure O -
- O -
volume O +
data O -
. O -

Taken O +
together O -
, O +
these O +
results O +
extend O +
previous O +
studies O +
and O +
demonstrate O +
that O +
cocaine O -
- O -
induced O +
cardiac B-Disease +
dysfunction L-Disease +
may O +
be O +
due O +
to O +
a O +
mitochondrial B-Disease +
defect L-Disease -
. O -

Trimethoprim O -
- O -
induced O +
immune O +
hemolytic B-Disease +
anemia L-Disease +
in O +
a O +
pediatric O +
oncology O +
patient O +
presenting O +
as O +
an O +
acute O +
hemolytic O +
transfusion O +
reaction O -
. O -

A O +
10-year O -
- O -
old O +
male O +
with O +
acute B-Disease +
leukemia L-Disease +
presented O +
with O +
post O -
- O -
chemotherapy O +
anemia U-Disease -
. O -

During O +
red O +
cell O +
transfusion O -
, O +
he O +
developed O +
hemoglobinuria U-Disease -
. O -

Transfusion O +
reaction O +
workup O +
was O +
negative O -
. O -

Drug O -
- O -
induced O +
immune O +
hemolytic B-Disease +
anemia L-Disease +
was O +
suspected O +
because O +
of O +
positive O +
direct O +
antiglobulin O +
test O -
, O +
negative O +
eluate O -
, O +
and O +
microspherocytes O +
on O +
smear O +
pre- O +
and O +
post O -
- O -
transfusion O -
. O -

Drug O +
studies O +
using O +
the O +
indirect O +
antiglobulin O +
test O +
were O +
strongly O +
positive O +
with O +
trimethoprim O +
and O +
trimethoprim O -
- O -
sulfamethoxazole O +
but O +
negative O +
with O +
sulfamethoxazole O -
. O -

The O +
patient O +
recovered O +
after O +
discontinuing O +
the O +
drug O -
, O +
with O +
no O +
recurrence O +
in O +
2 O +
years O -
. O -

Other O +
causes O +
of O +
anemia U-Disease +
should O +
be O +
considered O +
in O +
patients O +
with O +
worse O -
- O -
than O -
- O -
expected O +
anemia U-Disease +
after O +
chemotherapy O -
. O -

Furthermore O -
, O +
hemolysis U-Disease +
during O +
transfusion O +
is O +
not O +
always O +
a O +
transfusion O +
reaction O -
. O -

Verapamil O +
stimulation O +
test O +
in O +
hyperprolactinemia U-Disease -
: O +
loss O +
of O +
prolactin O +
response O +
in O +
anatomic O +
or O +
functional O +
stalk O +
effect O -
. O -

AIM O -
: O +
Verapamil O +
stimulation O +
test O +
was O +
previously O +
investigated O +
as O +
a O +
tool O +
for O +
differential O +
diagnosis O +
of O +
hyperprolactinemia U-Disease -
, O +
but O +
with O +
conflicting O +
results O -
. O -

Macroprolactinemia U-Disease +
was O +
never O +
considered O +
in O +
those O +
previous O +
studies O -
. O -

Here O -
, O +
we O +
aimed O +
to O +
re O -
- O -
investigate O +
the O +
diagnostic O +
value O +
of O +
verapamil O +
in O +
a O +
population O +
who O +
were O +
all O +
screened O +
for O +
macroprolactinemia U-Disease -
. O -

Prolactin O +
responses O +
to O +
verapamil O +
in O +
65 O +
female O +
patients O +
( O -
age O -
: O +
29.9 O +
+ O -
/- O +
8.1 O +
years O -
) O +
with O +
hyperprolactinemia U-Disease +
were O +
tested O +
in O +
a O +
descriptive O -
, O +
matched O +
case O -
- O -
control O +
study O -
. O -

METHODS O -
: O +
Verapamil O +
80 O +
mg O -
, O +
p.o O -
. O +
was O +
administered O -
, O +
and O +
then O +
PRL O +
levels O +
were O +
measured O +
at O +
8th O +
and O +
16th O +
hours O -
, O +
by O +
immunometric O +
chemiluminescence O -
. O -

Verapamil O +
responsiveness O +
was O +
determined O +
by O +
peak O +
percent O +
change O +
in O +
basal O +
prolactin O +
levels O +
( O -
PRL O -
) O -
. O -

RESULTS O -
: O +
Verapamil O +
significantly O +
increased O +
PRL O +
levels O +
in O +
healthy O +
controls O +
( O -
N. O +
8 O -
, O +
PRL O -
: O +
183 O -
% O -
) O -
, O +
macroprolactinoma U-Disease +
( O -
N. O +
8 O -
, O +
PRL O -
: O +
7 O -
% O -
) O -
, O +
microprolactinoma U-Disease +
( O -
N. O +
19 O -
, O +
PRL O -
: O +
21 O -
% O -
) O -
, O +
macroprolactinemia U-Disease +
( O -
N. O +
23 O -
, O +
PRL O -
: O +
126 O -
% O -
) O -
, O +
but O +
not O +
in O +
pseudoprolactinoma U-Disease +
( O -
N. O +
8 O -
, O +
PRL O -
: O +
0.8 O -
% O -
) O -
, O +
and O +
risperidone O -
- O -
induced O +
hyperprolactinemia U-Disease +
( O -
N. O +
7 O -
, O +
PRL O -
: O +
3 O -
% O -
) O -
. O -

ROC O +
curve O +
analysis O +
revealed O +
that O +
unresponsiveness O +
to O +
verapamil O +
defined O +
as O +
PRL O +
< O -
7 O -
% O -
, O +
discriminated O +
anatomical O +
or O +
functional O +
stalk O +
effect O +
( O -
sensitivity O -
: O +
74 O -
% O -
, O +
specificity O -
: O +
73 O -
% O -
, O +
AUC O -
: O +
0.855+ O -
/ O -
-0.04 O -
, O +
P O +
< O -
0.001 O -
, O +
CI O -
: O +
0.768 O -
- O -
0.942 O -
) O +
associated O +
with O +
pseudoprolactinoma U-Disease +
or O +
risperidone O -
- O -
induced O +
hyperprolactinemia U-Disease -
, O +
respectively O -
. O -

CONCLUSION O -
: O +
Verapamil O +
responsiveness O +
is O +
not O +
a O +
reliable O +
finding O +
for O +
the O +
differential O +
diagnosis O +
of O +
hyperprolactinemia U-Disease -
. O -

However O -
, O +
verapamil O +
unresponsiveness O +
discriminates O +
stalk O +
effect O +
( O -
i.e. O -
, O +
anatomically O +
or O +
functionally O +
inhibited O +
dopaminergic O +
tonus O -
) O +
from O +
other O +
causes O +
of O +
hyperprolactinemia U-Disease +
with O +
varying O +
degrees O +
of O +
responsiveness O -
. O -

Blockade O +
of O +
endothelial O -
- O -
mesenchymal O +
transition O +
by O +
a O +
Smad3 O +
inhibitor O +
delays O +
the O +
early O +
development O +
of O +
streptozotocin O -
- O -
induced O +
diabetic B-Disease +
nephropathy L-Disease -
. O -

OBJECTIVE O -
: O +
A O +
multicenter O -
, O +
controlled O +
trial O +
showed O +
that O +
early O +
blockade O +
of O +
the O +
renin O -
- O -
angiotensin O +
system O +
in O +
patients O +
with O +
type B-Disease +
1 I-Disease +
diabetes L-Disease +
and O +
normoalbuminuria O +
did O +
not O +
retard O +
the O +
progression O +
of O +
nephropathy U-Disease -
, O +
suggesting O +
that O +
other O +
mechanism O -
( O -
s O -
) O +
are O +
involved O +
in O +
the O +
pathogenesis O +
of O +
early O +
diabetic B-Disease +
nephropathy L-Disease +
( O -
diabetic B-Disease +
nephropathy L-Disease -
) O -
. O -

We O +
have O +
previously O +
demonstrated O +
that O +
endothelial O -
- O -
mesenchymal O -
- O -
transition O +
( O -
EndoMT O -
) O +
contributes O +
to O +
the O +
early O +
development O +
of O +
renal O +
interstitial O +
fibrosis U-Disease +
independently O +
of O +
microalbuminuria O +
in O +
mice O +
with O +
streptozotocin O +
( O -
STZ O -
) O -
-induced O +
diabetes U-Disease -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
hypothesized O +
that O +
blocking O +
EndoMT O +
reduces O +
the O +
early O +
development O +
of O +
diabetic B-Disease +
nephropathy L-Disease -
. O -

RESEARCH O +
DESIGN O +
AND O +
METHODS O -
: O +
EndoMT O +
was O +
induced O +
in O +
a O +
mouse O +
pancreatic O +
microvascular O +
endothelial O +
cell O +
line O +
( O -
MMEC O -
) O +
in O +
the O +
presence O +
of O +
advanced O +
glycation O +
end O +
products O +
( O -
AGEs O -
) O +
and O +
in O +
the O +
endothelial O +
lineage O -
- O -
traceble O +
mouse O +
line O +
Tie2-Cre;Loxp O -
- O -
EGFP O +
by O +
administration O +
of O +
AGEs O -
, O +
with O +
nonglycated O +
mouse O +
albumin O +
serving O +
as O +
a O +
control O -
. O -

Phosphorylated O +
Smad3 O +
was O +
detected O +
by O +
immunoprecipitation O -
/ O -
Western O +
blotting O +
and O +
confocal O +
microscopy O -
. O -

Blocking O +
studies O +
using O +
receptor O +
for O +
AGE O +
siRNA O +
and O +
a O +
specific O +
inhibitor O +
of O +
Smad3 O +
( O -
SIS3 O -
) O +
were O +
performed O +
in O +
MMECs O +
and O +
in O +
STZ O -
- O -
induced O +
diabetic B-Disease +
nephropathy L-Disease +
in O +
Tie2-Cre;Loxp O -
- O -
EGFP O +
mice O -
. O -

RESULTS O -
: O +
Confocal O +
microscopy O +
and O +
real O -
- O -
time O +
PCR O +
demonstrated O +
that O +
AGEs O +
induced O +
EndoMT O +
in O +
MMECs O +
and O +
in O +
Tie2-Cre;Loxp O -
- O -
EGFP O +
mice O -
. O -

Immunoprecipitation O -
/ O -
Western O +
blotting O +
showed O +
that O +
Smad3 O +
was O +
activated O +
by O +
AGEs O +
but O +
was O +
inhibited O +
by O +
SIS3 O +
in O +
MMECs O +
and O +
in O +
STZ O -
- O -
induced O +
diabetic B-Disease +
nephropathy L-Disease -
. O -

Confocal O +
microscopy O +
and O +
real O -
- O -
time O +
PCR O +
further O +
demonstrated O +
that O +
SIS3 O +
abrogated O +
EndoMT O -
, O +
reduced O +
renal O +
fibrosis U-Disease -
, O +
and O +
retarded O +
progression O +
of O +
nephropathy U-Disease -
. O -

CONCLUSIONS O -
: O +
EndoMT O +
is O +
a O +
novel O +
pathway O +
leading O +
to O +
early O +
development O +
of O +
diabetic B-Disease +
nephropathy L-Disease -
. O -

Blockade O +
of O +
EndoMT O +
by O +
SIS3 O +
may O +
provide O +
a O +
new O +
strategy O +
to O +
retard O +
the O +
progression O +
of O +
diabetic B-Disease +
nephropathy L-Disease +
and O +
other O +
diabetes B-Disease +
complications L-Disease -
. O -

Cytostatic O +
and O +
anti O -
- O -
angiogenic O +
effects O +
of O +
temsirolimus O +
in O +
refractory O +
mantle B-Disease +
cell I-Disease +
lymphoma L-Disease -
. O -

Mantle B-Disease +
cell I-Disease +
lymphoma L-Disease +
( O -
MCL U-Disease -
) O +
is O +
a O +
rare O +
and O +
aggressive O +
type O +
of O +
B B-Disease -
- I-Disease -
cell I-Disease +
non I-Disease -
- I-Disease -
Hodgkin I-Disease -
's I-Disease +
lymphoma L-Disease -
. O -

Patients O +
become O +
progressively O +
refractory O +
to O +
conventional O +
chemotherapy O -
, O +
and O +
their O +
prognosis O +
is O +
poor O -
. O -

However O -
, O +
a O +
38 O -
% O +
remission O +
rate O +
has O +
been O +
recently O +
reported O +
in O +
refractory O +
MCL U-Disease +
treated O +
with O +
temsirolimus O -
, O +
a O +
mTOR O +
inhibitor O -
. O -

Here O +
we O +
had O +
the O +
opportunity O +
to O +
study O +
a O +
case O +
of O +
refractory O +
MCL U-Disease +
who O +
had O +
tumor U-Disease +
regression O +
two O +
months O +
after O +
temsirolimus O +
treatment O -
, O +
and O +
a O +
progression O -
- O -
free O +
survival O +
of O +
10 O +
months O -
. O -

In O +
this O +
case O -
, O +
lymph O +
node O +
biopsies O +
were O +
performed O +
before O +
and O +
six O +
months O +
after O +
temsirolimus O +
therapy O -
. O -

Comparison O +
of O +
the O +
two O +
biopsies O +
showed O +
that O +
temsirolimus O +
inhibited O +
tumor U-Disease +
cell O +
proliferation O +
through O +
cell O +
cycle O +
arrest O -
, O +
but O +
did O +
not O +
induce O +
any O +
change O +
in O +
the O +
number O +
of O +
apoptotic O +
tumor U-Disease +
cells O -
. O -

Apart O +
from O +
this O +
cytostatic O +
effect O -
, O +
temsirolimus O +
had O +
an O +
antiangiogenic O +
effect O +
with O +
decrease O +
of O +
tumor U-Disease +
microvessel O +
density O +
and O +
of O +
VEGF O +
expression O -
. O -

Moreover O -
, O +
numerous O +
patchy O -
, O +
well O -
- O -
limited O +
fibrotic O +
areas O -
, O +
compatible O +
with O +
post O -
- O -
necrotic U-Disease +
tissue O +
repair O -
, O +
were O +
found O +
after O +
6-month O +
temsirolimus O +
therapy O -
. O -

Thus O -
, O +
temsirolimus O +
reduced O +
tumor U-Disease +
burden O +
through O +
associated O +
cytostatic O +
and O +
anti O -
- O -
angiogenic O +
effects O -
. O -

This O +
dual O +
effect O +
of O +
temsirolimus O +
on O +
tumor U-Disease +
tissue O +
could O +
contribute O +
to O +
its O +
recently O +
reported O +
efficiency O +
in O +
refractory O +
MCL U-Disease +
resistant O +
to O +
conventional O +
chemotherapy O -
. O -

Acute B-Disease +
renal I-Disease +
failure L-Disease +
due O +
to O +
rifampicin O -
. O -

A O +
23-year O -
- O -
old O +
male O +
patient O +
with O +
bacteriologically O +
proven O +
pulmonary B-Disease +
tuberculosis L-Disease +
was O +
treated O +
with O +
the O +
various O +
regimens O +
of O +
antituberculosis O +
drugs O +
for O +
nearly O +
15 O +
months O -
. O -

Rifampicin O +
was O +
administered O +
thrice O +
as O +
one O +
of O +
the O +
3 O -
- O -
4 O +
drug O +
regimen O +
and O +
each O +
time O +
he O +
developed O +
untoward O +
side O +
effects O +
like O +
nausea U-Disease -
, O +
vomiting U-Disease +
and O +
fever U-Disease +
with O +
chills O +
and O +
rigors O -
. O -

The O +
last O +
such O +
episode O +
was O +
of O +
acute O +
renal O +
failure O +
at O +
which O +
stage O +
the O +
patient O +
was O +
seen O +
by O +
the O +
authors O +
of O +
this O +
report O -
. O -

The O +
patient O -
, O +
however O -
, O +
made O +
a O +
full O +
recovery O -
. O -

Syncope U-Disease +
caused O +
by O +
hyperkalemia U-Disease +
during O +
use O +
of O +
a O +
combined O +
therapy O +
with O +
the O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
and O +
spironolactone O -
. O -

A O +
76 O +
year O -
- O -
old O +
woman O +
with O +
a O +
history O +
of O +
coronary O +
artery O +
bypass O +
grafting O +
and O +
prior O +
myocardial B-Disease +
infarction L-Disease +
was O +
transferred O +
to O +
the O +
emergency O +
room O +
with O +
loss B-Disease +
of I-Disease +
consciousness L-Disease +
due O +
to O +
marked O +
bradycardia U-Disease +
caused O +
by O +
hyperkalemia U-Disease -
. O -

The O +
concentration O +
of O +
serum O +
potassium O +
was O +
high O -
, O +
and O +
normal O +
sinus O +
rhythm O +
was O +
restored O +
after O +
correction O +
of O +
the O +
serum O +
potassium O +
level O -
. O -

The O +
cause O +
of O +
hyperkalemia U-Disease +
was O +
considered O +
to O +
be O +
several O +
doses O +
of O +
spiranolactone O -
, O +
an O +
aldosterone O +
antagonist O -
, O +
in O +
addition O +
to O +
the O +
long O -
- O -
term O +
intake O +
of O +
ramipril O -
, O +
an O +
ACE O +
inhibitor O -
. O -

This O +
case O +
is O +
a O +
good O +
example O +
of O +
electrolyte O +
imbalance O +
causing O +
acute O +
life O -
- O -
threatening O +
cardiac O +
events O -
. O -

Clinicians O +
should O +
be O +
alert O +
to O +
the O +
possibility O +
of O +
hyperkalemia U-Disease -
, O +
especially O +
in O +
elderly O +
patients O +
using O +
ACE O -
/ O -
ARB O +
in O +
combination O +
with O +
potassium O +
sparing O +
agents O +
and O +
who O +
have O +
mild O +
renal B-Disease +
disturbance L-Disease -
. O -

Diffuse O +
skeletal O +
pain U-Disease +
after O +
administration O +
of O +
alendronate O -
. O -

BACKGROUND O -
: O +
Osteoporosis U-Disease +
is O +
caused O +
by O +
bone O +
resorption O +
in O +
excess O +
of O +
bone O +
formation O -
, O +
and O +
bisphosphonates O -
, O +
are O +
used O +
to O +
inhibit O +
bone O +
resorption O -
. O -

Alendronate O -
, O +
a O +
biphosphonate O -
, O +
is O +
effective O +
for O +
both O +
the O +
treatment O +
and O +
prevention O +
of O +
osteoporosis U-Disease +
in O +
postmenopausal O +
women O -
. O -

Side O +
effects O +
are O +
relatively O +
few O +
and O +
prominently O +
gastrointestinal O -
. O -

Musculoskeletal B-Disease +
pain L-Disease +
may O +
be O +
an O +
important O +
side O +
effect O +
in O +
these O +
patients O -
. O -

We O +
presented O +
a O +
patient O +
admitted O +
to O +
our O +
out O -
- O -
patient O +
clinic O +
with O +
diffuse O +
skeletal O +
pain U-Disease +
after O +
three O +
consecutive O +
administration O +
of O +
alendronate O -
. O -

CONCLUSION O -
: O +
We O +
conclude O +
that O +
patients O +
with O +
osteoporosis U-Disease +
can O +
report O +
pain U-Disease -
, O +
and O +
bisphosphonate O -
- O -
related O +
pain U-Disease +
should O +
also O +
be O +
considered O +
before O +
ascribing O +
this O +
complaint O +
to O +
osteoporosis U-Disease -
. O -

Cerebrospinal O +
fluid O +
penetration O +
of O +
high O -
- O -
dose O +
daptomycin O +
in O +
suspected O +
Staphylococcus O +
aureus O +
meningitis U-Disease -
. O -

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
methicillin O -
- O -
sensitive O +
Staphylococcus O +
aureus O +
( O -
MSSA O -
) O +
bacteremia U-Disease +
with O +
suspected O +
MSSA O +
meningitis U-Disease +
treated O +
with O +
high O -
- O -
dose O +
daptomycin O +
assessed O +
with O +
concurrent O +
serum O +
and O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
concentrations O -
. O -

CASE O +
SUMMARY O -
: O +
A O +
54-year O -
- O -
old O +
male O +
presented O +
to O +
the O +
emergency O +
department O +
with O +
generalized O +
weakness U-Disease +
and O +
presumed O +
health O -
- O -
care O -
- O -
associated O +
pneumonia U-Disease +
shown O +
on O +
chest O +
radiograph O -
. O -

Treatment O +
was O +
empirically O +
initiated O +
with O +
vancomycin O -
, O +
levofloxacin O -
, O +
and O +
piperacillin O -
/ O -
tazobactam O -
. O -

Blood O +
cultures O +
revealed O +
S. O +
aureus O +
susceptible O +
to O +
oxacillin O -
. O -

Empiric O +
antibiotic O +
treatment O +
was O +
narrowed O +
to O +
nafcillin O +
on O +
day O +
4 O -
. O -

On O +
day O +
8 O -
, O +
the O +
patient O +
developed O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
( O -
serum O +
creatinine O +
1.9 O +
mg O -
/ O -
dL O -
, O +
increased O +
from O +
1.2 O +
mg O -
/ O -
dL O +
the O +
previous O +
day O +
and O +
0.8 O +
mg O -
/ O -
dL O +
on O +
admission O -
) O -
. O -

The O +
patient O -
's O +
Glasgow O +
Coma O +
Score O +
was O +
3 O -
, O +
with O +
normal O +
findings O +
shown O +
on O +
computed O +
tomography O +
scan O +
of O +
the O +
head O +
72 O +
hours O +
following O +
an O +
episode O +
of O +
cardiac B-Disease +
arrest L-Disease +
on O +
day O +
10 O -
. O -

The O +
patient O +
experienced O +
relapsing O +
MSSA O +
bacteremia U-Disease +
on O +
day O +
9 O -
, O +
increasing O +
the O +
suspicion O +
for O +
a O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
infection U-Disease -
. O -

Nafcillin O +
was O +
discontinued O +
and O +
daptomycin O +
9 O +
mg O -
/ O -
kg O +
daily O +
was O +
initiated O +
for O +
suspected O +
meningitis U-Disease +
and O +
was O +
continued O +
until O +
the O +
patient O -
's O +
death O +
on O +
day O +
16 O -
. O -

Daptomycin O +
serum O +
and O +
CSF O +
trough O +
concentrations O +
were O +
11.21 O +
ug O -
/ O -
mL O +
and O +
0.52 O +
ug O -
/ O -
mL O -
, O +
respectively O -
, O +
prior O +
to O +
the O +
third O +
dose O -
. O -

Lumbar O +
puncture O +
results O +
were O +
inconclusive O +
and O +
no O +
further O +
blood O +
cultures O +
were O +
positive O +
for O +
MSSA O -
. O -

Creatine O +
kinase O +
levels O +
were O +
normal O +
prior O +
to O +
daptomycin O +
therapy O +
and O +
were O +
not O +
reassessed O -
. O -

DISCUSSION O -
: O +
Daptomycin O +
was O +
initiated O +
in O +
our O +
patient O +
secondary O +
to O +
possible O +
nafcillin O -
- O -
induced O +
acute O +
interstitial B-Disease +
nephritis L-Disease +
and O +
relapsing O +
bacteremia U-Disease -
. O -

At O +
a O +
dose O +
of O +
9 O +
mg O -
/ O -
kg O -
, O +
resultant O +
penetration O +
of O +
5 O -
% O +
was O +
higher O +
than O +
in O +
previous O +
reports O -
, O +
more O +
consistent O +
with O +
inflamed O +
meninges O -
. O -

CONCLUSIONS O -
: O +
High O -
- O -
dose O +
daptomycin O +
may O +
be O +
an O +
alternative O +
option O +
for O +
MSSA O +
bacteremia U-Disease +
with O +
or O +
without O +
a O +
CNS O +
source O +
in O +
patients O +
who O +
have O +
failed O +
or O +
can O -
not O +
tolerate O +
standard O +
therapy O -
. O -

Further O +
clinical O +
evaluation O +
in O +
patients O +
with O +
confirmed O +
meningitis U-Disease +
is O +
warranted O -
. O -

The O +
role O +
of O +
nitric O +
oxide O +
in O +
convulsions U-Disease +
induced O +
by O +
lindane O +
in O +
rats O -
. O -

Lindane O +
is O +
an O +
organochloride O +
pesticide O +
and O +
scabicide O -
. O -

It O +
evokes O +
convulsions U-Disease +
mainly O +
trough O +
the O +
blockage O +
of O +
GABA O -
( O -
A O -
) O +
receptors O -
. O -

Nitric O +
oxide O +
( O -
NO O -
) O -
, O +
gaseous O +
neurotransmitter O -
, O +
has O +
contradictor O +
role O +
in O +
epileptogenesis O +
due O +
to O +
opposite O +
effects O +
of O +
L O -
- O -
arginine O -
, O +
precursor O +
of O +
NO O +
syntheses O +
( O -
NOS O -
) O -
, O +
and O +
L O -
- O -
NAME O +
( O -
NOS O +
inhibitor O -
) O +
observed O +
in O +
different O +
epilepsy U-Disease +
models O -
. O -

The O +
aim O +
of O +
the O +
current O +
study O +
was O +
to O +
determine O +
the O +
effects O +
of O +
NO O +
on O +
the O +
behavioral O +
and O +
EEG O +
characteristics O +
of O +
lindane O -
- O -
induced O +
epilepsy U-Disease +
in O +
male O +
Wistar O +
albino O +
rats O -
. O -

The O +
administration O +
of O +
L O -
- O -
arginine O +
( O -
600 O -
, O +
800 O +
and O +
1000 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
in O +
dose O -
- O -
dependent O +
manner O +
significantly O +
increased O +
convulsion U-Disease +
incidence O +
and O +
severity O +
and O +
shortened O +
latency O +
time O +
to O +
first O +
convulsion U-Disease +
elicited O +
by O +
lower O +
lindane O +
dose O +
( O -
4 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O -

On O +
the O +
contrary O -
, O +
pretreatment O +
with O +
L O -
- O -
NAME O +
( O -
500 O -
, O +
700 O +
and O +
900 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
decreased O +
convulsion U-Disease +
incidence O +
and O +
severity O +
and O +
prolonged O +
latency O +
time O +
to O +
convulsion U-Disease +
following O +
injection O +
with O +
a O +
convulsive U-Disease +
dose O +
of O +
lindane O +
( O -
8 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O -

EEG O +
analyses O +
showed O +
increase O +
of O +
number O +
and O +
duration O +
of O +
ictal O +
periods O +
in O +
EEG O +
of O +
rats O +
receiving O +
l O -
- O -
arginine O +
prior O +
to O +
lindane O +
and O +
decrease O +
of O +
this O +
number O +
in O +
rats O +
pretreated O +
with O +
L O -
- O -
NAME O -
. O -

These O +
results O +
support O +
the O +
conclusion O +
that O +
NO O +
plays O +
a O +
role O +
of O +
endogenous O +
convulsant O +
in O +
rat O +
model O +
of O +
lindane O +
seizures U-Disease -
. O -

Severe O +
polyneuropathy U-Disease +
and O +
motor O +
loss O +
after O +
intrathecal O +
thiotepa O +
combination O +
chemotherapy O -
: O +
description O +
of O +
two O +
cases O -
. O -

Two O +
cases O +
of O +
severe O +
delayed O +
neurologic B-Disease +
toxicity L-Disease +
related O +
to O +
the O +
administration O +
of O +
intrathecal O +
( O -
IT O -
) O +
combination O +
chemotherapy O +
including O +
thiotepa O +
( O -
TSPA O -
) O +
are O +
presented O -
. O -

Both O +
cases O +
developed O +
axonal B-Disease +
neuropathy L-Disease +
with O +
motor O +
predominance O +
in O +
the O +
lower O +
extremities O +
1 O +
and O +
6 O +
months O +
after O +
IT O +
chemotherapy O +
was O +
administered O -
. O -

Neurologic B-Disease +
toxicities L-Disease +
have O +
been O +
described O +
with O +
IT O -
- O -
methotrexate O -
, O +
IT O -
- O -
cytosine O +
arabinoside O +
and O +
IT O -
- O -
TSPA O -
. O -

To O +
our O +
knowledge O -
, O +
however O -
, O +
axonal B-Disease +
neuropathy L-Disease +
following O +
administration O +
of O +
these O +
three O +
agents O +
has O +
not O +
been O +
previously O +
described O -
. O -

In O +
spite O +
of O +
the O +
fact O +
that O +
TSPA O +
is O +
a O +
useful O +
IT O +
agent O -
, O +
its O +
combination O +
with O +
MTX O -
, O +
ara O -
- O -
C O +
and O +
radiotherapy O +
could O +
cause O +
severe O +
neurotoxicity U-Disease -
. O -

This O +
unexpected O +
complication O +
indicates O +
the O +
need O +
for O +
further O +
toxicology O +
research O +
on O +
IT O -
- O -
TSPA O -
. O -

Effects O +
of O +
cromakalim O +
and O +
pinacidil O +
on O +
large O +
epicardial O +
and O +
small O +
coronary O +
arteries O +
in O +
conscious O +
dogs O -
. O -

The O +
effects O +
of O +
i.v O -
. O -

bolus O +
administration O +
of O +
cromakalim O +
( O -
1 O -
- O -
10 O +
micrograms O -
/ O -
kg O -
) O +
and O +
pinacidil O +
( O -
3 O -
- O -
100 O +
micrograms O -
/ O -
kg O -
) O +
on O +
large O +
( O -
circumflex O +
artery O -
) O +
and O +
small O +
coronary O +
arteries O +
and O +
on O +
systemic O +
hemodynamics O +
were O +
investigated O +
in O +
chronically O +
instrumented O +
conscious O +
dogs O +
and O +
compared O +
to O +
those O +
of O +
nitroglycerin O +
( O -
0.03 O -
- O -
10 O +
micrograms O -
/ O -
kg O -
) O -
. O -

Nitroglycerin O -
, O +
up O +
to O +
0.3 O +
micrograms O -
/ O -
kg O -
, O +
selectively O +
increased O +
circumflex O +
artery O +
diameter O +
( O -
CxAD O -
) O +
without O +
simultaneously O +
affecting O +
any O +
other O +
cardiac O +
or O +
systemic O +
hemodynamic O +
parameter O -
. O -

In O +
contrast O -
, O +
cromakalim O +
and O +
pinacidil O +
at O +
all O +
doses O +
and O +
nitroglycerin O +
at O +
doses O +
higher O +
than O +
0.3 O +
micrograms O -
/ O -
kg O +
simultaneously O +
and O +
dose O -
- O -
dependently O +
increased O +
CxAD O -
, O +
coronary O +
blood O +
flow O +
and O +
heart O +
rate O +
and O +
decreased O +
coronary O +
vascular O +
resistance O +
and O +
aortic O +
pressure O -
. O -

Cromakalim O +
was O +
approximately O +
8- O +
to O +
9.5-fold O +
more O +
potent O +
than O +
pinacidil O +
in O +
increasing O +
CxAD O -
. O -

Vasodilation O +
of O +
large O +
and O +
small O +
coronary O +
vessels O +
and O +
hypotension U-Disease +
induced O +
by O +
cromakalim O +
and O +
pinacidil O +
were O +
not O +
affected O +
by O +
prior O +
combined O +
beta O +
adrenergic O +
and O +
muscarinic O +
receptors O +
blockade O +
but O +
drug O -
- O -
induced O +
tachycardia U-Disease +
was O +
abolished O -
. O -

When O +
circumflex O +
artery O +
blood O +
flow O +
was O +
maintained O +
constant O -
, O +
the O +
increases O +
in O +
CxAD O +
induced O +
by O +
cromakalim O +
( O -
10 O +
micrograms O -
/ O -
kg O -
) O -
, O +
pinacidil O +
( O -
30 O +
micrograms O -
/ O -
kg O -
) O +
and O +
nitroglycerin O +
( O -
10 O +
micrograms O -
/ O -
kg O -
) O +
were O +
reduced O +
by O +
68 O +
+ O -
/- O -

7 O -
, O +
54 O +
+ O -
/- O -

9 O +
and O +
1 O +
+ O -
/- O -

1 O -
% O -
, O +
respectively O -
. O -

Thus O -
, O +
whereas O +
nitroglycerin O +
preferentially O +
and O +
flow O -
- O -
independently O +
dilates O +
large O +
coronary O +
arteries O -
, O +
cromakalim O +
and O +
pinacidil O +
dilate O +
both O +
large O +
and O +
small O +
coronary O +
arteries O +
and O +
this O +
effect O +
is O +
not O +
dependent O +
upon O +
the O +
simultaneous O +
beta O +
adrenoceptors O -
- O -
mediated O +
rise O +
in O +
myocardial O +
metabolic O +
demand O -
. O -

Finally O -
, O +
two O +
mechanisms O +
at O +
least O -
, O +
direct O +
vasodilation O +
and O +
flow O +
dependency O -
, O +
are O +
involved O +
in O +
the O +
cromakalim- O +
and O +
pinacidil O -
- O -
induced O +
increase O +
in O +
CxAD O -
. O -

Mefenamic O +
acid O -
- O -
induced O +
neutropenia U-Disease +
and O +
renal B-Disease +
failure L-Disease +
in O +
elderly O +
females O +
with O +
hypothyroidism U-Disease -
. O -

We O +
report O +
mefenamic O +
acid O -
- O -
induced O +
non O -
- O -
oliguric O +
renal B-Disease +
failure L-Disease +
and O +
severe O +
neutropenia U-Disease +
occurring O +
simultaneously O +
in O +
two O +
elderly O +
females O -
. O -

The O +
neutropenia U-Disease +
was O +
due O +
to O +
maturation O +
arrest O +
of O +
the O +
myeloid O +
series O +
in O +
one O +
patient O -
. O -

Both O +
patients O +
were O +
also O +
hypothyroid U-Disease -
, O +
but O +
it O +
is O +
not O +
clear O +
whether O +
this O +
was O +
a O +
predisposing O +
factor O +
to O +
the O +
development O +
of O +
these O +
adverse O +
reactions O -
. O -

However O -
, O +
it O +
would O +
seem O +
prudent O +
not O +
to O +
use O +
mefenamic O +
acid O +
in O +
hypothyroid U-Disease +
patients O +
until O +
the O +
hypothyroidism U-Disease +
has O +
been O +
corrected O -
. O -

Etiology O +
of O +
hypercalcemia U-Disease +
in O +
hemodialysis O +
patients O +
on O +
calcium O +
carbonate O +
therapy O -
. O -

Fourteen O +
of O +
39 O +
dialysis O +
patients O +
( O -
36 O -
% O -
) O +
became O +
hypercalcemic U-Disease +
after O +
switching O +
to O +
calcium O +
carbonate O +
as O +
their O +
principal O +
phosphate O +
binder O -
. O -

In O +
order O +
to O +
identify O +
risk O +
factors O +
associated O +
with O +
the O +
development O +
of O +
hypercalcemia U-Disease -
, O +
indirect O +
parameters O +
of O +
intestinal O +
calcium O +
reabsorption O +
and O +
bone O +
turnover O +
rate O +
in O +
these O +
14 O +
patients O +
were O +
compared O +
with O +
results O +
in O +
14 O +
eucalcemic O +
patients O +
matched O +
for O +
age O -
, O +
sex O -
, O +
length O +
of O +
time O +
on O +
dialysis O -
, O +
and O +
etiology O +
of O +
renal B-Disease +
disease L-Disease -
. O -

In O +
addition O +
to O +
experiencing O +
hypercalcemic U-Disease +
episodes O +
with O +
peak O +
calcium O +
values O +
of O +
2.7 O +
to O +
3.8 O +
mmol O -
/ O -
L O +
( O -
10.7 O +
to O +
15.0 O +
mg O -
/ O -
dL O -
) O -
, O +
patients O +
in O +
the O +
hypercalcemic U-Disease +
group O +
exhibited O +
a O +
significant O +
increase O +
in O +
the O +
mean O +
calcium O +
concentration O +
obtained O +
during O +
6 O +
months O +
before O +
the O +
switch O -
, O +
compared O +
with O +
the O +
mean O +
value O +
obtained O +
during O +
the O +
7 O +
months O +
of O +
observation O +
after O +
the O +
switch O +
( O -
2.4 O +
+ O -
/- O -

0.03 O +
to O +
2.5 O +
+ O -
/- O -

0.03 O +
mmol O -
/ O -
L O +
[ O -
9.7 O +
+ O -
/- O -

0.2 O +
to O +
10.2 O +
+ O -
/- O -

0.1 O +
mg O -
/ O -
dL O -
] O -
, O +
P O +
= O +
0.006 O -
) O -
. O -

In O +
contrast O -
, O +
eucalcemic O +
patients O +
exhibited O +
no O +
change O +
in O +
mean O +
calcium O +
values O +
over O +
the O +
same O +
time O +
period O +
( O -
2.3 O +
+ O -
/- O -

0.05 O +
to O +
2.3 O +
+ O -
/- O -

0.05 O +
mmol O -
/ O -
L O +
[ O -
9.2 O +
+ O -
/- O -

0.2 O +
to O +
9.2 O +
+ O -
/- O -

0.2 O +
mg O -
/ O -
dL O -
] O -
) O -
. O -

CaCO3 O +
dosage O -
, O +
calculated O +
dietary O +
calcium O +
intake O -
, O +
and O +
circulating O +
levels O +
of O +
vitamin O +
D O +
metabolites O +
were O +
similar O +
in O +
both O +
groups O -
. O -

Physical O +
activity O +
index O +
and O +
predialysis O +
serum O +
bicarbonate O +
levels O +
also O +
were O +
similar O +
in O +
both O +
groups O -
. O -

However O -
, O +
there O +
was O +
a O +
significant O +
difference O +
in O +
parameters O +
reflecting O +
bone O +
turnover O +
rates O +
between O +
groups. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Methyldopa O -
- O -
induced O +
hemolytic B-Disease +
anemia L-Disease +
in O +
a O +
15 O +
year O +
old O +
presenting O +
as O +
near O -
- O -
syncope U-Disease -
. O -

Methyldopa O +
is O +
an O +
antihypertensive O +
medication O +
which O +
is O +
available O +
generically O +
and O +
under O +
the O +
trade O +
name O +
Aldomet O +
that O +
is O +
widely O +
prescribed O +
in O +
the O +
adult O +
population O +
and O +
infrequently O +
used O +
in O +
children O -
. O -

Methyldopa O +
causes O +
an O +
autoimmune B-Disease +
hemolytic I-Disease +
anemia L-Disease +
in O +
a O +
small O +
percentage O +
of O +
patients O +
who O +
take O +
the O +
drug O -
. O -

We O +
report O +
a O +
case O +
of O +
methyldopa O -
- O -
induced O +
hemolytic B-Disease +
anemia L-Disease +
in O +
a O +
15-year O -
- O -
old O +
boy O +
who O +
presented O +
to O +
the O +
emergency B-Disease +
department L-Disease +
with O +
near O -
- O -
syncope U-Disease -
. O -

The O +
boy O +
had O +
been O +
treated O +
with O +
intravenous O +
methyldopa O +
during O +
a O +
trauma U-Disease +
admission O +
seven O +
weeks O +
prior O +
to O +
presentation O -
. O -

Evaluation O +
revealed O +
a O +
hemoglobin O +
of O +
three O +
grams O -
, O +
3 O -
+ O +
Coombs O -
' O +
test O +
with O +
polyspecific O +
anti O -
- O -
human O +
globulin O +
and O +
monospecific O +
IgG O +
reagents O -
, O +
and O +
a O +
warm O +
reacting O +
autoantibody O -
. O -

Transfusion O +
and O +
corticosteroid O +
therapy O +
resulted O +
in O +
a O +
complete O +
recovery O +
of O +
the O +
patient O -
. O -

Emergency O +
physicians O +
treating O +
children O +
must O +
be O +
aware O +
of O +
this O +
syndrome O +
in O +
order O +
to O +
diagnose O +
and O +
treat O +
it O +
correctly O -
. O -

A O +
brief O +
review O +
of O +
autoimmune O +
and O +
drug O -
- O -
induced O +
hemolytic B-Disease +
anemias L-Disease +
is O +
provided O -
. O -

The O +
long O -
- O -
term O +
safety O +
of O +
danazol O +
in O +
women O +
with O +
hereditary B-Disease +
angioedema L-Disease -
. O -

Although O +
the O +
short O -
- O -
term O +
safety O +
( O -
less O +
than O +
or O +
equal O +
to O +
6 O +
months O -
) O +
of O +
danazol O +
has O +
been O +
established O +
in O +
a O +
variety O +
of O +
settings O -
, O +
no O +
information O +
exists O +
as O +
to O +
its O +
long O -
- O -
term O +
safety O -
. O -

We O +
therefore O +
investigated O +
the O +
long O -
- O -
term O +
safety O +
of O +
danazol O +
by O +
performing O +
a O +
retrospective O +
chart O +
review O +
of O +
60 O +
female O +
patients O +
with O +
hereditary B-Disease +
angioedema L-Disease +
treated O +
with O +
danazol O +
for O +
a O +
continuous O +
period O +
of O +
6 O +
months O +
or O +
longer O -
. O -

The O +
mean O +
age O +
of O +
the O +
patients O +
was O +
35.2 O +
years O +
and O +
the O +
mean O +
duration O +
of O +
therapy O +
was O +
59.7 O +
months O -
. O -

Virtually O +
all O +
patients O +
experienced O +
one O +
or O +
more O +
adverse O +
reactions O -
. O -

Menstrual B-Disease +
abnormalities L-Disease +
( O -
79 O -
% O -
) O -
, O +
weight B-Disease +
gain L-Disease +
( O -
60 O -
% O -
) O -
, O +
muscle B-Disease +
cramps L-Disease -
/ O -
myalgias U-Disease +
( O -
40 O -
% O -
) O -
, O +
and O +
transaminase O +
elevations O +
( O -
40 O -
% O -
) O +
were O +
the O +
most O +
common O +
adverse O +
reactions O -
. O -

The O +
drug O +
was O +
discontinued O +
due O +
to O +
adverse O +
reactions O +
in O +
8 O +
patients O -
. O -

No O +
patient O +
has O +
died O +
or O +
suffered O +
any O +
apparent O +
long O -
- O -
term O +
sequelae O +
that O +
were O +
directly O +
attributable O +
to O +
the O +
drug O -
. O -

We O +
conclude O +
that O -
, O +
despite O +
a O +
relatively O +
high O +
incidence O +
of O +
adverse O +
reactions O -
, O +
danazol O +
has O +
proven O +
to O +
be O +
remarkably O +
safe O +
over O +
the O +
long O -
- O -
term O +
in O +
this O +
group O +
of O +
patients O -
. O -

Patient O +
tolerance O +
study O +
of O +
topical O +
chlorhexidine O +
diphosphanilate O -
: O +
a O +
new O +
topical O +
agent O +
for O +
burns U-Disease -
. O -

Effective O +
topical O +
antimicrobial O +
agents O +
decrease O +
infection U-Disease +
and O +
mortality O +
in O +
burn U-Disease +
patients O -
. O -

Chlorhexidine O +
phosphanilate O +
( O -
CHP O -
) O -
, O +
a O +
new O +
broad O -
- O -
spectrum O +
antimicrobial O +
agent O -
, O +
has O +
been O +
evaluated O +
as O +
a O +
topical O +
burn U-Disease +
wound O +
dressing O +
in O +
cream O +
form O -
, O +
but O +
preliminary O +
clinical O +
trials O +
reported O +
that O +
it O +
was O +
painful O +
upon O +
application O -
. O -

This O +
study O +
compared O +
various O +
concentrations O +
of O +
CHP O +
to O +
determine O +
if O +
a O +
tolerable O +
concentration O +
could O +
be O +
identified O +
with O +
retention O +
of O +
antimicrobial O +
efficacy O -
. O -

Twenty O -
- O -
nine O +
burn U-Disease +
patients O -
, O +
each O +
with O +
two O +
similar O +
burns U-Disease +
which O +
could O +
be O +
separately O +
treated O -
, O +
were O +
given O +
pairs O +
of O +
treatments O +
at O +
successive O +
12-h O +
intervals O +
over O +
a O +
3-day O +
period O -
. O -

One O +
burn U-Disease +
site O +
was O +
treated O +
with O +
each O +
of O +
four O +
different O +
CHP O +
concentrations O -
, O +
from O +
0.25 O +
per O +
cent O +
to O +
2 O +
per O +
cent O -
, O +
their O +
vehicle O -
, O +
and O +
1 O +
per O +
cent O +
silver O +
sulphadiazine O +
( O -
AgSD O -
) O +
cream O -
, O +
an O +
antimicrobial O +
agent O +
frequently O +
used O +
for O +
topical O +
treatment O +
of O +
burn U-Disease +
wounds O -
. O -

The O +
other O +
site O +
was O +
always O +
treated O +
with O +
AgSD O +
cream O -
. O -

There O +
was O +
a O +
direct O +
relationship O +
between O +
CHP O +
concentration O +
and O +
patients O -
' O +
ratings O +
of O +
pain U-Disease +
on O +
an O +
analogue O +
scale O -
. O -

The O +
0.25 O +
per O +
cent O +
CHP O +
cream O +
was O +
closest O +
to O +
AgSD O +
in O +
pain U-Disease +
tolerance O -
; O +
however O -
, O +
none O +
of O +
the O +
treatments O +
differed O +
statistically O +
from O +
AgSD O +
or O +
from O +
each O +
other O -
. O -

In O +
addition O -
, O +
ease O +
of O +
application O +
of O +
CHP O +
creams O +
was O +
less O +
satisfactory O +
than O +
that O +
of O +
AgSD O -
. O -

It O +
was O +
concluded O +
that O +
formulations O +
at O +
or O +
below O +
0.5 O +
per O +
cent O +
CHP O +
may O +
prove O +
acceptable O +
for O +
wound O +
care O -
, O +
but O +
the O +
vehicle O +
system O +
needs O +
pharmaceutical O +
improvement O +
to O +
render O +
it O +
more O +
tolerable O +
and O +
easier O +
to O +
use O -
. O -

Dose O -
- O -
dependent O +
neurotoxicity U-Disease +
of O +
high O -
- O -
dose O +
busulfan O +
in O +
children O -
: O +
a O +
clinical O +
and O +
pharmacological O +
study O -
. O -

Busulfan O +
is O +
known O +
to O +
be O +
neurotoxic U-Disease +
in O +
animals O +
and O +
humans O -
, O +
but O +
its O +
acute O +
neurotoxicity U-Disease +
remains O +
poorly O +
characterized O +
in O +
children O -
. O -

We O +
report O +
here O +
a O +
retrospective O +
study O +
of O +
123 O +
children O +
( O -
median O +
age O -
, O +
6.5 O +
years O -
) O +
receiving O +
high O -
- O -
dose O +
busulfan O +
in O +
combined O +
chemotherapy O +
before O +
bone O +
marrow O +
transplantation O +
for O +
malignant O +
solid O +
tumors U-Disease -
, O +
brain B-Disease +
tumors L-Disease +
excluded O -
. O -

Busulfan O +
was O +
given O +
p.o O -
. O -
, O +
every O +
6 O +
hours O +
for O +
16 O +
doses O +
over O +
4 O +
days O -
. O -

Two O +
total O +
doses O +
were O +
consecutively O +
used O -
: O +
16 O +
mg O -
/ O -
kg O -
, O +
then O +
600 O +
mg O -
/ O -
m2 O -
. O -

The O +
dose O +
calculation O +
on O +
the O +
basis O +
of O +
body O +
surface O +
area O +
results O +
in O +
higher O +
doses O +
in O +
young O +
children O +
than O +
in O +
older O +
patients O +
( O -
16 O +
to O +
28 O +
mg O -
/ O -
kg O -
) O -
. O -

Ninety O -
- O -
six O +
patients O +
were O +
not O +
given O +
anticonvulsive O +
prophylaxis O -
; O +
7 O +
( O -
7.5 O -
% O -
) O +
developed O +
seizures U-Disease +
during O +
the O +
4 O +
days O +
of O +
the O +
busulfan O +
course O +
or O +
within O +
24 O +
h O +
after O +
the O +
last O +
dosing O -
. O -

When O +
the O +
total O +
busulfan O +
dose O +
was O +
taken O +
into O +
account O -
, O +
there O +
was O +
a O +
significant O +
difference O +
in O +
terms O +
of O +
neurotoxicity U-Disease +
incidence O +
among O +
patients O +
under O +
16 O +
mg O -
/ O -
kg O +
( O -
1 O +
of O +
57 O -
, O +
1.7 O -
% O -
) O +
and O +
patients O +
under O +
600 O +
mg O -
/ O -
m2 O +
( O -
6 O +
of O +
39 O -
, O +
15.4 O -
% O -
) O +
( O -
P O +
less O +
than O +
0.02 O -
) O -
. O -

Twenty O -
- O -
seven O +
patients O +
were O +
given O +
a O +
600-mg O -
/ O -
m2 O +
busulfan O +
total O +
dose O +
with O +
continuous O +
i.v O -
. O -

infusion O +
of O +
clonazepam O -
; O +
none O +
had O +
any O +
neurological B-Disease +
symptoms L-Disease -
. O -

Busulfan O +
levels O +
were O +
measured O +
by O +
a O +
gas O +
chromatographic O -
- O -
mass O +
spectrometry O +
assay O +
in O +
the O +
plasma O +
and O +
cerebrospinal O +
fluid O +
of O +
9 O +
children O +
without O +
central B-Disease +
nervous I-Disease +
system I-Disease +
disease L-Disease +
under O +
600 O +
mg O -
/ O -
m2 O +
busulfan O +
with O +
clonazepam O -
: O -
busulfan O +
cerebrospinal O +
fluid O -
: O -
plasma O +
ratio O +
was O +
1.39 O -
. O -

This O +
was O +
significantly O +
different O +
( O -
P O +
less O +
than O +
0.02 O -
) O +
from O +
the O +
cerebrospinal O +
fluid O -
: O -
plasma O +
ratio O +
previously O +
defined O +
in O +
children O +
receiving O +
a O +
16-mg O -
/ O -
kg O +
total O +
dose O +
of O +
busulfan O -
. O -

This O +
study O +
shows O +
that O +
busulfan O +
neurotoxicity U-Disease +
is O +
dose O -
- O -
dependent O +
in O +
children O +
and O +
efficiently O +
prevented O +
by O +
clonazepam O -
. O -

A O +
busulfan O +
dose O +
calculated O +
on O +
the O +
basis O +
of O +
body O +
surface O +
area O -
, O +
resulting O +
in O +
higher O +
doses O +
in O +
young O +
children O -
, O +
was O +
followed O +
by O +
increased O +
neurotoxicity U-Disease -
, O +
close O +
to O +
neurotoxicity U-Disease +
incidence O +
observed O +
in O +
adults O -
. O -

Since O +
plasma O +
pharmacokinetic O +
studies O +
showed O +
a O +
faster O +
busulfan O +
clearance O +
in O +
children O +
than O +
in O +
adults O -
, O +
this O +
new O +
dose O +
may O +
approximate O +
more O +
closely O +
the O +
adult O +
systemic O +
exposure O +
obtained O +
after O +
the O +
usual O +
16-mg O -
/ O -
kg O +
total O +
dose O -
, O +
with O +
potential O +
inferences O +
in O +
terms O +
of O +
anticancer O +
or O +
myeloablative O +
effects O -
. O -

The O +
busulfan O +
dose O +
in O +
children O +
and O +
infants O +
undergoing O +
bone O +
marrow O +
transplantation O +
should O +
be O +
reconsidered O +
on O +
the O +
basis O +
of O +
pharmacokinetic O +
studies O -
. O -

Long O -
- O -
term O +
oral O +
galactose O +
treatment O +
prevents O +
cognitive B-Disease +
deficits L-Disease +
in O +
male O +
Wistar O +
rats O +
treated O +
intracerebroventricularly O +
with O +
streptozotocin O -
. O -

Basic O +
and O +
clinical O +
research O +
has O +
demonstrated O +
that O +
dementia U-Disease +
of O +
sporadic O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
sAD O -
) O +
type O +
is O +
associated O +
with O +
dysfunction O +
of O +
the O +
insulin O -
- O -
receptor O +
( O -
IR O -
) O +
system O +
followed O +
by O +
decreased O +
glucose O +
transport O +
via O +
glucose O +
transporter O +
GLUT4 O +
and O +
decreased O +
glucose O +
metabolism O +
in O +
brain O +
cells O -
. O -

An O +
alternative O +
source O +
of O +
energy O +
is O +
d O -
- O -
galactose O +
( O -
the O +
C-4-epimer O +
of O +
d O -
- O -
glucose O -
) O +
which O +
is O +
transported O +
into O +
the O +
brain O +
by O +
insulin O -
- O -
independent O +
GLUT3 O +
transporter O +
where O +
it O +
might O +
be O +
metabolized O +
to O +
glucose O +
via O +
the O +
Leloir O +
pathway O -
. O -

Exclusively O +
parenteral O +
daily O +
injections O +
of O +
galactose O +
induce O +
memory B-Disease +
deterioration L-Disease +
in O +
rodents O +
and O +
are O +
used O +
to O +
generate O +
animal O +
aging O +
model O -
, O +
but O +
the O +
effects O +
of O +
oral O +
galactose O +
treatment O +
on O +
cognitive O +
functions O +
have O +
never O +
been O +
tested O -
. O -

We O +
have O +
investigated O +
the O +
effects O +
of O +
continuous O +
daily O +
oral O +
galactose O +
( O -
200 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
treatment O +
on O +
cognitive B-Disease +
deficits L-Disease +
in O +
streptozotocin O -
- O -
induced O +
( O -
STZ O -
- O -
icv O -
) O +
rat O +
model O +
of O +
sAD O -
, O +
tested O +
by O +
Morris O +
Water O +
Maze O +
and O +
Passive O +
Avoidance O +
test O -
, O +
respectively O -
. O -

One O +
month O +
of O +
oral O +
galactose O +
treatment O +
initiated O +
immediately O +
after O +
the O +
STZ O -
- O -
icv O +
administration O -
, O +
successfully O +
prevented O +
development O +
of O +
the O +
STZ O -
- O -
icv O -
- O -
induced O +
cognitive B-Disease +
deficits L-Disease -
. O -

Beneficial O +
effect O +
of O +
oral O +
galactose O +
was O +
independent O +
of O +
the O +
rat O +
age O +
and O +
of O +
the O +
galactose O +
dose O +
ranging O +
from O +
100 O +
to O +
300 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O -

Additionally O -
, O +
oral O +
galactose O +
administration O +
led O +
to O +
the O +
appearance O +
of O +
galactose O +
in O +
the O +
blood O -
. O -

The O +
increase O +
of O +
galactose O +
concentration O +
in O +
the O +
cerebrospinal O +
fluid O +
was O +
several O +
times O +
lower O +
after O +
oral O +
than O +
after O +
parenteral O +
administration O +
of O +
the O +
same O +
galactose O +
dose O -
. O -

Oral O +
galactose O +
exposure O +
might O +
have O +
beneficial O +
effects O +
on O +
learning O +
and O +
memory O +
ability O +
and O +
could O +
be O +
worth O +
investigating O +
for O +
improvement O +
of O +
cognitive B-Disease +
deficits L-Disease +
associated O +
with O +
glucose B-Disease +
hypometabolism L-Disease +
in O +
AD U-Disease -
. O -

Histamine O +
antagonists O +
and O +
d O -
- O -
tubocurarine O -
- O -
induced O +
hypotension U-Disease +
in O +
cardiac O +
surgical O +
patients O -
. O -

Hemodynamic O +
effects O +
and O +
histamine O +
release O +
by O +
bolus O +
injection O +
of O +
0.35 O +
mg O -
/ O -
kg O +
of O +
d O -
- O -
tubocurarine O +
were O +
studied O +
in O +
24 O +
patients O -
. O -

H1- O +
and O +
H2-histamine O +
antagonists O +
or O +
placebo O +
were O +
given O +
before O +
dosing O +
with O +
d O -
- O -
tubocurarine O +
in O +
a O +
randomized O +
double O -
- O -
blind O +
fashion O +
to O +
four O +
groups O -
: O +
group O +
1 O -
- O -
-placebo O -
; O +
group O +
2 O -
- O -
-cimetidine O -
, O +
4 O +
mg O -
/ O -
kg O -
, O +
plus O +
placebo O -
; O +
group O +
3 O -
- O -
-chlorpheniramine O -
, O +
0.1 O +
mg O -
/ O -
kg O -
, O +
plus O +
placebo O -
; O +
and O +
group O +
4 O -
- O -
-cimetidine O +
plus O +
chlorpheniramine O -
. O -

Histamine O +
release O +
occurred O +
in O +
most O +
patients O -
, O +
the O +
highest O +
level O +
2 O +
minutes O +
after O +
d O -
- O -
tubocurarine O +
dosing O -
. O -

Group O +
1 O +
had O +
a O +
moderate O +
negative O +
correlation O +
between O +
plasma O +
histamine O +
change O +
and O +
systemic O +
vascular O +
resistance O +
( O -
r O +
= O +
0.58 O -
; O +
P O +
less O +
than O +
0.05 O -
) O +
not O +
present O +
in O +
group O +
4 O -
. O -

Prior O +
dosing O +
with O +
antagonists O +
partially O +
prevented O +
the O +
fall O +
in O +
systemic O +
vascular O +
resistance O -
. O -

These O +
data O +
demonstrate O +
that O +
the O +
hemodynamic O +
changes O +
associated O +
with O +
d O -
- O -
tubocurarine O +
dosing O +
are O +
only O +
partially O +
explained O +
by O +
histamine O +
release O -
. O -

Thus O +
prior O +
dosing O +
with O +
H1- O +
and O +
H2-antagonists O +
provides O +
only O +
partial O +
protection O -
. O -

Convulsant O +
effect O +
of O +
lindane O +
and O +
regional O +
brain O +
concentration O +
of O +
GABA O +
and O +
dopamine O -
. O -

Lindane O +
( O -
gamma O -
- O -
hexachlorocyclohexane O -
) O +
is O +
an O +
organochlorine O +
insecticide O +
with O +
known O +
neurotoxic U-Disease +
effects O -
. O -

Its O +
mechanism O +
of O +
action O +
is O +
not O +
well O +
understood O +
although O +
it O +
has O +
been O +
proposed O +
that O +
lindane O +
acts O +
as O +
a O +
non O -
- O -
competitive O +
antagonist O +
at O +
the O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
-A O +
receptor O -
. O -

We O +
studied O +
the O +
effect O +
of O +
lindane O +
( O -
150 O +
mg O -
/ O -
kg O -
) O +
on O +
the O +
GABAergic O +
and O +
dopaminergic O +
systems O +
by O +
measuring O +
the O +
concentration O +
of O +
GABA O -
, O +
dopamine O +
and O +
its O +
metabolites O +
in O +
7 O +
brain O +
areas O +
at O +
the O +
onset O +
of O +
seizures U-Disease -
. O -

All O +
animals O +
suffered O +
tonic O +
convulsions U-Disease +
at O +
18.3 O +
+ O -
/- O -

1.4 O +
min O +
after O +
lindane O +
administration O -
. O -

The O +
concentration O +
of O +
GABA O +
was O +
only O +
slightly O +
but O +
significantly O +
decreased O +
in O +
the O +
colliculi O +
without O +
modifications O +
in O +
the O +
other O +
areas O -
. O -

The O +
concentration O +
of O +
dopamine O +
was O +
increased O +
in O +
the O +
mesencephalon O +
and O +
that O +
of O +
its O +
metabolite O +
DOPAC O +
was O +
also O +
increased O +
in O +
the O +
mesencephalon O +
and O +
the O +
striatum O -
. O -

Baboon B-Disease +
syndrome L-Disease +
induced O +
by O +
ketoconazole O -
. O -

A O +
27-year O -
- O -
old O +
male O +
patient O +
presented O +
with O +
a O +
maculopapular B-Disease +
eruption L-Disease +
on O +
the O +
flexural O +
areas O +
and O +
buttocks O +
after O +
using O +
oral O +
ketoconazole O -
. O -

The O +
patient O +
was O +
diagnosed O +
with O +
drug O -
- O -
induced O +
baboon B-Disease +
syndrome L-Disease +
based O +
on O +
his O +
history O -
, O +
which O +
included O +
prior O +
sensitivity O +
to O +
topical O +
ketoconazole O -
, O +
a O +
physical O +
examination O -
, O +
and O +
histopathological O +
findings O -
. O -

Baboon B-Disease +
syndrome L-Disease +
is O +
a O +
drug- O +
or O +
contact O +
allergen O -
- O -
related O +
maculopapular B-Disease +
eruption L-Disease +
that O +
typically O +
involves O +
the O +
flexural O +
and O +
gluteal O +
areas O -
. O -

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
reported O +
case O +
of O +
ketoconazole O -
- O -
induced O +
baboon B-Disease +
syndrome L-Disease +
in O +
the O +
English O +
literature O -
. O -

A O +
Case O +
of O +
Sudden B-Disease +
Cardiac I-Disease +
Death L-Disease +
due O +
to O +
Pilsicainide O -
- O -
Induced O +
Torsades B-Disease +
de I-Disease +
Pointes L-Disease -
. O -

An O +
84-year O -
- O -
old O +
male O +
received O +
oral O +
pilsicainide O -
, O +
a O +
pure O +
sodium O +
channel O +
blocker O +
with O +
slow O +
recovery O +
kinetics O -
, O +
to O +
convert O +
his O +
paroxysmal O +
atrial B-Disease +
fibrillation L-Disease +
to O +
a O +
sinus O +
rhythm O -
; O +
the O +
patient O +
developed O +
sudden B-Disease +
cardiac I-Disease +
death L-Disease +
two O +
days O +
later O -
. O -

The O +
Holter O +
electrocardiogram O -
, O +
which O +
was O +
worn O +
by O +
chance O -
, O +
revealed O +
torsade B-Disease +
de I-Disease +
pointes L-Disease +
with O +
gradually O +
prolonged O +
QT O +
intervals O -
. O -

This O +
drug O +
is O +
rapidly O +
absorbed O +
from O +
the O +
gastrointestinal O +
tract O -
, O +
and O +
most O +
of O +
it O +
is O +
excreted O +
from O +
the O +
kidney O -
. O -

Although O +
the O +
patient O -
's O +
renal O +
function O +
was O +
not O +
highly O +
impaired O +
and O +
the O +
dose O +
of O +
pilsicainide O +
was O +
low O -
, O +
the O +
plasma O +
concentration O +
of O +
pilsicainide O +
may O +
have O +
been O +
high O -
, O +
which O +
can O +
produce O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
in O +
the O +
octogenarian O -
. O -

Although O +
the O +
oral O +
administration O +
of O +
class O +
IC O +
drugs O -
, O +
including O +
pilsicainide O -
, O +
is O +
effective O +
to O +
terminate O +
atrial B-Disease +
fibrillation L-Disease -
, O +
careful O +
consideration O +
must O +
be O +
taken O +
before O +
giving O +
these O +
drugs O +
to O +
octogenarians O -
. O -

All O -
- O -
trans O +
retinoic O +
acid O -
- O -
induced O +
inflammatory O +
myositis U-Disease +
in O +
a O +
patient O +
with O +
acute B-Disease +
promyelocytic I-Disease +
leukemia L-Disease -
. O -

All O -
- O -
trans O +
retinoic O +
acid O +
( O -
ATRA O -
) O -
, O +
a O +
component O +
of O +
standard O +
therapy O +
for O +
acute B-Disease +
promyelocytic I-Disease +
leukemia L-Disease +
( O -
APL U-Disease -
) O -
, O +
is O +
associated O +
with O +
potentially O +
serious O +
but O +
treatable O +
adverse O +
effects O +
involving O +
numerous O +
organ O +
systems O -
, O +
including O +
rare O +
skeletal O +
muscle O +
involvement O -
. O -

Only O +
a O +
handful O +
of O +
cases O +
of O +
ATRA O -
- O -
induced O +
myositis U-Disease +
in O +
children O +
have O +
been O +
reported O -
, O +
and O +
none O +
in O +
the O +
radiology O +
literature O -
. O -

We O +
present O +
such O +
a O +
case O +
in O +
a O +
15-year O -
- O -
old O +
boy O +
with O +
APL U-Disease -
, O +
where O +
recognition O +
of O +
imaging O +
findings O +
played O +
a O +
crucial O +
role O +
in O +
making O +
the O +
diagnosis O +
and O +
facilitated O +
prompt O -
, O +
effective O +
treatment O -
. O -

Tolerability O +
of O +
lomustine O +
in O +
combination O +
with O +
cyclophosphamide O +
in O +
dogs O +
with O +
lymphoma U-Disease -
. O -

This O +
retrospective O +
study O +
describes O +
toxicity U-Disease +
associated O +
with O +
a O +
protocol O +
of O +
lomustine O +
( O -
CCNU O -
) O +
and O +
cyclophosphamide O +
( O -
CTX O -
) O +
in O +
dogs O +
with O +
lymphoma U-Disease -
. O -

CCNU O +
was O +
administered O +
per O +
os O +
( O -
PO O -
) O +
at O +
a O +
targeted O +
dosage O +
of O +
60 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
body O +
surface O +
area O +
on O +
day O +
0 O -
, O +
CTX O +
was O +
administered O +
PO O +
at O +
a O +
targeted O +
dosage O +
of O +
250 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
divided O +
over O +
days O +
0 O +
through O +
4 O -
, O +
and O +
all O +
dogs O +
received O +
prophylactic O +
antibiotics O -
. O -

Ninety O +
treatments O +
were O +
given O +
to O +
the O +
57 O +
dogs O +
included O +
in O +
the O +
study O -
. O -

Neutropenia U-Disease +
was O +
the O +
principal O +
toxic O +
effect O -
, O +
and O +
the O +
overall O +
frequency O +
of O +
grade O +
4 O +
neutropenia U-Disease +
after O +
the O +
first O +
treatment O +
of O +
CCNU O -
/ O -
CTX O +
was O +
30 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
19 O -
- O -
43 O -
% O -
) O -
. O -

The O +
mean O +
body O +
weight O +
of O +
dogs O +
with O +
grade O +
4 O +
neutropenia U-Disease +
( O -
19.7 O +
kg O +
+ O +
13.4 O +
kg O -
) O +
was O +
significantly O +
less O +
than O +
the O +
mean O +
body O +
weight O +
of O +
dogs O +
that O +
did O +
not O +
develop O +
grade O +
4 O +
neutropenia U-Disease +
( O -
31.7 O +
kg O +
+ O +
12.4 O +
kg O -
; O +
P O +
= O +
.005 O -
) O -
. O -

One O +
dog O +
( O -
3 O -
% O -
) O +
developed O +
hematologic O +
changes O +
suggestive O +
of O +
hepatotoxicity U-Disease -
. O -

No O +
dogs O +
had O +
evidence O +
of O +
either O +
renal B-Disease +
toxicity L-Disease +
or O +
hemorrhagic U-Disease +
cystitis U-Disease -
. O -

Adverse O +
gastrointestinal O +
effects O +
were O +
uncommon O -
. O -

On O +
the O +
basis O +
of O +
the O +
findings O +
reported O +
herein O -
, O +
a O +
dose O +
of O +
60 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
of O +
CCNU O +
combined O +
with O +
250 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
of O +
CTX O +
( O -
divided O +
over O +
5 O +
days O -
) O +
q O +
4 O +
wk O +
is O +
tolerable O +
in O +
tumor U-Disease -
- O -
bearing O +
dogs O -
. O -

Nelarabine O +
neurotoxicity U-Disease +
with O +
concurrent O +
intrathecal O +
chemotherapy O -
: O -

Case O +
report O +
and O +
review O +
of O +
literature O -
. O -

Severe O +
nelarabine O +
neurotoxicity U-Disease +
in O +
a O +
patient O +
who O +
received O +
concurrent O +
intrathecal O +
( O -
IT O -
) O +
chemotherapy O +
is O +
reported O -
. O -

A O +
37-year O -
- O -
old O +
Caucasian O +
woman O +
with O +
a O +
history O +
of O +
T B-Disease -
- I-Disease -
cell I-Disease +
lymphoblastic I-Disease +
lymphoma L-Disease +
was O +
admitted O +
for O +
relapsed O +
disease O -
. O -

She O +
was O +
originally O +
treated O +
with O +
induction O +
chemotherapy O +
followed O +
by O +
an O +
autologous O +
transplant O -
. O -

She O +
developed O +
relapsed O +
disease O +
10 O +
months O +
later O +
with O +
leukemic U-Disease +
involvement O -
. O -

She O +
was O +
re O -
- O -
induced O +
with O +
nelarabine O +
1500 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
on O +
days O +
1 O -
, O +
3 O -
, O +
and O +
5 O +
with O +
1 O +
dose O +
of O +
IT O +
cytarabine O +
100 O +
mg O +
on O +
day O +
2 O +
as O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
prophylaxis O -
. O -

At O +
the O +
time O +
of O +
treatment O -
, O +
she O +
was O +
on O +
continuous O +
renal O +
replacement O +
therapy O +
due O +
to O +
sequelae O +
of O +
tumor B-Disease +
lysis I-Disease +
syndrome L-Disease +
( O -
TLS U-Disease -
) O -
. O -

She O +
tolerated O +
therapy O +
well O -
, O +
entered O +
a O +
complete O +
remission O -
, O +
and O +
recovered O +
her O +
renal O +
function O -
. O -

She O +
received O +
a O +
second O +
cycle O +
of O +
nelarabine O +
without O +
additional O +
IT O +
prophylaxis O +
one O +
month O +
later O -
. O -

A O +
week O +
after O +
this O +
second O +
cycle O -
, O +
she O +
noted O +
numbness O +
in O +
her O +
lower O +
extremities O -
. O -

Predominantly O +
sensory O -
, O +
though O +
also O +
motor O +
and O +
autonomic O -
, O +
peripheral B-Disease +
neuropathy L-Disease +
started O +
in O +
her O +
feet O -
, O +
ascended O +
proximally O +
to O +
the O +
mid O -
- O -
thoracic O +
region O -
, O +
and O +
eventually O +
included O +
her O +
distal O +
upper O +
extremities O -
. O -

A O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
of O +
her O +
spine O +
demonstrated O +
changes O +
from O +
C2 O +
to O +
C6 O +
consistent O +
with O +
subacute O +
combined O +
degeneration O -
. O -

Nelarabine O +
was O +
felt O +
to O +
be O +
the O +
cause O +
of O +
her O +
symptoms O -
. O -

Her O +
neuropathy U-Disease +
stabilized O +
and O +
showed O +
slight O +
improvement O +
and O +
ultimately O +
received O +
an O +
unrelated O -
, O +
reduced O -
- O -
intensity O +
allogeneic O +
transplant O +
while O +
in O +
complete O +
remission O -
, O +
but O +
relapsed O +
disease O +
10 O +
weeks O +
later O -
. O -

She O +
is O +
currently O +
being O +
treated O +
with O +
best O +
supportive O +
care O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
published O +
case O +
report O +
of O +
severe O +
neurotoxicity U-Disease +
caused O +
by O +
nelarabine O +
in O +
a O +
patient O +
who O +
received O +
concurrent O +
IT O +
chemotherapy O -
. O -

Valproate O -
- O -
induced O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
in O +
a O +
renal O +
transplanted O +
patient O -
. O -

Neurological B-Disease +
complications L-Disease +
after O +
renal O +
transplantation O +
constitute O +
an O +
important O +
cause O +
of O +
morbidity O +
and O +
mortality O -
. O -

Their O +
differential O +
diagnosis O +
is O +
difficult O +
and O +
essential O +
for O +
subsequent O +
patient O -
's O +
management O -
. O -

Valproate O -
- O -
induced O +
hyperammonemic U-Disease +
encephalopathy U-Disease +
is O +
an O +
uncommon O +
but O +
serious O +
effect O +
of O +
valproate O +
treatment O -
. O -

Here O -
, O +
we O +
describe O +
the O +
case O +
of O +
a O +
15-year O -
- O -
old O +
girl O +
who O +
was O +
on O +
a O +
long O -
- O -
term O +
therapy O +
with O +
valproate O +
due O +
to O +
epilepsy U-Disease +
and O +
revealed O +
impaired B-Disease +
consciousness L-Disease +
with O +
hyperammonemia U-Disease +
12 O +
days O +
after O +
renal O +
transplantation O -
. O -

After O +
withdraw O +
of O +
valproate O -
, O +
patients O -
' O +
symptoms O +
resolved O +
within O +
24 O +
h. O +
Clinicians O +
should O +
increase O +
their O +
awareness O +
for O +
potential O +
complication O +
of O +
valproate O -
, O +
especially O +
in O +
transplanted O +
patients O -
. O -

Necrotising B-Disease +
fasciitis L-Disease +
after O +
bortezomib O +
and O +
dexamethasone O -
- O -
containing O +
regimen O +
in O +
an O +
elderly O +
patient O +
of O +
Waldenstrom B-Disease +
macroglobulinaemia L-Disease -
. O -

Bortezomib O +
and O +
high O -
- O -
dose O +
dexamethasone O -
- O -
containing O +
regimens O +
are O +
considered O +
to O +
be O +
generally O +
tolerable O +
with O +
few O +
severe O +
bacterial B-Disease +
infections L-Disease +
in O +
patients O +
with O +
B O -
- O -
cell O +
malignancies U-Disease -
. O -

However O -
, O +
information O +
is O +
limited O +
concerning O +
the O +
safety O +
of O +
the O +
regimen O +
in O +
elderly O +
patients O -
. O -

We O +
report O +
a O +
case O +
of O +
a O +
76-year O -
- O -
old O +
man O +
with O +
Waldenstrom B-Disease +
macroglobulinaemia L-Disease +
who O +
suffered O +
necrotising B-Disease +
fasciitis L-Disease +
without O +
neutropenia U-Disease +
after O +
the O +
combination O +
treatment O +
with O +
bortezomib O -
, O +
high O -
- O -
dose O +
dexamethasone O +
and O +
rituximab O -
. O -

Despite O +
immediate O +
intravenous O +
antimicrobial O +
therapy O -
, O +
he O +
succumbed O +
23 O +
h O +
after O +
the O +
onset O -
. O -

Physicians O +
should O +
recognise O +
the O +
possibility O +
of O +
fatal O +
bacterial B-Disease +
infections L-Disease +
related O +
to O +
bortezomib O +
plus O +
high O -
- O -
dose O +
dexamethasone O +
in O +
elderly O +
patients O -
, O +
and O +
we O +
believe O +
this O +
case O +
warrants O +
further O +
investigation O -
. O -

An O +
integrated O +
characterization O +
of O +
serological O -
, O +
pathological O -
, O +
and O +
functional O +
events O +
in O +
doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease -
. O -

Many O +
efficacious O +
cancer U-Disease +
treatments O +
cause O +
significant O +
cardiac O +
morbidity O -
, O +
yet O +
biomarkers O +
or O +
functional O +
indices O +
of O +
early O +
damage O -
, O +
which O +
would O +
allow O +
monitoring O +
and O +
intervention O -
, O +
are O +
lacking O -
. O -

In O +
this O +
study O -
, O +
we O +
have O +
utilized O +
a O +
rat O +
model O +
of O +
progressive O +
doxorubicin O +
( O -
DOX O -
) O -
-induced O +
cardiomyopathy U-Disease -
, O +
applying O +
multiple O +
approaches O -
, O +
including O +
cardiac O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O -
, O +
to O +
provide O +
the O +
most O +
comprehensive O +
characterization O +
to O +
date O +
of O +
the O +
timecourse O +
of O +
serological O -
, O +
pathological O -
, O +
and O +
functional O +
events O +
underlying O +
this O +
toxicity U-Disease -
. O -

Hannover O +
Wistar O +
rats O +
were O +
dosed O +
with O +
1.25 O +
mg O -
/ O -
kg O +
DOX O +
weekly O +
for O +
8 O +
weeks O +
followed O +
by O +
a O +
4 O +
week O +
off O -
- O -
dosing O +
" O -
recovery O -
" O +
period O -
. O -

Electron O +
microscopy O +
of O +
the O +
myocardium O +
revealed O +
subcellular B-Disease +
degeneration L-Disease +
and O +
marked O +
mitochondrial O +
changes O +
after O +
a O +
single O +
dose O -
. O -

Histopathological O +
analysis O +
revealed O +
progressive O +
cardiomyocyte B-Disease +
degeneration L-Disease -
, O +
hypertrophy U-Disease -
/ O -
cytomegaly O -
, O +
and O +
extensive O +
vacuolation O +
after O +
two O +
doses O -
. O -

Extensive O +
replacement O +
fibrosis U-Disease +
( O -
quantified O +
by O +
Sirius O +
red O +
staining O -
) O +
developed O +
during O +
the O +
off O -
- O -
dosing O +
period O -
. O -

Functional O +
indices O +
assessed O +
by O +
cardiac O +
MRI O +
( O -
including O +
left O +
ventricular O +
ejection O +
fraction O +
( O -
LVEF O -
) O -
, O +
cardiac O +
output O -
, O +
and O +
E O -
/ O -
A O +
ratio O -
) O +
declined O +
progressively O -
, O +
reaching O +
statistical O +
significance O +
after O +
two O +
doses O +
and O +
culminating O +
in O +
" O -
clinical O -
" O +
LV B-Disease +
dysfunction L-Disease +
by O +
12 O +
weeks O -
. O -

Significant O +
increases O +
in O +
peak O +
myocardial O +
contrast O +
enhancement O +
and O +
serological O +
cardiac O +
troponin O +
I O +
( O -
cTnI O -
) O +
emerged O +
after O +
eight O +
doses O -
, O +
importantly O +
preceding O +
the O +
LVEF O +
decline O +
to O +
< O -
50 O -
% O -
. O -

Troponin O +
I O +
levels O +
positively O +
correlated O +
with O +
delayed O +
and O +
peak O +
gadolinium O +
contrast O +
enhancement O -
, O +
histopathological O +
grading O -
, O +
and O +
diastolic B-Disease +
dysfunction L-Disease -
. O -

In O +
summary O -
, O +
subcellular O +
cardiomyocyte B-Disease +
degeneration L-Disease +
was O +
the O +
earliest O +
marker O -
, O +
followed O +
by O +
progressive O +
functional O +
decline O +
and O +
histopathological O +
manifestations O -
. O -

Myocardial O +
contrast O +
enhancement O +
and O +
elevations O +
in O +
cTnI O +
occurred O +
later O -
. O -

However O -
, O +
all O +
indices O +
predated O +
" O -
clinical O -
" O +
LV B-Disease +
dysfunction L-Disease +
and O +
thus O +
warrant O +
further O +
evaluation O +
as O +
predictive O +
biomarkers O -
. O -

Intradermal O +
glutamate O +
and O +
capsaicin O +
injections O -
: O +
intra- O +
and O +
interindividual O +
variability O +
of O +
provoked O +
hyperalgesia U-Disease +
and O +
allodynia U-Disease -
. O -

Intradermal O +
injections O +
of O +
glutamate O +
and O +
capsaicin O +
are O +
attractive O +
to O +
use O +
in O +
human O +
experimental O +
pain U-Disease +
models O +
because O +
hyperalgesia U-Disease +
and O +
allodynia U-Disease +
mimic O +
isolated O +
aspects O +
of O +
clinical O +
pain B-Disease +
disorders L-Disease -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
reproducibility O +
of O +
these O +
models O -
. O -

Twenty O +
healthy O +
male O +
volunteers O +
( O -
mean O +
age O +
24 O +
years O -
; O +
range O +
18 O -
- O -
38 O +
years O -
) O +
received O +
intradermal O +
injections O +
of O +
glutamate O +
and O +
capsaicin O +
in O +
the O +
volar O +
forearm O -
. O -

Magnitudes O +
of O +
secondary O +
pinprick O +
hyperalgesia U-Disease +
and O +
brush O -
- O -
evoked O +
allodynia U-Disease +
were O +
investigated O +
using O +
von O +
Frey O +
filaments O +
( O -
gauges O +
10 O -
, O +
15 O -
, O +
60 O +
and O +
100 O +
g O -
) O +
and O +
brush O +
strokes O -
. O -

Areas O +
of O +
secondary B-Disease +
hyperalgesia L-Disease +
and O +
allodynia U-Disease +
were O +
quantified O +
immediately O +
after O +
injection O +
and O +
after O +
15 O -
, O +
30 O +
and O +
60 O +
min O -
. O -

Two O +
identical O +
experiments O +
separated O +
by O +
at O +
least O +
7 O +
days O +
were O +
performed O -
. O -

Reproducibility O +
across O +
and O +
within O +
volunteers O +
( O -
inter- O +
and O +
intra O -
- O -
individual O +
variation O -
, O +
respectively O -
) O +
was O +
assessed O +
using O +
intraclass O +
correlation O +
coefficient O +
( O -
ICC O -
) O +
and O +
coefficient O +
of O +
variation O +
( O -
CV O -
) O -
. O -

Secondary O +
pinprick O +
hyperalgesia U-Disease +
was O +
observed O +
as O +
a O +
marked O +
increase O +
in O +
the O +
visual O +
analogue O +
scale O +
( O -
VAS O -
) O +
response O +
to O +
von O +
Frey O +
gauges O +
60 O +
and O +
100 O +
g O +
( O -
P O +
< O +
0.001 O -
) O +
after O +
glutamate O +
injection O -
. O -

For O +
capsaicin O -
, O +
secondary O +
pinprick O +
hyperalgesia U-Disease +
was O +
detected O +
with O +
all O +
von O +
Frey O +
gauges O +
( O -
P O +
< O +
0.001 O -
) O -
. O -

Glutamate O +
evoked O +
reproducible O +
VAS O +
response O +
to O +
all O +
von O +
Frey O +
gauges O +
( O -
ICC O +
> O +
0.60 O -
) O +
and O +
brush O +
strokes O +
( O -
ICC O +
> O +
0.83 O -
) O -
. O -

Capsaicin O +
injection O +
was O +
reproducible O +
for O +
secondary B-Disease +
hyperalgesia L-Disease +
( O -
ICC O +
> O +
0.70 O -
) O +
and O +
allodynia U-Disease +
( O -
ICC O +
> O +
0.71 O -
) O -
. O -

Intra O -
- O -
individual O +
variability O +
was O +
generally O +
lower O +
for O +
the O +
VAS O +
response O +
to O +
von O +
Frey O +
and O +
brush O +
compared O +
with O +
areas O +
of O +
secondary B-Disease +
hyperalgesia L-Disease +
and O +
allodynia U-Disease -
. O -

In O +
conclusion O -
, O +
glutamate O +
and O +
capsaicin O +
yield O +
reproducible O +
hyperalgesic U-Disease +
and O +
allodynic U-Disease +
responses O -
, O +
and O +
the O +
present O +
model O +
is O +
well O +
suited O +
for O +
basic O +
research O -
, O +
as O +
well O +
as O +
for O +
assessing O +
the O +
modulation O +
of O +
central O +
phenomena O -
. O -

Ocular O -
- O -
specific O +
ER O +
stress O +
reduction O +
rescues O +
glaucoma U-Disease +
in O +
murine O +
glucocorticoid O -
- O -
induced O +
glaucoma U-Disease -
. O -

Administration O +
of O +
glucocorticoids O +
induces O +
ocular B-Disease +
hypertension L-Disease +
in O +
some O +
patients O -
. O -

If O +
untreated O -
, O +
these O +
patients O +
can O +
develop O +
a O +
secondary O +
glaucoma U-Disease +
that O +
resembles O +
primary B-Disease +
open I-Disease -
- I-Disease -
angle I-Disease +
glaucoma L-Disease +
( O -
POAG U-Disease -
) O -
. O -

The O +
underlying O +
pathology O +
of O +
glucocorticoid O -
- O -
induced O +
glaucoma U-Disease +
is O +
not O +
fully O +
understood O -
, O +
due O +
in O +
part O +
to O +
lack O +
of O +
an O +
appropriate O +
animal O +
model O -
. O -

Here O -
, O +
we O +
developed O +
a O +
murine O +
model O +
of O +
glucocorticoid O -
- O -
induced O +
glaucoma U-Disease +
that O +
exhibits O +
glaucoma U-Disease +
features O +
that O +
are O +
observed O +
in O +
patients O -
. O -

Treatment O +
of O +
WT O +
mice O +
with O +
topical O +
ocular O +
0.1 O -
% O +
dexamethasone O +
led O +
to O +
elevation O +
of O +
intraocular O +
pressure O +
( O -
IOP O -
) O -
, O +
functional O +
and O +
structural O +
loss O +
of O +
retinal B-Disease +
ganglion L-Disease +
cells O -
, O +
and O +
axonal B-Disease +
degeneration L-Disease -
, O +
resembling O +
glucocorticoid O -
- O -
induced O +
glaucoma U-Disease +
in O +
human O +
patients O -
. O -

Furthermore O -
, O +
dexamethasone O -
- O -
induced O +
ocular B-Disease +
hypertension L-Disease +
was O +
associated O +
with O +
chronic O +
ER O +
stress O +
of O +
the O +
trabecular O +
meshwork O +
( O -
TM O -
) O -
. O -

Similar O +
to O +
patients O -
, O +
withdrawal O +
of O +
dexamethasone O +
treatment O +
reduced O +
elevated O +
IOP O +
and O +
ER O +
stress O +
in O +
this O +
animal O +
model O -
. O -

Dexamethasone O +
induced O +
the O +
transcriptional O +
factor O +
CHOP O -
, O +
a O +
marker O +
for O +
chronic O +
ER O +
stress O -
, O +
in O +
the O +
anterior O +
segment O +
tissues O -
, O +
and O +
Chop O +
deletion O +
reduced O +
ER O +
stress O +
in O +
these O +
tissues O +
and O +
prevented O +
dexamethasone O -
- O -
induced O +
ocular B-Disease +
hypertension L-Disease -
. O -

Furthermore O -
, O +
reduction O +
of O +
ER O +
stress O +
in O +
the O +
TM O +
with O +
sodium O +
4-phenylbutyrate O +
prevented O +
dexamethasone O -
- O -
induced O +
ocular B-Disease +
hypertension L-Disease +
in O +
WT O +
mice O -
. O -

Our O +
data O +
indicate O +
that O +
ER O +
stress O +
contributes O +
to O +
glucocorticoid O -
- O -
induced O +
ocular B-Disease +
hypertension L-Disease +
and O +
suggest O +
that O +
reducing O +
ER O +
stress O +
has O +
potential O +
as O +
a O +
therapeutic O +
strategy O +
for O +
treating O +
glucocorticoid O -
- O -
induced O +
glaucoma U-Disease -
. O -

Effects O +
of O +
ginsenosides O +
on O +
opioid O -
- O -
induced O +
hyperalgesia U-Disease +
in O +
mice O -
. O -

Opioid O -
- O -
induced O +
hyperalgesia U-Disease +
( O -
OIH U-Disease -
) O +
is O +
characterized O +
by O +
nociceptive O +
sensitization O +
caused O +
by O +
the O +
cessation O +
of O +
chronic O +
opioid O +
use O -
. O -

OIH U-Disease +
can O +
limit O +
the O +
clinical O +
use O +
of O +
opioid O +
analgesics O +
and O +
complicate O +
withdrawal O +
from O +
opioid B-Disease +
addiction L-Disease -
. O -

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
effects O +
of O +
Re O -
, O +
Rg1 O -
, O +
and O +
Rb1 O +
ginsenosides O -
, O +
the O +
bioactive O +
components O +
of O +
ginseng O -
, O +
on O +
OIH U-Disease -
. O -

OIH U-Disease +
was O +
achieved O +
in O +
mice O +
after O +
subcutaneous O +
administration O +
of O +
morphine O +
for O +
7 O +
consecutive O +
days O +
three O +
times O +
per O +
day O -
. O -

During O +
withdrawal O +
( O -
days O +
8 O +
and O +
9 O -
) O -
, O +
these O +
mice O +
were O +
administered O +
Re O -
, O +
Rg1 O -
, O +
or O +
Rb1 O +
intragastrically O +
two O +
times O +
per O +
day O -
. O -

On O +
the O +
test O +
day O +
( O -
day O +
10 O -
) O -
, O +
mice O +
were O +
subjected O +
to O +
the O +
thermal O +
sensitivity O +
test O +
and O +
the O +
acetic O +
acid O -
- O -
induced O +
writhing O +
test O -
. O -

Re O +
( O -
300 O +
mg O -
/ O -
kg O -
) O +
inhibited O +
OIH U-Disease +
in O +
both O +
the O +
thermal O +
sensitivity O +
test O +
and O +
the O +
acetic O +
acid O -
- O -
induced O +
writhing O +
test O -
. O -

However O -
, O +
the O +
Rg1 O +
and O +
Rb1 O +
ginsenosides O +
failed O +
to O +
prevent O +
OIH U-Disease +
in O +
either O +
test O -
. O -

Furthermore O -
, O +
Rg1 O +
showed O +
a O +
tendency O +
to O +
aggravate O +
OIH U-Disease +
in O +
the O +
acetic O +
acid O -
- O -
induced O +
writhing O +
test O -
. O -

Our O +
data O +
suggested O +
that O +
the O +
ginsenoside O +
Re O -
, O +
but O +
not O +
Rg1 O +
or O +
Rb1 O -
, O +
may O +
contribute O +
toward O +
reversal O +
of O +
OIH U-Disease -
. O -

A O +
comparison O +
of O +
severe O +
hemodynamic O +
disturbances O +
between O +
dexmedetomidine O +
and O +
propofol O +
for O +
sedation O +
in O +
neurocritical O +
care O +
patients O -
. O -

OBJECTIVE O -
: O +
Dexmedetomidine O +
and O +
propofol O +
are O +
commonly O +
used O +
sedatives O +
in O +
neurocritical O +
care O +
as O +
they O +
allow O +
for O +
frequent O +
neurologic O +
examinations O -
. O -

However O -
, O +
both O +
agents O +
are O +
associated O +
with O +
significant O +
hemodynamic O +
side O +
effects O -
. O -

The O +
primary O +
objective O +
of O +
this O +
study O +
is O +
to O +
compare O +
the O +
prevalence O +
of O +
severe O +
hemodynamic O +
effects O +
in O +
neurocritical O +
care O +
patients O +
receiving O +
dexmedetomidine O +
and O +
propofol O -
. O -

DESIGN O -
: O +
Multicenter O -
, O +
retrospective O -
, O +
propensity O -
- O -
matched O +
cohort O +
study O -
. O -

SETTING O -
: O +
Neurocritical O +
care O +
units O +
at O +
two O +
academic O +
medical O +
centers O +
with O +
dedicated O +
neurocritical O +
care O +
teams O +
and O +
board O -
- O -
certified O +
neurointensivists O -
. O -

PATIENTS O -
: O +
Neurocritical O +
care O +
patients O +
admitted O +
between O +
July O +
2009 O +
and O +
September O +
2012 O +
were O +
evaluated O +
and O +
then O +
matched O +
1:1 O +
based O +
on O +
propensity O +
scoring O +
of O +
baseline O +
characteristics O -
. O -

INTERVENTIONS O -
: O +
Continuous O +
sedation O +
with O +
dexmedetomidine O +
or O +
propofol O -
. O -

MEASUREMENTS O +
AND O +
MAIN O +
RESULTS O -
: O +
A O +
total O +
of O +
342 O +
patients O +
( O -
105 O +
dexmedetomidine O +
and O +
237 O +
propofol O -
) O +
were O +
included O +
in O +
the O +
analysis O -
, O +
with O +
190 O +
matched O +
( O -
95 O +
in O +
each O +
group O -
) O +
by O +
propensity O +
score O -
. O -

The O +
primary O +
outcome O +
of O +
this O +
study O +
was O +
a O +
composite O +
of O +
severe O +
hypotension U-Disease +
( O -
mean O +
arterial O +
pressure O +
< O +
60 O +
mm O +
Hg O -
) O +
and O +
bradycardia U-Disease +
( O -
heart O +
rate O +
< O +
50 O +
beats O -
/ O -
min O -
) O +
during O +
sedative O +
infusion O -
. O -

No O +
difference O +
in O +
the O +
primary O +
composite O +
outcome O +
in O +
both O +
the O +
unmatched O +
( O -
30 O -
% O +
vs O +
30 O -
% O -
, O +
p O +
= O +
0.94 O -
) O +
or O +
matched O +
cohorts O +
( O -
28 O -
% O +
vs O +
34 O -
% O -
, O +
p O +
= O +
0.35 O -
) O +
could O +
be O +
found O -
. O -

When O +
analyzed O +
separately O -
, O +
no O +
differences O +
could O +
be O +
found O +
in O +
the O +
prevalence O +
of O +
severe O +
hypotension U-Disease +
or O +
bradycardia U-Disease +
in O +
either O +
the O +
unmatched O +
or O +
matched O +
cohorts O -
. O -

CONCLUSIONS O -
: O +
Severe O +
hypotension U-Disease +
and O +
bradycardia U-Disease +
occur O +
at O +
similar O +
prevalence O +
in O +
neurocritical O +
care O +
patients O +
who O +
receive O +
dexmedetomidine O +
or O +
propofol O -
. O -

Providers O +
should O +
similarly O +
consider O +
the O +
likelihood O +
of O +
hypotension U-Disease +
or O +
bradycardia U-Disease +
before O +
starting O +
either O +
sedative O -
. O -

Hydroxytyrosol O +
ameliorates O +
oxidative O +
stress O +
and O +
mitochondrial B-Disease +
dysfunction L-Disease +
in O +
doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease +
in O +
rats O +
with O +
breast B-Disease +
cancer L-Disease -
. O -

Oxidative O +
stress O +
is O +
involved O +
in O +
several O +
processes O +
including O +
cancer U-Disease -
, O +
aging O +
and O +
cardiovascular B-Disease +
disease L-Disease -
, O +
and O +
has O +
been O +
shown O +
to O +
potentiate O +
the O +
therapeutic O +
effect O +
of O +
drugs O +
such O +
as O +
doxorubicin O -
. O -

Doxorubicin O +
causes O +
significant O +
cardiotoxicity U-Disease +
characterized O +
by O +
marked O +
increases O +
in O +
oxidative O +
stress O +
and O +
mitochondrial B-Disease +
dysfunction L-Disease -
. O -

Herein O -
, O +
we O +
investigate O +
whether O +
doxorubicin O -
- O -
associated O +
chronic O +
cardiac B-Disease +
toxicity L-Disease +
can O +
be O +
ameliorated O +
with O +
the O +
antioxidant O +
hydroxytyrosol O +
in O +
rats O +
with O +
breast B-Disease +
cancer L-Disease -
. O -

Thirty O -
- O -
six O +
rats O +
bearing O +
breast B-Disease +
tumors L-Disease +
induced O +
chemically O +
were O +
divided O +
into O +
4 O +
groups O -
: O +
control O -
, O +
hydroxytyrosol O +
( O -
0.5mg O -
/ O -
kg O -
, O +
5days O -
/ O -
week O -
) O -
, O +
doxorubicin O +
( O -
1mg O -
/ O -
kg O -
/ O -
week O -
) O -
, O +
and O +
doxorubicin O +
plus O +
hydroxytyrosol O -
. O -

Cardiac B-Disease +
disturbances L-Disease +
at O +
the O +
cellular O +
and O +
mitochondrial O +
level O -
, O +
mitochondrial O +
electron O +
transport O +
chain O +
complexes O +
I O -
- O -
IV O +
and O +
apoptosis O -
- O -
inducing O +
factor O -
, O +
and O +
oxidative O +
stress O +
markers O +
have O +
been O +
analyzed O -
. O -

Hydroxytyrosol O +
improved O +
the O +
cardiac B-Disease +
disturbances L-Disease +
enhanced O +
by O +
doxorubicin O +
by O +
significantly O +
reducing O +
the O +
percentage O +
of O +
altered O +
mitochondria O +
and O +
oxidative O +
damage O -
. O -

These O +
results O +
suggest O +
that O +
hydroxytyrosol O +
improve O +
the O +
mitochondrial O +
electron O +
transport O +
chain O -
. O -

This O +
study O +
demonstrates O +
that O +
hydroxytyrosol O +
protect O +
rat O +
heart B-Disease +
damage L-Disease +
provoked O +
by O +
doxorubicin O +
decreasing O +
oxidative O +
damage O +
and O +
mitochondrial O +
alterations O -
. O -

Amiodarone O -
- O -
induced O +
myxoedema U-Disease +
coma U-Disease -
. O -

A O +
62-year O -
- O -
old O +
man O +
was O +
found O +
to O +
have O +
bradycardia U-Disease -
, O +
hypothermia U-Disease +
and O +
respiratory B-Disease +
failure L-Disease +
3 O +
weeks O +
after O +
initiation O +
of O +
amiodarone O +
therapy O +
for O +
atrial B-Disease +
fibrillation L-Disease -
. O -

Thyroid O -
- O -
stimulating O +
hormone O +
was O +
found O +
to O +
be O +
168 O +
uIU O -
/ O -
mL O +
( O -
nl O -
. O -

0.3 O -
- O -
5 O +
uIU O -
/ O -
mL O -
) O +
and O +
free O +
thyroxine O +
( O -
FT4 O -
) O +
was O +
< O -
0.2 O +
ng O -
/ O -
dL O +
( O -
nl O -
. O +
0.8 O -
- O -
1.8 O +
ng O -
/ O -
dL O -
) O -
. O -

He O +
received O +
intravenous O +
fluids O -
, O +
vasopressor O +
therapy O +
and O +
stress O +
dose O +
steroids O -
; O +
he O +
was O +
intubated O +
and O +
admitted O +
to O +
the O +
intensive O +
care O +
unit O -
. O -

He O +
received O +
500 O +
ug O +
of O +
intravenous O +
levothyroxine O +
in O +
the O +
first O +
18 O +
h O +
of O +
therapy O -
, O +
and O +
150 O +
ug O +
intravenous O +
daily O +
thereafter O -
. O -

Haemodynamic O +
improvement O -
, O +
along O +
with O +
complete O +
recovery O +
of O +
mental O +
status O -
, O +
occurred O +
after O +
48 O +
h. O +
Twelve O +
hours O +
after O +
the O +
initiation O +
of O +
therapy O -
, O +
FT4 O +
was O +
0.96 O +
ng O -
/ O -
dL. O +
The O +
patient O +
was O +
maintained O +
on O +
levothyroxine O +
175 O +
( O -
g O +
POorally O +
daily O -
. O -

A O +
thyroid O +
ultrasound O +
showed O +
diffuse O +
heterogeneity O -
. O -

The O +
24 O +
hour O +
excretion O +
of O +
iodine O +
was O +
3657 O +
( O -
mcg O +
( O -
25 O -
- O -
756 O +
( O +
mcg O -
) O -
. O -

The O +
only O +
two O +
cases O +
of O +
amiodarone O -
- O -
induced O +
myxoedema U-Disease +
coma U-Disease +
in O +
the O +
literature O +
report O +
patient O +
death O +
despite O +
supportive O +
therapy O +
and O +
thyroid O +
hormone O +
replacement O -
. O -

This O +
case O +
represents O +
the O +
most O +
thoroughly O +
investigated O +
case O +
of O +
amiodarone O -
- O -
induced O +
myxoedema U-Disease +
coma U-Disease +
with O +
a O +
history O +
significant O +
for O +
subclinical O +
thyroid B-Disease +
disease L-Disease -
. O -

Use O +
of O +
argatroban O +
and O +
catheter O -
- O -
directed O +
thrombolysis U-Disease +
with O +
alteplase O +
in O +
an O +
oncology O +
patient O +
with O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease +
with O +
thrombosis U-Disease -
. O -

PURPOSE O -
: O +
The O +
case O +
of O +
an O +
oncology O +
patient O +
who O +
developed O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease +
with O +
thrombosis U-Disease +
( O -
HITT U-Disease -
) O +
and O +
was O +
treated O +
with O +
argatroban O +
plus O +
catheter O -
- O -
directed O +
thrombolysis U-Disease +
( O -
CDT O -
) O +
with O +
alteplase O +
is O +
presented O -
. O -

SUMMARY O -
: O +
A O +
63-year O -
- O -
old O +
Caucasian O +
man O +
with O +
renal O +
amyloidosis U-Disease +
undergoing O +
peripheral O +
blood O +
stem O +
cell O +
collection O +
for O +
an O +
autologous O +
stem O +
cell O +
transplant O +
developed O +
extensive O +
bilateral O +
upper B-Disease -
- I-Disease -
extremity I-Disease +
deep I-Disease +
venous I-Disease +
thrombosis L-Disease +
( O -
DVT U-Disease -
) O +
and O +
pulmonary B-Disease +
embolism L-Disease +
secondary O +
to O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
. O -

A O +
continuous O +
i.v O -
. O -

infusion O +
of O +
argatroban O +
was O +
initiated O -
, O +
and O +
the O +
patient O +
was O +
managed O +
on O +
the O +
general O +
medical O +
floor O -
. O -

After O +
one O +
week O +
of O +
therapy O -
, O +
he O +
was O +
transferred O +
to O +
the O +
intensive O +
care O +
unit O +
with O +
cardiopulmonary O +
compromise O +
related O +
to O +
superior B-Disease +
vena I-Disease +
cava I-Disease +
( I-Disease -
SVC I-Disease -
) I-Disease +
syndrome L-Disease -
. O -

A O +
percutaneous O +
mechanical O +
thrombectomy O +
and O +
CDT O +
with O +
alteplase O +
were O +
attempted O -
, O +
but O +
the O +
procedure O +
was O +
aborted O +
due O +
to O +
epistaxis U-Disease -
. O -

The O +
epistaxis U-Disease +
resolved O +
the O +
next O +
day O -
, O +
and O +
the O +
patient O +
was O +
restarted O +
on O +
argatroban O -
. O -

A O +
second O +
percutaneous O +
mechanical O +
thrombectomy O +
was O +
performed O +
six O +
days O +
later O +
and O +
resulted O +
in O +
partial O +
revascularization O +
of O +
the O +
SVC O +
and O +
central O +
veins O -
. O -

Postthrombectomy O +
continuous O +
CDT O +
with O +
alteplase O +
was O +
commenced O +
while O +
argatroban O +
was O +
withheld O -
, O +
and O +
complete O +
patency O +
of O +
the O +
SVC O +
and O +
central O +
veins O +
was O +
achieved O +
after O +
three O +
days O +
of O +
therapy O -
. O -

Alteplase O +
was O +
discontinued O -
, O +
and O +
the O +
patient O +
was O +
reinitiated O +
on O +
argatroban O -
; O +
ultimately O -
, O +
he O +
was O +
transitioned O +
to O +
warfarin O +
for O +
long O -
- O -
term O +
anticoagulation O -
. O -

Although O +
the O +
patient O +
recovered O -
, O +
he O +
experienced O +
permanent O +
vision B-Disease +
and I-Disease +
hearing I-Disease +
loss L-Disease -
, O +
as O +
well O +
as O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease -
. O -

CONCLUSION O -
: O +
A O +
63-year O -
- O -
old O +
man O +
with O +
renal O +
amyloidosis U-Disease +
and O +
SVC B-Disease +
syndrome L-Disease +
secondary O +
to O +
HITT U-Disease +
was O +
successfully O +
treated O +
with O +
argatroban O +
and O +
CDT O +
with O +
alteplase O -
. O -

Effects O +
of O +
dehydroepiandrosterone O +
in O +
amphetamine O -
- O -
induced O +
schizophrenia U-Disease +
models O +
in O +
mice O -
. O -

OBJECTIVE O -
: O +
To O +
examine O +
the O +
effects O +
of O +
dehydroepiandrosterone O +
( O -
DHEA O -
) O +
on O +
animal O +
models O +
of O +
schizophrenia U-Disease -
. O -

METHODS O -
: O +
Seventy O +
Swiss O +
albino O +
female O +
mice O +
( O -
25 O -
- O -
35 O +
g O -
) O +
were O +
divided O +
into O +
4 O +
groups O -
: O +
amphetamine O -
- O -
free O +
( O -
control O -
) O -
, O +
amphetamine O -
, O +
50 O -
, O +
and O +
100 O +
mg O -
/ O -
kg O +
DHEA O -
. O -

The O +
DHEA O +
was O +
administered O +
intraperitoneally O +
( O -
ip O -
) O +
for O +
5 O +
days O -
. O -

Amphetamine O +
( O -
3 O +
mg O -
/ O -
kg O +
ip O -
) O +
induced O +
hyper U-Disease +
locomotion O -
, O +
apomorphine O +
( O -
1.5 O +
mg O -
/ O -
kg O +
subcutaneously O +
[ O -
sc O -
] O -
) O +
induced O +
climbing O -
, O +
and O +
haloperidol O +
( O -
1.5 O +
mg O -
/ O -
kg O +
sc O -
) O +
induced O +
catalepsy U-Disease +
tests O +
were O +
used O +
as O +
animal O +
models O +
of O +
schizophrenia U-Disease -
. O -

The O +
study O +
was O +
conducted O +
at O +
the O +
Animal O +
Experiment O +
Laboratories O -
, O +
Department O +
of O +
Pharmacology O -
, O +
Medical O +
School O -
, O +
Eskisehir O +
Osmangazi O +
University O -
, O +
Eskisehir O -
, O +
Turkey O +
between O +
March O +
and O +
May O +
2012 O -
. O -

Statistical O +
analysis O +
was O +
carried O +
out O +
using O +
Kruskal O -
- O -
Wallis O +
test O +
for O +
hyper U-Disease +
locomotion O -
, O +
and O +
one O -
- O -
way O +
ANOVA O +
for O +
climbing O +
and O +
catalepsy U-Disease +
tests O -
. O -

RESULTS O -
: O +
In O +
the O +
amphetamine O -
- O -
induced O +
locomotion O +
test O -
, O +
there O +
were O +
significant O +
increases O +
in O +
all O +
movements O +
compared O +
with O +
the O +
amphetamine O -
- O -
free O +
group O -
. O -

Both O +
DHEA O +
50 O +
mg O -
/ O -
kg O +
( O -
p<0.05 O -
) O -
, O +
and O +
100 O +
mg O -
/ O -
kg O +
( O -
p<0.01 O -
) O +
significantly O +
decreased O +
all O +
movements O +
compared O +
with O +
the O +
amphetamine O -
- O -
induced O +
locomotion O +
group O -
. O -

There O +
was O +
a O +
significant O +
difference O +
between O +
groups O +
in O +
the O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease +
test O +
( O -
p<0.05 O -
) O -
. O -

There O +
was O +
no O +
significant O +
difference O +
between O +
groups O +
in O +
terms O +
of O +
total O +
climbing O +
time O +
in O +
the O +
apomorphine O -
- O -
induced O +
climbing O +
test O +
( O -
p>0.05 O -
) O -
. O -

CONCLUSION O -
: O +
We O +
observed O +
that O +
DHEA O +
reduced O +
locomotor O +
activity O +
and O +
increased O +
catalepsy U-Disease +
at O +
both O +
doses O -
, O +
while O +
it O +
had O +
no O +
effect O +
on O +
climbing O +
behavior O -
. O -

We O +
suggest O +
that O +
DHEA O +
displays O +
typical O +
neuroleptic O -
- O -
like O +
effects O -
, O +
and O +
may O +
be O +
used O +
in O +
the O +
treatment O +
of O +
schizophrenia U-Disease -
. O -

Availability O +
of O +
human O +
induced O +
pluripotent O +
stem O +
cell O -
- O -
derived O +
cardiomyocytes O +
in O +
assessment O +
of O +
drug O +
potential O +
for O +
QT B-Disease +
prolongation L-Disease -
. O -

Field O +
potential O +
duration O +
( O -
FPD O -
) O +
in O +
human O -
- O -
induced O +
pluripotent O +
stem O +
cell O -
- O -
derived O +
cardiomyocytes O +
( O -
hiPS O -
- O -
CMs O -
) O -
, O +
which O +
can O +
express O +
QT O +
interval O +
in O +
an O +
electrocardiogram O -
, O +
is O +
reported O +
to O +
be O +
a O +
useful O +
tool O +
to O +
predict O +
K O -
( O -
+ O -
) O +
channel O +
and O +
Ca O -
( O -
2 O -
+ O -
) O +
channel O +
blocker O +
effects O +
on O +
QT O +
interval O -
. O -

However O -
, O +
there O +
is O +
no O +
report O +
showing O +
that O +
this O +
technique O +
can O +
be O +
used O +
to O +
predict O +
multichannel O +
blocker O +
potential O +
for O +
QT B-Disease +
prolongation L-Disease -
. O -

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
show O +
that O +
FPD O +
from O +
MEA O +
( O -
Multielectrode O +
array O -
) O +
of O +
hiPS O -
- O -
CMs O +
can O +
detect O +
QT B-Disease +
prolongation L-Disease +
induced O +
by O +
multichannel O +
blockers O -
. O -

hiPS O -
- O -
CMs O +
were O +
seeded O +
onto O +
MEA O +
and O +
FPD O +
was O +
measured O +
for O +
2min O +
every O +
10min O +
for O +
30min O +
after O +
drug O +
exposure O +
for O +
the O +
vehicle O +
and O +
each O +
drug O +
concentration O -
. O -

IKr O +
and O +
IKs O +
blockers O +
concentration O -
- O -
dependently O +
prolonged O +
corrected O +
FPD O +
( O -
FPDc O -
) O -
, O +
whereas O +
Ca O -
( O -
2 O -
+ O -
) O +
channel O +
blockers O +
concentration O -
- O -
dependently O +
shortened O +
FPDc O -
. O -

Also O -
, O +
the O +
multichannel O +
blockers O +
Amiodarone O -
, O +
Paroxetine O -
, O +
Terfenadine O +
and O +
Citalopram O +
prolonged O +
FPDc O +
in O +
a O +
concentration O +
dependent O +
manner O -
. O -

Finally O -
, O +
the O +
IKr O +
blockers O -
, O +
Terfenadine O +
and O +
Citalopram O -
, O +
which O +
are O +
reported O +
to O +
cause O +
Torsade B-Disease +
de I-Disease +
Pointes L-Disease +
( O -
TdP U-Disease -
) O +
in O +
clinical O +
practice O -
, O +
produced O +
early O +
afterdepolarization O +
( O -
EAD O -
) O -
. O -

hiPS O -
- O -
CMs O +
using O +
MEA O +
system O +
and O +
FPDc O +
can O +
predict O +
the O +
effects O +
of O +
drug O +
candidates O +
on O +
QT O +
interval O -
. O -

This O +
study O +
also O +
shows O +
that O +
this O +
assay O +
can O +
help O +
detect O +
EAD O +
for O +
drugs O +
with O +
TdP U-Disease +
potential O -
. O -

Dermal O +
developmental O +
toxicity U-Disease +
of O +
N O -
- O -
phenylimide O +
herbicides O +
in O +
rats O -
. O -

BACKGROUND O -
: O +
S-53482 O +
and O +
S-23121 O +
are O +
N O -
- O -
phenylimide O +
herbicides O +
and O +
produced O +
embryolethality U-Disease -
, O +
teratogenicity U-Disease +
( O -
mainly O +
ventricular B-Disease +
septal I-Disease +
defects L-Disease +
and O +
wavy O +
ribs O -
) O -
, O +
and O +
growth B-Disease +
retardation L-Disease +
in O +
rats O +
in O +
conventional O +
oral O +
developmental O +
toxicity U-Disease +
studies O -
. O -

Our O +
objective O +
in O +
this O +
study O +
was O +
to O +
investigate O +
whether O +
the O +
compounds O +
induce O +
developmental O +
toxicity U-Disease +
via O +
the O +
dermal O +
route O -
, O +
which O +
is O +
more O +
relevant O +
to O +
occupational O +
exposure O -
, O +
hence O +
better O +
addressing O +
human O +
health O +
risks O -
. O -

METHODS O -
: O +
S-53482 O +
was O +
administered O +
dermally O +
to O +
rats O +
at O +
30 O -
, O +
100 O -
, O +
and O +
300 O +
mg O -
/ O -
kg O +
during O +
organogenesis O -
, O +
and O +
S-23121 O +
was O +
administered O +
at O +
200 O -
, O +
400 O -
, O +
and O +
800 O +
mg O -
/ O -
kg O +
( O -
the O +
maximum O +
applicable O +
dose O +
level O -
) O -
. O -

Fetuses O +
were O +
obtained O +
by O +
a O +
Cesarean O +
section O +
and O +
examined O +
for O +
external O -
, O +
visceral O -
, O +
and O +
skeletal O +
alterations O -
. O -

RESULTS O -
: O +
Dermal O +
exposure O +
of O +
rats O +
to O +
S-53482 O +
at O +
300 O +
mg O -
/ O -
kg O +
produced O +
patterns O +
of O +
developmental O +
toxicity U-Disease +
similar O +
to O +
those O +
resulting O +
from O +
oral O +
exposure O -
. O -

Toxicity U-Disease +
included O +
embryolethality U-Disease -
, O +
teratogenicity U-Disease -
, O +
and O +
growth B-Disease +
retardation L-Disease -
. O -

Dermal O +
administration O +
of O +
S-23121 O +
at O +
800 O +
mg O -
/ O -
kg O +
resulted O +
in O +
an O +
increased O +
incidence O +
of O +
embryonic B-Disease +
death L-Disease +
and O +
ventricular B-Disease +
septal I-Disease +
defect L-Disease -
, O +
but O +
retarded O +
fetal O +
growth O +
was O +
not O +
observed O +
as O +
it O +
was O +
following O +
oral O +
exposure O +
to O +
S-23121 O -
. O -

CONCLUSIONS O -
: O +
Based O +
on O +
the O +
results O -
, O +
S-53482 O +
and O +
S-23121 O +
were O +
teratogenic U-Disease +
when O +
administered O +
dermally O +
to O +
pregnant O +
rats O +
as O +
were O +
the O +
compounds O +
administered O +
orally O -
. O -

Thus O -
, O +
investigation O +
of O +
the O +
mechanism O +
and O +
its O +
human O +
relevancy O +
become O +
more O +
important O -
. O -

Rates O +
of O +
Renal B-Disease +
Toxicity L-Disease +
in O +
Cancer U-Disease +
Patients O +
Receiving O +
Cisplatin O +
With O +
and O +
Without O +
Mannitol O -
. O -

BACKGROUND O -
: O +
Cisplatin O +
is O +
a O +
widely O +
used O +
antineoplastic O -
. O -

One O +
of O +
the O +
major O +
complications O +
of O +
cisplatin O +
use O +
is O +
dose O -
- O -
limiting O +
nephrotoxicity U-Disease -
. O -

There O +
are O +
many O +
strategies O +
to O +
prevent O +
this O +
toxicity U-Disease -
, O +
including O +
the O +
use O +
of O +
mannitol O +
as O +
a O +
nephroprotectant O +
in O +
combination O +
with O +
hydration O -
. O -

OBJECTIVE O -
: O +
We O +
aimed O +
to O +
evaluate O +
the O +
rates O +
of O +
cisplatin O -
- O -
induced O +
nephrotoxicity U-Disease +
in O +
cancer U-Disease +
patients O +
receiving O +
single O -
- O -
agent O +
cisplatin O +
with O +
and O +
without O +
mannitol O -
. O -

METHODS O -
: O +
This O +
single O -
- O -
center O +
retrospective O +
analysis O +
was O +
a O +
quasi O +
experiment O +
created O +
by O +
the O +
national O +
mannitol O +
shortage O -
. O -

Data O +
were O +
collected O +
on O +
adult O +
cancer U-Disease +
patients O +
receiving O +
single O -
- O -
agent O +
cisplatin O +
as O +
an O +
outpatient O +
from O +
January O +
2011 O +
to O +
September O +
2012 O -
. O -

The O +
primary O +
outcome O +
was O +
acute B-Disease +
kidney I-Disease +
injury L-Disease +
( O -
AKI U-Disease -
) O -
. O -

RESULTS O -
: O +
We O +
evaluated O +
143 O +
patients O +
who O +
received O +
single O -
- O -
agent O +
cisplatin O -
; O +
97.2 O -
% O +
of O +
patients O +
had O +
head B-Disease +
and I-Disease +
neck I-Disease +
cancer L-Disease +
as O +
their O +
primary O +
malignancy U-Disease -
. O -

Patients O +
who O +
did O +
not O +
receive O +
mannitol O +
were O +
more O +
likely O +
to O +
develop O +
nephrotoxicity U-Disease -
: O +
odds O +
ratio O +
[ O -
OR O -
] O +
= O +
2.646 O +
( O -
95 O -
% O +
CI O +
= O +
1.008 O -
, O +
6.944 O -
; O +
P O +
= O +
0.048 O -
) O -
. O -

Patients O +
who O +
received O +
the O +
100 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
dosing O +
and O +
patients O +
who O +
had O +
a O +
history O +
of O +
hypertension U-Disease +
also O +
had O +
a O +
higher O +
likelihood O +
of O +
developing O +
nephrotoxicity U-Disease -
: O +
OR O +
= O +
11.494 O +
( O -
95 O -
% O +
CI O +
= O +
4.149 O -
, O +
32.258 O -
; O +
P O +
< O +
0.0001 O -
) O +
and O +
OR O +
= O +
3.219 O +
( O -
95 O -
% O +
CI O +
= O +
1.228 O -
, O +
8.439 O -
; O +
P O +
= O +
0.017 O -
) O -
, O +
respectively O -
. O -

CONCLUSIONS O -
: O +
When O +
limited O +
quantities O +
of O +
mannitol O +
are O +
available O -
, O +
it O +
should O +
preferentially O +
be O +
given O +
to O +
patients O +
at O +
particularly O +
high O +
risk O +
of O +
nephrotoxicity U-Disease -
. O -

Our O +
analysis O +
suggests O +
that O +
those O +
patients O +
receiving O +
the O +
dosing O +
schedule O +
of O +
100 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
cisplatin O +
every O +
3 O +
weeks O +
and O +
those O +
with O +
hypertension U-Disease +
are O +
at O +
the O +
greatest O +
risk O +
of O +
nephrotoxicity U-Disease +
and O +
would O +
benefit O +
from O +
the O +
addition O +
of O +
mannitol O -
. O -

Metformin O +
protects O +
against O +
seizures U-Disease -
, O +
learning B-Disease +
and I-Disease +
memory I-Disease +
impairments L-Disease +
and O +
oxidative O +
damage O +
induced O +
by O +
pentylenetetrazole O -
- O -
induced O +
kindling O +
in O +
mice O -
. O -

Cognitive B-Disease +
impairment L-Disease -
, O +
the O +
most O +
common O +
and O +
severe O +
comorbidity O +
of O +
epilepsy U-Disease -
, O +
greatly O +
diminishes O +
the O +
quality O +
of O +
life O -
. O -

However O -
, O +
current O +
therapeutic O +
interventions O +
for O +
epilepsy U-Disease +
can O +
also O +
cause O +
untoward O +
cognitive O +
effects O -
. O -

Thus O -
, O +
there O +
is O +
an O +
urgent O +
need O +
for O +
new O +
kinds O +
of O +
agents O +
targeting O +
both O +
seizures U-Disease +
and O +
cognition B-Disease +
deficits L-Disease -
. O -

Oxidative O +
stress O +
is O +
considered O +
to O +
play O +
an O +
important O +
role O +
in O +
epileptogenesis O +
and O +
cognitive B-Disease +
deficits L-Disease -
, O +
and O +
antioxidants O +
have O +
a O +
putative O +
antiepileptic O +
potential O -
. O -

Metformin O -
, O +
the O +
most O +
commonly O +
prescribed O +
antidiabetic O +
oral O +
drug O -
, O +
has O +
antioxidant O +
properties O -
. O -

This O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
ameliorative O +
effects O +
of O +
metformin O +
on O +
seizures U-Disease -
, O +
cognitive B-Disease +
impairment L-Disease +
and O +
brain O +
oxidative O +
stress O +
markers O +
observed O +
in O +
pentylenetetrazole O -
- O -
induced O +
kindling O +
animals O -
. O -

Male O +
C57BL O -
/ O -
6 O +
mice O +
were O +
administered O +
with O +
subconvulsive O +
dose O +
of O +
pentylenetetrazole O +
( O -
37 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
every O +
other O +
day O +
for O +
14 O +
injections O -
. O -

Metformin O +
was O +
injected O +
intraperitoneally O +
in O +
dose O +
of O +
200mg O -
/ O -
kg O +
along O +
with O +
alternate O -
- O -
day O +
PTZ O -
. O -

We O +
found O +
that O +
metformin O +
suppressed O +
the O +
progression O +
of O +
kindling O -
, O +
ameliorated O +
the O +
cognitive B-Disease +
impairment L-Disease +
and O +
decreased O +
brain O +
oxidative O +
stress O -
. O -

Thus O +
the O +
present O +
study O +
concluded O +
that O +
metformin O +
may O +
be O +
a O +
potential O +
agent O +
for O +
the O +
treatment O +
of O +
epilepsy U-Disease +
as O +
well O +
as O +
a O +
protective O +
medicine O +
against O +
cognitive B-Disease +
impairment L-Disease +
induced O +
by O +
seizures U-Disease -
. O -

P53 O +
inhibition O +
exacerbates O +
late O -
- O -
stage O +
anthracycline O +
cardiotoxicity U-Disease -
. O -

AIMS O -
: O +
Doxorubicin O +
( O -
DOX O -
) O +
is O +
an O +
effective O +
anti O -
- O -
cancer U-Disease +
therapeutic O -
, O +
but O +
is O +
associated O +
with O +
both O +
acute O +
and O +
late O -
- O -
stage O +
cardiotoxicity U-Disease -
. O -

Children O +
are O +
particularly O +
sensitive O +
to O +
DOX O -
- O -
induced O +
heart B-Disease +
failure L-Disease -
. O -

Here O -
, O +
the O +
impact O +
of O +
p53 O +
inhibition O +
on O +
acute O +
vs. O +
late O -
- O -
stage O +
DOX O +
cardiotoxicity U-Disease +
was O +
examined O +
in O +
a O +
juvenile O +
model O -
. O -

METHODS O +
AND O +
RESULTS O -
: O +
Two O -
- O -
week O -
- O -
old O +
MHC O -
- O -
CB7 O +
mice O +
( O -
which O +
express O +
dominant O -
- O -
interfering O +
p53 O +
in O +
cardiomyocytes O -
) O +
and O +
their O +
non O -
- O -
transgenic O +
( O -
NON O -
- O -
TXG O -
) O +
littermates O +
received O +
weekly O +
DOX O +
injections O +
for O +
5 O +
weeks O +
( O -
25 O +
mg O -
/ O -
kg O +
cumulative O +
dose O -
) O -
. O -

One O +
week O +
after O +
the O +
last O +
DOX O +
treatment O +
( O -
acute O +
stage O -
) O -
, O +
MHC O -
- O -
CB7 O +
mice O +
exhibited O +
improved O +
cardiac O +
function O +
and O +
lower O +
levels O +
of O +
cardiomyocyte O +
apoptosis O +
when O +
compared O +
with O +
the O +
NON O -
- O -
TXG O +
mice O -
. O -

Surprisingly O -
, O +
by O +
13 O +
weeks O +
following O +
the O +
last O +
DOX O +
treatment O +
( O -
late O +
stage O -
) O -
, O +
MHC O -
- O -
CB7 O +
exhibited O +
a O +
progressive O +
decrease O +
in O +
cardiac O +
function O +
and O +
higher O +
rates O +
of O +
cardiomyocyte O +
apoptosis O +
when O +
compared O +
with O +
NON O -
- O -
TXG O +
mice O -
. O -

p53 O +
inhibition O +
blocked O +
transient O +
DOX O -
- O -
induced O +
STAT3 O +
activation O +
in O +
MHC O -
- O -
CB7 O +
mice O -
, O +
which O +
was O +
associated O +
with O +
enhanced O +
induction O +
of O +
the O +
DNA O +
repair O +
proteins O +
Ku70 O +
and O +
Ku80 O -
. O -

Mice O +
with O +
cardiomyocyte O -
- O -
restricted O +
deletion O +
of O +
STAT3 O +
exhibited O +
worse O +
cardiac O +
function O -
, O +
higher O +
levels O +
of O +
cardiomyocyte O +
apoptosis O -
, O +
and O +
a O +
greater O +
induction O +
of O +
Ku70 O +
and O +
Ku80 O +
in O +
response O +
to O +
DOX O +
treatment O +
during O +
the O +
acute O +
stage O +
when O +
compared O +
with O +
control O +
animals O -
. O -

CONCLUSION O -
: O +
These O +
data O +
support O +
a O +
model O +
wherein O +
a O +
p53-dependent O +
cardioprotective O +
pathway O -
, O +
mediated O +
via O +
STAT3 O +
activation O -
, O +
mitigates O +
DOX O -
- O -
induced O +
myocardial O +
stress O +
during O +
drug O +
delivery O -
. O -

Furthermore O -
, O +
these O +
data O +
suggest O +
an O +
explanation O +
as O +
to O +
how O +
p53 O +
inhibition O +
can O +
result O +
in O +
cardioprotection O +
during O +
drug O +
treatment O +
and O -
, O +
paradoxically O -
, O +
enhanced O +
cardiotoxicity U-Disease +
long O +
after O +
the O +
cessation O +
of O +
drug O +
treatment O -
. O -

Metronidazole O -
- O -
induced O +
encephalopathy U-Disease -
: O +
an O +
uncommon O +
scenario O -
. O -

Metronidazole O +
can O +
produce O +
neurological O +
complications O +
although O +
it O +
is O +
not O +
a O +
common O +
scenario O -
. O -

We O +
present O +
a O +
case O +
where O +
a O +
patient O +
developed O +
features O +
of O +
encephalopathy U-Disease +
following O +
prolonged O +
metronidazole O +
intake O -
. O -

Magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
brain O +
showed O +
abnormal O +
signal O +
intensity O +
involving O +
both O +
dentate O +
nuclei O +
of O +
cerebellum O +
and O +
splenium O +
of O +
corpus O +
callosum O -
. O -

The O +
diagnosis O +
of O +
metronidazole O +
toxicity U-Disease +
was O +
made O +
by O +
the O +
MRI O +
findings O +
and O +
supported O +
clinically O -
. O -

Aconitine O -
- O -
induced O +
Ca2 O -
+ O +
overload O +
causes O +
arrhythmia U-Disease +
and O +
triggers O +
apoptosis O +
through O +
p38 O +
MAPK O +
signaling O +
pathway O +
in O +
rats O -
. O -

Aconitine O +
is O +
a O +
major O +
bioactive O +
diterpenoid O +
alkaloid O +
with O +
high O +
content O +
derived O +
from O +
herbal O +
aconitum O +
plants O -
. O -

Emerging O +
evidence O +
indicates O +
that O +
voltage O -
- O -
dependent O +
Na O -
( O -
+ O -
) O +
channels O +
have O +
pivotal O +
roles O +
in O +
the O +
cardiotoxicity U-Disease +
of O +
aconitine O -
. O -

However O -
, O +
no O +
reports O +
are O +
available O +
on O +
the O +
role O +
of O +
Ca O -
( O -
2 O -
+ O -
) O +
in O +
aconitine O +
poisoning U-Disease -
. O -

In O +
this O +
study O -
, O +
we O +
explored O +
the O +
importance O +
of O +
pathological O +
Ca O -
( O -
2 O -
+ O -
) O +
signaling O +
in O +
aconitine O +
poisoning U-Disease +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

We O +
found O +
that O +
Ca O -
( O -
2 O -
+ O -
) O +
overload O +
lead O +
to O +
accelerated O +
beating O +
rhythm O +
in O +
adult O +
rat O +
ventricular O +
myocytes O +
and O +
caused O +
arrhythmia U-Disease +
in O +
conscious O +
freely O +
moving O +
rats O -
. O -

To O +
investigate O +
effects O +
of O +
aconitine O +
on O +
myocardial B-Disease +
injury L-Disease -
, O +
we O +
performed O +
cytotoxicity U-Disease +
assay O +
in O +
neonatal O +
rat O +
ventricular O +
myocytes O +
( O -
NRVMs O -
) O -
, O +
as O +
well O +
as O +
measured O +
lactate O +
dehydrogenase O +
level O +
in O +
the O +
culture O +
medium O +
of O +
NRVMs O +
and O +
activities O +
of O +
serum O +
cardiac O +
enzymes O +
in O +
rats O -
. O -

The O +
results O +
showed O +
that O +
aconitine O +
resulted O +
in O +
myocardial B-Disease +
injury L-Disease +
and O +
reduced O +
NRVMs O +
viability O +
dose O -
- O -
dependently O -
. O -

To O +
confirm O +
the O +
pro O -
- O -
apoptotic O +
effects O -
, O +
we O +
performed O +
flow O +
cytometric O +
detection O -
, O +
cardiac O +
histology O -
, O +
transmission O +
electron O +
microscopy O +
and O +
terminal O +
deoxynucleotidyl O +
transferase O -
- O -
mediated O +
dUTP O -
- O -
biotin O +
nick O +
end O +
labeling O +
assay O -
. O -

The O +
results O +
showed O +
that O +
aconitine O +
stimulated O +
apoptosis O +
time O -
- O -
dependently O -
. O -

The O +
expression O +
analysis O +
of O +
Ca O -
( O -
2 O -
+ O -
) O +
handling O +
proteins O +
demonstrated O +
that O +
aconitine O +
promoted O +
Ca O -
( O -
2 O -
+ O -
) O +
overload O +
through O +
the O +
expression O +
regulation O +
of O +
Ca O -
( O -
2 O -
+ O -
) O +
handling O +
proteins O -
. O -

The O +
expression O +
analysis O +
of O +
apoptosis O -
- O -
related O +
proteins O +
revealed O +
that O +
pro O -
- O -
apoptotic O +
protein O +
expression O +
was O +
upregulated O -
, O +
and O +
anti O -
- O -
apoptotic O +
protein O +
BCL-2 O +
expression O +
was O +
downregulated O -
. O -

Furthermore O -
, O +
increased O +
phosphorylation O +
of O +
MAPK O +
family O +
members O -
, O +
especially O +
the O +
P O -
- O -
P38 O -
/ O -
P38 O +
ratio O +
was O +
found O +
in O +
cardiac O +
tissues O -
. O -

Hence O -
, O +
our O +
results O +
suggest O +
that O +
aconitine O +
significantly O +
aggravates O +
Ca O -
( O -
2 O -
+ O -
) O +
overload O +
and O +
causes O +
arrhythmia U-Disease +
and O +
finally O +
promotes O +
apoptotic O +
development O +
via O +
phosphorylation O +
of O +
P38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O -
. O -

Chronic O +
treatment O +
with O +
metformin O +
suppresses O +
toll O -
- O -
like O +
receptor O +
4 O +
signaling O +
and O +
attenuates O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease +
following O +
myocardial B-Disease +
infarction L-Disease -
. O -

Acute O +
treatment O +
with O +
metformin O +
has O +
a O +
protective O +
effect O +
in O +
myocardial B-Disease +
infarction L-Disease +
by O +
suppression O +
of O +
inflammatory O +
responses O +
due O +
to O +
activation O +
of O +
AMP O -
- O -
activated O +
protein O +
kinase O +
( O -
AMPK O -
) O -
. O -

In O +
the O +
present O +
study O -
, O +
the O +
effect O +
of O +
chronic O +
pre O -
- O -
treatment O +
with O +
metformin O +
on O +
cardiac B-Disease +
dysfunction L-Disease +
and O +
toll O -
- O -
like O +
receptor O +
4 O +
( O -
TLR4 O -
) O +
activities O +
following O +
myocardial B-Disease +
infarction L-Disease +
and O +
their O +
relation O +
with O +
AMPK O +
were O +
assessed O -
. O -

Male O +
Wistar O +
rats O +
were O +
randomly O +
assigned O +
to O +
one O +
of O +
5 O +
groups O +
( O -
n=6 O -
) O -
: O +
normal O +
control O +
and O +
groups O +
were O +
injected O +
isoproterenol O +
after O +
chronic O +
pre O -
- O -
treatment O +
with O +
0 O -
, O +
25 O -
, O +
50 O -
, O +
or O +
100mg O -
/ O -
kg O +
of O +
metformin O +
twice O +
daily O +
for O +
14 O +
days O -
. O -

Isoproterenol O +
( O -
100mg O -
/ O -
kg O -
) O +
was O +
injected O +
subcutaneously O +
on O +
the O +
13th O +
and O +
14th O +
days O +
to O +
induce O +
acute B-Disease +
myocardial I-Disease +
infarction L-Disease -
. O -

Isoproterenol O +
alone O +
decreased O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
myocardial O +
contractility O +
indexed O +
as O +
LVdp O -
/ O -
dtmax O +
and O +
LVdp O -
/ O -
dtmin O -
. O -

The O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease +
was O +
significantly O +
lower O +
in O +
the O +
groups O +
treated O +
with O +
25 O +
and O +
50mg O -
/ O -
kg O +
of O +
metformin O -
. O -

Metfromin O +
markedly O +
lowered O +
isoproterenol O -
- O -
induced O +
elevation O +
in O +
the O +
levels O +
of O +
TLR4 O +
mRNA O -
, O +
myeloid O +
differentiation O +
protein O +
88 O +
( O -
MyD88 O -
) O -
, O +
tumor U-Disease +
necrosis U-Disease +
factor O -
- O -
alpha O +
( O -
TNF O -
- O -
a O -
) O -
, O +
and O +
interleukin O +
6 O +
( O -
IL-6 O -
) O +
in O +
the O +
heart O +
tissues O -
. O -

Similar O +
changes O +
were O +
also O +
seen O +
in O +
the O +
serum O +
levels O +
of O +
TNF O -
- O -
a O +
and O +
IL-6 O -
. O -

However O -
, O +
the O +
lower O +
doses O +
of O +
25 O +
and O +
50mg O -
/ O -
kg O +
were O +
more O +
effective O +
than O +
100mg O -
/ O -
kg O -
. O -

Phosphorylated O +
AMPKa O +
( O -
p O -
- O -
AMPK O -
) O +
in O +
the O +
myocardium O +
was O +
significantly O +
elevated O +
by O +
25mg O -
/ O -
kg O +
of O +
metformin O -
, O +
slightly O +
by O +
50mg O -
/ O -
kg O -
, O +
but O +
not O +
by O +
100mg O -
/ O -
kg O -
. O -

Chronic O +
pre O -
- O -
treatment O +
with O +
metformin O +
reduces O +
post O -
- O -
myocardial B-Disease +
infarction L-Disease +
cardiac O +
dysfunction O +
and O +
suppresses O +
inflammatory O +
responses O -
, O +
possibly O +
through O +
inhibition O +
of O +
TLR4 O +
activities O -
. O -

This O +
mechanism O +
can O +
be O +
considered O +
as O +
a O +
target O +
to O +
protect O +
infarcted O +
myocardium O -
. O -

Unusual O +
complications O +
of O +
antithyroid O +
drug O +
therapy O -
: O +
four O +
case O +
reports O +
and O +
review O +
of O +
literature O -
. O -

Two O +
cases O +
of O +
propylthiouracil O -
- O -
associated O +
acute O +
hepatitis U-Disease -
, O +
one O +
case O +
of O +
fatal O +
methimazole O -
- O -
associated O +
hepatocellular B-Disease +
necrosis L-Disease +
and O +
one O +
case O +
of O +
propylthiouracil O -
- O -
associated O +
lupus B-Disease -
- I-Disease -
like I-Disease +
syndrome L-Disease +
are O +
described O -
. O -

The O +
literature O +
related O +
to O +
antithyroid O +
drug O +
side O +
effects O +
and O +
the O +
mechanisms O +
for O +
their O +
occurrence O +
are O +
reviewed O +
and O +
the O +
efficacy O +
and O +
complications O +
of O +
thyroidectomy O +
and O +
radioiodine O +
compared O +
to O +
those O +
of O +
antithyroid O +
drugs O -
. O -

It O +
is O +
concluded O +
that O +
in O +
most O +
circumstances O +
131I O +
is O +
the O +
therapy O +
of O +
choice O +
for O +
hyperthyroidism U-Disease -
. O -

Neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
induced O +
by O +
combination O +
therapy O +
with O +
tetrabenazine O +
and O +
tiapride O +
in O +
a O +
Japanese O +
patient O +
with O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
at O +
the O +
terminal O +
stage O +
of O +
recurrent O +
breast B-Disease +
cancer L-Disease -
. O -

We O +
herein O +
describe O +
the O +
case O +
of O +
an O +
81-year O -
- O -
old O +
Japanese O +
woman O +
with O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
that O +
occurred O +
36 O +
days O +
after O +
the O +
initiation O +
of O +
combination O +
therapy O +
with O +
tiapride O +
( O -
75 O +
mg O -
/ O -
day O -
) O +
and O +
tetrabenazine O +
( O -
12.5 O +
mg O -
/ O -
day O -
) O +
for O +
Huntington B-Disease -
's I-Disease +
disease L-Disease -
. O -

The O +
patient O +
had O +
been O +
treated O +
with O +
tiapride O +
or O +
tetrabenazine O +
alone O +
without O +
any O +
adverse O +
effects O +
before O +
the O +
administration O +
of O +
the O +
combination O +
therapy O -
. O -

She O +
also O +
had O +
advanced O +
breast B-Disease +
cancer L-Disease +
when O +
the O +
combination O +
therapy O +
was O +
initiated O -
. O -

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
the O +
occurrence O +
of O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
due O +
to O +
combination O +
therapy O +
with O +
tetrabenazine O +
and O +
tiapride O +
has O +
not O +
been O +
previously O +
reported O -
. O -

Tetrabenazine O +
should O +
be O +
administered O +
very O +
carefully O +
in O +
combination O +
with O +
other O +
neuroleptic O +
drugs O -
, O +
particularly O +
in O +
patients O +
with O +
a O +
worsening O +
general O +
condition O -
. O -

A O +
metoprolol O -
- O -
terbinafine O +
combination O +
induced O +
bradycardia U-Disease -
. O -

To O +
report O +
a O +
sinus B-Disease +
bradycardia L-Disease +
induced O +
by O +
metoprolol O +
and O +
terbinafine O +
drug O -
- O -
drug O +
interaction O +
and O +
its O +
management O -
. O -

A O +
63 O +
year O -
- O -
old O +
Caucasian O +
man O +
on O +
metoprolol O +
200 O +
mg O -
/ O -
day O +
for O +
stable O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
was O +
prescribed O +
a O +
90-day O +
course O +
of O +
oral O +
terbinafine O +
250 O +
mg O -
/ O -
day O +
for O +
onychomycosis U-Disease -
. O -

On O +
the O +
49th O +
day O +
of O +
terbinafine O +
therapy O -
, O +
he O +
was O +
brought O +
to O +
the O +
emergency O +
room O +
for O +
a O +
decrease O +
of O +
his O +
global O +
health O +
status O -
, O +
confusion U-Disease +
and O +
falls O -
. O -

The O +
electrocardiogram O +
revealed O +
a O +
37 O +
beats O -
/ O -
min O +
sinus B-Disease +
bradycardia L-Disease -
. O -

A O +
score O +
of O +
7 O +
on O +
the O +
Naranjo O +
adverse B-Disease +
drug I-Disease +
reaction L-Disease +
probability O +
scale O +
indicates O +
a O +
probable O +
relationship O +
between O +
the O +
patient O -
's O +
sinus B-Disease +
bradycardia L-Disease +
and O +
the O +
drug O +
interaction O +
between O +
metoprolol O +
and O +
terbinafine O -
. O -

The O +
heart O +
rate O +
ameliorated O +
first O +
with O +
a O +
decrease O +
in O +
the O +
dose O +
of O +
metoprolol O -
. O -

It O +
was O +
subsequently O +
changed O +
to O +
bisoprolol O +
and O +
the O +
heart O +
rate O +
remained O +
normal O -
. O -

By O +
inhibiting O +
the O +
cytochrome O +
P450 O +
2D6 O -
, O +
terbinafine O +
had O +
decreased O +
metoprolol O -
's O +
clearance O -
, O +
leading O +
in O +
metoprolol O +
accumulation O +
which O +
has O +
resulted O +
in O +
clinically O +
significant O +
sinus B-Disease +
bradycardia L-Disease -
. O -

Optochiasmatic O +
and O +
peripheral B-Disease +
neuropathy L-Disease +
due O +
to O +
ethambutol O +
overtreatment O -
. O -

Ethambutol O +
is O +
known O +
to O +
cause O +
optic B-Disease +
neuropathy L-Disease +
and O -
, O +
more O +
rarely O -
, O +
axonal O +
polyneuropathy U-Disease -
. O -

We O +
characterize O +
the O +
clinical O -
, O +
neurophysiological O -
, O +
and O +
neuroimaging O +
findings O +
in O +
a O +
72-year O -
- O -
old O +
man O +
who O +
developed O +
visual B-Disease +
loss L-Disease +
and O +
paresthesias U-Disease +
after O +
11 O +
weeks O +
of O +
exposure O +
to O +
a O +
supratherapeutic O +
dose O +
of O +
ethambutol O -
. O -

This O +
case O +
demonstrates O +
the O +
selective O +
vulnerability O +
of O +
the O +
anterior O +
visual O +
pathways O +
and O +
peripheral O +
nerves O +
to O +
ethambutol O +
toxicity U-Disease -
. O -

Testosterone O +
ameliorates O +
streptozotocin O -
- O -
induced O +
memory B-Disease +
impairment L-Disease +
in O +
male O +
rats O -
. O -

AIM O -
: O +
To O +
study O +
the O +
effects O +
of O +
testosterone O +
on O +
streptozotocin O +
( O -
STZ O -
) O -
-induced O +
memory B-Disease +
impairment L-Disease +
in O +
male O +
rats O -
. O -

METHODS O -
: O +
Adult O +
male O +
Wistar O +
rats O +
were O +
intracerebroventricularly O +
( O -
icv O -
) O +
infused O +
with O +
STZ O +
( O -
750 O +
ug O -
) O +
on O +
d O +
1 O +
and O +
d O +
3 O -
, O +
and O +
a O +
passive O +
avoidance O +
task O +
was O +
assessed O +
2 O +
weeks O +
after O +
the O +
first O +
injection O +
of O +
STZ O -
. O -

Castration O +
surgery O +
was O +
performed O +
in O +
another O +
group O +
of O +
rats O -
, O +
and O +
the O +
passive O +
avoidance O +
task O +
was O +
assessed O +
4 O +
weeks O +
after O +
the O +
operation O -
. O -

Testosterone O +
( O -
1 O +
mg.kg O -
( O -
-1 O -
) O -
.d O -
( O -
-1 O -
) O -
, O +
sc O -
) O -
, O +
the O +
androgen O +
receptor O +
antagonist O +
flutamide O +
( O -
10 O +
mg.kg O -
( O -
-1 O -
) O -
.d O -
( O -
-1 O -
) O -
, O +
ip O -
) O -
, O +
the O +
estrogen O +
receptor O +
antagonist O +
tamoxifen O +
( O -
1 O +
mg.kg O -
( O -
-1 O -
) O -
.d O -
( O -
-1 O -
) O -
, O +
ip O -
) O +
or O +
the O +
aromatase O +
inhibitor O +
letrozole O +
( O -
4 O +
mg.kg O -
( O -
-1 O -
) O -
.d O -
( O -
-1 O -
) O -
, O +
ip O -
) O +
were O +
administered O +
for O +
6 O +
d O +
after O +
the O +
first O +
injection O +
of O +
STZ O -
. O -

RESULTS O -
: O +
STZ O +
administration O +
and O +
castration O +
markedly O +
decreased O +
both O +
STL1 O +
( O -
the O +
short O +
memory O -
) O +
and O +
STL2 O +
( O -
the O +
long O +
memory O -
) O +
in O +
passive O +
avoidance O +
tests O -
. O -

Testosterone O +
replacement O +
almost O +
restored O +
the O +
STL1 O +
and O +
STL2 O +
in O +
castrated O +
rats O -
, O +
and O +
significantly O +
prolonged O +
the O +
STL1 O +
and O +
STL2 O +
in O +
STZ O -
- O -
treated O +
rats O -
. O -

Administration O +
of O +
flutamide O -
, O +
letrozole O +
or O +
tamoxifen O +
significantly O +
impaired B-Disease +
the I-Disease +
memory L-Disease +
in O +
intact O +
rats O -
, O +
and O +
significantly O +
attenuated O +
the O +
testosterone O +
replacement O +
in O +
improving O +
STZ- O +
and O +
castration O -
- O -
induced O +
memory B-Disease +
impairment L-Disease -
. O -

CONCLUSION O -
: O +
Testosterone O +
administration O +
ameliorates O +
STZ- O +
and O +
castration O -
- O -
induced O +
memory B-Disease +
impairment L-Disease +
in O +
male O +
Wistar O +
rats O -
. O -

Behavioral O +
and O +
neurochemical O +
studies O +
in O +
mice O +
pretreated O +
with O +
garcinielliptone O +
FC O +
in O +
pilocarpine O -
- O -
induced O +
seizures U-Disease -
. O -

Garcinielliptone O +
FC O +
( O -
GFC O -
) O +
isolated O +
from O +
hexanic O +
fraction O +
seed O +
extract O +
of O +
species O +
Platonia O +
insignis O +
Mart O -
. O -

It O +
is O +
widely O +
used O +
in O +
folk O +
medicine O +
to O +
treat O +
skin B-Disease +
diseases L-Disease +
in O +
both O +
humans O +
and O +
animals O +
as O +
well O +
as O +
the O +
seed O +
decoction O +
has O +
been O +
used O +
to O +
treat O +
diarrheas U-Disease +
and O +
inflammatory B-Disease +
diseases L-Disease -
. O -

However O -
, O +
there O +
is O +
no O +
research O +
on O +
GFC O +
effects O +
in O +
the O +
central O +
nervous O +
system O +
of O +
rodents O -
. O -

The O +
present O +
study O +
aimed O +
to O +
evaluate O +
the O +
GFC O +
effects O +
at O +
doses O +
of O +
25 O -
, O +
50 O +
or O +
75 O +
mg O -
/ O -
kg O +
on O +
seizure U-Disease +
parameters O +
to O +
determine O +
their O +
anticonvulsant O +
activity O +
and O +
its O +
effects O +
on O +
amino O +
acid O +
( O -
r O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
, O +
glutamine O -
, O +
aspartate O +
and O +
glutathione O -
) O +
levels O +
as O +
well O +
as O +
on O +
acetylcholinesterase O +
( O -
AChE O -
) O +
activity O +
in O +
mice O +
hippocampus O +
after O +
seizures U-Disease -
. O -

GFC O +
produced O +
an O +
increased O +
latency O +
to O +
first O +
seizure U-Disease -
, O +
at O +
doses O +
25mg O -
/ O -
kg O +
( O -
20.12 O +
+ O +
2.20 O +
min O -
) O -
, O +
50mg O -
/ O -
kg O +
( O -
20.95 O +
+ O +
2.21 O +
min O -
) O +
or O +
75 O +
mg O -
/ O -
kg O +
( O -
23.43 O +
+ O +
1.99 O +
min O -
) O +
when O +
compared O +
with O +
seized O +
mice O -
. O -

In O +
addition O -
, O +
GABA O +
content O +
of O +
mice O +
hippocampus O +
treated O +
with O +
GFC75 O +
plus O +
P400 O +
showed O +
an O +
increase O +
of O +
46.90 O -
% O +
when O +
compared O +
with O +
seized O +
mice O -
. O -

In O +
aspartate O -
, O +
glutamine O +
and O +
glutamate O +
levels O +
detected O +
a O +
decrease O +
of O +
5.21 O -
% O -
, O +
13.55 O -
% O +
and O +
21.80 O -
% O -
, O +
respectively O +
in O +
mice O +
hippocampus O +
treated O +
with O +
GFC75 O +
plus O +
P400 O +
when O +
compared O +
with O +
seized O +
mice O -
. O -

Hippocampus O +
mice O +
treated O +
with O +
GFC75 O +
plus O +
P400 O +
showed O +
an O +
increase O +
in O +
AChE O +
activity O +
( O -
63.30 O -
% O -
) O +
when O +
compared O +
with O +
seized O +
mice O -
. O -

The O +
results O +
indicate O +
that O +
GFC O +
can O +
exert O +
anticonvulsant O +
activity O +
and O +
reduce O +
the O +
frequency O +
of O +
installation O +
of O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease -
, O +
as O +
demonstrated O +
by O +
increase O +
in O +
latency O +
to O +
first O +
seizure U-Disease +
and O +
decrease O +
in O +
mortality O +
rate O +
of O +
animals O -
. O -

In O +
conclusion O -
, O +
our O +
data O +
suggest O +
that O +
GFC O +
may O +
influence O +
in O +
epileptogenesis O +
and O +
promote O +
anticonvulsant O +
actions O +
in O +
pilocarpine O +
model O +
by O +
modulating O +
the O +
GABA O +
and O +
glutamate O +
contents O +
and O +
of O +
AChE O +
activity O +
in O +
seized O +
mice O +
hippocampus O -
. O -

This O +
compound O +
may O +
be O +
useful O +
to O +
produce O +
neuronal O +
protection O +
and O +
it O +
can O +
be O +
considered O +
as O +
an O +
anticonvulsant O +
agent O -
. O -

Standard O +
operating O +
procedures O +
for O +
antibiotic O +
therapy O +
and O +
the O +
occurrence O +
of O +
acute B-Disease +
kidney I-Disease +
injury L-Disease -
: O +
a O +
prospective O -
, O +
clinical O -
, O +
non O -
- O -
interventional O -
, O +
observational O +
study O -
. O -

INTRODUCTION O -
: O +
Acute B-Disease +
kidney I-Disease +
injury L-Disease +
( O -
AKI U-Disease -
) O +
occurs O +
in O +
7 O -
% O +
of O +
hospitalized O +
and O +
66 O -
% O +
of O +
Intensive O +
Care O +
Unit O +
( O -
ICU O -
) O +
patients O -
. O -

It O +
increases O +
mortality O -
, O +
hospital O +
length O +
of O +
stay O -
, O +
and O +
costs O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O -
, O +
whether O +
there O +
is O +
an O +
association O +
between O +
adherence O +
to O +
guidelines O +
( O -
standard O +
operating O +
procedures O +
( O -
SOP O -
) O -
) O +
for O +
potentially O +
nephrotoxic U-Disease +
antibiotics O +
and O +
the O +
occurrence O +
of O +
AKI U-Disease -
. O -

METHODS O -
: O +
This O +
study O +
was O +
carried O +
out O +
as O +
a O +
prospective O -
, O +
clinical O -
, O +
non O -
- O -
interventional O -
, O +
observational O +
study O -
. O -

Data O +
collection O +
was O +
performed O +
over O +
a O +
total O +
of O +
170 O +
days O +
in O +
three O +
ICUs O +
at O +
Charite O +
- O +
Universitaetsmedizin O +
Berlin O -
. O -

A O +
total O +
of O +
675 O +
patients O +
were O +
included O -
; O +
163 O +
of O +
these O +
had O +
therapy O +
with O +
vancomycin O -
, O +
gentamicin O -
, O +
or O +
tobramycin O -
; O +
were O +
> O -
18 O +
years O -
; O +
and O +
treated O +
in O +
the O +
ICU O +
for O +
> O -
24 O +
hours O -
. O -

Patients O +
with O +
an O +
adherence O +
to O +
SOP O +
> O -
70 O -
% O +
were O +
classified O +
into O +
the O +
high O +
adherence O +
group O +
( O -
HAG O -
) O +
and O +
patients O +
with O +
an O +
adherence O +
of O +
< O -
70 O -
% O +
into O +
the O +
low O +
adherence O +
group O +
( O -
LAG O -
) O -
. O -

AKI U-Disease +
was O +
defined O +
according O +
to O +
RIFLE O +
criteria O -
. O -

Adherence O +
to O +
SOPs O +
was O +
evaluated O +
by O +
retrospective O +
expert O +
audit O -
. O -

Development O +
of O +
AKI U-Disease +
was O +
compared O +
between O +
groups O +
with O +
exact O +
Chi2-test O +
and O +
multivariate O +
logistic O +
regression O +
analysis O +
( O -
two O -
- O -
sided O +
P O +
< O -
0.05 O -
) O -
. O -

RESULTS O -
: O +
LAG O +
consisted O +
of O +
75 O +
patients O +
( O -
46 O -
% O -
) O +
versus O +
88 O +
HAG O +
patients O +
( O -
54 O -
% O -
) O -
. O -

AKI U-Disease +
occurred O +
significantly O +
more O +
often O +
in O +
LAG O +
with O +
36 O -
% O +
versus O +
21 O -
% O +
in O +
HAG O +
( O -
P O +
= O +
0.035 O -
) O -
. O -

Basic O +
characteristics O +
were O +
comparable O -
, O +
except O +
an O +
increased O +
rate O +
of O +
soft O +
tissue O +
infections U-Disease +
in O +
LAG O -
. O -

Multivariate O +
analysis O +
revealed O +
an O +
odds O +
ratio O +
of O +
2.5-fold O +
for O +
LAG O +
to O +
develop O +
AKI U-Disease +
compared O +
with O +
HAG O +
( O -
95 O -
% O +
confidence O +
interval O +
1.195 O +
to O +
5.124 O -
, O +
P O +
= O +
0.039 O -
) O -
. O -

CONCLUSION O -
: O +
Low O +
adherence O +
to O +
SOPs O +
for O +
potentially O +
nephrotoxic U-Disease +
antibiotics O +
was O +
associated O +
with O +
a O +
higher O +
occurrence O +
of O +
AKI U-Disease -
. O -

TRIAL O +
REGISTRATION O -
: O +
Current O +
Controlled O +
Trials O +
ISRCTN54598675 O -
. O -

Registered O +
17 O +
August O +
2007 O -
. O -

Rhabdomyolysis U-Disease +
in O +
a O +
hepatitis B-Disease +
C I-Disease +
virus I-Disease +
infected L-Disease +
patient O +
treated O +
with O +
telaprevir O +
and O +
simvastatin O -
. O -

A O +
46-year O +
old O +
man O +
with O +
a O +
chronic O +
hepatitis B-Disease +
C I-Disease +
virus I-Disease +
infection L-Disease +
received O +
triple O +
therapy O +
with O +
ribavirin O -
, O +
pegylated O +
interferon O +
and O +
telaprevir O -
. O -

The O +
patient O +
also O +
received O +
simvastatin O -
. O -

One O +
month O +
after O +
starting O +
the O +
antiviral O +
therapy O -
, O +
the O +
patient O +
was O +
admitted O +
to O +
the O +
hospital O +
because O +
he O +
developed O +
rhabdomyolysis U-Disease -
. O -

At O +
admission O +
simvastatin O +
and O +
all O +
antiviral O +
drugs O +
were O +
discontinued O +
because O +
toxicity U-Disease +
due O +
to O +
a O +
drug O -
- O -
drug O +
interaction O +
was O +
suspected O -
. O -

The O +
creatine O +
kinase O +
peaked O +
at O +
62,246 O +
IU O -
/ O -
L O +
and O +
the O +
patient O +
was O +
treated O +
with O +
intravenous O +
normal O +
saline O -
. O -

The O +
patient O -
's O +
renal O +
function O +
remained O +
unaffected O -
. O -

Fourteen O +
days O +
after O +
hospitalization O -
, O +
creatine O +
kinase O +
level O +
had O +
returned O +
to O +
230 O +
IU O -
/ O -
L O +
and O +
the O +
patient O +
was O +
discharged O -
. O -

Telaprevir O +
was O +
considered O +
the O +
probable O +
causative O +
agent O +
of O +
an O +
interaction O +
with O +
simvastatin O +
according O +
to O +
the O +
Drug O +
Interaction O +
Probability O +
Scale O -
. O -

The O +
interaction O +
is O +
due O +
to O +
inhibition O +
of O +
CYP3A4-mediated O +
simvastatin O +
clearance O -
. O -

Simvastatin O +
plasma O +
concentration O +
increased O +
30 O +
times O +
in O +
this O +
patient O +
and O +
statin O +
induced O +
muscle B-Disease +
toxicity L-Disease +
is O +
related O +
to O +
the O +
concentration O +
of O +
the O +
statin O +
in O +
blood O -
. O -

In O +
conclusion O -
, O +
with O +
this O +
case O +
we O +
illustrate O +
that O +
telaprevir O +
as O +
well O +
as O +
statins O +
are O +
susceptible O +
to O +
clinical O +
relevant O +
drug O -
- O -
drug O +
interactions O -
. O -

Combination O +
of O +
bortezomib O -
, O +
thalidomide O -
, O +
and O +
dexamethasone O +
( O -
VTD O -
) O +
as O +
a O +
consolidation O +
therapy O +
after O +
autologous O +
stem O +
cell O +
transplantation O +
for O +
symptomatic O +
multiple B-Disease +
myeloma L-Disease +
in O +
Japanese O +
patients O -
. O -

Consolidation O +
therapy O +
for O +
patients O +
with O +
multiple B-Disease +
myeloma L-Disease +
( O -
MM U-Disease -
) O +
has O +
been O +
widely O +
adopted O +
to O +
improve O +
treatment O +
response O +
following O +
autologous O +
stem O +
cell O +
transplantation O -
. O -

In O +
this O +
study O -
, O +
we O +
retrospectively O +
analyzed O +
the O +
safety O +
and O +
efficacy O +
of O +
combination O +
regimen O +
of O +
bortezomib O -
, O +
thalidomide O -
, O +
and O +
dexamethasone O +
( O -
VTD O -
) O +
as O +
consolidation O +
therapy O +
in O +
24 O +
Japanese O +
patients O +
with O +
newly O +
diagnosed O +
MM U-Disease -
. O -

VTD O +
consisted O +
of O +
bortezomib O +
at O +
a O +
dose O +
of O +
1.3 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
and O +
dexamethasone O +
at O +
a O +
dose O +
of O +
40 O +
mg O -
/ O -
day O +
on O +
days O +
1 O -
, O +
8 O -
, O +
15 O -
, O +
and O +
22 O +
of O +
a O +
35-day O +
cycle O -
, O +
with O +
daily O +
oral O +
thalidomide O +
at O +
a O +
dose O +
of O +
100 O +
mg O -
/ O -
day O -
. O -

Grade O +
3 O -
- O -
4 O +
neutropenia U-Disease +
and O +
thrombocytopenia U-Disease +
were O +
documented O +
in O +
four O +
and O +
three O +
patients O +
( O -
17 O +
and O +
13 O +
% O -
) O -
, O +
respectively O -
, O +
but O +
drug O +
dose O +
reduction O +
due O +
to O +
cytopenia U-Disease +
was O +
not O +
required O +
in O +
any O +
case O -
. O -

Peripheral B-Disease +
neuropathy L-Disease +
was O +
common O +
( O -
63 O +
% O -
) O -
, O +
but O +
severe O +
grade O +
3 O -
- O -
4 O +
peripheral B-Disease +
neuropathy L-Disease +
was O +
not O +
observed O -
. O -

Very O +
good O +
partial O +
response O +
or O +
better O +
response O +
( O -
> O -
VGPR O -
) O +
rates O +
before O +
and O +
after O +
consolidation O +
therapy O +
were O +
54 O +
and O +
79 O +
% O -
, O +
respectively O -
. O -

Patients O +
had O +
a O +
significant O +
probability O +
of O +
improving O +
from O +
< O -
VGPR O +
before O +
consolidation O +
therapy O +
to O +
> O -
VGPR O +
after O +
consolidation O +
therapy O +
( O -
p O +
= O +
0.041 O -
) O -
. O -

The O +
VTD O +
regimen O +
may O +
be O +
safe O +
and O +
effective O +
as O +
a O +
consolidation O +
therapy O +
in O +
the O +
treatment O +
of O +
MM O +
in O +
Japanese O +
population O -
. O -

Conversion O +
to O +
sirolimus O +
ameliorates O +
cyclosporine O -
- O -
induced O +
nephropathy U-Disease +
in O +
the O +
rat O -
: O +
focus O +
on O +
serum O -
, O +
urine O -
, O +
gene O -
, O +
and O +
protein O +
renal O +
expression O +
biomarkers O -
. O -

Protocols O +
of O +
conversion O +
from O +
cyclosporin O +
A O +
( O -
CsA O -
) O +
to O +
sirolimus O +
( O -
SRL O -
) O +
have O +
been O +
widely O +
used O +
in O +
immunotherapy O +
after O +
transplantation O +
to O +
prevent O +
CsA O -
- O -
induced O +
nephropathy U-Disease -
, O +
but O +
the O +
molecular O +
mechanisms O +
underlying O +
these O +
protocols O +
remain O +
nuclear O -
. O -

This O +
study O +
aimed O +
to O +
identify O +
the O +
molecular O +
pathways O +
and O +
putative O +
biomarkers O +
of O +
CsA O -
- O -
to O -
- O -
SRL O +
conversion O +
in O +
a O +
rat O +
model O -
. O -

Four O +
animal O +
groups O +
( O -
n O +
= O +
6 O -
) O +
were O +
tested O +
during O +
9 O +
weeks O -
: O +
control O -
, O +
CsA O -
, O +
SRL O -
, O +
and O +
conversion O +
( O -
CsA O +
for O +
3 O +
weeks O +
followed O +
by O +
SRL O +
for O +
6 O +
weeks O -
) O -
. O -

Classical O +
and O +
emergent O +
serum O -
, O +
urinary O -
, O +
and O +
kidney O +
tissue O +
( O -
gene O +
and O +
protein O +
expression O -
) O +
markers O +
were O +
assessed O -
. O -

Renal B-Disease +
lesions L-Disease +
were O +
analyzed O +
in O +
hematoxylin O +
and O +
eosin O -
, O +
periodic O +
acid O -
- O -
Schiff O -
, O +
and O +
Masson O -
's O +
trichrome O +
stains O -
. O -

SRL O -
- O -
treated O +
rats O +
presented O +
proteinuria U-Disease +
and O +
NGAL O +
( O -
serum O +
and O +
urinary O -
) O +
as O +
the O +
best O +
markers O +
of O +
renal B-Disease +
impairment L-Disease -
. O -

Short O +
CsA O +
treatment O +
presented O +
slight O +
or O +
even O +
absent O +
kidney B-Disease +
lesions L-Disease +
and O +
TGF O -
- O -
b O -
, O +
NF- O +
kb O -
, O +
mTOR O -
, O +
PCNA O -
, O +
TP53 O -
, O +
KIM-1 O -
, O +
and O +
CTGF O +
as O +
relevant O +
gene O +
and O +
protein O +
changes O -
. O -

Prolonged O +
CsA O +
exposure O +
aggravated O +
renal B-Disease +
damage L-Disease -
, O +
without O +
clear O +
changes O +
on O +
the O +
traditional O +
markers O -
, O +
but O +
with O +
changes O +
in O +
serums O +
TGF- O +
b O +
and O +
IL-7 O -
, O +
TBARs O +
clearance O -
, O +
and O +
kidney O +
TGF O -
- O -
b O +
and O +
mTOR O -
. O -

Conversion O +
to O +
SRL O +
prevented O +
CsA O -
- O -
induced O +
renal B-Disease +
damage L-Disease +
evolution O +
( O -
absent O -
/ O -
mild O +
grade O +
lesions O -
) O -
, O +
while O +
NGAL O +
( O -
serum O +
versus O +
urine O -
) O +
seems O +
to O +
be O +
a O +
feasible O +
biomarker O +
of O +
CsA O +
replacement O +
to O +
SRL O -
. O -

Kinin O +
B2 O +
receptor O +
deletion O +
and O +
blockage O +
ameliorates O +
cisplatin O -
- O -
induced O +
acute B-Disease +
renal I-Disease +
injury L-Disease -
. O -

Cisplatin O +
treatment O +
has O +
been O +
adopted O +
in O +
some O +
chemotherapies O -
; O +
however O -
, O +
this O +
drug O +
can O +
induce O +
acute B-Disease +
kidney I-Disease +
injury L-Disease +
due O +
its O +
ability O +
to O +
negatively O +
affect O +
renal O +
function O -
, O +
augment O +
serum O +
levels O +
of O +
creatinine O +
and O +
urea O -
, O +
increase O +
the O +
acute B-Disease +
tubular I-Disease +
necrosis L-Disease +
score O +
and O +
up O -
- O -
regulate O +
cytokines O +
( O -
e.g. O -
, O +
IL-1b O +
and O +
TNF O -
- O -
a O -
) O -
. O -

The O +
kinin O +
B2 O +
receptor O +
has O +
been O +
associated O +
with O +
the O +
inflammation U-Disease +
process O -
, O +
as O +
well O +
as O +
the O +
regulation O +
of O +
cytokine O +
expression O -
, O +
and O +
its O +
deletion O +
resulted O +
in O +
an O +
improvement O +
in O +
the O +
diabetic B-Disease +
nephropathy L-Disease +
status O -
. O -

To O +
examine O +
the O +
role O +
of O +
the O +
kinin O +
B2 O +
receptor O +
in O +
cisplatin O -
- O -
induced O +
acute B-Disease +
kidney I-Disease +
injury L-Disease -
, O +
kinin O +
B2 O +
receptor O +
knockout O +
mice O +
were O +
challenged O +
with O +
cisplatin O -
. O -

Additionally O -
, O +
WT O +
mice O +
were O +
treated O +
with O +
a O +
B2 O +
receptor O +
antagonist O +
after O +
cisplatin O +
administration O -
. O -

B2 O +
receptor O -
- O -
deficient O +
mice O +
were O +
less O +
sensitive O +
to O +
this O +
drug O +
than O +
the O +
WT O +
mice O -
, O +
as O +
shown O +
by O +
reduced O +
weight B-Disease +
loss L-Disease -
, O +
better O +
preservation O +
of O +
kidney O +
function O -
, O +
down O +
regulation O +
of O +
inflammatory O +
cytokines O +
and O +
less O +
acute B-Disease +
tubular I-Disease +
necrosis L-Disease -
. O -

Moreover O -
, O +
treatment O +
with O +
the O +
kinin O +
B2 O +
receptor O +
antagonist O +
effectively O +
reduced O +
the O +
levels O +
of O +
serum O +
creatinine O +
and O +
blood O +
urea O +
after O +
cisplatin O +
administration O -
. O -

Thus O -
, O +
our O +
data O +
suggest O +
that O +
the O +
kinin O +
B2 O +
receptor O +
is O +
involved O +
in O +
cisplatin O -
- O -
induced O +
acute B-Disease +
kidney I-Disease +
injury L-Disease +
by O +
mediating O +
the O +
necrotic U-Disease +
process O +
and O +
the O +
expression O +
of O +
inflammatory O +
cytokines O -
, O +
thus O +
resulting O +
in O +
declined O +
renal O +
function O -
. O -

These O +
results O +
highlight O +
the O +
kinin O +
B2 O +
receptor O +
antagonist O +
treatment O +
in O +
amelioration O +
of O +
nephrotoxicity U-Disease +
induced O +
by O +
cisplatin O +
therapy O -
. O -

Safety O +
and O +
efficacy O +
of O +
fluocinolone O +
acetonide O +
intravitreal O +
implant O +
( O -
0.59 O +
mg O -
) O +
in O +
birdshot B-Disease +
retinochoroidopathy L-Disease -
. O -

PURPOSE O -
: O +
To O +
report O +
the O +
treatment O +
outcomes O +
of O +
the O +
fluocinolone O +
acetonide O +
intravitreal O +
implant O +
( O -
0.59 O +
mg O -
) O +
in O +
patients O +
with O +
birdshot B-Disease +
retinochoroidopathy L-Disease +
whose O +
disease O +
is O +
refractory O +
or O +
intolerant O +
to O +
conventional O +
immunomodulatory O +
therapy O -
. O -

METHODS O -
: O +
A O +
retrospective O +
case O +
series O +
involving O +
11 O +
birdshot B-Disease +
retinochoroidopathy L-Disease +
patients O +
( O -
11 O +
eyes O -
) O -
. O -

Eleven O +
patients O +
( O -
11 O +
eyes O -
) O +
underwent O +
surgery O +
for O +
fluocinolone O +
acetonide O +
implant O +
( O -
0.59 O +
mg O -
) O -
. O -

Treatment O +
outcomes O +
of O +
interest O +
were O +
noted O +
at O +
baseline O -
, O +
before O +
fluocinolone O +
acetonide O +
implant O -
, O +
and O +
then O +
at O +
6 O +
months O -
, O +
1 O +
year O -
, O +
2 O +
years O -
, O +
3 O +
years O -
, O +
and O +
beyond O +
3 O +
years O -
. O -

Disease O +
activity O +
markers O -
, O +
including O +
signs O +
of O +
ocular O +
inflammation U-Disease -
, O +
evidence O +
of O +
retinal B-Disease +
vasculitis L-Disease -
, O +
Swedish O +
interactive O +
threshold O +
algorithm O -
- O -
short O +
wavelength O +
automated O +
perimetry O +
Humphrey O +
visual O +
field O +
analysis O -
, O +
electroretinographic O +
parameters O -
, O +
and O +
optical O +
coherence O +
tomography O +
were O +
recorded O -
. O -

Data O +
on O +
occurrence O +
of O +
cataract U-Disease +
and O +
raised B-Disease +
intraocular I-Disease +
pressure L-Disease +
were O +
collected O +
in O +
all O +
eyes O -
. O -

RESULTS O -
: O +
Intraocular O +
inflammation U-Disease +
was O +
present O +
in O +
54.5 O -
, O +
9.9 O -
, O +
11.1 O -
, O +
and O +
0 O -
% O +
of O +
patients O +
at O +
baseline O -
, O +
6 O +
months O -
, O +
1 O +
year O -
, O +
2 O +
years O -
, O +
3 O +
years O -
, O +
and O +
beyond O +
3 O +
years O +
after O +
receiving O +
the O +
implant O -
, O +
respectively O -
. O -

Active O +
vasculitis U-Disease +
was O +
noted O +
in O +
36.3 O -
% O +
patients O +
at O +
baseline O +
and O +
0 O -
% O +
at O +
3 O +
years O +
of O +
follow O -
- O -
up O -
. O -

More O +
than O +
20 O -
% O +
( O -
47.61 O -
- O -
67.2 O -
% O -
) O +
reduction O +
in O +
central O +
retinal O +
thickness O +
was O +
noted O +
in O +
all O +
patients O +
with O +
cystoid B-Disease +
macular I-Disease +
edema L-Disease +
at O +
6 O +
months O -
, O +
1 O +
year O -
, O +
2 O +
years O -
, O +
and O +
3 O +
years O +
postimplant O -
. O -

At O +
baseline O -
, O +
54.5 O -
% O +
patients O +
were O +
on O +
immunomodulatory O +
agents O -
. O -

This O +
percentage O +
decreased O +
to O +
45.45 O -
, O +
44.4 O -
, O +
and O +
14.28 O -
% O +
at O +
1 O +
year O -
, O +
2 O +
years O -
, O +
and O +
3 O +
years O +
postimplant O -
, O +
respectively O -
. O -

Adverse O +
events O +
included O +
increased B-Disease +
intraocular I-Disease +
pressure L-Disease +
( O -
54.5 O -
% O -
) O +
and O +
cataract U-Disease +
formation O +
( O -
100 O -
% O -
) O -
. O -

CONCLUSION O -
: O +
The O +
data O +
suggest O +
that O +
fluocinolone O +
acetonide O +
implant O +
( O -
0.59 O +
mg O -
) O +
helps O +
to O +
control O +
inflammation U-Disease +
in O +
otherwise O +
treatment O -
- O -
refractory O +
cases O +
of O +
birdshot B-Disease +
retinochoroidopathy L-Disease -
. O -

It O +
is O +
associated O +
with O +
significant O +
side O +
effects O +
of O +
cataract U-Disease +
and O +
ocular B-Disease +
hypertension L-Disease +
requiring O +
treatment O -
. O -

Optimal O +
precurarizing O +
dose O +
of O +
rocuronium O +
to O +
decrease O +
fasciculation U-Disease +
and O +
myalgia U-Disease +
following O +
succinylcholine O +
administration O -
. O -

BACKGROUND O -
: O +
Succinylcholine O +
commonly O +
produces O +
frequent O +
adverse O +
effects O -
, O +
including O +
muscle B-Disease +
fasciculation L-Disease +
and O +
myalgia U-Disease -
. O -

The O +
current O +
study O +
identified O +
the O +
optimal O +
dose O +
of O +
rocuronium O +
to O +
prevent O +
succinylcholine O -
- O -
induced O +
fasciculation U-Disease +
and O +
myalgia U-Disease +
and O +
evaluated O +
the O +
influence O +
of O +
rocuronium O +
on O +
the O +
speed O +
of O +
onset O +
produced O +
by O +
succinylcholine O -
. O -

METHODS O -
: O +
This O +
randomized O -
, O +
double O -
- O -
blinded O +
study O +
was O +
conducted O +
in O +
100 O +
patients O +
randomly O +
allocated O +
into O +
five O +
groups O +
of O +
20 O +
patients O +
each O -
. O -

Patients O +
were O +
randomized O +
to O +
receive O +
0.02 O -
, O +
0.03 O -
, O +
0.04 O -
, O +
0.05 O +
and O +
0.06 O +
mg O -
/ O -
kg O +
rocuronium O +
as O +
a O +
precurarizing O +
dose O -
. O -

Neuromuscular O +
monitoring O +
after O +
each O +
precurarizing O +
dose O +
was O +
recorded O +
from O +
the O +
adductor O +
pollicis O +
muscle O +
using O +
acceleromyography O +
with O +
train O -
- O -
of O -
- O -
four O +
stimulation O +
of O +
the O +
ulnar O +
nerve O -
. O -

All O +
patients O +
received O +
succinylcholine O +
1.5 O +
mg O -
/ O -
kg O +
at O +
2 O +
minutes O +
after O +
the O +
precurarization O -
, O +
and O +
were O +
assessed O +
the O +
incidence O +
and O +
severity O +
of O +
fasciculations U-Disease -
, O +
while O +
myalgia U-Disease +
was O +
assessed O +
at O +
24 O +
hours O +
after O +
surgery O -
. O -

RESULTS O -
: O +
The O +
incidence O +
and O +
severity O +
of O +
visible O +
muscle B-Disease +
fasciculation L-Disease +
was O +
significantly O +
less O +
with O +
increasing O +
the O +
amount O +
of O +
precurarizing O +
dose O +
of O +
rocuronium O +
( O -
P O +
< O +
0.001 O -
) O -
. O -

Those O +
of O +
myalgia U-Disease +
tend O +
to O +
decrease O +
according O +
to O +
increasing O +
the O +
amount O +
of O +
precurarizing O +
dose O +
of O +
rocuronium O -
, O +
but O +
there O +
was O +
no O +
significance O +
( O -
P O +
= O +
0.072 O -
) O -
. O -

The O +
onset O +
time O +
of O +
succinylcholine O +
was O +
significantly O +
longer O +
with O +
increasing O +
the O +
amount O +
of O +
precurarizing O +
dose O +
of O +
rocuronium O +
( O -
P O +
< O +
0.001 O -
) O -
. O -

CONCLUSIONS O -
: O +
Precurarization O +
with O +
0.04 O +
mg O -
/ O -
kg O +
rocuronium O +
was O +
the O +
optimal O +
dose O +
considering O +
the O +
reduction O +
in O +
the O +
incidence O +
and O +
severity O +
of O +
fasciculation U-Disease +
and O +
myalgia U-Disease +
with O +
acceptable O +
onset O +
time O -
, O +
and O +
the O +
safe O +
and O +
effective O +
precurarization O -
. O -

Absence O +
of O +
PKC O -
- O -
alpha O +
attenuates O +
lithium O -
- O -
induced O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease -
. O -

Lithium O -
, O +
an O +
effective O +
antipsychotic O -
, O +
induces O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease +
( O -
NDI U-Disease -
) O +
in O -
40 O -
% O +
of O +
patients O -
. O -

The O +
decreased O +
capacity O +
to O +
concentrate O +
urine O +
is O +
likely O +
due O +
to O +
lithium O +
acutely O +
disrupting O +
the O +
cAMP O +
pathway O +
and O +
chronically O +
reducing O +
urea O +
transporter O +
( O -
UT O -
- O -
A1 O -
) O +
and O +
water O +
channel O +
( O -
AQP2 O -
) O +
expression O +
in O +
the O +
inner O +
medulla O -
. O -

Targeting O +
an O +
alternative O +
signaling O +
pathway O -
, O +
such O +
as O +
PKC O -
- O -
mediated O +
signaling O -
, O +
may O +
be O +
an O +
effective O +
method O +
of O +
treating O +
lithium O -
- O -
induced O +
polyuria U-Disease -
. O -

PKC O -
- O -
alpha O +
null O +
mice O +
( O -
PKCa O +
KO O -
) O +
and O +
strain O -
- O -
matched O +
wild O +
type O +
( O -
WT O -
) O +
controls O +
were O +
treated O +
with O +
lithium O +
for O +
0 O -
, O +
3 O +
or O +
5 O +
days O -
. O -

WT O +
mice O +
had O +
increased O +
urine O +
output O +
and O +
lowered O +
urine O +
osmolality O +
after O +
3 O +
and O +
5 O +
days O +
of O +
treatment O +
whereas O +
PKCa O +
KO O +
mice O +
had O +
no O +
change O +
in O +
urine O +
output O +
or O +
concentration O -
. O -

Western O +
blot O +
analysis O +
revealed O +
that O +
AQP2 O +
expression O +
in O +
medullary O +
tissues O +
was O +
lowered O +
after O +
3 O +
and O +
5 O +
days O +
in O +
WT O +
mice O -
; O +
however O -
, O +
AQP2 O +
was O +
unchanged O +
in O +
PKCa O +
KO O -
. O -

Similar O +
results O +
were O +
observed O +
with O +
UT O -
- O -
A1 O +
expression O -
. O -

Animals O +
were O +
also O +
treated O +
with O +
lithium O +
for O +
6 O +
weeks O -
. O -

Lithium O -
- O -
treated O +
WT O +
mice O +
had O +
19-fold O +
increased O +
urine O +
output O +
whereas O +
treated O +
PKCa O +
KO O +
animals O +
had O +
a O +
4-fold O +
increase O +
in O +
output O -
. O -

AQP2 O +
and O +
UT O -
- O -
A1 O +
expression O +
was O +
lowered O +
in O +
6 O +
week O +
lithium O -
- O -
treated O +
WT O +
animals O +
whereas O +
in O +
treated O +
PKCa O +
KO O +
mice O -
, O +
AQP2 O +
was O +
only O +
reduced O +
by O +
2-fold O +
and O +
UT O -
- O -
A1 O +
expression O +
was O +
unaffected O -
. O -

Urinary O +
sodium O -
, O +
potassium O +
and O +
calcium O +
were O +
elevated O +
in O +
lithium O -
- O -
fed O +
WT O +
but O +
not O +
in O +
lithium O -
- O -
fed O +
PKCa O +
KO O +
mice O -
. O -

Our O +
data O +
show O +
that O +
ablation O +
of O +
PKCa O +
preserves O +
AQP2 O +
and O +
UT O -
- O -
A1 O +
protein O +
expression O +
and O +
localization O +
in O +
lithium O -
- O -
induced O +
NDI U-Disease -
, O +
and O +
prevents O +
the O +
development O +
of O +
the O +
severe O +
polyuria U-Disease +
associated O +
with O +
lithium O +
therapy O -
. O -

Is O +
Dysguesia U-Disease +
Going O +
to O +
be O +
a O +
Rare O +
or O +
a O +
Common O +
Side O -
- O -
effect O +
of O +
Amlodipine O -
? O -

A O +
very O +
rare O +
side O -
- O -
effect O +
of O +
amlodipine O +
is O +
dysguesia U-Disease -
. O -

A O +
review O +
of O +
the O +
literature O +
produced O +
only O +
one O +
case O -
. O -

We O +
report O +
a O +
case O +
about O +
a O +
female O +
with O +
essential O +
hypertension U-Disease +
on O +
drug O +
treatment O +
with O +
amlodipine O +
developed O +
loss B-Disease +
of I-Disease +
taste I-Disease +
sensation L-Disease -
. O -

Condition O +
moderately O +
improved O +
on O +
stoppage O +
of O +
the O +
drug O +
for O +
25 O +
days O -
. O -

We O +
conclude O +
that O +
amlodipine O +
can O +
cause O +
dysguesia U-Disease -
. O -

Here O -
, O +
we O +
describe O +
the O +
clinical O +
presentation O +
and O +
review O +
the O +
relevant O +
literature O +
on O +
amlodipine O +
and O +
dysguesia U-Disease -
. O -

Rhabdomyolysis U-Disease +
in O +
association O +
with O +
simvastatin O +
and O +
dosage O +
increment O +
in O +
clarithromycin O -
. O -

Clarithromycin O +
is O +
the O +
most O +
documented O +
cytochrome O +
P450 O +
3A4 O +
( O -
CYP3A4 O -
) O +
inhibitor O +
to O +
cause O +
an O +
adverse O +
interaction O +
with O +
simvastatin O -
. O -

This O +
particular O +
case O +
is O +
of O +
interest O +
as O +
rhabdomyolysis U-Disease +
only O +
occurred O +
after O +
an O +
increase O +
in O +
the O +
dose O +
of O +
clarithromycin O -
. O -

The O +
patient O +
developed O +
raised O +
cardiac O +
biomarkers O +
without O +
any O +
obvious O +
cardiac O +
issues O -
, O +
a O +
phenomenon O +
that O +
has O +
been O +
linked O +
to O +
rhabdomyolysis U-Disease +
previously O -
. O -

To O +
date O -
, O +
there O +
has O +
been O +
no O +
reported O +
effect O +
of O +
rhabdomyolysis U-Disease +
on O +
the O +
structure O +
and O +
function O +
of O +
cardiac O +
muscle O -
. O -

Clinicians O +
need O +
to O +
be O +
aware O +
of O +
prescribing O +
concomitant O +
medications O +
that O +
increase O +
the O +
risk O +
of O +
myopathy U-Disease +
or O +
inhibit O +
the O +
CYP3A4 O +
enzyme O -
. O -

Our O +
case O +
suggests O +
that O +
troponin O +
elevation O +
could O +
be O +
associated O +
with O +
statin O +
induced O +
rhabdomyolysis U-Disease -
, O +
which O +
may O +
warrant O +
further O +
studies O -
. O -

Characterization O +
of O +
a O +
novel O +
BCHE O +
" O -
silent O -
" O +
allele O -
: O +
point O +
mutation O +
( O -
p. O -

Val204Asp O -
) O +
causes O +
loss O +
of O +
activity O +
and O +
prolonged O +
apnea U-Disease +
with O +
suxamethonium O -
. O -

Butyrylcholinesterase B-Disease +
deficiency L-Disease +
is O +
characterized O +
by O +
prolonged O +
apnea U-Disease +
after O +
the O +
use O +
of O +
muscle O +
relaxants O +
( O -
suxamethonium O +
or O +
mivacurium O -
) O +
in O +
patients O +
who O +
have O +
mutations O +
in O +
the O +
BCHE O +
gene O -
. O -

Here O -
, O +
we O +
report O +
a O +
case O +
of O +
prolonged O +
neuromuscular O +
block O +
after O +
administration O +
of O +
suxamethonium O +
leading O +
to O +
the O +
discovery O +
of O +
a O +
novel O +
BCHE O +
variant O +
( O -
c.695T O -
> O -
A O -
, O +
p. O -

Val204Asp O -
) O -
. O -

Inhibition O +
studies O -
, O +
kinetic O +
analysis O +
and O +
molecular O +
dynamics O +
were O +
undertaken O +
to O +
understand O +
how O +
this O +
mutation O +
disrupts O +
the O +
catalytic O +
triad O +
and O +
determines O +
a O +
" O -
silent O -
" O +
phenotype O -
. O -

Low O +
activity O +
of O +
patient O +
plasma O +
butyrylcholinesterase O +
with O +
butyrylthiocholine O +
( O -
BTC O -
) O +
and O +
benzoylcholine O -
, O +
and O +
values O +
of O +
dibucaine O +
and O +
fluoride O +
numbers O +
fit O +
with O +
heterozygous O +
atypical O +
silent O +
genotype O -
. O -

Electrophoretic O +
analysis O +
of O +
plasma O +
BChE O +
of O +
the O +
proband O +
and O +
his O +
mother O +
showed O +
that O +
patient O +
has O +
a O +
reduced O +
amount O +
of O +
tetrameric O +
enzyme O +
in O +
plasma O +
and O +
that O +
minor O +
fast O -
- O -
moving O +
BChE O +
components O -
: O +
monomer O -
, O +
dimer O -
, O +
and O +
monomer O -
- O -
albumin O +
conjugate O +
are O +
missing O -
. O -

Kinetic O +
analysis O +
showed O +
that O +
the O +
p. O -

Val204Asp O -
/ O -
p O -
. O -

Asp70Gly O -
- O -
p O -
. O -

Ala539Thr O +
BChE O +
displays O +
a O +
pure O +
Michaelian O +
behavior O +
with O +
BTC O +
as O +
the O +
substrate O -
. O -

Both O +
catalytic O +
parameters O +
Km O +
= O +
265 O +
uM O +
for O +
BTC O -
, O +
two O +
times O +
higher O +
than O +
that O +
of O +
the O +
atypical O +
enzyme O -
, O +
and O +
a O +
low O +
Vmax O +
are O +
consistent O +
with O +
the O +
absence O +
of O +
activity O +
against O +
suxamethonium O -
. O -

Molecular O +
dynamic O +
( O -
MD O -
) O +
simulations O +
showed O +
that O +
the O +
overall O +
effect O +
of O +
the O +
mutation O +
p. O -

Val204Asp O +
is O +
disruption O +
of O +
hydrogen O +
bonding O +
between O +
Gln223 O +
and O +
Glu441 O -
, O +
leading O +
Ser198 O +
and O +
His438 O +
to O +
move O +
away O +
from O +
each O +
other O +
with O +
subsequent O +
disruption O +
of O +
the O +
catalytic O +
triad O +
functionality O +
regardless O +
of O +
the O +
type O +
of O +
substrate O -
. O -

MD O +
also O +
showed O +
that O +
the O +
enzyme O +
volume O +
is O +
increased O -
, O +
suggesting O +
a O +
pre O -
- O -
denaturation O +
state O -
. O -

This O +
fits O +
with O +
the O +
reduced O +
concentration O +
of O +
p. O -

Ala204Asp O -
/ O -
p O -
. O -

Asp70Gly O -
- O -
p O -
. O -

Ala539Thr O +
tetrameric O +
enzyme O +
in O +
the O +
plasma O +
and O +
non O -
- O -
detectable O +
fast O +
moving O -
- O -
bands O +
on O +
electrophoresis O +
gels O -
. O -

Delayed O +
anemia U-Disease +
after O +
treatment O +
with O +
injectable O +
artesunate O +
in O +
the O +
Democratic O +
Republic O +
of O +
the O +
Congo O -
: O +
a O +
manageable O +
issue O -
. O -

Cases O +
of O +
delayed O +
hemolytic B-Disease +
anemia L-Disease +
have O +
been O +
described O +
after O +
treatment O +
with O +
injectable O +
artesunate O -
, O +
the O +
current O +
World O +
Health O +
Organization O +
( O -
WHO O -
) O -
-recommended O +
first O -
- O -
line O +
drug O +
for O +
the O +
treatment O +
of O +
severe O +
malaria U-Disease -
. O -

A O +
total O +
of O +
350 O +
patients O +
( O -
215 O +
[ O -
61.4 O -
% O -
] O +
< O +
5 O +
years O +
of O +
age O +
and O +
135 O +
[ O -
38.6 O -
% O -
] O +
> O +
5 O +
years O +
of O +
age O -
) O +
were O +
followed O -
- O -
up O +
after O +
treatment O +
with O +
injectable O +
artesunate O +
for O +
severe O +
malaria U-Disease +
in O +
hospitals O +
and O +
health O +
centers O +
of O +
the O +
Democratic O +
Republic O +
of O +
the O +
Congo O -
. O -

Complete O +
series O +
of O +
hemoglobin O +
( O -
Hb O -
) O +
measurements O +
were O +
available O +
for O +
201 O +
patients O -
. O -

A O +
decrease O +
in O +
Hb O +
levels O +
between O +
2 O +
and O +
5 O +
g O -
/ O -
dL O +
was O +
detected O +
in O +
23 O +
( O -
11.4 O -
% O -
) O +
patients O +
during O +
the O +
follow O -
- O -
up O +
period O -
. O -

For O +
five O +
patients O -
, O +
Hb O +
levels O +
decreased O +
below O +
5 O +
g O -
/ O -
dL O +
during O +
at O +
least O +
one O +
follow O -
- O -
up O +
visit O -
. O -

All O +
cases O +
of O +
delayed O +
anemia U-Disease +
were O +
clinically O +
manageable O +
and O +
resolved O +
within O +
one O +
month O -
. O -

Regulation O +
of O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
and O +
apoptotic O +
pathways O +
by O +
betaine O +
attenuates O +
isoproterenol O -
- O -
induced O +
acute O +
myocardial B-Disease +
injury L-Disease +
in O +
rats O -
. O -

The O +
present O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
cardioprotective O +
effects O +
of O +
betaine O +
on O +
acute O +
myocardial B-Disease +
ischemia L-Disease +
induced O +
experimentally O +
in O +
rats O +
focusing O +
on O +
regulation O +
of O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O -
STAT3 O -
) O +
and O +
apoptotic O +
pathways O +
as O +
the O +
potential O +
mechanism O +
underlying O +
the O +
drug O +
effect O -
. O -

Male O +
Sprague O +
Dawley O +
rats O +
were O +
treated O +
with O +
betaine O +
( O -
100 O -
, O +
200 O -
, O +
and O +
400 O +
mg O -
/ O -
kg O -
) O +
orally O +
for O +
40 O +
days O -
. O -

Acute O +
myocardial B-Disease +
ischemic I-Disease +
injury L-Disease +
was O +
induced O +
in O +
rats O +
by O +
subcutaneous O +
injection O +
of O +
isoproterenol O +
( O -
85 O +
mg O -
/ O -
kg O -
) O -
, O +
for O +
two O +
consecutive O +
days O -
. O -

Serum O +
cardiac O +
marker O +
enzyme O -
, O +
histopathological O +
variables O +
and O +
expression O +
of O +
protein O +
levels O +
were O +
analyzed O -
. O -

Oral O +
administration O +
of O +
betaine O +
( O -
200 O +
and O +
400 O +
mg O -
/ O -
kg O -
) O +
significantly O +
reduced O +
the O +
level O +
of O +
cardiac O +
marker O +
enzyme O +
in O +
the O +
serum O +
and O +
prevented O +
left O +
ventricular B-Disease +
remodeling L-Disease -
. O -

Western O +
blot O +
analysis O +
showed O +
that O +
isoproterenol O -
- O -
induced O +
phosphorylation O +
of O +
STAT3 O +
was O +
maintained O +
or O +
further O +
enhanced O +
by O +
betaine O +
treatment O +
in O +
myocardium O -
. O -

Furthermore O -
, O +
betaine O +
( O -
200 O +
and O +
400 O +
mg O -
/ O -
kg O -
) O +
treatment O +
increased O +
the O +
ventricular O +
expression O +
of O +
Bcl-2 O +
and O +
reduced O +
the O +
level O +
of O +
Bax O -
, O +
therefore O +
causing O +
a O +
significant O +
increase O +
in O +
the O +
ratio O +
of O +
Bcl-2 O -
/ O -
Bax O -
. O -

The O +
protective O +
role O +
of O +
betaine O +
on O +
myocardial B-Disease +
damage L-Disease +
was O +
further O +
confirmed O +
by O +
histopathological O +
examination O -
. O -

In O +
summary O -
, O +
our O +
results O +
showed O +
that O +
betaine O +
pretreatment O +
attenuated O +
isoproterenol O -
- O -
induced O +
acute O +
myocardial B-Disease +
ischemia L-Disease +
via O +
the O +
regulation O +
of O +
STAT3 O +
and O +
apoptotic O +
pathways O -
. O -

Quetiapine O -
- O -
induced O +
neutropenia U-Disease +
in O +
a O +
bipolar U-Disease +
patient O +
with O +
hepatocellular B-Disease +
carcinoma L-Disease -
. O -

OBJECTIVE O -
: O +
Quetiapine O +
is O +
a O +
dibenzothiazepine O +
derivative O -
, O +
similar O +
to O +
clozapine O -
, O +
which O +
has O +
the O +
highest O +
risk O +
of O +
causing O +
blood B-Disease +
dyscrasias L-Disease -
, O +
especially O +
neutropenia U-Disease -
. O -

There O +
are O +
some O +
case O +
reports O +
about O +
this O +
side O +
effect O +
of O +
quetiapine O -
, O +
but O +
possible O +
risk O +
factors O +
are O +
seldom O +
discussed O +
and O +
identified O -
. O -

A O +
case O +
of O +
a O +
patient O +
with O +
hepatocellular B-Disease +
carcinoma L-Disease +
that O +
developed O +
neutropenia U-Disease +
after O +
treatment O +
with O +
quetiapine O +
is O +
described O +
here O -
. O -

CASE O +
REPORT O -
: O +
A O +
62-year O -
- O -
old O +
Taiwanese O +
widow O +
with O +
bipolar B-Disease +
disorder L-Disease +
was O +
diagnosed O +
with O +
hepatocellular B-Disease +
carcinoma L-Disease +
at O +
age O +
60 O -
. O -

She O +
developed O +
leucopenia U-Disease +
after O +
being O +
treated O +
with O +
quetiapine O -
. O -

After O +
quetiapine O +
was O +
discontinued O -
, O +
her O +
white O +
blood O +
cell O +
count O +
returned O +
to O +
normal O -
. O -

CONCLUSIONS O -
: O +
Although O +
neutropenia U-Disease +
is O +
not O +
a O +
common O +
side O +
effect O +
of O +
quetiapine O -
, O +
physicians O +
should O +
be O +
cautious O +
about O +
its O +
presentation O +
and O +
associated O +
risk O +
factors O -
. O -

Hepatic B-Disease +
dysfunction L-Disease +
may O +
be O +
one O +
of O +
the O +
possible O +
risk O +
factors O -
, O +
and O +
concomitant O +
fever U-Disease +
may O +
be O +
a O +
diagnostic O +
marker O +
for O +
adverse O +
reaction O +
to O +
quetiapine O -
. O -

Lateral O +
antebrachial O +
cutaneous O +
neuropathy U-Disease +
after O +
steroid O +
injection O +
at O +
lateral O +
epicondyle O -
. O -

BACKGROUND O +
AND O +
OBJECTIVES O -
: O +
This O +
report O +
aimed O +
to O +
present O +
a O +
case O +
of O +
lateral O +
antebrachial O +
cutaneous O +
neuropathy U-Disease +
( O -
LACNP O -
) O +
that O +
occurred O +
after O +
a O +
steroid O +
injection O +
in O +
the O +
lateral O +
epicondyle O +
to O +
treat O +
lateral B-Disease +
epicondylitis L-Disease +
in O +
a O +
40-year O -
- O -
old O +
woman O -
. O -

MATERIAL O +
AND O +
METHOD O -
: O +
A O +
40-year O -
- O -
old O +
woman O +
presented O +
with O +
decreased O +
sensation O +
and O +
paresthesia U-Disease +
over O +
her O +
right O +
lateral O +
forearm O -
; O +
the O +
paresthesia U-Disease +
had O +
occurred O +
after O +
a O +
steroid O +
injection O +
in O +
the O +
right O +
lateral O +
epicondyle O +
3 O +
months O +
before O -
. O -

Her O +
sensation O +
of O +
light O +
touch O +
and O +
pain U-Disease +
was O +
diminished O +
over O +
the O +
lateral O +
side O +
of O +
the O +
right O +
forearm O +
and O +
wrist O +
area O -
. O -

RESULTS O -
: O +
The O +
sensory O +
action O +
potential O +
amplitude O +
of O +
the O +
right O +
lateral O +
antebrachial O +
cutaneous O +
nerve O +
( O -
LACN O -
) O +
( O -
6.2 O +
uV O -
) O +
was O +
lower O +
than O +
that O +
of O +
the O +
left O +
( O -
13.1 O +
uV O -
) O -
. O -

The O +
difference O +
of O +
amplitude O +
between O +
both O +
sides O +
was O +
significant O +
because O +
there O +
was O +
more O +
than O +
a O +
50 O -
% O +
reduction O -
. O -

She O +
was O +
diagnosed O +
with O +
right O +
LACNP O +
( O -
mainly O +
axonal O +
involvement O -
) O +
on O +
the O +
basis O +
of O +
the O +
clinical O +
manifestation O +
and O +
the O +
electrodiagnostic O +
findings O -
. O -

Her O +
symptoms O +
improved O +
through O +
physical O +
therapy O +
but O +
persisted O +
to O +
some O +
degree O -
. O -

CONCLUSION O -
: O +
This O +
report O +
describes O +
the O +
case O +
of O +
a O +
woman O +
with O +
LACNP O +
that O +
developed O +
after O +
a O +
steroid O +
injection O +
for O +
the O +
treatment O +
of O +
lateral B-Disease +
epicondylitis L-Disease -
. O -

An O +
electrodiagnostic O +
study O -
, O +
including O +
a O +
nerve O +
conduction O +
study O +
of O +
the O +
LACN O -
, O +
was O +
helpful O +
to O +
diagnose O +
right O +
LACNP O +
and O +
to O +
find O +
the O +
passage O +
of O +
the O +
LACN O +
on O +
the O +
lateral O +
epicondyle O -
. O -

Curcumin O +
prevents O +
maleate O -
- O -
induced O +
nephrotoxicity U-Disease -
: O +
relation O +
to O +
hemodynamic O +
alterations O -
, O +
oxidative O +
stress O -
, O +
mitochondrial O +
oxygen O +
consumption O +
and O +
activity O +
of O +
respiratory O +
complex O +
I. O +
The O +
potential O +
protective O +
effect O +
of O +
the O +
dietary O +
antioxidant O +
curcumin O +
( O -
120 O +
mg O -
/ O -
Kg O -
/ O -
day O +
for O +
6 O +
days O -
) O +
against O +
the O +
renal B-Disease +
injury L-Disease +
induced O +
by O +
maleate O +
was O +
evaluated O -
. O -

Tubular O +
proteinuria U-Disease +
and O +
oxidative O +
stress O +
were O +
induced O +
by O +
a O +
single O +
injection O +
of O +
maleate O +
( O -
400 O +
mg O -
/ O -
kg O -
) O +
in O +
rats O -
. O -

Maleate O -
- O -
induced O +
renal B-Disease +
injury L-Disease +
included O +
increase O +
in O +
renal O +
vascular O +
resistance O +
and O +
in O +
the O +
urinary O +
excretion O +
of O +
total O +
protein O -
, O +
glucose O -
, O +
sodium O -
, O +
neutrophil O +
gelatinase O -
- O -
associated O +
lipocalin O +
( O -
NGAL O -
) O +
and O +
N O -
- O -
acetyl O +
b O -
- O -
D O -
- O -
glucosaminidase O +
( O -
NAG O -
) O -
, O +
upregulation O +
of O +
kidney B-Disease +
injury L-Disease +
molecule O +
( O -
KIM O -
) O -
-1 O -
, O +
decrease O +
in O +
renal O +
blood O +
flow O +
and O +
claudin-2 O +
expression O +
besides O +
of O +
necrosis U-Disease +
and O +
apoptosis O +
of O +
tubular O +
cells O +
on O +
24 O +
h. O +
Oxidative O +
stress O +
was O +
determined O +
by O +
measuring O +
the O +
oxidation O +
of O +
lipids O +
and O +
proteins O +
and O +
diminution O +
in O +
renal O +
Nrf2 O +
levels O -
. O -

Studies O +
were O +
also O +
conducted O +
in O +
renal O +
epithelial O +
LLC O -
- O -
PK1 O +
cells O +
and O +
in O +
mitochondria O +
isolated O +
from O +
kidneys O +
of O +
all O +
the O +
experimental O +
groups O -
. O -

Maleate O +
induced O +
cell O +
damage O +
and O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
production O +
in O +
LLC O -
- O -
PK1 O +
cells O +
in O +
culture O -
. O -

In O +
addition O -
, O +
maleate O +
treatment O +
reduced O +
oxygen O +
consumption O +
in O +
ADP O -
- O -
stimulated O +
mitochondria O +
and O +
diminished O +
respiratory O +
control O +
index O +
when O +
using O +
malate O -
/ O -
glutamate O +
as O +
substrate O -
. O -

The O +
activities O +
of O +
both O +
complex O +
I O +
and O +
aconitase O +
were O +
also O +
diminished O -
. O -

All O +
the O +
above O -
- O -
described O +
alterations O +
were O +
prevented O +
by O +
curcumin O -
. O -

It O +
is O +
concluded O +
that O +
curcumin O +
is O +
able O +
to O +
attenuate O +
in O +
vivo O +
maleate O -
- O -
induced O +
nephropathy U-Disease +
and O +
in O +
vitro O +
cell O +
damage O -
. O -

The O +
in O +
vivo O +
protection O +
was O +
associated O +
to O +
the O +
prevention O +
of O +
oxidative O +
stress O +
and O +
preservation O +
of O +
mitochondrial O +
oxygen O +
consumption O +
and O +
activity O +
of O +
respiratory O +
complex O +
I O -
, O +
and O +
the O +
in O +
vitro O +
protection O +
was O +
associated O +
to O +
the O +
prevention O +
of O +
ROS O +
production O -
. O -

Anticonvulsant O +
actions O +
of O +
MK-801 O +
on O +
the O +
lithium O -
- O -
pilocarpine O +
model O +
of O +
status B-Disease +
epilepticus L-Disease +
in O +
rats O -
. O -

MK-801 O -
, O +
a O +
noncompetitive O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptor O +
antagonist O -
, O +
was O +
tested O +
for O +
anticonvulsant O +
effects O +
in O +
rats O +
using O +
two O +
seizure U-Disease +
models O -
, O +
coadministration O +
of O +
lithium O +
and O +
pilocarpine O +
and O +
administration O +
of O +
a O +
high O +
dose O +
of O +
pilocarpine O +
alone O -
. O -

Three O +
major O +
results O +
are O +
reported O -
. O -

First O -
, O +
pretreatment O +
with O +
MK-801 O +
produced O +
an O +
effective O +
and O +
dose O -
- O -
dependent O +
anticonvulsant O +
action O +
with O +
the O +
lithium O -
- O -
pilocarpine O +
model O +
but O +
not O +
with O +
rats O +
treated O +
with O +
pilocarpine O +
alone O -
, O +
suggesting O +
that O +
different O +
biochemical O +
mechanisms O +
control O +
seizures U-Disease +
in O +
these O +
two O +
models O -
. O -

Second O -
, O +
the O +
anticonvulsant O +
effect O +
of O +
MK-801 O +
in O +
the O +
lithium O -
- O -
pilocarpine O +
model O +
only O +
occurred O +
after O +
initial O +
periods O +
of O +
seizure U-Disease +
activity O -
. O -

This O +
observation O +
is O +
suggested O +
to O +
be O +
an O +
in O +
vivo O +
demonstration O +
of O +
the O +
conclusion O +
derived O +
from O +
in O +
vitro O +
experiments O +
that O +
MK-801 O +
binding O +
requires O +
agonist O -
- O -
induced O +
opening O +
of O +
the O +
channel O +
sites O +
of O +
the O +
NMDA O +
receptor O -
. O -

Third O -
, O +
although O +
it O +
is O +
relatively O +
easy O +
to O +
block O +
seizures U-Disease +
induced O +
by O +
lithium O +
and O +
pilocarpine O +
by O +
administration O +
of O +
anticonvulsants O +
prior O +
to O +
pilocarpine O -
, O +
it O +
is O +
more O +
difficult O +
to O +
terminate O +
ongoing O +
status B-Disease +
epilepticus L-Disease +
and O +
block O +
the O +
lethality O +
of O +
the O +
seizures U-Disease -
. O -

Administration O +
of O +
MK-801 O +
30 O +
or O +
60 O +
min O +
after O +
pilocarpine O -
, O +
i.e. O -
, O +
during O +
status B-Disease +
epilepticus L-Disease -
, O +
gradually O +
reduced O +
electrical O +
and O +
behavioral O +
seizure U-Disease +
activity O +
and O +
greatly O +
enhanced O +
the O +
survival O +
rate O -
. O -

These O +
results O +
suggest O +
that O +
activation O +
of O +
NMDA O +
receptors O +
plays O +
an O +
important O +
role O +
in O +
status B-Disease +
epilepticus L-Disease +
and O +
brain B-Disease +
damage L-Disease +
in O +
the O +
lithium O -
- O -
pilocarpine O +
model O -
. O -

This O +
was O +
further O +
supported O +
by O +
results O +
showing O +
that O +
nonconvulsive O +
doses O +
of O +
NMDA O +
and O +
pilocarpine O +
were O +
synergistic O -
, O +
resulting O +
in O +
status B-Disease +
epilepticus L-Disease +
and O +
subsequent O +
mortality O -
. O -

Continuous O +
infusion O +
tobramycin O +
combined O +
with O +
carbenicillin O +
for O +
infections U-Disease +
in O +
cancer U-Disease +
patients O -
. O -

The O +
cure O +
rate O +
of O +
infections U-Disease +
in O +
cancer U-Disease +
patients O +
is O +
adversely O +
affected O +
by O +
neutropenia U-Disease +
( O -
less O +
than O +
1,000 O -
/ O -
mm3 O -
) O -
. O -

In O +
particular O -
, O +
patients O +
with O +
severe O +
neutropenia U-Disease +
( O -
less O +
than O +
100 O -
/ O -
mm3 O -
) O +
have O +
shown O +
a O +
poor O +
response O +
to O +
antibiotics O -
. O -

To O +
overcome O +
the O +
adverse O +
effects O +
of O +
neutropenia U-Disease -
, O +
tobramycin O +
was O +
given O +
by O +
continuous O +
infusion O +
and O +
combined O +
with O +
intermittent O +
carbenicillin O -
. O -

Tobramycin O +
was O +
given O +
to O +
a O +
total O +
daily O +
dose O +
of O +
300 O +
mg O -
/ O -
m2 O +
and O +
carbenicillin O +
was O +
given O +
at O +
a O +
dose O +
of O +
5 O +
gm O +
every O +
four O +
hours O -
. O -

There O +
were O +
125 O +
infectious O +
episodes O +
in O +
116 O +
cancer U-Disease +
patients O +
receiving O +
myelosuppressive O +
chemotherapy O -
. O -

The O +
overall O +
cure O +
rate O +
was O +
70 O -
% O -
. O -

Pneumonia U-Disease +
was O +
the O +
most O +
common O +
infection U-Disease +
and O +
61 O -
% O +
of O +
59 O +
episodes O +
were O +
cured O -
. O -

Gram O -
- O -
negative O +
bacilli O +
were O +
the O +
most O +
common O +
causative O +
organisms O +
and O +
69 O -
% O +
of O +
these O +
infections U-Disease +
were O +
cured O -
. O -

The O +
most O +
common O +
pathogen O +
was O +
Klebsiella O +
pneumoniae U-Disease +
and O +
this O -
, O +
together O +
with O +
Escherichia O +
coli O +
and O +
Pseudomonas O +
aeruginosa O -
, O +
accounted O +
for O +
74 O -
% O +
of O +
all O +
gram B-Disease -
- I-Disease -
negative I-Disease +
bacillary I-Disease +
infections L-Disease -
. O -

Response O +
was O +
not O +
influenced O +
by O +
the O +
initial O +
neutrophil O +
count O -
, O +
with O +
a O +
62 O -
% O +
cure O +
rate O +
for O +
39 O +
episodes O +
associated O +
with O +
severe O +
neutropenia U-Disease -
. O -

However O -
, O +
failure O +
of O +
the O +
neutrophil O +
count O +
to O +
increase O +
during O +
therapy O +
adversely O +
affected O +
response O -
. O -

Azotemia U-Disease +
was O +
the O +
major O +
side O +
effect O +
recognized O -
, O +
and O +
it O +
occurred O +
in O +
11 O -
% O +
of O +
episodes O -
. O -

Major O +
azotemia U-Disease +
( O -
serum O +
creatinine O +
greater O +
than O +
2.5 O +
mg O -
/ O -
dl O +
or O +
BUN O +
greater O +
than O +
50 O +
mg O -
/ O -
dl O -
) O +
occurred O +
in O +
only O +
2 O -
% O -
. O -

Azotemia U-Disease +
was O +
not O +
related O +
to O +
duration O +
of O +
therapy O +
or O +
serum O +
tobramycin O +
concentration O -
. O -

This O +
antibiotic O +
regimen O +
showed O +
both O +
therapeutic O +
efficacy O +
and O +
acceptable O +
renal B-Disease +
toxicity L-Disease +
for O +
these O +
patients O -
. O -

Incidence O +
of O +
solid O +
tumours U-Disease +
among O +
pesticide O +
applicators O +
exposed O +
to O +
the O +
organophosphate O +
insecticide O +
diazinon O +
in O +
the O +
Agricultural O +
Health O +
Study O -
: O +
an O +
updated O +
analysis O -
. O -

OBJECTIVE O -
: O +
Diazinon O -
, O +
a O +
common O +
organophosphate O +
insecticide O +
with O +
genotoxic O +
properties O -
, O +
was O +
previously O +
associated O +
with O +
lung B-Disease +
cancer L-Disease +
in O +
the O +
Agricultural O +
Health O +
Study O +
( O -
AHS O -
) O +
cohort O -
, O +
but O +
few O +
other O +
epidemiological O +
studies O +
have O +
examined O +
diazinon O -
- O -
associated O +
cancer U-Disease +
risk O -
. O -

We O +
used O +
updated O +
diazinon O +
exposure O +
and O +
cancer U-Disease +
incidence O +
information O +
to O +
evaluate O +
solid O +
tumour U-Disease +
risk O +
in O +
the O +
AHS O -
. O -

METHODS O -
: O +
Male O +
pesticide O +
applicators O +
in O +
Iowa O +
and O +
North O +
Carolina O +
reported O +
lifetime O +
diazinon O +
use O +
at O +
enrolment O +
( O -
1993 O -
- O -
1997 O -
) O +
and O +
follow O -
- O -
up O +
( O -
1998 O -
- O -
2005 O -
) O -
; O +
cancer U-Disease +
incidence O +
was O +
assessed O +
through O +
2010 O -
( O -
North O +
Carolina O -
) O -
/ O -
2011 O -
( O -
Iowa O -
) O -
. O -

Among O +
applicators O +
with O +
usage O +
information O +
sufficient O +
to O +
evaluate O +
exposure O -
- O -
response O +
patterns O -
, O +
we O +
used O +
Poisson O +
regression O +
to O +
estimate O +
adjusted O +
rate O +
ratios O +
( O -
RRs O -
) O +
and O +
95 O -
% O +
CI O +
for O +
cancer U-Disease +
sites O +
with O +
> O -
10 O +
exposed O +
cases O +
for O +
both O +
lifetime O +
( O -
LT O -
) O +
exposure O +
days O +
and O +
intensity O -
- O -
weighted O +
( O -
IW O -
) O +
lifetime O +
exposure O +
days O +
( O -
accounting O +
for O +
factors O +
impacting O +
exposure O -
) O -
. O -

RESULTS O -
: O +
We O +
observed O +
elevated O +
lung B-Disease +
cancer L-Disease +
risks O +
( O -
N=283 O -
) O +
among O +
applicators O +
with O +
the O +
greatest O +
number O +
of O +
LT O +
( O -
RR=1.60 O -
; O +
95 O -
% O +
CI O +
1.11 O +
to O +
2.31 O -
; O +
Ptrend=0.02 O -
) O +
and O +
IW O +
days O +
of O +
diazinon O +
use O +
( O -
RR=1.41 O -
; O +
95 O -
% O +
CI O +
0.98 O +
to O +
2.04 O -
; O +
Ptrend=0.08 O -
) O -
. O -

Kidney B-Disease +
cancer L-Disease +
( O -
N=94 O -
) O +
risks O +
were O +
non O -
- O -
significantly O +
elevated O +
( O -
RRLT O +
days=1.77 O -
; O +
95 O -
% O +
CI O +
0.90 O +
to O +
3.51 O -
; O +
Ptrend=0.09 O -
; O +
RRIW O +
days O +
1.37 O -
; O +
95 O -
% O +
CI O +
0.64 O +
to O +
2.92 O -
; O +
Ptrend=0.50 O -
) O -
, O +
as O +
were O +
risks O +
for O +
aggressive O +
prostate B-Disease +
cancer L-Disease +
( O -
N=656 O -
) O -
. O -

CONCLUSIONS O -
: O +
Our O +
updated O +
evaluation O +
of O +
diazinon O +
provides O +
additional O +
evidence O +
of O +
an O +
association O +
with O +
lung B-Disease +
cancer L-Disease +
risk O -
. O -

Newly O +
identified O +
links O +
to O +
kidney B-Disease +
cancer L-Disease +
and O +
associations O +
with O +
aggressive O +
prostate B-Disease +
cancer L-Disease +
require O +
further O +
evaluation O -
. O -

Associations O +
of O +
Ozone O +
and O +
PM2.5 O +
Concentrations O +
With O +
Parkinson B-Disease -
's I-Disease +
Disease L-Disease +
Among O +
Participants O +
in O +
the O +
Agricultural O +
Health O +
Study O -
. O -

OBJECTIVE O -
: O +
This O +
study O +
describes O +
associations O +
of O +
ozone O +
and O +
fine O +
particulate O +
matter O +
with O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
observed O +
among O +
farmers O +
in O +
North O +
Carolina O +
and O +
Iowa O -
. O -

METHODS O -
: O +
We O +
used O +
logistic O +
regression O +
to O +
determine O +
the O +
associations O +
of O +
these O +
pollutants O +
with O +
self O -
- O -
reported O -
, O +
doctor O -
- O -
diagnosed O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

Daily O +
predicted O +
pollutant O +
concentrations O +
were O +
used O +
to O +
derive O +
surrogates O +
of O +
long O -
- O -
term O +
exposure O +
and O +
link O +
them O +
to O +
study O +
participants O -
' O +
geocoded O +
addresses O -
. O -

RESULTS O -
: O +
We O +
observed O +
positive O +
associations O +
of O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
with O +
ozone O +
( O -
odds O +
ratio O +
= O +
1.39 O -
; O +
95 O -
% O +
CI O -
: O +
0.98 O +
to O +
1.98 O -
) O +
and O +
fine O +
particulate O +
matter O +
( O -
odds O +
ratio O +
= O +
1.34 O -
; O +
95 O -
% O +
CI O -
: O +
0.93 O +
to O +
1.93 O -
) O +
in O +
North O +
Carolina O +
but O +
not O +
in O +
Iowa O -
. O -

CONCLUSIONS O -
: O +
The O +
plausibility O +
of O +
an O +
effect O +
of O +
ambient O +
concentrations O +
of O +
these O +
pollutants O +
on O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
risk O +
is O +
supported O +
by O +
experimental O +
data O +
demonstrating O +
damage O +
to O +
dopaminergic O +
neurons O +
at O +
relevant O +
concentrations O -
. O -

Additional O +
studies O +
are O +
needed O +
to O +
address O +
uncertainties O +
related O +
to O +
confounding O +
and O +
to O +
examine O +
temporal O +
aspects O +
of O +
the O +
associations O +
we O +
observed O -
. O -

Low O +
functional O +
programming O +
of O +
renal O +
AT2R O +
mediates O +
the O +
developmental O +
origin O +
of O +
glomerulosclerosis U-Disease +
in O +
adult O +
offspring O +
induced O +
by O +
prenatal O +
caffeine O +
exposure O -
. O -

UNASSIGNED O -
: O +
Our O +
previous O +
study O +
has O +
indicated O +
that O +
prenatal O +
caffeine O +
exposure O +
( O -
PCE O -
) O +
could O +
induce O +
intrauterine B-Disease +
growth I-Disease +
retardation L-Disease +
( O -
IUGR U-Disease -
) O +
of O +
offspring O -
. O -

Recent O +
research O +
suggested O +
that O +
IUGR U-Disease +
is O +
a O +
risk O +
factor O +
for O +
glomerulosclerosis U-Disease -
. O -

However O -
, O +
whether O +
PCE O +
could O +
induce O +
glomerulosclerosis U-Disease +
and O +
its O +
underlying O +
mechanisms O +
remain O +
unknown O -
. O -

This O +
study O +
aimed O +
to O +
demonstrate O +
the O +
induction O +
to O +
glomerulosclerosis U-Disease +
in O +
adult O +
offspring O +
by O +
PCE O +
and O +
its O +
intrauterine O +
programming O +
mechanisms O -
. O -

A O +
rat O +
model O +
of O +
IUGR U-Disease +
was O +
established O +
by O +
PCE O -
, O +
male O +
fetuses O +
and O +
adult O +
offspring O +
at O +
the O +
age O +
of O +
postnatal O +
week O +
24 O +
were O +
euthanized O -
. O -

The O +
results O +
revealed O +
that O +
the O +
adult O +
offspring O +
kidneys O +
in O +
the O +
PCE O +
group O +
exhibited O +
glomerulosclerosis U-Disease +
as O +
well O +
as O +
interstitial B-Disease +
fibrosis L-Disease -
, O +
accompanied O +
by O +
elevated O +
levels O +
of O +
serum O +
creatinine O +
and O +
urine O +
protein O -
. O -

Renal O +
angiotensin O +
II O +
receptor O +
type O +
2 O +
( O -
AT2R O -
) O +
gene O +
expression O +
in O +
adult O +
offspring O +
was O +
reduced O +
by O +
PCE O -
, O +
whereas O +
the O +
renal O +
angiotensin O +
II O +
receptor O +
type O +
1a O +
( O -
AT1aR O -
) O -
/ O -
AT2R O +
expression O +
ratio O +
was O +
increased O -
. O -

The O +
fetal O +
kidneys O +
in O +
the O +
PCE O +
group O +
displayed O +
an O +
enlarged O +
Bowman O -
's O +
space O +
and O +
a O +
shrunken O +
glomerular O +
tuft O -
, O +
accompanied O +
by O +
a O +
reduced O +
cortex O +
width O +
and O +
an O +
increase O +
in O +
the O +
nephrogenic O +
zone O -
/ O -
cortical O +
zone O +
ratio O -
. O -

Observation O +
by O +
electronic O +
microscope O +
revealed O +
structural O +
damage O +
of O +
podocytes O -
; O +
the O +
reduced O +
expression O +
level O +
of O +
podocyte O +
marker O +
genes O -
, O +
nephrin O +
and O +
podocin O -
, O +
was O +
also O +
detected O +
by O +
q O -
- O -
PCR O -
. O -

Moreover O -
, O +
AT2R O +
gene O +
and O +
protein O +
expressions O +
in O +
fetal O +
kidneys O +
were O +
inhibited O +
by O +
PCE O -
, O +
associated O +
with O +
the O +
repression O +
of O +
the O +
gene O +
expression O +
of O +
glial O -
- O -
cell O -
- O -
line O -
- O -
derived O +
neurotrophic O +
factor O +
( O -
GDNF O -
) O -
/ O -
tyrosine O +
kinase O +
receptor O +
( O -
c O -
- O -
Ret O -
) O +
signaling O +
pathway O -
. O -

These O +
results O +
demonstrated O +
that O +
PCE O +
could O +
induce O +
dysplasia B-Disease +
of I-Disease +
fetal I-Disease +
kidneys L-Disease +
as O +
well O +
as O +
glomerulosclerosis U-Disease +
of O +
adult O +
offspring O -
, O +
and O +
the O +
low O +
functional O +
programming O +
of O +
renal O +
AT2R O +
might O +
mediate O +
the O +
developmental O +
origin O +
of O +
adult O +
glomerulosclerosis U-Disease -
. O -

1,3-Butadiene O -
, O +
CML U-Disease +
and O +
the O +
t O -
( O -
9:22 O -
) O +
translocation O -
: O +
A O +
reality O +
check O -
. O -

UNASSIGNED O -
: O +
Epidemiological O +
studies O +
of O +
1,3-butadiene O +
have O +
suggest O +
that O +
exposures O +
to O +
humans O +
are O +
associated O +
with O +
chronic B-Disease +
myeloid I-Disease +
leukemia L-Disease +
( O -
CML U-Disease -
) O -
. O -

CML U-Disease +
has O +
a O +
well O -
- O -
documented O +
association O +
with O +
ionizing O +
radiation O -
, O +
but O +
reports O +
of O +
associations O +
with O +
chemical O +
exposures O +
have O +
been O +
questioned O -
. O -

Ionizing O +
radiation O +
is O +
capable O +
of O +
inducing O +
the O +
requisite O +
CML U-Disease -
- O -
associated O +
t O -
( O -
9:22 O -
) O +
translocation O +
( O -
Philadelphia B-Disease +
chromosome L-Disease -
) O +
in O +
appropriate O +
cells O +
in O +
vitro O +
but O -
, O +
thus O +
far O -
, O +
chemicals O +
have O +
not O +
shown O +
this O +
capacity O -
. O -

We O +
have O +
proposed O +
that O +
1,3-butadiene O +
metabolites O +
be O +
so O +
tested O +
as O +
a O +
reality O +
check O +
on O +
the O +
epidemiological O +
reports O -
. O -

In O +
order O +
to O +
conduct O +
reliable O +
testing O +
in O +
this O +
regard O -
, O +
it O +
is O +
essential O +
that O +
a O +
positive O +
control O +
for O +
induction O +
be O +
available O -
. O -

We O +
have O +
used O +
ionizing O +
radiation O +
to O +
develop O +
such O +
a O +
control O -
. O -

Results O +
described O +
here O +
demonstrate O +
that O +
this O +
agent O +
does O +
in O +
fact O +
induce O +
pathogenic O +
t O -
( O -
9:22 O -
) O +
translocations O +
in O +
a O +
human O +
myeloid O +
cell O +
line O +
in O +
vitro O -
, O +
but O +
does O +
so O +
at O +
low O +
frequencies O -
. O -

Conditions O +
that O +
will O +
be O +
required O +
for O +
studies O +
of O +
1,3-butadiene O +
are O +
discussed O -
. O -

Cancer U-Disease +
incidence O +
and O +
metolachlor O +
use O +
in O +
the O +
Agricultural O +
Health O +
Study O -
: O +
An O +
update O -
. O -

UNASSIGNED O -
: O +
Metolachlor O -
, O +
a O +
widely O +
used O +
herbicide O -
, O +
is O +
classified O +
as O +
a O +
Group O +
C O +
carcinogen O +
by O +
the O +
U.S. O +
Environmental O +
Protection O +
Agency O +
based O +
on O +
increased O +
liver B-Disease +
neoplasms L-Disease +
in O +
female O +
rats O -
. O -

Epidemiologic O +
studies O +
of O +
the O +
health O +
effects O +
of O +
metolachlor O +
have O +
been O +
limited O -
. O -

The O +
Agricultural O +
Health O +
Study O +
( O -
AHS O -
) O +
is O +
a O +
prospective O +
cohort O +
study O +
including O +
licensed O +
private O +
and O +
commercial O +
pesticide O +
applicators O +
in O +
Iowa O +
and O +
North O +
Carolina O +
enrolled O +
1993 O -
- O -
1997 O -
. O -

We O +
evaluated O +
cancer U-Disease +
incidence O +
through O +
2010 O -
/ O -
2011 O +
( O -
NC O -
/ O -
IA O -
) O +
for O +
49,616 O +
applicators O -
, O +
53 O -
% O +
of O +
whom O +
reported O +
ever O +
using O +
metolachlor O -
. O -

We O +
used O +
Poisson O +
regression O +
to O +
evaluate O +
relations O +
between O +
two O +
metrics O +
of O +
metolachlor O +
use O +
( O -
lifetime O +
days O -
, O +
intensity O -
- O -
weighted O +
lifetime O +
days O -
) O +
and O +
cancer U-Disease +
incidence O -
. O -

We O +
saw O +
no O +
association O +
between O +
metolachlor O +
use O +
and O +
incidence O +
of O +
all O +
cancers U-Disease +
combined O +
( O -
n O +
= O +
5,701 O +
with O +
a O +
5-year O +
lag O -
) O +
or O +
most O +
site O -
- O -
specific O +
cancers U-Disease -
. O -

For O +
liver B-Disease +
cancer L-Disease -
, O +
in O +
analyses O +
restricted O +
to O +
exposed O +
workers O -
, O +
elevations O +
observed O +
at O +
higher O +
categories O +
of O +
use O +
were O +
not O +
statistically O +
significant O -
. O -

However O -
, O +
trends O +
for O +
both O +
lifetime O +
and O +
intensity O -
- O -
weighted O +
lifetime O +
days O +
of O +
metolachor O +
use O +
were O +
positive O +
and O +
statistically O +
significant O +
with O +
an O +
unexposed O +
reference O +
group O -
. O -

A O +
similar O +
pattern O +
was O +
observed O +
for O +
follicular B-Disease +
cell I-Disease +
lymphoma L-Disease -
, O +
but O +
no O +
other O +
lymphoma U-Disease +
subtypes O -
. O -

An O +
earlier O +
suggestion O +
of O +
increased O +
lung B-Disease +
cancer L-Disease +
risk O +
at O +
high O +
levels O +
of O +
metolachlor O +
use O +
in O +
this O +
cohort O +
was O +
not O +
confirmed O +
in O +
this O +
update O -
. O -

This O +
suggestion O +
of O +
an O +
association O +
between O +
metolachlor O +
and O +
liver B-Disease +
cancer L-Disease +
among O +
pesticide O +
applicators O +
is O +
a O +
novel O +
finding O +
and O +
echoes O +
observation O +
of O +
increased O +
liver B-Disease +
neoplasms L-Disease +
in O +
some O +
animal O +
studies O -
. O -

However O -
, O +
our O +
findings O +
for O +
both O +
liver B-Disease +
cancer L-Disease +
and O +
follicular O +
cell O +
lymphoma U-Disease +
warrant O +
follow O -
- O -
up O +
to O +
better O +
differentiate O +
effects O +
of O +
metolachlor O +
use O +
from O +
other O +
factors O -
. O -

Mechanisms O +
Underlying O +
Latent O +
Disease O +
Risk O +
Associated O +
with O +
Early O -
- O -
Life O +
Arsenic O +
Exposure O -
: O +
Current O +
Research O +
Trends O +
and O +
Scientific O +
Gaps O -
. O -

BACKGROUND O -
: O +
Millions O +
of O +
individuals O +
worldwide O -
, O +
particularly O +
those O +
living O +
in O +
rural O +
and O +
developing O +
areas O -
, O +
are O +
exposed O +
to O +
harmful O +
levels O +
of O +
inorganic O +
arsenic O +
( O -
iAs O -
) O +
in O +
their O +
drinking O +
water O -
. O -

Inorganic O +
As O +
exposure O +
during O +
key O +
developmental O +
periods O +
is O +
associated O +
with O +
a O +
variety O +
of O +
adverse O +
health O +
effects O +
including O +
those O +
that O +
are O +
evident O +
in O +
adulthood O -
. O -

There O +
is O +
considerable O +
interest O +
in O +
identifying O +
the O +
molecular O +
mechanisms O +
that O +
relate O +
early O -
- O -
life O +
iAs O +
exposure O +
to O +
the O +
development O +
of O +
these O +
latent O +
diseases O -
, O +
particularly O +
in O +
relationship O +
to O +
cancer U-Disease -
. O -

OBJECTIVES O -
: O +
This O +
work O +
summarizes O +
research O +
on O +
the O +
molecular O +
mechanisms O +
that O +
underlie O +
the O +
increased O +
risk O +
of O +
cancer U-Disease +
development O +
in O +
adulthood O +
that O +
is O +
associated O +
with O +
early O -
- O -
life O +
iAs O +
exposure O -
. O -

DISCUSSION O -
: O +
Epigenetic O +
reprogramming O +
that O +
imparts O +
functional O +
changes O +
in O +
gene O +
expression O -
, O +
the O +
development O +
of O +
cancer U-Disease +
stem O +
cells O -
, O +
and O +
immunomodulation O +
are O +
plausible O +
underlying O +
mechanisms O +
by O +
which O +
early O -
- O -
life O +
iAs O +
exposure O +
elicits O +
latent O +
carcinogenic O +
effects O -
. O -

CONCLUSIONS O -
: O +
Evidence O +
is O +
mounting O +
that O +
relates O +
early O -
- O -
life O +
iAs O +
exposure O +
and O +
cancer U-Disease +
development O +
later O +
in O +
life O -
. O -

Future O +
research O +
should O +
include O +
animal O +
studies O +
that O +
address O +
mechanistic O +
hypotheses O +
and O +
studies O +
of O +
human O +
populations O +
that O +
integrate O +
early O -
- O -
life O +
exposure O -
, O +
molecular O +
alterations O -
, O +
and O +
latent O +
disease O +
outcomes O -
. O -

Nifedipine O +
induced O +
bradycardia U-Disease +
in O +
a O +
patient O +
with O +
autonomic B-Disease +
neuropathy L-Disease -
. O -

An O +
80 O +
year O +
old O +
diabetic U-Disease +
male O +
with O +
evidence O +
of O +
peripheral B-Disease +
and I-Disease +
autonomic I-Disease +
neuropathy L-Disease +
was O +
admitted O +
with O +
chest B-Disease +
pain L-Disease -
. O -

He O +
was O +
found O +
to O +
have O +
atrial B-Disease +
flutter L-Disease +
at O +
a O +
ventricular O +
rate O +
of O +
70 O -
/ O -
min O +
which O +
slowed O +
down O +
to O +
30 O -
- O -
40 O -
/ O -
min O +
when O +
nifedipine O +
( O -
60 O +
mg O -
) O +
in O +
3 O +
divided O +
doses O -
, O +
during O +
which O +
he O +
was O +
paced O +
at O +
a O +
rate O +
of O +
70 O -
/ O -
min O -
. O -

This O +
is O +
inconsistent O +
with O +
the O +
well O -
- O -
established O +
finding O +
that O +
nifedipine O +
induces O +
tachycardia U-Disease +
in O +
normally O +
innervated O +
hearts O -
. O -

However O -
, O +
in O +
hearts O +
deprived O +
of O +
compensatory O +
sympathetic O +
drive O -
, O +
it O +
may O +
lead O +
to O +
bradycardia U-Disease -
. O -

The O +
effect O +
of O +
haloperidol O +
in O +
cocaine O +
and O +
amphetamine O +
intoxication O -
. O -

The O +
effectiveness O +
of O +
haloperidol O +
pretreatment O +
in O +
preventing O +
the O +
toxic O +
effects O +
of O +
high O +
doses O +
of O +
amphetamine O +
and O +
cocaine O +
was O +
studied O +
in O +
rats O -
. O -

In O +
this O +
model O -
, O +
toxic O +
effects O +
were O +
induced O +
by O +
intraperitoneal O +
( O -
i.p O -
. O -
) O +
injection O +
of O +
amphetamine O +
75 O +
mg O -
/ O -
kg O +
( O -
100 O -
% O +
death O +
rate O -
) O +
or O +
cocaine O +
70 O +
mg O -
/ O -
kg O +
( O -
82 O -
% O +
death O +
rate O -
) O -
. O -

Haloperidol O +
failed O +
to O +
prevent O +
amphetamine O -
- O -
induced O +
seizures U-Disease -
, O +
but O +
did O +
lower O +
the O +
mortality O +
rate O +
at O +
most O +
doses O +
tested O -
. O -

Haloperidol O +
decreased O +
the O +
incidence O +
of O +
cocaine O -
- O -
induced O +
seizures U-Disease +
at O +
the O +
two O +
highest O +
doses O -
, O +
but O +
the O +
lowering O +
of O +
the O +
mortality O +
rate O +
did O +
not O +
reach O +
statistical O +
significance O +
at O +
any O +
dose O -
. O -

These O +
data O +
suggest O +
a O +
protective O +
role O +
for O +
the O +
central O +
dopamine O +
blocker O +
haloperidol O +
against O +
death O +
from O +
high O -
- O -
dose O +
amphetamine O +
exposure O +
without O +
reducing O +
the O +
incidence O +
of O +
seizures U-Disease -
. O -

In O +
contrast O -
, O +
haloperidol O +
demonstrated O +
an O +
ability O +
to O +
reduce O +
cocaine O -
- O -
induced O +
seizures U-Disease +
without O +
significantly O +
reducing O +
mortality O -
. O -

Autoradiographic O +
evidence O +
of O +
estrogen O +
binding O +
sites O +
in O +
nuclei O +
of O +
diethylstilbesterol O +
induced O +
hamster O +
renal B-Disease +
carcinomas L-Disease -
. O -

Estrogen O +
binding O +
sites O +
were O +
demonstrated O +
by O +
autoradiography O +
in O +
one O +
transplantable O +
and O +
five O +
primary O +
diethylstilbesterol O +
induced O +
renal B-Disease +
carcinomas L-Disease +
in O +
three O +
hamsters O -
. O -

Radiolabelling O -
, O +
following O +
the O +
in O +
vivo O +
injection O +
of O +
3H-17 O +
beta O +
estradiol O -
, O +
was O +
increased O +
only O +
over O +
the O +
nuclei O +
of O +
tumor U-Disease +
cells O -
; O +
stereologic O +
analysis O +
revealed O +
a O +
4.5- O +
to O +
6.7-times O +
higher O +
concentration O +
of O +
reduced O +
silver O +
grains O +
over O +
nuclei O +
than O +
cytoplasm O +
of O +
these O +
cells O -
. O -

Despite O +
rapid O +
tubular O +
excretion O +
of O +
estradiol O +
which O +
peaked O +
in O +
less O +
than O +
1 O +
h O -
, O +
the O +
normal O +
cells O +
did O +
not O +
appear O +
to O +
bind O +
the O +
ligand O -
. O -

This O +
is O +
the O +
first O +
published O +
report O +
documenting O +
the O +
preferential O +
in O +
vivo O +
binding O +
of O +
estrogen O +
to O +
nuclei O +
of O +
cells O +
in O +
estrogen O +
induced O +
hamster O +
renal B-Disease +
carcinomas L-Disease -
. O -

Bradycardia U-Disease +
due O +
to O +
biperiden O -
. O -

In O +
a O +
38-year O -
- O -
old O +
male O +
patient O +
suffering O +
from O +
a O +
severe O +
postzosteric U-Disease +
trigeminal B-Disease +
neuralgia L-Disease -
, O +
intravenous O +
application O +
of O +
10 O +
mg O +
biperiden O +
lactate O +
led O +
to O +
a O +
long O -
- O -
lasting O +
paradoxical O +
reaction O +
characterized O +
by O +
considerable O +
bradycardia U-Disease -
, O +
dysarthria U-Disease -
, O +
and O +
dysphagia U-Disease -
. O -

The O +
heart O +
rate O +
was O +
back O +
to O +
normal O +
within O +
12 O +
hours O +
upon O +
administration O +
of O +
orciprenaline O +
under O +
cardiac O +
monitoring O +
in O +
an O +
intensive O +
care O +
unit O -
. O -

Bradycardia U-Disease +
induced O +
by O +
biperiden O +
is O +
attributed O +
to O +
the O +
speed O +
of O +
injection O +
and O +
to O +
a O +
dose O -
- O -
related O +
dual O +
effect O +
of O +
atropine O -
- O -
like O +
drugs O +
on O +
muscarine O +
receptors O -
. O -

Deliberate O +
hypotension U-Disease +
induced O +
by O +
labetalol O +
with O +
halothane O -
, O +
enflurane O +
or O +
isoflurane O +
for O +
middle O -
- O -
ear O +
surgery O -
. O -

The O +
feasibility O +
of O +
using O +
labetalol O -
, O +
an O +
alpha- O +
and O +
beta O -
- O -
adrenergic O +
blocking O +
agent O -
, O +
as O +
a O +
hypotensive U-Disease +
agent O +
in O +
combination O +
with O +
inhalation O +
anaesthetics O +
( O -
halothane O -
, O +
enflurane O +
or O +
isoflurane O -
) O +
was O +
studied O +
in O +
23 O +
adult O +
patients O +
undergoing O +
middle O -
- O -
ear O +
surgery O -
. O -

The O +
mean O +
arterial O +
pressure O +
was O +
decreased O +
from O +
86 O +
+ O -
/- O -

5 O +
( O -
s.e O -
. O +
mean O -
) O +
mmHg O +
to O +
52 O +
+ O -
/- O -

1 O +
mmHg O +
( O -
11.5 O +
+ O -
/- O -

0.7 O +
to O +
6.9 O +
+ O -
/- O -

0.1 O +
kPa O -
) O +
for O +
98 O +
+ O -
/- O -

10 O +
min O +
in O +
the O +
halothane O +
( O -
H O -
) O +
group O -
, O +
from O +
79 O +
+ O -
/- O -

5 O +
to O +
53 O +
+ O -
/- O -

1 O +
mmHg O +
( O -
10.5 O +
+ O -
/- O -

0.7 O +
to O +
7.1 O +
+ O -
/- O -

0.1 O +
kPa O -
) O +
for O +
129 O +
+ O -
/- O -

11 O +
min O +
in O +
the O +
enflurane O +
( O -
E O -
) O +
group O -
, O +
and O +
from O +
80 O +
+ O -
/- O -

4 O +
to O +
49 O +
+ O -
/- O -

1 O +
mmHg O +
( O -
10.7 O +
+ O -
/- O -

0.5 O +
to O +
6.5 O +
+ O -
/- O -

0.1 O +
kPa O -
) O +
for O +
135 O +
+ O -
/- O -

15 O +
min O +
in O +
the O +
isoflurane O +
( O -
I O -
) O +
group O -
. O -

The O +
mean O +
H O +
concentration O +
during O +
hypotension U-Disease +
in O +
the O +
inspiratory O +
gas O +
was O +
0.7 O +
+ O -
/- O -

0.1 O +
vol% O -
, O +
the O +
mean O +
E O +
concentration O +
1.6 O +
+ O -
/- O -

0.2 O +
vol% O -
, O +
and O +
the O +
mean O +
I O +
concentration O +
1.0 O +
+ O -
/- O -

0.1 O +
vol% O -
. O -

In O +
addition O -
, O +
the O +
patients O +
received O +
fentanyl O +
and O +
d O -
- O -
tubocurarine O -
. O -

The O +
initial O +
dose O +
of O +
labetalol O +
for O +
lowering O +
blood O +
pressure O +
was O +
similar O -
, O +
0.52 O -
- O -
0.59 O +
mg O -
/ O -
kg O -
, O +
in O +
all O +
the O +
groups O -
. O -

During O +
hypotension U-Disease -
, O +
the O +
heart O +
rate O +
was O +
stable O +
without O +
tachy- B-Disease +
or I-Disease +
bradycardia L-Disease -
. O -

The O +
operating O +
conditions O +
regarding O +
bleeding U-Disease +
were O +
estimated O +
in O +
a O +
double O -
- O -
blind O +
manner O -
, O +
and O +
did O +
not O +
differ O +
significantly O +
between O +
the O +
groups O -
. O -

During O +
hypotension U-Disease -
, O +
the O +
serum O +
creatinine O +
concentration O +
rose O +
significantly O +
in O +
all O +
groups O +
from O +
the O +
values O +
before O +
hypotension U-Disease +
and O +
returned O +
postoperatively O +
to O +
the O +
initial O +
level O +
in O +
the O +
other O +
groups O -
, O +
except O +
the O +
isoflurane O +
group O -
. O -

After O +
hypotension U-Disease +
there O +
was O +
no O +
rebound O +
phenomenon O +
in O +
either O +
blood O +
pressure O +
or O +
heart O +
rate O -
. O -

These O +
results O +
indicate O +
that O +
labetalol O +
induces O +
easily O +
adjustable O +
hypotension U-Disease +
without O +
compensatory O +
tachycardia U-Disease +
and O +
rebound O +
hypertension U-Disease -
. O -

Convulsion U-Disease +
following O +
intravenous O +
fluorescein O +
angiography O -
. O -

Tonic B-Disease -
- I-Disease -
clonic I-Disease +
seizures L-Disease +
followed O +
intravenous O +
fluorescein O +
injection O +
for O +
fundus O +
angiography O +
in O +
a O +
47-year O -
- O -
old O +
male O -
. O -

Despite O +
precautions O +
this O +
adverse O +
reaction O +
recurred O +
on O +
re O -
- O -
exposure O +
to O +
intravenous O +
fluorescein O -
. O -

Pharmacology O +
of O +
ACC-9653 O +
( O -
phenytoin O +
prodrug O -
) O -
. O -

ACC-9653 O -
, O +
the O +
disodium O +
phosphate O +
ester O +
of O +
3-hydroxymethyl-5,5-diphenylhydantoin O -
, O +
is O +
a O +
prodrug O +
of O +
phenytoin O +
with O +
advantageous O +
physicochemical O +
properties O -
. O -

ACC-9653 O +
is O +
rapidly O +
converted O +
enzymatically O +
to O +
phenytoin O +
in O +
vivo O -
. O -

ACC-9653 O +
and O +
phenytoin O +
sodium O +
have O +
equivalent O +
anticonvulsant O +
activity O +
against O +
seizures U-Disease +
induced O +
by O +
maximal O +
electroshock O +
( O -
MES O -
) O +
in O +
mice O +
following O +
i.p O -
. O -
, O +
oral O -
, O +
or O +
i.v O -
. O -

administration O -
. O -

The O +
ED50 O +
doses O +
were O +
16 O +
mg O -
/ O -
kg O +
for O +
i.v O -
. O -

ACC-9653 O +
and O +
8 O +
mg O -
/ O -
kg O +
for O +
i.v O -
. O -

phenytoin O +
sodium O -
. O -

ACC-9653 O +
and O +
phenytoin O +
sodium O +
have O +
similar O +
antiarrhythmic O +
activity O +
against O +
ouabain O -
- O -
induced O +
ventricular B-Disease +
tachycardia L-Disease +
in O +
anesthetized O +
dogs O -
. O -

The O +
total O +
doses O +
of O +
ACC-9653 O +
or O +
phenytoin O +
sodium O +
necessary O +
to O +
convert O +
the O +
arrhythmia U-Disease +
to O +
a O +
normal O +
sinus O +
rhythm O +
were O +
24 O +
+ O -
/- O -

6 O +
and O +
14 O +
+ O -
/- O -

3 O +
mg O -
/ O -
kg O -
, O +
respectively O -
. O -

Only O +
phenytoin O +
sodium O +
displayed O +
in O +
vitro O +
antiarrhythmic O +
activity O +
against O +
strophanthidin O -
- O -
induced O +
arrhythmias U-Disease +
in O +
guinea O +
pig O +
right O +
atria O -
. O -

In O +
anesthetized O +
dogs O -
, O +
a O +
high O +
dose O +
of O +
ACC-9653 O +
( O -
31 O +
mg O -
/ O -
kg O -
) O +
was O +
infused O +
over O +
15 O -
, O +
20 O -
, O +
and O +
30 O +
min O +
and O +
the O +
responses O +
were O +
compared O +
to O +
an O +
equimolar O +
dose O +
of O +
phenytoin O +
sodium O +
( O -
21 O +
mg O -
/ O -
kg O -
) O -
. O -

The O +
ACC-9653 O +
and O +
phenytoin O +
sodium O +
treatments O +
produced O +
similar O +
marked O +
reductions O +
in O +
diastolic O +
blood O +
pressure O +
and O +
contractile O +
force O +
( O -
LVdP O -
/ O -
dt O -
) O -
. O -

The O +
maximum O +
effects O +
of O +
each O +
treatment O +
occurred O +
at O +
the O +
time O +
of O +
maximum O +
phenytoin O +
sodium O +
levels O -
. O -

Acute O +
toxicity U-Disease +
studies O +
of O +
ACC-9653 O +
and O +
phenytoin O +
sodium O +
were O +
carried O +
out O +
in O +
mice O -
, O +
rats O -
, O +
rabbits O -
, O +
and O +
dogs O +
by O +
i.v O -
. O -
, O +
i.m O -
. O -
, O +
and O +
i.p O -
. O -

routes O +
of O +
administration O -
. O -

The O +
systemic O +
toxic O +
signs O +
of O +
both O +
agents O +
were O +
similar O +
and O +
occurred O +
at O +
approximately O +
equivalent O +
doses O -
. O -

Importantly O -
, O +
the O +
local O +
irritation O +
of O +
ACC-9653 O +
was O +
markedly O +
less O +
than O +
phenytoin O +
sodium O +
following O +
i.m O -
. O -

administration. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Tachyphylaxis O +
to O +
systemic O +
but O +
not O +
to O +
airway O +
responses O +
during O +
prolonged O +
therapy O +
with O +
high O +
dose O +
inhaled O +
salbutamol O +
in O +
asthmatics U-Disease -
. O -

High O +
doses O +
of O +
inhaled O +
salbutamol O +
produce O +
substantial O +
improvements O +
in O +
airway O +
response O +
in O +
patients O +
with O +
asthma U-Disease -
, O +
and O +
are O +
associated O +
with O +
dose O -
- O -
dependent O +
systemic O +
beta O -
- O -
adrenoceptor O +
responses O -
. O -

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
whether O +
tachyphylaxis O +
occurs O +
during O +
prolonged O +
treatment O +
with O +
high O +
dose O +
inhaled O +
salbutamol O -
. O -

Twelve O +
asthmatic U-Disease +
patients O +
( O -
FEV1 O -
, O +
81 O +
+ O -
/- O -

4 O -
% O +
predicted O -
) O -
, O +
requiring O +
only O +
occasional O +
inhaled O +
beta O -
- O -
agonists O +
as O +
their O +
sole O +
therapy O -
, O +
were O +
given O +
a O +
14-day O +
treatment O +
with O +
high O +
dose O +
inhaled O +
salbutamol O +
( O -
HDS O -
) O -
, O +
4,000 O +
micrograms O +
daily O -
, O +
low O +
dose O +
inhaled O +
salbutamol O +
( O -
LDS O -
) O -
, O +
800 O +
micrograms O +
daily O -
, O +
or O +
placebo O +
( O -
PI O -
) O +
by O +
metered O -
- O -
dose O +
inhaler O +
in O +
a O +
double O -
- O -
blind O -
, O +
randomized O +
crossover O +
design O -
. O -

During O +
the O +
14-day O +
run O -
- O -
in O +
and O +
during O +
washout O +
periods O -
, O +
inhaled O +
beta O -
- O -
agonists O +
were O +
withheld O +
and O +
ipratropium O +
bromide O +
was O +
substituted O +
for O +
rescue O +
purposes O -
. O -

At O +
the O +
end O +
of O +
each O +
14-day O +
treatment O -
, O +
a O +
dose O -
- O -
response O +
curve O +
( O -
DRC O -
) O +
was O +
performed O -
, O +
and O +
airway O +
( O -
FEV1 O -
, O +
FEF25 O -
- O -
75 O -
) O +
chronotropic O +
( O -
HR O -
) O -
, O +
tremor U-Disease -
, O +
and O +
metabolic O +
( O -
K O -
, O +
Glu O -
) O +
responses O +
were O +
measured O +
at O +
each O +
step O +
( O -
from O +
100 O +
to O +
4,000 O +
micrograms O -
) O -
. O -

Treatment O +
had O +
no O +
significant O +
effect O +
on O +
baseline O +
values O -
. O -

There O +
were O +
dose O -
- O -
dependent O +
increases O +
in O +
FEV1 O +
and O +
FEF25 O -
- O -
75 O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
and O +
pretreatment O +
with O +
HDS O +
did O +
not O +
displace O +
the O +
DRC O +
to O +
the O +
right O -
. O -

DRC O +
for O +
HR O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
K O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
and O +
Glu O +
( O -
p O +
less O +
than O +
0.005 O -
) O +
were O +
attenuated O +
after O +
treatment O +
with O +
HDS O +
compared O +
with O +
PI O -
. O -

There O +
were O +
also O +
differences O +
between O +
HDS O +
and O +
LDS O +
for O +
HR O +
( O -
p O +
less O +
than O +
0.001 O -
) O +
and O +
Glu O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
responses O -
. O -

Frequency O +
and O +
severity O +
of O +
subjective O +
adverse O +
effects O +
were O +
also O +
reduced O +
after O +
HDS O -
: O +
tremor U-Disease +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
palpitations U-Disease +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Phenytoin O +
induced O +
fatal O +
hepatic B-Disease +
injury L-Disease -
. O -

A O +
61 O +
year O +
old O +
female O +
developed O +
fatal O +
hepatic B-Disease +
failure L-Disease +
after O +
phenytoin O +
administration O -
. O -

A O +
typical O +
multisystem O +
clinical O +
pattern O +
precedes O +
the O +
manifestations O +
of O +
hepatic B-Disease +
injury L-Disease -
. O -

The O +
hematologic O -
, O +
biochemical O +
and O +
pathologic O +
features O +
indicate O +
a O +
mixed O +
hepatocellular B-Disease +
damage L-Disease +
due O +
to O +
drug B-Disease +
hypersensitivity L-Disease -
. O -

In O +
a O +
patient O +
receiving O +
phenytoin O +
who O +
presents O +
a O +
viral O -
- O -
like O +
illness O -
, O +
early O +
recognition O +
and O +
discontinuation O +
of O +
the O +
drug O +
are O +
mandatory O -
. O -

Treatment O +
of O +
lethal O +
pertussis O +
vaccine O +
reaction O +
with O +
histamine O +
H1 O +
antagonists O -
. O -

We O +
studied O +
mortality O +
after O +
pertussis U-Disease +
immunization O +
in O +
the O +
mouse O -
. O -

Without O +
treatment O -
, O +
73 O +
of O +
92 O +
animals O +
( O -
80 O -
% O -
) O +
died O +
after O +
injection O +
of O +
bovine O +
serum O +
albumin O +
( O -
BSA O -
) O +
on O +
day O +
+ O -
7 O +
of O +
pertussis U-Disease +
immunization O -
. O -

After O +
pretreatment O +
with O +
3 O +
mg O +
of O +
cyproheptadine O -
, O +
2 O +
mg O +
mianserin O -
, O +
or O +
2 O +
mg O +
chlorpheniramine O -
, O +
only O +
5 O +
of O +
105 O +
animals O +
( O -
5 O -
% O -
) O +
died O +
after O +
receiving O +
BSA O +
on O +
day O +
+ O -
7 O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O -

Blockade O +
of O +
histamine O +
H1 O +
receptors O +
may O +
reduce O +
mortality O +
in O +
pertussis U-Disease +
immunization O -
- O -
induced O +
encephalopathy U-Disease +
in O +
mice O -
. O -

Support O +
for O +
adrenaline O -
- O -
hypertension U-Disease +
hypothesis O -
: O +
18 O +
hour O +
pressor O +
effect O +
after O +
6 O +
hours O +
adrenaline O +
infusion O -
. O -

In O +
a O +
double O +
blind O -
, O +
crossover O +
study O +
6 O +
h O +
infusions O +
of O +
adrenaline O +
( O -
15 O +
ng O -
/ O -
kg O -
/ O -
min O -
; O +
1 O +
ng O +
= O +
5.458 O +
pmol O -
) O -
, O +
noradrenaline O +
( O -
30 O +
ng O -
/ O -
kg O -
/ O -
min O -
; O +
1 O +
ng O +
= O +
5.911 O +
pmol O -
) O -
, O +
and O +
a O +
5 O -
% O +
dextrose O +
solution O +
( O -
5.4 O +
ml O -
/ O -
h O -
) O -
, O +
were O +
given O +
to O +
ten O +
healthy O +
volunteers O +
in O +
random O +
order O +
2 O +
weeks O +
apart O -
. O -

By O +
means O +
of O +
intra O -
- O -
arterial O +
ambulatory O +
monitoring O +
the O +
haemodynamic O +
effects O +
were O +
followed O +
for O +
18 O +
h O +
after O +
the O +
infusions O +
were O +
stopped O -
. O -

Adrenaline O -
, O +
but O +
not O +
noradrenaline O -
, O +
caused O +
a O +
delayed O +
and O +
protracted O +
pressor O +
effect O -
. O -

Over O +
the O +
total O +
postinfusion O +
period O +
systolic O +
and O +
diastolic O +
arterial O +
pressure O +
were O +
6 O +
( O -
SEM O +
2 O -
) O -
% O +
and O +
7 O +
( O -
2 O -
) O -
% O -
, O +
respectively O -
, O +
higher O +
than O +
after O +
dextrose O +
infusion O +
( O -
ANOVA O -
, O +
p O +
less O +
than O +
0.001 O -
) O -
. O -

Thus O -
, O +
" O -
stress O -
" O +
levels O +
of O +
adrenaline O +
( O -
230 O +
pg O -
/ O -
ml O -
) O +
for O +
6 O +
h O +
cause O +
a O +
delayed O +
and O +
protracted O +
pressor O +
effect O -
. O -

These O +
findings O +
are O +
strong O +
support O +
for O +
the O +
adrenaline O -
- O -
hypertension U-Disease +
hypothesis O +
in O +
man O -
. O -

Effect O +
of O +
alkylxanthines O +
on O +
gentamicin O -
- O -
induced O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
in O +
the O +
rat O -
. O -

Adenosine O +
antagonists O +
have O +
been O +
previously O +
shown O +
to O +
be O +
of O +
benefit O +
in O +
some O +
ischaemic U-Disease +
and O +
nephrotoxic U-Disease +
models O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
( O -
ARF U-Disease -
) O -
. O -

In O +
the O +
present O +
study O -
, O +
the O +
effects O +
of O +
three O +
alkylxanthines O +
with O +
different O +
potencies O +
as O +
adenosine O +
antagonists O +
8-phenyltheophylline O -
, O +
theophylline O +
and O +
enprofylline O -
, O +
were O +
examined O +
in O +
rats O +
developing O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
after O +
4 O +
daily O +
injections O +
of O +
gentamicin O +
( O -
200 O +
mg O +
kg-1 O -
) O -
. O -

Renal O +
function O +
was O +
assessed O +
by O +
biochemical O +
( O -
plasma O +
urea O +
and O +
creatinine O -
) O -
, O +
functional O +
( O -
urine O +
analysis O +
and O +
[ O -
3H O -
] O -
inulin O +
and O +
[ O -
14C O -
] O -
p O -
- O -
aminohippuric O +
acid O +
clearances O -
) O +
and O +
morphological O +
( O -
degree O +
of O +
necrosis U-Disease -
) O +
indices O -
. O -

The O +
various O +
drug O +
treatments O +
produced O +
improvements O +
in O +
some O -
, O +
but O +
not O +
all O -
, O +
measurements O +
of O +
renal O +
function O -
. O -

However O -
, O +
any O +
improvement O +
produced O +
by O +
drug O +
treatment O +
was O +
largely O +
a O +
result O +
of O +
a O +
beneficial O +
effect O +
exerted O +
by O +
its O +
vehicle O +
( O -
polyethylene O +
glycol O +
and O +
NaOH O -
) O -
. O -

The O +
lack O +
of O +
any O +
consistent O +
protective O +
effect O +
noted O +
with O +
the O +
alkylxanthines O +
tested O +
in O +
the O +
present O +
study O +
indicates O +
that O +
adenosine O +
plays O +
little O -
, O +
if O +
any O -
, O +
pathophysiological O +
role O +
in O +
gentamicin O -
- O -
induced O +
ARF U-Disease -
. O -

Adverse O +
ocular O +
reactions O +
possibly O +
associated O +
with O +
isotretinoin O -
. O -

A O +
total O +
of O +
261 O +
adverse O +
ocular O +
reactions O +
occurred O +
in O +
237 O +
patients O +
who O +
received O +
isotretinoin O -
, O +
a O +
commonly O +
used O +
drug O +
in O +
the O +
treatment O +
of O +
severe O +
cystic O +
acne U-Disease -
. O -

Blepharoconjunctivitis U-Disease -
, O +
subjective O +
complaints O +
of O +
dry B-Disease +
eyes L-Disease -
, O +
blurred B-Disease +
vision L-Disease -
, O +
contact O +
lens O +
intolerance O -
, O +
and O +
photodermatitis U-Disease +
are O +
reversible O +
side O +
effects O -
. O -

More O +
serious O +
ocular O +
adverse O +
reactions O +
include O +
papilledema U-Disease -
, O +
pseudotumor B-Disease +
cerebri L-Disease -
, O +
and O +
white O +
or O +
gray O +
subepithelial O +
corneal B-Disease +
opacities L-Disease -
; O +
all O +
of O +
these O +
are O +
reversible O +
if O +
the O +
drug O +
is O +
discontinued O -
. O -

Reported O +
cases O +
of O +
decreased O +
dark O +
adaptation O +
are O +
under O +
investigation O -
. O -

Isotretinoin O +
is O +
contraindicated O +
in O +
pregnancy O +
because O +
of O +
the O +
many O +
reported O +
congenital B-Disease +
abnormalities L-Disease +
after O +
maternal O +
use O +
( O -
including O +
microphthalmos U-Disease -
, O +
orbital O +
hypertelorism U-Disease -
, O +
and O +
optic B-Disease +
nerve I-Disease +
hypoplasia L-Disease -
) O -
. O -

Procaterol O +
and O +
terbutaline O +
in O +
bronchial B-Disease +
asthma L-Disease -
. O -

A O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
cross O -
- O -
over O +
study O -
. O -

Procaterol O -
, O +
a O +
new O +
beta-2 O +
adrenoceptor O +
stimulant O -
, O +
was O +
studied O +
in O +
a O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
cross O -
- O -
over O +
trial O +
in O +
patients O +
with O +
bronchial B-Disease +
asthma L-Disease -
. O -

Oral O +
procaterol O +
50 O +
micrograms O +
b.d O -
. O -
, O +
procaterol O +
100 O +
micrograms O +
b.d O -
. O -
, O +
and O +
terbutaline O +
5 O +
mg O +
t.i.d O -
. O -
, O +
were O +
compared O +
when O +
given O +
randomly O +
in O +
1-week O +
treatment O +
periods O -
. O -

The O +
best O +
clinical O +
effect O +
was O +
found O +
with O +
terbutaline O -
. O -

Both O +
anti O -
- O -
asthmatic U-Disease +
and O +
tremorgenic U-Disease +
effects O +
of O +
procaterol O +
were O +
dose O -
- O -
related O -
. O -

Procaterol O +
appeared O +
effective O +
in O +
the O +
doses O +
tested O -
, O +
and O +
a O +
twice O +
daily O +
regimen O +
would O +
appear O +
to O +
be O +
suitable O +
with O +
this O +
drug O -
. O -

Subacute O +
effects O +
of O +
propranolol O +
and O +
B O +
24 O -
/ O -
76 O +
on O +
isoproterenol O -
- O -
induced O +
rat O +
heart B-Disease +
hypertrophy L-Disease +
in O +
correlation O +
with O +
blood O +
pressure O -
. O -

We O +
compared O +
the O +
potential O +
beta O -
- O -
receptor O +
blocker O -
, O +
B O +
24 O -
/ O -
76 O +
i.e. O +
1- O -
( O -
2,4-dichlorophenoxy O -
) O -
-3 O -
[ O -
2 O -
- O -
3,4-dimethoxyphenyl O -
) O -
ethanolamino O -
] O -
-prop O +
an-2-ol O -
, O +
which O +
is O +
characterized O +
by O +
beta O +
1-adrenoceptor O +
blocking O +
and O +
beta O +
2-adrenoceptor O +
stimulating O +
properties O +
with O +
propranolol O -
. O -

The O +
studies O +
were O +
performed O +
using O +
an O +
experimental O +
model O +
of O +
isoproterenol O -
- O -
induced O +
heart B-Disease +
hypertrophy L-Disease +
in O +
rats O -
. O -

A O +
correlation O +
of O +
the O +
blood O +
pressure O +
was O +
neither O +
found O +
in O +
the O +
development O +
nor O +
in O +
the O +
attempt O +
to O +
suppress O +
the O +
development O +
of O +
heart B-Disease +
hypertrophy L-Disease +
with O +
the O +
two O +
beta O -
- O -
receptor O +
blockers O -
. O -

Both O +
beta O -
- O -
blockers O +
influenced O +
the O +
development O +
of O +
hypertrophy U-Disease +
to O +
a O +
different O -
, O +
but O +
not O +
reproducible O +
extent O -
. O -

It O +
was O +
possible O +
to O +
suppress O +
the O +
increased O +
ornithine O +
decarboxylase O +
activity O +
with O +
both O +
beta O -
- O -
blockers O +
in O +
hypertrophied B-Disease +
hearts L-Disease -
, O +
but O +
there O +
was O +
no O +
effect O +
on O +
the O +
heart O +
mass O -
. O -

Neither O +
propranolol O +
nor O +
B O +
24 O -
/ O -
76 O +
could O +
stop O +
the O +
changes O +
in O +
the O +
characteristic O +
myosin O +
isoenzyme O +
pattern O +
of O +
the O +
hypertrophied U-Disease +
rat O +
heart O -
. O -

Thus O -
, O +
the O +
investigations O +
did O +
not O +
provide O +
any O +
evidence O +
that O +
the O +
beta O -
- O -
receptor O +
blockers O +
propranolol O +
and O +
B O +
24 O -
/ O -
76 O +
have O +
the O +
potency O +
to O +
prevent O +
isoproterenol O +
from O +
producing O +
heart B-Disease +
hypertrophy L-Disease -
. O -

Increased O +
anxiogenic O +
effects O +
of O +
caffeine O +
in O +
panic B-Disease +
disorders L-Disease -
. O -

The O +
effects O +
of O +
oral O +
administration O +
of O +
caffeine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
on O +
behavioral O +
ratings O -
, O +
somatic O +
symptoms O -
, O +
blood O +
pressure O +
and O +
plasma O +
levels O +
of O +
3-methoxy-4-hydroxyphenethyleneglycol O +
( O -
MHPG O -
) O +
and O +
cortisol O +
were O +
determined O +
in O +
17 O +
healthy O +
subjects O +
and O +
21 O +
patients O +
meeting O +
DSM O -
- O -
III O +
criteria O +
for O +
agoraphobia U-Disease +
with O +
panic B-Disease +
attacks L-Disease +
or O +
panic B-Disease +
disorder L-Disease -
. O -

Caffeine O +
produced O +
significantly O +
greater O +
increases O +
in O +
subject O -
- O -
rated O +
anxiety U-Disease -
, O +
nervousness O -
, O +
fear O -
, O +
nausea U-Disease -
, O +
palpitations U-Disease -
, O +
restlessness U-Disease -
, O +
and O +
tremors U-Disease +
in O +
the O +
patients O +
compared O +
with O +
healthy O +
subjects O -
. O -

In O +
the O +
patients O -
, O +
but O +
not O +
the O +
healthy O +
subjects O -
, O +
these O +
symptoms O +
were O +
significantly O +
correlated O +
with O +
plasma O +
caffeine O +
levels O -
. O -

Seventy O -
- O -
one O +
percent O +
of O +
the O +
patients O +
reported O +
that O +
the O +
behavioral O +
effects O +
of O +
caffeine O +
were O +
similar O +
to O +
those O +
experienced O +
during O +
panic B-Disease +
attacks L-Disease -
. O -

Caffeine O +
did O +
not O +
alter O +
plasma O +
MHPG O +
levels O +
in O +
either O +
the O +
healthy O +
subjects O +
or O +
patients O -
. O -

Caffeine O +
increased O +
plasma O +
cortisol O +
levels O +
equally O +
in O +
the O +
patient O +
and O +
healthy O +
groups O -
. O -

Because O +
caffeine O +
is O +
an O +
adenosine O +
receptor O +
antagonist O -
, O +
these O +
results O +
suggest O +
that O +
some O +
panic B-Disease +
disorder L-Disease +
patients O +
may O +
have O +
abnormalities B-Disease +
in I-Disease +
neuronal I-Disease +
systems L-Disease +
involving O +
adenosine O -
. O -

Patients O +
with O +
anxiety B-Disease +
disorders L-Disease +
may O +
benefit O +
by O +
avoiding O +
caffeine O -
- O -
containing O +
foods O +
and O +
beverages O -
. O -

Comparison O +
of O +
the O +
effect O +
of O +
oxitropium O +
bromide O +
and O +
of O +
slow O -
- O -
release O +
theophylline O +
on O +
nocturnal O +
asthma U-Disease -
. O -

The O +
effects O +
of O +
a O +
new O +
inhaled O +
antimuscarinic O +
drug O -
, O +
oxitropium O +
bromide O -
, O +
and O +
of O +
a O +
slow O -
- O -
release O +
theophylline O +
preparation O +
upon O +
nocturnal O +
asthma U-Disease +
were O +
compared O +
in O +
a O +
placebo O -
- O -
controlled O +
double O -
- O -
blind O +
study O -
. O -

Two O +
samples O +
were O +
studied O -
: O +
12 O +
patients O +
received O +
oxitropium O +
at O +
600 O +
micrograms O +
( O -
6 O +
subjects O -
) O +
or O +
at O +
400 O +
micrograms O +
t.i.d O -
. O -

( O -
6 O +
subjects O -
) O +
whereas O +
11 O +
received O +
theophylline O +
at O +
300 O +
mg O +
b.i.d O -
. O -

Morning O +
dipping O -
, O +
assessed O +
by O +
the O +
fall O +
in O +
peak O +
flow O +
overnight O -
, O +
was O +
significantly O +
reduced O +
in O +
the O +
periods O +
when O +
either O +
active O +
drug O +
was O +
taken O -
, O +
whereas O +
no O +
difference O +
was O +
noticed O +
during O +
the O +
placebo O +
administration O -
. O -

No O +
significant O +
difference O +
was O +
noticed O +
between O +
results O +
obtained O +
with O +
either O +
active O +
drug O -
, O +
as O +
well O +
as O +
with O +
either O +
dosage O +
of O +
oxitropium O -
. O -

No O +
subject O +
reported O +
side O +
effects O +
of O +
oxitropium O -
, O +
as O +
compared O +
to O +
three O +
subjects O +
reporting O +
nausea U-Disease -
, O +
vomiting U-Disease +
and O +
tremors U-Disease +
after O +
theophylline O -
. O -

Oxitropium O +
proves O +
to O +
be O +
a O +
valuable O +
alternative O +
to O +
theophylline O +
in O +
nocturnal O +
asthma U-Disease -
, O +
since O +
it O +
is O +
equally O +
potent O -
, O +
safer O +
and O +
does O +
not O +
require O +
the O +
titration O +
of O +
dosage O -
. O -

Penicillin O +
anaphylaxis U-Disease -
. O -

A O +
case O +
of O +
oral O +
penicillin O +
anaphylaxis U-Disease +
is O +
described O -
, O +
and O +
the O +
terminology O -
, O +
occurrence O -
, O +
clinical O +
manifestations O -
, O +
pathogenesis O -
, O +
prevention O -
, O +
and O +
treatment O +
of O +
anaphylaxis U-Disease +
are O +
reviewed O -
. O -

Emergency O +
physicians O +
should O +
be O +
aware O +
of O +
oral O +
penicillin O +
anaphylaxis U-Disease +
in O +
order O +
to O +
prevent O +
its O +
occurrence O +
by O +
prescribing O +
the O +
antibiotic O +
judiciously O +
and O +
knowledgeably O +
and O +
to O +
offer O +
optimal O +
medical O +
therapy O +
once O +
this O +
life O -
- O -
threatening O +
reaction O +
has O +
begun O -
. O -

Reversible O +
valproic O +
acid O -
- O -
induced O +
dementia U-Disease -
: O +
a O +
case O +
report O -
. O -

Reversible O +
valproic O +
acid O -
- O -
induced O +
dementia U-Disease +
was O +
documented O +
in O +
a O +
21-year O -
- O -
old O +
man O +
with O +
epilepsy U-Disease +
who O +
had O +
a O +
3-year O +
history O +
of O +
insidious O +
progressive O +
decline O +
in O +
global O +
cognitive O +
abilities O +
documented O +
by O +
serial O +
neuropsychological O +
studies O -
. O -

Repeat O +
neuropsychological O +
testing O +
7 O +
weeks O +
after O +
discontinuation O +
of O +
the O +
drug O +
revealed O +
dramatic O +
improvement O +
in O +
IQ O -
, O +
memory O -
, O +
naming O -
, O +
and O +
other O +
tasks O +
commensurate O +
with O +
clinical O +
recovery O +
in O +
his O +
intellectual O +
capacity O -
. O -

Possible O +
pathophysiological O +
mechanisms O +
which O +
may O +
have O +
been O +
operative O +
in O +
this O +
case O +
include O -
: O +
a O +
direct O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
toxic O +
effect O +
of O +
valproic O +
acid O -
; O +
a O +
paradoxical O +
epileptogenic O +
effect O +
secondary O +
to O +
the O +
drug O -
; O +
and O +
an O +
indirect O +
CNS O +
toxic O +
effect O +
mediated O +
through O +
valproic O +
acid O -
- O -
induced O +
hyperammonemia U-Disease -
. O -

Reversal O +
of O +
scopolamine O -
- O -
induced O +
amnesia U-Disease +
of O +
passive O +
avoidance O +
by O +
pre- O +
and O +
post O -
- O -
training O +
naloxone O -
. O -

In O +
a O +
series O +
of O +
five O +
experiments O -
, O +
the O +
modulating O +
role O +
of O +
naloxone O +
on O +
a O +
scopolamine O -
- O -
induced O +
retention B-Disease +
deficit L-Disease +
in O +
a O +
passive O +
avoidance O +
paradigm O +
was O +
investigated O +
in O +
mice O -
. O -

Scopolamine O -
, O +
but O +
not O +
methyl O +
scopolamine O +
( O -
1 O +
and O +
3 O +
mg O -
/ O -
kg O -
) O -
, O +
induced O +
an O +
amnesia U-Disease +
as O +
measured O +
by O +
latency O +
and O +
duration O +
parameters O -
. O -

Naloxone O +
( O -
0.3 O -
, O +
1 O -
, O +
3 O -
, O +
and O +
10 O +
mg O -
/ O -
kg O -
) O +
injected O +
prior O +
to O +
training O +
attenuated O +
the O +
retention B-Disease +
deficit L-Disease +
with O +
a O +
peak O +
of O +
activity O +
at O +
3 O +
mg O -
/ O -
kg O -
. O -

The O +
effect O +
of O +
naloxone O +
could O +
be O +
antagonized O +
with O +
morphine O +
( O -
1 O -
, O +
3 O -
, O +
and O +
10 O +
mg O -
/ O -
kg O -
) O -
, O +
demonstrating O +
the O +
opioid O +
specificity O +
of O +
the O +
naloxone O +
effect O -
. O -

Post O -
- O -
training O +
administration O +
of O +
naloxone O +
( O -
3 O +
mg O -
/ O -
kg O -
) O +
as O +
a O +
single O +
or O +
as O +
a O +
split O +
dose O +
also O +
attenuated O +
the O +
scopolamine O -
- O -
induced O +
amnesia U-Disease -
. O -

Control O +
experiments O +
indicated O +
that O +
neither O +
an O +
increase O +
in O +
pain U-Disease +
sensitivity O +
( O -
pre O -
- O -
training O +
naloxone O -
) O +
nor O +
an O +
induced O +
aversive O +
state O +
( O -
post O -
- O -
training O +
naloxone O -
) O +
appear O +
to O +
be O +
responsible O +
for O +
the O +
influence O +
of O +
naloxone O +
on O +
the O +
scopolamine O -
- O -
induced O +
retention B-Disease +
deficit L-Disease -
. O -

These O +
results O +
extend O +
previous O +
findings O +
implicating O +
a O +
cholinergic O -
- O -
opioid O +
interaction O +
in O +
memory O +
processes O -
. O -

A O +
possible O +
mechanism O +
for O +
this O +
interaction O +
involving O +
the O +
septo O -
- O -
hippocampal O +
cholinergic O +
pathway O +
is O +
discussed O -
. O -

Electron O +
microscopic O +
investigations O +
of O +
the O +
cyclophosphamide O -
- O -
induced O +
lesions B-Disease +
of I-Disease +
the I-Disease +
urinary I-Disease +
bladder L-Disease +
of O +
the O +
rat O +
and O +
their O +
prevention O +
by O +
mesna O -
. O -

Fully O +
developed O +
cyclophosphamide O -
- O -
induced O +
cystitis U-Disease +
is O +
characterized O +
by O +
nearly O +
complete O +
detachment O +
of O +
the O +
urothelium O -
, O +
severe O +
submucosal O +
edema U-Disease +
owing O +
to O +
damage O +
to O +
the O +
microvascular O +
bed O +
and O +
focal O +
muscle O +
necroses U-Disease -
. O -

The O +
initial O +
response O +
to O +
the O +
primary O +
attack O +
by O +
the O +
cyclophosphamide O +
metabolites O +
seems O +
to O +
be O +
fragmentation O +
of O +
the O +
luminal O +
membrane O -
. O -

This O +
damages O +
the O +
cellular O +
barrier O +
against O +
the O +
hypertonic O +
urine O -
. O -

Subsequent O +
breaks O +
in O +
the O +
lateral O +
cell O +
membranes O +
of O +
the O +
superficial O +
cells O +
and O +
in O +
all O +
the O +
plasma O +
membranes O +
of O +
the O +
intermediate O +
and O +
basal O +
cells O -
, O +
intercellular O +
and O +
intracellular O +
edema U-Disease +
and O +
disintegration O +
of O +
the O +
desmosomes O +
and O +
hemidesmosomes O +
lead O +
to O +
progressive O +
degeneration O +
and O +
detachment O +
of O +
the O +
epithelial O +
cells O +
with O +
exposure O +
and O +
splitting O +
of O +
the O +
basal O +
membrane O -
. O -

The O +
morphological O +
changes O +
of O +
the O +
endothelial O +
cells O -
, O +
which O +
become O +
more O +
pronounced O +
in O +
the O +
later O +
stages O +
of O +
the O +
experiment O -
, O +
the O +
involvement O +
of O +
blood O +
vessels O +
regardless O +
of O +
their O +
diameter O +
and O +
the O +
location O -
- O -
dependent O +
extent O +
of O +
the O +
damage O +
indicate O +
a O +
direct O +
type O +
of O +
damage O +
which O +
is O +
preceded O +
by O +
a O +
mediator O -
- O -
induced O +
increase O +
in O +
permeability O -
, O +
the O +
morphological O +
correlate O +
of O +
which O +
is O +
the O +
formation O +
of O +
gaps O +
in O +
the O +
interendothelial O +
cell O +
connections O +
on O +
the O +
venules O -
. O -

These O +
changes O +
can O +
be O +
effectively O +
prevented O +
by O +
mesna O -
. O -

The O +
only O +
sign O +
of O +
a O +
possible O +
involvement O +
is O +
the O +
increase O +
in O +
the O +
number O +
of O +
specific O +
granules O +
with O +
a O +
presumed O +
lysosomal O +
function O +
in O +
the O +
superficial O +
cells O -
. O -

Increase O +
in O +
intragastric O +
pressure O +
during O +
suxamethonium O -
- O -
induced O +
muscle B-Disease +
fasciculations L-Disease +
in O +
children O -
: O +
inhibition O +
by O +
alfentanil O -
. O -

Changes O +
in O +
intragastric O +
pressure O +
after O +
the O +
administration O +
of O +
suxamethonium O +
1.5 O +
mg O +
kg-1 O +
i.v O -
. O +
were O +
studied O +
in O +
32 O +
children O +
( O -
mean O +
age O +
6.9 O +
yr O -
) O +
pretreated O +
with O +
either O +
physiological O +
saline O +
or O +
alfentanil O +
50 O +
micrograms O +
kg-1 O -
. O -

Anaesthesia O +
was O +
induced O +
with O +
thiopentone O +
5 O +
mg O +
kg-1 O -
. O -

The O +
incidence O +
and O +
intensity O +
of O +
muscle B-Disease +
fasciculations L-Disease +
caused O +
by O +
suxamethonium O +
were O +
significantly O +
greater O +
in O +
the O +
control O +
than O +
in O +
the O +
alfentanil O +
group O -
. O -

The O +
intragastric O +
pressure O +
during O +
muscle B-Disease +
fasciculations L-Disease +
was O +
significantly O +
higher O +
in O +
the O +
control O +
group O +
( O -
16 O +
+ O -
/- O -

0.7 O +
( O -
SEM O -
) O +
cm O +
H2O O -
) O +
than O +
in O +
the O +
alfentanil O +
group O +
( O -
7.7 O +
+ O -
/- O -

1.5 O +
( O -
SEM O -
) O +
cm O +
H2O O -
) O -
. O -

The O +
increase O +
in O +
intragastric O +
pressure O +
was O +
directly O +
related O +
to O +
the O +
intensity O +
of O +
muscle B-Disease +
fasciculations L-Disease +
( O -
regression O +
line O -
: O +
y O +
= O +
0.5 O +
+ O +
4.78x O +
with O +
r O +
of O +
0.78 O -
) O -
. O -

It O +
is O +
concluded O +
that O +
intragastric O +
pressure O +
increases O +
significantly O +
during O +
muscle B-Disease +
fasciculations L-Disease +
caused O +
by O +
suxamethonium O +
in O +
healthy O +
children O -
. O -

Alfentanil O +
50 O +
micrograms O +
kg-1 O +
effectively O +
inhibits O +
the O +
incidence O +
and O +
intensity O +
of O +
suxamethonium O -
- O -
induced O +
muscle B-Disease +
fasciculations L-Disease -
; O +
moreover O -
, O +
intragastric O +
pressure O +
remains O +
at O +
its O +
control O +
value O -
. O -

Acute O +
insulin O +
treatment O +
normalizes O +
the O +
resistance O +
to O +
the O +
cardiotoxic U-Disease +
effect O +
of O +
isoproterenol O +
in O +
streptozotocin O +
diabetic U-Disease +
rats O -
. O -

A O +
morphometric O +
study O +
of O +
isoproterenol O +
induced O +
myocardial O +
fibrosis U-Disease -
. O -

The O +
acute O +
effect O +
of O +
insulin O +
treatment O +
on O +
the O +
earlier O +
reported O +
protective O +
effect O +
of O +
streptozotocin O +
diabetes U-Disease +
against O +
the O +
cardiotoxic U-Disease +
effect O +
of O +
high O +
doses O +
of O +
isoproterenol O +
( O -
ISO O -
) O +
was O +
investigated O +
in O +
rats O -
. O -

Thirty O +
to O +
135 O +
min O +
after O +
the O +
injection O +
of O +
crystalline O +
insulin O -
, O +
ISO O +
was O +
given O +
subcutaneously O +
and O +
when O +
ISO O +
induced O +
fibrosis U-Disease +
in O +
the O +
myocardium O +
was O +
morphometrically O +
analyzed O +
7 O +
days O +
later O -
, O +
a O +
highly O +
significant O +
correlation O +
( O -
r O +
= O +
0.83 O -
, O +
2 O +
p O +
= O +
0.006 O -
) O +
to O +
the O +
slope O +
of O +
the O +
fall O +
in O +
blood O +
glucose O +
after O +
insulin O +
treatment O +
appeared O -
. O -

The O +
myocardial O +
content O +
of O +
catecholamines O +
was O +
estimated O +
in O +
these O +
8 O +
day O +
diabetic U-Disease +
rats O -
. O -

The O +
norepinephrine O +
content O +
was O +
significantly O +
increased O +
while O +
epinephrine O +
remained O +
unchanged O -
. O -

An O +
enhanced O +
sympathetic O +
nervous O +
system O +
activity O +
with O +
a O +
consequent O +
down O +
regulation O +
of O +
the O +
myocardial O +
beta O -
- O -
adrenergic O +
receptors O +
could O -
, O +
therefore O -
, O +
explain O +
this O +
catecholamine O +
resistance O -
. O -

The O +
rapid O +
reversion O +
after O +
insulin O +
treatment O +
excludes O +
the O +
possibility O +
that O +
streptozotocin O +
in O +
itself O +
causes O +
the O +
ISO O +
resistance O +
and O +
points O +
towards O +
a O +
direct O +
insulin O +
effect O +
on O +
myocardial O +
catecholamine O +
sensitivity O +
in O +
diabetic U-Disease +
rats O -
. O -

The O +
phenomenon O +
described O +
might O +
elucidate O +
pathogenetic O +
mechanisms O +
behind O +
toxic O +
myocardial O +
cell O +
degeneration O +
and O +
may O +
possibly O +
have O +
relevance O +
for O +
acute O +
cardiovascular O +
complications O +
in O +
diabetic U-Disease +
patients O -
. O -

Differential O +
effects O +
of O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
on O +
seizures U-Disease +
produced O +
by O +
pilocarpine O +
in O +
rats O -
. O -

The O +
muscarinic O +
cholinergic O +
agonist O +
pilocarpine O +
induces O +
in O +
rats O +
seizures U-Disease +
and O +
status B-Disease +
epilepticus L-Disease +
followed O +
by O +
widespread O +
damage O +
to O +
the O +
forebrain O -
. O -

The O +
present O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
effect O +
of O +
5 O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O -
, O +
sodium O +
salicylate O -
, O +
phenylbutazone O -
, O +
indomethacin O -
, O +
ibuprofen O +
and O +
mefenamic O +
acid O -
, O +
on O +
seizures U-Disease +
produced O +
by O +
pilocarpine O -
. O -

Pretreatment O +
of O +
rats O +
with O +
sodium O +
salicylate O -
, O +
ED50 O +
103 O +
mg O -
/ O -
kg O +
( O -
60 O -
- O -
174 O -
) O -
, O +
and O +
phenylbutazone O -
, O +
59 O +
mg O -
/ O -
kg O +
( O -
50 O -
- O -
70 O -
) O +
converted O +
the O +
non O -
- O -
convulsant O +
dose O +
of O +
pilocarpine O -
, O +
200 O +
mg O -
/ O -
kg O -
, O +
to O +
a O +
convulsant O +
one O -
. O -

Indomethacin O -
, O +
1 O -
- O -
10 O +
mg O -
/ O -
kg O -
, O +
and O +
ibuprofen O -
, O +
10 O -
- O -
100 O +
mg O -
/ O -
kg O -
, O +
failed O +
to O +
modulate O +
seizures U-Disease +
produced O +
by O +
pilocarpine O -
. O -

Mefenamic O +
acid O -
, O +
26 O +
( O -
22 O -
- O -
30 O -
) O +
mg O -
/ O -
kg O -
, O +
prevented O +
seizures U-Disease +
and O +
protected O +
rats O +
from O +
seizure U-Disease -
- O -
related O +
brain B-Disease +
damage L-Disease +
induced O +
by O +
pilocarpine O -
, O +
380 O +
mg O -
/ O -
kg O -
. O -

These O +
results O +
indicate O +
that O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drugs O +
differentially O +
modulate O +
the O +
threshold O +
for O +
pilocarpine O -
- O -
induced O +
seizures U-Disease -
. O -

Acute B-Disease +
neurologic I-Disease +
dysfunction L-Disease +
after O +
high O -
- O -
dose O +
etoposide O +
therapy O +
for O +
malignant B-Disease +
glioma L-Disease -
. O -

Etoposide O +
( O -
VP-16 O -
- O -
213 O -
) O +
has O +
been O +
used O +
in O +
the O +
treatment O +
of O +
many O +
solid O +
tumors U-Disease +
and O +
hematologic B-Disease +
malignancies L-Disease -
. O -

When O +
used O +
in O +
high O +
doses O +
and O +
in O +
conjunction O +
with O +
autologous O +
bone O +
marrow O +
transplantation O -
, O +
this O +
agent O +
has O +
activity O +
against O +
several O +
treatment O -
- O -
resistant O +
cancers U-Disease +
including O +
malignant B-Disease +
glioma L-Disease -
. O -

In O +
six O +
of O +
eight O +
patients O +
( O -
75 O -
% O -
) O +
who O +
we O +
treated O +
for O +
recurrent O +
or O +
resistant O +
glioma U-Disease -
, O +
sudden O +
severe O +
neurologic B-Disease +
deterioration L-Disease +
occurred O -
. O -

This O +
developed O +
a O +
median O +
of O +
9 O +
days O +
after O +
initiation O +
of O +
high O -
- O -
dose O +
etoposide O +
therapy O -
. O -

Significant O +
clinical O +
manifestations O +
have O +
included O +
confusion U-Disease -
, O +
papilledema U-Disease -
, O +
somnolence U-Disease -
, O +
exacerbation O +
of O +
motor B-Disease +
deficits L-Disease -
, O +
and O +
sharp O +
increase O +
in O +
seizure U-Disease +
activity O -
. O -

These O +
abnormalities O +
resolved O +
rapidly O +
after O +
initiation O +
of O +
high O -
- O -
dose O +
intravenous O +
dexamethasone O +
therapy O -
. O -

In O +
all O +
patients O -
, O +
computerized O +
tomographic O +
( O -
CT O -
) O +
brain O +
scans O +
demonstrated O +
stability O +
in O +
tumor U-Disease +
size O +
and O +
peritumor O +
edema U-Disease +
when O +
compared O +
with O +
pretransplant O +
scans O -
. O -

This O +
complication O +
appears O +
to O +
represent O +
a O +
significant O +
new O +
toxicity U-Disease +
of O +
high O -
- O -
dose O +
etoposide O +
therapy O +
for O +
malignant B-Disease +
glioma L-Disease -
. O -

Progressive O +
bile B-Disease +
duct I-Disease +
injury L-Disease +
after O +
thiabendazole O +
administration O -
. O -

A O +
27-yr O -
- O -
old O +
man O +
developed O +
jaundice U-Disease +
2 O +
wk O +
after O +
exposure O +
to O +
thiabendazole O -
. O -

Cholestasis U-Disease +
persisted O +
for O +
3 O +
yr O -
, O +
at O +
which O +
time O +
a O +
liver O +
transplant O +
was O +
performed O -
. O -

Two O +
liver O +
biopsy O +
specimens O +
and O +
the O +
hepatectomy O +
specimen O +
were O +
remarkable O +
for O +
almost O +
complete O +
disappearance O +
of O +
interlobular O +
bile O +
ducts O -
. O -

Prominent O +
fibrosis U-Disease +
and O +
hepatocellular O +
regeneration O +
were O +
also O +
present O -
; O +
however O -
, O +
the O +
lobular O +
architecture O +
was O +
preserved O -
. O -

This O +
case O +
represents O +
an O +
example O +
of O +
" O -
idiosyncratic O -
" O +
drug B-Disease -
- I-Disease -
induced I-Disease +
liver I-Disease +
damage L-Disease +
in O +
which O +
the O +
primary O +
target O +
of O +
injury O +
is O +
the O +
bile O +
duct O -
. O -

An O +
autoimmune O +
pathogenesis O +
of O +
the O +
bile B-Disease +
duct I-Disease +
destruction L-Disease +
is O +
suggested O -
. O -

Differential O +
effects O +
of O +
1,4-dihydropyridine O +
calcium O +
channel O +
blockers O -
: O +
therapeutic O +
implications O -
. O -

Increasing O +
recognition O +
of O +
the O +
importance O +
of O +
calcium O +
in O +
the O +
pathogenesis O +
of O +
cardiovascular B-Disease +
disease L-Disease +
has O +
stimulated O +
research O +
into O +
the O +
use O +
of O +
calcium O +
channel O +
blocking O +
agents O +
for O +
treatment O +
of O +
a O +
variety O +
of O +
cardiovascular B-Disease +
diseases L-Disease -
. O -

The O +
favorable O +
efficacy O +
and O +
tolerability O +
profiles O +
of O +
these O +
agents O +
make O +
them O +
attractive O +
therapeutic O +
modalities O -
. O -

Clinical O +
applications O +
of O +
calcium O +
channel O +
blockers O +
parallel O +
their O +
tissue O +
selectivity O -
. O -

In O +
contrast O +
to O +
verapamil O +
and O +
diltiazem O -
, O +
which O +
are O +
roughly O +
equipotent O +
in O +
their O +
actions O +
on O +
the O +
heart O +
and O +
vascular O +
smooth O +
muscle O -
, O +
the O +
dihydropyridine O +
calcium O +
channel O +
blockers O +
are O +
a O +
group O +
of O +
potent O +
peripheral O +
vasodilator O +
agents O +
that O +
exert O +
minimal O +
electrophysiologic O +
effects O +
on O +
cardiac O +
nodal O +
or O +
conduction O +
tissue O -
. O -

As O +
the O +
first O +
dihydropyridine O +
available O +
for O +
use O +
in O +
the O +
United O +
States O -
, O +
nifedipine O +
controls O +
angina U-Disease +
and O +
hypertension U-Disease +
with O +
minimal O +
depression O +
of O +
cardiac O +
function O -
. O -

Additional O +
members O +
of O +
this O +
group O +
of O +
calcium O +
channel O +
blockers O +
have O +
been O +
studied O +
for O +
a O +
variety O +
of O +
indications O +
for O +
which O +
they O +
may O +
offer O +
advantages O +
over O +
current O +
therapy O -
. O -

Once O +
or O +
twice O +
daily O +
dosage O +
possible O +
with O +
nitrendipine O +
and O +
nisoldipine O +
offers O +
a O +
convenient O +
administration O +
schedule O -
, O +
which O +
encourages O +
patient O +
compliance O +
in O +
long O -
- O -
term O +
therapy O +
of O +
hypertension U-Disease -
. O -

The O +
coronary O +
vasodilating O +
properties O +
of O +
nisoldipine O +
have O +
led O +
to O +
the O +
investigation O +
of O +
this O +
agent O +
for O +
use O +
in O +
angina U-Disease -
. O -

Selectivity O +
for O +
the O +
cerebrovascular O +
bed O +
makes O +
nimodipine O +
potentially O +
useful O +
in O +
the O +
treatment O +
of O +
subarachnoid B-Disease +
hemorrhage L-Disease -
, O +
migraine B-Disease +
headache L-Disease -
, O +
dementia U-Disease -
, O +
and O +
stroke U-Disease -
. O -

In O +
general O -
, O +
the O +
dihydropyridine O +
calcium O +
channel O +
blockers O +
are O +
usually O +
well O +
tolerated O -
, O +
with O +
headache U-Disease -
, O +
facial O +
flushing U-Disease -
, O +
palpitations U-Disease -
, O +
edema U-Disease -
, O +
nausea U-Disease -
, O +
anorexia U-Disease -
, O +
and O +
dizziness U-Disease +
being O +
the O +
more O +
common O +
adverse O +
effects O -
. O -

The O +
enhancement O +
of O +
aminonucleoside O +
nephrosis U-Disease +
by O +
the O +
co O -
- O -
administration O +
of O +
protamine O -
. O -

An O +
experimental O +
model O +
of O +
focal B-Disease +
segmental I-Disease +
glomerular I-Disease +
sclerosis L-Disease +
( O -
FSGS U-Disease -
) O +
was O +
developed O +
in O +
rats O +
by O +
the O +
combined O +
administration O +
of O +
puromycin O -
- O -
aminonucleoside O +
( O -
AMNS O -
) O +
and O +
protamine O +
sulfate O +
( O -
PS O -
) O -
. O -

Male O +
Sprague O -
- O -
Dawley O +
rats O -
, O +
uninephrectomized O +
three O +
weeks O +
before O -
, O +
received O +
daily O +
injections O +
of O +
subcutaneous O +
AMNS O +
( O -
1 O +
mg O -
/ O -
100 O +
g O +
body O +
wt O -
) O +
and O +
intravenous O +
PS O +
( O -
2 O +
separated O +
doses O +
of O +
2.5 O +
mg O -
/ O -
100 O +
g O +
body O +
wt O -
) O +
for O +
four O +
days O -
. O -

The O +
series O +
of O +
injections O +
were O +
repeated O +
another O +
three O +
times O +
at O +
10 O +
day O +
intervals O -
. O -

The O +
animals O +
were O +
sacrificed O +
on O +
days O +
24 O -
, O +
52 O -
, O +
and O +
80 O -
. O -

They O +
developed O +
nephrotic B-Disease +
syndrome L-Disease +
and O +
finally O +
renal B-Disease +
failure L-Disease -
. O -

The O +
time O -
- O -
course O +
curve O +
of O +
creatinine O +
clearance O +
dropped O +
and O +
showed O +
significant O +
difference O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
from O +
that O +
of O +
each O +
control O +
group O -
, O +
such O +
as O -
, O +
AMNS O +
alone O -
, O +
PS O +
alone O +
or O +
saline O +
injected O -
. O -

Their O +
glomeruli O +
showed O +
changes O +
of O +
progressive O +
FSGS U-Disease -
. O -

The O +
ultrastructural O +
studies O +
in O +
the O +
initial O +
stage O +
revealed O +
significant O +
lack O +
of O +
particles O +
of O +
perfused O +
ruthenium O +
red O +
on O +
the O +
lamina O +
rara O +
externa O +
and O +
marked O +
changes O +
in O +
epithelial O +
cell O +
cytoplasm O -
. O -

Therefore O -
, O +
it O +
is O +
suggested O +
that O +
the O +
administration O +
of O +
PS O +
enhances O +
the O +
toxicity U-Disease +
of O +
AMNS O +
on O +
the O +
glomerulus O +
and O +
readily O +
produces O +
progressive O +
FSGS U-Disease +
in O +
rats O +
resulting O +
in O +
the O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease L-Disease -
. O -

Theophylline O +
neurotoxicity U-Disease +
in O +
pregnant O +
rats O -
. O -

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
determine O +
whether O +
the O +
neurotoxicity U-Disease +
of O +
theophylline O +
is O +
altered O +
in O +
advanced O +
pregnancy O -
. O -

Sprague O -
- O -
Dawley O +
rats O +
that O +
were O +
20 O +
days O +
pregnant O +
and O +
nonpregnant O +
rats O +
of O +
the O +
same O +
age O +
and O +
strain O +
received O +
infusions O +
of O +
aminophylline O +
until O +
onset O +
of O +
maximal O +
seizures U-Disease +
which O +
occurred O +
after O +
28 O +
and O +
30 O +
minutes O +
respectively O -
. O -

Theophylline O +
concentrations O +
at O +
this O +
endpoint O +
in O +
serum O +
( O -
total O -
) O +
and O +
CSF O +
were O +
similar O +
but O +
serum O +
( O -
free O -
) O +
and O +
brain O +
concentrations O +
were O +
slightly O +
different O +
in O +
pregnant O +
rats O -
. O -

Theophylline O +
serum O +
protein O +
binding O +
determined O +
by O +
equilibrium O +
dialysis O +
was O +
lower O +
in O +
pregnant O +
rats O -
. O -

Fetal O +
serum O +
concentrations O +
at O +
onset O +
of O +
seizures U-Disease +
in O +
the O +
mother O +
were O +
similar O +
to O +
maternal O +
brain O +
and O +
CSF O +
concentrations O +
and O +
correlated O +
significantly O +
with O +
the O +
former O -
. O -

It O +
is O +
concluded O +
that O +
advanced O +
pregnancy O +
has O +
a O +
negligible O +
effect O +
on O +
the O +
neurotoxic U-Disease +
response O +
to O +
theophylline O +
in O +
rats O -
. O -

Hyperkalemia U-Disease +
induced O +
by O +
indomethacin O +
and O +
naproxen O +
and O +
reversed O +
by O +
fludrocortisone O -
. O -

We O +
have O +
described O +
a O +
patient O +
with O +
severe O +
rheumatoid B-Disease +
arthritis L-Disease +
and O +
a O +
history O +
of O +
mefenamic O +
acid O +
nephropathy U-Disease +
in O +
whom O +
hyperkalemia U-Disease +
and O +
inappropriate O +
hypoaldosteronism U-Disease +
were O +
caused O +
by O +
both O +
indomethacin O +
and O +
naproxen O -
, O +
without O +
major O +
decline O +
in O +
renal O +
function O -
. O -

It O +
is O +
likely O +
that O +
preexisting O +
renal B-Disease +
disease L-Disease +
predisposed O +
this O +
patient O +
to O +
type B-Disease +
IV I-Disease +
renal I-Disease +
tubular I-Disease +
acidosis L-Disease +
with O +
prostaglandin O +
synthetase O +
inhibitors O -
. O -

Because O +
he O +
was O +
unable O +
to O +
discontinue O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
therapy O -
, O +
fludrocortisone O +
was O +
added O -
, O +
correcting O +
the O +
hyperkalemia U-Disease +
and O +
allowing O +
indomethacin O +
therapy O +
to O +
be O +
continued O +
safely O -
. O -

Hypotension U-Disease +
as O +
a O +
manifestation O +
of O +
cardiotoxicity U-Disease +
in O +
three O +
patients O +
receiving O +
cisplatin O +
and O +
5-fluorouracil O -
. O -

Cardiac O +
symptoms O -
, O +
including O +
hypotension U-Disease -
, O +
developed O +
in O +
three O +
patients O +
with O +
advanced O +
colorectal B-Disease +
carcinoma L-Disease +
while O +
being O +
treated O +
with O +
cisplatin O +
( O -
CDDP O -
) O +
and O +
5-fluorouracil O +
( O -
5-FU O -
) O -
. O -

In O +
two O +
patients O -
, O +
hypotension U-Disease +
was O +
associated O +
with O +
severe O +
left B-Disease +
ventricular I-Disease +
dysfunction L-Disease -
. O -

All O +
three O +
patients O +
required O +
therapy O +
discontinuation O -
. O -

Cardiac O +
enzymes O +
remained O +
normal O +
despite O +
transient O +
electrocardiographic O +
( O -
EKG O -
) O +
changes O -
. O -

The O +
presentation O +
and O +
cardiac O +
evaluation O +
( O -
hemodynamic O -
, O +
echocardiographic O -
, O +
and O +
scintigraphic O -
) O +
of O +
these O +
patients O +
suggest O +
new O +
manifestations O +
of O +
5-FU O +
cardiotoxicity U-Disease +
that O +
may O +
be O +
influenced O +
by O +
CDDP O -
. O -

The O +
possible O +
pathophysiologic O +
mechanisms O +
are O +
discussed O -
. O -

Fatal O +
aplastic B-Disease +
anemia L-Disease +
in O +
a O +
patient O +
treated O +
with O +
carbamazepine O -
. O -

A O +
case O +
of O +
fatal O +
aplastic B-Disease +
anemia L-Disease +
due O +
to O +
carbamazepine O +
treatment O +
in O +
an O +
epileptic U-Disease +
woman O +
is O +
reported O -
. O -

Despite O +
concerns O +
of O +
fatal O +
bone B-Disease +
marrow I-Disease +
toxicity L-Disease +
due O +
to O +
carbamazepine O -
, O +
this O +
is O +
only O +
the O +
fourth O +
documented O +
and O +
published O +
report O -
. O -

Carbamazepine O +
is O +
a O +
safe O +
drug O -
, O +
but O +
physicians O +
and O +
patients O +
should O +
be O +
aware O +
of O +
the O +
exceedingly O +
rare O +
but O +
potentially O +
fatal O +
side O +
effects O -
, O +
better O +
prevented O +
by O +
clinical O +
than O +
by O +
laboratory O +
monitoring O -
. O -

Participation O +
of O +
a O +
bulbospinal O +
serotonergic O +
pathway O +
in O +
the O +
rat O +
brain O +
in O +
clonidine O -
- O -
induced O +
hypotension U-Disease +
and O +
bradycardia U-Disease -
. O -

The O +
effects O +
of O +
microinjection O +
of O +
clonidine O +
( O -
1 O -
- O -
10 O +
micrograms O +
in O +
1 O +
microliter O -
) O +
into O +
a O +
region O +
adjacent O +
to O +
the O +
ventrolateral O +
surface O +
of O +
the O +
medulla O +
oblongata O +
on O +
cardiovascular O +
function O +
were O +
assessed O +
in O +
urethane O -
- O -
anesthetized O +
rats O -
. O -

Intramedullary O +
administration O +
of O +
clonidine O -
, O +
but O +
not O +
saline O +
vehicle O -
, O +
caused O +
a O +
dose O -
- O -
dependent O +
decrease O +
in O +
both O +
the O +
mean O +
arterial O +
pressure O +
and O +
the O +
heart O +
rate O -
. O -

The O +
clonidine O -
- O -
induced O +
hypotension U-Disease +
was O +
antagonized O +
by O +
prior O +
spinal O +
transection O -
, O +
but O +
not O +
bilateral O +
vagotomy O -
. O -

On O +
the O +
other O +
hand O -
, O +
the O +
clonidine O -
- O -
induced O +
bradycardia U-Disease +
was O +
antagonized O +
by O +
prior O +
bilateral O +
vagotomy O -
, O +
but O +
not O +
spinal O +
transection O -
. O -

Furthermore O -
, O +
selective O +
destruction O +
of O +
the O +
spinal O +
5-HT O +
nerves O -
, O +
produced O +
by O +
bilateral O +
spinal O +
injection O +
of O +
5,7-dihydroxytryptamine O -
, O +
reduced O +
the O +
magnitude O +
of O +
the O +
vasodepressor O +
or O +
the O +
bradycardiac U-Disease +
responses O +
to O +
clonidine O +
microinjected O +
into O +
the O +
area O +
near O +
the O +
ventrolateral O +
surface O +
of O +
the O +
medulla O +
oblongata O +
in O +
rats O -
. O -

The O +
data O +
indicate O +
that O +
a O +
bulbospinal O +
serotonergic O +
pathway O +
is O +
involved O +
in O +
development O +
of O +
clonidine O -
- O -
induced O +
hypotension U-Disease +
and O +
bradycardia U-Disease -
. O -

The O +
induced O +
hypotension U-Disease +
is O +
brought O +
about O +
by O +
a O +
decrease O +
in O +
sympathetic O +
efferent O +
activity O -
, O +
whereas O +
the O +
induced O +
bradycardia U-Disease +
was O +
due O +
to O +
an O +
increase O +
in O +
vagal O +
efferent O +
activity O -
. O -

Hypertension U-Disease +
in O +
neuroblastoma U-Disease +
induced O +
by O +
imipramine O -
. O -

Hypertension U-Disease +
is O +
a O +
well O -
- O -
known O +
finding O +
in O +
some O +
patients O +
with O +
neuroblastoma U-Disease -
. O -

However O -
, O +
it O +
has O +
not O +
previously O +
been O +
described O +
in O +
association O +
with O +
the O +
use O +
of O +
Imipramine O -
. O -

We O +
report O +
the O +
occurrence O +
of O +
severe O +
hypertension U-Disease +
( O -
blood O +
pressure O +
190 O -
/ O -
160 O -
) O +
in O +
a O +
4-year O -
- O -
old O +
girl O +
with O +
neuroblastoma U-Disease +
who O +
was O +
given O +
Imipramine O +
to O +
control O +
a O +
behavior B-Disease +
disorder L-Disease -
. O -

It O +
was O +
determined O +
later O +
that O +
this O +
patient O -
's O +
tumor U-Disease +
was O +
recurring O +
at O +
the O +
time O +
of O +
her O +
hypertensive U-Disease +
episode O -
. O -

Since O +
she O +
had O +
no O +
blood O +
pressure O +
elevation O +
at O +
initial O +
diagnosis O +
and O +
none O +
following O +
discontinuation O +
of O +
the O +
Imipramine O +
( O -
when O +
she O +
was O +
in O +
florid O +
relapse O -
) O -
, O +
we O +
believe O +
that O +
this O +
drug O +
rather O +
than O +
her O +
underlying O +
disease O +
alone O +
caused O +
her O +
hypertension U-Disease -
. O -

The O +
mechanism O +
for O +
this O +
reaction O +
is O +
believed O +
to O +
be O +
increased O +
levels O +
of O +
vasoactive O +
catecholamines O +
due O +
to O +
interference O +
of O +
their O +
physiologic O +
inactivation O +
by O +
Imipramine O -
. O -

From O +
this O +
experience O -
, O +
we O +
urge O +
extreme O +
caution O +
in O +
the O +
use O +
of O +
tricyclic O +
antidepressants O +
in O +
children O +
with O +
active O +
neuroblastoma U-Disease -
. O -

Rechallenge O +
of O +
patients O +
who O +
developed O +
oral B-Disease +
candidiasis L-Disease +
or O +
hoarseness U-Disease +
with O +
beclomethasone O +
dipropionate O -
. O -

Of O +
158 O +
asthmatic U-Disease +
patients O +
who O +
were O +
placed O +
on O +
inhaled O +
beclomethasone O -
, O +
15 O +
( O -
9.5 O -
% O -
) O +
developed O +
either O +
hoarseness U-Disease +
( O -
8) O -
, O +
oral O +
thrush U-Disease +
( O -
6 O -
) O -
, O +
or O +
both O +
( O -
1 O -
) O -
. O -

When O +
their O +
adverse O +
reactions O +
subsided O -
, O +
seven O +
of O +
these O +
15 O +
patients O +
were O +
rechallenged O +
with O +
inhaled O +
beclomethasone O -
. O -

These O +
included O +
five O +
cases O +
who O +
developed O +
hoarseness U-Disease +
and O +
three O +
who O +
developed O +
Candidiasis U-Disease -
. O -

One O +
patient O +
had O +
both O -
. O -

Oral O +
thrush U-Disease +
did O +
not O +
recur O -
, O +
but O +
60 O -
% O +
( O -
3 O -
/ O -
5 O -
) O +
of O +
patients O +
with O +
hoarseness U-Disease +
had O +
recurrence O -
. O -

We O +
conclude O +
that O +
patients O +
may O +
be O +
restarted O +
on O +
inhaled O +
beclomethasone O +
when O +
clinically O +
indicated O -
; O +
however O -
, O +
because O +
of O +
the O +
high O +
recurrence O +
rate O -
, O +
patients O +
who O +
develop O +
hoarseness U-Disease +
should O +
not O +
be O +
re O -
- O -
challenged O -
. O -

Concomitant O +
use O +
of O +
oral O +
prednisone O +
and O +
topical O +
beclomethasone O +
may O +
increase O +
the O +
risk O +
of O +
developing O +
hoarseness U-Disease +
or O +
candidiasis U-Disease -
. O -

Cyclophosphamide O +
cardiotoxicity U-Disease -
: O +
an O +
analysis O +
of O +
dosing O +
as O +
a O +
risk O +
factor O -
. O -

Patients O +
who O +
undergo O +
bone O +
marrow O +
transplantation O +
are O +
generally O +
immunosuppressed O +
with O +
a O +
dose O +
of O +
cyclophosphamide O +
( O -
CYA O -
) O +
which O +
is O +
usually O +
calculated O +
based O +
on O +
the O +
patient O -
's O +
weight O -
. O -

At O +
these O +
high O +
doses O +
of O +
CYA O -
, O +
serious O +
cardiotoxicity U-Disease +
may O +
occur O -
, O +
but O +
definitive O +
risk O +
factors O +
for O +
the O +
development O +
of O +
such O +
cardiotoxicity U-Disease +
have O +
not O +
been O +
described O -
. O -

Since O +
chemotherapeutic O +
agent O +
toxicity U-Disease +
generally O +
correlates O +
with O +
dose O +
per O +
body O +
surface O +
area O -
, O +
we O +
retrospectively O +
calculated O +
the O +
dose O +
of O +
CYA O +
in O +
patients O +
transplanted O +
at O +
our O +
institution O +
to O +
determine O +
whether O +
the O +
incidence O +
of O +
CYA O +
cardiotoxicity U-Disease +
correlated O +
with O +
the O +
dose O +
per O +
body O +
surface O +
area O -
. O -

Eighty O +
patients O +
who O +
were O +
to O +
receive O +
CYA O +
50 O +
mg O -
/ O -
kg O -
/ O -
d O +
for O +
four O +
days O +
as O +
preparation O +
for O +
marrow O +
grafting O +
underwent O +
a O +
total O +
of O +
84 O +
transplants O +
for O +
aplastic B-Disease +
anemia L-Disease -
, O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease -
, O +
or O +
severe B-Disease +
combined I-Disease +
immunodeficiency I-Disease +
syndrome L-Disease -
. O -

Fourteen O +
of O +
84 O +
( O -
17 O -
% O -
) O +
patients O +
had O +
symptoms O +
and O +
signs O +
consistent O +
with O +
CYA O +
cardiotoxicity U-Disease +
within O +
ten O +
days O +
of O +
receiving O +
1 O +
to O +
4 O +
doses O +
of O +
CYA O -
. O -

Six O +
of O +
the O +
14 O +
patients O +
died O +
with O +
congestive B-Disease +
heart I-Disease +
failure L-Disease -
. O -

The O +
dose O +
of O +
CYA O +
per O +
body O +
surface O +
area O +
was O +
calculated O +
for O +
all O +
patients O +
and O +
the O +
patients O +
were O +
divided O +
into O +
two O +
groups O +
based O +
on O +
daily O +
CYA O +
dose O -
: O +
Group O +
1 O -
, O +
CYA O +
less O +
than O +
or O +
equal O +
to O +
1.55 O +
g O -
/ O -
m2 O -
/ O -
d O -
; O +
Group O +
2 O -
, O +
CYA O +
greater O +
than O +
1.55 O +
g O -
/ O -
m2 O -
/ O -
d O -
. O -

Cardiotoxicity U-Disease +
that O +
was O +
thought O +
to O +
be O +
related O +
to O +
CYA O +
occurred O +
in O +
1 O -
/ O -
32 O +
( O -
3 O -
% O -
) O +
of O +
patients O +
in O +
Group O +
1 O +
and O +
in O +
13 O -
/ O -
52 O +
( O -
25 O -
% O -
) O +
patients O +
in O +
Group O +
2 O +
( O -
P O +
less O +
than O +
0.025 O -
) O -
. O -

Congestive B-Disease +
heart I-Disease +
failure L-Disease +
caused O +
or O +
contributed O +
to O +
death O +
in O +
0 O -
/ O -
32 O +
patients O +
in O +
Group O +
1 O +
v O +
6 O -
/ O -
52 O +
( O -
12 O -
% O -
) O +
of O +
patients O +
in O +
Group O +
2 O +
( O -
P O +
less O +
than O +
0.25 O -
) O -
. O -

There O +
was O +
no O +
difference O +
in O +
the O +
rate O +
of O +
engraftment O +
of O +
evaluable O +
patients O +
in O +
the O +
two O +
groups O +
( O -
P O +
greater O +
than O +
0.5 O -
) O -
. O -

We O +
conclude O +
that O +
the O +
CYA O +
cardiotoxicity U-Disease +
correlates O +
with O +
CYA O +
dosage O +
as O +
calculated O +
by O +
body O +
surface O +
area O -
, O +
and O +
that O +
patients O +
with O +
aplastic B-Disease +
anemia L-Disease +
and O +
immunodeficiencies U-Disease +
can O +
be O +
effectively O +
prepared O +
for O +
bone O +
marrow O +
grafting O +
at O +
a O +
CYA O +
dose O +
of O +
1.55 O +
g O -
/ O -
m2 O -
/ O -
d O +
for O +
four O +
days O +
with O +
a O +
lower O +
incidence O +
of O +
cardiotoxicity U-Disease +
than O +
patients O +
whose O +
CYA O +
dosage O +
is O +
calculated O +
based O +
on O +
weight O -
. O -

This O +
study O +
reaffirms O +
the O +
principle O +
that O +
drug O +
toxicity U-Disease +
correlates O +
with O +
dose O +
per O +
body O +
surface O +
area O -
. O -

Studies O +
of O +
risk O +
factors O +
for O +
aminoglycoside O +
nephrotoxicity U-Disease -
. O -

The O +
epidemiology O +
of O +
aminoglycoside O -
- O -
induced O +
nephrotoxicity U-Disease +
is O +
not O +
fully O +
understood O -
. O -

Experimental O +
studies O +
in O +
healthy O +
human O +
volunteers O +
indicate O +
aminoglycosides O +
cause O +
proximal O +
tubular O +
damage O +
in O +
most O +
patients O -
, O +
but O +
rarely O -
, O +
if O +
ever O -
, O +
cause O +
glomerular B-Disease +
or I-Disease +
tubular I-Disease +
dysfunction L-Disease -
. O -

Clinical O +
trials O +
of O +
aminoglycosides O +
in O +
seriously O +
ill O +
patients O +
indicate O +
that O +
the O +
relative O +
risk O +
for O +
developing O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
during O +
therapy O +
ranges O +
from O +
8 O +
to O +
10 O +
and O +
that O +
the O +
attributable O +
risk O +
is O +
70 O -
% O +
to O +
80 O -
% O -
. O -

Further O +
analysis O +
of O +
these O +
data O +
suggests O +
that O +
the O +
duration O +
of O +
therapy O -
, O +
plasma O +
aminoglycoside O +
levels O -
, O +
liver B-Disease +
disease L-Disease -
, O +
advanced O +
age O -
, O +
high O +
initial O +
estimated O +
creatinine O +
clearance O +
and O -
, O +
possibly O -
, O +
female O +
gender O +
all O +
increase O +
the O +
risk O +
for O +
nephrotoxicity U-Disease -
. O -

Other O +
causes O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease -
, O +
such O +
as O +
shock U-Disease -
, O +
appear O +
to O +
have O +
an O +
additive O +
effect O -
. O -

Predictive O +
models O +
have O +
been O +
developed O +
from O +
these O +
analyses O +
that O +
should O +
be O +
useful O +
for O +
identifying O +
patients O +
at O +
high O +
risk O -
. O -

These O +
models O +
may O +
also O +
be O +
useful O +
in O +
developing O +
insights O +
into O +
the O +
pathophysiology O +
of O +
aminoglycoside O -
- O -
induced O +
nephrotoxicity U-Disease -
. O -

Central O +
action O +
of O +
narcotic O +
analgesics O -
. O -

Part O +
IV O -
. O -

Noradrenergic O +
influences O +
on O +
the O +
activity O +
of O +
analgesics O +
in O +
rats O -
. O -

The O +
effect O +
of O +
clonidine O -
, O +
naphazoline O +
and O +
xylometazoline O +
on O +
analgesia O +
induced O +
by O +
morphine O -
, O +
codeine O -
, O +
fentanyl O +
and O +
pentazocine O -
, O +
and O +
on O +
cataleptic U-Disease +
effect O +
of O +
morphine O -
, O +
codine O +
and O +
fentanyl O +
was O +
studied O +
in O +
rats O -
. O -

The O +
biochemical O +
assays O +
on O +
the O +
influence O +
of O +
four O +
analgesics O +
on O +
the O +
brain O +
concentration O +
and O +
turnover O +
of O +
noradrenaline O +
( O -
NA O -
) O +
were O +
also O +
performed O -
. O -

It O +
was O +
found O +
that O +
three O +
drugs O +
stimulating O +
central O +
NA O +
receptors O +
failed O +
to O +
affect O +
the O +
analgesic O +
ED50 O +
of O +
all O +
antinociceptive O +
agents O +
and O +
they O +
enhanced O +
catalepsy U-Disease +
induced O +
by O +
morphine O +
and O +
fentanyl O -
. O -

Codeine O +
catalepsy U-Disease +
was O +
increased O +
by O +
clonidine O +
and O +
decreased O +
by O +
naphazoline O +
and O +
xylometazoline O -
. O -

The O +
brain O +
concentration O +
of O +
NA O +
was O +
not O +
changed O +
by O +
morphine O +
and O +
fentanyl O -
, O +
but O +
one O +
of O +
the O +
doses O +
of O +
codeine O +
( O -
45 O +
mg O -
/ O -
kg O -
) O +
slightly O +
enhanced O +
it O -
. O -

Pentazocine O +
dose O -
- O -
dependently O +
decreased O +
the O +
brain O +
level O +
of O +
NA O -
. O -

The O +
rate O +
of O +
NA O +
turnover O +
was O +
not O +
altered O +
by O +
analgesics O +
except O +
for O +
the O +
higher O +
dose O +
of O +
fentanyl O +
( O -
0.2 O +
mg O -
/ O -
kg O -
) O +
following O +
which O +
the O +
disappearance O +
of O +
NA O +
from O +
the O +
brain O +
was O +
diminished O -
. O -

The O +
results O +
are O +
discussed O +
in O +
the O +
light O +
of O +
various O +
and O +
non O -
- O -
uniform O +
data O +
from O +
the O +
literature O -
. O -

It O +
is O +
suggested O +
that O +
in O +
rats O +
the O +
brain O +
NA O +
plays O +
a O +
less O +
important O +
function O +
than O +
the O +
other O +
monoamines O +
in O +
the O +
behavioural O +
activity O +
of O +
potent O +
analgesics O -
. O -

Flurothyl O +
seizure U-Disease +
thresholds O +
in O +
mice O +
treated O +
neonatally O +
with O +
a O +
single O +
injection O +
of O +
monosodium O +
glutamate O +
( O -
MSG O -
) O -
: O +
evaluation O +
of O +
experimental O +
parameters O +
in O +
flurothyl O +
seizure U-Disease +
testing O -
. O -

Monosodium O +
glutamate O +
( O -
MSG O -
) O +
administration O +
to O +
neonatal O +
rodents O +
produces O +
convulsions U-Disease +
and O +
results O +
in O +
numerous O +
biochemical O +
and O +
behavioral O +
deficits O -
. O -

These O +
studies O +
were O +
undertaken O +
to O +
determine O +
if O +
neonatal O +
administration O +
of O +
MSG O +
produced O +
permanent O +
alterations O +
in O +
seizure U-Disease +
susceptibility O -
, O +
since O +
previous O +
investigations O +
were O +
inconclusive O -
. O -

A O +
flurothyl O +
ether O +
seizure U-Disease +
screening O +
technique O +
was O +
used O +
to O +
evaluate O +
seizure U-Disease +
susceptibility O +
in O +
adult O +
mice O +
that O +
received O +
neonatal O +
injections O +
of O +
MSG O +
( O -
4 O +
mg O -
/ O -
g O +
and O +
1 O +
mg O -
/ O -
g O -
) O -
. O -

MSG O +
treatment O +
resulted O +
in O +
significant O +
reductions O +
in O +
whole O +
brain O +
weight O +
but O +
did O +
not O +
alter O +
seizure U-Disease +
threshold O -
. O -

A O +
naloxone O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
challenge O +
was O +
also O +
ineffective O +
in O +
altering O +
the O +
seizure U-Disease +
thresholds O +
of O +
either O +
control O +
of O +
MSG O -
- O -
treated O +
mice O -
. O -

Flurothyl O +
ether O +
produced O +
hypothermia U-Disease +
which O +
was O +
correlated O +
with O +
the O +
duration O +
of O +
flurothyl O +
exposure O -
; O +
however O -
, O +
the O +
relationship O +
of O +
hypothermia U-Disease +
to O +
seizure U-Disease +
induction O +
was O +
unclear O -
. O -

Flurothyl O +
seizure U-Disease +
testing O +
proved O +
to O +
be O +
a O +
rapid O +
and O +
reliable O +
technique O +
with O +
which O +
to O +
evaluate O +
seizure U-Disease +
susceptibility O -
. O -

Susceptibility O +
to O +
seizures U-Disease +
produced O +
by O +
pilocarpine O +
in O +
rats O +
after O +
microinjection O +
of O +
isoniazid O +
or O +
gamma O -
- O -
vinyl O -
- O -
GABA O +
into O +
the O +
substantia O +
nigra O -
. O -

Pilocarpine O -
, O +
given O +
intraperitoneally O +
to O +
rats O -
, O +
reproduces O +
the O +
neuropathological O +
sequelae O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease +
and O +
provides O +
a O +
relevant O +
animal O +
model O +
for O +
studying O +
mechanisms O +
of O +
buildup O +
of O +
convulsive U-Disease +
activity O +
and O +
pathways O +
operative O +
in O +
the O +
generalization O +
and O +
propagation O +
of O +
seizures U-Disease +
within O +
the O +
forebrain O -
. O -

In O +
the O +
present O +
study O -
, O +
the O +
effects O +
of O +
manipulating O +
the O +
activity O +
of O +
the O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
-mediated O +
synaptic O +
inhibition O +
within O +
the O +
substantia O +
nigra O +
on O +
seizures U-Disease +
produced O +
by O +
pilocarpine O +
in O +
rats O -
, O +
were O +
investigated O -
. O -

In O +
animals O +
pretreated O +
with O +
microinjections O +
of O +
isoniazid O -
, O +
150 O +
micrograms O -
, O +
an O +
inhibitor O +
of O +
activity O +
of O +
the O +
GABA O -
- O -
synthesizing O +
enzyme O -
, O +
L O -
- O -
glutamic O +
acid O +
decarboxylase O -
, O +
into O +
the O +
substantia O +
nigra O +
pars O +
reticulata O +
( O -
SNR O -
) O -
, O +
bilaterally O -
, O +
non O -
- O -
convulsant O +
doses O +
of O +
pilocarpine O -
, O +
100 O +
and O +
200 O +
mg O -
/ O -
kg O -
, O +
resulted O +
in O +
severe O +
motor O +
limbic O +
seizures U-Disease +
and O +
status B-Disease +
epilepticus L-Disease -
. O -

Electroencephalographic O +
and O +
behavioral O +
monitoring O +
revealed O +
a O +
profound O +
reduction O +
of O +
the O +
threshold O +
for O +
pilocarpine O -
- O -
induced O +
convulsions U-Disease -
. O -

Morphological O +
analysis O +
of O +
frontal O +
forebrain O +
sections O +
with O +
light O +
microscopy O +
revealed O +
seizure U-Disease -
- O -
related O +
damage O +
to O +
the O +
hippocampal O +
formation O -
, O +
thalamus O -
, O +
amygdala O -
, O +
olfactory O +
cortex O -
, O +
substantia O +
nigra O +
and O +
neocortex O -
, O +
which O +
is O +
typically O +
observed O +
with O +
pilocarpine O +
in O +
doses O +
exceeding O +
350 O +
mg O -
/ O -
kg O -
. O -

Bilateral O +
intrastriatal O +
injections O +
of O +
isoniazid O +
did O +
not O +
augment O +
seizures U-Disease +
produced O +
by O +
pilocarpine O -
, O +
200 O +
mg O -
/ O -
kg O -
. O -

Application O +
of O +
an O +
irreversible O +
inhibitor O +
of O +
GABA O +
transaminase O -
, O +
gamma O -
- O -
vinyl O -
- O -
GABA O +
( O -
D O -
, O -
L-4-amino O -
- O -
hex-5-enoic O +
acid O -
) O -
, O +
5 O +
micrograms O -
, O +
into O +
the O +
SNR O -
, O +
bilaterally O -
, O +
suppressed O +
the O +
appearance O +
of O +
electrographic O +
and O +
behavioral O +
seizures U-Disease +
produced O +
by O +
pilocarpine O -
, O +
380 O +
mg O -
/ O -
kg O -
. O -

This O +
treatment O +
was O +
also O +
sufficient O +
to O +
protect O +
animals O +
from O +
the O +
occurrence O +
of O +
brain B-Disease +
damage L-Disease -
. O -

Microinjections O +
of O +
gamma O -
- O -
vinyl O -
- O -
GABA O -
, O +
5 O +
micrograms O -
, O +
into O +
the O +
dorsal O +
striatum O -
, O +
bilaterally O -
, O +
failed O +
to O +
prevent O +
the O +
development O +
of O +
convulsions U-Disease +
produced O +
by O +
pilocarpine O -
, O +
380 O +
mg O -
/ O -
kg O -
. O -

The O +
results O +
demonstrate O +
that O +
the O +
threshold O +
for O +
pilocarpine O -
- O -
induced O +
seizures U-Disease +
in O +
rats O +
is O +
subjected O +
to O +
the O +
regulation O +
of O +
the O +
GABA O -
- O -
mediated O +
synaptic O +
inhibition O +
within O +
the O +
substantia O +
nigra O -
. O -

Human O +
and O +
canine O +
ventricular O +
vasoactive O +
intestinal O +
polypeptide O -
: O +
decrease O +
with O +
heart B-Disease +
failure L-Disease -
. O -

Vasoactive O +
intestinal O +
polypeptide O +
( O -
VIP O -
) O +
is O +
a O +
systemic O +
and O +
coronary O +
vasodilator O +
that O +
may O +
have O +
positive O +
inotropic O +
properties O -
. O -

Myocardial O +
levels O +
of O +
VIP O +
were O +
assayed O +
before O +
and O +
after O +
the O +
development O +
of O +
heart B-Disease +
failure L-Disease +
in O +
two O +
canine O +
models O -
. O -

In O +
the O +
first O -
, O +
cobalt O +
cardiomyopathy U-Disease +
was O +
induced O +
in O +
eight O +
dogs O -
; O +
VIP O +
( O -
by O +
radioimmunoassay O -
) O +
decreased O +
from O +
35 O +
+ O -
/- O -

11 O +
pg O -
/ O -
mg O +
protein O +
( O -
mean O +
+ O -
/- O +
SD O -
) O +
to O +
5 O +
+ O -
/- O -

4 O +
pg O -
/ O -
mg O +
protein O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

In O +
six O +
dogs O +
with O +
doxorubicin O -
- O -
induced O +
heart B-Disease +
failure L-Disease -
, O +
VIP O +
decreased O +
from O +
31 O +
+ O -
/- O -

7 O +
to O +
11 O +
+ O -
/- O -

4 O +
pg O -
/ O -
mg O +
protein O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

In O +
addition O -
, O +
VIP O +
content O +
of O +
left O +
ventricular O +
muscle O +
of O +
resected O +
failing O +
hearts O +
in O +
10 O +
patients O +
receiving O +
a O +
heart O +
transplant O +
was O +
compared O +
with O +
the O +
papillary O +
muscles O +
in O +
14 O +
patients O +
( O -
five O +
with O +
rheumatic B-Disease +
disease L-Disease -
, O +
nine O +
with O +
myxomatous B-Disease +
degeneration L-Disease -
) O +
receiving O +
mitral O +
valve O +
prostheses O -
. O -

The O +
lowest O +
myocardial O +
VIP O +
concentration O +
was O +
found O +
in O +
the O +
hearts O +
of O +
patients O +
with O +
coronary B-Disease +
disease L-Disease +
( O -
one O +
patient O +
receiving O +
a O +
transplant O +
and O +
three O +
receiving O +
mitral O +
prostheses O -
) O +
( O -
6.3 O +
+ O -
/- O -

1.9 O +
pg O -
/ O -
mg O +
protein O -
) O -
. O -

The O +
other O +
patients O +
undergoing O +
transplantation O +
had O +
an O +
average O +
ejection O +
fraction O +
of O +
17 O -
% O +
+ O -
/- O -

6 O -
% O +
and O +
a O +
VIP O +
level O +
of O +
8.8 O +
+ O -
/- O -

3.9 O +
pg O -
/ O -
mg O +
protein O -
. O -

The O +
hearts O +
without O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
( O -
average O +
ejection O +
fraction O +
of O +
this O +
group O +
62 O -
% O +
+ O -
/- O -

10 O -
% O -
) O +
had O +
a O +
VIP O +
concentration O +
of O +
14.1 O +
+ O -
/- O -

7.9 O +
pg O -
/ O -
mg O +
protein O -
, O +
and O +
this O +
was O +
greater O +
than O +
in O +
hearts O +
of O +
the O +
patients O +
with O +
coronary B-Disease +
disease L-Disease +
and O +
the O +
hearts O +
of O +
patients O +
receiving O +
a O +
transplant O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

Myocardial O +
catecholamines O +
were O +
also O +
determined O +
in O +
14 O +
subjects O -
; O +
a O +
weak O +
correlation O +
( O -
r O +
= O +
0.57 O -
, O +
P O +
less O +
than O +
0.05 O -
) O +
between O +
the O +
tissue O +
concentrations O +
of O +
VIP O +
and O +
norepinephrine O +
was O +
noted. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Non O -
- O -
invasive O +
detection O +
of O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
by O +
body O +
surface O +
electrocardiographic O +
mapping O +
after O +
dipyridamole O +
infusion O -
. O -

Electrocardiographic O +
changes O +
after O +
dipyridamole O +
infusion O +
( O -
0.568 O +
mg O -
/ O -
kg O -
/ O -
4 O +
min O -
) O +
were O +
studied O +
in O +
41 O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
and O +
compared O +
with O +
those O +
after O +
submaximal O +
treadmill O +
exercise O +
by O +
use O +
of O +
the O +
body O +
surface O +
mapping O +
technique O -
. O -

Patients O +
were O +
divided O +
into O +
three O +
groups O -
; O +
19 O +
patients O +
without O +
myocardial B-Disease +
infarction L-Disease +
( O -
non O -
- O -
MI U-Disease +
group O -
) O -
, O +
14 O +
with O +
anterior B-Disease +
infarction L-Disease +
( O -
ANT B-Disease -
- I-Disease -
MI L-Disease -
) O +
and O +
eight O +
with O +
inferior B-Disease +
infarction L-Disease +
( O -
INF B-Disease -
- I-Disease -
MI L-Disease -
) O -
. O -

Eighty O -
- O -
seven O +
unipolar O +
electrocardiograms O +
( O -
ECGs O -
) O +
distributed O +
over O +
the O +
entire O +
thoracic O +
surface O +
were O +
simultaneously O +
recorded O -
. O -

After O +
dipyridamole O -
, O +
ischemic U-Disease +
ST O -
- O -
segment O +
depression U-Disease +
( O -
0.05 O +
mV O +
or O +
more O -
) O +
was O +
observed O +
in O +
84 O -
% O +
of O +
the O +
non O -
- O -
MI U-Disease +
group O -
, O +
29 O -
% O +
of O +
the O +
ANT B-Disease -
- I-Disease -
MI L-Disease +
group O -
, O +
63 O -
% O +
of O +
the O +
INF B-Disease -
- I-Disease -
MI L-Disease +
group O +
and O +
61 O -
% O +
of O +
the O +
total O +
population O -
. O -

Exercise O -
- O -
induced O +
ST O +
depression U-Disease +
was O +
observed O +
in O +
84 O -
% O +
of O +
the O +
non O -
- O -
MI U-Disease +
group O -
, O +
43 O -
% O +
of O +
the O +
ANT B-Disease -
- I-Disease -
MI L-Disease +
group O -
, O +
38 O -
% O +
of O +
the O +
INF B-Disease -
- I-Disease -
MI L-Disease +
group O +
and O +
61 O -
% O +
of O +
the O +
total O -
. O -

For O +
individual O +
patients O -
, O +
there O +
were O +
no O +
obvious O +
differences O +
between O +
the O +
body O +
surface O +
distribution O +
of O +
ST O +
depression U-Disease +
in O +
both O +
tests O -
. O -

The O +
increase O +
in O +
pressure O +
rate O +
product O +
after O +
dipyridamole O +
was O +
significantly O +
less O +
than O +
that O +
during O +
the O +
treadmill O +
exercise O -
. O -

The O +
data O +
suggest O +
that O +
the O +
dipyridamole O -
- O -
induced O +
myocardial B-Disease +
ischemia L-Disease +
is O +
caused O +
by O +
the O +
inhomogenous O +
distribution O +
of O +
myocardial O +
blood O +
flow O -
. O -

We O +
conclude O +
that O +
the O +
dipyridamole O +
ECG O +
test O +
is O +
as O +
useful O +
as O +
the O +
exercise O +
ECG O +
test O +
for O +
the O +
assessment O +
of O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
. O -

Bradycardia U-Disease +
after O +
high O -
- O -
dose O +
intravenous O +
methylprednisolone O +
therapy O -
. O -

In O +
5 O +
consecutive O +
patients O +
with O +
rheumatoid B-Disease +
arthritis L-Disease +
who O +
received O +
intravenous O +
high O -
- O -
dose O +
methylprednisolone O +
( O -
MP O -
) O +
therapy O +
( O -
1 O +
g O +
daily O +
for O +
2 O +
or O +
3 O +
consecutive O +
days O -
) O -
, O +
a O +
decline O +
in O +
pulse O +
rate O +
was O +
observed O -
, O +
most O +
pronounced O +
on O +
day O +
4 O -
. O -

In O +
one O +
of O +
the O +
5 O +
patients O +
the O +
bradycardia U-Disease +
was O +
associated O +
with O +
complaints O +
of O +
substernal O +
pressure O -
. O -

Reversal O +
to O +
normal O +
heart O +
rate O +
was O +
found O +
on O +
day O +
7 O -
. O -

Electrocardiographic O +
registrations O +
showed O +
sinus B-Disease +
bradycardia L-Disease +
in O +
all O +
cases O -
. O -

No O +
significant O +
changes O +
in O +
plasma O +
concentrations O +
of O +
electrolytes O +
were O +
found O -
. O -

Careful O +
observation O +
of O +
patients O +
receiving O +
high O -
- O -
dose O +
MP O +
is O +
recommended O -
. O -

High O -
- O -
dose O +
MP O +
may O +
be O +
contraindicated O +
in O +
patients O +
with O +
known O +
heart B-Disease +
disease L-Disease -
. O -

Two O +
cases O +
of O +
downbeat B-Disease +
nystagmus L-Disease +
and O +
oscillopsia U-Disease +
associated O +
with O +
carbamazepine O -
. O -

Downbeat B-Disease +
nystagmus L-Disease +
is O +
often O +
associated O +
with O +
structural O +
lesions O +
at O +
the O +
craniocervical O +
junction O -
, O +
but O +
has O +
occasionally O +
been O +
reported O +
as O +
a O +
manifestation O +
of O +
metabolic O +
imbalance O +
or O +
drug O +
intoxication O -
. O -

We O +
recorded O +
the O +
eye O +
movements O +
of O +
two O +
patients O +
with O +
reversible O +
downbeat B-Disease +
nystagmus L-Disease +
related O +
to O +
carbamazepine O +
therapy O -
. O -

The O +
nystagmus U-Disease +
of O +
both O +
patients O +
resolved O +
after O +
reduction O +
of O +
the O +
serum O +
carbamazepine O +
levels O -
. O -

Neuroradiologic O +
investigations O +
including O +
magnetic O +
resonance O +
imaging O +
scans O +
in O +
both O +
patients O +
showed O +
no O +
evidence O +
of O +
intracranial O +
abnormality O -
. O -

In O +
patients O +
with O +
downbeat B-Disease +
nystagmus L-Disease +
who O +
are O +
taking O +
anticonvulsant O +
medications O -
, O +
consideration O +
should O +
be O +
given O +
to O +
reduction O +
in O +
dose O +
before O +
further O +
investigation O +
is O +
undertaken O -
. O -

Improvement O +
by O +
denopamine O +
( O -
TA-064 O -
) O +
of O +
pentobarbital O -
- O -
induced O +
cardiac B-Disease +
failure L-Disease +
in O +
the O +
dog O +
heart O -
- O -
lung O +
preparation O -
. O -

The O +
efficacy O +
of O +
denopamine O -
, O +
an O +
orally O +
active O +
beta O +
1-adrenoceptor O +
agonist O -
, O +
in O +
improving O +
cardiac B-Disease +
failure L-Disease +
was O +
assessed O +
in O +
dog O +
heart O -
- O -
lung O +
preparations O -
. O -

Cardiac O +
functions O +
depressed O +
by O +
pentobarbital O +
( O -
118 O +
+ O -
/- O -

28 O +
mg O -
; O +
mean O +
value O +
+ O -
/- O -

SD O -
) O +
such O +
that O +
cardiac O +
output O +
and O +
maximum O +
rate O +
of O +
rise O +
of O +
left O +
ventricular O +
pressure O +
( O -
LV O +
dP O -
/ O -
dt O +
max O -
) O +
had O +
been O +
reduced O +
by O +
about O +
35 O -
% O +
and O +
26 O -
% O +
of O +
the O +
respective O +
controls O +
were O +
improved O +
by O +
denopamine O +
( O -
10 O -
- O -
300 O +
micrograms O -
) O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O -

With O +
100 O +
micrograms O +
denopamine O -
, O +
almost O +
complete O +
restoration O +
of O +
cardiac O +
performance O +
was O +
attained O -
, O +
associated O +
with O +
a O +
slight O +
increase O +
in O +
heart O +
rate O -
. O -

No O +
arrhythmias U-Disease +
were O +
induced O +
by O +
these O +
doses O +
of O +
denopamine O -
. O -

The O +
results O +
warrant O +
clinical O +
trials O +
of O +
denopamine O +
in O +
the O +
treatment O +
of O +
cardiac B-Disease +
failure L-Disease -
. O -

Clonazepam O +
monotherapy O +
for O +
epilepsy U-Disease +
in O +
childhood O -
. O -

Sixty O +
patients O +
( O -
age O -
- O -
range O +
one O +
month O +
to O +
14 O +
years O -
) O +
with O +
other O +
types O +
of O +
epilepsy U-Disease +
than O +
infantile B-Disease +
spasms L-Disease +
were O +
treated O +
with O +
clonazepam O -
. O -

Disappearance O +
of O +
seizures U-Disease +
and O +
normalization O +
of O +
abnormal O +
EEG O +
with O +
disappearance O +
of O +
seizures U-Disease +
were O +
recognized O +
in O +
77 O -
% O +
and O +
50 O -
% O -
, O +
respectively O -
. O -

Seizures U-Disease +
disappeared O +
in O +
71 O -
% O +
of O +
the O +
patients O +
with O +
generalized O +
seizures U-Disease +
and O +
89 O -
% O +
of O +
partial O +
seizures U-Disease -
. O -

Improvement O +
of O +
abnormal O +
EEG O +
was O +
noticed O +
in O +
76 O -
% O +
of O +
diffuse O +
paroxysms O +
and O +
in O +
67 O -
% O +
of O +
focal O +
paroxysms O -
. O -

In O +
excellent O +
cases O -
, O +
mean O +
effective O +
dosages O +
were O +
0.086 O +
+ O -
/- O -

0.021 O +
mg O -
/ O -
kg O -
/ O -
day O +
in O +
infants O +
and O +
0.057 O +
+ O -
/- O -

0.022 O +
mg O -
/ O -
kg O -
/ O -
day O +
in O +
schoolchildren O -
, O +
this O +
difference O +
was O +
statistically O +
significant O +
( O -
p O +
less O +
than O +
0.005 O -
) O -
. O -

The O +
incidence O +
of O +
side O +
effects O +
such O +
as O +
drowsiness U-Disease +
and O +
ataxia U-Disease +
was O +
only O +
5 O -
% O -
. O -

Postmarketing O +
study O +
of O +
timolol O -
- O -
hydrochlorothiazide O +
antihypertensive O +
therapy O -
. O -

A O +
postmarketing O +
surveillance O +
study O +
was O +
conducted O +
to O +
determine O +
the O +
safety O +
and O +
efficacy O +
of O +
a O +
fixed O -
- O -
ratio O +
combination O +
containing O +
10 O +
mg O +
of O +
timolol O +
maleate O +
and O +
25 O +
mg O +
of O +
hydrochlorothiazide O -
, O +
administered O +
twice O +
daily O +
for O +
one O +
month O +
to O +
hypertensive U-Disease +
patients O -
. O -

Data O +
on O +
9,037 O +
patients O +
were O +
collected O +
by O +
1,455 O +
participating O +
physicians O -
. O -

Mean O +
systolic O +
blood O +
pressure O +
decreased O +
25 O +
mmHg O +
and O +
mean O +
diastolic O +
blood O +
pressure O +
declined O +
15 O +
mmHg O +
after O +
one O +
month O +
of O +
timolol O -
- O -
hydrochlorothiazide O +
therapy O +
( O -
P O +
less O +
than O +
0.01 O -
, O +
both O +
comparisons O -
) O -
. O -

Age O -
, O +
race O -
, O +
and O +
sex O +
appeared O +
to O +
have O +
no O +
influence O +
on O +
the O +
decrease O +
in O +
blood O +
pressure O -
. O -

The O +
antihypertensive O +
effect O +
of O +
the O +
drug O +
was O +
greater O +
in O +
patients O +
with O +
more O +
severe O +
hypertension U-Disease -
. O -

Overall O -
, O +
1,453 O +
patients O +
experienced O +
a O +
total O +
of O +
2,658 O +
adverse O +
events O -
, O +
the O +
most O +
common O +
being O +
fatigue U-Disease -
, O +
dizziness U-Disease -
, O +
and O +
weakness U-Disease -
. O -

Treatment O +
in O +
590 O +
patients O +
was O +
discontinued O +
because O +
of O +
adverse O +
events O -
. O -

Salicylate O +
nephropathy U-Disease +
in O +
the O +
Gunn O +
rat O -
: O +
potential O +
role O +
of O +
prostaglandins O -
. O -

We O +
examined O +
the O +
potential O +
role O +
of O +
prostaglandins O +
in O +
the O +
development O +
of O +
analgesic O +
nephropathy U-Disease +
in O +
the O +
Gunn O +
strain O +
of O +
rat O -
. O -

The O +
homozygous O +
Gunn O +
rats O +
have O +
unconjugated O +
hyperbilirubinemia U-Disease +
due O +
to O +
the O +
absence O +
of O +
glucuronyl O +
transferase O -
, O +
leading O +
to O +
marked O +
bilirubin O +
deposition O +
in O +
renal O +
medulla O +
and O +
papilla O -
. O -

These O +
rats O +
are O +
also O +
highly O +
susceptible O +
to O +
develop O +
papillary B-Disease +
necrosis L-Disease +
with O +
analgesic O +
administration O -
. O -

We O +
used O +
homozygous O +
( O -
jj O -
) O +
and O +
phenotypically O +
normal O +
heterozygous O +
( O -
jJ O -
) O +
animals O -
. O -

Four O +
groups O +
of O +
rats O +
( O -
n O +
= O +
7 O -
) O +
were O +
studied O -
: O +
jj O +
and O +
jJ O +
rats O +
treated O +
either O +
with O +
aspirin O +
300 O +
mg O -
/ O -
kg O +
every O +
other O +
day O +
or O +
sham O -
- O -
treated O -
. O -

After O +
one O +
week O -
, O +
slices O +
of O +
cortex O -
, O +
outer O +
and O +
inner O +
medulla O +
from O +
one O +
kidney O +
were O +
incubated O +
in O +
buffer O +
and O +
prostaglandin O +
synthesis O +
was O +
determined O +
by O +
radioimmunoassay O -
. O -

The O +
other O +
kidney O +
was O +
examined O +
histologically O -
. O -

A O +
marked O +
corticomedullary O +
gradient O +
of O +
prostaglandin O +
synthesis O +
was O +
observed O +
in O +
all O +
groups O -
. O -

PGE2 O +
synthesis O +
was O +
significantly O +
higher O +
in O +
outer O +
medulla O -
, O +
but O +
not O +
cortex O +
or O +
inner O +
medulla O -
, O +
of O +
jj O +
( O -
38 O +
+ O -
/- O -

6 O +
ng O -
/ O -
mg O +
prot O -
) O +
than O +
jJ O +
rats O +
( O -
15 O +
+ O -
/- O -

3 O -
) O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
. O -

Aspirin O +
treatment O +
reduced O +
PGE2 O +
synthesis O +
in O +
all O +
regions O -
, O +
but O +
outer O +
medullary O +
PGE2 O +
remained O +
higher O +
in O +
jj O +
( O -
18 O +
+ O -
/- O -

3 O -
) O +
than O +
jJ O +
rats O +
( O -
9 O +
+ O -
/- O -

2 O -
) O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
. O -

PGF2 O +
alpha O +
was O +
also O +
significantly O +
higher O +
in O +
the O +
outer O +
medulla O +
of O +
jj O +
rats O +
with O +
and O +
without O +
aspirin O +
administration O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
. O -

The O +
changes O +
in O +
renal O +
prostaglandin O +
synthesis O +
were O +
accompanied O +
by O +
evidence O +
of O +
renal B-Disease +
damage L-Disease +
in O +
aspirin O -
- O -
treated O +
jj O +
but O +
not O +
jJ O +
rats O +
as O +
evidenced O +
by O -
: O +
increased O +
incidence O +
and O +
severity O +
of O +
hematuria U-Disease +
( O -
p O +
less O +
than O +
0.01 O -
) O -
; O +
increased O +
serum O +
creatinine O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
; O +
and O +
increase O +
in O +
outer O +
medullary O +
histopathologic O +
lesions O +
( O -
p O +
less O +
than O +
0.005 O +
compared O +
to O +
either O +
sham O -
- O -
treated O +
jj O +
or O +
aspirin O -
- O -
treated O +
jJ O -
) O -
. O -

These O +
results O +
suggest O +
that O +
enhanced O +
prostaglandin O +
synthesis O +
contributes O +
to O +
maintenance O +
of O +
renal O +
function O +
and O +
morphological O +
integrity O -
, O +
and O +
that O +
inhibition O +
of O +
prostaglandin O +
synthesis O +
may O +
lead O +
to O +
pathological B-Disease +
renal I-Disease +
medullary I-Disease +
lesions L-Disease +
and O +
deterioration B-Disease +
of I-Disease +
renal I-Disease +
function L-Disease -
. O -

Prophylactic O +
lidocaine O +
in O +
the O +
early O +
phase O +
of O +
suspected O +
myocardial B-Disease +
infarction L-Disease -
. O -

Four O +
hundred O +
two O +
patients O +
with O +
suspected O +
myocardial B-Disease +
infarction L-Disease +
seen O +
within O +
6 O +
hours O +
of O +
the O +
onset O +
of O +
symptoms O +
entered O +
a O +
double O -
- O -
blind O +
randomized O +
trial O +
of O +
lidocaine O +
vs O +
placebo O -
. O -

During O +
the O +
1 O +
hour O +
after O +
administration O +
of O +
the O +
drug O +
the O +
incidence O +
of O +
ventricular B-Disease +
fibrillation L-Disease +
or O +
sustained O +
ventricular B-Disease +
tachycardia L-Disease +
among O +
the O +
204 O +
patients O +
with O +
acute O +
myocardial B-Disease +
infarction L-Disease +
was O +
low O -
, O +
1.5 O -
% O -
. O -

Lidocaine O -
, O +
given O +
in O +
a O +
300 O +
mg O +
dose O +
intramuscularly O +
followed O +
by O +
100 O +
mg O +
intravenously O -
, O +
did O +
not O +
prevent O +
sustained O +
ventricular B-Disease +
tachycardia L-Disease -
, O +
although O +
there O +
was O +
a O +
significant O +
reduction O +
in O +
the O +
number O +
of O +
patients O +
with O +
warning O +
arrhythmias U-Disease +
between O +
15 O +
and O +
45 O +
minutes O +
after O +
the O +
administration O +
of O +
lidocaine O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
. O -

The O +
average O +
plasma O +
lidocaine O +
level O +
10 O +
minutes O +
after O +
administration O +
for O +
patients O +
without O +
a O +
myocardial B-Disease +
infarction L-Disease +
was O +
significantly O +
higher O +
than O +
that O +
for O +
patients O +
with O +
an O +
acute O +
infarction U-Disease -
. O -

The O +
mean O +
plasma O +
lidocaine O +
level O +
of O +
patients O +
on O +
beta O -
- O -
blocking O +
agents O +
was O +
no O +
different O +
from O +
that O +
in O +
patients O +
not O +
on O +
beta O +
blocking O +
agents O -
. O -

During O +
the O +
1-hour O +
study O +
period O -
, O +
the O +
incidence O +
of O +
central O +
nervous O +
system O +
side O +
effects O +
was O +
significantly O +
greater O +
in O +
the O +
lidocaine O +
group O -
, O +
hypotension U-Disease +
occurred O +
in O +
11 O +
patients O -
, O +
nine O +
of O +
whom O +
had O +
received O +
lidocaine O -
, O +
and O +
four O +
patients O +
died O +
from O +
asystole U-Disease -
, O +
three O +
of O +
whom O +
had O +
had O +
lidocaine O -
. O -

We O +
can O -
not O +
advocate O +
the O +
administration O +
of O +
lidocaine O +
prophylactically O +
in O +
the O +
early O +
hours O +
of O +
suspected O +
myocardial B-Disease +
infarction L-Disease -
. O -

Evidence O +
for O +
a O +
cholinergic O +
role O +
in O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease -
. O -

Experiments O +
in O +
mice O +
tested O +
previous O +
evidence O +
that O +
activation O +
of O +
cholinergic O +
systems O +
promotes O +
catalepsy U-Disease +
and O +
that O +
cholinergic O +
mechanisms O +
need O +
to O +
be O +
intact O +
for O +
full O +
expression O +
of O +
neuroleptic O -
- O -
induced O +
catalepsy U-Disease -
. O -

Large O +
doses O +
of O +
the O +
cholinomimetic O -
, O +
pilocarpine O -
, O +
could O +
induce O +
catalepsy U-Disease +
when O +
peripheral O +
cholinergic O +
receptors O +
were O +
blocked O -
. O -

Low O +
doses O +
of O +
pilocarpine O +
caused O +
a O +
pronounced O +
enhancement O +
of O +
the O +
catalepsy U-Disease +
that O +
was O +
induced O +
by O +
the O +
dopaminergic O +
blocker O -
, O +
haloperidol O -
. O -

A O +
muscarinic O +
receptor O +
blocker O -
, O +
atropine O -
, O +
disrupted O +
haloperidol O -
- O -
induced O +
catalepsy U-Disease -
. O -

Intracranial O +
injection O +
of O +
an O +
acetylcholine O -
- O -
synthesis O +
inhibitor O -
, O +
hemicholinium O -
, O +
prevented O +
the O +
catalepsy U-Disease +
that O +
is O +
usually O +
induced O +
by O +
haloperidol O -
. O -

These O +
findings O +
suggest O +
the O +
hypothesis O +
that O +
the O +
catalepsy U-Disease +
that O +
is O +
produced O +
by O +
neuroleptics O +
such O +
as O +
haloperidol O +
is O +
actually O +
mediated O +
by O +
intrinsic O +
central O +
cholinergic O +
systems O -
. O -

Alternatively O -
, O +
activation O +
of O +
central O +
cholinergic O +
systems O +
could O +
promote O +
catalepsy U-Disease +
by O +
suppression O +
of O +
dopaminergic O +
systems O -
. O -

Cardiovascular B-Disease +
dysfunction L-Disease +
and O +
hypersensitivity U-Disease +
to O +
sodium O +
pentobarbital O +
induced O +
by O +
chronic O +
barium O +
chloride O +
ingestion O -
. O -

Barium O -
- O -
supplemented O +
Long O -
- O -
Evans O +
hooded O +
rats O +
were O +
characterized O +
by O +
a O +
persistent O +
hypertension U-Disease +
that O +
was O +
evident O +
after O +
1 O +
month O +
of O +
barium O +
( O -
100 O +
micrograms O -
/ O -
ml O +
mineral O +
fortified O +
water O -
) O +
treatment O -
. O -

Analysis O +
of O +
in O +
vivo O +
myocardial O +
excitability O -
, O +
contractility O -
, O +
and O +
metabolic O +
characteristics O +
at O +
16 O +
months O +
revealed O +
other O +
significant O +
barium O -
- O -
induced O +
disturbances B-Disease +
within I-Disease +
the I-Disease +
cardiovascular I-Disease +
system L-Disease -
. O -

The O +
most O +
distinctive O +
aspect O +
of O +
the O +
barium O +
effect O +
was O +
a O +
demonstrated O +
hypersensitivity U-Disease +
of O +
the O +
cardiovascular O +
system O +
to O +
sodium O +
pentobarbital O -
. O -

Under O +
barbiturate O +
anesthesia O -
, O +
virtually O +
all O +
of O +
the O +
myocardial O +
contractile O +
indices O +
were O +
depressed O +
significantly O +
in O +
barium O -
- O -
exposed O +
rats O +
relative O +
to O +
the O +
corresponding O +
control O -
- O -
fed O +
rats O -
. O -

The O +
lack O +
of O +
a O +
similar O +
response O +
to O +
ketamine O +
and O +
xylazine O +
anesthesia O +
revealed O +
that O +
the O +
cardiovascular O +
actions O +
of O +
sodium O +
pentobarbital O +
in O +
barium O -
- O -
treated O +
rats O +
were O +
linked O +
specifically O +
to O +
this O +
anesthetic O -
, O +
and O +
were O +
not O +
representative O +
of O +
a O +
generalized O +
anesthetic O +
response O -
. O -

Other O +
myocardial O +
pathophysiologic O +
and O +
metabolic O +
changes O +
induced O +
by O +
barium O +
were O +
manifest O -
, O +
irrespective O +
of O +
the O +
anesthetic O +
employed O -
. O -

The O +
contractile O +
element O +
shortening O +
velocity O +
of O +
the O +
cardiac O +
muscle O +
fibers O +
was O +
significantly O +
slower O +
in O +
both O +
groups O +
of O +
barium O -
- O -
treated O +
rats O +
relative O +
to O +
the O +
control O +
groups O -
, O +
irrespective O +
of O +
the O +
anesthetic O +
regimen O -
. O -

Similarly O -
, O +
significant O +
disturbances O +
in O +
myocardial O +
energy O +
metabolism O +
were O +
detected O +
in O +
the O +
barium O -
- O -
exposed O +
rats O +
which O +
were O +
consistent O +
with O +
the O +
reduced O +
contractile O +
element O +
shortening O +
velocity O -
. O -

In O +
addition O -
, O +
the O +
excitability O +
of O +
the O +
cardiac O +
conduction O +
system O +
was O +
depressed O +
preferentially O +
in O +
the O +
atrioventricular O +
nodal O +
region O +
of O +
hearts O +
from O +
barium O -
- O -
exposed O +
rats O -
. O -

Overall O -
, O +
the O +
altered O +
cardiac O +
contractility O +
and O +
excitability O +
characteristics O -
, O +
the O +
myocardial O +
metabolic B-Disease +
disturbances L-Disease -
, O +
and O +
the O +
hypersensitivity U-Disease +
of O +
the O +
cardiovascular O +
system O +
to O +
sodium O +
pentobarbital O +
suggest O +
the O +
existence O +
of O +
a O +
heretofore O +
undescribed O +
cardiomyopathic B-Disease +
disorder L-Disease +
induced O +
by O +
chronic O +
barium O +
exposure O -
. O -

These O +
experimental O +
findings O +
represent O +
the O +
first O +
indication O +
that O +
life O -
- O -
long O +
barium O +
ingestion O +
may O +
have O +
significant O +
adverse O +
effects O +
on O +
the O +
mammalian O +
cardiovascular O +
system O -
. O -

Propranolol O +
antagonism O +
of O +
phenylpropanolamine O -
- O -
induced O +
hypertension U-Disease -
. O -

Phenylpropanolamine O +
( O -
PPA O -
) O +
overdose U-Disease +
can O +
cause O +
severe O +
hypertension U-Disease -
, O +
intracerebral B-Disease +
hemorrhage L-Disease -
, O +
and O +
death O -
. O -

We O +
studied O +
the O +
efficacy O +
and O +
safety O +
of O +
propranolol O +
in O +
the O +
treatment O +
of O +
PPA O -
- O -
induced O +
hypertension U-Disease -
. O -

Subjects O +
received O +
propranolol O +
either O +
by O +
mouth O +
for O +
48 O +
hours O +
before O +
PPA O +
or O +
as O +
a O +
rapid O +
intravenous O +
infusion O +
after O +
PPA O -
. O -

PPA O -
, O +
75 O +
mg O +
alone O -
, O +
increased O +
blood O +
pressure O +
( O -
31 O +
+ O -
/- O -

14 O +
mm O +
Hg O +
systolic O -
, O +
20 O +
+ O -
/- O -

5 O +
mm O +
Hg O +
diastolic O -
) O -
, O +
and O +
propranolol O +
pretreatment O +
antagonized O +
this O +
increase O +
( O -
12 O +
+ O -
/- O -

10 O +
mm O +
Hg O +
systolic O -
, O +
10 O +
+ O -
/- O -

7 O +
mm O +
Hg O +
diastolic O -
) O -
. O -

Intravenous O +
propranolol O +
after O +
PPA O +
also O +
decreased O +
blood O +
pressure O -
. O -

Left O +
ventricular O +
function O +
( O -
assessed O +
by O +
echocardiography O -
) O +
showed O +
that O +
PPA O +
increased O +
the O +
stroke U-Disease +
volume O +
30 O -
% O +
( O -
from O +
62.5 O +
+ O -
/- O -

20.9 O +
to O +
80.8 O +
+ O -
/- O -

22.4 O +
ml O -
) O -
, O +
the O +
ejection O +
fraction O +
9 O -
% O +
( O -
from O +
64 O -
% O +
+ O -
/- O -

10 O -
% O +
to O +
70 O -
% O +
+ O -
/- O -

7 O -
% O -
) O -
, O +
and O +
cardiac O +
output O +
14 O -
% O +
( O -
from O +
3.6 O +
+ O -
/- O -

0.6 O +
to O +
4.1 O +
+ O -
/- O -

1.0 O +
L O -
/ O -
min O -
) O -
. O -

Intravenous O +
propranolol O +
reversed O +
these O +
effects O -
. O -

Systemic O +
vascular O +
resistance O +
was O +
increased O +
by O +
PPA O +
28 O -
% O +
( O -
from O +
1710 O +
+ O -
/- O -

200 O +
to O +
2190 O +
+ O -
/- O -

700 O +
dyne O +
X O +
sec O -
/ O -
cm5 O -
) O +
and O +
was O +
further O +
increased O +
by O +
propranolol O +
22 O -
% O +
( O -
to O +
2660 O +
+ O -
/- O -

1200 O +
dyne O +
X O +
sec O -
/ O -
cm5 O -
) O -
. O -

We O +
conclude O +
that O +
PPA O +
increases O +
blood O +
pressure O +
by O +
increasing O +
systemic O +
vascular O +
resistance O +
and O +
cardiac O +
output O -
, O +
and O +
that O +
propranolol O +
antagonizes O +
this O +
increase O +
by O +
reversing O +
the O +
effect O +
of O +
PPA O +
on O +
cardiac O +
output O -
. O -

That O +
propranolol O +
antagonizes O +
the O +
pressor O +
effect O +
of O +
PPA O +
is O +
in O +
contrast O +
to O +
the O +
interaction O +
in O +
which O +
propranolol O +
enhances O +
the O +
pressor O +
effect O +
of O +
norepinephrine O -
. O -

This O +
is O +
probably O +
because O +
PPA O +
has O +
less O +
beta O +
2 O +
activity O +
than O +
does O +
norepinephrine O -
. O -

Mesangial O +
function O +
and O +
glomerular B-Disease +
sclerosis L-Disease +
in O +
rats O +
with O +
aminonucleoside O +
nephrosis U-Disease -
. O -

The O +
possible O +
relationship O +
between O +
mesangial B-Disease +
dysfunction L-Disease +
and O +
development O +
of O +
glomerular B-Disease +
sclerosis L-Disease +
was O +
studied O +
in O +
the O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O +
model O -
. O -

Five O +
male O +
Wistar O +
rats O +
received O +
repeated O +
subcutaneous O +
PAN O +
injections O -
; O +
five O +
controls O +
received O +
saline O +
only O -
. O -

After O +
4 O +
weeks O +
the O +
PAN O +
rats O +
were O +
severely O +
proteinuric U-Disease +
( O -
190 O +
+ O -
/- O -

80 O +
mg O -
/ O -
24 O +
hr O -
) O -
, O +
and O +
all O +
rats O +
were O +
given O +
colloidal O +
carbon O +
( O -
CC O -
) O +
intravenously O -
. O -

At O +
5 O +
months O +
glomerular B-Disease +
sclerosis L-Disease +
was O +
found O +
in O +
7.6 O +
+ O -
/- O -

3.4 O -
% O +
of O +
the O +
glomeruli O +
of O +
PAN O +
rats O -
; O +
glomeruli O +
of O +
the O +
controls O +
were O +
normal O -
. O -

Glomeruli O +
of O +
PAN O +
rats O +
contained O +
significantly O +
more O +
CC O +
than O +
glomeruli O +
of O +
controls O -
. O -

Glomeruli O +
with O +
sclerosis U-Disease +
contained O +
significantly O +
more O +
CC O +
than O +
non O -
- O -
sclerotic O +
glomeruli O +
in O +
the O +
same O +
kidneys O -
. O -

CC O +
was O +
preferentially O +
localized O +
within O +
the O +
sclerotic O +
areas O +
of O +
the O +
affected O +
glomeruli O -
. O -

Since O +
mesangial O +
CC O +
clearance O +
from O +
the O +
mesangium O +
did O +
not O +
change O +
during O +
chronic O +
PAN O +
treatment O -
, O +
we O +
conclude O +
that O +
this O +
preferential O +
CC O +
localization O +
within O +
the O +
lesions O +
is O +
caused O +
by O +
an O +
increased O +
CC O +
uptake O +
shortly O +
after O +
injection O +
in O +
apparent O +
vulnerable O +
areas O +
where O +
sclerosis U-Disease +
will O +
develop O +
subsequently O -
. O -

Cluster O +
analysis O +
showed O +
a O +
random O +
distribution O +
of O +
lesions O +
in O +
the O +
PAN O +
glomeruli O +
in O +
concordance O +
with O +
the O +
random O +
localization O +
of O +
mesangial O +
areas O +
with O +
dysfunction O +
in O +
this O +
model O -
. O -

Similar O +
to O +
the O +
remnant O +
kidney O +
model O +
in O +
PAN O +
nephrosis U-Disease +
the O +
development O +
of O +
glomerular B-Disease +
sclerosis L-Disease +
may O +
be O +
related O +
to O +
" O -
mesangial O +
overloading O -
. O -
" O -

Relationship O +
between O +
nicotine O -
- O -
induced O +
seizures U-Disease +
and O +
hippocampal O +
nicotinic O +
receptors O -
. O -

A O +
controversy O +
has O +
existed O +
for O +
several O +
years O +
concerning O +
the O +
physiological O +
relevance O +
of O +
the O +
nicotinic O +
receptor O +
measured O +
by O +
alpha O -
- O -
bungarotoxin O +
binding O -
. O -

Using O +
mice O +
derived O +
from O +
a O +
classical O +
F2 O +
and O +
backcross O +
genetic O +
design O -
, O +
a O +
relationship O +
between O +
nicotine O -
- O -
induced O +
seizures U-Disease +
and O +
alpha O -
- O -
bungarotoxin O +
nicotinic O +
receptor O +
concentration O +
was O +
found O -
. O -

Mice O +
sensitive O +
to O +
the O +
convulsant O +
effects O +
of O +
nicotine O +
had O +
greater O +
alpha O -
- O -
bungarotoxin O +
binding O +
in O +
the O +
hippocampus O +
than O +
seizure U-Disease +
insensitive O +
mice O -
. O -

The O +
binding O +
sites O +
from O +
seizure U-Disease +
sensitive O +
and O +
resistant O +
mice O +
were O +
equally O +
affected O +
by O +
treatment O +
with O +
dithiothreitol O -
, O +
trypsin O +
or O +
heat O -
. O -

Thus O +
it O +
appears O +
that O +
the O +
difference O +
between O +
seizure U-Disease +
sensitive O +
and O +
insensitive O +
animals O +
may O +
be O +
due O +
to O +
a O +
difference O +
in O +
hippocampal O +
nicotinic O +
receptor O +
concentration O +
as O +
measured O +
with O +
alpha O -
- O -
bungarotoxin O +
binding O -
. O -

The O +
role O +
of O +
p O -
- O -
aminophenol O +
in O +
acetaminophen O -
- O -
induced O +
nephrotoxicity U-Disease -
: O +
effect O +
of O +
bis O -
( O -
p O -
- O -
nitrophenyl O -
) O +
phosphate O +
on O +
acetaminophen O +
and O +
p O -
- O -
aminophenol O +
nephrotoxicity U-Disease +
and O +
metabolism O +
in O +
Fischer O +
344 O +
rats O -
. O -

Acetaminophen O +
( O -
APAP O -
) O +
produces O +
proximal O +
tubular B-Disease +
necrosis L-Disease +
in O +
Fischer O +
344 O +
( O -
F344 O -
) O +
rats O -
. O -

Recently O -
, O +
p O -
- O -
aminophenol O +
( O -
PAP O -
) O -
, O +
a O +
known O +
potent O +
nephrotoxicant O -
, O +
was O +
identified O +
as O +
a O +
metabolite O +
of O +
APAP O +
in O +
F344 O +
rats O -
. O -

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
if O +
PAP O +
formation O +
is O +
a O +
requisite O +
step O +
in O +
APAP O -
- O -
induced O +
nephrotoxicity U-Disease -
. O -

Therefore O -
, O +
the O +
effect O +
of O +
bis O -
( O -
p O -
- O -
nitrophenyl O -
) O +
phosphate O +
( O -
BNPP O -
) O -
, O +
an O +
acylamidase O +
inhibitor O -
, O +
on O +
APAP O +
and O +
PAP O +
nephrotoxicity U-Disease +
and O +
metabolism O +
was O +
determined O -
. O -

BNPP O +
( O -
1 O +
to O +
8 O +
mM O -
) O +
reduced O +
APAP O +
deacetylation O +
and O +
covalent O +
binding O +
in O +
F344 O +
renal O +
cortical O +
homogenates O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O -

Pretreatment O +
of O +
animals O +
with O +
BNPP O +
prior O +
to O +
APAP O +
or O +
PAP O +
administration O +
resulted O +
in O +
marked O +
reduction O +
of O +
APAP O +
( O -
900 O +
mg O -
/ O -
kg O -
) O +
nephrotoxicity U-Disease +
but O +
not O +
PAP O +
nephrotoxicity U-Disease -
. O -

This O +
result O +
was O +
not O +
due O +
to O +
altered O +
disposition O +
of O +
either O +
APAP O +
or O +
acetylated O +
metabolites O +
in O +
plasma O +
or O +
renal O +
cortical O +
and O +
hepatic O +
tissue O -
. O -

Rather O -
, O +
BNPP O +
pretreatment O +
reduced O +
the O +
fraction O +
of O +
APAP O +
excreted O +
as O +
PAP O +
by O +
64 O +
and O +
75 O -
% O +
after O +
APAP O +
doses O +
of O +
750 O +
and O +
900 O +
mg O -
/ O -
kg O -
. O -

BNPP O +
did O +
not O +
alter O +
the O +
excretion O +
of O +
APAP O +
or O +
any O +
of O +
its O +
non O -
- O -
deacetylated O +
metabolites O +
nor O +
did O +
BNPP O +
alter O +
excretion O +
of O +
PAP O +
or O +
its O +
metabolites O +
after O +
PAP O +
doses O +
of O +
150 O +
and O +
300 O +
mg O -
/ O -
kg O -
. O -

Therefore O -
, O +
the O +
BNPP O -
- O -
induced O +
reduction O +
in O +
APAP O -
- O -
induced O +
nephrotoxicity U-Disease +
appears O +
to O +
be O +
due O +
to O +
inhibition O +
of O +
APAP O +
deacetylation O -
. O -

It O +
is O +
concluded O +
that O +
PAP O +
formation O -
, O +
in O +
vivo O -
, O +
accounts O -
, O +
at O +
least O +
in O +
part O -
, O +
for O +
APAP O -
- O -
induced O +
renal B-Disease +
tubular I-Disease +
necrosis L-Disease -
. O -

Morphine O -
- O -
induced O +
seizures U-Disease +
in O +
newborn O +
infants O -
. O -

Two O +
neonates O +
suffered O +
from O +
generalized O +
seizures U-Disease +
during O +
the O +
course O +
of O +
intravenous O +
morphine O +
sulfate O +
for O +
post O -
- O -
operative O +
analgesia O -
. O -

They O +
received O +
morphine O +
in O +
doses O +
of O +
32 O +
micrograms O -
/ O -
kg O -
/ O -
hr O +
and O +
40 O +
micrograms O -
/ O -
kg O -
/ O -
hr O +
larger O +
than O +
a O +
group O +
of O +
10 O +
neonates O +
who O +
received O +
6 O -
- O -
24 O +
micrograms O -
/ O -
kg O -
/ O -
hr O +
and O +
had O +
no O +
seizures U-Disease -
. O -

Plasma O +
concentrations O +
of O +
morphine O +
in O +
these O +
neonates O +
was O +
excessive O +
( O -
60 O +
and O +
90 O +
mg O -
/ O -
ml O -
) O -
. O -

Other O +
known O +
reasons O +
for O +
seizures U-Disease +
were O +
ruled O +
out O +
and O +
the O +
convulsions U-Disease +
stopped O +
a O +
few O +
hours O +
after O +
cessation O +
of O +
morphine O +
and O +
did O +
not O +
reoccur O +
in O +
the O +
subsequent O +
8 O +
months O -
. O -

It O +
is O +
suggested O +
that O +
post O -
- O -
operative O +
intravenous O +
morphine O +
should O +
not O +
exceed O +
20 O +
micrograms O -
/ O -
kg O -
/ O -
ml O +
in O +
neonates O -
. O -

On O +
the O +
antiarrhythmic O +
activity O +
of O +
one O +
N O -
- O -
substituted O +
piperazine O +
derivative O +
of O +
trans-2-amino-3-hydroxy-1 O -
, O +
2 O -
, O +
3 O -
, O +
4-tetrahydroanaphthalene O -
. O -

The O +
antiarrhythmic O +
activity O +
of O +
the O +
compound O +
N- O -
( O -
trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl O -
) O -
-N- O -
( O -
3-oxo-3-phenyl-2-methylpropyl O -
) O -
-piperazine O +
hydrochloride O -
, O +
referred O +
to O +
as O +
P11 O -
, O +
is O +
studied O +
on O +
anaesthesized O +
cats O +
and O +
Wistar O +
albino O +
rats O -
, O +
as O +
well O +
as O +
on O +
non O -
- O -
anaesthesized O +
rabbits O -
. O -

Four O +
types O +
of O +
experimental O +
arrhythmia U-Disease +
are O +
used O -
-- O -
with O +
BaCl2 O -
, O +
with O +
chloroform O -
- O -
adrenaline O -
, O +
with O +
strophantine O +
G O +
and O +
with O +
aconitine O -
. O -

The O +
compound O +
P11 O +
is O +
introduced O +
in O +
doses O +
of O +
0.25 O +
and O +
0.50 O +
mg O -
/ O -
kg O +
intravenously O +
and O +
10 O +
mg O -
/ O -
kg O +
orally O -
. O -

The O +
compound O +
manifests O +
antiarrhythmic O +
activity O +
in O +
all O +
models O +
of O +
experimental O +
arrhythmia U-Disease +
used O -
, O +
causing O +
greatest O +
inhibition O +
on O +
the O +
arrhythmia U-Disease +
induced O +
by O +
chloroform O -
- O -
adrenaline O +
( O -
in O +
90 O +
per O +
cent O -
) O +
and O +
with O +
BaCl2 O +
( O -
in O +
84 O +
per O +
cent O -
) O -
. O -

The O +
results O +
obtained O +
are O +
associated O +
with O +
the O +
beta O -
- O -
adrenoblocking O +
and O +
with O +
the O +
membrane O -
- O -
stabilizing O +
action O +
of O +
the O +
compound O -
. O -

Recurrent O +
subarachnoid B-Disease +
hemorrhage L-Disease +
associated O +
with O +
aminocaproic O +
acid O +
therapy O +
and O +
acute B-Disease +
renal I-Disease +
artery I-Disease +
thrombosis L-Disease -
. O -

Case O +
report O -
. O -

Epsilon O +
aminocaproic O +
acid O +
( O -
EACA O -
) O +
has O +
been O +
used O +
to O +
prevent O +
rebleeding O +
in O +
patients O +
with O +
subarachnoid B-Disease +
hemorrhage L-Disease +
( O -
SAH U-Disease -
) O -
. O -

Although O +
this O +
agent O +
does O +
decrease O +
the O +
frequency O +
of O +
rebleeding O -
, O +
several O +
reports O +
have O +
described O +
thrombotic U-Disease +
complications O +
of O +
EACA O +
therapy O -
. O -

These O +
complications O +
have O +
included O +
clinical O +
deterioration O +
and O +
intracranial B-Disease +
vascular I-Disease +
thrombosis L-Disease +
in O +
patients O +
with O +
SAH U-Disease -
, O +
arteriolar O +
and O +
capillary O +
fibrin O +
thrombi U-Disease +
in O +
patients O +
with O +
fibrinolytic O +
syndromes O +
treated O +
with O +
EACA O -
, O +
or O +
other O +
thromboembolic B-Disease +
phenomena L-Disease -
. O -

Since O +
intravascular O +
fibrin O +
thrombi U-Disease +
are O +
often O +
observed O +
in O +
patients O +
with O +
fibrinolytic O +
disorders O -
, O +
EACA O +
should O +
not O +
be O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
fibrin O +
thrombi U-Disease +
in O +
patients O +
with O +
disseminated B-Disease +
intravascular I-Disease +
coagulation L-Disease +
or O +
other O +
" O -
consumption B-Disease +
coagulopathies L-Disease -
. O -
" O -

This O +
report O +
describes O +
subtotal O +
infarction U-Disease +
of O +
the O +
kidney O +
due O +
to O +
thrombosis B-Disease +
of I-Disease +
a I-Disease +
normal I-Disease +
renal I-Disease +
artery L-Disease -
. O -

This O +
occlusion O +
occurred O +
after O +
EACA O +
therapy O +
in O +
a O +
patient O +
with O +
SAH U-Disease +
and O +
histopathological O +
documentation O +
of O +
recurrent O +
SAH U-Disease -
. O -

The O +
corresponding O +
clinical O +
event O +
was O +
characterized O +
by O +
marked O +
hypertension U-Disease +
and O +
abrupt O +
neurological O +
deterioration O -
. O -

Effect O +
of O +
vincristine O +
sulfate O +
on O +
Pseudomonas B-Disease +
infections L-Disease +
in O +
monkeys O -
. O -

In O +
rhesus O +
monkeys O -
, O +
intravenous O +
challenge O +
with O +
0.6 O +
x O +
10 O -
( O -
10 O -
) O +
to O +
2.2 O +
x O +
10 O -
( O -
10 O -
) O -
Pseudomonas O +
aeruginosa O +
organisms O +
caused O +
acute O +
illness O +
of O +
4 O +
to O +
5 O +
days O -
' O +
duration O +
with O +
spontaneous O +
recovery O +
in O +
13 O +
of O +
15 O +
monkeys O -
; O +
blood O +
cultures O +
became O +
negative O +
3 O +
to O +
17 O +
days O +
after O +
challenge O -
. O -

Leukocytosis U-Disease +
was O +
observed O +
in O +
all O +
monkeys O -
. O -

Intravenous O +
or O +
intratracheal O +
inoculation O +
of O +
2.0 O +
to O +
2.5 O +
mg O +
of O +
vincristine O +
sulfate O +
was O +
followed O +
by O +
leukopenia U-Disease +
in O +
4 O +
to O +
5 O +
days O -
. O -

Intravenous O +
inoculation O +
of O +
4.2 O +
x O +
10 O -
( O -
10 O -
) O +
to O +
7.8 O +
x O +
10 O -
( O -
10 O -
) O +
pyocin O +
type O +
6 O +
Pseudomonas O +
organisms O +
in O +
monkeys O +
given O +
vincristine O +
sulfate O +
4 O +
days O +
previously O +
resulted O +
in O +
fatal O +
infection U-Disease +
in O +
11 O +
of O +
14 O +
monkeys O -
, O +
whereas O +
none O +
of O +
four O +
receiving O +
Pseudomonas O +
alone O +
died O -
. O -

These O +
studies O +
suggest O +
that O +
an O +
antimetabolite O -
- O -
induced O +
leukopenia U-Disease +
predisposes O +
to O +
severe O +
Pseudomonas O +
sepsis U-Disease +
and O +
that O +
such O +
monkeys O +
may O +
serve O +
as O +
a O +
biological O +
model O +
for O +
study O +
of O +
comparative O +
efficacy O +
of O +
antimicrobial O +
agents O -
. O -

Modification O +
by O +
propranolol O +
of O +
cardiovascular O +
effects O +
of O +
induced O +
hypoglycaemia U-Disease -
. O -

The O +
cardiovascular O +
effects O +
of O +
hypoglycaemia U-Disease -
, O +
with O +
and O +
without O +
beta O -
- O -
blockade O -
, O +
were O +
compared O +
in O +
fourteen O +
healthy O +
men O -
. O -

Eight O +
received O +
insulin O +
alone O -
, O +
and O +
eight O -
, O +
including O +
two O +
of O +
the O +
original O +
insulin O -
- O -
only O +
group O -
, O +
were O +
given O +
propranolol O +
and O +
insulin O -
. O -

In O +
the O +
insulin O -
- O -
group O +
the O +
period O +
of O +
hypoglycaemia U-Disease +
was O +
associated O +
with O +
an O +
increase O +
in O +
heart O -
- O -
rate O +
and O +
a O +
fall O +
in O +
diastolic O +
blood O -
- O -
pressure O -
. O -

In O +
the O +
propranolol O -
- O -
insulin O +
group O +
there O +
was O +
a O +
significant O +
fall O +
in O +
heart O -
- O -
rate O +
in O +
most O +
subjects O +
and O +
an O +
increase O +
in O +
diastolic O +
pressure O -
. O -

Typical O +
S O -
- O -
T O -
/ O -
T O +
changes O +
occurred O +
in O +
the O +
insulin O -
- O -
group O +
but O +
in O +
none O +
of O +
the O +
propranolol O -
- O -
insulin O +
group O -
. O -

Hypertension U-Disease +
in O +
diabetics U-Disease +
prone O +
to O +
hypoglycaemia U-Disease +
attacks O +
should O +
not O +
be O +
treated O +
with O +
beta O -
- O -
blockers O +
because O +
these O +
drugs O +
may O +
cause O +
a O +
sharp O +
rise O +
in O +
blood O -
- O -
pressure O +
in O +
such O +
patients O -
. O -

Long O -
- O -
term O +
propranolol O +
therapy O +
in O +
pregnancy O -
: O +
maternal O +
and O +
fetal O +
outcome O -
. O -

Propranolol O -
, O +
a O +
beta O -
- O -
adrenergic O +
blocking O +
agent O -
, O +
has O +
found O +
an O +
important O +
position O +
in O +
the O +
practice O +
of O +
medicine O -
. O -

Its O +
use O +
in O +
pregnancy O -
, O +
however O -
, O +
is O +
an O +
open O +
question O +
as O +
a O +
number O +
of O +
detrimental O +
side O +
effects O +
have O +
been O +
reported O +
in O +
the O +
fetus O +
and O +
neonate O -
. O -

Ten O +
patients O +
and O +
12 O +
pregnancies O +
are O +
reported O +
where O +
chronic O +
propranolol O +
has O +
been O +
administered O -
. O -

Five O +
patients O +
with O +
serial O +
pregnancies O +
with O +
and O +
without O +
propranolol O +
therapy O +
are O +
also O +
examined O -
. O -

Maternal O -
, O +
fetal O -
, O +
and O +
neonatal O +
complications O +
are O +
examined O -
. O -

An O +
attempt O +
is O +
made O +
to O +
differentiate O +
drug O -
- O -
related O +
complications O +
from O +
maternal O +
disease O -
-- O -
related O +
complications O -
. O -

We O +
conclude O +
that O +
previously O +
reported O +
hypoglycemia U-Disease -
, O +
hyperbilirubinemia U-Disease -
, O +
polycythemia U-Disease -
, O +
neonatal B-Disease +
apnea L-Disease -
, O +
and O +
bradycardia U-Disease +
are O +
not O +
invariable O +
and O +
can O -
not O +
be O +
statistically O +
correlated O +
with O +
chronic O +
propranolol O +
therapy O -
. O -

Growth B-Disease +
retardation L-Disease -
, O +
however O -
, O +
appears O +
to O +
be O +
significant O +
in O +
both O +
of O +
our O +
series O -
. O -

Central O +
excitatory O +
actions O +
of O +
flurazepam O -
. O -

Toxic O +
actions O +
of O +
flurazepam O +
( O -
FZP O -
) O +
were O +
studied O +
in O +
cats O -
, O +
mice O +
and O +
rats O -
. O -

High O +
doses O +
caused O +
an O +
apparent O +
central O +
excitation O -
, O +
most O +
clearly O +
seen O +
as O +
clonic O +
convulsions U-Disease -
, O +
superimposed O +
on O +
general O +
depression U-Disease -
. O -

Following O +
a O +
lethal O +
dose O -
, O +
death O +
was O +
always O +
associated O +
with O +
convulsions U-Disease -
. O -

Comparing O +
the O +
relative O +
sensitivity O +
to O +
central O +
depression U-Disease +
and O +
excitation O +
revealed O +
that O +
rats O +
were O +
least O +
likely O +
to O +
have O +
convulsions U-Disease +
at O +
doses O +
that O +
did O +
not O +
first O +
cause O +
loss B-Disease +
of I-Disease +
consciousness L-Disease -
, O +
while O +
cats O +
most O +
clearly O +
showed O +
marked O +
central O +
excitatory O +
actions O -
. O -

Signs O +
of O +
FZP O +
toxocity U-Disease +
in O +
cats O +
included O +
excessive O +
salivation U-Disease -
, O +
extreme O +
apprehensive O +
behavior O -
, O +
retching O -
, O +
muscle B-Disease +
tremors L-Disease +
and O +
convulsions U-Disease -
. O -

An O +
interaction O +
between O +
FZP O +
and O +
pentylenetetrazol O +
( O -
PTZ O -
) O +
was O +
shown O +
by O +
pretreating O +
mice O +
with O +
FZP O +
before O +
PTZ O +
challenge O -
. O -

As O +
a O +
function O +
of O +
dose O -
, O +
FZP O +
first O +
protected O +
against O +
convulsions U-Disease +
and O +
death O -
. O -

At O +
higher O +
doses O -
, O +
however O -
, O +
convulsions U-Disease +
again O +
emerged O -
. O -

These O +
doses O +
of O +
FZP O +
were O +
lower O +
than O +
those O +
that O +
would O +
alone O +
cause O +
convulsions U-Disease -
. O -

These O +
results O +
may O +
be O +
relevant O +
to O +
the O +
use O +
of O +
FZP O +
in O +
clinical O +
situations O +
in O +
which O +
there O +
is O +
increased O +
neural O +
excitability O -
, O +
such O +
as O +
epilepsy U-Disease +
or O +
sedative O -
- O -
hypnotic O +
drug O +
withdrawal O -
. O -

Use O +
of O +
propranolol O +
in O +
the O +
treatment O +
of O +
idiopathic B-Disease +
orthostatic I-Disease +
hypotension L-Disease -
. O -

Five O +
patients O +
with O +
idiopathic B-Disease +
orthostatic I-Disease +
hypotension L-Disease +
who O +
had O +
physiologic O +
and O +
biochemical O +
evidence O +
of O +
severe O +
autonomic O +
dysfunction O +
were O +
included O +
in O +
the O +
study O -
. O -

They O +
all O +
exhibited O +
markedly O +
reduced O +
plasma O +
catecholamines O +
and O +
plasma O +
renin O +
activity O +
in O +
both O +
recumbent O +
and O +
upright O +
positions O +
and O +
had O +
marked O +
hypersensitivity U-Disease +
to O +
the O +
pressor O +
effects O +
of O +
infused O +
norepinephrine O -
. O -

Treatment O +
with O +
propanolol O +
administered O +
intravenously O +
( O -
1 O -
- O -
5 O +
mg O -
) O +
produced O +
increases O +
in O +
supine O +
and O +
upright O +
blood O +
pressure O +
in O +
4 O +
of O +
the O +
5 O +
individuals O +
with O +
rises O +
ranging O +
from O +
11 O -
/ O -
6 O +
to O +
22 O -
/ O -
11 O +
mmHg O -
. O -

Chronic O +
oral O +
administration O +
of O +
propranolol O +
( O -
40 O -
- O -
160 O +
mg O -
/ O -
day O -
) O +
also O +
elevated O +
the O +
blood O +
pressures O +
of O +
these O +
individuals O +
with O +
increases O +
in O +
the O +
order O +
of O +
20 O -
- O -
35 O -
/ O -
15 O -
- O -
25 O +
mmg O +
being O +
observed O -
. O -

In O +
1 O +
patient O -
, O +
marked O +
hypertension U-Disease +
was O +
induced O +
by O +
propranolol O +
and O +
the O +
drug O +
had O +
to O +
be O +
withdrawn O -
. O -

It O +
otherwise O +
was O +
well O +
tolerated O +
and O +
no O +
important O +
side O +
effects O +
were O +
observed O -
. O -

Treatment O +
has O +
been O +
continued O +
in O +
3 O +
individuals O +
for O +
6 O -
- O -
13 O +
months O +
with O +
persistence O +
of O +
the O +
pressor O +
effect O -
, O +
although O +
there O +
appears O +
to O +
have O +
been O +
some O +
decrease O +
in O +
the O +
degree O +
of O +
response O +
with O +
time O -
. O -

Hemodynamic O +
measurements O +
in O +
1 O +
of O +
the O +
patients O +
demonstrated O +
an O +
increase O +
in O +
total O +
peripheral O +
resistance O +
and O +
essentially O +
no O +
change O +
in O +
cardiac O +
output O +
following O +
propranolol O +
therapy O -
. O -

The O +
studies O +
suggest O +
that O +
propranolol O +
is O +
a O +
useful O +
drug O +
in O +
selected O +
patients O +
with O +
severe O +
idiopathic B-Disease +
orthostatic I-Disease +
hypotension L-Disease -
. O -

Total O +
intravenous O +
anesthesia O +
with O +
etomidate O -
. O -

III O -
. O -

Some O +
observations O +
in O +
adults O -
. O -

An O +
investigation O +
was O +
undertaken O +
to O +
determine O +
the O +
dosage O +
of O +
etomidate O +
required O +
to O +
maintain O +
sleep O +
in O +
adults O +
undergoing O +
surgery O +
under O +
regional O +
local O +
anesthesia O -
. O -

Premedication O +
of O +
diazepam O +
10 O +
mg O +
and O +
atropine O +
0.5 O +
mg O +
was O +
given O -
, O +
and O +
sleep O +
was O +
induced O +
and O +
maintained O +
by O +
intermittent O +
intravenous O +
injections O +
of O +
etomidate O +
0.1 O -
/ O -
mg O -
/ O -
kg O -
, O +
given O +
whenever O +
the O +
patient O +
would O +
open O +
his O +
eyes O +
on O +
request O -
. O -

A O +
mean O +
overall O +
dose O +
of O +
etomidate O +
17.4 O +
microgram O -
/ O -
kg O -
/ O -
min O -
. O +
was O +
required O +
to O +
maintain O +
sleep O -
, O +
but O +
great O +
individual O +
variation O +
occurred O -
, O +
with O +
older O +
patients O +
requiring O +
less O +
drug O -
. O -

The O +
investigation O +
was O +
discontinued O +
after O +
18 O +
patients O +
because O +
of O +
the O +
frequency O +
and O +
intensity O +
of O +
side O -
- O -
effects O -
, O +
particularly O +
pain U-Disease +
and O +
myoclonia U-Disease -
, O +
which O +
caused O +
the O +
technique O +
to O +
be O +
abandoned O +
in O +
two O +
cases O -
. O -

It O +
is O +
considered O +
unlikely O +
that O +
etomidate O +
will O +
prove O +
to O +
be O +
the O +
hypnotic O +
of O +
choice O +
for O +
a O +
totally O +
intravenous O +
anesthetic O +
technique O +
in O +
adults O +
because O +
of O +
the O +
high O +
incidence O +
of O +
myoclonia U-Disease +
after O +
prolonged O +
administration O -
. O -

In O +
several O +
patients O +
uncontrollable O +
muscle O +
movements O +
persisted O +
for O +
many O +
minutes O +
after O +
complete O +
recovery O +
of O +
consciousness O -
. O -

Evidence O +
for O +
cardiac O +
beta O +
2-adrenoceptors O +
in O +
man O -
. O -

We O +
compared O +
the O +
effects O +
of O +
single O +
doses O +
of O +
50 O +
mg O +
atenolol O +
( O -
cardioselective O -
) O -
, O +
40 O +
mg O +
propranolol O +
( O -
nonselective O -
) O -
, O +
and O +
placebo O +
on O +
both O +
exercise- O +
and O +
isoproterenol O -
- O -
induced O +
tachycardia U-Disease +
in O +
two O +
experiments O +
involving O +
nine O +
normal O +
subjects O -
. O -

Maximal O +
exercise O +
heart O +
rate O +
was O +
reduced O +
from O +
187 O +
+ O -
/- O -

4 O -
( O -
SEM O -
) O +
after O +
placebo O +
to O +
146 O +
+ O -
/- O -

7 O +
bpm O +
after O +
atenolol O +
and O +
138 O +
+ O -
/- O -

6 O +
bpm O +
after O +
propranolol O -
, O +
but O +
there O +
were O +
no O +
differences O +
between O +
the O +
drugs O -
. O -

The O +
effects O +
on O +
isoproterenol O +
tachycardia U-Disease +
were O +
determined O +
before O +
and O +
after O +
atropine O +
( O -
0.04 O +
mg O -
/ O -
kg O +
IV O -
) O -
. O -

Isoproterenol O +
sensitivity O +
was O +
determined O +
as O +
the O +
intravenous O +
dose O +
that O +
increased O +
heart O +
rate O +
by O +
25 O +
bpm O +
( O -
CD25 O -
) O +
and O +
this O +
was O +
increased O +
from O +
1.8 O +
+ O -
/- O -

0.3 O +
micrograms O +
after O +
placebo O +
to O +
38.9 O +
+ O -
/- O -

8.3 O +
micrograms O +
after O +
propranolol O +
and O +
8.3 O +
+ O -
/- O -

1.7 O +
micrograms O +
after O +
atenolol O -
. O -

The O +
difference O +
in O +
the O +
effects O +
of O +
the O +
two O +
was O +
significant O -
. O -

After O +
atropine O +
the O +
CD25 O +
was O +
unchanged O +
after O +
placebo O +
( O -
2.3 O +
+ O -
/- O -

0.3 O +
micrograms O -
) O +
and O +
atenolol O +
( O -
7.7 O +
+ O -
/- O -

1.3 O +
micrograms O -
) O -
; O +
it O +
was O +
reduced O +
after O +
propranolol O +
( O -
24.8 O +
+ O -
/- O -

5.0 O +
micrograms O -
) O -
, O +
but O +
remained O +
different O +
from O +
atenolol O -
. O -

This O +
change O +
with O +
propranolol O +
sensitivity O +
was O +
calculated O +
as O +
the O +
apparent O +
Ka O -
, O +
this O +
was O +
unchanged O +
by O +
atropine O +
( O -
11.7 O +
+ O -
/- O -

2.1 O +
and O +
10.1 O +
+ O -
/- O -

2.5 O +
ml O -
/ O -
ng O -
) O -
. O -

These O +
data O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
exercise O -
- O -
induced O +
tachycardia U-Disease +
results O +
largely O +
from O +
beta O +
1-receptor O +
activation O +
that O +
is O +
blocked O +
by O +
both O +
cardioselective O +
and O +
nonselective O +
drugs O -
, O +
whereas O +
isoproterenol O +
activates O +
both O +
beta O +
1- O +
and O +
beta O +
2-receptors O +
so O +
that O +
after O +
cardioselective O +
blockade O +
there O +
remains O +
a O +
beta O +
2-component O +
that O +
can O +
be O +
blocked O +
with O +
a O +
nonselective O +
drug O -
. O -

While O +
there O +
appear O +
to O +
be O +
beta O +
2-receptors O +
in O +
the O +
human O +
heart O -
, O +
their O +
physiologic O +
or O +
pathologic O +
roles O +
remain O +
to O +
be O +
defined O -
. O -

Hormones O +
and O +
risk O +
of O +
breast B-Disease +
cancer L-Disease -
. O -

This O +
paper O +
reports O +
the O +
results O +
of O +
a O +
study O +
of O +
50 O +
menopausal O +
women O +
receiving O +
hormonal O +
replacement O +
therapy O -
. O -

The O +
majority O +
( O -
29 O -
) O +
had O +
surgical O +
menopause O -
; O +
their O +
mean O +
age O +
was O +
45.7 O +
years O -
. O -

It O +
was O +
hypothesized O +
that O +
progestins O +
could O +
equilibrate O +
the O +
effects O +
of O +
the O +
estrogenic O +
stimulation O +
on O +
the O +
mammary O +
and O +
endometrial O +
target O +
tissues O +
of O +
women O +
on O +
hormonal O +
replacement O +
therapy O -
. O -

The O +
treatment O +
schedule O +
consisted O +
of O +
conjugated O +
estrogens O +
( O -
Premarin O -
) O +
1.25 O +
mg O -
/ O -
day O +
for O +
21 O +
days O +
and O +
Medroxyprogesterone O +
acetate O +
10 O +
mg O -
/ O -
day O +
for O +
10 O +
days O +
in O +
each O +
month O -
. O -

The O +
mean O +
treatment O +
period O +
was O +
18 O +
months O -
. O -

During O +
the O +
follow O -
- O -
up O +
period O -
, O +
attention O +
was O +
paid O +
to O +
breast O +
modifications O +
as O +
evidenced O +
by O +
symptomatology O -
, O +
physical O +
examination O -
, O +
and O +
plate O +
thermography O -
. O -

Mastodynia U-Disease +
was O +
reported O +
by O +
21 O +
patients O -
, O +
and O +
physical O +
examination O +
revealed O +
a O +
light O +
increase O +
in O +
breast O +
firmness O +
in O +
12 O +
women O +
and O +
a O +
moderate O +
increase O +
in O +
breast O +
nodularity O +
in O +
2 O +
women O -
. O -

Themography O +
confirmed O +
the O +
existence O +
of O +
an O +
excessive O +
breast O +
stimulation O +
in O +
1 O +
women O +
who O +
complained O +
of O +
moderate O +
mastodynia U-Disease +
and O +
in O +
5 O +
of O +
the O +
7 O +
women O +
who O +
complained O +
of O +
severe O +
mastodynia U-Disease -
. O -

Normalization O +
was O +
obtained O +
by O +
halving O +
the O +
estrogen O +
dose O -
. O -

These O +
results O +
suggest O +
that O +
hormonal O +
replacement O +
therapy O +
can O +
be O +
safely O +
prescribed O +
if O +
the O +
following O +
criteria O +
are O +
satisfied O -
: O +
1 O -
) O +
preliminary O +
evaluation O +
of O +
patients O +
from O +
a O +
clinical O -
, O +
metabolic O -
, O +
cytologic O -
, O +
and O +
mammographic O +
perspective O -
; O +
2 O -
) O +
cyclic O +
treatment O +
schedule O -
, O +
with O +
a O +
progestative O +
phase O +
of O +
10 O +
days O -
; O +
and O +
3 O -
) O +
periodic O +
complete O +
follow O -
- O -
up O -
, O +
with O +
accurate O +
thermographic O +
evaluation O +
of O +
the O +
breast O +
target O +
tissues O -
. O -

Early O +
infections U-Disease +
in O +
kidney O -
, O +
heart O -
, O +
and O +
liver O +
transplant O +
recipients O +
on O +
cyclosporine O -
. O -

Eighty O -
- O -
one O +
renal O -
, O +
seventeen O +
heart O -
, O +
and O +
twenty O -
- O -
four O +
liver O +
transplant O +
patients O +
were O +
followed O +
for O +
infection U-Disease -
. O -

Seventeen O +
renal O +
patients O +
received O +
azathioprine O +
( O -
Aza O -
) O +
and O +
prednisone O +
as O +
part O +
of O +
a O +
randomized O +
trial O +
of O +
immunosuppression O +
with O +
21 O +
cyclosporine O -
- O -
and O -
- O -
prednisone O -
- O -
treated O +
renal O +
transplant O +
patients O -
. O -

All O +
others O +
received O +
cyclosporine O +
and O +
prednisone O -
. O -

The O +
randomized O +
Aza O +
patients O +
had O +
more O +
overall O +
infections U-Disease +
( O -
P O +
less O +
than O +
0.05 O -
) O +
and O +
more O +
nonviral O +
infections U-Disease +
( O -
P O +
less O +
than O +
0.02 O -
) O +
than O +
the O +
randomized O +
cyclosporine O +
patients O -
. O -

Heart O +
and O +
liver O +
patients O +
had O +
more O +
infections U-Disease +
than O +
cyclosporine O +
renal O +
patients O +
but O +
fewer O +
infections U-Disease +
than O +
the O +
Aza O +
renal O +
patients O -
. O -

There O +
were O +
no O +
infectious O +
deaths O +
in O +
renal O +
transplant O +
patients O +
on O +
cyclosporine O +
or O +
Aza O -
, O +
but O +
infection U-Disease +
played O +
a O +
major O +
role O +
in O +
3 O +
out O +
of O +
6 O +
cardiac O +
transplant O +
deaths O +
and O +
in O +
8 O +
out O +
of O +
9 O +
liver O +
transplant O +
deaths O -
. O -

Renal O +
patients O +
on O +
cyclosporine O +
had O +
the O +
fewest O +
bacteremias U-Disease -
. O -

Analysis O +
of O +
site O +
of O +
infection U-Disease +
showed O +
a O +
preponderance O +
of O +
abdominal B-Disease +
infections L-Disease +
in O +
liver O +
patients O -
, O +
intrathoracic O +
infections U-Disease +
in O +
heart O +
patients O -
, O +
and O +
urinary B-Disease +
tract I-Disease +
infections L-Disease +
in O +
renal O +
patients O -
. O -

Pulmonary O +
infections U-Disease +
were O +
less O +
common O +
in O +
cyclosporine O -
- O -
treated O +
renal O +
patients O +
than O +
in O +
Aza O -
- O -
treated O +
patients O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O -

Aza O +
patients O +
had O +
significantly O +
more O +
staphylococcal B-Disease +
infections L-Disease +
than O +
all O +
other O +
transplant O +
groups O +
( O -
P O +
less O +
than O +
0.005 O -
) O -
, O +
and O +
systemic O +
fungal B-Disease +
infections L-Disease +
occurred O +
only O +
in O +
the O +
liver O +
transplant O +
group O -
. O -

Cytomegalovirus O +
( O -
CMV O -
) O +
shedding O +
or O +
serological O +
rises O +
in O +
antibody O +
titer O -
, O +
or O +
both O +
occurred O +
in O +
78 O -
% O +
of O +
cyclosporine O +
patients O +
and O +
76 O -
% O +
of O +
Aza O +
patients O -
. O -

Of O +
the O +
cyclosporine O +
patients O -
, O +
15 O -
% O +
had O +
symptoms O +
related O +
to O +
CMV B-Disease +
infection L-Disease -
. O -

Serological O +
evidence O +
for O +
Epstein B-Disease +
Barr I-Disease +
Virus I-Disease +
infection L-Disease +
was O +
found O +
in O +
20 O -
% O +
of O +
65 O +
cyclosporine O +
patients O +
studied O -
. O -

Three O +
had O +
associated O +
symptoms O -
, O +
and O +
one O +
developed O +
a O +
lymphoma U-Disease -
. O -

Structure O -
- O -
activity O +
and O +
dose O -
- O -
effect O +
relationships O +
of O +
the O +
antagonism O +
of O +
picrotoxin O -
- O -
induced O +
seizures U-Disease +
by O +
cholecystokinin O -
, O +
fragments O +
and O +
analogues O +
of O +
cholecystokinin O +
in O +
mice O -
. O -

Intraperitoneal O +
administration O +
of O +
cholecystokinin O +
octapeptide O +
sulphate O +
ester O +
( O -
CCK-8-SE O -
) O +
and O +
nonsulphated O +
cholecystokinin O +
octapeptide O +
( O -
CCK-8-NS O -
) O +
enhanced O +
the O +
latency O +
of O +
seizures U-Disease +
induced O +
by O +
picrotoxin O +
in O +
mice O -
. O -

Experiments O +
with O +
N- O +
and O +
C O -
- O -
terminal O +
fragments O +
revealed O +
that O +
the O +
C O -
- O -
terminal O +
tetrapeptide O +
( O -
CCK-5 O -
- O -
8 O -
) O +
was O +
the O +
active O +
centre O +
of O +
the O +
CCK O +
octapeptide O +
molecule O -
. O -

The O +
analogues O +
CCK-8-SE O +
and O +
CCK-8-NS O +
( O -
dose O +
range O +
0.2 O -
- O -
6.4 O +
mumol O -
/ O -
kg O -
) O +
and O +
caerulein O +
dose O +
range O +
0.1 O -
- O -
0.8 O +
mumol O -
/ O -
kg O -
) O +
showed O +
bell O -
- O -
shaped O +
dose O -
- O -
effect O +
curves O -
, O +
with O +
the O +
greatest O +
maximum O +
inhibition O +
for O +
CCK-8-NS O -
. O -

The O +
peptide O +
CCK-5 O -
- O -
8 O +
had O +
weak O +
anticonvulsant O +
activity O +
in O +
comparison O +
to O +
the O +
octapeptides O -
, O +
3.2 O +
mumol O -
/ O -
kg O +
and O +
larger O +
doses O +
of O +
the O +
reference O +
drug O -
, O +
diazepam O -
, O +
totally O +
prevented O +
picrotoxin O -
- O -
induced O +
seizures U-Disease +
and O +
mortality O -
. O -

The O +
maximum O +
effect O +
of O +
the O +
peptides O +
tested O +
was O +
less O +
than O +
that O +
of O +
diazepam O -
. O -

Experiments O +
with O +
analogues O +
and O +
derivatives O +
of O +
CCK-5 O -
- O -
8 O +
demonstrated O +
that O +
the O +
effectiveness O +
of O +
the O +
beta O -
- O -
alanyl O +
derivatives O +
of O +
CCK-5 O -
- O -
8 O +
were O +
enhanced O +
and O +
that O +
they O +
were O +
equipotent O +
with O +
CCK-8-SE O -
. O -

Of O +
the O +
CCK-2 O -
- O -
8 O +
analogues O -
, O +
Ser O -
( O -
SO3H O -
) O -
7-Ac O -
- O -
CCK-2 O -
- O -
8-SE O +
and O +
Thr O -
( O -
SO3H O -
) O -
7-Ac O -
- O -
CCK-2 O -
- O -
8-SE O +
and O +
Hyp O -
( O -
SO3H O -
) O -
-Ac O -
- O -
CCK-2 O -
- O -
8-SE O +
were O +
slightly O +
more O +
active O +
than O +
CCK-8-SE O -
. O -

Vasopressin O +
as O +
a O +
possible O +
contributor O +
to O +
hypertension U-Disease -
. O -

The O +
role O +
of O +
vasopressin O +
as O +
a O +
pressor O +
agent O +
to O +
the O +
hypertensive U-Disease +
process O +
was O +
examined O -
. O -

Vasopressin O +
plays O +
a O +
major O +
role O +
in O +
the O +
pathogenesis O +
of O +
DOCA O -
- O -
salt O +
hypertension U-Disease -
, O +
since O +
the O +
elevation O +
of O +
blood O +
pressure O +
was O +
not O +
substantial O +
in O +
the O +
rats O +
with O +
lithium O -
- O -
treated O +
diabetes B-Disease +
insipidus L-Disease +
after O +
DOCA O -
- O -
salt O +
treatment O -
. O -

Administration O +
of O +
DDAVP O +
which O +
has O +
antidiuretic O +
action O +
but O +
minimal O +
vasopressor O +
effect O +
failed O +
to O +
increase O +
blood O +
pressure O +
to O +
the O +
levels O +
observed O +
after O +
administration O +
of O +
AVP O -
. O -

Furthermore O -
, O +
the O +
pressor O +
action O +
of O +
vasopressin O +
appears O +
to O +
be O +
important O +
in O +
the O +
development O +
of O +
this O +
model O +
of O +
hypertension U-Disease -
, O +
since O +
the O +
enhanced O +
pressor O +
responsiveness O +
to O +
the O +
hormone O +
was O +
observed O +
in O +
the O +
initial O +
stage O +
of O +
hypertension U-Disease -
. O -

Increased O +
secretion O +
of O +
vasopressin O +
from O +
neurohypophysis O +
also O +
promotes O +
the O +
function O +
of O +
the O +
hormone O +
as O +
a O +
pathogenetic O +
factor O +
in O +
hypertension U-Disease -
. O -

An O +
unproportional O +
release O +
of O +
vasopressin O +
compared O +
to O +
plasma O +
osmolality O +
may O +
be O +
induced O +
by O +
the O +
absence O +
of O +
an O +
adjusting O +
control O +
of O +
angiotensin O +
II O +
forming O +
and O +
receptor O +
binding O +
capacity O +
for O +
sodium O +
balance O +
in O +
the O +
brain O -
. O -

However O -
, O +
the O +
role O +
of O +
vasopressin O +
remains O +
to O +
be O +
determined O +
in O +
human O +
essential O +
hypertension U-Disease -
. O -

Toxic B-Disease +
hepatitis L-Disease +
induced O +
by O +
disulfiram O +
in O +
a O +
non O -
- O -
alcoholic O -
. O -

A O +
reversible O +
toxic B-Disease +
liver I-Disease +
damage L-Disease +
was O +
observed O +
in O +
a O +
non O -
- O -
alcoholic O +
woman O +
treated O +
with O +
disulfiram O -
. O -

The O +
causative O +
relationship O +
was O +
proven O +
by O +
challenge O -
. O -

Atrial B-Disease +
thrombosis L-Disease +
involving O +
the O +
heart O +
of O +
F-344 O +
rats O +
ingesting O +
quinacrine O +
hydrochloride O -
. O -

Quinacrine O +
hydrochloride O +
is O +
toxic O +
for O +
the O +
heart O +
of O +
F-344 O +
rats O -
. O -

Rats O +
treated O +
with O +
500 O +
ppm O +
quinacrine O +
hydrochloride O +
in O +
the O +
diet O +
all O +
developed O +
a O +
high O +
incidence O +
of O +
left O +
atrial B-Disease +
thrombosis L-Disease -
. O -

The O +
lesion O +
was O +
associated O +
with O +
cardiac B-Disease +
hypertrophy L-Disease +
and O +
dilatation O +
and O +
focal O +
myocardial B-Disease +
degeneration L-Disease -
. O -

Rats O +
died O +
from O +
cardiac B-Disease +
hypertrophy L-Disease +
with O +
severe O +
acute O +
and O +
chronic O +
congestion O +
of O +
the O +
lungs O -
, O +
liver O -
, O +
and O +
other O +
organs O -
. O -

Seventy O +
percent O +
of O +
rats O +
given O +
250 O +
ppm O +
quinacrine O +
hydrochloride O +
and O +
1,000 O +
ppm O +
sodium O +
nitrite O +
simultaneously O +
in O +
the O +
diet O +
had O +
thrombosis U-Disease +
of O +
the O +
atria O +
of O +
the O +
heart O -
, O +
while O +
untreated O +
control O +
rats O +
in O +
this O +
laboratory O +
did O +
not O +
have O +
atrial B-Disease +
thrombosis L-Disease -
. O -

Sodium O +
nitrite O +
in O +
combination O +
with O +
quinacrine O +
hydrochloride O +
appeared O +
to O +
have O +
no O +
additional O +
effect O -
. O -

Alternating B-Disease +
sinus I-Disease +
rhythm L-Disease +
and O +
intermittent O +
sinoatrial B-Disease +
block L-Disease +
induced O +
by O +
propranolol O -
. O -

Alternating B-Disease +
sinus I-Disease +
rhythm L-Disease +
and O +
intermittent O +
sinoatrial B-Disease +
( I-Disease -
S I-Disease -
- I-Disease -
A I-Disease -
) I-Disease +
block L-Disease +
was O +
observed O +
in O +
a O +
57-year O -
- O -
old O +
woman O -
, O +
under O +
treatment O +
for O +
angina U-Disease +
with O +
80 O +
mg O +
propranolol O +
daily O -
. O -

The O +
electrocardiogram O +
showed O +
alternation O +
of O +
long O +
and O +
short O +
P O -
- O -
P O +
intervals O +
and O +
occasional O +
pauses O -
. O -

These O +
pauses O +
were O +
always O +
preceded O +
by O +
the O +
short O +
P O -
- O -
P O +
intervals O +
and O +
were O +
usually O +
followed O +
by O +
one O +
or O +
two O +
P O -
- O -
P O +
intervals O +
of O +
0.92 O -
- O -
0.95 O +
s O +
representing O +
the O +
basic O +
sinus O +
cycle O -
. O -

Following O +
these O +
basic O +
sinus O +
cycles O -
, O +
alternating B-Disease +
rhythm L-Disease +
started O +
with O +
the O +
longer O +
P O -
- O -
P O +
interval O -
. O -

The O +
long O +
P O -
- O -
P O +
intervals O +
ranged O +
between O +
1.04 O -
- O -
1.12 O +
s O +
and O +
the O +
short O +
P O -
- O -
P O +
intervals O +
between O +
0.80 O -
- O -
0.84 O +
s O -
, O +
respectively O -
. O -

The O +
duration O +
of O +
the O +
pauses O +
were O +
equal O +
or O +
almost O +
equal O +
to O +
one O +
short O +
plus O +
one O +
long O +
P O -
- O -
P O +
interval O +
or O +
to O +
twice O +
the O +
basic O +
sinus O +
cycle O -
. O -

In O +
one O +
recording O +
a O +
short O +
period O +
of O +
regular O +
sinus O +
rhythm O +
with O +
intermittent O +
2 O -
/ O -
1 O +
S B-Disease -
- I-Disease -
A I-Disease +
block L-Disease +
was O +
observed O -
. O -

This O +
short O +
period O +
of O +
sinus O +
rhythm O +
was O +
interrupted O +
by O +
sudden O +
prolongation O +
of O +
the O +
P O -
- O -
P O +
interval O +
starting O +
the O +
alternative O +
rhythm O -
. O -

There O +
were O +
small O +
changes O +
in O +
the O +
shape O +
of O +
the O +
P O +
waves O +
and O +
P O -
- O -
R O +
intervals O -
. O -

S O -
- O -
A O +
conduction O +
through O +
two O +
pathways O -
, O +
the O +
first O +
with O +
2 O -
/ O -
1 O +
block O +
the O +
second O +
having O +
0.12 O -
- O -
0.14 O +
s O +
longer O +
conduction O +
time O +
and O +
with O +
occasional O +
2 O -
/ O -
1 O +
block O +
was O +
proposed O +
for O +
the O +
explanation O +
of O +
the O +
alternating O +
P O -
- O -
P O +
interval O +
and O +
other O +
electrocardiographic O +
features O +
seen O -
. O -

Atropine O +
1 O +
mg O +
given O +
intravenously O +
resulted O +
in O +
shortening O +
of O +
all O +
P O -
- O -
P O +
intervals O +
without O +
changing O +
the O +
rhythm O -
. O -

The O +
abnormal O +
rhythm O +
disappeared O +
with O +
the O +
withdrawal O +
of O +
propranolol O +
and O +
when O +
the O +
drug O +
was O +
restarted O +
a O +
2 O -
/ O -
1 O +
S B-Disease -
- I-Disease -
A I-Disease +
block L-Disease +
was O +
seen O -
. O -

This O +
was O +
accepted O +
as O +
evidence O +
for O +
propranolol O +
being O +
the O +
cause O +
of O +
this O +
conduction B-Disease +
disorder L-Disease -
. O -

Antitumor O +
effect O -
, O +
cardiotoxicity U-Disease -
, O +
and O +
nephrotoxicity U-Disease +
of O +
doxorubicin O +
in O +
the O +
IgM O +
solid O +
immunocytoma U-Disease -
- O -
bearing O +
LOU O -
/ O -
M O -
/ O -
WSL O +
rat O -
. O -

Antitumor O +
activity O -
, O +
cardiotoxicity U-Disease -
, O +
and O +
nephrotoxicity U-Disease +
induced O +
by O +
doxorubicin O +
were O +
studied O +
in O +
LOU O -
/ O -
M O -
/ O -
WSL O +
inbred O +
rats O +
each O +
bearing O +
a O +
transplantable O +
solid O +
IgM O +
immunocytoma U-Disease -
. O -

Animals O +
with O +
a O +
tumor U-Disease +
( O -
diameter O -
, O +
15.8 O +
+ O -
/- O -

3.3 O +
mm O -
) O +
were O +
treated O +
with O +
iv O +
injections O +
of O +
doxorubicin O +
on O +
5 O +
consecutive O +
days O -
, O +
followed O +
by O +
1 O +
weekly O +
injection O +
for O +
7 O +
weeks O +
( O -
dose O +
range O -
, O +
0.015 O -
- O -
4.0 O +
mg O -
/ O -
kg O +
body O +
wt O -
) O -
. O -

Tumor U-Disease +
regression O +
was O +
observed O +
with O +
0.5 O +
mg O +
doxorubicin O -
/ O -
kg O -
. O -

Complete O +
disappearance O +
of O +
the O +
tumor U-Disease +
was O +
induced O +
with O +
1.0 O +
mg O +
doxorubicin O -
/ O -
kg O -
. O -

Histologic O +
evidence O +
of O +
cardiotoxicity U-Disease +
scored O +
as O +
grade O +
III O +
was O +
only O +
observed O +
at O +
a O +
dose O +
of O +
1.0 O +
mg O +
doxorubicin O -
/ O -
kg O -
. O -

Light O +
microscopic O +
evidence O +
of O +
renal B-Disease +
damage L-Disease +
was O +
seen O +
above O +
a O +
dose O +
of O +
0.5 O +
mg O +
doxorubicin O -
/ O -
kg O -
, O +
which O +
resulted O +
in O +
albuminuria U-Disease +
and O +
very O +
low O +
serum O +
albumin O +
levels O -
. O -

In O +
the O +
group O +
that O +
received O +
1.0 O +
mg O +
doxorubicin O -
/ O -
kg O -
, O +
the O +
serum O +
albumin O +
level O +
decreased O +
from O +
33.6 O +
+ O -
/- O -

4.1 O +
to O +
1.5 O +
+ O -
/- O -

0.5 O +
g O -
/ O -
liter O -
. O -

Ascites U-Disease +
and O +
hydrothorax U-Disease +
were O +
observed O +
simultaneously O -
. O -

The O +
same O +
experiments O +
were O +
performed O +
with O +
non O -
- O -
tumor U-Disease -
- O -
bearing O +
rats O -
, O +
in O +
which O +
no O +
major O +
differences O +
were O +
observed O -
. O -

In O +
conclusion O -
, O +
antitumor O +
activity O -
, O +
cardiotoxicity U-Disease -
, O +
and O +
nephrotoxicity U-Disease +
were O +
studied O +
simultaneously O +
in O +
the O +
same O +
LOU O -
/ O -
M O -
/ O -
WSL O +
rat O -
. O -

Albuminuria U-Disease +
due O +
to O +
renal B-Disease +
damage L-Disease +
led O +
to O +
extremely O +
low O +
serum O +
albumin O +
levels O -
, O +
so O +
ascites U-Disease +
and O +
hydrothorax U-Disease +
were O +
not O +
necessarily O +
a O +
consequence O +
of O +
the O +
observed O +
cardiomyopathy U-Disease -
. O -

Intraoperative O +
bradycardia U-Disease +
and O +
hypotension U-Disease +
associated O +
with O +
timolol O +
and O +
pilocarpine O +
eye O +
drops O -
. O -

A O +
69-yr O -
- O -
old O +
man O -
, O +
who O +
was O +
concurrently O +
being O +
treated O +
with O +
pilocarpine O +
nitrate O +
and O +
timolol O +
maleate O +
eye O +
drops O -
, O +
developed O +
a O +
bradycardia U-Disease +
and O +
became O +
hypotensive U-Disease +
during O +
halothane O +
anaesthesia O -
. O -

Both O +
timolol O +
and O +
pilocarpine O +
were O +
subsequently O +
identified O +
in O +
a O +
24-h O +
collection O +
of O +
urine O -
. O -

Timolol O +
( O -
but O +
not O +
pilocarpine O -
) O +
was O +
detected O +
in O +
a O +
sample O +
of O +
plasma O +
removed O +
during O +
surgery O -
; O +
the O +
plasma O +
concentration O +
of O +
timolol O +
( O -
2.6 O +
ng O +
ml-1 O -
) O +
was O +
consistent O +
with O +
partial O +
beta O -
- O -
adrenoceptor O +
blockade O -
. O -

It O +
is O +
postulated O +
that O +
this O +
action O +
may O +
have O +
been O +
enhanced O +
during O +
halothane O +
anaesthesia O +
with O +
resultant O +
bradycardia U-Disease +
and O +
hypotension U-Disease -
. O -

Pilocarpine O +
may O +
have O +
had O +
a O +
contributory O +
effect O -
. O -

Succinylcholine O +
apnoea U-Disease -
: O +
attempted O +
reversal O +
with O +
anticholinesterases O -
. O -

Anticholinesterases O +
were O +
administered O +
in O +
an O +
attempt O +
to O +
antagonize O +
prolonged O +
neuromuscular B-Disease +
blockade L-Disease +
following O +
the O +
administration O +
of O +
succinylcholine O +
in O +
a O +
patient O +
later O +
found O +
to O +
be O +
homozygous O +
for O +
atypical O +
plasma O +
cholinesterase O -
. O -

Edrophonium O +
10 O +
mg O -
, O +
given O +
74 O +
min O +
after O +
succinylcholine O -
, O +
when O +
train O -
- O -
of O -
- O -
four O +
stimulation O +
was O +
characteristic O +
of O +
phase O +
II O +
block O -
, O +
produced O +
partial O +
antagonism O +
which O +
was O +
not O +
sustained O -
. O -

Repeated O +
doses O +
of O +
edrophonium O +
to O +
70 O +
mg O +
and O +
neostigmine O +
to O +
2.5 O +
mg O +
did O +
not O +
antagonize O +
or O +
augment O +
the O +
block O -
. O -

Spontaneous O +
respiration O +
recommenced O +
200 O +
min O +
after O +
succinylcholine O +
administration O -
. O -

It O +
is O +
concluded O +
that O +
anticholinesterases O +
are O +
only O +
partially O +
effective O +
in O +
restoring O +
neuromuscular O +
function O +
in O +
succinylcholine O +
apnoea U-Disease +
despite O +
muscle O +
twitch O +
activity O +
typical O +
of O +
phase O +
II O +
block O -
. O -

Effect O +
of O +
doxorubicin O +
on O +
[ O -
omega O -
- O -
I-131 O -
] O -
heptadecanoic O +
acid O +
myocardial O +
scintigraphy O +
and O +
echocardiography O +
in O +
dogs O -
. O -

The O +
effects O +
of O +
serial O +
treatment O +
with O +
doxorubicin O +
on O +
dynamic O +
myocardial O +
scintigraphy O +
with O +
[ O -
omega O -
- O -
I-131 O -
] O -
heptadecanoic O +
acid O +
( O -
I-131 O +
HA O -
) O -
, O +
and O +
on O +
global O +
left O -
- O -
ventricular O +
function O +
determined O +
echocardiographically O -
, O +
were O +
studied O +
in O +
a O +
group O +
of O +
nine O +
mongrel O +
dogs O -
. O -

Total O +
extractable O +
myocardial O +
lipid O +
was O +
compared O +
postmortem O +
between O +
a O +
group O +
of O +
control O +
dogs O +
and O +
doxorubicin O -
- O -
treated O +
dogs O -
. O -

A O +
significant O +
and O +
then O +
progressive O +
fall O +
in O +
global O +
LV O +
function O +
was O +
observed O +
at O +
a O +
cumulative O +
doxorubicin O +
dose O +
of O +
4 O +
mg O -
/ O -
kg O -
. O -

A O +
significant O +
increase O +
in O +
the O +
myocardial O +
t1 O -
/ O -
2 O +
of O +
the O +
I-131 O +
HA O +
was O +
observed O +
only O +
at O +
a O +
higher O +
cumulative O +
dose O -
, O +
10 O +
mg O -
/ O -
kg O -
. O -

No O +
significant O +
alteration O +
in O +
total O +
extractable O +
myocardial O +
lipids O +
was O +
observed O +
between O +
control O +
dogs O +
and O +
those O +
treated O +
with O +
doxorubicin O -
. O -

Our O +
findings O +
suggest O +
that O +
the O +
changes O +
leading O +
to O +
an O +
alteration O +
of O +
myocardial O +
dynamic O +
imaging O +
with O +
I-131 O +
HA O +
are O +
not O +
the O +
initiating O +
factor O +
in O +
doxorubicin O +
cardiotoxicity U-Disease -
. O -

Hemodynamics O +
and O +
myocardial O +
metabolism O +
under O +
deliberate O +
hypotension U-Disease -
. O -

An O +
experimental O +
study O +
in O +
dogs O -
. O -

Coronary O +
blood O +
flow O -
, O +
cardiac O +
work O +
and O +
metabolism O +
were O +
studied O +
in O +
dogs O +
under O +
sodium O +
nitroprusside O +
( O -
SNP O -
) O +
and O +
trimetaphan O +
( O -
TMP O -
) O +
deliberate O +
hypotension U-Disease +
( O -
20 O -
% O +
and O +
40 O -
% O +
mean O +
pressure O +
decrease O +
from O +
baseline O -
) O -
. O -

Regarding O +
the O +
effects O +
of O +
drug O -
- O -
induced O +
hypotension U-Disease +
on O +
coronary O +
blood O +
flow O -
, O +
aortic O +
and O +
coronary O +
sinus O +
metabolic O +
data O +
( O -
pH O -
, O +
pO2 O -
, O +
pCO2 O -
) O +
we O +
could O +
confirm O +
that O +
nitroprusside O +
hypotension U-Disease +
could O +
be O +
safely O +
used O +
to O +
30 O -
% O +
mean O +
blood O +
pressure O +
decrease O +
from O +
control O -
, O +
trimetaphan O +
hypotension U-Disease +
to O +
20 O -
% O +
mean O +
blood O +
pressure O +
decrease O -
. O -

Cardiac O +
work O +
was O +
significantly O +
reduced O +
during O +
SNP O +
hypotension U-Disease -
. O -

Myocardial O +
O2 O +
consumption O +
and O +
O2 O +
availability O +
were O +
directly O +
dependent O +
on O +
the O +
coronary O +
perfusion O -
. O -

Careful O +
invasive O +
monitoring O +
of O +
the O +
blood O +
pressure O -
, O +
blood O +
gases O +
and O +
of O +
the O +
ECG O +
ST O -
- O -
T O +
segment O +
is O +
mandatory O -
. O -

Evidence O +
for O +
a O +
selective O +
brain O +
noradrenergic O +
involvement O +
in O +
the O +
locomotor O +
stimulant O +
effects O +
of O +
amphetamine O +
in O +
the O +
rat O -
. O -

Male O +
rats O +
received O +
the O +
noradrenaline O +
neurotoxin O +
DSP4 O +
( O -
50 O +
mg O -
/ O -
kg O -
) O +
7 O +
days O +
prior O +
to O +
injection O +
of O +
D O -
- O -
amphetamine O +
( O -
10 O +
or O +
40 O +
mumol O -
/ O -
kg O +
i.p O -
. O -
) O -
. O -

The O +
hyperactivity U-Disease +
induced O +
by O +
D O -
- O -
amphetamine O +
( O -
10 O +
mumol O -
/ O -
kg O -
) O +
was O +
significantly O +
reduced O +
by O +
DSP4 O +
pretreatment O -
. O -

However O -
, O +
the O +
increased O +
rearings O +
and O +
the O +
amphetamine O -
- O -
induced O +
stereotypies U-Disease +
were O +
not O +
blocked O +
by O +
pretreatment O +
with O +
DSP4 O -
. O -

The O +
reduction O +
of O +
amphetamine O +
hyperactivity U-Disease +
induced O +
by O +
DSP4 O +
was O +
blocked O +
by O +
pretreatment O +
with O +
the O +
noradrenaline O -
- O -
uptake O +
blocking O +
agent O -
, O +
desipramine O -
, O +
which O +
prevents O +
the O +
neurotoxic U-Disease +
action O +
of O +
DSP4 O -
. O -

The O +
present O +
results O +
suggest O +
a O +
selective O +
involvement O +
of O +
central O +
noradrenergic O +
neurones O +
in O +
the O +
locomotor O +
stimulant O +
effect O +
of O +
amphetamine O +
in O +
the O +
rat O -
. O -

Accelerated B-Disease +
junctional I-Disease +
rhythms L-Disease +
during O +
oral O +
verapamil O +
therapy O -
. O -

This O +
study O +
examined O +
the O +
frequency O +
of O +
atrioventricular O +
( O -
AV O -
) O +
dissociation O +
and O +
accelerated B-Disease +
junctional I-Disease +
rhythms L-Disease +
in O +
59 O +
patients O +
receiving O +
oral O +
verapamil O -
. O -

Accelerated B-Disease +
junctional I-Disease +
rhythms L-Disease +
and O +
AV O +
dissociation O +
were O +
frequent O +
in O +
patients O +
with O +
supraventricular B-Disease +
tachyarrhythmias L-Disease -
, O +
particularly O +
AV O +
nodal O +
reentry O -
. O -

Verapamil O +
administration O +
to O +
these O +
patients O +
led O +
to O +
an O +
asymptomatic O +
increase O +
in O +
activity O +
of O +
these O +
junctional O +
pacemakers O -
. O -

In O +
patients O +
with O +
various O +
chest B-Disease +
pain L-Disease +
syndromes O -
, O +
verapamil O +
neither O +
increased O +
the O +
frequency O +
of O +
junctional O +
rhythms O +
nor O +
suppressed O +
their O +
role O +
as O +
escape O +
rhythms O +
under O +
physiologically O +
appropriate O +
circumstances O -
. O -

Interstrain O +
variation O +
in O +
acute O +
toxic O +
response O +
to O +
caffeine O +
among O +
inbred O +
mice O -
. O -

Acute O +
toxic O +
dosage O -
- O -
dependent O +
behavioral O +
effects O +
of O +
caffeine O +
were O +
compared O +
in O +
adult O +
males O +
from O +
seven O +
inbred O +
mouse O +
strains O +
( O -
A O -
/ O -
J O -
, O +
BALB O -
/ O -
cJ O -
, O +
CBA O -
/ O -
J O -
, O +
C3H O -
/ O -
HeJ O -
, O +
C57BL O -
/ O -
6J O -
, O +
DBA O -
/ O -
2J O -
, O +
SWR O -
/ O -
J O -
) O -
. O -

C57BL O -
/ O -
6J O -
, O +
chosen O +
as O +
a O +
" O -
prototypic O -
" O +
mouse O +
strain O -
, O +
was O +
used O +
to O +
determine O +
behavioral O +
responses O +
to O +
a O +
broad O +
range O +
( O -
5 O -
- O -
500 O +
mg O -
/ O -
kg O -
) O +
of O +
caffeine O +
doses O -
. O -

Five O +
phenotypic O +
characteristics O -
-- O -
locomotor O +
activity O -
, O +
righting O +
ability O -
, O +
clonic B-Disease +
seizure L-Disease +
induction O -
, O +
stress O -
- O -
induced O +
lethality O -
, O +
death O +
without O +
external O +
stress O -
-- O -
were O +
scored O +
at O +
various O +
caffeine O +
doses O +
in O +
drug O -
- O -
naive O +
animals O +
under O +
empirically O +
optimized O -
, O +
rigidly O +
constant O +
experimental O +
conditions O -
. O -

Mice O +
( O -
n O +
= O +
12 O +
for O +
each O +
point O -
) O +
received O +
single O +
IP O +
injections O +
of O +
a O +
fixed O +
volume O -
/ O -
g O +
body O +
weight O +
of O +
physiological O +
saline O +
carrier O +
with O +
or O +
without O +
caffeine O +
in O +
doses O +
ranging O +
from O +
125 O -
- O -
500 O +
mg O -
/ O -
kg O -
. O -

Loss O +
of O +
righting O +
ability O +
was O +
scored O +
at O +
1 O -
, O +
3 O -
, O +
5 O +
min O +
post O +
dosing O +
and O +
at O +
5 O +
min O +
intervals O +
thereafter O +
for O +
20 O +
min O -
. O -

In O +
the O +
same O +
animals O +
the O +
occurrence O +
of O +
clonic B-Disease +
seizures L-Disease +
was O +
scored O +
as O +
to O +
time O +
of O +
onset O +
and O +
severity O +
for O +
20 O +
min O +
after O +
drug O +
administration O -
. O -

When O +
these O +
proceeded O +
to O +
tonic B-Disease +
seizures L-Disease -
, O +
death O +
occurred O +
in O +
less O +
than O +
20 O +
min O -
. O -

Animals O +
surviving O +
for O +
20 O +
min O +
were O +
immediately O +
stressed O +
by O +
a O +
swim O +
test O +
in O +
25 O +
degrees O +
C O +
water O -
, O +
and O +
death O -
- O -
producing O +
tonic B-Disease +
seizures L-Disease +
were O +
scored O +
for O +
2 O +
min O -
. O -

In O +
other O +
animals O +
locomotor O +
activity O +
was O +
measured O +
15 O +
or O +
60 O +
min O +
after O +
caffeine O +
administration O -
. O -

By O +
any O +
single O +
behavioral O +
criterion O +
or O +
a O +
combination O +
of O +
these O +
criteria O -
, O +
marked O +
differences O +
in O +
response O +
to O +
toxic O +
caffeine O +
doses O +
were O +
observed O +
between O +
strains O -
. O -

These O +
results O +
indicate O +
that O +
behavioral O +
toxicity U-Disease +
testing O +
of O +
alkylxanthines O +
in O +
a O +
single O +
mouse O +
strain O +
may O +
be O +
misleading O +
and O +
suggest O +
that O +
toxic O +
responses O +
of O +
the O +
central O +
nervous O +
system O +
to O +
this O +
class O +
of O +
compounds O +
are O +
genetically O +
influenced O +
in O +
mammals O -
. O -

Treatment O +
of O +
ovarian B-Disease +
cancer L-Disease +
with O +
a O +
combination O +
of O +
cis O -
- O -
platinum O -
, O +
adriamycin O -
, O +
cyclophosphamide O +
and O +
hexamethylmelamine O -
. O -

During O +
the O +
last O +
2 O +
1 O -
/ O -
2 O +
years O -
, O +
38 O +
patients O +
with O +
ovarian B-Disease +
cancer L-Disease +
were O +
treated O +
with O +
a O +
combination O +
of O +
cisplatinum O +
( O -
CPDD O -
) O -
, O +
50 O +
mg O -
/ O -
m2 O -
, O +
adriamycin O -
, O +
30 O +
mg O -
/ O -
m2 O -
, O +
cyclophosphamide O -
, O +
300 O +
mg O -
/ O -
m2 O -
, O +
on O +
day O +
1 O -
; O +
and O +
hexamethylmelamine O +
( O -
HMM O -
) O -
, O +
6 O +
mg O -
/ O -
kg O +
daily O -
, O +
for O +
14 O +
days O -
. O -

Each O +
course O +
was O +
repeated O +
monthly O -
. O -

2 O +
patients O +
had O +
stage O +
II O -
, O +
14 O +
stage O +
III O +
and O +
22 O +
stage O +
IV O +
disease O -
. O -

14 O +
of O +
the O +
38 O +
patients O +
were O +
previously O +
treated O +
with O +
chemotherapy O -
, O +
1 O +
with O +
radiation O -
, O +
6 O +
with O +
both O +
chemotherapy O +
and O +
radiation O -
, O +
and O +
17 O +
did O +
not O +
have O +
any O +
treatment O +
before O +
CPDD O +
combination O -
. O -

31 O +
of O +
the O +
38 O +
cases O +
( O -
81.5 O -
% O -
) O +
demonstrated O +
objective O +
responses O +
lasting O +
for O +
2 O +
months O +
or O +
more O -
. O -

These O +
responses O +
were O +
partial O +
in O +
19 O +
and O +
complete O +
in O +
12 O +
cases O -
. O -

Hematologic B-Disease +
toxicity L-Disease +
was O +
moderate O +
and O +
with O +
reversible O +
anemia U-Disease +
developing O +
in O +
71 O -
% O +
of O +
patients O -
. O -

Gastrointestinal O +
side O +
effects O +
from O +
CPDD O +
were O +
universal O -
. O -

HMM O +
gastrointestinal B-Disease +
toxicity L-Disease +
necessitated O +
discontinuation O +
of O +
the O +
drug O +
in O +
5 O +
patients O -
. O -

Severe O +
nephrotoxicity U-Disease +
was O +
observed O +
in O +
2 O +
patients O +
but O +
was O +
reversible O -
. O -

There O +
were O +
no O +
drug O -
- O -
related O +
deaths O -
. O -

Nontraumatic O +
dissecting B-Disease +
aneurysm L-Disease +
of O +
the O +
basilar O +
artery O -
. O -

A O +
case O +
of O +
nontraumatic O +
dissecting B-Disease +
aneurysm L-Disease +
of O +
the O +
basilar O +
artery O +
in O +
association O +
with O +
hypertension U-Disease -
, O +
smoke O -
, O +
and O +
oral O +
contraceptives O +
is O +
reported O +
in O +
a O +
young O +
female O +
patient O +
with O +
a O +
locked B-Disease -
- I-Disease -
in I-Disease +
syndrome L-Disease -
. O -

A O +
method O +
for O +
the O +
measurement O +
of O +
tremor U-Disease -
, O +
and O +
a O +
comparison O +
of O +
the O +
effects O +
of O +
tocolytic O +
beta O -
- O -
mimetics O -
. O -

A O +
method O +
permitting O +
measurement O +
of O +
finger O +
tremor U-Disease +
as O +
a O +
displacement O -
- O -
time O +
curve O +
is O +
described O -
, O +
using O +
a O +
test O +
system O +
with O +
simple O +
amplitude O +
calibration O -
. O -

The O +
coordinates O +
of O +
the O +
inversion O +
points O +
of O +
the O +
displacement O -
- O -
time O +
curves O +
were O +
transferred O +
through O +
graphical O +
input O +
equipment O +
to O +
punched O +
tape O -
. O -

By O +
means O +
of O +
a O +
computer O +
program O -
, O +
periods O +
and O +
amplitudes O +
of O +
tremor U-Disease +
oscillations O +
were O +
calculated O +
and O +
classified O -
. O -

The O +
event O +
frequency O +
for O +
each O +
class O +
of O +
periods O +
and O +
amplitudes O +
was O +
determined O -
. O -

The O +
actions O +
of O +
fenoterol O -
- O -
hydrobromide O -
, O +
ritodrin O -
- O -
HCl O +
and O +
placebo O +
given O +
to O +
10 O +
healthy O +
subjects O +
by O +
intravenous O +
infusion O +
in O +
a O +
double O -
- O -
blind O +
crossover O +
study O +
were O +
tested O +
by O +
this O +
method O -
. O -

At O +
therapeutic O +
doses O +
both O +
substances O +
raised O +
the O +
mean O +
tremor U-Disease +
amplitude O +
to O +
about O +
three O +
times O +
the O +
control O +
level O -
. O -

At O +
the O +
same O +
time O -
, O +
the O +
mean O +
period O +
within O +
each O +
class O +
of O +
amplitudes O +
shortened O +
by O +
10 O -
- O -
-20 O +
ms O -
, O +
whereas O +
the O +
mean O +
periods O +
calculated O +
from O +
all O +
oscillations O +
together O +
did O +
not O +
change O +
significantly O -
. O -

After O +
the O +
end O +
of O +
fenoterol O -
- O -
hydrobromide O +
infusion O -
, O +
tremor U-Disease +
amplitudes O +
decreased O +
significantly O +
faster O +
than O +
those O +
following O +
ritodrin O -
- O -
HCl O +
infusion O -
. O -

Propylthiouracil O -
- O -
induced O +
hepatic B-Disease +
damage L-Disease -
. O -

Two O +
cases O +
of O +
propylthiouracil O -
- O -
induced O +
liver B-Disease +
damage L-Disease +
have O +
been O +
observed O -
. O -

The O +
first O +
case O +
is O +
of O +
an O +
acute O +
type O +
of O +
damage O -
, O +
proven O +
by O +
rechallenge O -
; O +
the O +
second O +
presents O +
a O +
clinical O +
and O +
histologic O +
picture O +
resembling O +
chronic B-Disease +
active I-Disease +
hepatitis L-Disease -
, O +
with O +
spontaneous O +
remission O -
. O -

Studies O +
on O +
the O +
bradycardia U-Disease +
induced O +
by O +
bepridil O -
. O -

Bepridil O -
, O +
a O +
novel O +
active O +
compound O +
for O +
prophylactic O +
treatment O +
of O +
anginal B-Disease +
attacks L-Disease -
, O +
induced O +
persistent O +
bradycardia U-Disease +
and O +
a O +
non O -
- O -
specific O +
anti O -
- O -
tachycardial U-Disease +
effect O -
, O +
the O +
mechanisms O +
of O +
which O +
were O +
investigated O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

In O +
vitro O +
perfusion O +
of O +
bepridil O +
in O +
the O +
life O -
- O -
support O +
medium O +
for O +
isolated O +
sino O -
- O -
atrial O +
tissue O +
from O +
rabbit O +
heart O -
, O +
caused O +
a O +
reduction O +
in O +
action O +
potential O +
( O -
AP O -
) O +
spike O +
frequency O +
( O -
recorded O +
by O +
KCl O +
microelectrodes O -
) O +
starting O +
at O +
doses O +
of O +
5 O +
X O +
10 O -
( O -
-6 O -
) O +
M. O +
This O +
effect O +
was O +
dose O -
- O -
dependent O +
up O +
to O +
concentrations O +
of O +
5 O +
X O +
10 O -
( O -
-5 O -
) O +
M O -
, O +
whereupon O +
blockade O +
of O +
sinus O +
activity O +
set O +
in O -
. O -

Bepridil O +
at O +
a O +
dose O +
of O +
5 O +
X O +
10 O -
( O -
-6 O -
) O +
M O -
, O +
induced O +
a O +
concomitant O +
reduction O +
in O +
AP O +
amplitude O +
( O -
falling O +
from O +
71 O +
+ O -
/- O -

8 O +
mV O +
to O +
47 O +
+ O -
/- O -

6 O +
mV O -
) O -
, O +
maximum O +
systolic O +
depolarization O +
velocity O +
( O -
phase O +
0 O -
) O +
which O +
fell O +
from O +
1.85 O +
+ O -
/- O -

0.35 O +
V O -
/ O -
s O +
to O +
0.84 O +
+ O -
/- O -

0.28 O +
V O -
/ O -
s O -
, O +
together O +
with O +
maximum O +
diastolic O +
depolarization O +
velocity O +
( O -
phase O +
4 O -
) O +
which O +
fell O +
from O +
38 O +
+ O -
/- O -

3 O +
mV O -
/ O -
s O +
to O +
24 O +
+ O -
/- O -

5 O +
mV O -
/ O -
s O -
. O -

In O +
vivo O +
injection O +
of O +
bepridil O +
at O +
a O +
dose O +
of O +
5 O +
mg O -
/ O -
kg O +
( O -
i.v O -
. O -
) O +
into O +
6 O +
anaesthetized O +
dogs O +
which O +
had O +
undergone O +
ablation O +
of O +
all O +
the O +
extrinsic O +
cardiac O +
afferent O +
nerve O +
supply O -
, O +
together O +
with O +
a O +
bilateral O +
medullo O -
- O -
adrenalectomy O -
, O +
caused O +
a O +
marked O +
reduction O +
in O +
heart O +
rate O +
which O +
fell O +
from O +
98.7 O +
+ O -
/- O -

4.2 O +
beats O -
/ O -
min O +
to O +
76 O +
+ O -
/- O -

5.3 O +
beats O -
/ O -
min O +
sustained O +
for O +
more O +
than O +
45 O +
min O -
. O -

It O +
is O +
concluded O +
that O +
bepridil O +
reduces O +
heart O +
rate O +
by O +
acting O +
directly O +
on O +
the O +
sinus O +
node O -
. O -

This O +
effect O -
, O +
which O +
results O +
in O +
a O +
flattening O +
of O +
the O +
phase O +
0 O +
and O +
phase O +
4 O +
slope O -
, O +
together O +
with O +
a O +
longer O +
AP O +
duration O -
, O +
may O +
be O +
due O +
to O +
an O +
increase O +
in O +
the O +
time O +
constants O +
of O +
slow O +
inward O +
ionic O +
currents O +
( O -
already O +
demonstrated O +
elsewhere O -
) O -
, O +
but O +
also O +
to O +
an O +
increased O +
time O +
constant O +
for O +
deactivation O +
of O +
the O +
outward O +
potassium O +
current O +
( O -
Ip O -
) O -
. O -

Hepatitis U-Disease +
and O +
renal B-Disease +
tubular I-Disease +
acidosis L-Disease +
after O +
anesthesia O +
with O +
methoxyflurane O -
. O -

A O +
69-year O -
- O -
old O +
man O +
operated O +
for O +
acute B-Disease +
cholecystitis L-Disease +
under O +
methoxyflurane O +
anesthesia O +
developed O +
postoperatively O +
a O +
hepatic B-Disease +
insufficiency I-Disease +
syndrome L-Disease +
and O +
renal B-Disease +
tubular I-Disease +
acidosis L-Disease -
. O -

Massive O +
bleeding U-Disease +
appeared O +
during O +
surgery O +
which O +
lasted O +
for O +
six O +
hours O -
. O -

Postoperative O +
evolution O +
under O +
supportive O +
therapy O +
was O +
favourable O -
. O -

Complete O +
recovery O +
was O +
confirmed O +
by O +
repeated O +
controls O +
performed O +
over O +
a O +
period O +
of O +
one O +
year O +
after O +
surgery O -
. O -

Pituitary O +
response O +
to O +
luteinizing O +
hormone O -
- O -
releasing O +
hormone O +
during O +
haloperidol O -
- O -
induced O +
hyperprolactinemia U-Disease -
. O -

The O +
effects O +
of O +
a O +
6-hour O +
infusion O +
with O +
haloperidol O +
on O +
serum O +
prolactin O +
and O +
luteinizing O +
hormone O +
( O -
LH O -
) O +
levels O +
was O +
studied O +
in O +
a O +
group O +
of O +
male O +
subjects O -
. O -

Five O +
hours O +
after O +
starting O +
the O +
infusions O -
, O +
a O +
study O +
of O +
the O +
pituitary O +
responses O +
to O +
LH O -
- O -
releasing O +
hormone O +
( O -
LH O -
- O -
RH O -
) O +
was O +
carried O +
out O -
. O -

Control O +
patients O +
received O +
infusions O +
of O +
0.9 O -
% O +
NaCl O +
solution O -
. O -

During O +
the O +
course O +
of O +
haloperidol O +
infusions O -
, O +
significant O +
hyperprolactinemia U-Disease +
was O +
found O -
, O +
together O +
with O +
an O +
abolished O +
pituitary O +
response O +
to O +
LH O -
- O -
RH O -
, O +
as O +
compared O +
with O +
responses O +
of O +
control O +
subjects O -
. O -

Antirifampicin O +
antibodies O +
in O +
acute O +
rifampicin O -
- O -
associated O +
renal B-Disease +
failure L-Disease -
. O -

5 O +
patients O +
with O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
( O -
3 O +
with O +
thrombopenia U-Disease +
and O +
hemolysis U-Disease -
) O +
induced O +
by O +
the O +
reintroduction O +
of O +
rifampicin O +
are O +
described O -
. O -

No O +
correlation O +
was O +
found O +
between O +
the O +
severity O +
of O +
clinical O +
manifestations O +
and O +
the O +
total O +
dose O +
taken O +
by O +
the O +
patients O -
. O -

In O +
all O +
but O +
1 O +
patient O -
, O +
antirifampicin O +
antibodies O +
were O +
detected O -
. O -

Antibodies O +
suggested O +
to O +
be O +
of O +
the O +
IgM O +
class O +
were O +
detected O +
in O +
all O +
3 O +
patients O +
with O +
hematological B-Disease +
disorders L-Disease -
. O -

The O +
pattern O +
of O +
non O -
- O -
specific O +
acute B-Disease +
tubular I-Disease +
necrosis L-Disease +
found O +
in O +
the O +
2 O +
biopsied O +
patients O -
, O +
indistinguishable O +
from O +
that O +
of O +
ischemic O +
origin O -
, O +
raised O +
the O +
possibility O +
of O +
a O +
vascular O -
- O -
mediated O +
damage O -
. O -

In O +
3 O +
patients O -
, O +
the O +
possibility O +
of O +
a O +
triggering O +
immunoallergic O +
mechanism O +
is O +
discussed O -
. O -

Cardiovascular O +
effects O +
of O +
hypotension U-Disease +
induced O +
by O +
adenosine O +
triphosphate O +
and O +
sodium O +
nitroprusside O +
on O +
dogs O +
with O +
denervated O +
hearts O -
. O -

Adenosine O +
triphosphate O +
( O -
ATP O -
) O +
and O +
sodium O +
nitroprusside O +
( O -
SNP O -
) O +
are O +
administered O +
to O +
patients O +
to O +
induce O +
and O +
control O +
hypotension U-Disease +
during O +
anesthesia O -
. O -

SNP O +
is O +
authorized O +
for O +
clinical O +
use O +
in O +
USA O +
and O +
UK O -
, O +
and O +
ATP O +
is O +
clinically O +
used O +
in O +
other O +
countries O +
such O +
as O +
Japan O -
. O -

We O +
investigated O +
how O +
these O +
two O +
drugs O +
act O +
on O +
the O +
cardiovascular O +
systems O +
of O +
20 O +
dogs O +
whose O +
hearts O +
had O +
been O +
denervated O +
by O +
a O +
procedure O +
we O +
had O +
devised O -
. O -

ATP O +
( O -
10 O +
dogs O -
) O +
or O +
SNP O +
( O -
10 O +
dogs O -
) O +
was O +
administered O +
to O +
reduce O +
mean O +
arterial O +
pressure O +
by O +
30 O -
% O +
to O +
70 O -
% O +
of O +
control O -
. O -

Before O -
, O +
during O +
and O +
after O +
induced O +
hypotension U-Disease -
, O +
we O +
measured O +
major O +
cardiovascular O +
parameters O -
. O -

Hypotension U-Disease +
induced O +
by O +
ATP O +
was O +
accompanied O +
by O +
significant O +
decreases O +
in O +
mean O +
pulmonary O +
arterial O +
pressure O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
central O +
venous O +
pressure O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
total O +
peripheral O +
resistance O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
rate O +
pressure O +
product O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
total O +
body O +
oxygen O +
consumption O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
, O +
and O +
heart O +
rate O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
; O +
all O +
these O +
variables O +
returned O +
normal O +
within O +
30 O +
min O +
after O +
ATP O +
was O +
stopped O -
. O -

Cardiac O +
output O +
did O +
not O +
change O -
. O -

During O +
hypotension U-Disease +
produced O +
by O +
SNP O +
similar O +
decreases O +
were O +
observed O +
in O +
mean O +
pulmonary O +
arterial O +
pressure O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
, O +
central O +
venous O +
pressure O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
, O +
total O +
peripheral O +
resistance O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
rate O +
pressure O +
product O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
and O +
oxygen O +
content O +
difference O +
between O +
arterial O +
and O +
mixed O +
venous O +
blood O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
, O +
while O +
heart O +
rate O +
( O -
p O +
less O +
than O +
0.001 O -
) O +
and O +
cardiac O +
output O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
were O +
increased O -
. O -

Recoveries O +
of O +
heart O +
rate O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
were O +
not O +
shown O +
within O +
60 O +
min O +
after O +
SNP O +
had O +
been O +
stopped O -
. O -

Both O +
ATP O +
and O +
SNP O +
should O +
act O +
on O +
the O +
pacemaker O +
tissue O +
of O +
the O +
heart O -
. O -

Comparative O +
study O -
: O +
Endografine O +
( O -
diatrizoate O -
) O -
, O +
Vasurix O +
polyvidone O +
( O -
acetrizoate O -
) O -
, O +
Dimer O -
- O -
X O +
( O -
iocarmate O -
) O +
and O +
Hexabrix O +
( O -
ioxaglate O -
) O +
in O +
hysterosalpingography O -
. O -

Side O +
effects O +
of O +
hysterosalpingography O +
with O +
Dimer O -
- O -
X O -
, O +
Hexabrix O -
, O +
Vasurix O +
polyvidone O +
and O +
Endografine O +
in O +
142 O +
consecutive O +
patients O -
, O +
receiving O +
one O +
of O +
the O +
four O +
tested O +
media O +
were O +
evaluated O +
from O +
replies O +
to O +
postal O +
questionnaires O -
. O -

The O +
Dimer O -
- O -
X O +
group O +
had O +
a O +
higher O +
incidence O +
of O +
nausea U-Disease +
and O +
dizziness U-Disease -
. O -

The O +
Endografine O +
group O +
had O +
a O +
higher O +
incidence O +
of O +
abdominal B-Disease +
pain L-Disease -
. O -

These O +
differences O +
occur O +
especially O +
in O +
the O +
age O +
groups O +
under O +
30 O +
years O -
. O -

Hexabrix O +
and O +
Vasurix O +
polyvidone O +
are O +
considered O +
the O +
best O +
contrast O +
media O +
for O +
hysterosalpingography O +
and O +
perhaps O +
because O +
of O +
its O +
low O +
toxicity U-Disease +
Hexabrix O +
should O +
be O +
preferred O -
. O -

Post O -
- O -
suxamethonium O +
pains U-Disease +
in O +
Nigerian O +
surgical O +
patients O -
. O -

Contrary O +
to O +
an O +
earlier O +
report O +
by O +
Coxon O -
, O +
scoline O +
pain U-Disease +
occurs O +
in O +
African O +
negroes O -
. O -

Its O +
incidence O +
was O +
determined O +
in O +
a O +
prospective O +
study O +
involving O +
a O +
total O +
of O +
100 O +
Nigerian O +
patients O +
( O -
50 O +
out O -
- O -
patients O +
and O +
50 O +
in O -
- O -
patients O -
) O -
. O -

About O +
62 O -
% O +
of O +
the O +
out O -
- O -
patients O +
developed O +
scoline O +
pain U-Disease +
as O +
compared O +
with O +
about O +
26 O -
% O +
among O +
the O +
in O -
- O -
patients O -
. O -

The O +
abolition O +
of O +
muscle O +
fasciculations U-Disease +
( O -
by O +
0.075mg O -
/ O -
kg O +
dose O +
of O +
Fazadinium O -
) O +
did O +
not O +
influence O +
the O +
occurrence O +
of O +
scoline O +
pain U-Disease -
. O -

Neither O +
the O +
type O +
of O +
induction O +
agent O +
( O -
Althesin O +
or O +
Thiopentone O -
) O +
nor O +
the O +
salt O +
preparation O +
of O +
suxamethonium O +
used O +
( O -
chloride O +
or O +
bromide O -
) O -
, O +
affected O +
the O +
incidence O +
of O +
scoline O +
pain U-Disease -
. O -

Invasive O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
pelvis L-Disease +
following O +
cyclophosphamide O +
therapy O +
for O +
nonmalignant O +
disease O -
. O -

A O +
47-year O -
- O -
old O +
woman O +
with O +
right O +
hydroureteronephrosis U-Disease +
due O +
to O +
ureterovesical O +
junction O +
obstruction O +
had O +
gross O +
hematuria U-Disease +
after O +
being O +
treated O +
for O +
five O +
years O +
wtih O +
cyclophosphamide O +
for O +
cerebral B-Disease +
vasculitis L-Disease -
. O -

A O +
right O +
nephroureterectomy O +
was O +
required O +
for O +
control O +
of O +
bleeding U-Disease -
. O -

The O +
pathology O +
specimen O +
contained O +
clinically O +
occult O +
invasive O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
pelvis L-Disease -
. O -

Although O +
the O +
ability O +
of O +
cyclophosphamide O +
to O +
cause O +
hemorrhagic U-Disease +
cystitis U-Disease +
and O +
urine O +
cytologic O +
abnormalities O +
indistinguishable O +
from O +
high O +
grade O +
carcinoma U-Disease +
is O +
well O +
known O -
, O +
it O +
is O +
less O +
widely O +
appreciated O +
that O +
it O +
is O +
also O +
associated O +
with O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
urinary I-Disease +
tract L-Disease -
. O -

Twenty O +
carcinomas B-Disease +
of I-Disease +
the I-Disease +
urinary I-Disease +
bladder L-Disease +
and O +
one O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
prostate L-Disease +
have O +
been O +
reported O +
in O +
association O +
with O +
its O +
use O -
. O -

The O +
present O +
case O +
is O +
the O +
first O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
pelvis L-Disease +
reported O +
in O +
association O +
with O +
cyclophosphamide O +
treatment O -
. O -

It O +
is O +
the O +
third O +
urinary B-Disease +
tract I-Disease +
cancer L-Disease +
reported O +
in O +
association O +
with O +
cyclophosphamide O +
treatment O +
for O +
nonmalignant O +
disease O -
. O -

The O +
association O +
of O +
the O +
tumor U-Disease +
with O +
preexisting O +
hydroureteronephrosis U-Disease +
suggests O +
that O +
stasis O +
prolonged O +
and O +
intensified O +
exposure O +
of O +
upper O +
urinary O +
tract O +
epithelium O +
to O +
cyclophosphamide O -
. O -

Patients O +
who O +
are O +
candidates O +
for O +
long O -
- O -
term O +
cyclophosphamide O +
treatment O +
should O +
be O +
routinely O +
evaluated O +
for O +
obstructive B-Disease +
uropathy L-Disease -
. O -

Medial O +
changes O +
in O +
arterial O +
spasm U-Disease +
induced O +
by O +
L O -
- O -
norepinephrine O -
. O -

In O +
normal O +
rats O -
, O +
the O +
media O +
of O +
small O +
arteries O +
( O -
0.4 O -
- O -
-0.2 O +
mm O +
in O +
diameter O -
) O +
previously O +
was O +
shown O +
to O +
contain O +
intracellular O +
vacuoles O -
, O +
identified O +
ultrastructurally O +
as O +
herniations O +
of O +
one O +
smooth O +
muscle O +
cell O +
into O +
another O -
. O -

The O +
hypothesis O +
that O +
intense O +
vasoconstriction O +
would O +
increase O +
the O +
number O +
of O +
such O +
vacuoles O +
has O +
been O +
tested O -
. O -

In O +
the O +
media O +
of O +
the O +
saphenous O +
artery O +
and O +
its O +
distal O +
branch O -
, O +
vasoconstriction O +
induced O +
by O +
L O -
- O -
norepinephrine O +
produced O +
many O +
cell O -
- O -
to O -
- O -
cell O +
hernias U-Disease +
within O +
15 O +
minutes O -
. O -

At O +
1 O +
day O +
their O +
number O +
was O +
reduced O +
to O +
about O +
1 O -
/ O -
10 O +
of O +
the O +
original O +
number O -
. O -

By O +
7 O +
days O +
the O +
vessel O +
was O +
almost O +
restored O +
to O +
normal O -
. O -

Triple O +
stimulation O +
over O +
1 O +
day O +
induced O +
more O +
severe O +
changes O +
in O +
the O +
media O -
. O -

These O +
findings O +
suggest O +
that O +
smooth O +
muscle O +
cells O +
are O +
susceptible O +
to O +
damage O +
in O +
the O +
course O +
of O +
their O +
specific O +
function O -
. O -

The O +
experimental O +
data O +
are O +
discussed O +
in O +
relation O +
to O +
medial O +
changes O +
observed O +
in O +
other O +
instances O +
of O +
arterial O +
spasm U-Disease -
. O -

Endothelial O +
changes O +
that O +
developed O +
in O +
the O +
same O +
experimental O +
model O +
were O +
described O +
in O +
a O +
previous O +
paper O -
. O -

Bilateral O +
retinal B-Disease +
artery I-Disease +
and I-Disease +
choriocapillaris I-Disease +
occlusion L-Disease +
following O +
the O +
injection O +
of O +
long O -
- O -
acting O +
corticosteroid O +
suspensions O +
in O +
combination O +
with O +
other O +
drugs O -
: O +
I. O +
Clinical O +
studies O -
. O -

Two O +
well O -
- O -
documented O +
cases O +
of O +
bilateral O +
retinal B-Disease +
artery I-Disease +
and I-Disease +
choriocapillaris I-Disease +
occlusions L-Disease +
with O +
blindness U-Disease +
following O +
head O +
and O +
neck O +
soft O -
- O -
tissue O +
injection O +
with O +
methylprednisolone O +
acetate O +
in O +
combination O +
with O +
lidocaine O -
, O +
epinephrine O -
, O +
or O +
penicillin O +
are O +
reported O -
. O -

One O +
case O +
had O +
only O +
a O +
unilateral O +
injection O -
. O -

The O +
acute O +
observations O +
included O +
hazy O +
sensorium O -
, O +
superior O +
gaze O +
palsy U-Disease -
, O +
pupillary B-Disease +
abnormalities L-Disease -
, O +
and O +
conjunctival O +
hemorrhages U-Disease +
with O +
edema U-Disease -
. O -

Follow O -
- O -
up O +
changes O +
showed O +
marked O +
visual B-Disease +
loss L-Disease -
, O +
constricted O +
visual O +
fields O -
, O +
optic O +
nerve O +
pallor O -
, O +
vascular O +
attenuation O -
, O +
and O +
chorioretinal B-Disease +
atrophy L-Disease -
. O -

The O +
literature O +
is O +
reviewed O -
, O +
and O +
possible O +
causes O +
are O +
discussed O -
. O -

Abnormalities O +
of O +
the O +
pupil O +
and O +
visual O -
- O -
evoked O +
potential O +
in O +
quinine O +
amblyopia U-Disease -
. O -

Total O +
blindness U-Disease +
with O +
a O +
transient O +
tonic B-Disease +
pupillary L-Disease +
response O -
, O +
denervation O +
supersensitivity O -
, O +
and O +
abnormal O +
visual O -
- O -
evoked O +
potentials O +
developed O +
in O +
a O +
54-year O -
- O -
old O +
man O +
after O +
the O +
use O +
of O +
quinine O +
sulfate O +
for O +
leg B-Disease +
cramps L-Disease -
. O -

He O +
later O +
recovered O +
normal O +
visual O +
acuity O -
. O -

A O +
transient O +
tonic B-Disease +
pupillary L-Disease +
response O -
, O +
denervation O +
supersensitivity O -
, O +
and O +
abnormal O +
visual O -
- O -
evoked O +
potentials O +
in O +
quinine O +
toxicity U-Disease -
, O +
to O +
our O +
knowledge O -
, O +
have O +
not O +
been O +
previously O +
reported O -
. O -

Suxamethonium O -
- O -
induced O +
jaw B-Disease +
stiffness L-Disease +
and O +
myalgia U-Disease +
associated O +
with O +
atypical O +
cholinesterase O -
: O +
case O +
report O -
. O -

An O +
11-year O -
- O -
old O +
boy O +
was O +
given O +
halothane O -
, O +
nitrous O +
oxide O +
and O +
oxygen O -
, O +
pancuronium O +
0.4 O +
mg O +
and O +
suxamethonium O +
100 O +
mg O +
for O +
induction O +
of O +
anaesthesia O -
. O -

In O +
response O +
to O +
this O +
a O +
marked O +
jaw B-Disease +
stiffness L-Disease +
occurred O +
which O +
lasted O +
for O +
two O +
minutes O +
and O +
the O +
anaesthesia O +
were O +
terminated O -
. O -

Four O +
hours O +
of O +
apnoea U-Disease +
ensued O +
and O +
he O +
suffered O +
generalized O +
severe O +
myalgia U-Disease +
lasting O +
for O +
one O +
week O -
. O -

He O +
was O +
found O +
to O +
have O +
atypical O +
plasma O +
cholinesterase O +
with O +
a O +
dibucaine O +
number O +
of O +
12 O -
, O +
indicating O +
homozygocity O -
. O -

This O +
was O +
verified O +
by O +
study O +
of O +
the O +
family O -
. O -

The O +
case O +
shows O +
that O +
prolonged B-Disease +
jaw I-Disease +
rigidity L-Disease +
and O +
myalgia U-Disease +
may O +
occur O +
after O +
suxamethonium O +
in O +
patients O +
with O +
atypical O +
cholinesterase O +
despite O +
pretreatment O +
with O +
pancuronium O -
. O -

Indomethacin O -
- O -
induced O +
hyperkalemia U-Disease +
in O +
three O +
patients O +
with O +
gouty B-Disease +
arthritis L-Disease -
. O -

We O +
describe O +
three O +
patients O +
in O +
whom O +
severe O -
, O +
life O -
- O -
threatening O +
hyperkalemia U-Disease +
and O +
renal B-Disease +
insufficiency L-Disease +
developed O +
after O +
treatment O +
of O +
acute O +
gouty B-Disease +
arthritis L-Disease +
with O +
indomethacin O -
. O -

This O +
complication O +
may O +
result O +
from O +
an O +
inhibition O +
of O +
prostaglandin O +
synthesis O +
and O +
consequent O +
hyporeninemic B-Disease +
hypoaidosteronism L-Disease -
. O -

Careful O +
attention O +
to O +
renal O +
function O +
and O +
potassium O +
balance O +
in O +
patients O +
receiving O +
indomethacin O +
or O +
other O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
agents O -
, O +
particularly O +
in O +
those O +
patients O +
with O +
diabetes B-Disease +
mellitus L-Disease +
or O +
preexisting O +
renal B-Disease +
disease L-Disease -
, O +
will O +
help O +
prevent O +
this O +
potentially O +
serious O +
complication O -
. O -

Etomidate O -
: O +
a O +
foreshortened O +
clinical O +
trial O -
. O -

A O +
clinical O +
evaluation O +
of O +
etomidate O +
for O +
outpatient O +
cystoscopy O +
was O +
embarked O +
upon O -
. O -

Unpremedicated O +
patients O +
were O +
given O +
fentanyl O +
1 O +
microgram O -
/ O -
kg O +
followed O +
by O +
etomidate O +
0.3 O +
mg O -
/ O -
kg O -
. O -

Anaesthesia O +
was O +
maintained O +
with O +
intermittent O +
etomidate O +
in O +
2 O -
- O -
4 O +
mg O +
doses O -
. O -

Patients O +
were O +
interviewed O +
personally O +
later O +
the O +
same O +
day O -
, O +
and O +
by O +
questionnaire O +
three O +
to O +
four O +
weeks O +
later O -
. O -

The O +
trial O +
was O +
discontinued O +
after O +
20 O +
cases O +
because O +
of O +
an O +
unacceptable O +
incidence O +
of O +
side O +
effects O -
. O -

Venous O +
pain U-Disease +
occurred O +
in O +
68 O -
% O +
of O +
patients O +
and O +
50 O -
% O +
had O +
redness O -
, O +
pain U-Disease +
or O +
swelling U-Disease +
related O +
to O +
the O +
injection O +
site O -
, O +
in O +
some O +
cases O +
lasting O +
up O +
to O +
three O +
weeks O +
after O +
anaesthesia O -
. O -

Skeletal O +
movements O +
occurred O +
in O +
50 O -
% O +
of O +
patients O -
; O +
30 O -
% O +
experienced O +
respiratory B-Disease +
upset L-Disease -
, O +
one O +
sufficiently O +
severe O +
to O +
necessitate O +
abandoning O +
the O +
technique O -
. O -

Nausea U-Disease +
and O +
vomiting U-Disease +
occurred O +
in O +
40 O -
% O +
and O +
25 O -
% O +
had O +
disturbing O +
emergence O +
psychoses U-Disease -
. O -

Levodopa O -
- O -
induced O +
dyskinesias U-Disease +
are O +
improved O +
by O +
fluoxetine O -
. O -

We O +
evaluated O +
the O +
severity O +
of O +
motor B-Disease +
disability L-Disease +
and O +
dyskinesias U-Disease +
in O +
seven O +
levodopa O -
- O -
responsive O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
after O +
an O +
acute O +
challenge O +
with O +
the O +
mixed O +
dopamine O +
agonist O -
, O +
apomorphine O -
, O +
before O +
and O +
after O +
the O +
administration O +
of O +
fluoxetine O +
( O -
20 O +
mg O +
twice O +
per O +
day O -
) O +
for O +
11 O +
+ O -
/- O -

1 O +
days O -
. O -

After O +
fluoxetine O +
treatment O -
, O +
there O +
was O +
a O +
significant O +
47 O -
% O +
improvement O +
( O -
p O +
< O +
0.05 O -
) O +
of O +
apomorphine O -
- O -
induced O +
dyskinesias U-Disease +
without O +
modification O +
of O +
parkinsonian U-Disease +
motor B-Disease +
disability L-Disease -
. O -

The O +
dyskinesias U-Disease +
were O +
reduced O +
predominantly O +
in O +
the O +
lower O +
limbs O +
during O +
the O +
onset O +
and O +
disappearance O +
of O +
dystonic U-Disease +
dyskinesias U-Disease +
( O -
onset- O +
and O +
end O -
- O -
of O -
- O -
dose O +
dyskinesias U-Disease -
) O +
and O +
in O +
the O +
upper O +
limbs O +
during O +
choreic U-Disease +
mid B-Disease -
- I-Disease -
dose I-Disease +
dyskinesias L-Disease -
. O -

The O +
results O +
suggest O +
that O +
increased O +
brain O +
serotoninergic O +
transmission O +
with O +
fluoxetine O +
may O +
reduce O +
levodopa- O +
or O +
dopamine O +
agonist O -
- O -
induced O +
dyskinesias U-Disease +
without O +
aggravating O +
parkinsonian U-Disease +
motor B-Disease +
disability L-Disease -
. O -

A O +
large O +
population O -
- O -
based O +
follow O -
- O -
up O +
study O +
of O +
trimethoprim O -
- O -
sulfamethoxazole O -
, O +
trimethoprim O -
, O +
and O +
cephalexin O +
for O +
uncommon O +
serious O +
drug B-Disease +
toxicity L-Disease -
. O -

We O +
conducted O +
a O +
population O -
- O -
based O +
45-day O +
follow O -
- O -
up O +
study O +
of O +
232,390 O +
people O +
who O +
were O +
prescribed O +
trimethoprim O -
- O -
sulfamethoxazole O +
( O -
TMP O -
- O -
SMZ O -
) O -
, O +
266,951 O +
prescribed O +
trimethoprim O +
alone O -
, O +
and O +
196,397 O +
prescribed O +
cephalexin O -
, O +
to O +
estimate O +
the O +
risk O +
of O +
serious O +
liver B-Disease -
, I-Disease +
blood I-Disease -
, I-Disease +
skin I-Disease -
, I-Disease +
and I-Disease +
renal I-Disease +
disorders L-Disease +
resulting O +
in O +
referral O +
or O +
hospitalization O +
associated O +
with O +
these O +
drugs O -
. O -

The O +
results O +
were O +
based O +
on O +
information O +
recorded O +
on O +
office O +
computers O +
by O +
selected O +
general O +
practitioners O +
in O +
the O +
United O +
Kingdom O -
, O +
together O +
with O +
a O +
review O +
of O +
clinical O +
records O -
. O -

The O +
risk O +
of O +
clinically O +
important O +
idiopathic O +
liver B-Disease +
disease L-Disease +
was O +
similar O +
for O +
persons O +
prescribed O +
TMP O -
- O -
SMZ O +
( O -
5.2 O -
/ O -
100,000 O -
) O +
and O +
those O +
prescribed O +
trimethoprim O +
alone O +
( O -
3.8 O -
/ O -
100,000 O -
) O -
. O -

The O +
risk O +
for O +
those O +
prescribed O +
cephalexin O +
was O +
somewhat O +
lower O +
( O -
2.0 O -
/ O -
100,000 O -
) O -
. O -

Only O +
five O +
patients O +
experienced O +
blood O +
disorders O -
, O +
one O +
of O +
whom O +
was O +
exposed O +
to O +
TMP O -
- O -
SMZ O -
; O +
of O +
seven O +
with O +
erythema B-Disease +
multiforme L-Disease +
and O +
Stevens B-Disease -
- I-Disease -
Johnson I-Disease +
syndrome L-Disease -
, O +
four O +
were O +
exposed O +
to O +
TMP O -
- O -
SMZ O -
. O -

The O +
one O +
case O +
of O +
toxic B-Disease +
epidermal I-Disease +
necrolysis L-Disease +
occurred O +
in O +
a O +
patient O +
who O +
took O +
cephalexin O -
. O -

Finally O -
, O +
only O +
five O +
cases O +
of O +
acute O +
parenchymal O +
renal B-Disease +
disease L-Disease +
occurred O -
, O +
none O +
likely O +
to O +
be O +
caused O +
by O +
a O +
study O +
drug O -
. O -

We O +
conclude O +
that O +
the O +
risk O +
of O +
the O +
serious O +
diseases O +
studied O +
is O +
small O +
for O +
the O +
three O +
agents O -
, O +
and O +
compares O +
reasonably O +
with O +
the O +
risk O +
for O +
many O +
other O +
antibiotics O -
. O -

Clinical O +
safety O +
of O +
lidocaine O +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
myocardial B-Disease +
infarction L-Disease -
. O -

STUDY O +
OBJECTIVE O -
: O +
To O +
evaluate O +
the O +
safety O +
of O +
lidocaine O +
in O +
the O +
setting O +
of O +
cocaine O -
- O -
induced O +
myocardial B-Disease +
infarction L-Disease +
( O -
MI U-Disease -
) O -
. O -

DESIGN O -
: O +
A O +
retrospective O -
, O +
multicenter O +
study O -
. O -

SETTING O -
: O +
Twenty O -
- O -
nine O +
university O -
, O +
university O -
- O -
affiliated O -
, O +
or O +
community O +
hospitals O +
during O +
a O +
6-year O +
period O +
( O -
total O +
of O +
117 O +
cumulative O +
hospital O -
- O -
years O -
) O -
. O -

PARTICIPANTS O -
: O +
Patients O +
with O +
cocaine O -
- O -
associated O +
MI U-Disease +
who O +
received O +
lidocaine O +
in O +
the O +
emergency O +
department O -
. O -

RESULTS O -
: O +
Of O +
29 O +
patients O +
who O +
received O +
lidocaine O +
in O +
the O +
setting O +
of O +
cocaine O -
- O -
associated O +
MI U-Disease -
, O +
no O +
patient O +
died O -
; O +
exhibited O +
bradydysrhythmias U-Disease -
, O +
ventricular B-Disease +
tachycardia L-Disease -
, O +
or O +
ventricular B-Disease +
fibrillation L-Disease -
; O +
or O +
experienced O +
seizures U-Disease +
after O +
administration O +
of O +
lidocaine O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
0 O -
% O +
to O +
11 O -
% O -
) O -
. O -

CONCLUSION O -
: O +
Despite O +
theoretical O +
concerns O +
that O +
lidocaine O +
may O +
enhance O +
cocaine O +
toxicity U-Disease -
, O +
the O +
use O +
of O +
lidocaine O +
in O +
patients O +
with O +
cocaine O -
- O -
associated O +
MI U-Disease +
was O +
not O +
associated O +
with O +
significant O +
cardiovascular B-Disease +
or I-Disease +
central I-Disease +
nervous I-Disease +
system I-Disease +
toxicity L-Disease -
. O -

Experimental O +
progressive O +
muscular B-Disease +
dystrophy L-Disease +
and O +
its O +
treatment O +
with O +
high O +
doses O +
anabolizing O +
agents O -
. O -

We O +
are O +
still O +
a O +
long O +
way O +
from O +
discovering O +
an O +
unequivocal O +
pathogenetic O +
interpretation O +
of O +
progressive O +
muscular B-Disease +
dystrophy L-Disease +
in O +
man O -
. O -

Noteworthy O +
efforts O +
have O +
been O +
made O +
in O +
the O +
experimental O +
field O -
; O +
a O +
recessive O +
autosomic O +
form O +
found O +
in O +
the O +
mouse O +
seems O +
to O +
bear O +
the O +
closest O +
resemblance O +
to O +
the O +
human O +
form O +
from O +
the O +
genetic O +
point O +
of O +
view O -
. O -

Myopathy U-Disease +
due O +
to O +
lack O +
of O +
vitamin O +
E O +
and O +
myopathy U-Disease +
induced O +
by O +
certain O +
viruses O +
have O +
much O +
in O +
common O +
anatomically O +
and O +
pathologically O +
with O +
the O +
human O +
form O -
. O -

The O +
authors O +
induced O +
myodystrophy U-Disease +
in O +
the O +
rat O +
by O +
giving O +
it O +
a O +
diet O +
lacking O +
in O +
vitamin O +
E. O +
The O +
pharmacological O +
characteristics O +
of O +
vitamin O +
E O +
and O +
the O +
degenerative O +
changes O +
brought O +
about O +
by O +
its O +
deficiency O -
, O +
especially O +
in O +
the O +
muscles O -
, O +
are O +
illustrated O -
. O -

It O +
is O +
thus O +
confirmed O +
that O +
the O +
histological O +
characteristics O +
of O +
myopathic U-Disease +
rat O +
muscle O +
induced O +
experimentally O +
are O +
extraordinarily O +
similar O +
to O +
those O +
of O +
human O +
myopathy U-Disease +
as O +
confirmed O +
during O +
biopsies O +
performed O +
at O +
the O +
Orthopaedic O +
Traumatological O +
Centre O -
, O +
Florence O -
. O -

The O +
encouraging O +
results O +
obtained O +
in O +
various O +
authoratative O +
departments O +
in O +
myopathic U-Disease +
patients O +
by O +
using O +
anabolizing O +
steroids O +
have O +
encouraged O +
the O +
authors O +
to O +
investigate O +
the O +
beneficial O +
effects O +
of O +
one O +
anabolizing O +
agent O +
( O -
Dianabol O -
, O +
CIBA O -
) O +
at O +
high O +
doses O +
in O +
rats O +
rendered O +
myopathic U-Disease +
by O +
a O +
diet O +
deficient O +
in O +
vitamin O +
E. O +
In O +
this O +
way O +
they O +
obtained O +
appreciable O +
changes O +
in O +
body O +
weight O +
( O -
increased O +
from O +
50 O +
to O +
70 O +
g O +
after O +
forty O +
days O +
at O +
a O +
dose O +
of O +
5 O +
mg O +
per O +
day O +
of O +
anabolizing O +
agent O -
) O -
, O +
but O +
most O +
of O +
all O +
they O +
found O +
histological O +
changes O +
due O +
to O +
" O -
regenerative O -
" O +
changes O +
in O +
the O +
muscle O +
tissue O -
, O +
which O +
however O +
maintained O +
its O +
myopathic U-Disease +
characteristics O +
in O +
the O +
control O +
animals O +
that O +
were O +
not O +
treated O +
with O +
the O +
anabolizing O +
agent O -
. O -

The O +
authors O +
conclude O +
by O +
affirming O +
the O +
undoubted O +
efficacy O +
of O +
the O +
anabolizing O +
steroids O +
in O +
experimental O +
myopathic B-Disease +
disease L-Disease -
, O +
but O +
they O +
have O +
reservations O +
as O +
to O +
the O +
transfer O +
of O +
the O +
results O +
into O +
the O +
human O +
field O -
, O +
where O +
high O +
dosage O +
can O -
not O +
be O +
carried O +
out O +
continuously O +
because O +
of O +
the O +
effects O +
of O +
the O +
drug O +
on O +
virility O -
; O +
because O +
the O +
tissue O +
injury O +
too O +
often O +
occurs O +
at O +
an O +
irreversible O +
stage O +
vis O -
- O -
a O -
- O -
vis O +
the O +
" O -
regeneration O -
" O +
of O +
the O +
muscle O +
tissue O -
; O +
and O +
finally O +
because O +
the O +
dystrophic O +
injurious O +
agent O +
is O +
certainly O +
not O +
the O +
lack O +
of O +
vitamin O +
E O +
but O +
something O +
as O +
yet O +
unknown O -
. O -

Paclitaxel O +
3-hour O +
infusion O +
given O +
alone O +
and O +
combined O +
with O +
carboplatin O -
: O +
preliminary O +
results O +
of O +
dose O -
- O -
escalation O +
trials O -
. O -

Paclitaxel O +
( O -
Taxol O -
; O +
Bristol O -
- O -
Myers O +
Squibb O +
Company O -
, O +
Princeton O -
, O +
NJ O -
) O +
by O +
3-hour O +
infusion O +
was O +
combined O +
with O +
carboplatin O +
in O +
a O +
phase O +
I O -
/ O -
II O +
study O +
directed O +
to O +
patients O +
with O +
non B-Disease -
- I-Disease -
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease -
. O -

Carboplatin O +
was O +
given O +
at O +
a O +
fixed O +
target O +
area O +
under O +
the O +
concentration O -
- O -
time O +
curve O +
of O +
6.0 O +
by O +
the O +
Calvert O +
formula O -
, O +
whereas O +
paclitaxel O +
was O +
escalated O +
in O +
patient O +
cohorts O +
from O +
150 O +
mg O -
/ O -
m2 O +
( O -
dose O +
level O +
I O -
) O +
to O +
175 O -
, O +
200 O -
, O +
225 O -
, O +
and O +
250 O +
mg O -
/ O -
m2 O -
. O -

The O +
225 O +
mg O -
/ O -
m2 O +
level O +
was O +
expanded O +
for O +
the O +
phase O +
II O +
study O +
since O +
the O +
highest O +
level O +
achieved O +
( O -
250 O +
mg O -
/ O -
m2 O -
) O +
required O +
modification O +
because O +
of O +
nonhematologic O +
toxicities U-Disease +
( O -
arthralgia U-Disease +
and O +
sensory B-Disease +
neuropathy L-Disease -
) O -
. O -

Therapeutic O +
effects O +
were O +
noted O +
at O +
all O +
dose O +
levels O -
, O +
with O +
objective O +
responses O +
in O +
17 O +
( O -
two O +
complete O +
and O +
15 O +
partial O +
regressions O -
) O +
of O +
41 O +
previously O +
untreated O +
patients O -
. O -

Toxicities U-Disease +
were O +
compared O +
with O +
a O +
cohort O +
of O +
patients O +
in O +
a O +
phase O +
I O +
trial O +
of O +
paclitaxel O +
alone O +
at O +
identical O +
dose O +
levels O -
. O -

Carboplatin O +
did O +
not O +
appear O +
to O +
add O +
to O +
the O +
hematologic B-Disease +
toxicities L-Disease +
observed O -
, O +
and O +
the O +
paclitaxel O -
/ O -
carboplatin O +
combination O +
could O +
be O +
dosed O +
every O +
3 O +
weeks O -
. O -

The O +
dose O -
- O -
dependent O +
effect O +
of O +
misoprostol O +
on O +
indomethacin O -
- O -
induced O +
renal B-Disease +
dysfunction L-Disease +
in O +
well O +
compensated O +
cirrhosis U-Disease -
. O -

Misoprostol O +
( O -
200 O +
micrograms O -
) O +
has O +
been O +
shown O +
to O +
acutely O +
counteract O +
the O +
indomethacin O -
- O -
induced O +
renal B-Disease +
dysfunction L-Disease +
in O +
well O +
compensated O +
cirrhotic U-Disease +
patients O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
determine O +
if O +
the O +
prophylactic O +
value O +
of O +
misoprostol O +
was O +
dose O -
- O -
dependent O -
. O -

Parameters O +
of O +
renal O +
hemodynamics O +
and O +
tubular O +
sodium O +
and O +
water O +
handling O +
were O +
assessed O +
by O +
clearance O +
techniques O +
in O +
26 O +
well O +
compensated O +
cirrhotic U-Disease +
patients O +
before O +
and O +
after O +
an O +
oral O +
combination O +
of O +
50 O +
mg O +
of O +
indomethacin O +
and O +
various O +
doses O +
of O +
misoprostol O -
. O -

The O +
200-micrograms O +
dose O +
was O +
able O +
to O +
totally O +
abolish O +
the O +
deleterious O +
renal O +
effects O +
of O +
indomethacin O -
, O +
whereas O +
the O +
800-micrograms O +
dose O +
resulted O +
in O +
significant O +
worsening O +
of O +
renal O +
hemodynamics O +
and O +
sodium O +
retention O -
. O -

These O +
changes O +
were O +
maximal O +
in O +
the O +
hour O +
immediately O +
after O +
medications O +
and O +
slowly O +
returned O +
toward O +
base O -
- O -
line O +
levels O +
thereafter O -
. O -

These O +
results O +
suggest O +
that O +
the O +
renal O +
protective O +
effects O +
of O +
misoprostol O +
is O +
dose O -
- O -
dependent O -
. O -

However O -
, O +
until O +
this O +
apparent O +
ability O +
of O +
200 O +
micrograms O +
of O +
misoprostol O +
to O +
prevent O +
the O +
adverse O +
effects O +
of O +
indomethacin O +
on O +
renal O +
function O +
is O +
confirmed O +
with O +
chronic O +
frequent O +
dosing O -
, O +
it O +
would O +
be O +
prudent O +
to O +
avoid O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
therapy O +
in O +
patients O +
with O +
cirrhosis U-Disease -
. O -

Increased O +
frequency O +
and O +
severity O +
of O +
angio B-Disease -
- I-Disease -
oedema L-Disease +
related O +
to O +
long O -
- O -
term O +
therapy O +
with O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
in O +
two O +
patients O -
. O -

Adverse O +
reactions O +
to O +
drugs O +
are O +
well O +
recognized O +
as O +
a O +
cause O +
of O +
acute O +
or O +
chronic O +
urticaria U-Disease -
, O +
and O +
angio B-Disease -
- I-Disease -
oedema L-Disease -
. O -

Angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitors O -
, O +
used O +
to O +
treat O +
hypertension U-Disease +
and O +
congestive B-Disease +
heart I-Disease +
failure L-Disease -
, O +
were O +
introduced O +
in O +
Europe O +
in O +
the O +
middle O +
of O +
the O +
eighties O -
, O +
and O +
the O +
use O +
of O +
these O +
drugs O +
has O +
increased O +
progressively O -
. O -

Soon O +
after O +
the O +
introduction O +
of O +
ACE O +
inhibitors O -
, O +
acute O +
bouts O +
of O +
angio B-Disease -
- I-Disease -
oedema L-Disease +
were O +
reported O +
in O +
association O +
with O +
the O +
use O +
of O +
these O +
drugs O -
. O -

We O +
wish O +
to O +
draw O +
attention O +
to O +
the O +
possibility O +
of O +
adverse O +
reactions O +
to O +
ACE O +
inhibitors O +
after O +
long O -
- O -
term O +
use O +
and O +
in O +
patients O +
with O +
pre O -
- O -
existing O +
angio B-Disease -
- I-Disease -
oedema L-Disease -
. O -

Myoclonus U-Disease +
associated O +
with O +
lorazepam O +
therapy O +
in O +
very O -
- O -
low O -
- O -
birth O -
- O -
weight O +
infants O -
. O -

Lorazepam O +
is O +
being O +
used O +
with O +
increasing O +
frequency O +
as O +
a O +
sedative O +
in O +
the O +
newborn O +
and O +
the O +
young O +
infant O -
. O -

Concern O +
has O +
been O +
raised O +
with O +
regard O +
to O +
the O +
safety O +
of O +
lorazepam O +
in O +
this O +
age O +
group O -
, O +
especially O +
in O +
very O -
- O -
low O -
- O -
birth O -
- O -
weight O +
( O -
VLBW O -
; O +
< O +
1,500 O +
g O -
) O +
infants O -
. O -

Three O +
young O +
infants O -
, O +
all O +
of O +
birth O +
weight O +
< O +
1,500 O +
g O -
, O +
experienced O +
myoclonus U-Disease +
following O +
the O +
intravenous O +
administration O +
of O +
lorazepam O -
. O -

The O +
potential O +
neurotoxic U-Disease +
effects O +
of O +
the O +
drug O +
( O -
and O +
its O +
vehicle O -
) O +
in O +
this O +
population O +
are O +
discussed O -
. O -

Injectable O +
lorazepam O +
should O +
be O +
used O +
with O +
caution O +
in O +
VLBW O +
infants O -
. O -

Transvenous O +
right O +
ventricular O +
pacing O +
during O +
cardiopulmonary O +
resuscitation O +
of O +
pediatric O +
patients O +
with O +
acute O +
cardiomyopathy U-Disease -
. O -

We O +
describe O +
the O +
cardiopulmonary O +
resuscitation O +
efforts O +
on O +
five O +
patients O +
who O +
presented O +
in O +
acute O +
circulatory B-Disease +
failure L-Disease +
from O +
myocardial B-Disease +
dysfunction L-Disease -
. O -

Three O +
patients O +
had O +
acute O +
viral O +
myocarditis U-Disease -
, O +
one O +
had O +
a O +
carbamazepine O -
- O -
induced O +
acute O +
eosinophilic U-Disease +
myocarditis U-Disease -
, O +
and O +
one O +
had O +
cardiac O +
hemosiderosis O +
resulting O +
in O +
acute O +
cardiogenic B-Disease +
shock L-Disease -
. O -

All O +
patients O +
were O +
continuously O +
monitored O +
with O +
central O +
venous O +
and O +
arterial O +
catheters O +
in O +
addition O +
to O +
routine O +
noninvasive O +
monitoring O -
. O -

An O +
introducer O +
sheath O -
, O +
a O +
pacemaker O -
, O +
and O +
sterile O +
pacing O +
wires O +
were O +
made O +
readily O +
available O +
for O +
the O +
patients O -
, O +
should O +
the O +
need O +
arise O +
to O +
terminate O +
resistant O +
cardiac O +
dysrhythmias U-Disease -
. O -

All O +
patients O +
developed O +
cardiocirculatory O +
arrest O +
associated O +
with O +
extreme O +
hypotension U-Disease +
and O +
dysrhythmias U-Disease +
within O +
the O +
first O +
48 O +
hours O +
of O +
their O +
admission O +
to O +
the O +
pediatric O +
intensive O +
care O +
unit O +
( O -
PICU O -
) O -
. O -

Right O +
ventricular O +
pacemaker O +
wires O +
were O +
inserted O +
in O +
all O +
of O +
them O +
during O +
cardiopulmonary O +
resuscitation O +
( O -
CPR O -
) O -
. O -

In O +
four O +
patients O -
, O +
cardiac O +
pacing O +
was O +
used O -
, O +
resulting O +
in O +
a O +
temporary O +
captured O +
rhythm O +
and O +
restoration O +
of O +
their O +
cardiac O +
output O -
. O -

These O +
patients O +
had O +
a O +
second O +
event O +
of O +
cardiac B-Disease +
arrest L-Disease -
, O +
resulting O +
in O +
death O -
, O +
within O +
10 O +
to O +
60 O +
minutes O -
. O -

In O +
one O +
patient O -
, O +
cardiac O +
pacing O +
was O +
not O +
used O -
, O +
because O +
he O +
converted O +
to O +
normal O +
sinus O +
rhythm O +
by O +
electrical O +
defibrillation O +
within O +
three O +
minutes O +
of O +
initiating O +
CPR O -
. O -

We O +
conclude O +
that O +
cardiac O +
pacing O +
during O +
resuscitative O +
efforts O +
in O +
pediatric O +
patients O +
suffering O +
from O +
acute O +
myocardial B-Disease +
dysfunction L-Disease +
may O +
not O +
have O +
long O -
- O -
term O +
value O +
in O +
and O +
of O +
itself O -
; O +
however O -
, O +
if O +
temporary O +
hemodynamic O +
stability O +
is O +
achieved O +
by O +
this O +
procedure O -
, O +
it O +
may O +
provide O +
additional O +
time O +
needed O +
to O +
institute O +
other O +
therapeutic O +
modalities O -
. O -

Efficacy O +
and O +
safety O +
of O +
granisetron O -
, O +
a O +
selective O +
5-hydroxytryptamine-3 O +
receptor O +
antagonist O -
, O +
in O +
the O +
prevention O +
of O +
nausea U-Disease +
and O +
vomiting U-Disease +
induced O +
by O +
high O -
- O -
dose O +
cisplatin O -
. O -

PURPOSE O -
: O +
To O +
assess O +
the O +
antiemetic O +
effects O +
and O +
safety O +
profile O +
of O +
four O +
different O +
doses O +
of O +
granisetron O +
( O -
Kytril O -
; O +
SmithKline O +
Beecham O +
Pharmaceuticals O -
, O +
Philadelphia O -
, O +
PA O -
) O +
when O +
administered O +
as O +
a O +
single O +
intravenous O +
( O -
IV O -
) O +
dose O +
for O +
prophylaxis O +
of O +
cisplatin O -
- O -
induced O +
nausea U-Disease +
and O +
vomiting U-Disease -
. O -

PATIENTS O +
AND O +
METHODS O -
: O +
One O +
hundred O +
eighty O -
- O -
four O +
chemotherapy O -
- O -
naive O +
patients O +
receiving O +
high O -
- O -
dose O +
cisplatin O +
( O -
81 O +
to O +
120 O +
mg O -
/ O -
m2 O -
) O +
were O +
randomized O +
to O +
receive O +
one O +
of O +
four O +
granisetron O +
doses O +
( O -
5 O -
, O +
10 O -
, O +
20 O -
, O +
or O +
40 O +
micrograms O -
/ O -
kg O -
) O +
administered O +
before O +
chemotherapy O -
. O -

Patients O +
were O +
observed O +
on O +
an O +
inpatient O +
basis O +
for O +
18 O +
to O +
24 O +
hours O -
, O +
and O +
vital O +
signs O -
, O +
nausea U-Disease -
, O +
vomiting U-Disease -
, O +
retching O -
, O +
and O +
appetite O +
were O +
assessed O -
. O -

Safety O +
analyses O +
included O +
incidence O +
of O +
adverse O +
experiences O +
and O +
laboratory O +
parameter O +
changes O -
. O -

RESULTS O -
: O +
After O +
granisetron O +
doses O +
of O +
5 O -
, O +
10 O -
, O +
20 O -
, O +
and O +
40 O +
micrograms O -
/ O -
kg O -
, O +
a O +
major O +
response O +
( O -
< O +
or O +
= O +
two O +
vomiting U-Disease +
or O +
retching O +
episodes O -
, O +
and O +
no O +
antiemetic O +
rescue O -
) O +
was O +
recorded O +
in O +
23 O -
% O -
, O +
57 O -
% O -
, O +
58 O -
% O -
, O +
and O +
60 O -
% O +
of O +
patients O -
, O +
respectively O -
, O +
and O +
a O +
complete O +
response O +
( O -
no O +
vomiting U-Disease +
or O +
retching O -
, O +
and O +
no O +
antiemetic O +
rescue O -
) O +
in O +
18 O -
% O -
, O +
41 O -
% O -
, O +
40 O -
% O -
, O +
and O +
47 O -
% O +
of O +
patients O -
, O +
respectively O -
. O -

There O +
was O +
a O +
statistically O +
longer O +
time O +
to O +
first O +
episode O +
of O +
nausea U-Disease +
( O -
P O +
= O +
.0015 O -
) O +
and O +
vomiting U-Disease +
( O -
P O +
= O +
.0001 O -
) O -
, O +
and O +
fewer O +
patients O +
were O +
administered O +
additional O +
antiemetic O +
medication O +
in O +
the O +
10-micrograms O -
/ O -
kg O +
dosing O +
groups O +
than O +
in O +
the O +
5-micrograms O -
/ O -
kg O +
dosing O +
group O -
. O -

As O +
granisetron O +
dose O +
increased O -
, O +
appetite O +
return O +
increased O +
( O -
P O +
= O +
.040 O -
) O -
. O -

Headache U-Disease +
was O +
the O +
most O +
frequently O +
reported O +
adverse O +
event O +
( O -
20 O -
% O -
) O -
. O -

CONCLUSION O -
: O +
A O +
single O +
10- O -
, O +
20- O -
, O +
or O +
40-micrograms O -
/ O -
kg O +
dose O +
of O +
granisetron O +
was O +
effective O +
in O +
controlling O +
vomiting U-Disease +
in O +
57 O -
% O +
to O +
60 O -
% O +
of O +
patients O +
who O +
received O +
cisplatin O +
at O +
doses O +
greater O +
than O +
81 O +
mg O -
/ O -
m2 O +
and O +
totally O +
prevented O +
vomiting U-Disease +
in O +
40 O -
% O +
to O +
47 O -
% O +
of O +
patients O -
. O -

There O +
were O +
no O +
statistically O +
significant O +
differences O +
in O +
efficacy O +
between O +
the O +
10-micrograms O -
/ O -
kg O +
dose O +
and O +
the O +
20- O +
and O +
40-micrograms O -
/ O -
kg O +
doses O -
. O -

Granisetron O +
was O +
well O +
tolerated O +
at O +
all O +
doses O -
. O -

Adverse O +
interaction O +
between O +
clonidine O +
and O +
verapamil O -
. O -

OBJECTIVE O -
: O +
To O +
report O +
two O +
cases O +
of O +
a O +
possible O +
adverse O +
interaction O +
between O +
clonidine O +
and O +
verapamil O +
resulting O +
in O +
atrioventricular B-Disease +
( I-Disease -
AV I-Disease -
) I-Disease +
block L-Disease +
in O +
both O +
patients O +
and O +
severe O +
hypotension U-Disease +
in O +
one O +
patient O -
. O -

CASE O +
SUMMARIES O -
: O +
A O +
54-year O -
- O -
old O +
woman O +
with O +
hyperaldosteronism U-Disease +
was O +
treated O +
with O +
verapamil O +
480 O +
mg O -
/ O -
d O +
and O +
spironolactone O +
100 O +
mg O -
/ O -
d O -
. O -

After O +
the O +
addition O +
of O +
a O +
minimal O +
dose O +
of O +
clonidine O +
( O -
0.15 O +
mg O +
bid O -
) O -
, O +
she O +
developed O +
complete O +
AV B-Disease +
block L-Disease +
and O +
severe O +
hypotension U-Disease -
, O +
which O +
resolved O +
upon O +
cessation O +
of O +
all O +
medications O -
. O -

A O +
65-year O -
- O -
old O +
woman O +
was O +
treated O +
with O +
extended O -
- O -
release O +
verapamil O +
240 O +
mg O -
/ O -
d O -
. O -

After O +
the O +
addition O +
of O +
clonidine O +
0.15 O +
mg O +
bid O +
she O +
developed O +
complete O +
AV B-Disease +
block L-Disease -
, O +
which O +
resolved O +
after O +
all O +
therapy O +
was O +
stopped O -
. O -

DISCUSSION O -
: O +
An O +
adverse O +
interaction O +
between O +
clonidine O +
and O +
verapamil O +
has O +
not O +
been O +
reported O +
previously O -
. O -

We O +
describe O +
two O +
such O +
cases O +
and O +
discuss O +
the O +
various O +
mechanisms O +
that O +
might O +
cause O +
such O +
an O +
interaction O -
. O -

Clinicians O +
should O +
be O +
acquainted O +
with O +
this O +
possibly O +
fatal O +
interaction O +
between O +
two O +
commonly O +
used O +
antihypertensive O +
drugs O -
. O -

CONCLUSIONS O -
: O +
Caution O +
is O +
recommended O +
in O +
combining O +
clonidine O +
and O +
verapamil O +
therapy O -
, O +
even O +
in O +
patients O +
who O +
do O +
not O +
have O +
sinus O +
or O +
AV O +
node O +
dysfunction O -
. O -

The O +
two O +
drugs O +
may O +
act O +
synergistically O +
on O +
both O +
the O +
AV O +
node O +
and O +
the O +
peripheral O +
circulation O -
. O -

Pharmacological O +
studies O +
on O +
a O +
new O +
dihydrothienopyridine O +
calcium O +
antagonist O -
, O +
S-312-d O -
. O -

5th O +
communication O -
: O +
anticonvulsant O +
effects O +
in O +
mice O -
. O -

S-312 O -
, O +
S-312-d O -
, O +
but O +
not O +
S-312-l O -
, O +
L O -
- O -
type O +
calcium O +
channel O +
antagonists O -
, O +
showed O +
anticonvulsant O +
effects O +
on O +
the O +
audiogenic B-Disease +
tonic I-Disease +
convulsions L-Disease +
in O +
DBA O -
/ O -
2 O +
mice O -
; O +
and O +
their O +
ED50 O +
values O +
were O +
18.4 O +
( O -
12.8 O -
- O -
27.1 O -
) O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O +
and O +
15.0 O +
( O -
10.2 O -
- O -
23.7 O -
) O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
, O +
respectively O -
, O +
while O +
that O +
of O +
flunarizine O +
was O +
34.0 O +
( O -
26.0 O -
- O -
44.8 O -
) O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -

Although O +
moderate O +
anticonvulsant O +
effects O +
of O +
S-312-d O +
in O +
higher O +
doses O +
were O +
observed O +
against O +
the O +
clonic O +
convulsions U-Disease +
induced O +
by O +
pentylenetetrazole O +
( O -
85 O +
mg O -
/ O -
kg O -
, O +
s.c O -
. O -
) O +
or O +
bemegride O +
( O -
40 O +
mg O -
/ O -
kg O -
, O +
s.c O -
. O -
) O -
, O +
no O +
effects O +
were O +
observed O +
in O +
convulsions U-Disease +
induced O +
by O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O -
, O +
picrotoxin O -
, O +
or O +
electroshock O +
in O +
Slc O -
: O -
ddY O +
mice O -
. O -

S-312-d O +
may O +
be O +
useful O +
in O +
the O +
therapy O +
of O +
certain O +
types O +
of O +
human O +
epilepsy U-Disease -
. O -

Transmural O +
myocardial B-Disease +
infarction L-Disease +
with O +
sumatriptan O -
. O -

For O +
sumatriptan O -
, O +
tightness O +
in O +
the O +
chest O +
caused O +
by O +
an O +
unknown O +
mechanism O +
has O +
been O +
reported O +
in O +
3 O -
- O -
5 O -
% O +
of O +
users O -
. O -

We O +
describe O +
a O +
47-year O -
- O -
old O +
woman O +
with O +
an O +
acute O +
myocardial B-Disease +
infarction L-Disease +
after O +
administration O +
of O +
sumatriptan O +
6 O +
mg O +
subcutaneously O +
for O +
cluster B-Disease +
headache L-Disease -
. O -

The O +
patient O +
had O +
no O +
history O +
of O +
underlying O +
ischaemic B-Disease +
heart I-Disease +
disease L-Disease +
or O +
Prinzmetal B-Disease -
's I-Disease +
angina L-Disease -
. O -

She O +
recovered O +
without O +
complications O -
. O -

Flumazenil O +
induces O +
seizures U-Disease +
and O +
death O +
in O +
mixed O +
cocaine O -
- O -
diazepam O +
intoxications O -
. O -

STUDY O +
HYPOTHESIS O -
: O +
Administration O +
of O +
the O +
benzodiazepine O +
antagonist O +
flumazenil O +
may O +
unmask O +
seizures U-Disease +
in O +
mixed O +
cocaine O -
- O -
benzodiazepine O +
intoxication O -
. O -

DESIGN O -
: O +
Male O +
Sprague O -
- O -
Dawley O +
rats O +
received O +
100 O +
mg O -
/ O -
kg O +
cocaine O +
IP O +
alone O -
, O +
5 O +
mg O -
/ O -
kg O +
diazepam O +
alone O -
, O +
or O +
a O +
combination O +
of O +
diazepam O +
and O +
cocaine O -
. O -

Three O +
minutes O +
later O -
, O +
groups O +
were O +
challenged O +
with O +
vehicle O +
or O +
flumazenil O +
5 O +
or O +
10 O +
mg O -
/ O -
kg O +
IP O -
. O -

Animal O +
behavior O -
, O +
seizures U-Disease +
( O -
time O +
to O +
and O +
incidence O -
) O -
, O +
death O +
( O -
time O +
to O +
and O +
incidence O -
) O -
, O +
and O +
cortical O +
EEG O +
tracings O +
were O +
recorded O -
. O -

INTERVENTIONS O -
: O +
Administration O +
of O +
flumazenil O +
to O +
animals O +
after O +
they O +
had O +
received O +
a O +
combination O +
dose O +
of O +
cocaine O +
and O +
diazepam O -
. O -

RESULTS O -
: O +
In O +
group O +
1 O -
, O +
animals O +
received O +
cocaine O +
followed O +
by O +
vehicle O -
. O -

This O +
resulted O +
in O +
100 O -
% O +
developing O +
seizures U-Disease +
and O +
death O -
. O -

Group O +
2 O +
received O +
diazepam O +
alone O +
followed O +
by O +
vehicle O -
. O -

Animals O +
became O +
somnolent O +
and O +
none O +
died O -
. O -

Group O +
3 O +
received O +
diazepam O +
followed O +
by O +
5 O +
mg O -
/ O -
kg O +
flumazenil O -
. O -

Animals O +
became O +
somnolent O +
after O +
diazepam O +
and O +
then O +
active O +
after O +
flumazenil O +
administration O -
. O -

In O +
group O +
4 O -
, O +
a O +
combination O +
of O +
cocaine O +
and O +
diazepam O +
was O +
administered O +
simultaneously O -
. O -

This O +
resulted O +
in O +
no O +
overt O +
or O +
EEG O -
- O -
detectable O +
seizures U-Disease +
and O +
a O +
50 O -
% O +
incidence O +
of O +
death O -
. O -

Group O +
5 O +
received O +
a O +
similar O +
combination O +
of O +
cocaine O +
and O +
diazepam O -
, O +
followed O +
later O +
by O +
5 O +
mg O -
/ O -
kg O +
flumazenil O -
. O -

This O +
resulted O +
in O +
an O +
increased O +
incidence O +
of O +
seizures U-Disease -
, O +
90 O -
% O +
( O -
P O +
< O +
.01 O -
) O -
, O +
and O +
death O -
, O +
100 O -
% O +
( O -
P O +
< O +
or O +
= O +
.01 O -
) O -
, O +
compared O +
with O +
group O +
4 O -
. O -

Group O +
6 O +
received O +
cocaine O +
and O +
diazepam O +
followed O +
by O +
10 O +
mg O -
/ O -
kg O +
flumazenil O -
. O -

This O +
also O +
resulted O +
in O +
an O +
increased O +
incidence O +
of O +
seizures U-Disease -
, O +
90 O -
% O +
( O -
P O +
< O +
or O +
= O +
.01 O -
) O -
, O +
and O +
death O -
, O +
90 O -
% O +
( O -
P O +
< O +
or O +
= O +
.05 O -
) O -
, O +
compared O +
with O +
group O +
4 O -
. O -

CONCLUSION O -
: O +
Flumazenil O +
can O +
unmask O +
seizures U-Disease +
and O +
increase O +
the O +
incidence O +
of O +
death O +
in O +
a O +
model O +
of O +
combined O +
cocaine O -
- O -
diazepam O +
intoxications O -
. O -

Mechanisms O +
for O +
protective O +
effects O +
of O +
free O +
radical O +
scavengers O +
on O +
gentamicin O -
- O -
mediated O +
nephropathy U-Disease +
in O +
rats O -
. O -

Studies O +
were O +
performed O +
to O +
examine O +
the O +
mechanisms O +
for O +
the O +
protective O +
effects O +
of O +
free O +
radical O +
scavengers O +
on O +
gentamicin O +
( O -
GM O -
) O -
-mediated O +
nephropathy U-Disease -
. O -

Administration O +
of O +
GM O +
at O +
40 O +
mg O -
/ O -
kg O +
sc O +
for O +
13 O +
days O +
to O +
rats O +
induced O +
a O +
significant O +
reduction O +
in O +
renal O +
blood O +
flow O +
( O -
RBF O -
) O +
and O +
inulin O +
clearance O +
( O -
CIn O -
) O +
as O +
well O +
as O +
marked O +
tubular B-Disease +
damage L-Disease -
. O -

A O +
significant O +
reduction O +
in O +
urinary O +
guanosine O +
3',5'-cyclic O +
monophosphate O +
( O -
cGMP O -
) O +
excretion O +
and O +
a O +
significant O +
increase O +
in O +
renal O +
cortical O +
renin O +
and O +
endothelin-1 O +
contents O +
were O +
also O +
observed O +
in O +
GM O -
- O -
mediated O +
nephropathy U-Disease -
. O -

Superoxide O +
dismutase O +
( O -
SOD O -
) O +
or O +
dimethylthiourea O +
( O -
DMTU O -
) O +
significantly O +
lessened O +
the O +
GM O -
- O -
induced O +
decrement O +
in O +
CIn O -
. O -

The O +
SOD O -
- O -
induced O +
increase O +
in O +
glomerular O +
filtration O +
rate O +
was O +
associated O +
with O +
a O +
marked O +
improvement O +
in O +
RBF O -
, O +
an O +
increase O +
in O +
urinary O +
cGMP O +
excretion O -
, O +
and O +
a O +
decrease O +
in O +
renal O +
renin O +
and O +
endothelin-1 O +
content O -
. O -

SOD O +
did O +
not O +
attenuate O +
the O +
tubular B-Disease +
damage L-Disease -
. O -

In O +
contrast O -
, O +
DMTU O +
significantly O +
reduced O +
the O +
tubular B-Disease +
damage L-Disease +
and O +
lipid O +
peroxidation O -
, O +
but O +
it O +
did O +
not O +
affect O +
renal O +
hemodynamics O +
and O +
vasoactive O +
substances O -
. O -

Neither O +
SOD O +
nor O +
DMTU O +
affected O +
the O +
renal O +
cortical O +
GM O +
content O +
in O +
GM O -
- O -
treated O +
rats O -
. O -

These O +
results O +
suggest O +
that O +
1 O -
) O +
both O +
SOD O +
and O +
DMTU O +
have O +
protective O +
effects O +
on O +
GM O -
- O -
mediated O +
nephropathy U-Disease -
, O +
2 O -
) O +
the O +
mechanisms O +
for O +
the O +
protective O +
effects O +
differ O +
for O +
SOD O +
and O +
DMTU O -
, O +
and O +
3 O -
) O +
superoxide O +
anions O +
play O +
a O +
critical O +
role O +
in O +
GM O -
- O -
induced O +
renal O +
vasoconstriction O -
. O -

Cephalothin O -
- O -
induced O +
immune O +
hemolytic B-Disease +
anemia L-Disease -
. O -

A O +
patient O +
with O +
renal B-Disease +
disease L-Disease +
developed O +
Coombs O -
- O -
positive O +
hemolytic B-Disease +
anemia L-Disease +
while O +
receiving O +
cephalothin O +
therapy O -
. O -

An O +
anti O -
- O -
cephalothin O +
IgG O +
antibody O +
was O +
detected O +
in O +
the O +
patient O -
's O +
serum O +
and O +
in O +
the O +
eluates O +
from O +
her O +
erythrocytes O -
. O -

In O +
addition O -
, O +
nonimmunologic O +
binding O +
of O +
normal O +
and O +
patient O -
's O +
serum O +
proteins O +
to O +
her O +
own O +
and O +
cephalothin O -
- O -
coated O +
normal O +
red O +
cells O +
was O +
demonstrated O -
. O -

Skin O +
tests O +
and O +
in O +
vitro O +
lymphocyte O +
stimulation O +
revealed O +
that O +
the O +
patient O +
was O +
sensitized O +
to O +
cephalothin O +
and O +
also O +
to O +
ampicillin O -
. O -

Careful O +
investigation O +
of O +
drug O -
- O -
induced O +
hemolytic B-Disease +
anemias L-Disease +
reveals O +
the O +
complexity O +
of O +
the O +
immune O +
mechanisms O +
involved O -
. O -

Assessment O +
of O +
cardiomyocyte O +
DNA O +
synthesis O +
during O +
hypertrophy U-Disease +
in O +
adult O +
mice O -
. O -

The O +
ability O +
of O +
cardiomyocytes O +
to O +
synthesize O +
DNA O +
in O +
response O +
to O +
experimentally O +
induced O +
cardiac B-Disease +
hypertrophy L-Disease +
was O +
assessed O +
in O +
adult O +
mice O -
. O -

Isoproterenol O +
delivered O +
by O +
osmotic O +
minipump O +
implantation O +
in O +
adult O +
C3Heb O -
/ O -
FeJ O +
mice O +
resulted O +
in O +
a O +
46 O -
% O +
increase O +
in O +
heart O +
weight O +
and O +
a O +
19.3 O -
% O +
increase O +
in O +
cardiomyocyte O +
area O -
. O -

No O +
DNA O +
synthesis O -
, O +
as O +
assessed O +
by O +
autoradiographic O +
analysis O +
of O +
isolated O +
cardiomyocytes O -
, O +
was O +
observed O +
in O +
control O +
or O +
hypertrophic B-Disease +
hearts L-Disease -
. O -

A O +
survey O +
of O +
15 O +
independent O +
inbred O +
strains O +
of O +
mice O +
revealed O +
that O +
ventricular O +
cardiomyocyte O +
nuclear O +
number O +
ranged O +
from O +
3 O +
to O +
13 O -
% O +
mononucleate O -
, O +
suggesting O +
that O +
cardiomyocyte O +
terminal O +
differentiation O +
is O +
influenced O +
directly O +
or O +
indirectly O +
by O +
genetic O +
background O -
. O -

To O +
determine O +
whether O +
the O +
capacity O +
for O +
reactive O +
DNA O +
synthesis O +
was O +
also O +
subject O +
to O +
genetic O +
regulation O -
, O +
cardiac B-Disease +
hypertrophy L-Disease +
was O +
induced O +
in O +
the O +
strains O +
of O +
mice O +
comprising O +
the O +
extremes O +
of O +
the O +
nuclear O +
number O +
survey O -
. O -

These O +
data O +
indicate O +
that O +
adult O +
mouse O +
atrial O +
and O +
ventricular O +
cardiomyocytes O +
do O +
not O +
synthesize O +
DNA O +
in O +
response O +
to O +
isoproterenol O -
- O -
induced O +
cardiac B-Disease +
hypertrophy L-Disease -
. O -

Central O +
cardiovascular O +
effects O +
of O +
AVP O +
and O +
ANP O +
in O +
normotensive O +
and O +
spontaneously O +
hypertensive U-Disease +
rats O -
. O -

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
compare O +
influence O +
of O +
central O +
arginine O +
vasopressin O +
( O -
AVP O -
) O +
and O +
of O +
atrial O +
natriuretic O +
peptide O +
( O -
ANP O -
) O +
on O +
control O +
of O +
arterial O +
blood O +
pressure O +
( O -
MAP O -
) O +
and O +
heart O +
rate O +
( O -
HR O -
) O +
in O +
normotensive O +
( O -
WKY O -
) O +
and O +
spontaneously O +
hypertensive U-Disease +
( O -
SHR O -
) O +
rats O -
. O -

Three O +
series O +
of O +
experiments O +
were O +
performed O +
on O +
30 O +
WKY O +
and O +
30 O +
SHR O -
, O +
chronically O +
instrumented O +
with O +
guide O +
tubes O +
in O +
the O +
lateral O +
ventricle O +
( O -
LV O -
) O +
and O +
arterial O +
and O +
venous O +
catheters O -
. O -

MAP O +
and O +
HR O +
were O +
monitored O +
before O +
and O +
after O +
i.v O -
. O -

injections O +
of O +
either O +
vehicle O +
or O +
1 O -
, O +
10 O +
and O +
50 O +
ng O +
of O +
AVP O +
and O +
25 O -
, O +
125 O +
and O +
500 O +
ng O +
of O +
ANP O -
. O -

Sensitivity O +
of O +
cardiac O +
component O +
of O +
baroreflex O +
( O -
CCB O -
) O -
, O +
expressed O +
as O +
a O +
slope O +
of O +
the O +
regression O +
line O +
was O +
determined O +
from O +
relationships O +
between O +
systolic O +
arterial O +
pressure O +
( O -
SAP O -
) O +
and O +
HR O +
period O +
( O -
HRp O -
) O +
during O +
phenylephrine O +
( O -
Phe O -
) O -
-induced O +
hypertension U-Disease +
and O +
sodium O +
nitroprusside O +
( O -
SN O -
) O -
-induced O +
hypotension U-Disease -
. O -

CCB O +
was O +
measured O +
before O +
and O +
after O +
administration O +
of O +
either O +
vehicle O -
, O +
AVP O -
, O +
ANP O -
, O +
or O +
both O +
peptides O +
together O -
. O -

Increases O +
of O +
MAP O +
occurred O +
after O +
LV O +
administration O +
of O +
1 O -
, O +
10 O +
and O +
50 O +
ng O +
of O +
AVP O +
in O +
WKY O +
and O +
of O +
10 O +
and O +
50 O +
ng O +
in O +
SHR O -
. O -

ANP O +
did O +
not O +
cause O +
significant O +
changes O +
in O +
MAP O +
in O +
both O +
strains O +
as O +
compared O +
to O +
vehicle O -
, O +
but O +
it O +
abolished O +
AVP O -
- O -
induced O +
MAP O +
increase O +
in O +
WKY O +
and O +
SHR O -
. O -

CCB O +
was O +
reduced O +
in O +
WKY O +
and O +
SHR O +
after O +
LV O +
administration O +
of O +
AVP O +
during O +
SN O -
- O -
induced O +
hypotension U-Disease -
. O -

In O +
SHR O +
but O +
not O +
in O +
WKY O +
administration O +
of O +
ANP O -
, O +
AVP O +
and O +
ANP O +
+ O +
AVP O +
decreased O +
CCB O +
during O +
Phe O -
- O -
induced O +
MAP O +
elevation O -
. O -

The O +
results O +
indicate O +
that O +
centrally O +
applied O +
AVP O +
and O +
ANP O +
exert O +
differential O +
effects O +
on O +
blood O +
pressure O +
and O +
baroreflex O +
control O +
of O +
heart O +
rate O +
in O +
WKY O +
and O +
SHR O +
and O +
suggest O +
interaction O +
of O +
these O +
two O +
peptides O +
in O +
blood O +
pressure O +
regulation O +
at O +
the O +
level O +
of O +
central O +
nervous O +
system O -
. O -

Cutaneous O +
exposure O +
to O +
warfarin O -
- O -
like O +
anticoagulant O +
causing O +
an O +
intracerebral B-Disease +
hemorrhage L-Disease -
: O +
a O +
case O +
report O -
. O -

A O +
case O +
of O +
intercerebral O +
hematoma U-Disease +
due O +
to O +
warfarin O -
- O -
induced O +
coagulopathy U-Disease +
is O +
presented O -
. O -

The O +
39-year O -
- O -
old O +
woman O +
had O +
spread O +
a O +
warfarin O -
- O -
type O +
rat O +
poison O +
around O +
her O +
house O +
weekly O +
using O +
her O +
bare O +
hands O -
, O +
with O +
no O +
washing O +
post O +
application O -
. O -

Percutaneous O +
absorption O +
of O +
warfarin O +
causing O +
coagulopathy U-Disease -
, O +
reported O +
three O +
times O +
in O +
the O +
past O -
, O +
is O +
a O +
significant O +
risk O +
if O +
protective O +
measures O -
, O +
such O +
as O +
gloves O -
, O +
are O +
not O +
used O -
. O -

An O +
adverse O +
drug O +
interaction O +
with O +
piroxicam O -
, O +
which O +
she O +
took O +
occasionally O -
, O +
may O +
have O +
exacerbated O +
the O +
coagulopathy U-Disease -
. O -

Pediatric O +
heart O +
transplantation O +
without O +
chronic O +
maintenance O +
steroids O -
. O -

From O +
1986 O +
to O +
February O +
1993 O -
, O +
40 O +
children O +
aged O +
2 O +
months O +
to O +
18 O +
years O +
( O -
average O +
age O +
10.4 O +
+ O -
/- O -

5.8 O +
years O -
) O +
underwent O +
heart O +
transplantation O -
. O -

Indications O +
for O +
transplantation O +
were O +
idiopathic B-Disease +
cardiomyopathy L-Disease +
( O -
52 O -
% O -
) O -
, O +
congenital B-Disease +
heart I-Disease +
disease L-Disease +
( O -
35 O -
% O -
) O +
with O +
and O +
without O +
prior O +
repair O +
( O -
71 O -
% O +
and O +
29 O -
% O -
, O +
respectively O -
) O -
, O +
hypertrophic B-Disease +
cardiomyopathy L-Disease +
( O -
5 O -
% O -
) O -
, O +
valvular B-Disease +
heart I-Disease +
disease L-Disease +
( O -
3 O -
% O -
) O -
, O +
and O +
doxorubicin O +
cardiomyopathy U-Disease +
( O -
5 O -
% O -
) O -
. O -

Patients O +
were O +
managed O +
with O +
cyclosporine O +
and O +
azathioprine O -
. O -

No O +
prophylaxis O +
with O +
antilymphocyte O +
globulin O +
was O +
used O -
. O -

Steroids O +
were O +
given O +
to O +
39 O -
% O +
of O +
patients O +
for O +
refractory O +
rejection O -
, O +
but O +
weaning O +
was O +
always O +
attempted O +
and O +
generally O +
successful O +
( O -
64 O -
% O -
) O -
. O -

Five O +
patients O +
( O -
14 O -
% O -
) O +
received O +
maintenance O +
steroids O -
. O -

Four O +
patients O +
died O +
in O +
the O +
perioperative O +
period O +
and O +
one O +
died O +
4 O +
months O +
later O -
. O -

There O +
have O +
been O +
no O +
deaths O +
related O +
to O +
rejection O +
or O +
infection U-Disease -
. O -

Average O +
follow O -
- O -
up O +
was O +
36 O +
+ O -
/- O -

19 O +
months O +
( O -
range O +
1 O +
to O +
65 O +
months O -
) O -
. O -

Cumulative O +
survival O +
is O +
88 O -
% O +
at O +
5 O +
years O -
. O -

In O +
patients O +
less O +
than O +
7 O +
years O +
of O +
age O -
, O +
rejection O +
was O +
monitored O +
noninvasively O -
. O -

In O +
the O +
first O +
postoperative O +
month O -
, O +
89 O -
% O +
of O +
patients O +
were O +
treated O +
for O +
rejection O -
. O -

Freedom O +
from O +
serious O +
infections U-Disease +
was O +
83 O -
% O +
at O +
1 O +
month O +
and O +
65 O -
% O +
at O +
1 O +
year O -
. O -

Cytomegalovirus B-Disease +
infections L-Disease +
were O +
treated O +
successfully O +
with O +
ganciclovir O +
in O +
11 O +
patients O -
. O -

No O +
impairment O +
of O +
growth O +
was O +
observed O +
in O +
children O +
who O +
underwent O +
transplantation O +
compared O +
with O +
a O +
control O +
population O -
. O -

Twenty O -
- O -
one O +
patients O +
( O -
60 O -
% O -
) O +
have O +
undergone O +
annual O +
catheterizations O +
and O +
no O +
sign O +
of O +
graft O +
atherosclerosis U-Disease +
has O +
been O +
observed O -
. O -

Seizures U-Disease +
occurred O +
in O +
five O +
patients O +
( O -
14 O -
% O -
) O +
and O +
hypertension U-Disease +
was O +
treated O +
in O +
10 O +
patients O +
( O -
28 O -
% O -
) O -
. O -

No O +
patient O +
was O +
disabled O +
and O +
no O +
lymphoproliferative B-Disease +
disorder L-Disease +
was O +
observed. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -

Delirium U-Disease +
during O +
fluoxetine O +
treatment O -
. O -

A O +
case O +
report O -
. O -

The O +
correlation O +
between O +
high O +
serum O +
tricyclic O +
antidepressant O +
concentrations O +
and O +
central O +
nervous O +
system O +
side O +
effects O +
has O +
been O +
well O +
established O -
. O -

Only O +
a O +
few O +
reports O +
exist O -
, O +
however O -
, O +
on O +
the O +
relationship O +
between O +
the O +
serum O +
concentrations O +
of O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
and O +
their O +
toxic O +
effects O -
. O -

In O +
some O +
cases O -
, O +
a O +
high O +
serum O +
concentration O +
of O +
citalopram O +
( O -
> O +
600 O +
nmol O -
/ O -
L O -
) O +
in O +
elderly O +
patients O +
has O +
been O +
associated O +
with O +
increased O +
somnolence U-Disease +
and O +
movement B-Disease +
difficulties L-Disease -
. O -

Widespread O +
cognitive B-Disease +
disorders L-Disease -
, O +
such O +
as O +
delirium U-Disease -
, O +
have O +
not O +
been O +
previously O +
linked O +
with O +
high O +
blood O +
levels O +
of O +
SSRIs O -
. O -

In O +
this O +
report O -
, O +
we O +
describe O +
a O +
patient O +
with O +
acute O +
hyperkinetic U-Disease +
delirium U-Disease +
connected O +
with O +
a O +
high O +
serum O +
total O +
fluoxetine O +
( O -
fluoxetine O +
plus O +
desmethylfluoxetine O -
) O +
concentration O -
. O -

Pulmonary B-Disease +
edema L-Disease +
and O +
shock U-Disease +
after O +
high O -
- O -
dose O +
aracytine O -
- O -
C O +
for O +
lymphoma U-Disease -
; O +
possible O +
role O +
of O +
TNF O -
- O -
alpha O +
and O +
PAF O -
. O -

Four O +
out O +
of O +
23 O +
consecutive O +
patients O +
treated O +
with O +
high O -
- O -
dose O +
Ara O -
- O -
C O +
for O +
lymphomas U-Disease +
in O +
our O +
institution O +
developed O +
a O +
strikingly O +
similar O +
syndrome O +
during O +
the O +
perfusion O -
. O -

It O +
was O +
characterized O +
by O +
the O +
onset O +
of O +
fever U-Disease -
, O +
diarrhea U-Disease -
, O +
shock U-Disease -
, O +
pulmonary B-Disease +
edema L-Disease -
, O +
acute B-Disease +
renal I-Disease +
failure L-Disease -
, O +
metabolic B-Disease +
acidosis L-Disease -
, O +
weight B-Disease +
gain L-Disease +
and O +
leukocytosis U-Disease -
. O -

Thorough O +
bacteriological O +
screening O +
failed O +
to O +
provide O +
evidence O +
of O +
infection U-Disease -
. O -

Sequential O +
biological O +
assays O +
of O +
IL-1 O -
, O +
IL-2 O -
, O +
TNF O +
and O +
PAF O +
were O +
performed O +
during O +
Ara O -
- O -
C O +
infusion O +
to O +
ten O +
patients O -
, O +
including O +
the O +
four O +
who O +
developed O +
the O +
syndrome O -
. O -

TNF O +
and O +
PAF O +
activity O +
was O +
found O +
in O +
the O +
serum O +
of O +
respectively O +
two O +
and O +
four O +
of O +
the O +
cases O -
, O +
but O +
not O +
in O +
the O +
six O +
controls O -
. O -

As O +
TNF O +
and O +
PAF O +
are O +
thought O +
to O +
be O +
involved O +
in O +
the O +
development O +
of O +
septic O +
shock U-Disease +
and O +
adult B-Disease +
respiratory I-Disease +
distress I-Disease +
syndrome L-Disease -
, O +
we O +
hypothesize O +
that O +
high O -
- O -
dose O +
Ara O -
- O -
C O +
may O +
be O +
associated O +
with O +
cytokine O +
release O -
. O -

Protective O +
effect O +
of O +
clentiazem O +
against O +
epinephrine O -
- O -
induced O +
cardiac B-Disease +
injury L-Disease +
in O +
rats O -
. O -

We O +
investigated O +
the O +
effects O +
of O +
clentiazem O -
, O +
a O +
1,5-benzothiazepine O +
calcium O +
antagonist O -
, O +
on O +
epinephrine O -
- O -
induced O +
cardiomyopathy U-Disease +
in O +
rats O -
. O -

With O +
2-week O +
chronic O +
epinephrine O +
infusion O -
, O +
16 O +
of O +
30 O +
rats O +
died O +
within O +
4 O +
days O -
, O +
and O +
severe O +
ischemic B-Disease +
lesions L-Disease +
and O +
fibrosis U-Disease +
of O +
the O +
left O +
ventricles O +
were O +
observed O -
. O -

In O +
epinephrine O -
- O -
treated O +
rats O -
, O +
left O +
atrial O +
and O +
left O +
ventricular O +
papillary O +
muscle O +
contractile O +
responses O +
to O +
isoproterenol O +
were O +
reduced O -
, O +
but O +
responses O +
to O +
calcium O +
were O +
normal O +
or O +
enhanced O +
compared O +
to O +
controls O -
. O -

Left O +
ventricular O +
alpha O +
and O +
beta O +
adrenoceptor O +
densities O +
were O +
also O +
reduced O +
compared O +
to O +
controls O -
. O -

Treatment O +
with O +
clentiazem O +
prevented O +
epinephrine O -
- O -
induced O +
death O +
( O -
P O +
< O +
.05 O -
) O -
, O +
and O +
attenuated O +
the O +
ventricular O +
ischemic B-Disease +
lesions L-Disease +
and O +
fibrosis U-Disease -
, O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O -

Left O +
atrial O +
and O +
left O +
ventricular O +
papillary O +
muscle O +
contractile O +
responses O +
to O +
isoproterenol O +
were O +
reduced O +
compared O +
to O +
controls O +
in O +
groups O +
treated O +
with O +
clentiazem O +
alone O -
, O +
but O +
combined O +
with O +
epinephrine O -
, O +
clentiazem O +
restored O +
left O +
atrial O +
responses O +
and O +
enhanced O +
left O +
ventricular O +
papillary O +
responses O +
to O +
isoproterenol O -
. O -

On O +
the O +
other O +
hand O +
clentiazem O +
did O +
not O +
prevent O +
epinephrine O -
- O -
induced O +
down O -
- O -
regulation O +
of O +
alpha O +
and O +
beta O +
adrenoceptors O -
. O -

Interestingly O -
, O +
clentiazem O -
, O +
infused O +
alone O -
, O +
resulted O +
in O +
decreased O +
adrenergic O +
receptor O +
densities O +
in O +
the O +
left O +
ventricle O -
. O -

Clentiazem O +
also O +
did O +
not O +
prevent O +
the O +
enhanced O +
responses O +
to O +
calcium O +
seen O +
in O +
the O +
epinephrine O -
- O -
treated O +
animals O -
, O +
although O +
the O +
high O +
dose O +
of O +
clentiazem O +
partially O +
attenuated O +
the O +
maximal O +
response O +
to O +
calcium O +
compared O +
to O +
epinephrine O -
- O -
treated O +
animals O -
. O -

In O +
conclusion O -
, O +
clentiazem O +
attenuated O +
epinephrine O -
- O -
induced O +
cardiac B-Disease +
injury L-Disease -
, O +
possibly O +
through O +
its O +
effect O +
on O +
the O +
adrenergic O +
pathway O -
. O -

Kaliuretic O +
effect O +
of O +
L O -
- O -
dopa O +
treatment O +
in O +
parkinsonian U-Disease +
patients O -
. O -

Hypokalemia U-Disease -
, O +
sometimes O +
severe O -
, O +
was O +
observed O +
in O +
some O +
L O -
- O -
dopa O -
- O -
treated O +
parkinsonian U-Disease +
patients O -
. O -

The O +
influence O +
of O +
L O -
- O -
dopa O +
on O +
the O +
renal O +
excretion O +
of O +
potassium O +
was O +
studied O +
in O +
3 O +
patients O +
with O +
hypokalemia U-Disease +
and O +
in O +
5 O +
normokalemic O +
patients O +
by O +
determination O +
of O +
renal O +
plasma O +
flow O -
, O +
glomerular O +
filtration O +
rate O -
, O +
plasma O +
concentration O +
of O +
potassium O +
and O +
sodium O +
as O +
well O +
as O +
urinary O +
excretion O +
of O +
potassium O -
, O +
sodium O +
and O +
aldosterone O -
. O -

L O -
- O -
Dopa O +
intake O +
was O +
found O +
to O +
cause O +
an O +
increased O +
excretion O +
of O +
potassium O -
, O +
and O +
sometimes O +
also O +
of O +
sodium O -
, O +
in O +
the O +
hypokalemic O +
but O +
not O +
in O +
the O +
normokalemic O +
patients O -
. O -

This O +
effect O +
on O +
the O +
renal O +
function O +
could O +
be O +
prohibited O +
by O +
the O +
administration O +
of O +
a O +
peripheral O +
dopa O +
decarbodylase O +
inhibitor O -
. O -

It O +
is O +
not O +
known O +
why O +
this O +
effect O +
occurred O +
in O +
some O +
individuals O +
but O +
not O +
in O +
others O -
, O +
but O +
our O +
results O +
indicate O +
a O +
correlation O +
between O +
aldosterone O +
production O +
and O +
this O +
renal O +
effect O +
of O +
L O -
- O -
dopa O -
. O -

Cocaine O +
induced O +
myocardial B-Disease +
ischemia L-Disease -
. O -

We O +
report O +
a O +
case O +
of O +
myocardial B-Disease +
ischemia L-Disease +
induced O +
by O +
cocaine O -
. O -

The O +
ischemia U-Disease +
probably O +
induced O +
by O +
coronary B-Disease +
artery I-Disease +
spasm L-Disease +
was O +
reversed O +
by O +
nitroglycerin O +
and O +
calcium O +
blocking O +
agents O -
. O -

Doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease +
monitored O +
by O +
ECG O +
in O +
freely O +
moving O +
mice O -
. O -

A O +
new O +
model O +
to O +
test O +
potential O +
protectors O -
. O -

In O +
laboratory O +
animals O -
, O +
histology O +
is O +
most O +
commonly O +
used O +
to O +
study O +
doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease -
. O -

However O -
, O +
for O +
monitoring O +
during O +
treatment O -
, O +
large O +
numbers O +
of O +
animals O +
are O +
needed O -
. O -

Recently O +
we O +
developed O +
a O +
new O +
method O +
to O +
measure O +
ECG O +
values O +
in O +
freely O +
moving O +
mice O +
by O +
telemetry O -
. O -

With O +
this O +
model O +
we O +
investigated O +
the O +
effect O +
of O +
chronic O +
doxorubicin O +
administration O +
on O +
the O +
ECG O +
of O +
freely O +
moving O +
BALB O -
/ O -
c O +
mice O +
and O +
the O +
efficacy O +
of O +
ICRF-187 O +
as O +
a O +
protective O +
agent O -
. O -

The O +
ST O +
interval O +
significantly O +
widened O +
from O +
15.0 O +
+ O -
/- O -

1.5 O +
to O +
56.8 O +
+ O -
/- O -

11.8 O +
ms O +
in O +
week O +
10 O +
( O -
7 O +
weekly O +
doses O +
of O +
4 O +
mg O -
/ O -
kg O +
doxorubicin O +
given O +
i.v O -
. O -

plus O +
3 O +
weeks O +
of O +
observation O -
) O -
. O -

The O +
ECG O +
of O +
the O +
control O +
animals O +
did O +
not O +
change O +
during O +
the O +
entire O +
study O -
. O -

After O +
sacrifice O +
the O +
hearts O +
of O +
doxorubicin O -
- O -
treated O +
animals O +
were O +
enlarged O +
and O +
the O +
atria O +
were O +
hypertrophic U-Disease -
. O -

As O +
this O +
schedule O +
exerted O +
more O +
toxicity U-Disease +
than O +
needed O +
to O +
investigate O +
protective O +
agents O -
, O +
the O +
protection O +
of O +
ICRF-187 O +
was O +
determined O +
using O +
a O +
dose O +
schedule O +
with O +
lower O +
general O +
toxicity U-Disease +
( O -
6 O +
weekly O +
doses O +
of O +
4 O +
mg O -
/ O -
kg O +
doxorubicin O +
given O +
i.v O -
. O +
plus O +
2 O +
weeks O +
of O +
observation O -
) O -
. O -

On O +
this O +
schedule O -
, O +
the O +
animals O -
' O +
hearts O +
appeared O +
normal O +
after O +
sacrifice O +
and O +
ICRF-187 O +
( O -
50 O +
mg O -
/ O -
kg O +
given O +
i.p O -
. O -

1 O +
h O +
before O +
doxorubicin O -
) O +
provided O +
almost O +
full O +
protection O -
. O -

These O +
data O +
were O +
confirmed O +
by O +
histology O -
. O -

The O +
results O +
indicate O +
that O +
this O +
new O +
model O +
is O +
very O +
sensitive O +
and O +
enables O +
monitoring O +
of O +
the O +
development O +
of O +
cardiotoxicity U-Disease +
with O +
time O -
. O -

These O +
findings O +
result O +
in O +
a O +
model O +
that O +
allows O +
the O +
testing O +
of O +
protectors O +
against O +
doxorubicin O -
- O -
induced O +
cardiotoxicity U-Disease +
as O +
demonstrated O +
by O +
the O +
protection O +
provided O +
by O +
ICRF-187 O -
. O -

Epinephrine O +
dysrhythmogenicity O +
is O +
not O +
enhanced O +
by O +
subtoxic O +
bupivacaine O +
in O +
dogs O -
. O -

Since O +
bupivacaine O +
and O +
epinephrine O +
may O +
both O +
precipitate O +
dysrhythmias U-Disease -
, O +
circulating O +
bupivacaine O +
during O +
regional O +
anesthesia O +
could O +
potentiate O +
dysrhythmogenic O +
effects O +
of O +
epinephrine O -
. O -

We O +
therefore O +
examined O +
whether O +
bupivacaine O +
alters O +
the O +
dysrhythmogenicity O +
of O +
subsequent O +
administration O +
of O +
epinephrine O +
in O +
conscious O -
, O +
healthy O +
dogs O +
and O +
in O +
anesthetized O +
dogs O +
with O +
myocardial B-Disease +
infarction L-Disease -
. O -

Forty O -
- O -
one O +
conscious O +
dogs O +
received O +
10 O +
micrograms.kg-1.min-1 O +
epinephrine O -
. O -

Seventeen O +
animals O +
responded O +
with O +
ventricular B-Disease +
tachycardia L-Disease +
( O -
VT U-Disease -
) O +
within O +
3 O +
min O -
. O -

After O +
3 O +
h O -
, O +
these O +
responders O +
randomly O +
received O +
1 O +
or O +
2 O +
mg O -
/ O -
kg O +
bupivacaine O +
or O +
saline O +
over O +
5 O +
min O -
, O +
followed O +
by O +
10 O +
micrograms.kg-1.min-1 O +
epinephrine O -
. O -

In O +
the O +
bupivacaine O +
groups O -
, O +
epinephrine O +
caused O +
fewer O +
prodysrhythmic O +
effects O +
than O +
without O +
bupivacaine O -
. O -

VT U-Disease +
appeared O +
in O +
fewer O +
dogs O +
and O +
at O +
a O +
later O +
time O -
, O +
and O +
there O +
were O +
more O +
sinoatrial O +
beats O +
and O +
less O +
ectopies O -
. O -

Epinephrine O +
shortened O +
QT O +
less O +
after O +
bupivacaine O +
than O +
in O +
control O +
animals O -
. O -

One O +
day O +
after O +
experimental O +
myocardial B-Disease +
infarction L-Disease -
, O +
six O +
additional O +
halothane O -
- O -
anesthetized O +
dogs O +
received O +
4 O +
micrograms.kg-1.min-1 O +
epinephrine O +
until O +
VT U-Disease +
appeared O -
. O -

After O +
45 O +
min O -
, O +
1 O +
mg O -
/ O -
kg O +
bupivacaine O +
was O +
injected O +
over O +
5 O +
min O -
, O +
again O +
followed O +
by O +
4 O +
micrograms.kg-1.min-1 O +
epinephrine O -
. O -

In O +
these O +
dogs O -
, O +
the O +
prodysrhythmic O +
response O +
to O +
epinephrine O +
was O +
also O +
mitigated O +
by O +
preceding O +
bupivacaine O -
. O -

Bupivacaine O +
antagonizes O +
epinephrine O +
dysrhythmogenicity O +
in O +
conscious O +
dogs O +
susceptible O +
to O +
VT U-Disease +
and O +
in O +
anesthetized O +
dogs O +
with O +
spontaneous O +
postinfarct O +
dysrhythmias U-Disease -
. O -

There O +
is O +
no O +
evidence O +
that O +
systemic O +
subtoxic O +
bupivacaine O +
administration O +
enhances O +
the O +
dysrhythmogenicity O +
of O +
subsequent O +
epinephrine O -
. O -

Milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease +
induced O +
by O +
1,25 O -
( O -
OH O -
) O -
2D O +
in O +
a O +
patient O +
with O +
hypoparathyroidism U-Disease -
. O -

Milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease +
was O +
first O +
described O +
70 O +
years O +
ago O +
in O +
the O +
context O +
of O +
the O +
treatment O +
of O +
peptic B-Disease +
ulcer I-Disease +
disease L-Disease +
with O +
large O +
amounts O +
of O +
calcium O +
and O +
alkali O -
. O -

Although O +
with O +
current O +
ulcer U-Disease +
therapy O +
( O -
H-2 O +
blockers O -
, O +
omeprazole O -
, O +
and O +
sucralfate O -
) O -
, O +
the O +
frequency O +
of O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease +
has O +
decreased O +
significantly O -
, O +
the O +
classic O +
triad O +
of O +
hypercalcemia U-Disease -
, O +
alkalosis U-Disease -
, O +
and O +
renal B-Disease +
impairment L-Disease +
remains O +
the O +
hallmark O +
of O +
the O +
syndrome O -
. O -

Milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease +
can O +
present O +
serious O +
and O +
occasionally O +
life O -
- O -
threatening O +
illness O +
unless O +
diagnosed O +
and O +
treated O +
appropriately O -
. O -

This O +
article O +
presents O +
a O +
patient O +
with O +
hypoparathyroidism U-Disease +
who O +
was O +
treated O +
with O +
calcium O +
carbonate O +
and O +
calcitriol O +
resulting O +
in O +
two O +
admissions O +
to O +
the O +
hospital O +
for O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease -
. O -

The O +
patient O +
was O +
successfully O +
treated O +
with O +
intravenous O +
pamidronate O +
on O +
his O +
first O +
admission O +
and O +
with O +
hydrocortisone O +
on O +
the O +
second O -
. O -

This O +
illustrates O +
intravenous O +
pamidronate O +
as O +
a O +
valuable O +
therapeutic O +
tool O +
when O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome L-Disease +
presents O +
as O +
hypercalcemic B-Disease +
emergency L-Disease -
. O -

Encephalopathy U-Disease +
during O +
amitriptyline O +
therapy O -
: O +
are O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
and O +
serotonin B-Disease +
syndrome L-Disease +
spectrum O +
disorders O -
? O -

This O +
report O +
describes O +
a O +
case O +
of O +
encephalopathy U-Disease +
developed O +
in O +
the O +
course O +
of O +
amitriptyline O +
therapy O -
, O +
during O +
a O +
remission O +
of O +
unipolar B-Disease +
depression L-Disease -
. O -

This O +
patient O +
could O +
have O +
been O +
diagnosed O +
as O +
having O +
either O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
( O -
NMS U-Disease -
) O +
or O +
serotonin B-Disease +
syndrome L-Disease +
( O -
SS U-Disease -
) O -
. O -

The O +
major O +
determinant O +
of O +
the O +
symptoms O +
may O +
have O +
been O +
dopamine O -
/ O -
serotonin O +
imbalance O +
in O +
the O +
central O +
nervous O +
system O -
. O -

The O +
NMS U-Disease -
- O -
like O +
encephalopathy U-Disease +
that O +
develops O +
in O +
association O +
with O +
the O +
use O +
of O +
antidepressants O +
indicates O +
that O +
NMS U-Disease +
and O +
SS U-Disease +
are O +
spectrum O +
disorders O +
induced O +
by O +
drugs O +
with O +
both O +
antidopaminergic O +
and O +
serotonergic O +
effects O -
. O -

Genetic O +
separation O +
of O +
tumor U-Disease +
growth O +
and O +
hemorrhagic U-Disease +
phenotypes O +
in O +
an O +
estrogen O -
- O -
induced O +
tumor U-Disease -
. O -

Chronic O +
administration O +
of O +
estrogen O +
to O +
the O +
Fischer O +
344 O +
( O -
F344 O -
) O +
rat O +
induces O +
growth O +
of O +
large O -
, O +
hemorrhagic U-Disease +
pituitary B-Disease +
tumors L-Disease -
. O -

Ten O +
weeks O +
of O +
diethylstilbestrol O +
( O -
DES O -
) O +
treatment O +
caused O +
female O +
F344 O +
rat O +
pituitaries O +
to O +
grow O +
to O +
an O +
average O +
of O +
109.2 O +
+ O -
/- O -

6.3 O +
mg O +
( O -
mean O +
+ O -
/- O +
SE O -
) O +
versus O +
11.3 O +
+ O -
/- O -

1.4 O +
mg O +
for O +
untreated O +
rats O -
, O +
and O +
to O +
become O +
highly O +
hemorrhagic U-Disease -
. O -

The O +
same O +
DES O +
treatment O +
produced O +
no O +
significant O +
growth O +
( O -
8.9 O +
+ O -
/- O -

0.5 O +
mg O +
for O +
treated O +
females O +
versus O +
8.7 O +
+ O -
/- O -

1.1 O +
for O +
untreated O +
females O -
) O +
or O +
morphological O +
changes O +
in O +
Brown O +
Norway O +
( O -
BN O -
) O +
rat O +
pituitaries O -
. O -

An O +
F1 O +
hybrid O +
of O +
F344 O +
and O +
BN O +
exhibited O +
significant O +
pituitary O +
growth O +
after O +
10 O +
weeks O +
of O +
DES O +
treatment O +
with O +
an O +
average O +
mass O +
of O +
26.3 O +
+ O -
/- O -

0.7 O +
mg O +
compared O +
with O +
8.6 O +
+ O -
/- O -

0.9 O +
mg O +
for O +
untreated O +
rats O -
. O -

Surprisingly O -
, O +
the O +
F1 O +
hybrid O +
tumors U-Disease +
were O +
not O +
hemorrhagic U-Disease +
and O +
had O +
hemoglobin O +
content O +
and O +
outward O +
appearance O +
identical O +
to O +
that O +
of O +
BN O -
. O -

Expression O +
of O +
both O +
growth O +
and O +
morphological O +
changes O +
is O +
due O +
to O +
multiple O +
genes O -
. O -

However O -
, O +
while O +
DES O -
- O -
induced O +
pituitary O +
growth O +
exhibited O +
quantitative O -
, O +
additive O +
inheritance O -
, O +
the O +
hemorrhagic U-Disease +
phenotype O +
exhibited O +
recessive O -
, O +
epistatic O +
inheritance O -
. O -

Only O +
5 O +
of O +
the O +
160 O +
F2 O +
pituitaries O +
exhibited O +
the O +
hemorrhagic U-Disease +
phenotype O -
; O +
36 O +
of O +
the O +
160 O +
F2 O +
pituitaries O +
were O +
in O +
the O +
F344 O +
range O +
of O +
mass O -
, O +
but O +
31 O +
of O +
these O +
were O +
not O +
hemorrhagic U-Disease -
, O +
indicating O +
that O +
the O +
hemorrhagic U-Disease +
phenotype O +
is O +
not O +
merely O +
a O +
consequence O +
of O +
extensive O +
growth O -
. O -

The O +
hemorrhagic U-Disease +
F2 O +
pituitaries O +
were O +
all O +
among O +
the O +
most O +
massive O -
, O +
indicating O +
that O +
some O +
of O +
the O +
genes O +
regulate O +
both O +
phenotypes O -
. O -

Increased O +
expression O +
of O +
neuronal O +
nitric O +
oxide O +
synthase O +
in O +
bladder O +
afferent O +
pathways O +
following O +
chronic O +
bladder B-Disease +
irritation L-Disease -
. O -

Immunocytochemical O +
techniques O +
were O +
used O +
to O +
examine O +
alterations O +
in O +
the O +
expression O +
of O +
neuronal O +
nitric O +
oxide O +
synthase O +
( O -
NOS O -
) O +
in O +
bladder O +
pathways O +
following O +
acute O +
and O +
chronic O +
irritation B-Disease +
of I-Disease +
the I-Disease +
urinary I-Disease +
tract L-Disease +
of O +
the O +
rat O -
. O -

Chemical O +
cystitis U-Disease +
was O +
induced O +
by O +
cyclophosphamide O +
( O -
CYP O -
) O +
which O +
is O +
metabolized O +
to O +
acrolein O -
, O +
an O +
irritant O +
eliminated O +
in O +
the O +
urine O -
. O -

Injection O +
of O +
CYP O +
( O -
n O +
= O +
10 O -
, O +
75 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
2 O +
hours O +
prior O +
to O +
perfusion O +
( O -
acute O +
treatment O -
) O +
of O +
the O +
animals O +
increased O +
Fos O -
- O -
immunoreactivity O +
( O -
IR O -
) O +
in O +
neurons O +
in O +
the O +
dorsal O +
commissure O -
, O +
dorsal O +
horn O -
, O +
and O +
autonomic O +
regions O +
of O +
spinal O +
segments O +
( O -
L1-L2 O +
and O +
L6-S1 O -
) O +
which O +
receive O +
afferent O +
inputs O +
from O +
the O +
bladder O -
, O +
urethra O -
, O +
and O +
ureter O -
. O -

Fos O -
- O -
IR O +
in O +
the O +
spinal O +
cord O +
was O +
not O +
changed O +
in O +
rats O +
receiving O +
chronic O +
CYP O +
treatment O +
( O -
n O +
= O +
15 O -
, O +
75 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
, O +
every O +
3rd O +
day O +
for O +
2 O +
weeks O -
) O -
. O -

In O +
control O +
animals O +
and O +
in O +
animals O +
treated O +
acutely O +
with O +
CYP O -
, O +
only O +
small O +
numbers O +
of O +
NOS O -
- O -
IR O +
cells O +
( O -
0.5 O -
- O -
0.7 O +
cell O +
profiles O -
/ O -
sections O -
) O +
were O +
detected O +
in O +
the O +
L6-S1 O +
dorsal O +
root O +
ganglia O +
( O -
DRG O -
) O -
. O -

Chronic O +
CYP O +
administration O +
significantly O +
( O -
P O +
< O +
or O +
= O +
.002 O -
) O +
increased O +
bladder O +
weight O +
by O +
60 O -
% O +
and O +
increased O +
( O -
7- O +
to O +
11-fold O -
) O +
the O +
numbers O +
of O +
NOS O -
- O -
immunoreactive O +
( O -
IR O -
) O +
afferent O +
neurons O +
in O +
the O +
L6-S1 O +
DRG O -
. O -

A O +
small O +
increase O +
( O -
1.5-fold O -
) O +
also O +
occurred O +
in O +
the O +
L1 O +
DRG O -
, O +
but O +
no O +
change O +
was O +
detected O +
in O +
the O +
L2 O +
and O +
L5 O +
DRG O -
. O -

Bladder O +
afferent O +
cells O +
in O +
the O +
L6-S1 O +
DRG O +
labeled O +
by O +
Fluorogold O +
( O -
40 O +
microliters O -
) O +
injected O +
into O +
the O +
bladder O +
wall O +
did O +
not O +
exhibit O +
NOS O -
- O -
IR O +
in O +
control O +
animals O -
; O +
however O -
, O +
following O +
chronic O +
CYP O +
administration O -
, O +
a O +
significant O +
percentage O +
of O +
bladder O +
afferent O +
neurons O +
were O +
NOS O -
- O -
IR O -
: O +
L6 O +
( O -
19.8 O +
+ O -
/- O -

4.6 O -
% O -
) O +
and O +
S1 O +
( O -
25.3 O +
+ O -
/- O -

2.9 O -
% O -
) O -
. O -

These O +
results O +
indicate O +
that O +
neuronal O +
gene O +
expression O +
in O +
visceral O +
sensory O +
pathways O +
can O +
be O +
upregulated O +
by O +
chemical O +
irritation O +
of O +
afferent O +
receptors O +
in O +
the O +
urinary O +
tract O +
and/or O +
that O +
pathological O +
changes O +
in O +
the O +
urinary O +
tract O +
can O +
initiate O +
chemical O +
signals O +
that O +
alter O +
the O +
chemical O +
properties O +
of O +
visceral O +
afferent O +
neurons O -
. O -

Effects O +
of O +
a O +
new O +
calcium O +
antagonist O -
, O +
CD-832 O -
, O +
on O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
ischemia L-Disease +
in O +
dogs O +
with O +
partial O +
coronary B-Disease +
stenosis L-Disease -
. O -

Effects O +
of O +
CD-832 O +
on O +
isoproterenol O +
( O -
ISO O -
) O -
-induced O +
myocardial B-Disease +
ischemia L-Disease +
were O +
studied O +
in O +
dogs O +
with O +
partial O +
coronary B-Disease +
stenosis L-Disease +
of O +
the O +
left O +
circumflex O +
coronary O +
artery O +
and O +
findings O +
were O +
compared O +
with O +
those O +
for O +
nifedipine O +
or O +
diltiazem O -
. O -

In O +
the O +
presence O +
of O +
coronary B-Disease +
artery I-Disease +
stenosis L-Disease -
, O +
3-min O +
periods O +
of O +
intracoronary O +
ISO O +
infusion O +
( O -
10 O +
ng O -
/ O -
kg O -
/ O -
min O -
) O +
increased O +
heart O +
rate O +
and O +
maximal O +
rate O +
of O +
left O +
ventricular O +
pressure O +
rise O -
, O +
which O +
resulted O +
in O +
a O +
decrease O +
in O +
percentage O +
segmental O +
shortening O +
and O +
ST O -
- O -
segment O +
elevation O +
of O +
the O +
epicardial O +
electrocardiogram O -
. O -

After O +
the O +
control O +
ISO O +
infusion O +
with O +
stenosis U-Disease +
was O +
performed O -
, O +
equihypotensive O +
doses O +
of O +
CD-832 O +
( O -
3 O +
and O +
10 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
, O +
n O +
= O +
7 O -
) O -
, O +
nifedipine O +
( O -
1 O +
and O +
3 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
, O +
n O +
= O +
9 O -
) O +
or O +
diltiazem O +
( O -
10 O +
and O +
30 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
, O +
n O +
= O +
7 O -
) O +
were O +
infused O +
5 O +
min O +
before O +
and O +
during O +
the O +
second O +
and O +
third O +
ISO O +
infusion O -
. O -

Both O +
CD-832 O +
and O +
diltiazem O -
, O +
but O +
not O +
nifedipine O -
, O +
significantly O +
reduced O +
the O +
increase O +
in O +
heart O +
rate O +
induced O +
by O +
ISO O +
infusion O -
. O -

In O +
contrast O +
to O +
nifedipine O -
, O +
CD-832 O +
( O -
10 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
) O +
prevented O +
the O +
decrease O +
in O +
percentage O +
segmental O +
shortening O +
from O +
32 O +
+ O -
/- O -

12 O -
% O +
to O +
115 O +
+ O -
/- O -

26 O -
% O +
of O +
the O +
control O +
value O +
( O -
P O +
< O +
.01 O -
) O +
and O +
ST O -
- O -
segment O +
elevation O +
from O +
5.6 O +
+ O -
/- O -

1.0 O +
mV O +
to O +
1.6 O +
+ O -
/- O -

1.3 O +
mV O +
( O -
P O +
< O +
.01 O -
) O +
at O +
3 O +
min O +
after O +
ISO O +
infusion O +
with O +
stenosis U-Disease -
. O -

Diltiazem O +
( O -
30 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
) O +
also O +
prevented O +
the O +
decrease O +
in O +
percentage O +
segmental O +
shortening O +
from O +
34 O +
+ O -
/- O -

14 O -
% O +
to O +
63 O +
+ O -
/- O -

18 O -
% O +
of O +
the O +
control O +
value O +
( O -
P O +
< O +
.05 O -
) O +
and O +
ST O -
- O -
segment O +
elevation O +
from O +
4.7 O +
+ O -
/- O -

0.7 O +
mV O +
to O +
2.1 O +
+ O -
/- O -

0.7 O +
mV O +
( O -
P O +
< O +
.01 O -
) O +
at O +
3 O +
min O +
after O +
ISO O +
infusion O +
with O +
stenosis U-Disease -
. O -

These O +
data O +
show O +
that O +
CD-832 O +
improves O +
myocardial B-Disease +
ischemia L-Disease +
during O +
ISO O +
infusion O +
with O +
stenosis U-Disease +
and O +
suggest O +
that O +
the O +
negative O +
chronotropic O +
property O +
of O +
CD-832 O +
plays O +
a O +
major O +
role O +
in O +
the O +
beneficial O +
effects O +
of O +
CD-832 O -
. O -

The O +
effect O +
of O +
recombinant O +
human O +
insulin O -
- O -
like O +
growth O +
factor O -
- O -
I O +
on O +
chronic O +
puromycin O +
aminonucleoside O +
nephropathy U-Disease +
in O +
rats O -
. O -

We O +
recently O +
demonstrated O +
that O +
recombinant O +
hGH O +
exacerbates O +
renal O +
functional O +
and O +
structural O +
injury O +
in O +
chronic O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O +
nephropathy U-Disease -
, O +
an O +
experimental O +
model O +
of O +
glomerular B-Disease +
disease L-Disease -
. O -

Therefore O -
, O +
we O +
examined O +
whether O +
recombinant O +
human O +
( O -
rh O -
) O +
IGF O -
- O -
I O +
is O +
a O +
safer O +
alternative O +
for O +
the O +
treatment O +
of O +
growth B-Disease +
failure L-Disease +
in O +
rats O +
with O +
chronic O +
PAN O +
nephropathy U-Disease -
. O -

The O +
glomerulopathy U-Disease +
was O +
induced O +
by O +
seven O +
serial O +
injections O +
of O +
PAN O +
over O +
12 O +
wk O -
. O -

Experimental O +
animals O +
( O -
n O +
= O +
6 O -
) O +
received O +
rhIGF O -
- O -
I O -
, O +
400 O +
micrograms O -
/ O -
d O -
, O +
whereas O +
control O +
rats O +
( O -
n O +
= O +
6 O -
) O +
received O +
the O +
vehicle O -
. O -

rhIGF O -
- O -
I O +
improved O +
weight O +
gain O +
by O +
14 O -
% O +
( O -
p O +
< O +
0.05 O -
) O -
, O +
without O +
altering O +
hematocrit O +
or O +
blood O +
pressure O +
in O +
rats O +
with O +
renal B-Disease +
disease L-Disease -
. O -

Urinary O +
protein O +
excretion O +
was O +
unaltered O +
by O +
rhIGF O -
- O -
I O +
treatment O +
in O +
rats O +
with O +
chronic O +
PAN O +
nephropathy U-Disease -
. O -

After O +
12 O +
wk O -
, O +
the O +
inulin O +
clearance O +
was O +
higher O +
in O +
rhIGF O -
- O -
I O -
- O -
treated O +
rats O -
, O +
0.48 O +
+ O -
/- O -

0.08 O +
versus O +
0.24 O +
+ O -
/- O -

0.06 O +
mL O -
/ O -
min O -
/ O -
100 O +
g O +
of O +
body O +
weight O +
in O +
untreated O +
PAN O +
nephropathy U-Disease +
animals O -
, O +
p O +
< O +
0.05 O -
. O -

The O +
improvement O +
in O +
GFR O +
was O +
not O +
associated O +
with O +
enhanced O +
glomerular B-Disease +
hypertrophy L-Disease +
or O +
increased O +
segmental O +
glomerulosclerosis U-Disease -
, O +
tubulointerstitial B-Disease +
injury L-Disease -
, O +
or O +
renal O +
cortical O +
malondialdehyde O +
content O -
. O -

In O +
rats O +
with O +
PAN O +
nephropathy U-Disease -
, O +
administration O +
of O +
rhIGF O -
- O -
I O +
increased O +
IGF O -
- O -
I O +
and O +
GH O +
receptor O +
gene O +
expression O -
, O +
without O +
altering O +
the O +
steady O +
state O +
level O +
of O +
IGF O -
- O -
I O +
receptor O +
mRNA O -
. O -

In O +
normal O +
rats O +
with O +
intact O +
kidneys O -
, O +
rhIGF O -
- O -
I O +
administration O +
( O -
n O +
= O +
4 O -
) O +
did O +
not O +
alter O +
weight O +
gain O -
, O +
blood O +
pressure O -
, O +
proteinuria U-Disease -
, O +
GFR O -
, O +
glomerular O +
planar O +
area O -
, O +
renal O +
cortical O +
malondialdehyde O +
content O -
, O +
or O +
glomerular O +
or O +
tubulointerstitial B-Disease +
damage L-Disease -
, O +
compared O +
with O +
untreated O +
animals O +
( O -
n O +
= O +
4 O -
) O -
. O -

rhIGF O -
- O -
I O +
treatment O +
reduced O +
the O +
steady O +
state O +
renal O +
IGF O -
- O -
I O +
mRNA O +
level O +
but O +
did O +
not O +
modify O +
gene O +
expression O +
of O +
the O +
IGF O -
- O -
I O +
or O +
GH O +
receptors O -
. O -

We O +
conclude O +
that O -
: O +
1 O -
) O +
administration O +
of O +
rhIGF O -
- O -
I O +
improves O +
growth O +
and O +
GFR O +
in O +
rats O +
with O +
chronic O +
PAN O +
nephropathy U-Disease +
and O +
2 O -
) O +
unlike O +
rhGH O -
, O +
long O -
- O -
term O +
use O +
of O +
rhIGF O -
- O -
I O +
does O +
not O +
worsen O +
renal O +
functional O +
and O +
structural O +
injury O +
in O +
this O +
disease O +
model O -
. O -

Nefiracetam O +
( O -
DM-9384 O -
) O +
reverses O +
apomorphine O -
- O -
induced O +
amnesia U-Disease +
of O +
a O +
passive O +
avoidance O +
response O -
: O +
delayed O +
emergence O +
of O +
the O +
memory O +
retention O +
effects O -
. O -

Nefiracetam O +
is O +
a O +
novel O +
pyrrolidone O +
derivative O +
which O +
attenuates O +
scopolamine O -
- O -
induced O +
learning B-Disease +
and I-Disease +
post I-Disease -
- I-Disease -
training I-Disease +
consolidation I-Disease +
deficits L-Disease -
. O -

Given O +
that O +
apomorphine O +
inhibits O +
passive O +
avoidance O +
retention O +
when O +
given O +
during O +
training O +
or O +
in O +
a O +
defined O +
10 O -
- O -
12h O +
post O -
- O -
training O +
period O -
, O +
we O +
evaluated O +
the O +
ability O +
of O +
nefiracetam O +
to O +
attenuate O +
amnesia U-Disease +
induced O +
by O +
dopaminergic O +
agonism O -
. O -

A O +
step O -
- O -
down O +
passive O +
avoidance O +
paradigm O +
was O +
employed O +
and O +
nefiracetam O +
( O -
3 O +
mg O -
/ O -
kg O -
) O +
and O +
apomorphine O +
( O -
0.5 O +
mg O -
/ O -
kg O -
) O +
were O +
given O +
alone O +
or O +
in O +
combination O +
during O +
training O +
and O +
at O +
the O +
10 O -
- O -
12h O +
post O -
- O -
training O +
period O +
of O +
consolidation O -
. O -

Co O -
- O -
administration O +
of O +
nefiracetam O +
and O +
apomorphine O +
during O +
training O +
or O +
10h O +
thereafter O +
produced O +
no O +
significant O +
anti O -
- O -
amnesic O +
effect O -
. O -

However O -
, O +
administration O +
of O +
nefiracetam O +
during O +
training O +
completely O +
reversed O +
the O +
amnesia U-Disease +
induced O +
by O +
apomorphine O +
at O +
the O +
10h O +
post O -
- O -
training O +
time O +
and O +
the O +
converse O +
was O +
also O +
true O -
. O -

These O +
effects O +
were O +
not O +
mediated O +
by O +
a O +
dopaminergic O +
mechanism O +
as O +
nefiracetam O -
, O +
at O +
millimolar O +
concentrations O -
, O +
failed O +
to O +
displace O +
either O +
[ O -
3H O -
] O -
SCH O +
23390 O +
or O +
[ O -
3H O -
] O -
spiperone O +
binding O +
from O +
D1 O +
or O +
D2 O +
dopamine O +
receptor O +
subtypes O -
, O +
respectively O -
. O -

It O +
is O +
suggested O +
that O +
nefiracetam O +
augments O +
molecular O +
processes O +
in O +
the O +
early O +
stages O +
of O +
events O +
which O +
ultimately O +
lead O +
to O +
consolidation O +
of O +
memory O -
. O -

Phenytoin O +
encephalopathy U-Disease +
as O +
probable O +
idiosyncratic O +
reaction O -
: O +
case O +
report O -
. O -

A O +
case O +
of O +
phenytoin O +
( O -
DPH O -
) O +
encephalopathy U-Disease +
with O +
increasing O +
seizures U-Disease +
and O +
EEG O +
and O +
mental O +
changes O +
is O +
described O -
. O -

Despite O +
adequate O +
oral O +
dosage O +
of O +
DPH O +
( O -
5 O +
mg O -
/ O -
kg O -
/ O -
daily O -
) O +
the O +
plasma O +
level O +
was O +
very O +
low O +
( O -
2.8 O +
microgramg O -
/ O -
ml O -
) O -
. O -

The O +
encephalopathy U-Disease +
was O +
probably O +
an O +
idiosyncratic O +
and O +
not O +
toxic O +
or O +
allergic O +
reaction O -
. O -

In O +
fact O +
the O +
concentration O +
of O +
free O +
DPH O +
was O +
normal O -
, O +
the O +
patient O +
presented O +
a O +
retarded O +
morbilliform O +
rash U-Disease +
during O +
DPH O +
treatment O -
, O +
the O +
protidogram O +
was O +
normal O -
, O +
and O +
an O +
intradermic O +
DPH O +
injection O +
had O +
no O +
local O +
effect O -
. O -

The O +
authors O +
conclude O +
that O +
in O +
a O +
patient O +
starting O +
DPH O +
treatment O +
an O +
unexpected O +
increase O +
in O +
seizures U-Disease -
, O +
with O +
EEG O +
and O +
mental O +
changes O +
occurring O +
simultaneously O -
, O +
should O +
alert O +
the O +
physician O +
to O +
the O +
possible O +
need O +
for O +
eliminating O +
DPH O +
from O +
the O +
therapeutic O +
regimen O -
, O +
even O +
if O +
plasma O +
concentrations O +
are O +
low O -
. O -

Prevention O +
and O +
treatment O +
of O +
endometrial B-Disease +
disease L-Disease +
in O +
climacteric O +
women O +
receiving O +
oestrogen O +
therapy O -
. O -

The O +
treatment O +
regimens O +
are O +
described O +
in O +
74 O +
patients O +
with O +
endometrial B-Disease +
disease L-Disease +
among O +
850 O +
climacteric O +
women O +
receiving O +
oestrogen O +
therapy O -
. O -

Cystic O +
hyperplasia U-Disease +
was O +
associated O +
with O +
unopposed O +
oestrogen O +
therapy O +
without O +
progestagen O -
. O -

Two O +
courses O +
of O +
21 O +
days O +
of O +
5 O +
mg O +
norethisterone O +
daily O +
caused O +
reversion O +
to O +
normal O +
in O +
all O +
57 O +
cases O +
of O +
cystic O +
hyperplasia U-Disease +
and O +
6 O +
of O +
the O +
8 O +
cases O +
of O +
atypical O +
hyperplasia U-Disease -
. O -

4 O +
cases O +
of O +
endometrial B-Disease +
carcinoma L-Disease +
referred O +
from O +
elsewhere O +
demonstrated O +
the O +
problems O +
of O +
inappropriate O +
and O +
unsupervised O +
unopposed O +
oestrogen O +
therapy O +
and O +
the O +
difficulty O +
in O +
distinguishing O +
severe O +
hyperplasia U-Disease +
from O +
malignancy U-Disease -
. O -

Cyclical O +
low O -
- O -
dose O +
oestrogen O +
therapy O +
with O +
7 O -
- O -
-13 O +
days O +
of O +
progestagen O +
does O +
not O +
seem O +
to O +
increase O +
the O +
risk O +
of O +
endometrial B-Disease +
hyperplasia L-Disease +
or O +
carcinoma U-Disease -
. O -

Effects O +
of O +
exercise O +
on O +
the O +
severity O +
of O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction L-Disease -
. O -

The O +
effect O +
of O +
exercise O +
on O +
the O +
severity O +
of O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction L-Disease +
was O +
studied O +
in O +
male O +
rats O -
. O -

Ninety O -
- O -
three O +
rats O +
were O +
randomly O +
divided O +
into O +
three O +
groups O -
. O -

The O +
exercise O -
- O -
isoproterenol O +
( O -
E-1 O -
) O +
and O +
exercise O +
control O +
( O -
EC O -
) O +
groups O +
exercised O +
daily O +
for O +
thirty O +
days O +
on O +
a O +
treadmill O +
at O +
1 O +
mph O -
, O +
2 O -
% O +
grade O +
while O +
animals O +
of O +
the O +
sedentary O -
- O -
isoproterenol O +
( O -
S O -
- O -
I O -
) O +
group O +
remained O +
sedentary O -
. O -

Eight O +
animals O +
were O +
assigned O +
to O +
the O +
sedentary O +
control O +
( O -
SC O -
) O +
group O +
which O +
remained O +
sedentary O +
throughout O +
the O +
experimental O +
period O -
. O -

Forty O -
- O -
eight O +
hours O +
after O +
the O +
final O +
exercise O +
period O -
, O +
S O -
- O -
I O +
and O +
E O -
- O -
I O +
animals O +
received O +
a O +
single O +
subcutaneous O +
injection O +
of O +
isoproterenol O +
( O -
250 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O -
. O -

Animals O +
of O +
the O +
S O -
- O -
I O +
group O +
exhibited O +
significantly O +
( O -
Pp O +
less O +
than O +
0.05 O -
) O +
greater O +
mortality O +
from O +
the O +
effects O +
of O +
isoproterenol O +
than O +
animals O +
of O +
the O +
E O -
- O -
I O +
group O -
. O -

Serum O +
CPK O +
activity O +
for O +
E O -
- O -
I O +
animals O +
was O +
significantly O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
greater O +
than O +
for O +
animals O +
in O +
the O +
S O -
- O -
I O +
and O +
EC O +
groups O +
twenty O +
hours O +
following O +
isoproterenol O +
injection O -
. O -

No O +
statistically O +
significant O +
differences O +
were O +
observed O +
between O +
the O +
two O +
isoproterenol O +
treated O +
groups O +
for O +
severity O +
of O +
the O +
induced O +
lesions O -
, O +
changes O +
in O +
heart O +
weight O -
, O +
or O +
heart O +
weight O +
to O +
body O +
weight O +
ratios O -
. O -

The O +
results O +
indicated O +
that O +
exercise O +
reduced O +
the O +
mortality O +
associated O +
with O +
the O +
effects O +
of O +
large O +
dosages O +
of O +
isoproterenol O +
but O +
had O +
little O +
on O +
the O +
severity O +
of O +
the O +
infarction U-Disease -
. O -

Human O +
corticotropin O -
- O -
releasing O +
hormone O +
and O +
thyrotropin O -
- O -
releasing O +
hormone O +
modulate O +
the O +
hypercapnic U-Disease +
ventilatory O +
response O +
in O +
humans O -
. O -

Human O +
corticotropin O -
- O -
releasing O +
hormone O +
( O -
hCRH O -
) O +
and O +
thyrotropin O -
- O -
releasing O +
hormone O +
( O -
TRH O -
) O +
are O +
known O +
to O +
stimulate O +
ventilation O +
after O +
i.v O -
. O -

administration O +
in O +
humans O -
. O -

In O +
a O +
placebo O -
- O -
controlled O -
, O +
single O -
- O -
blind O +
study O +
we O +
aimed O +
to O +
clarify O +
if O +
both O +
peptides O +
act O +
by O +
altering O +
central O +
chemosensitivity O -
. O -

Two O +
subsequent O +
CO2-rebreathing O +
tests O +
were O +
performed O +
in O +
healthy O +
young O +
volunteers O -
. O -

During O +
the O +
first O +
test O +
0.9 O -
% O +
NaCl O +
was O +
given O +
i.v O -
. O -
; O +
during O +
the O +
second O +
test O +
200 O +
micrograms O +
of O +
hCRH O +
( O -
n O +
= O +
12 O -
) O +
or O +
400 O +
micrograms O +
of O +
TRH O +
( O -
n O +
= O +
6 O -
) O +
was O +
administered O +
i.v O -
. O -

Nine O +
subjects O +
received O +
0.9 O -
% O +
NaCl O +
i.v O -
. O -

during O +
both O +
rebreathing O +
manoeuvres O -
. O -

The O +
CO2-response O +
curves O +
for O +
the O +
two O +
tests O +
were O +
compared O +
within O +
the O +
same O +
subject O -
. O -

In O +
the O +
hCRH O +
group O +
a O +
marked O +
parallel O +
shift O +
of O +
the O +
CO2-response O +
curve O +
to O +
the O +
left O +
was O +
observed O +
after O +
hCRH O +
( O -
P O +
< O +
0.01 O -
) O -
. O -

The O +
same O +
effect O +
occurred O +
following O +
TRH O +
but O +
was O +
less O +
striking O +
( O -
P O +
= O +
0.05 O -
) O -
. O -

hCRH O +
and O +
TRH O +
caused O +
a O +
reduction O +
in O +
the O +
CO2 O +
threshold O -
. O -

The O +
CO2-response O +
curves O +
in O +
the O +
control O +
group O +
were O +
nearly O +
identical O -
. O -

The O +
results O +
indicate O +
an O +
additive O +
effect O +
of O +
both O +
releasing O +
hormones O +
on O +
the O +
hypercapnic U-Disease +
ventilatory O +
response O +
in O +
humans O -
, O +
presumably O +
independent O +
of O +
central O +
chemosensitivity O -
. O -

Lamivudine O +
is O +
effective O +
in O +
suppressing O +
hepatitis B-Disease +
B L-Disease +
virus O +
DNA O +
in O +
Chinese O +
hepatitis O +
B O +
surface O +
antigen O +
carriers O -
: O +
a O +
placebo O -
- O -
controlled O +
trial O -
. O -

Lamivudine O +
is O +
a O +
novel O +
2',3'-dideoxy O +
cytosine O +
analogue O +
that O +
has O +
potent O +
inhibitory O +
effects O +
on O +
hepatitis B-Disease +
B L-Disease +
virus O +
replication O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

We O +
performed O +
a O +
single O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
study O +
to O +
assess O +
its O +
effectiveness O +
and O +
safety O +
in O +
Chinese O +
hepatitis O +
B O +
surface O +
antigen O +
( O -
HBsAg O -
) O +
carriers O -
. O -

Forty O -
- O -
two O +
Chinese O +
HBsAg O +
carriers O +
were O +
randomized O +
to O +
receive O +
placebo O +
( O -
6 O +
patients O -
) O +
or O +
lamivudine O +
orally O +
in O +
dosages O +
of O +
25 O +
mg O -
, O +
100 O +
mg O -
, O +
or O +
300 O +
mg O +
daily O +
( O -
12 O +
patients O +
for O +
each O +
dosage O -
) O -
. O -

The O +
drug O +
was O +
given O +
for O +
4 O +
weeks O -
. O -

The O +
patients O +
were O +
closely O +
monitored O +
clinically O -
, O +
biochemically O -
, O +
and O +
serologically O +
up O +
to O +
4 O +
weeks O +
after O +
drug O +
treatment O -
. O -

All O +
36 O +
patients O +
receiving O +
lamivudine O +
had O +
a O +
decrease O +
in O +
hepatitis B-Disease +
B L-Disease +
virus O +
( O -
HBV O -
) O +
DNA O +
values O +
of O +
> O -
90 O -
% O +
( O -
P O +
< O +
.001 O +
compared O +
with O +
placebo O -
) O -
. O -

Although O +
25 O +
mg O +
of O +
lamivudine O +
was O +
slightly O +
less O +
effective O +
than O +
100 O +
mg O +
( O -
P O +
= O +
.011 O -
) O +
and O +
300 O +
mg O +
( O -
P O +
= O +
.005 O -
) O -
, O +
it O +
still O +
induced O +
94 O -
% O +
suppression O +
of O +
HBV O +
DNA O +
after O +
the O +
fourth O +
week O +
of O +
therapy O -
. O -

HBV O +
DNA O +
values O +
returned O +
to O +
pretreatment O +
levels O +
within O +
4 O +
weeks O +
of O +
cessation O +
of O +
therapy O -
. O -

There O +
was O +
no O +
change O +
in O +
the O +
hepatitis B-Disease +
B L-Disease +
e O +
antigen O +
status O +
or O +
in O +
aminotransferase O +
levels O -
. O -

No O +
serious O +
adverse O +
events O +
were O +
observed O -
. O -

In O +
conclusion O -
, O +
a O +
4-week O +
course O +
of O +
lamivudine O +
was O +
safe O +
and O +
effective O +
in O +
suppression O +
of O +
HBV O +
DNA O +
in O +
Chinese O +
HBsAg O +
carriers O -
. O -

The O +
suppression O +
was O +
> O -
90 O -
% O +
but O +
reversible O -
. O -

Studies O +
with O +
long O -
- O -
term O +
lamivudine O +
administration O +
should O +
be O +
performed O +
to O +
determine O +
if O +
prolonged O +
suppression O +
of O +
HBV O +
DNA O +
can O +
be O +
achieved O -
. O -

Population O -
- O -
based O +
study O +
of O +
risk O +
of O +
venous B-Disease +
thromboembolism L-Disease +
associated O +
with O +
various O +
oral O +
contraceptives O -
. O -

BACKGROUND O -
: O +
Four O +
studies O +
published O +
since O +
December O -
, O +
1995 O -
, O +
reported O +
that O +
the O +
incidence O +
of O +
venous B-Disease +
thromboembolism L-Disease +
( O -
VTE U-Disease -
) O +
was O +
higher O +
in O +
women O +
who O +
used O +
oral O +
contraceptives O +
( O -
OCs O -
) O +
containing O +
the O +
third O -
- O -
generation O +
progestagens O +
gestodene O +
or O +
desogestrel O +
than O +
in O +
users O +
of O +
OCs O +
containing O +
second O -
- O -
generation O +
progestagens O -
. O -

However O -
, O +
confounding O +
and O +
bias O +
in O +
the O +
design O +
of O +
these O +
studies O +
may O +
have O +
affected O +
the O +
findings O -
. O -

The O +
aim O +
of O +
our O +
study O +
was O +
to O +
re O -
- O -
examine O +
the O +
association O +
between O +
risk O +
of O +
VTE U-Disease +
and O +
OC O +
use O +
with O +
a O +
different O +
study O +
design O +
and O +
analysis O +
to O +
avoid O +
some O +
of O +
the O +
bias O +
and O +
confounding O +
of O +
the O +
earlier O +
studies O -
. O -

METHODS O -
: O +
We O +
used O +
computer O +
records O +
of O +
patients O +
from O +
143 O +
general O +
practices O +
in O +
the O +
UK O -
. O -

The O +
study O +
was O +
based O +
on O +
the O +
medical O +
records O +
of O +
about O +
540,000 O +
women O +
born O +
between O +
1941 O +
and O +
1981 O -
. O -

All O +
women O +
who O +
had O +
a O +
recorded O +
diagnosis O +
of O +
deep B-Disease -
- I-Disease -
vein I-Disease +
thrombosis L-Disease -
, O +
venous B-Disease +
thrombosis L-Disease +
not O +
otherwise O +
specified O -
, O +
or O +
pulmonary O +
embolus O +
during O +
the O +
study O +
period O -
, O +
and O +
who O +
had O +
been O +
treated O +
with O +
an O +
anticoagulant O +
were O +
identified O +
as O +
potential O +
cases O +
of O +
VTE U-Disease -
. O -

We O +
did O +
a O +
cohort O +
analysis O +
to O +
estimate O +
and O +
compare O +
incidence O +
of O +
VTE U-Disease +
in O +
users O +
of O +
the O +
main O +
OC O +
preparations O -
, O +
and O +
a O +
nested O +
case O -
- O -
control O +
study O +
to O +
calculate O +
the O +
odds O +
ratios O +
of O +
VTE U-Disease +
associated O +
with O +
use O +
of O +
different O +
types O +
of O +
OC O -
, O +
after O +
adjustment O +
for O +
potential O +
confounding O +
factors O -
. O -

In O +
the O +
case O -
- O -
control O +
study O -
, O +
we O +
matched O +
cases O +
to O +
controls O +
by O +
exact O +
year O +
of O +
birth O -
, O +
practice O -
, O +
and O +
current O +
use O +
of O +
OCs O -
. O -

We O +
used O +
a O +
multiple O +
logistic O +
regression O +
model O +
that O +
included O +
body O -
- O -
mass O +
index O -
, O +
number O +
of O +
cycles O -
, O +
change O +
in O +
type O +
of O +
OC O +
prescribed O +
within O +
3 O +
months O +
of O +
the O +
event O -
, O +
previous O +
pregnancy O -
, O +
and O +
concurrent O +
disease O -
. O -

FINDINGS O -
: O +
85 O +
women O +
met O +
the O +
inclusion O +
criteria O +
for O +
VTE U-Disease -
, O +
two O +
of O +
whom O +
were O +
users O +
of O +
progestagen O -
- O -
only O +
OCs O -
. O -

Of O +
the O +
83 O +
cases O +
of O +
VTE U-Disease +
associated O +
with O +
use O +
of O +
combined O +
OCs O -
, O +
43 O +
were O +
recorded O +
as O +
deep B-Disease -
- I-Disease -
vein I-Disease +
thrombosis L-Disease -
, O +
35 O +
as O +
pulmonary O +
thrombosis U-Disease -
, O +
and O +
five O +
as O +
venous B-Disease +
thrombosis L-Disease +
not O +
otherwise O +
specified O -
. O -

The O +
crude O +
rate O +
of O +
VTE U-Disease +
per O +
10,000 O +
woman O -
- O -
years O +
was O +
4.10 O +
in O +
current O +
users O +
of O +
any O +
OC O -
, O +
3.10 O +
in O +
users O +
of O +
second O -
- O -
generation O +
OCs O -
, O +
and O +
4.96 O +
in O +
users O +
of O +
third O -
- O -
generation O +
preparations O -
. O -

After O +
adjustment O +
for O +
age O -
, O +
the O +
rate O +
ratio O +
of O +
VTE U-Disease +
in O +
users O +
of O +
third O -
- O -
generation O +
relative O +
to O +
second O -
- O -
generation O +
OCs O +
was O +
1.68 O +
( O -
95 O -
% O +
CI O +
1.04 O -
- O -
2.75 O -
) O -
. O -

Logistic O +
regression O +
showed O +
no O +
significant O +
difference O +
in O +
the O +
risk O +
of O +
VTE U-Disease +
between O +
users O +
of O +
third O -
- O -
generation O +
and O +
second O -
- O -
generation O +
OCs O -
. O -

Among O +
users O +
of O +
third O -
- O -
generation O +
progestagens O -
, O +
the O +
risk O +
of O +
VTE U-Disease +
was O +
higher O +
in O +
users O +
of O +
desogestrel O +
with O +
20 O +
g O +
ethinyloestradiol O +
than O +
in O +
users O +
of O +
gestodene O +
or O +
desogestrel O +
with O +
30 O +
g O +
ethinyloestradiol O -
. O -

With O +
all O +
second O -
- O -
generation O +
OCs O +
as O +
the O +
reference O -
, O +
the O +
odds O +
ratios O +
for O +
VTE U-Disease +
were O +
3.49 O +
( O -
1.21 O -
- O -
10.12 O -
) O +
for O +
desogestrel O +
plus O +
20 O +
g O +
ethinyloestradiol O +
and O +
1.18 O +
( O -
0.66 O -
- O -
2.17 O -
) O +
for O +
the O +
other O +
third O -
- O -
generation O +
progestagens O -
. O -

INTERPRETATION O -
: O +
The O +
previously O +
reported O +
increase O +
in O +
odds O +
ratio O +
associated O +
with O +
third O -
- O -
generation O +
OCs O +
when O +
compared O +
with O +
second O -
- O -
generation O +
products O +
is O +
likely O +
to O +
have O +
been O +
the O +
result O +
of O +
residual O +
confounding O +
by O +
age O -
. O -

The O +
increased O +
odds O +
ratio O +
associated O +
with O +
products O +
containing O +
20 O +
micrograms O +
ethinyloestradiol O +
and O +
desogestrel O +
compared O +
with O +
the O +
30 O +
micrograms O +
product O +
is O +
biologically O +
implausible O -
, O +
and O +
is O +
likely O +
to O +
be O +
the O +
result O +
of O +
preferential O +
prescribing O +
and O -
, O +
thus O -
, O +
confounding O -
. O -

MK-801 O +
augments O +
pilocarpine O -
- O -
induced O +
electrographic O +
seizure U-Disease +
but O +
protects O +
against O +
brain B-Disease +
damage L-Disease +
in O +
rats O -
. O -

1 O -
. O -

The O +
authors O +
examined O +
the O +
anticonvulsant O +
effects O +
of O +
MK-801 O +
on O +
the O +
pilocarpine O -
- O -
induced O +
seizure U-Disease +
model O -
. O -

Intraperitoneal O +
injection O +
of O +
pilocarpine O +
( O -
400 O +
mg O -
/ O -
kg O -
) O +
induced O +
tonic B-Disease +
and I-Disease +
clonic I-Disease +
seizure L-Disease -
. O -

Scopolamine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
and O +
pentobarbital O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
prevented O +
development O +
of O +
pilocarpine O -
- O -
induced O +
behavioral O +
seizure U-Disease +
but O +
MK-801 O +
( O -
0.5 O +
mg O -
/ O -
kg O -
) O +
did O +
not O -
. O -

2 O -
. O -

An O +
electrical O +
seizure U-Disease +
measured O +
with O +
hippocampal O +
EEG O +
appeared O +
in O +
the O +
pilocarpine O -
- O -
treated O +
group O -
. O -

Scopolamine O +
and O +
pentobarbital O +
blocked O +
the O +
pilocarpine O -
- O -
induced O +
electrographic O +
seizure U-Disease -
, O +
MK-801 O +
treatment O +
augmented O +
the O +
electrographic O +
seizure U-Disease +
induced O +
by O +
pilocarpine O -
. O -

3 O -
. O -

Brain B-Disease +
damage L-Disease +
was O +
assessed O +
by O +
examining O +
the O +
hippocampus O +
microscopically O -
. O -

Pilocarpine O +
produced O +
neuronal B-Disease +
death L-Disease +
in O +
the O +
hippocampus O -
, O +
which O +
showed O +
pyknotic O +
changes O -
. O -

Pentobarbital O -
, O +
scopolamine O +
and O +
MK-801 O +
protected O +
the O +
brain B-Disease +
damage L-Disease +
by O +
pilocarpine O -
, O +
though O +
in O +
the O +
MK-801-treated O +
group O -
, O +
the O +
pyramidal O +
cells O +
of O +
hippocampus O +
appeared O +
darker O +
than O +
normal O -
. O -

In O +
all O +
treatments O -
, O +
granule O +
cells O +
of O +
the O +
dentate O +
gyrus O +
were O +
not O +
affected O -
. O -

4 O -
. O -

These O +
results O +
indicate O +
that O +
status B-Disease +
epilepticus L-Disease +
induced O +
by O +
pilocarpine O +
is O +
initiated O +
by O +
cholinergic O +
overstimulation O +
and O +
propagated O +
by O +
glutamatergic O +
transmission O -
, O +
the O +
elevation O +
of O +
which O +
may O +
cause O +
brain B-Disease +
damage L-Disease +
through O +
an O +
excitatory O +
NMDA O +
receptor O -
- O -
mediated O +
mechanism O -
. O -

Paclitaxel O -
, O +
5-fluorouracil O -
, O +
and O +
folinic O +
acid O +
in O +
metastatic O +
breast B-Disease +
cancer L-Disease -
: O +
BRE-26 O -
, O +
a O +
phase O +
II O +
trial O -
. O -

5-Fluorouracil O +
plus O +
folinic O +
acid O +
and O +
paclitaxel O +
( O -
Taxol O -
; O +
Bristol O -
- O -
Myers O +
Squibb O +
Company O -
, O +
Princeton O -
, O +
NJ O -
) O +
are O +
effective O +
salvage O +
therapies O +
for O +
metastatic O +
breast B-Disease +
cancer L-Disease +
patients O -
. O -

Paclitaxel O +
and O +
5-fluorouracil O +
have O +
additive O +
cytotoxicity U-Disease +
in O +
MCF-7 O +
cell O +
lines O -
. O -

We O +
performed O +
a O +
phase O +
II O +
trial O +
of O +
paclitaxel O +
175 O +
mg O -
/ O -
m2 O +
over O +
3 O +
hours O +
on O +
day O +
I O +
followed O +
by O +
folinic O +
acid O +
300 O +
mg O +
over O +
1 O +
hour O +
before O +
5-fluorouracil O +
350 O +
mg O -
/ O -
m2 O +
on O +
days O +
1 O +
to O +
3 O +
every O +
28 O +
days O +
( O -
TFL O -
) O +
in O +
women O +
with O +
metastatic O +
breast B-Disease +
cancer L-Disease -
. O -

Analysis O +
is O +
reported O +
on O +
37 O +
patients O +
with O +
a O +
minimum O +
of O +
6 O +
months O +
follow O -
- O -
up O +
who O +
received O +
a O +
total O +
of O +
192 O +
cycles O +
of O +
TFL O -
: O +
nine O +
cycles O +
( O -
5 O -
% O -
) O +
were O +
associated O +
with O +
grade O +
3 O -
/ O -
4 O +
neutropenia U-Disease +
requiring O +
hospitalization O -
; O +
seven O +
( O -
4 O -
% O -
) O +
cycles O +
in O +
two O +
patients O +
required O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
due O +
to O +
neutropenia U-Disease -
; O +
no O +
patient O +
required O +
platelet O +
transfusions O -
. O -

Grade O +
3 O -
/ O -
4 O +
nonhematologic O +
toxicities U-Disease +
were O +
uncommon O -
. O -

Among O +
the O +
34 O +
patients O +
evaluable O +
for O +
response O -
, O +
there O +
were O +
three O +
complete O +
responses O +
( O -
9 O -
% O -
) O +
and O +
18 O +
partial O +
responses O +
( O -
53 O -
% O -
) O +
for O +
an O +
overall O +
response O +
rate O +
of O +
62 O -
% O -
. O -

Of O +
the O +
19 O +
evaluable O +
patients O +
with O +
prior O +
doxorubicin O +
exposure O -
, O +
11 O +
( O -
58 O -
% O -
) O +
responded O +
compared O +
with O +
nine O +
of O +
15 O +
( O -
60 O -
% O -
) O +
without O +
prior O +
doxorubicin O -
. O -

Plasma O +
paclitaxel O +
concentrations O +
were O +
measured O +
at O +
the O +
completion O +
of O +
paclitaxel O +
infusion O +
and O +
at O +
24 O +
hours O +
in O +
19 O +
patients O -
. O -

TFL O +
is O +
an O +
active O -
, O +
well O -
- O -
tolerated O +
regimen O +
in O +
metastatic O +
breast B-Disease +
cancer L-Disease -
. O -

Efficacy O +
and O +
proarrhythmia U-Disease +
with O +
the O +
use O +
of O +
d O -
, O -
l O -
- O -
sotalol O +
for O +
sustained O +
ventricular B-Disease +
tachyarrhythmias L-Disease -
. O -

This O +
study O +
prospectively O +
evaluated O +
the O +
clinical O +
efficacy O -
, O +
the O +
incidence O +
of O +
torsades B-Disease +
de I-Disease +
pointes L-Disease -
, O +
and O +
the O +
presumable O +
risk O +
factors O +
for O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
in O +
patients O +
treated O +
with O +
d O -
, O -
l O -
- O -
sotalol O +
for O +
sustained O +
ventricular B-Disease +
tachyarrhythmias L-Disease -
. O -

Eighty O -
- O -
one O +
consecutive O +
patients O +
( O -
54 O +
with O +
coronary B-Disease +
artery I-Disease +
disease L-Disease -
, O +
and O +
20 O +
with O +
dilated B-Disease +
cardiomyopathy L-Disease -
) O +
with O +
inducible O +
sustained O +
ventricular B-Disease +
tachycardia L-Disease +
or O +
ventricular B-Disease +
fibrillation L-Disease +
received O +
oral O +
d O -
, O -
l O -
- O -
sotalol O +
to O +
prevent O +
induction O +
of O +
the O +
ventricular B-Disease +
tachyarrhythmia L-Disease -
. O -

During O +
oral O +
loading O +
with O +
d O -
, O -
l O -
- O -
sotalol O -
, O +
continuous O +
electrocardiographic O +
( O -
ECG O -
) O +
monitoring O +
was O +
performed O -
. O -

Those O +
patients O +
in O +
whom O +
d O -
, O -
l O -
- O -
sotalol O +
prevented O +
induction O +
of O +
ventricular B-Disease +
tachycardia L-Disease +
or O +
ventricular B-Disease +
fibrillation L-Disease +
were O +
discharged O +
with O +
the O +
drug O +
and O +
followed O +
up O +
on O +
an O +
outpatient O +
basis O +
for O +
21 O +
+ O -
/- O -

18 O +
months O -
. O -

Induction O +
of O +
the O +
ventricular B-Disease +
tachyarrhythmia L-Disease +
was O +
prevented O +
by O +
oral O +
d O -
, O -
l O -
- O -
sotalol O +
in O +
35 O +
( O -
43 O -
% O -
) O +
patients O -
; O +
the O +
ventricular B-Disease +
tachyarrhythmia L-Disease +
remained O +
inducible O +
in O +
40 O +
( O -
49 O -
% O -
) O +
patients O -
; O +
and O +
two O +
( O -
2.5 O -
% O -
) O +
patients O +
did O +
not O +
tolerate O +
even O +
40 O +
mg O +
of O +
d O -
, O -
l O -
- O -
sotalol O +
once O +
daily O -
. O -

Four O +
( O -
5 O -
% O -
) O +
patients O +
had O +
from O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
during O +
the O +
initial O +
oral O +
treatment O +
with O +
d O -
, O -
l O -
- O -
sotalol O -
. O -

Neither O +
ECG O +
[ O -
sinus O -
- O -
cycle O +
length O +
( O -
SCL O -
) O -
, O +
QT O +
or O +
QTc O +
interval O -
, O +
or O +
U O +
wave O -
] O +
nor O +
clinical O +
parameters O +
identified O +
patients O +
at O +
risk O +
for O +
torsades B-Disease +
de I-Disease +
pointes L-Disease -
. O -

However O -
, O +
the O +
oral O +
dose O +
of O +
d O -
, O -
l O -
- O -
sotalol O +
was O +
significantly O +
lower O +
in O +
patients O +
with O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
( O -
200 O +
+ O -
/- O +
46 O +
vs. O +
328 O +
+ O -
/- O -

53 O +
mg O -
/ O -
day O -
; O +
p O +
= O +
0.0017 O -
) O -
. O -

Risk O +
factors O +
associated O +
with O +
the O +
development O +
of O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
were O +
the O +
appearance O +
of O +
an O +
U O +
wave O +
( O -
p O +
= O +
0.049 O -
) O -
, O +
female O +
gender O +
( O -
p O +
= O +
0.015 O -
) O -
, O +
and O +
significant O +
dose O -
- O -
corrected O +
changes O +
of O +
SCL O -
, O +
QT O +
interval O -
, O +
and O +
QTc O +
interval O +
( O -
p O +
< O +
0.05 O -
) O -
. O -

During O +
follow O -
- O -
up O -
, O +
seven O +
( O -
20 O -
% O -
) O +
patients O +
had O +
a O +
nonfatal O +
ventricular B-Disease +
tachycardia L-Disease +
recurrence O -
, O +
and O +
two O +
( O -
6 O -
% O -
) O +
patients O +
died O +
suddenly O -
. O -

One O +
female O +
patient O +
with O +
stable O +
cardiac B-Disease +
disease L-Disease +
had O +
recurrent O +
torsades B-Disease +
de I-Disease +
pointes L-Disease +
after O +
2 O +
years O +
of O +
successful O +
treatment O +
with O +
d O -
, O -
l O -
- O -
sotalol O -
. O -

Torsades B-Disease +
de I-Disease +
pointes L-Disease +
occurred O +
early O +
during O +
treatment O +
even O +
with O +
low O +
doses O +
of O +
oral O +
d O -
, O -
l O -
- O -
sotalol O -
. O -

Pronounced O +
changes O +
in O +
the O +
surface O +
ECG O +
( O -
cycle O +
length O -
, O +
QT O -
, O +
and O +
QTc O -
) O +
in O +
relation O +
to O +
the O +
dose O +
of O +
oral O +
d O -
, O -
l O -
- O -
sotalol O +
might O +
identify O +
a O +
subgroup O +
of O +
patients O +
with O +
an O +
increased O +
risk O +
for O +
torsades B-Disease +
de I-Disease +
pointes L-Disease -
. O -

Other O +
ECG O +
parameters O +
before O +
the O +
application O +
of O +
d O -
, O -
l O -
- O -
sotalol O +
did O +
not O +
identify O +
patients O +
at O +
increased O +
risk O +
for O +
torsades B-Disease +
de I-Disease +
pointes L-Disease -
. O -

Recurrence O +
rates O +
of O +
ventricular B-Disease +
tachyarrhythmias L-Disease +
are O +
high O +
despite O +
complete O +
suppression O +
of O +
the O +
arrhythmia U-Disease +
during O +
programmed O +
stimulation O -
. O -

Therefore O +
programmed O +
electrical O +
stimulation O +
in O +
the O +
case O +
of O +
d O -
, O -
l O -
- O -
sotalol O +
seems O +
to O +
be O +
of O +
limited O +
prognostic O +
value O -
. O -

Chronic O +
hyperprolactinemia U-Disease +
and O +
changes O +
in O +
dopamine O +
neurons O -
. O -

The O +
tuberoinfundibular O +
dopaminergic O +
( O -
TIDA O -
) O +
system O +
is O +
known O +
to O +
inhibit O +
prolactin O +
( O -
PRL O -
) O +
secretion O -
. O -

In O +
young O +
animals O +
this O +
system O +
responds O +
to O +
acute O +
elevations O +
in O +
serum O +
PRL O +
by O +
increasing O +
its O +
activity O -
. O -

However O -
, O +
this O +
responsiveness O +
is O +
lost O +
in O +
aging O +
rats O +
with O +
chronically O +
high O +
serum O +
PRL O +
levels O -
. O -

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
induce O +
hyperprolactinemia U-Disease +
in O +
rats O +
for O +
extended O +
periods O +
of O +
time O +
and O +
examine O +
its O +
effects O +
on O +
dopaminergic O +
systems O +
in O +
the O +
brain O -
. O -

Hyperprolactinemia U-Disease +
was O +
induced O +
by O +
treatment O +
with O +
haloperidol O -
, O +
a O +
dopamine O +
receptor O +
antagonist O -
, O +
and O +
Palkovits O -
' O +
microdissection O +
technique O +
in O +
combination O +
with O +
high O -
- O -
performance O +
liquid O +
chromatography O +
was O +
used O +
to O +
measure O +
neurotransmitter O +
concentrations O +
in O +
several O +
areas O +
of O +
the O +
brain O -
. O -

After O +
6 O +
months O +
of O +
hyperprolactinemia U-Disease -
, O +
dopamine O +
( O -
DA O -
) O +
concentrations O +
in O +
the O +
median O +
eminence O +
( O -
ME O -
) O +
increased O +
by O +
84 O -
% O +
over O +
the O +
control O +
group O -
. O -

Nine O +
months O +
of O +
hyperprolactinemia U-Disease +
produced O +
a O +
50 O -
% O +
increase O +
in O +
DA O +
concentrations O +
in O +
the O +
ME O +
over O +
the O +
control O +
group O -
. O -

However O -
, O +
DA O +
response O +
was O +
lost O +
if O +
a O +
9-month O +
long O +
haloperidol O -
- O -
induced O +
hyperprolactinemia U-Disease +
was O +
followed O +
by O +
a O +
1 O +
1 O -
/ O -
2 O +
month O -
- O -
long O +
extremely O +
high O +
increase O +
in O +
serum O +
PRL O +
levels O +
produced O +
by O +
implantation O +
of O +
MMQ O +
cells O +
under O +
the O +
kidney O +
capsule O -
. O -

There O +
was O +
no O +
change O +
in O +
the O +
levels O +
of O +
DA O -
, O +
norepinephrine O +
( O -
NE O -
) O -
, O +
serotonin O +
( O -
5-HT O -
) O -
, O +
or O +
their O +
metabolites O +
in O +
the O +
arcuate O +
nucleus O +
( O -
AN O -
) O -
, O +
medial O +
preoptic O +
area O +
( O -
MPA O -
) O -
, O +
caudate O +
putamen O +
( O -
CP O -
) O -
, O +
substantia O +
nigra O +
( O -
SN O -
) O -
, O +
and O +
zona O +
incerta O +
( O -
ZI O -
) O -
, O +
except O +
for O +
a O +
decrease O +
in O +
5-hydroxyindoleacetic O +
acid O +
( O -
5-HIAA O -
) O +
in O +
the O +
AN O +
after O +
6-months O +
of O +
hyperprolactinemia U-Disease +
and O +
an O +
increase O +
in O +
DA O +
concentrations O +
in O +
the O +
AN O +
after O +
9-months O +
of O +
hyperprolactinemia U-Disease -
. O -

These O +
results O +
demonstrate O +
that O +
hyperprolactinemia U-Disease +
specifically O +
affects O +
TIDA O +
neurons O +
and O +
these O +
effects O +
vary O -
, O +
depending O +
on O +
the O +
duration O +
and O +
intensity O +
of O +
hyperprolactinemia U-Disease -
. O -

The O +
age O -
- O -
related O +
decrease O +
in O +
hypothalamic O +
dopamine O +
function O +
may O +
be O +
associated O +
with O +
increases O +
in O +
PRL O +
secretion O -
. O -

Treatment O -
- O -
related O +
disseminated O +
necrotizing O +
leukoencephalopathy U-Disease +
with O +
characteristic O +
contrast O +
enhancement O +
of O +
the O +
white O +
matter O -
. O -

This O +
report O +
describes O +
unique O +
contrast O +
enhancement O +
of O +
the O +
white O +
matter O +
on O +
T1-weighted O +
magnetic O +
resonance O +
images O +
of O +
two O +
patients O +
with O +
disseminated O +
necrotizing O +
leukoencephalopathy U-Disease -
, O +
which O +
developed O +
from O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia L-Disease +
treated O +
with O +
high O -
- O -
dose O +
methotrexate O -
. O -

In O +
both O +
patients O -
, O +
the O +
enhancement O +
was O +
more O +
pronounced O +
near O +
the O +
base O +
of O +
the O +
brain O +
than O +
at O +
the O +
vertex O -
. O -

Necropsy O +
of O +
the O +
first O +
case O +
revealed O +
loss B-Disease +
of I-Disease +
myelination L-Disease +
and O +
necrosis U-Disease +
of O +
the O +
white O +
matter O -
. O -

Possible O +
mechanisms O +
causing O +
such O +
a O +
leukoencephalopathy U-Disease +
are O +
discussed O -
. O -

Thrombotic U-Disease +
complications O +
in O +
acute B-Disease +
promyelocytic I-Disease +
leukemia L-Disease +
during O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O +
therapy O -
. O -

A O +
case O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease -
, O +
due O +
to O +
occlusion B-Disease +
of I-Disease +
renal I-Disease +
vessels L-Disease +
in O +
a O +
patient O +
with O +
acute B-Disease +
promyelocytic I-Disease +
leukemia L-Disease +
( O -
APL U-Disease -
) O +
treated O +
with O +
all O -
- O -
trans O -
- O -
retinoic O +
acid O +
( O -
ATRA O -
) O +
and O +
tranexamic O +
acid O +
has O +
been O +
described O +
recently O -
. O -

We O +
report O +
a O +
case O +
of O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
in O +
an O +
APL U-Disease +
patient O +
treated O +
with O +
ATRA O +
alone O -
. O -

This O +
case O +
further O +
supports O +
the O +
concern O +
about O +
thromboembolic U-Disease +
complications O +
associated O +
with O +
ATRA O +
therapy O +
in O +
APL U-Disease +
patients O -
. O -

The O +
patients O -
, O +
a O +
43-year O -
- O -
old O +
man O -
, O +
presented O +
all O +
the O +
signs O +
and O +
symptoms O +
of O +
APL U-Disease +
and O +
was O +
included O +
in O +
a O +
treatment O +
protocol O +
with O +
ATRA O -
. O -

After O +
10 O +
days O +
of O +
treatment O -
, O +
he O +
developed O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
that O +
was O +
completely O +
reversible O +
after O +
complete O +
remission O +
of O +
APL U-Disease +
was O +
achieved O +
and O +
therapy O +
discontinued O -
. O -

We O +
conclude O +
that O +
ATRA O +
is O +
a O +
valid O +
therapeutic O +
choice O +
for O +
patients O +
with O +
APL U-Disease -
, O +
although O +
the O +
procoagulant O +
tendency O +
is O +
not O +
completely O +
corrected O -
. O -

Thrombotic U-Disease +
events O -
, O +
however O -
, O +
could O +
be O +
avoided O +
by O +
using O +
low O -
- O -
dose O +
heparin O -
. O -

Pupillary O +
changes O +
associated O +
with O +
the O +
development O +
of O +
stimulant O -
- O -
induced O +
mania U-Disease -
: O +
a O +
case O +
report O -
. O -

A O +
30-year O -
- O -
old O +
cocaine O -
- O -
dependent O +
man O +
who O +
was O +
a O +
subject O +
in O +
a O +
study O +
evaluating O +
the O +
anticraving O +
efficacy O +
of O +
the O +
stimulant O +
medication O +
diethylpropion O +
( O -
DEP O -
) O +
became O +
manic U-Disease +
during O +
his O +
second O +
week O +
on O +
the O +
study O +
drug O -
. O -

Pupillometric O +
changes O +
while O +
on O +
DEP O -
, O +
especially O +
changes O +
in O +
the O +
total O +
power O +
of O +
pupillary B-Disease +
oscillation L-Disease -
, O +
were O +
dramatically O +
different O +
than O +
those O +
observed O +
in O +
the O +
eight O +
other O +
study O +
subjects O +
who O +
did O +
not O +
become O +
manic U-Disease -
. O -

The O +
large O +
changes O +
in O +
total O +
power O +
of O +
pupillary B-Disease +
oscillation L-Disease +
occurred O +
a O +
few O +
days O +
before O +
the O +
patient O +
became O +
fully O +
manic U-Disease -
. O -

Such O +
medication O -
- O -
associated O +
changes O +
in O +
the O +
total O +
power O +
of O +
pupillary B-Disease +
oscillation L-Disease +
might O +
be O +
of O +
utility O +
in O +
identifying O +
persons O +
at O +
risk O +
for O +
manic U-Disease -
- O -
like O +
adverse O +
effects O +
during O +
the O +
medical O +
use O +
of O +
psychomotor O +
stimulants O +
or O +
sympathomimetic O +
agents O -
. O -

Fetal O +
risks O +
due O +
to O +
warfarin O +
therapy O +
during O +
pregnancy O -
. O -

Two O +
mothers O +
with O +
heart O +
valve O +
prosthesis O +
were O +
treated O +
with O +
warfarin O +
during O +
pregnancy O -
. O -

In O +
the O +
first O +
case O +
a O +
caesarean O +
section O +
was O +
done O +
one O +
week O +
after O +
replacement O +
of O +
warfarin O +
with O +
heparin O -
. O -

The O +
baby O +
died O +
of O +
cerebral B-Disease +
and I-Disease +
pulmonary I-Disease +
hemorrhage L-Disease -
. O -

The O +
second O +
mother O +
had O +
a O +
male O +
infant O +
by O +
caesarean O +
section O -
. O -

The O +
baby O +
showed O +
warfarin O -
- O -
induced O +
embryopathy U-Disease +
with O +
nasal B-Disease +
hypoplasia L-Disease +
and O +
stippled B-Disease +
epiphyses L-Disease +
( O -
chondrodysplasia B-Disease +
punctata L-Disease -
) O -
. O -

Nasal B-Disease +
hypoplasia L-Disease +
with O +
or O +
without O +
stippled B-Disease +
epiphyses L-Disease +
has O +
now O +
been O +
reported O +
in O +
11 O +
infants O +
born O +
to O +
mothers O +
treated O +
with O +
warfarin O +
during O +
the O +
first O +
trimester O -
, O +
and O +
a O +
causal O +
association O +
is O +
probable O -
. O -

In O +
view O +
of O +
the O +
risks O +
to O +
both O +
mother O +
and O +
fetus O +
in O +
women O +
with O +
prosthetic O +
cardiac O +
valves O +
it O +
is O +
recommended O +
that O +
therapeutic O +
abortion O +
be O +
advised O +
as O +
the O +
first O +
alternative O -
. O -

The O +
negative O +
mucosal O +
potential O -
: O +
separating O +
central O +
and O +
peripheral O +
effects O +
of O +
NSAIDs O +
in O +
man O -
. O -

OBJECTIVE O -
: O +
We O +
wanted O +
to O +
test O +
whether O +
assessment O +
of O +
both O +
a O +
central O +
pain U-Disease -
- O -
related O +
signal O +
( O -
chemo O -
- O -
somatosensory O +
evoked O +
potential O -
, O +
CSSEP O -
) O +
and O +
a O +
concomitantly O +
recorded O +
peripheral O +
signal O +
( O -
negative O +
mucosal O +
potential O -
, O +
NMP O -
) O +
allows O +
for O +
separation O +
of O +
central O +
and O +
peripheral O +
effects O +
of O +
NSAIDs O -
. O -

For O +
this O +
purpose O -
, O +
experimental O +
conditions O +
were O +
created O +
in O +
which O +
NSAIDs O +
had O +
previously O +
been O +
observed O +
to O +
produce O +
effects O +
on O +
phasic O +
and O +
tonic O +
pain U-Disease +
by O +
either O +
central O +
or O +
peripheral O +
mechanisms O -
. O -

METHODS O -
: O +
According O +
to O +
a O +
double O -
- O -
blind O -
, O +
randomised O -
, O +
controlled O -
, O +
threefold O +
cross O -
- O -
over O +
design O -
, O +
18 O +
healthy O +
subjects O +
( O -
11 O +
males O -
, O +
7 O +
females O -
; O +
mean O +
age O +
26 O +
years O -
) O +
received O +
either O +
placebo O -
, O +
400 O +
mg O +
ibuprofen O -
, O +
or O +
800 O +
mg O +
ibuprofen O -
. O -

Phasic O +
pain U-Disease +
was O +
applied O +
by O +
means O +
of O +
short O +
pulses O +
of O +
CO2 O +
to O +
the O +
nasal O +
mucosa O +
( O -
stimulus O +
duration O +
500 O +
ms O -
, O +
interval O +
approximately O +
60 O +
s O -
) O -
, O +
and O +
tonic O +
pain U-Disease +
was O +
induced O +
in O +
the O +
nasal O +
cavity O +
by O +
means O +
of O +
dry O +
air O +
of O +
controlled O +
temperature O -
, O +
humidity O +
and O +
flow O +
rate O +
( O -
22 O +
degrees O +
C O -
, O +
0 O -
% O +
relative O +
humidity O -
, O +
145 O +
ml.s-1 O -
) O -
. O -

Both O +
CSSEPs O +
as O +
central O +
and O +
NMPs O +
as O +
peripheral O +
correlates O +
of O +
pain U-Disease +
were O +
obtained O +
in O +
response O +
to O +
the O +
CO2 O +
stimuli O -
. O -

Additionally O -
, O +
the O +
subjects O +
rated O +
the O +
intensity O +
of O +
both O +
phasic O +
and O +
tonic O +
pain U-Disease +
by O +
means O +
of O +
visual O +
analogue O +
scales O -
. O -

RESULTS O -
: O +
As O +
described O +
earlier O -
, O +
administration O +
of O +
ibuprofen O +
was O +
followed O +
by O +
a O +
decrease O +
in O +
tonic O +
pain U-Disease +
but O -
- O -
relative O +
to O +
placebo O -
- O -
an O +
increase O +
in O +
correlates O +
of O +
phasic O +
pain U-Disease -
, O +
indicating O +
a O +
specific O +
effect O +
of O +
ibuprofen O +
on O +
the O +
interaction O +
between O +
the O +
pain U-Disease +
stimuli O +
under O +
these O +
special O +
experimental O +
conditions O -
. O -

Based O +
on O +
the O +
similar O +
behaviour O +
of O +
CSSEP O +
and O +
NMP O -
, O +
it O +
was O +
concluded O +
that O +
the O +
pharmacological O +
process O +
underlying O +
this O +
phenomenon O +
was O +
localised O +
in O +
the O +
periphery O -
. O -

By O +
means O +
of O +
the O +
simultaneous O +
recording O +
of O +
interrelated O +
peripheral O +
and O +
central O +
electrophysiologic O +
correlates O +
of O +
nociception O -
, O +
it O +
was O +
possible O +
to O +
separate O +
central O +
and O +
peripheral O +
effects O +
of O +
an O +
NSAID O -
. O -

The O +
major O +
advantage O +
of O +
this O +
pain U-Disease +
model O +
is O +
the O +
possibility O +
of O +
obtaining O +
peripheral O +
pain U-Disease -
- O -
related O +
activity O +
directly O +
using O +
a O +
non O -
- O -
invasive O +
technique O +
in O +
humans O -
. O -

Effect O +
of O +
D O -
- O -
Glucarates O +
on O +
basic O +
antibiotic O -
- O -
induced O +
renal B-Disease +
damage L-Disease +
in O +
rats O -
. O -

Dehydrated U-Disease +
rats O +
regularly O +
develop O +
acute B-Disease +
renal I-Disease +
failure L-Disease +
following O +
single O +
injection O +
of O +
aminoglycoside O +
antibiotics O +
combined O +
with O +
dextran O +
or O +
of O +
antibiotics O +
only O -
. O -

Oral O +
administration O +
of O +
2,5-di O -
- O -
O O -
- O -
acetyl O -
- O -
D O -
- O -
glucaro-1,4 O -
- O -
6,3-dilactone O +
protected O +
rats O +
against O +
renal B-Disease +
failure L-Disease +
induced O +
by O +
kanamycin O -
- O -
dextran O -
. O -

The O +
protective O +
effect O +
was O +
prevalent O +
among O +
D O -
- O -
glucarates O -
, O +
and O +
also O +
to O +
other O +
saccharic O +
acid O -
, O +
hexauronic O +
acids O +
and O +
hexaaldonic O +
acids O -
, O +
although O +
to O +
a O +
lesser O +
degree O -
, O +
but O +
not O +
to O +
a O +
hexaaldose O -
, O +
sugar O +
alcohols O -
, O +
substances O +
inthe O +
TCA O +
cycle O +
and O +
other O +
acidic O +
compounds O -
. O -

D O -
- O -
Glucarates O +
were O +
effective O +
against O +
renal B-Disease +
damage L-Disease +
induced O +
by O +
peptide O +
antibiotics O +
as O +
well O +
as O +
various O +
aminoglycoside O +
antibitocis O -
. O -

Dose O -
- O -
responses O +
were O +
observed O +
in O +
the O +
protective O +
effect O +
of O +
D O -
- O -
Glucarates O -
. O -

With O +
a O +
D O -
- O -
glucarate O +
of O +
a O +
fixed O +
size O +
of O +
dose O -
, O +
approximately O +
the O +
same O +
degree O +
of O +
protection O +
was O +
obtained O +
against O +
renal B-Disease +
damages L-Disease +
induced O +
by O +
different O +
basic O +
antibiotics O +
despite O +
large O +
disparities O +
in O +
administration O +
doses O +
of O +
different O +
antibiotics O -
. O -

D O -
- O -
Glucarates O +
had O +
the O +
ability O +
to O +
prevent O +
renal B-Disease +
damage L-Disease +
but O +
not O +
to O +
cure O +
it O -
. O -

Rats O +
excreted O +
acidic O +
urine O +
when O +
they O +
were O +
spared O +
from O +
renal B-Disease +
lesions L-Disease +
by O +
monosaccharides O -
. O -

The O +
reduction O +
effect O +
of O +
D O -
- O -
glucarates O +
against O +
nephrotoxicity U-Disease +
of O +
basic O +
antibiotics O +
was O +
discussed O -
. O -

Acute O +
severe O +
depression U-Disease +
following O +
peri O -
- O -
operative O +
ondansetron O -
. O -

A O +
41-year O -
- O -
old O +
woman O +
with O +
a O +
strong O +
history O +
of O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting L-Disease +
presented O +
for O +
abdominal O +
hysterectomy O +
3 O +
months O +
after O +
a O +
previous O +
anaesthetic O +
where O +
ondansetron O +
prophylaxis O +
had O +
been O +
used O -
. O -

She O +
had O +
developed O +
a O +
severe O +
acute O +
major B-Disease +
depression I-Disease +
disorder L-Disease +
almost O +
immediately O +
thereafter O -
, O +
possibly O +
related O +
to O +
the O +
use O +
of O +
a O +
serotonin O +
antagonist O -
. O -

Nine O +
years O +
before O +
she O +
had O +
experienced O +
a O +
self O -
- O -
limited O +
puerperal O +
depressive B-Disease +
episode L-Disease -
. O -

Anaesthesia O +
with O +
a O +
propofol O +
infusion O +
and O +
avoidance O +
of O +
serotonin O +
antagonists O +
provided O +
a O +
nausea U-Disease -
- O -
free O +
postoperative O +
course O +
without O +
exacerbation O +
of O +
the O +
depression B-Disease +
disorder L-Disease -
. O -

Hypertensive U-Disease +
response O +
during O +
dobutamine O +
stress O +
echocardiography O -
. O -

Among O +
3,129 O +
dobutamine O +
stress O +
echocardiographic O +
studies O -
, O +
a O +
hypertensive U-Disease +
response O -
, O +
defined O +
as O +
systolic O +
blood O +
pressure O +
( O -
BP O -
) O +
> O +
or O +
= O +
220 O +
mm O +
Hg O +
and/or O +
diastolic O +
BP O +
> O +
or O +
= O +
110 O +
mm O +
Hg O -
, O +
occurred O +
in O +
30 O +
patients O +
( O -
1 O -
% O -
) O -
. O -

Patients O +
with O +
this O +
response O +
more O +
often O +
had O +
a O +
history O +
of O +
hypertension U-Disease +
and O +
had O +
higher O +
resting O +
systolic O +
and O +
diastolic O +
BP O +
before O +
dobutamine O +
infusion O -
. O -

Continuously O +
nebulized O +
albuterol O +
in O +
severe O +
exacerbations O +
of O +
asthma U-Disease +
in O +
adults O -
: O +
a O +
case O -
- O -
controlled O +
study O -
. O -

A O +
retrospective O -
, O +
case O -
- O -
controlled O +
analysis O +
comparing O +
patients O +
admitted O +
to O +
a O +
medical O +
intensive O +
care O +
unit O +
with O +
severe O +
exacerbations O +
of O +
asthma U-Disease +
who O +
received O +
continuously O +
nebulized O +
albuterol O +
( O -
CNA O -
) O +
versus O +
intermittent O +
albuterol O +
( O -
INA O -
) O +
treatments O +
is O +
reported O -
. O -

Forty O +
matched O +
pairs O +
of O +
patients O +
with O +
asthma U-Disease +
are O +
compared O -
. O -

CNA O +
was O +
administered O +
for O +
a O +
mean O +
of O +
11 O +
+ O -
/- O -

10 O +
hr O -
. O -

The O +
incidence O +
of O +
cardiac B-Disease +
dysrhythmias L-Disease +
was O +
similar O +
between O +
groups O -
. O -

Symptomatic O +
hypokalemia U-Disease +
did O +
not O +
occur O -
. O -

CNA O +
patients O +
had O +
higher O +
heart O +
rates O +
during O +
treatment O -
, O +
which O +
may O +
reflect O +
severity O +
of O +
illness O -
. O -

The O +
incidence O +
of O +
intubation O +
was O +
similar O -
. O -

We O +
conclude O +
that O +
CNA O +
and O +
INA O +
demonstrated O +
similar O +
profiles O +
with O +
regard O +
to O +
safety O -
, O +
morbidity O -
, O +
and O +
mortality O -
. O -

Paraplegia U-Disease +
following O +
intrathecal O +
methotrexate O -
: O +
report O +
of O +
a O +
case O +
and O +
review O +
of O +
the O +
literature O -
. O -

A O +
patient O +
who O +
developed O +
paraplegia U-Disease +
following O +
the O +
intrathecal O +
instillation O +
of O +
methotrexate O +
is O +
discribed O -
. O -

The O +
ten O +
previously O +
reported O +
cases O +
of O +
this O +
unusual O +
complication O +
are O +
reviewed O -
. O -

The O +
following O +
factors O +
appear O +
to O +
predispose O +
to O +
the O +
development O +
of O +
this O +
complication O -
: O +
abnormal O +
cerebrospinal O +
dynamics O +
related O +
to O +
the O +
presence O +
of O +
central B-Disease +
nervous I-Disease +
system I-Disease +
leukemia L-Disease -
, O +
and O +
epidural O +
cerebrospinal O +
leakage O -
; O +
elevated O +
cerebrospinal O +
fluid O +
methothexate O +
concentration O +
related O +
to O +
abnormal O +
cerebrospinal O +
fluid O +
dynamics O +
and O +
to O +
inappropriately O +
high O +
methotrexate O +
doses O +
based O +
on O +
body O +
surface O +
area O +
calculations O +
in O +
older O +
children O +
and O +
adults O -
; O +
the O +
presence O +
of O +
neurotoxic U-Disease +
preservatives O +
in O +
commercially O +
available O +
methotrexate O +
preparations O +
and O +
diluents O -
; O +
and O +
the O +
use O +
of O +
methotrexate O +
diluents O +
of O +
unphysiologic O +
pH O -
, O +
ionic O +
content O +
and O +
osmolarity O -
. O -

The O +
role O +
of O +
methotrexate O +
contaminants O -
, O +
local O +
folate B-Disease +
deficiency L-Disease -
, O +
and O +
cranial O +
irradiation O +
in O +
the O +
pathogenesis O +
of O +
intrathecal O +
methotrexate O +
toxicity U-Disease +
is O +
unclear O -
. O -

The O +
incidence O +
of O +
neurotoxicity U-Disease +
may O +
be O +
reduced O +
by O +
employing O +
lower O +
doses O +
of O +
methotrexate O +
in O +
the O +
presence O +
of O +
central B-Disease +
nervous I-Disease +
system I-Disease +
leukemia L-Disease -
, O +
in O +
older O +
children O +
and O +
adults O -
, O +
and O +
in O +
the O +
presence O +
of O +
epidural O +
leakage O -
. O -

Only O +
preservative O -
- O -
free O +
methotrexate O +
in O +
Elliott O -
's O +
B O +
Solution O +
at O +
a O +
concentration O +
of O +
not O +
more O +
than O +
1 O +
mg O -
/ O -
ml O +
should O +
be O +
used O +
for O +
intrathecal O +
administration O -
. O -

Periodic O +
monitoring O +
of O +
cerebruspinal O +
fluid O +
methotrexate O +
levels O +
may O +
be O +
predictive O +
of O +
the O +
development O +
of O +
serious O +
neurotoxicity U-Disease -
. O -

Hyperosmolar B-Disease +
nonketotic I-Disease +
coma L-Disease +
precipitated O +
by O +
lithium O -
- O -
induced O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease -
. O -

A O +
45-year O -
- O -
old O +
man O -
, O +
with O +
a O +
10-year O +
history O +
of O +
manic B-Disease +
depression L-Disease +
treated O +
with O +
lithium O -
, O +
was O +
admitted O +
with O +
hyperosmolar B-Disease -
, I-Disease +
nonketotic I-Disease +
coma L-Disease -
. O -

He O +
gave O +
a O +
five O -
- O -
year O +
history O +
of O +
polyuria U-Disease +
and O +
polydipsia U-Disease -
, O +
during O +
which O +
time O +
urinalysis O +
had O +
been O +
negative O +
for O +
glucose O -
. O -

After O +
recovery O +
from O +
hyperglycaemia U-Disease -
, O +
he O +
remained O +
polyuric U-Disease +
despite O +
normal O +
blood O +
glucose O +
concentrations O -
; O +
water O +
deprivation O +
testing O +
indicated O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease -
, O +
likely O +
to O +
be O +
lithium O -
- O -
induced O -
. O -

We O +
hypothesize O +
that O +
when O +
this O +
man O +
developed O +
type B-Disease +
2 I-Disease +
diabetes L-Disease -
, O +
chronic O +
polyuria U-Disease +
due O +
to O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus L-Disease +
was O +
sufficient O +
to O +
precipitate O +
hyperosmolar O +
dehydration U-Disease -
. O -

Effects O +
of O +
the O +
intracoronary O +
infusion O +
of O +
cocaine O +
on O +
left O +
ventricular O +
systolic O +
and O +
diastolic O +
function O +
in O +
humans O -
. O -

BACKGROUND O -
: O +
In O +
dogs O -
, O +
a O +
large O +
amount O +
of O +
intravenous O +
cocaine O +
causes O +
a O +
profound O +
deterioration B-Disease +
of I-Disease +
left I-Disease +
ventricular I-Disease +
( I-Disease -
LV I-Disease -
) I-Disease +
systolic I-Disease +
function L-Disease +
and O +
an O +
increase O +
in O +
LV O +
end O -
- O -
diastolic O +
pressure O -
. O -

This O +
study O +
was O +
done O +
to O +
assess O +
the O +
influence O +
of O +
a O +
high O +
intracoronary O +
cocaine O +
concentration O +
on O +
LV O +
systolic O +
and O +
diastolic O +
function O +
in O +
humans O -
. O -

METHODS O +
AND O +
RESULTS O -
: O +
In O +
20 O +
patients O +
( O -
14 O +
men O +
and O +
6 O +
women O +
aged O +
39 O +
to O +
72 O +
years O -
) O +
referred O +
for O +
cardiac O +
catheterization O +
for O +
the O +
evaluation O +
of O +
chest B-Disease +
pain L-Disease -
, O +
we O +
measured O +
heart O +
rate O -
, O +
systemic O +
arterial O +
pressure O -
, O +
LV O +
pressure O +
and O +
its O +
first O +
derivative O +
( O -
dP O -
/ O -
dt O -
) O -
, O +
and O +
LV O +
volumes O +
and O +
ejection O +
fraction O +
before O +
and O +
during O +
the O +
final O +
2 O +
to O +
3 O +
minutes O +
of O +
a O +
15-minute O +
intracoronary O +
infusion O +
of O +
saline O +
( O -
n=10 O -
, O +
control O +
subjects O -
) O +
or O +
cocaine O +
hydrochloride O +
1 O +
mg O -
/ O -
min O +
( O -
n=10 O -
) O -
. O -

No O +
variable O +
changed O +
with O +
saline O -
. O -

With O +
cocaine O -
, O +
the O +
drug O +
concentration O +
in O +
blood O +
obtained O +
from O +
the O +
coronary O +
sinus O +
was O +
3.0+ O -
/ O -
-0.4 O +
( O -
mean+ O -
/ O -
-SD O -
) O +
mg O -
/ O -
L O -
, O +
similar O +
in O +
magnitude O +
to O +
the O +
blood O +
cocaine O +
concentration O +
reported O +
in O +
abusers O +
dying O +
of O +
cocaine O +
intoxication O -
. O -

Cocaine O +
induced O +
no O +
significant O +
change O +
in O +
heart O +
rate O -
, O +
LV O +
dP O -
/ O -
dt O +
( O -
positive O +
or O +
negative O -
) O -
, O +
or O +
LV O +
end O -
- O -
diastolic O +
volume O -
, O +
but O +
it O +
caused O +
an O +
increase O +
in O +
systolic O +
and O +
mean O +
arterial O +
pressures O -
, O +
LV O +
end O -
- O -
diastolic O +
pressure O -
, O +
and O +
LV O +
end O -
- O -
systolic O +
volume O -
, O +
as O +
well O +
as O +
a O +
decrease O +
in O +
LV O +
ejection O +
fraction O -
. O -

CONCLUSIONS O -
: O +
In O +
humans O -
, O +
the O +
intracoronary O +
infusion O +
of O +
cocaine O +
sufficient O +
in O +
amount O +
to O +
achieve O +
a O +
high O +
drug O +
concentration O +
in O +
coronary O +
sinus O +
blood O +
causes O +
a O +
deterioration B-Disease +
of I-Disease +
LV I-Disease +
systolic I-Disease +
and I-Disease +
diastolic I-Disease +
performance L-Disease -
. O -

Ascending O +
dose O +
tolerance O +
study O +
of O +
intramuscular O +
carbetocin O +
administered O +
after O +
normal O +
vaginal O +
birth O -
. O -

OBJECTIVE O -
: O +
To O +
determine O +
the O +
maximum O +
tolerated O +
dose O +
( O -
MTD O -
) O +
of O +
carbetocin O +
( O -
a O +
long O -
- O -
acting O +
synthetic O +
analogue O +
of O +
oxytocin O -
) O -
, O +
when O +
administered O +
immediately O +
after O +
vaginal O +
delivery O +
at O +
term O -
. O -

MATERIALS O +
AND O +
METHODS O -
: O +
Carbetocin O +
was O +
given O +
as O +
an O +
intramuscular O +
injection O +
immediately O +
after O +
the O +
birth O +
of O +
the O +
infant O +
in O +
45 O +
healthy O +
women O +
with O +
normal O +
singleton O +
pregnancies O +
who O +
delivered O +
vaginally O +
at O +
term O -
. O -

Dosage O +
groups O +
of O +
15 O -
, O +
30 O -
, O +
50 O -
, O +
75 O -
, O +
100 O -
, O +
125 O -
, O +
150 O -
, O +
175 O +
or O +
200 O +
microg O +
carbetocin O +
were O +
assigned O +
to O +
blocks O +
of O +
three O +
women O +
according O +
to O +
the O +
continual O +
reassessment O +
method O +
( O -
CRM O -
) O -
. O -

RESULTS O -
: O +
All O +
dosage O +
groups O +
consisted O +
of O +
three O +
women O -
, O +
except O +
those O +
with O +
100 O +
microg O +
( O -
n=6 O -
) O +
and O +
200 O +
microg O +
( O -
n=18 O -
) O -
. O -

Recorded O +
were O +
dose O -
- O -
limiting O +
adverse O +
events O -
: O +
hyper- B-Disease +
or I-Disease +
hypotension L-Disease +
( O -
three O -
) O -
, O +
severe O +
abdominal B-Disease +
pain L-Disease +
( O -
0 O -
) O -
, O +
vomiting U-Disease +
( O -
0 O -
) O +
and O +
retained B-Disease +
placenta L-Disease +
( O -
four O -
) O -
. O -

Serious O +
adverse O +
events O +
occurred O +
in O +
seven O +
women O -
: O +
six O +
cases O +
with O +
blood B-Disease +
loss L-Disease +
> O +
or O +
= O +
1000 O +
ml O -
, O +
four O +
cases O +
of O +
manual O +
placenta O +
removal O -
, O +
five O +
cases O +
of O +
additional O +
oxytocics O +
administration O +
and O +
five O +
cases O +
of O +
blood O +
transfusion O -
. O -

Maximum O +
blood B-Disease +
loss L-Disease +
was O +
greatest O +
at O +
the O +
upper O +
and O +
lower O +
dose O +
levels O -
, O +
and O +
lowest O +
in O +
the O +
70 O -
- O -
125 O +
microg O +
dose O +
range O -
. O -

Four O +
out O +
of O +
six O +
cases O +
with O +
blood B-Disease +
loss L-Disease +
> O +
or O +
= O +
1000 O +
ml O +
occurred O +
in O +
the O +
200 O +
microg O +
group O -
. O -

The O +
majority O +
of O +
additional O +
administration O +
of O +
oxytocics O +
( O -
4 O -
/ O -
5 O -
) O +
and O +
blood O +
transfusion O +
( O -
3 O -
/ O -
5 O -
) O +
occurred O +
in O +
the O +
dose O +
groups O +
of O +
200 O +
microg O -
. O -

All O +
retained O +
placentae O +
were O +
found O +
in O +
the O +
group O +
of O +
200 O +
microg O -
. O -

CONCLUSION O -
: O +
The O +
MTD O +
was O +
calculated O +
to O +
be O +
at O +
200 O +
microg O +
carbetocin O -
. O -

Heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
, O +
paradoxical O +
thromboembolism U-Disease -
, O +
and O +
other O +
side O +
effects O +
of O +
heparin O +
therapy O -
. O -

Although O +
several O +
new O +
anticoagulant O +
drugs O +
are O +
in O +
development O -
, O +
heparin O +
remains O +
the O +
drug O +
of O +
choice O +
for O +
most O +
anticoagulation O +
needs O -
. O -

The O +
clinical O +
effects O +
of O +
heparin O +
are O +
meritorious O -
, O +
but O +
side O +
effects O +
do O +
exist O -
. O -

Important O +
untoward O +
effects O +
of O +
heparin O +
therapy O +
including O +
heparin O -
- O -
induced O +
thrombocytopenia U-Disease -
, O +
heparin O -
- O -
associated O +
osteoporosis U-Disease -
, O +
eosinophilia U-Disease -
, O +
skin B-Disease +
reactions L-Disease -
, O +
allergic B-Disease +
reactions L-Disease +
other O +
than O +
thrombocytopenia U-Disease +
and O +
alopecia U-Disease +
will O +
be O +
discussed O +
in O +
this O +
article O -
. O -

Nonopaque O +
crystal O +
deposition O +
causing O +
ureteric B-Disease +
obstruction L-Disease +
in O +
patients O +
with O +
HIV O +
undergoing O +
indinavir O +
therapy O -
. O -

OBJECTIVE O -
: O +
We O +
describe O +
the O +
unique O +
CT O +
features O +
of O +
ureteric B-Disease +
calculi L-Disease +
in O +
six O +
HIV B-Disease -
- I-Disease -
infected L-Disease +
patients O +
receiving O +
indinavir O -
, O +
the O +
most O +
commonly O +
used O +
HIV O +
protease O +
inhibitor O -
, O +
which O +
is O +
associated O +
with O +
an O +
increased O +
incidence O +
of O +
urolithiasis U-Disease -
. O -

CONCLUSION O -
: O +
Ureteric B-Disease +
obstruction L-Disease +
caused O +
by O +
precipitated O +
indinavir O +
crystals O +
may O +
be O +
difficult O +
to O +
diagnose O +
with O +
unenhanced O +
CT O -
. O -

The O +
calculi O +
are O +
not O +
opaque O -
, O +
and O +
secondary O +
signs O +
of O +
obstruction O +
may O +
be O +
absent O +
or O +
minimal O +
and O +
should O +
be O +
sought O +
carefully O -
. O -

Images O +
may O +
need O +
to O +
be O +
obtained O +
using O +
i.v O -
. O -

contrast O +
material O +
to O +
enable O +
diagnosis O +
of O +
ureteric B-Disease +
stones L-Disease +
or B-Disease +
obstruction L-Disease +
in O +
patients O +
with O +
HIV B-Disease +
infection L-Disease +
who O +
receive O +
indinavir O +
therapy O -
. O -

Ischemic B-Disease +
colitis L-Disease +
and O +
sumatriptan O +
use O -
. O -

Sumatriptan O +
succinate O -
, O +
a O +
serotonin-1 O +
( O -
5-hydroxytryptamine-1 O -
) O +
receptor O +
agonist O -
, O +
is O +
an O +
antimigraine O +
drug O +
that O +
is O +
reported O +
to O +
act O +
by O +
selectively O +
constricting O +
intracranial O +
arteries O -
. O -

Recently O -
, O +
vasopressor O +
responses O +
that O +
are O +
distinct O +
from O +
the O +
cranial O +
circulation O +
have O +
been O +
demonstrated O +
to O +
occur O +
in O +
the O +
systemic O -
, O +
pulmonary O -
, O +
and O +
coronary O +
circulations O -
. O -

Cases O +
have O +
been O +
published O +
of O +
coronary B-Disease +
vasospasm L-Disease -
, O +
myocardial B-Disease +
ischemia L-Disease -
, O +
and O +
myocardial B-Disease +
infarction L-Disease +
occurring O +
after O +
sumatriptan O +
use O -
. O -

We O +
report O +
on O +
the O +
development O +
of O +
8 O +
serious O +
cases O +
of O +
ischemic B-Disease +
colitis L-Disease +
in O +
patients O +
with O +
migraine U-Disease +
treated O +
with O +
sumatriptan O -
. O -

Pallidotomy O +
with O +
the O +
gamma O +
knife O -
: O +
a O +
positive O +
experience O -
. O -

51 O +
patients O +
with O +
medically O +
refractory O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
underwent O +
stereotactic O +
posteromedial O +
pallidotomy O +
between O +
August O +
1993 O +
and O +
February O +
1997 O +
for O +
treatment O +
of O +
bradykinesia U-Disease -
, O +
rigidity U-Disease -
, O +
and O +
L O -
- O -
DOPA O -
- O -
induced O +
dyskinesias U-Disease -
. O -

In O +
29 O +
patients O -
, O +
the O +
pallidotomies O +
were O +
performed O +
with O +
the O +
Leksell O +
Gamma O +
Knife O +
and O +
in O +
22 O +
they O +
were O +
performed O +
with O +
the O +
standard O +
radiofrequency O +
( O -
RF O -
) O +
method O -
. O -

Clinical O +
assessment O +
as O +
well O +
as O +
blinded O +
ratings O +
of O +
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease L-Disease +
Rating O +
Scale O +
( O -
UPDRS O -
) O +
scores O +
were O +
carried O +
out O +
pre- O +
and O +
postoperatively O -
. O -

Mean O +
follow O -
- O -
up O +
time O +
is O +
20.6 O +
months O +
( O -
range O +
6 O -
- O -
48 O -
) O +
and O +
all O +
except O +
4 O +
patients O +
have O +
been O +
followed O +
more O +
than O +
one O +
year O -
. O -

85 O +
percent O +
of O +
patients O +
with O +
dyskinesias U-Disease +
were O +
relieved O +
of O +
symptoms O -
, O +
regardless O +
of O +
whether O +
the O +
pallidotomies O +
were O +
performed O +
with O +
the O +
Gamma O +
Knife O +
or O +
radiofrequency O +
methods O -
. O -

About O +
2 O -
/ O -
3 O +
of O +
the O +
patients O +
in O +
both O +
Gamma O +
Knife O +
and O +
radiofrequency O +
groups O +
showed O +
improvements O +
in O +
bradykinesia U-Disease +
and O +
rigidity U-Disease -
, O +
although O +
when O +
considered O +
as O +
a O +
group O +
neither O +
the O +
Gamma O +
Knife O +
nor O +
the O +
radiofrequency O +
group O +
showed O +
statistically O +
significant O +
improvements O +
in O +
UPDRS O +
scores O -
. O -

One O +
patient O +
in O +
the O +
Gamma O +
Knife O +
group O +
( O -
3.4 O -
% O -
) O +
developed O +
a O +
homonymous B-Disease +
hemianopsia L-Disease +
9 O +
months O +
following O +
treatment O +
and O +
5 O +
patients O +
( O -
27.7 O -
% O -
) O +
in O +
the O +
radiofrequency O +
group O +
became O +
transiently O +
confused O +
postoperatively O -
. O -

No O +
other O +
complications O +
were O +
seen O -
. O -

Gamma O +
Knife O +
pallidotomy O +
is O +
as O +
effective O +
as O +
radiofrequency O +
pallidotomy O +
in O +
controlling O +
certain O +
of O +
the O +
symptoms O +
of O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease -
. O -

It O +
may O +
be O +
the O +
only O +
practical O +
technique O +
available O +
in O +
certain O +
patients O -
, O +
such O +
as O +
those O +
who O +
take O +
anticoagulants O -
, O +
have O +
bleeding U-Disease +
diatheses O +
or O +
serious O +
systemic O +
medical O +
illnesses O -
. O -

It O +
is O +
a O +
viable O +
option O +
for O +
other O +
patients O +
as O +
well O -
. O -

Centrally O +
mediated O +
cardiovascular O +
effects O +
of O +
intracisternal O +
application O +
of O +
carbachol O +
in O +
anesthetized O +
rats O -
. O -

The O +
pressor O +
response O +
to O +
the O +
intracisternal O +
( O -
i.c O -
. O -
) O +
injection O +
of O +
carbachol O +
( O -
1 O +
mug O -
) O +
in O +
anesthetized O +
rats O +
was O +
analyzed O -
. O -

This O +
response O +
was O +
significantly O +
reduced O +
by O +
the O +
intravenous O +
( O -
i.v O -
. O -
) O +
injection O +
of O +
guanethidine O +
( O -
5 O +
mg O -
) O -
, O +
hexamethonium O +
( O -
10 O +
mg O -
) O +
or O +
phentolamine O +
( O -
5 O +
mg O -
) O -
, O +
and O +
conversely O -
, O +
potentiated O +
by O +
i.v O -
. O -

desmethylimipramine O +
( O -
0.3 O +
mg O -
) O -
, O +
while O +
propranolol O +
( O -
0.5 O +
mg O -
) O +
i.v O -
. O +
selectively O +
inhibited O +
the O +
enlargement B-Disease +
of I-Disease +
pulse I-Disease +
pressure L-Disease +
and O +
the O +
tachycardia U-Disease +
following O +
i.c O -
. O -

carbachol O +
( O -
1 O +
mug O -
) O -
. O -

On O +
the O +
other O +
hand O -
, O +
the O +
pressor O +
response O +
to O +
i.c O -
. O -

carbachol O +
( O -
1 O +
mug O -
) O +
was O +
almost O +
completely O +
blocked O +
by O +
i.c O -
. O -

atropine O +
( O -
3 O +
mug O -
) O +
or O +
hexamethonium O +
( O -
500 O +
mug O -
) O -
, O +
and O +
significantly O +
reduced O +
by O +
i.c O -
. O -

chlorpromazine O +
( O -
50 O +
mug O -
) O +
but O +
significantly O +
potentiated O +
by O +
i.c O -
. O -

desmethylimipramine O +
( O -
30 O +
mug O -
) O -
. O -

The O +
pressor O +
response O +
to O +
i.c O -
. O -

carbachol O +
( O -
1 O +
mug O -
) O +
remained O +
unchanged O +
after O +
sectioning O +
of O +
the O +
bilateral O +
cervical O +
vagal O +
nerves O +
but O +
disappeared O +
after O +
sectioning O +
of O +
the O +
spinal O +
cord O +
( O -
C7-C8 O -
) O -
. O -

From O +
the O +
above O +
result O +
it O +
is O +
suggested O +
that O +
the O +
pressor O +
response O +
to O +
i.c O -
. O -

carbachol O +
ortral O +
and O +
peripheral O +
adrenergic O +
mechanisms O -
, O +
and O +
that O +
the O +
sympathetic O +
trunk O +
is O +
the O +
main O +
pathway O -
. O -

Neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
and O +
methylphenidate O -
. O -

A O +
1-year O -
- O -
old O +
female O +
presented O +
with O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
probably O +
caused O +
by O +
methylphenidate O -
. O -

She O +
had O +
defects O +
in O +
the O +
supratentorial O +
brain O +
including O +
the O +
basal O +
ganglia O +
and O +
the O +
striatum O +
( O -
multicystic B-Disease +
encephalomalacia L-Disease -
) O +
due O +
to O +
severe O +
perinatal O +
hypoxic B-Disease -
- I-Disease -
ischemic I-Disease +
encephalopathy L-Disease -
, O +
which O +
was O +
considered O +
to O +
be O +
a O +
possible O +
predisposing O +
factor O +
causing O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease -
. O -

A O +
dopaminergic O +
blockade O +
mechanism O +
generally O +
is O +
accepted O +
as O +
the O +
pathogenesis O +
of O +
this O +
syndrome O -
. O -

However O -
, O +
methylphenidate O +
is O +
a O +
dopamine O +
agonist O +
via O +
the O +
inhibition O +
of O +
uptake O +
of O +
dopamine O -
, O +
and O +
therefore O +
dopaminergic O +
systems O +
in O +
the O +
brainstem O +
( O -
mainly O +
the O +
midbrain O -
) O +
and O +
the O +
spinal O +
cord O +
were O +
unlikely O +
to O +
participate O +
in O +
the O +
onset O +
of O +
this O +
syndrome O -
. O -

A O +
relative O +
gamma O -
- O -
aminobutyric O +
acid O -
- O -
ergic O +
deficiency O +
might O +
occur O +
because O +
diazepam O -
, O +
a O +
gamma O -
- O -
aminobutyric O +
acid O -
- O -
mimetic O +
agent O -
, O +
was O +
strikingly O +
effective O -
. O -

This O +
is O +
the O +
first O +
reported O +
patient O +
with O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome L-Disease +
probably O +
caused O +
by O +
methylphenidate O -
. O -

Differential O +
effects O +
of O +
17alpha O -
- O -
ethinylestradiol O +
on O +
the O +
neutral O +
and O +
acidic O +
pathways O +
of O +
bile O +
salt O +
synthesis O +
in O +
the O +
rat O -
. O -

Effects O +
of O +
17alpha O -
- O -
ethinylestradiol O +
( O -
EE O -
) O +
on O +
the O +
neutral O +
and O +
acidic O +
biosynthetic O +
pathways O +
of O +
bile O +
salt O +
( O -
BS O -
) O +
synthesis O +
were O +
evaluated O +
in O +
rats O +
with O +
an O +
intact O +
enterohepatic O +
circulation O +
and O +
in O +
rats O +
with O +
long O -
- O -
term O +
bile O +
diversion O +
to O +
induce O +
BS O +
synthesis O -
. O -

For O +
this O +
purpose O -
, O +
bile O +
salt O +
pool O +
composition O -
, O +
synthesis O +
of O +
individual O +
BS O +
in O +
vivo O -
, O +
hepatic O +
activities O -
, O +
and O +
expression O +
levels O +
of O +
cholesterol O +
7alpha O -
- O -
hydroxylase O +
( O -
CYP7A O -
) O -
, O +
and O +
sterol O +
27-hydroxylase O +
( O -
CYP27 O -
) O -
, O +
as O +
well O +
as O +
of O +
other O +
enzymes O +
involved O +
in O +
BS O +
synthesis O -
, O +
were O +
analyzed O +
in O +
rats O +
treated O +
with O +
EE O +
( O -
5 O +
mg O -
/ O -
kg O -
, O +
3 O +
days O -
) O +
or O +
its O +
vehicle O -
. O -

BS O +
pool O +
size O +
was O +
decreased O +
by O +
27 O -
% O +
but O +
total O +
BS O +
synthesis O +
was O +
not O +
affected O +
by O +
EE O +
in O +
intact O +
rats O -
. O -

Synthesis O +
of O +
cholate O +
was O +
reduced O +
by O +
68 O -
% O +
in O +
EE O -
- O -
treated O +
rats O -
, O +
while O +
that O +
of O +
chenodeoxycholate O +
was O +
increased O +
by O +
60 O -
% O -
. O -

The O +
recently O +
identified O +
Delta22-isomer O +
of O +
beta O -
- O -
muricholate O +
contributed O +
for O +
5.4 O -
% O +
and O +
18.3 O +
% O +
( O -
P O +
< O +
0.01 O -
) O +
to O +
the O +
pool O +
in O +
control O +
and O +
EE O -
- O -
treated O +
rats O -
, O +
respectively O -
, O +
but O +
could O +
not O +
be O +
detected O +
in O +
bile O +
after O +
exhaustion O +
of O +
the O +
pool O -
. O -

A O +
clear O +
reduction O +
of O +
BS O +
synthesis O +
was O +
found O +
in O +
bile O -
- O -
diverted O +
rats O +
treated O +
with O +
EE O -
, O +
yet O +
biliary O +
BS O +
composition O +
was O +
only O +
minimally O +
affected O -
. O -

Activity O +
of O +
CYP7A O +
was O +
decreased O +
by O +
EE O +
in O +
both O +
intact O +
and O +
bile O -
- O -
diverted O +
rats O -
, O +
whereas O +
the O +
activity O +
of O +
the O +
CYP27 O +
was O +
not O +
affected O -
. O -

Hepatic O +
mRNA O +
levels O +
of O +
CYP7A O +
were O +
significantly O +
reduced O +
by O +
EE O +
in O +
bile O -
- O -
diverted O +
rats O +
only O -
; O +
CYP27 O +
mRNA O +
levels O +
were O +
not O +
affected O +
by O +
EE O -
. O -

In O +
addition O -
, O +
mRNA O +
levels O +
of O +
sterol O +
12alpha O -
- O -
hydroxylase O +
and O +
lithocholate O +
6beta O -
- O -
hydroxylase O +
were O +
increased O +
by O +
bile O +
diversion O +
and O +
suppressed O +
by O +
EE O -
. O -

This O +
study O +
shows O +
that O +
17alpha O -
- O -
ethinylestradiol O +
( O -
EE O -
) O -
-induced O +
intrahepatic B-Disease +
cholestasis L-Disease +
in O +
rats O +
is O +
associated O +
with O +
selective O +
inhibition O +
of O +
the O +
neutral O +
pathway O +
of O +
bile O +
salt O +
( O -
BS O -
) O +
synthesis O -
. O -

Simultaneous O +
impairment O +
of O +
other O +
enzymes O +
in O +
the O +
BS O +
biosynthetic O +
pathways O +
may O +
contribute O +
to O +
overall O +
effects O +
of O +
EE O +
on O +
BS O +
synthesis O -
. O -

Glibenclamide O -
- O -
sensitive O +
hypotension U-Disease +
produced O +
by O +
helodermin O +
assessed O +
in O +
the O +
rat O -
. O -

The O +
effects O +
of O +
helodermin O -
, O +
a O +
basic O +
35-amino O +
acid O +
peptide O +
isolated O +
from O +
the O +
venom O +
of O +
a O +
lizard O +
salivary O +
gland O -
, O +
on O +
arterial O +
blood O +
pressure O +
and O +
heart O +
rate O +
were O +
examined O +
in O +
the O +
rat O -
, O +
focusing O +
on O +
the O +
possibility O +
that O +
activation O +
of O +
ATP O +
sensitive O +
K+ O +
( O -
K O -
( O -
ATP O -
) O -
) O +
channels O +
is O +
involved O +
in O +
the O +
responses O -
. O -

The O +
results O +
were O +
also O +
compared O +
with O +
those O +
of O +
vasoactive O +
intestinal O +
polypeptide O +
( O -
VIP O -
) O -
. O -

Helodermin O +
produced O +
hypotension U-Disease +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
with O +
approximately O +
similar O +
potency O +
and O +
duration O +
to O +
VIP O -
. O -

Hypotension U-Disease +
induced O +
by O +
both O +
peptides O +
was O +
significantly O +
attenuated O +
by O +
glibenclamide O -
, O +
which O +
abolished O +
a O +
levcromakalim O -
- O -
produced O +
decrease O +
in O +
arterial O +
blood O +
pressure O -
. O -

Oxyhemoglobin O +
did O +
not O +
affect O +
helodermin O -
- O -
induced O +
hypotension U-Disease -
, O +
whereas O +
it O +
shortened O +
the O +
duration O +
of O +
acetylcholine O +
( O -
ACh O -
) O -
-produced O +
hypotension U-Disease -
. O -

These O +
findings O +
suggest O +
that O +
helodermin O -
- O -
produced O +
hypotension U-Disease +
is O +
partly O +
attributable O +
to O +
the O +
activation O +
of O +
glibenclamide O -
- O -
sensitive O +
K+ O +
channels O +
( O -
K O -
( O -
ATP O -
) O +
channels O -
) O -
, O +
which O +
presumably O +
exist O +
on O +
arterial O +
smooth O +
muscle O +
cells O -
. O -

EDRF O +
( O -
endothelium O -
- O -
derived O +
relaxing O +
factor O -
) O -
/ O -
nitric O +
oxide O +
does O +
not O +
seem O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
peptide O -
- O -
produced O +
hypotension U-Disease -
. O -

Long O -
- O -
term O +
efficacy O +
and O +
adverse O +
event O +
of O +
nifedipine O +
sustained O -
- O -
release O +
tablets O +
for O +
cyclosporin O +
A O -
- O -
induced O +
hypertension U-Disease +
in O +
patients O +
with O +
psoriasis U-Disease -
. O -

Thirteen O +
psoriatic U-Disease +
patients O +
with O +
hypertension U-Disease +
during O +
the O +
course O +
of O +
cyclosporin O +
A O +
therapy O +
were O +
treated O +
for O +
25 O +
months O +
with O +
a O +
calcium O +
channel O +
blocker O -
, O +
sustained O -
- O -
release O +
nifedipine O -
, O +
to O +
study O +
the O +
clinical O +
antihypertensive O +
effects O +
and O +
adverse O +
events O +
during O +
treatment O +
with O +
both O +
drugs O -
. O -

Seven O +
of O +
the O +
13 O +
patients O +
had O +
exhibited O +
a O +
subclinical O +
hypertensive U-Disease +
state O +
before O +
cyclosporin O +
A O +
therapy O -
. O -

Both O +
systolic O +
and O +
diastolic O +
blood O +
pressures O +
of O +
these O +
13 O +
patients O +
were O +
decreased O +
significantly O +
after O +
4 O +
weeks O +
of O +
nifedipine O +
therapy O -
, O +
and O +
blood O +
pressure O +
was O +
maintained O +
within O +
the O +
normal O +
range O +
thereafter O +
for O +
25 O +
months O -
. O -

The O +
adverse O +
events O +
during O +
combined O +
therapy O +
with O +
cyclosporin O +
A O +
and O +
nifedipine O +
included O +
an O +
increase O +
in O +
blood O +
urea O +
nitrogen O +
levels O +
in O +
9 O +
of O +
the O +
13 O +
patients O +
and O +
development O +
of O +
gingival B-Disease +
hyperplasia L-Disease +
in O +
2 O +
of O +
the O +
13 O +
patients O -
. O -

Our O +
findings O +
indicate O +
that O +
sustained O -
- O -
release O +
nifedipine O +
is O +
useful O +
for O +
hypertensive U-Disease +
psoriatic U-Disease +
patients O +
under O +
long O -
- O -
term O +
treatment O +
with O +
cyclosporin O +
A O -
, O +
but O +
that O +
these O +
patients O +
should O +
be O +
monitored O +
for O +
gingival B-Disease +
hyperplasia L-Disease -
. O -

This O +
can O +
translate O +
into O +
global O +
effects O +
on O +
cellular O +
health O +
and O +
differentiation O +
state O -
. O -

Recently O -
, O +
several O +
reports O +
have O +
identified O +
crucial O +
roles O +
for O +
miRNAs O +
in O +
controlling O +
the O +
production O -
, O +
differentiation O -
, O +
and O +
health O +
of O +
myelinating O +
cells O +
of O +
the O +
mammalian O +
nervous O +
system O -
. O -

As O +
single O +
miRNAs O +
are O +
often O +
predicted O +
to O +
target O +
up O +
to O +
hundreds O +
of O +
individual O +
transcripts O -
, O +
miRNAs O +
are O +
able O +
to O +
broadly O +
affect O +
the O +
overall O +
protein O +
expression O +
state O +
of O +
the O +
cell O -
. O -

In O +
this O +
review O -
, O +
we O +
will O +
discuss O +
how O +
individual O +
miRNAs O +
regulate O +
these O +
various O +
processes O -
, O +
and O +
also O +
how O +
miRNA O +
production O +
in O +
general O +
is O +
required O +
for O +
several O +
stages O +
of O +
myelin O +
generation O +
and O +
maintenance O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
class O +
of O +
small O +
( O -
approx O -
. O +
22 O +
nt O -
) O +
noncoding O +
RNAs O +
that O +
are O +
capable O +
of O +
post O -
- O -
transcriptionally O +
silencing O +
mRNAs O +
that O +
contain O +
sequences O +
complementary O +
to O +
the O +
miRNAs O -
' O +
7- O +
to O +
8-bp O +
' O -
seed O -
' O +
sequence O -
. O -

MicroRNAs O +
in O +
oligodendrocyte O +
and O +
Schwann O +
cell O +
differentiation O -
. O -

Identification O +
of O +
blood O +
microRNAs O +
associated O +
to O +
Parkinsońs B-Disease +
disease I-Disease -
. L-Disease -

While O +
miR-1 O -
, O +
miR-22 O -
* O +
and O +
miR-29 O +
expression O +
levels O +
allowed O +
to O +
distinguish O +
non O -
- O -
treated O +
PD O +
from O +
healthy O +
subjects O -
, O +
miR-16 O -
- O -
2 O -
* O -
, O +
miR-26a2 O -
* O +
and O +
miR30a O +
differentiated O +
treated O +
from O +
untreated O +
patients O -
. O -

They O +
form O +
two O +
groups O +
according O +
to O +
their O +
expression O +
profile O +
in O +
control O -
, O +
non O -
- O -
treated O -
, O +
early O -
- O -
onset O +
and O +
treated O +
Parkinson O -
's B-Disease +
disease L-Disease +
subjects O -
. O -

A O +
set O +
of O +
six O +
differentially O +
expressed O +
microRNAs O +
were O +
identified O -
. O -

The O +
present O +
study O +
demonstrates O +
that O +
blood O +
samples O +
can O +
be O +
used O +
as O +
a O +
source O +
of O +
miRNA O +
identification O +
associated O +
to O +
Parkinson O -
's B-Disease +
disease L-Disease +
( O -
PD O -
) U-Disease -
. O -

This O +
study O +
is O +
innovative O +
in O +
contributing O +
to O +
the O +
development O +
of O +
effective O +
PD O +
biomarkers O -
. O -

Our O +
data O +
suggests O +
that O +
down O -
- O -
regulation O +
of O +
miRNA-128 O +
may O +
contribute O +
to O +
glioma U-Disease +
and O +
GBM U-Disease -
, O +
in O +
part O -
, O +
by O +
coordinately O +
up O -
- O -
regulating O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O -
, O +
resulting O +
in O +
the O +
proliferation O +
of O +
undifferentiated O +
GBM U-Disease +
cells O -
. O -

Addition O +
of O +
exogenous O +
miRNA-128 O +
to O +
CRL-1690 O +
and O +
CRL-2610 O +
GBM O +
cell O +
lines O +
( O -
a O -
) O +
restored O +
' O -
homeostatic O -
' O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O +
expression O -
, O +
and O +
( O -
b O -
) O +
significantly O +
decreased O +
the O +
proliferation O +
of O +
CRL-1690 O +
and O +
CRL-2610 O +
cell O +
lines O -
. O -

Three O +
bioinformatics O -
- O -
verified O +
miRNA-128 O +
targets O -
, O +
angiopoietin O -
- O -
related O +
growth O +
factor O +
protein O +
5 O +
( O -
ARP5 O -
; O +
ANGPTL6 O -
) O -
, O +
a O +
transcription O +
suppressor O +
that O +
promotes O +
stem O +
cell O +
renewal O +
and O +
inhibits O +
the O +
expression O +
of O +
known O +
tumor O +
suppressor O +
genes O +
involved O +
in O +
senescence O +
and O +
differentiation O -
, O +
Bmi-1 O -
, O +
and O +
a O +
transcription O +
factor O +
critical O +
for O +
the O +
control O +
of O +
cell O -
- O -
cycle O +
progression O -
, O +
E2F-3a O -
, O +
were O +
found O +
to O +
be O +
up O -
- O -
regulated O -
. O -

The O +
down O -
- O -
regulation O +
of O +
miRNA-128 O +
was O +
found O +
to O +
inversely O +
correlate O +
with O +
WHO O +
tumor U-Disease +
grade O -
. O -

High O +
density O +
micro O -
- O -
RNA O +
( O -
miRNA O -
) O +
arrays O -
, O +
fluorescent O -
- O -
reporter O +
miRNA O +
assay O +
and O +
Northern O +
miRNA O +
dot O -
- O -
blot O +
analysis O +
show O +
that O +
a O +
brain O -
- O -
enriched O +
miRNA-128 O +
is O +
significantly O +
down O -
- O -
regulated O +
in O +
glioblastoma B-Disease +
multiforme L-Disease +
( O -
GBM U-Disease -
) O +
and O +
in O +
GBM U-Disease +
cell O +
lines O +
when O +
compared O +
to O +
age O -
- O -
matched O +
controls O -
. O -

Micro O -
- O -
RNA-128 O +
( O -
miRNA-128 O -
) O +
down O -
- O -
regulation O +
in O +
glioblastoma U-Disease +
targets O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O -
, O +
key O +
regulators O +
of O +
brain O +
cell O +
proliferation O -
. O -

This O +
reveals O +
a O +
previously O +
unrecognized O +
signaling O +
cascade O +
involved O +
in O +
meningioma B-Disease +
tumor L-Disease +
development O +
and O +
highlights O +
a O +
novel O +
molecular O +
interaction O +
between O +
miR-200a O +
and O +
Wnt O +
signaling O -
, O +
thereby O +
providing O +
insights O +
into O +
novel O +
therapies O +
for O +
meningiomas U-Disease -
. O -

A O +
direct O +
correlation O +
was O +
found O +
between O +
the O +
downregulation O +
of O +
miR-200a O +
and O +
the O +
upregulation O +
of O +
beta O -
- O -
catenin O +
in O +
human O +
meningioma U-Disease +
samples O -
. O -

Thus O -
, O +
miR-200a O +
appears O +
to O +
act O +
as O +
a O +
multifunctional O +
tumor O +
suppressor O +
miRNA O +
in O +
meningiomas U-Disease +
through O +
effects O +
on O +
the O +
E O -
- O -
cadherin O +
and O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O +
pathways O -
. O -

miR-200a O +
was O +
found O +
to O +
directly O +
target O +
beta O -
- O -
catenin O +
mRNA O -
, O +
thereby O +
inhibiting O +
its O +
translation O +
and O +
blocking O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O -
, O +
which O +
is O +
frequently O +
involved O +
in O +
cancer U-Disease -
. O -

Downregulation O +
of O +
miR-200a O +
in O +
meningiomas U-Disease +
and O +
arachnoidal O +
cells O +
resulted O +
in O +
increased O +
expression O +
of O +
beta O -
- O -
catenin O +
and O +
cyclin O +
D1 O +
involved O +
in O +
cell O +
proliferation O -
. O -

Upregulation O +
of O +
miR-200a O +
decreased O +
the O +
expression O +
of O +
transcription O +
factors O +
ZEB1 O +
and O +
SIP1 O -
, O +
with O +
consequent O +
increased O +
expression O +
of O +
E O -
- O -
cadherin O -
, O +
an O +
adhesion O +
protein O +
associated O +
with O +
cell O +
differentiation O -
. O -

Elevated O +
levels O +
of O +
miR-200a O +
inhibited O +
meningioma U-Disease +
cell O +
growth O +
in O +
culture O +
and O +
in O +
a O +
tumor U-Disease +
model O +
in O +
vivo O -
. O -

Meningiomas U-Disease -
, O +
one O +
of O +
the O +
most O +
common O +
human O +
brain B-Disease +
tumors L-Disease -
, O +
are O +
derived O +
from O +
arachnoidal O +
cells O +
associated O +
with O +
brain O +
meninges O -
, O +
are O +
usually O +
benign O -
, O +
and O +
are O +
frequently O +
associated O +
with O +
neurofibromatosis B-Disease +
type I-Disease +
2 L-Disease -
. O +
Here O -
, O +
we O +
define O +
a O +
typical O +
human O +
meningioma U-Disease +
microRNA O +
( O -
miRNA O -
) O +
profile O +
and O +
characterize O +
the O +
effects O +
of O +
one O +
downregulated O +
miRNA O -
, O +
miR-200a O -
, O +
on O +
tumor U-Disease +
growth O -
. O -

Downregulated O +
microRNA-200a O +
in O +
meningiomas U-Disease +
promotes O +
tumor U-Disease +
growth O +
by O +
reducing O +
E O -
- O -
cadherin O +
and O +
activating O +
the O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O +
pathway O -
. O -

In O +
neurodegenerative B-Disease +
disorders L-Disease +
such O +
as O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O -
, O +
brain O +
miRNA O +
profiles O +
are O +
altered O -
; O +
thus O +
miRNA O +
dysfunction O +
could O +
be O +
both O +
a O +
cause O +
and O +
a O +
consequence O +
of O +
disease O -
. O -

These O +
small O +
non O -
- O -
coding O +
RNA O +
regulators O +
are O +
highly O +
enriched O +
in O +
brain O +
where O +
they O +
play O +
key O +
roles O +
in O +
neuronal O +
development O -
, O +
plasticity O +
and O +
disease O -
. O -

Normal O +
brain O +
development O +
and O +
function O +
depends O +
on O +
microRNA O +
( O -
miRNA O -
) O +
networks O +
to O +
fine O +
tune O +
the O +
balance O +
between O +
the O +
transcriptome O +
and O +
proteome O +
of O +
the O +
cell O -
. O -

Neuronal O +
microRNA O +
deregulation O +
in O +
response O +
to O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
amyloid O -
- O -
beta O -
. O -

Bioinformatic O +
analysis O +
predicts O +
that O +
the O +
deregulated O +
miRNAs O +
are O +
likely O +
to O +
affect O +
target O +
genes O +
present O +
in O +
prominent O +
neuronal O +
pathways O +
known O +
to O +
be O +
disrupted O +
in O +
AD U-Disease -
. O +
Remarkably O -
, O +
we O +
also O +
found O +
that O +
the O +
miRNA O +
deregulation O +
in O +
hippocampal O +
cultures O +
was O +
paralleled O +
in O +
vivo O +
by O +
a O +
deregulation O +
in O +
the O +
hippocampus O +
of O +
Abeta42-depositing O +
APP23 O +
mice O -
, O +
at O +
the O +
onset O +
of O +
Abeta O +
plaque O +
formation O -
. O -

Time O -
- O -
course O +
assays O +
of O +
neuronal O +
Abeta O +
treatments O +
show O +
that O +
Abeta O +
is O +
in O +
fact O +
a O +
powerful O +
regulator O +
of O +
miRNA O +
levels O +
as O +
the O +
response O +
of O +
certain O +
mature O +
miRNAs O +
is O +
extremely O +
rapid O -
. O -

We O +
used O +
sensitive O +
TaqMan O +
low O +
density O +
miRNA O +
arrays O +
( O -
TLDA O -
) O +
on O +
murine O +
primary O +
hippocampal O +
cultures O +
to O +
show O +
that O +
about O +
half O +
of O +
all O +
miRNAs O +
tested O +
were O +
down O -
- O -
regulated O +
in O +
response O +
to O +
Abeta O +
peptides O -
. O -

Our O +
study O +
dissects O +
the O +
complexity O +
of O +
human O +
AD U-Disease +
pathology O -
, O +
and O +
addresses O +
the O +
hypothesis O +
that O +
amyloid O -
- O -
beta O +
( O -
Abeta O -
) O +
itself O -
, O +
a O +
known O +
causative O +
factor O +
of O +
AD U-Disease -
, O +
causes O +
neuronal O +
miRNA O +
deregulation O -
, O +
which O +
could O +
contribute O +
to O +
the O +
pathomechanisms O +
of O +
AD U-Disease -
. O -

In O +
addition O -
, O +
the O +
miRNA O +
deregulation O +
in O +
hippocampal O +
cultures O +
and O +
APP23 O +
hippocampus O +
overlaps O +
with O +
those O +
obtained O +
in O +
human O +
AD U-Disease +
studies O -
. O -

Taken O +
together O -
, O +
our O +
findings O +
suggest O +
that O +
neuronal O +
miRNA O +
deregulation O +
in O +
response O +
to O +
an O +
insult O +
by O +
Abeta O +
may O +
be O +
an O +
important O +
factor O +
contributing O +
to O +
the O +
cascade O +
of O +
events O +
leading O +
to O +
AD U-Disease -
. O -

Isolation O +
and O +
characterization O +
of O +
a O +
novel O +
pituitary O +
tumor O +
apoptosis O +
gene O -
. O -

We O +
report O +
the O +
isolation O +
of O +
a O +
novel O +
differentially O +
methylated O +
chromosome O +
22 O +
CpG O +
island O -
- O -
associated O +
gene O +
( O -
C22orf3 O -
) O -
. O -

To O +
determine O +
mechanisms O +
for O +
pituitary O +
neoplasia O +
we O +
used O +
methylation O -
- O -
sensitive O +
arbitrarily O +
primed O -
- O -
PCR O +
to O +
isolate O +
novel O +
genes O +
that O +
are O +
differentially O +
methylated O +
relative O +
to O +
normal O +
pituitary O -
. O -

Sodium O +
bisulfite O +
sequencing O +
of O +
individual O +
adenomas U-Disease +
showed O +
that O +
6 O +
of O +
30 O +
( O -
20 O -
% O -
) O +
that O +
failed O +
to O +
express O +
pituitary O +
tumor O +
apoptosis O +
gene O +
( O -
PTAG O -
) O +
were O +
methylated O -
; O +
however O -
, O +
genetic O +
change O +
as O +
determined O +
by O +
loss O +
of O +
heterozygosity O +
and O +
sequence O +
analysis O +
was O +
not O +
apparent O +
in O +
the O +
remaining O +
tumors U-Disease +
that O +
failed O +
to O +
express O +
this O +
gene O -
. O -

Sodium O +
bisulfite O +
sequencing O +
of O +
pooled O +
tumor U-Disease +
cohorts O -
, O +
used O +
in O +
the O +
isolation O +
of O +
this O +
gene O -
, O +
showed O +
that O +
only O +
a O +
proportion O +
of O +
the O +
adenomas U-Disease +
within O +
the O +
pools O +
were O +
methylated O -
; O +
however O -
, O +
expression O +
analysis O +
by O +
quantitative O +
RT O -
- O -
PCR O +
of O +
individual O +
adenoma U-Disease +
irrespective O +
of O +
subtype O +
showed O +
the O +
majority O +
( O -
30 O +
of O +
38 O -
; O +
79 O -
% O -
) O +
failed O +
to O +
express O +
this O +
gene O +
relative O +
to O +
normal O +
pituitary O -
. O -

Enforced O +
expression O +
of O +
C22orf3 O +
in O +
AtT20 O +
cells O +
had O +
no O +
measurable O +
effects O +
on O +
cell O +
proliferation O +
or O +
viability O -
; O +
however O -
, O +
in O +
response O +
to O +
bromocriptine O +
challenge O +
( O -
10 O -
- O -
40 O +
microm O -
) O +
cells O +
expressing O +
this O +
gene O +
showed O +
a O +
significantly O +
augmented O +
apoptotic O +
response O +
as O +
determined O +
by O +
both O +
acridine O +
orange O +
staining O +
and O +
TUNEL O +
labeling O -
. O -

In O +
those O +
cases O +
where O +
the O +
CpG O +
island O +
of O +
these O +
genes O +
was O +
methylated O +
it O +
was O +
invariably O +
associated O +
with O +
loss O +
of O +
transcript O +
expression O -
. O -

In O +
addition O -
, O +
in O +
time O +
course O +
experiments O -
, O +
direct O +
measurement O +
of O +
active O +
caspases O +
by O +
fluorochrome O -
- O -
labeled O +
inhibition O +
of O +
caspases O -
, O +
showed O +
an O +
augmented O +
increase O +
( O -
approximately O +
2.4 O +
fold O -
) O +
in O +
active O +
caspases O +
in O +
response O +
to O +
bromocriptine O +
challenge O +
in O +
cells O +
expressing O +
C22orf3 O +
relative O +
to O +
those O +
harboring O +
an O +
empty O +
vector O +
control O -
. O -

The O +
apoptotic O +
response O +
to O +
bromocriptine O +
challenge O +
was O +
inhibited O +
in O +
coincubation O +
experiments O +
with O +
the O +
general O +
caspase O +
inhibitor O +
z O -
- O -
VAD O -
- O -
fmk O -
. O -

The O +
pituitary B-Disease +
tumor L-Disease +
derivation O +
and O +
its O +
role O +
in O +
apoptosis O +
of O +
this O +
gene O +
led O +
us O +
to O +
assign O +
the O +
acronym O +
PTAG O +
to O +
this O +
gene O +
and O +
its O +
protein O +
product O -
. O -

The O +
ability O +
of O +
cells O -
, O +
showing O +
reduced O +
expression O +
of O +
PTAG O -
, O +
to O +
evade O +
or O +
show O +
a O +
blunted O +
apoptotic O +
response O +
may O +
underlie O +
oncogenic O +
transformation O +
in O +
both O +
the O +
pituitary O +
and O +
other O +
tumor U-Disease +
types O -
. O -

It O +
has O +
been O +
recently O +
demonstrated O +
that O +
herpesviruses O +
encode O +
miRNAs O +
to O +
control O +
the O +
post O -
- O -
transcriptional O +
regulation O +
of O +
expression O +
from O +
their O +
own O +
genomes O +
and O +
possibly O +
that O +
of O +
their O +
host O -
, O +
thus O +
adding O +
an O +
additional O +
layer O +
of O +
complexity O +
to O +
the O +
physiological O +
cross O -
- O -
talk O +
between O +
host O +
and O +
pathogen O -
. O -

MicroRNAs O +
are O +
small O +
non O -
- O -
coding O +
RNAs O +
approximately O +
22 O +
nt O +
long O +
that O +
modulate O +
gene O +
expression O +
in O +
animals O +
and O +
plants O -
. O -

Co O -
- O -
expression O +
of O +
host O +
and O +
viral O +
microRNAs O +
in O +
porcine O +
dendritic O +
cells O +
infected O +
by O +
the O +
pseudorabies O +
virus O -
. O -

Almost O +
95 O -
% O +
of O +
reads O +
mapped O +
to O +
the O +
draft O +
pig O +
genome O +
sequence O +
and O +
pig O +
miRNAs O +
previously O +
annotated O +
in O +
dedicated O +
databases O +
were O +
detected O +
by O +
sequence O +
alignment O -
. O -

An O +
average O +
of O +
2 O +
million O +
reads O +
per O +
sample O +
with O +
a O +
size O +
of O +
21 O -
- O -
24 O +
nucleotides O +
was O +
obtained O +
from O +
six O +
libraries O +
representing O +
three O +
biological O +
replicates O +
of O +
infected O +
and O +
mock O -
- O -
infected O +
DCs O -
. O -

A O +
catalogue O +
of O +
porcine O +
and O +
viral O +
miRNAs O -
, O +
expressed O +
eight O +
hours O +
post O -
- O -
infection U-Disease -
, O +
was O +
established O +
by O +
deep O +
sequencing O -
. O -

The O +
present O +
study O +
focussed O +
on O +
the O +
interactions O +
between O +
porcine O +
dendritic O +
cells O +
( O -
DCs O -
) O +
and O +
the O +
Pseudorabies O +
virus O +
( O -
PRV O -
) O -
, O +
an O +
alpha O -
- O -
herpesvirus O +
causing O +
Aujeszky B-Disease -
's I-Disease +
disease L-Disease +
in O +
pigs O -
. O -

In O +
silico O +
prediction O +
allowed O +
the O +
identification O +
of O +
unknown O +
porcine O +
as O +
well O +
as O +
of O +
five O +
miRNAs O +
transcribed O +
by O +
the O +
Large O +
Latency O +
Transcript O +
( O -
LLT O -
) O +
of O +
PRV O -
. O -

The O +
gene O +
target O +
prediction O +
of O +
the O +
viral O +
miRNAs O +
and O +
the O +
Ingenuity O +
Pathway O +
Analysis O +
of O +
differentially O +
expressed O +
pig O +
miRNAs O +
were O +
conducted O +
to O +
contextualize O +
the O +
identified O +
small O +
RNA O +
molecules O +
and O +
functionally O +
characterize O +
their O +
involvement O +
in O +
the O +
post O -
- O -
transcriptional O +
regulation O +
of O +
gene O +
expression O -
. O -

The O +
results O +
support O +
a O +
role O +
for O +
PRV O +
miRNAs O +
in O +
the O +
maintenance O +
of O +
the O +
host O +
cell O +
latency O +
state O +
through O +
the O +
down O -
- O -
regulation O +
of O +
immediate O -
- O -
early O +
viral O +
genes O +
which O +
is O +
similar O +
to O +
other O +
herpesviruses O -
. O -

The O +
differentially O +
expressed O +
swine O +
miRNAs O +
identified O +
a O +
unique O +
network O +
of O +
target O +
genes O +
with O +
highly O +
significant O +
functions O +
in O +
the O +
development O +
and O +
function O +
of O +
the O +
nervous O +
system O +
and O +
in O +
infectious O +
mechanisms O -
, O +
suggesting O +
that O +
the O +
modulation O +
of O +
both O +
host O +
and O +
viral O +
miRNAs O +
is O +
necessary O +
for O +
the O +
establishment O +
of O +
PRV O +
latency O -
. O -

The O +
RAKE O +
assay O +
is O +
theoretically O +
versatile O +
and O +
may O +
be O +
used O +
for O +
other O +
applications O -
, O +
such O +
as O +
viral O +
gene O +
profiling O -
. O -

Furthermore O -
, O +
we O +
demonstrate O +
that O +
miRNAs O +
can O +
be O +
isolated O +
and O +
profiled O +
from O +
formalin O -
- O -
fixed O +
paraffin O -
- O -
embedded O +
tissue O -
, O +
which O +
opens O +
up O +
new O +
opportunities O +
for O +
analyses O +
of O +
small O +
RNAs O +
from O +
archival O +
human O +
tissue O -
. O -

RAKE O +
offers O +
unique O +
advantages O +
for O +
specificity O +
over O +
northern O +
blots O +
or O +
other O +
microarray O -
- O -
based O +
expression O +
profiling O +
platforms O -
. O -

We O +
show O +
that O +
the O +
RAKE O +
assay O +
is O +
sensitive O +
and O +
specific O +
for O +
miRNAs O +
and O +
is O +
ideally O +
suited O +
for O +
rapid O +
expression O +
profiling O +
of O +
all O +
known O +
miRNAs O -
. O -

We O +
used O +
RAKE O +
to O +
study O +
human O +
cell O +
lines O +
and O +
brain B-Disease +
tumors L-Disease -
. O -

The O +
technique O +
is O +
termed O +
the O +
RNA O -
- O -
primed O -
, O +
array O -
- O -
based O +
Klenow O +
enzyme O +
( O -
RAKE O -
) O +
assay O -
, O +
because O +
it O +
involves O +
on O -
- O -
slide O +
application O +
of O +
the O +
Klenow O +
fragment O +
of O +
DNA O +
polymerase O +
I O +
to O +
extend O +
unmodified O +
miRNAs O +
hybridized O +
to O +
immobilized O +
DNA O +
probes O -
. O -

We O +
describe O +
a O +
new O +
method O +
for O +
high O -
- O -
throughput O +
miRNA O +
detection O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
regulatory O +
RNAs O +
that O +
serve O +
fundamental O +
biological O +
roles O +
across O +
eukaryotic O +
species O -
. O -

Microarray O -
- O -
based O -
, O +
high O -
- O -
throughput O +
gene O +
expression O +
profiling O +
of O +
microRNAs O -
. O -

Brain O +
cells O +
maintain O +
distinct O +
populations O +
of O +
miRNAs O +
that O +
support O +
physiologically O +
normal O +
patterns O +
of O +
expression O -
, O +
however O -
, O +
certain O +
miRNA O +
abundances O +
are O +
significantly O +
altered O +
in O +
neurodegenerative B-Disease +
disorders L-Disease +
such O +
as O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O -
. O -

Here O +
we O +
provide O +
evidence O +
in O +
human O +
neural O +
( O -
HN O -
) O +
cells O +
of O +
an O +
aluminum O -
- O -
sulfate- O +
and O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O -
-mediated O +
up O -
- O -
regulation O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
sensitive O +
miRNA-146a O +
that O +
down O -
- O -
regulates O +
the O +
expression O +
of O +
complement O +
factor O +
H O +
( O -
CFH O -
) O -
, O +
an O +
important O +
repressor O +
of O +
inflammation O -
. O -

Characterization O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
regulated O -
, O +
miRNA-146a O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
complement O +
factor O +
H O +
( O -
CFH O -
) O +
in O +
metal O -
- O -
sulfate O -
- O -
stressed O +
human O +
brain O +
cells O -
. O -

Micro O +
RNAs O +
( O -
miRNAs O -
) O +
represent O +
a O +
family O +
of O +
small O +
ribonucleic O +
acids O +
( O -
RNAs O -
) O +
that O +
are O +
post O -
- O -
transcriptional O +
regulators O +
of O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
complexity O -
. O -

An O +
NF O -
- O -
kappaB O -
- O -
containing O +
miRNA-146a O -
- O -
promoter O -
- O -
luciferase O +
reporter O +
construct O +
transfected O +
into O +
HN O +
cells O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
miRNA-146a O +
after O +
aluminum O -
- O -
sulfate O +
treatment O +
that O +
corresponded O +
to O +
decreased O +
CFH O +
gene O +
expression O -
. O -

These O +
data O +
suggest O +
that O +
( O -
1 O -
) O +
as O +
in O +
AD U-Disease +
brain O -
, O +
NF O -
- O -
kappaB O -
- O -
sensitive O -
, O +
miRNA-146a O -
- O -
mediated O -
, O +
modulation O +
of O +
CFH O +
gene O +
expression O +
may O +
contribute O +
to O +
inflammatory O +
responses O +
in O +
aluminum O -
- O -
stressed O +
HN O +
cells O -
, O +
and O +
( O -
2 O -
) O +
underscores O +
the O +
potential O +
of O +
nanomolar O +
aluminum O +
to O +
drive O +
genotoxic O +
mechanisms O +
characteristic O +
of O +
neurodegenerative B-Disease +
disease L-Disease +
processes O -
. O -

This O +
NF O -
- O -
kappaB O -
- O -
miRNA-146a O -
- O -
CFH O +
signaling O +
circuit O +
is O +
known O +
to O +
be O +
similarly O +
affected O +
by O +
Abeta42 O +
peptides O +
and O +
in O +
AD U-Disease +
brain O -
. O -

These O +
aluminum O -
- O -
sulfate O -
- O -
inducible O +
events O +
were O +
not O +
observed O +
in O +
parallel O +
experiments O +
using O +
iron- O -
, O +
magnesium- O -
, O +
or O +
zinc O -
- O -
sulfate O -
- O -
stressed O +
HN O +
cells O -
. O -

A O +
specific O +
subset O +
of O +
five O +
miRNAs O +
revealed O +
by O +
in O +
silico O +
target O +
prediction O +
was O +
significantly O +
overexpressed O +
in O +
NFA O +
samples O -
; O +
three O +
miRs O +
( O -
miR-128a O -
, O +
miR-155 O -
, O +
and O +
miR-516a-3p O -
) O +
targeted O +
the O +
3'-untranslated O +
region O +
of O +
the O +
Wee1 O +
transcript O -
, O +
and O +
exogenous O +
overexpression O +
of O +
these O +
miRs O +
inhibited O +
Wee1 O +
protein O +
expression O +
and O +
HeLa O +
cell O +
proliferation O -
. O -

RESULTS O -
: O +
Wee1 O +
protein O +
expression O +
was O +
decreased O +
in O +
NFAs O +
and O +
GH O -
- O -
producing O +
tumors U-Disease +
with O +
or O +
without O +
prolactin O +
production O -
, O +
but O +
no O +
change O +
in O +
mRNA O +
expression O +
was O +
observed O +
with O +
qRT O -
- O -
PCR O -
. O -

CONCLUSIONS O -
: O +
To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
suggesting O +
that O +
regulation O +
of O +
Wee1 O +
kinase O +
by O +
miRs O +
may O +
be O +
linked O +
to O +
pituitary O +
tumorigenesis O -
. O -

CONTEXT O -
: O +
The O +
tumorigenic O +
mechanisms O +
involved O +
in O +
pituitary B-Disease +
adenomas L-Disease -
, O +
especially O +
of O +
nonfunctional O +
pituitary O +
adenomas O +
( O -
NFAs O -
) O -
, O +
remains O +
unclear O -
. O -

Down O -
- O -
regulation O +
of O +
Wee1 O +
kinase O +
by O +
a O +
specific O +
subset O +
of O +
microRNA O +
in O +
human O +
sporadic O +
pituitary B-Disease +
adenomas L-Disease -
. O -

OBJECTIVE O -
: O +
Our O +
objective O +
was O +
to O +
examine O +
the O +
expression O +
of O +
Wee1 O +
in O +
pituitary B-Disease +
tumors L-Disease +
and O +
to O +
identify O +
microRNAs O +
( O -
miRs O -
) O +
that O +
can O +
regulate O +
its O +
expression O -
. O -

Various O +
cell O +
cycle O +
inhibitors O +
have O +
been O +
found O +
to O +
be O +
underexpressed O +
in O +
pituitary B-Disease +
tumors L-Disease -
; O +
however O -
, O +
Wee1 O +
kinase O -
, O +
a O +
nuclear O +
protein O +
that O +
delays O +
mitosis O +
and O +
was O +
recently O +
recognized O +
as O +
a O +
tumor O +
suppressor O +
gene O -
, O +
has O +
not O +
been O +
previously O +
investigated O +
in O +
pituitary B-Disease +
tumors L-Disease -
. O -

Identification O +
of O +
miRs O +
targeting O +
the O +
Wee1 O +
3'-untranslated O +
region O +
was O +
performed O +
by O +
miR O +
array O +
followed O +
by O +
expression O +
analysis O +
of O +
identified O +
miRs O +
using O +
qRT O -
- O -
PCR O -
. O -

DESIGN O -
: O +
Expression O +
of O +
Wee1 O +
was O +
examined O +
by O +
immunohistochemistry O +
and O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O -

PATIENTS O -
: O +
A O +
total O +
of O +
57 O +
pituitary O +
tissue O +
samples O +
including O +
27 O +
NFAs O -
, O +
15 O +
GH O -
- O -
producing O +
adenomas U-Disease +
with O +
or O +
without O +
prolactin O +
overproduction O -
, O +
and O +
15 O +
normal O +
pituitary O +
glands O +
were O +
analyzed O -
. O -

Dual O -
- O -
luciferase O +
assay O +
and O +
transient O +
transfection O +
of O +
miRs O +
into O +
Hela O +
cells O +
followed O +
by O +
immunoblot O +
analysis O +
of O +
Wee1 O +
protein O +
and O +
cell O +
proliferation O +
analysis O +
were O +
carried O +
out O -
. O -

In O +
this O +
review O +
article O -
, O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
role O +
and O +
function O +
of O +
miRNAs O +
in O +
the O +
regulation O +
of O +
genes O +
involved O +
in O +
neurological O +
and O +
neurodegenerative B-Disease +
diseases L-Disease +
will O +
be O +
discussed O -
, O +
with O +
a O +
focus O +
on O +
the O +
fragile B-Disease +
X I-Disease +
syndrome L-Disease -
, O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O +
and O +
prion B-Disease +
disease L-Disease -
. O -

Likely O +
to O +
play O +
a O +
central O +
role O +
in O +
health O +
and O +
disease O -
, O +
a O +
dysfunctional O +
miRNA O -
- O -
based O +
regulation O +
of O +
gene O +
expression O +
may O +
represent O +
the O +
main O +
etiologic O +
factor O +
underlying O +
diseases O +
affecting O +
major O +
organs O -
, O +
such O +
as O +
the O +
brain O -
. O -

MicroRNAs O +
as O +
a O +
molecular O +
basis O +
for O +
mental B-Disease +
retardation L-Disease -
, O +
Alzheimer B-Disease -
's L-Disease +
and O +
prion B-Disease +
diseases L-Disease -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O -
, O +
approximately O +
21- O +
to O +
23-nucleotide O +
( O -
nt O -
) O +
non O -
- O -
coding O +
RNA O +
species O +
that O +
act O +
as O +
key O +
regulators O +
of O +
gene O +
expression O +
along O +
a O +
central O +
and O +
well O -
- O -
defined O +
cellular O +
process O +
known O +
as O +
RNA O +
silencing O -
, O +
and O +
involving O +
the O +
recognition O +
and O +
translational O +
control O +
of O +
specific O +
messenger O +
RNA O +
( O -
mRNAs O -
) O -
. O -

Generated O +
through O +
the O +
well O -
- O -
orchestrated O +
and O +
sequential O +
processing O +
of O +
miRNA O +
precursor O +
molecules O -
, O +
mature O +
miRNAs O +
are O +
subsequently O +
incorporated O +
into O +
miRNA O -
- O -
containing O +
ribonucleoprotein O +
effector O +
complexes O +
to O +
regulate O +
mRNA O +
translation O +
through O +
the O +
recognition O +
of O +
specific O +
binding O +
sites O +
of O +
imperfect O +
complementarity O +
located O +
mainly O +
in O +
the O +
3 O -
' O +
untranslated O +
region O -
. O -

Predicted O +
to O +
regulate O +
up O +
to O +
90 O -
% O +
of O +
the O +
genes O +
in O +
humans O -
, O +
miRNAs O +
may O +
thus O +
control O +
cellular O +
processes O +
in O +
all O +
cells O +
and O +
tissues O +
of O +
the O +
human O +
body O -
. O -

High O +
levels O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
also O +
significantly O +
correlated O +
with O +
the O +
proliferation O +
marker O +
Ki-67 O +
( O -
P<0.0001 O -
) O -
. O -

High O +
levels O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
were O +
more O +
frequently O +
observed O +
in O +
macroadenomas O +
than O +
in O +
microadenomas O +
( O -
P<0.05 O -
) O -
. O -

Overexpression O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
was O +
observed O +
in O +
39 O -
% O +
( O -
38 O -
/ O -
98 O -
) O +
of O +
pituitary B-Disease +
adenomas L-Disease +
compared O +
with O +
normal O +
adenohypophysial O +
tissue O +
and O +
was O +
frequently O +
found O +
in O +
adenomas U-Disease +
including O +
prolactin O +
( O -
PRL O -
) O -
, O +
adrenocorticotrophic O +
hormone O -
, O +
or O +
follicle O -
- O -
stimulating O +
hormone O -
/ O -
luteinizing O +
hormone O +
and O +
in O +
null O +
cell O +
adenomas U-Disease -
, O +
but O +
relatively O +
rare O +
in O +
growth O +
hormone O +
( O -
GH O -
) O +
and O +
mixed O +
GH O -
/ O -
PRL O +
adenomas U-Disease -
. O -

High O -
- O -
mobility O +
group O +
A2 O +
expression O +
was O +
significantly O +
associated O +
with O +
tumor U-Disease +
invasion O +
( O -
P<0.05 O -
) O +
and O +
was O +
significantly O +
higher O +
in O +
grade O +
IV O +
than O +
in O +
grades O +
I O -
, O +
II O -
, O +
and O +
III O +
adenomas U-Disease +
( O -
P<0.05 O -
) O -
. O -

However O -
, O +
no O +
studies O +
have O +
investigated O +
the O +
clinical O +
significance O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
and O +
its O +
relationship O +
to O +
the O +
let-7 O +
miRNA O +
family O +
in O +
human O +
pituitary B-Disease +
adenomas L-Disease -
. O -

Using O +
immunohistochemistry O -
, O +
we O +
analyzed O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
with O +
respect O +
to O +
various O +
clinicopathologic O +
factors O +
in O +
98 O +
pituitary B-Disease +
adenomas L-Disease -
. O -

Recent O +
studies O +
report O +
that O +
high O -
- O -
mobility O +
group O +
A2 O +
is O +
negatively O +
regulated O +
by O +
the O +
let-7 O +
microRNAs O +
( O -
miRNAs O -
) O +
family O +
in O +
vitro O -
. O -

The O +
development O +
of O +
pituitary B-Disease +
adenomas L-Disease +
in O +
high O -
- O -
mobility O +
group O +
A2 O +
transgenic O +
mice O +
showed O +
that O +
high O -
- O -
mobility O +
group O +
A2 O +
may O +
be O +
involved O +
in O +
pituitary O +
tumorigenesis O -
. O -

Overexpression O +
of O +
HMGA2 O +
relates O +
to O +
reduction O +
of O +
the O +
let-7 O +
and O +
its O +
relationship O +
to O +
clinicopathological O +
features O +
in O +
pituitary B-Disease +
adenomas L-Disease -
. O -

High O -
- O -
mobility O +
group O +
A2 O +
is O +
highly O +
expressed O +
during O +
embryogenesis O +
and O +
in O +
various O +
benign O +
and O +
malignant B-Disease +
tumors L-Disease -
. O -

Real O -
- O -
time O +
quantitative O +
RT O -
- O -
PCR O +
analysis O +
was O +
carried O +
out O +
to O +
evaluate O +
the O +
expression O +
of O +
let-7 O +
in O +
55 O +
pituitary B-Disease +
adenomas L-Disease -
. O -

Subsequently O -
, O +
decreased O +
expression O +
of O +
let-7 O +
was O +
confirmed O +
in O +
23 O +
of O +
55 O +
( O -
42 O -
% O -
) O +
adenomas U-Disease +
and O +
was O +
correlated O +
with O +
high B-Disease -
- I-Disease -
grade I-Disease +
tumors L-Disease +
( O -
P<0.05 O -
) O -
. O -

An O +
inverse O +
correlation O +
between O +
let-7 O +
and O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
was O +
evident O +
( O -
R=-0.33 O -
, O +
P<0.05 O -
) O -
. O -

These O +
findings O +
support O +
a O +
causal O +
link O +
between O +
let-7 O +
and O +
high O -
- O -
mobility O +
group O +
A2 O +
whereby O +
loss O +
of O +
let-7 O +
expression O +
induces O +
high O -
- O -
mobility O +
group O +
A2 O +
upregulation O +
that O +
represents O +
an O +
important O +
mechanism O +
in O +
pituitary O +
tumorigenesis O +
and O +
progression O -
. O -

The O +
proliferation O +
inhibition O +
and O +
induced O +
apoptosis O +
by O +
this O +
recombinant O +
with O +
an O +
apoptosis O +
ratio O +
of O +
21.89 O -
% O +
in O +
U87 O +
cell O +
were O +
also O +
observed O -
. O -

The O +
results O +
of O +
Western O +
blot O +
indicated O +
the O +
expression O +
of O +
Flag O +
of O +
No O +
1 O +
recombinant O +
plasmid O +
group O +
was O +
inhibited O +
heavily O +
with O +
a O +
34.3 O -
% O +
expression O +
level O +
by O +
compared O +
with O +
control O +
group O -
. O -

The O +
expressed O +
Flag O +
protein O +
was O +
detected O +
by O +
Western O +
blot O +
to O +
evaluate O +
the O +
inhibition O +
effect O +
of O +
targeting O +
sequences O -
. O -

The O +
confirmed O +
pGCSIL O -
- O -
GFP O +
recombinants O +
by O +
combining O +
with O +
pEGFP O -
- O -
miR-221 O +
were O +
transfected O +
into O +
293 O -
T O +
cells O +
seperately O -
. O -

RESULTS O -
: O +
The O +
resulting O +
recombinants O +
were O +
confirmed O +
by O +
sequencing O +
which O +
demonstrated O +
that O +
the O +
recombinant O +
plasmids O +
contained O +
the O +
correct O +
sequences O +
of O +
designed O +
transcript O +
templates O -
. O -

Then O +
a O +
recombinant O +
with O +
the O +
highest O +
anti O -
- O -
miR-221 O +
effect O +
was O +
screened O +
and O +
transfected O +
into O +
U87 O +
glioma U-Disease +
cell O -
, O +
and O +
its O +
anti O -
- O -
tumor O +
effect O +
was O +
evaluated O +
by O +
MTT O +
and O +
FCM O -
. O -

[ O -
Construction O +
and O +
screening O +
an O +
effective O +
anti O -
- O -
miR-221 O +
RNAi O +
vector O +
in O +
vitro O -
] O -
. O -

OBJECTIVE O -
: O +
To O +
construct O +
and O +
screen O +
an O +
effective O +
anti O -
- O -
miR-221 O +
vector O +
of O +
siRNA O -
. O -

METHODS O -
: O +
Four O +
hairpin O +
structure O +
of O +
siRNA O +
transcript O +
templates O +
targeting O +
miR-221 O +
and O +
a O +
negative O +
control O +
were O +
synthesized O -
, O +
then O +
ligated O +
with O +
pGCSIL O -
- O -
GFP O +
vector O +
and O +
a O +
pEGFP O -
- O -
miR-221 O +
which O +
express O +
pre O -
- O -
miR-221 O +
was O +
also O +
constructed O -
. O -

All O +
the O +
recombinants O +
were O +
sequenced O -
. O -

CONCLUSION O -
: O +
The O +
anti O -
- O -
miR-221 O +
expression O +
siRNA O +
espression O +
recombinants O +
were O +
constructed O +
successfully O -
, O +
and O +
one O +
sequence O +
with O +
the O +
highest O +
inhibition O +
efficiency O +
was O +
screened O +
out O -
, O +
which O +
could O +
inhibit O +
U87 O +
cell O +
proliferation O +
and O +
induce O +
cell O +
apoptosis O -
, O +
and O +
could O +
be O +
used O +
to O +
suppress O +
target O +
gene O +
for O +
further O +
study O +
in O +
tumor U-Disease +
biology O -
. O -

Expression O +
profiling O +
showed O +
strong O +
miRNA O +
and O +
isomiR O +
expression O +
deregulation O +
in O +
HD U-Disease -
, O +
most O +
being O +
common O +
to O +
both O +
FC O +
and O +
ST O -
. O -

Around O +
80 O -
- O -
90 O -
% O +
of O +
the O +
miRNAs O +
presented O +
modifications O +
in O +
the O +
3'-terminus O +
mainly O +
in O +
the O +
form O +
of O +
trimming O +
and/or O +
as O +
nucleotide O +
addition O +
variants O -
, O +
while O +
the O +
5'-terminus O +
of O +
the O +
miRNAs O +
was O +
specially O +
protected O +
from O +
changes O -
. O -

Deep O +
sequencing O +
revealed O +
length O +
and O +
sequence O +
heterogeneity O +
( O -
IsomiRs O -
) O +
for O +
the O +
vast O +
majority O +
of O +
miRNAs O -
. O -

More O +
than O +
80 O -
% O +
of O +
the O +
small O -
- O -
RNAs O +
were O +
annotated O +
as O +
microRNAs O +
( O -
miRNAs O -
) O +
in O +
all O +
samples O -
. O -

We O +
have O +
applied O +
the O +
Illumina O +
massively O +
parallel O +
sequencing O +
to O +
deeply O +
analyze O +
the O +
small O +
RNA O +
populations O +
of O +
two O +
different O +
forebrain O +
areas O -
, O +
the O +
frontal O +
cortex O +
( O -
FC O -
) O +
and O +
the O +
striatum O +
( O -
ST O -
) O +
of O +
healthy O +
individuals O +
and O +
individuals O +
with O +
HD U-Disease -
. O -

Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
is O +
a O +
neurodegenerative B-Disease +
disorder L-Disease +
that O +
predominantly O +
affects O +
neurons O +
of O +
the O +
forebrain O -
. O -

A O +
myriad O +
of O +
miRNA O +
variants O +
in O +
control O +
and O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
brain O +
regions O +
detected O +
by O +
massively O +
parallel O +
sequencing O -
. O -

Our O +
results O +
show O +
that O +
miRNA O +
variability O +
is O +
a O +
ubiquitous O +
phenomenon O +
in O +
the O +
adult O +
human O +
brain O -
, O +
which O +
may O +
influence O +
gene O +
expression O +
in O +
physiological O +
and O +
pathological O +
conditions O -
. O -

The O +
putative O +
targets O +
of O +
deregulated O +
miRNAs O +
and O +
seed O -
- O -
region O +
IsomiRs O +
strongly O +
suggest O +
that O +
their O +
altered O +
expression O +
contributes O +
to O +
the O +
aberrant O +
gene O +
expression O +
in O +
HD U-Disease -
. O -

The O +
analysis O +
of O +
the O +
upstream O +
regulatory O +
regions O +
in O +
co O -
- O -
regulated O +
miRNAs O +
suggests O +
a O +
role O +
for O +
RE1-Silencing O +
Transcription O +
Factor O +
( O -
REST O -
) O +
and O +
P53 O +
in O +
miRNAs O +
downregulation O +
in O +
HD U-Disease -
. O -

Moreover O -
, O +
LPS O +
stimulation O +
decreased O +
expression O +
of O +
microRNAs O +
( O -
miRNA O -
) O -
--miR-17 O -
- O -
5 O -
, O +
miR-20a O -
, O +
and O +
miR-93 O -
- O -
-which O +
target O +
MICA O -
, O +
implicating O +
a O +
novel O +
role O +
for O +
miRNAs O +
in O +
NKG2D O +
ligand O +
expression O -
. O -

However O -
, O +
it O +
was O +
not O +
sufficient O +
for O +
surface O +
protein O +
expression O -
, O +
which O +
was O +
controlled O +
posttranscriptionally O +
via O +
a O +
separate O +
pathway O +
involving O +
the O +
ataxia O +
telangiectasia O +
mutated O -
/ O -
ataxia O +
telangiectasia O +
and O +
Rad3 O +
related O +
kinases O -
. O -

Thus O -
, O +
TLR O +
stimulation O +
allows O +
expression O +
of O +
NKG2D O +
ligands O +
through O +
multiple O +
pathways O -
, O +
including O +
downmodulation O +
of O +
specific O +
miRNAs O -
. O -

In O +
this O +
paper O -
, O +
we O +
clarify O +
that O +
LPS O -
, O +
which O +
ligates O +
TLR-4 O -
, O +
preferentially O +
upregulated O +
MICA O +
and O +
not O +
MICB O -
; O +
CL097 O -
, O +
which O +
ligates O +
TLR-7 O -
/ O -
8 O -
, O +
upregulated O +
both O +
MICA O +
and O +
MICB O -
; O +
and O +
polyinosinic O -
- O -
polycytidylic O +
acid O -
, O +
which O +
ligates O +
TLR-3 O -
, O +
upregulated O +
neither O -
. O -

However O -
, O +
NKG2D O +
ligands O +
can O +
also O +
be O +
induced O +
on O +
human O +
macrophages O +
by O +
TLR O +
stimulation O -
, O +
which O +
has O +
been O +
far O +
less O +
studied O -
. O -

This O +
finding O +
suggests O +
that O +
increased O +
levels O +
of O +
MICA O +
mRNA O +
following O +
LPS O +
stimulation O +
resulted O +
from O +
increased O +
transcription O -
. O -

To O +
probe O +
how O +
LPS O +
stimulation O +
triggers O +
MICA O +
expression O -
, O +
we O +
determined O +
that O +
the O +
stability O +
of O +
MICA O +
mRNA O +
was O +
much O +
longer O +
than O +
that O +
of O +
MICB O +
mRNA O -
, O +
but O +
neither O +
was O +
changed O +
by O +
LPS O +
stimulation O -
. O -

Multiple O +
mechanisms O +
downstream O +
of O +
TLR-4 O +
stimulation O +
allow O +
expression O +
of O +
NKG2D O +
ligands O +
to O +
facilitate O +
macrophage O -
/ O -
NK O +
cell O +
crosstalk O -
. O -

This O +
establishes O +
recognition O +
of O +
" O -
induced O +
self O -
" O +
as O +
an O +
important O +
strategy O +
for O +
surveillance O +
of O +
infections U-Disease +
or O +
tumor U-Disease +
transformation O -
. O -

The O +
activating O +
receptor O +
NKG2D O +
recognizes O +
proteins O +
that O +
are O +
not O +
normally O +
expressed O +
at O +
the O +
surface O +
of O +
most O +
cells O +
but O +
are O +
expressed O +
during O +
a O +
cellular O +
" O -
stress O -
" O +
response O +
( O -
e.g. O -
, O +
upon O +
induction O +
of O +
the O +
DNA B-Disease +
damage L-Disease +
pathway O -
) O -
. O -

MicroRNA O +
in O +
Situ O +
Hybridization O +
in O +
the O +
Human O +
Entorhinal O +
and O +
Transentorhinal O +
Cortex O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
key O +
roles O +
in O +
gene O +
expression O +
regulation O +
in O +
both O +
healthy O +
and O +
disease O +
brains O -
. O -

To O +
better O +
understand O +
those O +
roles O -
, O +
it O +
is O +
necessary O +
to O +
characterize O +
the O +
miRNAs O +
that O +
are O +
expressed O +
in O +
particular O +
cell O +
types O +
under O +
a O +
range O +
of O +
conditions O -
. O -

In O +
situ O +
hybridization O +
( O -
ISH O -
) O +
can O +
demonstrate O +
cell- O +
and O +
lamina O -
- O -
specific O +
patterns O +
of O +
miRNA O +
expression O +
that O +
would O +
be O +
lost O +
in O +
tissue O -
- O -
level O +
expression O +
profiling O -
. O -

In O +
the O +
present O +
study O -
, O +
ISH O +
was O +
performed O +
with O +
special O +
focus O +
on O +
the O +
human O +
entorhinal O +
cortex O +
( O -
EC O -
) O +
and O +
transentorhinal O +
cortex O +
( O -
TEC O -
) O -
. O -

The O +
TEC O +
is O +
the O +
area O +
of O +
the O +
cerebral O +
cortex O +
that O +
first O +
develops O +
neurofibrillary O +
tangles O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O -
. O -

However O -
, O +
the O +
reason O +
for O +
TEC O -
's O +
special O +
vulnerability O +
to O +
AD U-Disease -
- O -
type O +
pathology O +
is O +
unknown O -
. O -

MiRNA O +
ISH O +
was O +
performed O +
on O +
three O +
human O +
brains O +
with O +
well O -
- O -
characterized O +
clinical O +
and O +
pathological O +
parameters O -
. O -

Locked O +
nucleic O +
acid O +
ISH O +
probes O +
were O +
used O +
referent O +
to O +
miR-107 O -
, O +
miR-124 O -
, O +
miR-125b O -
, O +
and O +
miR-320 O -
. O -

In O +
order O +
to O +
correlate O +
the O +
ISH O +
data O +
with O +
AD U-Disease +
pathology O -
, O +
the O +
ISH O +
staining O +
was O +
compared O +
with O +
near O -
- O -
adjacent O +
slides O +
processed O +
using O +
Thioflavine O +
stains O -
. O -

MiRNA O +
ISH O +
is O +
among O +
the O +
first O +
methods O +
to O +
show O +
special O +
staining O +
characteristics O +
of O +
cells O +
and O +
laminae O +
of O +
the O +
human O +
TEC O -
. O -

As O +
with O +
other O +
areas O +
of O +
brain O -
, O +
the O +
TEC O +
and O +
EC O +
have O +
characteristic O +
miRNA O +
expression O +
patterns O -
. O -

Not O +
all O +
neurons O +
or O +
cortical O +
lamina O +
stain O +
with O +
equal O +
intensity O +
for O +
individual O +
miRNAs O -
. O -

Our O +
in O +
vitro O +
results O +
suggested O +
that O +
Aβ42 O +
oligomer O -
- O -
induced O +
miR-106b O +
leads O +
to O +
impairment O +
in O +
TGF O -
- O -
β O +
signaling O +
through O +
TβR O +
II O -
, O +
concomitant O +
with O +
retinoic O +
acid O -
- O -
induced O +
neurodegeneration O +
in O +
SH O -
- O -
SY5Y O +
cells O -
. O -

These O +
results O +
show O +
that O +
TβR O +
II O +
is O +
a O +
functional O +
target O +
of O +
miR-106b O +
and O +
that O +
miR-106b O +
may O +
influence O +
TGF O -
- O -
β O +
signaling O -
, O +
thereby O +
contributing O +
to O +
the O +
pathogenesis O +
of O +
AD U-Disease -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
abundantly O +
expressed O +
in O +
the O +
brain O +
and O +
play O +
an O +
important O +
role O +
in O +
disorders O +
of O +
the O +
brain O -
, O +
including O +
Alzheimer B-Disease -
's I-Disease +
diseases L-Disease +
( O -
AD U-Disease -
) O -
. O -

miR-106b O +
aberrantly O +
expressed O +
in O +
a O +
double O +
transgenic O +
mouse O +
model O +
for O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
targets O +
TGF O -
- O -
β O +
type O +
II O +
receptor O -
. O -

However O -
, O +
it O +
is O +
unclear O +
whether O +
miRNAs O +
involved O +
in O +
AD U-Disease +
pathogenesis O +
by O +
regulating O +
TGF O -
- O -
β O +
signaling O -
. O -

Growing O +
body O +
of O +
evidence O +
suggests O +
that O +
the O +
TGF O -
- O -
β O +
signaling O +
pathway O +
plays O +
a O +
key O +
role O +
in O +
the O +
pathogenesis O +
of O +
AD U-Disease -
. O -

Sequence O +
analysis O +
revealed O +
two O +
putative O +
binding O +
sites O +
for O +
miR-106b O +
in O +
the O +
3 O -
' O +
UTR O +
of O +
the O +
TβR O +
II O +
mRNA O -
. O -

Here O +
we O +
found O +
that O +
miR-106b O +
and O +
TGF O -
- O -
β O +
type O +
II O +
receptor O +
( O -
TβR O +
II O -
) O +
were O +
aberrantly O +
expressed O +
in O +
APPswe O -
/ O -
PS∆E9 O +
mice O +
( O -
a O +
double O +
transgenic O +
mouse O +
model O +
for O +
AD U-Disease -
) O -
. O -

After O +
induced O +
neurodifferentiation O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O -
, O +
we O +
observed O +
significant O +
neurodegeneration O +
in O +
SH O -
- O -
SY5Y O +
cells O +
stably O +
transfected O +
with O +
miR-106b O -
. O -

Our O +
results O +
showed O +
that O +
the O +
expression O +
of O +
miR-106b O +
was O +
inversely O +
correlated O +
with O +
TβR O +
II O +
protein O +
levels O +
and O +
miR-106b O +
can O +
directly O +
inhibit O +
the O +
TβR O +
II O +
translation O +
in O +
vitro O -
. O -

Exposure O +
of O +
SH O -
- O -
SY5Y O +
cells O +
to O +
Aβ42 O +
oligomers O +
led O +
to O +
the O +
expression O +
of O +
miR-106b O +
was O +
first O +
increased O +
and O +
then O +
decreased O +
and O +
TβR O +
II O +
levels O +
reduced O -
. O -

Western O +
blot O +
analysis O +
revealed O +
unchanged O +
total O +
Smad2 O -
/ O -
3 O +
protein O +
levels O -
, O +
but O +
reduced O +
phospho O -
- O -
Smad2 O -
/ O -
3 O +
( O -
p O -
- O -
Smad2 O -
/ O -
3 O -
) O +
and O +
increased O +
Smad6 O -
/ O -
7 O +
protein O +
levels O +
in O +
the O +
miR-106b O +
stably O +
transfected O +
cell O +
line O -
. O -

Nuclear O +
factor O +
TDP-43 O +
can O +
affect O +
selected O +
microRNA O +
levels O -
. O -

TDP-43 O +
has O +
recently O +
been O +
described O +
as O +
the O +
major O +
component O +
of O +
the O +
inclusions O +
found O +
in O +
the O +
brain O +
of O +
patients O +
with O +
a O +
variety O +
of O +
neurodegenerative B-Disease +
diseases L-Disease -
, O +
such O +
as O +
frontotemporal B-Disease +
lobar I-Disease +
degeneration L-Disease +
and O +
amyotrophic B-Disease +
lateral I-Disease +
sclerosis L-Disease -
. O -

Apart O +
from O +
its O +
involvement O +
in O +
transcription O -
, O +
splicing O +
and O +
mRNA O +
stability O -
, O +
TDP-43 O +
has O +
also O +
been O +
described O +
as O +
a O +
Drosha O -
- O -
associated O +
protein O -
. O -

TDP-43 O +
is O +
a O +
ubiquitous O +
protein O +
whose O +
specific O +
functions O +
are O +
probably O +
crucial O +
to O +
establishing O +
its O +
pathogenic O +
role O -
. O -

Here O +
we O +
report O +
for O +
the O +
first O +
time O +
which O +
changes O +
occur O +
in O +
the O +
total O +
miRNA O +
population O +
following O +
TDP-43 O +
knockdown O +
in O +
culture O +
cells O -
. O -

However O -
, O +
our O +
knowledge O +
of O +
the O +
role O +
of O +
TDP-43 O +
in O +
the O +
microRNA O +
( O -
miRNA O -
) O +
synthesis O +
pathway O +
is O +
limited O +
to O +
the O +
association O +
mentioned O +
above O -
. O -

Interestingly O -
, O +
both O +
miRNAs O +
are O +
capable O +
of O +
binding O +
directly O +
to O +
TDP-43 O +
in O +
different O +
positions O -
: O +
within O +
the O +
miRNA O +
sequence O +
itself O +
( O -
let-7b O -
) O +
or O +
in O +
the O +
hairpin O +
precursor O +
( O -
miR-663 O -
) O -
. O -

In O +
particular O -
, O +
we O +
have O +
observed O +
that O +
let-7b O +
and O +
miR-663 O +
expression O +
levels O +
are O +
down- O +
and O +
upregulated O -
, O +
respectively O -
. O -

Using O +
microarray O +
data O +
and O +
real O -
- O -
time O +
PCR O +
we O +
have O +
also O +
identified O +
several O +
candidate O +
transcripts O +
whose O +
expression O +
levels O +
are O +
selectively O +
affected O +
by O +
these O +
TDP-43-miRNA O +
interactions O -
. O -

CONCLUSIONS O -
: O +
These O +
results O +
demonstrate O +
that O +
tissue O -
- O -
specific O +
miRNAs O +
may O +
serve O +
as O +
diagnostically O +
sensitive O +
plasma O +
biomarkers O +
of O +
tissue B-Disease +
injury L-Disease -
. O -

The O +
miR-124 O +
concentration O +
increased O +
in O +
the O +
plasma O +
of O +
rats O +
8 O +
h O +
after O +
surgery O +
to O +
produce O +
brain B-Disease +
injury L-Disease +
and O +
peaked O +
at O +
24 O +
h O -
, O +
while O +
the O +
miR-122 O +
and O +
miR-133a O +
concentrations O +
remained O +
at O +
baseline O +
values O -
. O -

Furthermore O -
, O +
miR-122 O +
exhibited O +
a O +
diagnostic O +
sensitivity O +
superior O +
to O +
that O +
of O +
ALT O +
when O +
the O +
results O +
were O +
correlated O +
to O +
the O +
liver O +
histopathologic O +
results O -
. O -

Plasma O +
MicroRNAs O +
as O +
sensitive O +
and O +
specific O +
biomarkers O +
of O +
tissue B-Disease +
injury L-Disease -
. O -

BACKGROUND O -
: O +
MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O -
, O +
small O +
noncoding O +
RNAs O -
. O -

Because O +
of O +
their O +
size O -
, O +
abundance O -
, O +
tissue O +
specificity O -
, O +
and O +
relative O +
stability O +
in O +
plasma O -
, O +
miRNAs O +
hold O +
promise O +
as O +
unique O +
accessible O +
biomarkers O +
to O +
monitor O +
tissue B-Disease +
injury L-Disease -
. O -

METHODS O -
: O +
We O +
investigated O +
the O +
use O +
of O +
liver- O -
, O +
muscle- O +
and O +
brain O -
- O -
specific O +
miRNAs O +
as O +
circulating O +
biomarkers O +
of O +
tissue B-Disease +
injury L-Disease -
. O -

We O +
used O +
a O +
highly O +
sensitive O +
quantitative O +
PCR O +
assay O +
to O +
measure O +
specific O +
miRNAs O +
( O -
miR-122 O -
, O +
miR-133a O -
, O +
and O +
miR-124 O -
) O +
in O +
plasma O +
samples O +
from O +
rats O +
treated O +
with O +
liver O +
or O +
muscle O +
toxicants O +
and O +
from O +
a O +
rat O +
surgical O +
model O +
of O +
stroke U-Disease -
. O -

RESULTS O -
: O +
We O +
observed O +
increases O +
in O +
plasma O +
concentrations O +
of O +
miR-122 O -
, O +
miR-133a O -
, O +
and O +
miR-124 O +
corresponding O +
to O +
injuries B-Disease +
in I-Disease +
liver L-Disease -
, O +
muscle O -
, O +
and O +
brain O -
, O +
respectively O -
. O -

miR-122 O +
and O +
miR-133a O +
illustrated O +
specificity O +
for O +
liver O +
and O +
muscle O +
toxicity O -
, O +
respectively O -
, O +
because O +
they O +
were O +
not O +
detectable O +
in O +
the O +
plasma O +
of O +
animals O +
with O +
toxicity O +
to O +
the O +
other O +
organ O -
. O -

This O +
result O +
contrasted O +
with O +
the O +
results O +
for O +
alanine O +
aminotransferase O +
( O -
ALT O -
) O +
and O +
aspartate O +
aminotransferase O -
, O +
which O +
were O +
both O +
increased O +
with O +
either O +
organ O +
toxicity O -
. O -

Meanwhile O -
, O +
3NP O +
rats O +
showed O +
dynamic O +
changes O +
in O +
the O +
miRNA O +
profiles O +
during O +
disease O +
development O +
and O +
a O +
few O +
miRNAs O +
with O +
altered O +
expression O -
. O -

In O +
10-week O -
- O -
old O +
R6 O -
/ O -
2 O +
mice O -
, O +
downregulation O +
was O +
dominant O +
in O +
the O +
miRNA O +
expressions O +
and O +
the O +
level O +
of O +
Drosha O +
decreased O +
concomitantly O -
. O -

Nine O +
miRNAs O +
( O -
miR-22 O -
, O +
miR-29c O -
, O +
miR-128 O -
, O +
miR-132 O -
, O +
miR-138 O -
, O +
miR-218 O -
, O +
miR-222 O -
, O +
miR-344 O -
, O +
and O +
miR-674 O -
* O -
) O +
were O +
commonly O +
down O -
- O -
regulated O +
in O +
both O +
the O +
12-month O -
- O -
old O +
YAC128 O +
and O +
10-week O -
- O -
old O +
R6 O -
/ O -
2 O +
mice O -
. O -

Concomitantly O -
, O +
the O +
expressions O +
of O +
Drosha O -
- O -
DGCR8 O -
, O +
Exportin-5 O -
, O +
and O +
Dcp1 O +
were O +
increased O +
at O +
5months O -
, O +
and O +
the O +
expression O +
of O +
Dicer O +
was O +
decreased O +
at O +
12 O +
months O -
. O -

YAC128 O +
mice O +
showed O +
upregulation O -
- O -
dominant O +
miRNA O +
expressions O +
at O +
5 O +
months O +
and O +
downregulation O -
- O -
dominant O +
expressions O +
at O +
12 O +
months O -
. O -

After O +
characterizing O +
the O +
phenotypes O +
by O +
behavioral O +
tests O +
and O +
histological O +
analyses O -
, O +
we O +
profiled O +
striatal O +
miRNAs O +
using O +
a O +
miRNA O +
microarray O +
and O +
we O +
measured O +
the O +
key O +
molecules O +
involved O +
in O +
miRNA O +
biogenesis O +
and O +
function O -
. O -

Here O -
, O +
we O +
analyzed O +
the O +
miRNA O +
expression O +
and O +
miRNA O +
regulators O +
in O +
two O +
transgenic O +
models O +
of O +
HD U-Disease -
, O +
YAC128 O +
and O +
R6 O -
/ O -
2 O +
mice O -
, O +
and O +
in O +
a O +
3-nitropropionic O +
acid O +
( O -
3NP O -
) O -
-induced O +
striatal O +
degeneration O +
rat O +
model O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
RNA O +
molecules O +
regulating O +
gene O +
expression O -
, O +
and O +
are O +
implicated O +
in O +
a O +
variety O +
of O +
diseases O +
including O +
HD U-Disease -
. O +
However O -
, O +
the O +
profiles O +
and O +
regulation O +
of O +
miRNAs O +
in O +
HD U-Disease +
are O +
not O +
fully O +
understood O -
. O -

Huntington B-Disease -
's I-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
is O +
a O +
genetic O +
neurodegenerative B-Disease +
disease L-Disease +
caused O +
by O +
abnormal O +
CAG O +
expansion O -
. O -

Altered O +
microRNA O +
regulation O +
in O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
models O -
. O -

This O +
information O +
should O +
aid O +
in O +
future O +
studies O +
on O +
therapeutic O +
application O +
of O +
miRNAs O +
in O +
HD U-Disease -
. O -

Our O +
results O +
show O +
that O +
transgenic O +
HD U-Disease +
mice O +
have O +
abnormal O +
miRNA O +
biogenesis O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
of O +
miRNA O +
profiles O +
in O +
A. O +
cantonensis O -
, O +
which O +
may O +
represent O +
a O +
new O +
platform O +
for O +
studying O +
regulation O +
of O +
genes O +
and O +
their O +
networks O +
in O +
A. O +
cantonensis O -
. O -

Nucleotide O +
bias O +
analysis O +
showed O +
that O +
uracil O +
was O +
the O +
prominent O +
nucleotide O -
, O +
particularly O +
at O +
positions O +
of O +
1 O -
, O +
10 O -
, O +
14 O -
, O +
17 O +
and O +
22 O -
, O +
approximately O +
at O +
the O +
beginning O -
, O +
middle O +
and O +
the O +
end O +
of O +
the O +
conserved O +
miRNAs O -
. O -

No O +
new O +
miRNA O +
sequence O +
was O +
found O -
. O -

A O +
total O +
of O +
8861,260 O +
and O +
10,957,957 O +
high O +
quality O +
reads O +
with O +
20 O +
and O +
23 O +
conserved O +
miRNAs O +
were O +
obtained O +
in O +
females O +
and O +
males O -
, O +
respectively O -
. O -

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
and O +
characterize O +
miRNAs O +
of O +
female O +
and O +
male O +
adults O +
of O +
A. O +
cantonensis O +
by O +
Solexa O +
deep O +
sequencing O -
. O -

They O +
have O +
been O +
identified O +
in O +
a O +
diverse O +
range O +
of O +
organisms O -
. O -

microRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
small O +
non O -
- O -
coding O +
RNAs O +
that O +
play O +
crucial O +
roles O +
in O +
gene O +
expression O +
regulation O -
, O +
cellular O +
function O +
and O +
defense O -
, O +
homeostasis O +
and O +
pathogenesis O -
. O -

Angiostrongylus O +
cantonensis O +
causes O +
eosinophilic B-Disease +
meningitis L-Disease +
and O +
eosinophilic B-Disease +
pleocytosis L-Disease +
in O +
humans O +
and O +
is O +
of O +
significant O +
socio O -
- O -
economic O +
importance O +
globally O -
. O -

Angiostrongylus O +
cantonensis O -
: O +
Identification O +
and O +
characterization O +
of O +
microRNAs O +
in O +
male O +
and O +
female O +
adults O -
. O -

However O -
, O +
none O +
of O +
these O +
individuals O +
reported O +
here O +
have O +
epilepsy U-Disease -
, O +
although O +
two O +
have O +
an O +
abnormal O +
EEG O -
. O -

CONCLUSIONS O -
: O +
The O +
phenotype O +
of O +
chromosome O +
15q13.2q13.3 O +
BP4-BP5 O +
microdeletion O -
/ O -
duplication O +
syndrome O +
may O +
include O +
features O +
of O +
autism B-Disease +
spectrum I-Disease +
disorder L-Disease -
, O +
a O +
variety O +
of O +
neuropsychiatric B-Disease +
disorders L-Disease -
, O +
and O +
cognitive B-Disease +
impairment L-Disease -
. O -

Recognition O +
of O +
this O +
broader O +
phenotype O +
has O +
implications O +
for O +
clinical O +
diagnostic O +
testing O +
and O +
efforts O +
to O +
understand O +
the O +
underlying O +
aetiology O +
of O +
this O +
syndrome O -
. O -

PATIENTS O -
: O +
DNA O +
samples O +
from O +
1445 O +
unrelated O +
patients O +
submitted O +
consecutively O +
for O +
clinical O +
array O +
comparative O +
genomic O +
hybridisation O +
( O -
CGH O -
) O +
testing O +
at O +
Children O -
's O +
Hospital O +
Boston O +
and O +
DNA O +
samples O +
from O +
1441 O +
individuals O +
with O +
autism U-Disease +
from O +
751 O +
families O +
in O +
the O +
Autism U-Disease +
Genetic O +
Resource O +
Exchange O +
( O -
AGRE O -
) O +
repository O -
. O -

RESULTS O -
: O +
We O +
report O +
the O +
clinical O +
features O +
of O +
five O +
patients O +
with O +
a O +
BP4-BP5 O +
deletion O -
, O +
three O +
with O +
a O +
BP4-BP5 O +
duplication O -
, O +
and O +
two O +
with O +
an O +
overlapping O +
but O +
smaller O +
duplication O +
identified O +
by O +
whole O +
genome O +
high O +
resolution O +
oligonucleotide O +
array O +
CGH O -
. O -

Microdeletion O -
/ O -
duplication O +
at O +
15q13.2q13.3 O +
among O +
individuals O +
with O +
features O +
of O +
autism U-Disease +
and O +
other O +
neuropsychiatric B-Disease +
disorders L-Disease -
. O -

BACKGROUND O -
: O +
Segmental O +
duplications O +
at O +
breakpoints O +
( O -
BP4-BP5 O -
) O +
of O +
chromosome O +
15q13.2q13.3 O +
mediate O +
a O +
recurrent O +
genomic O +
imbalance O +
syndrome O +
associated O +
with O +
mental B-Disease +
retardation L-Disease -
, O +
epilepsy U-Disease -
, O +
and/or O +
electroencephalogram B-Disease +
( I-Disease -
EEG I-Disease -
) I-Disease +
abnormalities L-Disease -
. O -

BP4-BP5 O +
covers O +
approximately O +
1.5 O +
Mb O +
( O -
chr15:28.719 O -
- O -
30.298 O +
Mb O -
) O +
and O +
includes O +
six O +
reference O +
genes O +
and O +
1 O +
miRNA O +
gene O -
, O +
while O +
the O +
smaller O +
duplications O +
cover O +
approximately O +
500 O +
kb O +
( O -
chr15:28.902 O -
- O -
29.404 O +
Mb O -
) O +
and O +
contain O +
three O +
reference O +
genes O +
and O +
one O +
miRNA O +
gene O -
. O -

Cognitive B-Disease +
impairment L-Disease +
varied O +
from O +
moderate O +
mental B-Disease +
retardation L-Disease +
to O +
normal O +
IQ O +
with O +
learning B-Disease +
disability L-Disease -
. O -

These O +
BP4-BP5 O +
deletion O +
cases O +
exhibit O +
minor O +
dysmorphic O +
features O -
, O +
significant O +
expressive O +
language O +
deficits O -
, O +
and O +
a O +
spectrum O +
of O +
neuropsychiatric B-Disease +
impairments L-Disease +
that O +
include O +
autism B-Disease +
spectrum I-Disease +
disorder L-Disease -
, O +
attention B-Disease +
deficit I-Disease +
hyperactivity I-Disease +
disorder L-Disease -
, O +
anxiety B-Disease +
disorder L-Disease -
, O +
and O +
mood B-Disease +
disorder L-Disease -
. O -

The O +
BP4-BP5 O +
deletion O +
and O +
duplication O +
events O +
span O +
CHRNA7 O -
, O +
a O +
candidate O +
gene O +
for O +
seizures U-Disease -
. O -

The O +
KIAA0226 O +
gene O +
encodes O +
a O +
protein O +
that O +
we O +
named O +
rundataxin O -
, O +
with O +
two O +
conserved O +
domains O -
: O +
an O +
N O -
- O -
terminal O +
RUN O +
domain O +
and O +
a O +
C O -
- O -
terminal O +
domain O +
containing O +
a O +
diacylglycerol O +
binding O -
- O -
like O +
motif O -
. O -

Mutation O +
screening O +
of O +
all O +
coding O +
sequences O +
revealed O +
a O +
single O +
nucleotide O +
deletion O -
, O +
2927delC O -
, O +
in O +
exon O +
19 O +
of O +
the O +
KIAA0226 O +
gene O -
, O +
which O +
results O +
in O +
a O +
frame O +
shift O +
of O +
the O +
C O -
- O -
terminal O +
domain O +
( O -
p O -
. O -
Ala943ValfsX146 O -
) O -
. O -

The O +
rundataxin O +
pathway O +
appears O +
therefore O +
distinct O +
from O +
the O +
ataxia U-Disease +
pathways O +
involving O +
deficiency O +
in O +
mitochondrial O +
or O +
nuclear O +
proteins O +
and O +
broadens O +
the O +
range O +
of O +
mechanisms O +
leading O +
to O +
recessive O +
ataxias U-Disease -
. O -

The O +
closest O +
paralogue O +
of O +
rundataxin O -
, O +
the O +
plekstrin O +
homology O +
domain O +
family O +
member O +
M1 O -
, O +
has O +
been O +
shown O +
to O +
colocalize O +
with O +
Rab7 O -
, O +
a O +
small O +
GTPase O +
associated O +
with O +
late O +
endosomes O -
/ O -
lysosomes O -
, O +
suggesting O +
that O +
rundataxin O +
may O +
also O +
be O +
associated O +
with O +
vesicular O +
trafficking O +
and O +
signalling O +
pathways O +
through O +
its O +
RUN O +
and O +
diacylglycerol O +
binding O -
- O -
like O +
domains O -
. O -

The O +
three O +
patients O +
presented O +
with O +
childhood O +
onset O +
gait O +
and O +
limb O +
ataxia U-Disease -
, O +
dysarthria U-Disease +
and O +
had O +
limited O +
walking O +
without O +
aid O +
into O +
their O +
teenage O +
years O -
. O -

We O +
have O +
identified O +
a O +
novel O +
form O +
of O +
recessive O +
ataxia U-Disease +
that O +
segregates O +
in O +
three O +
children O +
of O +
a O +
large O +
consanguineous O +
Saudi O +
Arabian O +
family O -
. O -

Linkage O +
studies O +
allowed O +
us O +
to O +
identify O +
a O +
single O +
locus O +
that O +
segregated O +
with O +
the O +
disease O +
on O +
chromosome O +
3q28-qter O -
. O -

Two O +
patients O +
developed O +
epilepsy U-Disease +
at O +
7 O +
months O +
without O +
relapse O +
after O +
treatment O -
, O +
and O +
mental B-Disease +
retardation L-Disease -
. O -

Rundataxin O -
, O +
a O +
novel O +
protein O +
with O +
RUN O +
and O +
diacylglycerol O +
binding O +
domains O -
, O +
is O +
mutant O +
in O +
a O +
new O +
recessive O +
ataxia U-Disease -
. O -

A O +
novel O +
microRNA O +
and O +
transcription O +
factor O +
mediated O +
regulatory O +
network O +
in O +
schizophrenia U-Disease -
. O -

Previous O +
studies O +
have O +
suggested O +
that O +
changes O +
in O +
gene O +
expression O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
etiology O +
of O +
schizophrenia U-Disease -
, O +
and O +
that O +
microRNAs O +
( O -
miRNAs O -
) O +
and O +
transcription O +
factors O +
( O -
TFs O -
) O +
are O +
primary O +
regulators O +
of O +
this O +
gene O +
expression O -
. O -

BACKGROUND O -
: O +
Schizophrenia U-Disease +
is O +
a O +
complex O +
brain B-Disease +
disorder L-Disease +
with O +
molecular O +
mechanisms O +
that O +
have O +
yet O +
to O +
be O +
elucidated O -
. O -

We O +
hypothesized O +
that O +
miRNAs O +
and O +
TFs O +
might O +
play O +
combinatory O +
regulatory O +
roles O +
for O +
schizophrenia U-Disease +
genes O +
and O -
, O +
thus O -
, O +
explored O +
miRNA O -
- O -
TF O +
regulatory O +
networks O +
in O +
schizophrenia U-Disease -
. O -

So O +
far O -
, O +
several O +
miRNA O -
- O -
TF O +
mediated O +
regulatory O +
modules O +
have O +
been O +
verified O -
. O -

Our O +
evaluation O +
revealed O +
that O +
these O +
observed O +
FFLs O +
were O +
significantly O +
enriched O +
in O +
schizophrenia U-Disease +
genes O -
. O -

RESULTS O -
: O +
We O +
identified O +
32 O +
feed O -
- O -
forward O +
loops O +
( O -
FFLs O -
) O +
among O +
our O +
compiled O +
schizophrenia U-Disease -
- O -
related O +
miRNAs O -
, O +
TFs O +
and O +
genes O -
. O -

By O +
converging O +
the O +
FFLs O +
and O +
mutual O +
feedback O +
loops O -
, O +
we O +
constructed O +
a O +
novel O +
miRNA O -
- O -
TF O +
regulatory O +
network O +
for O +
schizophrenia U-Disease -
. O -

Our O +
analysis O +
revealed O +
EGR3 O +
and O +
hsa O -
- O -
miR-195 O +
were O +
core O +
regulators O +
in O +
this O +
regulatory O +
network O -
. O -

We O +
next O +
proposed O +
a O +
model O +
highlighting O +
EGR3 O +
and O +
miRNAs O +
involved O +
in O +
signaling O +
pathways O +
and O +
regulatory O +
networks O +
in O +
the O +
nervous O +
system O -
. O -

It O +
represents O +
the O +
first O +
investigation O +
of O +
a O +
miRNA O -
- O -
TF O +
regulatory O +
network O +
for O +
a O +
complex O +
disease O -
, O +
as O +
demonstrated O +
in O +
schizophrenia U-Disease -
. O -

CONCLUSIONS O -
: O +
This O +
study O +
provides O +
many O +
insights O +
on O +
the O +
regulatory O +
mechanisms O +
of O +
genes O +
involved O +
in O +
schizophrenia U-Disease -
. O -

Finally O -
, O +
we O +
suggested O +
several O +
single O +
nucleotide O +
polymorphisms O +
( O -
SNPs O -
) O +
located O +
on O +
miRNAs O -
, O +
their O +
target O +
sites O -
, O +
and O +
TFBSs O -
, O +
which O +
may O +
have O +
an O +
effect O +
in O +
schizophrenia U-Disease +
gene O +
regulation O -
. O -

MicroRNA O +
expression O +
in O +
ACTH O -
- O -
producing O +
pituitary B-Disease +
tumors L-Disease -
: O +
up O -
- O -
regulation O +
of O +
microRNA-122 O +
and O +
-493 O +
in O +
pituitary B-Disease +
carcinomas L-Disease -
. O -

Real O -
- O -
time O +
RT O -
- O -
PCR O +
and O +
in O +
situ O +
hybridization O +
were O +
used O +
to O +
confirm O +
and O +
independently O +
validate O +
miRNAs O +
that O +
were O +
significantly O +
up O -
- O -
regulated O +
or O +
down O -
- O -
regulated O +
between O +
the O +
pituitary O +
tissues O -
. O -

We O +
used O +
miRNA O +
profiling O +
with O +
1,145 O +
probes O +
to O +
study O +
miRNA O +
expression O +
in O +
normal O +
anterior O +
pituitary O +
( O -
6 O +
cases O -
) O -
, O +
adrenocorticotropin O +
( O -
ACTH O -
) O -
-producing O +
adenomas U-Disease +
( O -
8 O +
cases O -
) O -
, O +
and O +
ACTH O -
- O -
producing O +
pituitary B-Disease +
carcinomas L-Disease +
( O -
two O +
cases O -
) O -
. O -

The O +
expression O +
of O +
miRNAs O +
in O +
pituitary B-Disease +
carcinomas L-Disease +
has O +
not O +
been O +
previously O +
examined O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
involved O +
in O +
cell O +
proliferation O -
, O +
differentiation O -
, O +
and O +
apoptosis O -
, O +
and O +
can O +
function O +
as O +
tumor O +
suppressor O +
genes O +
or O +
oncogenes O -
. O -

MiRNA-493 O +
was O +
also O +
up O -
- O -
regulated O +
in O +
carcinomas U-Disease +
compared O +
to O +
ACTH O +
adenomas U-Disease -
. O -

Analysis O +
of O +
genes O +
that O +
miRNA-493 O +
interacts O +
with O +
included O +
LGALS3 O +
and O +
RUNX2 O +
( O +
http://microrna.sanger.ac.uk O +
) O +
both O +
of O +
which O +
have O +
been O +
shown O +
to O +
have O +
roles O +
in O +
pituitary B-Disease +
tumor L-Disease +
cell O +
growth O -
. O -

There O +
were O +
more O +
miRNAs O +
up- O +
( O -
188 O -
) O +
or O +
down O -
- O -
regulated O +
( O -
160 O -
) O +
between O +
adenomas U-Disease +
and O +
normal O +
pituitaries O +
compared O +
to O +
carcinomas U-Disease +
and O +
normal O +
pituitaries O +
( O -
92 O +
up- O +
and O +
91 O +
down O -
- O -
regulated O -
) O +
or O +
between O +
carcinomas U-Disease +
and O +
adenomas U-Disease +
( O -
46 O +
up- O +
and O +
52 O +
down O -
- O -
regulated O -
) O -
. O -

Both O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
and O +
in O +
situ O +
hybridization O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
miRNA-122 O +
between O +
pituitary B-Disease +
carcinomas L-Disease +
and O +
adenomas U-Disease -
. O -

These O +
results O +
provide O +
information O +
about O +
marker O +
miRNAs O +
that O +
may O +
lead O +
to O +
further O +
insights O +
into O +
the O +
regulation O +
of O +
pituitary B-Disease +
tumor L-Disease +
growth O +
and O +
development O -
. O -

Vascular B-Disease +
injury L-Disease +
triggers O +
dedifferentiation O +
and O +
cytoskeletal O +
remodeling O +
of O +
smooth O +
muscle O +
cells O +
( O -
SMCs O -
) O -
, O +
culminating O +
in O +
vessel B-Disease +
occlusion L-Disease -
. O -

MicroRNAs O +
miR-143 O +
and O +
miR-145 O +
modulate O +
cytoskeletal O +
dynamics O +
and O +
responsiveness O +
of O +
smooth O +
muscle O +
cells O +
to O +
injury U-Disease -
. O -

Serum O +
response O +
factor O +
( O -
SRF O -
) O +
and O +
its O +
coactivator O -
, O +
myocardin O -
, O +
play O +
a O +
central O +
role O +
in O +
the O +
control O +
of O +
smooth O +
muscle O +
phenotypes O +
by O +
regulating O +
the O +
expression O +
of O +
cytoskeletal O +
genes O -
. O -

We O +
show O +
that O +
SRF O +
and O +
myocardin O +
regulate O +
a O +
cardiovascular O -
- O -
specific O +
microRNA O +
( O -
miRNA O -
) O +
cluster O +
encoding O +
miR-143 O +
and O +
miR-145 O -
. O -

To O +
assess O +
the O +
functions O +
of O +
these O +
miRNAs O +
in O +
vivo O -
, O +
we O +
systematically O +
deleted O +
them O +
singly O +
and O +
in O +
combination O +
in O +
mice O -
. O -

Mice O +
lacking O +
both O +
miR-143 O +
and O +
miR-145 O +
are O +
viable O +
and O +
do O +
not O +
display O +
overt O +
abnormalities O +
in O +
smooth O +
muscle O +
differentiation O -
, O +
although O +
they O +
show O +
a O +
significant O +
reduction O +
in O +
blood O +
pressure O +
due O +
to O +
reduced O +
vascular O +
tone O -
. O -

Remarkably O -
, O +
however O -
, O +
neointima B-Disease +
formation L-Disease +
in O +
response O +
to O +
vascular B-Disease +
injury L-Disease +
is O +
profoundly O +
impeded O +
in O +
mice O +
lacking O +
these O +
miRNAs O -
, O +
due O +
to O +
disarray O +
of O +
actin O +
stress O +
fibers O +
and O +
diminished O +
migratory O +
activity O +
of O +
SMCs O -
. O -

These O +
abnormalities O +
reflect O +
the O +
regulation O +
of O +
a O +
cadre O +
of O +
modulators O +
of O +
SRF O +
activity O +
and O +
actin O +
dynamics O +
by O +
miR-143 O +
and O +
miR-145 O -
. O -

Thus O -
, O +
miR-143 O +
and O +
miR-145 O +
act O +
as O +
integral O +
components O +
of O +
the O +
regulatory O +
network O +
whereby O +
SRF O +
controls O +
cytoskeletal O +
remodeling O +
and O +
phenotypic O +
switching O +
of O +
SMCs O +
during O +
vascular B-Disease +
disease L-Disease -
. O -

Plasma O +
concentrations O +
of O +
miR-124 O +
were O +
significantly O +
elevated O +
at O +
6 O +
h O -
, O +
and O +
remained O +
elevated O +
at O +
48 O +
h O +
after O +
MCAO U-Disease +
introduction O -
. O -

Thus O -
, O +
plasma O +
concentration O +
of O +
miR-124 O +
provides O +
a O +
promising O +
candidate O +
biomarker O +
for O +
early O +
detection O +
of O +
cerebral B-Disease +
infarction L-Disease -
. O -

In O +
this O +
study O -
, O +
miRNA O +
array O +
analysis O +
in O +
various O +
tissues O +
showed O +
that O +
miR-124 O +
is O +
almost O +
exclusively O +
expressed O +
in O +
the O +
central O +
nervous O +
system O +
and O +
neuronal O +
cells O -
, O +
suggesting O +
that O +
it O +
might O +
be O +
useful O +
as O +
a O +
potential O +
biomarker O +
for O +
neurological B-Disease +
diseases L-Disease -
. O -

We O +
examined O +
whether O +
plasma O +
concentrations O +
of O +
brain O -
- O -
specific O +
miRNA O +
can O +
serve O +
as O +
a O +
biomarker O +
for O +
cerebral B-Disease +
infarction L-Disease -
, O +
where O +
the O +
cerebral B-Disease +
infarction L-Disease +
was O +
modeled O +
by O +
middle B-Disease +
cerebral I-Disease +
artery I-Disease +
occlusion L-Disease +
( O -
MCAO U-Disease -
) O +
in O +
the O +
rat O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
small O +
RNAs O +
that O +
play O +
an O +
important O +
role O +
in O +
various O +
physiological O +
processes O +
by O +
downregulating O +
target O +
genes O -
. O -

Recently O -
, O +
plasma O +
miRNAs O +
have O +
been O +
investigated O +
as O +
biomarkers O +
for O +
various O +
diseases O -
. O -

Plasma O +
miR-124 O +
as O +
a O +
biomarker O +
for O +
cerebral B-Disease +
infarction L-Disease -
. O -

METHODS O -
: O +
Surgical O +
outcome O +
data O +
were O +
prospectively O +
collected O +
for O +
2 O +
to O +
11 O +
years O +
in O +
161 O +
consecutive O +
patients O +
with O +
MTLE U-Disease -
/ O +
HS U-Disease -
. O +
Eighty O +
patients O +
underwent O +
an O +
ATL O +
and O +
81 O +
an O +
SA O -
. O +
Seizure U-Disease +
control O +
achieved O +
with O +
each O +
technique O +
was O +
compared O +
using O +
the O +
Engel O +
classification O +
scheme O -
. O -

Postoperative O +
memory O +
testing O +
was O +
performed O +
in O +
86 O +
patients O +
( O -
53 O -
% O -
) O -
. O -

At O +
the O +
last O +
follow O +
up O -
, O +
72 O -
% O +
of O +
the O +
patients O +
who O +
had O +
undergone O +
an O +
ATL O +
( O -
mean O +
follow O +
up O +
6.7 O +
years O -
) O +
and O +
71 O -
% O +
of O +
those O +
who O +
had O +
undergone O +
an O +
SA O +
( O -
mean O +
follow O +
up O +
4.5 O +
years O -
) O +
were O +
seizure U-Disease +
free O +
( O -
Engle O +
Class O +
IA O -
) O -
. O -

Estimated O +
survival O +
in O +
patients O +
in O +
Engel O +
Classes O +
I O -
, O +
IA O -
, O +
and O +
I O +
and O +
II O +
combined O +
did O +
not O +
differ O +
between O +
the O +
two O +
surgical O +
techniques O -
. O -

Preoperatively O -
, O +
58 O -
% O +
of O +
the O +
patients O +
had O +
verbal O +
memory O +
scores O +
one O +
standard O +
deviation O +
( O -
SD O -
) O +
below O +
the O +
normal O +
mean O -
. O -

One O +
third O +
of O +
the O +
patients O +
with O +
preoperative O +
scores O +
in O +
the O +
normal O +
range O +
worsened O +
after O +
surgery O -
, O +
although O +
this O +
outcome O +
was O +
not O +
related O +
to O +
the O +
surgical O +
technique O -
. O -

In O +
contrast O -
, O +
one O +
third O +
of O +
those O +
whose O +
preoperative O +
scores O +
were O +
less O +
than O +
-1 O +
SD O +
experienced O +
improvement O +
after O +
surgery O -
. O -

Nine O +
( O -
18 O -
% O -
) O +
of O +
the O +
50 O +
patients O +
whose O +
left O +
side O +
had O +
been O +
surgically O +
treated O +
improved O +
their O +
verbal O +
memory O +
scores O +
by O +
more O +
than O +
one O +
SD O -
. O +
Seven O +
( O -
78 O -
% O -
) O +
of O +
these O +
nine O +
underwent O +
an O +
SA O +
( O -
p O +
= O +
0.05 O -
) O -
. O -

OBJECT O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
seizure U-Disease +
and O +
memory O +
outcome O +
in O +
patients O +
with O +
medically O +
refractory O +
mesial B-Disease +
temporal I-Disease +
lobe I-Disease +
epilepsy L-Disease +
due O +
to O +
hippocampal B-Disease +
sclerosis L-Disease +
( O -
MTLE U-Disease -
/ O -
HS U-Disease -
) O +
treated O +
using O +
an O +
anterior O +
temporal O +
lobectomy O +
( O -
ATL O -
) O +
or O +
a O +
selective O +
amygdalohippocampectomy O +
( O -
SA O -
) O -
. O -

Seizure U-Disease +
and O +
memory O +
outcome O +
following O +
temporal O +
lobe O +
surgery O -
: O +
selective O +
compared O +
with O +
nonselective O +
approaches O +
for O +
hippocampal B-Disease +
sclerosis L-Disease -
. O -

Preliminary O +
data O +
suggest O +
that O +
postoperative O +
verbal O +
memory O +
scores O +
may O +
improve O +
in O +
patients O +
who O +
undergo O +
selective O +
resection O +
of O +
a O +
sclerotic O +
hippocampus O +
in O +
the O +
dominant O +
temporal O +
lobe O -
. O -

CONCLUSIONS O -
: O +
Both O +
ATL O +
and O +
SA O +
can O +
lead O +
to O +
similar O +
favorable O +
seizure U-Disease +
control O +
in O +
patients O +
with O +
MTLE U-Disease -
/ O -
HS U-Disease -
. O -

These O +
data O +
suggest O +
a O +
role O +
for O +
HSV-1-induced O +
miRNA-146a O +
in O +
the O +
evasion O +
of O +
HSV-1 O +
from O +
the O +
complement O +
system O -
, O +
and O +
the O +
activation O +
of O +
key O +
elements O +
of O +
the O +
arachidonic O +
acid O +
cascade O +
known O +
to O +
contribute O +
to O +
Alzheimer U-Disease -
- O -
type O +
neuropathological O +
change O -
. O -

A O +
known O +
miRNA-146a O +
target O +
in O +
the O +
brain O -
, O +
complement O +
factor O +
H O -
, O +
was O +
downregulated O -
. O -

Expression O +
of O +
cytoplasmic O +
phospholipase O +
A2 O -
, O +
the O +
inducible O +
prostaglandin O +
synthase O +
cyclooxygenase-2 O -
, O +
and O +
the O +
neuroinflammatory O +
cytokine O +
interleukin-1beta O +
were O +
each O +
upregulated O -
. O -

We O +
report O +
that O +
infection U-Disease +
of O +
human O +
primary O +
neural O +
cells O +
with O +
a O +
high O +
phenotypic O +
reactivator O +
HSV-1 O +
( O -
17syn+ O -
) O +
induces O +
upregulation O +
of O +
a O +
brain O -
- O -
enriched O +
microRNA O +
( O -
miRNA O -
) O -
-146a O +
that O +
is O +
associated O +
with O +
proinflammatory O +
signaling O +
in O +
stressed O +
brain O +
cells O +
and O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease -
. O -

Herpes B-Disease +
simplex I-Disease +
virus I-Disease +
type-1 I-Disease +
( I-Disease -
HSV-1 I-Disease -
) I-Disease +
infection L-Disease +
of O +
human O +
brain O +
cells O +
induces O +
changes O +
in O +
gene O +
expression O +
favorable O +
to O +
the O +
propagation O +
of O +
the O +
infecting O +
agent O +
and O +
detrimental O +
to O +
the O +
function O +
of O +
the O +
host O +
cells O -
. O -

HSV-1 B-Disease +
infection L-Disease +
of O +
human O +
brain O +
cells O +
induces O +
miRNA-146a O +
and O +
Alzheimer U-Disease -
- O -
type O +
inflammatory O +
signaling O -
. O -

This O +
study O +
reveals O +
the O +
occurrence O +
of O +
novel O +
mechanisms O +
of O +
HIF O +
regulation O -
, O +
which O +
might O +
contribute O +
to O +
developing O +
novel O +
strategies O +
for O +
therapeutic O +
intervention O +
of O +
HIF O -
- O -
related O +
pathologies O -
, O +
including O +
heart B-Disease +
attack L-Disease -
, O +
cancer U-Disease -
, O +
and O +
stroke U-Disease -
. O -

One O +
remarkable O +
hit O +
was O +
the O +
argonaute O +
1 O +
( O -
ago1 O -
) O +
gene O -
, O +
a O +
central O +
element O +
of O +
the O +
microRNA O +
( O -
miRNA O -
) O +
translational O +
silencing O +
machinery O -
. O -

Further O +
studies O +
confirmed O +
the O +
physiological O +
role O +
of O +
the O +
miRNA O +
machinery O +
in O +
HIF O -
- O -
dependent O +
transcription O -
. O -

After O +
3 O +
rounds O +
of O +
selection O -
, O +
30 O +
genes O +
emerged O +
as O +
critical O +
HIF O +
regulators O +
in O +
hypoxia U-Disease -
, O +
most O +
of O +
which O +
had O +
not O +
been O +
previously O +
associated O +
with O +
HIF O +
biology O -
. O -

The O +
list O +
of O +
genes O +
includes O +
components O +
of O +
chromatin O +
remodeling O +
complexes O -
, O +
transcription O +
elongation O +
factors O -
, O +
and O +
translational O +
regulators O -
. O -

Molecular O +
mechanisms O +
that O +
mediate O +
oxygen O -
- O -
dependent O +
HIF O +
regulation O +
operate O +
at O +
the O +
level O +
of O +
the O +
alpha O +
subunit O -
, O +
controlling O +
protein O +
stability O -
, O +
subcellular O +
localization O -
, O +
and O +
transcriptional O +
coactivator O +
recruitment O -
. O -

We O +
have O +
conducted O +
an O +
unbiased O +
genome O -
- O -
wide O +
RNA O +
interference O +
( O -
RNAi O -
) O +
screen O +
in O +
Drosophila O +
cells O +
aimed O +
to O +
the O +
identification O +
of O +
genes O +
required O +
for O +
HIF O +
activity O -
. O -

Drosophila O +
genome O -
- O -
wide O +
RNAi O +
screen O +
identifies O +
multiple O +
regulators O +
of O +
HIF O -
- O -
dependent O +
transcription O +
in O +
hypoxia U-Disease -
. O -

Hypoxia O -
- O -
inducible O +
factors O +
( O -
HIFs O -
) O +
are O +
a O +
family O +
of O +
evolutionary O +
conserved O +
alpha O -
- O -
beta O +
heterodimeric O +
transcription O +
factors O +
that O +
induce O +
a O +
wide O +
range O +
of O +
genes O +
in O +
response O +
to O +
low O +
oxygen O +
tension O -
. O -

Follow O +
up O +
functional O +
enrichment O +
analysis O +
of O +
these O +
FFLs O +
uncovered O +
some O +
functions O +
important O +
to O +
carcinogenesis O +
but O +
also O +
some O +
unique O +
functions O +
specific O +
to O +
the O +
FFLs O +
we O +
identified O -
. O -

Transcriptional O +
aberrations O +
may O +
play O +
a O +
vital O +
role O +
in O +
the O +
etiology O +
of O +
glioblastoma U-Disease -
, O +
which O +
might O +
be O +
caused O +
by O +
both O +
genomic O +
alterations O +
and O +
other O +
regulation O +
molecules O -
. O -

Illustrating O +
the O +
functions O +
being O +
disturbed O +
during O +
carcinogenesis O +
and O +
how O +
they O +
are O +
deregulated O +
is O +
very O +
important O +
for O +
us O +
to O +
understand O +
its O +
underlying O +
mechanism O -
. O -

We O +
searched O +
glioblastoma U-Disease -
- O -
specific O +
regulatory O +
networks O +
by O +
integrating O +
glioblastoma U-Disease +
related O +
miRNAs O -
, O +
TFs O +
and O +
genes O -
, O +
and O +
identified O +
54 O +
feed O -
- O -
forward O +
loops O +
( O -
FFLs O -
) O -
. O -

In O +
this O +
study O -
, O +
we O +
investigated O +
possible O +
cooperative O +
deregulation O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
and O +
transcription O +
factors O +
( O -
TFs O -
) O +
in O +
glioblastoma U-Disease -
, O +
under O +
the O +
hypothesis O +
that O +
miRNAs O +
and O +
TFs O +
might O +
have O +
a O +
combinational O +
regulatory O +
effect O +
on O +
glioblastoma U-Disease +
genes O -
. O -

Glioblastoma U-Disease +
is O +
the O +
most O +
common O +
and O +
most O +
lethal O +
brain B-Disease +
tumour L-Disease +
in O +
humans O -
. O -

Gene O +
regulation O +
in O +
glioblastoma U-Disease -
: O +
a O +
combinatorial O +
analysis O +
of O +
microRNAs O +
and O +
transcription O +
factors O -
. O -

These O +
data O +
support O +
the O +
hypothesis O +
that O +
patterns O +
of O +
miRNA O +
expression O +
in O +
cortical O +
GM O +
may O +
contribute O +
to O +
AD U-Disease +
pathogenetically O -
, O +
because O +
the O +
aggregate O +
change O +
in O +
miRNA O +
expression O +
observed O +
early O +
in O +
the O +
disease O +
would O +
be O +
predicted O +
to O +
cause O +
profound O +
changes O +
in O +
gene O +
expression O -
. O -

Patterns O +
of O +
microRNA O +
expression O +
in O +
normal O +
and O +
early O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
human O +
temporal O +
cortex O -
: O +
white O +
matter O +
versus O +
gray O +
matter O -
. O -

MicroRNA O +
( O -
miRNA O -
) O +
expression O +
was O +
assessed O +
in O +
human O +
cerebral O +
cortical O +
gray O +
matter O +
( O -
GM O -
) O +
and O +
white O +
matter O +
( O -
WM O -
) O +
in O +
order O +
to O +
provide O +
the O +
first O +
insights O +
into O +
the O +
difference O +
between O +
GM O +
and O +
WM O +
miRNA O +
repertoires O +
across O +
a O +
range O +
of O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O +
pathology O -
. O -

RNA O +
was O +
isolated O +
separately O +
from O +
GM O +
and O +
WM O +
portions O +
of O +
superior O +
and O +
middle O +
temporal O +
cerebral O +
cortex O +
( O -
N O +
= O +
10 O +
elderly O +
females O -
, O +
postmortem O +
interval O +
< O +
4 O +
h O -
) O -
. O -

miRNA O +
profiling O +
experiments O +
were O +
performed O +
using O +
state O -
- O -
of O -
- O -
the O -
- O -
art O +
Exiqon O -
( O -
© O -
) O +
LNA O -
- O -
microarrays O -
. O -

A O +
subset O +
of O +
miRNAs O +
that O +
appeared O +
to O +
be O +
strongly O +
expressed O +
according O +
to O +
the O +
microarrays O +
did O +
not O +
appear O +
to O +
be O +
conventional O +
miRNAs O +
according O +
to O +
Northern O +
blot O +
analyses O -
. O -

Some O +
well O -
- O -
characterized O +
miRNAs O +
were O +
substantially O +
enriched O +
in O +
WM O +
as O +
expected O -
. O -

However O -
, O +
most O +
of O +
the O +
miRNA O +
expression O +
variability O +
that O +
correlated O +
with O +
the O +
presence O +
of O +
early O +
AD U-Disease -
- O -
related O +
pathology O +
was O +
seen O +
in O +
GM O -
. O -

We O +
confirm O +
that O +
downregulation O +
of O +
a O +
set O +
of O +
miRNAs O +
in O +
GM O +
( O -
including O +
several O +
miR-15 O -
/ O -
107 O +
genes O +
and O +
miR-29 O +
paralogs O -
) O +
correlated O +
strongly O +
with O +
the O +
density O +
of O +
diffuse O +
amyloid B-Disease +
plaques L-Disease +
detected O +
in O +
adjacent O +
tissue O -
. O -

A O +
few O +
miRNAs O +
were O +
differentially O +
expressed O +
in O +
WM O -
, O +
including O +
miR-212 O +
that O +
is O +
downregulated O +
in O +
AD U-Disease +
and O +
miR-424 O +
which O +
is O +
upregulated O +
in O +
AD U-Disease -
. O -

The O +
expression O +
of O +
certain O +
miRNAs O +
correlates O +
with O +
other O +
miRNAs O +
across O +
different O +
cases O -
, O +
and O +
particular O +
subsets O +
of O +
miRNAs O +
are O +
coordinately O +
expressed O +
in O +
relation O +
to O +
AD U-Disease -
- O -
related O +
pathology O -
. O -

Leukodystrophy U-Disease +
and O +
gene O +
therapy O +
with O +
a O +
dimmer O +
switch O -
. O -

The O +
authors O +
reviewed O +
the O +
records O +
of O +
nineteen O +
consecutive O +
children O +
with O +
newly O +
diagnosed O +
IIH O +
in O +
order O +
to O +
compare O +
demographic O +
characteristics O -
, O +
clinical O +
pictures O +
and O +
ophthalmologic O +
aspects O +
as O +
optic O +
disc O +
evaluation O +
and O +
visual O +
field O +
evaluation O -
, O +
as O +
well O +
as O +
treatment O +
modalities O +
and O +
follow O +
up O -
. O -

Beside O +
obesity U-Disease +
and O +
female O +
gender O -
, O +
potential O +
alternative O +
risk O +
factors O +
remains O +
to O +
be O +
investigated O -
, O +
which O +
need O +
a O +
good O +
collaboration O +
between O +
neuro O -
- O -
ophthalmologists O +
and O +
pediatric O +
neurologists O -
. O -

Idiopathic B-Disease +
intracranial I-Disease +
hypertension L-Disease +
( O -
IIH U-Disease -
) O +
is O +
a O +
clinical O +
condition O +
characterized O +
by O +
elevated B-Disease +
intracranial I-Disease +
pressure L-Disease +
and O +
absence O +
of O +
clinical O -
, O +
laboratory O +
or O +
radiographic O +
evidence O +
of O +
central B-Disease +
nervous I-Disease +
system I-Disease +
infection L-Disease -
, O +
vascular B-Disease +
malformation L-Disease -
, O +
intracranial O +
space O +
occupying O +
lesion U-Disease +
or O +
hydrocephalus U-Disease -
. O -

In O +
the O +
last O +
years O +
the O +
raising O +
understanding O +
of O +
pediatric O +
IIH O -
, O +
especially O +
concerning O +
its O +
demographics O +
and O +
epidemiology O -
, O +
has O +
brought O +
up O +
to O +
a O +
redefinition O +
of O +
diagnostic O +
criteria O +
and O +
reevaluation O +
of O +
pathogenesis O +
and O +
treatment O -
. O -

Pediatric O +
idiopathic B-Disease +
intracranial I-Disease +
hypertension L-Disease -
: O +
clinical O +
and O +
demographic O +
features O -
. O -

Although O +
microRNAs O +
are O +
expressed O +
extensively O +
in O +
the O +
central O +
nervous O +
system O +
in O +
physiological O +
and O +
pathological O +
conditions O -
, O +
their O +
expression O +
in O +
neurological B-Disease +
disorder L-Disease +
of O +
epilepsy U-Disease +
has O +
not O +
been O +
well O +
characterized O -
. O -

Expression O +
profile O +
of O +
microRNAs O +
in O +
rat O +
hippocampus O +
following O +
lithium O -
- O -
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus L-Disease -
. O -

Rat O +
MicroRNA O +
array O +
and O +
differential O +
analysis O +
had O +
detected O +
19 O +
up O -
- O -
regulated O +
microRNAs O +
and O +
7 O +
down O -
- O -
regulated O +
microRNAs O +
in O +
rat O +
hippocampus O -
, O +
and O +
four O +
randomly O +
selected O +
deregulated O +
microRNAs O +
( O -
microRNA-34a O -
, O +
microRNA-22 O -
, O +
microRNA-125a O -
, O +
microRNA-21 O -
) O +
were O +
confirmed O +
by O +
qRT O -
- O -
PCR O -
, O +
then O +
their O +
expression O +
alterations O +
in O +
rat O +
peripheral O +
blood O +
were O +
analyzed O -
. O -

Here O +
we O +
investigated O +
microRNA O +
expression O +
pattern O +
in O +
post O +
status B-Disease +
epilepticus L-Disease +
rats O +
( O -
24h O +
after O +
status O -
) O -
. O -

Thus O -
, O +
our O +
results O +
have O +
not O +
only O +
characterized O +
the O +
microRNA O +
expression O +
profile O +
in O +
post O +
status B-Disease +
epilepticus L-Disease +
rat O +
hippocampus O +
but O +
also O +
demonstrated O +
that O +
some O +
rat O +
hippocampal O +
microRNAs O +
were O +
probably O +
associated O +
with O +
rat O +
peripheral O +
blood O +
microRNAs O -
. O -

We O +
found O +
that O +
these O +
four O +
deregulated O +
microRNAs O +
were O +
also O +
differentially O +
expressed O +
in O +
rat O +
peripheral O +
blood O -
, O +
and O +
trends O +
for O +
their O +
blood O +
expression O +
alterations O +
were O +
just O +
the O +
same O +
as O +
their O +
counterparts O +
in O +
rat O +
hippocampus O -
. O -

Moreover O -
, O +
targets O +
of O +
these O +
deregulated O +
microRNAs O +
were O +
analyzed O +
using O +
bioinformatics O +
and O +
the O +
identified O +
enriched O +
MAPK O +
pathway O +
and O +
long O -
- O -
term O +
potentiation O +
pathway O +
might O +
have O +
been O +
involved O +
in O +
molecular O +
mechanisms O +
concerning O +
neuronal B-Disease +
death L-Disease -
, O +
inflammation U-Disease +
and O +
epileptogenesis U-Disease -
. O -

Remarks O +
are O +
also O +
provided O +
to O +
point O +
out O +
the O +
unanswered O +
questions O +
and O +
to O +
outline O +
the O +
new O +
directions O +
for O +
the O +
future O +
research O +
of O +
the O +
field O -
. O -

Speculations O +
on O +
the O +
development O +
of O +
miRNAs O +
as O +
potential O +
therapeutic O +
targets O +
are O +
also O +
presented O -
. O -

These O +
small O +
molecules O +
act O +
by O +
repressing O +
the O +
expression O +
of O +
either O +
the O +
proapoptotic O +
or O +
antiapoptotic O +
genes O +
to O +
produce O +
antiapoptotic O +
or O +
proapoptotic O +
effects O -
. O -

Appealing O +
evidence O +
has O +
been O +
accumulating O +
for O +
the O +
involvement O +
of O +
miRNAs O +
in O +
human O +
diseases O +
associated O +
with O +
apoptotic O +
cell O +
death O +
and O +
the O +
potential O +
of O +
miRNAs O +
as O +
novel O +
therapeutic O +
targets O +
for O +
the O +
treatment O +
of O +
the O +
diseases O -
. O -

The O +
importance O +
of O +
miRNAs O +
has O +
steadily O +
gained O +
appreciation O +
and O +
miRNA O +
biology O +
has O +
exploded O +
into O +
a O +
massive O +
swell O +
of O +
interest O +
with O +
enormous O +
range O +
and O +
potential O +
in O +
almost O +
every O +
biological O +
discipline O +
because O +
of O +
their O +
widespread O +
expression O +
and O +
diverse O +
functions O +
in O +
both O +
animals O +
and O +
humans O -
. O -

It O +
has O +
been O +
established O +
that O +
miRNAs O +
are O +
critical O +
regulators O +
of O +
apoptosis O +
of O +
various O +
cell O +
types O -
. O -

Tremendous O +
efforts O +
have O +
been O +
made O +
to O +
improve O +
our O +
understanding O +
of O +
the O +
molecular O +
mechanisms O +
and O +
signaling O +
pathways O +
involved O +
in O +
apoptosistic O +
cell O +
death O -
. O -

Once O +
ignored O +
completely O +
or O +
overlooked O +
as O +
cellular O +
detritus O -
, O +
microRNAs O +
( O -
miRNAs O -
) O +
that O +
were O +
discovered O +
only O +
a O +
decade O +
ago O -
, O +
have O +
recently O +
taken O +
many O +
by O +
surprise O -
. O -

MicroRNA O -
: O +
A O +
matter O +
of O +
life O +
or O +
death O -
. O -

Progressive O +
cell O +
loss O +
due O +
to O +
apoptosis O +
is O +
a O +
pathological O +
hallmark O +
implicated O +
in O +
a O +
wide O +
spectrum O +
of O +
degenerative O +
diseases O +
such O +
as O +
heart B-Disease +
disease L-Disease -
, O +
atherosclerotic O +
arteries O +
and O +
hypertensive U-Disease +
vessels O -
, O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
and O +
other O +
neurodegenerative B-Disease +
disorders L-Disease -
. O -

This O +
editorial O +
aims O +
to O +
convey O +
this O +
message O +
and O +
to O +
boost O +
up O +
the O +
research O +
interest O +
by O +
providing O +
a O +
timely O -
, O +
comprehensive O +
overview O +
on O +
regulation O +
of O +
apoptosis O +
by O +
miRNAs O +
and O +
a O +
synopsis O +
on O +
the O +
pathophysiologic O +
implications O +
of O +
this O +
novel O +
regulatory O +
network O +
based O +
on O +
the O +
currently O +
available O +
data O +
in O +
the O +
literature O -
. O -

It O +
begins O +
with O +
a O +
brief O +
introduction O +
to O +
apoptosis O +
and O +
miRNAs O -
, O +
followed O +
by O +
the O +
description O +
of O +
the O +
fundamental O +
aspects O +
of O +
miRNA O +
biogenesis O +
and O +
action O -
, O +
and O +
the O +
role O +
of O +
miRNAs O +
in O +
regulating O +
apoptosis O +
of O +
cancer U-Disease +
cells O +
and O +
cardiovascular O +
cells O -
. O -

The O +
accurate O +
diagnosis O +
of O +
brain O +
malignancies O +
is O +
essential O +
for O +
selection O +
of O +
proper O +
treatment O -
. O -

A O +
recurring O +
challenge O +
for O +
brain O +
pathologists O +
is O +
to O +
diagnose O +
whether O +
a O +
brain O +
malignancy O +
is O +
a O +
primary B-Disease +
tumor L-Disease +
or O +
a O +
metastasis O +
from O +
some O +
other O +
tissue O -
. O -

MiR-92b O +
and O +
miR-9 O -
/ O -
9 O -
* O +
are O +
specifically O +
expressed O +
in O +
brain O +
primary B-Disease +
tumors L-Disease +
and O +
can O +
be O +
used O +
to O +
differentiate O +
primary O +
from O +
metastatic B-Disease +
brain I-Disease +
tumors L-Disease -
. O -

These O +
microRNAs O +
thus O +
represent O +
excellent O +
biomarkers O +
for O +
brain B-Disease +
primary I-Disease +
tumors L-Disease -
. O -

By O +
considering O +
the O +
expression O +
of O +
only O +
these O +
two O +
microRNAs O -
, O +
it O +
is O +
possible O +
to O +
distinguish O +
between O +
primary O +
and O +
metastatic B-Disease +
brain I-Disease +
tumors L-Disease +
with O +
very O +
high O +
accuracy O -
. O -

Using O +
microRNA O +
expression O +
profiling O -
, O +
we O +
found O +
that O +
hsa O -
- O -
miR-92b O +
and O +
hsa O -
- O -
miR-9 O -
/ O -
hsa O -
- O -
miR-9 O -
* O +
are O +
over O -
- O -
expressed O -
, O +
specifically O +
in O +
brain B-Disease +
primary I-Disease +
tumors L-Disease -
, O +
as O +
compared O +
to O +
primary B-Disease +
tumors L-Disease +
from O +
other O +
tissues O +
and O +
their O +
metastases O +
to O +
the O +
brain O -
. O -

MicroRNAs O +
are O +
a O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNA O +
species O +
that O +
regulate O +
gene O +
expression O -
; O +
many O +
exhibit O +
tissue O -
- O -
specific O +
expression O +
and O +
are O +
misregulated O +
in O +
cancer U-Disease -
. O -

Previous O +
reports O +
have O +
found O +
that O +
hsa O -
- O -
miR-92b O +
and O +
hsa O -
- O -
miR-9 O -
/ O -
hsa O -
- O -
miR-9 O -
* O +
are O +
expressed O +
more O +
strongly O +
in O +
developing O +
neurons O +
and O +
brain O +
than O +
in O +
adult O +
brain O -
. O -

Thus O -
, O +
their O +
specific O +
over O -
- O -
expression O +
in O +
brain B-Disease +
primary I-Disease +
tumors L-Disease +
supports O +
a O +
functional O +
role O +
for O +
these O +
microRNAs O +
or O +
a O +
link O +
between O +
neuronal O +
stem O +
cells O +
and O +
brain O +
tumorigenesis O -
. O -

These O +
results O +
are O +
the O +
first O +
to O +
demonstrate O +
that O +
levels O +
of O +
human O +
APP O +
can O +
be O +
regulated O +
by O +
miRNAs O -
. O -

Over O -
- O -
expression O +
of O +
these O +
miRNAs O -
, O +
but O +
not O +
control O +
miRNAs O -
, O +
results O +
in O +
translational O +
repression O +
of O +
APP O +
mRNA O +
and O +
significantly O +
reduces O +
APP O +
protein O +
levels O -
. O -

Here O +
we O +
test O +
the O +
hypothesis O +
that O +
APP O +
protein O +
levels O +
can O +
be O +
regulated O +
by O +
miRNAs O -
, O +
evolutionarily O +
conserved O +
small O +
noncoding O +
RNA O +
molecules O +
that O +
play O +
an O +
important O +
role O +
in O +
regulating O +
gene O +
expression O -
. O -

Utilizing O +
human O +
cell O +
lines O -
, O +
we O +
demonstrate O +
that O +
miRNAs O +
hsa O -
- O -
mir-106a O +
and O +
hsa O -
- O -
mir-520c O +
bind O +
to O +
their O +
predicted O +
target O +
sequences O +
in O +
the O +
APP O +
3'UTR O +
and O +
negatively O +
regulate O +
reporter O +
gene O +
expression O -
. O -

ABSTRACT O -
: O +
A O +
number O +
of O +
studies O +
have O +
shown O +
that O +
increased O +
APP O +
levels O -
, O +
resulting O +
from O +
either O +
a O +
genomic O +
locus O +
duplication O +
or O +
alteration O +
in O +
APP O +
regulatory O +
sequences O -
, O +
can O +
lead O +
to O +
development O +
of O +
early O -
- O -
onset O +
dementias U-Disease -
, O +
including O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O -
. O -

Therefore O -
, O +
understanding O +
how O +
APP O +
levels O +
are O +
regulated O +
could O +
provide O +
valuable O +
insight O +
into O +
the O +
genetic O +
basis O +
of O +
AD U-Disease +
and O +
illuminate O +
novel O +
therapeutic O +
avenues O +
for O +
AD U-Disease -
. O -

MicroRNAs O +
can O +
regulate O +
human O +
APP O +
levels O -
. O -

MicroRNA O +
expression O +
profiling O +
for O +
molecular O +
classification O +
of O +
pediatric B-Disease +
brain I-Disease +
tumors L-Disease -
. O -

The O +
transcription O +
factor O +
REST O +
silences O +
neuronal O +
gene O +
expression O +
in O +
non O -
- O -
neuronal O +
cells O -
. O -

The O +
bifunctional O +
microRNA O +
miR-9 O -
/ O -
miR-9 O -
* O +
regulates O +
REST O +
and O +
CoREST O +
and O +
is O +
downregulated O +
in O +
Huntington B-Disease -
's I-Disease +
disease L-Disease -
. O -

Polyglutamine O +
expansions O +
in O +
huntingtin O -
, O +
which O +
causes O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O -
, O +
abrogates O +
REST O -
- O -
huntingtin O +
binding O -
. O -

In O +
neurons O -
, O +
the O +
protein O +
is O +
sequestered O +
in O +
the O +
cytoplasm O +
in O +
part O +
through O +
binding O +
to O +
huntingtin O -
. O -

In O +
this O +
work O -
, O +
we O +
found O +
that O +
levels O +
of O +
several O +
microRNAs O +
( O -
miRNAs O -
) O +
with O +
upstream O +
RE1 O +
sites O +
are O +
decreased O +
in O +
HD U-Disease +
patient O +
cortices O +
relative O +
to O +
healthy O +
controls O -
. O -

Consequently O -
, O +
REST O +
translocates O +
to O +
the O +
nucleus O -
, O +
occupies O +
RE1 O +
repressor O +
sequences O +
and O +
decreases O +
neuronal O +
gene O +
expression O -
. O -

Interestingly O -
, O +
one O +
of O +
these O -
, O +
the O +
bifunctional O +
brain O +
enriched O +
miR-9 O -
/ O -
miR-9 O -
* O -
, O +
targets O +
two O +
components O +
of O +
the O +
REST O +
complex O -
: O +
miR-9 O +
targets O +
REST O +
and O +
miR-9 O -
* O +
targets O +
CoREST O -
. O -

These O +
data O +
provide O +
evidence O +
for O +
a O +
double O +
negative O +
feedback O +
loop O +
between O +
the O +
REST O +
silencing O +
complex O +
and O +
the O +
miRNAs O +
it O +
regulates O -
. O -

Specificity O -
, O +
duplex O +
degradation O +
and O +
subcellular O +
localization O +
of O +
antagomirs O -
. O -

Finally O -
, O +
we O +
show O +
that O +
antagomirs O -
, O +
although O +
incapable O +
of O +
silencing O +
miRNAs O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
when O +
injected O +
systemically O -
, O +
efficiently O +
target O +
miRNAs O +
when O +
injected O +
locally O +
into O +
the O +
mouse O +
cortex O -
. O -

Our O +
data O +
further O +
validate O +
the O +
effectiveness O +
of O +
antagomirs O +
in O +
vivo O +
and O +
should O +
facilitate O +
future O +
studies O +
to O +
silence O +
miRNAs O +
for O +
functional O +
analysis O +
and O +
in O +
clinically O +
relevant O +
settings O -
. O -

We O +
demonstrate O +
that O +
antagomirs O +
harbor O +
optimized O +
phosphorothioate O +
modifications O -
, O +
require O +
> O -
19-nt O +
length O +
for O +
highest O +
efficiency O +
and O +
can O +
discriminate O +
between O +
single O +
nucleotide O +
mismatches O +
of O +
the O +
targeted O +
miRNA O -
. O -

Degradation O +
of O +
different O +
chemically O +
protected O +
miRNA O -
/ O -
antagomir O +
duplexes O +
in O +
mouse O +
livers O +
and O +
localization O +
of O +
antagomirs O +
in O +
a O +
cytosolic O +
compartment O +
that O +
is O +
distinct O +
from O +
processing O +
( O -
P O -
) O -
-bodies O +
indicates O +
a O +
degradation O +
mechanism O +
independent O +
of O +
the O +
RNA O +
interference O +
( O -
RNAi O -
) O +
pathway O -
. O -

We O +
recently O +
demonstrated O +
silencing O +
miRNA O +
function O +
in O +
mice O +
using O +
chemically O +
modified O +
and O +
cholesterol O -
- O -
conjugated O +
RNAs O +
termed O +
' O -
antagomirs O -
' O -
. O -

Here O -
, O +
we O +
further O +
characterize O +
the O +
properties O +
and O +
function O +
of O +
antagomirs O +
in O +
mice O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
an O +
abundant O +
class O +
of O +
20 O -
- O -
23-nt O +
long O +
regulators O +
of O +
gene O +
expression O -
. O -

The O +
study O +
of O +
miRNA O +
function O +
in O +
mice O +
and O +
potential O +
therapeutic O +
approaches O +
largely O +
depend O +
on O +
modified O +
oligonucleotides O -
. O -

Altered O +
microRNAs O +
in O +
STHdh O -
( O -
Q111 O -
) O -
/ O -
Hdh O -
( O -
Q111 O -
) O +
cells O -
: O +
miR-146a O +
targets O +
TBP O -
. O -

We O +
studied O +
expression O +
of O +
90 O +
miRNAs O +
in O +
STHdh O -
( O -
Q111 O -
) O -
/ O -
Hdh O -
( O -
Q111 O -
) O +
cells O -
, O +
a O +
model O +
for O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
and O +
compared O +
with O +
that O +
obtained O +
in O +
STHdh O -
( O -
Q7 O -
) O -
/ O -
Hdh O -
( O -
Q7 O -
) O +
cells O -
. O -

Fifteen O +
miRNAs O +
were O +
down O +
regulated O +
and O +
12 O +
miRNAs O +
were O +
up O +
regulated O +
more O +
than O +
2-fold O -
. O -

Such O +
changes O +
were O +
statistically O +
significant O -
. O -

One O +
hundred O +
and O +
forty O -
- O -
two O +
genes O +
are O +
experimentally O +
known O +
targets O +
of O +
these O +
altered O +
miRNAs O -
. O -

Using O +
luciferase O +
reporter O +
assays O +
with O +
3'-UTRs O +
of O +
TBP O -
, O +
over O -
- O -
expression O +
and O +
inhibition O +
of O +
miR-146a O -
, O +
we O +
showed O +
that O +
miR-146a O +
targets O +
TBP O -
. O -

It O +
has O +
been O +
predicted O +
that O +
miR-146a O +
may O +
target O +
Tata O +
Binding O +
Protein O +
( O -
TBP O -
) O -
. O -

Regulation O +
of O +
TBP O +
by O +
miR-146a O +
may O +
contribute O +
to O +
HD U-Disease +
pathogenesis O -
. O -

Many O +
of O +
these O +
pathways O +
were O +
first O +
identified O +
in O +
genetic O +
screens O +
in O +
Drosophila O +
and O +
other O +
lower O +
organisms O -
. O -

In O +
the O +
last O +
20 O +
years O -
, O +
it O +
has O +
become O +
clear O +
that O +
developmental O +
genes O +
and O +
their O +
regulators O -
, O +
noncoding O +
RNAs O +
including O +
microRNAs O +
and O +
long O -
- O -
noncoding O +
RNAs O -
, O +
within O +
signaling O +
pathways O +
play O +
a O +
critical O +
role O +
in O +
the O +
pathogenesis O +
of O +
cancer U-Disease -
. O -

Genes O +
and O +
pathways O +
expressed O +
during O +
embryonic O +
development O -
, O +
including O +
the O +
Notch O -
, O +
Wnt O -
/ O -
β O -
- O -
Catenin O -
, O +
TGF O -
- O -
β O -
/ O -
BMP O -
, O +
Shh O -
/ O -
Patched O -
, O +
and O +
Hippo O +
pathways O +
are O +
mutated O -
, O +
lost O -
, O +
or O +
aberrantly O +
regulated O +
in O +
a O +
wide O +
variety O +
of O +
human B-Disease +
cancers L-Disease -
, O +
including O +
skin O -
, O +
breast O -
, O +
blood O -
, O +
and O +
brain B-Disease +
cancers L-Disease -
, O +
including O +
medulloblastoma U-Disease -
. O -

Mammalian O +
orthologs O +
were O +
subsequently O +
identified O +
and O +
genes O +
within O +
the O +
pathways O +
cloned O +
and O +
found O +
to O +
regulate O +
cell O +
growth O -
. O -

Cerebellum O +
development O +
and O +
medulloblastoma U-Disease -
. O -

Medulloblastoma U-Disease -
, O +
the O +
most O +
common O +
malignant O +
nervous O +
system O +
tumor U-Disease +
in O +
childhood O -
, O +
are O +
thought O +
to O +
arise O +
from O +
disruptions O +
in O +
cerebellar O +
development O +
[ O -
reviewed O +
by O +
Marino O -
, O +
S. O +
( O -
2005 O -
) O -
] O -
. O -

These O +
biochemical O +
pathways O +
affect O +
cell O +
fate O +
determination O -
, O +
axis O +
formation O -
, O +
and O +
patterning O +
during O +
development O +
and O +
regulate O +
tissue O +
homeostasis O +
and O +
regeneration O +
in O +
adults O -
. O -

In O +
this O +
chapter O -
, O +
we O +
will O +
review O +
the O +
development O +
of O +
the O +
cerebellar O +
cortex O -
, O +
highlighting O +
signaling O +
pathways O +
of O +
potential O +
relevance O +
to O +
tumorigenesis O -
. O -

Defining O +
the O +
extracellular O +
cues O +
and O +
intracellular O +
signaling O +
pathways O +
that O +
control O +
cerebellar O +
neurogenesis O -
, O +
especially O +
granule O +
cell O +
progenitor O +
( O -
GCP O -
) O +
proliferation O +
and O +
differentiation O +
has O +
been O +
useful O +
for O +
developing O +
models O +
to O +
unravel O +
the O +
mechanisms O +
underlying O +
medulloblastoma U-Disease +
formation O +
and O +
growth O -
. O -

This O +
is O -
, O +
to O +
our O +
knowledge O -
, O +
the O +
first O +
case O +
of O +
this O +
kind O +
found O +
in O +
Argentina O +
and O +
is O +
additional O +
evidence O +
that O +
HAM U-Disease -
/ O -
TSP U-Disease +
solely O +
related O +
to O +
HTLV B-Disease -
- I-Disease -
II I-Disease +
infection L-Disease +
occurs O +
in O +
HTLV O -
- O -
I O -
- O -
negative O +
subjects O -
. O -

A O +
case O +
of O +
neurological B-Disease +
disease L-Disease +
featuring O +
human B-Disease +
T I-Disease +
lymphocyte I-Disease +
virus I-Disease -
- I-Disease -
associated I-Disease +
myelopathy L-Disease -
/ O -
tropical B-Disease +
spastic I-Disease +
paraparesis L-Disease +
( O -
HAM U-Disease -
/ O -
TSP U-Disease -
) O +
was O +
diagnosed O +
by O +
serological O +
( O -
Western O +
blot O -
) O +
and O +
molecular O +
( O -
polymerase O +
chain O +
reaction O -
) O +
criteria O +
as O +
related O +
to O +
human B-Disease +
T I-Disease +
lymphocyte I-Disease +
virus I-Disease +
( I-Disease -
HTLV I-Disease -
) I-Disease -
-II I-Disease +
infection L-Disease -
. O -

A O +
possible O +
case O +
of O +
myelopathy U-Disease -
/ O -
tropical B-Disease +
spastic I-Disease +
paraparesis L-Disease +
in O +
an O +
Argentinian O +
woman O +
with O +
human O +
T O +
lymphocyte O +
virus O +
type O +
II O -
. O -

Co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
directly O +
resulted O +
in O +
the O +
up O -
- O -
regulation O +
of O +
p27Kip1 O +
in O +
the O +
tested O +
cells O -
, O +
consequently O -
, O +
affects O +
their O +
growth O +
potential O +
by O +
reducing O +
a O +
G1 O +
to O +
S O +
shift O +
in O +
the O +
cell O +
cycle O -
. O -

Consistently O -
, O +
miR-221 O -
/ O -
222 O +
knocked O -
- O -
down O +
through O +
antisense O +
2'-OME O -
- O -
oligonucleotides O +
increased O +
p27Kip1 O +
in O +
U251 O +
glioma U-Disease +
subcutaneous O +
mice O +
and O +
strongly O +
reduced O +
tumor U-Disease +
growth O +
in O +
vivo O +
through O +
up O +
regulation O +
of O +
p27Kip1 O -
. O -

Our O +
results O +
suggest O +
that O +
miR-221 O -
/ O -
222 O +
is O +
a O +
regulator O +
of O +
the O +
tumor O +
suppressor O +
gene O +
p27Kip1 O -
, O +
and O +
co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
expression O +
in O +
advanced O +
gliomas U-Disease +
may O +
inhibit O +
glioma U-Disease +
cell O +
proliferation O +
by O +
a O +
mechanism O +
involving O +
the O +
up O -
- O -
regulation O +
of O +
p27Kip1 O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
cluster O +
suppresses O +
human B-Disease +
glioma L-Disease +
cell O +
growth O +
by O +
targeting O +
p27kip1 O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

MicroRNAs O +
are O +
short O +
regulatory O +
RNAs O +
that O +
negatively O +
modulate O +
protein O +
expression O +
at O +
a O +
post O -
- O -
transcriptional O +
level O -
. O -

Emerging O +
evidence O +
suggests O +
that O +
altered O +
regulation O +
of O +
miRNA O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
several O +
types O +
of O +
cancers U-Disease -
. O -

In O +
the O +
current O +
study O -
, O +
an O +
inverse O +
relationship O +
between O +
the O +
expression O +
of O +
miR-221 O -
/ O -
miR-222 O +
and O +
the O +
cell O +
cycle O +
inhibitor O +
p27Kip1 O +
was O +
identified O +
in O +
U251 O +
glioma U-Disease +
cells O -
. O -

The O +
mRNA O +
expression O +
of O +
the O +
RNases O +
Drosha O +
and O +
Dicer O -
, O +
cofactor O +
Pasha O -
, O +
and O +
the O +
pre O -
- O -
miRNA O +
transporter O +
exportin-5 O -
, O +
which O +
modulate O +
miRNA O +
biogenesis O -
, O +
were O +
not O +
altered O +
after O +
transient O +
middle O +
cerebral B-Disease +
artery I-Disease +
occlusion L-Disease -
. O -

Thus O -
, O +
the O +
present O +
studies O +
indicate O +
a O +
critical O +
role O +
of O +
miRNAs O +
in O +
controlling O +
mRNA O +
transcription O +
and O +
translation O +
in O +
the O +
postischemic O +
brain O -
. O -

Bioinformatics O +
analysis O +
indicated O +
a O +
correlation O +
between O +
miRNAs O +
altered O +
to O +
several O +
mRNAs O +
known O +
to O +
mediate O +
inflammation U-Disease -
, O +
transcription O -
, O +
neuroprotection O -
, O +
receptors O +
function O -
, O +
and O +
ionic O +
homeostasis O -
. O -

Of O +
those O -
, O +
17 O +
showed O +
> O -
5 O +
fold O +
change O -
. O -

In O +
silico O +
analysis O +
showed O +
sequence O +
complementarity O +
of O +
eight O +
miRNAs O +
induced O +
after O +
focal B-Disease +
ischemia L-Disease +
to O +
877 O +
promoters O +
indicating O +
the O +
possibility O +
of O +
noncoding O +
RNA O -
- O -
induced O +
activation O +
of O +
gene O +
expression O -
. O -

Antagomir O -
- O -
mediated O +
prevention O +
of O +
mir-145 O +
expression O +
led O +
to O +
an O +
increased O +
protein O +
expression O +
of O +
its O +
downstream O +
target O +
superoxide O +
dismutase-2 O +
in O +
the O +
postischemic O +
brain O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
approximately O +
22 O +
nucleotides O +
long O -
, O +
noncoding O +
RNAs O +
that O +
control O +
cellular O +
function O +
by O +
either O +
degrading O +
mRNAs O +
or O +
arresting O +
their O +
translation O -
. O -

Transient B-Disease +
focal I-Disease +
ischemia L-Disease +
induces O +
extensive O +
temporal O +
changes O +
in O +
rat O +
cerebral O +
microRNAome O -
. O -

Of O +
the O +
238 O +
miRNAs O +
evaluated O -
, O +
8 O +
showed O +
increased O +
and O +
12 O +
showed O +
decreased O +
expression O +
at O +
least O +
at O +
4 O +
out O +
of O +
5 O +
reperfusion O +
time O +
points O +
studied O +
between O +
3 O +
h O +
and O +
3 O +
days O +
compared O +
with O +
sham O -
. O -

To O +
understand O +
their O +
functional O +
significance O +
in O +
ischemic O +
pathophysiology O -
, O +
we O +
profiled O +
miRNAs O +
in O +
adult O +
rat O +
brain O +
as O +
a O +
function O +
of O +
reperfusion O +
time O +
after O +
transient O +
middle B-Disease +
cerebral I-Disease +
artery I-Disease +
occlusion L-Disease -
. O -

The O +
therapy O +
employed O -
, O +
in O +
a O +
single O +
baculoviral O +
vector O -
, O +
a O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
gene O +
promoter O +
and O +
the O +
repeated O +
target O +
sequences O +
of O +
three O +
miRNAs O +
that O +
are O +
enriched O +
in O +
astrocytes O +
but O +
downregulated O +
in O +
glioblastoma U-Disease +
cells O +
to O +
control O +
the O +
expression O +
of O +
the O +
herpes O +
simplex O +
virus O +
thymidine O +
kinase O +
( O -
HSVtk O -
) O +
gene O -
. O -

This O +
resulted O +
in O +
significantly O +
improved O +
in O +
vivo O +
selectivity O +
over O +
the O +
use O +
of O +
a O +
control O +
vector O +
without O +
miRNA O +
regulation O -
, O +
enabling O +
effective O +
elimination O +
of O +
human B-Disease +
glioma L-Disease +
xenografts O +
while O +
producing O +
negligible O +
toxic O +
effects O +
on O +
normal O +
astrocytes O -
. O -

In O +
the O +
context O +
of O +
cancer U-Disease +
suicide O +
gene O +
therapy O -
, O +
this O +
approach O +
may O +
lead O +
to O +
cytotoxic O +
effects O +
in O +
both O +
cancer U-Disease +
and O +
nontarget O +
normal O +
cells O -
. O -

Considering O +
microRNA O +
( O -
miRNA O -
) O +
function O +
in O +
post O -
- O -
transcriptional O +
regulation O +
of O +
gene O +
expression O -
, O +
we O +
have O +
developed O +
a O +
viral O +
vector O +
platform O +
combining O +
cellular O +
promoter O -
- O -
based O +
transcriptional O +
targeting O +
with O +
miRNA O +
regulation O +
for O +
a O +
glioma U-Disease +
suicide O +
gene O +
therapy O +
in O +
the O +
mouse O +
brain O -
. O -

Thus O -
, O +
incorporating O +
miRNA O +
regulation O +
into O +
a O +
transcriptional O +
targeting O +
vector O +
adds O +
an O +
extra O +
layer O +
of O +
security O +
to O +
prevent O +
off O -
- O -
target O +
transgene O +
expression O +
and O +
should O +
be O +
useful O +
for O +
the O +
development O +
of O +
gene O +
delivery O +
vectors O +
with O +
high O +
targeting O +
specificity O +
for O +
cancer U-Disease +
therapy O -
. O -

Transcriptional O +
targeting O +
using O +
a O +
tissue O -
- O -
specific O +
cellular O +
promoter O +
is O +
proving O +
to O +
be O +
a O +
powerful O +
means O +
for O +
restricting O +
transgene O +
expression O +
in O +
targeted O +
tissues O -
. O -

Combinatorial O +
control O +
of O +
suicide O +
gene O +
expression O +
by O +
tissue O -
- O -
specific O +
promoter O +
and O +
microRNA O +
regulation O +
for O +
cancer U-Disease +
therapy O -
. O -

The O +
possible O +
use O +
of O +
RNAi O +
in O +
the O +
treatment O +
of O +
spinocerebellar B-Disease +
ataxia L-Disease +
or O +
amyotrophic B-Disease +
lateral I-Disease +
sclerosis L-Disease -
, O +
with O +
its O +
advantages O +
and O +
pitfalls O +
and O +
possible O +
extensions O +
to O +
other O +
diseases O +
are O +
discussed O -
. O -

RNAi O +
has O +
moved O +
from O +
a O +
purely O +
experimental O +
technique O +
to O +
the O +
stage O +
of O +
potential O +
clinical O +
applications O -
. O -

RNAi O +
utilises O +
cellular O +
machinery O +
associated O +
with O +
the O +
processing O +
of O +
naturally O +
occurring O +
micro O +
RNA O +
( O -
miRNAs O -
) O -
. O -

RNAi O +
has O +
both O +
admirers O +
and O +
detractors O -
, O +
but O +
is O +
undeniably O +
a O +
technique O +
with O +
great O +
potential O -
, O +
which O +
has O +
come O +
a O +
long O +
way O +
in O +
the O +
short O +
time O +
since O +
its O +
discovery O -
. O -

RNA O +
interference O +
has O +
become O +
the O +
tool O +
of O +
choice O +
to O +
analyse O +
the O +
loss O -
- O -
of O -
- O -
function O +
of O +
individual O +
genes O +
and O +
has O +
been O +
exploited O +
to O +
identify O +
complex O +
regulatory O +
pathways O +
following O +
genomic O +
screening O -
. O -

Design O +
of O +
shRNAs O +
for O +
RNAi O -
- O -
A O +
lesson O +
from O +
pre O -
- O -
miRNA O +
processing O -
: O +
possible O +
clinical O +
applications O -
. O -

The O +
cellular O +
processing O +
of O +
shRNAs O +
shares O +
common O +
features O +
with O +
the O +
biogenesis O +
of O +
naturally O +
occurring O +
miRNA O +
such O +
as O +
cleavage O +
by O +
nuclear O +
RNase O +
Drosha O -
, O +
export O +
from O +
the O +
nucleus O -
, O +
processing O +
by O +
a O +
cytoplasmic O +
RNase O +
Dicer O -
, O +
and O +
incorporation O +
into O +
the O +
RNA O -
- O -
induced O +
silencing O +
complex O +
( O -
RISC O -
) O -
. O -

Each O +
step O +
has O +
a O +
crucial O +
influence O +
on O +
the O +
efficiency O +
of O +
RNAi O +
and O +
their O +
consideration O +
should O +
be O +
a O +
part O +
of O +
a O +
standard O +
experimental O +
design O -
. O -

More O +
recently O +
an O +
introduction O +
of O +
short O +
approximately O +
22 O +
nucleotide O +
RNA O +
duplexes O +
has O +
become O +
the O +
standard O +
in O +
short O -
- O -
term O +
experiments O -
, O +
but O +
is O +
insufficient O +
for O +
long O -
- O -
term O +
knock O -
- O -
down O +
assays O -
. O -

Long O -
- O -
term O +
expression O +
of O +
siRNAs O +
has O +
been O +
achieved O +
by O +
in O +
vivo O +
transcription O +
from O +
plasmids O +
coding O +
for O +
short O +
hairpin O +
RNAs O +
( O -
shRNAs O -
) O -
. O -

Effective O +
use O +
of O +
RNAi O +
requires O +
detailed O +
knowledge O +
of O +
the O +
individual O +
steps O +
and O +
the O +
proteins O +
involved O -
, O +
as O +
well O +
as O +
the O +
similarities O +
and O +
distinctions O +
between O +
miRNA O +
and O +
siRNA O +
pathways O -
. O -

RNAi O +
was O +
originally O +
induced O +
by O +
the O +
introduction O +
of O +
long O +
double O +
stranded O +
RNAs O +
( O -
dsRNAs O -
) O +
into O +
cells O +
in O +
which O +
the O +
RNA O +
was O +
cleaved O +
into O +
short O +
RNAs O +
which O +
effectively O +
interfered O +
with O +
a O +
transcription O +
of O +
cognate O +
mRNA O -
. O -

[ O -
AD O -
- O -
FTLD O +
spectrum O -
-- O -
new O +
findings O +
on O +
risk O +
genes O +
in O +
neurodegenerative B-Disease +
diseases L-Disease -
] O -
. O -

Our O +
microarray O +
based O +
analysis O +
of O +
microRNA O +
expression O +
in O +
rat O +
cerebral O +
cortex O +
after O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease +
has O +
shown O +
that O +
some O +
microRNA O +
such O +
as O +
miR-21 O +
could O +
be O +
involved O +
in O +
the O +
intricate O +
process O +
of O +
TBI U-Disease +
course O -
. O -

Furthermore O -
, O +
we O +
revealed O +
global O +
up O -
- O -
regulation O +
of O +
miR-21 O +
expression O +
within O +
all O +
the O +
four O +
time O +
points O +
post O +
injury U-Disease -
. O -

Our O +
research O +
revealed O +
that O +
136 O +
miRNAs O +
were O +
expressing O +
at O +
6 O +
h O +
post O +
injury U-Disease -
, O +
in O +
which O +
13 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
14 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
118 O +
miRNAs O +
were O +
expressing O +
at O +
24 O +
h O +
post O +
injury U-Disease -
, O +
in O +
which O +
4 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
23 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
149 O +
miRNAs O +
were O +
expressing O +
at O +
48 O +
h O +
post O +
injury U-Disease -
, O +
in O +
which O +
16 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
11 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
and O +
203 O +
miRNAs O +
were O +
expressing O +
at O +
72 O +
h O +
post O +
injury U-Disease -
, O +
in O +
which O +
19 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
5 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
. O -

The O +
qRT O -
- O -
PCR O +
results O +
indicated O +
good O +
consistency O +
with O +
the O +
results O +
of O +
the O +
microarray O +
method O -
. O -

Finally O -
, O +
we O +
utilized O +
qRT O -
- O -
PCR O +
methods O +
to O +
verify O +
the O +
microarray O +
results O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
very O +
important O +
regulators O +
of O +
biological O +
processes O +
such O +
as O +
development O -
, O +
cellular O +
differentiation O -
, O +
and O +
tumor U-Disease +
generation O -
. O -

MiRNA O +
microarray O +
has O +
been O +
found O +
to O +
be O +
a O +
high O +
throughput O +
global O +
analysis O +
tool O +
for O +
detecting O +
miRNA O +
expression O +
profiling O -
, O +
and O +
miRNA O +
expression O +
profiling O +
will O +
facilitate O +
the O +
study O +
of O +
the O +
biological O +
function O +
of O +
miRNAs O -
. O -

In O +
this O +
report O -
, O +
we O +
describe O +
the O +
miRNA O +
expression O +
level O +
in O +
rat O +
cerebral O +
cortex O +
after O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease +
using O +
microarray O +
method O -
. O -

We O +
choose O +
several O +
time O +
points O +
post O +
brain B-Disease +
injury L-Disease -
: O +
6 O +
h O -
, O +
24 O +
h O -
, O +
48 O +
h O +
and O +
72 O +
h O -
, O +
respectively O -
, O +
to O +
reveal O +
differential O +
expression O +
of O +
miRNAs O +
in O +
rat O +
brain O +
cortex O +
compared O +
with O +
control O +
groups O -
. O -

Microarray O +
based O +
analysis O +
of O +
microRNA O +
expression O +
in O +
rat O +
cerebral O +
cortex O +
after O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease -
. O -

Ectopic O +
expression O +
of O +
miR-29b O +
decreased O +
hPGRN O +
expression O +
at O +
the O +
both O +
mRNA O +
and O +
protein O +
levels O -
. O -

To O +
examine O +
the O +
direct O +
effect O +
of O +
manipulating O +
endogenous O +
miR-29b O +
on O +
hPGRN O +
expression O -
, O +
we O +
established O +
a O +
stable O +
NIH3T3 O +
cell O +
line O +
that O +
expresses O +
hPGRN O +
under O +
the O +
control O +
of O +
the O +
cytomegalovirus O +
promoter O -
. O -

Endogenous O +
hPGRN O +
in O +
HEK O +
293 O +
cells O +
was O +
also O +
regulated O +
by O +
miR-29b O -
. O -

Conversely O -
, O +
knockdown O +
of O +
endogenous O +
miR-29b O +
with O +
locked O +
nucleic O +
acid O +
increased O +
the O +
production O +
and O +
secretion O +
of O +
hPGRN O +
in O +
NIH3T3 O +
cells O -
. O -

How O +
progranulin O +
( O -
PGRN O -
) O +
expression O +
is O +
regulated O +
is O +
largely O +
unknown O -
. O -

Progranulin O +
deficiency O +
is O +
thought O +
to O +
cause O +
some O +
forms O +
of O +
frontotemporal B-Disease +
dementia L-Disease +
( O -
FTD U-Disease -
) O -
, O +
a O +
major O +
early O -
- O -
onset O +
age O -
- O -
dependent O +
neurodegenerative B-Disease +
disease L-Disease -
. O -

miR-29b O +
downregulates O +
the O +
expression O +
of O +
luciferase O +
through O +
hPGRN O +
or O +
mouse O +
PGRN O +
( O -
mPGRN O -
) O +
3'UTRs O -
, O +
and O +
the O +
regulation O +
was O +
abolished O +
by O +
mutations O +
in O +
the O +
miR-29b O +
binding O +
site O -
. O -

We O +
identified O +
an O +
evolutionarily O +
conserved O +
binding O +
site O +
for O +
microRNA-29b O +
( O -
miR-29b O -
) O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
( O -
3'UTR O -
) O +
of O +
the O +
human O +
PGRN O +
( O -
hPGRN O -
) O +
mRNA O -
. O -

MicroRNA-29b O +
regulates O +
the O +
expression O +
level O +
of O +
human O +
progranulin O -
, O +
a O +
secreted O +
glycoprotein O +
implicated O +
in O +
frontotemporal B-Disease +
dementia L-Disease -
. O -

These O +
findings O +
identify O +
miR-29b O +
as O +
a O +
novel O +
posttranscriptional O +
regulator O +
of O +
PGRN O +
expression O -
, O +
raising O +
the O +
possibility O +
that O +
miR-29b O +
or O +
other O +
miRNAs O +
might O +
be O +
targeted O +
therapeutically O +
to O +
increase O +
hPGRN O +
levels O +
in O +
some O +
FTD U-Disease +
patients O -
. O -

We O +
studied O +
the O +
expression O +
of O +
selected O +
miRNAs O +
following O +
infection U-Disease +
of O +
CBA O +
mice O +
with O +
Plasmodium O +
berghei O +
ANKA O +
( O -
PbA O -
) O -
, O +
which O +
causes O +
cerebral B-Disease +
malaria L-Disease +
( O -
CM U-Disease -
) O -
, O +
or O +
Plasmodium O +
berghei O +
K173 O +
( O -
PbK O -
) O -
, O +
which O +
causes O +
severe O +
malaria U-Disease +
but O +
without O +
cerebral O +
complications O -
, O +
termed O +
non O -
- O -
CM O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
posttranscriptional O +
regulatory O +
molecules O +
that O +
have O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
immune O +
responses O -
, O +
but O +
their O +
role O +
in O +
the O +
immune O +
response O +
to O +
Plasmodium B-Disease +
infection L-Disease +
is O +
unknown O -
. O -

Differential O +
MicroRNA O +
Expression O +
in O +
Experimental O +
Cerebral O +
and O +
Noncerebral O +
Malaria U-Disease -
. O -

To O +
investigate O +
the O +
involvement O +
of O +
let-7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O +
in O +
CM U-Disease -
- O -
resistant O +
mice O -
, O +
we O +
assessed O +
the O +
expression O +
levels O +
in O +
gamma O +
interferon O +
knockout O +
( O -
IFN O -
- O -
γ O -
( O -
- O -
/ O -
- O -
) O -
) O +
mice O +
on O +
a O +
C57BL O -
/ O -
6 O +
genetic O +
background O -
. O -

In O +
contrast O -
, O +
no O +
miRNA O +
changes O +
were O +
detected O +
in O +
the O +
heart O -
, O +
an O +
organ O +
with O +
no O +
known O +
pathology O +
during O +
acute B-Disease +
malaria L-Disease -
. O -

We O +
identified O +
three O +
miRNAs O +
that O +
were O +
differentially O +
expressed O +
in O +
the O +
brain O +
of O +
PbA O -
- O -
infected O +
CBA O +
mice O -
: O +
let7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O -
. O -

The O +
differential O +
expression O +
profiles O +
of O +
selected O +
miRNAs O +
( O -
let-7i O -
, O +
miR-27a O -
, O +
miR-150 O -
, O +
miR-126 O -
, O +
miR-210 O -
, O +
and O +
miR-155 O -
) O +
were O +
analyzed O +
in O +
mouse O +
brain O +
and O +
heart O +
tissue O +
by O +
quantitative O +
reverse O +
transcription O -
- O -
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O -

Our O +
data O +
suggest O +
that O +
in O +
the O +
CBA O +
mouse O +
at O +
least O -
, O +
miRNA O +
may O +
have O +
a O +
regulatory O +
role O +
in O +
the O +
pathogenesis O +
of O +
severe O +
malaria U-Disease -
. O -

Overexpression O +
of O +
these O +
three O +
miRNAs O +
during O +
PbA O -
, O +
but O +
not O +
PbK O -
, O +
infection U-Disease +
in O +
WT O +
mice O +
may O +
be O +
critical O +
for O +
the O +
triggering O +
of O +
the O +
neurological B-Disease +
syndrome L-Disease +
via O +
regulation O +
of O +
their O +
potential O +
downstream O +
targets O -
. O -

The O +
expression O +
of O +
let-7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O +
was O +
unchanged O +
in O +
both O +
wild O -
- O -
type O +
( O -
WT O -
) O +
and O +
IFN O -
- O -
γ O -
( O -
- O -
/ O -
- O -
) O +
mice O +
following O +
infection U-Disease -
. O -

[ O -
Genetic O +
and O +
molecular O +
abnormalities O +
of O +
glioblastomas U-Disease +
( O -
GBM U-Disease -
) O -
] O -
. O -

This O +
presentation O +
reports O +
a O +
series O +
of O +
data O +
dealing O +
with O +
recurrent O +
genetic O +
abnormalities O +
and O +
gene O +
expression O +
profiles O +
that O +
characterize O +
primary B-Disease +
glioblastomas L-Disease +
and O +
secondary B-Disease +
glioblastomas L-Disease +
resulting O +
from O +
the O +
transformation O +
of O +
low B-Disease +
grade I-Disease +
tumors L-Disease +
( O -
grade O +
II O +
and O +
III O +
astrocytomas U-Disease +
and O +
oligodendrogliomas U-Disease -
) O -
. O -

Finally O -
, O +
a O +
short O +
description O +
of O +
exosomes O +
as O +
vectors O +
of O +
tumor U-Disease +
information O +
will O +
be O +
presented O -
. O -

The O +
most O +
recent O +
aspects O +
of O +
the O +
concept O +
of O +
tumor U-Disease +
stem O +
cells O +
that O +
may O +
explain O +
the O +
relentless O +
growth O +
of O +
GBM U-Disease +
will O +
be O +
reported O -
. O -

Molecular O +
features O +
of O +
tumor U-Disease +
neoangiogenesis O +
will O +
be O +
described O -
. O -

Epigenetic O +
alterations O +
and O +
deregulation O +
of O +
gene O +
expression O +
by O +
microRNAs O +
( O -
miRs O -
) O +
will O +
be O +
also O +
included O -
. O -

Some O +
aspects O +
of O +
tumor U-Disease +
predisposition O +
will O +
be O +
also O +
discussed O -
. O -

In O +
an O +
effort O +
to O +
shed O +
light O +
on O +
consequences O +
mediated O +
by O +
p53 O +
inactivation O +
in O +
gliomas U-Disease -
, O +
we O +
established O +
the O +
Tet O -
- O -
On O +
system O +
for O +
p53 O +
in O +
the O +
LN O -
- O -
Z308 O +
glioblastoma U-Disease +
cell O +
line O -
. O -

p53 O +
is O +
activated O +
upon O +
various O +
kinds O +
of O +
cellular O +
stress O +
leading O +
to O +
apoptosis O +
or O +
cell O +
cycle O +
arrest O -
, O +
but O +
is O +
also O +
implicated O +
in O +
complex O +
biological O +
processes O +
such O +
as O +
inhibition O +
of O +
angiogenesis O +
and O +
metastasis O -
. O -

Oxygen O +
deprivation O -
, O +
an O +
important O +
cellular O +
stress O -
, O +
revealed O +
MIC-1 O +
as O +
an O +
anoxia U-Disease +
responsive O +
gene O +
in O +
glioblastoma U-Disease +
cell O +
lines O -
. O -

The O +
macrophage O +
inhibitory O +
cytokine-1 O +
( O -
MIC-1 O -
) O +
gene O +
was O +
identified O +
as O +
a O +
most O +
prominent O +
p53 O +
target O +
gene O +
upon O +
gene O +
expression O +
profiling O -
. O -

Furthermore O -
, O +
ectopic O +
expression O +
of O +
MIC-1 O +
in O +
LN O -
- O -
Z308 O +
cell O +
line O +
completely O +
abolished O +
its O +
inherent O +
tumorigenicity O +
in O +
nude O +
mice O -
, O +
while O +
proliferation O +
in O +
vitro O +
was O +
not O +
affected O -
. O -

MIC-1 O +
up O -
- O -
regulation O +
by O +
anoxia U-Disease +
is O +
mediated O +
through O +
an O +
alternative O -
, O +
p53 O +
and O +
hypoxia O +
inducible O +
factor O +
1 O +
( O -
HIF-1 O -
) O +
independent O +
pathway O -
. O -

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
MIC-1 O +
is O +
an O +
important O +
downstream O +
mediator O +
of O +
p53 O +
function O -
, O +
while O +
acting O +
itself O +
as O +
an O +
intercessor O +
of O +
cellular O +
stress O +
signaling O +
and O +
exerting O +
anti O -
- O -
tumorigenic O +
activities O -
. O -

In O +
the O +
present O +
experimental O +
model O +
MIC-1 O +
may O +
exert O +
its O +
anti O -
- O -
tumorigenic O +
properties O +
via O +
a O +
paracrine O +
mechanism O +
mediated O +
by O +
host O +
cells O +
in O +
vivo O -
. O -

Human O +
astrocytic B-Disease +
brain I-Disease +
tumors L-Disease +
select O +
for O +
mutations O +
in O +
the O +
p53 O +
tumor O +
suppressor O +
gene O +
early O +
in O +
malignant O +
progression O -
. O -

Anoxia U-Disease +
induces O +
macrophage O +
inhibitory O +
cytokine-1 O +
( O -
MIC-1 O -
) O +
in O +
glioblastoma U-Disease +
cells O +
independently O +
of O +
p53 O +
and O +
HIF-1 O -
. O -

Reduction O +
of O +
miR-21 O +
induces O +
glioma U-Disease +
cell O +
apoptosis O +
via O +
activating O +
caspase O +
9 O +
and O +
3 O -
. O -
Extensive O +
data O +
indicate O +
that O +
miR-21 O +
plays O +
a O +
critical O +
role O +
in O +
gliomagenesis O -
, O +
however O -
, O +
knowledge O +
is O +
limited O +
on O +
the O +
mechanism O +
of O +
action O +
of O +
miR-21 O -
, O +
including O +
cell O +
proliferation O -
, O +
apoptosis O -
, O +
and O +
migration O -
. O -

Moreover O -
, O +
reduction O +
of O +
miR-21 O +
activated O +
caspase O +
9 O +
and O +
3 O -
, O +
which O +
may O +
be O +
mediated O +
by O +
modulating O +
multiple O +
potential O +
target O +
genes O -
, O +
such O +
as O +
TIMP3 O -
. O -

In O +
this O +
study O -
, O +
we O +
showed O +
that O +
down O -
- O -
regulation O +
of O +
miR-21 O +
expression O +
by O +
antisense O +
oligonucleotides O +
inhibited O +
glioma U-Disease +
cell O +
proliferation O +
and O +
induced O +
cell O +
apoptosis O -
. O -

Together O -
, O +
these O +
findings O +
indicate O +
that O +
miR-21 O +
plays O +
a O +
key O +
role O +
in O +
regulating O +
cell O +
apoptosis O +
in O +
gliomas U-Disease +
and O +
may O +
serve O +
as O +
a O +
target O +
for O +
effective O +
therapies O -
. O -

Membership O +
in O +
this O +
group O +
is O +
defined O +
based O +
on O +
sequence O +
similarity O +
near O +
the O +
mature O +
miRNAs O -
' O +
5 O -
' O +
end O -
: O +
all O +
include O +
the O +
sequence O +
AGCAGC O -
. O -

Here O +
we O +
provide O +
an O +
overview O +
of O +
the O +
following O -
: O +
( O -
1 O -
) O +
the O +
evolution O +
of O +
miR-15 O -
/ O -
107 O +
group O +
member O +
genes O -
; O +
( O -
2 O -
) O +
the O +
expression O +
levels O +
of O +
miRNAs O +
in O +
mammalian O +
tissues O -
; O +
( O -
3 O -
) O +
evidence O +
for O +
overlapping O +
gene O -
- O -
regulatory O +
functions O +
by O +
different O +
miRNAs O -
; O +
( O -
4 O -
) O +
the O +
normal O +
biochemical O +
pathways O +
regulated O +
by O +
miR-15 O -
/ O -
107 O +
group O +
miRNAs O -
; O +
and O +
( O -
5 O -
) O +
the O +
roles O +
played O +
by O +
these O +
miRNAs O +
in O +
human O +
diseases O -
. O -

While O +
all O +
vertebrates O +
studied O +
to O +
date O +
express O +
miR-15a O -
, O +
miR-15b O -
, O +
miR-16 O -
, O +
miR-103 O -
, O +
and O +
miR-107 O -
, O +
mammals O +
alone O +
are O +
known O +
to O +
express O +
miR-195 O -
, O +
miR-424 O -
, O +
miR-497 O -
, O +
miR-503 O -
, O +
and O +
miR-646 O -
. O -

Phylogeny O +
of O +
this O +
group O +
of O +
miRNAs O +
is O +
incomplete O -
; O +
thus O -
, O +
a O +
definitive O +
taxonomic O +
classification O +
( O -
e.g. O -
, O +
designation O +
as O +
a O +
" O -
superfamily O -
" O -
) O +
is O +
currently O +
not O +
possible O -
. O -

We O +
present O +
data O +
on O +
the O +
expression O +
of O +
all O +
known O +
miR-15 O -
/ O -
107 O +
group O +
members O +
in O +
human O +
cerebral O +
cortical O +
gray O +
matter O +
and O +
white O +
matter O +
using O +
new O +
miRNA O +
profiling O +
microarrays O -
. O -

Multiple O +
different O +
miRNAs O +
in O +
the O +
miR-15 O -
/ O -
107 O +
group O +
are O +
expressed O +
at O +
moderate O +
to O +
high O +
levels O +
in O +
human O +
tissues O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
of O +
microRNA O +
genes O -
: O +
evolutionary O +
biology O -
, O +
cellular O +
functions O -
, O +
and O +
roles O +
in O +
human O +
diseases O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
of O +
microRNA O +
( O -
miRNA O -
) O +
gene O +
is O +
increasingly O +
appreciated O +
to O +
serve O +
key O +
functions O +
in O +
humans O -
. O -

These O +
miRNAs O +
regulate O +
gene O +
expression O +
involved O +
in O +
cell O +
division O -
, O +
metabolism O -
, O +
stress O +
response O -
, O +
and O +
angiogenesis O +
in O +
vertebrate O +
species O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
has O +
also O +
been O +
implicated O +
in O +
human O +
cancers U-Disease -
, O +
cardiovascular B-Disease +
disease L-Disease +
and O +
neurodegenerative B-Disease +
disease L-Disease -
, O +
including O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease -
. O -

In O +
conclusion O -
, O +
the O +
miR-15 O -
/ O -
107 O +
group O +
of O +
miRNA O +
genes O +
is O +
a O +
fascinating O +
topic O +
of O +
study O +
for O +
evolutionary O +
biologists O -
, O +
miRNA O +
biochemists O -
, O +
and O +
clinically O +
oriented O +
translational O +
researchers O +
alike O -
. O -

We O +
show O +
new O +
data O +
from O +
cultured O +
H4 O +
cancer U-Disease +
cells O +
that O +
demonstrate O +
similarities O +
in O +
mRNAs O +
targeted O +
by O +
miR-16 O +
and O +
miR-103 O +
and O +
also O +
support O +
the O +
importance O +
of O +
the O +
mature O +
miRNAs O -
' O +
5 O -
' O +
seed O +
region O +
in O +
mRNA O +
target O +
recognition O -
. O -

There O +
is O +
extensive O +
overlap O +
in O +
the O +
mRNAs O +
targeted O +
by O +
miR-15 O -
/ O -
107 O +
group O +
members O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNAs O +
comprising O +
21 O -
- O -
23 O +
nucleotides O +
that O +
regulate O +
gene O +
expression O +
by O +
transcriptionally O +
repressing O +
their O +
complementary O +
mRNAs O -
. O -

Let-7 O +
microRNA O +
inhibits O +
the O +
proliferation O +
of O +
human B-Disease +
glioblastoma L-Disease +
cells O -
. O -

Transfection O +
of O +
let-7 O +
miRNA O +
reduced O +
expression O +
of O +
pan O -
- O -
RAS O -
, O +
N O -
- O -
RAS O -
, O +
and O +
K O -
- O -
RAS O +
in O +
the O +
glioblastoma U-Disease +
cells O -
. O -

Human B-Disease +
glioblastoma L-Disease +
cells O +
( O -
U251 O +
or O +
U87 O +
cells O -
) O +
were O +
transfected O +
with O +
let-7 O +
miRNA O +
and O +
assayed O +
for O +
in O -
- O -
vitro O +
proliferation O -
, O +
migration O -
, O +
and O +
in O -
- O -
vivo O +
tumor U-Disease +
formation O -
. O -

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
anti O -
- O -
tumorigenic O +
effect O +
of O +
let-7 O +
miRNA O +
in O +
glioblastoma U-Disease +
cells O -
. O -

In O +
particular O -
, O +
let-7 O +
miRNA O +
has O +
been O +
postulated O +
to O +
function O +
as O +
a O +
tumor O +
suppressor O +
in O +
various O +
cancer U-Disease +
cells O -
, O +
but O +
not O +
yet O +
in O +
glioblastoma U-Disease -
. O -

These O +
results O +
indicate O +
that O +
let-7 O +
miRNA O +
has O +
an O +
anti O -
- O -
tumorigenic O +
effect O +
on O +
glioblastoma U-Disease +
cells O -
, O +
and O +
suggest O +
possible O +
use O +
of O +
let-7 O +
miRNA O +
for O +
treating O +
glioblastoma U-Disease -
. O -

However O -
, O +
let-7 O +
miRNA O +
exerted O +
no O +
effect O +
on O +
the O +
proliferation O +
of O +
normal O +
human O +
astrocytes O -
. O -

Let-7 O +
miRNA O +
also O +
reduced O +
the O +
in O -
- O -
vitro O +
proliferation O +
and O +
migration O +
of O +
the O +
cells O -
, O +
and O +
reduced O +
the O +
sizes O +
of O +
the O +
tumors U-Disease +
produced O +
after O +
transplantation O +
into O +
nude O +
mice O -
. O -

MiRNAs O +
microarray O +
analysis O +
results O +
showed O +
that O +
125 O +
miRNAs O +
were O +
detected O +
in O +
the O +
hippocampus O +
of O +
lithium O -
- O -
pilocarpine O -
- O -
induced O +
TLE U-Disease +
rats O +
and O +
normal O +
rats O -
. O -

To O +
understand O +
the O +
role O +
of O +
miRNAs O +
in O +
the O +
molecular O +
mechanisms O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease +
( O -
TLE U-Disease -
) O -
, O +
we O +
investigated O +
the O +
changes O +
in O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
profiles O +
of O +
chronic O +
TLE U-Disease +
rat O +
models O -
. O -

Temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease +
induces O +
differential O +
expression O +
of O +
hippocampal O +
miRNAs O +
including O +
let-7e O +
and O +
miR-23a O -
/ O -
b O -
. O -

let-7e O +
was O +
detected O +
down O -
- O -
regulated O +
expression O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
2days O -
, O +
7days O -
, O +
50days O +
after O +
SE U-Disease +
and O +
up O -
- O -
regulated O +
expression O +
at O +
12h O -
, O +
24h O -
, O +
10days O -
, O +
30days O +
after O +
SE U-Disease -
, O +
which O +
was O +
significantly O +
up O -
- O -
regulated O +
expression O +
at O +
24h O +
after O +
SE U-Disease +
( O -
10.49 O +
folds O -
, O +
P<0.01 O -
) O -
. O -

miR-23a O -
/ O -
b O +
was O +
detected O +
down O -
- O -
regulated O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
12h O -
, O +
2days O -
, O +
7days O -
, O +
10days O -
, O +
30days O +
after O +
SE U-Disease +
and O +
significantly O +
up O -
- O -
regulated O +
at O +
24h O +
( O -
4.49 O +
folds O +
P<0.01 O -
) O -
, O +
50d O +
( O -
2.4 O +
folds O -
, O +
P<0.01 O -
) O +
after O +
SE U-Disease -
. O +
TLE U-Disease +
alters O +
the O +
expression O +
levels O +
of O +
a O +
subset O +
of O +
miRNAs O +
in O +
the O +
hippocampus O +
and O +
these O +
deregulated O +
miRNAs O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
epilepsy U-Disease +
directly O +
or O +
indirectly O -
. O -

Compared O +
with O +
normal O +
rats O +
( O -
control O +
group O -
) O -
, O +
23 O +
of O +
the O +
125 O +
miRNAs O +
were O +
expressed O +
differentially O +
in O +
TLE U-Disease +
rats O +
including O +
5 O +
down O -
- O -
regulated O +
miRNAs O +
( O -
let-7e O +
included O -
) O +
and O +
18 O +
up O -
- O -
regulated O +
miRNAs O +
( O -
miR-23a O -
/ O -
b O +
included O -
) O -
. O -

Furthermore O -
, O +
let-7e O +
and O +
miR-23a O -
/ O -
b O +
analysis O +
in O +
rat O +
hippocampus O +
were O +
performed O +
by O +
real O -
- O -
time O +
quantitative O +
polymerase O +
chain O +
reaction O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
12h O -
, O +
24h O -
, O +
2days O -
, O +
7days,10days O -
, O +
30days,50days O +
after O +
induction O +
of O +
status B-Disease +
epilepticus L-Disease +
( O -
SE U-Disease -
) O -
. O -

Also O +
the O +
temporal O +
change O +
of O +
the O +
let-7e O +
and O +
miR-23a O -
/ O -
b O +
expression O +
in O +
the O +
epileptogenesis O +
indicated O +
their O +
underlying O +
functions O +
on O +
TLE U-Disease -
. O -

The O +
findings O +
also O +
indicate O +
that O +
allopregnanolone O +
and O +
perhaps O +
other O +
neurosteroid O -
- O -
like O +
compounds O +
might O +
represent O +
potential O +
biomarkers O +
or O +
therapies O +
for O +
multiple B-Disease +
sclerosis L-Disease -
. O -

These O +
multi O -
- O -
platform O +
studies O +
point O +
to O +
impaired O +
neurosteroidogenesis O +
in O +
both O +
multiple B-Disease +
sclerosis L-Disease +
and O +
experimental O +
autoimmune B-Disease +
encephalomyelitis L-Disease -
. O -

Allopregnanolone O +
treatment O +
of O +
the O +
experimental O +
autoimmune B-Disease +
encephalomyelitis L-Disease +
mouse O +
model O +
limited O +
the O +
associated O +
neuropathology O -
, O +
including O +
neuroinflammation U-Disease -
, O +
myelin O +
and O +
axonal B-Disease +
injury L-Disease +
and O +
reduced O +
neurobehavioral O +
deficits O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Levels O +
of O +
important O +
neurosteroids O -
, O +
including O +
allopregnanolone O -
, O +
were O +
suppressed O +
in O +
the O +
white O +
matter O +
of O +
patients O +
with O +
multiple B-Disease +
sclerosis L-Disease +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Induction O +
of O +
the O +
murine O +
micro O -
- O -
RNAs O -
, O +
miR-338 O +
and O +
miR-155 O -
, O +
accompanied O +
by O +
diminished O +
expression O +
of O +
neurosteroidogenic O +
enzymes O +
and O +
allopregnanolone O -
, O +
was O +
also O +
observed O +
in O +
the O +
brains O +
of O +
mice O +
with O +
experimental O +
autoimmune B-Disease +
encephalomyelitis L-Disease +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Analysis O +
of O +
the O +
neurosteroidogenic O +
pathways O +
targeted O +
by O +
micro O -
- O -
RNAs O +
revealed O +
suppression O +
of O +
enzyme O +
transcript O +
and O +
protein O +
levels O +
in O +
the O +
white O +
matter O +
of O +
patients O +
with O +
multiple B-Disease +
sclerosis L-Disease +
( O -
P O +
< O +
0.05 O -
) O -
. O -

This O +
was O +
confirmed O +
by O +
firefly O -
/ O -
Renilla O +
luciferase O +
micro O -
- O -
RNA O +
target O +
knockdown O +
experiments O +
( O -
P O +
< O +
0.05 O -
) O +
and O +
detection O +
of O +
specific O +
micro O -
- O -
RNAs O +
by O +
in O +
situ O +
hybridization O +
in O +
the O +
brains O +
of O +
patients O +
with O +
or O +
without O +
multiple B-Disease +
sclerosis L-Disease -
. O -

These O +
observations O +
were O +
verified O +
using O +
the O +
in O +
vivo O +
multiple B-Disease +
sclerosis L-Disease +
model O -
, O +
experimental O +
autoimmune B-Disease +
encephalomyelitis L-Disease -
. O -

Brains O +
of O +
patients O +
with O +
or O +
without O +
multiple B-Disease +
sclerosis L-Disease +
demonstrated O +
differential O +
expression O +
of O +
multiple O +
micro O -
- O -
RNAs O -
, O +
but O +
expression O +
of O +
three O +
neurosteroid O +
synthesis O +
enzyme O -
- O -
specific O +
micro O -
- O -
RNAs O +
( O -
miR-338 O -
, O +
miR-155 O +
and O +
miR-491 O -
) O +
showed O +
a O +
bias O +
towards O +
induction O +
in O +
patients O +
with O +
multiple B-Disease +
sclerosis L-Disease +
( O -
P O +
< O +
0.05 O -
) O -
. O -

High O -
- O -
throughput O +
technologies O +
have O +
led O +
to O +
advances O +
in O +
the O +
recognition O +
of O +
disease O +
pathways O +
and O +
their O +
underlying O +
mechanisms O -
. O -

To O +
investigate O +
the O +
impact O +
of O +
micro O -
- O -
RNAs O +
on O +
the O +
disease O +
process O +
in O +
multiple B-Disease +
sclerosis L-Disease -
, O +
a O +
prototypic B-Disease +
inflammatory I-Disease +
neurological I-Disease +
disorder L-Disease -
, O +
we O +
examined O +
cerebral O +
white O +
matter O +
from O +
patients O +
with O +
or O +
without O +
the O +
disease O +
by O +
micro O -
- O -
RNA O +
profiling O -
, O +
together O +
with O +
confirmatory O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
analysis O -
, O +
immunoblotting O +
and O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O -
. O -

Impaired O +
neurosteroid O +
synthesis O +
in O +
multiple B-Disease +
sclerosis L-Disease -
. O -

This O +
review O +
reports O +
the O +
current O +
knowledge O +
of O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
in O +
pituitary B-Disease +
adenomas L-Disease -
, O +
focusing O +
on O +
recent O +
microarray O +
data O -
. O -

Moreover O -
, O +
a O +
discussion O +
is O +
provided O +
concerning O +
the O +
possible O +
role O +
of O +
validated O +
and O +
putative O +
targets O +
of O +
the O +
most O +
dysregulated O +
miRNA O +
in O +
pituitary B-Disease +
adenoma L-Disease +
pathogenesis O -
. O -

MicroRNAs O +
and O +
possible O +
role O +
in O +
pituitary B-Disease +
adenoma L-Disease -
. O -

These O +
findings O +
indicate O +
that O +
miR-107 O +
contributes O +
to O +
GRN O +
expression O +
regulation O +
with O +
implications O +
for O +
brain B-Disease +
disorders L-Disease -
. O -

In O +
brain O +
tissue O +
subjacent O +
to O +
1.0 O +
mm O +
depth O +
controlled O +
cortical O +
impact O -
, O +
surviving O +
hippocampal O +
neurons O +
show O +
decreased O +
miR-107 O +
with O +
augmentation O +
of O +
neuronal O +
GRN O +
expression O -
. O -

We O +
also O +
tested O +
a O +
mouse O +
model O +
where O +
miR-107 O +
has O +
been O +
shown O +
to O +
be O +
down O -
- O -
regulated O -
. O -

However O -
, O +
GRN O +
regulation O +
expression O +
is O +
poorly O +
understood O -
. O -

A O +
high O -
- O -
throughput O +
experimental O +
microRNA O +
assay O +
showed O +
that O +
GRN O +
is O +
the O +
strongest O +
target O +
for O +
miR-107 O +
in O +
human O +
H4 O +
neuroglioma U-Disease +
cells O -
. O -

miR-107 O +
has O +
been O +
implicated O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
pathogenesis O -
, O +
and O +
sequence O +
elements O +
in O +
the O +
open O +
reading O +
frame O -
- O -
rather O +
than O +
the O +
3 O -
' O +
untranslated O +
region O -
- O -
of O +
GRN O +
mRNA O +
are O +
recognized O +
by O +
miR-107 O +
and O +
are O +
highly O +
conserved O +
among O +
vertebrate O +
species O -
. O -

To O +
better O +
understand O +
the O +
mechanism O +
of O +
this O +
interaction O -
, O +
FLAG O -
- O -
tagged O +
Argonaute O +
constructs O +
were O +
used O +
following O +
miR-107 O +
transfection O -
. O -

miR-107 O +
regulates O +
granulin O -
/ O -
progranulin O +
with O +
implications O +
for O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease +
and O +
neurodegenerative B-Disease +
disease L-Disease -
. O -

Granulin O +
( O -
GRN O -
, O +
or O +
progranulin O -
) O +
is O +
a O +
protein O +
involved O +
in O +
wound U-Disease +
repair O -
, O +
inflammation U-Disease -
, O +
and O +
neoplasia U-Disease -
. O -

GRN O +
has O +
also O +
been O +
directly O +
implicated O +
in O +
frontotemporal B-Disease +
dementia L-Disease +
and O +
may O +
contribute O +
to O +
Alzheimer B-Disease -
's I-Disease +
disease L-Disease +
pathogenesis O -
. O -

GRN O +
mRNA O +
interacts O +
preferentially O +
with O +
Argonaute O +
2 O -
. O +
In O +
vitro O +
and O +
in O +
vivo O +
studies O +
indicate O +
that O +
regulation O +
of O +
GRN O +
by O +
miR-107 O +
may O +
be O +
functionally O +
important O -
. O -

Glucose O +
supplementation O +
in O +
cultured O +
cells O +
that O +
leads O +
to O +
increased O +
miR-107 O +
levels O +
also O +
results O +
in O +
decreased O +
GRN O +
expression O -
, O +
including O +
changes O +
in O +
cell O +
compartmentation O +
and O +
decreased O +
secretion O +
of O +
GRN O +
protein O -
. O -

This O +
effect O +
was O +
eliminated O +
following O +
miR-107 O +
transfection O -
. O -

Many O +
miRNA O +
targets O +
have O +
been O +
computationally O +
predicted O +
but O +
only O +
a O +
limited O +
number O +
of O +
these O +
were O +
experimentally O +
validated O -
. O -

However O -
, O +
interactions O +
between O +
miRNAs O +
and O +
their O +
targets O +
are O +
complex O +
and O +
very O +
often O +
there O +
are O +
numerous O +
putative O +
miRNA O +
recognition O +
sites O +
in O +
mRNAs O -
. O -

Therefore O -
, O +
it O +
is O +
of O +
particular O +
interest O +
to O +
reliably O +
predict O +
potential O +
miRNA O +
targets O +
which O +
might O +
be O +
involved O +
in O +
these O +
diseases O -
. O -

Both O +
the O +
deregulation O +
of O +
genes O +
controlled O +
by O +
miRNAs O +
and O +
the O +
altered O +
miRNA O +
expression O +
have O +
been O +
linked O +
to O +
many O +
disorders O -
, O +
including O +
cancer U-Disease -
, O +
cardiovascular O -
, O +
metabolic O +
and O +
neurodegenerative B-Disease +
diseases L-Disease -
. O -

In O +
this O +
review O -
, O +
currently O +
available O +
and O +
frequently O +
used O +
computational O +
tools O +
for O +
miRNA O +
target O +
prediction O -
, O +
i.e. O -
, O +
PicTar O -
, O +
TargetScan O -
, O +
DIANA O -
- O -
microT O -
, O +
miRanda O -
, O +
rna22 O +
and O +
PITA O +
are O +
outlined O +
and O +
various O +
practical O +
aspects O +
of O +
miRNA O +
target O +
analysis O +
are O +
extensively O +
discussed O -
. O -

Hence O -
, O +
finding O +
a O +
functional O +
miRNA O +
target O +
is O +
still O +
a O +
challenging O +
task O -
. O -

Although O +
a O +
variety O +
of O +
miRNA O +
target O +
prediction O +
algorithms O +
are O +
available O -
, O +
results O +
of O +
their O +
application O +
are O +
often O +
inconsistent O -
. O -

microRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
non O -
- O -
coding O +
RNAs O +
that O +
control O +
gene O +
expression O +
at O +
the O +
posttranscriptional O +
level O -
. O -

These O +
small O +
regulatory O +
molecules O +
play O +
a O +
key O +
role O +
in O +
the O +
majority O +
of O +
biological O +
processes O +
and O +
their O +
expression O +
is O +
also O +
tightly O +
regulated O -
. O -

Practical O +
Aspects O +
of O +
microRNA O +
Target O +
Prediction O -
. O -

Moreover O -
, O +
the O +
performance O +
of O +
three O +
algorithms O +
( O -
PicTar O -
, O +
TargetScan O +
and O +
DIANA O -
- O -
microT O -
) O +
is O +
both O +
demonstrated O +
and O +
evaluated O +
by O +
performing O +
an O +
in O -
- O -
depth O +
analysis O +
of O +
miRNA O +
interactions O +
with O +
mRNAs O +
derived O +
from O +
genes O +
triggering O +
hereditary O +
neurological B-Disease +
disorders L-Disease +
known O +
as O +
trinucleotide B-Disease +
repeat I-Disease +
expansion I-Disease +
diseases L-Disease +
( O -
TREDs U-Disease -
) O -
, O +
such O +
as O +
Huntington B-Disease -
's I-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O -
, O +
a O +
number O +
of O +
spinocerebellar B-Disease +
ataxias L-Disease +
( O -
SCAs U-Disease -
) O -
, O +
and O +
myotonic B-Disease +
dystrophy I-Disease +
type I-Disease +
1 L-Disease +
( O -
DM1 U-Disease -
) O -
. O -

Our O +
study O +
shows O +
that O +
one O +
aspect O +
of O +
miR-155 O +
function O +
is O +
the O +
promotion O +
of O +
T O +
cell O -
- O -
dependent O +
tissue O +
inflammation U-Disease -
, O +
suggesting O +
that O +
miR-155 O +
might O +
be O +
a O +
promising O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
autoimmune B-Disease +
disorders L-Disease -
. O -

miR-155 O +
functions O +
in O +
the O +
hematopoietic O +
compartment O +
to O +
promote O +
the O +
development O +
of O +
inflammatory O +
T O +
cells O +
including O +
the O +
T O +
helper O +
17 O +
( O -
Th17 O -
) O +
cell O +
and O +
Th1 O +
cell O +
subsets O -
. O -

Furthermore O -
, O +
the O +
major O +
contribution O +
of O +
miR-155 O +
to O +
EAE U-Disease +
was O +
CD4 O -
( O -
+ O -
) O +
T O +
cell O +
intrinsic O -
, O +
whereas O +
miR-155 O +
was O +
also O +
required O +
for O +
optimum O +
dendritic O +
cell O +
production O +
of O +
cytokines O +
that O +
promoted O +
Th17 O +
cell O +
formation O -
. O -

Here O -
, O +
we O +
have O +
investigated O +
the O +
role O +
of O +
miR-155 O +
during O +
an O +
autoimmune B-Disease +
inflammatory I-Disease +
disease L-Disease -
. O -

Consistent O +
with O +
a O +
positive O +
role O +
for O +
miR-155 O +
in O +
mediating O +
inflammatory O +
responses O -
, O +
Mir155 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
were O +
highly O +
resistant O +
to O +
experimental B-Disease +
autoimmune I-Disease +
encephalomyelitis L-Disease +
( O -
EAE U-Disease -
) O -
. O -

MicroRNA-155 O +
promotes O +
autoimmune B-Disease +
inflammation L-Disease +
by O +
enhancing O +
inflammatory O +
T O +
cell O +
development O -
. O -

Mammalian O +
noncoding O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
class O +
of O +
gene O +
regulators O +
that O +
have O +
been O +
linked O +
to O +
immune O +
system O +
function O -
. O -

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
in O +
cancer U-Disease -
: O +
discovery O -
, O +
function O +
and O +
future O +
perspectives O -
. O -

Expression O +
of O +
these O +
miRNAs O +
inhibits O +
cell O +
proliferation O -
, O +
promotes O +
apoptosis O +
of O +
cancer U-Disease +
cells O -
, O +
and O +
suppresses O +
tumorigenicity O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
encoded O +
by O +
the O +
miR-15 O -
/ O -
16 O +
cluster O +
are O +
known O +
to O +
act O +
as O +
tumor O +
suppressors O -
. O -

Down O -
- O -
regulation O +
of O +
these O +
miRNAs O +
has O +
been O +
reported O +
in O +
chronic B-Disease +
lymphocytic I-Disease +
lymphoma L-Disease +
( O -
CLL U-Disease -
) O -
, O +
pituitary B-Disease +
adenomas L-Disease -
, O +
and O +
prostate B-Disease +
carcinoma L-Disease -
. O -

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
function O +
by O +
targeting O +
multiple O +
oncogenes O -
, O +
including O +
BCL2 O -
, O +
MCL1 O -
, O +
CCND1 O -
, O +
and O +
WNT3A O -
. O -

This O +
review O +
summarizes O +
the O +
discovery O -
, O +
functions O -
, O +
and O +
clinical O +
relevance O +
of O +
these O +
miRNAs O +
in O +
cancer U-Disease -
, O +
particularly O +
CLL U-Disease -
. O -

During O +
experimental B-Disease +
autoimmune I-Disease +
encephalomyelitis L-Disease +
( O -
EAE U-Disease -
) O -
, O +
miR-124 O +
was O +
downregulated O +
in O +
activated O +
microglia O -
. O -

Peripheral O +
administration O +
of O +
miR-124 O +
in O +
EAE U-Disease +
caused O +
systemic O +
deactivation O +
of O +
macrophages O -
, O +
reduced O +
activation O +
of O +
myelin O -
- O -
specific O +
T O +
cells O +
and O +
marked O +
suppression O +
of O +
disease O -
. O -

Conversely O -
, O +
knockdown O +
of O +
miR-124 O +
in O +
microglia O +
and O +
macrophages O +
resulted O +
in O +
activation O +
of O +
these O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

These O +
findings O +
identify O +
miR-124 O +
both O +
as O +
a O +
key O +
regulator O +
of O +
microglia O +
quiescence O +
in O +
the O +
central O +
nervous O +
system O +
and O +
as O +
a O +
previously O +
unknown O +
modulator O +
of O +
monocyte O +
and O +
macrophage O +
activation O -
. O -

MicroRNA-124 O +
promotes O +
microglia O +
quiescence O +
and O +
suppresses O +
EAE U-Disease +
by O +
deactivating O +
macrophages O +
via O +
the O +
C O -
/ O -
EBP O -
- O -
α O -
- O -
PU.1 O +
pathway O -
. O -

MicroRNAs O +
are O +
a O +
family O +
of O +
regulatory O +
molecules O +
involved O +
in O +
many O +
physiological O +
processes O -
, O +
including O +
differentiation O +
and O +
activation O +
of O +
cells O +
of O +
the O +
immune O +
system O -
. O -

We O +
found O +
that O +
brain O -
- O -
specific O +
miR-124 O +
is O +
expressed O +
in O +
microglia O +
but O +
not O +
in O +
peripheral O +
monocytes O +
or O +
macrophages O -
. O -

When O +
overexpressed O +
in O +
macrophages O -
, O +
miR-124 O +
directly O +
inhibited O +
the O +
transcription O +
factor O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O -
- O -
α O +
( O -
C O -
/ O -
EBP O -
- O -
α O -
) O +
and O +
its O +
downstream O +
target O +
PU.1 O -
, O +
resulting O +
in O +
transformation O +
of O +
these O +
cells O +
from O +
an O +
activated O +
phenotype O +
into O +
a O +
quiescent O +
CD45 O -
( O -
low O -
) O -
, O +
major O +
histocompatibility O +
complex O +
( O -
MHC O -
) O +
class O +
II O -
( O -
low O -
) O +
phenotype O +
resembling O +
resting O +
microglia O -
. O -

Molecular O +
and O +
cellular O +
neurobiological O +
studies O +
of O +
the O +
miRNAs O +
in O +
neurodegeneration O +
represent O +
the O +
exploration O +
of O +
a O +
new O +
Frontier O +
of O +
miRNAs O +
biology O +
and O +
the O +
potential O +
development O +
of O +
new O +
diagnostic O +
tests O +
and O +
genetic O +
therapies O +
for O +
neurodegenerative B-Disease +
diseases L-Disease -
. O -

MiRNA O +
studies O +
in O +
neurobiology O +
showed O +
their O +
involvement O +
in O +
synaptic O +
plasticity O +
and O +
brain B-Disease +
diseases L-Disease -
. O -

In O +
this O +
review O +
, O -
correlations O +
between O +
miRNA O -
- O -
mediated O +
gene O +
silencing O +
and O +
Alzheimer B-Disease -
's L-Disease -
, O +
Parkinson B-Disease -
's L-Disease -
, O +
and O +
other O +
neurodegenerative B-Disease +
diseases L-Disease +
will O +
be O +
discussed O -
. O -

In O +
few O +
years O +
our O +
understanding O +
of O +
microRNA O +
( O -
miRNA O -
) O +
biogenesis O -
, O +
molecular O +
mechanisms O +
by O +
which O +
miRNAs O +
regulate O +
gene O +
expression O -
, O +
and O +
the O +
functional O +
roles O +
of O +
miRNAs O +
has O +
been O +
expanded O -
. O -

Interestingly O -
, O +
numerous O +
miRNAs O +
are O +
expressed O +
in O +
a O +
spatially O +
and O +
temporally O +
controlled O +
manner O +
in O +
the O +
nervous O +
system O -
, O +
suggesting O +
that O +
their O +
posttrascriptional O +
regulation O +
may O +
be O +
particularly O +
relevant O +
in O +
neural O +
development O +
and O +
function O -
. O -

Searching O +
for O +
MIND O -
: O +
microRNAs O +
in O +
neurodegenerative B-Disease +
diseases L-Disease -
. O -

In O +
gliomas U-Disease -
, O +
microRNA-21 O +
( O -
miR-21 O -
) O +
levels O +
have O +
been O +
reported O +
to O +
be O +
elevated O +
and O +
their O +
knockdown O +
is O +
associated O +
with O +
increased O +
apoptotic O +
activity O -
. O -

We O +
hypothesized O +
that O +
suppression O +
of O +
miR-21 O +
might O +
sensitize O +
gliomas U-Disease +
for O +
cytotoxic O +
tumor O +
therapy O -
. O -

With O +
the O +
use O +
of O +
locked O +
nucleic O +
acid O +
( O -
LNA O -
) O -
-antimiR-21 O +
oligonucleotides O -
, O +
bimodal O +
imaging O +
vectors O -
, O +
and O +
neural O +
precursor O +
cells O +
( O -
NPC O -
) O +
expressing O +
a O +
secretable O +
variant O +
of O +
the O +
cytotoxic O +
agent O +
tumor O +
necrosis O +
factor O -
- O -
related O +
apoptosis O +
inducing O +
ligand O +
( O -
S O -
- O -
TRAIL O -
) O -
, O +
we O +
show O +
that O +
the O +
combined O +
suppression O +
of O +
miR-21 O +
and O +
NPC O -
- O -
S O -
- O -
TRAIL O +
leads O +
to O +
a O +
synergistic O +
increase O +
in O +
caspase O +
activity O +
and O +
significantly O +
decreased O +
cell O +
viability O +
in O +
human B-Disease +
glioma L-Disease +
cells O +
in O +
vitro O -
. O -

This O +
phenomenon O +
persists O +
in O +
vivo O -
, O +
as O +
we O +
observed O +
complete O +
eradication O +
of O +
LNA O -
- O -
antimiR-21-treated O +
gliomas U-Disease +
subjected O +
to O +
the O +
presence O +
of O +
NPC O -
- O -
S O -
- O -
TRAIL O +
in O +
the O +
murine O +
brain O -
. O -

Our O +
results O +
reveal O +
the O +
efficacy O +
of O +
miR-21 O +
antagonism O +
in O +
murine O +
glioma U-Disease +
models O +
and O +
implicate O +
miR-21 O +
as O +
a O +
target O +
for O +
therapeutic O +
intervention O -
. O -

Furthermore O -
, O +
our O +
findings O +
provide O +
the O +
basis O +
for O +
developing O +
combination O +
therapies O +
using O +
miRNA O +
modulation O +
and O +
cytotoxic O +
tumor O +
therapies O -
. O -

MicroRNA-21 O +
knockdown O +
disrupts O +
glioma U-Disease +
growth O +
in O +
vivo O +
and O +
displays O +
synergistic O +
cytotoxicity O +
with O +
neural O +
precursor O +
cell O +
delivered O +
S O -
- O -
TRAIL O +
in O +
human B-Disease +
gliomas L-Disease -
. O -

Mounting O +
evidence O +
indicates O +
that O +
microRNAs O +
( O -
miRNA O -
) O +
might O +
play O +
a O +
fundamental O +
role O +
in O +
tumorigenesis O -
, O +
controlling O +
cell O +
proliferation O +
and O +
apoptosis O -
. O -

Despite O +
the O +
development O +
of O +
new O +
glioma U-Disease +
therapies O +
that O +
allow O +
for O +
tumor U-Disease -
- O -
targeted O +
in O +
situ O +
delivery O +
of O +
cytotoxic O +
drugs O -
, O +
tumor O +
resistance O +
to O +
apoptosis O +
remains O +
a O +
key O +
impediment O +
to O +
effective O +
treatment O -
. O -

CONCLUSIONS O -
: O +
The O +
irregularity O +
of O +
prolactin O +
secretion O +
in O +
patients O +
with O +
NPG U-Disease +
is O +
not O +
dependant O +
on O +
the O +
presence O +
of O +
a O +
pituitary B-Disease +
tumour L-Disease +
which O +
suggests O +
that O +
a O +
hypothalamic B-Disease +
dysfunction L-Disease +
underlies O +
this O +
condition O -
. O -

An O +
irregular O +
secretion O +
and O +
a O +
higher O +
daily O +
mass O +
production O +
of O +
prolactin O +
in O +
patients O +
with O +
NPG U-Disease +
could O +
explain O +
both O +
galactorrhea U-Disease +
and O +
infertility U-Disease -
. O -

BACKGROUND O -
: O +
Abnormal O +
frequency O +
and O +
pulse O +
amplitud O +
of O +
prolactin O +
secretion O +
in O +
micro O +
and O +
macroprolactinomas U-Disease +
has O +
been O +
atributed O +
to O +
a O +
dysfunctional O +
tumoral O +
lactotrope O -
. O -

[ O -
Irregular O +
secretion O +
of O +
prolactin O +
in O +
infertile O +
women O +
with O +
normoprolactinemic B-Disease +
galactorrhea L-Disease -
] O -
. O -

The O +
regularity O +
of O +
prolactin O +
secretion O +
has O +
not O +
been O +
studied O +
with O +
cuantitative O +
methods O +
in O +
patients O +
with O +
normoprolactinemic B-Disease +
galactorrhea L-Disease +
( O -
NPG U-Disease -
) O +
which O +
could O +
be O +
considered O +
an O +
entity O +
that O +
precedes O +
non O +
tumoral O +
and O +
tumoral B-Disease +
hyperprolactinemia L-Disease -
. O -

Previous O +
evidence O +
suggests O +
that O +
non B-Disease +
tumoral I-Disease +
hyperprolactinemia L-Disease +
is O +
caused O +
by O +
a O +
hypothalamic B-Disease +
dysfunction L-Disease -
. O -

PATIENTS O +
AND O +
METHODS O -
: O +
A O +
transversal O -
- O -
comparative O +
study O +
was O +
carried O +
out O +
in O +
6 O +
infertile O +
women O +
with O +
normoprolactinemic B-Disease +
galactorrhea L-Disease +
and O +
4 O +
healthy O +
women O +
as O +
controls O -
. O -

Objective O -
: O +
To O +
analyze O +
the O +
24-hour O +
prolactin O +
secretion O +
pattern O +
and O +
its O +
secretion O +
regularity O +
in O +
a O +
group O +
of O +
infertile O +
women O +
with O +
normoprolactinemic O +
galatorea O -
. O -

RESULTS O -
: O +
Blunting O +
of O +
the O +
nyctohemeral O +
rythm O +
and O +
nocturn B-Disease +
hyperprolactinaemia L-Disease +
occurred O +
in O +
patients O +
with O +
normoprolactinemic B-Disease +
galactorrhea L-Disease +
( O -
NPG U-Disease -
) O -
. O -

The O +
24 O +
hour O +
prolactin O +
profile O -
, O +
the O +
ratio O +
night O +
time O +
mean O +
concentration O -
/ O -
daytime O +
mean O +
concentrattion O +
( O -
NM O -
/ O -
DM O +
ratio O -
) O +
and O +
apparent O +
entropy O +
( O -
Ap O +
En O -
, O +
Ap O +
En O +
ratio O -
) O +
were O +
compared O +
in O +
the O +
two O +
groups O -
. O -

Higher O +
irregularity O +
of O +
prolactin O +
secretion O +
was O +
found O +
in O +
patients O +
with O +
NPG U-Disease +
( O -
ApEn O -
: O +
0.853 O +
+ O -
/- O +
0.158 O +
vs O +
0.608 O +
+ O -
/- O +
0.171 O -
, O +
p=0.04 O -
; O +
Ap O +
En O +
ratio O -
: O +
0.839 O +
+ O -
/- O +
0.11 O +
vs O +
0.661 O +
+ O -
/- O +
0.14 O -
; O +
p=0.04 O -
) O -
. O -

NM O -
/ O -
DM O +
ratio O +
was O +
lower O +
in O +
patients O +
with O +
NPG U-Disease +
than O +
in O +
controls O +
( O -
1.28 O +
+ O -
/- O +
0.25 O +
vs. O +
1.75 O +
+ O -
/- O +
0.05 O -
; O +
p= O +
0.01 O -
) O -
. O -

We O +
therefore O +
sought O +
to O +
determine O +
whether O +
microRNA O +
targets O +
could O +
be O +
engineered O +
into O +
VSV O +
to O +
ameliorate O +
its O +
neuropathogenicity O -
. O -

Using O +
a O +
panel O +
of O +
recombinant O +
VSVs O +
incorporating O +
microRNA O +
target O +
sequences O +
corresponding O +
to O +
neuron O -
- O -
specific O +
or O +
control O +
microRNAs O +
( O -
in O +
forward O +
and O +
reverse O +
orientations O -
) O -
, O +
we O +
tested O +
viral O +
replication O +
kinetics O +
in O +
cell O +
lines O +
treated O +
with O +
microRNA O +
mimics O -
, O +
neurotoxicity U-Disease +
after O +
direct O +
intracerebral O +
inoculation O +
in O +
mice O -
, O +
and O +
antitumor O +
efficacy O -
. O -

Compared O +
to O +
picornaviruses O +
and O +
adenoviruses O -
, O +
the O +
engineered O +
VSVs O +
were O +
relatively O +
resistant O +
to O +
microRNA O -
- O -
mediated O +
inhibition O -
, O +
but O +
neurotoxicity U-Disease +
could O +
nevertheless O +
be O +
ameliorated O +
significantly O +
using O +
this O +
approach O -
, O +
without O +
compromise O +
to O +
antitumor O +
efficacy O -
. O -

Neurotoxicity U-Disease +
was O +
most O +
profoundly O +
reduced O +
in O +
a O +
virus O +
carrying O +
four O +
tandem O +
copies O +
of O +
a O +
neuronal O +
mir125 O +
target O +
sequence O +
inserted O +
in O +
the O +
3'-untranslated O +
region O +
of O +
the O +
viral O +
polymerase O +
( O -
L O -
) O +
gene O -
. O -

Attenuation O +
of O +
vesicular B-Disease +
stomatitis I-Disease +
virus I-Disease +
encephalitis L-Disease +
through O +
microRNA O +
targeting O -
. O -

Vesicular O +
stomatitis O +
virus O +
( O -
VSV O -
) O +
has O +
long O +
been O +
regarded O +
as O +
a O +
promising O +
recombinant O +
vaccine O +
platform O +
and O +
oncolytic O +
agent O +
but O +
has O +
not O +
yet O +
been O +
tested O +
in O +
humans O +
because O +
it O +
causes O +
encephalomyelitis U-Disease +
in O +
rodents O +
and O +
primates O -
. O -

Recent O +
studies O +
have O +
shown O +
that O +
specific O +
tropisms O +
of O +
several O +
viruses O +
could O +
be O +
eliminated O +
by O +
engineering O +
microRNA O +
target O +
sequences O +
into O +
their O +
genomes O -
, O +
thereby O +
inhibiting O +
spread O +
in O +
tissues O +
expressing O +
cognate O +
microRNAs O -
. O -

Alteration O +
of O +
miRNA O +
expression O +
by O +
disease O +
and O +
insult O +
also O +
holds O +
the O +
potential O +
for O +
improved O +
diagnostic O +
tools O -
. O -

Finally O -
, O +
miRNAs O +
have O +
been O +
shown O +
to O +
control O +
cellular O +
proliferation O +
and O +
specification O -
, O +
suggesting O +
that O +
manipulation O +
of O +
miRNAs O +
in O +
cultured O +
cells O +
could O +
result O +
in O +
more O +
convenient O +
generation O +
of O +
pure O +
cell O +
populations O +
for O +
transplantation O -
. O -

miRNAs O +
appear O +
to O +
be O +
dysregulated O +
in O +
a O +
number O +
of O +
neurodegenerative B-Disease +
diseases L-Disease -
, O +
developmental B-Disease +
disorders L-Disease -
, O +
and O +
as O +
a O +
result O +
of O +
stroke U-Disease -
. O -

MicroRNAS O +
( O -
miRNAs O -
) O +
have O +
been O +
suggested O +
to O +
play O +
important O +
roles O +
in O +
the O +
central O +
nervous O +
system O +
during O +
development O +
as O +
well O +
as O +
disease O -
. O -

The O +
therapeutic O +
potential O +
of O +
microRNAs O +
in O +
nervous O +
system O +
damage O -
, O +
degeneration O -
, O +
and O +
repair O -
. O -

Artificial O +
miRNAs O +
have O +
also O +
been O +
generated O +
for O +
the O +
repression O +
of O +
specific O +
transcripts O -
. O -

Both O +
viral O +
delivery O +
and O +
administration O +
of O +
modified O +
oligonucleotides O +
mimicking O +
or O +
inhibiting O +
specific O +
miRNAs O +
have O +
been O +
effective O +
in O +
model O +
systems O -
. O -

Recent O +
findings O +
suggest O +
that O +
it O +
may O +
eventually O +
be O +
possible O +
to O +
treat O +
some O +
neurological B-Disease +
disorders L-Disease +
by O +
restoring O +
or O +
inhibiting O +
miRNAs O +
altered O +
by O +
disease O +
pathology O -
. O -

Each O +
miRNA O +
has O +
the O +
ability O +
to O +
regulate O +
hundreds O +
of O +
messenger O +
RNA O +
transcripts O -
, O +
both O +
by O +
causing O +
degradation O +
of O +
the O +
mRNA O +
and O +
by O +
inhibition O +
of O +
protein O +
translation O -
. O -

MicroRNA-210 O +
as O +
a O +
novel O +
blood O +
biomarker O +
in O +
acute O +
cerebral B-Disease +
ischemia L-Disease -
. O -

MicroRNA-210 O +
( O -
miR-210 O -
) O -
, O +
a O +
master O +
and O +
pleiotropic O +
hypoxia U-Disease -
- O -
microRNA O -
, O +
plays O +
multiple O +
roles O +
in O +
brain B-Disease +
ischemia L-Disease -
. O -

However O -
, O +
miR-210 O +
expression O +
and O +
its O +
function O +
in O +
humans O +
have O +
not O +
been O +
explored O -
. O -

The O +
aim O +
of O +
our O +
study O +
is O +
to O +
evaluate O +
the O +
correlation O +
of O +
blood O +
miR-210 O +
with O +
clinical O +
findings O +
in O +
acute B-Disease +
ischemic I-Disease +
stroke L-Disease -
. O -

Blood O +
samples O +
were O +
obtained O +
from O +
stroke U-Disease +
patients O +
( O -
n=112 O -
) O +
and O +
healthy O +
controls O +
( O -
n= O +
60 O -
) O -
. O -

MiR-210 O +
was O +
measured O +
at O +
within O +
3 O -
, O +
7 O +
and O +
14 O +
days O +
after O +
stroke U-Disease +
using O +
a O +
quantitative O +
PCR O +
technique O -
. O -

Stroke U-Disease +
severity O +
and O +
clinical O +
outcome O +
were O +
evaluated O +
by O +
NIHSS O +
and O +
modified O +
Rankin O +
Score O -
. O -

Both O +
blood O +
and O +
brain O +
miR-210 O +
in O +
ischemic O +
mice O +
was O +
examined O +
and O +
the O +
correlation O +
was O +
investigated O -
. O -

Compared O +
to O +
healthy O +
controls O -
, O +
blood O +
miRNA-210 O +
was O +
significantly O +
decreased O +
in O +
stroke U-Disease +
patients O +
( O -
0.93 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O -
, O +
especially O +
at O +
7 O +
days O +
( O -
0.56 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O +
and O +
14 O +
days O +
of O +
stroke U-Disease +
onset O +
( O -
0.50 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O -
. O -

The O +
cut O +
off O +
point O +
of O +
miR-210 O +
in O +
diagnosis O +
was O +
0.505 O +
with O +
88.3 O +
per O +
cent O +
sensitivity O -
. O -

MiR-210 O +
level O +
in O +
stroke U-Disease +
patients O +
with O +
good O +
outcome O +
was O +
significantly O +
higher O +
than O +
patients O +
with O +
poor O +
outcome O +
( O -
1.2 O +
vs. O +
0.44 O -
; O +
P=0.012 O -
) O -
. O -

The O +
correlation O +
between O +
blood O +
and O +
brain O +
miR-210 O +
in O +
ischemic O +
mice O +
was O +
positive O +
( O -
R2=0.57 O -
, O +
P=0.001 O -
) O -
. O -

Blood O +
miR-210 O +
is O +
a O +
novel O +
sensitive O +
biomarker O +
for O +
clinical O +
diagnosis O +
and O +
prognosis O +
in O +
acute B-Disease +
cerebral I-Disease +
ischemia L-Disease -
. O -

Out O +
of O +
the O +
5 O +
positive O +
samples O -
, O +
one O +
was O +
an O +
HTLV O -
, O +
three O +
HTLV-1 O +
and O +
one O +
HTLV-2 O -
. O -

These O +
blood O +
donors O +
were O +
residents O +
of O +
Posadas O -
, O +
Eldorado O +
and O +
Oberá O -
, O +
with O +
no O +
risk O +
antecedents O -
. O -

This O +
study O +
demonstrates O +
the O +
presence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
a O +
population O +
of O +
Misiones O +
with O +
a O +
prevalence O +
rate O +
similar O +
to O +
those O +
reported O +
among O +
blood O +
donors O +
from O +
non O -
- O -
endemic O +
areas O -
. O -

[ O -
Seroprevalence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
blood O +
donors O +
from O +
Misiones O +
Province O -
] O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
estimate O +
the O +
seroprevalence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
a O +
blood O +
donor O +
population O +
from O +
Misiones O +
province O -
. O -

They O +
are O +
transmitted O +
through O +
sex O +
contact O -
, O +
parenterally O +
and O +
from O +
mother O +
to O +
child O -
. O -

HTLV-1 O -
/ O -
2 O +
screening O +
was O +
performed O +
with O +
ELISA O +
and O +
particle O +
agglutination O -
, O +
and O +
reactive O +
samples O +
were O +
confirmed O +
by O +
Western O +
Blot O -
. O -

A O +
total O +
of O +
6912 O +
accepted O +
blood O +
donations O +
in O +
2008 O +
were O +
analyzed O -
. O -

It O +
is O +
endemic O +
worldwide O -
, O +
including O +
the O +
North O +
of O +
Argentina O +
where O +
both O +
associated O +
diseases O +
have O +
also O +
been O +
detected O -
. O -

Human O +
T O -
- O -
cell O +
Lymphotropic O +
viruses O +
type O +
1 O +
( O -
HTLV-1 O -
) O -
, O +
the O +
first O +
human O +
oncoretrovirus O +
to O +
be O +
discovered O -
, O +
is O +
the O +
etiologic O +
agent O +
of O +
Adult B-Disease +
T I-Disease -
- I-Disease -
cell I-Disease +
Leukemia L-Disease +
( O -
ATL U-Disease -
) O +
and O +
HTLV-1 B-Disease +
Associated I-Disease +
Mielopathy L-Disease +
or O +
Tropical B-Disease +
Spastic I-Disease +
Paraparesis L-Disease +
( O -
HAM U-Disease -
/ O -
TSP U-Disease -
) O -
. O -

Both O +
retroviruses O +
are O +
endemic O +
in O +
native O +
populations O +
of O +
The O +
Americas O -
, O +
Africa O +
and O +
at O -
- O -
risk O +
populations O -
. O -

No O +
etiologic O +
role O +
has O +
been O +
described O +
for O +
HTLV-2 O -
, O +
although O +
it O +
has O +
been O +
associated O +
with O +
HAM U-Disease -
/ O -
TSP U-Disease -
- O -
like O +
neurologic B-Disease +
syndromes L-Disease -
. O -

From O +
the O +
total O -
, O +
5 O +
samples O +
resulted O +
seropositive O +
with O +
a O +
final O +
prevalence O +
of O +
0.00072 O -
. O -

Furthermore O -
, O +
in O +
patient O +
samples O +
expression O +
of O +
miR O +
124a O +
is O +
significantly O +
decreased O -
. O -

Our O +
data O +
strongly O +
indicate O +
that O +
CDK6 O +
is O +
regulated O +
by O +
microRNA O +
124 O +
in O +
medulloblastoma U-Disease +
and O +
that O +
miR O +
124 O +
modulates O +
medulloblastoma U-Disease +
cell O +
growth O -
. O -

We O +
hypothesized O +
that O +
CDK6 O +
expression O +
is O +
also O +
regulated O +
by O +
microRNAs O +
in O +
medulloblastoma U-Disease -
. O -

Genomic O +
amplification O +
accounts O +
for O +
some O -
, O +
but O +
not O +
all O +
of O +
the O +
CDK6 O +
over O -
- O -
expression O -
. O -

Expression O +
of O +
miR O +
124a O +
was O +
significantly O +
decreased O +
in O +
medulloblastoma U-Disease +
cells O +
compared O +
to O +
normal O +
adult O +
cerebellum O -
. O -

We O +
identified O +
putative O +
miR O +
sites O +
in O +
the O +
CDK6 O +
including O +
microRNA O +
124a O -
, O +
a O +
brain O +
enriched O +
microRNA O -
. O -

Additionally O -
, O +
re O -
- O -
expression O +
of O +
miR O +
124a O +
in O +
medulloblastoma U-Disease +
cells O +
decreased O +
expression O +
of O +
CDK6 O +
protein O -
. O -

Functional O +
association O +
between O +
miR O +
124a O +
and O +
CDK6 O +
in O +
medulloblastoma U-Disease +
was O +
established O +
using O +
luciferase O +
assays O -
. O -

Transfection O +
of O +
miR O +
124 O +
significantly O +
decreases O +
medulloblastoma U-Disease +
cell O +
growth O +
but O +
does O +
not O +
alter O +
apoptosis O -
. O -

Regulation O +
of O +
cyclin O +
dependent O +
kinase O +
6 O +
by O +
microRNA O +
124 O +
in O +
medulloblastoma U-Disease -
. O -

Despite O +
recent O +
advances O +
in O +
treatment O +
medulloblastoma U-Disease +
continues O +
to O +
remain O +
a O +
vexing O +
problem O -
. O -

Recently O +
increased O +
expression O +
of O +
cyclin O +
dependent O +
kinase O +
6 O +
( O -
CDK6 O -
) O +
was O +
identified O +
as O +
an O +
adverse O +
prognostic O +
marker O +
in O +
medulloblastoma U-Disease -
. O -

CONCLUSIONS O -
: O +
The O +
study O +
suggests O +
that O +
spatial O +
orientation O +
memory O +
relies O +
on O +
the O +
integrity O +
of O +
the O +
right O +
hippocampus O -
. O -

Nevertheless O -
, O +
further O +
studies O +
are O +
necessary O +
to O +
confirm O +
this O +
hypothesis O -
. O -

The O +
subjects O +
were O +
submitted O +
to O +
a O +
neuropsychologic O +
evaluation O +
through O +
the O +
Route O +
Learning O +
Test O +
and O +
the O +
Childhood O +
Home O +
Test O +
in O +
the O +
preoperative O +
period O -
. O -

The O +
statistical O +
analysis O +
was O +
performed O +
using O +
the O +
Kruskal O -
- O -
Wallis O -
, O +
analysis O +
of O +
variance O -
, O +
χ O -
, O +
and O +
Mann O -
- O -
Whitney O +
U O +
tests O -
. O -

RESULTS O -
: O +
There O +
was O +
no O +
significant O +
difference O +
in O +
performance O +
in O +
the O +
remote O +
visuospatial O +
memory O +
( O -
as O +
measured O +
by O +
the O +
Childhood O +
Home O +
Test O -
) O +
across O +
the O +
groups O +
( O -
LTLE O -
, O +
RTLE O -
, O +
and O +
control O -
) O -
. O -

Concerning O +
the O +
spatial O +
orientation O +
memory O -
, O +
however O -
, O +
there O +
was O +
a O +
significant O +
difference O +
between O +
the O +
LTLE O +
and O +
controls O +
as O +
compared O +
with O +
the O +
RTLE O +
group O +
( O -
P<0.001 O -
) O -
, O +
the O +
latter O +
showing O +
a O +
poorer O +
performance O -
. O -

However O -
, O +
evaluations O +
of O +
the O +
right O +
hippocampal O +
functions O +
have O +
not O +
been O +
consistent O -
. O -

In O +
ablative O +
interventions O -
, O +
neuropsychologic O +
testing O +
of O +
memory O +
is O +
a O +
crucial O +
step O -
. O -

METHODS O -
: O +
A O +
controlled O +
study O +
of O +
patients O +
with O +
left O +
( O -
LTLE O -
) O +
or O +
right O +
( O -
RTLE O -
) O +
TLE U-Disease -
. O -

AIM O -
: O +
To O +
assess O +
the O +
hippocampal O +
function O +
in O +
remote O +
orientation O +
and O +
visuospatial O +
memory O +
in O +
patients O +
with O +
refractory B-Disease +
temporal I-Disease +
epilepsy L-Disease -
. O -

INTRODUCTION O -
: O +
In O +
temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease +
( O -
TLE U-Disease -
) O -
, O +
about O +
30 O -
% O +
of O +
the O +
patients O +
do O +
not O +
achieve O +
adequate O +
pharmacologic O +
control O +
of O +
refractory O +
crises O -
, O +
and O +
surgery O +
becomes O +
an O +
alternative O -
. O -

Route O +
Learning O +
Performance O -
: O +
Is O +
it O +
a O +
Hippocampus O +
Function O -
? O -

Thrombolytic O +
therapy O +
involving O +
recombinant O +
tissue O +
plasminogen O +
activator O +
( O -
rtPA O -
) O +
has O +
been O +
shown O +
to O +
be O +
beneficial O +
only O +
when O +
used O +
within O +
4.5 O +
hours O +
of O +
onset O +
of O +
acute B-Disease +
ischemic I-Disease +
stroke L-Disease -
. O -

There O +
are O +
two O +
major O +
types O +
of O +
stroke U-Disease -
: O +
cerebral B-Disease +
ischemia L-Disease +
caused O +
by O +
obstruction O +
of O +
blood O +
vessels O +
in O +
the O +
brain O +
and O +
haemorrhagic B-Disease +
stroke L-Disease +
that O +
is O +
triggered O +
by O +
the O +
disruption O +
of O +
blood O +
vessels O -
. O -

Stroke U-Disease +
is O +
one O +
of O +
the O +
leading O +
causes O +
of O +
death O +
and O +
disability O +
worldwide O -
. O -

microRNAs O +
in O +
stroke U-Disease +
pathogenesis O -
. O -

Although O +
the O +
biochemistry O +
of O +
stroke U-Disease +
and O +
related O +
diseases O +
is O +
quite O +
well O +
understood O -
, O +
the O +
knowledge O +
on O +
the O +
molecular O +
mechanisms O +
underlying O +
these O +
diseases O +
is O +
still O +
at O +
its O +
infancy O -
. O -

microRNAs O +
that O +
form O +
a O +
unique O +
class O +
of O +
endogenous O +
riboregulators O +
of O +
gene O +
function O -
, O +
offer O +
tremendous O +
potential O +
in O +
unraveling O +
the O +
mechanisms O +
underlying O +
stroke U-Disease +
pathogenesis O -
. O -

rtPA O +
treatment O +
beyond O +
this O +
time O +
window O +
has O +
been O +
found O +
to O +
be O +
unsuitable O +
and O +
usually O +
resulting O +
in O +
haemorrhagic O +
transformation O -
. O -

Stroke U-Disease +
is O +
a O +
multifactorial O +
disease O +
that O +
forms O +
a O +
possible O +
end O +
state O +
for O +
majority O +
of O +
patients O +
suffering O +
from O +
diabetes U-Disease -
, O +
atherosclerosis U-Disease +
and O +
hypertension U-Disease +
which O +
are O +
known O +
risk O +
factors O -
. O -

microRNA O +
expression O +
also O +
reflects O +
the O +
response O +
of O +
individuals O +
to O +
drugs O +
and O +
therapy O -
. O -

Several O +
microRNAs O +
and O +
their O +
target O +
genes O -
, O +
known O +
to O +
be O +
involved O +
in O +
endothelial B-Disease +
dysfunction L-Disease -
, O +
dysregulation O +
of O +
neurovascular O +
integrity O -
, O +
edema B-Disease +
formation L-Disease -
, O +
pro O -
- O -
apoptosis O -
, O +
inflammation U-Disease +
and O +
extra O -
- O -
cellular O +
matrix O +
remodeling O +
contribute O +
to O +
the O +
critical O +
processes O +
in O +
the O +
pathogenesis O +
of O +
stroke U-Disease -
. O -

In O +
this O +
review O -
, O +
we O +
will O +
also O +
be O +
discussing O +
the O +
role O +
of O +
microRNAs O +
as O +
possible O +
diagnostic O +
and O +
prognostic O +
biomarkers O +
as O +
well O +
as O +
potential O +
therapeutic O +
targets O +
in O +
stroke U-Disease +
pathogenesis O -
. O -

Mutations O +
in O +
ABHD12 O +
cause O +
the O +
neurodegenerative B-Disease +
disease L-Disease +
PHARC U-Disease -
: O +
An O +
inborn O +
error O +
of O +
endocannabinoid O +
metabolism O -
. O -

Previously O -
, O +
we O +
mapped O +
this O +
Refsum O -
- O -
like O +
disorder O +
to O +
a O +
16 O +
Mb O +
region O +
on O +
chromosome O +
20 O -
. O -

Polyneuropathy U-Disease -
, O +
hearing B-Disease +
loss L-Disease -
, O +
ataxia U-Disease -
, O +
retinitis B-Disease +
pigmentosa L-Disease -
, O +
and O +
cataract U-Disease +
( O -
PHARC U-Disease -
) O +
is O +
a O +
neurodegenerative B-Disease +
disease L-Disease +
marked O +
by O +
early O -
- O -
onset O +
cataract U-Disease +
and O +
hearing B-Disease +
loss L-Disease -
, O +
retinitis B-Disease +
pigmentosa L-Disease -
, O +
and O +
involvement O +
of O +
both O +
the O +
central O +
and O +
peripheral O +
nervous O +
systems O -
, O +
including O +
demyelinating O +
sensorimotor O +
polyneuropathy U-Disease +
and O +
cerebellar B-Disease +
ataxia L-Disease -
. O -

Our O +
findings O +
show O +
that O +
ABHD12 O +
performs O +
essential O +
functions O +
in O +
both O +
the O +
central O +
and O +
peripheral O +
nervous O +
systems O +
and O +
the O +
eye O -
. O -

Any O +
future O +
drug O -
- O -
mediated O +
interference O +
with O +
this O +
enzyme O +
should O +
consider O +
the O +
potential O +
risk O +
of O +
long O -
- O -
term O +
adverse O +
effects O -
. O -

Here O +
we O +
report O +
that O +
mutations O +
in O +
the O +
ABHD12 O +
gene O +
cause O +
PHARC U-Disease +
disease O +
and O +
we O +
describe O +
the O +
clinical O +
manifestations O +
in O +
a O +
total O +
of O +
19 O +
patients O +
from O +
four O +
different O +
countries O -
. O -

The O +
ABHD12 O +
enzyme O +
was O +
recently O +
shown O +
to O +
hydrolyze O +
2-arachidonoyl O +
glycerol O +
( O -
2-AG O -
) O -
, O +
the O +
main O +
endocannabinoid O +
lipid O +
transmitter O +
that O +
acts O +
on O +
cannabinoid O +
receptors O +
CB1 O +
and O +
CB2 O -
. O -

Our O +
data O +
therefore O +
represent O +
an O +
example O +
of O +
an O +
inherited O +
disorder O +
related O +
to O +
endocannabinoid O +
metabolism O -
. O -

The O +
endocannabinoid O +
system O +
is O +
involved O +
in O +
a O +
wide O +
range O +
of O +
physiological O +
processes O +
including O +
neurotransmission O -
, O +
mood O -
, O +
appetite O -
, O +
pain U-Disease +
appreciation O -
, O +
addiction O +
behavior O -
, O +
and O +
inflammation U-Disease -
, O +
and O +
several O +
potential O +
drugs O +
targeting O +
these O +
pathways O +
are O +
in O +
development O +
for O +
clinical O +
applications O -
. O -

These O +
cellular O +
responses O +
are O +
mediated O +
by O +
augmented O +
expression O +
of O +
the O +
direct O +
targets O +
of O +
miR-10b O -
, O +
including O +
BCL2L11 O -
/ O -
Bim O -
, O +
TFAP2C O -
/ O -
AP-2γ O -
, O +
CDKN1A O -
/ O -
p21 O -
, O +
and O +
CDKN2A O -
/ O -
p16 O -
, O +
which O +
normally O +
protect O +
cells O +
from O +
uncontrolled O +
growth O -
. O -

Analysis O +
of O +
The O +
Cancer O +
Genome O +
Atlas O +
expression O +
data O +
set O +
reveals O +
a O +
strong O +
positive O +
correlation O +
between O +
numerous O +
genes O +
sustaining O +
cellular O +
growth O +
and O +
miR-10b O +
levels O +
in O +
human B-Disease +
glioblastomas L-Disease -
, O +
while O +
proapoptotic O +
genes O +
anticorrelate O +
with O +
the O +
expression O +
of O +
miR-10b O -
. O -

Molecular O +
functions O +
of O +
these O +
miRNAs O +
in O +
gliomagenesis O +
are O +
mainly O +
unknown O -
. O -

We O +
show O +
that O +
inhibition O +
of O +
miR-10b O -
, O +
a O +
miRNA O +
not O +
expressed O +
in O +
human O +
brain O +
and O +
strongly O +
upregulated O +
in O +
both O +
low O -
- O -
grade O +
and O +
high B-Disease -
- I-Disease -
grade I-Disease +
gliomas L-Disease -
, O +
reduces O +
glioma U-Disease +
cell O +
growth O +
by O +
cell O -
- O -
cycle O +
arrest O +
and O +
apoptosis O -
. O -

Human B-Disease +
glioma L-Disease +
growth O +
is O +
controlled O +
by O +
microRNA-10b O -
. O -

MicroRNA O +
( O -
miRNA O -
) O +
expression O +
profiling O +
studies O +
revealed O +
a O +
number O +
of O +
miRNAs O +
dysregulated O +
in O +
the O +
malignant B-Disease +
brain I-Disease +
tumor I-Disease +
glioblastoma L-Disease -
. O -

Altogether O -
, O +
our O +
experiments O +
validate O +
an O +
important O +
role O +
of O +
miR-10b O +
in O +
gliomagenesis O -
, O +
reveal O +
a O +
novel O +
mechanism O +
of O +
miR-10b O -
- O -
mediated O +
regulation O -
, O +
and O +
suggest O +
the O +
possibility O +
of O +
its O +
future O +
use O +
as O +
a O +
therapeutic O +
target O +
in O +
gliomas U-Disease -
. O -

Furthermore O -
, O +
survival O +
of O +
glioblastoma U-Disease +
patients O +
expressing O +
high O +
levels O +
of O +
miR-10 O +
family O +
members O +
is O +
significantly O +
reduced O +
in O +
comparison O +
to O +
patients O +
with O +
low O +
miR-10 O +
levels O -
, O +
indicating O +
that O +
miR-10 O +
may O +
contribute O +
to O +
glioma U-Disease +
growth O +
in O +
vivo O -
. O -

Finally O -
, O +
inhibition O +
of O +
miR-10b O +
in O +
a O +
mouse O +
model O +
of O +
human B-Disease +
glioma L-Disease +
results O +
in O +
significant O +
reduction O +
of O +
tumor U-Disease +
growth O -
. O -

MRI O +
scan O +
showed O +
an O +
area O +
of O +
encephalomalacia U-Disease +
in O +
the O +
left O +
temporal O +
lobe O -
, O +
as O +
well O +
as O +
post O -
- O -
surgical O +
changes O +
in O +
the O +
left O +
frontal O +
area O -
. O -

He O +
presented O +
with O +
status B-Disease +
epilepticus L-Disease +
every O +
two O +
or O +
three O +
months O -
, O +
and O +
required O +
long O +
periods O +
of O +
hospitalization O +
on O +
each O +
occasion O +
for O +
post B-Disease -
- I-Disease -
ictal I-Disease +
confusion L-Disease +
and O +
aphasia U-Disease -
. O -

He O +
continued O +
to O +
have O +
frequent O +
seizures U-Disease +
despite O +
treatment O +
with O +
multiple O +
combinations O +
of O +
antiepileptic O +
medications O -
. O -

EEG O +
telemetry O +
recorded O +
multiple B-Disease +
seizures L-Disease -
, O +
all O +
with O +
a O +
clear O +
focus O +
in O +
the O +
left O +
temporal O +
area O -
. O -

Scalp O +
EEG O +
showed O +
continuous O +
spikes O +
and O +
polyspikes O +
and O +
persistent O +
slowing O +
in O +
the O +
left O +
temporal O +
area O -
, O +
as O +
well O +
as O +
spikes O +
in O +
the O +
left O +
frontal O +
area O -
. O -

CASE O +
REPORT O -
: O +
We O +
report O +
a O +
case O +
of O +
a O +
75-year O -
- O -
old O +
right O -
- O -
handed O +
man O +
who O +
underwent O +
a O +
left O +
fronto O -
- O -
temporal O +
craniotomy O +
for O +
resection O +
of O +
a O +
suprasellar B-Disease +
meningioma L-Disease +
in O +
2002 O -
. O -

Immediately O +
following O +
hospital O +
discharge O -
, O +
he O +
began O +
to O +
experience O +
complex O +
partial O +
seizures U-Disease -
. O -

BACKGROUND O -
: O +
Epilepsy U-Disease +
surgery O +
is O +
increasingly O +
well O -
- O -
supported O +
as O +
an O +
effective O +
treatment O +
for O +
patients O +
with O +
intractable O +
epilepsy U-Disease -
. O -

It O +
is O +
most O +
often O +
performed O +
on O +
younger O +
patients O +
and O +
the O +
safety O +
and O +
efficacy O +
of O +
epilepsy U-Disease +
surgery O +
in O +
elderly O +
patients O +
are O +
not O +
frequently O +
described O -
. O -

Epilepsy U-Disease +
surgery O +
in O +
the O +
elderly O -
: O +
an O +
unusual O +
case O +
of O +
a O +
75-year O -
- O -
old O +
man O +
with O +
recurrent O +
status B-Disease +
epilepticus L-Disease -
. O -

In O +
addition O -
, O +
few O +
cases O +
with O +
such O +
a O +
malignant O +
evolution O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy L-Disease +
have O +
been O +
described O +
in O +
this O +
age O +
group O -
. O -

A O +
left O +
anteromesial O +
temporal O +
lobectomy O +
was O +
performed O +
with O +
intraoperative O +
electrocorticography O -
. O -

Neuropsychological O +
testing O +
showed O +
bilateral B-Disease +
memory I-Disease +
impairment L-Disease +
with O +
no O +
significant O +
cognitive O +
decline O +
expected O +
after O +
unilateral O +
temporal O +
lobe O +
resection O -
. O -

CONCLUSIONS O -
: O +
This O +
is O +
one O +
of O +
the O +
oldest O +
patients O +
reported O +
in O +
the O +
literature O +
with O +
epilepsy U-Disease +
surgery O +
and O +
supports O +
the O +
possibility O +
of O +
epilepsy U-Disease +
surgery O +
in O +
elderly O +
patients O +
for O +
particular O +
cases O -
. O -

Since O +
surgery O -
, O +
the O +
patient O +
was O +
not O +
seizure U-Disease -
- O -
free O +
( O -
Engel O +
class O +
II O -
- O -
b O -
) O -
, O +
but O +
had O +
no O +
further O +
episodes O +
of O +
status B-Disease +
epilepticus L-Disease +
in O +
one O +
year O +
and O +
two O +
months O +
of O +
follow O -
- O -
up O -
. O -

Adult O -
- O -
onset O +
autosomal O +
dominant O +
leukodystrophy U-Disease -
: O +
linking O +
nuclear O +
envelope O +
to O +
myelin O -
. O -

Aberrant O +
expression O +
of O +
miRNAs O +
can O +
lead O +
to O +
diseases O -
, O +
including O +
cancer U-Disease -
. O -

Expression O +
of O +
many O +
miRNAs O +
in O +
the O +
de B-Disease -
- I-Disease -
differentiated I-Disease +
brain I-Disease +
tumor L-Disease +
cancer U-Disease +
stem O +
cells O +
resembles O +
that O +
of O +
neural O +
stem O +
cells O -
. O -

MicroRNAs O -
: O +
regulators O +
of O +
oncogenesis O +
and O +
stemness O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
essential O +
post O -
- O -
transcriptional O +
regulators O +
that O +
determine O +
cell O +
identity O +
and O +
fate O -
. O -

In O +
this O +
issue O +
of O +
BMC O +
Medicine O -
, O +
Silber O +
et O +
al O +
provide O +
evidence O +
of O +
the O +
expression O +
of O +
such O +
miRNAs O +
and O +
their O +
potential O +
to O +
mediate O +
differentiation O +
in O +
both O +
stem O +
cell O +
populations O -
. O -

In O +
this O +
commentary O -
, O +
we O +
discuss O +
the O +
known O +
functions O +
of O +
miRNAs O +
in O +
cancer U-Disease +
and O +
stem O +
cells O -
, O +
their O +
therapeutic O +
potential O +
and O +
how O +
the O +
findings O +
of O +
Silber O +
et O +
al O +
provide O +
insight O +
into O +
the O +
role O +
of O +
miR-124 O -
/ O -
miR-137 O +
dysregulation O +
in O +
glioblastomas U-Disease -
. O -

The O +
emerging O +
role O +
of O +
epigenetics O +
in O +
stroke U-Disease -
: O +
II O -
. O +
RNA O +
regulatory O +
circuitry O -
. O -

These O +
non O -
- O -
protein O -
- O -
coding O +
RNAs O +
( O -
ncRNAs O -
) O +
include O +
subclasses O +
that O +
are O +
well O +
known O -
, O +
such O +
as O +
transfer O +
RNAs O +
and O +
ribosomal O +
RNAs O -
, O +
as O +
well O +
as O +
those O +
that O +
have O +
more O +
recently O +
been O +
characterized O -
, O +
such O +
as O +
microRNAs O -
, O +
small O +
nucleolar O +
RNAs O -
, O +
and O +
long O +
ncRNAs O -
. O -

In O +
this O +
review O -
, O +
we O +
examine O +
the O +
role O +
of O +
these O +
novel O +
ncRNAs O +
in O +
the O +
nervous O +
system O +
and O +
highlight O +
emerging O +
evidence O +
that O +
implicates O +
RNA O -
- O -
based O +
networks O +
in O +
the O +
molecular O +
pathogenesis O +
of O +
stroke U-Disease -
. O -

Recent O +
scientific O +
advances O +
have O +
demonstrated O +
the O +
existence O +
of O +
extensive O +
RNA O -
- O -
based O +
regulatory O +
networks O +
involved O +
in O +
orchestrating O +
nearly O +
every O +
cellular O +
process O +
in O +
health O +
and O +
various O +
disease O +
states O -
. O -

This O +
previously O +
hidden O +
layer O +
of O +
functional O +
RNAs O +
is O +
derived O +
largely O +
from O +
non O -
- O -
protein O -
- O -
coding O +
DNA O +
sequences O +
that O +
constitute O +
more O +
than O +
98 O -
% O +
of O +
the O +
genome O +
in O +
humans O -
. O -

These O +
novel O +
approaches O +
for O +
neural O +
cell- O +
and O +
tissue O -
- O -
selective O +
reprogramming O +
of O +
epigenetic O +
regulatory O +
mechanisms O +
are O +
likely O +
to O +
promote O +
more O +
effective O +
neuroprotective O +
and O +
neural O +
regenerative O +
responses O +
for O +
safeguarding O +
and O +
even O +
restoring O +
central O +
nervous O +
system O +
function O -
. O -

We O +
also O +
describe O +
RNA O +
editing O -
, O +
a O +
related O +
epigenetic O +
mechanism O +
that O +
is O +
partly O +
responsible O +
for O +
generating O +
the O +
exquisite O +
degrees O +
of O +
environmental O +
responsiveness O +
and O +
molecular O +
diversity O +
that O +
characterize O +
ncRNAs O -
. O -

In O +
addition O -
, O +
we O +
discuss O +
the O +
development O +
of O +
future O +
therapeutic O +
strategies O +
for O +
locus O -
- O -
specific O +
and O +
genome O -
- O -
wide O +
regulation O +
of O +
genes O +
and O +
functional O +
gene O +
networks O +
through O +
the O +
modulation O +
of O +
RNA O +
transcription O -
, O +
posttranscriptional O +
RNA O +
processing O +
( O -
eg O -
, O +
RNA O +
modifications O -
, O +
quality O +
control O -
, O +
intracellular O +
trafficking O -
, O +
and O +
local O +
and O +
long O -
- O -
distance O +
intercellular O +
transport O -
) O -
, O +
and O +
RNA O +
translation O -
. O -

These O +
results O +
indicate O +
that O +
miRNAs O +
are O +
differentially O +
expressed O +
in O +
C. O +
elegans O +
PD U-Disease +
models O +
and O +
suggest O +
a O +
role O +
for O +
these O +
molecules O +
in O +
disease O +
pathogenesis O -
. O -

Here O -
, O +
we O +
show O +
that O +
12 O +
specific O +
miRNAs O +
are O +
differentially O +
regulated O +
in O +
the O +
animals O +
overexpressing O +
alpha O -
- O -
synuclein O -
, O +
five O +
in O +
cat-1 O -
, O +
and O +
three O +
in O +
the O +
pdr-1 O +
mutants O -
. O -

The O +
family O +
of O +
miR-64 O +
and O +
miR-65 O +
are O +
co O -
- O -
underexpressed O +
in O +
the O +
alpha O -
- O -
synuclein O +
transgenic O +
and O +
cat-1 O +
strains O -
, O +
and O +
members O +
of O +
let-7 O +
family O +
co O -
- O -
underexpressed O +
in O +
the O +
alpha O -
- O -
synuclein O +
and O +
pdr-1 O +
strains O -
; O +
mdl-1 O +
and O +
ptc-1 O +
genes O +
are O +
target O +
candidates O +
for O +
miR-64 O +
and O +
miR-65 O +
and O +
are O +
overexpressed O +
in O +
alpha O -
- O -
synuclein O +
transgenic O +
as O +
well O +
as O +
miR-64 O -
/ O -
65 O +
( O -
tm3711 O -
) O +
knockout O +
animals O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
an O +
important O +
role O +
in O +
human O +
brain O +
development O +
and O +
maintenance O -
. O -

To O +
search O +
for O +
miRNAs O +
that O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
Parkinsons B-Disease +
disease L-Disease +
( O -
PD U-Disease -
) O -
, O +
we O +
utilized O +
miRNA O +
microarrays O +
to O +
identify O +
potential O +
gene O +
expression O +
changes O +
in O +
115 O +
annotated O +
miRNAs O +
in O +
PD U-Disease -
- O -
associated O +
Caenorhabditis O +
elegans O +
models O +
that O +
either O +
overexpress O +
human O +
A53 O -
T O +
alpha O -
- O -
synuclein O +
or O +
have O +
mutations O +
within O +
the O +
vesicular O +
catecholamine O +
transporter O +
( O -
cat-1 O -
) O +
or O +
parkin O +
( O -
pdr-1 O -
) O +
ortholog O -
. O -

Global O +
microRNA O +
expression O +
profiling O +
of O +
Caenorhabditis O +
elegans O +
Parkinson B-Disease -
's I-Disease +
disease L-Disease +
models O -
. O -

A O +
series O +
of O +
novel O +
and O +
established O +
medulloblastoma U-Disease +
defects O +
were O +
detected O +
( O -
MYC O +
amplification O +
( O -
n O +
= O +
4 O -
) O -
, O +
17q21.31 O +
high O -
- O -
level O +
gain O +
( O -
n O +
= O +
1 O -
) O -
; O +
9p21.1-p21.3 O +
( O -
n O +
= O +
1 O -
) O +
and O +
6q23.1 O +
( O -
n O +
= O +
1 O -
) O +
homozygous O +
deletion O -
) O -
. O -

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
We O +
performed O +
a O +
SNP O -
- O -
array O +
based O +
genome O -
- O -
wide O +
copy O +
number O +
analysis O +
in O +
medulloblastoma U-Disease +
cell O +
lines O -
, O +
to O +
identify O +
regions O +
of O +
genomic O +
amplification O +
and O +
homozygous O +
deletion O -
, O +
which O +
may O +
harbour O +
critical O +
disease O +
genes O -
. O -

Most O +
notably O -
, O +
a O +
novel O +
recurrent O +
region O +
of O +
genomic O +
amplification O +
at O +
8q24.22-q24.23 O +
was O +
identified O +
( O -
n O +
= O +
2 O -
) O -
, O +
and O +
selected O +
for O +
further O +
investigation O -
. O -

Amplification O +
and O +
overexpression O +
of O +
Hsa O -
- O -
miR-30b O -
, O +
Hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
at O +
8q24.22-q24.23 O +
in O +
medulloblastoma U-Disease -
. O -

The O +
identification O +
of O +
critical O +
genes O +
involved O +
in O +
its O +
pathogenesis O +
will O +
be O +
central O +
to O +
advances O +
in O +
our O +
understanding O +
of O +
its O +
molecular O +
basis O -
, O +
and O +
the O +
development O +
of O +
improved O +
therapeutic O +
approaches O -
. O -

BACKGROUND O -
: O +
Medulloblastoma U-Disease +
is O +
the O +
most O +
common O +
malignant B-Disease +
brain I-Disease +
tumour L-Disease +
of O +
childhood O -
. O -

Of O +
these O -
, O +
only O +
expression O +
of O +
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
correlated O +
with O +
copy O +
number O +
status O -
, O +
and O +
all O +
three O +
of O +
these O +
transcripts O +
also O +
displayed O +
evidence O +
of O +
elevated O +
expression O +
in O +
sub O -
- O -
sets O +
of O +
primary O +
medulloblastomas U-Disease -
, O +
measured O +
relative O +
to O +
the O +
normal O +
cerebellum O -
. O -

Additional O +
analysis O +
by O +
interphase O +
fluorescence O +
in O +
situ O +
hybridisation O +
( O -
iFISH O -
) O -
, O +
PCR O -
- O -
based O +
mapping O +
and O +
SNP O -
- O -
array O +
revealed O +
this O +
novel O +
amplification O +
at O +
8q24.22-q24.23 O +
is O +
independent O +
of O +
MYC O +
amplification O +
at O +
8q24.21 O -
, O +
and O +
is O +
unique O +
to O +
medulloblastoma U-Disease +
in O +
over O +
800 O +
cancer U-Disease +
cell O +
lines O +
assessed O +
from O +
different O +
tumour U-Disease +
types O -
, O +
suggesting O +
it O +
contains O +
key O +
genes O +
specifically O +
involved O +
in O +
medulloblastoma U-Disease +
development O -
. O -

Detailed O +
mapping O +
identified O +
a O +
3Mb O +
common O +
minimal O +
region O +
of O +
amplification O +
harbouring O +
3 O +
coding O +
genes O +
( O -
ZFAT1 O -
, O +
LOC286094 O -
, O +
KHDRBS3 O -
) O +
and O +
two O +
genes O +
encoding O +
micro O -
- O -
RNAs O +
( O -
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O -
) O -
. O -

Our O +
findings O +
suggest O +
critical O +
roles O +
for O +
these O +
genes O +
in O +
medulloblastoma U-Disease +
development O -
, O +
and O +
further O +
support O +
the O +
contribution O +
of O +
micro O -
- O -
RNA O +
species O +
to O +
medulloblastoma U-Disease +
pathogenesis O -
. O -

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
These O +
data O +
implicate O +
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
as O +
putative O +
oncogenic O +
target O -
( O -
s O -
) O +
of O +
a O +
novel O +
recurrent O +
medulloblastoma U-Disease +
amplicon O +
at O +
8q24.22-q24.23 O -
. O -

PURPOSE O +
Medulloblastomas U-Disease +
are O +
heterogeneous O +
tumors U-Disease +
that O +
collectively O +
represent O +
the O +
most O +
common O +
malignant O +
brain B-Disease +
tumor L-Disease +
in O +
children O -
. O -

Integrative O +
genomic O +
analysis O +
of O +
medulloblastoma U-Disease +
identifies O +
a O +
molecular O +
subgroup O +
that O +
drives O +
poor O +
clinical O +
outcome O -
. O -

We O +
reveal O +
the O +
relative O +
contribution O +
of O +
each O +
subgroup O +
to O +
clinical O +
outcome O +
as O +
a O +
whole O +
and O +
show O +
that O +
a O +
previously O +
unidentified O +
molecular O +
subgroup O -
, O +
characterized O +
genetically O +
by O +
c O -
- O -
MYC O +
copy O +
number O +
gains O +
and O +
transcriptionally O +
by O +
enrichment O +
of O +
photoreceptor O +
pathways O +
and O +
increased O +
miR-183∼96∼182 O +
expression O -
, O +
is O +
associated O +
with O +
significantly O +
lower O +
rates O +
of O +
event O -
- O -
free O +
and O +
overall O +
survivals O -
. O -

Results O +
Identified O +
are O +
six O +
molecular O +
subgroups O +
of O +
medulloblastoma U-Disease -
, O +
each O +
with O +
a O +
unique O +
combination O +
of O +
numerical O +
and O +
structural O +
chromosomal B-Disease +
aberrations L-Disease +
that O +
globally O +
influence O +
mRNA O +
and O +
miRNA O +
expression O -
. O -

CONCLUSION O +
Our O +
results O +
detail O +
the O +
complex O +
genomic O +
heterogeneity O +
of O +
medulloblastomas U-Disease +
and O +
identify O +
a O +
previously O +
unrecognized O +
molecular O +
subgroup O +
with O +
poor O +
clinical O +
outcome O +
for O +
which O +
more O +
effective O +
therapeutic O +
strategies O +
should O +
be O +
developed O -
. O -

PATIENTS O +
AND O +
METHODS O +
We O +
profiled O +
the O +
mRNA O +
transcriptome O +
of O +
194 O +
medulloblastomas U-Disease +
and O +
performed O +
high O -
- O -
density O +
single O +
nucleotide O +
polymorphism O +
array O +
and O +
miRNA O +
analysis O +
on O +
115 O +
and O +
98 O +
of O +
these O -
, O +
respectively O -
. O -

To O +
understand O +
the O +
molecular O +
characteristics O +
underlying O +
their O +
heterogeneity O +
and O +
to O +
identify O +
whether O +
such O +
characteristics O +
represent O +
risk O +
factors O +
for O +
patients O +
with O +
this O +
disease O -
, O +
we O +
performed O +
an O +
integrated O +
genomic O +
analysis O +
of O +
a O +
large O +
series O +
of O +
primary O +
tumors U-Disease -
. O -

We O +
additionally O +
validated O +
our O +
findings O +
in O +
three O +
previously O +
published O +
independent O +
medulloblastoma U-Disease +
data O +
sets O -
. O -

Non O -
- O -
negative O +
matrix O +
factorization O -
- O -
based O +
clustering O +
of O +
mRNA O +
expression O +
data O +
was O +
used O +
to O +
identify O +
molecular O +
subgroups O +
of O +
medulloblastoma U-Disease -
; O +
DNA O +
copy O +
number O -
, O +
miRNA O +
profiles O -
, O +
and O +
clinical O +
outcomes O +
were O +
analyzed O +
for O +
each O -
. O -

The O +
reason O +
why O +
a O +
mild B-Disease +
TBI L-Disease +
results O +
in O +
varying O +
clinical O +
symptoms O +
is O +
currently O +
unknown O -
. O -

Based O +
on O +
evidence O +
that O +
microRNA O +
species O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMCs O -
) O +
may O +
reflect O +
molecular O +
alterations O +
in O +
neurodegenerative B-Disease +
disorders L-Disease -
, O +
it O +
can O +
be O +
hypothesized O +
that O +
at O +
early O -
, O +
preclinical O +
phases O +
of O +
the O +
disease O -
, O +
PBMC O +
may O +
provide O +
an O +
ideal O +
and O +
clinically O +
assessable O +
" O -
window O -
" O +
into O +
the O +
brain O -
. O -

Patients O +
who O +
have O +
sustained O +
a O +
mild B-Disease +
traumatic I-Disease +
brain I-Disease +
injury L-Disease +
( O -
TBI U-Disease -
) O +
from O +
both O +
civilian O +
and O +
military O +
populations O +
exhibit O +
clinical O +
symptoms O +
of O +
varying O +
severity O +
with O +
minimal O +
to O +
profound O +
impact O +
on O +
their O +
daily O +
functioning O -
. O -

Although O +
most O +
patients O +
make O +
a O +
full O +
recovery O -
, O +
a O +
subgroup O +
of O +
mild B-Disease +
TBI L-Disease +
patients O +
develop O +
cognitive O -
, O +
somatic O -
, O +
and O +
neurobehavioral O +
sequelae O +
that O +
generally O +
resolve O +
over O +
3 O +
to O +
6 O +
months O -
; O +
a O +
smaller O +
subgroup O +
develop O +
persisting O +
symptoms O -
. O -

Personalized O +
medicine O +
in O +
traumatic B-Disease +
brain I-Disease +
injury L-Disease -
. O -

Thus O -
, O +
it O +
is O +
conceivable O +
that O +
changes O +
in O +
the O +
expression O +
profile O +
of O +
clinically O +
accessible O +
biological O +
indices O +
( O -
biomarkers O -
) O -
, O +
such O +
as O +
microRNA O +
in O +
PBMC O -
, O +
may O +
reflect O +
molecular O +
alterations O +
following O +
TBI U-Disease +
that O +
contribute O +
to O +
the O +
onset O +
and O +
progression O +
of O +
TBI U-Disease +
phenotypes O +
including O +
chronic B-Disease +
traumatic I-Disease +
encephalopathy L-Disease -
. O -

It O +
is O +
possible O +
that O +
the O +
availability O +
of O +
TBI U-Disease +
biomarkers O +
may O +
provide O +
potential O +
elements O +
with O +
clinical O +
relevance O +
to O +
prevention O -
, O +
prognosis O -
, O +
and O +
treatment O +
of O +
postconcussive B-Disease +
disorders L-Disease -
. O -

This O +
opportunistic O +
mycosis B-Disease +
infection L-Disease +
presented O +
with O +
clinically O +
totally O +
nonspecific O +
signs O +
and O +
symptoms O +
of O +
CNS O +
affection O -
. O -

Therefore O -
, O +
we O +
suspected O +
affection O +
of O +
CNS O +
with O +
SLE U-Disease -
. O -

Even O +
though O +
all O +
diagnostic O +
procedures O +
were O +
made O +
on O +
time O +
and O +
that O +
adequate O +
antifungal O +
and O +
supportive O +
agents O +
were O +
applied O +
very O +
early O +
after O +
the O +
infection U-Disease +
onset O -
, O +
the O +
outcome O +
was O +
fatal O -
. O -

Because O +
of O +
infective O +
diathesis O +
in O +
patients O +
with O +
SLE U-Disease -
, O +
which O +
present O +
with O +
common O +
and O +
opportunistic B-Disease +
infections L-Disease -
, O +
and O +
due O +
to O +
high O +
mortality O +
rates O +
caused O +
by O +
these O +
infections U-Disease -
, O +
we O +
have O +
tried O +
to O +
emphasise O +
the O +
importance O +
of O +
taking O +
adequate O +
specimens O +
early O +
after O +
infection U-Disease +
outcome O +
for O +
these O +
rare O +
infective O +
agents O +
like O +
C. O +
neophormans O -
. O -

It O +
was O +
meningitis U-Disease +
caused O +
by O +
C. O +
neoformans O -
. O -

Reports O +
from O +
Europe O +
are O +
very O +
rare O -
, O +
and O +
this O +
case O +
is O +
the O +
one O +
of O +
that O +
kind O +
in O +
Croatia O -
. O -

In O +
recent O +
medical O +
literature O +
are O +
dominant O +
cases O +
reported O +
in O +
Asia O -
. O -

Systemic B-Disease +
erythematosus I-Disease +
lupus L-Disease +
( O -
SLE U-Disease -
) O +
is O +
a O +
disease O +
with O +
wide O +
range O +
of O +
clinical O +
manifestations O -
, O +
signs O +
and O +
symptoms O -
. O -

[ O -
Cryptococcal B-Disease +
meningitis L-Disease +
as O +
a O +
diagnostic O +
problem O +
in O +
a O +
patient O +
with O +
SLE U-Disease -
-- O -
case O +
report O -
] O -
. O -

Very O +
important O +
cause O +
of O +
death O +
in O +
patients O +
with O +
SLE U-Disease +
is O +
infection U-Disease -
. O -

Disease O +
outcome O +
depends O +
mostly O +
on O +
the O +
affection O +
of O +
kidneys O +
and O +
central O +
nervous O +
system O +
by O +
the O +
disease O -
. O -

During O +
one O +
of O +
the O +
disease O +
flares O +
the O +
patient O +
was O +
hospitalized O +
an O +
opportunistic O +
infection U-Disease +
developed O -
. O -

As O +
an O +
outcome O +
of O +
the O +
combined O +
effect O +
of O +
disease O +
and O +
immunosuppressive O +
agents O +
used O +
in O +
the O +
treatment O +
of O +
the O +
disease O -
, O +
the O +
patient O +
had O +
increased O +
infective O +
diathesis O +
( O -
repeated O +
infections U-Disease +
caused O +
by O +
S. O +
enteritidis O -
-- O -
urinary B-Disease +
infections L-Disease +
and O +
sepsis U-Disease -
) O -
. O -

In O +
this O +
case O +
report O +
we O +
have O +
presented O +
a O +
patient O +
with O +
SLE U-Disease +
who O +
initially O +
had O +
severe O +
renal O +
affection O -
, O +
but O +
also O +
complications O +
of O +
immunosuppressive O +
therapy O +
that O +
was O +
administered O -
. O -

Infections U-Disease +
are O +
very O +
common O +
among O +
these O +
patients O +
due O +
to O +
aggressive O +
immunosuppressive O +
treatment O +
that O +
is O +
needed O +
for O +
the O +
disease O +
inflammatory O +
activity O +
control O -
. O -

Because O +
of O +
lupus B-Disease +
nephropathy L-Disease -
, O +
in O +
the O +
early O +
phase O +
of O +
the O +
disease O +
we O +
administered O +
aggressive O +
immunosuppressive O +
therapy O +
( O -
combined O +
parenteral O +
therapy O +
of O +
glucocorticoides O +
and O +
cyclophosphamide O -
) O -
. O -

Even O +
though O +
the O +
disease O +
was O +
accidentally O +
diagnosed O -
, O +
it O +
had O +
a O +
severe O +
clinical O +
progress O -
. O -

Prolactin O +
and O +
dopamine O +
: O +
what O +
is O +
the O +
connection O +
? O -

A O +
review O +
article O +
. O -

Dopamine O +
( O +
DA O +
) O +
holds O +
a O +
predominant O +
role O +
in O +
the O +
regulation O +
of O +
prolactin O +
( O +
PRL O +
) O +
secretion O +
. O -

Through O +
a O +
direct O +
effect O +
on O +
anterior O +
pituitary O +
lactotrophs O +
, O +
DA O +
inhibits O +
the O +
basally O +
high O +
- O +
secretory O +
tone O +
of O +
the O +
cell O +
. O -

It O +
accomplishes O +
this O +
by O +
binding O +
to O +
D2 O +
receptors O +
expressed O +
on O +
the O +
cell O +
membrane O +
of O +
the O +
lactotroph O +
, O +
activation O +
of O +
which O +
results O +
in O +
a O +
reduction O +
of O +
PRL O +
exocytosis O +
and O +
gene O +
expression O +
by O +
a O +
variety O +
of O +
intracellular O +
signalling O +
mechanisms O +
. O -

The O +
hypothalamic O +
dopaminergic O +
neurons O +
, O +
which O +
provide O +
DA O +
to O +
the O +
anterior O +
pituitary O +
gland O +
, O +
are O +
themselves O +
regulated O +
by O +
feedback O +
from O +
PRL O +
through O +
a O +
's O +
hort O +
- O +
loop O +
feedback O +
mechanism O +
' O +
. O -

A O +
variety O +
of O +
other O +
modulators O +
of O +
prolactin O +
secretion O +
act O +
at O +
the O +
hypothalamic O +
level O +
by O +
either O +
disinhibition O +
of O +
the O +
dopaminergic O +
tone O +
( O +
e.g. O +
serotonin O +
, O +
GABA O +
, O +
oestrogens O +
and O +
opioids O +
) O +
or O +
by O +
reinforcing O +
it O +
( O +
e.g. O +
substance O +
P O +
) O +
. O -

All O +
typical O +
antipsychotic O +
medications O +
are O +
associated O +
with O +
sustained B-Disease +
hyperprolactinaemia L-Disease +
due O +
to O +
their O +
high O +
affinity O +
for O +
the O +
D2 O +
receptor O +
and O +
their O +
slow O +
dissociation O +
from O +
the O +
receptor O +
once O +
bound O +
, O +
but O +
atypicals O +
differ O +
quite O +
dramatically O +
in O +
their O +
propensity O +
to O +
cause O +
prolonged O +
high O +
prolactin O +
levels O +
. O -

Of O +
those O +
atypicals O +
that O +
are O +
associated O +
with O +
prolactin O +
elevation O +
, O +
the O +
main O +
causative O +
factor O +
appears O +
to O +
be O +
a O +
higher O +
peripheral O +
- O +
to O +
- O +
central O +
dopamine O +
receptor O +
potency O +
of O +
either O +
the O +
parent O +
drug O +
or O +
its O +
active O +
metabolite O +
( O +
e.g. O +
risperidone O +
, O +
9 O +
- O +
hydroxy O +
- O +
risperidone O +
and O +
amisulpride O +
) O +
. O -

Antipsychotics O +
that O +
easily O +
cross O +
the O +
blood O +
- O +
brain O +
barrier O +
and O +
exhibit O +
fast O +
dissociation O +
from O +
the O +
dopamine O +
receptor O +
once O +
bound O +
do O +
not O +
result O +
in O +
sustained B-Disease +
hyperprolactinaemia L-Disease +
. O -

Arsenic O +
upregulates O +
MMP O +
- O +
9 O +
and O +
inhibits O +
wound U-Disease +
repair O +
in O +
human O +
airway O +
epithelial O +
cells O +
. O -

As O +
part O +
of O +
the O +
innate O +
immune O +
defense O +
, O +
the O +
polarized O +
conducting O +
lung O +
epithelium O +
acts O +
as O +
a O +
barrier O +
to O +
keep O +
particulates O +
carried O +
in O +
respiration O +
from O +
underlying O +
tissue O +
. O -

Arsenic O +
is O +
a O +
metalloid O +
toxicant O +
that O +
can O +
affect O +
the O +
lung O +
via O +
inhalation O +
or O +
ingestion O +
. O -

We O +
have O +
recently O +
shown O +
that O +
chronic O +
exposure O +
of O +
mice O +
or O +
humans O +
to O +
arsenic O +
( O +
10 O -
- O -
50 O +
ppb O +
) O +
in O +
drinking O +
water O +
alters O +
bronchiolar O +
lavage O +
or O +
sputum O +
proteins O +
consistent O +
with O +
reduced O +
epithelial O +
cell O +
migration O +
and O +
wound U-Disease +
repair O +
in O +
the O +
airway O +
. O -

In O +
this O +
report O +
, O +
we O +
used O +
an O +
in O +
vitro O +
model O +
to O +
examine O +
effects O +
of O +
acute O +
exposure O +
of O +
arsenic O +
( O +
15 O -
- O -
290 O +
ppb O +
) O +
on O +
conducting O +
airway O +
lung O +
epithelium O +
. O -

We O +
found O +
that O +
arsenic O +
at O +
concentrations O +
as O +
low O +
as O +
30 O +
ppb O +
inhibits O +
reformation O +
of O +
the O +
epithelial O +
monolayer O +
following O +
scrape O +
wounds O +
of O +
monolayer O +
cultures O +
. O -

In O +
an O +
effort O +
to O +
understand O +
functional O +
contributions O +
to O +
epithelial O +
wound U-Disease +
repair O +
altered O +
by O +
arsenic O +
, O +
we O +
showed O +
that O +
acute O +
arsenic O +
exposure O +
increases O +
activity O +
and O +
expression O +
of O +
matrix O +
metalloproteinase O +
( O +
MMP O +
) O +
- O +
9 O +
, O +
an O +
important O +
protease O +
in O +
lung O +
function O +
. O -

Furthermore O +
, O +
inhibition O +
of O +
MMP O +
- O +
9 O +
in O +
arsenic O +
- O +
treated O +
cells O +
improved O +
wound U-Disease +
repair O +
. O -

We O +
propose O +
that O +
arsenic O +
in O +
the O +
airway O +
can O +
alter O +
the O +
airway O +
epithelial O +
barrier O +
by O +
restricting O +
proper O +
wound U-Disease +
repair O +
in O +
part O +
through O +
the O +
upregulation O +
of O +
MMP O +
- O +
9 O +
by O +
lung O +
epithelial O +
cells O +
. O -

Stem O +
cell O +
mobilization O +
with O +
cyclophosphamide O +
overcomes O +
the O +
suppressive O +
effect O +
of O +
lenalidomide O +
therapy O +
on O +
stem O +
cell O +
collection O +
in O +
multiple B-Disease +
myeloma L-Disease +
. O -

A O +
total O +
of O +
28 O +
treatment O +
- O +
na O +
? O -

ve O +
patients O +
with O +
stage O +
II O +
or O +
III O +
multiple B-Disease +
myeloma L-Disease +
( O +
MM U-Disease +
) O +
were O +
treated O +
with O +
the O +
combination O +
of O +
clarithromycin O +
, O +
lenalidomide O +
, O +
and O +
dexamethasone O +
( O +
BiRD O +
) O +
. O -

Stem O +
cells O +
were O +
collected O +
following O +
granulocyte O +
- O +
colony O +
stimulating O +
factor O +
( O +
G O +
- O +
CSF O +
) O +
or O +
cyclophosphamide O +
( O +
Cy O +
) O +
plus O +
G O +
- O +
CSF O +
mobilization O +
at O +
maximum O +
response O +
. O -

Sufficient O +
stem O +
cells O +
for O +
2 O +
autologous O +
stem O +
cell O +
transplants O +
were O +
collected O +
from O +
all O +
patients O +
mobilized O +
with O +
Cy O +
plus O +
G O +
- O +
CSF O +
, O +
versus O +
33 O -
% O +
mobilized O +
with O +
G O +
- O +
CSF O +
alone O +
( O +
P O +
< O +
.0001 O +
) O +
. O -

The O +
duration O +
of O +
prior O +
lenalidomide O +
therapy O +
did O +
not O +
correlate O +
with O +
success O +
of O +
stem O +
cell O +
harvests O +
( O +
P O +
= O +
.91 O +
) O +
. O -

In O +
conclusion O +
, O +
Cy O +
can O +
be O +
added O +
to O +
G O +
- O +
CSF O +
for O +
stem O +
cell O +
mobilization O +
to O +
successfully O +
overcome O +
the O +
suppressive O +
effect O +
of O +
prior O +
treatment O +
with O +
lenalidomide O +
. O -

Fluctuating O +
functions O +
related O +
to O +
quality O +
of O +
life O +
in O +
advanced O +
Parkinson O +
disease O +
: O +
effects O +
of O +
duodenal O +
levodopa O +
infusion O +
. O -

OBJECTIVE O +
: O +
To O +
assess O +
fluctuations O +
in O +
quality O +
of O +
life O +
( O +
QoL O +
) O +
and O +
motor O +
performance O +
in O +
patients O +
with O +
advanced O +
Parkinson O +
disease O +
( O +
PD O +
) O +
treated O +
with O +
continuous O +
daytime O +
duodenal O +
levodopa O +
/ O +
carbidopa O +
infusion O +
or O +
conventional O +
therapy O +
. O -

METHODS O +
: O +
Of O +
18 O +
patients O +
completing O +
a O +
6 O +
- O +
week O +
trial O +
( O +
DIREQT O +
) O +
, O +
12 O +
were O +
followed O +
for O +
up O +
to O +
6 O +
months O +
and O +
assessed O +
using O +
electronic O +
diaries O +
and O +
the O +
PD O +
Questionnaire O +
- O +
39 O +
( O +
PDQ O +
- O +
39 O +
) O +
. O -

RESULTS O +
: O +
During O +
the O +
trial O +
and O +
follow O +
- O +
up O +
, O +
major O +
diurnal O +
fluctuations O +
were O +
observed O +
, O +
especially O +
for O +
hyperkinesia U-Disease +
, O +
' O +
off O +
' O +
time O +
, O +
ability O +
to O +
walk O +
and O +
depression U-Disease +
. O -

Duodenal O +
infusion O +
was O +
associated O +
with O +
significantly O +
more O +
favourable O +
outcomes O +
compared O +
with O +
conventional O +
treatment O +
for O +
satisfaction O +
with O +
overall O +
functioning O +
, O +
' O +
off O +
' O +
time O +
and O +
ability O +
to O +
walk O +
, O +
with O +
improved O +
outcomes O +
with O +
PDQ O +
- O +
39 O +
. O -

CONCLUSIONS O +
: O +
Relative O +
to O +
conventional O +
treatment O +
, O +
infusion O +
therapy O +
may O +
stabilize O +
and O +
significantly O +
improve O +
motor O +
function O +
and O +
patient O +
's O +
QoL O +
. O -

The O +
potential O +
for O +
daily O +
fluctuation O +
in O +
PD O +
symptoms O +
means O +
single O +
measures O +
of O +
treatment O +
effectiveness O +
can O +
result O +
in O +
bias O +
in O +
effect O +
estimates O +
and O +
hence O +
repeated O +
measures O +
are O +
recommended O +
. O -

Apaziquone O +
for O +
non B-Disease +
- I-Disease +
muscle I-Disease +
invasive I-Disease +
bladder I-Disease +
cancer L-Disease +
: O +
a O +
critical O +
review O +
. O -

OBJECTIVE O +
: O +
To O +
describe O +
clinical O +
needs O +
in O +
non B-Disease +
- I-Disease +
muscle I-Disease +
invasive I-Disease +
bladder I-Disease +
cancer L-Disease +
( O +
NMIBC U-Disease +
) O +
and O +
review O +
the O +
potential O +
of O +
apaziquone O +
in O +
this O +
respect O +
. O -

METHODS O +
: O +
Epidemiology O +
and O +
clinical O +
practice O +
in O +
NMIBC U-Disease +
, O +
as O +
well O +
as O +
new O +
drugs O +
and O +
strategies O +
are O +
reviewed O +
. O -

RESULTS O +
: O +
Bladder B-Disease +
cancer L-Disease +
is O +
a O +
heterogeneous O +
and O +
frequent O +
disease O +
. O -

Clinical O +
risk O +
factors O +
help O +
in O +
determining O +
additional O +
therapy O +
after O +
initial O +
resection O +
. O -

However O +
, O +
current O +
treatments O +
have O +
clear O +
limitations O +
with O +
regard O +
to O +
efficacy O +
and O +
/ O +
or O +
toxicity O +
. O -

New O +
drugs O +
and O +
strategies O +
have O +
been O +
tested O +
recently O +
and O +
are O +
in O +
( O +
pre O +
) O +
clinical O +
use O +
. O -

Intravesical O +
apaziquone O +
( O +
EOquin O +
) O +
is O +
a O +
new O +
drug O +
. O -

It O +
has O +
theoretical O +
advantages O +
for O +
intravesical O +
use O +
, O +
has O +
proven O +
safety O +
and O +
is O +
presently O +
under O +
further O +
clinical O +
evaluation O +
. O -

CONCLUSION O +
: O +
Apaziquone O +
is O +
a O +
promising O +
drug O +
for O +
intravesical O +
use O +
in O +
patients O +
with O +
NMIBC U-Disease +
. O -

Allopregnanolone O +
impairs O +
episodic O +
memory O +
in O +
healthy O +
women O +
. O -

OBJECTIVE O +
: O +
Allopregnanolone O +
is O +
an O +
endogenous O +
neuroactive O +
steroid O +
that O +
, O +
through O +
its O +
binding O +
to O +
the O +
gamma O +
- O +
aminobutyric O +
acid O +
( O +
GABA O +
) O +
A O +
receptor O +
, O +
has O +
GABA O +
- O +
active O +
properties O +
. O -

Animal O +
studies O +
indicate O +
that O +
allopregnanolone O +
administration O +
results O +
in O +
diminished B-Disease +
learning L-Disease +
and O +
memory B-Disease +
impairment L-Disease +
. O -

The O +
aim O +
of O +
the O +
current O +
study O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
intravenously O +
administered O +
allopregnanolone O +
on O +
episodic O +
memory O +
, O +
semantic O +
memory O +
, O +
and O +
working O +
memory O +
in O +
healthy O +
women O +
. O -

MATERIALS O +
AND O +
METHODS O +
: O +
Twenty O +
- O +
eight O +
healthy O +
women O +
were O +
included O +
in O +
the O +
study O +
. O -

The O +
participants O +
were O +
scheduled O +
for O +
the O +
memory O +
tests O +
twice O +
in O +
the O +
follicular O +
phase O +
. O -

During O +
the O +
test O +
sessions O +
, O +
an O +
intravenous O +
allopregnanolone O +
and O +
placebo O +
infusion O +
were O +
administered O +
in O +
a O +
double O +
- O +
blinded O +
, O +
randomized O +
order O +
at O +
intervals O +
of O +
48 O +
h O +
. O -

Before O +
and O +
10 O +
min O +
after O +
the O +
allopregnanolone O +
/ O +
placebo O +
injections O +
, O +
memory O +
tasks O +
were O +
performed O +
. O -

RESULTS O +
: O +
The O +
study O +
demonstrated O +
that O +
allopregnanolone O +
impaired O +
episodic O +
memory O +
in O +
healthy O +
women O +
. O -

There O +
was O +
a O +
significant O +
difference O +
between O +
pre O +
- O +
and O +
postallopregnanolone O +
injection O +
episodic O +
memory O +
scores O +
( O +
p O +
< O +
0.05 O +
) O +
, O +
whereas O +
there O +
was O +
no O +
change O +
in O +
episodic O +
memory O +
performance O +
following O +
the O +
placebo O +
injections O +
. O -

There O +
was O +
also O +
a O +
significant O +
difference O +
between O +
allopregnanolone O +
and O +
placebo O +
postinjection O +
episodic O +
memory O +
scores O +
( O +
p O +
< O +
0.05 O +
) O +
. O -

There O +
were O +
no O +
effects O +
of O +
allopregnanolone O +
on O +
the O +
semantic O +
memory O +
task O +
or O +
working O +
memory O +
task O +
. O -

CONCLUSION O +
: O +
Intravenous O +
allopregnanolone O +
impairs O +
episodic O +
memory O +
in O +
healthy O +
women O +
, O +
but O +
there O +
is O +
a O +
high O +
degree O +
of O +
individual O +
variability O +
. O -

Effect O +
of O +
carbocisteine O +
on O +
acute O +
exacerbation O +
of O +
chronic B-Disease +
obstructive I-Disease +
pulmonary I-Disease +
disease L-Disease +
( O +
PEACE O +
Study O +
) O +
: O +
a O +
randomised O +
placebo O +
- O +
controlled O +
study O +
. O -

BACKGROUND O +
: O +
Chronic B-Disease +
obstructive I-Disease +
pulmonary I-Disease +
disease L-Disease +
( O +
COPD U-Disease +
) O +
is O +
characterised O +
by O +
airflow O +
limitation O +
, O +
and O +
has O +
many O +
components O +
including O +
mucus O +
hypersecretion O +
, O +
oxidative O +
stress O +
, O +
and O +
airway O +
inflammation O +
. O -

We O +
aimed O +
to O +
assess O +
whether O +
carbocisteine O +
, O +
a O +
mucolytic O +
agent O +
with O +
anti O +
- O +
inflammatory O +
and O +
antioxidation O +
activities O +
, O +
could O +
reduce O +
the O +
yearly O +
exacerbation O +
rate O +
in O +
patients O +
with O +
COPD U-Disease +
. O -

METHODS O +
: O +
We O +
did O +
a O +
randomised O +
, O +
double O +
- O +
blind O +
, O +
placebo O +
- O +
controlled O +
study O +
of O +
709 O +
patients O +
from O +
22 O +
centres O +
in O +
China O +
. O -

Participants O +
were O +
eligible O +
if O +
they O +
were O +
diagnosed O +
as O +
having O +
COPD U-Disease +
with O +
a O +
postbronchodilator O +
forced O +
expiratory O +
volume O +
in O +
1 O +
s O +
( O +
FEV O +
( O +
1 O +
) O +
) O +
to O +
forced O +
vital O +
capacity O +
( O +
FVC O +
) O +
ratio O +
( O +
FEV O +
( O +
1 O +
) O +
/ O +
FVC O +
) O +
of O +
less O +
than O +
0.7 O +
and O +
an O +
FEV O +
( O +
1 O +
) O +
between O +
25 O -
% O +
and O +
79 O -
% O +
of O +
the O +
predicted O +
value O +
, O +
were O +
aged O +
between O +
40 O +
and O +
80 O +
years O +
, O +
had O +
a O +
history O +
of O +
at O +
least O +
two O +
COPD U-Disease +
exacerbations O +
within O +
the O +
previous O +
2 O +
years O +
, O +
and O +
had O +
remained O +
clinically O +
stable O +
for O +
over O +
4 O +
weeks O +
before O +
the O +
study O +
. O -

Patients O +
were O +
randomly O +
assigned O +
to O +
receive O +
1500 O +
mg O +
carbocisteine O +
or O +
placebo O +
per O +
day O +
for O +
a O +
year O +
. O -

The O +
primary O +
endpoint O +
was O +
exacerbation O +
rate O +
over O +
1 O +
year O +
, O +
and O +
analysis O +
was O +
by O +
intention O +
to O +
treat O +
. O -

This O +
trial O +
is O +
registered O +
with O +
the O +
Japan O +
Clinical O +
Trials O +
Registry O +
( O +
http://umin.ac.jp/ctr/index/htm O +
) O +
number O +
UMIN O +
- O +
CRT O +
C000000233 O +
. O -

FINDINGS O +
: O +
354 O +
patients O +
were O +
assigned O +
to O +
the O +
carbocisteine O +
group O +
and O +
355 O +
to O +
the O +
placebo O +
group O +
. O -

Numbers O +
of O +
exacerbations O +
per O +
patient O +
per O +
year O +
declined O +
significantly O +
in O +
the O +
carbocisteine O +
group O +
compared O +
with O +
the O +
placebo O +
group O +
( O +
1.01 O +
[ O +
SE O +
0.06 O +
] O +
vs O +
1.35 O +
[ O +
SE O +
0.06 O +
] O +
) O +
, O +
risk O +
ratio O +
0.75 O +
( O +
95 O -
% O +
CI O +
0.62 O -
- O -
0.92 O +
, O +
p O +
= O +
0.004 O +
) O +
. O -

Non O +
- O +
significant O +
interactions O +
were O +
found O +
between O +
the O +
preventive O +
effects O +
and O +
COPD U-Disease +
severity O +
, O +
smoking O +
, O +
as O +
well O +
as O +
concomitant O +
use O +
of O +
inhaled O +
corticosteroids O +
. O -

Carbocisteine O +
was O +
well O +
tolerated O +
. O -

INTERPRETATION O +
: O +
Mucolytics O +
, O +
such O +
as O +
carbocisteine O +
, O +
should O +
be O +
recognised O +
as O +
a O +
worthwhile O +
treatment O +
for O +
prevention O +
of O +
exacerbations O +
in O +
Chinese O +
patients O +
with O +
COPD U-Disease +
. O -

Induction O +
of O +
the O +
multixenobiotic O +
/ O +
multidrug O +
resistance O +
system O +
in O +
various O +
cell O +
lines O +
in O +
response O +
to O +
perfluorinated O +
carboxylic O +
acids O +
. O -

The O +
multixenobiotic O +
resistance O +
( O +
closely O +
related O +
to O +
multidrug O +
resistance O +
) O +
system O +
controls O +
transport O +
across O +
the O +
plasma O +
membrane O +
as O +
a O +
defense O +
against O +
toxic O +
molecules O +
. O -

Multixenobiotic O +
resistance O +
system O +
consists O +
of O +
an O +
efflux O +
pump O +
, O +
ABCB1 O +
( O +
also O +
named O +
P O +
- O +
glycoprotein O +
, O +
P O +
- O +
gp O +
) O +
, O +
and O +
/ O +
or O +
a O +
molecule O +
of O +
the O +
ABCC O +
family O +
( O +
also O +
named O +
multiple O +
resistance O +
associated O +
protein O +
, O +
MRP O +
) O +
. O -

ABCB1 O +
is O +
able O +
to O +
increase O +
efflux O +
of O +
many O +
low O +
- O +
molecular O +
foreign O +
molecules O +
. O -

Measuring O +
system O +
induction O +
may O +
be O +
used O +
as O +
a O +
biomarker O +
of O +
cell O +
/ O +
organism O +
exposure O +
to O +
foreign O +
substances O +
. O -

Various O +
established O +
cell O +
lines O +
were O +
tested O +
for O +
constitutive O +
and O +
induced O +
multixenobiotic O +
resistance O +
proteins O +
by O +
Western O +
blotting O +
immunodetection O +
. O -

The O +
pumping O +
function O +
was O +
indirectly O +
assayed O +
with O +
Rhodamine O +
B O +
by O +
visualization O +
of O +
cell O +
fluorescence O +
in O +
the O +
presence O +
of O +
verapamil O +
. O -

Changes O +
in O +
ABC O +
proteins O +
were O +
measured O +
by O +
flow O +
cytometry O +
after O +
exposition O +
to O +
various O +
perfluorinated O +
carboxylic O +
acids O +
. O -

MCF7 O +
and O +
HeLa O +
cells O +
were O +
found O +
to O +
contain O +
the O +
highest O +
constitutive O +
level O +
of O +
both O +
ABCB1 O +
and O +
ABCC1 O +
. O -

HEK293 O +
exhibited O +
much O +
less O +
ABCB1 O +
and O +
no O +
activity O +
of O +
pumping O +
out O +
Rhodamine O +
B O +
. O -

The O +
pumping O +
activity O +
was O +
found O +
to O +
be O +
related O +
to O +
the O +
amount O +
of O +
the O +
cell O +
- O +
type O +
specific O +
170 O +
kDa O +
ABCB1 O +
protein O +
. O -

An O +
8 O +
- O +
day O +
exposure O +
to O +
10 O +
( O +
- O +
4 O +
) O +
M O +
perfluorononanoic O +
acid O +
resulted O +
in O +
about O +
2 O -
- O -
2.5 O +
- O +
fold O +
increase O +
of O +
ABCB1 O +
level O +
. O -

That O +
was O +
confirmed O +
also O +
for O +
short O +
times O +
by O +
flow O +
cytometry O +
of O +
cells O +
exposed O +
to O +
perfluorinated O +
acids O +
and O +
its O +
natural O +
congeners O +
. O -

Both O +
ABCB1 O +
- O +
and O +
ABCC1 O +
- O +
related O +
fluorescence O +
increased O +
along O +
with O +
the O +
carbon O +
chain O +
in O +
acids O +
from O +
C O +
( O +
6 O +
) O +
up O +
to O +
C O +
( O +
9 O +
) O +
and O +
decreased O +
for O +
C O +
( O +
10 O +
) O +
. O -

Measuring O +
of O +
multixenobiotic O +
resistance O +
changes O +
in O +
vitro O +
induced O +
by O +
chemicals O +
may O +
be O +
a O +
convenient O +
test O +
for O +
screening O +
for O +
their O +
potential O +
toxicity O +
. O -

Phase O +
I O +
/ O +
II O +
study O +
of O +
biweekly O +
paclitaxel O +
and O +
radiation O +
in O +
androgen O +
- O +
ablated O +
locally O +
advanced O +
prostate B-Disease +
cancer L-Disease +
. O -

PURPOSE O +
: O +
To O +
determine O +
the O +
maximum O +
- O +
tolerated O +
dose O +
( O +
MTD O +
) O +
of O +
concurrent O +
paclitaxel O +
and O +
radiation O +
therapy O +
( O +
RT O +
) O +
in O +
patients O +
with O +
locally O +
advanced O +
prostate B-Disease +
cancer L-Disease +
. O -

MATERIALS O +
AND O +
METHODS O +
: O +
Eligible O +
patients O +
had O +
T2 O +
- O +
4 O +
tumors U-Disease +
with O +
Gleason O +
scores O +
greater O +
than O +
7 O +
and O +
/ O +
or O +
PSA O +
levels O +
greater O +
than O +
10 O +
ng O +
/ O +
mL O +
and O +
/ O +
or O +
had O +
tumors U-Disease +
with O +
pathologic O +
stage O +
TxN1 O +
. O -

Hormonal O +
ablation O +
was O +
initiated O +
3 O +
months O +
before O +
RT O +
and O +
was O +
given O +
for O +
9 O +
months O +
. O -

RT O +
was O +
delivered O +
daily O +
( O +
1.8 O +
Gy O +
) O +
with O +
concurrent O +
twice O +
- O +
weekly O +
paclitaxel O +
( O +
30 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
) O +
. O -

The O +
whole O +
pelvis O +
was O +
irradiated O +
to O +
39.6 O +
Gy O +
. O -

The O +
radiation O +
dose O +
was O +
escalated O +
as O +
follows O +
: O +
63 O +
Gy O +
, O +
66.6 O +
Gy O +
, O +
70.2 O +
Gy O +
, O +
and O +
73.8 O +
Gy O +
. O -

The O +
last O +
RT O +
dose O +
level O +
was O +
fixed O +
at O +
73.8 O +
Gy O +
. O -

RESULTs O +
: O +
Between O +
January O +
2000 O +
and O +
October O +
2006 O +
, O +
22 O +
patients O +
were O +
enrolled O +
. O -

The O +
median O +
age O +
was O +
59 O +
years O +
( O +
range O +
, O +
48 O +
to O +
72 O +
years O +
) O +
; O +
the O +
median O +
PSA O +
level O +
was O +
22.4 O +
ng O +
/ O +
mL O +
( O +
range O +
, O +
2.8 O +
to O +
113 O +
ng O +
/ O +
mL O +
) O +
. O -

The O +
number O +
of O +
patients O +
per O +
stage O +
was O +
as O +
follows O +
: O +
three O +
with O +
T1 O +
, O +
eight O +
with O +
T2 O +
, O +
11 O +
with O +
T3 O +
, O +
and O +
five O +
with O +
pN1 O +
= O +
5 O +
. O -

No O +
grade O +
3 O +
toxicities O +
occurred O +
at O +
63 O +
Gy O +
. O -

Grade O +
3 O +
diarrhea U-Disease +
occurred O +
in O +
three O +
patients O +
at O +
66.6 O +
Gy O +
. O -

The O +
protocol O +
then O +
was O +
amended O +
to O +
treat O +
the O +
prostate O +
volume O +
first O +
followed O +
by O +
the O +
whole O +
pelvis O +
. O -

No O +
grade O +
3 O +
toxicities O +
were O +
observed O +
at O +
70.2 O +
Gy O +
. O -

One O +
patient O +
experienced O +
grade O +
3 O +
diarrhea U-Disease +
at O +
73.8 O +
Gy O +
. O -

Five O +
additional O +
patients O +
were O +
treated O +
to O +
73.8 O +
Gy O +
without O +
grade O +
3 O +
toxicity O +
, O +
which O +
established O +
the O +
MTD O +
for O +
combined O +
paclitaxel O +
and O +
RT O +
at O +
73.8 O +
Gy O +
. O -

At O +
38 O +
months O +
median O +
follow O +
- O +
up O +
( O +
range O +
, O +
9 O +
to O +
87 O +
months O +
) O +
, O +
21 O +
( O +
95 O -
% O +
) O +
of O +
22 O +
patients O +
are O +
alive O +
. O -

Six O +
( O +
27 O -
% O +
) O +
of O +
22 O +
experienced O +
recurrence O +
. O -

CONCLUSION O +
: O +
Concurrent O +
biweekly O +
paclitaxel O +
with O +
RT O +
is O +
feasible O +
, O +
with O +
an O +
MTD O +
of O +
73.8 O +
Gy O +
. O -

Recovery O +
of O +
gonadal O +
function O +
occurs O +
in O +
the O +
majority O +
of O +
patients O +
. O -

These O +
results O +
encourage O +
testing O +
in O +
a O +
phase O +
III O +
setting O +
. O -

Application O +
of O +
a O +
high O +
- O +
content O +
multiparameter O +
cytotoxicity U-Disease +
assay O +
to O +
prioritize O +
compounds O +
based O +
on O +
toxicity O +
potential O +
in O +
humans O +
. O -

Prioritization O +
of O +
compounds O +
based O +
on O +
human O +
hepatotoxicity U-Disease +
potential O +
is O +
currently O +
a O +
key O +
unmet O +
need O +
in O +
drug O +
discovery O +
, O +
as O +
it O +
can O +
become O +
a O +
major O +
problem O +
for O +
several O +
lead O +
compounds O +
in O +
later O +
stages O +
of O +
the O +
drug O +
discovery O +
pipeline O +
. O -

The O +
authors O +
report O +
the O +
validation O +
and O +
implementation O +
of O +
a O +
high O +
- O +
content O +
multiparametric O +
cytotoxicity U-Disease +
assay O +
based O +
on O +
simultaneous O +
measurement O +
of O +
8 O +
key O +
cell O +
health O +
indicators O +
associated O +
with O +
nuclear O +
morphology O +
, O +
plasma O +
membrane O +
integrity O +
, O +
mitochondrial O +
function O +
, O +
and O +
cell O +
proliferation O +
. O -

Compounds O +
are O +
prioritized O +
by O +
( O +
a O +
) O +
computing O +
an O +
in O +
vitro O +
safety O +
margin O +
using O +
the O +
minimum O +
cytotoxic O +
concentration O +
( O +
IC O +
( O +
20 O +
) O +
) O +
across O +
all O +
8 O +
indicators O +
and O +
cell O +
- O +
based O +
efficacy O +
data O +
and O +
( O +
b O +
) O +
using O +
the O +
minimal O +
cytotoxic O +
concentration O +
alone O +
to O +
take O +
into O +
account O +
concentration O +
of O +
drug O +
in O +
tissues O +
. O -

Feasibility O +
data O +
using O +
selected O +
compounds O +
, O +
including O +
quinolone O +
antibiotics O +
, O +
thiazolidinediones O +
, O +
and O +
statins O +
, O +
suggest O +
the O +
viability O +
of O +
this O +
approach O +
. O -

To O +
increase O +
overall O +
throughput O +
of O +
compound O +
prioritization O +
, O +
the O +
authors O +
have O +
identified O +
the O +
higher O +
throughput O +
, O +
plate O +
reader O +
- O +
based O +
CyQUANT O +
assay O +
that O +
is O +
similar O +
to O +
the O +
high O +
- O +
content O +
screening O +
( O +
HCS O +
) O +
assay O +
in O +
sensitivity O +
of O +
measuring O +
inhibition O +
of O +
cell O +
proliferation O +
. O -

It O +
is O +
expected O +
that O +
the O +
phenotypic O +
output O +
from O +
the O +
multiparametric O +
HCS O +
assay O +
in O +
combination O +
with O +
other O +
highly O +
sensitive O +
approaches O +
, O +
such O +
as O +
microarray O +
- O +
based O +
expression O +
analysis O +
of O +
toxic O +
signatures O +
, O +
will O +
contribute O +
to O +
a O +
better O +
understanding O +
and O +
predictivity O +
of O +
human O +
hepatotoxicity U-Disease +
potential O +
. O -

Amended O +
final O +
report O +
of O +
the O +
safety O +
assessment O +
of O +
cocamidopropylamine O +
oxide O +
. O -

Cocamidopropylamine O +
Oxide O +
is O +
a O +
tertiary O +
amine O +
oxide O +
which O +
functions O +
as O +
a O +
hair O +
- O +
conditioning O +
agent O +
and O +
as O +
a O +
surfactant O +
, O +
currently O +
used O +
in O +
60 O +
cosmetic O +
formulations O +
at O +
concentrations O +
between O +
0.07 O -
% O +
and O +
4.0 O -
% O +
. O -

In O +
an O +
earlier O +
safety O +
assessment O +
, O +
the O +
Cosmetic O +
Ingredient O +
Review O +
( O +
CIR O +
) O +
Expert O +
Panel O +
had O +
determined O +
that O +
the O +
available O +
data O +
were O +
insufficient O +
to O +
support O +
the O +
safety O +
of O +
this O +
ingredient O +
in O +
cosmetic O +
products O +
. O -

Additional O +
data O +
have O +
now O +
been O +
provided O +
and O +
reviewed O +
. O -

Cocamidopropylamine O +
Oxide O +
was O +
determined O +
to O +
have O +
an O +
acute O +
oral O +
LD O +
( O +
50 O +
) O +
between O +
500 O +
and O +
1000 O +
mg O +
/ O +
kg O +
day O +
( O +
- O +
1 O +
) O +
using O +
rats O +
. O -

The O +
acute O +
dermal O +
LD O +
( O +
50 O +
) O +
in O +
rats O +
was O +
> O +
2174 O +
mg O +
/ O +
kg O +
day O +
( O +
- O +
1 O +
) O +
. O -

A O +
28 O +
- O +
day O +
repeated O +
oral O +
dose B-Disease +
toxicity L-Disease +
study O +
in O +
rats O +
found O +
hemolytic B-Disease +
anemia L-Disease +
at O +
150 O +
and O +
1000 O +
mg O +
/ O +
kg O +
day O +
( O +
- O +
1 O +
) O +
, O +
with O +
a O +
no O +
observed O +
effect O +
level O +
( O +
NOEL O +
) O +
of O +
15 O +
mg O +
/ O +
kg O +
day O +
( O +
- O +
1 O +
) O +
. O -

At O +
5 O -
% O +
, O +
Cocamidopropylamine O +
Oxide O +
solution O +
was O +
not O +
a O +
primary O +
dermal O +
irritant O +
. O -

Application O +
of O +
81.5 O -
% O +
Cocamidopropylamine O +
Oxide O +
to O +
rabbit O +
skin O +
caused O +
moderate O +
irritation U-Disease +
under O +
Draize O +
classification O +
scale O +
, O +
but O +
81.5 O -
% O +
Cocamidopropylamine O +
Oxide O +
in O +
rabbit O +
eyes O +
caused O +
severe O +
irritation U-Disease +
. O -

A O +
maximization O +
study O +
classified O +
Cocamidopropylamine O +
Oxide O +
as O +
a O +
nonsensitizer O +
to O +
guinea O +
pig O +
skin O +
. O -

Cocamidopropylamine O +
Oxide O +
was O +
not O +
mutagenic O +
in O +
an O +
Ames O +
test O +
, O +
with O +
and O +
without O +
metabolic O +
activation O +
. O -

No O +
evidence O +
of O +
increased O +
chromosomal O +
aberrations O +
were O +
noted O +
in O +
human O +
lymphocytes O +
treated O +
with O +
81.5 O -
% O +
Cocamidopropylamine O +
Oxide O +
. O -

In O +
a O +
clinical O +
study O +
, O +
7.5 O -
% O +
Cocamidopropylamine O +
Oxide O +
was O +
not O +
a O +
sensitizer O +
, O +
although O +
it O +
did O +
produce O +
some O +
reactions O +
typical O +
of O +
mild O +
irritation U-Disease +
. O -

Although O +
the O +
impurities O +
, O +
amidoamine O +
and O +
dimethylaminopropylamine O +
, O +
have O +
been O +
implicated O +
in O +
contact B-Disease +
allergy L-Disease +
reactions O +
to O +
products O +
containing O +
cocamidopropylamine O +
betaine O +
, O +
clinical O +
testing O +
of O +
a O +
product O +
with O +
cocamidopropylamine O +
betaine O +
containing O +
these O +
impurities O +
, O +
at O +
levels O +
comparable O +
to O +
those O +
found O +
in O +
Cocamidopropylamine O +
Oxide O +
, O +
failed O +
to O +
produce O +
a O +
reaction O +
in O +
10 O +
individuals O +
known O +
to O +
be O +
sensitive O +
to O +
cocamidopropylamine O +
betaine O +
. O -

Two O +
repeat O +
- O +
insult O +
patch O +
tests O +
using O +
a O +
facial O +
wash O +
with O +
1 O -
% O +
raw O +
material O +
containing O +
35 O -
% O +
to O +
36.5 O -
% O +
Cocamidopropylamine O +
Oxide O +
did O +
not O +
find O +
evidence O +
of O +
dermal B-Disease +
sensitization L-Disease +
. O -

Tests O +
for O +
dermal B-Disease +
phototoxicity L-Disease +
and O +
photoallergenicity U-Disease +
with O +
the O +
same O +
facial O +
wash O +
product O +
also O +
did O +
not O +
produce O +
evidence O +
of O +
effect O +
. O -

The O +
CIR O +
Expert O +
Panel O +
recognizes O +
that O +
there O +
are O +
data O +
gaps O +
regarding O +
the O +
use O +
and O +
concentration O +
of O +
this O +
ingredient O +
. O -

However O +
, O +
the O +
overall O +
information O +
available O +
on O +
types O +
of O +
products O +
in O +
which O +
this O +
ingredient O +
is O +
used O +
and O +
at O +
what O +
concentration O +
indicate O +
a O +
pattern O +
of O +
use O +
, O +
which O +
was O +
considered O +
by O +
the O +
Expert O +
Panel O +
in O +
assessing O +
safety O +
. O -

Overall O +
, O +
these O +
data O +
demonstrate O +
that O +
Cocamidopropylamine O +
Oxide O +
has O +
low O +
toxicity O +
in O +
animal O +
and O +
in O +
vitro O +
tests O +
. O -

Although O +
there O +
are O +
no O +
available O +
carcinogenicity U-Disease +
data O +
, O +
the O +
available O +
genotoxicity U-Disease +
data O +
, O +
combined O +
with O +
the O +
absence O +
of O +
any O +
structural O +
alerts O +
, O +
suggest O +
no O +
carcinogenic O +
potential O +
. O -

The O +
Panel O +
noted O +
the O +
absence O +
of O +
reproductive O +
and O +
developmental B-Disease +
toxicity L-Disease +
data O +
. O -

Because O +
this O +
ingredient O +
has O +
a O +
highly O +
polarized O +
molecular O +
structure O +
, O +
the O +
Panel O +
considered O +
that O +
it O +
would O +
be O +
, O +
at O +
most O +
, O +
slowly O +
absorbed O +
. O -

Given O +
that O +
most O +
of O +
the O +
uses O +
and O +
the O +
highest O +
use O +
concentration O +
of O +
4 O -
% O +
is O +
found O +
in O +
rinse O +
- O +
off O +
products O +
, O +
the O +
Panel O +
determined O +
that O +
the O +
available O +
data O +
suggest O +
that O +
Cocamidopropylamine O +
Oxide O +
is O +
safe O +
as O +
used O +
in O +
rinse O +
- O +
off O +
products O +
. O -

Although O +
dermal O +
penetration O +
may O +
be O +
slow O +
, O +
data O +
on O +
the O +
extent O +
of O +
dermal O +
penetration O +
of O +
Cocamidopropylamine O +
Oxide O +
are O +
needed O +
to O +
support O +
the O +
safety O +
of O +
leave O +
- O +
on O +
uses O +
. O -

If O +
there O +
is O +
significant O +
dermal O +
absorption O +
, O +
dermal O +
reproductive O +
and O +
developmental B-Disease +
toxicity L-Disease +
data O +
may O +
be O +
needed O +
. O -

Intravenous O +
fat O +
emulsion O +
: O +
a O +
potential O +
novel O +
antidote O +
. O -

Intravenous O +
fat O +
emulsions O +
( O +
IFE O +
) O +
are O +
traditionally O +
used O +
as O +
a O +
component O +
of O +
parenteral O +
nutrition O +
therapy O +
. O -

Recently O +
, O +
IFE O +
was O +
used O +
to O +
resuscitate O +
severe O +
local B-Disease +
anesthetic I-Disease +
drug I-Disease +
toxicity L-Disease +
. O -

This O +
review O +
focuses O +
on O +
the O +
potential O +
role O +
of O +
IFE O +
in O +
treatment O +
of O +
toxicity O +
due O +
to O +
local O +
anesthetics O +
and O +
other O +
lipid O +
- O +
soluble O +
drugs O +
. O -

The O +
general O +
properties O +
of O +
IFE O +
, O +
metabolic O +
fate O +
, O +
and O +
associated O +
adverse O +
events O +
are O +
described O +
. O -

Cases O +
of O +
local B-Disease +
anesthetic I-Disease +
toxicity L-Disease +
treated O +
with O +
IFE O +
are O +
presented O +
along O +
with O +
a O +
discussion O +
of O +
the O +
possible O +
antidotal O +
mechanisms O +
. O -

Initial O +
investigations O +
into O +
the O +
antidotal O +
use O +
of O +
IFE O +
for O +
lipophilic O +
central O +
nervous O +
and O +
cardiovascular B-Disease +
drug I-Disease +
toxicity L-Disease +
are O +
also O +
reviewed O +
. O -

The O +
use O +
of O +
ultrasound O +
and O +
micelles O +
in O +
cancer U-Disease +
treatment O +
. O -

The O +
high O +
toxicity O +
of O +
potent O +
chemotherapeutic O +
drugs O +
like O +
Doxorubicin O +
( O +
Dox O +
) O +
limits O +
the O +
therapeutic O +
window O +
in O +
which O +
they O +
can O +
be O +
applied O +
. O -

This O +
window O +
can O +
be O +
expanded O +
by O +
controlling O +
the O +
drug O +
delivery O +
in O +
both O +
space O +
and O +
time O +
such O +
that O +
non O +
- O +
targeted O +
tissues O +
are O +
not O +
adversely O +
affected O +
. O -

Recent O +
research O +
has O +
shown O +
that O +
ultrasound O +
( O +
US O +
) O +
can O +
be O +
used O +
to O +
control O +
the O +
release O +
of O +
Dox O +
and O +
other O +
hydrophobic O +
drugs O +
from O +
polymeric O +
micelles O +
in O +
both O +
time O +
and O +
space O +
. O -

It O +
has O +
also O +
been O +
shown O +
using O +
an O +
in O +
vivo O +
rat O +
tumor O +
model O +
that O +
Dox O +
activity O +
can O +
be O +
enhanced O +
by O +
ultrasound O +
in O +
one O +
region O +
, O +
while O +
in O +
an O +
adjacent O +
region O +
there O +
is O +
little O +
or O +
no O +
effect O +
of O +
the O +
drug O +
. O -

In O +
this O +
article O +
, O +
we O +
review O +
the O +
in O +
vivo O +
and O +
in O +
vitro O +
research O +
being O +
conducted O +
in O +
the O +
area O +
of O +
using O +
ultrasound O +
to O +
enhance O +
and O +
target O +
micellar O +
drug O +
delivery O +
to O +
cancerous O +
tissues O +
. O -

Additionally O +
, O +
we O +
summarize O +
our O +
previously O +
published O +
mathematical O +
models O +
that O +
attempt O +
to O +
represent O +
the O +
release O +
and O +
re O +
- O +
encapsulation O +
phenomena O +
of O +
Dox O +
from O +
Pluronic O +
P105 O +
micelles O +
upon O +
the O +
application O +
of O +
ultrasound O +
. O -

The O +
potential O +
benefits O +
of O +
such O +
controlled O +
chemotherapy O +
compels O +
a O +
thorough O +
investigation O +
of O +
the O +
role O +
of O +
ultrasound O +
( O +
US O +
) O +
and O +
the O +
mechanisms O +
by O +
which O +
US O +
accomplishes O +
drug O +
release O +
and O +
/ O +
or O +
enhances O +
drug O +
potency O +
. O -

Therefore O +
we O +
will O +
summarize O +
our O +
findings O +
related O +
to O +
the O +
mechanism O +
involved O +
in O +
acoustically O +
activated O +
micellar O +
drug O +
delivery O +
to O +
tumors U-Disease +
. O -

Drug O +
insight O +
: O +
aggrecanases O +
as O +
therapeutic O +
targets O +
for O +
osteoarthritis U-Disease +
. O -

In O +
healthy O +
cartilage O +
, O +
effective O +
weight O +
- O +
bearing O +
requires O +
a O +
high O +
concentration O +
of O +
intact O +
aggrecan O +
. O -

Degradation O +
and O +
loss O +
of O +
aggrecan O +
are O +
features O +
of O +
osteoarthritis U-Disease +
( O +
OA U-Disease +
) O +
. O -

It O +
is O +
unclear O +
whether O +
ADAMTS O +
- O +
4 O +
, O +
ADAMTS O +
- O +
5 O +
, O +
or O +
both O +
of O +
these O +
aggrecanases O +
from O +
the O +
ADAMTS O +
( O +
a O +
disintegrin O +
and O +
metalloproteinase O +
with O +
thrombospondin O +
motifs O +
) O +
enzyme O +
family O +
, O +
are O +
responsible O +
for O +
aggrecanolysis O +
in O +
human O +
OA U-Disease +
, O +
and O +
at O +
what O +
stage O +
of O +
disease O +
these O +
enzymes O +
are O +
active O +
. O -

Several O +
potential O +
disease O +
- O +
modifying O +
agents O +
for O +
OA U-Disease +
include O +
glucosamine O +
and O +
chondroitin O +
sulfate O +
, O +
diacerhein O +
, O +
and O +
pentosan O +
polysulfate O +
; O +
although O +
their O +
mechanisms O +
of O +
action O +
in O +
vivo O +
are O +
unknown O +
, O +
data O +
from O +
in O +
vitro O +
studies O +
and O +
animal O +
models O +
suggest O +
that O +
their O +
efficacy O +
might O +
be O +
partly O +
due O +
to O +
inhibition O +
of O +
proinflammatory O +
pathways O +
that O +
lead O +
to O +
downregulation O +
of O +
ADAMTS O +
enzymes O +
. O -

Some O +
histone O +
deacetylase O +
inhibitors O +
that O +
are O +
successfully O +
used O +
to O +
treat O +
cancer U-Disease +
can O +
block O +
ADAMTS O +
- O +
5 O +
expression O +
; O +
however O +
, O +
these O +
inhibitors O +
will O +
only O +
be O +
considered O +
as O +
potential O +
therapies O +
for O +
OA U-Disease +
if O +
their O +
toxicity O +
is O +
markedly O +
reduced O +
. O -

ADAMTS O +
inhibitors O +
currently O +
in O +
development O +
are O +
expected O +
to O +
show O +
excellent O +
specificity O +
now O +
that O +
crystal O +
structures O +
for O +
several O +
ADAMTS O +
enzymes O +
are O +
available O +
to O +
guide O +
drug O +
design O +
. O -

ADAMTS O +
- O +
4 O +
and O +
ADAMTS O +
- O +
5 O +
are O +
appropriate O +
targets O +
for O +
OA U-Disease +
therapies O +
, O +
but O +
ultimately O +
, O +
inhibitors O +
of O +
these O +
enzymes O +
will O +
form O +
only O +
part O +
of O +
a O +
larger O +
arsenal O +
of O +
therapies O +
. O -

Long O +
- O +
term O +
clinical O +
and O +
surrogate O +
marker O +
effects O +
of O +
subcutaneous O +
intermittent O +
interleukin O +
- O +
2 O +
without O +
antiretroviral O +
therapy O +
in O +
HIV O +
- O +
infected O +
patients O +
. O -

OBJECTIVES O +
: O +
Subcutaneous O +
administration O +
of O +
interleukin O +
- O +
2 O +
( O +
IL O +
- O +
2 O +
) O +
has O +
been O +
shown O +
to O +
increase O +
CD4 O +
counts O +
in O +
HIV O +
- O +
infected O +
patients O +
. O -

It O +
remains O +
unclear O +
whether O +
this O +
effect O +
is O +
associated O +
with O +
a O +
clinical O +
benefit O +
. O -

PATIENTS O +
AND O +
METHODS O +
: O +
We O +
conducted O +
a O +
long O +
- O +
term O +
follow O +
- O +
up O +
in O +
the O +
cohort O +
of O +
the O +
UK O +
- O +
Vanguard O +
study O +
in O +
which O +
three O +
groups O +
of O +
12 O +
antiretroviral O +
- O +
naive O +
subjects O +
with O +
CD4 O +
cell O +
counts O +
> O +
350 O +
cells O +
/ O +
mm O +
( O +
3 O +
) O +
received O +
no O +
treatment O +
or O +
IL O +
- O +
2 O +
at O +
either O +
4.5 O +
or O +
7.5 O +
MIU O +
twice O +
daily O +
in O +
5 O +
day O +
cycles O +
, O +
respectively O +
. O -

RESULTS O +
: O +
Mean O +
follow O +
- O +
up O +
was O +
376 O +
weeks O +
. O -

IL O +
- O +
2 O +
therapy O +
was O +
associated O +
with O +
a O +
higher O +
area O +
under O +
the O +
curve O +
of O +
CD4 O +
cell O +
count O +
change O +
from O +
baseline O +
at O +
week O +
48 O +
but O +
not O +
thereafter O +
. O -

HIV O +
- O +
RNA O +
levels O +
were O +
unaffected O +
. O -

Highly O +
active O +
antiretroviral O +
therapy O +
( O +
HAART O +
) O +
was O +
initiated O +
after O +
a O +
mean O +
of O +
172 O +
, O +
175 O +
and O +
152 O +
weeks O +
in O +
the O +
control O +
group O +
, O +
low O +
- O +
dose O +
and O +
high O +
- O +
dose O +
IL O +
- O +
2 O +
treatment O +
group O +
, O +
respectively O +
, O +
a O +
statistically O +
non O +
- O +
significant O +
difference O +
. O -

There O +
was O +
a O +
tendency O +
to O +
start O +
HAART O +
soon O +
after O +
discontinuation O +
of O +
IL O +
- O +
2 O +
therapy O +
which O +
may O +
have O +
been O +
triggered O +
by O +
the O +
steep O +
decay O +
of O +
CD4 O +
counts O +
. O -

There O +
were O +
two O +
serious O +
adverse O +
events O +
in O +
the O +
control O +
group O +
, O +
seven O +
in O +
the O +
low O +
- O +
dose O +
IL O +
- O +
2 O +
group O +
and O +
eight O +
in O +
the O +
high O +
- O +
dose O +
IL O +
- O +
2 O +
group O +
. O -

No O +
pattern O +
of O +
disease O +
was O +
detected O +
, O +
making O +
an O +
association O +
with O +
IL O +
- O +
2 O +
therapy O +
unlikely O +
. O -

CONCLUSIONS O +
: O +
We O +
could O +
detect O +
neither O +
a O +
benefit O +
of O +
IL O +
- O +
2 O +
therapy O +
after O +
week O +
48 O +
nor O +
delayed O +
initiation O +
of O +
HAART O +
. O -

This O +
is O +
currently O +
the O +
longest O +
follow O +
- O +
up O +
data O +
comparing O +
IL O +
- O +
2 O +
therapy O +
with O +
no O +
therapy O +
in O +
antiretroviral O +
- O +
naive O +
HIV O +
- O +
infected O +
patients O +
and O +
does O +
not O +
show O +
a O +
persistent O +
benefit O +
of O +
the O +
intervention O +
. O -

Altered O +
first O +
- O +
pass O +
effects O +
in O +
a O +
liver O +
transplant O +
recipient O +
explained O +
intraindividual O +
variation O +
in O +
calcineurin O +
inhibitor O +
concentrations O +
: O +
a O +
case O +
report O +
. O -

BACKGROUND O +
: O +
The O +
significant O +
interindividual O +
and O +
intraindividual O +
variability O +
in O +
the O +
blood O +
concentrations O +
of O +
the O +
most O +
commonly O +
used O +
calcineurin O +
inhibitors O +
such O +
as O +
tacrolimus O +
and O +
cyclosporine O +
makes O +
the O +
exact O +
dosing O +
of O +
these O +
agents O +
in O +
transplant O +
recipients O +
very O +
challenging O +
. O -

As O +
both O +
of O +
these O +
drugs O +
have O +
narrow O +
therapeutic O +
index O +
and O +
are O +
metabolized O +
by O +
hepatic O +
and O +
intestinal O +
cytochrome O +
P450 O +
3A O +
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
these O +
variations O +
are O +
secondary O +
to O +
varying O +
first O +
- O +
pass O +
effects O +
in O +
the O +
gut O +
and O +
the O +
liver O +
over O +
a O +
period O +
of O +
time O +
. O -

CASE O +
REPORT O +
: O +
A O +
liver O +
transplant O +
recipient O +
, O +
who O +
had O +
previously O +
presented O +
with O +
tacrolimus B-Disease +
toxicity L-Disease +
on O +
his O +
usual O +
dosing O +
regimen O +
and O +
intolerant O +
to O +
standard O +
doses O +
of O +
cyclosporine O +
, O +
was O +
selected O +
to O +
undergo O +
the O +
study O +
. O -

Oral O +
and O +
intravenous O +
midazolam O +
was O +
used O +
as O +
the O +
probe O +
to O +
measure O +
hepatic O +
and O +
intestinal O +
CYP3A4 O +
activities O +
at O +
two O +
different O +
time O +
points O +
( O +
phases O +
one O +
and O +
two O +
) O +
. O -

Small O +
intestinal O +
biopsies O +
were O +
also O +
obtained O +
for O +
measuring O +
CYP3A4 O +
activity O +
for O +
in O +
vitro O +
studies O +
. O -

On O +
serially O +
determining O +
the O +
patient O +
's O +
hepatic O +
and O +
intestinal O +
CYP3A O +
activities O +
, O +
we O +
concluded O +
that O +
the O +
variability O +
in O +
the O +
dosing O +
requirements O +
is O +
due O +
to O +
altered O +
first O +
- O +
pass O +
effects O +
in O +
the O +
intestine O +
. O -

DISCUSSION O +
: O +
Transplant O +
recipients O +
receive O +
multiple O +
medications O +
that O +
may O +
inhibit O +
or O +
induce O +
these O +
metabolizing O +
enzymes O +
, O +
which O +
eventually O +
determine O +
the O +
concentrations O +
of O +
these O +
narrow O +
therapeutic O +
agents O +
. O -

If O +
no O +
obvious O +
etiology O +
of O +
intolerance O +
to O +
calcineurin O +
inhibitors O +
in O +
a O +
transplant O +
recipient O +
is O +
identified O +
, O +
one O +
should O +
consider O +
altered O +
first O +
- O +
pass O +
effects O +
in O +
the O +
gut O +
and O +
the O +
liver O +
contributing O +
to O +
intraindividual O +
variations O +
in O +
the O +
blood O +
concentrations O +
. O -

AIDS B-Disease +
- I-Disease +
related I-Disease +
malignancies L-Disease +
: O +
state O +
of O +
the O +
art O +
and O +
therapeutic O +
challenges O +
. O -

Despite O +
the O +
impact O +
of O +
combination O +
antiretroviral O +
therapy O +
( O +
cART O +
) O +
on O +
HIV O +
- O +
related O +
mortality O +
, O +
malignancy O +
remains O +
an O +
important O +
cause O +
of O +
death O +
in O +
the O +
current O +
era O +
. O -

Although O +
the O +
advent O +
of O +
cART O +
has O +
resulted O +
in O +
reductions O +
in O +
the O +
incidence O +
of O +
Kaposi B-Disease +
's I-Disease +
sarcoma L-Disease +
and O +
non B-Disease +
- I-Disease +
Hodgkin I-Disease +
's I-Disease +
lymphoma L-Disease +
, O +
non B-Disease +
- I-Disease +
AIDS I-Disease +
- I-Disease +
defining I-Disease +
malignancies L-Disease +
present O +
an O +
increased O +
risk O +
for O +
HIV O +
- O +
infected O +
patients O +
, O +
characterized O +
by O +
some O +
common O +
clinical O +
features O +
, O +
generally O +
with O +
a O +
more O +
aggressive B-Disease +
behavior L-Disease +
and O +
a O +
more O +
advanced O +
disease O +
at O +
diagnosis O +
, O +
which O +
is O +
responsible O +
for O +
poorer O +
patient O +
outcomes O +
. O -

Specific O +
therapeutic O +
recommendations O +
are O +
lacking O +
for O +
these O +
new O +
nonopportunistic O +
malignancies U-Disease +
, O +
such O +
as O +
Hodgkin B-Disease +
's I-Disease +
lymphoma L-Disease +
, O +
anal B-Disease +
cancer L-Disease +
, O +
lung B-Disease +
cancer L-Disease +
, O +
hepatocarcinoma U-Disease +
, O +
and O +
many O +
others O +
. O -

Antiretroviral O +
agents O +
have O +
a O +
propensity O +
for O +
causing O +
drug O +
interactions O +
as O +
a O +
result O +
of O +
their O +
ability O +
to O +
either O +
inhibit O +
or O +
induce O +
the O +
cytochrome O +
P450 O +
( O +
CYP O +
) O +
enzyme O +
system O +
. O -

Because O +
many O +
antineoplastic O +
drugs O +
are O +
also O +
metabolized O +
by O +
the O +
CYP O +
system O +
, O +
coadministration O +
with O +
cART O +
could O +
result O +
in O +
either O +
drug O +
accumulation O +
with O +
increased O +
toxicity O +
, O +
or O +
decreased O +
efficacy O +
of O +
one O +
or O +
both O +
classes O +
of O +
drugs O +
. O -

Further O +
research O +
delineating O +
the O +
combined O +
safety O +
and O +
pharmacokinetics O +
of O +
antiretrovirals O +
and O +
antineoplastic O +
therapy O +
is O +
necessary O +
. O -

Special O +
considerations O +
of O +
these O +
AIDS O +
- O +
related O +
and O +
non B-Disease +
- I-Disease +
AIDS I-Disease +
- I-Disease +
related I-Disease +
malignancies L-Disease +
and O +
their O +
clinical O +
and O +
therapeutic O +
aspects O +
constitute O +
the O +
subject O +
of O +
this O +
review O +
. O -

Doxorubicin O +
, O +
cardiac O +
risk O +
factors O +
, O +
and O +
cardiac B-Disease +
toxicity L-Disease +
in O +
elderly O +
patients O +
with O +
diffuse O +
B B-Disease +
- I-Disease +
cell I-Disease +
non I-Disease +
- I-Disease +
Hodgkin I-Disease +
's I-Disease +
lymphoma L-Disease +
. O -

PURPOSE O +
: O +
Anthracycline O +
- O +
based O +
chemotherapy O +
, O +
which O +
improves O +
survival O +
for O +
patients O +
with O +
non B-Disease +
- I-Disease +
Hodgkin I-Disease +
's I-Disease +
lymphoma L-Disease +
, O +
is O +
often O +
withheld O +
from O +
elderly O +
patients O +
because O +
of O +
its O +
cardiotoxicity U-Disease +
. O -

We O +
studied O +
the O +
cardiac O +
effects O +
of O +
doxorubicin O +
in O +
a O +
population O +
- O +
based O +
sample O +
of O +
older O +
patients O +
with O +
diffuse B-Disease +
large I-Disease +
B I-Disease +
- I-Disease +
cell I-Disease +
lymphoma L-Disease +
( O +
DLBCL U-Disease +
) O +
. O -

PATIENTS O +
AND O +
METHODS O +
: O +
Among O +
patients O +
age O +
> O +
or O +
= O +
65 O +
years O +
diagnosed O +
with O +
DLBCL U-Disease +
from O +
1991 O +
to O +
2002 O +
in O +
the O +
Surveillance O +
, O +
Epidemiology O +
, O +
and O +
End O +
Results O +
- O +
Medicare O +
database O +
, O +
we O +
developed O +
logistic O +
regression O +
models O +
of O +
the O +
associations O +
of O +
doxorubicin O +
with O +
demographic O +
, O +
clinical O +
, O +
and O +
cardiac O +
variables O +
. O -

We O +
then O +
developed O +
Cox O +
proportional O +
hazards O +
models O +
of O +
the O +
association O +
between O +
doxorubicin O +
and O +
subsequent O +
congestive B-Disease +
heart I-Disease +
failure L-Disease +
( O +
CHF U-Disease +
) O +
, O +
taking O +
predictors O +
of O +
CHF U-Disease +
into O +
account O +
. O -

RESULTS O +
: O +
Of O +
9,438 O +
patients O +
with O +
DLBCL U-Disease +
, O +
3,164 O +
( O +
42 O -
% O +
) O +
received O +
doxorubicin O +
- O +
based O +
chemotherapy O +
. O -

Any O +
doxorubicin O +
use O +
was O +
associated O +
with O +
a O +
29 O -
% O +
increase O +
in O +
risk O +
of O +
CHF U-Disease +
( O +
95 O -
% O +
CI O +
, O +
1.02 O +
to O +
1.62 O +
) O +
; O +
CHF U-Disease +
risk O +
increased O +
with O +
number O +
of O +
doxorubicin O +
claims O +
, O +
increasing O +
age O +
, O +
prior B-Disease +
heart I-Disease +
disease L-Disease +
, O +
comorbidities O +
, O +
diabetes U-Disease +
, O +
and O +
hypertension U-Disease +
; O +
hypertension U-Disease +
intensified O +
the O +
effect O +
of O +
doxorubicin O +
on O +
risk O +
of O +
CHF U-Disease +
( O +
hazard O +
ratio O +
= O +
1.8 O +
; O +
P O +
< O +
.01 O +
) O +
. O -

In O +
the O +
8 O +
years O +
after O +
diagnosis O +
, O +
the O +
adjusted O +
CHF O +
- O +
free O +
survival O +
rate O +
was O +
74 O -
% O +
in O +
doxorubicin O +
- O +
treated O +
patients O +
versus O +
79 O -
% O +
in O +
patients O +
not O +
treated O +
with O +
doxorubicin O +
. O -

CONCLUSION O +
: O +
Among O +
patients O +
receiving O +
chemotherapy O +
for O +
DLBCL U-Disease +
, O +
those O +
with O +
prior B-Disease +
heart I-Disease +
disease L-Disease +
were O +
less O +
likely O +
than O +
others O +
to O +
be O +
treated O +
with O +
doxorubicin O +
, O +
and O +
those O +
who O +
received O +
doxorubicin O +
were O +
more O +
likely O +
than O +
others O +
to O +
develop O +
CHF U-Disease +
. O -

Various O +
cardiac O +
risk O +
factors O +
increased O +
CHF U-Disease +
risk O +
, O +
but O +
only O +
hypertension U-Disease +
was O +
synergistic O +
with O +
doxorubicin O +
. O -

Doxorubicin O +
has O +
dramatically O +
improved O +
survival O +
of O +
DLBCL U-Disease +
patients O +
; O +
nonetheless O +
, O +
some O +
subgroups O +
may O +
benefit O +
from O +
efforts O +
to O +
reduce O +
doxorubicin O +
- O +
related O +
CHF U-Disease +
risk O +
. O -

A O +
high O +
throughput O +
in O +
vitro O +
analytical O +
approach O +
to O +
screen O +
for O +
oxidative O +
stress O +
potential O +
exerted O +
by O +
nanomaterials O +
using O +
a O +
biologically O +
relevant O +
matrix O +
: O +
human O +
blood O +
serum O +
. O -

Limited O +
studies O +
have O +
shown O +
that O +
selected O +
nanomaterials O +
( O +
NMs O +
) O +
impart O +
various O +
forms O +
of O +
toxicity O +
in O +
biological O +
systems O +
; O +
however O +
, O +
a O +
common O +
metric O +
to O +
screen O +
for O +
potential O +
toxicity O +
is O +
needed O +
. O -

This O +
study O +
optimized O +
and O +
utilized O +
a O +
' O +
Ferric O +
reducing O +
ability O +
of O +
serum O +
( O +
FRAS O +
) O +
' O +
assay O +
as O +
a O +
screening O +
tool O +
to O +
quantitate O +
the O +
degree O +
of O +
oxidative O +
damage O +
induced O +
by O +
NMs O +
on O +
human O +
blood O +
serum O +
. O -

Antioxidants O +
in O +
blood O +
protect O +
against O +
oxidative O +
damage O +
caused O +
by O +
free O +
radicals O +
via O +
chemical O +
quenching O +
and O +
will O +
decrease O +
when O +
exposed O +
to O +
oxidatively O +
stressful O +
materials O +
. O -

Using O +
this O +
approach O +
, O +
the O +
antioxidant O +
capacity O +
of O +
NM O +
treated O +
serum O +
was O +
significantly O +
decreased O +
by O +
nano O +
- O +
silver O +
, O +
a O +
series O +
of O +
nano O +
- O +
carbon O +
blacks O +
, O +
fullerene O +
soot O +
, O +
and O +
nano O +
- O +
TiO O +
( O +
2 O +
) O +
( O +
anatase O +
, O +
p O +
< O +
0.05 O +
) O +
, O +
but O +
not O +
with O +
nano O +
- O +
alumina O +
, O +
fullerite O +
, O +
purified O +
fullerene O +
, O +
fine O +
TiO O +
( O +
2 O +
) O +
( O +
rutile O +
) O +
and O +
Min O +
- O +
U O +
- O +
Sil O +
5 O +
. O -

Particle O +
surface O +
area O +
and O +
not O +
biological O +
particle O +
size O +
was O +
highly O +
associated O +
with O +
the O +
degree O +
of O +
oxidative O +
stress O +
observed O +
. O -

This O +
approach O +
appears O +
responsive O +
to O +
multiple O +
determinants O +
of O +
oxidative O +
damage O +
, O +
including O +
particle O +
chemistry O +
, O +
surface O +
area O +
and O +
impurities O +
, O +
and O +
may O +
be O +
a O +
valid O +
screening O +
method O +
to O +
determine O +
oxidative O +
damage O +
imparted O +
by O +
nanomaterials O +
. O -

Efficacy O +
and O +
safety O +
of O +
two O +
doses O +
of O +
pemetrexed O +
supplemented O +
with O +
folic O +
acid O +
and O +
vitamin O +
B12 O +
in O +
previously O +
treated O +
patients O +
with O +
non B-Disease +
- I-Disease +
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
. O -

PURPOSE O +
: O +
The O +
objective O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
efficacy O +
and O +
safety O +
of O +
two O +
doses O +
of O +
pemetrexed O +
supplemented O +
with O +
folic O +
acid O +
and O +
vitamin O +
B O +
( O +
12 O +
) O +
in O +
pretreated O +
Japanese O +
patients O +
with O +
advanced O +
non B-Disease +
- I-Disease +
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
( O +
NSCLC U-Disease +
) O +
. O -

EXPERIMENTAL O +
DESIGN O +
: O +
Patients O +
with O +
an O +
Eastern O +
Cooperative O +
Oncology O +
Group O +
performance O +
status O +
0 O +
to O +
2 O +
, O +
stage O +
III O +
or O +
IV O +
, O +
and O +
who O +
received O +
previously O +
one O +
or O +
two O +
chemotherapy O +
regimens O +
were O +
randomized O +
to O +
receive O +
500 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
pemetrexed O +
( O +
P500 O +
) O +
or O +
1,000 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
pemetrexed O +
( O +
P1000 O +
) O +
on O +
day O +
1 O +
every O +
3 O +
weeks O +
. O -

The O +
primary O +
endpoint O +
was O +
response O +
rate O +
. O -

RESULTS O +
: O +
Of O +
the O +
216 O +
patients O +
evaluable O +
for O +
efficacy O +
( O +
108 O +
in O +
each O +
arm O +
) O +
, O +
response O +
rates O +
were O +
18.5 O -
% O +
( O +
90 O -
% O +
confidence O +
interval O +
, O +
12.6 O -
- O -
25.8 O -
% O +
) O +
and O +
14.8 O -
% O +
( O +
90 O -
% O +
confidence O +
interval O +
, O +
9.5 O -
- O -
21.6 O -
% O +
) O +
, O +
median O +
survival O +
times O +
were O +
16.0 O +
and O +
12.6 O +
months O +
, O +
1 O +
- O +
year O +
survival O +
rates O +
were O +
59.2 O -
% O +
and O +
53.7 O -
% O +
, O +
and O +
median O +
progression O +
- O +
free O +
survival O +
were O +
3.0 O +
and O +
2.5 O +
months O +
for O +
the O +
P500 O +
and O +
P1000 O +
, O +
respectively O +
. O -

Cox O +
multiple O +
regression O +
analysis O +
indicated O +
that O +
pemetrexed O +
dose O +
was O +
not O +
a O +
significant O +
prognostic O +
factor O +
. O -

Drug B-Disease +
- I-Disease +
related I-Disease +
toxicity L-Disease +
was O +
generally O +
tolerable O +
for O +
both O +
doses O +
; O +
however O +
, O +
the O +
safety O +
profile O +
of O +
P500 O +
showed O +
generally O +
milder O +
toxicity O +
. O -

Main O +
adverse O +
drug O +
reactions O +
of O +
severity O +
grade O +
3 O +
or O +
4 O +
were O +
neutrophil B-Disease +
count I-Disease +
decreased L-Disease +
( O +
20.2 O -
% O +
) O +
and O +
alanine B-Disease +
aminotransferase I-Disease +
( I-Disease +
glutamine I-Disease +
pyruvic I-Disease +
transaminase I-Disease +
) I-Disease +
increased L-Disease +
( O +
15.8 O -
% O +
) O +
in O +
P500 O +
and O +
neutrophil B-Disease +
count I-Disease +
decreased L-Disease +
( O +
24.3 O -
% O +
) O +
, O +
WBC B-Disease +
count I-Disease +
decreased L-Disease +
( O +
20.7 O -
% O +
) O +
, O +
and O +
lymphocyte B-Disease +
count I-Disease +
decreased L-Disease +
( O +
18.0 O -
% O +
) O +
in O +
P1000 O +
. O -

One O +
drug O +
- O +
related O +
death O +
from O +
interstitial B-Disease +
lung I-Disease +
disease L-Disease +
occurred O +
in O +
the O +
P500 O +
. O -

CONCLUSION O +
: O +
P500 O +
and O +
P1000 O +
are O +
similarly O +
active O +
with O +
promising O +
efficacy O +
and O +
acceptable O +
safety O +
outcomes O +
in O +
pretreated O +
patients O +
with O +
NSCLC U-Disease +
. O -

These O +
results O +
support O +
the O +
use O +
of O +
P500 O +
as O +
a O +
second O +
- O +
and O +
third O +
- O +
line O +
treatment O +
of O +
NSCLC U-Disease +
. O -

Pharmacogenetics O +
of O +
analgesics O +
: O +
toward O +
the O +
individualization O +
of O +
prescription O +
. O -

The O +
use O +
of O +
analgesics O +
is O +
based O +
on O +
the O +
empiric O +
administration O +
of O +
a O +
given O +
drug O +
with O +
clinical O +
monitoring O +
for O +
efficacy O +
and O +
toxicity O +
. O -

However O +
, O +
individual O +
responses O +
to O +
drugs O +
are O +
influenced O +
by O +
a O +
combination O +
of O +
pharmacokinetic O +
and O +
pharmacodynamic O +
factors O +
that O +
can O +
sometimes O +
be O +
regulated O +
by O +
genetic O +
factors O +
. O -

Whereas O +
polymorphic O +
drug O +
- O +
metabolizing O +
enzymes O +
and O +
drug O +
transporters O +
may O +
affect O +
the O +
pharmacokinetics O +
of O +
drugs O +
, O +
polymorphic O +
drug O +
targets O +
and O +
disease O +
- O +
related O +
pathways O +
may O +
influence O +
the O +
pharmacodynamic O +
action O +
of O +
drugs O +
. O -

After O +
a O +
usual O +
dose O +
, O +
variations O +
in O +
drug B-Disease +
toxicity L-Disease +
and O +
inefficacy O +
can O +
be O +
observed O +
depending O +
on O +
the O +
polymorphism O +
, O +
the O +
analgesic O +
considered O +
and O +
the O +
presence O +
or O +
absence O +
of O +
active O +
metabolites O +
. O -

For O +
opioids O +
, O +
the O +
most O +
studied O +
being O +
morphine O +
, O +
mutations O +
in O +
the O +
ABCB1 O +
gene O +
, O +
coding O +
for O +
P O +
- O +
glycoprotein O +
( O +
P O +
- O +
gp O +
) O +
, O +
and O +
in O +
the O +
micro O +
- O +
opioid O +
receptor O +
reduce O +
morphine O +
potency O +
. O -

Cytochrome O +
P450 O +
( O +
CYP O +
) O +
2D6 O +
mutations O +
influence O +
the O +
analgesic O +
effect O +
of O +
codeine O +
and O +
tramadol O +
, O +
and O +
polymorphism O +
of O +
CYP2C9 O +
is O +
potentially O +
linked O +
to O +
an O +
increase O +
in O +
nonsteroidal O +
anti O +
- O +
inflammatory O +
drug O +
- O +
induced O +
adverse O +
events O +
. O -

Furthermore O +
, O +
drug O +
interactions O +
can O +
mimic O +
genetic O +
deficiency O +
and O +
contribute O +
to O +
the O +
variability O +
in O +
response O +
to O +
analgesics O +
. O -

This O +
review O +
summarizes O +
the O +
available O +
data O +
on O +
the O +
pharmacokinetic O +
and O +
pharmacodynamic O +
consequences O +
of O +
known O +
polymorphisms O +
of O +
drug O +
- O +
metabolizing O +
enzymes O +
, O +
drug O +
transporters O +
, O +
drug O +
targets O +
and O +
other O +
nonopioid O +
biological O +
systems O +
on O +
central O +
and O +
peripheral O +
analgesics O +
. O -

Effect O +
of O +
repeated O +
doses O +
of O +
darunavir O +
plus O +
low O +
- O +
dose O +
ritonavir O +
on O +
the O +
pharmacokinetics O +
of O +
sildenafil O +
in O +
healthy O +
male O +
subjects O +
: O +
phase O +
I O +
randomized O +
, O +
open O +
- O +
label O +
, O +
two O +
- O +
way O +
crossover O +
study O +
. O -

BACKGROUND O +
AND O +
OBJECTIVES O +
: O +
Darunavir O +
( O +
DRV O +
, O +
TMC114 O +
) O +
is O +
a O +
novel O +
protease O +
inhibitor O +
administered O +
in O +
combination O +
with O +
low O +
- O +
dose O +
ritonavir O +
( O +
DRV O +
/ O +
r O +
) O +
and O +
is O +
highly O +
active O +
against O +
both O +
wild O +
- O +
type O +
and O +
multidrug O +
- O +
resistant O +
HIV O +
- O +
1 O +
strains O +
. O -

Sildenafil O +
is O +
an O +
oral O +
therapy O +
for O +
erectile B-Disease +
dysfunction L-Disease +
. O -

Concomitant O +
administration O +
of O +
protease O +
inhibitors O +
and O +
sildenafil O +
increases O +
sildenafil O +
plasma O +
concentrations O +
. O -

The O +
potential O +
for O +
a O +
pharmacokinetic O +
drug O +
interaction O +
exists O +
when O +
sildenafil O +
and O +
DRV O +
/ O +
r O +
are O +
co O +
- O +
administered O +
, O +
as O +
these O +
drugs O +
are O +
primarily O +
metabolized O +
by O +
cytochrome O +
P450 O +
( O +
CYP O +
) O +
3A O +
, O +
and O +
darunavir O +
and O +
ritonavir O +
are O +
CYP3A O +
inhibitors O +
. O -

The O +
primary O +
objective O +
of O +
this O +
open O +
- O +
label O +
, O +
crossover O +
, O +
phase O +
I O +
study O +
was O +
to O +
assess O +
the O +
effect O +
of O +
multiple O +
doses O +
of O +
DRV O +
/ O +
r O +
on O +
the O +
pharmacokinetics O +
of O +
sildenafil O +
and O +
its O +
active O +
metabolite O +
N O +
- O +
desmethyl O +
sildenafil O +
. O -

The O +
secondary O +
objective O +
was O +
to O +
assess O +
the O +
short O +
- O +
term O +
safety O +
and O +
tolerability O +
of O +
co O +
- O +
administration O +
of O +
sildenafil O +
and O +
DRV O +
/ O +
r O +
. O -

METHODS O +
: O +
Sixteen O +
HIV O +
- O +
negative O +
healthy O +
male O +
subjects O +
were O +
randomized O +
to O +
one O +
of O +
two O +
sequences O +
. O -

In O +
two O +
sessions O +
each O +
subject O +
received O +
treatments O +
A O +
and O +
B O +
. O -

In O +
treatment O +
A O +
, O +
a O +
single O +
dose O +
of O +
sildenafil O +
100 O +
mg O +
was O +
administered O +
. O -

In O +
treatment O +
B O +
, O +
the O +
subjects O +
received O +
DRV O +
/ O +
r O +
400 O -
/ O -
100 O +
mg O +
twice O +
daily O +
for O +
8 O +
days O +
and O +
on O +
day O +
7 O +
a O +
single O +
dose O +
of O +
sildenafil O +
25 O +
mg O +
was O +
co O +
- O +
administered O +
. O -

Full O +
pharmacokinetic O +
profiles O +
of O +
sildenafil O +
, O +
N O +
- O +
desmethyl O +
sildenafil O +
, O +
darunavir O +
and O +
ritonavir O +
were O +
determined O +
. O -

Safety O +
and O +
tolerability O +
were O +
also O +
assessed O +
. O -

RESULTS O +
: O +
Sildenafil O +
exposure O +
( O +
area O +
under O +
the O +
plasma O +
concentration O +
- O +
time O +
curve O +
[ O +
AUC O +
] O +
) O +
was O +
comparable O +
between O +
the O +
two O +
treatments O +
despite O +
administration O +
of O +
a O +
lower O +
dose O +
of O +
sildenafil O +
( O +
25 O +
mg O +
) O +
with O +
DRV O +
/ O +
r O +
than O +
when O +
sildenafil O +
( O +
100 O +
mg O +
) O +
was O +
administered O +
alone O +
. O -

When O +
sildenafil O +
25 O +
mg O +
was O +
co O +
- O +
administered O +
with O +
DRV O +
/ O +
r O +
, O +
the O +
sildenafil O +
maximum O +
plasma O +
concentration O +
( O +
Cmax O +
) O +
was O +
38 O -
% O +
lower O +
compared O +
with O +
Cmax O +
after O +
administration O +
of O +
sildenafil O +
alone O +
at O +
a O +
dose O +
of O +
100 O +
mg O +
. O -

N O +
- O +
desmethyl O +
sildenafil O +
Cmax O +
and O +
AUC O +
from O +
the O +
time O +
of O +
administration O +
until O +
the O +
last O +
time O +
point O +
with O +
a O +
measurable O +
concentration O +
after O +
dosing O +
( O +
calculated O +
by O +
linear O +
trapezoidal O +
summation O +
[ O +
AUClast O +
] O +
) O +
values O +
decreased O +
by O +
approximately O +
95 O -
% O +
when O +
sildenafil O +
25 O +
mg O +
was O +
co O +
- O +
administered O +
with O +
DRV O +
/ O +
r O +
compared O +
with O +
sildenafil O +
100 O +
mg O +
alone O +
. O -

Combined O +
treatment O +
with O +
DRV O +
/ O +
r O +
and O +
sildenafil O +
was O +
generally O +
safe O +
and O +
well O +
tolerated O +
. O -

CONCLUSION O +
: O +
Sildenafil O +
exposure O +
is O +
increased O +
in O +
the O +
presence O +
of O +
DRV O +
/ O +
r O +
. O -

In O +
this O +
setting O +
, O +
a O +
dose O +
adjustment O +
for O +
sildenafil O +
is O +
warranted O +
; O +
no O +
more O +
than O +
25 O +
mg O +
of O +
sildenafil O +
is O +
recommended O +
over O +
a O +
48 O +
- O +
hour O +
period O +
when O +
co O +
- O +
administered O +
with O +
DRV O +
/ O +
r O +
. O -

Paternal O +
exposure O +
and O +
counselling O +
: O +
experience O +
of O +
a O +
Teratology O +
Information O +
Service O +
. O -

We O +
describe O +
paternal O +
exposure O +
and O +
counselling O +
in O +
a O +
selected O +
population O +
calling O +
to O +
an O +
Italian O +
Teratology O +
Information O +
Service O +
( O +
TIS O +
) O +
. O -

The O +
majority O +
of O +
callers O +
asked O +
for O +
paternal O +
drug O +
exposure O +
( O +
76 O -
% O +
, O +
drugs O +
except O +
chemotherapy O +
) O +
and O +
treatment O +
for O +
cancer U-Disease +
( O +
17 O -
% O +
, O +
chemotherapy O +
and O +
/ O +
or O +
radiotherapy O +
) O +
. O -

Others O +
asked O +
for O +
exposure O +
to O +
diagnostic O +
radiations O +
( O +
4 O -
% O +
) O +
, O +
recreational O +
drugs O +
( O +
2 O -
% O +
) O +
and O +
occupational O +
chemicals O +
( O +
1 O -
% O +
) O +
. O -

Among O +
paternal O +
drugs O +
neurological O +
compounds O +
, O +
immunosuppressive O +
drugs O +
and O +
antiviral O +
agents O +
were O +
the O +
main O +
reasons O +
for O +
calling O +
. O -

In O +
humans O +
, O +
there O +
are O +
no O +
evidences O +
of O +
birth B-Disease +
defects L-Disease +
after O +
paternal O +
exposures O +
, O +
but O +
to O +
minimize O +
any O +
possible O +
risk O +
, O +
counselling O +
in O +
men O +
exposed O +
to O +
radio O +
and O +
chemotherapy O +
should O +
recommend O +
delaying O +
conception O +
for O +
at O +
least O +
3 O +
months O +
after O +
the O +
end O +
of O +
the O +
therapy O +
. O -

Male O +
patients O +
treated O +
with O +
drugs O +
, O +
whose O +
teratogenic O +
potential O +
has O +
been O +
well O +
assessed O +
or O +
suspected O +
for O +
maternal O +
exposure O +
, O +
should O +
be O +
advised O +
to O +
practice O +
effective O +
birth O +
control O +
during O +
therapy O +
and O +
up O +
to O +
one O +
or O +
two O +
cycles O +
of O +
spermatogenesis O +
and O +
to O +
avoid O +
semen O +
contact O +
with O +
vaginal O +
walls O +
during O +
first O +
trimester O +
of O +
pregnancy O +
. O -

A O +
randomized O +
, O +
double O +
- O +
blind O +
, O +
crossover O +
study O +
of O +
once O +
- O +
daily O +
dexmethylphenidate O +
in O +
children O +
with O +
attention B-Disease +
- I-Disease +
deficit I-Disease +
hyperactivity I-Disease +
disorder L-Disease +
: O +
rapid O +
onset O +
of O +
effect O +
. O -

BACKGROUND O +
: O +
Long O +
- O +
acting O +
methylphenidate O +
formulations O +
provide O +
control O +
of O +
attention B-Disease +
- I-Disease +
deficit I-Disease +
hyperactivity I-Disease +
disorder L-Disease +
( O +
ADHD U-Disease +
) O +
symptoms O +
for O +
up O +
to O +
12 O +
hours O +
; O +
however O +
, O +
not O +
all O +
formulations O +
have O +
rapid O +
onset O +
of O +
therapeutic O +
effect O +
, O +
which O +
is O +
essential O +
for O +
providing O +
symptom O +
control O +
during O +
morning O +
hours O +
. O -

The O +
primary O +
objective O +
of O +
this O +
randomized O +
, O +
double O +
- O +
blind O +
, O +
crossover O +
study O +
was O +
to O +
assess O +
the O +
efficacy O +
of O +
dexmethylphenidate O +
extended O +
release O +
( O +
ER O +
) O +
versus O +
placebo O +
by O +
measuring O +
the O +
change O +
from O +
pre O +
- O +
dose O +
to O +
0.5 O +
hours O +
post O +
- O +
dose O +
on O +
the O +
Swanson O +
, O +
Kotkin O +
, O +
Agler O +
, O +
M O +
- O +
Flynn O +
and O +
Pelham O +
( O +
SKAMP O +
) O +
rating O +
scale O +
. O -

METHODS O +
: O +
Eighty O +
- O +
six O +
children O +
( O +
6 O -
- O -
12 O +
years O +
) O +
with O +
ADHD U-Disease +
diagnosed O +
using O +
the O +
DSM O +
- O +
IV O +
criteria O +
were O +
randomized O +
to O +
receive O +
dexmethylphenidate O +
ER O +
20 O +
mg O +
/ O +
day O +
or O +
placebo O +
, O +
sequentially O +
, O +
for O +
7 O +
days O +
, O +
with O +
the O +
final O +
dose O +
administered O +
in O +
a O +
laboratory O +
classroom O +
setting O +
on O +
day O +
7 O +
of O +
each O +
treatment O +
period O +
. O -

The O +
primary O +
efficacy O +
comparison O +
was O +
change O +
in O +
the O +
SKAMP O +
- O +
Combined O +
score O +
from O +
pre O +
- O +
dose O +
to O +
0.5 O +
hours O +
post O +
- O +
dose O +
, O +
with O +
additional O +
secondary O +
assessments O +
at O +
1 O +
, O +
2 O +
, O +
4 O +
, O +
6 O +
and O +
8 O +
hours O +
post O +
- O +
dose O +
. O -

Secondary O +
efficacy O +
measures O +
included O +
change O +
from O +
pre O +
- O +
dose O +
at O +
all O +
timepoints O +
in O +
the O +
SKAMP O +
- O +
Attention O +
and O +
SKAMP O +
- O +
Deportment O +
, O +
Math O +
Test O +
- O +
Attempted O +
and O +
Math O +
Test O +
- O +
Correct O +
scores O +
, O +
and O +
change O +
from O +
baseline O +
on O +
the O +
Conners O +
' O +
ADHD U-Disease +
/ O +
DSM O +
- O +
IV O +
Scale O +
for O +
Parents O +
( O +
CADS O +
- O +
P O +
) O +
. O -

In O +
an O +
exploratory O +
analysis O +
, O +
a O +
daily O +
diary O +
card O +
was O +
completed O +
by O +
parents O +
on O +
the O +
children O +
's O +
in O +
- O +
home O +
behaviour O +
before O +
school O +
. O -

Safety O +
was O +
assessed O +
by O +
occurrence O +
of O +
adverse O +
events O +
, O +
monitoring O +
of O +
vital O +
signs O +
and O +
interpretation O +
of O +
ECGs O +
. O -

RESULTS O +
: O +
Significant O +
improvements O +
were O +
noted O +
at O +
0.5 O +
hours O +
and O +
at O +
all O +
timepoints O +
post O +
- O +
dose O +
throughout O +
the O +
8 O +
- O +
hour O +
laboratory O +
classroom O +
day O +
for O +
dexmethylphenidate O +
ER O +
vs O +
placebo O +
in O +
the O +
primary O +
outcome O +
measure O +
of O +
the O +
SKAMP O +
- O +
Combined O +
scores O +
( O +
p O +
< O +
0.001 O +
) O +
, O +
as O +
well O +
as O +
SKAMP O +
- O +
Attention O +
, O +
SKAMP O +
- O +
Deportment O +
, O +
Math O +
Test O +
- O +
Attempted O +
and O +
Math O +
Test O +
- O +
Correct O +
scores O +
( O +
p O +
< O +
0.05 O +
) O +
. O -

The O +
changes O +
from O +
baseline O +
in O +
CADS O +
- O +
P O +
scores O +
were O +
significantly O +
greater O +
with O +
dexmethylphenidate O +
ER O +
than O +
placebo O +
( O +
- O +
16.382 O +
vs O +
- O +
4.622 O +
; O +
p O +
< O +
0.001 O +
) O +
. O -

Responses O +
to O +
all O +
diary O +
questions O +
indicated O +
significant O +
improvement O +
with O +
dexmethylphenidate O +
ER O +
treatment O +
versus O +
placebo O +
( O +
all O +
p O +
< O +
0.001 O +
) O +
. O -

The O +
most O +
common O +
adverse O +
events O +
were O +
abdominal B-Disease +
pain L-Disease +
( O +
dexmethylphenidate O +
ER O +
3.5 O -
% O +
; O +
placebo O +
4.7 O -
% O +
) O +
, O +
headache U-Disease +
( O +
dexmethylphenidate O +
ER O +
3.5 O -
% O +
; O +
placebo O +
2.3 O -
% O +
) O +
and O +
increased B-Disease +
appetite L-Disease +
( O +
dexmethylphenidate O +
ER O +
0 O -
% O +
; O +
placebo O +
3.5 O -
% O +
) O +
. O -

CONCLUSION O +
: O +
Compared O +
with O +
placebo O +
, O +
once O +
- O +
daily O +
dexmethylphenidate O +
ER O +
20 O +
mg O +
provided O +
rapid O +
and O +
significant O +
improvement O +
at O +
0.5 O +
hours O +
post O +
- O +
dose O +
in O +
attention O +
, O +
deportment O +
and O +
academic O +
performance O +
, O +
which O +
was O +
sustained O +
for O +
8 O +
hours O +
post O +
- O +
dose O +
. O -

Overall O +
, O +
once O +
- O +
daily O +
dexmethylphenidate O +
ER O +
20 O +
mg O +
was O +
well O +
tolerated O +
. O -

In O +
an O +
analysis O +
of O +
parental O +
assessment O +
of O +
diary O +
responses O +
, O +
children O +
appeared O +
more O +
organized O +
, O +
and O +
morning O +
preparation O +
for O +
school O +
was O +
smoother O +
and O +
less O +
frustrating O +
with O +
once O +
- O +
daily O +
dexmethylphenidate O +
ER O +
compared O +
with O +
placebo O +
. O -

Clostridium O +
perfringens O +
enterotoxin O +
in O +
antibiotic B-Disease +
- I-Disease +
associated I-Disease +
diarrhea L-Disease +
. O -

Clostridium O +
perfringens O +
type O +
A O +
is O +
associated O +
with O +
5 O -
- O -
20 O -
% O +
cases O +
of O +
antibiotic B-Disease +
- I-Disease +
associated I-Disease +
diarrhea L-Disease +
( O +
AAD O +
) O +
even O +
though O +
Clostridium O +
difficile O +
is O +
implicated O +
in O +
the O +
most O +
severe O +
cases O +
. O -

Fecal O +
specimens O +
from O +
one O +
hundred O +
hospitalized O +
patients O +
, O +
who O +
developed O +
diarrhea U-Disease +
regardless O +
of O +
antibiotic O +
intake O +
and O +
who O +
were O +
negative O +
for O +
C O +
. O -

difficile O +
toxin O +
assay O +
, O +
were O +
investigated O +
for O +
C O +
. O -

perfringens O +
enterotoxin O +
( O +
CPE O +
) O +
. O -

Simultaneously O +
, O +
cultures O +
were O +
set O +
up O +
for O +
other O +
possible O +
aetiological O +
factors O +
. O -

Ten U-Disease +
healthy O +
controls O +
were O +
also O +
similarly O +
investigated O +
. O -

CPE O +
was O +
positive O +
in O +
2 O -
/ O -
100 O +
( O +
2 O -
% O +
) O +
of O +
the O +
patients O +
and O +
the O +
samples O +
were O +
also O +
positive O +
for O +
the O +
organism O +
in O +
culture O +
. O -

Other O +
organisms O +
isolated O +
were O +
non O +
- O +
toxigenic O +
C O +
. O -

difficile O +
( O +
4 O -
% O +
) O +
, O +
staphylococci O +
( O +
6 O -
% O +
) O +
, O +
Candida O +
( O +
18 O -
% O +
) O +
and O +
Klebsiella O +
pneumoniae O +
( O +
1 O -
% O +
) O +
. O -

Stool O +
samples O +
from O +
healthy O +
controls O +
grew O +
mixed O +
growth O +
of O +
no O +
significance O +
and O +
CPE O +
was O +
negative O +
in O +
all O +
of O +
them O +
. O -

Detection O +
of O +
CPE O +
is O +
not O +
part O +
of O +
routine O +
laboratory O +
investigation O +
due O +
to O +
resource O +
implication O +
. O -

Criteria O +
for O +
initiating O +
investigations O +
have O +
to O +
be O +
therefore O +
established O +
by O +
understanding O +
the O +
true O +
burden O +
of O +
C O +
. O -

perfringens O +
- O +
associated O +
AAD O +
by O +
further O +
research O +
. O -

Should O +
we O +
abandon O +
corticosteroids O +
during O +
septic B-Disease +
shock L-Disease +
? O -

No O +
. O -

PURPOSE O +
OF O +
REVIEW O +
: O +
With O +
the O +
publication O +
of O +
the O +
results O +
of O +
the O +
recent O +
CORTICUS O +
trial O +
, O +
stress O +
( O +
' O +
low O +
' O +
) O +
doses O +
of O +
corticosteroids O +
for O +
the O +
treatment O +
of O +
vasopressor O +
- O +
dependent O +
septic B-Disease +
shock L-Disease +
in O +
adults O +
can O +
still O +
be O +
considered O +
controversial O +
. O -

The O +
purpose O +
of O +
this O +
narrative O +
review O +
is O +
to O +
elaborate O +
the O +
pros O +
and O +
cons O +
of O +
this O +
treatment O +
in O +
clinical O +
practice O +
and O +
to O +
formulate O +
clinical O +
and O +
research O +
directions O +
. O -

RECENT O +
FINDINGS O +
: O +
The O +
recent O +
CORTICUS O +
study O +
only O +
shows O +
a O +
beneficial O +
effect O +
of O +
stress O +
doses O +
of O +
corticosteroids O +
in O +
the O +
time O +
interval O +
to O +
shock O +
reversal O +
and O +
not O +
on O +
mortality O +
, O +
potentially O +
explained O +
by O +
an O +
increased O +
risk O +
for O +
superinfection U-Disease +
. O -

The O +
mortality O +
in O +
the O +
placebo O +
arm O +
was O +
relatively O +
low O +
and O +
lower O +
than O +
in O +
earlier O +
randomized O +
studies O +
in O +
which O +
stress O +
doses O +
of O +
corticosteroids O +
had O +
a O +
favorable O +
hemodynamic O +
effect O +
and O +
conferred O +
a O +
survival O +
benefit O +
in O +
septic B-Disease +
shock L-Disease +
. O -

SUMMARY O +
: O +
Treatment O +
by O +
stress O +
doses O +
of O +
corticosteroids O +
should O +
not O +
be O +
abandoned O +
during O +
septic B-Disease +
shock L-Disease +
. O -

Additional O +
studies O +
are O +
needed O +
, O +
however O +
, O +
to O +
better O +
delineate O +
the O +
patient O +
group O +
with O +
the O +
highest O +
likelihood O +
to O +
benefit O +
from O +
this O +
therapy O +
, O +
as O +
a O +
function O +
of O +
severity O +
of O +
illness O +
, O +
response O +
to O +
adrenocorticotrophic O +
hormone O +
testing O +
or O +
both O +
. O -

For O +
now O +
, O +
results O +
of O +
the O +
CORTICUS O +
study O +
should O +
not O +
change O +
current O +
clinical O +
practice O +
of O +
administering O +
200 O -
- O -
300 O +
mg O +
of O +
hydrocortisone O +
daily O +
( O +
in O +
divided O +
doses O +
) O +
in O +
case O +
of O +
fluid O +
and O +
vasopressor O +
- O +
insensitive O +
septic B-Disease +
shock L-Disease +
and O +
rapid O +
tapering O +
of O +
this O +
treatment O +
on O +
the O +
basis O +
of O +
a O +
hemodynamic O +
response O +
. O -

Inhibition O +
of O +
cell O +
- O +
cycle O +
progression O +
in O +
human O +
colorectal O +
carcinoma O +
Lovo O +
cells O +
by O +
andrographolide O +
. O -

In O +
recent O +
years O +
, O +
attention O +
has O +
been O +
focused O +
on O +
the O +
anti O +
- O +
cancer O +
properties O +
of O +
pure O +
components O +
, O +
an O +
important O +
role O +
in O +
the O +
prevention O +
of O +
disease O +
. O -

Andrographolide O +
( O +
Andro O +
) O +
, O +
the O +
major O +
constituent O +
of O +
Andrographis O +
paniculata O +
( O +
Burm O +
. O +
F O +
. O +
) O -

Nees O +
plant O +
, O +
is O +
implicated O +
towards O +
its O +
pharmacological O +
activity O +
. O -

To O +
investigate O +
the O +
mechanism O +
basis O +
for O +
the O +
anti O +
- O +
tumor O +
properties O +
of O +
Andro O +
, O +
Andro O +
was O +
used O +
to O +
examine O +
its O +
effect O +
on O +
cell O +
- O +
cycle O +
progression O +
in O +
human O +
colorectal O +
carcinoma O +
Lovo O +
cells O +
. O -

The O +
data O +
from O +
cell O +
growth O +
experiment O +
showed O +
that O +
Andro O +
exhibited O +
the O +
anti O +
- O +
proliferation O +
effect O +
on O +
Lovo O +
cells O +
in O +
a O +
time O +
- O +
and O +
dose O +
- O +
dependent O +
manner O +
. O -

This O +
event O +
was O +
accompanied O +
the O +
arrest O +
of O +
the O +
cells O +
at O +
the O +
G1 O +
- O +
S O +
phase O +
by O +
Andro O +
at O +
the O +
tested O +
concentrations O +
of O +
0 O -
- O -
30 O +
microM O +
. O -

Cellular O +
uptake O +
of O +
Andro O +
and O +
Andro O +
was O +
confirmed O +
by O +
capillary O +
electrophoresis O +
analysis O +
and O +
the O +
intracellular O +
accumulation O +
of O +
Andro O +
( O +
0.61 O +
+ O +
/ O +
- O +
0.07 O +
microM O +
/ O +
mg O +
protein O +
) O +
was O +
observed O +
when O +
treatment O +
of O +
Lovo O +
cells O +
with O +
Andro O +
for O +
12h O +
. O -

In O +
addition O +
, O +
an O +
accumulation O +
of O +
the O +
cells O +
in O +
G1 O +
phase O +
( O +
15 O -
% O +
increase O +
for O +
10 O +
microM O +
of O +
Andro O +
) O +
was O +
observed O +
as O +
well O +
as O +
by O +
the O +
association O +
with O +
a O +
marked O +
decrease O +
in O +
the O +
protein O +
expression O +
of O +
Cyclin O +
A O +
, O +
Cyclin O +
D1 O +
, O +
Cdk2 O +
and O +
Cdk4 O +
. O -

Andro O +
also O +
inducted O +
the O +
content O +
of O +
Cdk O +
inhibitor O +
p21 O +
and O +
p16 O +
, O +
and O +
the O +
phosphorylation O +
of O +
p53 O +
. O -

Further O +
immunoprecipitation O +
studies O +
found O +
that O +
, O +
in O +
response O +
to O +
the O +
treatment O +
, O +
the O +
formation O +
of O +
Cyclin O +
D1 O +
/ O +
Cdk4 O +
and O +
Cyclin O +
A O +
/ O +
Cdk2 O +
complexes O +
had O +
declined O +
, O +
preventing O +
the O +
phosphorylation O +
of O +
Rb O +
and O +
the O +
subsequent O +
dissociation O +
of O +
Rb O +
/ O +
E2F O +
complex O +
. O -

These O +
results O +
suggested O +
Andro O +
can O +
inhibit O +
Lovo O +
cell O +
growth O +
by O +
G1 O +
- O +
S O +
phase O +
arrest O +
, O +
and O +
was O +
exerted O +
by O +
inducing O +
the O +
expression O +
of O +
p53 O +
, O +
p21 O +
and O +
p16 O +
that O +
, O +
in O +
turn O +
, O +
repressed O +
the O +
activity O +
of O +
Cyclin O +
D1 O +
/ O +
Cdk4 O +
and O +
/ O +
or O +
Cyclin O +
A O +
/ O +
Cdk2 O +
, O +
as O +
well O +
as O +
Rb O +
phosphorylation O +
. O -

Impact O +
of O +
antioxidant O +
supplementation O +
on O +
chemotherapeutic B-Disease +
toxicity L-Disease +
: O +
a O +
systematic O +
review O +
of O +
the O +
evidence O +
from O +
randomized O +
controlled O +
trials O +
. O -

Much O +
debate O +
has O +
focused O +
on O +
whether O +
antioxidants O +
interfere O +
with O +
the O +
efficacy O +
of O +
cancer U-Disease +
chemotherapy O +
. O -

The O +
objective O +
of O +
this O +
study O +
is O +
to O +
systematically O +
review O +
the O +
randomized O +
, O +
controlled O +
clinical O +
trial O +
evidence O +
evaluating O +
the O +
effects O +
of O +
concurrent O +
use O +
of O +
antioxidants O +
with O +
chemotherapy O +
on O +
toxic O +
side O +
effects O +
. O -

We O +
performed O +
a O +
search O +
of O +
literature O +
from O +
1966 O +
- O +
October O +
2007 O +
using O +
MEDLINE O +
, O +
Cochrane O +
, O +
CinAhl O +
, O +
AMED O +
, O +
AltHealthWatch O +
and O +
EMBASE O +
databases O +
. O -

Randomized O +
, O +
controlled O +
clinical O +
trials O +
reporting O +
antioxidant O +
- O +
based O +
mitigation O +
of O +
chemotherapy B-Disease +
toxicity L-Disease +
were O +
included O +
in O +
the O +
final O +
tally O +
. O -

Searches O +
were O +
performed O +
following O +
a O +
standardized O +
protocol O +
for O +
systematic O +
reviews O +
. O -

Only O +
33 O +
of O +
965 O +
articles O +
considered O +
, O +
including O +
2,446 O +
subjects O +
, O +
met O +
the O +
inclusion O +
criteria O +
. O -

Antioxidants O +
evaluated O +
were O +
: O +
glutathione O +
( O +
11 O +
) O +
, O +
melatonin O +
( O +
7 O +
) O +
, O +
vitamin O +
A O +
( O +
1 O +
) O +
, O +
an O +
antioxidant O +
mixture O +
( O +
2 O +
) O +
, O +
N O +
- O +
acetylcysteine O +
( O +
2 O +
) O +
, O +
vitamin O +
E O +
( O +
5 O +
) O +
, O +
selenium O +
( O +
2 O +
) O +
, O +
L O +
- O +
carnitine O +
( O +
1 O +
) O +
, O +
Co O +
- O +
Q10 O +
( O +
1 O +
) O +
and O +
ellagic O +
acid O +
( O +
1 O +
) O +
. O -

The O +
majority O +
( O +
24 O +
) O +
of O +
the O +
33 O +
studies O +
included O +
reported O +
evidence O +
of O +
decreased O +
toxicities O +
from O +
the O +
concurrent O +
use O +
of O +
antioxidants O +
with O +
chemotherapy O +
. O -

Nine O +
studies O +
reported O +
no O +
difference O +
in O +
toxicities O +
between O +
the O +
2 O +
groups O +
. O -

Only O +
1 O +
study O +
( O +
vitamin O +
A O +
) O +
reported O +
a O +
significant O +
increase O +
in O +
toxicity O +
in O +
the O +
antioxidant O +
group O +
. O -

Five O +
studies O +
reported O +
the O +
antioxidant O +
group O +
completed O +
more O +
full O +
doses O +
of O +
chemotherapy O +
or O +
had O +
less O +
- O +
dose O +
reduction O +
than O +
control O +
groups O +
. O -

Statistical O +
power O +
and O +
poor O +
study O +
quality O +
were O +
concerns O +
with O +
some O +
studies O +
. O -

This O +
review O +
provides O +
the O +
first O +
systematically O +
reviewed O +
evidence O +
that O +
antioxidant O +
supplementation O +
during O +
chemotherapy O +
holds O +
potential O +
for O +
reducing O +
dose O +
- O +
limiting O +
toxicities O +
. O -

However O +
, O +
well O +
- O +
designed O +
studies O +
evaluating O +
larger O +
populations O +
of O +
patients O +
given O +
specific O +
antioxidants O +
defined O +
by O +
dose O +
and O +
schedule O +
relative O +
to O +
chemotherapy O +
are O +
warranted O +
. O -

Optimizing O +
docetaxel O +
chemotherapy O +
in O +
patients O +
with O +
cancer B-Disease +
of I-Disease +
the I-Disease +
gastric I-Disease +
and I-Disease +
gastroesophageal I-Disease +
junction L-Disease +
: O +
evolution O +
of O +
the O +
docetaxel O +
, O +
cisplatin O +
, O +
and O +
5 O +
- O +
fluorouracil O +
regimen O +
. O -

Advanced O +
gastroesophageal B-Disease +
cancer L-Disease +
patients O +
are O +
often O +
treated O +
with O +
systemic O +
combination O +
chemotherapy O +
. O -

The O +
V O +
- O +
325 O +
study O +
demonstrated O +
that O +
adding O +
docetaxel O +
( O +
D O +
) O +
to O +
a O +
frequently O +
used O +
regimen O +
of O +
cisplatin O +
and O +
5 O +
- O +
fluorouracil O +
( O +
CF O +
) O +
provided O +
benefits O +
with O +
regard O +
to O +
overall O +
survival O +
, O +
response O +
rate O +
, O +
time O +
- O +
to O +
- O +
disease O +
progression O +
, O +
clinical O +
benefit O +
, O +
and O +
health O +
- O +
related O +
quality O +
of O +
life O +
. O -

Although O +
the O +
DCF O +
regimen O +
provides O +
these O +
advantages O +
, O +
it O +
is O +
accompanied O +
by O +
an O +
increase O +
in O +
toxicity O +
compared O +
with O +
the O +
doublet O +
regimen O +
. O -

The O +
toxicity O +
profile O +
of O +
DCF O +
is O +
acceptable O +
only O +
with O +
appropriately O +
selected O +
patients O +
and O +
comprehensive O +
toxicity O +
management O +
strategies O +
. O -

The O +
objective O +
of O +
the O +
current O +
review O +
was O +
to O +
identify O +
trials O +
that O +
investigated O +
modifications O +
to O +
the O +
original O +
DCF O +
regimen O +
to O +
improve O +
its O +
toxicity O +
profile O +
and O +
summarize O +
response O +
rate O +
and O +
toxicities O +
. O -

An O +
attempt O +
was O +
also O +
made O +
to O +
summarize O +
ongoing O +
modifications O +
of O +
the O +
DCF O +
regimen O +
. O -

MEDLINE O +
, O +
major O +
meeting O +
proceedings O +
, O +
and O +
the O +
government O +
clinical O +
trials O +
website O +
were O +
searched O +
until O +
2007 O +
. O -

The O +
modified O +
DCF O +
regimens O +
appear O +
to O +
improve O +
the O +
toxicity O +
profile O +
when O +
compared O +
with O +
the O +
original O +
DCF O +
regimen O +
. O -

The O +
docetaxel O +
- O +
based O +
triplet O +
combinations O +
appear O +
to O +
have O +
a O +
higher O +
response O +
rate O +
than O +
the O +
doublet O +
combinations O +
. O -

Many O +
institutions O +
and O +
cooperative O +
groups O +
continue O +
to O +
study O +
docetaxel O +
- O +
based O +
modifications O +
of O +
the O +
DCF O +
regimen O +
to O +
treat O +
patients O +
with O +
gastroesophageal B-Disease +
carcinoma L-Disease +
. O -

However O +
, O +
although O +
modified O +
DCF O +
reduces O +
the O +
frequency O +
of O +
severe O +
toxicities O +
previously O +
reported O +
with O +
DCF O +
, O +
considerably O +
more O +
advances O +
are O +
needed O +
to O +
improve O +
the O +
safety O +
, O +
survival O +
, O +
and O +
convenience O +
of O +
patients O +
with O +
advanced O +
gastroesophageal B-Disease +
cancer L-Disease +
. O -

Pentachlorophenol O +
decreases O +
ATP O +
levels O +
in O +
human O +
natural O +
killer O +
cells O +
. O -

Pentachlorophenol O +
( O +
PCP O +
) O +
is O +
used O +
as O +
a O +
wood O +
preservative O +
and O +
is O +
found O +
in O +
human O +
blood O +
and O +
urine O +
. O -

PCP O +
causes O +
significant O +
decreases O +
in O +
the O +
tumor O +
- O +
killing O +
( O +
lytic O +
) O +
function O +
of O +
human O +
natural O +
killer O +
( O +
NK O +
) O +
cells O +
, O +
a O +
critical O +
immune O +
defense O +
. O -

The O +
current O +
study O +
examined O +
the O +
association O +
between O +
decreased O +
lytic O +
function O +
and O +
decreased O +
ATP O +
levels O +
, O +
as O +
well O +
as O +
the O +
ability O +
of O +
antioxidants O +
( O +
vitamin O +
E O +
and O +
reduced O +
glutathione O +
) O +
to O +
prevent O +
PCP O +
- O +
induced O +
decreases O +
in O +
either O +
ATP O +
levels O +
or O +
lytic O +
function O +
. O -

Exposure O +
of O +
NK O +
cells O +
to O +
10 O +
microm O +
PCP O +
decreased O +
ATP O +
levels O +
by O +
15 O -
% O +
at O +
24 O +
h O +
, O +
and O +
exposure O +
to O +
5 O +
microm O +
PCP O +
decreased O +
ATP O +
levels O +
by O +
32 O -
% O +
at O +
48 O +
h O +
. O -

No O +
effects O +
were O +
seen O +
with O +
0.5 O +
microm O +
at O +
48 O +
h O +
or O +
with O +
5 O +
microm O +
at O +
24 O +
h O +
. O -

However O +
, O +
10 O +
microm O +
PCP O +
decreased O +
lytic O +
function O +
by O +
69 O -
% O +
at O +
24 O +
h O +
and O +
5 O +
microm O +
decreased O +
it O +
by O +
90 O -
% O +
at O +
48 O +
h O +
. O -

Even O +
0.5 O +
microm O +
PCP O +
decreased O +
lytic O +
function O +
by O +
46 O -
% O +
at O +
48 O +
h O +
. O -

None O +
of O +
these O +
effects O +
were O +
prevented O +
by O +
pretreatment O +
with O +
1 O +
mm O +
vitamin O +
E O +
or O +
reduced O +
glutathione O +
. O -

Using O +
dietary O +
exposure O +
and O +
physiologically O +
based O +
pharmacokinetic O +
/ O +
pharmacodynamic O +
modeling O +
in O +
human O +
risk O +
extrapolations O +
for O +
acrylamide B-Disease +
toxicity L-Disease +
. O -

The O +
discovery O +
of O +
acrylamide O +
( O +
AA O +
) O +
in O +
many O +
common O +
cooked O +
starchy O +
foods O +
has O +
presented O +
significant O +
challenges O +
to O +
toxicologists O +
, O +
food O +
scientists O +
, O +
and O +
national O +
regulatory O +
and O +
public O +
health O +
organizations O +
because O +
of O +
the O +
potential O +
for O +
producing O +
neurotoxicity U-Disease +
and O +
cancer U-Disease +
. O -

This O +
paper O +
reviews O +
some O +
of O +
the O +
underlying O +
experimental O +
bases O +
for O +
AA B-Disease +
toxicity L-Disease +
and O +
earlier O +
risk O +
assessments O +
. O -

Then O +
, O +
dietary O +
exposure O +
modeling O +
is O +
used O +
to O +
estimate O +
probable O +
AA O +
intake O +
in O +
the O +
U O +
. O -

S O +
. O -

population O +
, O +
and O +
physiologically O +
based O +
pharmacokinetic O +
/ O +
pharmacodynamic O +
( O +
PBPK O +
/ O +
PD O +
) O +
modeling O +
is O +
used O +
to O +
integrate O +
the O +
findings O +
of O +
rodent O +
neurotoxicity U-Disease +
and O +
cancer U-Disease +
into O +
estimates O +
of O +
risks O +
from O +
human O +
AA O +
exposure O +
through O +
the O +
diet O +
. O -

The O +
goal O +
of O +
these O +
modeling O +
techniques O +
is O +
to O +
reduce O +
the O +
uncertainty O +
inherent O +
in O +
extrapolating O +
toxicological O +
findings O +
across O +
species O +
and O +
dose O +
by O +
comparing O +
common O +
exposure O +
biomarkers O +
. O -

PBPK O +
/ O +
PD O +
modeling O +
estimated O +
population O +
- O +
based O +
lifetime O +
excess O +
cancer U-Disease +
risks O +
from O +
average O +
AA O +
consumption O +
in O +
the O +
diet O +
in O +
the O +
range O +
of O +
1 O -
- O -
4 O +
x O +
10 O +
( O +
- O +
4 O +
) O +
; O +
however O +
, O +
modeling O +
did O +
not O +
support O +
a O +
link O +
between O +
dietary O +
AA O +
exposure O +
and O +
human O +
neurotoxicity U-Disease +
because O +
marginal O +
exposure O +
ratios O +
were O +
50 O -
- O -
300 O +
lower O +
than O +
in O +
rodents O +
. O -

In O +
addition O +
, O +
dietary O +
exposure O +
modeling O +
suggests O +
that O +
because O +
AA O +
is O +
found O +
in O +
so O +
many O +
common O +
foods O +
, O +
even O +
big O +
changes O +
in O +
concentration O +
for O +
single O +
foods O +
or O +
groups O +
of O +
foods O +
would O +
probably O +
have O +
a O +
small O +
impact O +
on O +
overall O +
population O +
- O +
based O +
intake O +
and O +
risk O +
. O -

These O +
results O +
suggest O +
that O +
a O +
more O +
holistic O +
analysis O +
of O +
dietary B-Disease +
cancer L-Disease +
risks O +
may O +
be O +
appropriate O +
, O +
by O +
which O +
potential O +
risks O +
from O +
AA O +
should O +
be O +
considered O +
in O +
conjunction O +
with O +
other O +
risks O +
and O +
benefits O +
from O +
foods O +
. O -

Review O +
article O +
: O +
new O +
drug O +
formulations O +
, O +
chemical O +
entities O +
and O +
therapeutic O +
approaches O +
for O +
the O +
management O +
of O +
ulcerative B-Disease +
colitis L-Disease +
. O -

BACKGROUND O +
: O +
Treatment O +
options O +
for O +
ulcerative B-Disease +
colitis L-Disease +
( O +
UC U-Disease +
) O +
are O +
expanding O +
with O +
the O +
development O +
of O +
novel O +
drug O +
formulations O +
and O +
dosing O +
regimens O +
and O +
new O +
chemical O +
entities O +
. O -

Although O +
the O +
goals O +
of O +
medical O +
therapy O +
for O +
UC U-Disease +
remain O +
unchanged O +
, O +
that O +
is O +
to O +
induce O +
and O +
to O +
maintain O +
remission O +
, O +
focus O +
has O +
also O +
centred O +
on O +
improving O +
patient O +
compliance O +
, O +
modifying O +
the O +
natural O +
course O +
of O +
disease O +
and O +
healing O +
the O +
mucosa O +
. O -

AIM O +
: O +
To O +
examine O +
novel O +
formulations O +
, O +
new O +
chemical O +
entities O +
and O +
novel O +
therapeutic O +
approaches O +
to O +
the O +
management O +
of O +
UC U-Disease +
. O -

METHODS O +
: O +
Searches O +
for O +
all O +
studies O +
related O +
to O +
UC U-Disease +
treatment O +
in O +
Medline O +
and O +
abstracts O +
from O +
major O +
national O +
and O +
international O +
meetings O +
published O +
in O +
the O +
last O +
10 O +
years O +
. O -

RESULTS O +
: O +
5 O +
- O +
Aminosalicylic O +
acids O +
( O +
5 O +
- O +
ASA O +
) O +
remain O +
the O +
standard O +
first O +
- O +
line O +
treatment O +
for O +
patients O +
with O +
mild O +
to O +
moderately O +
active O +
UC U-Disease +
. O -

New O +
formulations O +
with O +
altered O +
delivery O +
, O +
and O +
new O +
dosing O +
regimens O +
have O +
demonstrated O +
possible O +
improvements O +
in O +
efficacy O +
compared O +
with O +
historically O +
available O +
preparations O +
and O +
dosing O +
patterns O +
. O -

Once O +
- O +
daily O +
dosing O +
, O +
micropellet O +
formulations O +
, O +
and O +
high O +
- O +
dose O +
tablets O +
offer O +
enhanced O +
efficacy O +
and O +
improved O +
compliance O +
. O -

5 O +
- O +
ASA O +
is O +
now O +
recognized O +
as O +
a O +
ligand O +
for O +
peroxisome O +
proliferator O +
activated O +
receptor O +
- O +
gamma O +
( O +
PPAR O +
- O +
gamma O +
) O +
and O +
it O +
has O +
a O +
role O +
as O +
a O +
chemo O +
- O +
preventive O +
agent O +
in O +
long O +
- O +
standing O +
UC U-Disease +
. O -

New O +
colonic O +
release O +
corticosteroid O +
formulations O +
help O +
to O +
limit O +
systemic B-Disease +
toxicity L-Disease +
; O +
turmeric O +
, O +
tacrolimus O +
and O +
infliximab O +
have O +
shown O +
promising O +
results O +
. O -

New O +
anti O +
- O +
inflammatory O +
targeted O +
therapies O +
include O +
an O +
anti O +
- O +
CD3 O +
antibody O +
, O +
selective O +
integrin O +
blockers O +
, O +
anti O +
- O +
IL O +
- O +
2 O +
antibody O +
and O +
PPAR O +
- O +
gamma O +
agonists O +
. O -

CONCLUSION O +
: O +
The O +
evolution O +
of O +
novel O +
oral O +
5 O +
- O +
ASA O +
formulations O +
and O +
dosage O +
regimens O +
, O +
and O +
recent O +
development O +
of O +
new O +
molecules O +
have O +
expanded O +
the O +
therapeutic O +
armamentarium O +
of O +
UC U-Disease +
. O -

Dietary O +
flavonoids O +
inhibit O +
the O +
anticancer O +
effects O +
of O +
the O +
proteasome O +
inhibitor O +
bortezomib O +
. O -

Dietary O +
flavonoids O +
have O +
many O +
health O +
- O +
promoting O +
actions O +
, O +
including O +
anticancer O +
activity O +
via O +
proteasome O +
inhibition O +
. O -

Bor O +
- O +
tezomib O +
is O +
a O +
dipeptide O +
boronate O +
proteasome O +
inhibitor O +
that O +
has O +
activity O +
in O +
the O +
treatment O +
of O +
multiple B-Disease +
myeloma L-Disease +
but O +
is O +
not O +
effective O +
in O +
chronic B-Disease +
lymphocytic I-Disease +
leukemia L-Disease +
( O +
CLL U-Disease +
) O +
. O -

Although O +
CLL U-Disease +
cells O +
are O +
sensitive O +
in O +
vitro O +
to O +
bortezomib O +
- O +
induced O +
apoptosis U-Disease +
when O +
cultured O +
in O +
medium O +
, O +
the O +
killing O +
activity O +
was O +
blocked O +
when O +
cultured O +
in O +
50 O -
% O +
fresh O +
autologous O +
plasma O +
. O -

Dietary O +
flavonoids O +
, O +
quercetin O +
and O +
myricetin O +
, O +
which O +
are O +
abundant O +
in O +
plasma O +
, O +
inhibited O +
bortezomib O +
- O +
induced O +
apoptosis U-Disease +
of O +
primary O +
CLL U-Disease +
and O +
malignant O +
B O +
- O +
cell O +
lines O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O -

This O +
inhibitory O +
effect O +
was O +
associated O +
with O +
chemical O +
reactions O +
between O +
quercetin O +
and O +
the O +
boronic O +
acid O +
group O +
, O +
- O +
RB O +
( O +
OH O +
) O +
2 O +
, O +
in O +
bortezomib O +
. O -

The O +
addition O +
of O +
boric O +
acid O +
diminished O +
the O +
inhibitory O +
effect O +
of O +
both O +
quercetin O +
and O +
plasma O +
on O +
bortezomib O +
- O +
induced O +
apoptosis U-Disease +
. O -

The O +
protective O +
effect O +
was O +
also O +
reduced O +
when O +
myeloma U-Disease +
cell O +
lines O +
, O +
but O +
not O +
B O +
- O +
cell O +
lines O +
, O +
were O +
preincubated O +
with O +
quercetin O +
, O +
indicating O +
a O +
direct O +
effect O +
of O +
quercetin O +
on O +
myeloma U-Disease +
cells O +
. O -

At O +
high O +
doses O +
, O +
quercetin O +
itself O +
induced O +
tumor O +
cell B-Disease +
death L-Disease +
. O -

These O +
data O +
indicate O +
that O +
dietary O +
flavonoids O +
limit O +
the O +
efficacy O +
of O +
bortezomib O +
, O +
whereas O +
supplemental O +
inorganic O +
boric O +
acid O +
is O +
able O +
to O +
reverse O +
this O +
. O -

The O +
complex O +
interactions O +
between O +
quercetin O +
, O +
tumor O +
cells O +
, O +
and O +
bortezomib O +
mean O +
caution O +
is O +
required O +
when O +
giving O +
dietary O +
advice O +
to O +
patients O +
. O -

Nitrate O +
- O +
induced O +
toxicity O +
and O +
preconditioning O +
: O +
a O +
rationale O +
for O +
reconsidering O +
the O +
use O +
of O +
these O +
drugs O +
. O -

Although O +
organic O +
nitrates O +
have O +
been O +
clinically O +
used O +
for O +
more O +
than O +
a O +
century O +
, O +
findings O +
in O +
the O +
last O +
decade O +
have O +
radically O +
challenged O +
our O +
traditional O +
view O +
concerning O +
the O +
mechanism O +
( O +
s O +
) O +
of O +
their O +
clinical O +
effects O +
and O +
implications O +
. O -

While O +
their O +
hemodynamic O +
properties O +
are O +
well O +
known O +
, O +
the O +
knowledge O +
that O +
nitrates O +
possess O +
previously O +
unexpected O +
nonhemodynamic O +
effects O +
is O +
a O +
unique O +
opportunity O +
of O +
which O +
clinicians O +
should O +
be O +
aware O +
but O +
, O +
at O +
the O +
same O +
time O +
, O +
it O +
also O +
provides O +
a O +
rationale O +
to O +
worry O +
about O +
previously O +
unanticipated O +
clinical O +
consequences O +
of O +
long O +
- O +
term O +
treatment O +
with O +
these O +
drugs O +
. O -

The O +
effect O +
of O +
QuYuHuaTanTongLuo O +
Decoction O +
on O +
the O +
non B-Disease +
- I-Disease +
alcoholic I-Disease +
steatohepatitis L-Disease +
. O -

Non B-Disease +
- I-Disease +
alcoholic I-Disease +
steatohepatitis L-Disease +
( O +
NASH O +
) O +
is O +
the O +
most O +
common O +
cause O +
of O +
cryptogenic B-Disease +
cirrhosis L-Disease +
, O +
is O +
becoming O +
more O +
prevalent O +
in O +
China O +
. O -

However O +
, O +
there O +
is O +
as O +
yet O +
no O +
clearly O +
established O +
therapy O +
for O +
reversing O +
fatty B-Disease +
liver L-Disease +
. O -

Our O +
aim O +
is O +
to O +
explore O +
the O +
effect O +
of O +
traditional O +
Chinese O +
herbs O +
QuYuHuaTanTongLuo O +
Decoction O +
( O +
QYHTTLD O +
) O +
on O +
non B-Disease +
- I-Disease +
alcoholic I-Disease +
steatohepatitis L-Disease +
. O -

Sixty O +
- O +
nine O +
non B-Disease +
- I-Disease +
alcoholic I-Disease +
steatohepatitis L-Disease +
patients O +
were O +
randomly O +
divided O +
into O +
two O +
groups O +
. O -

One O +
group O +
of O +
35 O +
patients O +
were O +
treated O +
by O +
QYHTTLD O +
, O +
another O +
group O +
of O +
34 O +
patients O +
were O +
treated O +
by O +
Ursodeoxycholic O +
acid O +
( O +
UDCA O +
) O +
. O -

The O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
8 O +
, O +
MDA O +
level O +
, O +
SOD O +
activity O +
and O +
liver O +
function O +
, O +
as O +
well O +
as O +
B O +
ultrasonic O +
image O +
were O +
detected O +
before O +
and O +
after O +
being O +
treated O +
. O -

The O +
results O +
showed O +
: O +
after O +
6 O +
months O +
treatment O +
, O +
MBI O +
of O +
the O +
treatment O +
group O +
was O +
obviously O +
decreased O +
( O +
p O +
< O +
0.05 O +
) O +
. O -

The O +
levels O +
of O +
TC O +
, O +
TG O +
and O +
LDL O +
- O +
C O +
were O +
significantly O +
decreased O +
whereas O +
the O +
level O +
of O +
HDL O +
- O +
C O +
increased O +
( O +
p O +
< O +
0.01 O +
, O +
p O +
< O +
0.05 O +
, O +
p O +
< O +
0.05 O +
, O +
and O +
p O +
< O +
0.05 O +
, O +
respectively O +
) O +
in O +
the O +
treatment O +
group O +
, O +
the O +
levels O +
of O +
TC O +
, O +
TG O +
, O +
LDL O +
- O +
C O +
and O +
HDL O +
- O +
C O +
had O +
no O +
significant O +
difference O +
in O +
the O +
control O +
group O +
( O +
p O +
> O +
0.05 O +
) O +
. O -

The O +
levels O +
of O +
TNF O +
- O +
alpha O +
, O +
IL O +
- O +
8 O +
and O +
MDA O +
were O +
significantly O +
decreased O +
whereas O +
SOD O +
activity O +
was O +
significantly O +
increased O +
( O +
p O +
< O +
0.01 O +
, O +
p O +
< O +
0.05 O +
, O +
p O +
< O +
0.01 O +
, O +
and O +
p O +
< O +
0.01 O +
, O +
respectively O +
) O +
in O +
the O +
treatment O +
group O +
, O +
the O +
level O +
of O +
MDA O +
was O +
significantly O +
decreased O +
in O +
the O +
control O +
group O +
( O +
p O +
< O +
0.05 O +
) O +
. O -

B O +
ultrasonic O +
images O +
were O +
ameliorated O +
in O +
different O +
degree O +
( O +
p O +
< O +
0.01 O +
and O +
p O +
< O +
0.01 O +
, O +
respectively O +
) O +
. O -

Both O +
QYHTTLD O +
and O +
UDCA O +
had O +
the O +
effect O +
in O +
improving O +
the O +
scores O +
of O +
symptoms O +
and O +
signs O +
of O +
patients O +
, O +
however O +
, O +
the O +
difference O +
value O +
of O +
the O +
scores O +
in O +
treatment O +
group O +
were O +
significantly O +
higher O +
than O +
that O +
in O +
control O +
group O +
after O +
being O +
treated O +
for O +
6 O +
months O +
( O +
p O +
< O +
0.05 O +
) O +
. O -

Conclusion O +
: O +
QYHTTLD O +
is O +
effective O +
for O +
treating O +
non B-Disease +
- I-Disease +
alcoholic I-Disease +
steatohepatitis L-Disease +
, O +
and O +
its O +
effect O +
seems O +
to O +
relate O +
with O +
the O +
ways O +
of O +
QYHTTL O +
down O +
- O +
regulating O +
inflammation U-Disease +
cytokine O +
IL O +
- O +
8 O +
level O +
and O +
relieving O +
lipid O +
peroxidation O +
of O +
liver O +
. O -

Fragrance O +
material O +
review O +
on O +
sclareol O +
. O -

A O +
toxicologic O +
and O +
dermatologic O +
review O +
of O +
sclareol O +
when O +
used O +
as O +
a O +
fragrance O +
ingredient O +
is O +
presented O +
. O -

Fragrance O +
Material O +
Review O +
on O +
isopulegol O +
. O -

A O +
toxicologic O +
and O +
dermatologic O +
review O +
of O +
isopulegol O +
when O +
used O +
as O +
a O +
fragrance O +
ingredient O +
is O +
presented O +
. O -

Fragrance O +
material O +
review O +
on O +
ocimenol O +
. O -

A O +
toxicologic O +
and O +
dermatologic O +
review O +
of O +
ocimenol O +
when O +
used O +
as O +
a O +
fragrance O +
ingredient O +
is O +
presented O +
. O -

Topical O +
pyrethrin B-Disease +
toxicity L-Disease +
leading O +
to O +
acute B-Disease +
- I-Disease +
onset I-Disease +
stuttering L-Disease +
in O +
a O +
toddler O +
. O -

Pyrethrin O +
compounds O +
can O +
cause O +
neurotoxicity U-Disease +
when O +
used O +
in O +
an O +
excessive O +
dose O +
. O -

A O +
case O +
of O +
stuttering U-Disease +
and O +
general O +
clumsiness U-Disease +
in O +
a O +
toddler O +
associated O +
with O +
topical O +
pyrethrin O +
use O +
is O +
described O +
. O -

Antitumor O +
properties O +
of O +
a O +
sulfated O +
polysaccharide O +
from O +
the O +
red O +
seaweed O +
Champia O +
feldmannii O +
( O +
Diaz O +
- O +
Pifferer O +
) O +
. O -

In O +
recent O +
years O +
, O +
much O +
attention O +
has O +
been O +
focused O +
on O +
polysaccharides O +
isolated O +
from O +
natural O +
sources O +
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
in O +
vitro O +
and O +
in O +
vivo O +
antitumor O +
properties O +
of O +
a O +
sulfated O +
polysaccharide O +
isolated O +
from O +
the O +
seaweed O +
C O +
. O -

feldmannii O +
( O +
Cf O +
- O +
PLS O +
) O +
. O -

Hematological O +
, O +
biochemical O +
and O +
histopathological O +
analyses O +
were O +
performed O +
in O +
order O +
to O +
evaluate O +
the O +
toxicological O +
aspects O +
related O +
to O +
Cf O +
- O +
PLS O +
treatment O +
. O -

Its O +
effects O +
on O +
the O +
immunological O +
system O +
were O +
also O +
investigated O +
. O -

The O +
Cf O +
- O +
PLS O +
did O +
not O +
show O +
any O +
significant O +
in O +
vitro O +
cytotoxicity U-Disease +
at O +
the O +
experimental O +
exposure O +
levels O +
that O +
were O +
used O +
, O +
but O +
showed O +
in O +
vivo O +
antitumor O +
effect O +
. O -

The O +
inhibition O +
rates O +
of O +
sarcoma U-Disease +
180 O +
tumor U-Disease +
development O +
were O +
48.62 O +
and O +
48.16 O -
% O +
at O +
the O +
doses O +
of O +
10 O +
and O +
25 O +
mg O +
kg O +
( O +
- O +
1 O +
) O +
, O +
respectively O +
. O -

In O +
addition O +
, O +
Cf O +
- O +
PLS O +
was O +
also O +
able O +
to O +
increase O +
the O +
response O +
elicited O +
by O +
5 O +
- O +
fluorouracil O +
( O +
5 O +
- O +
FU O +
) O +
from O +
48.66 O +
to O +
68.32 O -
% O +
. O -

The O +
histopathological O +
analysis O +
of O +
liver O +
and O +
kidney O +
showed O +
that O +
both O +
organs O +
were O +
moderately O +
affected O +
by O +
Cf O +
- O +
PLS O +
- O +
treatment O +
. O -

Neither O +
enzymatic O +
activity O +
of O +
alanine O +
aminotransferase O +
nor O +
urea O +
or O +
creatinine O +
levels O +
were O +
significantly O +
altered O +
. O -

In O +
hematological O +
analysis O +
, O +
leucopeny U-Disease +
was O +
observed O +
after O +
5 O +
- O +
FU O +
treatment O +
, O +
but O +
this O +
effect O +
was O +
prevented O +
when O +
the O +
treatment O +
was O +
associated O +
with O +
the O +
Cf O +
- O +
PLS O +
. O -

It O +
was O +
also O +
demonstrated O +
that O +
Cf O +
- O +
PLS O +
acts O +
as O +
an O +
immunomodulatory O +
agent O +
, O +
raising O +
the O +
production O +
of O +
specific O +
antibodies O +
, O +
and O +
increasing O +
the O +
production O +
of O +
OVA O +
- O +
specific O +
antibodies O +
. O -

It O +
also O +
induced O +
a O +
discreet O +
hyperplasia B-Disease +
of I-Disease +
lymphoid I-Disease +
folicules L-Disease +
of O +
the O +
white O +
pulp O +
in O +
the O +
spleen O +
of O +
treated O +
mice O +
. O -

In O +
conclusion O +
, O +
Cf O +
- O +
PLS O +
has O +
some O +
interesting O +
anticancer O +
activity O +
that O +
could O +
be O +
associated O +
with O +
its O +
immunostimulating O +
properties O +
. O -

A O +
multi O +
- O +
centre O +
dose O +
- O +
escalation O +
and O +
pharmacokinetic O +
study O +
of O +
diflomotecan O +
in O +
patients O +
with O +
advanced O +
malignancy U-Disease +
. O -

PURPOSE O +
: O +
Diflomotecan O +
, O +
a O +
homocamptothecin O +
, O +
targets O +
DNA O +
topoisomerase O +
I O +
. O -

Previous O +
clinical O +
trials O +
have O +
demonstrated O +
a O +
variable O +
degree O +
of O +
dose B-Disease +
limiting I-Disease +
toxicity L-Disease +
. O -

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
further O +
evaluate O +
the O +
safety O +
and O +
pharmacokinetic O +
profile O +
of O +
a O +
range O +
of O +
diflomotecan O +
doses O +
administered O +
intravenously O +
. O -

METHODS O +
: O +
Patients O +
with O +
advanced O +
solid O +
malignant B-Disease +
tumours L-Disease +
, O +
refractory O +
to O +
standard O +
therapies O +
, O +
with O +
adequate O +
haematologic O +
, O +
renal O +
and O +
hepatic O +
function O +
, O +
received O +
diflomotecan O +
administered O +
as O +
a O +
20 O +
min O +
intravenous O +
infusion O +
every O +
21 O +
days O +
. O -

Cohorts O +
of O +
six O +
patients O +
were O +
recruited O +
sequentially O +
to O +
one O +
of O +
three O +
fixed O +
starting O +
dose O +
groups O +
- O +
2 O +
, O +
4 O +
, O +
or O +
7 O +
mg O +
, O +
with O +
drug O +
administered O +
by O +
fixed O +
- O +
dose O +
rather O +
than O +
dosing O +
by O +
body O +
surface O +
area O +
. O -

Pharmacokinetic O +
analyses O +
were O +
performed O +
on O +
serial O +
blood O +
samples O +
taken O +
over O +
the O +
first O +
24 O +
h O +
after O +
diflomotecan O +
administration O +
( O +
cycles O +
1 O +
and O +
2 O +
) O +
. O -

Cytochrome O +
P450 O +
3A4 O +
( O +
CYP3A4 O +
) O +
activity O +
was O +
determined O +
by O +
an O +
erythromycin O +
breath O +
test O +
( O +
EBT O +
) O +
prior O +
to O +
diflomotecan O +
administration O +
in O +
cycles O +
1 O +
and O +
2 O +
. O -

RESULTS O +
: O +
Thirteen O +
patients O +
, O +
were O +
treated O +
with O +
a O +
starting O +
dose O +
of O +
either O +
2 O +
mg O +
( O +
n O +
= O +
8 O +
) O +
or O +
4 O +
mg O +
( O +
n O +
= O +
5 O +
) O +
of O +
diflomotecan O +
. O -

Dose O +
limiting O +
toxicities O +
( O +
DLTs O +
) O +
were O +
observed O +
in O +
1 O +
patient O +
in O +
the O +
2 O +
mg O +
starting O +
dose O +
level O +
( O +
grade O +
4 O +
neutropenia U-Disease +
which O +
lasted O +
for O +
8 O +
days O +
) O +
, O +
and O +
in O +
2 O +
of O +
5 O +
patients O +
enrolled O +
at O +
the O +
4 O +
mg O +
starting O +
dose O +
level O +
( O +
grade O +
4 O +
neutropenia U-Disease +
for O +
11 O +
days O +
; O +
grade O +
4 O +
neutropenia U-Disease +
leading O +
to O +
withdrawal O +
from O +
the O +
study O +
) O +
, O +
and O +
no O +
further O +
dose O +
escalation O +
was O +
performed O +
. O -

Pharmacokinetic O +
analyses O +
revealed O +
a O +
less O +
than O +
dose O +
- O +
proportional O +
increase O +
in O +
diflomotecan O +
and O +
for O +
the O +
two O +
metabolites O +
BN80942 O +
and O +
P O +
- O +
20 O +
, O +
with O +
a O +
magnitude O +
of O +
P O +
- O +
20 O +
exposure O +
similar O +
to O +
the O +
parent O +
drug O +
. O -

There O +
was O +
a O +
high O +
inter O +
- O +
patient O +
variability O +
in O +
diflomotecan O +
exposure O +
similar O +
to O +
that O +
observed O +
with O +
other O +
camptothecin O +
derivatives O +
. O -

One O +
minor O +
response O +
was O +
observed O +
in O +
a O +
patient O +
with O +
oesophageal B-Disease +
cancer L-Disease +
. O -

CONCLUSIONS O +
: O +
Diflomotecan O +
administered O +
as O +
a O +
20 O +
- O +
min O +
intravenous O +
infusion O +
3 O +
- O +
weekly O +
is O +
characterised O +
by O +
a O +
variable O +
pharmacokinetic O +
profile O +
. O -

Alternative O +
oral O +
dosing O +
schedules O +
of O +
diflomotecan O +
have O +
been O +
shown O +
to O +
display O +
a O +
more O +
predictable O +
PK O +
/ O +
PD O +
and O +
safety O +
profile O +
and O +
should O +
be O +
selected O +
for O +
further O +
evaluation O +
in O +
Phase O +
II O +
clinical O +
trials O +
. O -

Hepatic O +
protection O +
by O +
noni O +
fruit O +
juice O +
against O +
CCl O +
( O +
4 O +
) O +
- O +
induced O +
chronic B-Disease +
liver I-Disease +
damage L-Disease +
in O +
female O +
SD O +
rats O +
. O -

Morinda O +
citrifolia O +
L O +
. O -

( O +
noni O +
) O +
has O +
been O +
used O +
throughout O +
the O +
Pacific O +
, O +
Southeast O +
Asia O +
, O +
Central O +
America O +
, O +
and O +
the O +
Caribbean O +
for O +
a O +
variety O +
of O +
health O +
conditions O +
, O +
including O +
heart O +
and O +
liver O +
ailments O +
. O -

In O +
this O +
study O +
, O +
we O +
examined O +
the O +
hepatoprotective O +
effects O +
of O +
TAHITIAN O +
NONI O +
Juice O +
( O +
TNJ O +
) O +
against O +
CCl O +
( O +
4 O +
) O +
- O +
induced O +
chronic B-Disease +
liver I-Disease +
damage L-Disease +
in O +
female O +
Sprague O +
Dawley O +
( O +
SD O +
) O +
rats O +
. O -

Twelve O +
female O +
SD O +
rats O +
were O +
divided O +
into O +
control O +
, O +
placebo O +
and O +
TNJ O +
( O +
6 O +
mL O +
/ O +
rat O +
/ O +
day O +
) O +
groups O +
. O -

On O +
day O +
15 O +
, O +
animals O +
in O +
the O +
placebo O +
and O +
TNJ O +
groups O +
received O +
0.25 O +
mL O +
/ O +
kg O +
CCl O +
( O +
4 O +
) O +
in O +
corn O +
oil O +
once O +
a O +
week O +
for O +
12 O +
successive O +
weeks O +
. O -

All O +
animals O +
were O +
sacrificed O +
at O +
week O +
16 O +
. O -

Blood O +
and O +
liver O +
were O +
collected O +
for O +
liver O +
function O +
, O +
lipid O +
panel O +
tests O +
, O +
and O +
histological O +
observation O +
. O -

Histopathological O +
examination O +
revealed O +
that O +
liver O +
sections O +
from O +
the O +
TNJ O +
+ O +
CCl O +
( O +
4 O +
) O +
appeared O +
similar O +
to O +
controls O +
, O +
whereas O +
typical O +
hepatic B-Disease +
steatosis L-Disease +
was O +
observed O +
in O +
the O +
placebo O +
+ O +
CCl O +
( O +
4 O +
) O +
group O +
. O -

Serum O +
alkaline O +
phosphatase O +
( O +
ALP O +
) O +
, O +
aspartate O +
aminotransferase O +
( O +
AST O +
) O +
, O +
alanine O +
transaminase O +
( O +
ALT O +
) O +
, O +
total O +
cholesterol O +
( O +
TC O +
) O +
, O +
triglycerides O +
( O +
TG O +
) O +
, O +
low O +
- O +
density O +
lipoprotein O +
( O +
LDL O +
) O +
, O +
and O +
very O +
low O +
- O +
density O +
lipoprotein O +
( O +
VLDL O +
) O +
levels O +
were O +
increased O +
in O +
the O +
placebo O +
group O +
compared O +
with O +
the O +
TNJ O +
group O +
. O -

In O +
contrast O +
, O +
high O +
- O +
density O +
lipoprotein O +
( O +
HDL O +
) O +
was O +
increased O +
in O +
the O +
TNJ O +
group O +
and O +
decreased O +
in O +
the O +
placebo O +
group O +
. O -

Thus O +
, O +
TNJ O +
juice O +
appears O +
to O +
protect O +
the O +
liver O +
from O +
chronic O +
exogenous O +
CCl O +
( O +
4 O +
) O +
exposures O +
. O -

Such O +
protective O +
mechanisms O +
are O +
supportive O +
evidence O +
for O +
the O +
utility O +
of O +
noni O +
in O +
traditional O +
medicine O +
for O +
liver O +
ailments O +
. O -

Chronopharmacology O +
and O +
antimicrobial O +
therapeutics O +
. O -

Chronobiology O +
studies O +
the O +
phenomenon O +
of O +
rhythmicity O +
in O +
living O +
organisms O +
. O -

Circadian O +
rhythms O +
are O +
genetically O +
determined O +
and O +
are O +
regulated O +
by O +
external O +
synchronizers O +
( O +
i.e. O +
light O +
/ O +
day O +
cycle O +
) O +
. O -

Several O +
biological O +
processes O +
involved O +
in O +
the O +
pharmacokinetics O +
and O +
pharmacodynamics O +
of O +
drugs O +
are O +
subject O +
to O +
circadian O +
variations O +
. O -

Chronopharmacology O +
studies O +
how O +
biological O +
rhythms O +
impact O +
on O +
drug O +
pharmacokinetic O +
( O +
chronokinetics O +
) O +
, O +
pharmacodynamics O +
( O +
chronoesthesy O +
) O +
and O +
toxicity O +
and O +
determines O +
whether O +
time O +
of O +
day O +
administration O +
modifies O +
drug O +
's O +
pharmacological O +
characteristics O +
. O -

Chronotherapy O +
applies O +
chronopharmacological O +
studies O +
to O +
clinical O +
treatments O +
, O +
determining O +
the O +
best O +
biological O +
time O +
for O +
its O +
dosing O +
, O +
i.e. O +
when O +
beneficial O +
effects O +
are O +
maximal O +
and O +
incidence O +
and O +
/ O +
or O +
intensity O +
of O +
related O +
side O +
- O +
effects O +
and O +
toxicity O +
are O +
minimal O +
. O -

Significant O +
variations O +
in O +
the O +
pharmacokinetics O +
and O +
toxicity O +
of O +
antibiotics O +
( O +
aminoglycosides O +
, O +
beta O +
- O +
lactams O +
and O +
fluoroquinolones O +
) O +
related O +
to O +
administration O +
time O +
are O +
well O +
known O +
. O -

The O +
aims O +
of O +
this O +
review O +
are O +
to O +
discuss O +
, O +
briefly O +
, O +
the O +
currently O +
accepted O +
model O +
of O +
the O +
circadian O +
system O +
that O +
substantiates O +
endogenous O +
rhythmicity O +
and O +
to O +
provide O +
an O +
update O +
on O +
the O +
knowledge O +
of O +
circadian O +
rhythms O +
applied O +
to O +
drugs O +
used O +
as O +
medicines O +
, O +
with O +
a O +
special O +
mention O +
to O +
the O +
possible O +
impact O +
on O +
antimicrobial O +
treatments O +
. O -

It O +
is O +
concluded O +
that O +
the O +
dosing O +
time O +
of O +
an O +
antimicrobial O +
agent O +
might O +
be O +
clinically O +
relevant O +
in O +
some O +
treatments O +
, O +
thus O +
, O +
clinicians O +
should O +
be O +
aware O +
that O +
the O +
dosing O +
time O +
might O +
affect O +
the O +
clinical O +
response O +
of O +
a O +
drug O +
. O -

Chemoimmunotherapy O +
reinduction O +
with O +
epratuzumab O +
in O +
children O +
with O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia L-Disease +
in O +
marrow O +
relapse O +
: O +
a O +
Children O +
's O +
Oncology O +
Group O +
Pilot O +
Study O +
. O -

PURPOSE O +
: O +
To O +
determine O +
the O +
tolerability O +
and O +
serum O +
concentration O +
of O +
epratuzumab O +
, O +
a O +
humanized O +
monoclonal O +
antibody O +
targeting O +
CD22 O +
, O +
administered O +
alone O +
and O +
in O +
combination O +
with O +
reinduction O +
chemotherapy O +
in O +
children O +
with O +
relapsed O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia L-Disease +
( O +
ALL U-Disease +
) O +
, O +
and O +
to O +
preliminarily O +
assess O +
tumor O +
targeting O +
and O +
efficacy O +
. O -

PATIENTS O +
AND O +
METHODS O +
: O +
Therapy O +
consisted O +
of O +
a O +
single O +
- O +
agent O +
phase O +
( O +
epratuzumab O +
360 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
/ O +
dose O +
intravenously O +
twice O +
weekly O +
x O +
four O +
doses O +
) O +
, O +
followed O +
by O +
four O +
weekly O +
doses O +
of O +
epratuzumab O +
in O +
combination O +
with O +
standard O +
reinduction O +
chemotherapy O +
. O -

Morphologic O +
and O +
minimal O +
residual O +
disease O +
( O +
MRD O +
) O +
responses O +
were O +
determined O +
at O +
the O +
end O +
of O +
this O +
6 O +
- O +
week O +
period O +
. O -

Serum O +
concentrations O +
of O +
epratuzumab O +
were O +
determined O +
before O +
and O +
30 O +
minutes O +
after O +
infusions O +
, O +
and O +
CD22 O +
targeting O +
efficiency O +
was O +
determined O +
by O +
quantifying O +
changes O +
in O +
CD22 O +
expression O +
after O +
epratuzumab O +
administration O +
. O -

RESULTS O +
: O +
Fifteen O +
patients O +
( O +
12 O +
fully O +
assessable O +
for O +
toxicity O +
) O +
with O +
first O +
or O +
later O +
CD22 O +
- O +
positive O +
ALL U-Disease +
marrow O +
relapse O +
enrolled O +
on O +
the O +
feasibility O +
portion O +
of O +
this O +
study O +
from O +
December O +
2005 O +
to O +
June O +
2006 O +
. O -

Two O +
dose O +
- O +
limiting O +
toxicities O +
occurred O +
: O +
one O +
grade O +
4 O +
seizure U-Disease +
of O +
unclear O +
etiology O +
and O +
one O +
asymptomatic O +
grade O +
3 O +
ALT O +
elevation O +
. O -

In O +
all O +
but O +
one O +
patient O +
, O +
surface O +
CD22 O +
was O +
not O +
detected O +
by O +
flow O +
cytometry O +
on O +
peripheral O +
blood O +
leukemic O +
blasts O +
within O +
24 O +
hours O +
of O +
drug O +
administration O +
, O +
indicating O +
effective O +
targeting O +
of O +
leukemic O +
cells O +
by O +
epratuzumab O +
. O -

Nine O +
patients O +
achieved O +
a O +
complete O +
remission O +
after O +
chemoimmunotherapy O +
, O +
seven O +
of O +
whom O +
were O +
MRD O +
negative O +
. O -

CONCLUSION O +
: O +
Treatment O +
with O +
epratuzumab O +
plus O +
standard O +
reinduction O +
chemotherapy O +
is O +
feasible O +
and O +
acceptably O +
tolerated O +
in O +
children O +
with O +
relapsed O +
CD22 O +
- O +
positive O +
ALL U-Disease +
. O -

CD22 O +
targeting O +
was O +
efficient O +
, O +
and O +
the O +
majority O +
of O +
patients O +
achieved O +
favorable O +
early O +
responses O +
. O -

Pharmacokinetic O +
interaction O +
between O +
ethinyl O +
estradiol O +
, O +
norethindrone O +
and O +
darunavir O +
with O +
low O +
- O +
dose O +
ritonavir O +
in O +
healthy O +
women O +
. O -

BACKGROUND O +
: O +
An O +
open O +
- O +
label O +
, O +
randomized O +
, O +
crossover O +
study O +
was O +
performed O +
to O +
investigate O +
the O +
effect O +
of O +
multiple O +
doses O +
of O +
darunavir O +
co O +
- O +
administered O +
with O +
low O +
- O +
dose O +
ritonavir O +
( O +
DRV O +
/ O +
r O +
) O +
on O +
the O +
steady O +
- O +
state O +
pharmacokinetics O +
of O +
the O +
oral O +
contraceptives O +
ethinyl O +
estradiol O +
( O +
EE O +
) O +
and O +
norethindrone O +
( O +
NE O +
) O +
( O +
commercial O +
name O +
of O +
the O +
combined O +
drug O +
Ortho O +
- O +
Novum O +
1 O -
/ O -
35 O +
) O +
in O +
19 O +
HIV O +
- O +
negative O +
healthy O +
women O +
. O -

METHODS O +
: O +
In O +
session O +
1 O +
, O +
participants O +
received O +
35 O +
microg O +
EE O +
and O +
1.0 O +
mg O +
NE O +
from O +
days O +
1 O +
to O +
21 O +
. O -

In O +
session O +
2 O +
, O +
participants O +
received O +
the O +
same O +
oral O +
contraceptive O +
treatment O +
as O +
in O +
session O +
1 O +
on O +
days O +
1 O +
to O +
21 O +
plus O +
DRV O +
/ O +
r O +
( O +
600 O +
mg O +
/ O +
100 O +
mg O +
twice O +
daily O +
) O +
on O +
days O +
1 O +
to O +
14 O +
. O -

Pharmacokinetic O +
assessments O +
were O +
performed O +
on O +
day O +
14 O +
for O +
each O +
session O +
. O -

RESULTS O +
: O +
Steady O +
- O +
state O +
systemic O +
exposure O +
to O +
EE O +
and O +
NE O +
decreased O +
when O +
DRV O +
/ O +
r O +
was O +
co O +
- O +
administered O +
, O +
based O +
on O +
the O +
ratio O +
of O +
least O +
square O +
means O +
of O +
the O +
minimum O +
plasma O +
concentration O +
( O +
Cmin O +
) O +
, O +
the O +
maximum O +
plasma O +
concentration O +
( O +
Cmax O +
) O +
, O +
and O +
the O +
area O +
under O +
the O +
curve O +
( O +
AUC24h O +
) O +
of O +
EE O +
( O +
which O +
decreased O +
by O +
62 O -
% O +
, O +
32 O -
% O +
and O +
44 O -
% O +
, O +
respectively O +
) O +
and O +
NE O +
( O +
which O +
decreased O +
by O +
30 O -
% O +
, O +
10 O -
% O +
and O +
14 O -
% O +
, O +
respectively O +
) O +
compared O +
with O +
administration O +
of O +
EE O +
and O +
NE O +
alone O +
. O -

Five O +
participants O +
discontinued O +
the O +
study O +
due O +
to O +
grade O +
2 O +
cutaneous O +
events O +
, O +
as O +
required O +
per O +
protocol O +
, O +
during O +
treatment O +
with O +
EE O +
and O +
NE O +
in O +
combination O +
with O +
DRV O +
/ O +
r O +
. O -

There O +
were O +
no O +
clinically O +
relevant O +
findings O +
for O +
laboratory O +
and O +
cardiovascular O +
parameters O +
. O -

CONCLUSIONS O +
: O +
The O +
pharmacokinetic O +
interaction O +
observed O +
here O +
is O +
considered O +
to O +
be O +
clinically O +
relevant O +
as O +
EE O +
concentrations O +
are O +
considerably O +
reduced O +
when O +
DRV O +
/ O +
r O +
is O +
co O +
- O +
administered O +
with O +
EE O +
and O +
NE O +
. O -

Alternative O +
or O +
additional O +
contraceptive O +
measures O +
should O +
be O +
used O +
when O +
oestrogen O +
- O +
based O +
contraceptives O +
are O +
co O +
- O +
administered O +
with O +
DRV O +
/ O +
r O +
. O -

Eosinophil O +
- O +
derived O +
neurotoxin O +
/ O +
RNase O +
2 O +
: O +
connecting O +
the O +
past O +
, O +
the O +
present O +
and O +
the O +
future O +
. O -

The O +
eosinophil O +
- O +
derived O +
neurotoxin O +
( O +
EDN O +
, O +
also O +
known O +
as O +
eosinophil O +
protein O +
- O +
X O +
) O +
is O +
best O +
- O +
known O +
as O +
one O +
of O +
the O +
four O +
major O +
proteins O +
found O +
in O +
the O +
large O +
specific O +
granules O +
of O +
human O +
eosinophilic O +
leukocytes O +
. O -

Although O +
it O +
was O +
named O +
for O +
its O +
discovery O +
and O +
initial O +
characterization O +
as O +
a O +
neurotoxin O +
, O +
it O +
is O +
also O +
expressed O +
constitutively O +
in O +
human O +
liver O +
tissue O +
and O +
its O +
expression O +
can O +
be O +
induced O +
in O +
macrophages O +
by O +
proinflammatory O +
stimuli O +
. O -

EDN O +
and O +
its O +
divergent O +
orthologs O +
in O +
rodents O +
have O +
ribonuclease O +
activity O +
, O +
and O +
are O +
members O +
of O +
the O +
extensive O +
RNase O +
A O +
superfamily O +
, O +
although O +
the O +
relationship O +
between O +
the O +
characterized O +
physiologic O +
functions O +
and O +
enzymatic O +
activity O +
remains O +
poorly O +
understood O +
. O -

Recent O +
explorations O +
into O +
potential O +
physiologic O +
functions O +
for O +
EDN O +
have O +
provided O +
us O +
with O +
some O +
insights O +
into O +
its O +
role O +
in O +
antiviral O +
host O +
defense O +
, O +
as O +
a O +
chemoattractant O +
for O +
human O +
dendritic O +
cells O +
, O +
and O +
most O +
recently O +
, O +
as O +
an O +
endogenous O +
ligand O +
for O +
toll O +
- O +
like O +
receptor O +
( O +
TLR O +
) O +
2 O +
. O -

Endogenous O +
alpha O +
- O +
calcitonin O +
gene O +
- O +
related O +
peptide O +
mitigates O +
liver B-Disease +
fibrosis L-Disease +
in O +
chronic B-Disease +
hepatitis L-Disease +
induced O +
by O +
repeated O +
administration O +
of O +
concanavalin O +
A O +
. O -

BACKGROUND O +
: O +
Alpha O +
- O +
calcitonin O +
gene O +
- O +
related O +
peptide O +
( O +
alphaCGRP O +
) O +
is O +
a O +
37 O +
- O +
amino O +
acid O +
pleiotropic O +
peptide O +
that O +
we O +
previously O +
showed O +
to O +
exert O +
a O +
hepatoprotective O +
effect O +
during O +
concanavalin O +
A B-Disease +
( I-Disease +
Con I-Disease +
A I-Disease +
) I-Disease +
- I-Disease +
induced I-Disease +
acute I-Disease +
hepatitis L-Disease +
. O -

In O +
the O +
present O +
study O +
, O +
we O +
used O +
alphaCGRP O +
( O +
- O +
/ O +
- O +
) O +
mice O +
to O +
further O +
investigate O +
the O +
antifibrogenic O +
and O +
hepatoprotective O +
effects O +
of O +
endogenous O +
alphaCGRP O +
in O +
Con O +
A O +
- O +
induced O +
chronic B-Disease +
hepatitis L-Disease +
. O -

METHODS O +
: O +
Chronic B-Disease +
hepatitis L-Disease +
was O +
induced O +
in O +
alphaCGRP O +
( O +
- O +
/ O +
- O +
) O +
and O +
wild O +
- O +
type O +
mice O +
by O +
repeated O +
administration O +
of O +
Con O +
A O +
. O -

Serum O +
transaminases O +
were O +
measured O +
to O +
assess O +
hepatic O +
injury U-Disease +
. O -

The O +
severity O +
of O +
fibrosis U-Disease +
and O +
the O +
activation O +
of O +
hepatic O +
stellate O +
cells O +
( O +
HSCs O +
) O +
were O +
analysed O +
by O +
Masson O +
trichrome O +
staining O +
and O +
immunohistochemical O +
staining O +
of O +
alpha O +
- O +
smooth O +
muscle O +
actin O +
( O +
alpha O +
- O +
SMA O +
) O +
respectively O +
. O -

Altered O +
expression O +
of O +
fibrosis O +
- O +
and O +
inflammation O +
- O +
related O +
genes O +
was O +
evaluated O +
using O +
a O +
quantitative O +
real O +
- O +
time O +
polymerase O +
chain O +
reaction O +
. O -

Activation O +
and O +
proliferation O +
of O +
HSCs O +
were O +
analysed O +
using O +
both O +
primary O +
cultured O +
HSCs O +
from O +
the O +
mice O +
and O +
the O +
LI90 O +
HSC O +
cell O +
line O +
. O -

RESULTS O +
: O +
alphaCGRP O +
( O +
- O +
/ O +
- O +
) O +
mice O +
showed O +
more O +
severe O +
liver B-Disease +
fibrosis L-Disease +
than O +
wild O +
- O +
type O +
mice O +
in O +
a O +
Con O +
A O +
- O +
induced O +
chronic B-Disease +
hepatitis L-Disease +
model O +
. O -

In O +
histological O +
and O +
gene O +
expression O +
analyses O +
, O +
alphaCGRP O +
( O +
- O +
/ O +
- O +
) O +
mice O +
showed O +
greater O +
inflammatory O +
and O +
fibrotic O +
changes O +
, O +
greater O +
HSC O +
activation O +
and O +
a O +
higher O +
incidence O +
of O +
apoptosis U-Disease +
among O +
nonparenchymal O +
cells O +
than O +
wild O +
- O +
type O +
mice O +
. O -

CONCLUSIONS O +
: O +
Endogenous O +
alphaCGRP O +
mitigates O +
liver B-Disease +
fibrosis L-Disease +
in O +
chronic B-Disease +
hepatitis L-Disease +
induced O +
by O +
repeated O +
administration O +
of O +
Con O +
A O +
. O -

alphaCGRP O +
could O +
be O +
a O +
useful O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
chronic B-Disease +
hepatitis L-Disease +
. O -

Novel O +
roles O +
for O +
ceramides O +
, O +
calpains O +
and O +
caspases O +
in O +
kidney O +
proximal O +
tubule O +
cell O +
apoptosis O +
: O +
lessons O +
from O +
in O +
vitro O +
cadmium B-Disease +
toxicity L-Disease +
studies O +
. O -

Apoptosis O +
is O +
a O +
tightly O +
regulated O +
physiological O +
process O +
, O +
which O +
can O +
be O +
initiated O +
by O +
toxic O +
stimuli O +
, O +
such O +
as O +
cadmium O +
( O +
Cd2 O -
+ O +
) O +
. O -

Cd2 O -
+ O +
( O +
10 O -
- O -
50 O +
microM O +
) O +
induces O +
a O +
rapid O +
increase O +
in O +
reactive O +
oxygen O +
species O +
( O +
ROS O +
) O +
( O +
> O +
or O +
= O +
30 O +
min O +
) O +
in O +
a O +
cell O +
line O +
derived O +
from O +
the O +
S1 O +
segment O +
of O +
rat O +
kidney O +
proximal O +
tubule O +
, O +
without O +
any O +
apparent O +
mitochondrial O +
dysfunction O +
. O -

The O +
sphingolipid O +
ceramide O +
is O +
an O +
important O +
second O +
messenger O +
in O +
apoptosis O +
. O -

Short O +
exposure O +
to O +
Cd2 O -
+ O +
( O +
3h O +
) O +
causes O +
an O +
increase O +
in O +
ceramides O +
, O +
which O +
occurs O +
downstream O +
of O +
ROS O +
formation O +
, O +
and O +
may O +
interact O +
with O +
cellular O +
components O +
, O +
such O +
as O +
endoplasmic O +
reticulum O +
and O +
mitochondria O +
. O -

Following O +
apoptosis O +
initiation O +
, O +
execution O +
must O +
take O +
place O +
. O -

The O +
classical O +
executioners O +
of O +
apoptosis O +
are O +
caspases O +
, O +
a O +
family O +
of O +
cysteine O +
proteases O +
. O -

However O +
, O +
increasing O +
studies O +
report O +
caspase O +
- O +
independent O +
apoptosis O +
, O +
which O +
questions O +
the O +
essentiality O +
of O +
caspases O +
for O +
apoptosis O +
implementation O +
. O -

With O +
low O +
micromolar O +
Cd2 O -
+ O +
concentrations O +
( O +
< O +
10 O +
microM O +
) O +
, O +
caspases O +
are O +
only O +
activated O +
after O +
24h O +
and O +
not O +
at O +
earlier O +
time O +
points O +
, O +
which O +
supports O +
the O +
notion O +
of O +
caspase O +
- O +
independent O +
apoptosis O +
. O -

Due O +
to O +
increased O +
cytosolic O +
Ca O +
( O +
2 O -
+ O +
) O +
under O +
pathological O +
conditions O +
, O +
a O +
role O +
for O +
the O +
Ca2 O -
+ O +
- O +
dependent O +
proteases O +
, O +
calpains O +
, O +
has O +
emerged O +
. O -

Calpain O +
activation O +
by O +
Cd2 O -
+ O +
( O +
3 O -
- O -
6 O +
h O +
) O +
seems O +
to O +
be O +
regulated O +
by O +
ceramide O +
levels O +
, O +
in O +
order O +
to O +
induce O +
apoptosis O +
. O -

Calpain O +
and O +
caspase O +
substrates O +
overlap O +
but O +
yield O +
different O +
fragments O +
, O +
which O +
may O +
explain O +
their O +
diverse O +
downstream O +
targets O +
. O -

Furthermore O +
, O +
calpains O +
and O +
caspases O +
may O +
interact O +
with O +
one O +
another O +
to O +
enhance O +
, O +
as O +
seen O +
by O +
Cd2 O -
+ O +
, O +
or O +
diminish O +
apoptosis O +
. O -

In O +
this O +
review O +
, O +
we O +
discuss O +
novel O +
roles O +
for O +
ceramides O +
, O +
calpains O +
and O +
caspases O +
as O +
part O +
of O +
Cd2 O -
+ O +
- O +
induced O +
apoptotic O +
signalling O +
pathways O +
in O +
the O +
kidney O +
proximal O +
tubule O +
and O +
their O +
in O +
vivo O +
relevance O +
to O +
Cd2 O -
+ O +
- O +
induced O +
nephrotoxicity U-Disease +
. O -

Effect O +
of O +
darbepoetin O +
alfa O +
administered O +
once O +
monthly O +
on O +
maintaining O +
hemoglobin O +
levels O +
in O +
older O +
patients O +
with O +
chronic B-Disease +
kidney I-Disease +
disease L-Disease +
. O -

BACKGROUND O +
: O +
The O +
anemia B-Disease +
of I-Disease +
chronic I-Disease +
kidney I-Disease +
disease L-Disease +
( O +
CKD U-Disease +
) O +
is O +
associated O +
with O +
increased O +
hospitalizations O +
, O +
increased O +
cardiovascular O +
morbidity O +
and O +
mortality O +
, O +
and O +
diminished O +
quality O +
of O +
life O +
in O +
the O +
elderly O +
. O -

Darbepoetin O +
alfa O +
is O +
an O +
erythropoiesis O +
- O +
stimulating O +
agent O +
that O +
has O +
been O +
shown O +
to O +
be O +
effective O +
in O +
treating O +
anemia U-Disease +
in O +
patients O +
with O +
CKD U-Disease +
( O +
but O +
not O +
on O +
dialysis O +
) O +
when O +
administered O +
using O +
extended O +
- O +
dosing O +
regimens O +
. O -

OBJECTIVE O +
: O +
The O +
purpose O +
of O +
this O +
post O +
hoc O +
analysis O +
was O +
to O +
examine O +
the O +
efficacy O +
and O +
safety O +
profile O +
of O +
once O +
- O +
monthly O +
( O +
QM O +
) O +
darbepoetin O +
alfa O +
in O +
study O +
patients O +
stratified O +
according O +
to O +
age O +
( O +
ie O +
, O +
< O +
65 O +
, O +
65 O -
- O -
74 O +
, O +
and O +
> O +
or O +
= O +
75 O +
years O +
) O +
. O -

METHODS O +
: O +
Patients O +
with O +
CKD U-Disease +
but O +
not O +
on O +
dialysis O +
, O +
receiving O +
darbepoetin O +
alfa O +
every O +
other O +
week O +
( O +
Q2W O +
) O +
, O +
and O +
with O +
stable O +
hemoglobin O +
( O +
Hb O +
) O +
levels O +
between O +
11 O +
and O +
13 O +
g O +
/ O +
dL O +
, O +
inclusive O +
, O +
were O +
enrolled O +
in O +
this O +
33 O +
- O +
week O +
, O +
multicenter O +
, O +
open O +
- O +
label O +
, O +
single O +
- O +
arm O +
study O +
. O -

The O +
study O +
was O +
carried O +
out O +
at O +
36 O +
US O +
centers O +
and O +
consisted O +
of O +
a O +
24 O +
- O +
week O +
QM O +
darbepoetin O +
alfa O +
dose O +
- O +
titration O +
period O +
followed O +
by O +
an O +
8 O +
- O +
week O +
evaluation O +
period O +
. O -

Hb O +
levels O +
were O +
measured O +
Q2W O +
. O -

Study O +
results O +
were O +
stratified O +
according O +
to O +
patient O +
age O +
( O +
< O +
65 O +
, O +
65 O -
- O -
74 O +
, O +
and O +
> O +
or O +
= O +
75 O +
years O +
) O +
. O -

RESULTS O +
: O +
A O +
total O +
of O +
152 O +
patients O +
( O +
79 O +
women O +
, O +
73 O +
men O +
) O +
were O +
enrolled O +
; O +
55 O +
patients O +
( O +
36 O -
% O +
) O +
were O +
< O +
65 O +
years O +
of O +
age O +
, O +
46 O +
( O +
30 O -
% O +
) O +
were O +
65 O +
to O +
74 O +
years O +
of O +
age O +
, O +
and O +
51 O +
( O +
34 O -
% O +
) O +
were O +
> O +
or O +
= O +
75 O +
years O +
of O +
age O +
. O -

In O +
patients O +
who O +
received O +
> O +
or O +
= O +
1 O +
dose O +
of O +
darbepoetin O +
alfa O +
, O +
Hb O +
levels O +
> O +
or O +
= O +
11 O +
g O +
/ O +
dL O +
were O +
maintained O +
in O +
76 O -
% O +
, O +
80 O -
% O +
, O +
and O +
71 O -
% O +
of O +
patients O +
aged O +
< O +
65 O +
, O +
65 O +
to O +
74 O +
, O +
and O +
> O +
or O +
= O +
75 O +
years O +
, O +
respectively O +
. O -

For O +
patients O +
who O +
completed O +
the O +
study O +
, O +
the O +
proportions O +
who O +
maintained O +
Hb O +
levels O +
> O +
or O +
= O +
11 O +
g O +
/ O +
dL O +
were O +
83 O -
% O +
, O +
88 O -
% O +
, O +
and O +
85 O -
% O +
, O +
respectively O +
, O +
for O +
the O +
3 O +
age O +
groups O +
. O -

The O +
safety O +
profile O +
of O +
QM O +
darbepoetin O +
alfa O +
in O +
this O +
study O +
was O +
consistent O +
with O +
that O +
expected O +
in O +
patients O +
with O +
CKD U-Disease +
not O +
receiving O +
dialysis O +
. O -

CONCLUSIONS O +
: O +
Darbepoetin O +
alfa O +
administered O +
QM O +
maintained O +
Hb O +
levels O +
> O +
or O +
= O +
11 O +
g O +
/ O +
dL O +
in O +
patients O +
with O +
CKD U-Disease +
( O +
not O +
on O +
dialysis O +
) O +
aged O +
< O +
65 O +
, O +
65 O +
to O +
74 O +
, O +
and O +
> O +
or O +
= O +
75 O +
years O +
. O -

This O +
treatment O +
regimen O +
may O +
help O +
optimize O +
anemia U-Disease +
management O +
for O +
older O +
community O +
- O +
dwelling O +
and O +
long O +
- O +
term O +
care O +
patients O +
. O -

EF24 O +
, O +
a O +
novel O +
curcumin O +
analog O +
, O +
disrupts O +
the O +
microtubule O +
cytoskeleton O +
and O +
inhibits O +
HIF O +
- O +
1 O +
. O -

Curcumin O +
, O +
the O +
yellow O +
pigment O +
of O +
the O +
spice O +
turmeric O +
, O +
has O +
emerged O +
as O +
a O +
promising O +
anticancer O +
agent O +
due O +
to O +
its O +
antiproliferative O +
and O +
antiangiogenic O +
properties O +
. O -

However O +
, O +
the O +
molecular O +
mechanism O +
of O +
action O +
of O +
this O +
compound O +
remains O +
a O +
subject O +
of O +
debate O +
. O -

In O +
addition O +
, O +
curcumin O +
's O +
low O +
bioavailability O +
and O +
efficacy O +
profile O +
in O +
vivo O +
further O +
hinders O +
its O +
clinical O +
development O +
. O -

This O +
study O +
focuses O +
on O +
the O +
mechanism O +
of O +
action O +
of O +
EF24 O +
, O +
a O +
novel O +
curcumin O +
analog O +
with O +
greater O +
than O +
curcumin O +
biological O +
activity O +
and O +
bioavailability O +
, O +
but O +
no O +
increased O +
toxicity O +
. O -

Treatment O +
of O +
MDA O +
- O +
MB231 O +
breast O +
and O +
PC3 O +
prostate B-Disease +
cancer L-Disease +
cells O +
with O +
EF24 O +
or O +
curcumin O +
led O +
to O +
inhibition O +
of O +
HIF O +
- O +
1alpha O +
protein O +
levels O +
and O +
, O +
consequently O +
, O +
inhibition O +
of O +
HIF O +
transcriptional O +
activity O +
. O -

This O +
drug O +
- O +
induced O +
HIF O +
inhibition O +
occurred O +
in O +
a O +
VHL O +
- O +
dependent O +
but O +
proteasome O +
- O +
independent O +
manner O +
. O -

We O +
found O +
that O +
, O +
while O +
curcumin O +
inhibited O +
HIF O +
- O +
1alpha O +
gene O +
transcription O +
, O +
EF24 O +
exerted O +
its O +
activity O +
by O +
inhibiting O +
HIF O +
- O +
1alpha O +
posttranscriptionally O +
. O -

This O +
result O +
suggested O +
that O +
the O +
two O +
compounds O +
are O +
structurally O +
similar O +
but O +
mechanistically O +
distinct O +
. O -

Another O +
cellular O +
effect O +
that O +
further O +
differentiated O +
the O +
two O +
compounds O +
was O +
the O +
ability O +
of O +
EF24 O +
, O +
but O +
not O +
curcumin O +
, O +
to O +
induce O +
microtubule O +
stabilization O +
in O +
cells O +
. O -

EF24 O +
had O +
no O +
stabilizing O +
effect O +
on O +
tubulin O +
polymerization O +
in O +
an O +
in O +
vitro O +
assay O +
using O +
purified O +
bovine O +
brain O +
tubulin O +
, O +
suggesting O +
that O +
the O +
EF24 O +
- O +
induced O +
cytoskeletal O +
disruption O +
in O +
cells O +
may O +
be O +
the O +
result O +
of O +
upstream O +
signaling O +
events O +
rather O +
than O +
EF24 O +
direct O +
binding O +
to O +
tubulin O +
. O -

In O +
summary O +
, O +
our O +
study O +
identifies O +
EF24 O +
as O +
a O +
novel O +
curcumin O +
- O +
related O +
compound O +
possessing O +
a O +
distinct O +
mechanism O +
of O +
action O +
, O +
which O +
we O +
believe O +
contributes O +
to O +
the O +
potent O +
anticancer O +
activity O +
of O +
this O +
agent O +
and O +
can O +
be O +
further O +
exploited O +
to O +
investigate O +
the O +
therapeutic O +
potential O +
of O +
EF24 O +
. O -

How O +
can O +
biologically O +
- O +
based O +
modeling O +
of O +
arsenic O +
kinetics O +
and O +
dynamics O +
inform O +
the O +
risk O +
assessment O +
process O +
? O -

- O +
A O +
workshop O +
review O +
. O -

Quantitative O +
biologically O +
- O +
based O +
models O +
describing O +
key O +
events O +
in O +
the O +
continuum O +
from O +
arsenic O +
exposure O +
to O +
the O +
development O +
of O +
adverse O +
health O +
effects O +
provide O +
a O +
framework O +
to O +
integrate O +
information O +
obtained O +
across O +
diverse O +
research O +
areas O +
. O -

For O +
example O +
, O +
genetic O +
polymorphisms O +
in O +
arsenic O +
metabolizing O +
enzymes O +
can O +
lead O +
to O +
differences O +
in O +
target O +
tissue O +
dosimetry O +
for O +
key O +
metabolites O +
causative O +
in O +
toxic O +
and O +
carcinogenic B-Disease +
response L-Disease +
. O -

This O +
type O +
of O +
variation O +
can O +
be O +
quantitatively O +
incorporated O +
into O +
pharmacokinetic O +
( O +
PK O +
) O +
models O +
and O +
used O +
together O +
with O +
population O +
- O +
based O +
modeling O +
approaches O +
to O +
evaluate O +
the O +
impact O +
of O +
genetic O +
variation O +
in O +
methylation O +
capacity O +
on O +
dose O +
of O +
key O +
metabolites O +
to O +
target O +
tissue O +
. O -

The O +
PK O +
model O +
is O +
an O +
essential O +
bridge O +
to O +
the O +
pharmacodynamic O +
( O +
PD O +
) O +
models O +
. O -

A O +
particular O +
benefit O +
of O +
PD O +
modeling O +
for O +
arsenic O +
is O +
that O +
alternative O +
models O +
can O +
be O +
constructed O +
for O +
multiple O +
proposed O +
modes O +
of O +
action O +
for O +
arsenicals O +
. O -

Genomics O +
data O +
will O +
prove O +
useful O +
for O +
identifying O +
the O +
key O +
pathways O +
involved O +
in O +
particular O +
responses O +
and O +
aid O +
in O +
determining O +
other O +
types O +
of O +
data O +
needed O +
for O +
quantitative O +
modeling O +
. O -

These O +
models O +
, O +
when O +
linked O +
with O +
PK O +
models O +
, O +
can O +
be O +
used O +
to O +
better O +
understand O +
and O +
explain O +
dose O +
- O +
and O +
time O +
- O +
response O +
behaviors O +
. O -

This O +
in O +
turn O +
assists O +
in O +
prioritizing O +
modes O +
of O +
action O +
with O +
respect O +
to O +
their O +
risk O +
assessment O +
relevance O +
and O +
future O +
research O +
. O -

This O +
type O +
of O +
integrated O +
modeling O +
approach O +
can O +
form O +
the O +
basis O +
for O +
a O +
highly O +
informative O +
mode O +
- O +
of O +
- O +
action O +
directed O +
risk O +
assessment O +
for O +
inorganic O +
arsenic O +
( O +
iAs O +
) O +
. O -

This O +
paper O +
will O +
address O +
both O +
practical O +
and O +
theoretical O +
aspects O +
of O +
integrating O +
PK O +
and O +
PD O +
data O +
in O +
a O +
modeling O +
framework O +
, O +
including O +
practical O +
barriers O +
to O +
its O +
application O +
. O -

Enhanced O +
PDE4B O +
expression O +
augments O +
LPS O +
- O +
inducible O +
TNF O +
expression O +
in O +
ethanol O +
- O +
primed O +
monocytes O +
: O +
relevance O +
to O +
alcoholic B-Disease +
liver I-Disease +
disease L-Disease +
. O -

Increased O +
plasma O +
and O +
hepatic O +
TNF O +
- O +
alpha O +
expression O +
is O +
well O +
documented O +
in O +
patients O +
with O +
alcoholic B-Disease +
hepatitis L-Disease +
and O +
is O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
alcoholic B-Disease +
liver I-Disease +
disease L-Disease +
. O -

We O +
have O +
previously O +
shown O +
that O +
monocytes O +
from O +
patients O +
with O +
alcoholic B-Disease +
hepatitis L-Disease +
show O +
increased O +
constitutive O +
and O +
LPS O +
- O +
induced O +
NF O +
- O +
kappaB O +
activation O +
and O +
TNF O +
- O +
alpha O +
production O +
. O -

Our O +
recent O +
studies O +
showed O +
that O +
chronic O +
ethanol O +
exposure O +
significantly O +
decreased O +
cellular O +
cAMP O +
levels O +
in O +
both O +
LPS O +
- O +
stimulated O +
and O +
unstimulated O +
monocytes O +
and O +
Kupffer O +
cells O +
, O +
leading O +
to O +
an O +
increase O +
in O +
LPS O +
- O +
inducible O +
TNF O +
- O +
alpha O +
production O +
by O +
affecting O +
NF O +
- O +
kappaB O +
activation O +
and O +
induction O +
of O +
TNF O +
mRNA O +
expression O +
. O -

Accordingly O +
, O +
the O +
mechanisms O +
underlying O +
this O +
ethanol O +
- O +
induced O +
decrease O +
in O +
cellular O +
cAMP O +
leading O +
to O +
an O +
increase O +
in O +
TNF O +
expression O +
were O +
examined O +
in O +
monocytes O +
/ O +
macrophages O +
. O -

In O +
this O +
study O +
, O +
chronic O +
ethanol O +
exposure O +
was O +
observed O +
to O +
significantly O +
increase O +
LPS O +
- O +
inducible O +
expression O +
of O +
cAMP O +
- O +
specific O +
phosphodiesterase O +
( O +
PDE O +
) O +
4B O +
that O +
degrades O +
cellular O +
cAMP O +
. O -

Increased O +
PDE4B O +
expression O +
was O +
associated O +
with O +
enhanced O +
NF O +
- O +
kappaB O +
activation O +
and O +
transcriptional O +
activity O +
and O +
subsequent O +
priming O +
of O +
monocytes O +
/ O +
macrophages O +
leading O +
to O +
enhanced O +
LPS O +
- O +
inducible O +
TNF O +
- O +
alpha O +
production O +
. O -

Selective O +
inhibition O +
of O +
PDE4 O +
by O +
rolipram O +
abrogated O +
LPS O +
- O +
mediated O +
TNF O +
- O +
alpha O +
expression O +
at O +
both O +
protein O +
and O +
mRNA O +
levels O +
in O +
control O +
and O +
ethanol O +
- O +
treated O +
cells O +
. O -

Notably O +
, O +
PDE4 O +
inhibition O +
did O +
not O +
affect O +
LPS O +
- O +
inducible O +
NF O +
- O +
kappaB O +
activation O +
but O +
significantly O +
decreased O +
NF O +
- O +
kappaB O +
transcriptional O +
activity O +
. O -

These O +
findings O +
strongly O +
support O +
the O +
pathogenic O +
role O +
of O +
PDE4B O +
in O +
the O +
ethanol O +
- O +
mediated O +
priming O +
of O +
monocytes O +
/ O +
macrophages O +
and O +
increased O +
LPS O +
- O +
inducible O +
TNF O +
production O +
and O +
the O +
subsequent O +
development O +
of O +
alcoholic B-Disease +
liver I-Disease +
disease L-Disease +
( O +
ALD U-Disease +
) O +
. O -

Since O +
enhanced O +
TNF O +
expression O +
plays O +
a O +
significant O +
role O +
in O +
the O +
evolution O +
of O +
clinical O +
and O +
experimental O +
ALD U-Disease +
, O +
its O +
downregulation O +
via O +
selective O +
PDE4B O +
inhibitors O +
could O +
constitute O +
a O +
novel O +
therapeutic O +
approach O +
in O +
the O +
treatment O +
of O +
ALD U-Disease +
. O -

The O +
molecular O +
basis O +
of O +
class O +
side O +
effects O +
due O +
to O +
treatment O +
with O +
inhibitors O +
of O +
the O +
VEGF O +
/ O +
VEGFR O +
pathway O +
. O -

Vascular O +
Endothelial O +
Growth O +
Factor O +
( O +
VEGF O +
) O +
is O +
considered O +
to O +
be O +
one O +
of O +
the O +
most O +
important O +
regulators O +
of O +
angiogenesis O +
and O +
a O +
new O +
key O +
target O +
in O +
anti O +
- O +
cancer O +
treatment O +
. O -

Various O +
clinical O +
trials O +
have O +
validated O +
the O +
clinical O +
importance O +
of O +
anti O +
- O +
VEGF O +
or O +
anti O +
- O +
VEGF O +
receptor O +
( O +
VEGFR O +
) O +
therapy O +
. O -

Currently O +
the O +
humanized O +
monoclonal O +
antibody O +
bevacizumab O +
( O +
blocks O +
VEGF O +
- O +
A O +
) O +
, O +
and O +
the O +
tyrosine O +
kinase O +
inhibitors O +
sunitinib O +
and O +
sorafenib O +
( O +
inhibit O +
VEGFRs O +
) O +
are O +
approved O +
for O +
patients O +
with O +
various O +
malignancies U-Disease +
and O +
several O +
others O +
are O +
expected O +
in O +
the O +
coming O +
years O +
. O -

Unfortunately O +
, O +
anti O +
- O +
VEGF O +
/ O +
VEGFR O +
treatment O +
is O +
not O +
void O +
of O +
side O +
effects O +
. O -

An O +
array O +
of O +
unexpected O +
side O +
effects O +
is O +
now O +
seen O +
in O +
clinical O +
practice O +
. O -

Management O +
of O +
these O +
side O +
effects O +
is O +
extremely O +
important O +
in O +
the O +
development O +
of O +
the O +
various O +
anti O +
- O +
VEGF O +
/ O +
VEGFR O +
therapies O +
and O +
their O +
optimal O +
use O +
. O -

This O +
review O +
provides O +
an O +
overview O +
of O +
the O +
toxicity O +
profile O +
of O +
this O +
class O +
of O +
agents O +
, O +
the O +
molecular O +
basis O +
behind O +
these O +
side O +
effects O +
and O +
indicates O +
potential O +
options O +
for O +
management O +
. O -

VEGF O +
and O +
its O +
receptors O +
play O +
an O +
important O +
role O +
in O +
normal O +
tissues O +
and O +
are O +
widely O +
expressed O +
. O -

It O +
is O +
likely O +
that O +
interference O +
with O +
this O +
pathway O +
induces O +
an O +
array O +
of O +
side O +
effects O +
due O +
to O +
the O +
lack O +
of O +
normal O +
function O +
of O +
VEGF O +
. O -

A O +
consistent O +
pattern O +
of O +
side O +
effects O +
is O +
now O +
emerging O +
. O -

Hypertension U-Disease +
, O +
gastro B-Disease +
- I-Disease +
intestinal I-Disease +
toxicity L-Disease +
, O +
hypothyroidism U-Disease +
, O +
proteinuria U-Disease +
, O +
coagulation B-Disease +
disorders L-Disease +
and O +
neurotoxicity U-Disease +
are O +
side O +
effects O +
observed O +
with O +
both O +
anti O +
- O +
VEGF O +
and O +
anti O +
- O +
VEGFR O +
inhibitors O +
. O -

For O +
these O +
side O +
effects O +
the O +
role O +
of O +
VEGF O +
/ O +
VEGFR O +
pathway O +
in O +
normal O +
tissue O +
was O +
reviewed O +
in O +
order O +
to O +
provide O +
a O +
molecular O +
mechanism O +
that O +
linked O +
side O +
effect O +
with O +
physiological O +
activity O +
of O +
VEGF O +
/ O +
VEGFR O +
. O -

Insight O +
into O +
the O +
molecular O +
basis O +
may O +
aid O +
specific O +
supportive O +
care O +
measures O +
to O +
ensure O +
optimal O +
use O +
of O +
this O +
class O +
of O +
agents O +
. O -

Conclusion O +
: O +
Inhibiting O +
the O +
VEGF O +
/ O +
VEGFR O +
pathway O +
is O +
an O +
effective O +
approach O +
to O +
treat O +
cancer U-Disease +
. O -

It O +
has O +
also O +
provided O +
new O +
insight O +
into O +
the O +
physiological O +
role O +
of O +
this O +
pathway O +
in O +
various O +
organs O +
. O -

Integrating O +
the O +
knowledge O +
in O +
daily O +
oncological O +
practice O +
will O +
be O +
a O +
challenge O +
for O +
the O +
future O +
. O -

Safety O +
of O +
drug O +
eluting O +
stents O +
: O +
current O +
concerns O +
and O +
controversies O +
. O -

Coronary O +
artery O +
stenting O +
is O +
currently O +
the O +
most O +
frequently O +
performed O +
percutaneous O +
coronary O +
intervention O +
for O +
the O +
treatment O +
of O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
. O -

Recently O +
, O +
drug O +
- O +
eluting O +
stents O +
, O +
loaded O +
with O +
anti O +
- O +
inflammatory O +
, O +
anti O +
- O +
migratory O +
, O +
anti O +
- O +
proliferative O +
or O +
pro O +
- O +
healing O +
drugs O +
, O +
have O +
revolutionized O +
the O +
management O +
of O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
by O +
markedly O +
reducing O +
in O +
- O +
stent O +
restenosis O +
. O -

Despite O +
the O +
excellent O +
short O +
- O +
and O +
mid O +
- O +
term O +
results O +
of O +
randomized O +
controlled O +
trials O +
observed O +
with O +
drug O +
- O +
eluting O +
stents O +
, O +
there O +
remain O +
a O +
number O +
of O +
unresolved O +
issues O +
and O +
valid O +
concerns O +
about O +
long O +
- O +
term O +
safety O +
and O +
efficacy O +
of O +
this O +
revolutionary O +
technology O +
. O -

Important O +
safety O +
issues O +
such O +
as O +
thrombosis U-Disease +
, O +
late O +
stent B-Disease +
malapposition L-Disease +
, O +
aneurysm U-Disease +
formation O +
, O +
edge B-Disease +
effect L-Disease +
, O +
late O +
inflammation U-Disease +
due O +
to O +
choice O +
of O +
polymer O +
used O +
to O +
bind O +
the O +
drug O +
, O +
the O +
release O +
of O +
toxins O +
, O +
and O +
potential O +
interactions O +
with O +
brachytherapy O +
and O +
drugs O +
have O +
not O +
been O +
completely O +
addressed O +
. O -

This O +
review O +
article O +
evaluates O +
current O +
available O +
scientific O +
evidence O +
on O +
the O +
various O +
safety O +
issues O +
related O +
to O +
the O +
use O +
of O +
drug O +
- O +
eluting O +
stents O +
. O -

Evidence O +
for O +
altered O +
hippocampal O +
volume O +
and O +
brain O +
metabolites O +
in O +
workers O +
occupationally O +
exposed O +
to O +
lead O +
: O +
a O +
study O +
by O +
magnetic O +
resonance O +
imaging O +
and O +
( O +
1 O +
) O +
H O +
magnetic O +
resonance O +
spectroscopy O +
. O -

Environmental O +
and O +
occupational O +
exposure O +
to O +
lead O +
( O +
Pb O +
) O +
remains O +
to O +
be O +
a O +
major O +
public O +
health O +
issue O +
. O -

The O +
purpose O +
of O +
this O +
cross O +
- O +
sectional O +
study O +
was O +
to O +
use O +
non O +
- O +
invasive O +
magnetic O +
resonance O +
imaging O +
( O +
MRI O +
) O +
and O +
proton O +
magnetic O +
resonance O +
spectroscopy O +
( O +
( O +
1 O +
) O +
H O +
MRS O +
) O +
techniques O +
to O +
investigate O +
whether O +
chronic O +
exposure O +
to O +
Pb O +
in O +
an O +
occupational O +
setting O +
altered O +
brain O +
structure O +
and O +
function O +
of O +
Pb O +
- O +
exposed O +
workers O +
. O -

The O +
Pb O +
- O +
exposed O +
group O +
consisted O +
of O +
15 O +
workers O +
recruited O +
from O +
either O +
a O +
Pb O +
- O +
smelting O +
factory O +
or O +
a O +
Pb O +
- O +
battery O +
manufacturer O +
. O -

The O +
control O +
group O +
had O +
19 O +
healthy O +
volunteers O +
who O +
had O +
no O +
history O +
of O +
Pb O +
exposure O +
in O +
working O +
environment O +
or O +
at O +
home O +
. O -

The O +
average O +
airborne O +
Pb O +
concentrations O +
in O +
fume O +
and O +
dust O +
were O +
0.43 O +
and O +
0.44 O +
mg O +
/ O +
m O +
( O +
3 O +
) O +
, O +
respectively O +
, O +
in O +
the O +
smeltery O +
, O +
and O +
0.10 O +
and O +
1.06 O +
mg O +
/ O +
m O +
( O +
3 O +
) O +
, O +
respectively O +
, O +
in O +
the O +
Pb O +
battery O +
workshop O +
. O -

The O +
average O +
blood O +
Pb O +
concentrations O +
( O +
BPb O +
) O +
in O +
Pb O +
- O +
exposed O +
and O +
control O +
workers O +
were O +
63.5 O +
and O +
8.7 O +
microg O +
/ O +
dL O +
, O +
respectively O +
. O -

The O +
MRI O +
examination O +
showed O +
that O +
brain O +
hippocampal O +
volume O +
among O +
Pb O +
- O +
exposed O +
workers O +
was O +
significantly O +
diminished O +
in O +
comparison O +
to O +
age O +
- O +
matched O +
control O +
subjects O +
( O +
p O +
< O +
0.01 O +
) O +
, O +
although O +
the O +
extent O +
of O +
this O +
reduction O +
was O +
relatively O +
small O +
( O +
5 O -
- O -
6 O -
% O +
of O +
the O +
control O +
values O +
) O +
. O -

Linear O +
regression O +
analyses O +
revealed O +
significant O +
inverse O +
associations O +
between O +
BPb O +
and O +
the O +
decreased O +
hippocampal O +
volume O +
on O +
both O +
sides O +
of O +
brain O +
hemisphere O +
. O -

Among O +
five O +
brain O +
metabolites O +
investigated O +
by O +
MRS O +
, O +
i.e. O +
, O +
N O +
- O +
acetyl O +
- O +
aspartate O +
( O +
NAA O +
) O +
, O +
creatine O +
( O +
Cr O +
) O +
, O +
choline O +
( O +
Cho O +
) O +
, O +
inosine O +
( O +
mI O +
) O +
, O +
glutamate O +
/ O +
glutamine O +
( O +
Glx O +
) O +
and O +
lipids O +
( O +
Lip O +
) O +
, O +
a O +
significant O +
decrease O +
in O +
NAA O +
/ O +
Cr O +
ratio O +
( O +
7 O -
% O +
of O +
controls O +
, O +
p O +
< O +
0.05 O +
) O +
and O +
a O +
remarkable O +
increase O +
in O +
Lip O +
/ O +
Cr O +
ratio O +
( O +
40 O -
% O +
, O +
p O +
< O +
0.01 O +
) O +
were O +
observed O +
in O +
the O +
brains O +
of O +
Pb O +
- O +
exposed O +
workers O +
as O +
compared O +
to O +
controls O +
. O -

Furthermore O +
, O +
the O +
increased O +
Lip O +
/ O +
Cr O +
ratio O +
was O +
significantly O +
associated O +
with O +
BPb O +
( O +
r O +
= O +
0.46 O +
, O +
p O +
< O +
0.01 O +
) O +
. O -

Taken O +
together O +
, O +
this O +
study O +
suggests O +
that O +
occupational O +
exposure O +
to O +
Pb O +
may O +
cause O +
subtle O +
structural O +
and O +
functional O +
alteration O +
in O +
human O +
brains O +
. O -

The O +
MRI O +
and O +
MRS O +
brain O +
imaging O +
techniques O +
can O +
be O +
used O +
as O +
the O +
non O +
- O +
invasive O +
means O +
to O +
evaluate O +
Pb O +
- O +
induced O +
neurotoxicity U-Disease +
. O -

Anemia U-Disease +
during O +
sequential O +
induction O +
chemotherapy O +
and O +
chemoradiation O +
for O +
head B-Disease +
and I-Disease +
neck I-Disease +
cancer L-Disease +
: O +
the O +
impact O +
of O +
blood O +
transfusion O +
on O +
treatment O +
outcome O +
. O -

PURPOSE O +
: O +
Sequential O +
treatment O +
( O +
chemotherapy O +
followed O +
by O +
concomitant O +
chemoradiation O +
; O +
CCRT O +
) O +
is O +
increasingly O +
being O +
used O +
for O +
radical O +
treatment O +
of O +
squamous B-Disease +
cell I-Disease +
cancer I-Disease +
of I-Disease +
the I-Disease +
head I-Disease +
and I-Disease +
neck L-Disease +
( O +
SCCHN U-Disease +
) O +
, O +
which O +
results O +
in O +
increased O +
myelosuppression U-Disease +
. O -

In O +
this O +
study O +
, O +
we O +
review O +
the O +
incidence O +
of O +
anemia U-Disease +
and O +
the O +
effect O +
of O +
a O +
policy O +
of O +
hemoglobin O +
( O +
Hb O +
) O +
maintenance O +
by O +
blood O +
transfusion O +
on O +
disease O +
outcomes O +
in O +
these O +
patients O +
. O -

METHODS O +
AND O +
MATERIALS O +
: O +
Retrospective O +
review O +
of O +
the O +
records O +
of O +
patients O +
with O +
SCCHN U-Disease +
treated O +
with O +
sequential O +
CCRT O +
formed O +
the O +
basis O +
of O +
this O +
study O +
. O -

The O +
incidence O +
of O +
anemia U-Disease +
and O +
statistics O +
on O +
blood O +
transfusion O +
were O +
documented O +
. O -

For O +
the O +
purpose O +
of O +
outcome O +
analyses O +
, O +
patients O +
were O +
divided O +
into O +
four O +
categories O +
by O +
( O +
1 O +
) O +
transfusion O +
status O +
, O +
( O +
2 O +
) O +
nadir O +
Hb O +
concentration O +
, O +
( O +
3 O +
) O +
number O +
of O +
transfusion O +
episodes O +
, O +
and O +
( O +
4 O +
) O +
number O +
of O +
units O +
of O +
blood O +
transfused O +
( O +
NOUT O +
) O +
. O -

Data O +
on O +
3 O +
- O +
year O +
locoregional O +
control O +
( O +
LRC O +
) O +
, O +
relapse O +
- O +
free O +
survival O +
( O +
RFS O +
) O +
, O +
disease O +
- O +
specific O +
survival O +
( O +
DSS O +
) O +
, O +
and O +
overall O +
survival O +
( O +
OS O +
) O +
were O +
analyzed O +
. O -

RESULTS O +
: O +
One O +
hundred O +
and O +
sixty O +
- O +
nine O +
patients O +
were O +
identified O +
. O -

The O +
median O +
follow O +
- O +
up O +
was O +
23.6 O +
months O +
. O -

The O +
RFS O +
( O +
52 O -
% O +
vs. O +
41 O -
% O +
, O +
p O +
= O +
0.03 O +
) O +
, O +
DSS O +
( O +
71 O -
% O +
vs. O +
66 O -
% O +
, O +
p O +
= O +
0.02 O +
) O +
, O +
and O +
OS O +
( O +
58 O -
% O +
vs. O +
42 O -
% O +
p O +
= O +
0.005 O +
) O +
were O +
significantly O +
better O +
for O +
patients O +
who O +
did O +
not O +
have O +
a O +
transfusion O +
vs. O +
those O +
who O +
did O +
. O -

The O +
LRC O +
, O +
RFS O +
, O +
DSS O +
, O +
and O +
OS O +
were O +
also O +
significantly O +
better O +
for O +
patients O +
with O +
nadir O +
Hb O +
level O +
> O +
12 O +
vs. O +
< O +
12 O +
g O +
/ O +
dL O +
and O +
NOUT O +
1 O -
- O -
4 O +
vs. O +
> O +
4 O +
. O -

CONCLUSION O +
: O +
Our O +
study O +
seems O +
to O +
suggest O +
that O +
blood O +
transfusion O +
during O +
radical O +
treatment O +
for O +
SCCHN U-Disease +
might O +
be O +
detrimental O +
. O -

Further O +
research O +
should O +
be O +
undertaken O +
into O +
the O +
complex O +
interactions O +
among O +
tumor B-Disease +
hypoxia L-Disease +
, O +
anemia U-Disease +
, O +
and O +
the O +
treatment O +
of O +
anemia U-Disease +
before O +
making O +
treatment O +
recommendations O +
. O -

Disparities O +
in O +
the O +
use O +
of O +
chemotherapy O +
and O +
monoclonal O +
antibody O +
therapy O +
for O +
elderly O +
advanced O +
colorectal B-Disease +
cancer L-Disease +
patients O +
in O +
the O +
community O +
oncology O +
setting O +
. O -

BACKGROUND O +
: O +
The O +
clinical O +
trials O +
on O +
which O +
the O +
treatment O +
of O +
advanced O +
colorectal U-Disease +
( O +
CRC U-Disease +
) O +
is O +
based O +
enroll O +
few O +
elderly O +
patients O +
. O -

Furthermore O +
, O +
few O +
investigations O +
have O +
determined O +
the O +
use O +
and O +
outcomes O +
of O +
the O +
treatment O +
of O +
advanced O +
CRC U-Disease +
in O +
practice O +
. O -

This O +
study O +
evaluated O +
the O +
treatment O +
of O +
advanced O +
CRC U-Disease +
in O +
community O +
oncology O +
practices O +
, O +
focusing O +
on O +
age O +
- O +
related O +
differences O +
in O +
treatment O +
and O +
outcome O +
. O -

METHODS O +
: O +
A O +
national O +
, O +
retrospective O +
chart O +
review O +
was O +
conducted O +
to O +
evaluate O +
the O +
management O +
of O +
advanced O +
CRC U-Disease +
in O +
10 O +
community O +
practices O +
across O +
the O +
U O +
. O -

S O +
. O -

All O +
medical O +
records O +
of O +
patients O +
diagnosed O +
with O +
advanced O +
CRC U-Disease +
initiating O +
chemotherapy O +
treatment O +
after O +
January O +
1 O +
, O +
2003 O +
through O +
2006 O +
were O +
included O +
. O -

The O +
primary O +
aim O +
was O +
to O +
compare O +
the O +
proportion O +
receiving O +
doublet O +
chemotherapy O +
( O +
irinotecan O +
or O +
oxaliplatin O +
with O +
a O +
fluoropyrimidine O +
) O +
as O +
initial O +
therapy O +
in O +
young O +
( O +
age O +
< O +
or O +
= O +
65 O +
years O +
) O +
and O +
elderly O +
( O +
age O +
> O +
65 O +
years O +
) O +
patients O +
. O -

Additional O +
aims O +
included O +
age O +
- O +
based O +
comparisons O +
of O +
the O +
addition O +
of O +
bevacizumab O +
to O +
chemotherapy O +
, O +
overall O +
chemotherapy O +
use O +
, O +
all O +
- O +
cause O +
mortality O +
, O +
and O +
toxicity O +
- O +
related O +
events O +
. O -

RESULTS O +
: O +
Overall O +
, O +
520 O +
patients O +
( O +
56 O -
% O +
elderly O +
) O +
received O +
6,253 O +
cycles O +
of O +
chemotherapy O +
. O -

Of O +
the O +
younger O +
patients O +
, O +
84 O -
% O +
received O +
doublet O +
chemotherapy O +
first O +
- O +
line O +
, O +
compared O +
with O +
58 O -
% O +
of O +
elderly O +
patients O +
( O +
p O +
< O +
.001 O +
) O +
. O -

The O +
use O +
of O +
each O +
of O +
the O +
medications O +
- O +
- O +
irinotecan O +
, O +
oxaliplatin O +
, O +
and O +
bevacizumab O +
- O +
- O +
was O +
lower O +
in O +
elderly O +
patients O +
( O +
p O +
< O +
.001 O +
) O +
. O -

Independent O +
predictors O +
of O +
a O +
higher O +
risk O +
for O +
mortality O +
were O +
age O +
> O +
65 O +
( O +
adjusted O +
hazards O +
ratio O +
[ O +
HR O +
] O +
, O +
1.19 O +
; O +
95 O -
% O +
confidence O +
interval O +
[ O +
CI O +
] O +
, O +
1.02 O -
- O -
1.39 O +
) O +
and O +
performance O +
status O +
score O +
> O +
or O +
= O +
2 O +
( O +
HR O +
, O +
1.65 O +
; O +
95 O -
% O +
CI O +
, O +
1.41 O -
- O -
1.91 O +
) O +
. O -

CONCLUSION O +
: O +
Elderly O +
patients O +
are O +
less O +
likely O +
to O +
receive O +
first O +
- O +
line O +
doublet O +
chemotherapy O +
than O +
younger O +
patients O +
. O -

Age O +
and O +
performance O +
status O +
are O +
independent O +
predictors O +
of O +
treatment O +
and O +
overall O +
survival O +
. O -

Pharmacological O +
profile O +
, O +
efficacy O +
and O +
safety O +
of O +
rupatadine O +
in O +
allergic B-Disease +
rhinitis L-Disease +
. O -

Allergic B-Disease +
rhinitis L-Disease +
( O +
AR U-Disease +
) O +
is O +
a O +
disease O +
with O +
high O +
prevalence O +
. O -

In O +
AR U-Disease +
, O +
exposure O +
to O +
airborne O +
allergens O +
elicits O +
an O +
allergic O +
response O +
which O +
involves O +
epithelial O +
accumulation O +
of O +
effector O +
cells O +
- O +
e.g. O +
mast O +
cells O +
and O +
basophils O +
- O +
and O +
subsequent O +
inflammation U-Disease +
. O -

During O +
the O +
early O +
response O +
in O +
AR U-Disease +
, O +
histamine O +
has O +
been O +
found O +
to O +
be O +
the O +
most O +
abundant O +
mediator O +
and O +
it O +
is O +
associated O +
with O +
many O +
symptoms O +
of O +
this O +
disease O +
mediated O +
through O +
the O +
histamine O +
H1 O +
receptor O +
. O -

Therefore O +
, O +
anti O +
- O +
histamines O +
have O +
a O +
role O +
to O +
play O +
in O +
the O +
management O +
of O +
AR U-Disease +
. O -

However O +
, O +
the O +
available O +
antihistamines O +
have O +
certain O +
well O +
- O +
known O +
side O +
effects O +
like O +
sedation U-Disease +
and O +
potential O +
pro B-Disease +
- I-Disease +
arrythmic I-Disease +
effects L-Disease +
owing O +
to O +
their O +
interactions O +
with O +
other O +
drugs O +
, O +
as O +
well O +
as O +
having O +
poor O +
or O +
no O +
effect O +
on O +
platelet O +
activating O +
factor O +
( O +
PAF O +
) O +
which O +
also O +
plays O +
an O +
important O +
role O +
in O +
AR U-Disease +
. O -

This O +
article O +
is O +
a O +
qualitative O +
systematic O +
literature O +
review O +
on O +
the O +
pharmacological O +
profile O +
of O +
rupatadine O +
in O +
order O +
to O +
evaluate O +
its O +
safety O +
and O +
efficacy O +
in O +
AR U-Disease +
as O +
compared O +
to O +
other O +
anti O +
- O +
histamines O +
. O -

Rupatadine O +
is O +
a O +
once O +
- O +
daily O +
non O +
- O +
sedative O +
, O +
selective O +
, O +
long O +
- O +
acting O +
H1 O +
anti O +
- O +
histamine O +
with O +
antagonistic O +
PAF O +
effects O +
through O +
its O +
interaction O +
with O +
specific O +
receptors O +
. O -

Rupatadine O +
significantly O +
improves O +
nasal O +
symptoms O +
in O +
patients O +
with O +
AR U-Disease +
. O -

It O +
has O +
a O +
good O +
safety O +
profile O +
and O +
is O +
devoid O +
of O +
arrythmogenic B-Disease +
effects L-Disease +
. O -

These O +
properties O +
make O +
rupatadine O +
a O +
suitable O +
first O +
line O +
anti O +
- O +
histamine O +
for O +
the O +
treatment O +
of O +
AR U-Disease +
. O -

Variability O +
in O +
platelet O +
response O +
to O +
a O +
single O +
daily O +
dose O +
of O +
150 O +
mg O +
enteric O +
coated O +
aspirin O +
in O +
a O +
high O +
risk O +
population O +
. O -

PURPOSE O +
: O +
Previous O +
studies O +
have O +
reported O +
inadequate O +
anti O +
- O +
platelet O +
effect O +
in O +
0.4 O -
- O -
35 O -
% O +
of O +
patients O +
taking O +
aspirin O +
. O -

Such O +
studies O +
have O +
arbitrarily O +
defined O +
the O +
terms O +
" O +
semi O +
- O +
responders O +
" O +
, O +
" O +
non O +
- O +
responders O +
" O +
or O +
" O +
resistant O +
" O +
to O +
variable O +
doses O +
of O +
aspirin O +
on O +
the O +
basis O +
of O +
absolute O +
values O +
derived O +
from O +
different O +
ex O +
- O +
vivo O +
platelet O +
aggregation O +
( O +
PA O +
) O +
methods O +
. O -

Our O +
objective O +
was O +
to O +
define O +
response O +
to O +
150 O +
- O +
mg O +
dose O +
of O +
aspirin O +
in O +
terms O +
of O +
normally O +
distributed O +
values O +
using O +
an O +
ex O +
- O +
vivo O +
measure O +
of O +
PA O +
in O +
a O +
population O +
at O +
high O +
risk O +
for O +
vascular O +
events O +
. O -

METHODS O +
: O +
We O +
prospectively O +
studied O +
high O +
risk O +
patients O +
with O +
either O +
established O +
coronary B-Disease +
artery I-Disease +
disease L-Disease +
( O +
CAD U-Disease +
) O +
or O +
stroke U-Disease +
or O +
transient B-Disease +
ischemic I-Disease +
attack L-Disease +
( O +
TIA U-Disease +
) O +
or O +
peripheral B-Disease +
vascular I-Disease +
disease L-Disease +
or O +
with O +
multiple O +
atherothrombotic O +
risk O +
factors O +
like O +
diabetes U-Disease +
plus O +
one O +
of O +
the O +
following O +
- O +
- O +
hypertension U-Disease +
, O +
increased O +
total O +
cholesterol O +
, O +
cigarette O +
smoking O +
, O +
micro O +
- O +
albuminuria O +
, O +
low O +
- O +
high O +
density O +
lipoprotein O +
( O +
HDL O +
) O +
, O +
family O +
history O +
of O +
CAD U-Disease +
and O +
receiving O +
single O +
150 O +
mg O +
dose O +
of O +
aspirin O +
daily O +
. O -

PA O +
was O +
assessed O +
by O +
chronolog O +
lumi O +
- O +
aggregometer O +
( O +
490 O -
- O -
2 O +
D O +
) O +
using O +
arachidonic O +
acid O +
( O +
AA O +
) O +
reagent O +
. O -

RESULTS O +
: O +
130 O +
patients O +
were O +
studied O +
. O -

The O +
response O +
of O +
subjects O +
to O +
aspirin O +
followed O +
a O +
normal O +
, O +
bell O +
shaped O +
distribution O +
curve O +
with O +
a O +
mean O +
and O +
standard O +
deviation O +
( O +
S O +
. O -

D O +
. O +
) O +
of O +
13.1 O +
+ O +
/ O +
- O +
4.4 O -
% O +
. O -

3.1 O -
% O +
patients O +
had O +
PA O +
values O +
more O +
than O +
2 O +
S O +
. O -

D O +
. O +
of O +
the O +
mean O +
, O +
hence O +
termed O +
as O +
hypo O +
- O +
responders O +
to O +
aspirin O +
while O +
another O +
3.1 O -
% O +
patients O +
had O +
PA O +
values O +
less O +
than O +
2 O +
S O +
. O -

D O +
. O +
of O +
the O +
mean O +
, O +
hence O +
termed O +
as O +
hyper O +
- O +
responders O +
to O +
aspirin O +
. O -

CONCLUSION O +
: O +
There O +
is O +
minimal O +
inter O +
- O +
individual O +
variability O +
in O +
the O +
response O +
to O +
aspirin O +
when O +
tested O +
with O +
AA O +
as O +
the O +
reagent O +
. O -

The O +
response O +
to O +
aspirin O +
follows O +
a O +
normal O +
Gaussian O +
distribution O +
. O -

The O +
prevalence O +
of O +
hypo O +
- O +
responders O +
to O +
aspirin O +
in O +
high O +
risk O +
population O +
is O +
only O +
3.1 O -
% O +
. O -

This O +
is O +
the O +
first O +
study O +
to O +
document O +
" O +
hypo O +
" O +
and O +
" O +
hyper O +
- O +
responders O +
" O +
to O +
single O +
daily O +
dose O +
of O +
150 O +
mg O +
aspirin O +
. O -

The O +
clinical O +
relevance O +
of O +
these O +
findings O +
remains O +
to O +
be O +
determined O +
. O -

Effect O +
of O +
2 O +
- O +
hydroxyethyl O +
- O +
methacrylate O +
( O +
HEMA O +
) O +
on O +
the O +
phagocytic O +
and O +
respiratory O +
burst O +
activity O +
of O +
human O +
neutrophils O +
and O +
monocytes O +
. O -

Neutrophils O +
and O +
monocytes O +
/ O +
macrophages O +
( O +
M O +
? O +
) O +
, O +
found O +
in O +
oral O +
mucosa O +
and O +
gingival O +
sulcus O +
, O +
phagocytose O +
and O +
kill O +
bacteria O +
using O +
products O +
produced O +
during O +
a O +
respiratory O +
burst O +
. O -

2 O +
- O +
Hydroxyethyl O +
- O +
methacrylate O +
( O +
HEMA O +
) O +
is O +
a O +
major O +
component O +
released O +
from O +
resin O +
glass O +
ionomer O +
and O +
dental O +
adhesives O +
. O -

Hence O +
, O +
in O +
pulp O +
and O +
gingiva O +
, O +
phagocytes O +
can O +
come O +
into O +
contact O +
with O +
unpolymerized O +
HEMA O +
monomers O +
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
effects O +
of O +
exposure O +
to O +
HEMA O +
on O +
neutrophil O +
and O +
monocyte O +
bactericidal O +
function O +
. O -

Blood O +
collected O +
from O +
five O +
female O +
volunteers O +
was O +
exposed O +
in O +
vitro O +
to O +
HEMA O +
for O +
2 O +
h O +
and O +
then O +
phagocytosis O +
, O +
respiratory O +
burst O +
, O +
and O +
cellular O +
integrity O +
were O +
measured O +
using O +
flow O +
cytometry O +
. O -

Respiratory O +
burst O +
was O +
quantified O +
by O +
measuring O +
fluorescent O +
rhodamine O +
123 O +
generated O +
via O +
oxidation O +
of O +
dihydrorhodamine O +
123 O +
. O -

Cellular O +
membrane O +
integrity O +
was O +
evaluated O +
by O +
staining O +
with O +
propidium O +
iodide O +
. O -

The O +
respiratory O +
burst O +
activity O +
of O +
the O +
neutrophils O +
was O +
significantly O +
decreased O +
by O +
exposure O +
to O +
7.5 O +
and O +
15 O +
mM O +
HEMA O +
. O -

No O +
significant O +
effect O +
of O +
HEMA O +
was O +
seen O +
on O +
the O +
number O +
of O +
granulocytes O +
or O +
monocytes O +
capable O +
of O +
performing O +
respiratory O +
burst O +
. O -

Furthermore O +
, O +
there O +
was O +
no O +
significant O +
effect O +
of O +
HEMA O +
on O +
the O +
phagocytic O +
activity O +
of O +
the O +
monocytes O +
or O +
the O +
granulocytes O +
. O -

In O +
conclusion O +
, O +
HEMA O +
did O +
not O +
affect O +
the O +
phagocytosis O +
activity O +
of O +
neutrophils O +
; O +
however O +
, O +
the O +
ability O +
of O +
the O +
cells O +
to O +
kill O +
internalized O +
prey O +
was O +
significantly O +
reduced O +
. O -

Methods O +
in O +
safety O +
pharmacology O +
in O +
focus O +
. O -

This O +
focused O +
issue O +
of O +
the O +
Journal O +
of O +
Pharmacological O +
and O +
Toxicological O +
Methods O +
is O +
the O +
fifth O +
to O +
highlight O +
Methods O +
in O +
Safety O +
Pharmacology O +
and O +
includes O +
a O +
number O +
of O +
articles O +
from O +
the O +
7th O +
Annual O +
Safety O +
Pharmacology O +
Society O +
( O +
SPS O +
) O +
meeting O +
that O +
was O +
held O +
in O +
Edinburgh O +
, O +
Scotland O +
, O +
September O +
19 O -
- O -
21 O +
, O +
2007 O +
. O -

However O +
, O +
unlike O +
issues O +
of O +
the O +
past O +
, O +
in O +
which O +
content O +
predominantly O +
focused O +
on O +
cardiovascular O +
issues O +
( O +
specifically O +
QT O +
interval O +
prolongation O +
, O +
QT O +
- O +
HR O +
correction O +
methods O +
and O +
validation O +
of O +
non O +
- O +
clinical O +
cardiovascular O +
models O +
) O +
this O +
issue O +
is O +
composed O +
of O +
a O +
number O +
of O +
non O +
- O +
cardiovascular O +
methods O +
papers O +
and O +
review O +
articles O +
. O -

Of O +
particular O +
interest O +
to O +
readers O +
will O +
be O +
articles O +
related O +
to O +
CNS O +
studies O +
, O +
in O +
particular O +
neurobehavioral O +
assessments O +
in O +
non O +
- O +
human O +
primates O +
and O +
the O +
effects O +
of O +
drugs O +
in O +
juvenile O +
and O +
adult O +
rats O +
( O +
an O +
article O +
that O +
may O +
be O +
relevant O +
in O +
light O +
of O +
recent O +
EU O +
/ O +
US O +
pediatric O +
legislation O +
) O +
. O -

While O +
cardiovascular O +
function O +
may O +
not O +
dominate O +
there O +
are O +
several O +
useful O +
methodological O +
papers O +
including O +
an O +
assessment O +
of O +
cardiovascular O +
sensitivity O +
of O +
drugs O +
in O +
conscious O +
and O +
anesthetized O +
non O +
- O +
human O +
primates O +
, O +
and O +
a O +
mathematical O +
model O +
( O +
fractal O +
analysis O +
) O +
applied O +
to O +
canine O +
heartbeat O +
dynamics O +
. O -

A O +
first O +
for O +
the O +
journal O +
is O +
a O +
paper O +
by O +
Vargas O +
et O +
al. O +
, O +
( O +
2008 O +
- O +
this O +
issue O +
) O +
in O +
which O +
members O +
of O +
the O +
SPS O +
formed O +
a O +
working O +
group O +
in O +
order O +
to O +
assess O +
and O +
review O +
safety O +
pharmacology O +
testing O +
of O +
biological O +
therapeutic O +
agents O +
( O +
specifically O +
monoclonal O +
antibodies O +
, O +
mAbs O +
) O +
. O -

The O +
group O +
provides O +
recommendations O +
that O +
will O +
likely O +
shape O +
regulatory O +
strategy O +
and O +
discussions O +
in O +
the O +
yet O +
to O +
be O +
fully O +
discussed O +
area O +
of O +
biological O +
safety O +
testing O +
. O -

In O +
the O +
tradition O +
of O +
obtaining O +
a O +
perspective O +
on O +
industry O +
safety O +
pharmacology O +
program O +
practices O +
Lindgren O +
et O +
al. O +
, O +
( O +
2008 O +
- O +
this O +
issue O +
) O +
provide O +
the O +
results O +
of O +
a O +
recent O +
SPS O +
survey O +
that O +
examines O +
ICH O +
S7A O +
and O +
S7B O +
trends O +
, O +
aspects O +
of O +
early O +
' O +
frontloading O +
' O +
safety O +
studies O +
, O +
abuse O +
and O +
dependence O +
liability O +
and O +
Contract O +
Research O +
Organization O +
( O +
CRO O +
) O +
tests O +
/ O +
assays O +
used O +
in O +
safety O +
assessment O +
of O +
core O +
battery O +
and O +
supplementary O +
organ O +
systems O +
. O -

In O +
keeping O +
with O +
the O +
translation O +
track O +
aspect O +
of O +
the O +
2007 O +
meeting O +
is O +
an O +
overview O +
of O +
the O +
Distinguished O +
Service O +
Award O +
lecture O +
to O +
Dr. O +
T O +
. O -

Hammond O +
that O +
discusses O +
many O +
aspects O +
of O +
safety O +
pharmacology O +
including O +
its O +
evolution O +
, O +
impact O +
, O +
value O +
and O +
translation O +
of O +
non O +
- O +
clinical O +
findings O +
to O +
humans O +
. O -

Finally O +
, O +
perspectives O +
are O +
presented O +
on O +
the O +
use O +
of O +
the O +
zebrafish O +
as O +
an O +
early O +
safety O +
pharmacology O +
- O +
screening O +
assay O +
. O -

Intensity O +
- O +
modulated O +
radiotherapy O +
in O +
postoperative O +
treatment O +
of O +
oral B-Disease +
cavity I-Disease +
cancers L-Disease +
. O -

PURPOSE O +
: O +
To O +
present O +
our O +
single O +
- O +
institution O +
experience O +
of O +
intensity O +
- O +
modulated O +
radiotherapy O +
( O +
IMRT O +
) O +
for O +
oral B-Disease +
cavity I-Disease +
cancer L-Disease +
. O -

METHODS O +
AND O +
MATERIALS O +
: O +
Between O +
September O +
2000 O +
and O +
December O +
2006 O +
, O +
35 O +
patients O +
with O +
histologically O +
confirmed O +
squamous B-Disease +
cell I-Disease +
carcinoma I-Disease +
of I-Disease +
the I-Disease +
oral I-Disease +
cavity L-Disease +
underwent O +
surgery O +
followed O +
by O +
postoperative O +
IMRT O +
. O -

The O +
sites O +
included O +
were O +
buccal O +
mucosa O +
in O +
8 O +
, O +
oral O +
tongue O +
in O +
11 O +
, O +
floor O +
of O +
the O +
mouth O +
in O +
9 O +
, O +
gingiva O +
in O +
4 O +
, O +
hard O +
palate O +
in O +
2 O +
, O +
and O +
retromolar O +
trigone O +
in O +
1 O +
. O -

Most O +
patients O +
had O +
Stage O +
III O +
- O +
IV O +
disease O +
( O +
80 O -
% O +
) O +
. O -

Ten O +
patients O +
( O +
29 O -
% O +
) O +
also O +
received O +
concurrent O +
postoperative O +
chemotherapy O +
with O +
IMRT O +
. O -

The O +
median O +
prescribed O +
radiation O +
dose O +
was O +
60 O +
Gy O +
. O -

RESULTS O +
: O +
The O +
median O +
follow O +
- O +
up O +
for O +
surviving O +
patients O +
was O +
28.1 O +
months O +
( O +
range O +
, O +
11.9 O -
- O -
85.1 O +
) O +
. O -

Treatment O +
failure O +
occurred O +
in O +
11 O +
cases O +
as O +
follows O +
: O +
local O +
in O +
4 O +
, O +
regional O +
in O +
2 O +
, O +
and O +
distant O +
metastases O +
in O +
5 O +
. O -

Of O +
the O +
5 O +
patients O +
with O +
distant O +
metastases O +
, O +
2 O +
presented O +
with O +
dermal O +
metastases O +
. O -

The O +
2 O +
- O +
and O +
3 O +
- O +
year O +
estimates O +
of O +
locoregional O +
progression O +
- O +
free O +
survival O +
, O +
distant O +
metastasis O +
- O +
free O +
survival O +
, O +
disease O +
- O +
free O +
survival O +
, O +
and O +
overall O +
survival O +
were O +
84 O -
% O +
and O +
77 O -
% O +
, O +
85 O -
% O +
and O +
85 O -
% O +
, O +
70 O -
% O +
and O +
64 O -
% O +
, O +
and O +
74 O -
% O +
and O +
74 O -
% O +
, O +
respectively O +
. O -

Acute O +
Grade O +
2 O +
or O +
greater O +
dermatitis U-Disease +
, O +
mucositis U-Disease +
, O +
and O +
esophageal B-Disease +
reactions L-Disease +
were O +
experienced O +
by O +
54 O -
% O +
, O +
66 O -
% O +
, O +
and O +
40 O -
% O +
of O +
the O +
patients O +
, O +
respectively O +
. O -

Documented O +
late O +
complications O +
included O +
trismus U-Disease +
( O +
17 O -
% O +
) O +
and O +
osteoradionecrosis U-Disease +
( O +
5 O -
% O +
) O +
. O -

CONCLUSION O +
: O +
IMRT O +
as O +
an O +
adjuvant O +
treatment O +
after O +
surgical O +
resection O +
for O +
oral B-Disease +
cavity I-Disease +
tumors L-Disease +
is O +
feasible O +
and O +
effective O +
, O +
with O +
promising O +
results O +
and O +
acceptable O +
toxicity O +
. O -

Breakthrough O +
cryptococcosis U-Disease +
in O +
a O +
patient O +
with O +
systemic B-Disease +
lupus I-Disease +
erythematosus L-Disease +
( O +
SLE U-Disease +
) O +
receiving O +
micafungin O +
. O -

A O +
67 O +
- O +
year O +
- O +
old O +
woman O +
with O +
systemic B-Disease +
lupus I-Disease +
erythematosus L-Disease +
( O +
SLE U-Disease +
) O +
was O +
admitted O +
to O +
our O +
hospital O +
because O +
of O +
lupus B-Disease +
nephritis L-Disease +
. O -

Methylprednisolone O +
minipulse O +
therapy O +
dramatically O +
reduced O +
her O +
proteinuria U-Disease +
; O +
however O +
; O +
she O +
then O +
complained O +
of O +
general O +
fatigue U-Disease +
with O +
low O +
- O +
grade O +
fever U-Disease +
. O -

Radiological O +
and O +
culture O +
studies O +
revealed O +
no O +
infectious O +
focus O +
, O +
but O +
she O +
was O +
treated O +
with O +
meropenem O +
and O +
micafungin O +
, O +
considering O +
her O +
immunosuppressive O +
state O +
. O -

Cytomegalovirus O +
antigenemia O +
was O +
later O +
determined O +
and O +
ganciclovir O +
was O +
added O +
. O -

She O +
became O +
afebrile O +
, O +
but O +
complained O +
of O +
nausea U-Disease +
and O +
headache U-Disease +
, O +
and O +
disorientation U-Disease +
, O +
without O +
meningeal B-Disease +
signs L-Disease +
. O -

Because O +
a O +
brain O +
computed O +
tomography O +
( O +
CT O +
) O +
scan O +
showed O +
no O +
abnormality O +
, O +
we O +
initially O +
suspected O +
some O +
kind O +
of O +
drug O +
interaction O +
. O -

Despite O +
the O +
discontinuation O +
of O +
all O +
drugs O +
, O +
however O +
, O +
she O +
still O +
suffered O +
from O +
disturbance O +
of O +
consciousness O +
. O -

A O +
lumbar O +
puncture O +
revealed O +
yeast O +
cells O +
stained O +
by O +
India O +
ink O +
. O -

A O +
diagnosis O +
of O +
cryptococcal B-Disease +
meningitis L-Disease +
was O +
confirmed O +
. O -

Though O +
fluconazole O +
and O +
meropenem O +
were O +
administered O +
, O +
the O +
patient O +
died O +
. O -

Autopsy O +
findings O +
revealed O +
disseminated B-Disease +
cryptococcosis L-Disease +
concomitant O +
with O +
pulmonary B-Disease +
aspergillosis L-Disease +
. O -

Micafungin O +
is O +
a O +
recently O +
approved O +
echinocandin O +
- O +
class O +
antifungal O +
agent O +
that O +
is O +
now O +
widely O +
used O +
in O +
Japan O +
because O +
of O +
its O +
minimal O +
toxicity O +
and O +
broadspectrum O +
activity O +
. O -

However O +
, O +
such O +
echinocandins O +
have O +
limited O +
activity O +
against O +
a O +
number O +
of O +
fungi O +
. O -

Indeed O +
, O +
breakthrough O +
trichosporonosis O +
is O +
becoming O +
a O +
significant O +
problem O +
in O +
patients O +
with O +
hematological B-Disease +
malignancies L-Disease +
who O +
are O +
receiving O +
echinocandins O +
. O -

To O +
the O +
best O +
of O +
our O +
knowledge O +
, O +
breakthrough O +
cryptococcosis U-Disease +
, O +
as O +
seen O +
in O +
our O +
patient O +
, O +
has O +
not O +
been O +
reported O +
previously O +
in O +
patients O +
who O +
were O +
receiving O +
micafungin O +
as O +
an O +
empiric O +
antifungal O +
therapy O +
. O -

This O +
case O +
highlights O +
that O +
cryptococcosis U-Disease +
should O +
be O +
kept O +
in O +
mind O +
as O +
a O +
possible O +
breakthrough O +
infection U-Disease +
during O +
the O +
administration O +
of O +
echinocandins O +
, O +
especially O +
in O +
patients O +
with O +
cellular B-Disease +
immunodeficiency L-Disease +
. O -

Multicenter O +
clinical O +
study O +
on O +
the O +
efficacy O +
and O +
safety O +
of O +
inhalable O +
insulin O +
aerosol O +
in O +
the O +
treatment O +
of O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
. O -

BACKGROUND O +
: O +
A O +
new O +
inhalable O +
insulin O +
aerosol O +
( O +
Inh O +
- O +
Ins O +
) O +
was O +
developed O +
in O +
China O +
. O -

The O +
aim O +
of O +
this O +
multicenter O +
clinical O +
study O +
was O +
to O +
evaluate O +
the O +
efficacy O +
and O +
safety O +
of O +
this O +
new O +
Inh O +
- O +
Ins O +
as O +
a O +
treatment O +
of O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
. O -

Regular O +
porcine O +
insulin O +
( O +
RI O +
) O +
was O +
used O +
as O +
a O +
control O +
. O -

METHODS O +
: O +
This O +
study O +
is O +
a O +
prospective O +
, O +
randomized O +
, O +
open O +
- O +
label O +
, O +
parallel O +
- O +
group O +
multicenter O +
clinical O +
trial O +
in O +
which O +
253 O +
qualified O +
patients O +
with O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
received O +
the O +
insulin O +
Glargine O +
daily O +
at O +
bedtime O +
plus O +
either O +
a O +
pre O +
- O +
meal O +
Inh O +
- O +
Ins O +
or O +
a O +
pre O +
- O +
meal O +
subcutaneous O +
RI O +
for O +
12 O +
weeks O +
. O -

HbA1c O +
, O +
fasting O +
plasma O +
glucose O +
( O +
FPG O +
) O +
, O +
the O +
1 O +
- O +
hour O +
- O +
postprandial O +
blood O +
glucose O +
( O +
1hPBG O +
) O +
and O +
the O +
2 O +
- O +
hour O +
- O +
postprandial O +
blood O +
glucose O +
( O +
2hPBG O +
) O +
were O +
measured O +
. O -

Events O +
were O +
monitored O +
for O +
adverse O +
effects O +
. O -

RESULTS O +
: O +
After O +
12 O +
weeks O +
, O +
the O +
HbA1c O +
decreased O +
significantly O +
from O +
baseline O +
in O +
both O +
treatment O +
groups O +
, O +
with O +
no O +
significant O +
difference O +
between O +
the O +
two O +
regimens O +
. O -

In O +
the O +
Inh O +
- O +
Ins O +
group O +
, O +
FPG O +
, O +
both O +
1hPBG O +
and O +
2hPBG O +
significantly O +
declined O +
from O +
baseline O +
after O +
the O +
8th O +
- O +
and O +
12th O +
- O +
weeks O +
of O +
treatment O +
. O -

The O +
reduced O +
values O +
of O +
FPG O +
or O +
1hPBG O +
between O +
the O +
two O +
groups O +
showed O +
a O +
more O +
significant O +
hypoglycemic O +
effect O +
with O +
the O +
Inh O +
- O +
Ins O +
than O +
the O +
RI O +
. O -

After O +
12 O +
weeks O +
, O +
the O +
pulmonary O +
carbon O +
monoxide O +
diffusing O +
capacity O +
( O +
DLco O +
) O +
was O +
significantly O +
lower O +
in O +
Inh O +
- O +
Ins O +
group O +
than O +
in O +
the O +
RI O +
. O -

The O +
main O +
side O +
effects O +
of O +
Inh O +
- O +
Ins O +
were O +
coughing U-Disease +
, O +
excessive B-Disease +
sputum L-Disease +
, O +
and O +
hypoglycemia U-Disease +
. O -

CONCLUSIONS O +
: O +
Inh O +
- O +
Ins O +
was O +
effective O +
in O +
decreasing O +
HbA1c O +
like O +
the O +
RI O +
. O -

It O +
was O +
better O +
in O +
lowering O +
the O +
FPG O +
and O +
the O +
1hPBG O +
than O +
the O +
RI O +
. O -

Its O +
main O +
side O +
effects O +
were O +
coughing U-Disease +
, O +
excessive B-Disease +
sputum L-Disease +
, O +
and O +
hypoglycemia U-Disease +
. O -

Also O +
, O +
Inh O +
- O +
Ins O +
slightly O +
impaired O +
DLco O +
. O -

Choosing O +
a O +
skeletal O +
muscle O +
relaxant O +
. O -

Skeletal O +
muscle O +
relaxants O +
are O +
widely O +
used O +
in O +
treating O +
musculoskeletal O +
conditions O +
. O -

However O +
, O +
evidence O +
of O +
their O +
effectiveness O +
consists O +
mainly O +
of O +
studies O +
with O +
poor O +
methodologic O +
design O +
. O -

In O +
addition O +
, O +
these O +
drugs O +
have O +
not O +
been O +
proven O +
to O +
be O +
superior O +
to O +
acetaminophen O +
or O +
nonsteroidal O +
anti O +
- O +
inflammatory O +
drugs O +
for O +
low B-Disease +
back I-Disease +
pain L-Disease +
. O -

Systematic O +
reviews O +
and O +
meta O +
- O +
analyses O +
support O +
using O +
skeletal O +
muscle O +
relaxants O +
for O +
short O +
- O +
term O +
relief O +
of O +
acute B-Disease +
low I-Disease +
back I-Disease +
pain L-Disease +
when O +
nonsteroidal O +
anti O +
- O +
inflammatory O +
drugs O +
or O +
acetaminophen O +
are O +
not O +
effective O +
or O +
tolerated O +
. O -

Comparison O +
studies O +
have O +
not O +
shown O +
one O +
skeletal O +
muscle O +
relaxant O +
to O +
be O +
superior O +
to O +
another O +
. O -

Cyclobenzaprine O +
is O +
the O +
most O +
heavily O +
studied O +
and O +
has O +
been O +
shown O +
to O +
be O +
effective O +
for O +
various O +
musculoskeletal O +
conditions O +
. O -

The O +
sedative O +
properties O +
of O +
tizanidine O +
and O +
cyclobenzaprine O +
may O +
benefit O +
patients O +
with O +
insomnia U-Disease +
caused O +
by O +
severe O +
muscle B-Disease +
spasms L-Disease +
. O -

Methocarbamol O +
and O +
metaxalone O +
are O +
less O +
sedating O +
, O +
although O +
effectiveness O +
evidence O +
is O +
limited O +
. O -

Adverse O +
effects O +
, O +
particularly O +
dizziness U-Disease +
and O +
drowsiness U-Disease +
, O +
are O +
consistently O +
reported O +
with O +
all O +
skeletal O +
muscle O +
relaxants O +
. O -

The O +
potential O +
adverse O +
effects O +
should O +
be O +
communicated O +
clearly O +
to O +
the O +
patient O +
. O -

Because O +
of O +
limited O +
comparable O +
effectiveness O +
data O +
, O +
choice O +
of O +
agent O +
should O +
be O +
based O +
on O +
side O +
- O +
effect O +
profile O +
, O +
patient O +
preference O +
, O +
abuse U-Disease +
potential O +
, O +
and O +
possible O +
drug O +
interactions O +
. O -

Two O +
rare O +
cases O +
of O +
methotrexate O +
- O +
induced O +
pneumonitis U-Disease +
and O +
pleurisy U-Disease +
in O +
patients O +
with O +
gestational B-Disease +
trophoblastic I-Disease +
neoplasms L-Disease +
. O -

BACKGROUND O +
: O +
Pneumonitis U-Disease +
is O +
a O +
serious O +
and O +
unpredictable O +
side O +
- O +
effect O +
of O +
treatment O +
with O +
methotrexate O +
( O +
MTX O +
) O +
that O +
may O +
result O +
in O +
a O +
life O +
- O +
threatening O +
outcome O +
. O -

Pulmonary B-Disease +
toxicity L-Disease +
of O +
methotrexate O +
in O +
patients O +
with O +
a O +
gestational B-Disease +
trophoblastic I-Disease +
neoplasm L-Disease +
( O +
GTN U-Disease +
) O +
has O +
rarely O +
been O +
reported O +
before O +
. O -

CASE O +
REPORTS O +
: O +
For O +
the O +
first O +
time O +
two O +
cases O +
of O +
methotrexate O +
- O +
induced O +
pneumonitis U-Disease +
and O +
pleurisy U-Disease +
in O +
GTN U-Disease +
patients O +
of O +
Chinese O +
ethnicity O +
are O +
presented O +
. O -

Two O +
patients O +
were O +
both O +
categorized O +
as O +
the O +
low O +
- O +
risk O +
group O +
, O +
and O +
underwent O +
a O +
single O +
regimen O +
therapy O +
of O +
methotrexate O +
. O -

Their O +
symptoms O +
, O +
such O +
as O +
fever U-Disease +
, O +
chest B-Disease +
pain L-Disease +
, O +
acute B-Disease +
nonproductive I-Disease +
cough L-Disease +
, O +
dyspnea U-Disease +
and O +
hypoxemia U-Disease +
did O +
not O +
respond O +
to O +
antibiotics O +
immediately O +
. O -

Treatment O +
with O +
corticosteroids O +
may O +
be O +
helpful O +
. O -

CONCLUSION O +
: O +
Awareness O +
of O +
pneumonitis U-Disease +
and O +
pleurisy U-Disease +
, O +
potentially O +
life O +
- O +
threatening O +
complications O +
of O +
MTX O +
, O +
is O +
very O +
necessary O +
and O +
important O +
to O +
early O +
recognition O +
and O +
treatment O +
. O -

Reduced O +
weight O +
gain O +
with O +
insulin O +
detemir O +
compared O +
to O +
NPH O +
insulin O +
is O +
not O +
explained O +
by O +
a O +
reduction O +
in O +
hypoglycemia U-Disease +
. O -

BACKGROUND O +
: O +
Weight O +
gain O +
often O +
occurs O +
when O +
insulin O +
therapy O +
is O +
initiated O +
. O -

The O +
long O +
- O +
acting O +
insulin O +
analog O +
insulin O +
detemir O +
has O +
been O +
shown O +
to O +
be O +
effective O +
and O +
well O +
tolerated O +
when O +
used O +
in O +
basal O +
- O +
bolus O +
regimens O +
or O +
as O +
an O +
add O +
- O +
on O +
to O +
oral O +
antidiabetic O +
drugs O +
( O +
OADs O +
) O +
and O +
causes O +
less O +
weight O +
gain O +
than O +
other O +
insulins O +
. O -

The O +
aim O +
of O +
this O +
exploratory O +
analysis O +
was O +
to O +
investigate O +
any O +
correlations O +
between O +
weight O +
change O +
and O +
occurrence O +
of O +
hypoglycemia U-Disease +
with O +
NPH O +
insulin O +
and O +
insulin O +
detemir O +
. O -

METHODS O +
: O +
The O +
analysis O +
was O +
based O +
on O +
a O +
26 O +
- O +
week O +
, O +
randomized O +
, O +
multicenter O +
, O +
open O +
- O +
label O +
, O +
parallel O +
- O +
group O +
trial O +
in O +
which O +
glycemic O +
control O +
, O +
hypoglycemia U-Disease +
, O +
and O +
weight O +
change O +
were O +
compared O +
between O +
insulin O +
detemir O +
and O +
NPH O +
insulin O +
. O -

A O +
total O +
of O +
476 O +
insulin O +
- O +
naive O +
patients O +
with O +
type B-Disease +
2 I-Disease +
diabetes L-Disease +
treated O +
with O +
one O +
or O +
two O +
OADs O +
added O +
insulin O +
detemir O +
( O +
n O +
= O +
237 O +
) O +
or O +
NPH O +
insulin O +
( O +
n O +
= O +
239 O +
) O +
morning O +
and O +
evening O +
to O +
their O +
current O +
oral O +
treatment O +
. O -

Weight O +
gain O +
data O +
from O +
this O +
study O +
were O +
analyzed O +
as O +
a O +
function O +
of O +
hypoglycemia U-Disease +
frequency O +
. O -

RESULTS O +
: O +
Both O +
groups O +
achieved O +
excellent O +
glycosylated O +
hemoglobin O +
control O +
( O +
insulin O +
detemir O +
, O +
6.6 O -
% O +
; O +
NPH O +
insulin O +
, O +
6.5 O -
% O +
[ O +
difference O +
not O +
significant O +
] O +
) O +
. O -

Weight O +
gain O +
with O +
insulin O +
detemir O +
was O +
less O +
than O +
half O +
that O +
of O +
NPH O +
insulin O +
( O +
1.2 O +
vs. O +
2.8 O +
kg O +
, O +
respectively O +
[ O +
P O +
< O +
0.001 O +
] O +
) O +
, O +
and O +
the O +
overall O +
risk O +
of O +
hypoglycemia U-Disease +
was O +
47 O -
% O +
lower O +
with O +
insulin O +
detemir O +
( O +
P O +
< O +
0.001 O +
) O +
. O -

No O +
significant O +
relationship O +
between O +
hypoglycemia U-Disease +
and O +
weight O +
gain O +
was O +
seen O +
with O +
insulin O +
detemir O +
( O +
P O +
= O +
0.2 O +
) O +
, O +
while O +
a O +
statistically O +
significant O +
correlation O +
was O +
found O +
for O +
NPH O +
insulin O +
( O +
P O +
= O +
0.003 O +
) O +
. O -

CONCLUSIONS O +
: O +
Hypoglycemia U-Disease +
is O +
predictive O +
of O +
weight O +
gain O +
with O +
NPH O +
insulin O +
, O +
but O +
the O +
same O +
relationship O +
is O +
not O +
seen O +
with O +
insulin O +
detemir O +
. O -

It O +
is O +
therefore O +
likely O +
that O +
the O +
weight O +
- O +
sparing O +
effect O +
of O +
insulin O +
detemir O +
involves O +
other O +
mechanisms O +
. O -

Lung B-Disease +
fibrosis L-Disease +
10 O +
years O +
after O +
cessation O +
of O +
bleomycin O +
therapy O +
. O -

Bleomycin O +
( O +
BLM O +
) O +
is O +
a O +
chemotherapeutic O +
agent O +
used O +
for O +
the O +
treatment O +
of O +
several O +
types O +
of O +
malignancy O +
, O +
including O +
germ B-Disease +
cell I-Disease +
tumors L-Disease +
, O +
lymphoma U-Disease +
, O +
and O +
certain O +
types O +
of O +
squamous B-Disease +
- I-Disease +
cell I-Disease +
carcinoma L-Disease +
. O -

The O +
common O +
adverse O +
effect O +
of O +
BLM O +
is O +
interstitial B-Disease +
pneumonitis L-Disease +
, O +
followed O +
by O +
pulmonary B-Disease +
fibrosis L-Disease +
. O -

BLM O +
- O +
induced O +
pneumonitis U-Disease +
occurs O +
in O +
up O +
to O +
46 O -
% O +
of O +
patients O +
treated O +
with O +
BLM O +
- O +
containing O +
chemotherapy O +
and O +
lung B-Disease +
toxicity L-Disease +
usually O +
appears O +
during O +
treatment O +
. O -

Here O +
we O +
describe O +
a O +
patient O +
with O +
lung B-Disease +
fibrosis L-Disease +
, O +
who O +
presented O +
with O +
slow O +
progressive B-Disease +
breathlessness L-Disease +
and O +
pneumothorax U-Disease +
more O +
than O +
10 O +
years O +
after O +
cessation O +
of O +
BLM O +
therapy O +
. O -

A O +
15 O +
year O +
- O +
old O +
girl O +
presented O +
with O +
abnormal O +
shadows O +
on O +
chest O +
X O +
- O +
ray O +
. O -

The O +
patient O +
had O +
a O +
yolk B-Disease +
sac I-Disease +
carcinoma L-Disease +
in O +
the O +
sacral O +
region O +
at O +
1 O +
year O +
of O +
age O +
and O +
obtained O +
complete O +
remission O +
after O +
being O +
treated O +
with O +
tumor U-Disease +
resection O +
, O +
radiation O +
, O +
and O +
several O +
anti O +
- O +
cancer O +
drugs O +
including O +
BLM O +
. O -

There O +
were O +
no O +
abnormal O +
findings O +
in O +
chest O +
X O +
- O +
ray O +
until O +
she O +
reached O +
3 O +
years O +
of O +
age O +
, O +
when O +
she O +
had O +
developed O +
respiratory B-Disease +
distress L-Disease +
that O +
worsened O +
with O +
age O +
. O -

The O +
patient O +
had O +
experienced O +
an O +
episode O +
of O +
pneumothorax U-Disease +
at O +
13 O +
years O +
of O +
age O +
. O -

Chest O +
CT O +
at O +
the O +
time O +
revealed O +
interstitial O +
reticular O +
opacities O +
. O -

Radiological O +
findings O +
and O +
pathological O +
examination O +
of O +
the O +
lung O +
tissue O +
obtained O +
during O +
bullectomy O +
with O +
video O +
- O +
assisted O +
thoracic O +
surgery O +
were O +
compatible O +
with O +
BLM O +
- O +
induced O +
pneumonitis U-Disease +
. O -

The O +
present O +
study O +
suggests O +
that O +
lung B-Disease +
fibrosis L-Disease +
may O +
surface O +
more O +
than O +
10 O +
years O +
after O +
cessation O +
of O +
BLM O +
therapy O +
at O +
the O +
age O +
of O +
1 O +
year O +
, O +
with O +
no O +
chest O +
radiographic O +
findings O +
1 O +
year O +
after O +
completion O +
of O +
chemotherapy O +
. O -

The O +
use O +
of O +
BLM O +
in O +
infants O +
requires O +
strict O +
supervision O +
and O +
observation O +
and O +
careful O +
long O +
- O +
term O +
follow O +
up O +
. O -

Riluzole O +
in O +
psychiatry O +
: O +
a O +
systematic O +
review O +
of O +
the O +
literature O +
. O -

BACKGROUND O +
: O +
The O +
glutamate O +
system O +
seems O +
to O +
be O +
an O +
important O +
contributor O +
to O +
the O +
pathophysiology O +
of O +
mood O +
and O +
anxiety B-Disease +
disorders L-Disease +
. O -

Thus O +
, O +
glutamatergic O +
modulators O +
are O +
reasonable O +
candidate O +
drugs O +
to O +
test O +
in O +
patients O +
with O +
mood O +
and O +
anxiety B-Disease +
disorders L-Disease +
. O -

Riluzole O +
, O +
a O +
neuroprotective O +
agent O +
with O +
anticonvulsant O +
properties O +
approved O +
for O +
the O +
treatment O +
of O +
amyotrophic B-Disease +
lateral I-Disease +
sclerosis L-Disease +
( O +
ALS U-Disease +
) O +
is O +
one O +
such O +
agent O +
. O -

OBJECTIVE O +
: O +
To O +
assess O +
the O +
potential O +
risks O +
and O +
benefits O +
of O +
riluzole O +
treatment O +
in O +
psychiatric O +
patients O +
. O -

METHODS O +
: O +
A O +
PubMed O +
search O +
was O +
performed O +
using O +
the O +
keywords O +
' O +
riluzole O +
' O +
, O +
' O +
inhibitor O +
of O +
glutamate O +
release O +
' O +
and O +
' O +
glutamatergic O +
modulator O +
' O +
to O +
identify O +
all O +
clinical O +
studies O +
and O +
case O +
reports O +
involving O +
riluzole O +
in O +
psychiatric O +
patients O +
. O -

RESULTS O +
/ O +
CONCLUSION O +
: O +
Riluzole O +
's O +
side O +
effect O +
profile O +
is O +
favorable O +
and O +
preliminary O +
results O +
regarding O +
riluzole O +
for O +
the O +
treatment O +
of O +
severe O +
mood O +
, O +
anxiety U-Disease +
and O +
impulsive B-Disease +
disorders L-Disease +
are O +
encouraging O +
. O -

Estimates O +
of O +
cancer U-Disease +
potency O +
of O +
2,3,4,7,8 O +
- O +
pentachlorodibenzofuran O +
using O +
both O +
nonlinear O +
and O +
linear O +
approaches O +
. O -

Cancer U-Disease +
potency O +
estimates O +
were O +
derived O +
for O +
2,3,4,7,8 O +
- O +
pentachlorodibenzofuran O +
( O +
4 O +
- O +
PeCDF O +
) O +
using O +
data O +
collected O +
from O +
the O +
recently O +
published O +
National O +
Toxicology O +
Program O +
bioassay O +
in O +
female O +
Sprague O +
- O +
Dawley O +
rats O +
. O -

By O +
using O +
a O +
toxicokinetic O +
model O +
for O +
4 O +
- O +
PeCDF O +
, O +
the O +
dose O +
- O +
response O +
relationship O +
for O +
combined O +
liver B-Disease +
tumors L-Disease +
( O +
hepatocellular B-Disease +
adenomas L-Disease +
and O +
cholangiocarcinomas U-Disease +
) O +
in O +
rats O +
was O +
assessed O +
in O +
terms O +
of O +
lifetime O +
average O +
liver O +
concentration O +
and O +
lifetime O +
average O +
adipose O +
concentration O +
with O +
data O +
from O +
both O +
the O +
lifetime O +
and O +
the O +
stop O +
- O +
exposure O +
components O +
of O +
the O +
bioassay O +
. O -

Benchmark O +
dose O +
modeling O +
was O +
performed O +
to O +
estimate O +
tissue O +
concentrations O +
at O +
two O +
points O +
of O +
departure O +
( O +
EC O +
( O +
10 O +
) O +
and O +
EC O +
( O +
01 O +
) O +
and O +
their O +
95 O -
% O +
upper O +
and O +
lower O +
confidence O +
limits O +
) O +
. O -

The O +
same O +
toxicokinetic O +
model O +
with O +
human O +
input O +
values O +
was O +
then O +
used O +
to O +
back O +
- O +
extrapolate O +
human O +
equivalent O +
doses O +
that O +
corresponded O +
to O +
the O +
internal O +
tissue O +
concentration O +
measures O +
at O +
the O +
points O +
of O +
departure O +
. O -

Information O +
regarding O +
the O +
cancer U-Disease +
mode O +
of O +
action O +
was O +
used O +
to O +
support O +
the O +
development O +
of O +
several O +
toxicity O +
criterion O +
values O +
based O +
on O +
a O +
nonlinear O +
method O +
, O +
e.g. O +
, O +
reference O +
dose O +
or O +
tolerable O +
daily O +
intake O +
. O -

Nonlinear O +
estimates O +
of O +
toxicity O +
criteria O +
based O +
on O +
observed O +
noncancer O +
toxic O +
events O +
as O +
possible O +
precursors O +
to O +
tumor U-Disease +
formation O +
were O +
also O +
derived O +
and O +
were O +
similar O +
in O +
value O +
to O +
those O +
based O +
on O +
combined O +
liver B-Disease +
tumors L-Disease +
. O -

For O +
comparison O +
purposes O +
, O +
linear O +
estimates O +
of O +
cancer U-Disease +
potency O +
were O +
also O +
derived O +
. O -

Phase O +
II O +
preradiation O +
R115777 O +
( O +
tipifarnib O +
) O +
in O +
newly O +
diagnosed O +
GBM O +
with O +
residual O +
enhancing O +
disease O +
. O -

Glioblastoma B-Disease +
multiforme L-Disease +
( O +
GBM U-Disease +
) O +
is O +
a O +
lethal O +
primary O +
malignant B-Disease +
brain I-Disease +
tumor L-Disease +
in O +
adults O +
. O -

R115777 O +
( O +
tipifarnib O +
) O +
is O +
an O +
oral O +
agent O +
with O +
antiproliferative O +
effects O +
, O +
being O +
a O +
potent O +
and O +
selective O +
inhibitor O +
of O +
farnesyltransferase O +
. O -

This O +
multicenter O +
, O +
open O +
- O +
label O +
phase O +
II O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
efficacy O +
and O +
safety O +
of O +
R115777 O +
given O +
after O +
surgery O +
and O +
prior O +
to O +
radiation O +
in O +
patients O +
with O +
newly O +
diagnosed O +
and O +
residual O +
enhancing O +
GBM U-Disease +
. O -

Following O +
surgery O +
, O +
an O +
MRI O +
confirmed O +
the O +
presence O +
of O +
residual O +
enhancing O +
tumor O +
. O -

Patients O +
on O +
enzyme O +
- O +
inducing O +
antiseizure O +
drugs O +
( O +
EIASDs O +
) O +
received O +
600 O +
mg O +
twice O +
per O +
day O +
, O +
and O +
those O +
not O +
on O +
EIASDs O +
received O +
300 O +
mg O +
twice O +
per O +
day O +
. O -

One O +
to O +
three O +
monthly O +
cycles O +
of O +
R115777 O +
were O +
administered O +
, O +
and O +
radiation O +
was O +
initiated O +
with O +
progression O +
or O +
after O +
three O +
cycles O +
. O -

A O +
cycle O +
consisted O +
of O +
3 O +
weeks O +
of O +
continuous O +
R115777 O +
followed O +
by O +
a O +
1 O +
- O +
week O +
rest O +
. O -

MRI O +
was O +
done O +
monthly O +
. O -

The O +
primary O +
end O +
point O +
was O +
overall O +
survival O +
; O +
secondary O +
end O +
points O +
were O +
tumor U-Disease +
response O +
rate O +
and O +
toxicity O +
. O -

A O +
total O +
of O +
28 O +
confirmed O +
GBM O +
patients O +
entered O +
the O +
study O +
; O +
15 O +
patients O +
( O +
54 O -
% O +
) O +
were O +
on O +
EIASDs O +
. O -

The O +
overall O +
median O +
time O +
of O +
survival O +
was O +
7.7 O +
months O +
. O -

There O +
were O +
no O +
tumor U-Disease +
responses O +
. O -

Eight O +
patients O +
( O +
29 O -
% O +
) O +
had O +
stable O +
disease O +
as O +
the O +
best O +
response O +
. O -

The O +
study O +
was O +
stopped O +
early O +
due O +
to O +
progression O +
of O +
the O +
disease O +
in O +
12 O +
patients O +
( O +
48 O -
% O +
) O +
. O -

A O +
total O +
of O +
24 O +
patients O +
( O +
85 O -
% O +
) O +
were O +
off O +
study O +
before O +
the O +
planned O +
treatment O +
schedule O +
for O +
radiation O +
therapy O +
. O -

R115777 O +
administered O +
prior O +
to O +
radiation O +
therapy O +
in O +
patients O +
with O +
newly O +
diagnosed O +
GBM U-Disease +
and O +
residual O +
enhancing O +
disease O +
did O +
not O +
result O +
in O +
any O +
measurable O +
responses O +
or O +
improvement O +
in O +
survival O +
. O -

R115777 O +
administered O +
prior O +
to O +
radiation O +
therapy O +
is O +
not O +
recommended O +
for O +
patients O +
with O +
newly O +
diagnosed O +
GBM U-Disease +
. O -

Effect O +
of O +
calpain O +
and O +
proteasome O +
inhibition O +
on O +
Ca2 O -
+ O +
- O +
dependent O +
proteolysis O +
and O +
muscle O +
histopathology O +
in O +
the O +
mdx O +
mouse O +
. O -

Dystrophin O +
deficiency O +
is O +
the O +
underlying O +
molecular O +
cause O +
of O +
progressive B-Disease +
muscle I-Disease +
weakness L-Disease +
observed O +
in O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O +
DMD U-Disease +
) O +
. O -

Loss O +
of O +
functional O +
dystrophin O +
leads O +
to O +
elevated O +
levels O +
of O +
intracellular O +
Ca O +
( O +
2 O -
+ O +
) O +
, O +
a O +
key O +
step O +
in O +
the O +
cellular O +
pathology O +
of O +
DMD U-Disease +
. O -

The O +
cysteine O +
protease O +
calpain O +
is O +
activated O +
in O +
dystrophin O +
- O +
deficient O +
muscle O +
, O +
and O +
its O +
inhibition O +
is O +
regarded O +
as O +
a O +
potential O +
therapeutic O +
approach O +
. O -

In O +
addition O +
, O +
previous O +
work O +
has O +
shown O +
that O +
the O +
ubiquitin O +
- O +
proteasome O +
system O +
also O +
contributes O +
to O +
muscle O +
protein O +
breakdown O +
in O +
dystrophic O +
muscle O +
and O +
, O +
therefore O +
, O +
also O +
qualifies O +
as O +
a O +
potential O +
target O +
for O +
therapeutic O +
intervention O +
in O +
DMD U-Disease +
. O -

The O +
relative O +
contribution O +
of O +
calpain O +
- O +
and O +
proteasome O +
- O +
mediated O +
proteolysis O +
induced O +
by O +
increased O +
Ca O +
( O +
2 O -
+ O +
) O +
levels O +
was O +
characterized O +
in O +
cultured O +
muscle O +
cells O +
and O +
revealed O +
initial O +
Ca O +
( O +
2 O -
+ O +
) O +
influx O +
- O +
dependent O +
calpain O +
activity O +
and O +
subsequent O +
Ca O +
( O +
2 O -
+ O +
) O +
- O +
independent O +
activity O +
of O +
the O +
ubiquitin O +
- O +
proteasome O +
system O +
. O -

We O +
then O +
set O +
out O +
to O +
optimize O +
novel O +
small O +
- O +
molecule O +
inhibitors O +
that O +
inhibit O +
both O +
calpain O +
as O +
well O +
as O +
the O +
20S O +
proteasome O +
in O +
a O +
cellular O +
system O +
with O +
impaired O +
Ca O +
( O +
2 O -
+ O +
) O +
homeostasis O +
. O -

On O +
administration O +
of O +
such O +
inhibitors O +
to O +
mdx O +
mice O +
, O +
quantitative O +
histological O +
parameters O +
improved O +
significantly O +
, O +
in O +
particular O +
with O +
compounds O +
strongly O +
inhibiting O +
the O +
20S O +
proteasome O +
. O -

To O +
investigate O +
the O +
role O +
of O +
calpain O +
inhibition O +
without O +
interfering O +
with O +
the O +
ubiquitin O +
- O +
proteasome O +
system O +
, O +
we O +
crossed O +
mdx O +
mice O +
with O +
transgenic O +
mice O +
, O +
overexpressing O +
the O +
endogenous O +
calpain O +
inhibitor O +
calpastatin O +
. O -

Although O +
our O +
data O +
show O +
that O +
proteolysis O +
by O +
calpain O +
is O +
strongly O +
inhibited O +
in O +
the O +
transgenic O +
mdx O +
mouse O +
, O +
this O +
calpain O +
inhibition O +
did O +
not O +
ameliorate O +
muscle O +
histology O +
. O -

Our O +
results O +
indicate O +
that O +
inhibition O +
of O +
the O +
proteasome O +
rather O +
than O +
calpain O +
is O +
required O +
for O +
histological O +
improvement O +
of O +
dystrophin O +
- O +
deficient O +
muscle O +
. O -

In O +
conclusion O +
, O +
we O +
have O +
identified O +
novel O +
proteasome O +
inhibitors O +
that O +
qualify O +
as O +
potential O +
candidates O +
for O +
pharmacological O +
intervention O +
in O +
muscular B-Disease +
dystrophy L-Disease +
. O -

Effects O +
of O +
in O +
vitro O +
brevetoxin O +
exposure O +
on O +
apoptosis O +
and O +
cellular O +
metabolism O +
in O +
a O +
leukemic O +
T O +
cell O +
line O +
( O +
Jurkat O +
) O +
. O -

Harmful O +
algal O +
blooms O +
( O +
HABs O +
) O +
of O +
the O +
toxic O +
dinoflagellate O +
, O +
Karenia O +
brevis O +
, O +
produce O +
red O +
tide O +
toxins O +
, O +
or O +
brevetoxins O +
. O -

Significant O +
health O +
effects O +
associated O +
with O +
red O +
tide O +
toxin O +
exposure O +
have O +
been O +
reported O +
in O +
sea O +
life O +
and O +
in O +
humans O +
, O +
with O +
brevetoxins O +
documented O +
within O +
immune O +
cells O +
from O +
many O +
species O +
. O -

The O +
objective O +
of O +
this O +
research O +
was O +
to O +
investigate O +
potential O +
immunotoxic O +
effects O +
of O +
brevetoxins O +
using O +
a O +
leukemic O +
T O +
cell O +
line O +
( O +
Jurkat O +
) O +
as O +
an O +
in O +
vitro O +
model O +
system O +
. O -

Viability O +
, O +
cell O +
proliferation O +
, O +
and O +
apoptosis O +
assays O +
were O +
conducted O +
using O +
brevetoxin O +
congeners O +
PbTx O +
- O +
2 O +
, O +
PbTx O +
- O +
3 O +
, O +
and O +
PbTx O +
- O +
6 O +
. O -

The O +
effects O +
of O +
in O +
vitro O +
brevetoxin O +
exposure O +
on O +
cell O +
viability O +
and O +
cellular O +
metabolism O +
or O +
proliferation O +
were O +
determined O +
using O +
trypan O +
blue O +
and O +
MTT O +
( O +
1 O +
- O +
( O +
4,5 O +
- O +
dimethylthiazol O +
- O +
2 O +
- O +
yl O +
) O +
- O +
3,5 O +
- O +
diphenylformazan O +
) O +
, O +
respectively O +
. O -

Using O +
MTT O +
, O +
cellular O +
metabolic O +
activity O +
was O +
decreased O +
in O +
Jurkat O +
cells O +
exposed O +
to O +
5 O +
- O +
10 O +
microg O +
/ O +
ml O +
PbTx O +
- O +
2 O +
or O +
PbTx O +
- O +
6 O +
. O -

After O +
3 O +
h O +
, O +
no O +
significant O +
effects O +
on O +
cell O +
viability O +
were O +
observed O +
with O +
any O +
toxin O +
congener O +
in O +
concentrations O +
up O +
to O +
10 O +
microg O +
/ O +
ml O +
. O -

Viability O +
decreased O +
dramatically O +
after O +
24 O +
h O +
in O +
cells O +
treated O +
with O +
PbTx O +
- O +
2 O +
or O +
- O +
6 O +
. O -

Apoptosis O +
, O +
as O +
measured O +
by O +
caspase O +
- O +
3 O +
activity O +
, O +
was O +
significantly O +
increased O +
in O +
cells O +
exposed O +
to O +
PbTx O +
- O +
2 O +
or O +
PbTx O +
- O +
6 O +
. O -

In O +
summary O +
, O +
brevetoxin O +
congeners O +
varied O +
in O +
effects O +
on O +
Jurkat O +
cells O +
, O +
with O +
PbTx O +
- O +
2 O +
and O +
PbTx O +
- O +
6 O +
eliciting O +
greater O +
cellular O +
effects O +
compared O +
to O +
PbTx O +
- O +
3 O +
. O -

Influence O +
of O +
valproic O +
acid O +
on O +
outcome O +
of O +
high O +
- O +
grade O +
gliomas O +
in O +
children O +
. O -

BACKGROUND O +
: O +
Chemotherapy O +
has O +
limited O +
effects O +
in O +
the O +
treatment O +
of O +
high O +
- O +
grade O +
gliomas U-Disease +
( O +
HGGs U-Disease +
) O +
. O -

Valproic O +
acid O +
( O +
VPA O +
) O +
, O +
a O +
histone O +
deacetylase O +
( O +
HDAC O +
) O +
inhibitor O +
, O +
may O +
sensitize O +
HGGs O +
to O +
radiochemotherapy O +
. O -

As O +
the O +
drug O +
has O +
been O +
given O +
frequently O +
as O +
an O +
antiepileptic O +
drug O +
, O +
a O +
retrospective O +
analysis O +
was O +
conducted O +
to O +
ensure O +
relevant O +
information O +
was O +
not O +
missed O +
before O +
a O +
prospective O +
study O +
was O +
launched O +
. O -

MATERIALS O +
AND O +
METHODS O +
: O +
An O +
analysis O +
of O +
66 O +
pediatric O +
patients O +
( O +
range O +
, O +
1 O -
- O -
19 O +
years O +
of O +
age O +
) O +
with O +
glioblastoma B-Disease +
multiforme L-Disease +
( O +
GBM U-Disease +
) O +
( O +
n O +
= O +
40 O +
) O +
or O +
anaplastic B-Disease +
astrocytoma L-Disease +
( O +
AA U-Disease +
) O +
( O +
n O +
= O +
26 O +
) O +
was O +
retrospectively O +
conducted O +
for O +
predictors O +
of O +
survival O +
and O +
response O +
and O +
for O +
effects O +
of O +
VPA O +
on O +
outcome O +
or O +
toxicity O +
. O -

RESULTS O +
: O +
The O +
overall O +
survival O +
( O +
OS O +
) O +
was O +
better O +
for O +
AA U-Disease +
( O +
p O +
= O +
0.0114 O +
) O +
and O +
complete O +
resection O +
( O +
p O +
< O +
0.00005 O +
) O +
and O +
event O +
- O +
free O +
survival O +
( O +
EFS O +
) O +
was O +
better O +
for O +
complete O +
resection O +
( O +
p O +
= O +
0.0049 O +
) O +
. O -

Nine O +
patients O +
received O +
VPA O +
( O +
for O +
seizure U-Disease +
) O +
plus O +
further O +
oncological O +
treatment O +
. O -

The O +
most O +
severe O +
adverse O +
effect O +
was O +
a O +
pulmonary B-Disease +
embolism L-Disease +
( O +
n O +
= O +
1 O +
) O +
; O +
no O +
other O +
severe O +
side O +
- O +
effects O +
were O +
noted O +
. O -

The O +
response O +
to O +
nonsurgical O +
treatment O +
after O +
8 O +
weeks O +
was O +
: O +
complete O +
response O +
( O +
CR O +
) O +
: O +
0 O +
, O +
partial O +
response O +
( O +
PR O +
) O +
: O +
3 O +
, O +
stable O +
disease O +
( O +
SD O +
) O +
: O +
4 O +
, O +
progressive O +
disease O +
( O +
PD O +
) O +
: O +
2 O +
. O -

Some O +
of O +
the O +
patients O +
with O +
SD O +
responded O +
later O +
resulting O +
in O +
best O +
response O +
: O +
CR O +
: O +
0 O +
, O +
PR O +
: O +
5 O +
, O +
SD O +
: O +
2 O +
, O +
PD O +
: O +
2 O +
. O -

CONCLUSION O +
: O +
Treatment O +
with O +
VPA O +
plus O +
radiochemotherapy O +
is O +
well O +
tolerated O +
with O +
an O +
encouraging O +
response O +
rate O +
. O -

Tacrolimus O +
for O +
the O +
treatment O +
of O +
systemic B-Disease +
lupus I-Disease +
erythematosus L-Disease +
with O +
pure O +
class O +
V O +
nephritis U-Disease +
. O -

OBJECTIVES O +
: O +
The O +
treatment O +
of O +
pure O +
membranous O +
( O +
class O +
V O +
) O +
lupus B-Disease +
nephropathy L-Disease +
remains O +
unsatisfactory O +
. O -

We O +
studied O +
the O +
efficacy O +
and O +
safety O +
of O +
tacrolimus O +
in O +
the O +
treatment O +
of O +
membranous B-Disease +
nephritis L-Disease +
secondary O +
to O +
SLE U-Disease +
. O -

METHODS O +
: O +
We O +
recruited O +
18 O +
consecutive O +
SLE U-Disease +
patients O +
( O +
tacrolimus O +
group O +
) O +
with O +
recently O +
confirmed O +
biopsy O +
- O +
proven O +
class O +
V O +
lupus B-Disease +
nephritis L-Disease +
. O -

They O +
were O +
treated O +
with O +
a O +
tailing O +
dose O +
of O +
oral O +
prednisolone O +
and O +
tacrolimus O +
0.1 O -
- O -
0.2 O +
mg O +
/ O +
kg O +
/ O +
day O +
for O +
6 O +
months O +
, O +
followed O +
by O +
maintenance O +
prednisolone O +
and O +
AZA O +
. O -

The O +
rate O +
of O +
resolution O +
of O +
proteinuria U-Disease +
and O +
SLEDAI O +
were O +
compared O +
with O +
19 O +
historical O +
controls O +
treated O +
with O +
oral O +
cyclophosphamide O +
or O +
AZA O +
( O +
control O +
group O +
) O +
. O -

All O +
patients O +
were O +
followed O +
for O +
12 O +
months O +
. O -

RESULTS O +
: O +
Baseline O +
clinical O +
characteristics O +
were O +
comparable O +
between O +
the O +
groups O +
. O -

For O +
the O +
tacrolimus O +
group O +
, O +
the O +
complete O +
and O +
partial O +
remission O +
rates O +
were O +
27.8 O +
and O +
50.0 O -
% O +
, O +
respectively O +
at O +
12 O +
weeks O +
; O +
for O +
the O +
control O +
group O +
, O +
they O +
were O +
15.8 O +
and O +
47.4 O -
% O +
, O +
respectively O +
( O +
overall O +
chi O +
- O +
square O +
test O +
, O +
P O +
= O +
0.5 O +
) O +
. O -

However O +
, O +
tacrolimus O +
group O +
had O +
faster O +
resolution O +
of O +
proteinuria U-Disease +
than O +
the O +
control O +
group O +
by O +
the O +
general O +
linear O +
model O +
with O +
repeated O +
measures O +
( O +
P O +
= O +
0.032 O +
) O +
. O -

At O +
12 O +
weeks O +
, O +
proteinuria U-Disease +
was O +
reduced O +
by O +
76.2 O +
+ O +
/ O +
- O +
17.0 O -
% O +
for O +
the O +
tacrolimus O +
group O +
and O +
47.1 O +
+ O +
/ O +
- O +
51.1 O -
% O +
for O +
the O +
control O +
group O +
( O +
P O +
= O +
0.028 O +
) O +
. O -

Serial O +
change O +
in O +
renal O +
function O +
and O +
SLEDAI O +
score O +
did O +
not O +
differ O +
between O +
the O +
groups O +
. O -

During O +
the O +
study O +
period O +
, O +
four O +
patients O +
of O +
the O +
tacrolimus O +
group O +
, O +
and O +
11 O +
of O +
the O +
control O +
group O +
, O +
developed O +
lupus B-Disease +
flare L-Disease +
( O +
P O +
= O +
0.027 O +
) O +
. O -

There O +
was O +
no O +
serious O +
adverse O +
effect O +
in O +
the O +
tacrolimus O +
group O +
. O -

CONCLUSIONS O +
: O +
A O +
6 O +
- O +
month O +
course O +
of O +
tacrolimus O +
is O +
a O +
safe O +
and O +
effective O +
treatment O +
of O +
pure O +
class O +
V O +
( O +
membranous O +
) O +
lupus B-Disease +
nephritis L-Disease +
. O -

As O +
compared O +
with O +
conventional O +
cytotoxic O +
treatment O +
, O +
tacrolimus O +
possibly O +
results O +
in O +
a O +
faster O +
resolution O +
of O +
proteinuria U-Disease +
, O +
and O +
a O +
lower O +
risk O +
of O +
lupus B-Disease +
flare L-Disease +
within O +
1 O +
yr O +
. O -

The O +
long O +
- O +
term O +
effect O +
and O +
optimal O +
regimen O +
of O +
tacrolimus O +
require O +
further O +
study O +
. O -

7 O +
- O +
Deaza O +
- O +
6 O +
- O +
benzylthioinosine O +
analogues O +
as O +
subversive O +
substrate O +
of O +
Toxoplasma O +
gondii O +
adenosine O +
kinase O +
: O +
activities O +
and O +
selective O +
toxicities O +
. O -

Toxoplasma O +
gondii O +
adenosine O +
kinase O +
( O +
EC O +
.2 O +
.7 O +
.1 O +
.20 O +
) O +
is O +
the O +
major O +
route O +
of O +
adenosine O +
metabolism O +
in O +
this O +
parasite O +
. O -

The O +
enzyme O +
is O +
significantly O +
more O +
active O +
than O +
any O +
other O +
enzyme O +
of O +
the O +
purine O +
salvage O +
in O +
T O +
. O -

gondii O +
and O +
has O +
been O +
established O +
as O +
a O +
potential O +
chemotherapeutic O +
target O +
for O +
the O +
treatment O +
of O +
toxoplasmosis U-Disease +
. O -

Certain O +
6 O +
- O +
benzylthioinosines O +
act O +
as O +
subversive O +
substrates O +
of O +
T O +
. O -

gondii O +
, O +
but O +
not O +
human O +
, O +
adenosine O +
kinase O +
. O -

Therefore O +
, O +
these O +
compounds O +
are O +
preferentially O +
metabolized O +
to O +
their O +
respective O +
nucleotides O +
and O +
become O +
selectively O +
toxic O +
against O +
the O +
parasites O +
but O +
not O +
their O +
host O +
. O -

Moreover O +
, O +
7 O +
- O +
deazaadenosine O +
( O +
tubercidin O +
) O +
was O +
shown O +
to O +
be O +
an O +
excellent O +
ligand O +
of O +
T O +
. O -

gondii O +
adenosine O +
kinase O +
. O -

Therefore O +
, O +
we O +
synthesized O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosine O +
, O +
and O +
analogues O +
with O +
various O +
substitutions O +
at O +
their O +
phenyl O +
ring O +
, O +
to O +
increase O +
the O +
binding O +
affinity O +
of O +
the O +
6 O +
- O +
benzylthioinosines O +
to O +
T O +
. O -

gondii O +
adenosine O +
kinase O +
. O -

Indeed O +
, O +
the O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosine O +
analogues O +
were O +
better O +
ligands O +
of O +
T O +
. O -

gondii O +
adenosine O +
kinase O +
than O +
the O +
parent O +
compounds O +
, O +
6 O +
- O +
benzylthioinosine O +
and O +
7 O +
- O +
deazainosine O +
. O -

Herein O +
, O +
we O +
report O +
the O +
testing O +
of O +
the O +
metabolism O +
of O +
these O +
newly O +
synthesized O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosines O +
, O +
as O +
well O +
as O +
their O +
efficacy O +
as O +
anti O +
- O +
toxoplasmic O +
agents O +
in O +
cell O +
culture O +
. O -

All O +
the O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosine O +
analogues O +
were O +
metabolized O +
to O +
their O +
5 O -
' O +
- O +
monophosphate O +
derivatives O +
, O +
albeit O +
to O +
different O +
degrees O +
. O -

These O +
results O +
indicate O +
that O +
these O +
compounds O +
are O +
not O +
only O +
ligands O +
but O +
also O +
substrates O +
of O +
T O +
. O -

gondii O +
adenosine O +
kinase O +
. O -

All O +
the O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosine O +
analogues O +
showed O +
a O +
selective O +
antitoxoplasmic O +
effect O +
against O +
wild O +
type O +
parasites O +
, O +
but O +
not O +
mutants O +
lacking O +
adenosine O +
kinase O +
. O -

The O +
efficacy O +
of O +
these O +
compounds O +
varied O +
with O +
the O +
position O +
and O +
nature O +
of O +
the O +
substitution O +
on O +
their O +
phenyl O +
ring O +
. O -

Moreover O +
, O +
none O +
of O +
these O +
analogues O +
exhibited O +
host O +
toxicity O +
. O -

The O +
best O +
compounds O +
were O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
( O +
p O +
- O +
methoxybenzylthio O +
) O +
inosine O +
( O +
IC O +
( O +
50 O +
) O +
= O +
4.6 O +
microM O +
) O +
, O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
( O +
p O +
- O +
methoxycarbonylbenzylthio O +
) O +
inosine O +
( O +
IC O +
( O +
50 O +
) O +
= O +
5.0 O +
microM O +
) O +
, O +
and O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
( O +
p O +
- O +
cyanobenzylthio O +
) O +
inosine O +
( O +
IC O +
( O +
50 O +
) O +
= O +
5.3 O +
microM O +
) O +
. O -

These O +
results O +
further O +
confirm O +
that O +
T O +
. O -

gondii O +
adenosine O +
kinase O +
is O +
an O +
excellent O +
target O +
for O +
chemotherapy O +
and O +
that O +
7 O +
- O +
deaza O +
- O +
6 O +
- O +
benzylthioinosines O +
are O +
potential O +
antitoxoplasmic O +
agents O +
. O -

INN O +
- O +
toxin O +
, O +
a O +
highly O +
lethal O +
peptide O +
from O +
the O +
venom O +
of O +
Indian O +
cobra O +
( O +
Naja O +
naja O +
) O +
venom O +
- O +
Isolation O +
, O +
characterization O +
and O +
pharmacological O +
actions O +
. O -

A O +
novel O +
toxic O +
polypeptide O +
, O +
INN O +
- O +
toxin O +
, O +
is O +
purified O +
from O +
the O +
venom O +
of O +
Naja O +
naja O +
using O +
combination O +
of O +
gel O +
- O +
permeation O +
and O +
ion O +
- O +
exchange O +
chromatography O +
. O -

It O +
has O +
a O +
molecular O +
mass O +
of O +
6951.6 O +
Da O +
as O +
determined O +
by O +
MALDI O +
- O +
TOF O +
/ O +
MS O +
and O +
the O +
N O +
- O +
terminal O +
sequence O +
of O +
LKXNKLVPLF O +
. O -

It O +
showed O +
both O +
neurotoxic O +
as O +
well O +
as O +
cytotoxic B-Disease +
activities L-Disease +
. O -

INN O +
- O +
toxin O +
is O +
lethal O +
to O +
mice O +
with O +
a O +
LD O +
( O +
50 O +
) O +
of O +
1.2 O +
mg O +
/ O +
kg O +
body O +
weight O +
. O -

IgY O +
raised O +
in O +
chicks O +
against O +
basic O +
peptide O +
pool O +
neutralized O +
the O +
toxicity O +
of O +
INN O +
- O +
toxin O +
. O -

INN O +
- O +
toxin O +
did O +
not O +
inhibit O +
cholinesterase O +
activity O +
. O -

It O +
is O +
toxic O +
to O +
Ehrlich O +
ascites O +
tumor O +
( O +
EAT O +
) O +
cells O +
, O +
but O +
it O +
is O +
not O +
toxic O +
to O +
leukocyte O +
culture O +
. O -

The O +
toxin O +
appears O +
to O +
be O +
specific O +
in O +
its O +
mode O +
of O +
action O +
. O -

Interaction O +
of O +
N O +
- O +
bromosuccinamide O +
( O +
NBS O +
) O +
with O +
the O +
peptide O +
resulted O +
in O +
the O +
modification O +
of O +
tryptophan O +
residues O +
and O +
loss O +
of O +
lethal O +
toxicity O +
of O +
INN O +
- O +
toxin O +
. O -

Role O +
and O +
relevance O +
of O +
PEPT2 O +
in O +
drug O +
disposition O +
, O +
dynamics O +
, O +
and O +
toxicity O +
. O -

Pept2 O +
knockout O +
mice O +
are O +
an O +
important O +
tool O +
to O +
evaluate O +
the O +
evolving O +
role O +
and O +
relevance O +
of O +
this O +
proton O +
- O +
coupled O +
oligopeptide O +
transporter O +
beyond O +
drug O +
disposition O +
, O +
where O +
the O +
transporter O +
also O +
modulates O +
the O +
pharmacodynamic O +
and O +
toxicodynamic O +
effects O +
of O +
drug O +
substrates O +
. O -

Our O +
in O +
vivo O +
studies O +
with O +
glycylsarcosine O +
in O +
Pept2 O +
knockout O +
mice O +
have O +
established O +
" O +
proof O +
of O +
concept O +
" O +
that O +
PEPT2 O +
can O +
have O +
a O +
significant O +
effect O +
on O +
dipeptide O +
disposition O +
. O -

Subsequent O +
studies O +
with O +
the O +
aminocephalosporin O +
antibiotic O +
cefadroxil O +
have O +
shown O +
relevance O +
to O +
pharmacology O +
and O +
infectious O +
disease O +
. O -

Finally O +
, O +
studies O +
with O +
the O +
endogenous O +
peptidomimetic O +
5 O +
- O +
aminolevulinic O +
acid O +
have O +
demonstrated O +
relevance O +
to O +
toxicology O +
in O +
the O +
framework O +
of O +
porphyria O +
- O +
and O +
lead O +
- O +
induced O +
neurotoxicity U-Disease +
. O -

These O +
studies O +
have O +
consistently O +
demonstrated O +
the O +
dual O +
action O +
of O +
PEPT2 O +
with O +
respect O +
to O +
its O +
apical O +
localization O +
in O +
choroid O +
plexus O +
epithelium O +
and O +
kidney O +
in O +
: O +
1 O +
) O +
effluxing O +
substrates O +
from O +
CSF O +
into O +
choroid O +
plexus O +
, O +
thereby O +
affecting O +
regional O +
pharmacokinetics O +
in O +
brain O +
; O +
and O +
2 O +
) O +
reabsorbing O +
substrates O +
from O +
renal O +
tubular O +
fluid O +
into O +
proximal O +
tubules O +
, O +
thereby O +
affecting O +
systemic O +
pharmacokinetics O +
and O +
exposure O +
. O -

Moreover O +
, O +
these O +
studies O +
have O +
shown O +
that O +
the O +
regional O +
effect O +
of O +
PEPT2 O +
in O +
limiting O +
substrate O +
concentrations O +
in O +
the O +
CSF O +
is O +
more O +
dramatic O +
than O +
its O +
effect O +
in O +
increasing O +
systemic O +
exposure O +
. O -

In O +
the O +
case O +
of O +
5 O +
- O +
aminolevulinic O +
acid O +
, O +
such O +
regional O +
modulation O +
of O +
drug O +
disposition O +
translates O +
directly O +
into O +
significant O +
changes O +
in O +
neurotoxicity U-Disease +
. O -

Amiodarone O +
pulmonary B-Disease +
toxicity L-Disease +
after O +
lung O +
transplantation O +
. O -

Atrial B-Disease +
fibrillation L-Disease +
occurs O +
frequently O +
after O +
lung O +
transplantation O +
and O +
is O +
commonly O +
treated O +
with O +
amiodarone O +
. O -

Pulmonary B-Disease +
toxicity L-Disease +
may O +
result O +
from O +
amiodarone O +
exposure O +
and O +
is O +
characterized O +
by O +
non O +
- O +
specific O +
respiratory O +
manifestations O +
. O -

To O +
our O +
knowledge O +
, O +
there O +
are O +
no O +
reports O +
of O +
this O +
complication O +
occurring O +
after O +
lung O +
transplantation O +
. O -

We O +
present O +
a O +
patient O +
who O +
developed O +
radiologic O +
evidence O +
of O +
amiodarone O +
deposition O +
in O +
the O +
lungs O +
after O +
bilateral O +
lung O +
transplantation O +
. O -

The O +
phenomenology O +
of O +
the O +
psychotic O +
break O +
and O +
Huxley O +
's O +
trip O +
: O +
substance O +
use O +
and O +
the O +
onset O +
of O +
psychosis U-Disease +
. O -

BACKGROUND O +
: O +
While O +
considerable O +
research O +
attention O +
has O +
been O +
devoted O +
to O +
the O +
causal O +
relationship O +
between O +
substance O +
use O +
and O +
psychosis U-Disease +
, O +
the O +
phenomenology O +
of O +
the O +
association O +
between O +
the O +
two O +
has O +
largely O +
been O +
ignored O +
. O -

This O +
is O +
a O +
significant O +
shortcoming O +
, O +
because O +
it O +
blinds O +
researchers O +
to O +
the O +
possibility O +
that O +
there O +
may O +
be O +
elements O +
of O +
the O +
subjective O +
experience O +
of O +
substance O +
use O +
and O +
psychosis U-Disease +
that O +
contribute O +
to O +
their O +
apparent O +
relationship O +
in O +
empirical O +
studies O +
. O -

SAMPLING O +
AND O +
METHODS O +
: O +
The O +
current O +
paper O +
examines O +
the O +
phenomenology O +
of O +
the O +
onset O +
of O +
psychosis U-Disease +
and O +
the O +
phenomenology O +
of O +
substance O +
intoxication O +
through O +
consideration O +
of O +
two O +
texts O +
: O +
Sass O +
's O +
account O +
of O +
the O +
phenomenology O +
of O +
psychosis U-Disease +
onset O +
and O +
Huxley O +
's O +
account O +
of O +
the O +
experience O +
of O +
hallucinogenic B-Disease +
intoxication L-Disease +
. O -

Sass O +
's O +
account O +
of O +
psychosis U-Disease +
onset O +
includes O +
four O +
components O +
: O +
Unreality O +
, O +
Fragmentation O +
, O +
Mere O +
Being O +
, O +
and O +
Apophany O +
. O -

RESULTS O +
: O +
The O +
analysis O +
reveals O +
significant O +
parallels O +
- O +
and O +
also O +
some O +
differences O +
- O +
between O +
this O +
account O +
and O +
the O +
phenomenology O +
of O +
substance O +
intoxication O +
. O -

CONCLUSIONS O +
: O +
We O +
discuss O +
the O +
implications O +
of O +
this O +
for O +
the O +
causal O +
relationship O +
between O +
psychosis U-Disease +
and O +
substance O +
use O +
and O +
suggest O +
several O +
ways O +
of O +
understanding O +
the O +
overlapping O +
phenomenologies O +
. O -

This O +
includes O +
the O +
suggestion O +
of O +
a O +
shared O +
factor O +
, O +
perhaps O +
best O +
described O +
as O +
psychotic O +
- O +
like O +
experience O +
, O +
which O +
seems O +
to O +
involve O +
a O +
breakdown O +
of O +
the O +
sign O +
- O +
referent O +
relationship O +
and O +
relationship O +
with O +
the O +
common O +
- O +
sense O +
, O +
practical O +
world O +
. O -

However O +
, O +
in O +
the O +
onset O +
of O +
psychosis U-Disease +
, O +
this O +
breakdown O +
is O +
primarily O +
experienced O +
as O +
a O +
sense O +
of O +
alienation O +
from O +
self O +
and O +
world O +
, O +
whereas O +
in O +
the O +
hallucinogenic O +
state O +
a O +
sense O +
of O +
mystical O +
union O +
and O +
revelation O +
seems O +
predominant O +
. O -

Further O +
research O +
may O +
extend O +
this O +
analysis O +
by O +
looking O +
at O +
experiences O +
with O +
other O +
drugs O +
, O +
particularly O +
cannabis O +
, O +
and O +
by O +
examining O +
the O +
phenomenology O +
of O +
psychotic B-Disease +
disorder L-Disease +
beyond O +
the O +
first O +
episode O +
. O -

Phase O +
I O +
study O +
of O +
capecitabine O +
in O +
combination O +
with O +
cisplatin O +
and O +
irinotecan O +
in O +
patients O +
with O +
advanced O +
solid B-Disease +
malignancies L-Disease +
. O -

PURPOSE O +
: O +
This O +
phase O +
I O +
trial O +
assessed O +
the O +
safety O +
and O +
the O +
maximum O +
tolerated O +
dose O +
of O +
capecitabine O +
given O +
for O +
10 O +
days O +
prior O +
to O +
a O +
combination O +
of O +
cisplatin O +
and O +
irinotecan O +
in O +
patients O +
with O +
advanced O +
solid B-Disease +
malignancies L-Disease +
. O -

It O +
also O +
evaluated O +
the O +
changes O +
in O +
cisplatin O +
DNA O +
adducts O +
induced O +
by O +
capecitabine O +
. O -

PATIENTS O +
AND O +
METHODS O +
: O +
Patients O +
with O +
refractory O +
solid O +
tumors O +
who O +
had O +
not O +
failed O +
5 O +
- O +
fluorouracil O +
( O +
5 O +
- O +
FU O +
) O +
analogs O +
or O +
topoisomerase O +
I O +
inhibitors O +
were O +
eligible O +
. O -

All O +
cohorts O +
of O +
patients O +
first O +
received O +
a O +
28 O +
- O +
day O +
cycle O +
of O +
cisplatin O +
and O +
irinotecan O +
. O -

Both O +
drugs O +
were O +
given O +
at O +
a O +
dose O +
of O +
50 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
intravenously O +
on O +
day O +
1 O +
, O +
followed O +
by O +
irinotecan O +
on O +
days O +
8 O +
and O +
15 O +
at O +
the O +
same O +
dose O +
. O -

The O +
first O +
cycle O +
served O +
as O +
an O +
internal O +
control O +
. O -

Starting O +
from O +
the O +
second O +
cycle O +
, O +
patients O +
received O +
increasing O +
doses O +
per O +
cohort O +
of O +
capecitabine O +
from O +
day O +
1 O +
to O +
10 O +
of O +
each O +
cycle O +
, O +
followed O +
by O +
cisplatin O +
on O +
day O +
11 O +
and O +
irinotecan O +
on O +
days O +
11 O +
, O +
18 O +
and O +
25 O +
, O +
both O +
at O +
same O +
doses O +
as O +
the O +
first O +
cycle O +
. O -

Cycles O +
were O +
repeated O +
every O +
38 O +
days O +
. O -

The O +
starting O +
dose O +
of O +
capecitabine O +
was O +
500 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
/ O +
day O +
which O +
was O +
escalated O +
by O +
250 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
/ O +
day O +
in O +
the O +
subsequent O +
cohort O +
of O +
patients O +
to O +
reach O +
the O +
maximum O +
tolerated O +
dose O +
( O +
MTD O +
) O +
. O -

Later O +
, O +
additional O +
patients O +
were O +
treated O +
at O +
the O +
MTD O +
of O +
capecitabine O +
to O +
further O +
evaluate O +
the O +
safety O +
, O +
pharmacodynamics O +
, O +
and O +
tumor O +
response O +
. O -

Patients O +
blood O +
was O +
tested O +
for O +
cisplatin O +
- O +
DNA O +
adducts O +
to O +
determine O +
the O +
impact O +
of O +
capecitabine O +
on O +
cisplatin O +
- O +
based O +
therapy O +
. O -

RESULTS O +
: O +
Fifteen O +
patients O +
received O +
at O +
least O +
2 O +
cycles O +
of O +
treatment O +
. O -

At O +
1,250 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
, O +
two O +
DLT O +
of O +
prolonged O +
neutropenia U-Disease +
of O +
grade O +
> O +
or O +
= O +
3 O +
were O +
observed O +
. O -

The O +
MTD O +
for O +
capecitabine O +
was O +
thus O +
determined O +
to O +
be O +
1000 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
/ O +
day O +
. O -

Fatigue U-Disease +
and O +
diarrhea U-Disease +
of O +
grade O +
1 O +
or O +
2 O +
were O +
the O +
most O +
frequent O +
toxicities O +
at O +
this O +
dose O +
level O +
. O -

No O +
significant O +
hematologic B-Disease +
toxicity L-Disease +
was O +
observed O +
at O +
the O +
MTD O +
. O -

Two O +
complete O +
and O +
three O +
partial O +
remissions O +
were O +
observed O +
. O -

Four O +
of O +
the O +
responders O +
had O +
received O +
a O +
platinum O +
agent O +
and O +
/ O +
or O +
5 O +
- O +
FU O +
in O +
the O +
past O +
. O -

CONCLUSIONS O +
: O +
A O +
sequential O +
treatment O +
with O +
capecitabine O +
followed O +
by O +
cisplatin O +
and O +
irinotecan O +
is O +
well O +
tolerated O +
and O +
demonstrates O +
clinical O +
activity O +
in O +
patients O +
with O +
advanced O +
solid B-Disease +
malignancies L-Disease +
. O -

The O +
influence O +
of O +
capecitabine O +
, O +
if O +
any O +
, O +
on O +
the O +
efficacy O +
of O +
the O +
cisplatin O +
- O +
irinotecan O +
combination O +
is O +
not O +
related O +
to O +
a O +
variation O +
in O +
cisplatin O +
- O +
DNA O +
adducts O +
. O -

The O +
safety O +
of O +
long O +
- O +
acting O +
beta O +
- O +
agonists O +
among O +
patients O +
with O +
asthma U-Disease +
using O +
inhaled O +
corticosteroids O +
: O +
systematic O +
review O +
and O +
metaanalysis O +
. O -

RATIONALE O +
: O +
Inhaled O +
long O +
- O +
acting O +
beta O +
- O +
agonists O +
( O +
LABAs O +
) O +
, O +
when O +
used O +
as O +
monotherapy O +
in O +
asthma U-Disease +
, O +
may O +
increase O +
asthma O +
- O +
related O +
hospitalizations O +
, O +
life O +
threatening O +
events O +
requiring O +
intubation O +
/ O +
mechanical O +
ventilation O +
, O +
and O +
asthma O +
- O +
related O +
deaths O +
, O +
but O +
concomitant O +
use O +
of O +
inhaled O +
corticosteroids O +
( O +
ICS O +
) O +
may O +
modify O +
this O +
effect O +
. O -

Objectives O +
: O +
To O +
determine O +
the O +
safety O +
of O +
long O +
- O +
acting O +
beta O +
- O +
agonists O +
among O +
patients O +
with O +
asthma U-Disease +
using O +
corticosteroids O +
. O -

METHODS O +
: O +
We O +
conducted O +
a O +
systematic O +
review O +
and O +
metaanalysis O +
of O +
parallel O +
- O +
group O +
, O +
blinded O +
, O +
randomized O +
, O +
controlled O +
trials O +
with O +
at O +
least O +
12 O +
weeks O +
of O +
treatment O +
addressing O +
the O +
impact O +
of O +
LABA O +
on O +
asthma U-Disease +
- O +
related O +
and O +
total O +
morbidity O +
and O +
mortality O +
in O +
patients O +
concomitantly O +
using O +
ICS O +
. O -

We O +
searched O +
MEDLINE O +
, O +
EMBASE O +
, O +
ACPJC O +
, O +
and O +
Cochrane O +
( O +
Central O +
) O +
databases O +
, O +
and O +
contacted O +
authors O +
and O +
sponsors O +
. O -

MEASUREMENTS O +
AND O +
MAIN O +
RESULTS O +
: O +
We O +
used O +
a O +
random O +
effects O +
model O +
to O +
pool O +
results O +
from O +
different O +
studies O +
as O +
odds O +
ratios O +
( O +
ORs O +
) O +
( O +
95 O -
% O +
confidence O +
interval O +
[ O +
CI O +
] O +
) O +
( O +
OR O +
< O +
1.0 O +
favors O +
LABA O +
) O +
. O -

The O +
search O +
yielded O +
62 O +
relevant O +
studies O +
included O +
in O +
this O +
analysis O +
. O -

Among O +
over O +
29,000 O +
participants O +
( O +
15,710 O +
taking O +
LABA O +
, O +
with O +
over O +
8,000 O +
patient O +
- O +
years O +
observed O +
in O +
the O +
LABA O +
groups O +
) O +
, O +
there O +
were O +
three O +
asthma U-Disease +
- O +
related O +
deaths O +
and O +
two O +
asthma U-Disease +
- O +
related O +
, O +
nonfatal O +
intubations O +
( O +
all O +
in O +
LABA O +
groups O +
; O +
< O +
or O +
= O +
one O +
event O +
per O +
study O +
) O +
. O -

Differences O +
in O +
asthma O +
- O +
related O +
hospitalizations O +
( O +
OR O +
, O +
0.74 O +
; O +
95 O -
% O +
CI O +
, O +
0.53 O -
- O -
1.03 O +
) O +
and O +
asthma O +
- O +
related O +
serious O +
adverse O +
events O +
( O +
mostly O +
hospitalizations O +
; O +
OR O +
, O +
0.75 O +
; O +
95 O -
% O +
CI O +
, O +
0.54 O -
- O -
1.03 O +
) O +
failed O +
to O +
reach O +
statistical O +
significance O +
. O -

The O +
OR O +
for O +
total O +
mortality O +
was O +
1.26 O +
( O +
95 O -
% O +
CI O +
, O +
0.58 O -
- O -
2.74 O +
) O +
, O +
reflecting O +
14 O +
deaths O +
in O +
LABA O +
groups O +
and O +
eight O +
deaths O +
in O +
control O +
groups O +
, O +
respectively O +
. O -

CONCLUSIONS O +
: O +
In O +
patients O +
with O +
asthma U-Disease +
using O +
ICS O +
, O +
LABA O +
did O +
not O +
increase O +
the O +
risk O +
of O +
asthma O +
- O +
related O +
hospitalizations O +
. O -

There O +
were O +
very O +
few O +
asthma O +
- O +
related O +
deaths O +
and O +
intubations O +
, O +
and O +
events O +
were O +
too O +
infrequent O +
to O +
establish O +
LABA O +
's O +
relative O +
effect O +
on O +
these O +
outcomes O +
. O -

Adjuvant O +
treatment O +
with O +
vindesine O +
in O +
comparison O +
to O +
observation O +
alone O +
in O +
patients O +
with O +
metastasized B-Disease +
melanoma L-Disease +
after O +
complete O +
metastasectomy O +
: O +
a O +
randomized O +
multicenter O +
trial O +
of O +
the O +
German O +
Dermatologic O +
Cooperative O +
Oncology O +
Group O +
. O -

To O +
evaluate O +
the O +
efficacy O +
and O +
safety O +
of O +
vindesine O +
in O +
patients O +
with O +
metastatic B-Disease +
melanoma L-Disease +
after O +
complete O +
metastasectomy O +
. O -

One O +
hundred O +
and O +
forty O +
- O +
two O +
patients O +
with O +
metastatic O +
spread O +
to O +
regional O +
sites O +
, O +
lymph O +
nodes O +
, O +
and O +
distant O +
sites O +
after O +
complete O +
metastasectomy O +
were O +
randomized O +
to O +
receive O +
either O +
treatment O +
with O +
vindesine O +
for O +
2 O +
years O +
or O +
observation O +
alone O +
. O -

Vindesine O +
3 O +
mg O +
/ O +
m O +
intravenously O +
was O +
administered O +
biweekly O +
for O +
the O +
first O +
26 O +
weeks O +
following O +
3 O +
- O +
week O +
intervals O +
for O +
an O +
additional O +
26 O +
weeks O +
and O +
thereafter O +
every O +
4 O +
weeks O +
for O +
52 O +
weeks O +
. O -

One O +
hundred O +
and O +
thirty O +
- O +
nine O +
patients O +
were O +
eligible O +
for O +
intent O +
- O +
to O +
- O +
treat O +
analysis O +
. O -

Median O +
follow O +
- O +
up O +
time O +
was O +
46 O +
months O +
. O -

Median O +
recurrence O +
free O +
survival O +
was O +
7.9 O +
months O +
in O +
the O +
vindesine O +
group O +
and O +
7.6 O +
months O +
in O +
the O +
observational O +
group O +
( O +
P O +
= O +
0.40 O +
) O +
. O -

Three O +
- O +
year O +
overall O +
survival O +
rate O +
was O +
54.9 O -
% O +
( O +
37 O +
patients O +
) O +
for O +
patients O +
receiving O +
vindesine O +
in O +
comparison O +
to O +
43.6 O -
% O +
( O +
31 O +
patients O +
) O +
in O +
the O +
observation O +
arm O +
( O +
P O +
= O +
0.07 O +
) O +
. O -

No O +
grade O +
IV O +
toxicity O +
was O +
observed O +
. O -

The O +
two O +
major O +
side O +
effects O +
in O +
the O +
vindesine O +
group O +
were O +
alopecia U-Disease +
and O +
peripheral B-Disease +
neuropathy L-Disease +
. O -

Ten O +
patients O +
went O +
off O +
treatment O +
because O +
of O +
grade O +
III O +
toxicity O +
. O -

Adjuvant O +
treatment O +
with O +
vindesine O +
did O +
not O +
significantly O +
prolong O +
disease O +
free O +
or O +
overall O +
survival O +
in O +
high O +
- O +
risk O +
melanoma U-Disease +
patients O +
. O -

Thus O +
, O +
this O +
randomized O +
trial O +
did O +
not O +
confirm O +
earlier O +
reports O +
of O +
beneficial O +
effects O +
of O +
adjuvant O +
vindesine O +
and O +
can O +
therefore O +
not O +
be O +
recommended O +
. O -

Risk O +
assessment O +
of O +
khat O +
use O +
in O +
the O +
Netherlands O +
: O +
a O +
review O +
based O +
on O +
adverse O +
health O +
effects O +
, O +
prevalence O +
, O +
criminal O +
involvement O +
and O +
public O +
order O +
. O -

In O +
preparing O +
a O +
decision O +
about O +
the O +
legal O +
status O +
of O +
khat O +
in O +
the O +
Netherlands O +
, O +
the O +
Dutch O +
Minister O +
of O +
Health O +
requested O +
CAM O +
( O +
Coordination O +
point O +
Assessment O +
and O +
Monitoring O +
new O +
drugs O +
) O +
to O +
assess O +
the O +
overall O +
risk O +
of O +
khat O +
in O +
the O +
Netherlands O +
. O -

The O +
present O +
paper O +
is O +
a O +
redraft O +
of O +
a O +
report O +
which O +
formed O +
the O +
scientific O +
basis O +
of O +
the O +
risk O +
evaluation O +
procedure O +
( O +
October O +
2007 O +
) O +
. O -

This O +
report O +
reviews O +
the O +
scientific O +
data O +
about O +
khat O +
available O +
in O +
the O +
international O +
literature O +
. O -

In O +
addition O +
, O +
the O +
report O +
contains O +
some O +
information O +
specific O +
for O +
the O +
Netherlands O +
( O +
prevalence O +
, O +
availability O +
of O +
khat O +
and O +
public O +
order O +
aspects O +
) O +
. O -

The O +
main O +
psychoactive O +
compounds O +
in O +
khat O +
leaves O +
are O +
cathine O +
and O +
cathinone O +
, O +
which O +
are O +
some O +
2 O +
- O +
to O +
10 O +
- O +
fold O +
less O +
active O +
than O +
amphetamine O +
. O -

Acute O +
health O +
problems O +
are O +
rarely O +
seen O +
, O +
and O +
are O +
usually O +
related O +
with O +
malnutrition O +
, O +
social O +
and O +
financial O +
problems O +
. O -

Khat O +
has O +
a O +
low O +
addictive O +
potential O +
. O -

Chronic B-Disease +
toxicity L-Disease +
of O +
khat O +
is O +
modest O +
when O +
used O +
in O +
low O +
amounts O +
, O +
whereas O +
at O +
high O +
levels O +
, O +
khat O +
use O +
is O +
associated O +
with O +
adverse O +
effects O +
, O +
like O +
hypertension U-Disease +
, O +
heart B-Disease +
rhythm I-Disease +
disorders L-Disease +
, O +
insomnia U-Disease +
and O +
loss B-Disease +
of I-Disease +
appetite L-Disease +
. O -

In O +
addition O +
, O +
khat O +
users O +
show O +
a O +
higher O +
prevalence O +
of O +
cancers U-Disease +
in O +
the O +
digestive O +
tract O +
. O -

At O +
population O +
level O +
, O +
khat O +
does O +
not O +
lead O +
to O +
specific O +
health O +
risks O +
in O +
the O +
Netherlands O +
, O +
as O +
its O +
use O +
is O +
confined O +
to O +
East O +
- O +
African O +
immigrants O +
. O -

A O +
relationship O +
between O +
khat O +
use O +
and O +
psychiatric O +
disorders O +
has O +
been O +
suggested O +
, O +
but O +
the O +
reports O +
are O +
contradictory O +
, O +
and O +
such O +
studies O +
are O +
presumably O +
heavily O +
confounded O +
by O +
posttraumatic O +
and O +
social O +
stress O +
. O -

In O +
the O +
Netherlands O +
( O +
and O +
other O +
countries O +
) O +
, O +
khat O +
use O +
occasionally O +
leads O +
to O +
minor O +
disturbance O +
of O +
civil O +
order O +
in O +
the O +
public O +
domain O +
( O +
loud O +
talking O +
, O +
spitting O +
) O +
, O +
but O +
is O +
not O +
related O +
to O +
criminal O +
activities O +
. O -

Following O +
the O +
assessment O +
, O +
CAM O +
estimated O +
the O +
overall O +
risk O +
potential O +
of O +
khat O +
use O +
in O +
the O +
Netherlands O +
as O +
very O +
low O +
. O -

A O +
similar O +
conclusion O +
may O +
be O +
drawn O +
for O +
countries O +
with O +
a O +
comparable O +
prevalence O +
of O +
khat O +
use O +
and O +
khat O +
related O +
public O +
order O +
disturbance O +
. O -

High O +
- O +
dose O +
methylprednisolone O +
in O +
a O +
pregnant O +
woman O +
with O +
Crohn B-Disease +
's I-Disease +
disease L-Disease +
and O +
adrenal B-Disease +
suppression L-Disease +
in O +
her O +
newborn O +
. O -

BACKGROUND O +
: O +
The O +
synthetic O +
corticosteroid O +
methylprednisolone O +
is O +
used O +
for O +
the O +
treatment O +
of O +
acute O +
exacerbations O +
of O +
Crohn B-Disease +
's I-Disease +
disease L-Disease +
, O +
also O +
in O +
pregnancy O +
. O -

Its O +
use O +
is O +
considered O +
to O +
be O +
less O +
harmful O +
than O +
the O +
effect O +
of O +
active O +
disease O +
on O +
the O +
fetus O +
. O -

Adrenal B-Disease +
suppression L-Disease +
in O +
a O +
fetus O +
due O +
to O +
administration O +
of O +
methylprednisolone O +
has O +
hitherto O +
been O +
rarely O +
published O +
. O -

OBJECTIVE O +
: O +
To O +
present O +
a O +
case O +
of O +
neonatal B-Disease +
adrenal I-Disease +
suppression L-Disease +
due O +
to O +
the O +
use O +
of O +
high O +
- O +
dose O +
methylprednisolone O +
in O +
late O +
pregnancy O +
of O +
a O +
woman O +
with O +
Crohn B-Disease +
's I-Disease +
disease L-Disease +
. O -

METHODS O +
AND O +
RESULTS O +
: O +
Clinical O +
signs O +
of O +
adrenal B-Disease +
suppression L-Disease +
were O +
observed O +
in O +
the O +
newborn O +
3 O +
h O +
after O +
birth O +
. O -

After O +
hydrocortisone O +
supplementation O +
and O +
intensive O +
therapy O +
the O +
baby O +
recovered O +
completely O +
. O -

CONCLUSIONS O +
: O +
Life O +
- O +
threatening O +
adrenal B-Disease +
suppression L-Disease +
, O +
requiring O +
hydrocortisone O +
supplementation O +
and O +
intensive O +
therapy O +
, O +
was O +
observed O +
and O +
successfully O +
treated O +
in O +
a O +
newborn O +
, O +
whose O +
mother O +
had O +
received O +
high O +
- O +
dose O +
methylprednisolone O +
in O +
late O +
pregnancy O +
. O -

Effect O +
of O +
ranitidine O +
on O +
the O +
pharmacokinetics O +
and O +
pharmacodynamics O +
of O +
prasugrel O +
and O +
clopidogrel O +
. O -

OBJECTIVE O +
: O +
Clopidogrel O +
is O +
an O +
oral O +
thienopyridine O +
antiplatelet O +
agent O +
indicated O +
for O +
the O +
treatment O +
of O +
atherothrombotic O +
events O +
in O +
patients O +
with O +
acute B-Disease +
coronary I-Disease +
syndrome L-Disease +
( O +
ACS O +
) O +
. O -

Prasugrel O +
, O +
a O +
novel O +
oral O +
thienopyridine O +
, O +
is O +
under O +
investigation O +
for O +
the O +
reduction O +
of O +
atherothrombotic O +
events O +
in O +
patients O +
with O +
ACS O +
undergoing O +
percutaneous O +
coronary O +
intervention O +
. O -

Prasugrel O +
's O +
solubility O +
decreases O +
with O +
increasing O +
pH O +
, O +
suggesting O +
that O +
concomitantly O +
- O +
administered O +
medications O +
that O +
increase O +
gastric O +
pH O +
may O +
lower O +
the O +
rate O +
and O +
/ O +
or O +
extent O +
of O +
prasugrel O +
absorption O +
. O -

This O +
study O +
evaluated O +
the O +
influence O +
of O +
ranitidine O +
coadministration O +
on O +
the O +
pharmacokinetics O +
and O +
pharmacodynamics O +
of O +
the O +
respective O +
active O +
metabolite O +
of O +
prasugrel O +
and O +
clopidogrel O +
. O -

RESEARCH O +
DESIGN O +
AND O +
METHODS O +
: O +
In O +
this O +
open O +
- O +
label O +
, O +
two O +
- O +
period O +
, O +
two O +
- O +
treatment O +
, O +
crossover O +
study O +
, O +
47 O +
healthy O +
male O +
subjects O +
were O +
randomized O +
to O +
one O +
of O +
two O +
study O +
arms O +
, O +
receiving O +
either O +
prasugrel O +
( O +
60 O +
- O +
mg O +
loading O +
dose O +
[ O +
LD O +
] O +
, O +
10 O +
- O +
mg O +
maintenance O +
dose O +
[ O +
MD O +
] O +
for O +
7 O +
days O +
; O +
n O +
= O +
23 O +
) O +
or O +
clopidogrel O +
( O +
600 O +
- O +
mg O +
LD O +
, O +
75 O +
- O +
mg O +
MD O +
for O +
7 O +
days O +
; O +
n O +
= O +
24 O +
) O +
. O -

In O +
one O +
treatment O +
period O +
, O +
subjects O +
received O +
prasugrel O +
or O +
clopidogrel O +
alone O +
, O +
and O +
in O +
the O +
alternate O +
period O +
received O +
the O +
same O +
thienopyridine O +
with O +
ranitidine O +
( O +
150 O +
mg O +
twice O +
daily O +
, O +
starting O +
1 O +
day O +
before O +
the O +
LD O +
) O +
. O -

Pharmacokinetic O +
parameter O +
estimates O +
( O +
AUC O +
( O +
0 O +
- O +
t O +
last O +
) O +
, O +
C O +
( O +
max O +
) O +
, O +
and O +
t O +
( O +
max O +
) O +
) O +
and O +
inhibition O +
of O +
platelet O +
aggregation O +
( O +
IPA O +
) O +
by O +
light O +
transmission O +
aggregometry O +
were O +
assessed O +
at O +
multiple O +
time O +
points O +
after O +
the O +
LD O +
and O +
final O +
MD O +
. O -

RESULTS O +
: O +
Ranitidine O +
had O +
no O +
clinically O +
significant O +
effect O +
on O +
the O +
area O +
under O +
the O +
plasma O +
- O +
concentration O +
- O +
time O +
curve O +
( O +
AUC O +
) O +
and O +
did O +
not O +
affect O +
the O +
time O +
to O +
C O +
( O +
max O +
) O +
( O +
t O +
( O +
max O +
) O +
) O +
for O +
active O +
metabolites O +
of O +
either O +
prasugrel O +
or O +
clopidogrel O +
. O -

It O +
reduced O +
the O +
geometric O +
mean O +
maximum O +
concentrations O +
of O +
active O +
metabolite O +
( O +
C O +
( O +
max O +
) O +
) O +
after O +
a O +
prasugrel O +
and O +
clopidogrel O +
LD O +
by O +
14 O -
% O +
and O +
10 O -
% O +
, O +
respectively O +
, O +
but O +
these O +
differences O +
were O +
not O +
statistically O +
significant O +
. O -

When O +
coadministered O +
with O +
a O +
60 O +
- O +
mg O +
prasugrel O +
LD O +
, O +
ranitidine O +
did O +
not O +
affect O +
the O +
time O +
to O +
, O +
or O +
magnitude O +
of O +
, O +
peak O +
IPA O +
, O +
but O +
did O +
result O +
in O +
a O +
modest O +
reduction O +
at O +
0.5 O +
h O +
from O +
67.4 O +
to O +
55.1 O -
% O +
( O +
p O +
< O +
0.001 O +
) O +
. O -

Ranitidine O +
did O +
not O +
affect O +
prasugrel O +
IPA O +
during O +
MD O +
. O -

For O +
clopidogrel O +
, O +
IPA O +
was O +
not O +
affected O +
by O +
ranitidine O +
. O -

Prasugrel O +
and O +
clopidogrel O +
were O +
both O +
well O +
- O +
tolerated O +
, O +
with O +
/ O +
without O +
ranitidine O +
. O -

CONCLUSIONS O +
: O +
Results O +
from O +
this O +
study O +
suggest O +
that O +
there O +
is O +
no O +
significant O +
drug O +
- O +
drug O +
interaction U-Disease +
between O +
oral O +
ranitidine O +
therapy O +
and O +
concomitantly O +
- O +
administered O +
prasugrel O +
or O +
clopidogrel O +
. O -

Dielectrophoretic O +
field O +
- O +
flow O +
fractionation O +
system O +
for O +
detection O +
of O +
aquatic O +
toxicants O +
. O -

Dielectrophoretic O +
field O +
- O +
flow O +
fractionation O +
( O +
dFFF O +
) O +
was O +
applied O +
as O +
a O +
contact O +
- O +
free O +
way O +
to O +
sense O +
changes O +
in O +
the O +
plasma O +
membrane O +
capacitances O +
and O +
conductivities O +
of O +
cultured O +
human O +
HL O +
- O +
60 O +
cells O +
in O +
response O +
to O +
toxicant O +
exposure O +
. O -

A O +
micropatterned O +
electrode O +
imposed O +
electric O +
forces O +
on O +
cells O +
in O +
suspension O +
in O +
a O +
parabolic O +
flow O +
profile O +
as O +
they O +
moved O +
through O +
a O +
thin O +
chamber O +
. O -

Relative O +
changes O +
in O +
the O +
dFFF O +
peak O +
elution O +
time O +
, O +
reflecting O +
changes O +
in O +
cell O +
membrane O +
area O +
and O +
ion O +
permeability O +
, O +
were O +
measured O +
as O +
indices O +
of O +
response O +
during O +
the O +
first O +
150 O +
min O +
of O +
exposure O +
to O +
eight O +
toxicants O +
having O +
different O +
single O +
or O +
mixed O +
modes O +
of O +
action O +
( O +
acrylonitrile O +
, O +
actinomycin O +
D O +
, O +
carbon O +
tetrachloride O +
, O +
endosulfan O +
, O +
N O +
- O +
nitroso O +
- O +
N O +
- O +
methylurea O +
( O +
NMU O +
) O +
, O +
paraquat O +
dichloride O +
, O +
puromycin O +
, O +
and O +
styrene O +
oxide O +
) O +
. O -

The O +
dFFF O +
method O +
was O +
compared O +
with O +
the O +
cell O +
viability O +
assay O +
for O +
all O +
toxicants O +
and O +
with O +
the O +
mitochondrial O +
potentiometric O +
dye O +
assay O +
or O +
DNA O +
alkaline O +
comet O +
assay O +
according O +
to O +
the O +
mode O +
of O +
action O +
of O +
the O +
specific O +
agents O +
. O -

Except O +
for O +
low O +
doses O +
of O +
nucleic O +
acid O +
- O +
targeting O +
agents O +
( O +
actinomycin O +
D O +
and O +
NMU O +
) O +
, O +
the O +
dFFF O +
method O +
detected O +
all O +
toxicants O +
more O +
sensitively O +
than O +
other O +
assays O +
, O +
in O +
some O +
cases O +
up O +
to O +
10 O +
( O +
5 O +
) O +
times O +
more O +
sensitively O +
than O +
the O +
viability O +
approach O +
. O -

The O +
results O +
suggest O +
the O +
dFFF O +
method O +
merits O +
additional O +
study O +
for O +
possible O +
applicability O +
in O +
toxicology O +
. O -

Hyperthermia U-Disease +
adds O +
to O +
chemotherapy O +
. O -

The O +
hallmarks O +
of O +
hyperthermia U-Disease +
and O +
its O +
pleotropic O +
effects O +
are O +
in O +
favour O +
of O +
its O +
combined O +
use O +
with O +
chemotherapy O +
. O -

Preclinical O +
research O +
reveals O +
that O +
for O +
heat O +
killing O +
and O +
synergistic O +
effects O +
the O +
thermal O +
dose O +
is O +
most O +
critical O +
. O -

Thermal O +
enhancement O +
of O +
drug B-Disease +
cytotoxicity L-Disease +
is O +
accompanied O +
by O +
cellular O +
death O +
and O +
necrosis O +
without O +
increasing O +
its O +
oncogenic O +
potential O +
. O -

The O +
induction O +
of O +
genetically O +
defined O +
stress O +
responses O +
can O +
deliver O +
danger O +
signals O +
to O +
activate O +
the O +
host O +
's O +
immune O +
system O +
. O -

The O +
positive O +
results O +
of O +
randomised O +
trials O +
have O +
definitely O +
established O +
hyperthermia U-Disease +
in O +
combination O +
with O +
chemotherapy O +
as O +
a O +
novel O +
clinical O +
modality O +
for O +
the O +
treatment O +
of O +
cancer U-Disease +
. O -

Hyperthermia U-Disease +
targets O +
the O +
action O +
of O +
chemotherapy O +
within O +
the O +
heated O +
tumour U-Disease +
region O +
without O +
affecting O +
systemic B-Disease +
toxicity L-Disease +
. O -

In O +
specific O +
clinical O +
settings O +
regional B-Disease +
hyperthermia L-Disease +
( O +
RHT U-Disease +
) O +
or O +
hyperthermic O +
perfusion O +
has O +
proved O +
its O +
value O +
and O +
deserve O +
a O +
greater O +
focus O +
and O +
investigation O +
in O +
other O +
malignancies O +
. O -

In O +
Europe O +
, O +
more O +
specialised O +
centres O +
should O +
be O +
created O +
and O +
maintained O +
as O +
network O +
of O +
excellence O +
for O +
hyperthermia U-Disease +
in O +
the O +
field O +
of O +
oncology O +
. O -

Multiple O +
- O +
pool O +
cell O +
lifespan O +
models O +
for O +
neutropenia U-Disease +
to O +
assess O +
the O +
population O +
pharmacodynamics O +
of O +
unbound O +
paclitaxel O +
from O +
two O +
formulations O +
in O +
cancer U-Disease +
patients O +
. O -

PURPOSE O +
: O +
Our O +
objective O +
was O +
to O +
build O +
a O +
mechanism O +
- O +
based O +
pharmacodynamic O +
model O +
for O +
the O +
time O +
course O +
of O +
neutropenia U-Disease +
in O +
cancer U-Disease +
patients O +
following O +
paclitaxel O +
treatment O +
with O +
a O +
tocopherol O +
- O +
based O +
Cremophor O +
- O +
free O +
formulation O +
( O +
Tocosol O +
Paclitaxel O +
) O +
and O +
Cremophor O +
EL O +
- O +
formulated O +
paclitaxel O +
( O +
Taxol O +
) O +
. O -

METHODS O +
: O +
A O +
randomized O +
two O +
- O +
way O +
crossover O +
trial O +
was O +
performed O +
with O +
35 O +
adult O +
patients O +
who O +
received O +
175 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
paclitaxel O +
as O +
either O +
15 O +
min O +
( O +
Tocosol O +
Paclitaxel O +
) O +
or O +
3 O +
h O +
( O +
Taxol O +
) O +
intravenous O +
infusions O +
. O -

Paclitaxel O +
concentrations O +
were O +
measured O +
by O +
LC O +
- O +
MS O +
/ O +
MS O +
. O -

NONMEM O +
VI O +
was O +
used O +
for O +
population O +
pharmacodynamics O +
. O -

RESULTS O +
: O +
The O +
cytotoxic B-Disease +
effect L-Disease +
on O +
neutrophils O +
was O +
described O +
by O +
four O +
mechanism O +
- O +
based O +
models O +
predicated O +
on O +
known O +
properties O +
of O +
paclitaxel O +
that O +
used O +
unbound O +
concentrations O +
in O +
the O +
central O +
, O +
deep O +
peripheral O +
or O +
an O +
intracellular O +
compartment O +
as O +
forcing O +
functions O +
. O -

Tocosol O +
Paclitaxel O +
was O +
estimated O +
to O +
release O +
9.8 O -
% O +
of O +
the O +
dose O +
directly O +
into O +
the O +
deep O +
peripheral O +
compartment O +
( O +
DPC O +
) O +
. O -

All O +
models O +
provided O +
reasonable O +
fitting O +
of O +
neutropenic O +
effects O +
. O -

The O +
model O +
with O +
the O +
best O +
predictive O +
performance O +
assumed O +
that O +
this O +
dose O +
fraction O +
was O +
released O +
into O +
22.5 O -
% O +
of O +
the O +
DPC O +
which O +
included O +
the O +
site O +
of O +
toxicity O +
. O -

The O +
second O +
- O +
order O +
cytotoxic O +
rate O +
constant O +
was O +
0.00211 O +
mL O +
/ O +
ng O +
per O +
hour O +
( O +
variability O +
: O +
52 O -
% O +
CV O +
) O +
. O -

The O +
relative O +
exposure O +
at O +
the O +
site O +
of O +
toxicity O +
was O +
2.21 O +
+ O +
/ O +
- O +
0.41 O +
times O +
( O +
average O +
+ O +
/ O +
- O +
SD O +
) O +
larger O +
for O +
Tocosol O +
Paclitaxel O +
compared O +
to O +
Taxol O +
. O -

Lifespan O +
was O +
11.0 O +
days O +
for O +
progenitor O +
cells O +
, O +
1.95 O +
days O +
for O +
maturating O +
cells O +
, O +
and O +
4.38 O +
days O +
for O +
neutrophils O +
. O -

Total O +
drug O +
exposure O +
in O +
blood O +
explained O +
half O +
of O +
the O +
variance O +
in O +
nadir O +
to O +
baseline O +
neutrophil O +
count O +
ratio O +
. O -

CONCLUSIONS O +
: O +
The O +
relative O +
exposure O +
of O +
unbound O +
paclitaxel O +
at O +
the O +
site O +
of O +
toxicity O +
was O +
twice O +
as O +
large O +
for O +
Tocosol O +
Paclitaxel O +
compared O +
to O +
Taxol O +
. O -

The O +
proposed O +
mechanism O +
- O +
based O +
models O +
explained O +
the O +
extent O +
and O +
time O +
course O +
of O +
neutropenia U-Disease +
jointly O +
for O +
both O +
formulations O +
. O -

Effect O +
of O +
ABCG2 O +
on O +
cytotoxicity U-Disease +
of O +
platinum O +
drugs O +
: O +
interference O +
of O +
EGFP O +
. O -

ATP O +
- O +
binding O +
drug O +
efflux O +
transporters O +
decrease O +
intracellular O +
concentrations O +
of O +
cytotoxic O +
drugs O +
, O +
causing O +
multidrug O +
resistance O +
in O +
cancer U-Disease +
. O -

In O +
this O +
study O +
, O +
we O +
examined O +
possible O +
interactions O +
of O +
ABCG2 O +
transporter O +
with O +
platinum O +
cytotoxic O +
drugs O +
. O -

We O +
demonstrate O +
here O +
an O +
interference O +
of O +
platinum O +
drugs O +
with O +
enhanced O +
green O +
fluorescence O +
protein O +
( O +
EGFP O +
) O +
in O +
the O +
cellular O +
models O +
, O +
where O +
EGFP O +
was O +
employed O +
as O +
a O +
reporter O +
gene O +
. O -

Cytotoxicity U-Disease +
of O +
cisplatin O +
( O +
CIP O +
) O +
, O +
carboplatin O +
( O +
CAP O +
) O +
and O +
oxaliplatin O +
( O +
OXP O +
) O +
was O +
significantly O +
lowered O +
in O +
MDCKII O +
cells O +
transfected O +
with O +
ABCG2 O +
transporter O +
and O +
EGFP O +
reporter O +
. O -

The O +
IC O +
( O +
50 O +
) O +
values O +
in O +
MDCKII O +
- O +
ABCG2 O +
were O +
25.7 O +
, O +
164 O +
and O +
165 O +
microM O +
for O +
CIP O +
, O +
CAP O +
and O +
OXP O +
, O +
respectively O +
, O +
whereas O +
IC O +
( O +
50 O +
) O +
for O +
the O +
same O +
cytostatics O +
in O +
MDCKII O +
cells O +
were O +
as O +
follows O +
: O +
15.4 O +
, O +
133 O +
and O +
50.3 O +
microM O +
. O -

Addition O +
of O +
fumitremorgin O +
C O +
( O +
FTC O +
) O +
, O +
a O +
potent O +
ABCG2 O +
inhibitor O +
, O +
significantly O +
suppressed O +
the O +
resistance O +
of O +
MDCKII O +
- O +
ABCG2 O +
to O +
OXP O +
, O +
suggesting O +
that O +
OXP O +
interacts O +
with O +
ABCG2 O +
. O -

However O +
, O +
FTC O +
did O +
not O +
change O +
the O +
sensitivity O +
of O +
the O +
cells O +
to O +
CIP O +
and O +
CAP O +
. O -

We O +
assume O +
that O +
EGFP O +
rather O +
than O +
ABCG2 O +
causes O +
the O +
diminished O +
toxicity O +
of O +
the O +
platinum O +
cytostatics O +
in O +
the O +
transfected O +
cells O +
. O -

This O +
hypothesis O +
was O +
confirmed O +
in O +
human O +
Hep2 O +
cells O +
expressing O +
EGFP O +
: O +
using O +
MTT O +
test O +
, O +
IC O +
( O +
50 O +
) O +
of O +
30.0 O +
, O +
247 O +
and O +
27.9 O +
microM O +
were O +
obtained O +
for O +
CIP O +
, O +
CAP O +
and O +
OXP O +
, O +
respectively O +
, O +
while O +
12.3 O +
, O +
106 O +
and O +
20.5 O +
microM O +
were O +
observed O +
in O +
the O +
parent O +
Hep2 O +
cells O +
. O -

Employing O +
neutral O +
red O +
cytotoxicity U-Disease +
assay O +
, O +
similar O +
data O +
were O +
obtained O +
( O +
IC O +
( O +
50 O +
) O +
7.73 O +
, O +
685 O +
and O +
112 O +
microM O +
for O +
CIP O +
, O +
CAP O +
, O +
and O +
OXP O +
, O +
respectively O +
, O +
in O +
the O +
Hep2 O +
- O +
EGFP O +
cells O +
and O +
1.65 O +
, O +
79.4 O +
and O +
24.5 O +
microM O +
in O +
the O +
parent O +
Hep2 O +
cells O +
) O +
. O -

Caspase O +
- O +
3 O -
/ O -
7 O +
assay O +
revealed O +
lower O +
susceptibility O +
of O +
EGFP O +
expressing O +
Hep2 O +
cells O +
to O +
apoptosis O +
induced O +
by O +
CIP O +
when O +
compared O +
to O +
the O +
parent O +
cell O +
line O +
. O -

We O +
therefore O +
conclude O +
that O +
EGFP O +
in O +
transfected O +
cells O +
interferes O +
with O +
cytotoxicity U-Disease +
of O +
platinum O +
drugs O +
by O +
hindering O +
the O +
drug O +
induced O +
apoptosis O +
and O +
could O +
cause O +
misinterpretation O +
of O +
results O +
obtained O +
in O +
cytotoxicity U-Disease +
studies O +
. O -

Protective O +
effects O +
of O +
asiatic O +
acid O +
on O +
rotenone O +
- O +
or O +
H2O2 O +
- O +
induced O +
injury O +
in O +
SH O +
- O +
SY5Y O +
cells O +
. O -

Parkinson B-Disease +
's I-Disease +
disease L-Disease +
( O +
PD U-Disease +
) O +
is O +
a O +
progressive B-Disease +
neurodegenerative I-Disease +
disorder L-Disease +
with O +
a O +
prevalence O +
of O +
1 O -
- O -
2 O -
% O +
in O +
people O +
over O +
the O +
age O +
of O +
50 O +
. O -

Mitochondrial O +
dysfunction O +
occurred O +
in O +
PD U-Disease +
patients O +
showing O +
a O +
15 O -
- O -
30 O -
% O +
loss O +
of O +
activity O +
in O +
complex O +
I O +
. O -

Asiatic O +
acid O +
( O +
AA O +
) O +
, O +
a O +
triterpenoid O +
, O +
is O +
an O +
antioxidant O +
and O +
used O +
for O +
depression U-Disease +
treatment O +
, O +
but O +
the O +
effect O +
of O +
AA O +
against O +
PD U-Disease +
- O +
like O +
damage O +
has O +
never O +
been O +
reported O +
. O -

In O +
the O +
present O +
study O +
, O +
we O +
investigated O +
the O +
protective O +
effects O +
of O +
AA O +
against O +
H O +
( O +
2 O +
) O +
O O +
( O +
2 O +
) O +
or O +
rotenone O +
- O +
induced O +
cellular B-Disease +
injury L-Disease +
and O +
mitochondrial O +
dysfunction O +
in O +
SH O +
- O +
SY5Y O +
cells O +
. O -

Mitochondrial O +
membrane O +
potential O +
( O +
MMP O +
) O +
and O +
the O +
expression O +
of O +
voltage O +
- O +
dependent O +
anion O +
channel O +
( O +
VDAC O +
) O +
were O +
detected O +
with O +
or O +
without O +
AA O +
pretreatment O +
following O +
cellular B-Disease +
injury L-Disease +
to O +
address O +
the O +
possible O +
mechanisms O +
of O +
AA O +
neuroprotection O +
. O -

The O +
results O +
showed O +
that O +
pre O +
- O +
treatment O +
of O +
AA O +
( O +
0.01 O -
- O -
100 O +
nM O +
) O +
protected O +
cells O +
against O +
the O +
toxicity O +
induced O +
by O +
rotenone O +
or O +
H O +
( O +
2 O +
) O +
O O +
( O +
2 O +
) O +
. O -

In O +
addition O +
, O +
MMP O +
dissipation O +
occurred O +
following O +
the O +
exposure O +
of O +
rotenone O +
, O +
which O +
could O +
be O +
prevented O +
by O +
AA O +
treatment O +
. O -

More O +
interestingly O +
, O +
pre O +
- O +
administration O +
of O +
AA O +
inhibited O +
the O +
elevation O +
of O +
VDAC O +
mRNA O +
and O +
protein O +
levels O +
induced O +
by O +
rotenone O +
( O +
100 O +
nM O +
) O +
or O +
H O +
( O +
2 O +
) O +
O O +
( O +
2 O +
) O +
( O +
300 O +
microM O +
) O +
. O -

These O +
data O +
indicate O +
that O +
AA O +
could O +
protect O +
neuronal O +
cells O +
against O +
mitochondrial O +
dysfunctional O +
injury O +
and O +
suggest O +
that O +
AA O +
might O +
be O +
developed O +
as O +
an O +
agent O +
for O +
PD O +
prevention O +
or O +
therapy O +
. O -

Efficient O +
telomerase O +
inhibition O +
in O +
human O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
cells O +
by O +
liposomal O +
delivery O +
of O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
. O -

The O +
antisense O +
oligonucleotide O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
is O +
a O +
selective O +
telomerase O +
inhibitor O +
targeting O +
the O +
telomerase O +
RNA O +
component O +
and O +
represents O +
a O +
potential O +
candidate O +
for O +
anticancer O +
therapy O +
. O -

The O +
poor O +
cellular O +
uptake O +
of O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
is O +
a O +
limiting O +
factor O +
that O +
may O +
contribute O +
to O +
the O +
lack O +
of O +
functional O +
efficacy O +
. O -

To O +
improve O +
delivery O +
of O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
and O +
consequently O +
antitumoral O +
efficiency O +
in O +
human O +
lung O +
cancer O +
cells O +
, O +
we O +
have O +
investigated O +
several O +
transfection O +
reagents O +
. O -

The O +
transfection O +
reagents O +
DOTAP O +
, O +
MegaFectin O +
60 O +
, O +
SuperFect O +
, O +
FuGENE O +
6 O +
and O +
MATra O +
- O +
A O +
were O +
tested O +
for O +
intracellular O +
delivery O +
. O -

A O +
FAM O +
- O +
labeled O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
was O +
used O +
to O +
assess O +
the O +
intracellular O +
distribution O +
by O +
confocal O +
laser O +
scanning O +
microscopy O +
in O +
A549 O +
human O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
cells O +
. O -

Telomerase O +
activity O +
was O +
measured O +
using O +
the O +
telomeric O +
repeat O +
amplification O +
protocol O +
. O -

Cell O +
viability O +
after O +
transfection O +
was O +
quantified O +
by O +
the O +
MTT O +
assay O +
. O -

All O +
transfection O +
reagents O +
enhanced O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
uptake O +
in O +
A549 O +
cells O +
but O +
the O +
cationic O +
lipid O +
reagents O +
DOTAP O +
and O +
MegaFectin O +
60 O +
were O +
most O +
efficient O +
in O +
the O +
delivery O +
of O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
resulting O +
in O +
telomerase O +
inhibition O +
. O -

Among O +
both O +
DOTAP O +
exhibited O +
the O +
lowest O +
cytotoxicity U-Disease +
. O -

Our O +
experiments O +
show O +
that O +
DOTAP O +
is O +
the O +
most O +
suitable O +
transfection O +
reagent O +
for O +
the O +
delivery O +
of O +
2 O -
' O +
- O +
O O +
- O +
methyl O +
- O +
RNA O +
in O +
human O +
lung O +
cancer O +
cells O +
according O +
to O +
its O +
relatively O +
low O +
cytotoxicity U-Disease +
and O +
its O +
ability O +
to O +
promote O +
efficient O +
uptake O +
leading O +
to O +
the O +
inhibition O +
of O +
telomerase O +
. O -

Particulate O +
matter O +
inhibits O +
DNA O +
repair O +
and O +
enhances O +
mutagenesis O +
. O -

Exposure O +
to O +
ambient O +
air O +
pollution O +
has O +
been O +
associated O +
with O +
adverse O +
health O +
effects O +
including O +
lung B-Disease +
cancer L-Disease +
. O -

A O +
recent O +
epidemiology O +
study O +
has O +
established O +
that O +
each O +
10 O +
microg O +
/ O +
m3 O +
elevation O +
in O +
long O +
- O +
term O +
exposure O +
to O +
average O +
PM2 O +
.5 O +
ambient O +
concentration O +
was O +
associated O +
with O +
approximately O +
8 O -
% O +
of O +
lung B-Disease +
cancer L-Disease +
mortality O +
. O -

The O +
underlying O +
mechanisms O +
of O +
how O +
PM O +
contributes O +
to O +
lung O +
carcinogenesis O +
, O +
however O +
, O +
remain O +
to O +
be O +
elucidated O +
. O -

We O +
have O +
recently O +
found O +
that O +
transition O +
metals O +
such O +
as O +
nickel O +
and O +
chromium O +
and O +
oxidative O +
stress O +
induced O +
lipid O +
peroxidation O +
metabolites O +
such O +
as O +
aldehydes O +
can O +
greatly O +
inhibit O +
nucleotide O +
excision O +
repair O +
( O +
NER O +
) O +
and O +
enhance O +
carcinogen O +
- O +
induced O +
mutations O +
. O -

Because O +
PM O +
is O +
rich O +
in O +
metal O +
and O +
aldehyde O +
content O +
and O +
can O +
induce O +
oxidative O +
stress O +
, O +
we O +
tested O +
the O +
effect O +
of O +
PM O +
on O +
DNA O +
repair O +
capacity O +
in O +
cultured O +
human O +
lung O +
cells O +
using O +
in O +
vitro O +
DNA O +
repair O +
synthesis O +
and O +
host O +
cell O +
reactivation O +
assays O +
. O -

We O +
found O +
that O +
PM O +
greatly O +
inhibits O +
NER O +
for O +
ultraviolet O +
( O +
UV O +
) O +
light O +
and O +
benzo O +
( O +
a O +
) O +
pyrene O +
diol O +
epoxide O +
( O +
BPDE O +
) O +
induced O +
DNA O +
damage O +
in O +
human O +
lung O +
cells O +
. O -

We O +
further O +
demonstrated O +
that O +
PM O +
exposure O +
can O +
significantly O +
increase O +
both O +
spontaneous O +
and O +
UV O +
- O +
induced O +
mutagenesis O +
. O -

These O +
results O +
together O +
suggest O +
that O +
the O +
carcinogenicity U-Disease +
of O +
PM O +
may O +
act O +
through O +
its O +
combined O +
effect O +
on O +
suppression O +
of O +
DNA O +
repair O +
and O +
enhancement O +
of O +
DNA O +
replication O +
errors O +
. O -

Nicotine O +
and O +
4 O +
- O +
( O +
methylnitrosamino O +
) O +
- O +
1 O +
- O +
( O +
3 O +
- O +
pyridyl O +
) O +
- O +
1 O +
- O +
butanone O +
induce O +
cyclooxygenase O +
- O +
2 O +
activity O +
in O +
human O +
gastric O +
cancer O +
cells O +
: O +
Involvement O +
of O +
nicotinic O +
acetylcholine O +
receptor O +
( O +
nAChR O +
) O +
and O +
beta O +
- O +
adrenergic O +
receptor O +
signaling O +
pathways O +
. O -

Induction O +
of O +
cyclooxygenase O +
- O +
2 O +
( O +
COX O +
- O +
2 O +
) O +
associates O +
with O +
cigarette O +
smoke O +
exposure O +
in O +
many O +
malignancies O +
. O -

Nicotine O +
and O +
its O +
derivative O +
, O +
4 O +
- O +
( O +
methylnitrosamino O +
) O +
- O +
1 O +
- O +
( O +
3 O +
- O +
pyridyl O +
) O +
- O +
1 O +
- O +
butanone O +
( O +
NNK O +
) O +
, O +
are O +
the O +
two O +
important O +
components O +
in O +
cigarette O +
smoke O +
that O +
contributes O +
to O +
cancer U-Disease +
development O +
. O -

However O +
, O +
the O +
molecular O +
mechanism O +
( O +
s O +
) O +
by O +
which O +
nicotine O +
or O +
NNK O +
promotes O +
gastric O +
carcinogenesis O +
remains O +
largely O +
unknown O +
. O -

We O +
found O +
that O +
nicotine O +
and O +
NNK O +
significantly O +
enhanced O +
cell O +
proliferation O +
in O +
AGS O +
cells O +
that O +
expressed O +
both O +
alpha7 O +
nicotinic O +
acetylcholine O +
receptor O +
( O +
alpha7 O +
nAChR O +
) O +
and O +
beta O +
- O +
adrenergic O +
receptors O +
. O -

Treatment O +
of O +
cells O +
with O +
alpha O +
- O +
bungarotoxin O +
( O +
alpha O +
- O +
BTX O +
, O +
alpha7nAChR O +
antagonist O +
) O +
or O +
propranolol O +
( O +
beta O +
- O +
adrenergic O +
receptor O +
antagonist O +
) O +
blocked O +
NNK O +
- O +
induced O +
COX O +
- O +
2 O +
/ O +
PGE O +
( O +
2 O +
) O +
and O +
cell O +
proliferation O +
, O +
while O +
nicotine O +
- O +
mediated O +
cell O +
growth O +
and O +
COX O +
- O +
2 O +
/ O +
PGE O +
( O +
2 O +
) O +
induction O +
can O +
only O +
be O +
suppressed O +
by O +
propranolol O +
, O +
but O +
not O +
alpha O +
- O +
BTX O +
. O -

Moreover O +
, O +
in O +
contrast O +
to O +
the O +
dependence O +
of O +
growth O +
promoting O +
effect O +
of O +
nicotine O +
on O +
Erk O +
activation O +
, O +
inhibitor O +
of O +
p38 O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
repressed O +
NNK O +
- O +
induced O +
COX O +
- O +
2 O +
upregulation O +
and O +
resulted O +
in O +
suppression O +
of O +
cell O +
growth O +
. O -

In O +
addition O +
, O +
nicotine O +
and O +
NNK O +
mediated O +
COX O +
- O +
2 O +
induction O +
via O +
different O +
receptors O +
to O +
modulate O +
several O +
G1 O +
/ O +
S O +
transition O +
regulatory O +
proteins O +
and O +
promote O +
gastric O +
cancer O +
cell O +
growth O +
. O -

Selective O +
COX O +
- O +
2 O +
inhibitor O +
( O +
SC O +
- O +
236 O +
) O +
caused O +
G1 O +
arrest O +
and O +
abrogated O +
nicotine O +
/ O +
NNK O +
- O +
induced O +
cell O +
proliferation O +
. O -

Aberrant O +
expression O +
of O +
cyclin O +
D1 O +
and O +
other O +
G1 O +
regulatory O +
proteins O +
are O +
reversed O +
by O +
blockade O +
of O +
COX O +
- O +
2 O +
. O -

These O +
results O +
pointed O +
to O +
the O +
importance O +
of O +
adrenergic O +
and O +
nicotinic O +
receptors O +
in O +
gastric B-Disease +
tumor L-Disease +
growth O +
through O +
MAPK O +
/ O +
COX O +
- O +
2 O +
activation O +
, O +
which O +
may O +
perhaps O +
provide O +
a O +
chemoprevention O +
strategy O +
for O +
cigarette O +
smoke O +
- O +
related O +
gastric B-Disease +
carcinogenesis L-Disease +
. O -

Selenium O +
nanoparticles O +
fabricated O +
in O +
Undaria O +
pinnatifida O +
polysaccharide O +
solutions O +
induce O +
mitochondria O +
- O +
mediated O +
apoptosis O +
in O +
A375 O +
human O +
melanoma O +
cells O +
. O -

Selenium O +
nanoparticle O +
( O +
Nano O +
- O +
Se O +
) O +
is O +
a O +
novel O +
Se O +
species O +
with O +
novel O +
biological O +
activities O +
and O +
low O +
toxicity O +
. O -

In O +
the O +
present O +
study O +
, O +
we O +
demonstrated O +
a O +
simple O +
method O +
for O +
synthesis O +
of O +
size O +
- O +
controlled O +
Nano O +
- O +
Se O +
by O +
adding O +
Undaria O +
pinnatifida O +
polysaccharides O +
to O +
the O +
redox O +
system O +
of O +
selenite O +
and O +
ascorbic O +
acid O +
. O -

A O +
panel O +
of O +
four O +
human O +
cancer O +
cell O +
lines O +
was O +
shown O +
to O +
be O +
susceptible O +
to O +
Nano O +
- O +
Se O +
, O +
with O +
IC O +
( O +
50 O +
) O +
values O +
ranging O +
from O +
3.0 O +
to O +
14.1 O +
microM O +
. O -

Treatment O +
of O +
A375 O +
human O +
melanoma O +
cells O +
with O +
the O +
Nano O +
- O +
Se O +
resulted O +
in O +
dose O +
- O +
dependent O +
cell O +
apoptosis O +
as O +
indicated O +
by O +
DNA O +
fragmentation O +
and O +
phosphatidylserine O +
translocation O +
. O -

Further O +
investigation O +
on O +
intracellular O +
mechanisms O +
found O +
that O +
Nano O +
- O +
Se O +
treatment O +
triggered O +
apoptotic O +
cell O +
death O +
in O +
A375 O +
cells O +
with O +
the O +
involvement O +
of O +
oxidative O +
stress O +
and O +
mitochondrial O +
dysfunction O +
. O -

Our O +
results O +
suggest O +
that O +
Nano O +
- O +
Se O +
may O +
be O +
a O +
candidate O +
for O +
further O +
evaluation O +
as O +
a O +
chemopreventive O +
and O +
chemotherapeutic O +
agent O +
for O +
human O +
cancers O +
, O +
especially O +
melanoma B-Disease +
cancer L-Disease +
. O -

An O +
EORTC O +
phase O +
I O +
study O +
of O +
Bortezomib O +
in O +
combination O +
with O +
oxaliplatin O +
, O +
leucovorin O +
and O +
5 O +
- O +
fluorouracil O +
in O +
patients O +
with O +
advanced O +
colorectal B-Disease +
cancer L-Disease +
. O -

The O +
combination O +
of O +
oxaliplatin O +
, O +
leucovorin O +
and O +
5 O +
- O +
fluorouracil O +
( O +
FOLFOX O +
- O +
4 O +
) O +
is O +
still O +
a O +
reference O +
regimen O +
in O +
advanced O +
colorectal B-Disease +
cancer L-Disease +
; O +
however O +
, O +
the O +
addition O +
of O +
new O +
biologic O +
compounds O +
represents O +
a O +
significant O +
way O +
forward O +
. O -

Bortezomib O +
is O +
an O +
inhibitor O +
of O +
proteasome O +
, O +
a O +
multicatalytic O +
enzyme O +
complex O +
that O +
degrades O +
several O +
intracellular O +
proteins O +
. O -

In O +
this O +
study O +
, O +
escalating O +
doses O +
of O +
Bortezomib O +
were O +
administered O +
along O +
with O +
the O +
standard O +
FOLFOX O +
- O +
4 O +
doses O +
, O +
in O +
order O +
to O +
evaluate O +
the O +
dose B-Disease +
- I-Disease +
limiting I-Disease +
toxicity L-Disease +
( O +
DLT U-Disease +
) O +
, O +
toxicity O +
profile O +
and O +
activity O +
of O +
the O +
combination O +
. O -

Patients O +
with O +
advanced O +
colorectal B-Disease +
cancer L-Disease +
, O +
unpretreated O +
for O +
metastatic B-Disease +
disease L-Disease +
, O +
were O +
enroled O +
in O +
the O +
study O +
. O -

Bortezomib O +
starting O +
dose O +
was O +
1.3 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
, O +
which O +
was O +
to O +
be O +
escalated O +
in O +
the O +
subsequent O +
steps O +
according O +
to O +
the O +
toxicities O +
observed O +
after O +
first O +
cycle O +
. O -

Exploratory O +
pharmacogenetics O +
research O +
was O +
conducted O +
by O +
analysing O +
the O +
association O +
between O +
clinical O +
outcomes O +
and O +
polymorphisms O +
in O +
candidate O +
genes O +
for O +
response O +
to O +
each O +
of O +
the O +
used O +
drugs O +
. O -

Correlation O +
between O +
tumour O +
marker O +
changes O +
and O +
response O +
was O +
also O +
investigated O +
. O -

One O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
( O +
DL O +
- O +
1 O +
) O +
was O +
defined O +
as O +
being O +
the O +
maximum O +
tolerated O +
dose O +
since O +
only O +
1 O +
DLT O +
was O +
observed O +
in O +
6 O +
patients O +
. O -

The O +
main O +
toxicities O +
were O +
haematologic O +
, O +
neuropathy U-Disease +
, O +
diarrhoea U-Disease +
and O +
fatigue U-Disease +
. O -

Amongst O +
13 O +
evaluable O +
patients O +
, O +
five O +
had O +
a O +
partial O +
response O +
, O +
five O +
had O +
a O +
stable O +
disease O +
and O +
three O +
patients O +
progressed O +
. O -

Two O +
patients O +
are O +
long O +
- O +
term O +
survivors O +
after O +
a O +
combined O +
chemosurgical O +
approach O +
. O -

Further O +
trials O +
of O +
the O +
current O +
combination O +
may O +
be O +
justified O +
. O -

Derivation O +
of O +
a O +
chronic O +
reference O +
dose O +
and O +
reference O +
concentration O +
for O +
trimethylbenzenes O +
and O +
C9 O +
aromatic O +
hydrocarbon O +
solvents O +
. O -

Trimethylbenzenes O +
( O +
TMBs O +
) O +
and O +
C9 O +
aromatic O +
hydrocarbon O +
solvents O +
are O +
structurally O +
similar O +
and O +
have O +
similar O +
toxicity O +
. O -

Based O +
on O +
a O +
review O +
of O +
the O +
entire O +
TMB O +
and O +
C9 O +
aromatic O +
hydrocarbon O +
solvents O +
toxicology O +
database O +
, O +
oral O +
and O +
inhalation O +
studies O +
were O +
identified O +
to O +
serve O +
as O +
the O +
basis O +
for O +
a O +
Reference O +
dose O +
( O +
RfD O +
) O +
and O +
Reference O +
concentrations O +
( O +
RfC O +
) O +
. O -

The O +
RfD O +
and O +
RfC O +
were O +
derived O +
using O +
standard O +
USEPA O +
methods O +
and O +
assumptions O +
. O -

The O +
RfD O +
was O +
calculated O +
to O +
be O +
0.4 O +
mg O +
/ O +
kg O +
/ O +
day O +
using O +
a O +
90 O +
- O +
day O +
oral O +
study O +
that O +
resulted O +
in O +
a O +
NOAEL O +
of O +
600 O +
mg O +
/ O +
kg O +
/ O +
day O +
, O +
based O +
on O +
a O +
lack O +
of O +
adverse O +
effects O +
at O +
the O +
highest O +
dose O +
level O +
( O +
reversible O +
effects O +
such O +
as O +
increased O +
serum O +
phosphorus O +
levels O +
and O +
liver O +
and O +
kidney O +
weights O +
) O +
, O +
along O +
with O +
a O +
total O +
uncertainty O +
factor O +
of O +
1000 O +
. O -

For O +
the O +
RfC O +
, O +
three O +
studies O +
were O +
considered O +
based O +
on O +
different O +
study O +
designs O +
and O +
toxicological O +
endpoints O +
, O +
including O +
neurotoxicity U-Disease +
, O +
systemic B-Disease +
toxicity L-Disease +
, O +
and O +
potential O +
developmental O +
and O +
reproductive B-Disease +
toxicity L-Disease +
. O -

For O +
all O +
three O +
studies O +
, O +
as O +
the O +
calculated O +
RfCs O +
were O +
consistent O +
( O +
3 O -
- O -
4 O +
mg O +
/ O +
m3 O +
) O +
, O +
the O +
most O +
conservative O +
RfC O +
, O +
3 O -
mg O +
/ O +
m3 O +
, O +
was O +
selected O +
. O -

The O +
C9 O +
aromatic O +
hydrocarbon O +
solvents O +
referred O +
to O +
herein O +
are O +
based O +
on O +
chemistries O +
assessed O +
as O +
part O +
of O +
the O +
TSCA O +
Section O +
4 O +
Test O +
Rule O +
. O -

These O +
solvents O +
contain O +
primarily O +
ethyl O +
toluene O +
and O +
tri O +
- O +
methyl O +
benzene O +
isomers O +
, O +
but O +
the O +
specific O +
compositions O +
can O +
vary O +
based O +
on O +
feedstock O +
and O +
manufacturing O +
process O +
, O +
thus O +
, O +
it O +
is O +
important O +
to O +
consider O +
the O +
composition O +
of O +
any O +
specific O +
solvent O +
to O +
assess O +
similarity O +
to O +
that O +
assessed O +
in O +
the O +
TSCA O +
Section O +
4 O +
Test O +
Rule O +
program O +
. O -

Fatal O +
toxic B-Disease +
epidermal I-Disease +
necrolysis L-Disease +
and O +
severe O +
granulocytopenia U-Disease +
following O +
therapy O +
with O +
cefuroxime O +
. O -

Toxic B-Disease +
epidermal I-Disease +
necrolysis L-Disease +
( O +
TEN U-Disease +
) O +
is O +
one O +
of O +
the O +
most O +
threatening O +
adverse O +
reactions O +
to O +
various O +
drugs O +
. O -

No O +
case O +
of O +
concomitant O +
occurrence O +
TEN U-Disease +
and O +
severe O +
granulocytopenia U-Disease +
following O +
the O +
treatment O +
with O +
cefuroxime O +
has O +
been O +
reported O +
to O +
date O +
. O -

Herein O +
we O +
present O +
a O +
case O +
of O +
TEN U-Disease +
that O +
developed O +
eighteen O +
days O +
of O +
the O +
initiation O +
of O +
cefuroxime O +
axetil O +
therapy O +
for O +
urinary B-Disease +
tract I-Disease +
infection L-Disease +
in O +
a O +
73 O +
- O +
year O +
- O +
old O +
woman O +
with O +
chronic B-Disease +
renal I-Disease +
failure L-Disease +
and O +
no O +
previous O +
history O +
of O +
allergic B-Disease +
diathesis L-Disease +
. O -

The O +
condition O +
was O +
associated O +
with O +
severe O +
granulocytopenia U-Disease +
and O +
followed O +
by O +
gastrointestinal B-Disease +
hemorrhage L-Disease +
, O +
severe O +
sepsis U-Disease +
and O +
multiple B-Disease +
organ I-Disease +
failure I-Disease +
syndrome L-Disease +
development O +
. O -

Despite O +
intensive O +
medical O +
treatment O +
the O +
patient O +
died O +
. O -

The O +
present O +
report O +
underlines O +
the O +
potential O +
of O +
cefuroxime O +
to O +
simultaneously O +
induce O +
life O +
threatening O +
adverse O +
effects O +
such O +
as O +
TEN U-Disease +
and O +
severe O +
granulocytopenia U-Disease +
. O -

Further O +
on O +
, O +
because O +
the O +
patient O +
was O +
also O +
taking O +
furosemide O +
for O +
chronic B-Disease +
renal I-Disease +
failure L-Disease +
, O +
the O +
possible O +
unfavorable O +
interactions O +
between O +
the O +
two O +
drugs O +
could O +
be O +
hypothesized O +
. O -

Therefore O +
, O +
awareness O +
of O +
the O +
possible O +
drug O +
interaction O +
is O +
necessary O +
, O +
especially O +
when O +
given O +
in O +
conditions O +
of O +
their O +
altered O +
pharmacokinetics O +
as O +
in O +
case O +
of O +
chronic B-Disease +
renal I-Disease +
failure L-Disease +
. O -

Spatial O +
and O +
temporal O +
aspects O +
of O +
muscle B-Disease +
hyperalgesia L-Disease +
induced O +
by O +
nerve O +
growth O +
factor O +
in O +
humans O +
. O -

Intramuscular O +
injection O +
of O +
nerve O +
growth O +
factor O +
( O +
NGF O +
) O +
has O +
been O +
shown O +
to O +
induce O +
long O +
- O +
term O +
sensitisation O +
and O +
time O +
- O +
dependent O +
hyperalgesia U-Disease +
indicating O +
potential O +
involvement O +
of O +
both O +
central O +
and O +
peripheral O +
pain U-Disease +
mechanisms O +
. O -

This O +
double O +
- O +
blind O +
placebo O +
- O +
controlled O +
study O +
was O +
designed O +
to O +
describe O +
the O +
spatial O +
distribution O +
of O +
muscle B-Disease +
hyperalgesia L-Disease +
over O +
time O +
( O +
immediately O +
after O +
, O +
3 O +
h O +
, O +
1 O +
, O +
4 O +
, O +
7 O +
and O +
21 O +
days O +
) O +
after O +
injecting O +
NGF O +
( O +
5 O +
mug O +
) O +
into O +
the O +
tibialis O +
anterior O +
( O +
TA O +
) O +
muscle O +
, O +
to O +
explore O +
possibly O +
involved O +
central O +
pain U-Disease +
mechanisms O +
and O +
to O +
investigate O +
the O +
effect O +
of O +
gender O +
on O +
development O +
of O +
hyperalgesia U-Disease +
. O -

Totally O +
20 O +
healthy O +
volunteers O +
( O +
10 O +
men O +
and O +
10 O +
women O +
) O +
participated O +
in O +
the O +
study O +
. O -

An O +
isotonic O +
saline O +
injection O +
into O +
the O +
contralateral O +
TA O +
muscle O +
served O +
as O +
a O +
control O +
condition O +
for O +
the O +
NGF O +
injection O +
. O -

Pressure O +
pain U-Disease +
thresholds O +
( O +
PPT O +
) O +
were O +
used O +
to O +
test O +
for O +
muscle B-Disease +
hyperalgesia L-Disease +
along O +
the O +
TA O +
( O +
seven O +
sites O +
) O +
muscle O +
at O +
the O +
extensor O +
digitorum O +
longus O +
and O +
at O +
the O +
web O +
between O +
1st O +
and O +
2nd O +
metatarsal O +
( O +
central O +
involvement O +
) O +
. O -

One O +
day O +
after O +
the O +
NGF O +
/ O +
control O +
injections O +
, O +
hypertonic O +
saline O +
( O +
0.5 O +
ml O +
, O +
5.8 O -
% O +
) O +
was O +
injected O +
into O +
the O +
left O +
and O +
right O +
TA O +
to O +
study O +
the O +
pain U-Disease +
response O +
to O +
chemical O +
stimulation O +
of O +
the O +
hyperalgesic O +
muscle O +
tissue O +
. O -

Scores O +
on O +
a O +
modified O +
Likert O +
scale O +
were O +
used O +
to O +
assess O +
soreness O +
during O +
muscle O +
function O +
. O -

An O +
area O +
of O +
hyperalgesia U-Disease +
was O +
observed O +
locally O +
at O +
the O +
injected O +
site O +
3 O +
h O +
after O +
injection O +
of O +
NGF O +
, O +
which O +
expanded O +
both O +
proximally O +
and O +
distally O +
on O +
day O +
1 O +
; O +
this O +
effect O +
subsided O +
on O +
day O +
4 O +
. O -

Decreased O +
PPT O +
was O +
also O +
found O +
between O +
1st O +
and O +
2nd O +
metatarsal O +
on O +
day O +
1 O +
. O -

Hypertonic O +
saline O +
evoked O +
more O +
pain U-Disease +
in O +
men O +
when O +
injected O +
in O +
the O +
NGF O +
treated O +
TA O +
compared O +
to O +
the O +
control O +
leg O +
. O -

Injection O +
of O +
NGF O +
increased O +
muscle B-Disease +
soreness L-Disease +
during O +
muscle O +
activity O +
for O +
7 O +
days O +
. O -

In O +
this O +
material O +
there O +
was O +
no O +
gender O +
effect O +
of O +
NGF O +
- O +
induced O +
muscle B-Disease +
hyperalgesia L-Disease +
. O -

The O +
expansion O +
of O +
muscle B-Disease +
hyperalgesia L-Disease +
to O +
distant O +
areas O +
indicates O +
that O +
central O +
mechanisms O +
are O +
involved O +
. O -

Occupational O +
hazard O +
: O +
treating O +
cocaine O +
body O +
packers O +
in O +
Caribbean O +
countries O +
. O -

Body O +
packing O +
is O +
a O +
common O +
method O +
of O +
smuggling O +
cocaine O +
where O +
individuals O +
ingest O +
several O +
drug O +
- O +
filled O +
parcels O +
for O +
transport O +
. O -

When O +
identified O +
by O +
the O +
authorities O +
, O +
body O +
packers O +
are O +
usually O +
taken O +
to O +
hospital O +
for O +
evaluation O +
. O -

There O +
are O +
several O +
points O +
during O +
management O +
of O +
these O +
patients O +
when O +
the O +
health O +
care O +
team O +
may O +
be O +
placed O +
at O +
risk O +
. O -

We O +
explore O +
the O +
hazards O +
encountered O +
during O +
the O +
management O +
of O +
these O +
patients O +
in O +
developing O +
Caribbean O +
nations O +
. O -

The O +
addition O +
of O +
rituximab O +
to O +
front O +
- O +
line O +
therapy O +
with O +
CHOP O +
( O +
R O +
- O +
CHOP O +
) O +
results O +
in O +
a O +
higher O +
response O +
rate O +
and O +
longer O +
time O +
to O +
treatment O +
failure O +
in O +
patients O +
with O +
lymphoplasmacytic B-Disease +
lymphoma L-Disease +
: O +
results O +
of O +
a O +
randomized O +
trial O +
of O +
the O +
German O +
Low O +
- O +
Grade O +
Lymphoma U-Disease +
Study O +
Group O +
( O +
GLSG O +
) O +
. O -

Lymphoplasmacytic B-Disease +
lymphoma L-Disease +
( O +
LPL U-Disease +
) O +
is O +
an O +
indolent O +
lymphoma U-Disease +
with O +
moderate O +
sensitivity O +
to O +
conventional O +
chemotherapy O +
. O -

This O +
study O +
investigated O +
whether O +
the O +
addition O +
of O +
rituximab O +
to O +
standard O +
chemotherapy O +
improves O +
treatment O +
outcome O +
in O +
LPL U-Disease +
and O +
the O +
subgroup O +
of O +
LPL U-Disease +
patients O +
fulfilling O +
the O +
criteria O +
of O +
Waldenstroem B-Disease +
's I-Disease +
macroglobulinemia L-Disease +
( O +
WM U-Disease +
) O +
. O -

A O +
total O +
of O +
69 O +
patients O +
with O +
previously O +
untreated O +
LPL U-Disease +
were O +
enrolled O +
into O +
the O +
trial O +
; O +
64 O +
patients O +
were O +
evaluable O +
for O +
treatment O +
outcome O +
. O -

In O +
all O +
, O +
48 O +
of O +
the O +
64 O +
LPL U-Disease +
patients O +
fulfilled O +
the O +
criteria O +
of O +
WM O +
. O -

Patients O +
were O +
randomly O +
assigned O +
to O +
R O +
- O +
CHOP O +
( O +
rituximab O +
, O +
cyclophosphamide O +
, O +
doxorubicin O +
, O +
vincristine O +
and O +
prednisone O +
, O +
n O +
= O +
34 O +
) O +
or O +
CHOP O +
( O +
n O +
= O +
30 O +
) O +
. O -

R O +
- O +
CHOP O +
resulted O +
in O +
significantly O +
higher O +
overall O +
response O +
( O +
OR O +
) O +
rate O +
( O +
94 O +
vs O +
67 O -
% O +
, O +
P O +
= O +
0.0085 O +
) O +
in O +
the O +
LPL U-Disease +
patients O +
and O +
in O +
the O +
WM U-Disease +
subgroup O +
( O +
91 O +
vs O +
60 O -
% O +
, O +
P O +
= O +
0.0188 O +
) O +
. O -

With O +
a O +
median O +
observation O +
time O +
of O +
42 O +
months O +
, O +
R O +
- O +
CHOP O +
induced O +
a O +
significantly O +
longer O +
time O +
to O +
treatment O +
failure O +
( O +
TTF O +
) O +
with O +
a O +
median O +
of O +
63 O +
months O +
for O +
R O +
- O +
CHOP O +
vs O +
22 O +
months O +
in O +
the O +
CHOP O +
arm O +
in O +
the O +
LPL U-Disease +
patients O +
( O +
P O +
= O +
0.0033 O +
) O +
and O +
in O +
the O +
WM U-Disease +
subgroup O +
( O +
P O +
= O +
0.0241 O +
) O +
. O -

There O +
was O +
no O +
major O +
difference O +
of O +
treatment B-Disease +
- I-Disease +
associated I-Disease +
toxicity L-Disease +
between O +
both O +
treatment O +
groups O +
. O -

These O +
data O +
indicate O +
that O +
the O +
addition O +
of O +
rituximab O +
to O +
front O +
- O +
line O +
chemotherapy O +
improves O +
treatment O +
outcome O +
in O +
patients O +
with O +
LPL U-Disease +
or O +
WM U-Disease +
. O -

Novel O +
therapeutic O +
agents O +
targeting O +
the O +
glucocorticoid O +
receptor O +
for O +
inflammation U-Disease +
and O +
cancer U-Disease +
. O -

Glucocorticoids O +
, O +
through O +
their O +
interaction O +
with O +
the O +
ubiquitous O +
glucocorticoid O +
receptor O +
( O +
GR O +
) O +
, O +
have O +
extensive O +
and O +
disparate O +
effects O +
on O +
different O +
cells O +
and O +
tissues O +
. O -

They O +
have O +
long O +
been O +
used O +
in O +
the O +
treatment O +
of O +
asthma U-Disease +
, O +
arthritis U-Disease +
and O +
autoimmune B-Disease +
diseases L-Disease +
based O +
on O +
their O +
anti O +
- O +
inflammatory O +
and O +
immunosuppressive O +
effects O +
. O -

For O +
these O +
reasons O +
, O +
as O +
well O +
as O +
for O +
their O +
ability O +
to O +
induce O +
massive O +
apoptosis O +
in O +
hematological B-Disease +
malignancies L-Disease +
, O +
they O +
are O +
also O +
commonly O +
used O +
as O +
cotreatment O +
in O +
cancers U-Disease +
. O -

Despite O +
their O +
wide O +
usage O +
, O +
chronic O +
glucocorticoid O +
therapy O +
has O +
deleterious O +
side O +
effects O +
, O +
including O +
weight O +
gain O +
, O +
osteoporosis U-Disease +
and O +
diabetes B-Disease +
mellitus L-Disease +
, O +
and O +
has O +
been O +
shown O +
to O +
diminish O +
the O +
tumor B-Disease +
toxicity L-Disease +
of O +
chemotherapy O +
, O +
preventing O +
the O +
full O +
potential O +
of O +
glucocorticoid O +
treatment O +
from O +
being O +
realized O +
. O -

Technological O +
advances O +
have O +
contributed O +
to O +
a O +
better O +
understanding O +
of O +
the O +
mechanism O +
of O +
glucocorticoid O +
action O +
, O +
prompting O +
the O +
development O +
of O +
tailored O +
therapeutics O +
targeting O +
the O +
desired O +
outcomes O +
of O +
GR O +
signaling O +
. O -

This O +
review O +
discusses O +
recent O +
advances O +
in O +
the O +
development O +
of O +
novel O +
therapeutic O +
agents O +
for O +
inflammation U-Disease +
and O +
cancer U-Disease +
through O +
targeting O +
the O +
GR O +
. O -

Inhibition O +
of O +
hydroxyapatite O +
dissolution O +
by O +
whole O +
casein O +
: O +
the O +
effects O +
of O +
pH O +
, O +
protein O +
concentration O +
, O +
calcium O +
, O +
and O +
ionic O +
strength O +
. O -

Formulating O +
drinks O +
with O +
reduced O +
erosive O +
potential O +
is O +
one O +
approach O +
for O +
reducing O +
dental O +
erosion O +
. O -

In O +
this O +
study O +
, O +
whole O +
casein O +
was O +
added O +
to O +
citric O +
acid O +
solutions O +
representative O +
of O +
soft O +
drinks O +
, O +
and O +
the O +
hydroxyapatite O +
dissolution O +
rate O +
was O +
assessed O +
. O -

Adding O +
0.02 O -
% O +
( O +
w O +
/ O +
v O +
) O +
casein O +
to O +
acid O +
solutions O +
significantly O +
reduced O +
the O +
hydroxyapatite O +
dissolution O +
rate O +
by O +
51 O +
+ O +
/ O +
- O +
4 O -
% O +
at O +
pH O +
values O +
of O +
2.80 O +
, O +
3.00 O +
, O +
3.20 O +
, O +
3.40 O +
, O +
and O +
3.60 O +
, O +
although O +
the O +
baseline O +
dissolution O +
rates O +
of O +
course O +
varied O +
as O +
a O +
function O +
of O +
pH O +
. O -

The O +
protein O +
concentration O +
[ O +
0.002 O +
, O +
0.02 O +
, O +
and O +
0.2 O -
% O +
( O +
w O +
/ O +
v O +
) O +
casein O +
] O +
had O +
no O +
significant O +
effect O +
on O +
dissolution O +
inhibition O +
. O -

Adding O +
both O +
casein O +
and O +
calcium O +
to O +
citric O +
acid O +
resulted O +
in O +
a O +
further O +
reduction O +
in O +
the O +
dissolution O +
rate O +
at O +
low O +
and O +
intermediate O +
calcium O +
concentrations O +
( O +
5 O +
and O +
10 O +
mM O +
) O +
but O +
not O +
at O +
higher O +
calcium O +
concentrations O +
( O +
20 O +
and O +
50 O +
mM O +
) O +
. O -

Ionic O +
strength O +
had O +
no O +
significant O +
impact O +
on O +
the O +
efficacy O +
of O +
casein O +
. O -

Casein O +
also O +
significantly O +
reduced O +
the O +
hydroxyapatite O +
dissolution O +
rate O +
when O +
the O +
hydroxyapatite O +
was O +
coated O +
with O +
a O +
salivary O +
pellicle O +
. O -

The O +
reduction O +
in O +
dissolution O +
rate O +
is O +
ascribed O +
to O +
firmly O +
adsorbed O +
casein O +
on O +
the O +
hydroxyapatite O +
surface O +
, O +
which O +
stabilizes O +
the O +
crystal O +
surface O +
and O +
inhibits O +
ion O +
detachment O +
. O -

A O +
phase O +
II O +
study O +
of O +
oxaliplatin O +
, O +
pemetrexed O +
, O +
and O +
bevacizumab O +
in O +
previously O +
treated O +
advanced O +
non B-Disease +
- I-Disease +
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
. O -

INTRODUCTION O +
: O +
Single O +
agent O +
chemotherapy O +
is O +
standard O +
for O +
second O +
and O +
third O +
line O +
treatment O +
of O +
non B-Disease +
- I-Disease +
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
( O +
NSCLC U-Disease +
) O +
. O -

Combination O +
therapy O +
to O +
date O +
has O +
not O +
proven O +
to O +
be O +
superior O +
to O +
single O +
agents O +
in O +
this O +
setting O +
, O +
often O +
adding O +
toxicity O +
without O +
any O +
additional O +
efficacy O +
. O -

We O +
investigated O +
the O +
activity O +
and O +
tolerability O +
of O +
the O +
combination O +
of O +
oxaliplatin O +
, O +
pemetrexed O +
, O +
and O +
bevacizumab O +
in O +
patients O +
with O +
previously O +
treated O +
advanced O +
NSCLC U-Disease +
. O -

METHODS O +
: O +
This O +
multicenter O +
phase O +
II O +
trial O +
evaluated O +
the O +
safety O +
and O +
efficacy O +
of O +
the O +
combination O +
of O +
pemetrexed O +
( O +
500 O +
mg O +
/ O +
m O +
) O +
, O +
oxaliplatin O +
( O +
120 O +
mg O +
/ O +
m O +
) O +
, O +
and O +
bevacizumab O +
( O +
15 O +
mg O +
/ O +
kg O +
) O +
, O +
given O +
every O +
21 O +
days O +
, O +
in O +
patients O +
with O +
previously O +
treated O +
advanced O +
NSCLC U-Disease +
. O -

Eligibility O +
criteria O +
included O +
performance O +
status O +
0 O +
to O +
1 O +
, O +
nonsquamous O +
histology O +
, O +
and O +
at O +
least O +
one O +
prior O +
chemotherapy O +
regimen O +
. O -

Patients O +
with O +
treated O +
brain B-Disease +
metastases L-Disease +
were O +
allowed O +
. O -

The O +
primary O +
end O +
point O +
was O +
response O +
rate O +
, O +
with O +
secondary O +
endpoints O +
of O +
progression O +
- O +
free O +
survival O +
and O +
overall O +
survival O +
. O -

RESULTS O +
: O +
Thirty O +
- O +
six O +
patients O +
were O +
enrolled O +
on O +
this O +
study O +
. O -

Treatment O +
was O +
well O +
tolerated O +
; O +
the O +
most O +
common O +
grade O +
3 O +
toxicity O +
was O +
hypertension U-Disease +
, O +
which O +
was O +
easily O +
managed O +
with O +
oral O +
medications O +
. O -

The O +
nine O +
( O +
25 O -
% O +
) O +
patients O +
with O +
treated O +
brain B-Disease +
metastases L-Disease +
had O +
no O +
episodes O +
of O +
cerebral B-Disease +
hemorrhage L-Disease +
. O -

Of O +
the O +
34 O +
patients O +
evaluable O +
for O +
tumor U-Disease +
response O +
, O +
none O +
had O +
complete O +
response O +
, O +
nine O +
( O +
27 O -
% O +
) O +
had O +
partial O +
response O +
, O +
15 O +
( O +
44 O -
% O +
) O +
had O +
stable O +
disease O +
, O +
and O +
10 O +
( O +
29 O -
% O +
) O +
had O +
progressive O +
disease O +
. O -

Median O +
progression O +
- O +
free O +
survival O +
was O +
5.8 O +
months O +
( O +
95 O -
% O +
confidence O +
interval O +
4.1 O -
- O -
7.8 O +
months O +
) O +
and O +
median O +
overall O +
survival O +
was O +
12.5 O +
months O +
( O +
95 O -
% O +
confidence O +
interval O +
7.3 O -
- O -
17 O +
months O +
) O +
. O -

CONCLUSIONS O +
: O +
Treatment O +
with O +
oxaliplatin O +
and O +
pemetrexed O +
in O +
combination O +
with O +
the O +
targeted O +
antiangiogenic O +
agent O +
bevacizumab O +
yielded O +
promising O +
efficacy O +
with O +
manageable O +
toxicity O +
in O +
the O +
previously O +
treated O +
advanced O +
NSCLC U-Disease +
population O +
. O -

Early O +
- O +
onset O +
pancytopenia U-Disease +
and O +
skin B-Disease +
ulcer L-Disease +
following O +
low O +
- O +
dose O +
methotrexate O +
therapy O +
. O -

Pancytopenia U-Disease +
is O +
a O +
rare O +
but O +
serious O +
adverse O +
effect O +
of O +
low O +
- O +
dose O +
methotrexate O +
( O +
MTX O +
) O +
sodium O +
therapy O +
, O +
and O +
this O +
case O +
report O +
describes O +
a O +
very O +
early O +
- O +
onset O +
of O +
pancytopenia U-Disease +
and O +
cutaneous B-Disease +
lesions L-Disease +
after O +
three O +
days O +
of O +
ingestion O +
. O -

A O +
64 O +
- O +
year O +
- O +
old O +
man O +
was O +
presented O +
to O +
Emergency O +
Department O +
with O +
weakness U-Disease +
, O +
fever U-Disease +
, O +
poor B-Disease +
appetite L-Disease +
, O +
nausea U-Disease +
, O +
and O +
vomiting U-Disease +
after O +
he O +
had O +
had O +
accidentally O +
ingested O +
MTX O +
tablets O +
( O +
2.5 O +
mg O +
) O +
twice O +
a O +
day O +
for O +
the O +
last O +
three O +
days O +
. O -

On O +
initial O +
examination O +
, O +
several O +
painful B-Disease +
lesions L-Disease +
in O +
his O +
oral O +
mucosa O +
and O +
a O +
cutaneous B-Disease +
ulceration L-Disease +
on O +
his O +
right O +
foot O +
were O +
also O +
observed O +
. O -

He O +
had O +
severe O +
pancytopenia U-Disease +
, O +
poor O +
kidney O +
functions O +
, O +
and O +
abnormal B-Disease +
coagulation L-Disease +
parameters O +
. O -

The O +
blood O +
level O +
of O +
MTX O +
was O +
found O +
to O +
be O +
within O +
therapeutic O +
range O +
. O -

He O +
was O +
treated O +
with O +
leucovorine O +
, O +
intravenous O +
antibiotics O +
, O +
and O +
appropriate O +
blood O +
transfusions O +
; O +
he O +
was O +
discharged O +
from O +
hospital O +
without O +
any O +
sequela O +
. O -

Pancytopenia U-Disease +
associated O +
with O +
low O +
- O +
dose O +
( O +
cumulative O +
dose O +
of O +
15 O +
mg O +
in O +
3 O +
days O +
) O +
MTX O +
therapy O +
had O +
not O +
been O +
reported O +
previously O +
. O -

The O +
Naranjo O +
probability O +
scale O +
showed O +
pancytopenia U-Disease +
and O +
skin B-Disease +
ulcer L-Disease +
associated O +
with O +
low O +
- O +
dose O +
MTX O +
therapy O +
as O +
probable O +
adverse O +
reactions O +
. O -

Risk O +
factors O +
for O +
pancytopenia U-Disease +
such O +
as O +
renal B-Disease +
insufficiency L-Disease +
, O +
hypoalbuminemia U-Disease +
, O +
low O +
folate O +
levels O +
, O +
concomitant B-Disease +
infections L-Disease +
, O +
concomitant O +
use O +
of O +
drugs O +
, O +
and O +
folate O +
supplementation O +
were O +
not O +
identified O +
in O +
our O +
patient O +
. O -

Although O +
pancytopenia U-Disease +
associated O +
with O +
low O +
- O +
dose O +
MTX O +
therapy O +
is O +
not O +
expected O +
as O +
early O +
as O +
3 O +
days O +
after O +
initiation O +
of O +
the O +
therapy O +
, O +
physicians O +
should O +
also O +
be O +
aware O +
of O +
this O +
life O +
threatening O +
adverse O +
effect O +
during O +
the O +
very O +
first O +
days O +
of O +
MTX O +
therapy O +
for O +
rheumatoid B-Disease +
arthritis L-Disease +
patients O +
. O -

Limited O +
place O +
for O +
plasma O +
monitoring O +
of O +
new O +
antiepileptic O +
drugs O +
in O +
clinical O +
practice O +
. O -

Therapeutic O +
drug O +
monitoring O +
( O +
TDM O +
) O +
has O +
been O +
recognized O +
as O +
a O +
useful O +
guide O +
in O +
the O +
clinical O +
management O +
of O +
patients O +
with O +
epilepsy U-Disease +
, O +
in O +
particular O +
those O +
on O +
therapy O +
with O +
traditional O +
antiepileptic O +
drugs O +
( O +
AEDs O +
) O +
. O -

The O +
demonstration O +
of O +
significant O +
drug O +
interactions O +
and O +
the O +
introduction O +
of O +
the O +
concept O +
" O +
therapeutic O +
range O +
" O +
have O +
also O +
contributed O +
to O +
the O +
view O +
that O +
monotherapy O +
should O +
be O +
considered O +
the O +
" O +
gold O +
standard O +
" O +
in O +
the O +
treatment O +
of O +
epilepsy U-Disease +
. O -

Ten O +
new O +
AEDs O +
have O +
been O +
approved O +
and O +
released O +
to O +
the O +
market O +
in O +
the O +
last O +
fifteen O +
years O +
. O -

The O +
most O +
obvious O +
consequence O +
has O +
been O +
an O +
increased O +
number O +
of O +
patients O +
on O +
polytherapy O +
. O -

In O +
general O +
, O +
newer O +
AEDs O +
have O +
better O +
and O +
more O +
predictable O +
pharmacokinetics O +
than O +
older O +
AEDs O +
and O +
usually O +
show O +
lower O +
risk O +
of O +
interactions O +
leading O +
to O +
toxicity O +
as O +
well O +
as O +
large O +
therapeutic O +
indexes O +
. O -

This O +
pragmatic O +
review O +
focuses O +
on O +
practical O +
suggestions O +
about O +
the O +
potential O +
clinical O +
usefulness O +
of O +
TDM O +
of O +
newer O +
AEDs O +
in O +
relation O +
to O +
their O +
mechanism O +
of O +
action O +
and O +
pharmacokinetic O +
characteristics O +
and O +
in O +
response O +
to O +
patient O +
- O +
specific O +
problems O +
. O -

Overall O +
, O +
the O +
usefulness O +
of O +
TDM O +
of O +
newer O +
AEDs O +
seems O +
to O +
be O +
limited O +
and O +
its O +
indiscriminate O +
use O +
is O +
not O +
justified O +
. O -

However O +
, O +
in O +
selected O +
cases O +
or O +
in O +
response O +
to O +
a O +
specific O +
clinical O +
question O +
, O +
a O +
wise O +
use O +
of O +
TDM O +
of O +
some O +
new O +
AEDs O +
could O +
represent O +
a O +
useful O +
tool O +
in O +
the O +
management O +
of O +
epileptic O +
patients O +
. O -

Exceptions O +
are O +
thus O +
represented O +
by O +
special O +
conditions O +
such O +
as O +
renal B-Disease +
failure L-Disease +
, O +
dialysis O +
, O +
ascertainment O +
of O +
non O +
- O +
compliance O +
, O +
and O +
pregnancy O +
. O -

For O +
some O +
new O +
AEDs O +
, O +
TDM O +
could O +
be O +
selectively O +
and O +
properly O +
used O +
in O +
response O +
to O +
a O +
single O +
patient O +
- O +
specific O +
pharmacokinetic O +
or O +
pharmacodynamic O +
issue O +
. O -

Synthesis O +
and O +
biological O +
evaluation O +
of O +
bile O +
acid O +
dimers O +
linked O +
with O +
1,2,3 O +
- O +
triazole O +
and O +
bis O +
- O +
beta O +
- O +
lactam O +
. O -

We O +
report O +
herein O +
the O +
synthesis O +
and O +
biological O +
evaluation O +
of O +
bile O +
acid O +
dimers O +
linked O +
through O +
1,2,3 O +
- O +
triazole O +
and O +
bis O +
- O +
beta O +
- O +
lactam O +
. O -

The O +
dimers O +
were O +
synthesized O +
using O +
1,3 O +
- O +
dipolar O +
cycloaddition O +
reaction O +
of O +
diazido O +
bis O +
- O +
beta O +
- O +
lactams O +
, O +
and O +
terminal O +
alkynes O +
derived O +
from O +
cholic O +
acid O +
/ O +
deoxycholic O +
acid O +
in O +
the O +
presence O +
of O +
Cu O +
( O +
i O +
) O +
catalyst O +
( O +
click O +
chemistry O +
) O +
. O -

These O +
novel O +
molecules O +
were O +
evaluated O +
in O +
vitro O +
for O +
their O +
antifungal O +
and O +
antibacterial O +
activity O +
. O -

Most O +
of O +
the O +
compounds O +
exhibited O +
significant O +
antifungal O +
as O +
well O +
as O +
antibacterial O +
activity O +
against O +
all O +
the O +
tested O +
fungal O +
and O +
bacterial O +
strains O +
. O -

Moreover O +
, O +
their O +
in O +
vitro O +
cytotoxicities U-Disease +
towards O +
HEK O +
- O +
293 O +
and O +
MCF O +
- O +
7 O +
cells O +
were O +
also O +
established O +
. O -

Platinum O +
versus O +
non O +
- O +
platinum O +
chemotherapy O +
regimens O +
for O +
small B-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
. O -

BACKGROUND O +
: O +
Small B-Disease +
cell I-Disease +
lung I-Disease +
cancer L-Disease +
( O +
SCLC U-Disease +
) O +
is O +
a O +
very O +
fast O +
growing O +
form O +
of O +
cancer U-Disease +
and O +
is O +
characterised O +
by O +
early O +
metastasis U-Disease +
. O -

As O +
a O +
result O +
, O +
chemotherapy O +
is O +
the O +
mainstay O +
of O +
treatment O +
. O -

A O +
number O +
of O +
different O +
platinum O +
- O +
based O +
chemotherapy O +
regimens O +
and O +
non O +
- O +
platinum O +
- O +
based O +
chemotherapy O +
regimens O +
have O +
been O +
used O +
for O +
the O +
treatment O +
of O +
SCLC U-Disease +
, O +
with O +
varying O +
results O +
. O -

This O +
review O +
was O +
conducted O +
to O +
analyse O +
the O +
data O +
from O +
these O +
trials O +
in O +
order O +
to O +
compare O +
their O +
effectiveness O +
. O -

OBJECTIVES O +
: O +
To O +
determine O +
the O +
effectiveness O +
of O +
platinum O +
chemotherapy O +
regimens O +
compared O +
with O +
non O +
- O +
platinum O +
chemotherapy O +
regimens O +
in O +
the O +
treatment O +
of O +
SCLC U-Disease +
with O +
respect O +
to O +
survival O +
, O +
tumour U-Disease +
response O +
, O +
toxicity O +
and O +
quality O +
of O +
life O +
. O -

SEARCH O +
STRATEGY O +
: O +
We O +
searched O +
the O +
biomedical O +
literature O +
databases O +
CENTRAL O +
( O +
The O +
Cochrane O +
Library O +
2007 O +
, O +
Issue O +
2 O +
) O +
, O +
MEDLINE O +
, O +
EMBASE O +
and O +
CINAHL O +
from O +
1966 O +
to O +
April O +
2007 O +
. O -

In O +
addition O +
, O +
we O +
handsearched O +
reference O +
lists O +
from O +
relevant O +
resources O +
. O -

SELECTION O +
CRITERIA O +
: O +
All O +
randomised O +
controlled O +
trials O +
involving O +
patients O +
with O +
pathologically O +
confirmed O +
( O +
cytological O +
or O +
histological O +
) O +
SCLC U-Disease +
and O +
the O +
use O +
of O +
a O +
platinum O +
- O +
based O +
chemotherapy O +
regimen O +
in O +
at O +
least O +
one O +
treatment O +
arm O +
and O +
a O +
non O +
- O +
platinum O +
- O +
based O +
chemotherapy O +
regimen O +
in O +
a O +
separate O +
arm O +
. O -

DATA O +
COLLECTION O +
AND O +
ANALYSIS O +
: O +
Two O +
authors O +
independently O +
assessed O +
search O +
results O +
. O -

We O +
assessed O +
included O +
studies O +
for O +
methodological O +
quality O +
and O +
recorded O +
the O +
following O +
outcome O +
data O +
: O +
survival O +
, O +
tumour U-Disease +
response O +
, O +
toxicity O +
and O +
quality O +
of O +
life O +
. O -

We O +
combined O +
the O +
results O +
of O +
the O +
survival O +
, O +
tumour U-Disease +
response O +
and O +
toxicity O +
data O +
in O +
a O +
meta O +
- O +
analysis O +
. O -

MAIN O +
RESULTS O +
: O +
A O +
total O +
of O +
29 O +
trials O +
involving O +
5530 O +
patients O +
were O +
included O +
in O +
this O +
systematic O +
review O +
. O -

There O +
was O +
no O +
statistically O +
significant O +
difference O +
between O +
treatment O +
groups O +
in O +
terms O +
of O +
survival O +
at O +
6 O +
months O +
, O +
12 O +
months O +
and O +
24 O +
months O +
. O -

There O +
was O +
also O +
no O +
statistically O +
significant O +
difference O +
in O +
terms O +
of O +
overall O +
tumour U-Disease +
response O +
. O -

However O +
, O +
platinum O +
- O +
based O +
treatment O +
regimens O +
did O +
have O +
a O +
significantly O +
higher O +
rate O +
of O +
complete O +
response O +
. O -

Platinum O +
- O +
based O +
chemotherapy O +
regimens O +
had O +
significantly O +
higher O +
rates O +
of O +
nausea U-Disease +
and O +
vomiting U-Disease +
, O +
anaemia U-Disease +
and O +
thrombocytopenia U-Disease +
toxicity O +
. O -

Three O +
trials O +
presented O +
quality O +
of O +
life O +
data O +
but O +
the O +
data O +
presented O +
were O +
not O +
complete O +
and O +
therefore O +
could O +
not O +
be O +
combined O +
in O +
a O +
meta O +
- O +
analysis O +
. O -

AUTHORS O +
' O +
CONCLUSIONS O +
: O +
Platinum O +
- O +
based O +
chemotherapy O +
regimens O +
did O +
not O +
offer O +
a O +
statistically O +
significant O +
benefit O +
in O +
survival O +
or O +
overall O +
tumour U-Disease +
response O +
compared O +
with O +
non O +
- O +
platinum O +
- O +
based O +
regimens O +
. O -

However O +
, O +
platinum O +
- O +
based O +
chemotherapy O +
regimens O +
did O +
increase O +
complete O +
response O +
rates O +
, O +
at O +
the O +
cost O +
of O +
higher O +
adverse O +
events O +
including O +
nausea U-Disease +
and O +
vomiting U-Disease +
, O +
anaemia U-Disease +
and O +
thrombocytopenia U-Disease +
toxicity O +
. O -

These O +
data O +
suggest O +
non O +
- O +
platinum O +
chemotherapy O +
regimens O +
have O +
a O +
more O +
advantageous O +
risk O +
- O +
benefit O +
profile O +
. O -

This O +
systematic O +
review O +
highlights O +
the O +
lack O +
of O +
quality O +
of O +
life O +
data O +
in O +
trials O +
involving O +
chemotherapy O +
treatment O +
for O +
SCLC U-Disease +
. O -

With O +
poor O +
long O +
- O +
term O +
survival O +
associated O +
with O +
both O +
treatment O +
groups O +
, O +
the O +
issue O +
of O +
the O +
quality O +
of O +
the O +
survival O +
period O +
takes O +
on O +
even O +
more O +
significance O +
. O -

It O +
would O +
be O +
beneficial O +
for O +
future O +
trials O +
in O +
this O +
area O +
to O +
include O +
a O +
quality O +
of O +
life O +
assessment O +
. O -

Blood O +
pressure U-Disease +
lowering O +
efficacy O +
of O +
renin O +
inhibitors O +
for O +
primary B-Disease +
hypertension L-Disease +
. O -

BACKGROUND O +
: O +
Hypertension U-Disease +
is O +
a O +
chronic O +
condition O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
mortality O +
and O +
morbidity O +
. O -

The O +
renin O +
- O +
angiotensin O +
- O +
aldosterone O +
system O +
is O +
an O +
important O +
target O +
site O +
for O +
five O +
antihypertensive O +
drug O +
classes O +
: O +
beta O +
blockers O +
, O +
renin O +
inhibitors O +
, O +
ACE O +
inhibitors O +
, O +
angiotensin O +
receptor O +
blockers O +
( O +
ARBs O +
) O +
and O +
aldosterone O +
inhibitors O +
. O -

Renin O +
is O +
the O +
enzyme O +
responsible O +
for O +
converting O +
angiotensinogen O +
to O +
angiotensin O +
I O +
, O +
which O +
is O +
then O +
converted O +
to O +
angiotensin O +
II O +
. O -

Renin O +
inhibitors O +
prevent O +
the O +
formation O +
of O +
both O +
angiotensin O +
I O +
and O +
angiotensin O +
II O +
. O -

Renin O +
inhibitors O +
do O +
not O +
affect O +
kinin O +
metabolism O +
and O +
may O +
produce O +
fewer O +
adverse O +
effects O +
than O +
ACE O +
inhibitors O +
such O +
as O +
dry B-Disease +
cough L-Disease +
or O +
angioedema U-Disease +
. O -

OBJECTIVES O +
: O +
To O +
quantify O +
the O +
dose O +
- O +
related O +
blood O +
pressure U-Disease +
lowering O +
efficacy O +
of O +
renin O +
inhibitors O +
versus O +
placebo O +
in O +
the O +
treatment O +
of O +
primary B-Disease +
hypertension L-Disease +
. O -

SEARCH O +
STRATEGY O +
: O +
We O +
searched O +
the O +
following O +
databases O +
for O +
randomised O +
, O +
double O +
blind U-Disease +
, O +
placebo O +
- O +
controlled O +
trials O +
of O +
renin O +
inhibitors O +
: O +
Medline O +
( O +
1966 O +
- O +
March O +
2008 O +
) O +
, O +
EMBASE O +
( O +
1988 O +
- O +
March O +
2008 O +
) O +
, O +
Cochrane O +
CENTRAL O +
, O +
and O +
bibliographic O +
citations O +
from O +
retrieved O +
references O +
. O -

No O +
language O +
restrictions O +
were O +
applied O +
. O -

SELECTION O +
CRITERIA O +
: O +
Study O +
design O +
had O +
to O +
meet O +
the O +
following O +
criteria O +
: O +
double O +
- O +
blinded O +
, O +
placebo O +
- O +
controlled O +
; O +
random O +
allocation O +
to O +
a O +
specific O +
dose O +
of O +
renin O +
inhibitor O +
group O +
and O +
parallel O +
placebo O +
group O +
; O +
duration O +
of O +
follow O +
- O +
up O +
of O +
at O +
least O +
three O +
weeks O +
. O -

DATA O +
COLLECTION O +
AND O +
ANALYSIS O +
: O +
Two O +
reviewers O +
independently O +
extracted O +
data O +
and O +
assessed O +
trial O +
quality O +
using O +
risk O +
of O +
bias O +
tables O +
. O -

Disagreements O +
were O +
resolved O +
by O +
discussion O +
or O +
a O +
third O +
reviewer O +
. O -

Data O +
synthesis O +
and O +
analyses O +
were O +
done O +
using O +
the O +
Cochrane O +
Review O +
Manager O +
software O +
, O +
RevMan O +
5 O +
. O -

Data O +
for O +
continuous O +
variables O +
were O +
combined O +
using O +
a O +
weighted O +
mean O +
difference O +
method O +
. O -

Dichotomous O +
variables O +
were O +
analysed O +
using O +
relative O +
risk O +
. O -

MAIN O +
RESULTS O +
: O +
Six O +
trials O +
( O +
N O +
= O +
3694 O +
) O +
met O +
the O +
inclusion O +
criteria O +
for O +
this O +
review O +
. O -

Aliskiren O +
was O +
the O +
only O +
renin O +
inhibitor O +
studied O +
in O +
these O +
studies O +
. O -

The O +
meta O +
- O +
analysis O +
shows O +
that O +
aliskiren O +
has O +
a O +
dose O +
- O +
related O +
both O +
systolic O +
/ O +
diastolic O +
blood O +
pressure U-Disease +
lowering O +
effect O +
as O +
compared O +
to O +
placebo O +
: O +
aliskiren O +
75 O +
mg O +
- O +
2.9 O +
/ O +
- O +
2.3 O +
mmHg O +
, O +
aliskiren O +
150 O +
mg O +
- O +
5.5 O +
/ O +
- O +
3.0 O +
mmHg O +
, O +
aliskiren O +
300 O +
mg O +
- O +
8.7 O +
/ O +
- O +
5.0 O +
, O +
aliskiren O +
600 O +
mg O +
- O +
11.4 O +
/ O +
- O +
6.6 O +
mmHg O +
. O -

Aliskiren O +
300 O +
mg O +
significantly O +
lowered O +
both O +
SBP O +
and O +
DBP O +
as O +
compared O +
to O +
aliskiren O +
150 O +
mg O +
( O +
SBP O +
: O +
- O +
2.97 O +
( O +
95 O -
% O +
CI O +
- O +
3.99 O +
, O +
- O +
1.95 O +
) O +
and O +
DBP O +
: O +
- O +
1.66 O +
( O +
95 O -
% O +
CI O +
- O +
2.32 O +
, O +
- O +
1.0 O +
) O +
. O -

Aliskiren O +
has O +
no O +
effect O +
on O +
blood O +
pressure U-Disease +
variability O +
. O -

No O +
data O +
was O +
available O +
to O +
assess O +
the O +
effect O +
of O +
aliskiren O +
on O +
heart O +
rate O +
and O +
pulse O +
pressure U-Disease +
. O -

This O +
review O +
found O +
weak O +
evidence O +
that O +
with O +
short O +
- O +
term O +
use O +
, O +
aliskiren O +
does O +
not O +
increase O +
withdrawals O +
due O +
to O +
adverse O +
effects O +
as O +
compared O +
to O +
placebo O +
. O -

AUTHORS O +
' O +
CONCLUSIONS O +
: O +
Aliskiren O +
has O +
a O +
dose O +
- O +
related O +
blood O +
pressure U-Disease +
lowering O +
effect O +
better O +
than O +
placebo O +
. O -

This O +
effect O +
is O +
similar O +
to O +
that O +
determined O +
for O +
ACE O +
inhibitors O +
and O +
ARBs O +
. O -

Fragrance O +
material O +
review O +
on O +
tricyclodecanyl O +
acetate O +
. O -

A O +
toxicologic O +
and O +
dermatologic O +
review O +
of O +
tricyclodecanyl O +
acetate O +
when O +
used O +
as O +
a O +
fragrance O +
ingredient O +
is O +
presented O +
. O -

NRF2 O +
as O +
a O +
determinant O +
of O +
cellular O +
resistance O +
in O +
retinoic O +
acid O +
cytotoxicity U-Disease +
. O -

Clinical O +
use O +
of O +
retinoic O +
acids O +
( O +
RA O +
) O +
is O +
hindered O +
by O +
toxicity O +
possibly O +
related O +
to O +
oxidative O +
stress O +
. O -

Recently O +
, O +
RA O +
at O +
relatively O +
low O +
concentrations O +
was O +
shown O +
to O +
inhibit O +
NRF2 O +
and O +
the O +
expression O +
of O +
its O +
target O +
antioxidative O +
genes O +
. O -

This O +
raises O +
the O +
possibility O +
that O +
RA B-Disease +
toxicity L-Disease +
may O +
result O +
from O +
cellular O +
inability O +
to O +
cope O +
with O +
resultant O +
oxidative O +
stress O +
. O -

Using O +
in O +
vitro O +
cell O +
and O +
in O +
vivo O +
mouse O +
models O +
, O +
we O +
report O +
that O +
RA O +
, O +
specifically O +
all O +
- O +
trans O +
- O +
RA O +
( O +
atRA O +
) O +
at O +
concentrations O +
implicated O +
in O +
toxicity O +
, O +
can O +
activate O +
NRF2 O +
and O +
induce O +
NRF2 O +
target O +
genes O +
, O +
particularly O +
the O +
subunits O +
of O +
the O +
rate O +
- O +
limiting O +
enzyme O +
of O +
glutathione O +
biosynthesis O +
, O +
glutamate O +
cysteine O +
ligase O +
( O +
GCLM O +
/ O +
GCLC O +
) O +
. O -

RNA O +
interference O +
- O +
mediated O +
silencing O +
of O +
NRF2 O +
, O +
but O +
not O +
of O +
retinoid O +
X O +
receptor O +
- O +
alpha O +
and O +
- O +
beta O +
, O +
reduced O +
basal O +
and O +
atRA O +
- O +
induced O +
GCLM O +
/ O +
GCLC O +
gene O +
expression O +
. O -

Moreover O +
, O +
RA O +
increased O +
nuclear O +
accumulation O +
of O +
NRF2 O +
, O +
antioxidant O +
response O +
element O +
( O +
ARE O +
) O +
reporter O +
activity O +
, O +
and O +
NRF2 O +
occupancy O +
at O +
AREs O +
. O -

4 O +
- O +
Hydroxynonenal O +
, O +
a O +
lipid O +
peroxidation O +
product O +
, O +
was O +
increased O +
by O +
RA O +
. O -

Inhibition O +
of O +
MEK1 O +
/ O +
ERK O +
mitogen O +
- O +
activated O +
protein O +
kinases O +
significantly O +
suppressed O +
atRA O +
- O +
induced O +
NRF2 O +
activation O +
and O +
ARE O +
- O +
regulated O +
gene O +
expression O +
, O +
reducing O +
cell O +
resistance O +
against O +
toxic O +
concentrations O +
of O +
RA O +
. O -

NRF2 O +
- O +
silenced O +
cells O +
were O +
vulnerable O +
to O +
atRA O +
- O +
induced O +
mitochondrial B-Disease +
toxicity L-Disease +
and O +
apoptosis O +
. O -

In O +
conclusion O +
, O +
toxic O +
RA O +
activates O +
NRF2 O +
, O +
thereby O +
triggering O +
an O +
adaptive O +
response O +
against O +
the O +
resultant O +
oxidative O +
stress O +
. O -

NRF2 O +
enhancement O +
as O +
a O +
therapeutic O +
target O +
of O +
retinoid O +
toxicity O +
awaits O +
further O +
investigation O +
. O -

Renin O +
- O +
angiotensin O +
- O +
aldosterone O +
responsiveness O +
to O +
low O +
sodium O +
and O +
blood O +
pressure O +
reactivity O +
to O +
angiotensin O +
- O +
II O +
are O +
unrelated O +
to O +
cholesteryl O +
ester O +
transfer O +
protein O +
mass O +
in O +
healthy O +
subjects O +
. O -

BACKGROUND O +
: O +
The O +
blood O +
pressure O +
increase O +
associated O +
with O +
the O +
cholesteryl O +
ester O +
transfer O +
protein O +
( O +
CETP O +
) O +
inhibitor O +
, O +
torcetrapib O +
is O +
probably O +
attributable O +
to O +
an O +
off O +
- O +
target O +
effect O +
but O +
it O +
is O +
unknown O +
whether O +
activation O +
of O +
the O +
renin O +
- O +
angiotensin O +
- O +
aldosterone O +
system O +
( O +
RAAS O +
) O +
may O +
be O +
related O +
to O +
variation O +
in O +
the O +
plasma O +
CETP O +
level O +
. O -

We O +
questioned O +
whether O +
the O +
plasma O +
CETP O +
level O +
would O +
affect O +
RAAS O +
responsiveness O +
to O +
low O +
sodium O +
diet O +
and O +
the O +
blood O +
pressure O +
response O +
to O +
angiotensin O +
- O +
II O +
infusion O +
in O +
healthy O +
subjects O +
. O -

METHODS O +
: O +
RAAS O +
parameters O +
and O +
blood O +
pressure O +
were O +
determined O +
during O +
liberal O +
sodium O +
diet O +
( O +
200 O +
mmol O +
/ O +
24 O +
h O +
) O +
and O +
low O +
sodium O +
diet O +
( O +
50 O +
mmol O +
/ O +
24 O +
h O +
) O +
in O +
67 O +
healthy O +
men O +
. O -

Blood O +
pressure O +
response O +
to O +
incremental O +
angiotensin O +
- O +
II O +
infusion O +
was O +
assessed O +
in O +
34 O +
subjects O +
during O +
liberal O +
sodium O +
diet O +
. O -

Correlation O +
analysis O +
was O +
performed O +
to O +
test O +
whether O +
RAAS O +
responsiveness O +
and O +
blood O +
pressure O +
were O +
related O +
to O +
plasma O +
CETP O +
mass O +
, O +
high O +
- O +
density O +
lipoprotein O +
- O +
cholesterol O +
( O +
HDL O +
- O +
C O +
) O +
and O +
apolipoprotein O +
A O +
- O +
I O +
measured O +
during O +
liberal O +
sodium O +
diet O +
. O -

RESULTS O +
: O +
CETP O +
mass O +
ranged O +
from O +
1.29 O +
to O +
2.95 O +
mg O +
/ O +
l O +
. O -

No O +
significant O +
differences O +
in O +
( O +
changes O +
) O +
in O +
mean O +
arterial O +
pressure O +
, O +
aldosterone O +
and O +
active O +
plasma O +
renin O +
concentration O +
in O +
response O +
to O +
low O +
sodium O +
were O +
observed O +
between O +
the O +
lowest O +
and O +
highest O +
tertiles O +
of O +
CETP O +
mass O +
, O +
HDL O +
- O +
C O +
and O +
apolipoprotein O +
A O +
- O +
I O +
. O -

These O +
outcome O +
variables O +
were O +
also O +
not O +
significantly O +
correlated O +
with O +
CETP O +
, O +
HDL O +
- O +
C O +
and O +
apolipoprotein O +
A O +
- O +
I O +
, O +
except O +
for O +
a O +
modest O +
relation O +
of O +
aldosterone O +
measured O +
during O +
low O +
sodium O +
with O +
apolipoprotein O +
A O +
- O +
I O +
( O +
r O +
= O +
0.28 O +
, O +
p O +
= O +
0.022 O +
) O +
. O -

Blood O +
pressure O +
response O +
to O +
angiotensin O +
- O +
II O +
was O +
similar O +
between O +
CETP O +
tertiles O +
. O -

CONCLUSIONS O +
: O +
Mineralocorticoid O +
and O +
blood O +
pressure O +
responsiveness O +
to O +
dietary O +
salt O +
intake O +
are O +
not O +
significantly O +
related O +
to O +
physiological O +
interindividual O +
differences O +
in O +
plasma O +
CETP O +
. O -

We O +
suggest O +
that O +
a O +
lower O +
CETP O +
mass O +
does O +
not O +
exert O +
adverse O +
effects O +
on O +
blood O +
pressure O +
regulation O +
. O -

D O +
- O +
chiro O +
- O +
inositol O +
- O +
enriched O +
tartary O +
buckwheat O +
bran O +
extract O +
lowers O +
the O +
blood O +
glucose O +
level O +
in O +
KK O +
- O +
Ay O +
mice O +
. O -

D O +
- O +
chiro O +
- O +
inositol O +
( O +
DCI O +
) O +
is O +
an O +
active O +
compound O +
in O +
tartary O +
buckwheat O +
[ O +
Fagopyrum O +
tataricum O +
( O +
L O +
. O +
) O -

Gaench O +
] O +
with O +
an O +
insulin O +
- O +
like O +
bioactivity O +
. O -

The O +
present O +
study O +
was O +
performed O +
to O +
( O +
i O +
) O +
prepare O +
DCI O +
- O +
enriched O +
tartary O +
buckwheat O +
bran O +
extract O +
( O +
TBBE O +
) O +
, O +
( O +
ii O +
) O +
evaluate O +
its O +
acute B-Disease +
toxicity L-Disease +
in O +
mice O +
, O +
and O +
( O +
iii O +
) O +
examine O +
its O +
blood O +
glucose O +
lowering O +
activity O +
in O +
diabetic O +
mice O +
. O -

It O +
was O +
found O +
that O +
steaming O +
buckwheat O +
bran O +
in O +
an O +
autoclave O +
at O +
1.6 O +
MPa O +
and O +
120 O +
degrees O +
C O +
for O +
60 O +
min O +
could O +
significantly O +
enrich O +
the O +
DCI O +
level O +
in O +
TBBE O +
from O +
0.03 O +
to O +
0.22 O -
% O +
and O +
further O +
to O +
22 O -
% O +
after O +
passage O +
of O +
the O +
TBBE O +
through O +
activated O +
carbon O +
and O +
ion O +
exchange O +
resins O +
. O -

An O +
acute B-Disease +
toxicity L-Disease +
test O +
demonstrated O +
that O +
the O +
LD O +
50 O +
of O +
TBBE O +
was O +
> O +
20 O +
g O +
/ O +
kg O +
of O +
body O +
weight O +
in O +
mice O +
, O +
suggesting O +
that O +
TBBE O +
was O +
in O +
general O +
nontoxic O +
and O +
safe O +
in O +
mice O +
. O -

Male O +
KK O +
- O +
A O +
( O +
y O +
) O +
mice O +
( O +
type B-Disease +
2 I-Disease +
diabetic L-Disease +
) O +
and O +
C57BL O +
/ O +
6 O +
mice O +
( O +
the O +
control O +
) O +
were O +
used O +
to O +
investigate O +
the O +
antidiabetic O +
activity O +
of O +
TBBE O +
. O -

In O +
KK O +
- O +
A O +
( O +
y O +
) O +
mice O +
, O +
the O +
blood O +
glucose O +
, O +
plasma O +
C O +
- O +
peptide O +
, O +
glucagon O +
, O +
total O +
cholesterol O +
, O +
triglyceride O +
, O +
and O +
blood O +
urea O +
nitrogen O +
( O +
BUN O +
) O +
levels O +
were O +
significantly O +
higher O +
than O +
those O +
in O +
the O +
C57BL O +
/ O +
6 O +
mice O +
. O -

In O +
addition O +
, O +
KK O +
- O +
A O +
( O +
y O +
) O +
mice O +
showed O +
an O +
obvious O +
decrease O +
in O +
insulin O +
immunoreactivity O +
in O +
the O +
pancreas O +
. O -

The O +
present O +
study O +
clearly O +
demonstrated O +
that O +
oral O +
administration O +
of O +
DCI O +
- O +
enriched O +
TBBE O +
could O +
lower O +
plasma O +
glucose O +
, O +
C O +
- O +
peptide O +
, O +
glucagon O +
, O +
triglyceride O +
, O +
and O +
BUN O +
, O +
improve O +
glucose O +
tolerance U-Disease +
, O +
and O +
enhance O +
insulin O +
immunoreactivity O +
in O +
KK O +
- O +
A O +
( O +
y O +
) O +
mice O +
. O -

Optimal O +
timing O +
for O +
adjuvant O +
radiation O +
therapy O +
in O +
breast B-Disease +
cancer L-Disease +
: O +
a O +
comprehensive O +
review O +
and O +
perspectives O +
. O -

PURPOSE O +
: O +
The O +
optimal O +
sequence O +
of O +
modalities O +
involved O +
in O +
breast B-Disease +
cancer L-Disease +
treatment O +
with O +
respect O +
to O +
radiotherapy O +
and O +
the O +
maximum O +
acceptable O +
interval O +
between O +
radiotherapy O +
and O +
surgery O +
need O +
to O +
be O +
determined O +
. O -

DESIGN O +
: O +
This O +
review O +
attempts O +
a O +
critical O +
reading O +
of O +
the O +
literature O +
. O -

RESULTS O +
: O +
A O +
delay O +
of O +
radiotherapy O +
more O +
than O +
8 O -
- O -
12 O +
weeks O +
after O +
surgery O +
adversely O +
affects O +
local O +
recurrence O +
. O -

Radiotherapy O +
should O +
be O +
administered O +
within O +
7 O +
months O +
after O +
surgery O +
, O +
when O +
chemotherapy O +
is O +
administered O +
first O +
. O -

Several O +
chemotherapy O +
regimens O +
can O +
be O +
safely O +
administered O +
concurrently O +
with O +
radiotherapy O +
. O -

The O +
concurrent O +
use O +
of O +
tamoxifen O +
with O +
chemotherapy O +
should O +
be O +
avoided O +
, O +
but O +
not O +
with O +
radiotherapy O +
. O -

Data O +
is O +
insufficient O +
with O +
regard O +
to O +
concurrent O +
use O +
of O +
aromatase O +
inhibitors O +
with O +
radiotherapy O +
. O -

The O +
use O +
of O +
trastuzumab O +
concomitantly O +
with O +
radiotherapy O +
may O +
enhance O +
toxicities O +
but O +
may O +
also O +
improve O +
its O +
efficacy O +
. O -

CONCLUSIONS O +
: O +
Although O +
the O +
issue O +
of O +
radiotherapy O +
delay O +
and O +
that O +
of O +
sequence O +
with O +
chemotherapy O +
or O +
tamoxifen O +
are O +
clarified O +
, O +
the O +
sequence O +
of O +
radiotherapy O +
with O +
aromatase O +
inhibitors O +
and O +
trastuzumab O +
needs O +
to O +
be O +
defined O +
. O -

Individual O +
radiosensitivity O +
may O +
influence O +
toxicity O +
. O -

New O +
biologic O +
markers O +
have O +
to O +
be O +
determined O +
in O +
the O +
future O +
for O +
tailoring O +
radiotherapy O +
in O +
breast B-Disease +
cancer L-Disease +
. O -

Determinants O +
of O +
negative O +
white O +
- O +
coat O +
effect O +
in O +
treated O +
hypertensive O +
patients O +
: O +
the O +
Jichi O +
Morning O +
Hypertension U-Disease +
Research O +
( O +
J O +
- O +
MORE O +
) O +
study O +
. O -

BACKGROUND O +
: O +
The O +
negative O +
white O +
- O +
coat O +
effect O +
( O +
WCE O +
) O +
, O +
a O +
phenomenon O +
in O +
which O +
out O +
- O +
of O +
- O +
office O +
blood O +
pressure O +
( O +
BP O +
) O +
is O +
higher O +
than O +
clinic O +
BP O +
, O +
has O +
not O +
been O +
well O +
examined O +
, O +
unlike O +
the O +
WCE O +
. O -

METHODS O +
: O +
As O +
part O +
of O +
the O +
Jichi O +
Morning O +
Hypertension U-Disease +
Research O +
study O +
, O +
in O +
which O +
clinic O +
and O +
home O +
BP O +
were O +
measured O +
in O +
969 O +
hypertensive O +
outpatients O +
, O +
405 O +
patients O +
with O +
normal O +
clinic O +
BP O +
were O +
separately O +
analyzed O +
. O -

Clinic O +
BP O +
was O +
measured O +
on O +
two O +
different O +
occasions O +
, O +
and O +
home O +
BP O +
was O +
measured O +
twice O +
in O +
the O +
morning O +
and O +
twice O +
in O +
the O +
evening O +
for O +
three O +
consecutive O +
days O +
. O -

Clinic O +
and O +
home O +
BP O +
were O +
each O +
averaged O +
from O +
all O +
readings O +
, O +
and O +
negative O +
WCE O +
was O +
defined O +
as O +
clinic O +
systolic O +
BP O +
( O +
SBP O +
) O +
lower O +
than O +
home O +
SBP O +
. O -

RESULTS O +
: O +
Negative O +
WCE O +
was O +
observed O +
in O +
324 O +
( O +
33 O -
% O +
) O +
of O +
the O +
patients O +
overall O +
and O +
in O +
173 O +
( O +
42 O -
% O +
) O +
of O +
the O +
patients O +
with O +
controlled O +
BP O +
( O +
clinic O +
BP O +
< O +
140 O -
/ O -
90 O +
mm O +
Hg O +
) O +
. O -

In O +
multiple O +
logistic O +
regression O +
analysis O +
adjusting O +
for O +
covariates O +
including O +
home O +
SBP O +
and O +
pulse O +
rate O +
, O +
negative O +
WCE O +
was O +
correlated O +
with O +
older O +
age O +
( O +
odds O +
ratio O +
( O +
OR O +
) O +
1.03 O +
, O +
95 O -
% O +
confidence O +
interval O +
( O +
CI O +
) O +
1.01 O -
- O -
1.06 O +
) O +
and O +
male O +
gender O +
( O +
OR O +
1.08 O +
, O +
95 O -
% O +
CI O +
1.01 O -
- O -
1.14 O +
) O +
in O +
overall O +
subjects O +
. O -

Among O +
patients O +
with O +
well O +
- O +
controlled O +
clinic O +
BP O +
, O +
negative O +
WCE O +
was O +
significantly O +
correlated O +
with O +
the O +
presence O +
of O +
ischemic B-Disease +
heart I-Disease +
disease L-Disease +
( O +
OR O +
1.17 O +
, O +
95 O -
% O +
CI O +
1.04 O -
- O -
1.31 O +
) O +
. O -

The O +
association O +
of O +
negative O +
WCE O +
with O +
age O +
and O +
male O +
gender O +
remained O +
significant O +
under O +
stringent O +
criteria O +
( O +
negative O +
WCE O +
< O +
- O +
10.2 O +
mm O +
Hg O +
( O +
the O +
mean O +
- O +
1 O +
s O +
. O -

d O +
. O +
) O +
) O +
. O -

CONCLUSIONS O +
: O +
Negative O +
WCE O +
remaining O +
even O +
after O +
clinic O +
BP O +
is O +
controlled O +
may O +
be O +
related O +
to O +
cardiovascular O +
risk O +
factors O +
such O +
as O +
older O +
age O +
, O +
male O +
gender O +
, O +
and O +
a O +
history O +
of O +
ischemic B-Disease +
heart I-Disease +
disease L-Disease +
. O -

Addition O +
of O +
sildenafil O +
to O +
long O +
- O +
term O +
intravenous O +
epoprostenol O +
therapy O +
in O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
: O +
a O +
randomized O +
trial O +
. O -

BACKGROUND O +
: O +
Oral O +
sildenafil O +
and O +
intravenous O +
epoprostenol O +
have O +
independently O +
been O +
shown O +
to O +
be O +
effective O +
in O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
. O -

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
effect O +
of O +
adding O +
oral O +
sildenafil O +
to O +
long O +
- O +
term O +
intravenous O +
epoprostenol O +
in O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
. O -

DESIGN O +
: O +
A O +
16 O +
- O +
week O +
, O +
double O +
- O +
blind O +
, O +
placebo O +
- O +
controlled O +
, O +
parallel O +
- O +
group O +
study O +
. O -

SETTING O +
: O +
Multinational O +
study O +
at O +
41 O +
centers O +
in O +
11 O +
countries O +
from O +
3 O +
July O +
2003 O +
to O +
27 O +
January O +
2006 O +
. O -

PATIENTS O +
: O +
267 O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
( O +
idiopathic O +
, O +
associated O +
anorexigen O +
use O +
or O +
connective B-Disease +
tissue I-Disease +
disease L-Disease +
, O +
or O +
corrected O +
congenital B-Disease +
heart I-Disease +
disease L-Disease +
) O +
who O +
were O +
receiving O +
long O +
- O +
term O +
intravenous O +
epoprostenol O +
therapy O +
. O -

INTERVENTION O +
: O +
Patients O +
were O +
randomly O +
assigned O +
to O +
receive O +
placebo O +
or O +
sildenafil O +
, O +
20 O +
mg O +
three O +
times O +
daily O +
, O +
titrated O +
to O +
40 O +
mg O +
and O +
80 O +
mg O +
three O +
times O +
daily O +
, O +
as O +
tolerated O +
, O +
at O +
4 O +
- O +
week O +
intervals O +
. O -

Of O +
265 O +
patients O +
who O +
received O +
treatment O +
, O +
256 O +
( O +
97 O -
% O +
) O +
patients O +
( O +
123 O +
in O +
the O +
placebo O +
group O +
and O +
133 O +
in O +
the O +
sildenafil O +
group O +
) O +
completed O +
the O +
study O +
. O -

MEASUREMENTS O +
: O +
Change O +
from O +
baseline O +
in O +
exercise O +
capacity O +
measured O +
by O +
6 O +
- O +
minute O +
walk O +
distance O +
( O +
primary O +
end O +
point O +
) O +
and O +
hemodynamic O +
measurements O +
, O +
time O +
to O +
clinical O +
worsening O +
, O +
and O +
Borg O +
dyspnea U-Disease +
score O +
( O +
secondary O +
end O +
points O +
) O +
. O -

RESULTS O +
: O +
A O +
placebo O +
- O +
adjusted O +
increase O +
of O +
28.8 O +
meters O +
( O +
95 O -
% O +
CI O +
, O +
13.9 O +
to O +
43.8 O +
meters O +
) O +
in O +
the O +
6 O +
- O +
minute O +
walk O +
distance O +
occurred O +
in O +
patients O +
in O +
the O +
sildenafil O +
group O +
; O +
these O +
improvements O +
were O +
most O +
prominent O +
among O +
patients O +
with O +
baseline O +
distances O +
of O +
325 O +
meters O +
or O +
more O +
. O -

Relative O +
to O +
epoprostenol O +
monotherapy O +
, O +
addition O +
of O +
sildenafil O +
resulted O +
in O +
a O +
greater O +
change O +
in O +
mean O +
pulmonary O +
arterial O +
pressure O +
by O +
- O +
3.8 O +
mm O +
Hg O +
( O +
CI O +
, O +
- O +
5.6 O +
to O +
- O +
2.1 O +
mm O +
Hg O +
) O +
; O +
cardiac O +
output O +
by O +
0.9 O +
L O +
/ O +
min O +
( O +
CI O +
, O +
0.5 O +
to O +
1.2 O +
L O +
/ O +
min O +
) O +
; O +
and O +
longer O +
time O +
to O +
clinical O +
worsening O +
, O +
with O +
a O +
smaller O +
proportion O +
of O +
patients O +
experiencing O +
a O +
worsening O +
event O +
in O +
the O +
sildenafil O +
group O +
( O +
0.062 O +
) O +
than O +
in O +
the O +
placebo O +
group O +
( O +
0.195 O +
) O +
by O +
week O +
16 O +
( O +
P O +
= O +
0.002 O +
) O +
. O -

Health O +
- O +
related O +
quality O +
of O +
life O +
also O +
improved O +
in O +
patients O +
who O +
received O +
combined O +
therapy O +
compared O +
with O +
those O +
who O +
received O +
epoprostenol O +
monotherapy O +
. O -

There O +
was O +
no O +
effect O +
on O +
the O +
Borg O +
dyspnea O +
score O +
. O -

Of O +
the O +
side O +
effects O +
generally O +
associated O +
with O +
sildenafil O +
treatment O +
, O +
the O +
most O +
commonly O +
reported O +
in O +
the O +
placebo O +
and O +
sildenafil O +
groups O +
, O +
respectively O +
, O +
were O +
headache U-Disease +
( O +
34 O -
% O +
and O +
57 O -
% O +
; O +
difference O +
, O +
23 O +
percentage O +
points O +
[ O +
CI O +
, O +
12 O +
to O +
35 O +
percentage O +
points O +
] O +
) O +
, O +
dyspepsia U-Disease +
( O +
2 O -
% O +
and O +
16 O -
% O +
; O +
difference O +
, O +
13 O +
percentage O +
points O +
[ O +
CI O +
, O +
7 O +
to O +
20 O +
percentage O +
points O +
] O +
) O +
, O +
pain U-Disease +
in O +
extremity O +
( O +
18 O -
% O +
and O +
25 O -
% O +
; O +
difference O +
, O +
8 O +
percentage O +
points O +
[ O +
CI O +
, O +
- O +
2 O +
to O +
18 O +
percentage O +
points O +
] O +
) O +
, O +
and O +
nausea U-Disease +
( O +
18 O -
% O +
and O +
25 O -
% O +
; O +
difference O +
, O +
8 O +
percentage O +
points O +
[ O +
CI O +
, O +
- O +
2 O +
to O +
18 O +
percentage O +
points O +
] O +
) O +
. O -

LIMITATIONS O +
: O +
The O +
study O +
excluded O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
associated O +
with O +
other O +
causes O +
. O -

There O +
was O +
an O +
imbalance O +
in O +
missing O +
data O +
between O +
groups O +
, O +
with O +
8 O +
placebo O +
recipients O +
having O +
no O +
postbaseline O +
walk O +
assessment O +
compared O +
with O +
1 O +
sildenafil O +
recipient O +
. O -

These O +
patients O +
were O +
excluded O +
from O +
the O +
analysis O +
. O -

CONCLUSION O +
: O +
In O +
some O +
patients O +
with O +
pulmonary B-Disease +
arterial I-Disease +
hypertension L-Disease +
, O +
the O +
addition O +
of O +
sildenafil O +
to O +
long O +
- O +
term O +
intravenous O +
epoprostenol O +
therapy O +
improves O +
exercise O +
capacity O +
, O +
hemodynamic O +
measurements O +
, O +
time O +
to O +
clinical O +
worsening O +
, O +
and O +
quality O +
of O +
life O +
, O +
but O +
not O +
Borg O +
dyspnea U-Disease +
score O +
. O -

Increased O +
rates O +
of O +
headache U-Disease +
and O +
dyspepsia U-Disease +
occurred O +
with O +
the O +
addition O +
of O +
sildenafil O +
. O -

Capecitabine O +
: O +
have O +
we O +
got O +
the O +
dose O +
right O +
? O -

In O +
the O +
past O +
5 O -
- O -
10 O +
years O +
there O +
has O +
been O +
a O +
growing O +
trend O +
for O +
substituting O +
conventional O +
5 O +
- O +
fluorouracil O +
with O +
the O +
oral O +
prodrug O +
of O +
5 O +
- O +
fluorouracil O +
, O +
capecitabine O +
, O +
in O +
chemotherapy O +
regimens O +
. O -

This O +
regimen O +
change O +
is O +
based O +
on O +
evidence O +
of O +
the O +
efficacy O +
equivalence O +
of O +
these O +
two O +
drugs O +
and O +
the O +
lack O +
of O +
an O +
increase O +
in O +
overall O +
toxic O +
effects O +
when O +
capecitabine O +
is O +
used O +
. O -

Many O +
investigators O +
in O +
different O +
parts O +
of O +
the O +
world O +
have O +
determined O +
their O +
own O +
starting O +
dose O +
for O +
capecitabine O +
, O +
usually O +
based O +
on O +
their O +
experience O +
of O +
toxic O +
events O +
within O +
the O +
population O +
of O +
patients O +
they O +
treat O +
. O -

This O +
starting O +
dose O +
is O +
usually O +
between O +
1,000 O -
- O -
1,250 O +
mg O +
/ O +
m O +
( O +
2 O +
) O +
, O +
which O +
is O +
generally O +
administered O +
twice O +
daily O +
for O +
14 O +
days O +
followed O +
by O +
7 O +
days O +
rest O +
. O -

This O +
Review O +
summarizes O +
why O +
there O +
may O +
indeed O +
not O +
be O +
a O +
universally O +
applicable O +
starting O +
dose O +
for O +
capecitabine O +
because O +
of O +
interpatient O +
differences O +
in O +
basic O +
physiology O +
, O +
pharmacogenomics O +
and O +
diet O +
. O -

This O +
article O +
also O +
explores O +
which O +
of O +
these O +
factors O +
contribute O +
to O +
the O +
observed O +
inter O +
- O +
regional O +
geographical O +
variation O +
in O +
capecitabine O +
toxicity O +
, O +
and O +
explains O +
why O +
even O +
within O +
a O +
region O +
various O +
factors O +
should O +
prompt O +
a O +
clinician O +
to O +
modify O +
the O +
starting O +
dose O +
. O -

Predicting O +
and O +
preventing O +
acute B-Disease +
kidney I-Disease +
injury L-Disease +
after O +
cardiac O +
surgery O +
. O -

PURPOSE O +
OF O +
REVIEW O +
: O +
Acute B-Disease +
kidney I-Disease +
injury L-Disease +
( O +
AKI U-Disease +
) O +
after O +
cardiac O +
surgery O +
is O +
associated O +
with O +
significant O +
morbidity O +
and O +
mortality O +
. O -

Despite O +
the O +
proliferation O +
of O +
predictive O +
clinical O +
scoring O +
models O +
of O +
renal O +
risk O +
after O +
cardiac O +
surgery O +
, O +
limitations O +
in O +
preventing O +
AKI O +
through O +
the O +
use O +
of O +
pharmacological O +
agents O +
remain O +
. O -

Here O +
we O +
review O +
the O +
evolution O +
of O +
predictive O +
models O +
of O +
renal O +
risk O +
after O +
cardiac O +
surgery O +
, O +
and O +
highlight O +
the O +
important O +
gains O +
made O +
in O +
preventing O +
its O +
occurrence O +
. O -

RECENT O +
FINDINGS O +
: O +
Simple O +
risk O +
indices O +
predicting O +
AKI O +
after O +
cardiac O +
surgery O +
have O +
been O +
developed O +
and O +
can O +
now O +
be O +
readily O +
applied O +
clinically O +
. O -

However O +
, O +
studies O +
focusing O +
on O +
preventing O +
AKI O +
after O +
surgery O +
have O +
yet O +
to O +
demonstrate O +
any O +
consistent O +
renoprotective O +
effect O +
. O -

SUMMARY O +
: O +
Clinical O +
scoring O +
systems O +
predicting O +
AKI O +
risk O +
after O +
cardiac O +
surgery O +
are O +
available O +
and O +
should O +
be O +
employed O +
in O +
the O +
preoperative O +
assessment O +
. O -

Elucidation O +
of O +
beneficial O +
preventive O +
strategies O +
of O +
AKI O +
after O +
cardiac O +
surgery O +
requires O +
ongoing O +
research O +
. O -

Transient O +
gene O +
delivery O +
for O +
functional O +
enrichment O +
of O +
differentiating O +
embryonic O +
stem O +
cells O +
. O -

There O +
is O +
a O +
critical O +
need O +
for O +
new O +
sources O +
of O +
hepatocytes O +
, O +
both O +
clinically O +
to O +
provide O +
support O +
for O +
patients O +
with O +
liver B-Disease +
failure L-Disease +
and O +
in O +
drug O +
discovery O +
for O +
toxicity O +
, O +
metabolic O +
and O +
pharmacokinetic O +
screening O +
of O +
new O +
drug O +
entities O +
. O -

We O +
have O +
reported O +
previously O +
a O +
variety O +
of O +
methods O +
for O +
differentiating O +
murine O +
embryonic O +
stem O +
( O +
ES O +
) O +
cells O +
into O +
hepatocyte O +
- O +
like O +
cells O +
. O -

One O +
major O +
challenge O +
of O +
our O +
work O +
and O +
others O +
in O +
the O +
field O +
has O +
been O +
the O +
ability O +
to O +
selectively O +
purify O +
and O +
enrich O +
these O +
cells O +
from O +
a O +
heterogeneous O +
population O +
. O -

Traditional O +
approaches O +
for O +
inserting O +
new O +
genes O +
( O +
e.g. O +
, O +
stable O +
transfection O +
, O +
knock O +
- O +
in O +
, O +
retroviral O +
transduction O +
) O +
involve O +
permanent O +
alterations O +
in O +
the O +
genome O +
. O -

These O +
approaches O +
can O +
lead O +
to O +
mutations O +
and O +
involve O +
the O +
extra O +
costs O +
and O +
time O +
of O +
developing O +
, O +
validating O +
and O +
maintaining O +
new O +
cell O +
lines O +
. O -

We O +
have O +
developed O +
a O +
transient O +
gene O +
delivery O +
system O +
that O +
uses O +
fluorescent O +
gene O +
reporters O +
for O +
purification O +
of O +
the O +
cells O +
. O -

Following O +
a O +
transient O +
transfection O +
, O +
the O +
cells O +
are O +
purified O +
through O +
a O +
fluorescence O +
- O +
activated O +
cell O +
sorter O +
( O +
FACS O +
) O +
, O +
re O +
- O +
plated O +
in O +
secondary O +
culture O +
and O +
subsequent O +
phenotypic O +
analysis O +
is O +
performed O +
. O -

In O +
an O +
effort O +
to O +
test O +
the O +
ability O +
of O +
the O +
reporters O +
to O +
work O +
in O +
a O +
transient O +
environment O +
for O +
our O +
differentiation O +
system O +
, O +
we O +
engineered O +
two O +
non O +
- O +
viral O +
plasmid O +
reporters O +
, O +
the O +
first O +
driven O +
by O +
the O +
mouse O +
albumin O +
enhancer O +
/ O +
promoter O +
and O +
the O +
second O +
by O +
the O +
mouse O +
cytochrome O +
P450 O +
7A1 O +
( O +
Cyp7A1 O +
) O +
promoter O +
. O -

We O +
optimized O +
the O +
transfection O +
efficiency O +
of O +
delivering O +
these O +
genes O +
into O +
spontaneously O +
differentiated O +
ES O +
cells O +
and O +
sorted O +
independent O +
fractions O +
positive O +
for O +
each O +
reporter O +
17 O +
days O +
after O +
inducing O +
differentiation O +
. O -

We O +
found O +
that O +
cells O +
sorted O +
based O +
on O +
the O +
Cyp7A1 O +
promoter O +
showed O +
significant O +
enrichment O +
in O +
terms O +
of O +
albumin O +
secretion O +
, O +
urea O +
secretion O +
and O +
cytochrome O +
P450 O +
1A2 O +
detoxification O +
activity O +
as O +
compared O +
to O +
enrichment O +
garnered O +
by O +
the O +
albumin O +
promoter O +
- O +
based O +
cell O +
sort O +
. O -

Development O +
of O +
gene O +
reporter O +
systems O +
that O +
allow O +
us O +
to O +
identify O +
, O +
purify O +
and O +
assess O +
homogeneous O +
populations O +
of O +
cells O +
is O +
important O +
in O +
better O +
understanding O +
stem O +
cell O +
differentiation O +
pathways O +
. O -

And O +
engineering O +
cellular O +
systems O +
without O +
making O +
permanent O +
gene O +
changes O +
will O +
be O +
critical O +
for O +
the O +
generation O +
of O +
clinically O +
acceptable O +
cellular O +
material O +
in O +
the O +
future O +
. O -

Dominant O +
negative O +
effect O +
of O +
the O +
APC1309 O +
mutation O -
: O +
a O +
possible O +
explanation O +
for O +
genotype O -
- O -
phenotype O +
correlations O +
in O +
familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease -
. O -

Inactivation O +
of O +
the O +
adenomatous B-Disease +
polyposis I-Disease +
coli L-Disease +
( O -
APC U-Disease -
) O +
gene O +
product O +
initiates O +
colorectal O +
tumorigenesis O -
. O -

Patients O +
with O +
familial B-Disease +
APC L-Disease +
( O -
FAP U-Disease -
) O +
carry O +
germ O -
- O -
line O +
mutations O +
in O +
the O +
APC U-Disease +
gene O +
and O +
develop O +
multiple O +
colorectal B-Disease +
adenomas L-Disease +
and O +
subsequent O +
carcinomas U-Disease +
early O +
in O +
life O -
. O -

The O +
severity O +
of O +
the O +
disease O +
correlates O +
with O +
the O +
position O +
of O +
the O +
inherited O +
APC U-Disease +
mutation O +
( O -
genotype O -
- O -
phenotype O +
correlation O -
) O -
. O -

Together O +
with O +
the O +
fact O +
that O +
both O +
germ O -
- O -
line O +
and O +
sporadic O +
APC U-Disease +
mutations O +
cluster O +
in O +
the O +
central O +
region O +
of O +
the O +
APC U-Disease +
gene O -
, O +
this O +
points O +
to O +
a O +
dominant O +
negative O +
effect O +
of O +
certain O +
APC U-Disease +
mutants O -
. O -

Loss O +
of O +
APC U-Disease +
function O +
was O +
recently O +
shown O +
to O +
result O +
in O +
enhanced O +
beta O -
- O -
catenin- O -
/ O -
Tcf O -
- O -
mediated O +
transcription O +
in O +
colon O +
epithelial O +
cells O -
. O -

Here O -
, O +
we O +
provide O +
experimental O +
evidence O +
for O +
a O +
dominant O +
negative O +
effect O +
of O +
APC U-Disease +
gene O +
products O +
associated O +
with O +
severe O +
polyposis U-Disease -
. O -

Wild O -
- O -
type O +
APC U-Disease +
activity O +
in O +
beta O -
- O -
catenin- O -
/ O -
Tcf O -
- O -
mediated O +
transcription O +
was O +
strongly O +
inhibited O +
by O +
a O +
mutant O +
APC U-Disease +
that O +
is O +
truncated O +
at O +
codon O +
1309 O -
. O -

In O +
contrast O -
, O +
mutant O +
APC U-Disease +
gene O +
products O +
that O +
are O +
associated O +
with O +
attenuated B-Disease +
polyposis L-Disease +
( O -
codon O +
386 O +
or O +
1465 O -
) O +
interfered O +
only O +
weakly O +
with O +
wild O -
- O -
type O +
APC U-Disease +
activity O -
. O -

These O +
results O +
suggest O +
a O +
molecular O +
explanation O +
for O +
the O +
genotype O -
- O -
phenotype O +
correlation O +
in O +
FAP U-Disease +
patients O +
and O +
support O +
the O +
idea O +
that O +
colorectal B-Disease +
tumor L-Disease +
growth O +
might O +
be O -
, O +
in O +
part O -
, O +
driven O +
by O +
selection O +
for O +
a O +
mutation O +
in O +
the O +
mutation O +
cluster O +
region O -
.. O -

Overgrowth B-Disease +
of I-Disease +
oral I-Disease +
mucosa I-Disease +
and I-Disease +
facial I-Disease +
skin L-Disease -
, O +
a O +
novel O +
feature O +
of O +
aspartylglucosaminuria U-Disease -
. O -

Aspartylglucosaminuria U-Disease +
( O -
AGU U-Disease -
) O +
is O +
a O +
lysosomal B-Disease +
storage I-Disease +
disorder L-Disease +
caused O +
by O +
deficiency B-Disease +
of I-Disease +
aspartylglucosaminidase L-Disease +
( O -
AGA O -
) O -
. O -

The O +
main O +
symptom O +
is O +
progressive O +
mental B-Disease +
retardation L-Disease -
. O -

A O +
spectrum O +
of O +
different O +
mutations O +
has O +
been O +
reported O +
in O +
this O +
disease O -
, O +
one O +
missense O +
mutation O +
( O -
Cys163Ser O -
) O +
being O +
responsible O +
for O +
the O +
majority O +
of O +
Finnish O +
cases O -
. O -

We O +
were O +
able O +
to O +
examine O +
66 O +
Finnish O +
AGU U-Disease +
patients O +
for O +
changes O +
in O +
the O +
oral O +
mucosa O +
and O +
44 O +
of O +
these O +
for O +
changes O +
in O +
facial O +
skin O -
. O -

Biopsy O +
specimens O +
of O +
16 O +
oral O +
lesions O -
, O +
12 O +
of O +
them O +
associated O +
with O +
the O +
teeth O -
, O +
plus O +
two O +
facial B-Disease +
lesions L-Disease +
were O +
studied O +
histologically O -
. O -

Immunohistochemical O +
staining O +
for O +
AGA O +
was O +
performed O +
on O +
15 O +
oral O +
specimens O -
. O -

Skin O +
was O +
seborrhoeic O +
in O +
adolescent O +
and O +
adult O +
patients O -
, O +
with O +
erythema B-Disease +
of I-Disease +
the I-Disease +
facial I-Disease +
skin L-Disease +
already O +
common O +
in O +
childhood O -
. O -

Of O +
44 O +
patients O -
, O +
nine O +
( O -
20 O -
% O -
) O +
had O +
facial B-Disease +
angiofibromas L-Disease -
, O +
tumours U-Disease +
primarily O +
occurring O +
in O +
association O +
with O +
tuberous B-Disease +
sclerosis L-Disease -
. O -

Oedemic B-Disease +
buccal I-Disease +
mucosa L-Disease +
( O -
leucoedema U-Disease -
) O +
and O +
gingival B-Disease +
overgrowths L-Disease +
were O +
more O +
frequent O +
in O +
AGU U-Disease +
patients O +
than O +
in O +
controls O +
( O -
p O +
< O +
0 O -
. O +
001 O -
) O -
. O -

Of O +
16 O +
oral B-Disease +
mucosal I-Disease +
lesions L-Disease +
studied O +
histologically O -
, O +
15 O +
represented O +
fibroepithelial B-Disease +
or I-Disease +
epithelial I-Disease +
hyperplasias L-Disease +
and O +
were O +
reactive O +
in O +
nature O -
. O -

Cytoplasmic O +
vacuolisation O +
was O +
evident O +
in O +
four O -
. O -

Immunohistochemically O -
, O +
expression O +
of O +
AGA O +
in O +
AGU U-Disease +
patients O +
mucosal B-Disease +
lesions L-Disease +
did O +
not O +
differ O +
from O +
that O +
seen O +
in O +
corresponding O +
lesions O +
of O +
normal O +
subjects O -
. O -

Thus O -
, O +
the O +
high O +
frequency O +
of O +
mucosal B-Disease +
overgrowth L-Disease +
in O +
AGU U-Disease +
patients O +
does O +
not O +
appear O +
to O +
be O +
directly O +
associated O +
with O +
lysosomal O +
storage O +
or O +
with O +
alterations O +
in O +
the O +
level O +
of O +
AGA O +
expression O -
. O -

Sulfate O +
transport O +
is O +
not O +
impaired O +
in O +
pendred B-Disease +
syndrome L-Disease +
thyrocytes O -
. O -

Pendred B-Disease +
syndrome L-Disease +
is O +
the O +
most O +
common O +
form O +
of O +
syndromic B-Disease +
deafness L-Disease -
, O +
characterized O +
by O +
dyshormonogenic B-Disease +
goiter L-Disease +
associated O +
with O +
sensory B-Disease -
- I-Disease -
neural I-Disease +
deafness L-Disease -
. O -

The O +
gene O +
responsible O +
for O +
the O +
disease O +
( O -
PDS U-Disease -
) O +
has O +
been O +
cloned O -
, O +
but O +
its O +
function O +
is O +
as O +
yet O +
unknown O +
and O +
the O +
connection O +
between O +
thyroid B-Disease +
goiter L-Disease +
and O +
sensory B-Disease -
- I-Disease -
neural I-Disease +
deafness L-Disease +
remains O +
an O +
enigma O -
. O -

PDS O +
codes O +
for O +
a O +
novel O +
protein O -
, O +
pendrin O -
, O +
which O +
is O +
closely O +
related O +
to O +
a O +
number O +
of O +
sufate O +
transporters O -
. O -

Mechanisms O +
by O +
which O +
abnormal O +
sulfate O +
transport O +
could O +
deleteriously O +
affect O +
iodide O +
organification O +
have O +
been O +
proposed O -
. O -

We O +
tested O +
sulfate O +
transport O +
in O +
thyrocytes O +
obtained O +
from O +
Pendred B-Disease +
syndrome L-Disease +
patients O +
and O +
found O +
that O +
it O +
was O +
not O +
defective O -
. O -

This O +
suggests O +
that O +
pendrin O +
in O +
fact O +
may O +
not O +
be O +
a O +
sulfate O +
transporter O -
, O +
and O +
emphasizes O +
the O +
importance O +
of O +
functional O +
studies O +
on O +
this O +
novel O +
protein O -
.. O -

Mutational O +
analysis O +
of O +
the O +
HGO O +
gene O +
in O +
Finnish O +
alkaptonuria U-Disease +
patients O -
. O -

Alkaptonuria U-Disease +
( O -
AKU U-Disease -
) O -
, O +
the O +
prototypic O +
inborn B-Disease +
error I-Disease +
of I-Disease +
metabolism L-Disease -
, O +
has O +
recently O +
been O +
shown O +
to O +
be O +
caused O +
by O +
loss O +
of O +
function O +
mutations O +
in O +
the O +
homogentisate-1 O -
, O +
2-dioxygenase O +
gene O +
( O -
HGO O -
) O -
. O -

So O +
far O +
17 O +
mutations O +
have O +
been O +
characterised O +
in O +
AKU U-Disease +
patients O +
of O +
different O +
ethnic O +
origin O -
. O -

We O +
describe O +
three O +
novel O +
mutations O +
( O -
R58fs O -
, O +
R330S O -
, O +
and O +
H371R O -
) O +
and O +
one O +
common O +
AKU U-Disease +
mutation O +
( O -
M368V O -
) O -
, O +
detected O +
by O +
mutational O +
and O +
polymorphism O +
analysis O +
of O +
the O +
HGO O +
gene O +
in O +
five O +
Finnish O +
AKU U-Disease +
pedigrees O -
. O -

The O +
three O +
novel O +
AKU U-Disease +
mutations O +
are O +
most O +
likely O +
specific O +
for O +
the O +
Finnish O +
population O +
and O +
have O +
originated O +
recently O -
.. O -

Genetic O +
analysis O -
, O +
phenotypic O +
diagnosis O -
, O +
and O +
risk O +
of O +
venous B-Disease +
thrombosis L-Disease +
in O +
families O +
with O +
inherited O +
deficiencies B-Disease +
of I-Disease +
protein I-Disease +
S. L-Disease +
Protein B-Disease +
S I-Disease +
deficiency L-Disease +
is O +
a O +
recognized O +
risk O +
factor O +
for O +
venous B-Disease +
thrombosis L-Disease -
. O -

Of O +
all O +
the O +
inherited O +
thrombophilic B-Disease +
conditions L-Disease -
, O +
it O +
remains O +
the O +
most O +
difficult O +
to O +
diagnose O +
because O +
of O +
phenotypic O +
variability O -
, O +
which O +
can O +
lead O +
to O +
inconclusive O +
results O -
. O -

We O +
have O +
overcome O +
this O +
problem O +
by O +
studying O +
a O +
cohort O +
of O +
patients O +
from O +
a O +
single O +
center O +
where O +
the O +
diagnosis O +
was O +
confirmed O +
at O +
the O +
genetic O +
level O -
. O -

Twenty O -
- O -
eight O +
index O +
patients O +
with O +
protein B-Disease +
S I-Disease +
deficiency L-Disease +
and O +
a O +
PROS1 B-Disease +
gene I-Disease +
defect L-Disease +
were O +
studied O -
, O +
together O +
with O +
109 O +
first O -
- O -
degree O +
relatives O -
. O -

To O +
avoid O +
selection O +
bias O -
, O +
we O +
confined O +
analysis O +
of O +
total O +
and O +
free O +
protein O +
S O +
levels O +
and O +
thrombotic O +
risk O +
to O +
the O +
patients O +
relatives O -
. O -

In O +
this O +
group O +
of O +
relatives O -
, O +
a O +
low O +
free O +
protein O +
S O +
level O +
was O +
the O +
most O +
reliable O +
predictor O +
of O +
a O +
PROS1 B-Disease +
gene I-Disease +
defect L-Disease +
( O -
sensitivity O +
97 O -
. O +
7 O -
% O -
, O +
specificity O +
100 O -
% O -
) O -
. O -

First O -
- O -
degree O +
relatives O +
with O +
a O +
PROS1 B-Disease +
gene I-Disease +
defect L-Disease +
had O +
a O +
5 O -
. O -

0-fold O +
higher O +
risk O +
of O +
thrombosis U-Disease +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
1 O -
. O +
5 O -
- O -
16 O -
. O -

8) O +
than O +
those O +
with O +
a O +
normal O +
PROS1 O +
gene O +
and O +
no O +
other O +
recognized O +
thrombophilic B-Disease +
defect L-Disease -
. O -

Although O +
pregnancy O -
/ O -
puerperium O +
and O +
immobility O -
/ O -
trauma U-Disease +
were O +
important O +
precipitating O +
factors O +
for O +
thrombosis U-Disease -
, O +
almost O +
half O +
of O +
the O +
events O +
were O +
spontaneous O -
. O -

Relatives O +
with O +
splice O -
- O -
site O +
or O +
major O +
structural O +
defects B-Disease +
in I-Disease +
the I-Disease +
PROS1 I-Disease +
gene L-Disease +
were O +
more O +
likely O +
to O +
have O +
had O +
a O +
thrombotic O +
event O +
and O +
had O +
significantly O +
lower O +
total O +
and O +
free O +
protein O +
S O +
levels O +
than O +
those O +
relatives O +
having O +
missense O +
mutations O -
. O -

We O +
conclude O +
that O +
persons O +
with O +
PROS1 B-Disease +
gene I-Disease +
defects L-Disease +
and O +
protein B-Disease +
S I-Disease +
deficiency L-Disease +
are O +
at O +
increased O +
risk O +
of O +
thrombosis U-Disease +
and O +
that O +
free O +
protein O +
S O +
estimation O +
offers O +
the O +
most O +
reliable O +
way O +
of O +
diagnosing O +
the O +
deficiency O -
. O -

( O -
Blood O -
. O -

2000 O -
; O +
95 O -
1935 O -
- O -
1941 O -
) O -
. O -

Autoinhibition O +
and O +
activation O +
mechanisms O +
of O +
the O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
protein O -
. O -

The O +
Rho O -
- O -
family O +
GTPase O -
, O +
Cdc42 O -
, O +
can O +
regulate O +
the O +
actin O +
cytoskeleton O +
through O +
activation O +
of O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
protein O +
( O -
WASP O -
) O +
family O +
members O -
. O -

Activation O +
relieves O +
an O +
autoinhibitory O +
contact O +
between O +
the O +
GTPase O -
- O -
binding O +
domain O +
and O +
the O +
carboxy O -
- O -
terminal O +
region O +
of O +
WASP O +
proteins O -
. O -

Here O +
we O +
report O +
the O +
autoinhibited O +
structure O +
of O +
the O +
GTPase O -
- O -
binding O +
domain O +
of O +
WASP O -
, O +
which O +
can O +
be O +
induced O +
by O +
the O +
C O -
- O -
terminal O +
region O +
or O +
by O +
organic O +
co O -
- O -
solvents O -
. O -

In O +
the O +
autoinhibited O +
complex O -
, O +
intramolecular O +
interactions O +
with O +
the O +
GTPase O -
- O -
binding O +
domain O +
occlude O +
residues O +
of O +
the O +
C O +
terminus O +
that O +
regulate O +
the O +
Arp2 O -
/ O -
3 O +
actin O -
- O -
nucleating O +
complex O -
. O -

Binding O +
of O +
Cdc42 O +
to O +
the O +
GTPase O -
- O -
binding O +
domain O +
causes O +
a O +
dramatic O +
conformational O +
change O -
, O +
resulting O +
in O +
disruption O +
of O +
the O +
hydrophobic O +
core O +
and O +
release O +
of O +
the O +
C O +
terminus O -
, O +
enabling O +
its O +
interaction O +
with O +
the O +
actin O +
regulatory O +
machinery O -
. O -

These O +
data O +
show O +
that O +
intrinsically O +
unstructured O +
peptides O +
such O +
as O +
the O +
GTPase O -
- O -
binding O +
domain O +
of O +
WASP O +
can O +
be O +
induced O +
into O +
distinct O +
structural O +
and O +
functional O +
states O +
depending O +
on O +
context O -
.. O -

Locus O +
heterogeneity O +
in O +
Friedreich B-Disease +
ataxia L-Disease -
. O -

Friedreich B-Disease +
ataxia L-Disease +
( O -
FRDA U-Disease -
) O +
is O +
the O +
most O +
common O +
form O +
of O +
autosomal B-Disease +
recessive I-Disease +
ataxia L-Disease -
. O -

The O +
disease O +
locus O +
was O +
assigned O +
to O +
chromosome O +
9 O +
and O +
the O +
disease O +
gene O -
, O +
STM7 O -
/ O -
X25 O -
, O +
has O +
been O +
isolated O -
. O -

To O +
date O +
most O +
data O +
suggest O +
locus O +
homogeneity O +
in O +
FRDA U-Disease -
. O -

We O +
now O +
provide O +
strong O +
evidence O +
of O +
a O +
second O +
FRDA U-Disease +
locus O -
. O -

Studying O +
two O +
siblings O +
with O +
FRDA U-Disease +
from O +
two O +
families O +
we O +
did O +
not O +
detect O +
a O +
mutation O +
in O +
STM7 O -
/ O -
X25 O -
. O -

Haplotype O +
analysis O +
of O +
the O +
STM7 O -
/ O -
X25 O +
region O +
of O +
chromosome O +
9 O +
demonstrated O +
that O +
the O +
relevant O +
portion O +
of O +
chromosome O +
9 O +
differs O +
in O +
the O +
patients O -
. O -

Although O +
the O +
patients O +
studied O +
had O +
typical O +
FRDA U-Disease -
, O +
one O +
sibpair O +
had O +
the O +
uncommon O +
symptom O +
of O +
retained O +
tendon O +
reflexes O -
. O -

In O +
order O +
to O +
investigate O +
whether O +
retained O +
tendon O +
reflexes O +
are O +
characteristic O +
of O +
FRDA U-Disease +
caused O +
by O +
the O +
second O +
locus O -
, O +
FRDA2 O -
, O +
we O +
studied O +
an O +
unrelated O +
FRDA U-Disease +
patient O +
with O +
retained O +
tendon O +
reflexes O -
. O -

The O +
observation O +
of O +
typical O +
mutations O +
in O +
STM7 O -
/ O -
X25 O +
( O -
GAA O +
expansions O -
) O +
in O +
this O +
patient O +
demonstrates O +
that O +
the O +
two O +
genetically O +
different O +
forms O +
of O +
FRDA U-Disease +
can O -
not O +
be O +
distinguished O +
clinically O -
.. O -

Restoration O +
of O +
photoreceptor O +
ultrastructure O +
and O +
function O +
in O +
retinal B-Disease +
degeneration L-Disease +
slow O +
mice O +
by O +
gene O +
therapy O -
. O -

The O +
gene O +
Prph2 O +
encodes O +
a O +
photoreceptor O -
- O -
specific O +
membrane O +
glycoprotein O -
, O +
peripherin-2 O +
( O -
also O +
known O +
as O +
peripherin O -
/ O -
rds O -
) O -
, O +
which O +
is O +
inserted O +
into O +
the O +
rims O +
of O +
photoreceptor O +
outer O +
segment O +
discs O +
in O +
a O +
complex O +
with O +
rom-1 O +
( O -
ref O -
. O -

2 O -
) O -
. O -

The O +
complex O +
is O +
necessary O +
for O +
the O +
stabilization O +
of O +
the O +
discs O -
, O +
which O +
are O +
renewed O +
constantly O +
throughout O +
life O -
, O +
and O +
which O +
contain O +
the O +
visual O +
pigments O +
necessary O +
for O +
photon O +
capture O -
. O -

Mutations O +
in O +
Prph2 O +
have O +
been O +
shown O +
to O +
result O +
in O +
a O +
variety O +
of O +
photoreceptor B-Disease +
dystrophies L-Disease -
, O +
including O +
autosomal B-Disease +
dominant I-Disease +
retinitis I-Disease +
pigmentosa L-Disease +
and O +
macular B-Disease +
dystrophy L-Disease -
. O -

A O +
common O +
feature O +
of O +
these O +
diseases O +
is O +
the O +
loss O +
of O +
photoreceptor O +
function O -
, O +
also O +
seen O +
in O +
the O +
retinal B-Disease +
degeneration L-Disease +
slow O +
( O -
rds O +
or O +
Prph2 O +
Rd2 O -
/ O -
Rd2 O -
) O +
mouse O -
, O +
which O +
is O +
homozygous O +
for O +
a O +
null O +
mutation O +
in O +
Prph2 O -
. O -

It O +
is O +
characterized O +
by O +
a O +
complete O +
failure O +
to O +
develop O +
photoreceptor O +
discs O +
and O +
outer O +
segments O -
, O +
downregulation O +
of O +
rhodopsin O +
and O +
apoptotic O +
loss O +
of O +
photoreceptor O +
cells O -
. O -

The O +
electroretinograms O +
( O -
ERGs O -
) O +
of O +
Prph2Rd2 O -
/ O -
Rd2 O +
mice O +
have O +
greatly O +
diminished O +
a O -
- O -
wave O +
and O +
b O -
- O -
wave O +
amplitudes O -
, O +
which O +
decline O +
to O +
virtually O +
undetectable O +
concentrations O +
by O +
two O +
months O -
. O -

Subretinal O +
injection O +
of O +
recombinant O +
adeno O -
- O -
associated O +
virus O +
( O -
AAV O -
) O +
encoding O +
a O +
Prph2 O +
transgene O +
results O +
in O +
stable O +
generation O +
of O +
outer O +
segment O +
structures O +
and O +
formation O +
of O +
new O +
stacks O +
of O +
discs O +
containing O +
both O +
perpherin-2 O +
and O +
rhodopsin O -
, O +
which O +
in O +
many O +
cases O +
are O +
morphologically O +
similar O +
to O +
normal O +
outer O +
segments O -
. O -

Moreover O -
, O +
the O +
re O -
- O -
establishment O +
of O +
the O +
structural O +
integrity O +
of O +
the O +
photoreceptor O +
layer O +
also O +
results O +
in O +
electrophysiological O +
correction O -
. O -

These O +
studies O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
a O +
complex O +
ultrastructural O +
cell O +
defect O +
can O +
be O +
corrected O +
both O +
morphologically O +
and O +
functionally O +
by O +
in O +
vivo O +
gene O +
transfer O -
.. O -

Function O +
of O +
an O +
axonal O +
chemoattractant O +
modulated O +
by O +
metalloprotease O +
activity O -
. O -

The O +
axonal O +
chemoattractant O +
netrin-1 O +
guides O +
spinal O +
commissural O +
axons O +
by O +
activating O +
its O +
receptor O +
DCC O +
( O -
Deleted O +
in O +
Colorectal B-Disease +
Cancer L-Disease +
) O -
. O -

We O +
have O +
found O +
that O +
chemical O +
inhibitors O +
of O +
metalloproteases O +
potentiate O +
netrin O -
- O -
mediated O +
axon O +
outgrowth O +
in O +
vitro O -
. O -

We O +
have O +
also O +
found O +
that O +
DCC O +
is O +
a O +
substrate O +
for O +
metalloprotease O -
- O -
dependent O +
ectodomain O +
shedding O -
, O +
and O +
that O +
the O +
inhibitors O +
block O +
proteolytic O +
processing O +
of O +
DCC O +
and O +
cause O +
an O +
increase O +
in O +
DCC O +
protein O +
levels O +
on O +
axons O +
within O +
spinal O +
cord O +
explants O -
. O -

Thus O -
, O +
potentiation O +
of O +
netrin O +
activity O +
by O +
inhibitors O +
may O +
result O +
from O +
stabilization O +
of O +
DCC O +
on O +
the O +
axons O -
, O +
and O +
proteolytic O +
activity O +
may O +
regulate O +
axon O +
migration O +
by O +
controlling O +
the O +
number O +
of O +
functional O +
extracellular O +
axon O +
guidance O +
receptors O -
.. O -

Myotonic B-Disease +
dystrophy L-Disease +
in O +
transgenic O +
mice O +
expressing O +
an O +
expanded O +
CUG O +
repeat O -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O -
, O +
the O +
most O +
common O +
form O +
of O +
muscular B-Disease +
dystrophy L-Disease +
in O +
adult O +
humans O -
, O +
results O +
from O +
expansion O +
of O +
a O +
CTG O +
repeat O +
in O +
the O +
3 O +
untranslated O +
region O +
of O +
the O +
DMPK O +
gene O -
. O -

The O +
mutant O +
DMPK O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
contains O +
an O +
expanded O +
CUG O +
repeat O +
and O +
is O +
retained O +
in O +
the O +
nucleus O -
. O -

We O +
have O +
expressed O +
an O +
untranslated O +
CUG O +
repeat O +
in O +
an O +
unrelated O +
mRNA O +
in O +
transgenic O +
mice O -
. O -

Mice O +
that O +
expressed O +
expanded O +
CUG O +
repeats O +
developed O +
myotonia U-Disease +
and O +
myopathy U-Disease -
, O +
whereas O +
mice O +
expressing O +
a O +
nonexpanded O +
repeat O +
did O +
not O -
. O -

Thus O -
, O +
transcripts O +
with O +
expanded O +
CUG O +
repeats O +
are O +
sufficient O +
to O +
generate O +
a O +
DM U-Disease +
phenotype O -
. O -

This O +
result O +
supports O +
a O +
role O +
for O +
RNA O +
gain O +
of O +
function O +
in O +
disease O +
pathogenesis O -
.. O -

Malignant B-Disease +
neoplasms L-Disease +
in O +
the O +
families O +
of O +
patients O +
with O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
. O -

Ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
syndrome L-Disease +
associated O +
with O +
a O +
greatly O +
increased O +
incidence O +
of O +
malignant B-Disease +
neoplasms L-Disease +
in O +
homozygous O +
affected O +
individuals O -
. O -

Heterozygotes O +
for O +
the O +
gene O +
for O +
A B-Disease -
- I-Disease -
T L-Disease +
are O +
thought O +
to O +
comprise O +
about O +
1 O -
% O +
of O +
the O +
general O +
population O +
and O -
, O +
therefore O -
, O +
it O +
is O +
important O +
to O +
know O +
whether O +
this O +
gene O +
also O +
predisposes O +
the O +
heterozygous O +
carrier O +
to O +
cancers U-Disease -
. O -

Heterozygous O +
carriers O +
of O +
this O +
gene O +
are O +
common O +
among O +
the O +
close O +
relatives O +
of O +
patients O +
with O +
A B-Disease -
- I-Disease -
T L-Disease -
, O +
although O +
individual O +
carriers O +
can O -
not O +
be O +
identified O +
by O +
any O +
clinical O +
criterion O +
or O +
laboratory O +
test O -
. O -

For O +
this O +
reason O -
, O +
we O +
compared O +
the O +
incidence O +
of O +
death O +
from O +
malignant B-Disease +
neoplasms L-Disease +
in O +
2 O +
families O +
of O +
patients O +
with O +
A B-Disease -
- I-Disease -
T L-Disease +
to O +
that O +
expected O +
in O +
a O +
random O +
sample O +
of O +
the O +
general O +
population O -
. O -

There O +
were O +
59 O +
deaths O +
from O +
malignant B-Disease +
neoplasms L-Disease +
in O +
relatives O +
dying O +
before O +
age O +
75 O -
, O +
compared O +
to O +
42 O -
. O -

6 O +
expected O +
( O -
p O +
less O +
than O +
0 O -
. O +
02 O -
) O -
. O -

For O +
A B-Disease -
- I-Disease -
T L-Disease +
heterozygotes O +
younger O +
than O +
age O +
45 O -
, O +
the O +
risk O +
of O +
dying O +
from O +
a O +
malignant B-Disease +
neoplasm L-Disease +
was O +
estimated O +
to O +
be O +
greater O +
than O +
5 O +
times O +
the O +
risk O +
for O +
the O +
general O +
population O -
. O -

A B-Disease -
- I-Disease -
T L-Disease +
heterozygotes O +
may O +
comprise O +
more O +
than O +
5 O -
% O +
of O +
all O +
persons O +
dying O +
from O +
a O +
cancer U-Disease +
before O +
age O +
45 O -
. O -

The O +
incidence O +
of O +
ovarian B-Disease -
, I-Disease +
gastric I-Disease -
, I-Disease +
and I-Disease +
biliary I-Disease +
system I-Disease +
carcinomas L-Disease +
and O +
of O +
leukemia U-Disease +
and O +
lymphoma U-Disease +
was O +
increased O +
in O +
these O +
A B-Disease -
- I-Disease -
T L-Disease +
families O -
. O -

Other O +
neoplasms U-Disease +
that O +
may O +
be O +
associated O +
with O +
this O +
gene O +
in O +
heterozygotes O +
include O +
pancreatic B-Disease -
, I-Disease +
basal I-Disease +
cell I-Disease -
, I-Disease +
colonic I-Disease -
, I-Disease +
breast I-Disease -
, I-Disease +
and I-Disease +
cervical I-Disease +
carcinomas L-Disease -
. O -

Analbuminemia U-Disease +
in O +
an O +
American O +
Indian O +
girl O -
. O -

Analbuminemia U-Disease +
was O +
fortuitously O +
detected O +
in O +
a O +
nonedematous O +
12-year O -
- O -
old O +
American O +
Indian O +
girl O +
with O +
atopic B-Disease +
dermatitis L-Disease -
, O +
mild O +
bronchial B-Disease +
asthma L-Disease -
, O +
a O +
mild O +
seizure B-Disease +
disorder L-Disease -
, O +
and O +
hyperlipoproteinemia U-Disease +
with O +
a O +
corneal B-Disease +
arcus L-Disease -
. O -

Immunologic O +
methods O +
revealed O +
trace O +
amounts O +
( O -
17 O +
mg O -
/ O -
100 O +
ml O -
) O +
of O +
apparently O +
normal O +
serum O +
albumin O -
. O -

The O +
patients O +
parents O +
were O +
remotely O +
related O -
. O -

The O +
pedigree O +
and O +
clinical O +
findings O +
were O +
compatible O +
with O +
autosomal O +
recessive O +
transmission O +
of O +
analbuminemia U-Disease -
. O -

Heterozygotes O +
had O +
subnormal O +
levels O +
of O +
serum O +
albumin O -
. O -

The O +
Gc O -
- O -
locus O +
is O +
closely O +
linked O +
to O +
the O +
structural O +
albumin O +
locus O -
. O -

Gc O -
- O -
protein O +
levels O +
were O +
normal O +
in O +
the O +
patient O +
and O +
together O +
with O +
normal O +
chromosomal O +
banding O +
studies O +
make O +
it O +
unlikely O +
that O +
a O +
chromosomal O +
deletion O +
caused O +
analbuminemia U-Disease -
. O -

Gc O -
- O -
types O +
in O +
the O +
family O +
were O +
compatible O +
with O -
, O +
but O +
did O +
not O +
prove O -
, O +
linkage O +
of O +
analbuminemia U-Disease +
to O +
the O +
Gc O -
- O -
locus O -
. O -

These O +
findings O +
suggest O +
a O +
" O +
thalassemia U-Disease +
" O +
-like O +
mutation O +
for O +
this O +
disorder O -
.. O -

Detection O +
of O +
a O +
nonsense O +
mutation O +
in O +
the O +
dystrophin O +
gene O +
by O +
multiple O +
SSCP O -
. O -

A O +
combination O +
of O +
multiplex O +
PCR O +
with O +
the O +
single O +
strand O +
conformation O +
polymorphism O +
( O -
SSCP O -
) O +
technique O +
was O +
employed O +
to O +
screen O +
for O +
point O +
mutations O +
in O +
the O +
human O +
dystrophin O +
gene O -
. O -

Co O -
- O -
amplification O +
of O +
11 O +
exons O +
from O +
genomic O +
DNA O +
of O +
Duchenne B-Disease +
and I-Disease +
Becker I-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
DMD U-Disease -
/ O -
BMD U-Disease -
) O +
patients O +
with O +
no O +
deletion O +
or O +
duplication O +
was O +
performed O +
and O +
the O +
samples O +
subjected O +
to O +
multiple O +
SSCP O +
analysis O -
. O -

We O +
report O +
the O +
case O +
of O +
a O +
nonsense O +
mutation O +
in O +
a O +
Duchenne U-Disease +
patient O +
identified O +
by O +
this O +
approach O -
. O -

The O +
mutation O +
introduces O +
a O +
termination O +
codon O +
within O +
exon O +
8 O +
of O +
the O +
dystrophin O +
gene O -
. O -

It O +
is O +
predicted O +
to O +
cause O +
a O +
very O +
premature O +
translational O +
termination O +
accounting O +
for O +
the O +
severe O +
phenotype O +
observed O -
. O -

The O +
patient O +
inherited O +
this O +
mutation O +
from O +
his O +
mother O -
. O -

In O +
addition O +
the O +
analysis O +
revealed O +
5 O +
polymorphisms O +
useful O +
for O +
internal O +
control O -
.. O -

Linkage O +
of O +
gene O +
for O +
C2 B-Disease +
deficiency L-Disease +
and O +
the O +
major O +
histocompatibility O +
complex O +
MHC O +
in O +
man O -
. O -

Family O +
study O +
of O +
a O +
further O +
case O -
. O -

Close O +
linkage O +
between O +
HL O -
- O -
A O +
and O +
C2 B-Disease +
deficiency L-Disease +
was O +
first O +
reported O +
by O +
FU O +
and O +
co O -
- O -
workers O +
in O +
1974 O -
. O -

We O +
present O +
here O +
a O +
pedigree O +
of O +
a O +
31-year O -
- O -
old O +
C2-deficient U-Disease +
individual O +
with O +
clinical O +
manifestations O +
of O +
Hodgkins B-Disease +
disease L-Disease -
. O -

The O +
following O +
markers O +
were O +
tested O -
C2 O +
levels O -
, O +
factor O +
B O +
polymorphism O -
, O +
blood O +
groups O -
, O +
and O +
enzyme O +
typing O -
. O -

In O +
addition O +
to O +
close O +
linkage O +
between O +
HL O -
- O -
A O +
and O +
C2 B-Disease +
deficiency L-Disease -
, O +
both O +
parents O +
were O +
heterozygous O +
for O +
Bf O +
( O -
HL O -
- O -
A O +
linked O -
, O +
electrophoretic O +
variation O +
of O +
B O -
) O -
. O -

The O +
two O +
HL O -
- O -
A O +
haplotypes O +
closely O +
linked O +
to O +
C2 B-Disease +
deficiency L-Disease +
are O +
different O -
2 O -
, O +
W18 O +
and O +
W24 O -
, O +
W18 O -
. O -

They O +
share O -
, O +
however O -
, O +
the O +
SD2 O +
antigen O +
W18 O +
and O +
the O +
LD O +
type O +
7a O -
.. O -

Late O -
- O -
onset O +
metachromatic B-Disease +
leukodystrophy L-Disease -
: O +
molecular O +
pathology O +
in O +
two O +
siblings O -
. O -

We O +
report O +
on O +
a O +
new O +
allele O +
at O +
the O +
arylsulfatase O +
A O +
( O -
ARSA O -
) O +
locus O +
causing O +
late O -
- O -
onset O +
metachromatic B-Disease +
leukodystrophy L-Disease +
( O -
MLD U-Disease -
) O -
. O -

In O +
that O +
allele O +
arginine84 O -
, O +
a O +
residue O +
that O +
is O +
highly O +
conserved O +
in O +
the O +
arylsulfatase O +
gene O +
family O -
, O +
is O +
replaced O +
by O +
glutamine O -
. O -

In O +
contrast O +
to O +
alleles O +
that O +
cause O +
early O -
- O -
onset O +
MLD U-Disease -
, O +
the O +
arginine84 O +
to O +
glutamine O +
substitution O +
is O +
associated O +
with O +
some O +
residual O +
ARSA O +
activity O -
. O -

A O +
comparison O +
of O +
genotypes O -
, O +
ARSA O +
activities O -
, O +
and O +
clinical O +
data O +
on O +
4 O +
individuals O +
carrying O +
the O +
allele O +
of O +
81 O +
patients O +
with O +
MLD U-Disease +
examined O -
, O +
further O +
validates O +
the O +
concept O +
that O +
different O +
degrees O +
of O +
residual O +
ARSA O +
activity O +
are O +
the O +
basis O +
of O +
phenotypical O +
variation O +
in O +
MLD U-Disease -
.. O -

Trisomy B-Disease +
15 L-Disease +
with O +
loss O +
of O +
the O +
paternal O +
15 O +
as O +
a O +
cause O +
of O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
due O +
to O +
maternal B-Disease +
disomy L-Disease -
. O -

Uniparental B-Disease +
disomy L-Disease +
has O +
recently O +
been O +
recognized O +
to O +
cause O +
human O +
disorders O -
, O +
including O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
( O -
PWS U-Disease -
) O -
. O -

We O +
describe O +
a O +
particularly O +
instructive O +
case O +
which O +
raises O +
important O +
issues O +
concerning O +
the O +
mechanisms O +
producing O +
uniparental B-Disease +
disomy L-Disease +
and O +
whose O +
evaluation O +
provides O +
evidence O +
that O +
trisomy O +
may O +
precede O +
uniparental B-Disease +
disomy L-Disease +
in O +
a O +
fetus O -
. O -

Chorionic O +
villus O +
sampling O +
performed O +
for O +
advanced O +
maternal O +
age O +
revealed O +
trisomy B-Disease +
15 L-Disease +
in O +
all O +
direct O +
and O +
cultured O +
cells O -
, O +
though O +
the O +
fetus O +
appeared O +
normal O -
. O -

Chromosome O +
analysis O +
of O +
amniocytes O +
obtained O +
at O +
15 O +
wk O +
was O +
normal O +
in O +
over O +
100 O +
cells O +
studied O -
. O -

The O +
child O +
was O +
hypotonic U-Disease +
at O +
birth O -
, O +
and O +
high O -
- O -
resolution O +
banding O +
failed O +
to O +
reveal O +
the O +
deletion O +
of O +
15q11 O -
- O -
13 O -
, O +
a O +
deletion O +
which O +
is O +
found O +
in O +
50 O -
% O +
-70 O -
% O +
of O +
patients O +
with O +
PWS U-Disease -
. O -

Over O +
time O -
, O +
typical O +
features O +
of O +
PWS U-Disease +
developed O -
. O -

Molecular O +
genetic O +
analysis O +
using O +
probes O +
for O +
chromosome O +
15 O +
revealed O +
maternal O +
disomy O -
. O -

Maternal O +
nondisjunction O +
with O +
fertilization O +
of O +
a O +
disomic O +
egg O +
by O +
a O +
normal O +
sperm O -
, O +
followed O +
by O +
loss O +
of O +
the O +
paternal O +
15 O -
, O +
is O +
a O +
likely O +
cause O +
of O +
confined O +
placental O +
mosaicism O +
and O +
uniparental B-Disease +
disomy L-Disease +
in O +
this O +
case O +
of O +
PWS U-Disease -
, O +
and O +
advanced O +
maternal O +
age O +
may O +
be O +
a O +
predisposing O +
factor O -
.. O -

Genetic O +
heterogeneity O +
in O +
X B-Disease -
- I-Disease -
linked I-Disease +
amelogenesis I-Disease +
imperfecta L-Disease -
. O -

The O +
AMELX O +
gene O +
located O +
at O +
Xp22 O -
. O -

1-p22 O -
. O -

3 O +
encodes O +
for O +
the O +
enamel O +
protein O +
amelogenin O +
and O +
has O +
been O +
implicated O +
as O +
the O +
gene O +
responsible O +
for O +
the O +
inherited B-Disease +
dental I-Disease +
abnormality L-Disease +
X B-Disease -
- I-Disease -
linked I-Disease +
amelogenesis I-Disease +
imperfecta L-Disease +
( O -
XAI U-Disease -
) O -
. O -

Three O +
families O +
with O +
XAI U-Disease +
have O +
been O +
investigated O +
using O +
polymorphic O +
DNA O +
markers O +
flanking O +
the O +
position O +
of O +
AMELX O -
. O -

Using O +
two O -
- O -
point O +
linkage O +
analysis O -
, O +
linkage O +
was O +
established O +
between O +
XAI U-Disease +
and O +
several O +
of O +
these O +
markers O +
in O +
two O +
families O -
, O +
with O +
a O +
combined O +
lod O +
score O +
of O +
6 O -
. O -

05 O +
for O +
DXS16 O +
at O +
theta O +
= O +
0 O -
. O +
04 O +
04 O -
. O -

This O +
supports O +
the O +
involvement O +
of O +
AMELX O -
, O +
located O +
close O +
to O +
DXS16 O -
, O +
in O +
the O +
XAI B-Disease +
disease L-Disease +
process O +
( O -
AIH1 O -
) O +
in O +
those O +
families O -
. O -

Using O +
multipoint O +
linkage O +
analysis O -
, O +
the O +
combined O +
maximum O +
lod O +
score O +
for O +
these O +
two O +
families O +
was O +
7 O -
. O +
30 O +
for O +
a O +
location O +
of O +
AIH1 O +
at O +
2 O +
cM O +
distal O +
to O +
DXS16 O -
. O -

The O +
support O +
interval O +
around O +
this O +
location O +
extended O +
about O +
8 O +
cM O +
proximal O +
to O +
DXS92 O -
, O +
and O +
the O +
AIH1 O +
location O +
could O +
not O +
be O +
precisely O +
defined O +
by O +
multipoint O +
mapping O -
. O -

Study O +
of O +
recombination O +
events O +
indicated O +
that O +
AIH1 O +
lies O +
in O +
the O +
interval O +
between O +
DXS143 O +
and O +
DXS85 O -
. O -

There O +
was O +
significant O +
evidence O +
against O +
linkage O +
to O +
this O +
region O +
in O +
the O +
third O +
family O -
, O +
indicating O +
locus O +
heterogeneity O +
in O +
XAI U-Disease -
. O -

Further O +
analysis O +
with O +
markers O +
on O +
the O +
long O +
arm O +
of O +
the O +
X O +
chromosome O +
showed O +
evidence O +
of O +
linkage O +
to O +
DXS144E O +
and O +
F9 O +
with O +
no O +
recombination O +
with O +
either O +
of O +
these O +
markers O -
. O -

Two O -
- O -
point O +
analysis O +
gave O +
a O +
peak O +
lod O +
score O +
at O +
DXS144E O +
with O +
a O +
maximum O +
lod O +
score O +
of O +
2 O -
. O -

83 O +
at O +
theta O +
= O +
0 O -
, O +
with O +
a O +
peak O +
lod O +
score O +
in O +
multipoint O +
linkage O +
analysis O +
of O +
2 O -
. O +
84 O +
at O +
theta O +
= O +
0 O -
. O -

The O +
support O +
interval O +
extended O +
9 O +
cM O +
proximal O +
to O +
DXS144E O +
and O +
14 O +
cM O +
distal O +
to O +
F9 O -
. O -

( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O -
. O -

Typical O +
and O +
partial O +
cat B-Disease +
eye I-Disease +
syndrome L-Disease -
: O +
identification O +
of O +
the O +
marker O +
chromosome O +
by O +
FISH O -
. O -

Three O +
children O +
are O +
reported O +
with O +
typical O +
cat B-Disease +
eye I-Disease +
syndrome L-Disease +
( O -
CES U-Disease -
) O +
and O +
three O +
more O +
children O +
with O +
partial O +
CES U-Disease +
because O +
of O +
absence O +
of O +
coloboma O -
, O +
in O +
which O +
the O +
supernumerary O +
marker O +
chromosome O +
was O +
studied O +
by O +
FISH O -
. O -

Using O +
a O +
genomic O +
library O -
, O +
and O +
also O +
a O +
centromeric O +
and O +
particularly O +
a O +
cosmid O +
probe O +
of O +
22q11 O -
, O +
partial O +
tetrasomy U-Disease +
was O +
shown O +
in O +
all O +
cases O -
.. O -

Linkage O +
analysis O +
in O +
X B-Disease -
- I-Disease -
linked I-Disease +
adrenoleukodystrophy L-Disease +
and O +
application O +
in O +
post- O +
and O +
prenatal O +
diagnosis O -
. O -

We O +
have O +
performed O +
linkage O +
analysis O +
with O +
the O +
DNA O +
markers O +
DXS52 O +
and O +
the O +
clotting O +
factor O +
VIII O +
gene O +
( O -
F8C O -
) O -
, O +
in O +
several O +
large O +
families O +
with O +
X B-Disease -
- I-Disease -
linked I-Disease +
adrenoleukodystrophy L-Disease +
( O -
ALD U-Disease -
) O -
. O -

The O +
tight O +
linkage O +
to O +
DXS52 O +
could O +
be O +
extended O +
giving O +
a O +
maximal O +
LOD O +
score O +
of O +
22 O -
. O -

5 O +
at O +
1 O +
cM. O +
F8C O +
was O +
also O +
tightly O +
linked O +
to O +
ALD U-Disease +
with O +
a O +
maximal O +
LOD O +
score O +
of O +
7 O -
. O +
8 O +
without O +
recombination O -
. O -

Multipoint O +
linkage O +
analysis O +
with O +
the O +
markers O +
DXS304 O -
, O +
DXS52 O -
, O +
and O +
F8C O +
indicated O +
that O +
both O +
the O +
gene O +
for O +
ALD U-Disease +
and O +
for O +
F8C O +
are O +
distal O +
to O +
DXS52 O -
. O -

In O +
four O +
patients O +
with O +
ALD U-Disease -
, O +
no O +
major O +
structural O +
rearrangement O +
in O +
the O +
Xqter O +
region O +
was O +
observed O -
; O +
in O +
particular O -
, O +
there O +
were O +
no O +
abnormalities B-Disease +
in I-Disease +
the I-Disease +
vision I-Disease +
blindness I-Disease +
genes L-Disease -
. O -

DNA O +
analysis O +
appeared O +
to O +
be O +
of O +
use O +
in O +
determination O +
of O +
the O +
carrier O +
status O +
of O +
females O +
at O +
risk O -
, O +
for O +
the O +
determination O +
of O +
the O +
origin O +
of O +
the O +
mutation O +
in O +
a O +
particular O +
family O -
, O +
and O +
for O +
prenatal O +
diagnosis O -
. O -

Huntington B-Disease +
disease L-Disease +
and O +
childhood O -
- O -
onset O +
Tourette B-Disease +
syndrome L-Disease -
. O -

A O +
40-year O -
- O -
old O +
man O +
with O +
childhood O -
- O -
onset O +
Tourette B-Disease +
syndrome L-Disease +
( O -
TS U-Disease -
) O +
developed O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O -
. O -

We O +
believe O +
this O +
to O +
be O +
the O +
first O +
reported O +
case O +
of O +
childhood O -
- O -
onset O +
TS U-Disease +
with O +
adult O +
onset O +
HD U-Disease -
. O -

Discovery O +
of O +
other O +
cases O +
with O +
both O +
disorders O +
may O +
provide O +
clues O +
to O +
the O +
pathophysiology O +
of O +
both O +
conditions O -
.. O -

Linkage O +
of O +
aspartylglucosaminuria U-Disease +
( O -
AGU U-Disease -
) O +
to O +
marker O +
loci O +
on O +
the O +
long O +
arm O +
of O +
chromosome O +
4 O -
. O -

Aspartylglucosaminuria U-Disease +
( O -
AGU U-Disease -
) O +
is O +
caused O +
by O +
deficient O +
activity O +
of O +
the O +
enzyme O +
aspartylglucosaminidase O +
( O -
AGA O -
) O -
. O -

The O +
structural O +
gene O +
for O +
AGA O +
has O +
been O +
assigned O +
to O +
the O +
region O +
4q21-qter O +
of O +
chromosome O +
4 O -
. O -

We O +
have O +
studied O +
the O +
map O +
position O +
of O +
the O +
AGU O +
locus O +
in O +
relation O +
to O +
other O +
marker O +
loci O +
on O +
the O +
long O +
arm O +
of O +
chromosome O +
4 O +
using O +
linkage O +
analyses O -
. O -

Restriction O +
fragment O +
length O +
polymorphism O +
alleles O +
for O +
the O +
ADH2 O -
, O +
ADH3 O -
, O +
EGF O -
, O +
FG O +
alpha O +
and O +
FG O +
beta O +
loci O +
and O +
blood O +
group O +
antigens O +
for O +
the O +
MNS O +
locus O +
were O +
determined O +
in O +
a O +
panel O +
of O +
12 O +
Finnish O +
AGU U-Disease +
families O -
. O -

The O +
heterozygous O +
family O +
members O +
were O +
identified O +
by O +
reduced O +
activity O +
of O +
AGA O +
in O +
lymphocytes O -
. O -

Linkage O +
studies O +
were O +
performed O +
using O +
both O +
pairwise O +
and O +
multipoint O +
analyses O -
. O -

Loose O +
linkage O +
of O +
the O +
AGU U-Disease +
locus O +
to O +
the O +
FG O +
and O +
MNS O +
loci O +
was O +
observed O +
( O -
z O +
= O +
1 O -
. O +
16 O -
, O +
z O +
= O +
1 O -
. O +
39 O -
, O +
respectively O -
) O -
. O -

Multipoint O +
analysis O +
to O +
the O +
fixed O +
map O +
[ O -
ADH- O +
( O -
0 O -
. O +
03 O -
) O +
-EGF- O +
( O -
0 O -
. O +
35 O -
) O +
-FG- O +
( O -
0 O -
. O +
11 O -
) O +
-MNS O -
] O +
suggests O +
that O +
the O +
location O +
of O +
the O +
AGU O +
locus O +
is O +
0 O -
. O +
05 O -
- O -
0 O -
. O +
30 O +
recombination O +
units O +
distal O +
to O +
MNS O +
( O -
z O +
= O +
3 O -
. O +
03 O -
) O -
. O -

The O +
order O +
cen O -
- O -
ADH O -
- O -
EGF O -
- O -
FG O -
- O -
MNS O -
- O -
AGU O +
is O +
35 O +
times O +
more O +
likely O +
than O +
the O +
next O +
best O +
order O +
cen O -
- O -
ADH O -
- O -
EGF O -
- O -
AGU O -
- O -
FG O -
- O -
MNS O -
. O -

Detection O +
of O +
98 O -
% O +
of O +
DMD U-Disease -
/ O -
BMD U-Disease +
gene O +
deletions O +
by O +
polymerase O +
chain O +
reaction O -
. O -

We O +
describe O +
oligonucleotide O +
primer O +
sequences O +
that O +
can O +
be O +
used O +
to O +
amplify O +
eight O +
exons O +
plus O +
the O +
muscle O +
promoter O +
of O +
the O +
dystrophin O +
gene O +
in O +
a O +
single O +
multiplex O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O -
. O -

When O +
used O +
in O +
conjunction O +
with O +
an O +
existing O +
primer O +
set O -
, O +
these O +
two O +
multiplex O +
reactions O +
detect O +
about O +
98 O -
% O +
of O +
deletions O +
in O +
patients O +
with O +
Duchenne B-Disease +
or I-Disease +
Becker I-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
DMD U-Disease -
, O +
BMD U-Disease -
) O -
. O -

Furthermore O -
, O +
these O +
primers O +
amplify O +
most O +
of O +
the O +
exons O +
in O +
the O +
deletion O +
prone O +
" O +
hot O +
spot O +
" O +
region O +
around O +
exons O +
44 O +
to O +
53 O -
, O +
allowing O +
determination O +
of O +
deletion O +
endpoints O +
and O +
prediction O +
of O +
mutational O +
effects O +
on O +
the O +
translational O +
reading O +
frame O -
. O -

Thus O -
, O +
use O +
of O +
these O +
PCR O -
- O -
based O +
assays O +
will O +
allow O +
deletion O +
detection O +
and O +
prenatal O +
diagnosis O +
for O +
most O +
DMD U-Disease -
/ O -
BMD U-Disease +
patients O +
in O +
a O +
fraction O +
of O +
the O +
time O +
required O +
for O +
Southern O +
blot O +
analysis O -
.. O -

Statistical O +
analysis O +
of O +
the O +
two O +
stage O +
mutation O +
model O +
in O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
disease L-Disease -
, O +
and O +
in O +
sporadic B-Disease +
cerebellar I-Disease +
haemangioblastoma L-Disease +
and O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease -
. O -

Analysis O +
of O +
the O +
age O +
incidence O +
curves O +
for O +
unilateral B-Disease +
and I-Disease +
bilateral I-Disease +
retinoblastoma L-Disease +
led O +
Knudson O +
to O +
propose O +
that O +
hereditary B-Disease +
tumours L-Disease +
may O +
arise O +
by O +
a O +
single O +
event O +
and O +
sporadic B-Disease +
tumours L-Disease +
by O +
a O +
two O +
stage O +
mutation O +
process O -
. O -

It O +
has O +
been O +
suggested O +
recently O +
that O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease +
may O +
arise O +
from O +
a O +
two O +
stage O +
mutation O +
process O -
. O -

We O +
analysed O +
the O +
age O +
incidence O +
curves O +
for O +
symptomatic O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
( O -
n O +
= O +
26 O -
) O +
and O +
cerebellar B-Disease +
haemangioblastoma L-Disease +
( O -
n O +
= O +
68 O -
) O +
in O +
109 O +
patients O +
with O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
( I-Disease -
VHL I-Disease -
) I-Disease +
disease L-Disease -
, O +
and O +
compared O +
them O +
to O +
104 O +
patients O +
with O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease +
and O +
43 O +
patients O +
with O +
sporadic B-Disease +
cerebellar I-Disease +
haemangioblastoma L-Disease -
. O -

The O +
age O +
incidence O +
curves O +
for O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
and O +
cerebellar B-Disease +
haemangioblastoma L-Disease +
in O +
VHL B-Disease +
disease L-Disease +
were O +
compatible O +
with O +
a O +
single O +
mutation O +
model O -
, O +
whereas O +
the O +
age O +
incidence O +
curves O +
for O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease +
and O +
cerebellar B-Disease +
haemangioblastoma L-Disease +
suggested O +
a O +
two O +
stage O +
mutation O +
process O -
. O -

These O +
data O +
are O +
compatible O +
with O +
the O +
VHL U-Disease +
gene O +
functioning O +
as O +
a O +
recessive O +
tumour U-Disease +
suppressor O +
gene O -
. O -

Sporadic B-Disease +
cerebellar I-Disease +
haemangioblastoma L-Disease +
and O +
some O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
may O +
arise O +
from O +
somatic O +
mutations O +
inactivating O +
both O +
alleles O +
at O +
the O +
VHL U-Disease +
locus O -
.. O -

Molecular O +
and O +
phenotypic O +
analysis O +
of O +
patients O +
with O +
deletions O +
within O +
the O +
deletion O -
- O -
rich O +
region O +
of O +
the O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
DMD U-Disease -
) O +
gene O -
. O -

Eighty O +
unrelated O +
individuals O +
with O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
DMD U-Disease -
) O -
or O +
Becker B-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
BMD U-Disease -
) O +
were O +
found O +
to O +
have O +
deletions O +
in O +
the O +
major O +
deletion O -
- O -
rich O +
region O +
of O +
the O +
DMD U-Disease +
locus O -
. O -

This O +
region O +
includes O +
the O +
last O +
five O +
exons O +
detected O +
by O +
cDNA5b-7 O -
, O +
all O +
exons O +
detected O +
by O +
cDNA8 O -
, O +
and O +
the O +
first O +
two O +
exons O +
detected O +
by O +
cDNA9 O -
. O -

These O +
80 O +
individuals O +
account O +
for O +
approximately O +
75 O -
% O +
of O +
109 O +
deletions O +
of O +
the O +
gene O -
, O +
detected O +
among O +
181 O +
patients O +
analyzed O +
with O +
the O +
entire O +
dystrophin O +
cDNA O -
. O -

Endpoints O +
for O +
many O +
of O +
these O +
deletions O +
were O +
further O +
characterized O +
using O +
two O +
genomic O +
probes O -
, O +
p20 O +
( O -
DXS269 O -
; O +
Wapenaar O +
et O +
al. O -
) O +
and O +
GMGX11 O +
( O -
DXS239 O -
; O +
present O +
paper O -
) O -
. O -

Clinical O +
findings O +
are O +
presented O +
for O +
all O +
80 O +
patients O +
allowing O +
a O +
correlation O +
of O +
phenotypic O +
severity O +
with O +
the O +
genotype O -
. O -

Thirty O -
- O -
eight O +
independent O +
patients O +
were O +
old O +
enough O +
to O +
be O +
classified O +
as O +
DMD U-Disease -
, O +
BMD U-Disease -
, O +
or O +
intermediate O +
phenotype O +
and O +
had O +
deletions O +
of O +
exons O +
with O +
sequenced O +
intron O -
/ O -
exon O +
boundaries O -
. O -

Of O +
these O -
, O +
eight O +
BMD U-Disease +
patients O +
and O +
one O +
intermediate O +
patient O +
had O +
gene O +
deletions O +
predicted O +
to O +
leave O +
the O +
reading O +
frame O +
intact O -
, O +
while O +
21 O +
DMD U-Disease +
patients O -
, O +
7 O +
intermediate O +
patients O -
, O +
and O +
1 O +
BMD U-Disease +
patient O +
had O +
gene O +
deletions O +
predicted O +
to O +
disrupt O +
the O +
reading O +
frame O -
. O -

Thus O -
, O +
with O +
two O +
exceptions O -
, O +
frameshift O +
deletions O +
of O +
the O +
gene O +
resulted O +
in O +
more O +
severe O +
phenotype O +
than O +
did O +
in O -
- O -
frame O +
deletions O -
. O -

This O +
is O +
in O +
agreement O +
with O +
recent O +
findings O +
by O +
Baumbach O +
et O +
al. O +
and O +
Koenig O +
et O +
al. O +
but O +
is O +
in O +
contrast O +
to O +
findings O -
, O +
by O +
Malhotra O +
et O +
al. O +
at O +
the O +
5 O +
' O +
end O +
of O +
the O +
gene O -
. O -

X B-Disease -
- I-Disease -
linked I-Disease +
glucose-6-phosphate I-Disease +
dehydrogenase I-Disease +
deficiency L-Disease +
in O +
Mus O +
musculus O -
. O -

A O +
mouse O +
with O +
X B-Disease -
- I-Disease -
linked I-Disease +
glucose-6-phosphate I-Disease +
dehydrogenase I-Disease +
( I-Disease -
G6PD I-Disease -
) I-Disease +
deficiency L-Disease +
has O +
been O +
recovered O +
in O +
offspring O +
of O +
1-ethyl-1-nitrosourea O -
- O -
treated O +
male O +
mice O -
. O -

The O +
activity O +
alteration O +
was O +
detected O +
in O +
blood O +
but O +
can O +
also O +
be O +
observed O +
in O +
other O +
tissue O +
extracts O -
. O -

Hemizygous O -
, O +
heterozygous O -
, O +
and O +
homozygous O +
mutants O +
have O -
, O +
respectively O -
, O +
about O +
15 O -
, O +
60 O -
, O +
and O +
15 O -
% O +
G6PD O +
remaining O +
activity O +
in O +
the O +
blood O +
as O +
compared O +
to O +
the O +
wild O +
type O -
. O -

Erythrocyte O +
indices O +
did O +
not O +
show O +
differences O +
between O +
mutants O +
and O +
wild O +
types O -
. O -

The O +
mutation O +
does O +
not O +
affect O +
the O +
electrophoretic O +
migration O -
, O +
the O +
isoelectric O +
point O -
, O +
or O +
the O +
thermal O +
stability O -
. O -

Kinetic O +
properties O -
, O +
such O +
as O +
the O +
Km O +
for O +
glucose-6-phosphate O +
or O +
for O +
NADP O +
and O +
the O +
relative O +
utilization O +
of O +
substrate O +
analogues O -
, O +
showed O +
no O +
differences O +
between O +
wild O +
types O +
and O +
mutants O +
with O +
the O +
exception O +
of O +
the O +
relative O +
utilization O +
of O +
deamino O -
- O -
NADP O +
which O +
was O +
significantly O +
lower O +
in O +
mutants O -
. O -

This O +
is O +
presently O +
the O +
only O +
animal O +
model O +
for O +
X B-Disease -
- I-Disease -
linked I-Disease +
G6PD I-Disease +
deficiency L-Disease +
in O +
humans O -
.. O -

Genetic O +
analysis O +
in O +
families O +
with O +
van B-Disease +
der I-Disease +
Woude I-Disease +
syndrome L-Disease -
. O -

We O +
have O +
brought O +
together O +
information O +
on O +
864 O +
affected O +
individuals O +
in O +
164 O +
families O +
( O -
including O +
three O +
new O +
pedigrees O -
) O +
reported O +
in O +
the O +
137 O +
year O +
period O +
since O +
1845 O +
when O +
Demarquay O +
first O +
described O +
a O +
family O +
with O +
what O +
was O +
later O +
called O +
van B-Disease +
der I-Disease +
Woude I-Disease +
syndrome L-Disease +
( O -
VWS U-Disease -
) O -
. O -

Both O +
types O +
of O +
oral B-Disease +
cleft L-Disease -
, O +
cleft B-Disease +
palate L-Disease +
( O -
CP U-Disease -
) O +
and O +
cleft B-Disease +
lip L-Disease +
with O +
or O +
without O +
CP U-Disease +
( O -
CLP U-Disease -
) O -
, O +
segregate O +
in O +
these O +
families O +
together O +
with O +
lower O +
lip B-Disease +
pits L-Disease +
or O +
fistulae U-Disease +
in O +
an O +
autosomal O +
dominant O +
mode O +
with O +
high O +
penetrance O +
estimated O +
to O +
be O +
K O +
= O -
. O -

89 O +
and O -
. O +
99 O +
by O +
different O +
methods O -
. O -

Cleft O +
types O +
( O -
CLP U-Disease +
and O +
CP U-Disease -
) O +
occur O +
in O +
VWS U-Disease +
in O +
the O +
same O +
proportions O +
as O +
in O +
the O +
general O +
non O -
- O -
VWS O +
population O -
, O +
ie O -
, O +
about O +
twice O +
as O +
many O +
cleft O -
- O -
bearing O +
individuals O +
have O +
CLP U-Disease +
as O +
have O +
CP U-Disease -
. O -

On O +
the O +
other O +
hand O -
, O +
we O +
do O +
not O +
find O +
the O +
usually O +
observed O +
excess O +
of O +
females O +
with O +
CP U-Disease +
and O +
excess O +
of O +
males O +
with O +
CLP U-Disease -
; O +
in O +
VWS U-Disease +
the O +
sex O +
ratios O +
are O +
more O +
nearly O +
equal O -
. O -

Lip B-Disease +
pits L-Disease +
also O +
are O +
equally O +
distributed O +
between O +
the O +
sexes O -
. O -

Affected O +
males O +
and O +
females O +
are O +
equally O +
likely O +
to O +
transmit O +
VWS U-Disease -
. O -

However O -
, O +
there O +
is O +
an O +
excess O +
of O +
less O +
severely O +
affected O +
individuals O +
among O +
transmitters O +
and O +
a O +
deficiency O +
of O +
more O +
severely O +
affected O -
, O +
brought O +
about O +
by O +
a O +
proband O +
bias O +
and O +
differential O +
fecundity O -
. O -

The O +
expression O +
of O +
VWS U-Disease +
is O +
significantly O +
modified O +
by O +
the O +
genetic O +
background O -
More O +
extreme O +
phenotypes O +
in O +
parents O +
tend O +
to O +
produce O +
more O +
extreme O +
expression O +
in O +
their O +
children O -
. O -

For O +
a O +
VWS U-Disease +
gene O +
carrier O +
the O +
relative O +
risk O +
of O +
transmitting O +
a O +
cleft O +
is O +
26 O -
. O +
45 O -
% O -
; O +
that O +
of O +
transmitting O +
lower O +
lip B-Disease +
pits L-Disease +
is O +
23 O -
. O +
55 O -
% O -
. O -

Three O +
pedigrees O +
of O +
lip B-Disease +
pits L-Disease +
in O +
the O +
literature O +
show O +
no O +
clefts O +
among O +
a O +
significant O +
number O +
of O +
affected O +
individuals O -
. O -

Control O +
of O +
gene O +
expression O +
in O +
VWS U-Disease +
in O +
the O +
three O +
target O +
tissues O +
appears O +
to O +
be O +
independent O +
and O +
separately O +
designated O -
. O -

Mutation O +
rate O +
of O +
the O +
VWS U-Disease +
gene O +
is O +
calculated O +
to O +
be O +
1 O -
. O +
8 O +
X O +
10 O +
( O -
-5 O -
) O -

Familial B-Disease +
discoid I-Disease +
lupus I-Disease +
erythematosus L-Disease +
associated O +
with O +
heterozygote O +
C2 B-Disease +
deficiency L-Disease -
. O -

Two O +
siblings O +
with O +
chronic B-Disease +
discoid I-Disease +
lupus I-Disease +
erythematosus L-Disease +
and O +
several O +
family O +
members O +
were O +
found O +
with O +
heterozygous O +
C2 B-Disease +
deficiency L-Disease -
. O -

An O +
association O +
with O +
histocompatibility O +
markers O +
HLA O -
- O -
B18 O +
and O +
HLA O -
- O -
Dw2 O +
was O +
demonstrated O -
, O +
and O +
the O +
slow O +
allotype O +
of O +
factor O +
B O +
was O +
present O -
. O -

Linkage O +
studies O +
in O +
this O +
family O +
suggested O +
a O +
close O +
linkage O +
between O +
the O +
C2 B-Disease +
deficiency L-Disease +
gene O +
and O +
genes O +
coding O +
for O +
B18 O -
, O +
Dw2 O -
, O +
and O +
BfS O +
antigens O -
. O -

One O +
HLA O -
- O -
ACB O -
/ O -
DBf O +
recombinant O +
was O +
observed O +
showing O +
closer O +
linkage O +
between O +
HLA O -
- O -
D O +
and O +
Bf O +
than O +
between O +
HLA O -
- O -
B O +
and O +
Bf O -
.. O -

New O +
genetic O +
variants O +
of O +
glucose O +
6-phosphate O +
dehydrogenase O +
( O -
G6PD O -
) O +
in O +
Italy O -
. O -

Six O +
new O +
variants O +
of O +
human O +
erythrocyte O +
G6PD O +
have O +
been O +
characterized O -
. O -

All O +
of O +
them O +
were O +
found O +
in O +
Italian O +
males O +
and O +
all O +
were O +
associated O +
with O +
enzyme B-Disease +
deficiency L-Disease -
, O +
but O +
only O +
two O +
with O +
signs O +
of O +
haemolysis U-Disease -
. O -

These O +
and O +
other O +
variants O +
reported O +
in O +
the O +
literature O -
, O +
which O +
must O +
thus O +
far O +
be O +
regarded O +
as O +
sporadic O -
, O +
are O +
found O +
to O +
map O +
in O +
parts O +
of O +
Italy O +
where O +
common O +
types O +
of O +
G6PD B-Disease +
deficiency L-Disease +
are O +
also O +
prevalent O -
.. O -

Aberrant O +
subcellular O +
localization O +
of O +
BRCA1 O +
in O +
breast B-Disease +
cancer L-Disease -
. O -

The O +
BRCA1 O +
gene O +
product O +
was O +
identified O +
as O +
a O +
220-kilodalton O +
nuclear O +
phosphoprotein O +
in O +
normal O +
cells O -
, O +
including O +
breast O +
ductal O +
epithelial O +
cells O -
, O +
and O +
in O +
18 O +
of O +
20 O +
tumor U-Disease +
cell O +
lines O +
derived O +
from O +
tissues O +
other O +
than O +
breast O +
and O +
ovary O -
. O -

In O +
16 O +
of O +
17 O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
lines O +
and O +
17 O +
of O +
17 O +
samples O +
of O +
cells O +
obtained O +
from O +
malignant O +
effusions O -
, O +
however O -
, O +
BRCA1 O +
localized O +
mainly O +
in O +
cytoplasm O -
. O -

Absence O +
of O +
BRCA1 O +
or O +
aberrant O +
subcellular O +
location O +
was O +
also O +
observed O +
to O +
a O +
variable O +
extent O +
in O +
histological O +
sections O +
of O +
many O +
breast B-Disease +
cancer L-Disease +
biopsies O -
. O -

These O +
findings O +
suggest O +
that O +
BRCA1 B-Disease +
abnormalities L-Disease +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
many O +
breast B-Disease +
cancers L-Disease -
, O +
sporadic O +
as O +
well O +
as O +
familial O -
.. O -

The O +
carrier O +
frequency O +
of O +
the O +
BRCA1 O +
185delAG O +
mutation O +
is O +
approximately O +
1 O +
percent O +
in O +
Ashkenazi O +
Jewish O +
individuals O -
. O -

Since O +
BRCA1 O -
, O +
the O +
first O +
major O +
gene O +
responsible O +
for O +
inherited B-Disease +
breast I-Disease +
cancer L-Disease -
, O +
was O +
cloned O -
, O +
more O +
than O +
50 O +
unique O +
mutations O +
have O +
been O +
detected O +
in O +
the O +
germline O +
of O +
individuals O +
with O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

In O +
high O -
- O -
risk O +
pedigrees O -
, O +
female O +
carriers O +
of O +
BRCA1 O +
mutations O +
have O +
an O +
80 O -
- O -
90 O -
% O +
lifetime O +
risk O +
of O +
breast B-Disease +
cancer L-Disease -
, O +
and O +
a O +
40 O -
- O -
50 O -
% O +
risk O +
of O +
ovarian B-Disease +
cancer L-Disease -
. O -

However O -
, O +
the O +
mutation O +
stats O +
of O +
individuals O +
unselected O +
for O +
breast B-Disease +
or I-Disease +
ovarian I-Disease +
cancer L-Disease +
has O +
not O +
been O +
determined O -
, O +
and O +
it O +
is O +
not O +
known O +
whether O +
mutations O +
in O +
such O +
individuals O +
confer O +
the O +
same O +
risk O +
of O +
cancer U-Disease +
as O +
in O +
individuals O +
from O +
the O +
high O -
- O -
risk O +
families O +
studied O +
so O +
far O -
. O -

Following O +
the O +
finding O +
of O +
a O +
185delAG O +
frameshift O +
mutation O +
in O +
several O +
Ashkenazi O +
Jewish O +
breast O -
/ O -
ovarian O +
families O -
, O +
we O +
have O +
determined O +
the O +
frequency O +
of O +
this O +
mutation O +
in O +
858 O +
Ashkenazim O +
seeking O +
genetic O +
testing O +
for O +
conditions O +
unrelated O +
to O +
cancer U-Disease -
, O +
and O +
in O +
815 O +
reference O +
individuals O +
not O +
selected O +
for O +
ethnic O +
origin O -
. O -

We O +
observed O +
the O +
185delAG O +
mutation O +
in O +
0 O -
. O +
9 O -
% O +
of O +
Ashkenazim O +
( O -
95 O -
% O +
confidence O +
limit O -
, O +
0 O -
. O +
4 O -
- O -
1 O -
. O +
8 O -
% O -
) O +
and O +
in O +
none O +
of O +
the O +
reference O +
samples O -
. O -

Our O +
results O +
suggest O +
that O +
one O +
in O +
a O +
hundred O +
women O +
of O +
Ashkenazi O +
descent O +
may O +
be O +
at O +
especially O +
high O +
risk O +
of O +
developing O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

The O +
protein O +
deficient O +
in O +
Lowe B-Disease +
syndrome L-Disease +
is O +
a O +
phosphatidylinositol-4,5-bisphosphate O +
5-phosphatase O -
. O -

Lowe B-Disease +
syndrome L-Disease -
, O +
also O +
known O +
as O +
oculocerebrorenal B-Disease +
syndrome L-Disease -
, O +
is O +
caused O +
by O +
mutations O +
in O +
the O +
X O +
chromosome O -
- O -
encoded O +
OCRL O +
gene O -
. O -

The O +
OCRL O +
protein O +
is O +
51 O -
% O +
identical O +
to O +
inositol O +
polyphosphate O +
5-phosphatase O +
II O +
( O -
5-phosphatase O +
II O -
) O +
from O +
human O +
platelets O +
over O +
a O +
span O +
of O +
744 O +
aa O -
, O +
suggesting O +
that O +
OCRL O +
may O +
be O +
a O +
similar O +
enzyme O -
. O -

We O +
engineered O +
a O +
construct O +
of O +
the O +
OCRL O +
cDNA O +
that O +
encodes O +
amino O +
acids O +
homologous O +
to O +
the O +
platelet O +
5-phosphatase O +
for O +
expression O +
in O +
baculovirus O -
- O -
infected O +
Sf9 O +
insect O +
cells O -
. O -

This O +
cDNA O +
encodes O +
aa O +
264 O -
- O -
968 O +
of O +
the O +
OCRL O +
protein O -
. O -

The O +
recombinant O +
protein O +
was O +
found O +
to O +
catalyze O +
the O +
reactions O +
also O +
carried O +
out O +
by O +
platelet O +
5-phosphatase O +
II O -
. O -

Thus O +
OCRL O +
converts O +
inositol O +
1 O -
, O +
4 O -
, O +
5-trisphosphate O +
to O +
inositol O +
1 O -
, O +
4-bisphosphate O -
, O +
and O +
it O +
converts O +
inositol O +
1 O -
, O +
3 O -
, O +
4 O -
, O +
5-tetrakisphosphate O +
to O +
inositol O +
1 O -
, O +
3 O -
, O +
4-trisphosphate O -
. O -

Most O +
important O -
, O +
the O +
enzyme O +
converts O +
phosphatidylinositol O +
4 O -
, O +
5-bisphosphate O +
to O +
phosphatidylinositol O +
4-phosphate O -
. O -

The O +
relative O +
ability O +
of O +
OCRL O +
to O +
catalyze O +
the O +
three O +
reactions O +
is O +
different O +
from O +
that O +
of O +
5-phosphatase O +
II O +
and O +
from O +
that O +
of O +
another O +
5-phosphatase O +
isoenzyme O +
from O +
platelets O -
, O +
5-phosphatase O +
I. O +
The O +
recombinant O +
OCRL O +
protein O +
hydrolyzes O +
the O +
phospholipid O +
substrate O +
10- O +
to O +
30-fold O +
better O +
than O +
5-phosphatase O +
II O -
, O +
and O +
5-phosphatase O +
I O +
does O +
not O +
cleave O +
the O +
lipid O +
at O +
all O -
. O -

We O +
also O +
show O +
that O +
OCRL O +
functions O +
as O +
a O +
phosphatidylinositol O +
4 O -
, O +
5-bisphosphate O +
5-phosphatase O +
in O +
OCRL O -
- O -
expressing O +
Sf9 O +
cells O -
. O -

These O +
results O +
suggest O +
that O +
OCRL O +
is O +
mainly O +
a O +
lipid O +
phosphatase O +
that O +
may O +
control O +
cellular O +
levels O +
of O +
a O +
critical O +
metabolite O -
, O +
phosphatidylinositol O +
4 O -
, O +
5-bisphosphate O -
. O -

Deficiency O +
of O +
this O +
enzyme O +
apparently O +
causes O +
the O +
protean O +
manifestations O +
of O +
Lowe B-Disease +
syndrome L-Disease -
.. O -

A O +
single O +
amino O +
acid O +
substitution O +
( O -
G103D O -
) O +
in O +
the O +
type O +
II O +
collagen O +
triple O +
helix O +
produces O +
Kniest B-Disease +
dysplasia L-Disease -
. O -

Kniest B-Disease +
dysplasia L-Disease +
is O +
a O +
moderately O +
severe O +
chondrodysplasia U-Disease +
phenotype O +
that O +
results O +
from O +
mutations O +
in O +
the O +
gene O +
for O +
type O +
II O +
collagen O -
, O +
COL2A1 O -
. O -

Characteristics O +
of O +
the O +
disorder O +
include O +
a O +
short B-Disease +
trunk I-Disease +
and I-Disease +
extremities L-Disease -
, O +
mid B-Disease -
- I-Disease -
face I-Disease +
hypoplasia L-Disease -
, O +
cleft B-Disease +
palate L-Disease -
, O +
myopia U-Disease -
, O +
retinal B-Disease +
detachment L-Disease -
, O +
and O +
hearing B-Disease +
loss L-Disease -
. O -

Recently O -
, O +
deletions O +
of O +
all O +
or O +
part O +
of O +
exon O +
12 O +
have O +
been O +
identified O +
in O +
individuals O +
with O +
Kniest B-Disease +
dysplasia L-Disease -
, O +
suggesting O +
that O +
mutations O +
within O +
this O +
region O +
of O +
the O +
protein O +
may O +
primarily O +
result O +
in O +
the O +
Kniest B-Disease +
dysplasia L-Disease +
phenotype O -
. O -

We O +
used O +
SSCP O +
to O +
analyze O +
an O +
amplified O +
genomic O +
DNA O +
fragment O +
containing O +
exon O +
12 O +
from O +
seven O +
individuals O +
with O +
Kniest B-Disease +
dysplasia L-Disease -
. O -

An O +
abnormality O +
was O +
identified O +
in O +
one O +
patient O -
. O -

DNA O +
sequence O +
analysis O +
demonstrated O +
that O +
the O +
patient O +
was O +
heterozygous O +
for O +
a O +
G O +
to O +
A O +
transition O +
that O +
implied O +
substitution O +
of O +
glycine103 O +
of O +
the O +
triple O +
helical O +
domain O +
by O +
aspartate O -
. O -

The O +
mutation O +
was O +
not O +
observed O +
in O +
DNA O +
from O +
either O +
of O +
the O +
clinically O +
unaffected O +
parents O +
of O +
the O +
proband O -
. O -

Protein O +
microsequencing O +
demonstrated O +
expression O +
of O +
the O +
abnormal O +
allele O +
in O +
cartilage O -
. O -

These O +
data O +
demonstrate O +
that O +
point O +
mutations O +
which O +
result O +
in O +
single O +
amino O +
acid O +
substitutions O +
can O +
produce O +
Kniest B-Disease +
dysplasia L-Disease +
and O +
further O +
support O +
the O +
hypothesis O +
that O +
alteration O +
of O +
a O +
domain O -
, O +
which O +
includes O +
the O +
region O +
encoded O +
by O +
exon O +
12 O -
, O +
in O +
the O +
type O +
II O +
collagen O +
protein O +
leads O +
to O +
this O +
disorder O -
.. O -

Mutation O +
spectrum O +
in O +
the O +
CHM U-Disease +
gene O +
of O +
Danish O +
and O +
Swedish O +
choroideremia U-Disease +
patients O -
. O -

The O +
recent O +
isolation O +
of O +
the O +
complete O +
open O +
reading O +
frame O +
of O +
the O +
choroideremia U-Disease +
( O -
CHM U-Disease -
) O +
gene O +
and O +
the O +
characterization O +
of O +
the O +
exon O -
- O -
intron O +
boundaries O +
has O +
paved O +
the O +
way O +
to O +
mutation O +
detection O +
in O +
patients O +
with O +
classical O +
choroideremia U-Disease -
. O -

We O +
have O +
performed O +
mutation O +
screening O +
in O +
patients O +
from O +
15 O +
Danish O +
and O +
Swedish O +
families O +
by O +
using O +
Southern O +
blot O +
hybridization O +
and O +
the O +
polymerase O +
chain O +
reaction O +
single O -
- O -
strand O +
conformation O +
polymorphism O +
( O -
PCR O -
- O -
SSCP O -
) O +
technique O -
. O -

Causative O +
mutations O +
in O +
the O +
CHM U-Disease +
gene O +
were O +
detected O +
in O +
at O +
least O +
12 O +
families O -
, O +
indicating O +
that O +
a O +
substantial O +
part O +
of O +
the O +
mutations O +
can O +
be O +
identified O +
by O +
this O +
approach O -
. O -

In O +
four O +
of O +
these O +
families O +
deletions O +
of O +
different O +
sizes O +
were O +
found O -
. O -

Thus O -
, O +
in O +
one O +
patient O -
, O +
the O +
deletion O +
resulted O +
in O +
the O +
absence O +
of O +
only O +
one O +
exon O -
, O +
while O +
in O +
another O +
the O +
deletion O +
comprised O +
the O +
entire O +
CHM U-Disease +
gene O -
. O -

Mapping O +
of O +
the O +
deletion O +
endpoints O +
in O +
these O +
four O +
patients O +
and O +
in O +
another O +
11 O +
male O +
patients O +
with O +
sizeable O +
deletions O +
enabled O +
us O +
to O +
construct O +
a O +
very O +
detailed O +
map O +
of O +
intervals O +
2 O +
and O +
3 O +
of O +
Xq21 O -
. O -

In O +
the O +
remaining O +
11 O +
Danish O +
and O +
Swedish O +
families O +
at O +
least O +
8 O +
causative O +
mutations O +
were O +
found O +
by O +
PCR O -
- O -
SSCP O +
analysis O +
and O +
direct O +
sequencing O -
. O -

Interestingly O -
, O +
all O +
CHM U-Disease +
gene O +
mutations O +
detected O +
thus O +
far O +
in O +
choroideremia U-Disease +
patients O +
give O +
rise O +
to O +
the O +
introduction O +
of O +
a O +
premature O +
stop O +
codon O -
.. O -

X B-Disease -
- I-Disease -
linked I-Disease +
spastic I-Disease +
paraplegia L-Disease +
and O +
Pelizaeus B-Disease -
- I-Disease -
Merzbacher I-Disease +
disease L-Disease +
are O +
allelic B-Disease +
disorders L-Disease +
at O +
the O +
proteolipid O +
protein O +
locus O -
. O -

Three O +
forms O +
of O +
X B-Disease -
- I-Disease -
linked I-Disease +
spastic I-Disease +
paraplegia L-Disease +
( O -
SPG U-Disease -
) O +
have O +
been O +
defined O -
. O -

One O +
locus O +
( O -
SPG O +
1 O -
) O +
maps O +
to O +
Xq28 O +
while O +
two O +
clinically O +
distinct O +
forms O +
map O +
to O +
Xq22 O +
( O -
SPG2 O -
) O -
. O -

A O +
rare O +
X B-Disease -
- I-Disease -
linked I-Disease +
dysmyelinating I-Disease +
disorder L-Disease +
of O +
the O +
central O +
nervous O +
system O -
, O +
Pelizaeus B-Disease -
- I-Disease -
Merzbacher I-Disease +
disease L-Disease +
( O -
PMD U-Disease -
) O -
, O +
has O +
also O +
been O +
mapped O +
to O +
Xq21-q22 O -
, O +
and O +
is O +
caused O +
by O +
mutations O +
in O +
the O +
proteolipid O +
protein O +
gene O +
( O -
PLP O -
) O +
which O +
encodes O +
two O +
myelin O +
proteins O -
, O +
PLP O +
and O +
DM20 O -
. O -

While O +
narrowing O +
the O +
genetic O +
interval O +
containing O +
SPG2 O +
in O +
a O +
large O +
pedigree O -
, O +
we O +
found O +
that O +
PLP O +
was O +
the O +
closest O +
marker O +
to O +
the O +
disease O +
locus O -
, O +
implicating O +
PLP O +
as O +
a O +
possible O +
candidate O +
gene O -
. O -

We O +
have O +
found O +
that O +
a O +
point O +
mutation O +
( O -
His139Tyr O -
) O +
in O +
exon O +
3B O +
of O +
an O +
affected O +
male O +
produces O +
a O +
mutant O +
PLP O +
but O +
a O +
normal O +
DM20 O -
, O +
and O +
segregates O +
with O +
the O +
disease O +
( O -
Zmax O +
= O +
6 O -
. O +
63 O -
, O +
theta O +
= O +
0 O -
. O +
00 O -
) O -
. O -

It O +
appears O -
, O +
therefore O -
, O +
that O +
SPG2 O +
and O +
PMD U-Disease +
are O +
allelic B-Disease +
disorders L-Disease -

Huntington B-Disease +
disease L-Disease +
without O +
CAG O +
expansion O -
: O +
phenocopies O +
or O +
errors O +
in O +
assignment O -
? O -

Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
has O +
been O +
shown O +
to O +
be O +
associated O +
with O +
an O +
expanded O +
CAG O +
repeat O +
within O +
a O +
novel O +
gene O +
on O +
4p16 O -
. O -

3 O +
( O -
IT15 O -
) O -
. O -

A O +
total O +
of O +
30 O +
of O +
1 O -
, O +
022 O +
affected O +
persons O +
( O -
2 O -
. O +
9 O -
% O +
of O +
our O +
cohort O -
) O +
did O +
not O +
have O +
an O +
expanded O +
CAG O +
in O +
the O +
disease O +
range O -
. O -

The O +
reasons O +
for O +
not O +
observing O +
expansion O +
in O +
affected O +
individuals O +
are O +
important O +
for O +
determining O +
the O +
sensitivity O +
of O +
using O +
repeat O +
length O +
both O +
for O +
diagnosis O +
of O +
affected O +
patients O +
and O +
for O +
predictive O +
testing O +
programs O +
and O +
may O +
have O +
biological O +
relevance O +
for O +
the O +
understanding O +
of O +
the O +
molecular O +
mechanism O +
underlying O +
HD U-Disease -
. O -

Here O +
we O +
show O +
that O +
the O +
majority O +
( O -
18 O -
) O +
of O +
the O +
individuals O +
with O +
normal O +
sized O +
alleles O +
represent O +
misdiagnosis O -
, O +
sample O +
mix O -
- O -
up O -
, O +
or O +
clerical O +
error O -
. O -

The O +
remaining O +
12 O +
patients O +
represent O +
possible O +
phenocopies O +
for O +
HD U-Disease -
. O -

In O +
at O +
least O +
four O +
cases O -
, O +
family O +
studies O +
of O +
these O +
phenocopies O +
excluded O +
4p16 O -
. O -

3 O +
as O +
the O +
region O +
responsible O +
for O +
the O +
phenotype O -
. O -

Mutations O +
in O +
the O +
HD U-Disease +
gene O +
that O +
are O +
other O +
than O +
CAG O +
expansion O +
have O +
not O +
been O +
excluded O +
for O +
the O +
remaining O +
eight O +
cases O -
; O +
however O -
, O +
in O +
as O +
many O +
as O +
seven O +
of O +
these O +
persons O -
, O +
retrospective O +
review O +
of O +
these O +
patients O +
clinical O +
features O +
identified O +
characteristics O +
not O +
typical O +
for O +
HD U-Disease -
. O -

This O +
study O +
shows O +
that O +
on O +
rare O +
occasions O +
mutations O +
in O +
other O -
, O +
as O -
- O -
yet O -
- O -
undefined O +
genes O +
can O +
present O +
with O +
a O +
clinical O +
phenotype O +
very O +
similar O +
to O +
that O +
of O +
HD U-Disease -

Assignment O +
of O +
the O +
human O +
Na+ O -
/ O -
glucose O +
cotransporter O +
gene O +
SGLT1 O +
to O +
chromosome O +
22q13.1 O -
. O -

The O +
Na O +
+ O -
/glucose O +
cotransporter O +
gene O +
SGLT1 O +
encodes O +
the O +
primary O +
carrier O +
protein O +
responsible O +
for O +
the O +
uptake O +
of O +
the O +
dietary O +
sugars O +
glucose O +
and O +
galactose O +
from O +
the O +
intestinal O +
lumen O -
. O -

SGLT1 O +
transport O +
activity O +
is O +
currently O +
exploited O +
in O +
oral O +
rehydration O +
therapy O -
. O -

The O +
75-kDa O +
glycoprotein O +
is O +
localized O +
in O +
the O +
brush O +
border O +
of O +
the O +
intestinal O +
epithelium O +
and O +
is O +
predicted O +
to O +
comprise O +
12 O +
membrane O +
spans O -
. O -

In O +
two O +
patients O +
with O +
the O +
autosomal B-Disease +
recessive I-Disease +
disease I-Disease +
glucose I-Disease -
/ I-Disease -
galactose I-Disease +
malabsorption L-Disease -
, O +
the O +
underlying O +
cause O +
was O +
found O +
to O +
be O +
a O +
missense O +
mutation O +
in O +
SGLT1 O -
, O +
and O +
the O +
Asp28 O -
- O -
- O +
> O +
Asn O +
change O +
was O +
demonstrated O +
in O +
vitro O +
to O +
eliminate O +
SGLT1 O +
transport O +
activity O -
. O -

The O +
SGLT1 O +
gene O +
was O +
previously O +
shown O +
to O +
reside O +
on O +
the O +
distal O +
q O +
arm O +
of O +
chromosome O +
22 O +
( O -
11 O -
. O +
2 O -
- O -
- O +
> O +
qter O -
) O -
. O -

We O +
have O +
used O +
a O +
cosmid O +
probe O +
for O +
fluorescence O +
in O +
situ O +
hybridization O -
, O +
which O +
refines O +
the O +
localization O +
to O +
22q13 O -
. O -

1 O -
, O +
and O +
provide O +
an O +
example O +
of O +
the O +
utility O +
of O +
the O +
SGLT1 O +
probe O +
as O +
a O +
diagnostic O +
for O +
genetic B-Disease +
diseases L-Disease +
associated O +
with O +
translocations O +
of O +
chromosome O +
22 O -
. O -

Haplotype O +
studies O +
in O +
Wilson B-Disease +
disease L-Disease -
. O -

In O +
51 O +
families O +
with O +
Wilson B-Disease +
disease L-Disease -
, O +
we O +
have O +
studied O +
DNA O +
haplotypes O +
of O +
dinucleotide O +
repeat O +
polymorphisms O +
( O -
CA O +
repeats O -
) O +
in O +
the O +
13q14 O -
. O -

3 O +
region O -
, O +
to O +
examine O +
these O +
markers O +
for O +
association O +
with O +
the O +
Wilson B-Disease +
disease L-Disease +
gene O +
( O -
WND U-Disease -
) O -
. O -

In O +
addition O +
to O +
a O +
marker O +
( O -
D13S133 O -
) O +
described O +
elsewhere O -
, O +
we O +
have O +
developed O +
three O +
new O +
highly O +
polymorphic O +
markers O +
( O -
D13S314 O -
, O +
D13S315 O -
, O +
and O +
D13S316 O -
) O +
close O +
to O +
the O +
WND U-Disease +
locus O -
. O -

We O +
have O +
examined O +
the O +
distribution O +
of O +
marker O +
alleles O +
at O +
the O +
loci O +
studied O +
and O +
have O +
found O +
that O +
D13S314 O -
, O +
D13S133 O -
, O +
and O +
D13S316 O +
each O +
show O +
nonrandom O +
distribution O +
on O +
chromosomes O +
carrying O +
the O +
WND U-Disease +
mutation O -
. O -

We O +
have O +
studied O +
haplotypes O +
of O +
these O +
three O +
markers O +
and O +
have O +
found O +
that O +
there O +
are O +
highly O +
significant O +
differences O +
between O +
WND U-Disease +
and O +
normal O +
haplotypes O +
in O +
northern O +
European O +
families O -
. O -

These O +
findings O +
have O +
important O +
implications O +
for O +
mutation O +
detection O +
and O +
molecular O +
diagnosis O +
in O +
families O +
with O +
Wilson B-Disease +
disease L-Disease -
. O -

Brca1 B-Disease +
deficiency L-Disease +
results O +
in O +
early O +
embryonic B-Disease +
lethality L-Disease +
characterized O +
by O +
neuroepithelial B-Disease +
abnormalities L-Disease -
. O -

The O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
susceptibility O +
gene O -
, O +
BRCA1 O -
, O +
has O +
been O +
cloned O +
and O +
shown O +
to O +
encode O +
a O +
zinc O -
- O -
finger O +
protein O +
of O +
unknown O +
function O -
. O -

Mutations O +
in O +
BRCA1 O +
account O +
for O +
at O +
least O +
80 O -
% O +
of O +
families O +
with O +
both O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
, O +
as O +
well O +
as O +
some O +
non O -
- O -
familial O +
sporadic O +
ovarian B-Disease +
cancers L-Disease -
. O -

The O +
loss O +
of O +
wild O -
- O -
type O +
BRCA1 O +
in O +
tumours U-Disease +
of O +
individuals O +
carrying O +
one O +
nonfunctional O +
BRCA1 O +
allele O +
suggests O +
that O +
BRCA1 O +
encodes O +
a O +
tumour U-Disease +
suppressor O +
that O +
may O +
inhibit O +
the O +
proliferation O +
of O +
mammary O +
epithelial O +
cells O -
. O -

To O +
examine O +
the O +
role O +
of O +
BRCA1 O +
in O +
normal O +
tissue O +
growth O +
and O +
differentiation O -
, O +
and O +
to O +
generate O +
a O +
potential O +
model O +
for O +
the O +
cancer U-Disease +
susceptibility O +
associated O +
with O +
loss O +
of O +
BRCA1 O +
function O -
, O +
we O +
have O +
created O +
a O +
mouse O +
line O +
carrying O +
a O +
mutation O +
in O +
one O +
Brca1 O +
allele O -
. O -

Analysis O +
of O +
mice O +
homozygous O +
for O +
the O +
mutant O +
allele O +
indicate O +
that O +
Brca1 O +
is O +
critical O +
for O +
normal O +
development O -
, O +
as O +
these O +
mice O +
died O +
in O +
utero O +
between O +
10 O +
and O +
13 O +
days O +
of O +
gestation O +
( O -
E10-E13 O -
) O -
. O -

Abnormalities O +
in O +
Brca1-deficient U-Disease +
embryos O +
were O +
most O +
evident O +
in O +
the O +
neural O +
tube O -
, O +
with O +
40 O -
% O +
of O +
the O +
embryos O +
presenting O +
with O +
varying O +
degrees O +
of O +
spina B-Disease +
bifida L-Disease +
and O +
anencephaly U-Disease -
. O -

In O +
addition O -
, O +
the O +
neuroepithelium O +
in O +
Brca1-deficient U-Disease +
embryos O +
appeared O +
disorganized O -
, O +
with O +
signs O +
of O +
both O +
rapid O +
proliferation O +
and O +
excessive O +
cell O +
death O -
.. O -

BRCA1 O +
is O +
secreted O +
and O +
exhibits O +
properties O +
of O +
a O +
granin O -
. O -

Germline O +
mutations O +
in O +
BRCA1 O +
are O +
responsible O +
for O +
most O +
cases O +
of O +
inherited B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
. O -

However O -
, O +
the O +
function O +
of O +
the O +
BRCA1 O +
protein O +
has O +
remained O +
elusive O -
. O -

We O +
now O +
show O +
that O +
BRCA1 O +
encodes O +
a O +
190-kD O +
protein O +
with O +
sequence O +
homology O +
and O +
biochemical O +
analogy O +
to O +
the O +
granin O +
protein O +
family O -
. O -

Interestingly O -
, O +
BRCA2 O +
also O +
includes O +
a O +
motif O +
similar O +
to O +
the O +
granin O +
consensus O +
at O +
the O +
C O +
terminus O +
of O +
the O +
protein O -
. O -

Both O +
BRCA1 O +
and O +
the O +
granins O +
localize O +
to O +
secretory O +
vesicles O -
, O +
are O +
secreted O +
by O +
a O +
regulated O +
pathway O -
, O +
are O +
post O -
- O -
translationally O +
glycosylated O +
and O +
are O +
responsive O +
to O +
hormones O -
. O -

As O +
a O +
regulated O +
secretory O +
protein O -
, O +
BRCA1 O +
appears O +
to O +
function O +
by O +
a O +
mechanism O +
not O +
previously O +
described O +
for O +
tumour U-Disease +
suppressor O +
gene O +
products O -
.. O -

Ovarian B-Disease +
cancer L-Disease +
risk O +
in O +
BRCA1 O +
carriers O +
is O +
modified O +
by O +
the O +
HRAS1 O +
variable O +
number O +
of O +
tandem O +
repeat O +
( O -
VNTR O -
) O +
locus O -
. O -

Women O +
who O +
carry O +
a O +
mutation O +
in O +
the O +
BRCA1 O +
gene O +
( O -
on O +
chromosome O +
17q21 O -
) O -
, O +
have O +
an O +
80 O -
% O +
risk O +
of O +
breast B-Disease +
cancer L-Disease +
and O +
a O +
40 O -
% O +
risk O +
of O +
ovarian B-Disease +
cancer L-Disease +
by O +
the O +
age O +
of O +
70 O +
( O -
ref O -
. O -

1 O -
) O -
. O -

The O +
variable O +
penetrance O +
of O +
BRCA1 O +
suggests O +
that O +
other O +
genetic O +
and O +
non O -
- O -
genetic O +
factors O +
play O +
a O +
role O +
in O +
tumourigenesis O +
in O +
these O +
individuals O -
. O -

The O +
HRAS1 O +
variable O +
number O +
of O +
tandem O +
repeats O +
( O -
VNTR O -
) O +
polymorphism O -
, O +
located O +
1 O +
kilobase O +
( O -
kb O -
) O +
downstream O +
of O +
the O +
HRAS1 O +
proto O -
- O -
oncogene O +
( O -
chromosome O +
11p15 O -
. O -

5 O -
) O +
is O +
one O +
possible O +
genetic O +
modifier O +
of O +
cancer U-Disease +
penetrance O -
. O -

Individuals O +
who O +
have O +
rare O +
alleles O +
of O +
the O +
VNTR O +
have O +
an O +
increased O +
risk O +
of O +
certain O +
types O +
of O +
cancers U-Disease -
, O +
including O +
breast B-Disease +
cancer L-Disease +
( O -
2 O -
- O -
4 O -
) O -
. O -

To O +
investigate O +
whether O +
the O +
presence O +
of O +
rare O +
HRAS1 O +
alleles O +
increases O +
susceptibility O +
to O +
hereditary B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
, O +
we O +
have O +
typed O +
a O +
panel O +
of O +
307 O +
female O +
BRCA1 O +
carriers O +
at O +
this O +
locus O +
using O +
a O +
PCR O -
- O -
based O +
technique O -
. O -

The O +
risk O +
for O +
ovarian B-Disease +
cancer L-Disease +
was O +
2 O -
. O +
11 O +
times O +
greater O +
for O +
BRCA1 O +
carriers O +
harbouring O +
one O +
or O +
two O +
rare O +
HRAS1 O +
alleles O -
, O +
compared O +
to O +
carriers O +
with O +
only O +
common O +
alleles O +
( O -
P O +
= O +
0 O -
. O +
015 O -
) O -
. O -

The O +
magnitude O +
of O +
the O +
relative O +
risk O +
associated O +
with O +
a O +
rare O +
HRAS1 O +
allele O +
was O +
not O +
altered O +
by O +
adjusting O +
for O +
the O +
other O +
known O +
risk O +
factors O +
for O +
hereditary B-Disease +
ovarian I-Disease +
cancer L-Disease +
( O -
5 O -
) O -
. O -

Susceptibility O +
to O +
breast B-Disease +
cancer L-Disease +
did O +
not O +
appear O +
to O +
be O +
affected O +
by O +
the O +
presence O +
of O +
rare O +
HRAS1 O +
alleles O -
. O -

This O +
study O +
is O +
the O +
first O +
to O +
show O +
the O +
effect O +
of O +
a O +
modifying O +
gene O +
on O +
the O +
penetrance O +
of O +
an O +
inherited B-Disease +
cancer I-Disease +
syndrome L-Disease -

A O +
novel O +
homeodomain O -
- O -
encoding O +
gene O +
is O +
associated O +
with O +
a O +
large O +
CpG O +
island O +
interrupted O +
by O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
unstable O +
( O -
CTG O -
) O -
n O +
repeat O -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
associated O +
with O +
a O +
( O -
CTG O -
) O +
n O +
trinucleotide O +
repeat O +
expansion O +
in O +
the O +
3-untranslated O +
region O +
of O +
a O +
protein O +
kinase O -
- O -
encoding O +
gene O -
, O +
DMPK O -
, O +
which O +
maps O +
to O +
chromosome O +
19q13 O -
. O -

3 O -
. O +
Characterisation O +
of O +
the O +
expression O +
of O +
this O +
gene O +
in O +
patient O +
tissues O +
has O +
thus O +
far O +
generated O +
conflicting O +
data O +
on O +
alterations O +
in O +
the O +
steady O +
state O +
levels O +
of O +
DMPK O +
mRNA O -
, O +
and O +
on O +
the O +
final O +
DMPK O +
protein O +
levels O +
in O +
the O +
presence O +
of O +
the O +
expansion O -
. O -

The O +
DM U-Disease +
region O +
of O +
chromosome O +
19 O +
is O +
gene O +
rich O -
, O +
and O +
it O +
is O +
possible O +
that O +
the O +
repeat O +
expansion O +
may O +
lead O +
to O +
dysfunction O +
of O +
a O +
number O +
of O +
transcription O +
units O +
in O +
the O +
vicinity O -
, O +
perhaps O +
as O +
a O +
consequence O +
of O +
chromatin O +
disruption O -
. O -

We O +
have O +
searched O +
for O +
genes O +
associated O +
with O +
a O +
CpG O +
island O +
at O +
the O +
3 O +
end O +
of O +
DMPK O -
. O -

Sequencing O +
of O +
this O +
region O +
shows O +
that O +
the O +
island O +
extends O +
over O +
3 O -
. O +
5 O +
kb O +
and O +
is O +
interrupted O +
by O +
the O +
( O -
CTG O -
) O +
n O +
repeat O -
. O -

Comparison O +
of O +
genomic O +
sequences O +
downstream O +
( O -
centromeric O -
) O +
of O +
the O +
repeat O +
in O +
human O +
and O +
mouse O +
identified O +
regions O +
of O +
significant O +
homology O -
. O -

These O +
correspond O +
to O +
exons O +
of O +
a O +
gene O +
predicted O +
to O +
encode O +
a O +
homeodomain O +
protein O -
. O -

RT O -
- O -
PCR O +
analysis O +
shows O +
that O +
this O +
gene O -
, O +
which O +
we O +
have O +
called O +
DM U-Disease +
locus O -
- O -
associated O +
homeodomain O +
protein O +
( O -
DMAHP O -
) O -
, O +
is O +
expressed O +
in O +
a O +
number O +
of O +
human O +
tissues O -
, O +
including O +
skeletal O +
muscle O -
, O +
heart O +
and O +
brain O -
. O -

Germline O +
mutations O +
in O +
the O +
RB1 O +
gene O +
in O +
patients O +
with O +
hereditary B-Disease +
retinoblastoma L-Disease -
. O -

We O +
have O +
analyzed O +
the O +
27 O +
exons O +
and O +
the O +
promoter O +
region O +
of O +
the O +
RB1 O +
gene O +
in O +
familial B-Disease +
or I-Disease +
sporadic I-Disease +
bilateral I-Disease +
retinoblastoma L-Disease +
by O +
using O +
single O -
- O -
strand O +
conformation O +
polymorphism O +
analysis O -
. O -

For O +
improvement O +
over O +
previous O +
studies O -
, O +
a O +
new O +
set O +
of O +
primers O +
has O +
been O +
designed O -
, O +
which O +
allow O +
for O +
amplification O +
of O +
the O +
coding O +
and O +
splicing O +
sequences O +
only O -
. O -

The O +
positioning O +
of O +
the O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O +
primers O +
was O +
such O +
that O +
the O +
resulting O +
PCR O +
products O +
were O +
of O +
different O +
sizes O -
, O +
which O +
enabled O +
us O +
to O +
analyze O +
two O +
different O +
exons O +
simultaneously O +
and O +
still O +
distinguish O +
between O +
the O +
banding O +
profiles O +
for O +
both O +
( O -
biplex O +
analysis O -
) O -
. O -

By O +
using O +
this O +
approach O -
, O +
we O +
were O +
able O +
to O +
identify O +
mutation O +
in O +
22 O +
new O +
patients O -
, O +
but O +
the O +
overall O +
efficiency O +
of O +
the O +
procedure O +
when O +
we O +
used O +
a O +
single O -
- O -
pass O +
regimen O +
was O +
only O +
48 O -
% O -
. O -

The O +
mutations O +
were O +
small O +
insertions O +
and O +
deletions O +
and O +
point O +
mutations O +
in O +
roughly O +
equal O +
proportions O -
.. O -

Type B-Disease +
II I-Disease +
human I-Disease +
complement I-Disease +
C2 I-Disease +
deficiency L-Disease -
. O -

Allele O -
- O -
specific O +
amino O +
acid O +
substitutions O +
( O -
Ser189 O +
-- O -
> O +
Phe O -
; O +
Gly444 O +
-- O -
> O +
Arg O -
) O +
cause O +
impaired O +
C2 O +
secretion O -
. O -

Type B-Disease +
II I-Disease +
complement I-Disease +
protein I-Disease +
C2 I-Disease +
deficiency L-Disease +
is O +
characterized O +
by O +
a O +
selective O +
block O +
in O +
C2 O +
secretion O -
. O -

The O +
Type O +
II O +
C2 O +
null O +
allele O +
( O -
C2Q0 O -
) O +
is O +
linked O +
to O +
two O +
major O +
histocompatibility O +
haplotypes O +
( O -
MHC O -
) O +
that O +
differ O +
from O +
the O +
MHC O +
of O +
the O +
more O +
common O +
Type B-Disease +
I I-Disease +
C2 I-Disease +
deficiency L-Disease -
. O -

To O +
determine O +
the O +
molecular O +
basis O +
of O +
Type B-Disease +
II I-Disease +
deficiency L-Disease +
the O +
two O +
Type O +
II O +
C2Q0 O +
genes O +
were O +
isolated O +
and O +
transfected O +
separately O +
into O +
L O -
- O -
cells O -
. O -

Subsequent O +
molecular O +
biology O -
, O +
biosynthetic O -
, O +
and O +
immunofluorescence O +
studies O +
demonstrated O +
that O +
C2 O +
secretion O +
is O +
impaired O +
in O +
Type B-Disease +
II I-Disease +
C2 I-Disease +
deficiency L-Disease +
because O +
of O +
different O +
missense O +
mutations O +
at O +
highly O +
conserved O +
residues O +
in O +
each O +
of O +
the O +
C2Q0 O +
alleles O -
. O -

One O +
is O +
in O +
exon O +
5 O +
( O -
nucleotide O +
C566 O +
-- O +
> O +
T O -
; O +
Ser189 O +
-- O +
> O +
Phe O -
) O +
of O +
the O +
C2Q0 O +
gene O +
linked O +
to O +
the O +
MHC O +
haplotype O +
A11 O -
, O +
B35 O -
, O +
DRw1 O -
, O +
BFS O -
, O +
C4A0B1 O -
. O -

The O +
other O +
is O +
in O +
exon O +
11 O +
( O -
G1930 O +
-- O +
> O +
A O -
; O +
Gly444 O +
-- O +
> O +
Arg O -
) O +
of O +
the O +
C2Q0 O +
gene O +
linked O +
to O +
the O +
MHC O +
haplotype O +
A2 O -
, O +
B5 O -
, O +
DRw4 O -
, O +
BFS O -
, O +
C4A3B1 O -
. O -

Each O +
mutant O +
C2 O +
gene O +
product O +
is O +
retained O +
early O +
in O +
the O +
secretory O +
pathway O -
. O -

These O +
mutants O +
provide O +
models O +
for O +
elucidating O +
the O +
C2 O +
secretory O +
pathway O -
.. O -

Defective O +
dimerization O +
of O +
von B-Disease +
Willebrand L-Disease +
factor O +
subunits O +
due O +
to O +
a O +
Cys- O -
> O +
Arg O +
mutation O +
in O +
type B-Disease +
IID I-Disease +
von I-Disease +
Willebrand I-Disease +
disease L-Disease -
. O -

The O +
same O +
heterozygous O +
T O +
- O +
> O +
C O +
transition O +
at O +
nt O +
8567 O +
of O +
the O +
von B-Disease +
Willebrand L-Disease +
factor O +
( O -
vWF O -
) O +
transcript O +
was O +
found O +
in O +
two O +
unrelated O +
patients O +
with O +
type B-Disease +
IID I-Disease +
von I-Disease +
Willebrand I-Disease +
disease L-Disease -
, O +
with O +
no O +
other O +
apparent O +
abnormality O -
. O -

In O +
one O +
family O -
, O +
both O +
alleles O +
were O +
normal O +
in O +
the O +
parents O +
and O +
one O +
sister O -
; O +
thus O -
, O +
the O +
mutation O +
originated O +
de O +
novo O +
in O +
the O +
proposita O -
. O -

The O +
second O +
patient O +
also O +
had O +
asymptomatic O +
parents O +
who O -
, O +
however O -
, O +
were O +
not O +
available O +
for O +
study O -
. O -

The O +
structural O +
consequences O +
of O +
the O +
identified O +
mutation O -
, O +
resulting O +
in O +
the O +
CyS2010 O +
- O +
> O +
Arg O +
substitution O -
, O +
were O +
evaluated O +
by O +
expression O +
of O +
the O +
vWF O +
carboxyl O -
- O -
terminal O +
domain O +
containing O +
residues O +
1366 O -
- O -
2050 O -
. O -

Insect O +
cells O +
infected O +
with O +
recombinant O +
baculovirus O +
expressing O +
normal O +
vWF O +
sequence O +
secreted O +
a O +
disulfide O +
linked O +
dimeric O +
molecule O +
with O +
an O +
apparent O +
molecular O +
mass O +
of O +
150 O +
kDa O +
before O +
reduction O -
, O +
yielding O +
a O +
single O +
band O +
of O +
80 O +
kDa O +
after O +
disulfide O +
bond O +
reduction O -
. O -

In O +
contrast O -
, O +
cells O +
expressing O +
the O +
mutant O +
fragment O +
secreted O +
a O +
monomeric O +
molecule O +
of O +
apparent O +
molecular O +
mass O +
of O +
80 O +
kDa O -
, O +
which O +
remained O +
unchanged O +
after O +
reduction O -
. O -

We O +
conclude O +
that O +
CyS2010 O +
is O +
essential O +
for O +
normal O +
dimerization O +
of O +
vWF O +
subunits O +
through O +
disulfide O +
bonding O +
of O +
carboxyl O -
- O -
terminal O +
domains O +
and O +
that O +
a O +
heterozygous O +
mutation O +
in O +
the O +
corresponding O +
codon O +
is O +
responsible O +
for O +
defective O +
multimer O +
formation O +
in O +
type B-Disease +
IID I-Disease +
von I-Disease +
Willebrand I-Disease +
disease L-Disease -
.. O -

Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
protein O -
, O +
a O +
novel O +
effector O +
for O +
the O +
GTPase O +
CDC42Hs O -
, O +
is O +
implicated O +
in O +
actin O +
polymerization O -
. O -

The O +
Rho O +
family O +
of O +
GTPases O +
control O +
diverse O +
biological O +
processes O -
, O +
including O +
cell O +
morphology O +
and O +
mitogenesis O -
. O -

We O +
have O +
identified O +
WASP O -
, O +
the O +
protein O +
that O +
is O +
defective O +
in O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
( O -
WAS U-Disease -
) O -
, O +
as O +
a O +
novel O +
effector O +
for O +
CDC42Hs O -
, O +
but O +
not O +
for O +
the O +
other O +
Rho O +
family O +
members O -
, O +
Rac O +
and O +
Rho O -
. O -

This O +
interaction O +
is O +
dependent O +
on O +
the O +
presence O +
of O +
the O +
G O +
protein O -
- O -
binding O +
domain O -
. O -

Cellular O +
expression O +
of O +
epitope O -
- O -
tagged O +
WASP O +
produces O +
clusters O +
of O +
WASP O +
that O +
are O +
highly O +
enriched O +
in O +
polymerized O +
actin O -
. O -

This O +
clustering O +
is O +
not O +
observed O +
with O +
a O +
C O -
- O -
terminally O +
deleted O +
WASP O +
and O +
is O +
inhibited O +
by O +
coexpression O +
with O +
dominant O +
negative O +
CDC42Hs O -
- O -
N17 O -
, O +
but O +
not O +
with O +
dominant O +
negative O +
forms O +
of O +
Rac O +
or O +
Rho O -
. O -

Thus O -
, O +
WASP O +
provides O +
a O +
novel O +
link O +
between O +
CDC42Hs O +
and O +
the O +
actin O +
cytoskeleton O -
, O +
which O +
suggests O +
a O +
molecular O +
mechanism O +
for O +
many O +
of O +
the O +
cellular O +
abnormalities O +
in O +
WAS U-Disease -
. O -

The O +
WASP O +
sequence O +
contains O +
two O +
novel O +
domains O +
that O +
are O +
homologous O +
to O +
other O +
proteins O +
involved O +
in O +
action O +
organization O -
.. O -

X B-Disease -
- I-Disease -
linked I-Disease +
adrenoleukodystrophy L-Disease +
is O +
a O +
frequent O +
cause O +
of O +
idiopathic O +
Addison B-Disease -
's I-Disease +
disease L-Disease +
in O +
young O +
adult O +
male O +
patients O -
. O -

X B-Disease -
- I-Disease -
Linked I-Disease +
adrenoleukodystrophy L-Disease +
( O -
ALD U-Disease -
) O +
is O +
a O +
genetic B-Disease +
disease L-Disease +
associated O +
with O +
demyelination B-Disease +
of I-Disease +
the I-Disease +
central I-Disease +
nervous I-Disease +
system L-Disease -
, O +
adrenal B-Disease +
insufficiency L-Disease -
, O +
and O +
accumulation O +
of O +
very O +
long O +
chain O +
fatty O +
acids O +
in O +
tissue O +
and O +
body O +
fluids O -
. O -

ALD U-Disease +
is O +
due O +
to O +
mutation O +
of O +
a O +
gene O +
located O +
in O +
Xq28 O +
that O +
encodes O +
a O +
peroxisomal O +
transporter O +
protein O +
of O +
unknown O +
function O -
. O -

The O +
most O +
common O +
phenotype O +
of O +
ALD U-Disease +
is O +
the O +
cerebral O +
form O +
( O -
45 O -
% O -
) O +
that O +
develops O +
in O +
boys O +
between O +
5 O -
- O -
12 O +
yr O -
. O -

Adrenomyeloneuropathy U-Disease +
( O -
AMN U-Disease -
) O +
involves O +
the O +
spinal O +
cord O +
and O +
peripheral O +
nerves O +
in O +
young O +
adults O +
( O -
35 O -
% O -
) O -
. O -

Adrenal B-Disease +
insufficiency L-Disease +
( O -
Addisons B-Disease +
disease L-Disease -
) O +
is O +
frequently O +
associated O +
with O +
AMN U-Disease +
or O +
cerebral B-Disease +
ALD L-Disease +
and O +
may O +
remain O +
the O +
only O +
clinical O +
expression O +
of O +
ALD U-Disease +
( O -
8 O -
% O +
of O +
cases O -
) O -
. O -

The O +
prevalence O +
of O +
ALD U-Disease +
among O +
adults O +
with O +
Addisons B-Disease +
disease L-Disease +
remains O +
unknown O -
. O -

To O +
evaluate O +
this O +
prevalence O -
, O +
we O +
performed O +
biochemical O +
analysis O +
of O +
very O +
long O +
chain O +
fatty O +
acids O +
in O +
14 O +
male O +
patients O +
( O -
age O +
ranging O +
from O +
12 O -
- O -
45 O +
yr O +
at O +
diagnosis O -
) O +
previously O +
diagnosed O +
as O +
having O +
primary O +
idiopathic O +
adrenocortical B-Disease +
insufficiency L-Disease -
. O -

In O +
5 O +
of O +
14 O +
patients O +
( O -
35 O -
% O -
) O -
, O +
elevated O +
plasma O +
concentrations O +
of O +
very O +
long O +
chain O +
fatty O +
acids O +
were O +
detected O -
. O -

None O +
of O +
these O +
patients O +
had O +
adrenocortical O +
antibodies O -
. O -

By O +
electrophysiological O +
tests O +
and O +
magnetic O +
resonance O +
imaging O +
it O +
was O +
determined O +
that O +
two O +
patients O +
had O +
cerebral B-Disease +
ALD L-Disease -
, O +
one O +
had O +
adrenomyeloneuropathy U-Disease +
with O +
cerebral O +
involvement O -
, O +
and O +
two O +
had O +
preclinical O +
AMN U-Disease -
. O -

Our O +
data O +
support O +
the O +
hypothesis O +
that O +
ALD U-Disease +
is O +
a O +
frequent O +
cause O +
of O +
idiopathic O +
Addisons B-Disease +
disease L-Disease +
in O +
children O +
and O +
adults O -
.. O -

Tumor U-Disease +
suppression O +
and O +
apoptosis O +
of O +
human O +
prostate B-Disease +
carcinoma L-Disease +
mediated O +
by O +
a O +
genetic O +
locus O +
within O +
human O +
chromosome O +
10pter O -
- O -
q11 O -
. O -

Prostate B-Disease +
cancer L-Disease +
is O +
the O +
second O +
leading O +
cause O +
of O +
male O +
cancer U-Disease +
deaths O +
in O +
the O +
United O +
States O -
. O -

Yet O -
, O +
despite O +
a O +
large O +
international O +
effort O -
, O +
little O +
is O +
known O +
about O +
the O +
molecular O +
mechanisms O +
that O +
underlie O +
this O +
devastating O +
disease O -
. O -

Prostate O +
secretory O +
epithelial O +
cells O +
and O +
androgen O -
- O -
dependent O +
prostate B-Disease +
carcinomas L-Disease +
undergo O +
apoptosis O +
in O +
response O +
to O +
androgen O +
deprivation O +
and O -
, O +
furthermore O -
, O +
most O +
prostate B-Disease +
carcinomas L-Disease +
become O +
androgen O +
independent O +
and O +
refractory O +
to O +
further O +
therapeutic O +
manipulations O +
during O +
disease O +
progression O -
. O -

Definition O +
of O +
the O +
genetic O +
events O +
that O +
trigger O +
apoptosis O +
in O +
the O +
prostate O +
could O +
provide O +
important O +
insights O +
into O +
critical O +
pathways O +
in O +
normal O +
development O +
as O +
well O +
as O +
elucidate O +
the O +
perturbations O +
of O +
those O +
key O +
pathways O +
in O +
neoplastic O +
transformation O -
. O -

We O +
report O +
the O +
functional O +
definition O +
of O +
a O +
novel O +
genetic O +
locus O +
within O +
human O +
chromosome O +
10pter O -
- O -
q11 O +
that O +
mediates O +
both O +
in O +
vivo O +
tumor O +
suppression O +
and O +
in O +
vitro O +
apoptosis O +
of O +
prostatic B-Disease +
adenocarcinoma L-Disease +
cells O -
. O -

A O +
defined O +
fragment O +
of O +
human O +
chromosome O +
10 O +
was O +
transferred O +
via O +
microcell O +
fusion O +
into O +
a O +
prostate B-Disease +
adenocarcinoma L-Disease +
cell O +
line O -
. O -

Microcell O +
hybrids O +
containing O +
only O +
the O +
region O +
10pter O -
- O -
q11 O +
were O +
suppressed O +
for O +
tumorigenicity O +
following O +
injection O +
of O +
microcell O +
hybrids O +
into O +
nude O +
mice O -
. O -

Furthermore O -
, O +
the O +
complemented O +
hybrids O +
undergo O +
programmed O +
cell O +
death O +
in O +
vitro O +
via O +
a O +
mechanism O +
that O +
does O +
not O +
require O +
nuclear O +
localization O +
of O +
p53 O -
. O -

These O +
data O +
functionally O +
define O +
a O +
novel O +
genetic O +
locus O -
, O +
designated O +
PAC1 O -
, O +
for O +
prostate O +
adenocarcinoma O +
1 O -
, O +
involved O +
in O +
tumor O +
suppression O +
of O +
human O +
prostate B-Disease +
carcinoma L-Disease +
and O +
furthermore O +
strongly O +
suggest O +
that O +
the O +
cell O +
death O +
pathway O +
can O +
be O +
functionally O +
restored O +
in O +
prostatic B-Disease +
adenocarcinoma L-Disease -
.. O -

Low O +
incidence O +
of O +
BRCA2 O +
mutations O +
in O +
breast B-Disease +
carcinoma L-Disease +
and O +
other O +
cancers U-Disease -
. O -

Inherited O +
mutant O +
alleles O +
of O +
familial O +
tumour U-Disease +
suppressor O +
genes O +
predispose O +
individuals O +
to O +
particular O +
types O +
of O +
cancer U-Disease -
. O -

In O +
addition O +
to O +
an O +
involvement O +
in O +
inherited O +
susceptibility O +
to O +
cancer U-Disease -
, O +
these O +
tumour U-Disease +
suppressor O +
genes O +
are O +
targets O +
for O +
somatic O +
mutations O +
in O +
sporadic B-Disease +
cancers L-Disease +
of O +
the O +
same O +
type O +
found O +
in O +
the O +
familial O +
forms O -
. O -

An O +
exception O +
is O +
BRCA1 O -
, O +
which O +
contributes O +
to O +
a O +
significant O +
fraction O +
of O +
familial B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
, O +
but O +
undergoes O +
mutation O +
at O +
very O +
low O +
rates O +
in O +
sporadic B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancers L-Disease -
. O -

This O +
finding O +
suggests O +
that O +
other O +
genes O +
may O +
be O +
the O +
principal O +
targets O +
for O +
somatic O +
mutation O +
in O +
breast B-Disease +
carcinoma L-Disease -
. O -

A O +
second O -
, O +
recently O +
identified O +
familial B-Disease +
breast I-Disease +
cancer L-Disease +
gene O -
, O +
BRCA2 O +
( O -
refs O +
5 O -
- O -
8 O -
) O -
, O +
accounts O +
for O +
a O +
proportion O +
of O +
breast B-Disease +
cancer L-Disease +
roughly O +
equal O +
to O +
BRCA1 O -
. O -

Like O +
BRCA1 O -
, O +
BRCA2 O +
behaves O +
as O +
a O +
dominantly O +
inherited O +
tumour U-Disease +
suppressor O +
gene O -
. O -

Individuals O +
who O +
inherit O +
one O +
mutant O +
allele O +
are O +
at O +
increased O +
risk O +
for O +
breast B-Disease +
cancer L-Disease -
, O +
and O +
the O +
tumours U-Disease +
they O +
develop O +
lose O +
the O +
wild O -
- O -
type O +
allele O +
by O +
heterozygous O +
deletion O -
. O -

The O +
BRCA2 O +
coding O +
sequence O +
is O +
huge O -
, O +
composed O +
of O +
26 O +
exons O +
that O +
span O +
10 O -
, O +
443 O +
bp O -
. O -

Here O +
we O +
investigate O +
the O +
rate O +
of O +
BRCA2 O +
mutation O +
in O +
sporadic B-Disease +
breast I-Disease +
cancers L-Disease +
and O +
in O +
a O +
set O +
of O +
cell O +
lines O +
that O +
represent O +
twelve O +
other O +
tumour U-Disease +
types O -
. O -

Surprisingly O -
, O +
mutations O +
in O +
BRCA2 O +
are O +
infrequent O +
in O +
cancers U-Disease +
including O +
breast B-Disease +
carcinoma L-Disease -
. O -

However O -
, O +
a O +
probable O +
germline O +
mutation O +
in O +
a O +
pancreatic B-Disease +
tumour L-Disease +
cell O +
line O +
suggests O +
a O +
role O +
for O +
BRCA2 O +
in O +
susceptibility O +
to O +
pancreatic B-Disease +
cancer L-Disease -
.. O -

Founding O +
BRCA1 O +
mutations O +
in O +
hereditary B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
in O +
southern O +
Sweden O -
. O -

Nine O +
different O +
germ O -
- O -
line O +
mutations O +
in O +
the O +
BRCA1 O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
susceptibility O +
gene O +
were O +
identified O +
in O +
15 O +
of O +
47 O +
kindreds O +
from O +
southern O +
Sweden O -
, O +
by O +
use O +
of O +
SSCP O +
and O +
heteroduplex O +
analysis O +
of O +
all O +
exons O +
and O +
flanking O +
intron O +
region O +
and O +
by O +
a O +
protein O -
- O -
truncation O +
test O +
for O +
exon O +
11 O -
, O +
followed O +
by O +
direct O +
sequencing O -
. O -

All O +
but O +
one O +
of O +
the O +
mutations O +
are O +
predicted O +
to O +
give O +
rise O +
to O +
premature O +
translation O +
termination O +
and O +
include O +
seven O +
frameshift O +
insertions O +
or O +
deletions O -
, O +
a O +
nonsense O +
mutation O -
, O +
and O +
a O +
splice O +
acceptor O +
site O +
mutation O -
. O -

The O +
remaining O +
mutation O +
is O +
a O +
missense O +
mutation O +
( O -
Cys61Gly O -
) O +
in O +
the O +
zinc O -
- O -
binding O +
motif O -
. O -

Four O +
novel O +
Swedish O +
founding O +
mutations O +
were O +
identified O -
the O +
nucleotide O +
2595 O +
deletion O +
A O +
was O +
found O +
in O +
five O +
families O -
, O +
the O +
C O +
1806 O +
T O +
nonsense O +
mutation O +
in O +
three O +
families O -
, O +
the O +
3166 O +
insertion O +
TGAGA O +
in O +
three O +
families O -
, O +
and O +
the O +
nucleotide O +
1201 O +
deletion O +
11 O +
in O +
two O +
families O -
. O -

Analysis O +
of O +
the O +
intragenic O +
polymorphism O +
D17S855 O +
supports O +
common O +
origins O +
of O +
the O +
mutations O -
. O -

Eleven O +
of O +
the O +
15 O +
kindreds O +
manifesting O +
BRCA1 O +
mutations O +
were O +
breast B-Disease -
- I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O -
, O +
several O +
of O +
them O +
with O +
a O +
predominant O +
ovarian B-Disease +
cancer L-Disease +
phenotype O -
. O -

The O +
set O +
of O +
32 O +
families O +
in O +
which O +
no O +
BRCA1 O +
alterations O +
were O +
detected O +
included O +
1 O +
breast B-Disease -
- I-Disease -
ovarian I-Disease +
cancer L-Disease +
kindred O +
manifesting O +
clear O +
linkage O +
to O +
the O +
BRCA1 O +
region O +
and O +
loss O +
of O +
the O +
wild O -
- O -
type O +
chromosome O +
in O +
associated O +
tumors U-Disease -
. O -

Other O +
tumor U-Disease +
types O +
found O +
in O +
BRCA1 O +
mutation O -
/ O -
haplotype O +
carriers O +
included O +
prostatic B-Disease -
, I-Disease +
pancreas I-Disease -
, I-Disease +
skin I-Disease -
, I-Disease +
and I-Disease +
lung I-Disease +
cancer L-Disease -
, O +
a O +
malignant B-Disease +
melanoma L-Disease -
, O +
an O +
oligodendroglioma U-Disease -
, O +
and O +
a O +
carcinosarcoma U-Disease -
. O -

In O +
all O -
, O +
12 O +
of O +
16 O +
kindreds O +
manifesting O +
BRCA1 O +
mutation O +
or O +
linkage O +
contained O +
ovarian B-Disease +
cancer L-Disease -
, O +
as O +
compared O +
with O +
only O +
6 O +
of O +
the O +
remaining O +
31 O +
families O +
( O -
P O +
< O -
. O -

001 O -
) O -
. O -

The O +
present O +
study O +
confirms O +
the O +
involvement O +
of O +
BRCA1 O +
in O +
disease O +
predisposition O +
for O +
a O +
subset O +
of O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease +
families O +
often O +
characterized O +
by O +
ovarian B-Disease +
cancers L-Disease -
. O -

Rapid O +
detection O +
of O +
regionally O +
clustered O +
germ O -
- O -
line O +
BRCA1 O +
mutations O +
by O +
multiplex O +
heteroduplex O +
analysis O -
. O -

UKCCCR O +
Familial O +
Ovarian B-Disease +
Cancer L-Disease +
Study O +
Group O -
. O -

Germ O -
- O -
line O +
mutations O +
of O +
the O +
BRCA1 O +
gene O +
are O +
responsible O +
for O +
a O +
substantial O +
proportion O +
of O +
families O +
with O +
multiple O +
cases O +
of O +
early O -
- O -
onset O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

Since O +
the O +
isolation O +
of O +
BRCA1 O +
last O +
year O -
, O +
> O +
65 O +
distinct O +
mutations O +
scattered O +
throughout O +
the O +
coding O +
region O +
have O +
been O +
detected O -
, O +
making O +
analysis O +
of O +
the O +
gene O +
time O +
consuming O +
and O +
technically O +
challenging O -
. O -

We O +
have O +
developed O +
a O +
multiplex O +
heteroduplex O +
analysis O +
that O +
is O +
designed O +
to O +
analyze O +
one O -
- O -
quarter O +
of O +
the O +
coding O +
sequence O +
in O +
a O +
single O -
- O -
step O +
screening O +
procedure O +
and O +
that O +
will O +
detect O +
approximately O +
50 O -
% O +
of O +
all O +
BRCA1 O +
mutations O +
so O +
far O +
reported O +
in O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O -
. O -

We O +
have O +
used O +
this O +
technique O +
to O +
analyze O +
BRCA1 O +
in O +
162 O +
families O +
with O +
a O +
history O +
of O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease +
and O +
identified O +
12 O +
distinct O +
mutations O +
in O +
35 O +
families O -
.. O -

A O +
previously O +
undescribed O +
mutation O +
within O +
the O +
tetramerisation O +
domain O +
of O +
TP53 O +
in O +
a O +
family O +
with O +
Li B-Disease -
- I-Disease -
Fraumeni I-Disease +
syndrome L-Disease -
. O -

We O +
report O +
details O +
of O +
a O +
family O +
with O +
classic O +
Li B-Disease -
- I-Disease -
Fraumeni I-Disease +
syndrome L-Disease +
in O +
which O +
there O +
is O +
a O +
mutation O +
in O +
codon O +
344 O +
of O +
the O +
tumour U-Disease +
suppressor O +
gene O +
TP53 O -
. O -

Codon O +
344 O +
is O +
a O +
key O +
residue O +
within O +
the O +
tetramerisation O +
domain O -
, O +
and O +
the O +
amino O +
acid O +
substitution O +
of O +
a O +
proline O +
for O +
a O +
leucine O +
is O +
predicted O +
to O +
have O +
profound O +
implications O +
for O +
tetramerisation O +
and O +
potentially O +
DNA O +
binding O -
. O -

This O +
is O +
the O +
first O +
report O +
of O +
a O +
mutation O +
at O +
this O +
residue O +
in O +
either O +
sporadic B-Disease +
tumours L-Disease +
or O +
in O +
the O +
germline O +
and O +
the O +
first O +
report O +
of O +
a O +
germline O +
mutation O +
within O +
the O +
tetramerisation O +
domain O -
. O -

The O +
family O +
does O +
not O +
appear O +
to O +
be O +
remarkable O +
in O +
the O +
spectrum O +
of O +
tumours U-Disease -
, O +
and O +
there O +
is O +
loss O +
of O +
the O +
wild O -
- O -
type O +
allele O +
in O +
a O +
leiomyosarcoma U-Disease +
from O +
the O +
proband O -
. O -

A O +
cell O +
line O +
has O +
been O +
established O +
from O +
the O +
tumour U-Disease +
of O +
the O +
proband O +
and O +
cytogenetic O +
and O +
molecular O +
studies O +
carried O +
out O -
, O +
providing O +
an O +
extensive O +
analysis O +
in O +
this O +
family O -
.. O -

The O +
spectrum O +
of O +
RB1 O +
germ O -
- O -
line O +
mutations O +
in O +
hereditary B-Disease +
retinoblastoma L-Disease -
. O -

We O +
have O +
searched O +
for O +
germ O -
- O -
line O +
RB1 O +
mutations O +
in O +
119 O +
patients O +
with O +
hereditary B-Disease +
retinoblastoma L-Disease -
. O -

Previous O +
investigations O +
by O +
Southern O +
blot O +
hybridization O +
and O +
PCR O +
fragment O -
- O -
length O +
analysis O +
had O +
revealed O +
mutations O +
in O +
48 O +
patients O -
. O -

Here O +
we O +
report O +
on O +
the O +
analysis O +
of O +
the O +
remaining O +
71 O +
patients O -
. O -

By O +
applying O +
heteroduplex O +
analysis O -
, O +
nonisotopic O +
SSCP O -
, O +
and O +
direct O +
sequencing O -
, O +
we O +
detected O +
germ O -
- O -
line O +
mutations O +
resulting O +
in O +
premature O +
termination O +
codons O +
or O +
disruption O +
of O +
splice O +
signals O +
in O +
51 O +
( O -
72 O -
% O -
) O +
of O +
the O +
71 O +
patients O -
. O -

Four O +
patients O +
also O +
showed O +
rare O +
sequence O +
variants O -
. O -

No O +
region O +
of O +
the O +
RB1 O +
gene O +
was O +
preferentially O +
involved O +
in O +
single O +
base O +
substitutions O -
. O -

Recurrent O +
transitions O +
were O +
observed O +
at O +
most O +
of O +
the O +
14 O +
codons O +
within O +
the O +
RB1 O -
. O -

No O +
mutation O +
was O +
observed O +
in O +
exons O +
25 O -
- O -
27 O -
, O +
although O +
this O +
region O +
contains O +
two O +
CGA O +
codons O -
. O -

This O +
suggests O +
that O +
mutations O +
within O +
the O +
3-terminal O +
region O +
of O +
the O +
RB1 O +
gene O +
may O +
not O +
be O +
oncogenic O -
. O -

When O +
these O +
data O +
were O +
combined O +
with O +
the O +
results O +
of O +
our O +
previous O +
investigations O -
, O +
mutations O +
were O +
identified O +
in O +
a O +
total O +
of O +
99 O +
( O -
83 O -
% O -
) O +
of O +
119 O +
patients O -
. O -

The O +
spectrum O +
comprises O +
15 O -
% O +
large O +
deletions O -
, O +
26 O -
% O +
small O +
length O +
alterations O -
, O +
and O +
42 O -
% O +
base O +
substitutions O -
. O -

No O +
correlation O +
between O +
the O +
location O +
of O +
frameshift O +
or O +
nonsense O +
mutations O +
and O +
phenotypic O +
features O -
, O +
including O +
age O +
at O +
diagnosis O -
, O +
the O +
number O +
of O +
tumor U-Disease +
foci O -
, O +
and O +
manifestation O +
of O +
nonocular B-Disease +
tumors L-Disease +
was O +
observed O -
.. O -

Phenotypic O +
characterization O +
of O +
individuals O +
with O +
30 O -
- O -
40 O +
CAG O +
repeats O +
in O +
the O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
gene O +
reveals O +
HD U-Disease +
cases O +
with O +
36 O +
repeats O +
and O +
apparently O +
normal O +
elderly O +
individuals O +
with O +
36 O -
- O -
39 O +
repeats O -
. O -

Abnormal O +
CAG O +
expansions O +
in O +
the O +
IT-15 O +
gene O +
are O +
associated O +
with O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O -
. O -

In O +
the O +
diagnostic O +
setting O +
it O +
is O +
necessary O +
to O +
define O +
the O +
limits O +
of O +
the O +
CAG O +
size O +
ranges O +
on O +
normal O +
and O +
HD U-Disease -
- O -
associated O +
chromosomes O -
. O -

Most O +
large O +
analyses O +
that O +
defined O +
the O +
limits O +
of O +
the O +
normal O +
and O +
pathological O +
size O +
ranges O +
employed O +
PCR O +
assays O -
, O +
which O +
included O +
the O +
CAG O +
repeats O +
and O +
a O +
CCG O +
repeat O +
tract O +
that O +
was O +
thought O +
to O +
be O +
invariant O -
. O -

Many O +
of O +
these O +
experiments O +
found O +
an O +
overlap O +
between O +
the O +
normal O +
and O +
disease O +
size O +
ranges O -
. O -

Subsequent O +
findings O +
that O +
the O +
CCG O +
repeats O +
vary O +
by O +
8 O +
trinucleotide O +
lengths O +
suggested O +
that O +
the O +
limits O +
of O +
the O +
normal O +
and O +
disease O +
size O +
ranges O +
should O +
be O +
reevaluated O +
with O +
assays O +
that O +
exclude O +
the O +
CCG O +
polymorphism O -
. O -

Since O +
patients O +
with O +
between O +
30 O +
and O +
40 O +
repeats O +
are O +
rare O -
, O +
a O +
consortium O +
was O +
assembled O +
to O +
collect O +
such O +
individuals O -
. O -

All O +
178 O +
samples O +
were O +
reanalyzed O +
in O +
Cambridge O +
by O +
using O +
assays O +
specific O +
for O +
the O +
CAG O +
repeats O -
. O -

We O +
have O +
optimized O +
methods O +
for O +
reliable O +
sizing O +
of O +
CAG O +
repeats O +
and O +
show O +
cases O +
that O +
demonstrate O +
the O +
dangers O +
of O +
using O +
PCR O +
assays O +
that O +
include O +
both O +
the O +
CAG O +
and O +
CCG O +
polymorphisms O -
. O -

Seven O +
HD U-Disease +
patients O +
had O +
36 O +
repeats O -
, O +
which O +
confirms O +
that O +
this O +
allele O +
is O +
associated O +
with O +
disease O -
. O -

Individuals O +
without O +
apparent O +
symptoms O +
or O +
signs O +
of O +
HD U-Disease +
were O +
found O +
at O +
36 O +
repeats O +
( O -
aged O +
74 O -
, O +
78 O -
, O +
79 O -
, O +
and O +
87 O +
years O -
) O -
, O +
37 O +
repeats O +
( O -
aged O +
69 O +
years O -
) O -
, O +
38 O +
repeats O +
( O -
aged O +
69 O +
and O +
90 O +
years O -
) O -
, O +
and O +
39 O +
repeats O +
( O -
aged O +
67 O -
, O +
90 O -
, O +
and O +
95 O +
years O -
) O -
. O -

The O +
detailed O +
case O +
histories O +
of O +
an O +
exceptional O +
case O +
from O +
this O +
series O +
will O +
be O +
presented O -
a O +
95-year O -
- O -
old O +
man O +
with O +
39 O +
repeats O +
who O +
did O +
not O +
have O +
classical O +
features O +
of O +
HD U-Disease -
. O -

The O +
apparently O +
healthy O +
survival O +
into O +
old O +
age O +
of O +
some O +
individuals O +
with O +
36 O -
- O -
39 O +
repeats O +
suggests O +
that O +
the O +
HD U-Disease +
mutation O +
may O +
not O +
always O +
be O +
fully O +
penetrant O -
.. O -

Identification O +
and O +
expression O +
of O +
eight O +
novel O +
mutations O +
among O +
non O -
- O -
Jewish O +
patients O +
with O +
Canavan B-Disease +
disease L-Disease -
. O -

Canavan B-Disease +
disease L-Disease +
is O +
inherited O +
as O +
an O +
autosomal O +
recessive O +
trait O +
that O +
is O +
caused O +
by O +
the O +
deficiency B-Disease +
of I-Disease +
aspartoacylase L-Disease +
( O -
ASPA O -
) O -
. O -

The O +
majority O +
of O +
patients O +
with O +
Canavan B-Disease +
disease L-Disease +
are O +
from O +
an O +
Ashkenazi O +
Jewish O +
background O -
. O -

Mutations O +
in O +
ASPA O +
that O +
lead O +
to O +
loss O +
of O +
enzymatic O +
activity O +
have O +
been O +
identified O -
, O +
and O +
E285A O +
and O +
Y231X O +
are O +
the O +
two O +
predominant O +
mutations O +
that O +
account O +
for O +
97 O -
% O +
of O +
the O +
mutant O +
chromosomes O +
in O +
Ashkenazi O +
Jewish O +
patients O -
. O -

The O +
current O +
study O +
was O +
aimed O +
at O +
finding O +
the O +
molecular O +
basis O +
of O +
Canavan B-Disease +
disease L-Disease +
in O +
25 O +
independent O +
patients O +
of O +
non O -
- O -
Jewish O +
background O -
. O -

Eight O +
novel O +
and O +
three O +
previously O +
characterized O +
mutations O +
accounted O +
for O +
80 O -
% O +
( O -
40 O -
/ O -
50 O -
) O +
of O +
mutant O +
chromosomes O -
. O -

The O +
A305E O +
missense O +
mutation O +
accounted O +
for O +
48 O -
% O +
( O -
24 O -
/ O -
50 O -
) O +
of O +
mutant O +
chromosomes O +
in O +
patients O +
of O +
western O +
European O +
descent O -
, O +
while O +
the O +
two O +
predominant O +
Jewish O +
mutations O +
each O +
accounted O +
for O +
a O +
single O +
mutant O +
chromosome O -
. O -

The O +
eight O +
novel O +
mutations O +
identified O +
included O +
1- O +
and O +
4-bp O +
deletions O +
( O -
32 O +
deltaT O +
and O +
876 O +
deltaAGAA O -
, O +
respectively O -
) O +
and O +
I16 O -
T O -
, O +
G27R O -
, O +
D114E O -
, O +
G123E O -
, O +
C152Y O -
, O +
and O +
R168C O +
missense O +
mutations O -
. O -

The O +
homozygous O +
32 O +
deltaT O +
deletion O +
was O +
identified O +
in O +
the O +
only O +
known O +
patient O +
of O +
African O -
- O -
American O +
origin O +
with O +
Canavan B-Disease +
disease L-Disease -
. O -

The O +
heterozygosity O +
for O +
876 O +
deltaAGAA O +
mutation O +
was O +
identified O +
in O +
three O +
independent O +
patients O +
from O +
England O -
. O -

Six O +
single O -
- O -
base O +
changes O +
leading O +
to O +
missense O +
mutations O +
were O +
identified O +
in O +
patients O +
from O +
Turkey O +
( O -
D114E O -
, O +
R168C O -
) O -
, O +
The O +
Netherlands O +
( O -
I16 O -
T O -
) O -
, O +
Germany O +
( O -
G27R O -
) O -
, O +
Ireland O +
( O -
C152Y O -
) O -
, O +
and O +
Canada O +
( O -
G123E O -
) O -
. O -

A O +
PCR O -
- O -
based O +
protocol O +
is O +
described O +
that O +
was O +
used O +
to O +
introduce O +
mutations O +
in O +
wild O -
- O -
type O +
cDNA O -
. O -

In O +
vitro O +
expression O +
of O +
mutant O +
cDNA O +
clones O +
demonstrated O +
that O +
all O +
of O +
these O +
mutations O +
led O +
to O +
a O +
deficiency B-Disease +
of I-Disease +
ASPA L-Disease +
and O +
should O +
therefore O +
result O +
in O +
Canavan B-Disease +
disease L-Disease -
.. O -

Identification O +
and O +
chromosomal O +
localization O +
of O +
Atm O -
, O +
the O +
mouse O +
homolog O +
of O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
gene O -
. O -

Atm O -
, O +
the O +
mouse O +
homolog O +
of O +
the O +
human O +
ATM O +
gene O +
defective O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O -
, O +
has O +
been O +
identified O -
. O -

The O +
entire O +
coding O +
sequence O +
of O +
the O +
Atm O +
transcript O +
was O +
cloned O +
and O +
found O +
to O +
contain O +
an O +
open O +
reading O +
frame O +
encoding O +
a O +
protein O +
of O +
3066 O +
amino O +
acids O +
with O +
84 O -
% O +
overall O +
identity O +
and O +
91 O -
% O +
similarity O +
to O +
the O +
human O +
ATM O +
protein O -
. O -

Variable O +
levels O +
of O +
expression O +
of O +
Atm O +
were O +
observed O +
in O +
different O +
tissues O -
. O -

Fluorescence O +
in O +
situ O +
hybridization O +
and O +
linkage O +
analysis O +
located O +
the O +
Atm O +
gene O +
on O +
mouse O +
chromosome O +
9 O -
, O +
band O +
9C O -
, O +
in O +
a O +
region O +
homologous O +
to O +
the O +
ATM O +
region O +
on O +
human O +
chromosome O +
11q22-q23 O -
.. O -

The O +
mouse O +
homolog O +
of O +
the O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
protein O +
( O -
WASP O -
) O +
gene O +
is O +
highly O +
conserved O +
and O +
maps O +
near O +
the O +
scurfy O +
( O -
sf O -
) O +
mutation O +
on O +
the O +
X O +
chromosome O -
. O -

The O +
mouse O +
WASP O +
gene O -
, O +
the O +
homolog O +
of O +
the O +
gene O +
mutated O +
in O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease -
, O +
has O +
been O +
isolated O +
and O +
sequenced O -
. O -

the O +
predicted O +
amino O +
acid O +
sequence O +
is O +
86 O -
% O +
identical O +
to O +
the O +
human O +
WASP O +
sequence O -
. O -

A O +
distinct O +
feature O +
of O +
the O +
mouse O +
gene O +
is O +
an O +
expanded O +
polymorphic O +
GGA O +
trinucleotide O +
repeat O +
that O +
codes O +
for O +
polyglycine O +
and O +
varies O +
from O +
15 O +
to O +
17 O +
triplets O +
in O +
different O +
Mus O +
musculus O +
strains O -
. O -

The O +
genomic O +
structure O +
of O +
the O +
mouse O +
WASP O +
gene O +
is O +
expressed O +
as O +
an O +
approximately O +
2 O -
. O -

4-kb O +
mRNA O +
in O +
thymus O +
and O +
spleen O -
. O -

Chromosomal O +
mapping O +
in O +
an O +
interspecific O +
M. O +
Musculus O -
/ O -
M. O +
spretus O +
backcross O +
placed O +
the O +
Wasp O +
locus O +
near O +
the O +
centromere O +
of O +
the O +
mouse O +
X O +
chromosome O -
, O +
inseparable O +
from O +
Gata1 O -
, O +
Tcfe3 O -
, O +
and O +
scurfy O +
( O -
sf O -
) O -
. O -

This O +
localization O +
makes O +
Wasp O +
a O +
candidate O +
for O +
involvement O +
in O +
scurfy O -
, O +
a O +
T O +
cell O -
- O -
mediated O +
fatal B-Disease +
lymphoreticular I-Disease +
disease L-Disease +
of O +
mice O +
that O +
has O +
previously O +
been O +
proposed O +
as O +
a O +
mouse O +
homolog O +
of O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease -
. O -

Northern O +
analysis O +
of O +
sf O +
tissue O +
samples O +
indicated O +
the O +
presence O +
of O +
WASP O +
mRNA O +
in O +
liver O +
and O +
skin O -
, O +
presumably O +
as O +
a O +
consequence O +
of O +
lymphocytic O +
infiltration O -
, O +
but O +
non O +
abnormalities O +
in O +
the O +
amount O +
or O +
size O +
of O +
mRNA O +
present O -
. O -

Colchicine O +
in O +
breast O +
milk O +
of O +
patients O +
with O +
familial B-Disease +
Mediterranean I-Disease +
fever L-Disease -
. O -

OBJECTIVE O -
. O -

To O +
clarify O +
whether O +
colchicine O +
is O +
excreted O +
in O +
breast O +
milk O -
, O +
and O +
to O +
compare O +
its O +
concentrations O +
in O +
the O +
serum O +
and O +
breast O +
milk O +
of O +
lactating O +
women O +
who O +
have O +
familial B-Disease +
Mediterranean I-Disease +
fever L-Disease +
( O -
FMF U-Disease -
) O -
. O -

METHODS O -
. O -

Using O +
a O +
specific O +
radioimmunoassay O -
, O +
we O +
determined O +
colchicine O +
concentrations O +
in O +
the O +
serum O +
and O +
breast O +
milk O +
of O +
4 O +
patients O +
at O +
various O +
time O +
points O -
, O +
following O +
oral O +
administration O +
of O +
the O +
drug O -
. O -

The O +
study O +
evaluated O +
4 O +
patients O +
with O +
FMF U-Disease +
who O +
had O +
been O +
taking O +
colchicine O +
on O +
a O +
long O -
- O -
term O +
basis O -
. O -

RESULTS O -
. O -

Colchicine O +
was O +
found O +
to O +
be O +
excreted O +
in O +
breast O +
milk O -
. O -

Its O +
levels O +
ranged O +
between O +
1 O -
. O +
9 O +
and O +
8 O -
. O +
6 O +
ng O -
/ O -
ml O -
, O +
which O +
were O +
similar O +
to O +
those O +
found O +
in O +
the O +
serum O +
( O -
parallel O +
concentration O +
time O +
curves O -
) O -
. O -

However O -
, O +
there O +
appeared O +
to O +
be O +
a O +
considerable O +
variation O +
in O +
colchicine O +
milk O +
concentration O +
among O +
the O +
different O +
patients O -
, O +
which O +
might O +
be O +
related O +
to O +
individual O +
breast O +
milk O +
composition O +
and O -
, O +
possibly O -
, O +
to O +
other O +
nutritional O +
or O +
metabolic O +
factors O -
. O -

CONCLUSION O -
. O -

The O +
extensive O +
peripheral O +
tissue O +
binding O +
and O +
relatively O +
low O +
concentration O +
of O +
colchicine O +
in O +
breast O +
milk O +
suggests O +
that O +
the O +
amount O +
ingested O +
by O +
the O +
infant O +
is O +
small O -
. O -

Furthermore O -
, O +
based O +
on O +
our O +
clinical O +
experience O -
, O +
nursing O +
appears O +
to O +
be O +
safe O +
for O +
lactating O +
women O +
with O +
FMF U-Disease +
who O +
continue O +
to O +
take O +
colchicine O -
. O -

Abnormal O +
myotonic B-Disease +
dystrophy L-Disease +
protein O +
kinase O +
levels O +
produce O +
only O +
mild O +
myopathy U-Disease +
in O +
mice O -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
commonly O +
associated O +
with O +
CTG O +
repeat O +
expansions O +
within O +
the O +
gene O +
for O +
DM O -
- O -
protein O +
kinase O +
( O -
DMPK O -
) O -
. O -

The O +
effect O +
of O +
altered O +
expression O +
levels O +
of O +
DMPK O -
, O +
which O +
is O +
ubiquitously O +
expressed O +
in O +
all O +
muscle O +
cell O +
lineages O +
during O +
development O -
, O +
was O +
examined O +
by O +
disrupting O +
the O +
endogenous O +
Dmpk O +
gene O +
and O +
overexpressing O +
a O +
normal O +
human O +
DMPK O +
transgene O +
in O +
mice O -
. O -

Nullizygous O +
( O -
- O -
/ O -
- O -
) O +
mice O +
showed O +
only O +
inconsistent O +
and O +
minor O +
size O +
changes O +
in O +
head O +
and O +
neck O +
muscle O +
fibres O +
at O +
older O +
age O -
, O +
animals O +
with O +
the O +
highest O +
DMPK O +
transgene O +
expression O +
showed O +
hypertrophic B-Disease +
cardiomyopathy L-Disease +
and O +
enhanced O +
neonatal O +
mortality O -
. O -

However O -
, O +
both O +
models O +
lack O +
other O +
frequent O +
DM U-Disease +
symptoms O +
including O +
the O +
fibre O -
- O -
type O +
dependent O +
atrophy U-Disease -
, O +
myotonia U-Disease -
, O +
cataract U-Disease +
and O +
male B-Disease -
- I-Disease -
infertility L-Disease -
. O -

These O +
results O +
strengthen O +
the O +
contention O +
that O +
simple O +
loss- O +
or O +
gain O -
- O -
of O -
- O -
expression O +
of O +
DMPK O +
is O +
not O +
the O +
only O +
crucial O +
requirement O +
for O +
development O +
of O +
the O +
disease O -
.. O -

Mice O +
lacking O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
protein O +
kinase O +
develop O +
a O +
late O +
onset O +
progressive O +
myopathy U-Disease -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
disorder L-Disease +
resulting O +
from O +
the O +
expansion O +
of O +
a O +
CTG O +
repeat O +
in O +
the O +
3 O +
untranslated O +
region O +
of O +
a O +
putative O +
protein O +
kinase O +
( O -
DMPK O -
) O -
. O -

To O +
elucidate O +
the O +
role O +
of O +
DMPK O +
in O +
DM U-Disease +
pathogenesis O +
we O +
have O +
developed O +
Dmpk B-Disease +
deficient L-Disease +
( O -
Dmpk- O -
/ O -
- O -
) O +
mice O -
. O -

Dmpk- O -
/ O -
-mice O +
develop O +
a O +
late O -
- O -
onset O -
, O +
progressive B-Disease +
skeletal I-Disease +
myopathy L-Disease +
that O +
shares O +
some O +
pathological O +
features O +
with O +
DM U-Disease -
. O -

Muscles O +
from O +
mature O +
mice O +
show O +
variation O +
in O +
fibre O +
size O -
, O +
increased O +
fibre B-Disease +
degeneration L-Disease +
and O +
fibrosis U-Disease -
. O -

Adult O +
Dmpk- O -
/ O -
-mice O +
show O +
ultrastructural O +
changes O +
in O +
muscle O +
and O +
a O +
50 O -
% O +
decrease O +
in O +
force O +
generation O +
compared O +
to O +
young O +
mice O -
. O -

Our O +
results O +
indicate O +
that O +
DMPK O +
may O +
be O +
necessary O +
for O +
the O +
maintenance O +
of O +
skeletal O +
muscle O +
structure O +
and O +
function O +
and O +
suggest O +
that O +
a O +
decrease O +
in O +
DMPK O +
levels O +
may O +
contribute O +
to O +
DM U-Disease +
pathology O -
.. O -

The O +
tumor U-Disease +
suppressor O +
gene O +
Brca1 O +
is O +
required O +
for O +
embryonic O +
cellular O +
proliferation O +
in O +
the O +
mouse O -
. O -

Mutations O +
of O +
the O +
BRCA1 O +
gone O +
in O +
humans O +
are O +
associated O +
with O +
predisposition O +
to O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancers L-Disease -
. O -

We O +
show O +
here O +
that O +
Brca1 O +
+ O -
/- O -

mice O +
are O +
normal O +
and O +
fertile O +
and O +
lack O +
tumors U-Disease +
by O +
age O +
eleven O +
months O -
. O -

Homozygous O +
Brca1 O +
( O -
5 O -
- O -
6 O -
) O +
mutant O +
mice O +
die O +
before O +
day O +
7 O -
. O -

5 O +
of O +
embryogenesis O -
. O -

Mutant O +
embryos O +
are O +
poorly O +
developed O -
, O +
with O +
no O +
evidence O +
of O +
mesoderm O +
formation O -
. O -

The O +
extraembryonic O +
region O +
is O +
abnormal O -
, O +
but O +
aggregation O +
with O +
wild O -
- O -
type O +
tetraploid O +
embryos O +
does O +
not O +
rescue O +
the O +
lethality O -
. O -

In O +
vivo O -
, O +
mutant O +
embryos O +
do O +
not O +
exhibit O +
increased O +
apoptosis O +
but O +
show O +
reduced O +
cell O +
proliferation O +
accompanied O +
by O +
decreased O +
expression O +
of O +
cyclin O +
E O +
and O +
mdm-2 O -
, O +
a O +
regulator O +
of O +
p53 O +
activity O -
. O -

The O +
expression O +
of O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
p21 O +
is O +
dramatically O +
increased O +
in O +
the O +
mutant O +
embryos O -
. O -

Buttressing O +
these O +
in O +
vivo O +
observations O +
is O +
the O +
fact O +
that O +
mutant O +
blastocyst O +
growth O +
is O +
grossly O +
impaired O +
in O +
vitro O -
. O -

Thus O -
, O +
the O +
death O +
of O +
Brca1 O +
( O -
5 O -
- O -
6 O -
) O +
mutant O +
embryos O +
prior O +
to O +
gastrulation O +
may O +
be O +
due O +
to O +
a O +
failure O +
of O +
the O +
proliferative O +
burst O +
required O +
for O +
the O +
development O +
of O +
the O +
different O +
germ O +
layers O -
. O -

Increased O +
coronary B-Disease +
heart I-Disease +
disease L-Disease +
in O +
Japanese O -
- O -
American O +
men O +
with O +
mutation O +
in O +
the O +
cholesteryl O +
ester O +
transfer O +
protein O +
gene O +
despite O +
increased O +
HDL O +
levels O -
. O -

Plasma O +
high O +
density O +
lipoprotein O +
( O -
HDL O -
) O +
levels O +
are O +
strongly O +
genetically O +
determined O +
and O +
show O +
a O +
general O +
inverse O +
relationship O +
with O +
coronary B-Disease +
heart I-Disease +
disease L-Disease +
( O -
CHD U-Disease -
) O -
. O -

The O +
cholesteryl O +
ester O +
transfer O +
protein O +
( O -
CETP O -
) O +
mediates O +
the O +
transfer O +
of O +
cholesteryl O +
esters O +
from O +
HDL O +
to O +
other O +
lipoproteins O +
and O +
is O +
a O +
key O +
participant O +
in O +
the O +
reverse O +
transport O +
of O +
cholesterol O +
from O +
the O +
periphery O +
to O +
the O +
liver O -
. O -

A O +
high O +
prevalence O +
of O +
two O +
different O +
CETP O +
gene O +
mutations O +
( O -
D442 O -
G O -
, O +
5 O -
. O +
1 O -
% O -
; O +
intron O +
14 O -
G O -
A O -
, O +
0 O -
. O +
5 O -
% O -
) O -
, O +
was O +
found O +
in O +
3 O -
, O +
469 O +
men O +
of O +
Japanese O +
ancestry O +
in O +
the O +
Honolulu O +
Heart O +
Program O +
and O +
mutations O +
were O +
associated O +
with O +
decreased O +
CETP O +
( O -
-35 O -
% O -
) O +
and O +
increased O +
HDL O +
chol O +
levels O +
( O -
+ O +
10 O -
% O +
for O +
D442 O -
G O -
) O -
. O -

However O -
, O +
the O +
overall O +
prevalence O +
of O +
definite O +
CHD U-Disease +
was O +
21 O -
% O +
in O +
men O +
with O +
mutations O +
and O +
16 O -
% O +
in O +
men O +
without O +
mutations O -
. O -

The O +
relative O +
risk O +
( O -
RR O -
) O +
of O +
CHD U-Disease +
was O +
1 O -
. O +
43 O +
in O +
men O +
with O +
mutations O +
( O -
P O +
< O -
. O +
05 O -
) O -
; O +
after O +
adjustment O +
for O +
CHD U-Disease +
risk O +
factors O -
, O +
the O +
RR O +
was O +
1 O -
. O +
55 O +
( O -
P O +
= O -
. O +
02 O -
) O -
; O +
after O +
additional O +
adjustment O +
for O +
HDL O +
levels O -
, O +
the O +
RR O +
was O +
1 O -
. O +
68 O +
( O -
P O +
= O -
. O +
008 O -
) O -
. O -

Similar O +
RR O +
values O +
were O +
obtained O +
for O +
the O +
D442 O -
G O +
mutation O +
alone O -
. O -

Increased O +
CHD U-Disease +
in O +
men O +
with O +
mutations O +
was O +
primarily O +
observed O +
for O +
HDL O +
chol O +
41 O -
- O -
60 O +
mg O -
/ O -
dl O -
; O +
for O +
HDL O +
chol O +
> O +
60 O +
mg O -
/ O -
dl O +
men O +
with O +
and O +
without O +
mutations O +
had O +
low O +
CHD U-Disease +
prevalence O -
. O -

Thus O -
, O +
genetic O +
CETP B-Disease +
deficiency L-Disease +
appears O +
to O +
be O +
an O +
independent O +
risk O +
factor O +
for O +
CHD U-Disease -
, O +
primarily O +
due O +
to O +
increased O +
CHD U-Disease +
prevalence O +
in O +
men O +
with O +
the O +
D442 O -
G O +
mutation O +
and O +
HDL O +
cholesterol O +
between O +
41 O +
and O +
60 O +
mg O -
/ O -
dl O -
. O -

The O +
findings O +
suggest O +
that O +
both O +
HDL O +
concentration O +
and O +
the O +
dynamics O +
of O +
cholesterol O +
transport O +
through O +
HDL O +
( O -
i. O +
e. O -
, O +
reverse O +
cholesterol O +
transport O -
) O +
determine O +
the O +
anti O -
- O -
atherogenicity O +
of O +
the O +
HDL O +
fraction O -
. O -

Mapping O +
the O +
homolog O +
of O +
the O +
human O +
Rb1 O +
gene O +
to O +
chromosome O +
14 O +
of O +
higher O +
primates O -
. O -

The O +
Rb1 O +
gene O +
has O +
been O +
implicated O +
with O +
retinoblastoma U-Disease +
and O +
is O +
located O +
on O +
human O +
Chromosome O +
( O -
Chr O -
) O +
13q14 O -
. O -

2 O +
2 O -
. O -

A O +
unique O +
sequence O +
human O +
Rb1 O +
cosmid O +
DNA O +
probe O +
has O +
been O +
used O +
to O +
localize O +
this O +
region O +
on O +
apes O +
Chr O +
14 O +
by O +
the O +
FISH O +
technique O -
. O -

The O +
conservation O +
of O +
the O +
Rb1 O +
gene O +
in O +
higher O +
primates O +
at O +
the O +
corresponding O +
equivalent O +
chromosome O +
locus O +
( O -
14q14 O -
) O +
of O +
the O +
human O +
may O +
serve O +
as O +
a O +
phylogenetic O +
marker O +
to O +
further O +
trace O +
the O +
evolutionary O +
pathway O +
of O +
human O +
descent O -
. O -

Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease -
: O +
no O +
strict O +
genotype O -
- O -
phenotype O +
correlations O +
but O +
clustering O +
of O +
missense O +
mutations O +
in O +
the O +
amino O -
- O -
terminal O +
part O +
of O +
the O +
WASP O +
gene O +
product O -
. O -

The O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
protein O +
( O -
WASP O -
) O +
gene O +
was O +
found O +
to O +
be O +
mutated O +
in O +
patients O +
presenting O +
with O +
WAS U-Disease +
and O +
in O +
patients O +
showing O +
X B-Disease -
- I-Disease -
linked I-Disease +
thrombocytopenia L-Disease -
. O -

Mutation O +
analysis O +
in O +
19 O +
families O +
of O +
German O -
, O +
Swiss O +
and O +
Turkish O +
descent O +
by O +
single O -
- O -
strand O +
conformation O +
polymorphism O +
and O +
sequencing O +
resulted O +
in O +
the O +
detection O +
of O +
seven O +
novel O +
and O +
10 O +
known O +
mutations O -
. O -

A O +
striking O +
clustering O +
of O +
missense O +
mutations O +
in O +
the O +
first O +
four O +
exons O +
contrasted O +
with O +
a O +
random O +
distribution O +
of O +
nonsense O +
mutations O -
. O -

More O +
than O +
85 O -
% O +
of O +
all O +
known O +
missense O +
mutations O +
were O +
localized O +
in O +
the O +
amino O -
- O -
terminal O +
stretch O +
of O +
the O +
WASP O +
gene O +
product O -
; O +
this O +
region O +
contained O +
a O +
mutational O +
hot O +
spot O +
at O +
codon O +
86 O -
. O -

No O +
genotype O -
- O -
phenotype O +
correlation O +
emerged O +
after O +
a O +
comparison O +
of O +
the O +
identified O +
mutations O +
with O +
the O +
resulting O +
clinical O +
picture O +
for O +
a O +
classical O +
WAS U-Disease +
phenotype O -
. O -

A O +
substitution O +
at O +
codon O +
86 O +
resulted O +
in O +
an O +
extremely O +
variable O +
expression O +
of O +
the O +
disease O +
in O +
a O +
large O +
Swiss O +
family O -
. O -

An O +
extended O +
homology O +
search O +
revealed O +
a O +
distant O +
relationship O +
of O +
this O +
stretch O +
to O +
the O +
vasodilator O -
- O -
stimulated O +
phosphoprotein O +
( O -
VASP O -
) O -
, O +
which O +
is O +
involved O +
in O +
the O +
maintenance O +
of O +
cyto O -
- O -
architecture O +
by O +
interacting O +
with O +
actin O -
- O -
like O +
filaments O -
.. O -

Influence O +
of O +
PAX6 O +
gene O +
dosage O +
on O +
development O -
: O +
overexpression O +
causes O +
severe O +
eye B-Disease +
abnormalities L-Disease -
. O -

Aniridia U-Disease +
in O +
man O +
and O +
Small O +
eye O +
in O +
mice O +
are O +
semidominant B-Disease +
developmental I-Disease +
disorders L-Disease +
caused O +
by O +
mutations O +
within O +
the O +
paired O +
box O +
gene O +
PAX6 O -
. O -

Whereas O +
heterozygotes O +
suffer O +
from O +
iris B-Disease +
hypoplasia L-Disease -
, O +
homozygous O +
mice O +
lack O +
eyes O +
and O +
nasal O +
cavities O +
and O +
exhibit O +
brain B-Disease +
abnormalities L-Disease -
. O -

To O +
investigate O +
the O +
role O +
of O +
gene O +
dosage O +
in O +
more O +
detail O -
, O +
we O +
have O +
generated O +
yeast O +
artificial O +
chromosome O +
transgenic O +
mice O +
carrying O +
the O +
human O +
PAX6 O +
locus O -
. O -

When O +
crossed O +
onto O +
the O +
Small O +
eye O +
background O -
, O +
the O +
transgene O +
rescues O +
the O +
mutant O +
phenotype O -
. O -

Strikingly O -
, O +
mice O +
carrying O +
multiple O +
copies O +
on O +
a O +
wild O -
- O -
type O +
background O +
show O +
specific O +
developmental B-Disease +
abnormalities I-Disease +
of I-Disease +
the I-Disease +
eye L-Disease -
, O +
but O +
not O +
of O +
other O +
tissues O +
expressing O +
the O +
gene O -
. O -

Thus O -
, O +
at O +
least O +
five O +
different O +
eye O +
phenotypes O +
are O +
associated O +
with O +
changes O +
in O +
PAX6 O +
expression O -
. O -

We O +
provide O +
evidence O +
that O +
not O +
only O +
reduced O -
, O +
but O +
also O +
increased O +
levels O +
of O +
transcriptional O +
regulators O +
can O +
cause O +
developmental B-Disease +
defects L-Disease -
.. O -

Heterodimer O +
formation O +
and O +
activity O +
in O +
the O +
human O +
enzyme O +
galactose-1-phosphate O +
uridylyltransferase O -
. O -

One O +
of O +
the O +
fundamental O +
questions O +
concerning O +
expression O +
and O +
function O +
of O +
dimeric O +
enzymes O +
involves O +
the O +
impact O +
of O +
naturally O +
occurring O +
mutations O +
on O +
subunit O +
assembly O +
and O +
heterodimer O +
activity O -
. O -

This O +
question O +
is O +
of O +
particular O +
interest O +
for O +
the O +
human O +
enzyme O +
galactose O -
- O -
l O -
- O -
phosphate O +
uridylyl O -
- O -
transferase O +
( O -
GALT O -
) O -
, O +
impairment O +
of O +
which O +
results O +
in O +
the O +
inherited B-Disease +
metabolic I-Disease +
disorder L-Disease +
galactosemia U-Disease -
, O +
because O +
many O +
if O +
not O +
most O +
patients O +
studied O +
to O +
date O +
are O +
compound O +
heterozygotes O +
rather O +
than O +
true O +
molecular O +
homozygotes O -
. O -

Furthermore O -
, O +
the O +
broad O +
range O +
of O +
phenotypic O +
severity O +
observed O +
in O +
these O +
patients O +
raises O +
the O +
possibility O +
that O +
allelic O +
combination O -
, O +
not O +
just O +
allelic O +
constitution O -
, O +
may O +
play O +
some O +
role O +
in O +
determining O +
outcome O -
. O -

In O +
the O +
work O +
described O +
herein O -
, O +
we O +
have O +
selected O +
two O +
distinct O +
naturally O +
occurring O +
null O +
mutations O +
of O +
GALT O -
, O +
Q188R O +
and O +
R333W O -
, O +
and O +
asked O +
the O +
questions O +
( O -
i O -
) O +
what O +
are O +
the O +
impacts O +
of O +
these O +
mutations O +
on O +
subunit O +
assembly O -
, O +
and O +
( O -
ii O -
) O +
if O +
heterodimers O +
do O +
form O -
, O +
are O +
they O +
active O +
? O -

To O +
answer O +
these O +
questions O -
, O +
we O +
have O +
established O +
a O +
yeast O +
system O +
for O +
the O +
coexpression O +
of O +
epitope O -
- O -
tagged O +
alleles O +
of O +
human O +
GALT O +
and O +
investigated O +
both O +
the O +
extent O +
of O +
specific O +
GALT O +
subunit O +
interactions O +
and O +
the O +
activity O +
of O +
defined O +
heterodimer O +
pools O -
. O -

We O +
have O +
found O +
that O +
both O +
homodimers O +
and O +
heterodimers O +
do O +
form O +
involving O +
each O +
of O +
the O +
mutant O +
subunits O +
tested O +
and O +
that O +
both O +
heterodimer O +
pools O +
retain O +
substantial O +
enzymatic O +
activity O -
. O -

These O +
results O +
are O +
significant O +
not O +
only O +
in O +
terms O +
of O +
their O +
implications O +
for O +
furthering O +
our O +
understanding O +
of O +
galactosemia U-Disease +
and O +
GALT O +
holoenzyme O +
structure O -
- O -
function O +
relationships O +
but O +
also O +
because O +
the O +
system O +
described O +
may O +
serve O +
as O +
a O +
model O +
for O +
similar O +
studies O +
of O +
other O +
complexes O +
composed O +
of O +
multiple O +
subunits O -
.. O -

Cleavage O +
of O +
huntingtin O +
by O +
apopain O -
, O +
a O +
proapoptotic O +
cysteine O +
protease O -
, O +
is O +
modulated O +
by O +
the O +
polyglutamine O +
tract O -
. O -

Apoptosis O +
has O +
recently O +
been O +
recognized O +
as O +
a O +
mode O +
of O +
cell O +
death O +
in O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O -
. O -

Apopain O -
, O +
a O +
human O +
counterpart O +
of O +
the O +
nematode O +
cysteine O +
protease O +
death O -
- O -
gene O +
product O -
, O +
CED-3 O -
, O +
has O +
a O +
key O +
role O +
in O +
proteolytic O +
events O +
leading O +
to O +
apoptosis O -
. O -

Here O +
we O +
show O +
that O +
apoptotic O +
extracts O +
and O +
apopain O +
itself O +
specifically O +
cleave O +
the O +
HD U-Disease +
gene O +
product O -
, O +
huntingtin O -
. O -

The O +
rate O +
of O +
cleavage O +
increases O +
with O +
the O +
length O +
of O +
the O +
huntingtin O +
polyglutamine O +
tract O -
, O +
providing O +
an O +
explanation O +
for O +
the O +
gain O -
- O -
of O -
- O -
function O +
associated O +
with O +
CAG O +
expansion O -
. O -

Our O +
results O +
show O +
that O +
huntingtin O +
is O +
cleaved O +
by O +
cysteine O +
proteases O +
and O +
suggest O +
that O +
HD U-Disease +
might O +
be O +
a O +
disorder B-Disease +
of I-Disease +
inappropriate I-Disease +
apoptosis L-Disease -
.. O -

The O +
5 O -
' O +
end O +
of O +
the O +
BRCA1 O +
gene O +
lies O +
within O +
a O +
duplicated O +
region O +
of O +
human O +
chromosome O +
17q21 O -
. O -

To O +
begin O +
to O +
address O +
the O +
hypothesis O +
that O +
abnormal O +
regulation O +
of O +
the O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
susceptibility O +
gene O +
BRCA1 O +
is O +
a O +
critical O +
step O +
in O +
sporadic O +
breast O -
/ O -
ovarian O +
tumorigenesis O -
, O +
we O +
have O +
determined O +
the O +
detailed O +
structure O +
of O +
the O +
BRCA1 O +
genomic O +
region O -
. O -

We O +
show O +
that O +
this O +
region O +
of O +
the O +
genome O +
contains O +
a O +
tandem O +
duplication O +
of O +
approximately O +
30 O +
kilobases O -
, O +
which O +
results O +
in O +
two O +
copies O +
of O +
BRCA1 O +
exons O +
1 O +
and O +
2 O -
, O +
of O +
exons O +
1 O +
and O +
3 O +
of O +
the O +
adjacent O +
1A1 O -
- O -
3B O +
gene O +
and O +
of O +
the O +
previously O +
reported O +
295 O +
base O +
pair O +
intergenic O +
region O -
. O -

Sequence O +
analysis O +
of O +
the O +
duplicated O +
exons O +
of O +
BRCA1 O +
and O +
1A1 O -
- O -
3B O +
and O +
flanking O +
genomic O +
DNA O +
reveals O +
maintenance O +
of O +
the O +
intron O -
- O -
exon O +
structure O +
and O +
a O +
high O +
degree O +
of O +
nucleotide O +
sequence O +
identity O -
, O +
suggesting O +
that O +
these O +
are O +
non O -
- O -
processed O +
pseudogenes O +
and O +
that O +
the O +
duplication O +
is O +
a O +
recent O +
event O +
in O +
evolutionary O +
terms O -
. O -

We O +
also O +
show O +
that O +
a O +
processed O +
pseudogene O +
of O +
the O +
acidic O +
ribosomal O +
phosphoprotein O +
P1 O +
( O -
ARPP1 O -
) O +
is O +
inserted O +
directly O +
upstream O +
of O +
pseudo O -
- O -
BRCA1 O +
exon O +
1A O -
. O -

We O +
believe O +
that O +
these O +
findings O +
could O +
not O +
only O +
confound O +
BRCA1 O +
mutation O +
analysis O -
, O +
but O +
could O +
have O +
implications O +
for O +
the O +
normal O +
and O +
abnormal O +
regulation O +
of O +
BRCA1 O +
transcription O -
, O +
translation O +
and O +
function O -
.. O -

Deletion O +
of O +
small O +
nuclear O +
ribonucleoprotein O +
polypeptide O +
N O +
( O -
SNRPN O -
) O +
in O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
detected O +
by O +
fluorescence O +
in O +
situ O +
hybridization O -
: O +
two O +
sibs O +
with O +
the O +
typical O +
phenotype O +
without O +
a O +
cytogenetic O +
deletion O +
in O +
chromosome O +
15q O -
. O -

The O +
small O +
nuclear O +
ribonucleoprotein O +
polypeptide O +
N O +
( O -
SNRPN O -
) O +
gene O +
is O +
regarded O +
as O +
one O +
of O +
the O +
candidates O +
for O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
( O -
PWS U-Disease -
) O -
. O -

We O +
describe O +
two O +
sibs O +
with O +
typical O +
PWS U-Disease +
presenting O +
deletion O +
of O +
SNRPN O +
detected O +
by O +
fluorescence O +
in O +
situ O +
hybridization O +
( O -
FISH O -
) O -
. O -

Neither O +
a O +
cytogenetically O +
detectable O +
15q12 O +
deletion O +
nor O +
a O +
deletion O +
for O +
the O +
D15S11 O -
, O +
D15S10 O -
, O +
and O +
GABRB3 O +
cosmid O +
probes O +
were O +
found O +
in O +
either O +
patient O -
. O -

This O +
implies O +
a O +
smaller O +
deletion O +
limited O +
to O +
the O +
PWS U-Disease +
critical O +
region O -
. O -

FISH O +
with O +
a O +
SNRPN O +
probe O +
will O +
permit O +
analysis O +
of O +
PWS U-Disease +
patients O +
with O +
limited O +
deletions O +
not O +
detectable O +
with O +
other O +
probes O -
.. O -

Expression O +
of O +
the O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
disease I-Disease +
tumour L-Disease +
suppressor O +
gene O +
during O +
human O +
embryogenesis O -
. O -

The O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
( I-Disease -
VHL I-Disease -
) I-Disease +
disease L-Disease +
product O +
is O +
thought O +
to O +
down O -
- O -
regulate O +
transcription O +
by O +
antagonizing O +
elongin O -
- O -
enhanced O +
transcriptional O +
elongation O -
. O -

Germline O +
VHL U-Disease +
gene O +
mutations O +
predispose O +
to O +
the O +
development O +
of O +
retinal B-Disease -
, I-Disease +
cerebellar I-Disease +
and I-Disease +
spinal I-Disease +
haemangioblastomas L-Disease -
, O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
and O +
phaeochromocytoma U-Disease -
. O -

In O +
addition O -
, O +
somatic O +
Inactivation O +
of O +
the O +
VHL U-Disease +
gene O +
is O +
frequent O +
in O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease +
and O +
haemangioblastoma U-Disease -
. O -

Regulation O +
of O +
transcript O +
elongation O +
is O +
an O +
important O +
control O +
mechanism O +
for O +
gene O +
expression O +
and O +
the O +
VHL U-Disease +
gene O +
might O +
modify O +
the O +
expression O +
of O +
proto O -
- O -
oncogenes O +
and O +
growth O +
suppressor O +
genes O +
during O +
embryogenesis O -
. O -

We O +
therefore O +
investigated O +
the O +
expression O +
of O +
VHL U-Disease +
mRNA O +
during O +
human O +
embryogenesis O +
by O +
in O +
situ O +
hybridization O +
studies O +
at O +
4 O -
, O +
6 O +
and O +
10 O +
weeks O +
post O +
conception O -
. O -

Although O +
VHL U-Disease +
mRNA O +
was O +
expressed O +
in O +
all O +
three O +
germ O +
layers O -
, O +
strong O +
expression O +
was O +
noted O +
in O +
the O +
central O +
nervous O +
system O -
, O +
kidneys O -
, O +
testis O +
and O +
lung O -
. O -

Within O +
the O +
kidney O -
, O +
VHL U-Disease +
mRNA O +
was O +
differentially O +
expressed O +
within O +
renal O +
tubules O +
suggesting O +
that O +
the O +
VHL U-Disease +
gene O +
product O +
may O +
have O +
a O +
specific O +
role O +
in O +
kidney O +
development O -
. O -

Two O +
alternatively O +
spliced O +
VHL U-Disease +
mRNAs O +
characterized O +
by O +
inclusion O +
( O -
isoform O +
I O -
) O +
or O +
exclusion O +
( O -
isoform O +
II O -
) O +
of O +
exon O +
2 O +
are O +
transcribed O +
in O +
adult O +
tissues O -
. O -

To O +
investigate O +
if O +
the O +
two O +
isoforms O +
are O +
differentially O +
expressed O +
during O +
embryogenesis O -
, O +
VHL U-Disease +
mRNA O +
was O +
reverse O +
transcribed O +
from O +
13 O +
fetal O +
tissues O +
( O -
8 O -
- O -
10 O +
weeks O +
gestation O -
) O -
. O -

The O +
quantitative O +
distribution O +
of O +
VHL U-Disease +
mRNA O +
within O +
fetal O +
tissues O +
reflected O +
that O +
seen O +
by O +
in O +
situ O +
hybridization O +
and O +
the O +
ratio O +
of O +
the O +
two O +
VHL U-Disease +
isoforms O +
was O +
similar O +
between O +
tissues O -
. O -

Although O +
the O +
genes O +
regulated O +
by O +
the O +
VHL U-Disease +
gene O +
product O +
have O +
not O +
yet O +
been O +
identified O -
, O +
our O +
findings O +
are O +
compatible O +
with O +
the O +
hypothesis O +
that O +
VHL U-Disease -
- O -
mediated O +
control O +
of O +
transcriptional O +
elongation O +
may O +
have O +
a O +
role O +
in O +
normal O +
human O +
development O -
.. O -

Genetic O +
heterogeneity O +
in O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease -
: O +
role O +
of O +
BRCA1 O +
and O +
BRCA2 O -
. O -

The O +
common O +
hereditary O +
forms O +
of O +
breast B-Disease +
cancer L-Disease +
have O +
been O +
largely O +
attributed O +
to O +
the O +
inheritance O +
of O +
mutations O +
in O +
the O +
BRCA1 O +
or O +
BRCA2 O +
genes O -
. O -

However O -
, O +
it O +
is O +
not O +
yet O +
clear O +
what O +
proportion O +
of O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease +
is O +
explained O +
by O +
BRCA1 O +
and O +
BRCA2 O +
or O +
by O +
some O +
other O +
unidentified O +
susceptibility O +
gene O +
( O -
s O -
) O -
. O -

We O +
describe O +
the O +
proportion O +
of O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease +
explained O +
by O +
BRCA1 O +
or O +
BRCA2 O +
in O +
a O +
sample O +
of O +
North O +
American O +
hereditary B-Disease +
breast I-Disease +
cancers L-Disease +
and O +
assess O +
the O +
evidence O +
for O +
additional O +
susceptibility O +
genes O +
that O +
may O +
confer O +
hereditary B-Disease +
breast I-Disease +
or I-Disease +
ovarian I-Disease +
cancer L-Disease +
risk O -
. O -

Twenty O -
- O -
three O +
families O +
were O +
identified O +
through O +
two O +
high O -
- O -
risk O +
breast B-Disease +
cancer L-Disease +
research O +
programs O -
. O -

Genetic O +
analysis O +
was O +
undertaken O +
to O +
establish O +
linkage O +
between O +
the O +
breast B-Disease +
or I-Disease +
ovarian I-Disease +
cancer L-Disease +
cases O +
and O +
markers O +
on O +
chromosomes O +
17q O +
( O -
BRCA1 O -
) O +
and O +
13q O +
( O -
BRCA2 O -
) O -
. O -

Mutation O +
analysis O +
in O +
the O +
BRCA1 O +
and O +
BRCA2 O +
genes O +
was O +
also O +
undertaken O +
in O +
all O +
families O -
. O -

The O +
pattern O +
of O +
hereditary B-Disease +
cancer L-Disease +
in O +
14 O +
( O -
61 O -
% O -
) O +
of O +
the O +
23 O +
families O +
studied O +
was O +
attributed O +
to O +
BRCA1 O +
by O +
a O +
combination O +
of O +
linkage O +
and O +
mutation O +
analyses O -
. O -

No O +
families O +
were O +
attributed O +
to O +
BRCA2 O -
. O -

Five O +
families O +
( O -
22 O -
% O -
) O +
provided O +
evidence O +
against O +
linkage O +
to O +
both O +
BRCA1 O +
and O +
BRCA2 O -
. O -

No O +
BRCA1 O +
or O +
BRCA2 O +
mutations O +
were O +
detected O +
in O +
these O +
five O +
families O -
. O -

The O +
BRCA1 O +
or O +
BRCA2 O +
status O +
of O +
four O +
families O +
( O -
17 O -
% O -
) O +
could O +
not O +
be O +
determined O -
. O -

BRCA1 O +
and O +
BRCA2 O +
probably O +
explain O +
the O +
majority O +
of O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease +
that O +
exists O +
in O +
the O +
North O +
American O +
population O -
. O -

However O -
, O +
one O +
or O +
more O +
additional O +
genes O +
may O +
yet O +
be O +
found O +
that O +
explain O +
some O +
proportion O +
of O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease -
.. O -

An O +
intronic O +
mutation O +
in O +
a O +
lariat O +
branchpoint O +
sequence O +
is O +
a O +
direct O +
cause O +
of O +
an O +
inherited B-Disease +
human I-Disease +
disorder L-Disease +
( O -
fish B-Disease -
- I-Disease -
eye I-Disease +
disease L-Disease -
) O -
. O -

The O +
first O +
step O +
in O +
the O +
splicing O +
of O +
an O +
intron O +
from O +
nuclear O +
precursors O +
of O +
mRNA O +
results O +
in O +
the O +
formation O +
of O +
a O +
lariat O +
structure O -
. O -

A O +
distinct O +
intronic O +
nucleotide O +
sequence O -
, O +
known O +
as O +
the O +
branchpoint O +
region O -
, O +
plays O +
a O +
central O +
role O +
in O +
this O +
process O -
. O -

We O +
here O +
describe O +
a O +
point O +
mutation O +
in O +
such O +
a O +
sequence O -
. O -

Three O +
sisters O +
were O +
shown O +
to O +
suffer O +
from O +
fish B-Disease -
- I-Disease -
eye I-Disease +
disease L-Disease +
( O -
FED U-Disease -
) O -
, O +
a O +
disorder O +
which O +
is O +
caused O +
by O +
mutations O +
in O +
the O +
gene O +
coding O +
for O +
lecithin O -
cholesterol O +
acyltransferase O +
( O -
LCAT O -
) O -
. O -

Sequencing O +
of O +
the O +
LCAT O +
gene O +
of O +
all O +
three O +
probands O +
revealed O +
compound O +
heterozygosity O +
for O +
a O +
missense O +
mutation O +
in O +
exon O +
4 O +
which O +
is O +
reported O +
to O +
underlie O +
the O +
FED U-Disease +
phenotype O -
, O +
and O +
a O +
point O +
mutation O +
located O +
in O +
intron O +
4 O +
( O -
IVS4 O -
T-22C O -
) O -
. O -

By O +
performing O +
in O +
vitro O +
expression O +
of O +
LCAT O +
minigenes O +
and O +
reverse O +
transcriptase O +
PCR O +
on O +
mRNA O +
isolated O +
from O +
leukocytes O +
of O +
the O +
patient O -
, O +
this O +
gene O +
defect O +
was O +
shown O +
to O +
cause O +
a O +
null O +
allele O +
as O +
the O +
result O +
of O +
complete O +
intron O +
retention O -
. O -

In O +
conclusion O -
, O +
we O +
demonstrated O +
that O +
a O +
point O +
mutation O +
in O +
a O +
lariat O +
branchpoint O +
consensus O +
sequence O +
causes O +
a O +
null O +
allele O +
in O +
a O +
patient O +
with O +
FED U-Disease -
. O -

In O +
addition O -
, O +
our O +
finding O +
illustrates O +
the O +
importance O +
of O +
this O +
sequence O +
for O +
normal O +
human O +
mRNA O +
processing O -
. O -

Finally O -
, O +
this O +
report O +
provides O +
a O +
widely O +
applicable O +
strategy O +
which O +
ensures O +
fast O +
and O +
effective O +
screening O +
for O +
intronic O +
defects O +
that O +
underlie O +
differential O +
gene O +
expression O -
.. O -

Mutations O +
associated O +
with O +
variant O +
phenotypes O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
. O -

We O +
have O +
identified O +
14 O +
families O +
with O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
in O +
which O +
mutation O +
of O +
the O +
ATM O +
gene O +
is O +
associated O +
with O +
a O +
less O +
severe O +
clinical O +
and O +
cellular O +
phenotype O +
( O -
approximately O +
10 O -
% O +
-15 O -
% O +
of O +
A B-Disease -
- I-Disease -
T L-Disease +
families O +
identified O +
in O +
the O +
United O +
Kingdom O -
) O -
. O -

In O +
10 O +
of O +
these O +
families O -
, O +
all O +
the O +
homozygotes O +
have O +
a O +
137-bp O +
insertion O +
in O +
their O +
cDNA O +
caused O +
by O +
a O +
point O +
mutation O +
in O +
a O +
sequence O +
resembling O +
a O +
splice O -
- O -
donor O +
site O -
. O -

The O +
second O +
A B-Disease -
- I-Disease -
T L-Disease +
allele O +
has O +
a O +
different O +
mutation O +
in O +
each O +
patient O -
. O -

We O +
show O +
that O +
the O +
less O +
severe O +
phenotype O +
in O +
these O +
patients O +
is O +
caused O +
by O +
some O +
degree O +
of O +
normal O +
splicing O -
, O +
which O +
occurs O +
as O +
an O +
alternative O +
product O +
from O +
the O +
insertion O -
- O -
containing O +
allele O -
. O -

The O +
level O +
of O +
the O +
137-bp O +
PCR O +
product O +
containing O +
the O +
insertion O +
was O +
lowest O +
in O +
two O +
patients O +
who O +
showed O +
a O +
later O +
onset O +
of O +
cerebellar B-Disease +
ataxia L-Disease -
. O -

A O +
further O +
four O +
families O +
who O +
do O +
not O +
have O +
this O +
insertion O +
have O +
been O +
identified O -
. O -

Mutations O +
detected O +
in O +
two O +
of O +
four O +
of O +
these O +
are O +
missense O +
mutations O -
, O +
normally O +
rare O +
in O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O -
. O -

The O +
demonstration O +
of O +
mutations O +
giving O +
rise O +
to O +
a O +
slightly O +
milder O +
phenotype O +
in O +
A B-Disease -
- I-Disease -
T L-Disease +
raises O +
the O +
interesting O +
question O +
of O +
what O +
range O +
of O +
phenotypes O +
might O +
occur O +
in O +
individuals O +
in O +
whom O +
both O +
mutations O +
are O +
milder O -
. O -

One O +
possibility O +
might O +
be O +
that O +
individuals O +
who O +
are O +
compound O +
heterozygotes O +
for O +
ATM O +
mutations O +
are O +
more O +
common O +
than O +
we O +
realize O -
.. O -

Mutation O +
of O +
the O +
VHL O +
gene O +
is O +
associated O +
exclusively O +
with O +
the O +
development O +
of O +
non B-Disease -
- I-Disease -
papillary I-Disease +
renal I-Disease +
cell I-Disease +
carcinomas L-Disease -
. O -

To O +
define O +
the O +
possible O +
role O +
of O +
the O +
VHL U-Disease +
gene O +
in O +
the O +
development O +
of O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinomas L-Disease -
, O +
91 O +
different O +
parenchymal B-Disease +
tumours I-Disease +
of I-Disease +
the I-Disease +
kidney L-Disease +
have O +
been O +
investigated O +
for O +
mutation O +
of O +
the O +
VHL U-Disease +
gene O +
by O +
single O +
strand O +
conformation O +
polymorphism O +
( O -
SSCP O -
) O +
and/or O +
heteroduplex O +
( O -
HD O -
) O +
techniques O -
. O -

Chromosome O +
3p O +
deletion O +
was O +
detected O +
in O +
98 O +
per O +
cent O +
of O +
non B-Disease -
- I-Disease -
papillary I-Disease +
renal I-Disease +
cell I-Disease +
carcinomas L-Disease +
and O +
in O +
25 O +
per O +
cent O +
of O +
chromophobe O +
renal B-Disease +
cell I-Disease +
carcinomas L-Disease -
. O -

In O +
22 O +
of O +
the O +
43 O +
non B-Disease -
- I-Disease -
papillary I-Disease +
renal I-Disease +
cell I-Disease +
carcinomas L-Disease -
, O +
abnormally O +
migrating O +
DNA O +
bands O +
were O +
detected O +
by O +
SSCP O +
and/or O +
HD O +
analysis O -
. O -

No O +
mobility O +
shift O +
was O +
seen O +
in O +
any O +
of O +
the O +
23 O +
chromophobe O +
renal B-Disease +
cell I-Disease +
carcinomas L-Disease -
. O -

In O +
addition O -
, O +
15 O +
papillary B-Disease +
renal I-Disease +
cell I-Disease +
tumours L-Disease +
and O +
ten O +
renal B-Disease +
oncocytomas L-Disease -
, O +
which O +
are O +
characterized O +
by O +
genetic O +
changes O +
other O +
than O +
loss O +
of O +
chromosome O +
3p O +
sequences O -
, O +
were O +
analysed O +
for O +
mutation O +
of O +
the O +
VHL U-Disease +
gene O -
. O -

None O +
of O +
these O +
tumours U-Disease +
showed O +
abnormal O +
migration O +
patterns O -
. O -

The O +
results O +
indicate O +
that O +
mutation O +
of O +
the O +
VHL U-Disease +
gene O +
is O +
associated O +
exclusively O +
with O +
the O +
development O +
of O +
non B-Disease -
- I-Disease -
papillary I-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease -
.. O -

The O +
Emery B-Disease -
- I-Disease -
Dreifuss I-Disease +
muscular I-Disease +
dystrophy L-Disease +
protein O -
, O +
emerin O -
, O +
is O +
a O +
nuclear O +
membrane O +
protein O -
. O -

A O +
large O +
fragment O +
of O +
emerin O +
cDNA O +
was O +
prepared O +
by O +
PCR O +
and O +
expressed O +
as O +
a O +
recombinant O +
protein O +
in O +
Escherichia O +
coli O -
. O -

Using O +
this O +
as O +
immunogen O -
, O +
we O +
prepared O +
a O +
panel O +
of O +
12 O +
monoclonal O +
antibodies O +
which O +
recognise O +
at O +
least O +
four O +
different O +
epitopes O +
on O +
emerin O +
in O +
order O +
to O +
ensure O +
that O +
emerin O +
can O +
be O +
distinguished O +
from O +
non O -
- O -
specific O +
cross O -
- O -
reacting O +
proteins O -
. O -

All O +
the O +
mAbs O +
recognised O +
a O +
34 O +
kDa O +
protein O +
in O +
all O +
tissues O +
tested O -
, O +
though O +
minor O +
emerin O -
- O -
related O +
bands O +
were O +
also O +
detected O +
in O +
some O +
tissues O -
. O -

Immunofluorescence O +
microscopy O +
showed O +
that O +
emerin O +
is O +
located O +
at O +
the O +
nuclear O +
rim O +
in O +
all O +
tissues O +
examined O -
. O -

A O +
muscle O +
biopsy O +
from O +
an O +
Emery B-Disease -
- I-Disease -
Dreifuss I-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
EMDM U-Disease -
) O +
patient O +
showed O +
complete O +
absence O +
of O +
emerin O +
by O +
both O +
Western O +
blotting O +
and O +
immunohistochemistry O -
, O +
suggesting O +
a O +
simple O +
diagnostic O +
antibody O +
test O +
for O +
EDMD U-Disease +
families O -
. O -

Biochemical O +
fractionation O +
of O +
brain O +
and O +
liver O +
tissues O +
showed O +
that O +
emerin O +
was O +
present O +
in O +
nuclei O +
purified O +
by O +
centrifugation O +
through O +
65 O -
% O +
sucrose O +
and O +
was O +
absent O +
from O +
soluble O +
fractions O +
( O -
post-100 O -
, O +
000 O +
g O -
) O -
. O -

From O +
these O +
results O -
, O +
together O +
with O +
sequence O +
and O +
structural O +
homologies O +
between O +
emerin O -
, O +
thymopoietins O +
and O +
the O +
nuclear O +
lamina O -
- O -
associated O +
protein O -
, O +
LAP2 O -
, O +
we O +
suggest O +
that O +
emerin O +
will O +
prove O +
to O +
be O +
one O +
member O +
of O +
a O +
family O +
of O +
inner O +
nuclear O +
membrane O +
proteins O -
.. O -

Mutation O +
of O +
MSH3 O +
in O +
endometrial B-Disease +
cancer L-Disease +
and O +
evidence O +
for O +
its O +
functional O +
role O +
in O +
heteroduplex O +
repair O -
. O -

Many O +
human O +
tumours U-Disease +
have O +
length O +
alterations O +
in O +
repetitive O +
sequence O +
elements O -
. O -

Although O +
this O +
microsatellite B-Disease +
instability L-Disease +
has O +
been O +
attributed O +
to O +
mutations O +
in O +
four O +
DNA O +
mismatch O +
repair O +
genes O +
in O +
hereditary B-Disease +
nonpolyposis I-Disease +
colorectal I-Disease +
cancer L-Disease +
( O -
HNPCC U-Disease -
) O +
kindreds O -
, O +
many O +
sporadic B-Disease +
tumours L-Disease +
exhibit O +
instability O +
but O +
no O +
detectable O +
mutations O +
in O +
these O +
genes O -
. O -

It O +
is O +
therefore O +
of O +
interest O +
to O +
identify O +
other O +
genes O +
that O +
contribute O +
to O +
this O +
instability O -
. O -

In O +
yeast O -
, O +
mutations O +
in O +
several O +
genes O -
, O +
including O +
RTH O +
and O +
MSH3 O -
, O +
cause O +
microsatellite O +
instability O -
. O -

Thus O -
, O +
we O +
screened O +
16 O +
endometrial B-Disease +
carcinomas L-Disease +
with O +
microsatellite O +
instability O +
for O +
alterations O +
in O +
FEN1 O +
( O -
the O +
human O +
homolog O +
of O +
RTH O -
) O +
and O +
in O +
MSH3 O +
( O -
refs O +
12 O -
- O -
14 O -
) O -
. O -

Although O +
we O +
found O +
no O +
FEN1 O +
mutations O -
, O +
a O +
frameshift O +
mutation O +
in O +
MSH3 O +
was O +
observed O +
in O +
an O +
endometrial B-Disease +
carcinoma L-Disease +
and O +
in O +
an O +
endometrial B-Disease +
carcinoma L-Disease +
cell O +
line O -
. O -

Extracts O +
of O +
the O +
cell O +
line O +
were O +
deficient O +
in O +
repair O +
of O +
DNA O +
substrates O +
containing O +
mismatches O +
or O +
extra O +
nucleotides O -
. O -

Introducing O +
chromosome O +
5 O -
, O +
encoding O +
the O +
MSH3 O +
gene O -
, O +
into O +
the O +
mutant O +
cell O +
line O +
increased O +
the O +
stability O +
of O +
some O +
but O +
not O +
all O +
microsatellites O -
. O -

Extracts O +
of O +
these O +
cells O +
repaired O +
certain O +
substrates O +
containing O +
extra O +
nucleotides O -
, O +
but O +
were O +
deficient O +
in O +
repair O +
of O +
those O +
containing O +
mismatches O +
or O +
other O +
extra O +
nucleotides O -
. O -

A O +
subsequent O +
search O +
revealed O +
a O +
second O +
gene O +
mutation O +
in O +
HHUA O +
cells O -
, O +
a O +
missense O +
mutation O +
in O +
the O +
MSH6 O +
gene O -
. O -

Together O +
the O +
data O +
suggest O +
that O +
the O +
MSH3 O +
gene O +
encodes O +
a O +
product O +
that O +
functions O +
in O +
repair O +
of O +
some O +
but O +
not O +
all O +
pre O -
- O -
mutational O +
intermediates O -
, O +
its O +
mutation O +
in O +
tumours U-Disease +
can O +
result O +
in O +
genomic O +
instability O +
and O -
, O +
as O +
in O +
yeast O -
, O +
MSH3 O +
and O +
MSH6 O +
are O +
partially O +
redundant O +
for O +
mismatch O +
repair O -
.. O -

Comparative O +
genome O +
mapping O +
of O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
region O +
in O +
mouse O -
, O +
rat O -
, O +
and O +
Syrian O +
hamster O -
. O -

Chromosomal O +
locations O +
of O +
the O +
Atm O +
( O -
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
AT U-Disease -
) O +
-mutated O -
) O +
and O +
Acat1 O +
( O -
mitochondrial O +
acetoacetyl O -
- O -
CoA O +
thiolase O -
) O +
genes O +
in O +
mouse O -
, O +
rat O -
, O +
and O +
Syrian O +
hamster O +
were O +
determined O +
by O +
direct O +
R O -
- O -
banding O +
FISH O -
. O -

Both O +
genes O +
were O +
colocalized O +
to O +
the O +
C O -
- O -
D O +
band O +
of O +
mouse O +
chromosome O +
9 O -
, O +
the O +
proximal O +
end O +
of O +
q24 O -
. O -

1 O +
of O +
rat O +
chromosome O +
8 O -
, O +
and O +
qa4-qa5 O +
of O +
Syrian O +
hamster O +
chromosome O +
12 O -
. O -

The O +
regions O +
in O +
the O +
mouse O +
and O +
rat O +
were O +
homologous O +
to O +
human O +
chromosome O +
11q O -
. O -

Fine O +
genetic O +
linkage O +
mapping O +
of O +
the O +
mouse O +
AT U-Disease +
region O +
was O +
performed O +
using O +
the O +
interspecific O +
backcross O +
mice O -
. O -

Atm O -
, O +
Acat1 O -
, O +
and O +
Npat O -
, O +
which O +
is O +
a O +
new O +
gene O +
isolated O +
from O +
the O +
AT O +
region O -
, O +
and O +
12 O +
flanking O +
microsatellite O +
DNA O +
markers O +
were O +
examined O -
. O -

No O +
recombinations O +
were O +
found O +
among O +
the O +
Atm O -
, O +
Npat O -
, O +
Acat1 O -
, O +
and O +
D9Mit6 O +
loci O -
, O +
and O +
these O +
loci O +
were O +
mapped O +
2 O -
. O -

0 O +
cM O +
distal O +
to O +
D9Mit99 O +
and O +
1 O -
. O +
3 O +
cM O +
proximal O +
to O +
D9Mit102 O -
. O -

Comparison O +
of O +
the O +
linkage O +
map O +
of O +
mouse O +
chromosome O +
9 O +
( O -
MMU9 O -
) O +
and O +
that O +
of O +
human O +
chromosome O +
11 O +
( O -
HSA11 O -
) O +
indicates O +
that O +
there O +
is O +
a O +
chromosomal O +
rearrangement O +
due O +
to O +
an O +
inversion O +
between O +
Ets1 O +
and O +
Atm O -
- O -
Npat O -
- O -
Acat1 O +
and O +
that O +
the O +
inversion O +
of O +
MMU9 O +
originated O +
from O +
the O +
chromosomal O +
breakage O +
at O +
the O +
boundary O +
between O +
Gria4 O +
and O +
Atm O -
- O -
Npat O -
- O -
Acat1 O +
on O +
HSA11 O -
. O -

This O +
type O +
of O +
inversion O +
appeared O +
to O +
be O +
conserved O +
in O +
the O +
three O +
rodent O +
species O -
, O +
mouse O -
, O +
rat O -
, O +
and O +
Syrian O +
hamster O -
, O +
using O +
additional O +
comparative O +
mapping O +
data O +
with O +
the O +
Rck O +
gene O -

An O +
animal O +
model O +
for O +
Norrie B-Disease +
disease L-Disease +
( O -
ND U-Disease -
) O -
: O +
gene O +
targeting O +
of O +
the O +
mouse O +
ND U-Disease +
gene O -
. O -

In O +
order O +
to O +
elucidate O +
the O +
cellular O +
and O +
molecular O +
processes O +
which O +
are O +
involved O +
in O +
Norrie B-Disease +
disease L-Disease +
( O -
ND U-Disease -
) O -
, O +
we O +
have O +
used O +
gene O +
targeting O +
technology O +
to O +
generate O +
ND U-Disease +
mutant O +
mice O -
. O -

The O +
murine O +
homologue O +
of O +
the O +
ND U-Disease +
gene O +
was O +
cloned O +
and O +
shown O +
to O +
encode O +
a O +
polypeptide O +
that O +
shares O +
94 O -
% O +
of O +
the O +
amino O +
acid O +
sequence O +
with O +
its O +
human O +
counterpart O -
. O -

RNA O +
in O +
situ O +
hybridization O +
revealed O +
expression O +
in O +
retina O -
, O +
brain O +
and O +
the O +
olfactory O +
bulb O +
and O +
epithelium O +
of O +
2 O +
week O +
old O +
mice O -
. O -

Hemizygous O +
mice O +
carrying O +
a O +
replacement O +
mutation O +
in O +
exon O +
2 O +
of O +
the O +
ND U-Disease +
gene O +
developed O +
retrolental O +
structures O +
in O +
the O +
vitreous O +
body O +
and O +
showed O +
an O +
overall O +
disorganization O +
of O +
the O +
retinal O +
ganglion O +
cell O +
layer O -
. O -

The O +
outer O +
plexiform O +
layer O +
disappears O +
occasionally O -
, O +
resulting O +
in O +
a O +
juxtaposed O +
inner O +
and O +
outer O +
nuclear O +
layer O -
. O -

At O +
the O +
same O +
regions O -
, O +
the O +
outer O +
segments O +
of O +
the O +
photoreceptor O +
cell O +
layer O +
are O +
no O +
longer O +
present O -
. O -

These O +
ocular O +
findings O +
are O +
consistent O +
with O +
observations O +
in O +
ND U-Disease +
patients O +
and O +
the O +
generated O +
mouse O +
line O +
provides O +
a O +
faithful O +
model O +
for O +
study O +
of O +
early O +
pathogenic O +
events O +
in O +
this O +
severe O +
X B-Disease -
- I-Disease -
linked I-Disease +
recessive I-Disease +
neurological I-Disease +
disorder L-Disease -
.. O -

The O +
hybrid O +
PAX3-FKHR O +
fusion O +
protein O +
of O +
alveolar B-Disease +
rhabdomyosarcoma L-Disease +
transforms O +
fibroblasts O +
in O +
culture O -
. O -

Pediatric B-Disease +
alveolar I-Disease +
rhabdomyosarcoma L-Disease +
is O +
characterized O +
by O +
a O +
chromosomal O +
translocation O +
that O +
fuses O +
parts O +
of O +
the O +
PAX3 O +
and O +
FKHR O +
genes O -
. O -

PAX3 O +
codes O +
for O +
a O +
transcriptional O +
regulator O +
that O +
controls O +
developmental O +
programs O -
, O +
and O +
FKHR O +
codes O +
for O +
a O +
forkhead O -
- O -
winged O +
helix O +
protein O -
, O +
also O +
a O +
likely O +
transcription O +
factor O -
. O -

The O +
PAX3-FKHR O +
fusion O +
product O +
retains O +
the O +
DNA O +
binding O +
domains O +
of O +
the O +
PAX3 O +
protein O +
and O +
the O +
putative O +
activator O +
domain O +
of O +
the O +
FKHR O +
protein O -
. O -

The O +
PAX3-FKHR O +
protein O +
has O +
been O +
shown O +
to O +
function O +
as O +
a O +
transcriptional O +
activator O -
. O -

Using O +
the O +
RCAS O +
retroviral O +
vector O -
, O +
we O +
have O +
introduced O +
the O +
PAX3-FKHR O +
gene O +
into O +
chicken O +
embryo O +
fibroblasts O -
. O -

Expression O +
of O +
the O +
PAX3-FKHR O +
protein O +
in O +
these O +
cells O +
leads O +
to O +
transformation O -
the O +
cells O +
become O +
enlarged O -
, O +
grow O +
tightly O +
packed O +
and O +
in O +
multiple O +
layers O -
, O +
and O +
acquire O +
the O +
ability O +
for O +
anchorage O -
- O -
independent O +
growth O -
. O -

This O +
cellular O +
transformation O +
in O +
vitro O +
will O +
facilitate O +
studies O +
on O +
the O +
mechanism O +
of O +
PAX3-FKHR O -
- O -
induced O +
oncogenesis O -
.. O -

Somatic O -
- O -
cell O +
selection O +
is O +
a O +
major O +
determinant O +
of O +
the O +
blood O -
- O -
cell O +
phenotype O +
in O +
heterozygotes O +
for O +
glucose-6-phosphate O +
dehydrogenase O +
mutations O +
causing O +
severe O +
enzyme B-Disease +
deficiency L-Disease -
. O -

X O -
- O -
chromosome O +
inactivation O +
in O +
mammals O +
is O +
regarded O +
as O +
an O +
essentially O +
random O +
process O -
, O +
but O +
the O +
resulting O +
somatic O -
- O -
cell O +
mosaicism O +
creates O +
the O +
opportunity O +
for O +
cell O +
selection O -
. O -

In O +
most O +
people O +
with O +
red O -
- O -
blood O -
- O -
cell O +
glucose-6-phosphate B-Disease +
dehydrogenase I-Disease +
( I-Disease -
G6PD I-Disease -
) I-Disease +
deficiency L-Disease -
, O +
the O +
enzyme O -
- O -
deficient O +
phenotype O +
is O +
only O +
moderately O +
expressed O +
in O +
nucleated O +
cells O -
. O -

However O -
, O +
in O +
a O +
small O +
subset O +
of O +
hemizygous O +
males O +
who O +
suffer O +
from O +
chronic B-Disease +
nonspherocytic I-Disease +
hemolytic I-Disease +
anemia L-Disease -
, O +
the O +
underlying O +
mutations O +
( O -
designated O +
class O +
I O -
) O +
cause O +
more O -
- O -
severe O +
G6PD B-Disease +
deficiency L-Disease -
, O +
and O +
this O +
might O +
provide O +
an O +
opportunity O +
for O +
selection O +
in O +
heterozygous O +
females O +
during O +
development O -
. O -

In O +
order O +
to O +
test O +
this O +
possibility O +
we O +
have O +
analyzed O +
four O +
heterozygotes O +
for O +
class O +
I O +
G6PD O +
mutations O -
two O +
with O +
G6PD O +
Portici O +
( O -
1178G-- O +
> O +
A O -
) O +
and O +
two O +
with O +
G6PD O +
Bari O +
( O -
1187C-- O +
> O +
T O -
) O -
. O -

We O +
found O +
that O +
in O +
fractionated O +
blood O +
cell O +
types O +
( O -
including O +
erythroid O -
, O +
myeloid O -
, O +
and O +
lymphoid O +
cell O +
lineages O -
) O +
there O +
was O +
a O +
significant O +
excess O +
of O +
G6PD O -
- O -
normal O +
cells O -
. O -

The O +
significant O +
concordance O +
that O +
we O +
have O +
observed O +
in O +
the O +
degree O +
of O +
imbalance O +
in O +
the O +
different O +
blood O -
- O -
cell O +
lineages O +
indicates O +
that O +
a O +
selective O +
mechanism O +
is O +
likely O +
to O +
operate O +
at O +
the O +
level O +
of O +
pluripotent O +
blood O +
stem O +
cells O -
. O -

Thus O -
, O +
it O +
appears O +
that O +
severe O +
G6PD B-Disease +
deficiency L-Disease +
affects O +
adversely O +
the O +
proliferation O +
or O +
the O +
survival O +
of O +
nucleated O +
blood O +
cells O +
and O +
that O +
this O +
phenotypic O +
characteristic O +
is O +
critical O +
during O +
hematopoiesis O -
.. O -

Analysis O +
of O +
meiotic O +
segregation O -
, O +
using O +
single O -
- O -
sperm O +
typing O -
: O +
meiotic O +
drive O +
at O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
locus O -
. O -

Meiotic O +
drive O +
at O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
locus O +
has O +
recently O +
been O +
suggested O +
as O +
being O +
responsible O +
for O +
maintaining O +
the O +
frequency O -
, O +
in O +
the O +
human O +
population O -
, O +
of O +
DM U-Disease +
chromosomes O +
capable O +
of O +
expansion O +
to O +
the O +
disease O +
state O -
. O -

In O +
order O +
to O +
test O +
this O +
hypothesis O -
, O +
we O +
have O +
studied O +
samples O +
of O +
single O +
sperm O +
from O +
three O +
individuals O +
heterozygous O +
at O +
the O +
DM U-Disease +
locus O -
, O +
each O +
with O +
one O +
allele O +
larger O +
and O +
one O +
allele O +
smaller O +
than O +
19 O +
CTG O +
repeats O -
. O -

To O +
guard O +
against O +
the O +
possible O +
problem O +
of O +
differential O +
PCR O +
amplification O +
rates O +
based O +
on O +
the O +
lengths O +
of O +
the O +
alleles O -
, O +
the O +
sperm O +
were O +
also O +
typed O +
at O +
another O +
closely O +
linked O +
marker O +
whose O +
allele O +
size O +
was O +
unrelated O +
to O +
the O +
allele O +
size O +
at O +
the O +
DM U-Disease +
locus O -
. O -

Using O +
statistical O +
models O +
specifically O +
designed O +
to O +
study O +
single O -
- O -
sperm O +
segregation O +
data O -
, O +
we O +
find O +
no O +
evidence O +
of O +
meiotic O +
segregation O +
distortion O -
. O -

The O +
upper O +
limit O +
of O +
the O +
two O -
- O -
sided O +
95 O -
% O +
confidence O +
interval O +
for O +
the O +
estimate O +
of O +
the O +
common O +
segregation O +
probability O +
for O +
the O +
three O +
donors O +
is O +
at O +
or O +
below O -
. O -

515 O +
for O +
all O +
models O +
considered O -
, O +
and O +
no O +
statistically O +
significant O +
difference O +
from O -
. O -

5 O +
is O +
detected O +
in O +
any O +
of O +
the O +
models O -
. O -

This O +
suggests O +
that O +
any O +
greater O +
amount O +
of O +
segregation O +
distortion O +
at O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
locus O +
must O +
result O +
from O +
events O +
following O +
sperm O +
ejaculation O -
. O -

LPP O -
, O +
the O +
preferred O +
fusion O +
partner O +
gene O +
of O +
HMGIC O +
in O +
lipomas U-Disease -
, O +
is O +
a O +
novel O +
member O +
of O +
the O +
LIM O +
protein O +
gene O +
family O -
. O -

A O +
major O +
cytogenetic O +
subgroup O +
of O +
lipomas U-Disease +
is O +
characterized O +
by O +
recurrent O +
chromosome O +
aberrations O -
, O +
mainly O +
translocations O -
, O +
that O +
involve O +
chromosome O +
segment O +
12q13-q15 O -
. O -

Multiple O +
chromosomes O +
have O +
been O +
found O +
as O +
the O +
translocation O +
partners O +
of O +
chromosome O +
12 O +
but O +
3q27-q28 O +
is O +
preferentially O +
involved O -
. O -

In O +
previous O +
studies O -
, O +
it O +
has O +
been O +
shown O +
that O +
the O +
high O +
mobility O +
group O +
( O -
HMG O -
) O +
protein O +
gene O +
HMGIC O +
at O +
12q15 O +
is O +
consistently O +
rearranged O +
as O +
a O +
consequence O +
of O +
these O +
translocations O -
. O -

Here O -
, O +
we O +
report O +
the O +
identification O +
and O +
characterization O +
of O +
the O +
chromosome O +
3-derived O +
translocation O +
partner O +
gene O -
, O +
which O +
we O +
have O +
designated O +
LPP O +
( O -
lipoma U-Disease +
preferred O +
partner O +
gene O -
) O -
. O -

Using O +
3-RACE O +
analysis O +
of O +
HMGIC O +
fusion O +
transcripts O +
in O +
lipoma U-Disease +
cell O +
line O +
Li-501 O -
/ O -
SV40 O -
, O +
ectopic O +
genetic O +
sequences O +
were O +
obtained O -
, O +
which O +
by O +
CASH O +
( O -
chromosome O +
assignment O +
using O +
somatic O +
cell O +
hybrids O -
) O +
and O +
FISH O +
( O -
fluorescence O +
in O +
situ O +
hybridization O -
) O +
analysis O +
were O +
found O +
to O +
originate O +
from O +
chromosome O +
segment O +
3q27-q28 O -
. O -

In O +
Northern O +
blot O +
analysis O -
, O +
an O +
mRNA O +
of O +
over O +
10 O +
kb O +
was O +
detected O +
by O +
these O +
ectopic O +
sequences O +
in O +
a O +
variety O +
of O +
human O +
tissues O +
but O +
not O +
in O +
brain O +
and O +
peripheral O +
blood O +
leukocytes O -
. O -

Upon O +
partial O +
cDNA O +
cloning O -
, O +
features O +
of O +
the O +
genetic O +
organization O +
of O +
LPP O +
were O +
established O -
. O -

The O +
gene O +
was O +
found O +
to O +
span O +
a O +
genomic O +
region O +
of O +
over O +
400 O +
kb O -
. O -

Nucleotide O +
sequence O +
analysis O +
of O +
a O +
composite O +
cDNA O +
of O +
LPP O +
revealed O +
an O +
open O +
reading O +
frame O +
of O +
1836 O +
nucleotides O +
encoding O +
a O +
proline O -
- O -
rich O +
protein O +
containing O +
a O +
leucine O -
- O -
zipper O +
motif O +
in O +
its O +
amino O -
- O -
terminal O +
region O +
and O +
three O +
LIM O +
domains O +
in O +
its O +
carboxy O -
- O -
terminal O +
region O -
. O -

The O +
LPP O -
- O -
encoded O +
protein O +
should O +
be O +
classified O +
as O +
a O +
novel O +
member O +
of O +
the O +
group O +
3 O +
proteins O +
of O +
the O +
LIM O +
protein O +
gene O +
family O -
. O -

Using O +
reverse O +
transcriptase O +
combined O +
with O +
polymerase O +
chain O +
reactions O +
in O +
the O +
analysis O +
of O +
a O +
number O +
of O +
lipoma U-Disease +
cell O +
lines O +
and O +
primary B-Disease +
lipomas L-Disease -
, O +
it O +
appeared O +
that O +
LPP O +
is O +
frequently O +
rearranged O +
also O +
in O +
cases O +
without O +
a O +
cytogenetically O +
detectable O +
involvement O +
of O +
3q27-q28 O -
. O -

Two O +
alternative O +
HMGIC O -
/ O -
LPP O +
hybrid O +
transcripts O +
have O +
been O +
detected O -
; O +
the O +
difference O +
between O +
them O +
is O +
mainly O +
the O +
presence O +
of O +
either O +
two O +
or O +
three O +
LIM O +
domains O +
in O +
the O +
predicted O +
HMGI O -
- O -
C O -
/ O -
LPP O +
fusion O +
proteins O -
.. O -

Absence O +
of O +
disease O +
phenotype O +
and O +
intergenerational O +
stability O +
of O +
the O +
CAG O +
repeat O +
in O +
transgenic O +
mice O +
expressing O +
the O +
human O +
Huntington B-Disease +
disease L-Disease +
transcript O -
. O -

The O +
mutation O +
underlying O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
is O +
CAG O +
expansion O +
in O +
the O +
first O +
exon O +
of O +
the O +
HD U-Disease +
gene O -
. O -

In O +
order O +
to O +
investigate O +
the O +
role O +
of O +
CAG O +
expansion O +
in O +
the O +
pathogenesis O +
of O +
HD U-Disease -
, O +
we O +
have O +
produced O +
transgenic O +
mice O +
containing O +
the O +
full O +
length O +
human O +
HD U-Disease +
cDNA O +
with O +
44 O +
CAG O +
repeats O -
. O -

By O +
1 O +
year O -
, O +
these O +
mice O +
have O +
no O +
behavioral B-Disease +
abnormalities L-Disease +
and O +
morphometric O +
analysis O +
at O +
6 O +
( O -
one O +
animal O -
) O +
and O +
9 O +
( O -
two O +
animals O -
) O +
months O +
age O +
revealed O +
no O +
changes O -
. O -

Despite O +
high O +
levels O +
of O +
mRNA O +
expression O -
, O +
there O +
was O +
no O +
evidence O +
of O +
the O +
HD U-Disease +
gene O +
product O +
in O +
any O +
of O +
these O +
transgenic O +
mice O -
. O -

In O +
vitro O +
transfection O +
studies O +
indicated O +
that O +
the O +
inclusion O +
of O +
120 O +
bp O +
of O +
the O +
5 O +
UTR O +
in O +
the O +
cDNA O +
construct O +
and O +
the O +
presence O +
of O +
a O +
frameshift O +
mutation O +
at O +
nucleotide O +
2349 O +
prevented O +
expression O +
of O +
the O +
HD U-Disease +
cDNA O -
. O -

These O +
findings O +
suggest O +
that O +
the O +
pathogenesis O +
of O +
HD U-Disease +
is O +
not O +
mediated O +
through O +
DNA O -
- O -
protein O +
interaction O +
and O +
that O +
presence O +
of O +
the O +
RNA O +
transcript O +
with O +
an O +
expanded O +
CAG O +
repeat O +
is O +
insufficient O +
to O +
cause O +
the O +
disease O -
. O -

Rather O -
, O +
translation O +
of O +
the O +
CAG O +
is O +
crucial O +
for O +
the O +
pathogenesis O +
of O +
HD U-Disease -
. O -

In O +
contrast O +
to O +
that O +
seen O +
in O +
humans O -
, O +
the O +
CAG O +
repeat O +
in O +
these O +
mice O +
was O +
remarkably O +
stable O +
in O +
97 O +
meioses O -
. O -

This O +
suggests O +
that O +
genomic O +
sequences O +
may O +
play O +
a O +
critical O +
role O +
in O +
influencing O +
repeat O +
instability O -
.. O -

FISH O +
studies O +
in O +
a O +
patient O +
with O +
sporadic B-Disease +
aniridia L-Disease +
and O +
t O -
( O -
7;11 O -
) O +
( O -
q31.2;p13 O -
) O -
. O -

A O +
2 O +
year O +
old O +
female O +
presenting O +
with O +
bilateral B-Disease +
sporadic I-Disease +
aniridia L-Disease +
was O +
found O +
to O +
have O +
an O +
apparently O +
balanced O +
reciprocal O +
translocation O +
with O +
a O +
chromosome O +
11 O +
breakpoint O +
within O +
band O +
p13 O -
. O -

Fluorescence O +
in O +
situ O +
hybridisation O +
( O -
FISH O -
) O +
studies O +
with O +
distal O +
11p13 O +
specific O +
cosmids O +
showed O +
that O +
the O +
chromosome O +
11 O +
breakpoint O +
lay O +
between O +
the O +
aniridia U-Disease +
( O -
PAX6 O -
) O +
locus O +
and O +
a O +
region O +
approximately O +
100 O +
kb O +
distal O +
to O +
PAX6 O +
defined O +
by O +
the O +
cosmid O +
FO2121 O -
. O -

Although O +
this O +
patient O +
did O +
not O +
have O +
a O +
detectable O +
deletion O +
within O +
PAX6 O -
, O +
her O +
aniridia U-Disease +
may O +
have O +
resulted O +
from O +
a O +
disruption O +
of O +
the O +
distal O +
chromatin O +
domain O +
containing O +
either O +
enhancers O +
or O +
regulators O +
for O +
PAX6 O -
. O -

This O +
case O +
may O +
therefore O +
be O +
another O +
example O +
of O +
aniridia U-Disease +
caused O +
by O +
a O +
position O +
effect O +
as O +
recently O +
described O +
in O +
two O +
familial B-Disease +
aniridia L-Disease +
patients O +
in O +
which O +
the O +
phenotype O +
cosegregated O +
with O +
chromosome B-Disease +
abnormalities L-Disease +
with O +
11p13 O +
breakpoints O -
.. O -

Muscle O +
expression O +
of O +
glucose-6-phosphate B-Disease +
dehydrogenase I-Disease +
deficiency L-Disease +
in O +
different O +
variants O -
. O -

Muscle O +
expression O +
of O +
G6PD B-Disease +
deficiency L-Disease +
has O +
been O +
investigated O +
in O +
Mediterranean O -
, O +
Seattle O -
- O -
like O +
and O +
A O -
- O -
variants O -
. O -

G6PD O +
activity O +
was O +
detected O +
in O +
samples O +
obtained O +
from O +
biopsies O +
on O +
the O +
quadriceps O +
muscle O +
of O +
seven O +
males O +
and O +
one O +
female O -
. O -

The O +
type O +
of O +
genetic O +
variant O +
was O +
determined O +
by O +
molecular O +
analysis O +
of O +
DNA O -
, O +
extracted O +
from O +
blood O +
samples O -
. O -

All O +
variants O +
showed O +
the O +
enzyme O +
defect O +
in O +
muscle O -
. O -

A O +
statistically O +
significant O +
relationship O +
was O +
found O +
in O +
the O +
activity O +
of O +
G6PD O +
between O +
erythrocytes O +
and O +
muscle O +
of O +
the O +
male O +
subjects O +
( O -
r O +
= O +
0 O -
. O +
968 O -
; O +
p O +
= O +
0 O -
. O +
00008 O -
) O -
. O -

The O +
equation O +
for O +
the O +
best O +
fit O +
line O +
was O -
Y O +
= O +
0 O -
. O -

390X O +
+ O +
0 O -
. O +
198 O +
198 O -
. O -

The O +
results O +
suggest O +
that O -
, O +
for O +
a O +
given O +
variant O -
, O +
the O +
extent O +
of O +
the O +
enzyme O +
defect O +
in O +
muscle O +
may O +
be O +
determined O -
, O +
using O +
this O +
equation O -
, O +
from O +
the O +
G6PD O +
activity O +
of O +
erythrocytes O -

Gene O +
therapy O +
for O +
phenylketonuria U-Disease -
. O -

Classical O +
phenylketonuria U-Disease +
( O -
PKU U-Disease -
) O +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
disorder L-Disease +
caused O +
by O +
a O +
deficiency B-Disease +
of I-Disease +
hepatic I-Disease +
phenylalanine I-Disease +
hydroxylase L-Disease +
( O -
PAH O -
) O -
. O -

Limitations O +
of O +
the O +
current O +
dietary O +
treatment O +
for O +
PKU U-Disease +
have O +
led O +
to O +
the O +
development O +
of O +
potential O +
treatments O +
based O +
on O +
somatic O +
gene O +
transfer O -
. O -

Three O +
different O +
vector O +
systems O +
have O +
been O +
examined O -
. O -

Vectors O +
derived O +
from O +
a O +
recombinant O +
retrovirus O +
or O +
a O +
DNA O -
/ O -
protein O +
complex O +
can O +
efficiently O +
transduce O +
the O +
PAH O +
cDNA O +
into O +
PAH B-Disease -
- I-Disease -
deficient L-Disease +
hepatocytes O +
in O +
vitro O -
, O +
but O +
the O +
application O +
of O +
these O +
vector O +
systems O +
is O +
presently O +
limited O +
by O +
their O +
low O +
transduction O +
efficiency O +
in O +
vivo O -
. O -

In O +
contrast O -
, O +
a O +
vector O +
derived O +
from O +
a O +
recombinant O +
adenovirus O +
can O +
restore O +
10 O -
% O +
-80 O -
% O +
of O +
normal O +
hepatic O +
PAH O +
activity O +
into O +
PAH B-Disease -
- I-Disease -
deficient L-Disease +
mice O -
, O +
which O +
completely O +
normalizes O +
serum O +
phenylalanine O +
levels O -
. O -

This O +
treatment O +
is O +
transient O +
and O +
can O -
not O +
be O +
effectively O +
re O -
- O -
administered O +
due O +
to O +
the O +
presence O +
of O +
neutralizing O +
antibodies O +
directed O +
against O +
the O +
recombinant O +
adenoviral O +
vector O -
. O -

However O -
, O +
these O +
findings O +
suggest O +
that O +
PKU U-Disease +
can O +
be O +
completely O +
corrected O +
by O +
somatic O +
gene O +
therapy O -
, O +
and O +
provide O +
some O +
direction O +
for O +
the O +
future O +
development O +
of O +
adenoviral O +
vectors O -
.. O -

Exon O -
- O -
intron O +
structure O +
of O +
the O +
human O +
neuronal O +
nicotinic O +
acetylcholine O +
receptor O +
alpha O +
4 O +
subunit O +
( O -
CHRNA4 O -
) O -
. O -

The O +
human O +
neuronal O +
nicotinic O +
acetylcholine O +
receptor O +
alpha O +
4 O +
subunit O +
gene O +
( O -
CHRNA4 O -
) O +
is O +
located O +
in O +
the O +
candidate O +
region O +
for O +
three O +
different O +
phenotypes O -
benign B-Disease +
familial I-Disease +
neonatal I-Disease +
convulsions L-Disease -
, O +
autosomal B-Disease +
dominant I-Disease +
nocturnal I-Disease +
frontal I-Disease +
lobe I-Disease +
epilepsy L-Disease -
, O +
and O +
low O -
- O -
voltage O +
EEG O -
. O -

Recently O -
, O +
a O +
missense O +
mutation O +
in O +
transmembrane O +
domain O +
2 O +
of O +
CHRNA4 O +
was O +
found O +
to O +
be O +
associated O +
with O +
autosomal B-Disease +
dominant I-Disease +
nocturnal I-Disease +
frontal I-Disease +
lobe I-Disease +
epilepsy L-Disease +
in O +
one O +
extended O +
pedigree O -
. O -

We O +
have O +
determined O +
the O +
genomic O +
organization O +
of O +
CHRNA4 O -
, O +
which O +
consists O +
of O +
six O +
exons O +
distributed O +
over O +
approximately O +
17 O +
kb O +
of O +
genomic O +
DNA O -
. O -

The O +
nucleotide O +
sequence O +
obtained O +
from O +
the O +
genomic O +
regions O +
adjacent O +
to O +
the O +
exon O +
boundaries O +
enabled O +
us O +
to O +
develop O +
a O +
set O +
of O +
primer O +
pairs O +
for O +
PCR O +
amplification O +
of O +
the O +
complete O +
coding O +
region O -
. O -

The O +
sequence O +
analysis O +
provides O +
the O +
basis O +
for O +
a O +
comprehensive O +
mutation O +
screening O +
of O +
CHRNA4 O +
in O +
the O +
above O -
- O -
mentioned O +
phenotypes O +
and O +
possibly O +
in O +
other O +
types O +
of O +
idiopathic B-Disease +
epilepsies L-Disease -
.. O -

Ashkenazi O +
Jewish O +
population O +
frequencies O +
for O +
common O +
mutations O +
in O +
BRCA1 O +
and O +
BRCA2 O -
. O -

BRCA1 O +
and O +
BRCA2 O +
are O +
the O +
two O +
major O +
identified O +
causes O +
of O +
inherited B-Disease +
breast I-Disease +
cancer L-Disease -
, O +
with O +
mutations O +
in O +
either O +
gene O +
conferring O +
up O +
to O +
80 O -
- O -
90 O -
% O +
lifetime O +
risk O +
of O +
breast B-Disease +
cancer L-Disease +
in O +
carrier O +
females O -
. O -

Mutations O +
in O +
BRCA1 O +
account O +
for O +
approximately O +
45 O -
% O +
of O +
familial B-Disease +
breast I-Disease +
cancer L-Disease +
and O +
90 O -
% O +
of O +
inherited B-Disease +
breast I-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease -
, O +
whereas O +
mutations O +
in O +
BRCA2 O +
account O +
for O +
a O +
comparable O +
percentage O +
of O +
inherited B-Disease +
breast I-Disease +
cancer L-Disease +
cases O -
. O -

Over O +
85 O +
distinct O +
BRCA1 O +
mutations O +
and O +
a O +
growing O +
list O +
of O +
BRCA2 O +
mutations O +
have O +
been O +
identified O -
, O +
with O +
the O +
majority O +
resulting O +
in O +
protein O +
truncation O -
. O -

A O +
specific O +
BRCA1 O +
mutation O -
, O +
185delAG O -
, O +
has O +
a O +
reported O +
increased O +
carrier O +
frequency O +
of O +
approximately O +
0 O -
. O +
9 O -
% O +
in O +
the O +
Ashkenazi O +
Jewish O +
population O -
, O +
but O +
is O +
also O +
found O +
in O +
rare O +
non O -
- O -
Jewish O +
patients O +
with O +
a O +
different O +
haplotype O -
. O -

The O +
6174delT O +
mutation O +
in O +
BRCA2 O +
was O +
recently O +
identified O +
as O +
a O +
frequent O +
mutation O +
in O +
8 O +
out O +
of O +
107 O +
Ashkenazi O +
Jewish O +
women O +
diagnosed O +
with O +
breast B-Disease +
cancer L-Disease +
by O +
age O +
50 O +
( O -
ref O -
. O -

8) O -
, O +
as O +
well O +
as O +
in O +
three O +
Ashkenazi O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
patients O -
. O -

We O +
have O +
conducted O +
a O +
large O -
- O -
scale O +
population O +
study O +
to O +
investigate O +
the O +
prevalence O +
of O +
specific O +
BRCA1 O +
and O +
BRCA2 O +
mutations O +
in O +
Ashkenazi O +
Jewish O +
individuals O +
who O +
were O +
unselected O +
for O +
breast B-Disease +
cancer L-Disease -
. O -

BRCA1 O +
mutation O +
screening O +
on O +
approximately O +
3 O -
, O +
000 O +
Ashkenazi O +
Jewish O +
samples O +
determined O +
a O +
carrier O +
frequency O +
of O +
1 O -
. O +
09 O -
% O +
for O +
the O +
185delAG O +
mutation O +
and O +
0 O -
. O +
13 O -
% O +
for O +
the O +
5382insC O +
mutation O -
. O -

BRCA2 O +
analysis O +
on O +
3 O -
, O +
085 O +
individuals O +
from O +
the O +
same O +
population O +
showed O +
a O +
carrier O +
frequency O +
of O +
1 O -
. O +
52 O -
% O +
for O +
the O +
6174delT O +
mutation O -
. O -

This O +
expanded O +
population O -
- O -
based O +
study O +
confirms O +
that O +
the O +
BRCA1 O +
185delAG O +
mutation O +
and O +
the O +
BRCA2 O +
6174delT O +
mutation O +
constitute O +
the O +
two O +
most O +
frequent O +
mutation O +
alleles O +
predisposing O +
to O +
hereditary B-Disease +
breast I-Disease +
cancer L-Disease +
among O +
the O +
Ashkenazim O -
, O +
and O +
suggests O +
a O +
relatively O +
lower O +
penetrance O +
for O +
the O +
6174delT O +
mutation O +
in O +
BRCA2 O -

Dual O +
roles O +
of O +
ATM O +
in O +
the O +
cellular O +
response O +
to O +
radiation O +
and O +
in O +
cell O +
growth O +
control O -
. O -

The O +
gene O +
mutated O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
AT U-Disease -
) O +
patients O -
, O +
denoted O +
ATM O -
, O +
encodes O +
a O +
putative O +
protein O +
or O +
lipid O +
kinase O -
. O -

To O +
elucidate O +
the O +
functions O +
of O +
ATM O -
, O +
we O +
disrupted O +
the O +
mouse O +
ATM O +
gene O +
through O +
homologous O +
recombination O +
in O +
mice O -
. O -

Consistent O +
with O +
cellular O +
defects O +
of O +
AT U-Disease +
patients O -
, O +
the O +
ATM- O -
/ O -
- O +
cells O +
are O +
hypersensitive O +
to O +
gamma O -
- O -
irradiation O +
and O +
defective O +
in O +
cell O -
- O -
cycle O +
arrest O +
following O +
radiation O -
, O +
correlating O +
with O +
a O +
defective O +
up O -
- O -
regulation O +
of O +
p53 O -
. O -

In O +
addition O -
, O +
ATM- O -
/ O -
- O +
mouse O +
thymocytes O +
are O +
more O +
resistant O +
to O +
apoptosis O +
induced O +
by O +
gamma O -
- O -
irradiation O +
than O +
normal O +
thymocytes O -
. O -

ATM- O -
/ O -
- O +
fibroblasts O +
are O +
inefficient O +
in O +
G1 O +
to O +
S O -
- O -
phase O +
progression O +
following O +
serum O +
stimulation O +
and O +
senesce O +
after O +
only O +
a O +
few O +
passages O +
in O +
culture O -
. O -

They O +
have O +
an O +
increased O +
constitutive O +
level O +
of O +
p21CP1 O -
/ O -
WAF1 O -
. O -

The O +
ATM O +
protein O +
is O +
therefore O +
critical O +
both O +
for O +
cellular O +
responses O +
to O +
ionizing O +
radiation O +
and O +
for O +
normal O +
cell O -
- O -
cycle O +
progression O -
. O -

ATM O +
+ O -
/- O +
fibroblasts O +
and O +
thymocytes O +
showed O +
intermediately O +
defective O +
responses O +
to O +
irradiation O +
but O +
no O +
growth O +
defect O -
, O +
suggesting O +
that O +
the O +
increased O +
cancer U-Disease +
risk O +
of O +
AT U-Disease +
heterozygotes O +
could O +
be O +
attributable O +
to O +
poor O +
checkpoint O +
function O -
.. O -

Targeted O +
disruption O +
of O +
ATM O +
leads O +
to O +
growth B-Disease +
retardation L-Disease -
, O +
chromosomal B-Disease +
fragmentation I-Disease +
during I-Disease +
meiosis L-Disease -
, O +
immune B-Disease +
defects L-Disease -
, O +
and O +
thymic B-Disease +
lymphoma L-Disease -
. O -

ATM O -
, O +
the O +
gene O +
mutated O +
in O +
the O +
inherited B-Disease +
human I-Disease +
disease L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
, O +
is O +
a O +
member O +
of O +
a O +
family O +
of O +
kinases O +
involved O +
in O +
DNA O +
metabolism O +
and O +
cell O -
- O -
cycle O +
checkpoint O +
control O -
. O -

To O +
help O +
clarify O +
the O +
physiological O +
roles O +
of O +
the O +
ATM O +
protein O -
, O +
we O +
disrupted O +
the O +
ATM O +
gene O +
in O +
mice O +
through O +
homologous O +
recombination O -
. O -

Initial O +
evaluation O +
of O +
the O +
ATM O +
knockout O +
animals O +
indicates O +
that O +
inactivation O +
of O +
the O +
mouse O +
ATM O +
gene O +
recreates O +
much O +
of O +
the O +
phenotype O +
of O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
. O -

The O +
homozygous O +
mutant O +
( O -
ATM- O -
/ O -
- O -
) O +
mice O +
are O +
viable O -
, O +
growth O -
- O -
retarded O -
, O +
and O +
infertile O -
. O -

The O +
infertility U-Disease +
of O +
ATM- O -
/ O -
- O +
mice O +
results O +
from O +
meiotic O +
failure O -
. O -

Meiosis O +
is O +
arrested O +
at O +
the O +
zygotene O -
/ O -
pachytene O +
stage O +
of O +
prophase O +
I O +
as O +
a O +
result O +
of O +
abnormal O +
chromosomal O +
synapsis O +
and O +
subsequent O +
chromosome O +
fragmentation O -
. O -

Immune B-Disease +
defects L-Disease +
also O +
are O +
evident O +
in O +
ATM- O -
/ O -
- O +
mice O -
, O +
including O +
reduced O +
numbers O +
of O +
B220 O +
+ O +
CD43- O +
pre O -
- O -
B O +
cells O -
, O +
thymocytes O -
, O +
and O +
peripheral O +
T O +
cells O -
, O +
as O +
well O +
as O +
functional O +
impairment O +
of O +
T O -
- O -
cell O -
- O -
dependent O +
immune O +
responses O -
. O -

The O +
cerebella O +
of O +
ATM- O -
/ O -
- O +
mice O +
appear O +
normal O +
by O +
histologic O +
examination O +
at O +
3 O +
to O +
4 O +
months O +
and O +
the O +
mice O +
have O +
no O +
gross O +
behavioral B-Disease +
abnormalities L-Disease -
. O -

The O +
majority O +
of O +
mutant O +
mice O +
rapidly O +
develop O +
thymic B-Disease +
lymphomas L-Disease +
and O +
die O +
before O +
4 O +
months O +
of O +
age O -
. O -

These O +
findings O +
indicate O +
that O +
the O +
ATM O +
gene O +
product O +
plays O +
an O +
essential O +
role O +
in O +
a O +
diverse O +
group O +
of O +
cellular O +
processes O -
, O +
including O +
meiosis O -
, O +
the O +
normal O +
growth O +
of O +
somatic O +
tissues O -
, O +
immune O +
development O -
, O +
and O +
tumor U-Disease +
suppression O -
.. O -

Cloning O +
and O +
characterization O +
of O +
human O +
very O -
- O -
long O -
- O -
chain O +
acyl O -
- O -
CoA O +
dehydrogenase O +
cDNA O -
, O +
chromosomal O +
assignment O +
of O +
the O +
gene O +
and O +
identification O +
in O +
four O +
patients O +
of O +
nine O +
different O +
mutations O +
within O +
the O +
VLCAD O +
gene O -
. O -

Very O -
- O -
long O -
- O -
chain O +
acyl O -
- O -
CoA O +
dehydrogenase O +
( O -
VLCAD O -
) O +
is O +
one O +
of O +
four O +
straight O -
- O -
chain O +
acyl O -
- O -
CoA O +
dehydrogenase O +
( O -
ACD O -
) O +
enzymes O -
, O +
which O +
are O +
all O +
nuclear O +
encoded O +
mitochondrial O +
flavoproteins O +
catalyzing O +
the O +
initial O +
step O +
in O +
fatty O +
acid O +
beta O -
- O -
oxidation O -
. O -

We O +
have O +
used O +
the O +
very O +
fast O -
, O +
Rapid O +
Amplification O +
of O +
cDNA O +
Ends O +
( O -
RACE O -
) O +
based O +
strategy O +
to O +
obtain O +
the O +
sequence O +
of O +
cDNAs O +
encoding O +
human O +
VLCAD O +
from O +
placenta O +
and O +
fibroblasts O -
. O -

Alignment O +
of O +
the O +
predicted O +
amino O +
acid O +
sequence O +
of O +
human O +
VLCAD O +
with O +
those O +
of O +
the O +
other O +
human O +
ACD O +
enzymes O +
revealed O +
extensive O +
sequence O +
homology O -
. O -

Moreover O -
, O +
human O +
VLCAD O +
and O +
human O +
acyl O -
- O -
CoA O +
oxidase O +
showed O +
extensive O +
sequence O +
homology O +
corroborating O +
the O +
notion O +
that O +
these O +
genes O +
are O +
evolutionarily O +
related O -
. O -

Southern O +
blot O +
analysis O +
of O +
genomic O +
DNA O +
from O +
hybrid O +
cell O +
lines O +
was O +
used O +
to O +
localize O +
the O +
VLCAD O +
gene O +
to O +
human O +
chromosome O +
17p11 O -
. O -

2-p11 O -
. O -

13105 O -
. O -

Using O +
Northern O +
and O +
Western O +
blot O +
analysis O +
to O +
investigate O +
the O +
tissue O +
specific O +
distribution O +
of O +
VLCAD O +
mRNA O +
and O +
protein O +
in O +
several O +
human O +
tissues O +
we O +
showed O +
that O +
VLCAD O +
is O +
most O +
abundant O +
in O +
heart O +
and O +
skeletal O +
muscle O -
. O -

This O +
agrees O +
well O +
with O +
the O +
fact O +
that O +
cardiac O +
and O +
muscle O +
symptoms O +
are O +
characteristic O +
for O +
patients O +
with O +
VLCAD B-Disease +
deficiency L-Disease -
. O -

Northern O +
blot O +
analysis O +
and O +
sequencing O +
of O +
cloned O +
PCR O +
amplified O +
VLCAD O +
cDNA O +
from O +
four O +
unrelated O +
patients O +
with O +
VLCAD B-Disease +
deficiency L-Disease +
showed O +
that O +
VLCAD O +
mRNA O +
was O +
undetectable O +
in O +
one O +
patient O +
and O +
that O +
the O +
other O +
three O +
have O +
mutations O +
in O +
both O +
VLCAD O +
alleles O -
. O -

Western O +
blot O +
analysis O +
of O +
patient O +
fibroblasts O +
showed O +
that O +
the O +
identified O +
mutations O +
result O +
in O +
severely O +
reduced O +
amounts O +
of O +
VLCAD O +
protein O -
. O -

Molecular O +
bases O +
of O +
combined B-Disease +
subtotal I-Disease +
deficiencies I-Disease +
of I-Disease +
C6 I-Disease +
and I-Disease +
C7 L-Disease -
: O +
their O +
effects O +
in O +
combination O +
with O +
other O +
C6 B-Disease +
and I-Disease +
C7 I-Disease +
deficiencies L-Disease -
. O -

Combined B-Disease +
subtotal I-Disease +
deficiency I-Disease +
of I-Disease +
C6 I-Disease +
and I-Disease +
C7 L-Disease -
, O +
in O +
which O +
both O +
proteins O +
are O +
expressed O +
at O +
very O +
low O +
levels O -
, O +
has O +
been O +
observed O +
in O +
homozygous O +
form O +
in O +
two O +
families O -
. O -

A O +
defect O +
at O +
the O +
5 O +
splice O +
donor O +
site O +
of O +
intron O +
15 O +
of O +
the O +
C6 O +
gene O +
explains O +
the O +
low O +
molecular O +
weight O +
of O +
the O +
C6 O +
protein O +
and O +
is O +
probably O +
responsible O +
for O +
its O +
low O +
expressed O +
concentration O -
. O -

The O +
C7 O +
defect O +
is O +
more O +
enigmatic O -
the O +
protein O +
is O +
of O +
normal O +
molecular O +
weight O -
, O +
low O +
circulating O +
concentration O -
, O +
and O +
altered O +
isoelectric O +
point O -
. O -

An O +
Arg O +
> O +
Ser O +
codon O +
substitution O +
in O +
exon O +
11 O +
is O +
the O +
only O +
molecular O +
alteration O +
within O +
the O +
mature O +
C7 O +
protein O -
. O -

These O +
defects O +
are O +
associated O +
with O +
a O +
characteristic O +
set O +
of O +
polymorphic O +
DNA O +
markers O +
in O +
the O +
C6 O -
/ O -
C7 O +
region O -
, O +
forming O +
a O +
distinct O +
haplotype O -
. O -

The O +
haplotype O +
has O +
been O +
found O +
in O +
combination O +
with O +
a O +
number O +
of O +
other O +
haplotypes O +
containing O +
defective O +
genes O +
that O +
lead O +
either O +
to O +
C6 B-Disease +
or I-Disease +
C7 I-Disease +
deficiency L-Disease -
, O +
but O +
with O +
different O +
consequences O -
. O -

Where O +
it O +
is O +
combined O +
with O +
a O +
C6-deficient U-Disease +
gene O -
, O +
the O +
serum O +
C7 O +
levels O +
can O +
be O +
surprisingly O +
high O -
, O +
possibly O +
because O +
there O +
is O +
no O +
C6 O +
generating O +
C56 O +
to O +
consume O +
the O +
C7 O -
. O -

In O +
contrast O -
, O +
where O +
the O +
C7 O +
genes O +
are O +
both O +
defective O +
( O -
but O +
still O +
partially O +
functional O -
) O -
, O +
there O +
may O +
be O +
a O +
profound O +
deficit O +
of O +
circulating O +
C7 O +
because O +
there O +
is O +
ample O +
C6 O +
to O +
produce O +
C56 O +
and O +
consume O +
the O +
already O +
small O +
amount O +
of O +
C7 O -
. O -

Each O +
molecular O +
defect O +
has O +
also O +
been O +
found O +
in O +
isolation O +
and O +
has O +
the O +
expected O +
effect O -
.. O -

Genetic O +
bases O +
of O +
human O +
complement B-Disease +
C7 I-Disease +
deficiency L-Disease -
. O -

Complement B-Disease +
C7 I-Disease +
deficiency L-Disease +
( O -
C7D U-Disease -
) O +
is O +
associated O +
frequently O +
with O +
recurrent O +
bacterial B-Disease +
infections L-Disease -
, O +
especially O +
meningitis U-Disease +
caused O +
by O +
Neisseria B-Disease +
meningitidis L-Disease -
. O -

We O +
report O +
in O +
this O +
work O +
the O +
molecular O +
bases O +
of O +
C7D U-Disease +
in O +
two O +
unrelated O +
Japanese O +
males O -
. O -

We O +
used O +
exon O -
- O -
specific O +
PCR O -
/ O -
single O -
- O -
strand O +
conformation O +
polymorphism O +
analysis O +
as O +
a O +
screening O +
step O +
for O +
mutations O -
. O -

Subsequent O +
direct O +
sequencing O +
of O +
the O +
target O +
exons O +
identified O +
homozygous O +
mutations O +
in O +
exon O +
16 O +
of O +
case O +
1 O +
and O +
in O +
exon O +
15 O +
of O +
case O +
2 O -
. O -

The O +
mutation O +
of O +
case O +
1 O +
was O +
a O +
homozygous O +
T O +
to O +
A O +
transversion O +
at O +
nucleotide O +
2250 O -
, O +
the O +
third O +
nucleotide O +
of O +
the O +
codon O +
TGT O +
for O +
Cys728 O -
, O +
leading O +
to O +
a O +
stop O +
codon O +
TGA O +
( O -
C728X O -
) O -
. O -

In O +
case O +
2 O -
, O +
a O +
homozygous O +
2-bp O +
deletion O +
( O -
2137delTG O -
/ O -
2138delGT O -
/ O -
2139delTG O -
) O +
caused O +
a O +
frameshift O -
, O +
generating O +
a O +
premature O +
termination O +
codon O +
4 O +
to O +
6 O +
nucleotides O +
downstream O -
. O -

Family O +
study O +
in O +
case O +
1 O +
confirmed O +
the O +
genetic O +
nature O +
of O +
the O +
defect O -
. O -

Moreover O -
, O +
we O +
detected O +
a O +
novel O +
polymorphism O +
in O +
intron O +
11 O +
that O +
presumably O +
is O +
linked O +
to O +
the O +
mutation O +
responsible O +
for O +
C7D U-Disease +
in O +
case O +
1 O -
. O -

Our O +
results O +
indicate O +
that O +
the O +
pathogenesis O +
of O +
C7D U-Disease +
is O +
heterogeneous O +
like O +
most O +
of O +
the O +
other O +
deficiencies B-Disease +
of I-Disease +
complement I-Disease +
components L-Disease -
.. O -

HPRT B-Disease -
- I-Disease -
APRT I-Disease -
- I-Disease -
deficient L-Disease +
mice O +
are O +
not O +
a O +
model O +
for O +
lesch B-Disease -
- I-Disease -
nyhan I-Disease +
syndrome L-Disease -
. O -

Complete B-Disease +
hypoxanthine I-Disease -
- I-Disease -
guanine I-Disease +
phosphoribosyl I-Disease -
- I-Disease -
transferase I-Disease +
( I-Disease -
HPRT I-Disease -
) I-Disease +
deficiency L-Disease +
in O +
humans O +
results O +
in O +
the O +
Lesch B-Disease -
- I-Disease -
Nyhan I-Disease +
syndrome L-Disease +
which O +
is O +
characterized O -
, O +
among O +
other O +
features O -
, O +
by O +
compulsive O +
self O -
- O -
injurious O +
behavior O -
. O -

HPRT B-Disease -
- I-Disease -
deficient L-Disease +
mice O +
generated O +
using O +
mouse O +
embryonic O +
stem O +
cells O +
exhibit O +
none O +
of O +
the O +
behavioral O +
symptoms O +
associated O +
with O +
the O +
Lesch B-Disease -
- I-Disease -
Nyhan I-Disease +
syndrome L-Disease -
. O -

Administration O +
of O +
drugs O +
that O +
inhibit O +
adenine O +
phosphoribosyltransferase O +
( O -
APRT O -
) O +
in O +
HPRT B-Disease -
- I-Disease -
deficient L-Disease +
mice O +
has O +
produced O +
the O +
suggestion O +
that O +
deficiency B-Disease +
of I-Disease +
APRT L-Disease +
in O +
combination O +
with O +
HPRT B-Disease -
- I-Disease -
deficiency L-Disease +
in O +
mice O +
may O +
lead O +
to O +
self O -
- O -
mutilation O +
behavior O +
[ O -
C. O +
L. O +
Wu O +
and O +
D. O +
W. O +
Melton O +
( O -
1993 O -
) O +
Nature O +
Genet O -
. O -

3 O -
, O +
235 O -
- O -
240 O -
] O -
. O -

To O +
test O +
this O +
proposition O -
, O +
we O +
bred O +
HPRT B-Disease -
- I-Disease -
APRT I-Disease -
- I-Disease -
deficient L-Disease +
mice O -
. O -

Although O +
the O +
doubly O -
- O -
deficient O +
mice O +
excrete O +
adenine O +
and O +
its O +
highly O +
insoluble O +
derivative O -
, O +
2 O -
, O +
8-dihydroxyadenine O -
, O +
which O +
are O +
also O +
associated O +
with O +
human O +
APRT B-Disease +
deficiency L-Disease -
, O +
additional O +
abnormalities O +
or O +
any O +
self O -
- O -
injurious O +
behavior O +
were O +
not O +
detected O -
. O -

Thus O -
, O +
APRT B-Disease -
- I-Disease -
HPRT I-Disease -
- I-Disease -
deficient L-Disease +
mice O -
, O +
which O +
are O +
devoid O +
of O +
any O +
purine O +
salvage O +
pathways O -
, O +
show O +
no O +
novel O +
phenotype O +
and O +
are O +
not O +
a O +
model O +
for O +
the O +
behavioral B-Disease +
abnormalities L-Disease +
associated O +
with O +
the O +
Lesch B-Disease -
- I-Disease -
Nyhan I-Disease +
syndrome L-Disease +
as O +
previously O +
suggested O -

Somatic O +
alterations O +
of O +
the O +
DPC4 O +
gene O +
in O +
human O +
colorectal B-Disease +
cancers L-Disease +
in O +
vivo O -
. O -

BACKGROUND O +
& O +
AIMS O -
The O +
chromosome O +
region O +
18q21 O +
has O +
been O +
shown O +
to O +
be O +
frequently O +
deleted O +
in O +
colorectal B-Disease +
cancers L-Disease -
, O +
and O +
such O +
frequent O +
allelic O +
loss O +
is O +
a O +
hallmark O +
of O +
the O +
presence O +
of O +
a O +
tumor O -
- O -
suppressor O +
gene O -
. O -

The O +
DPC4 O +
gene O -
, O +
which O +
is O +
located O +
at O +
18q21 O -
, O +
has O +
been O +
identified O +
as O +
a O +
tumor O -
- O -
suppressor O +
gene O +
from O +
examination O +
of O +
pancreatic B-Disease +
cancers L-Disease -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
if O +
it O +
might O +
also O +
be O +
altered O +
in O +
colorectal B-Disease +
cancers L-Disease -
. O -

METHODS O -
Mutation O +
analyses O +
of O +
the O +
DPC4 O +
gene O +
were O +
performed O +
on O +
complementary O +
DNA O +
samples O +
from O +
31 O +
primary O +
colorectal B-Disease +
cancer L-Disease +
specimens O +
using O +
a O +
combination O +
of O +
polymerase O +
chain O +
reaction O -
, O +
single O -
- O -
strand O +
conformation O +
polymorphism O -
, O +
and O +
DNA O +
sequencing O -
. O -

RESULTS O -
Four O +
missense O +
mutations O +
producing O +
amino O +
acid O +
substitutions O +
and O +
a O +
somatic O +
12-base O +
pair O +
deletion O +
in O +
the O +
coding O +
region O +
of O +
the O +
DPC4 O +
gene O +
were O +
detected O +
in O +
the O +
31 O +
cancers U-Disease +
( O -
16 O -
% O -
; O +
5 O +
of O +
31 O -
) O -
. O -

CONCLUSIONS O -
The O +
DPC4 O +
gene O +
may O +
play O +
a O +
role O +
as O +
a O +
tumor O -
- O -
suppressor O +
gene O +
in O +
a O +
fraction O +
of O +
colorectal B-Disease +
cancers L-Disease -
; O +
however O -
, O +
while O +
allelic O +
loss O +
at O +
18q21 O +
is O +
very O +
often O +
seen O +
in O +
colorectal B-Disease +
cancers L-Disease -
, O +
only O +
a O +
minority O +
show O +
DPC4 O +
mutations O -
, O +
suggesting O +
that O +
there O +
might O +
be O +
another O +
tumor O -
- O -
suppressor O +
gene O +
in O +
this O +
chromosome O +
region O -
.. O -

Pleiotropic O +
defects O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
protein O -
- O -
deficient O +
mice O -
. O -

We O +
have O +
generated O +
a O +
mouse O +
model O +
for O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
by O +
using O +
gene O +
targeting O +
to O +
generate O +
mice O +
that O +
do O +
not O +
express O +
the O +
Atm O +
protein O -
. O -

Atm O -
- O -
deficient O +
mice O +
are O +
retarded O +
in O +
growth O -
, O +
do O +
not O +
produce O +
mature O +
sperm O -
, O +
and O +
exhibit O +
severe O +
defects O +
in O +
T O +
cell O +
maturation O +
while O +
going O +
on O +
to O +
develop O +
thymomas U-Disease -
. O -

Atm O -
- O -
deficient O +
fibroblasts O +
grow O +
poorly O +
in O +
culture O +
and O +
display O +
a O +
high O +
level O +
of O +
double O -
- O -
stranded O +
chromosome O +
breaks O -
. O -

Atm O -
- O -
deficient O +
thymocytes O +
undergo O +
spontaneous O +
apoptosis O +
in O +
vitro O +
significantly O +
more O +
than O +
controls O -
. O -

Atm O -
- O -
deficient O +
mice O +
then O +
exhibit O +
many O +
of O +
the O +
same O +
symptoms O +
found O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
patients O +
and O +
in O +
cells O +
derived O +
from O +
them O -
. O -

Furthermore O -
, O +
we O +
demonstrate O +
that O +
the O +
Atm O +
protein O +
exists O +
as O +
two O +
discrete O +
molecular O +
species O -
, O +
and O +
that O +
loss O +
of O +
one O +
or O +
of O +
both O +
of O +
these O +
can O +
lead O +
to O +
the O +
development O +
of O +
the O +
disease O -
.. O -

The O +
DCC O +
protein O +
and O +
prognosis O +
in O +
colorectal B-Disease +
cancer L-Disease -
. O -

BACKGROUND O -
Allelic O +
loss O +
of O +
chromosome O +
18q O +
predicts O +
a O +
poor O +
outcome O +
in O +
patients O +
with O +
stage B-Disease +
II I-Disease +
colorectal I-Disease +
cancer L-Disease -
. O -

Although O +
the O +
specific O +
gene O +
inactivated O +
by O +
this O +
allelic O +
loss O +
has O +
not O +
been O +
elucidated O -
, O +
the O +
DCC O +
( O -
deleted O +
in O +
colorectal B-Disease +
cancer L-Disease -
) O +
gene O +
is O +
a O +
candidate O -
. O -

We O +
investigated O +
whether O +
the O +
expression O +
of O +
the O +
DCC O +
protein O +
in O +
tumor U-Disease +
cells O +
is O +
a O +
prognostic O +
marker O +
in O +
colorectal B-Disease +
carcinoma L-Disease -
. O -

METHODS O -
The O +
expression O +
of O +
DCC O +
was O +
evaluated O +
immunohistochemically O +
in O +
132 O +
paraffin O -
- O -
embedded O +
samples O +
from O +
patients O +
with O +
curatively O +
resected O +
stage B-Disease +
II I-Disease +
and I-Disease +
III I-Disease +
colorectal I-Disease +
carcinomas L-Disease -
. O -

The O +
Cox O +
proportional O -
- O -
hazards O +
model O +
was O +
used O +
to O +
adjust O +
for O +
covariates O +
including O +
age O -
, O +
sex O -
, O +
tumor U-Disease +
site O -
, O +
degree O +
of O +
tumor U-Disease +
differentiation O -
, O +
and O +
use O +
of O +
adjuvant O +
therapy O -
. O -

RESULTS O -
The O +
expression O +
of O +
DCC O +
was O +
a O +
strong O +
positive O +
predictive O +
factor O +
for O +
survival O +
in O +
both O +
stage B-Disease +
II I-Disease +
and I-Disease +
stage I-Disease +
III I-Disease +
colorectal I-Disease +
carcinomas L-Disease -
. O -

In O +
patients O +
with O +
stage O +
II O +
disease O +
whose O +
tumors U-Disease +
expressed O +
DCC O -
, O +
the O +
five O -
- O -
year O +
survival O +
rate O +
was O +
94 O -
. O +
3 O +
percent O -
, O +
whereas O +
in O +
patients O +
with O +
DCC B-Disease -
- I-Disease -
negative I-Disease +
tumors L-Disease -
, O +
the O +
survival O +
rate O +
was O +
61 O -
. O +
6 O +
percent O +
( O -
P O +
< O +
0 O -
. O +
001 O -
) O -
. O -

In O +
patients O +
with O +
stage B-Disease +
III I-Disease +
disease L-Disease -
, O +
the O +
respective O +
survival O +
rates O +
were O +
59 O -
. O -

3 O +
percent O +
and O +
33 O -
. O -

2 O +
percent O +
( O -
P O +
= O +
0 O -
. O +
03 O -
) O -
. O -

CONCLUSIONS O -
DCC O +
is O +
a O +
prognostic O +
marker O +
in O +
patients O +
with O +
stage B-Disease +
II I-Disease +
or I-Disease +
stage I-Disease +
III I-Disease +
colorectal I-Disease +
cancer L-Disease -
. O -

In O +
stage B-Disease +
II I-Disease +
colorectal I-Disease +
carcinomas L-Disease -
, O +
the O +
absence O +
of O +
DCC O +
identifies O +
a O +
subgroup O +
of O +
patients O +
with O +
lesions O +
that O +
behave O +
like O +
stage B-Disease +
III I-Disease +
cancers L-Disease -
. O -

These O +
findings O +
may O +
thus O +
have O +
therapeutic O +
implications O +
in O +
this O +
group O +
of O +
patients O -

Association O +
of O +
anxiety B-Disease -
- I-Disease -
related I-Disease +
traits L-Disease +
with O +
a O +
polymorphism O +
in O +
the O +
serotonin O +
transporter O +
gene O +
regulatory O +
region O -
. O -

Transporter O -
- O -
facilitated O +
uptake O +
of O +
serotonin O +
( O -
5-hydroxytryptamine O +
or O +
5-HT O -
) O +
has O +
been O +
implicated O +
in O +
anxiety U-Disease +
in O +
humans O +
and O +
animal O +
models O +
and O +
is O +
the O +
site O +
of O +
action O +
of O +
widely O +
used O +
uptake O -
- O -
inhibiting O +
antidepressant O +
and O +
antianxiety O +
drugs O -
. O -

Human O +
5-HT O +
transporter O +
( O -
5-HTT O -
) O +
gene O +
transcription O +
is O +
modulated O +
by O +
a O +
common O +
polymorphism O +
in O +
its O +
upstream O +
regulatory O +
region O -
. O -

The O +
short O +
variant O +
of O +
the O +
polymorphism O +
reduces O +
the O +
transcriptional O +
efficiency O +
of O +
the O +
5-HTT O +
gene O +
promoter O -
, O +
resulting O +
in O +
decreased O +
5-HTT O +
expression O +
and O +
5-HT O +
uptake O +
in O +
lymphoblasts O -
. O -

Association O +
studies O +
in O +
two O +
independent O +
samples O +
totaling O +
505 O +
individuals O +
revealed O +
that O +
the O +
5-HTT O +
polymorphism O +
accounts O +
for O +
3 O +
to O +
4 O +
percent O +
of O +
total O +
variation O +
and O +
7 O +
to O +
9 O +
percent O +
of O +
inherited O +
variance O +
in O +
anxiety B-Disease -
- I-Disease -
related I-Disease +
personality I-Disease +
traits L-Disease +
in O +
individuals O +
as O +
well O +
as O +
sibships O -
.. O -

Phenotypic O +
and O +
genotypic O +
overlap O +
between O +
atelosteogenesis B-Disease +
type I-Disease +
2 L-Disease +
and O +
diastrophic B-Disease +
dysplasia L-Disease -
. O -

Mutations O +
in O +
the O +
diastrophic B-Disease +
dysplasia L-Disease +
sulfate O +
transporter O +
gene O +
DTDST O +
have O +
been O +
associated O +
with O +
a O +
family O +
of O +
chondrodysplasias U-Disease +
that O +
comprises O -
, O +
in O +
order O +
of O +
increasing O +
severity O -
, O +
diastrophic B-Disease +
dysplasia L-Disease +
( O -
DTD U-Disease -
) O -
, O +
atelosteogenesis B-Disease +
type I-Disease +
2 L-Disease +
( O -
AO2 U-Disease -
) O -
, O +
and O +
achondrogenesis B-Disease +
type I-Disease +
1B L-Disease +
( O -
ACG1B U-Disease -
) O -
. O -

To O +
learn O +
more O +
about O +
the O +
molecular O +
basis O +
of O +
DTDST B-Disease +
chondrodysplasias L-Disease +
and O +
about O +
genotype O -
- O -
phenotype O +
correlations O -
, O +
we O +
studied O +
fibroblast O +
cultures O +
of O +
three O +
new O +
patients O -
one O +
with O +
AO-2 U-Disease -
, O +
one O +
with O +
DTD U-Disease -
, O +
and O +
one O +
with O +
an O +
intermediate O +
phenotype O +
( O -
AO2 U-Disease -
/ O -
DTD U-Disease -
) O -
. O -

Reduced O +
incorporation O +
of O +
inorganic O +
sulfate O +
into O +
macromolecules O +
was O +
found O +
in O +
all O +
three O -
. O -

Each O +
of O +
the O +
three O +
patients O +
was O +
found O +
to O +
be O +
heterozygous O +
for O +
a O +
c862 O -
t O +
transition O +
predicting O +
a O +
R279W O +
substitution O +
in O +
the O +
third O +
extracellular O +
loop O +
of O +
DTDST O -
. O -

In O +
two O +
patients O +
( O -
DTD U-Disease +
and O +
AO2 U-Disease -
/ O -
DTD U-Disease -
) O -
, O +
no O +
other O +
structural O +
mutation O +
was O +
found O -
, O +
but O +
polymerase O +
chain O +
reaction O +
amplification O +
and O +
single O -
- O -
strand O +
conformation O +
polymorphism O +
analysis O +
of O +
fibroblast O +
cDNA O +
showed O +
reduced O +
mRNA O +
levels O +
of O +
the O +
wild O -
- O -
type O +
DTDST O +
allele O -
these O +
two O +
patients O +
may O +
be O +
compound O +
heterozygotes O +
for O +
the O +
" O +
Finnish O +
" O +
mutation O +
( O -
as O +
yet O +
uncharacterized O +
at O +
the O +
DNA O +
level O -
) O -
, O +
which O +
causes O +
reduced O +
expression O +
of O +
DTDST O -
. O -

The O +
third O +
patient O +
( O -
with O +
AO2 U-Disease -
) O +
had O +
the O +
R279W O +
mutation O +
compounded O +
with O +
a O +
novel O +
mutation O -
, O +
the O +
deletion O +
of O +
cytosine O +
418 O +
( O -
delta O +
c418 O -
) O -
, O +
predicting O +
a O +
frameshift O +
with O +
premature O +
termination O -
. O -

Also O +
the O +
delta O +
c418 O +
allele O +
was O +
underrepresented O +
in O +
the O +
cDNA O -
, O +
in O +
accordance O +
with O +
previous O +
observations O +
that O +
premature O +
stop O +
codons O +
reduce O +
mRNA O +
levels O -
. O -

The O +
presence O +
of O +
the O +
DTDST O +
R279W O +
mutation O +
in O +
a O +
total O +
of O +
11 O +
patients O +
with O +
AO2 U-Disease +
or O +
DTD U-Disease +
emphasizes O +
the O +
overlap O +
between O +
these O +
conditions O -
. O -

This O +
mutation O +
has O +
not O +
been O +
found O +
so O +
far O +
in O +
8 O +
analyzed O +
ACG1B U-Disease +
patients O -
, O +
suggesting O +
that O +
it O +
allows O +
some O +
residual O +
activity O +
of O +
the O +
sulfate O +
transporter O -
.. O -

Identification O +
of O +
WASP O +
mutations O -
, O +
mutation O +
hotspots O +
and O +
genotype O -
- O -
phenotype O +
disparities O +
in O +
24 O +
patients O +
with O +
the O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease -
. O -

The O +
Wiskott B-Disease -
- I-Disease -
Aldrich I-Disease +
syndrome L-Disease +
( O -
WAS U-Disease -
) O -
, O +
an O +
X B-Disease -
- I-Disease -
linked I-Disease +
immunodeficiency I-Disease +
disease L-Disease +
caused O +
by O +
mutation O +
in O +
the O +
recently O +
isolated O +
gene O +
encoding O +
WAS U-Disease +
protein O +
( O -
WASP O -
) O -
, O +
is O +
known O +
to O +
be O +
associated O +
with O +
extensive O +
clinical O +
heterogeneity O -
. O -

Cumulative O +
mutation O +
data O +
have O +
revealed O +
that O +
WASP O +
genotypes O +
are O +
also O +
highly O +
variable O +
among O +
WAS U-Disease +
patients O -
, O +
but O +
the O +
relationship O +
of O +
phenotype O +
with O +
genotype O +
in O +
this O +
disease O +
remains O +
unclear O -
. O -

To O +
address O +
this O +
issue O +
we O +
characterized O +
WASP O +
mutations O +
in O +
24 O +
unrelated O +
WAS U-Disease +
patients O -
, O +
including O +
18 O +
boys O +
with O +
severe O +
classical O +
WAS U-Disease +
and O +
6 O +
boys O +
expressing O +
mild O +
forms O +
of O +
the O +
disease O -
, O +
and O +
then O +
examined O +
the O +
degree O +
of O +
correlation O +
of O +
these O +
as O +
well O +
as O +
all O +
previously O +
published O +
WASP O +
mutations O +
with O +
disease O +
severity O -
. O -

By O +
analysis O +
of O +
these O +
compiled O +
mutation O +
data O -
, O +
we O +
demonstrated O +
clustering O +
of O +
WASP O +
mutations O +
within O +
the O +
four O +
most O +
N O -
- O -
terminal O +
exons O +
of O +
the O +
gene O +
and O +
also O +
identified O +
several O +
sites O +
within O +
this O +
region O +
as O +
hotspots O +
for O +
WASP O +
mutation O -
. O -

These O +
characteristics O +
were O +
observed O -
, O +
however O -
, O +
in O +
both O +
severe O +
and O +
mild O +
cases O +
of O +
the O +
disease O -
. O -

Similarly O -
, O +
while O +
the O +
cumulative O +
data O +
revealed O +
a O +
predominance O +
of O +
missense O +
mutations O +
among O +
the O +
WASP O +
gene O +
lesions O +
observed O +
in O +
boys O +
with O +
isolated B-Disease +
thrombocytopenia L-Disease -
, O +
missense O +
mutations O +
were O +
not O +
exclusively O +
associated O +
with O +
milder O +
WAS U-Disease +
phenotypes O -
, O +
but O +
also O +
comprised O +
a O +
substantial O +
portion O +
( O -
38 O -
% O -
) O +
of O +
the O +
WASP O +
gene O +
defects O +
found O +
in O +
patients O +
with O +
severe O +
disease O -
. O -

These O +
findings O -
, O +
as O +
well O +
as O +
the O +
detection O +
of O +
identical O +
WASP O +
mutations O +
in O +
patients O +
with O +
disparate O +
phenotypes O -
, O +
reveal O +
a O +
lack O +
of O +
phenotype O +
concordance O +
with O +
genotype O +
in O +
WAS U-Disease +
and O +
thus O +
imply O +
that O +
phenotypic O +
outcome O +
in O +
this O +
disease O +
can O -
not O +
be O +
reliably O +
predicted O +
solely O +
on O +
the O +
basis O +
of O +
WASP O +
genotypes O -
.. O -

Germline O +
mutations O +
in O +
the O +
3 O -
' O +
part O +
of O +
APC U-Disease +
exon O +
15 O +
do O +
not O +
result O +
in O +
truncated O +
proteins O +
and O +
are O +
associated O +
with O +
attenuated O +
adenomatous B-Disease +
polyposis I-Disease +
coli L-Disease -
. O -

Familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease +
( O -
FAP U-Disease -
) O +
is O +
an O +
inherited O +
predisposition O +
to O +
colorectal B-Disease +
cancer L-Disease +
characterized O +
by O +
the O +
development O +
of O +
numerous O +
adenomatous B-Disease +
polyps L-Disease +
predominantly O +
in O +
the O +
colorectal O +
region O -
. O -

Germline O +
mutations O +
in O +
the O +
adenomatous B-Disease +
polyposis I-Disease +
coli L-Disease +
( O -
APC U-Disease -
) O +
gene O +
are O +
responsible O +
for O +
most O +
cases O +
of O +
FAP U-Disease -
. O -

Mutations O +
at O +
the O +
5 O +
end O +
of O +
APC U-Disease +
are O +
known O +
to O +
be O +
associated O +
with O +
a O +
relatively O +
mild O +
form O +
of O +
the O +
disease O -
, O +
called O +
attenuated B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
coli L-Disease +
( O -
AAPC U-Disease -
) O -
. O -

We O +
identified O +
a O +
frameshift O +
mutation O +
in O +
the O +
3 O +
part O +
of O +
exon O +
15 O -
, O +
resulting O +
in O +
a O +
stop O +
codon O +
at O +
1862 O -
, O +
in O +
a O +
large O +
Dutch O +
kindred O +
with O +
AAPC U-Disease -
. O -

Western O +
blot O +
analysis O +
of O +
lymphoblastoid O +
cell O +
lines O +
derived O +
from O +
affected O +
family O +
members O +
from O +
this O +
kindred O -
, O +
as O +
well O +
as O +
from O +
a O +
previously O +
reported O +
Swiss O +
family O +
carrying O +
a O +
frameshift O +
mutation O +
at O +
codon O +
1987 O +
and O +
displaying O +
a O +
similar O +
attenuated O +
phenotype O -
, O +
showed O +
only O +
the O +
wild O -
- O -
type O +
APC U-Disease +
protein O -
. O -

Our O +
study O +
indicates O +
that O +
chain O -
- O -
terminating O +
mutations O +
located O +
in O +
the O +
3 O +
part O +
of O +
APC U-Disease +
do O +
not O +
result O +
in O +
detectable O +
truncated O +
polypeptides O +
and O +
we O +
hypothesize O +
that O +
this O +
is O +
likely O +
to O +
be O +
the O +
basis O +
for O +
the O +
observed O +
AAPC U-Disease +
phenotype O -
.. O -

Complete O +
genomic O +
sequence O +
and O +
analysis O +
of O +
117 O +
kb O +
of O +
human O +
DNA O +
containing O +
the O +
gene O +
BRCA1 O -
. O -

Over O +
100 O +
distinct O +
disease O -
- O -
associated O +
mutations O +
have O +
been O +
identified O +
in O +
the O +
breast B-Disease -
- I-Disease -
ovarian I-Disease +
cancer L-Disease +
susceptibility O +
gene O +
BRCA1 O -
. O -

Loss O +
of O +
the O +
wild O -
- O -
type O +
allele O +
in O +
> O +
90 O -
% O +
of O +
tumors U-Disease +
from O +
patients O +
with O +
inherited O +
BRCA1 O +
mutations O +
indicates O +
tumor U-Disease +
suppressive O +
function O -
. O -

The O +
low O +
incidence O +
of O +
somatic O +
mutations O +
suggests O +
that O +
BRCA1 O +
inactivation O +
in O +
sporadic O +
tumors U-Disease +
occurs O +
by O +
alternative O +
mechanisms O -
, O +
such O +
as O +
interstitial O +
chromosomal O +
deletion O +
or O +
reduced O +
transcription O -
. O -

To O +
identify O +
possible O +
features O +
of O +
the O +
BRCA1 O +
genomic O +
region O +
that O +
may O +
contribute O +
to O +
chromosomal O +
instability O +
as O +
well O +
as O +
potential O +
transcriptional O +
regulatory O +
elements O -
, O +
a O +
117 O -
, O +
143-bp O +
DNA O +
sequence O +
encompassing O +
BRCA1 O +
was O +
obtained O +
by O +
random O +
sequencing O +
of O +
four O +
cosmids O +
identified O +
from O +
a O +
human O +
chromosome O +
17 O +
specific O +
library O -
. O -

The O +
24 O +
exons O +
of O +
BRCA1 O +
span O +
an O +
81-kb O +
region O +
that O +
has O +
an O +
unusually O +
high O +
density O +
of O +
Alu O +
repetitive O +
DNA O +
( O -
41 O -
. O +
5 O -
% O -
) O -
, O +
but O +
relatively O +
low O +
density O +
( O -
4 O -
. O +
8 O -
% O -
) O +
of O +
other O +
repetitive O +
sequences O -
. O -

BRCA1 O +
intron O +
lengths O +
range O +
in O +
size O +
from O +
403 O +
bp O +
to O +
9 O -
. O +
2 O +
kb O +
and O +
contain O +
the O +
intragenic O +
microsatellite O +
markers O +
D17S1323 O -
, O +
D17S1322 O -
, O +
and O +
D17S855 O -
, O +
which O +
localize O +
to O +
introns O +
12 O -
, O +
19 O -
, O +
and O +
20 O -
, O +
respectively O -
. O -

In O +
addition O +
to O +
BRCA1 O -
, O +
the O +
contig O +
contains O +
two O +
complete O +
genes O -
Rho7 O -
, O +
a O +
member O +
of O +
the O +
rho O +
family O +
of O +
GTP O +
binding O +
proteins O -
, O +
and O +
VAT1 O -
, O +
an O +
abundant O +
membrane O +
protein O +
of O +
cholinergic O +
synaptic O +
vesicles O -
. O -

Partial O +
sequences O +
of O +
the O +
1A1 O -
- O -
3B O +
B O -
- O -
box O +
protein O +
pseudogene O +
and O +
IFP O +
35 O -
, O +
an O +
interferon O +
induced O +
leucine O +
zipper O +
protein O -
, O +
reside O +
within O +
the O +
contig O -
. O -

An O +
L21 O +
ribosomal O +
protein O +
pseudogene O +
is O +
embedded O +
in O +
BRCA1 O +
intron O +
13 O -
. O -

The O +
order O +
of O +
genes O +
on O +
the O +
chromosome O +
is O -
centromere-1FP O +
35-VAT1-Rho7-BRCA1 O -
- O -
1A1 O -
- O -
3B O -
- O -
telomere O -

Identification O +
of O +
a O +
RING O +
protein O +
that O +
can O +
interact O +
in O +
vivo O +
with O +
the O +
BRCA1 O +
gene O +
product O -
. O -

The O +
hereditary B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
gene O -
, O +
BRCA1 O -
, O +
encodes O +
a O +
large O +
polypeptide O +
that O +
contains O +
the O +
cysteine O -
- O -
rich O +
RING O +
motif O -
, O +
a O +
zinc O -
- O -
binding O +
domain O +
found O +
in O +
a O +
variety O +
of O +
regulatory O +
proteins O -
. O -

Here O +
we O +
describe O +
a O +
novel O +
protein O +
that O +
interacts O +
in O +
vivo O +
with O +
the O +
N O -
- O -
terminal O +
region O +
of O +
BRCA1 O -
. O -

This O +
BRCA1-associated O +
RING O +
domain O +
( O -
BARD1 O -
) O +
protein O +
contains O +
an O +
N O -
- O -
terminal O +
RING O +
motif O -
, O +
three O +
tandem O +
ankyrin O +
repeats O -
, O +
and O +
a O +
C O -
- O -
terminal O +
sequence O +
with O +
significant O +
homology O +
to O +
the O +
phylogenetically O +
conserved O +
BRCT O +
domains O +
that O +
lie O +
near O +
the O +
C O +
terminus O +
of O +
BRCA1 O -
. O -

The O +
BARD1 O -
/ O -
BRCA1 O +
interaction O +
is O +
disrupted O +
by O +
BRCA1 O +
missense O +
mutations O +
that O +
segregate O +
with O +
breast B-Disease +
cancer L-Disease +
susceptibility O -
, O +
indicating O +
that O +
BARD1 O +
may O +
be O +
involved O +
in O +
mediating O +
tumour U-Disease +
suppression O +
by O +
BRCA1 O -
.. O -

Detection O +
of O +
heterozygous O +
mutations O +
in O +
BRCA1 O +
using O +
high O +
density O +
oligonucleotide O +
arrays O +
and O +
two O -
- O -
colour O +
fluorescence O +
analysis O -
. O -

The O +
ability O +
to O +
scan O +
a O +
large O +
gene O +
rapidly O +
and O +
accurately O +
for O +
all O +
possible O +
heterozygous O +
mutations O +
in O +
large O +
numbers O +
of O +
patient O +
samples O +
will O +
be O +
critical O +
for O +
the O +
future O +
of O +
medicine O -
. O -

We O +
have O +
designed O +
high O -
- O -
density O +
arrays O +
consisting O +
of O +
over O +
96 O -
, O +
600 O +
oligonucleotides O +
20-nucleotides O +
( O -
nt O -
) O +
in O +
length O +
to O +
screen O +
for O +
a O +
wide O +
range O +
of O +
heterozygous O +
mutations O +
in O +
the O +
3 O -
. O -

45-kilobases O +
( O -
kb O -
) O +
exon O +
11 O +
of O +
the O +
hereditary B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
gene O +
BRCA1 O -
. O -

Reference O +
and O +
test O +
samples O +
were O +
co O -
- O -
hybridized O +
to O +
these O +
arrays O +
and O +
differences O +
in O +
hybridization O +
patterns O +
quantitated O +
by O +
two O -
- O -
colour O +
analysis O -
. O -

Fourteen O +
of O +
fifteen O +
patient O +
samples O +
with O +
known O +
mutations O +
were O +
accurately O +
diagnosed O -
, O +
and O +
no O +
false O +
positive O +
mutations O +
were O +
identified O +
in O +
20 O +
control O +
samples O -
. O -

Eight O +
single O +
nucleotide O +
polymorphisms O +
were O +
also O +
readily O +
detected O -
. O -

DNA O +
chip O -
- O -
based O +
assays O +
may O +
provide O +
a O +
valuable O +
new O +
technology O +
for O +
high O -
- O -
throughput O +
cost O -
- O -
efficient O +
detection O +
of O +
genetic O +
alterations O -
. O -

Autosomal O +
dominant O +
primary O +
hyperparathyroidism B-Disease +
and I-Disease +
jaw I-Disease +
tumor I-Disease +
syndrome L-Disease +
associated O +
with O +
renal B-Disease +
hamartomas L-Disease +
and O +
cystic B-Disease +
kidney I-Disease +
disease L-Disease -
: O +
linkage O +
to O +
1q21-q32 O +
and O +
loss O +
of O +
the O +
wild O +
type O +
allele O +
in O +
renal B-Disease +
hamartomas L-Disease -
. O -

Hereditary B-Disease +
hyperparathyroidism I-Disease -
- I-Disease -
jaw I-Disease +
tumor I-Disease +
syndrome L-Disease +
( O -
HPT B-Disease -
- I-Disease -
JT L-Disease -
) O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
disease L-Disease +
( O -
OMIM O +
145001 O -
) O +
that O +
has O +
recently O +
been O +
mapped O +
to O +
chromosomal O +
region O +
1q21-q32 O +
( O -
HRPT2 O -
) O -
. O -

Here O +
we O +
report O +
two O +
families O +
with O +
HPT B-Disease -
- I-Disease -
JT I-Disease +
syndrome L-Disease +
in O +
which O +
adult B-Disease +
renal I-Disease +
hamartomas L-Disease +
or O +
cystic B-Disease +
kidney I-Disease +
disease L-Disease +
were O +
prominent O +
associated O +
features O -
, O +
possibly O +
representing O +
a O +
new O +
phenotypic O +
variant O +
of O +
the O +
HPT B-Disease -
- I-Disease -
JT I-Disease +
syndrome L-Disease -
. O -

In O +
the O +
first O +
family O -
, O +
renal B-Disease +
lesions L-Disease +
were O +
present O +
in O +
five O +
out O +
of O +
six O +
affected O +
individuals O -
, O +
whereas O +
HPT U-Disease +
and O +
JT U-Disease +
were O +
seen O +
in O +
four O +
and O +
two O +
cases O -
, O +
respectively O -
. O -

In O +
the O +
second O +
family O -
, O +
JT U-Disease +
was O +
found O +
in O +
three O +
of O +
the O +
five O +
affected O +
individuals O +
and O +
two O +
affected O +
members O +
also O +
exhibited O +
polycystic B-Disease +
kidney I-Disease +
disease L-Disease -
. O -

The O +
possibility O +
of O +
the O +
latter O +
cosegregating O +
as O +
a O +
separate O +
autosomal O +
dominant O +
gene O +
can O +
not O +
be O +
ruled O +
out O -
. O -

A O +
sex O -
- O -
dependent O +
penetrance O +
of O +
primary B-Disease +
HPT L-Disease -
, O +
resulting O +
in O +
predominantly O +
male O -
- O -
affected O +
cases O +
was O +
evident O +
in O +
the O +
two O +
families O -
. O -

Twenty O +
microsatellite O +
markers O +
in O +
the O +
HRPT2 O +
region O +
were O +
typed O -
, O +
in O +
addition O +
to O +
markers O +
in O +
the O +
multiple B-Disease +
endocrine I-Disease +
neoplasia I-Disease +
( I-Disease -
MEN I-Disease -
) I-Disease +
types I-Disease +
1 I-Disease +
and I-Disease +
2 L-Disease +
regions O +
at O +
11q13 O +
and O +
10q11 O -
. O -

The O +
disease O +
in O +
these O +
two O +
kindreds O +
was O +
linked O +
to O +
five O +
markers O +
in O +
the O +
1q21-q32 O +
region O +
( O -
logarithm O -
- O -
of O -
- O -
odds O +
scores O -
3 O -
. O +
2 O -
- O -
4 O +
2 O -
- O -
4 O -
. O +
2 O -
) O -
, O +
whereas O +
linkage O +
to O +
the O +
MEN1 U-Disease +
and O +
MEN2 U-Disease +
regions O +
was O +
excluded O -
. O -

Meiotic O +
recombinations O +
detected O +
in O +
affected O +
individuals O +
placed O +
the O +
locus O +
telomeric O +
of O +
D1S215 O -
, O +
thus O +
narrowing O +
the O +
HRPT2 O +
region O +
from O +
> O +
60 O +
to O +
approximately O +
34 O +
centimorgans O -
. O -

Loss O +
of O +
heterozygosity O +
was O +
studied O +
in O +
seven O +
renal B-Disease +
hamartomas L-Disease +
from O +
two O +
affected O +
individuals O +
in O +
the O +
first O +
family O -
, O +
as O +
well O +
as O +
in O +
a O +
jaw B-Disease +
tumor L-Disease +
and O +
a O +
parathyroid B-Disease +
tumor L-Disease +
from O +
the O +
second O +
family O -
. O -

All O +
renal B-Disease +
hamartomas L-Disease +
showed O +
loss O +
of O +
heterozygosity O +
at O +
the O +
1q21-q32 O +
region O -
. O -

The O +
losses O +
invariably O +
involved O +
the O +
wild O +
type O +
allele O +
derived O +
from O +
the O +
unaffected O +
parent O -
, O +
suggesting O +
the O +
inactivation O +
of O +
a O +
tumor U-Disease +
suppressor O +
gene O +
in O +
this O +
region O -

Independent O +
origin O +
of O +
single O +
and O +
double O +
mutations O +
in O +
the O +
human O +
glucose O +
6-phosphate O +
dehydrogenase O +
gene O -
. O -

The O +
vast O +
majority O +
of O +
both O +
polymorphic O +
and O +
sporadic O +
G6PD O +
variants O +
are O +
due O +
to O +
single O +
missense O +
mutations O -
. O -

In O +
the O +
four O +
polymorphic O +
variants O +
that O +
have O +
two O +
point O +
mutations O -
, O +
one O +
of O +
the O +
mutations O +
is O +
always O +
376 O +
A-- O +
> O +
G O +
( O -
126 O +
Asn-- O +
> O +
Asp O -
) O -
, O +
which O +
on O +
its O +
own O +
gives O +
rise O +
to O +
the O +
nondeficient O +
polymorphic O +
variant O -
, O +
G6PD O +
A. O +
In O +
a O +
study O +
of O +
G6PD B-Disease +
deficient L-Disease +
patients O +
who O +
presented O +
with O +
clinical O +
favism U-Disease +
in O +
Spain O -
, O +
we O +
have O +
found O +
a O +
new O +
polymorphic O +
variant O +
that O +
we O +
have O +
called O +
G6PD O +
Malaga O -
, O +
whose O +
only O +
abnormality O +
is O +
a O +
542 O +
A-- O +
> O +
T O +
( O -
181 O +
Asp-- O +
> O +
Val O -
) O +
mutation O -
. O -

This O +
is O +
the O +
same O +
mutation O +
as O +
previously O +
found O +
in O +
association O +
with O +
the O +
mutation O +
of O +
G6PD O +
A O +
in O +
the O +
double O +
mutant O -
, O +
G6PD O +
Santamaria O -
. O -

G6PD O +
Malaga O +
is O +
associated O +
with O +
enzyme B-Disease +
deficiency L-Disease +
( O -
class O +
III O -
) O -
, O +
and O +
the O +
enzymic O +
properties O +
of O +
G6PD O +
Malaga O +
and O +
G6PD O +
Santamaria O +
are O +
quite O +
similar O -
, O +
indicating O +
that O +
in O +
this O +
case O +
the O +
effects O +
of O +
the O +
two O +
mutations O +
are O +
additive O +
rather O +
than O +
synergistic O -
. O -

G6PD O +
Santamaria O +
might O +
have O +
been O +
produced O +
by O +
recombination O +
between O +
G6PD O +
A O +
and O +
G6PD O +
Malaga O -
; O +
however O +
haplotype O +
analysis O -
, O +
including O +
the O +
use O +
of O +
a O +
new O +
silent O +
polymorphism O -
, O +
suggests O +
that O +
the O +
same O +
542 O +
A-- O +
> O +
T O +
mutation O +
has O +
taken O +
place O +
independently O +
in O +
a O +
G6PD O +
B O +
gene O +
to O +
give O +
G6PD O +
Malaga O +
and O +
in O +
a O +
G6PD O +
A O +
gene O +
to O +
give O +
G6PD O +
Santamaria O -
. O -

These O +
findings O +
help O +
to O +
outline O +
the O +
relationship O +
and O +
evolution O +
of O +
mutations O +
in O +
the O +
human O +
G6PD O +
locus O -
.. O -

BRCA1 O +
R841W O -
: O +
a O +
strong O +
candidate O +
for O +
a O +
common O +
mutation O +
with O +
moderate O +
phenotype O -
. O -

BRCA1 O +
mutations O +
cause O +
increased O +
risk O +
for O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
, O +
frequently O +
of O +
early O +
onset O -
. O -

Many O +
different O +
mutations O +
occur O +
in O +
BRCA1 O -
, O +
including O +
several O +
examples O +
of O +
recurrent O +
mutations O -
, O +
each O +
of O +
which O +
accounts O +
for O +
a O +
significant O +
number O +
of O +
families O +
with O +
heritable O +
cancer U-Disease +
predisposition O -
. O -

These O +
common O +
mutations O +
have O +
an O +
etiological O +
role O +
in O +
many O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
cases O +
and O +
provide O +
the O +
opportunity O +
to O +
examine O +
genotype O -
- O -
phenotype O +
correlations O +
and O +
genotype O -
- O -
environment O +
interactions O +
in O +
individuals O +
with O +
the O +
identical O +
BRCA1 O +
lesion O -
. O -

We O +
report O +
a O +
novel O +
missense O +
change O +
in O +
BRCA1 O -
, O +
2640 O +
C-- O +
> O +
T O +
( O -
R841W O -
) O -
, O +
found O +
in O +
3 O +
cases O +
from O +
a O +
subject O +
group O +
of O +
305 O +
breast B-Disease +
and I-Disease +
79 I-Disease +
ovarian I-Disease +
cancer L-Disease +
cases O +
from O +
Orange O +
County O -
, O +
CA O -
. O -

These O +
are O +
consecutive O -
, O +
population O -
- O -
based O +
cases O +
not O +
selected O +
for O +
age O +
or O +
family O +
history O -
. O -

In O +
all O +
three O +
cases O -
, O +
there O +
is O +
a O +
strong O +
family O +
history O +
of O +
breast B-Disease -
, I-Disease +
ovarian I-Disease -
, I-Disease +
or I-Disease +
other I-Disease +
cancers L-Disease +
possibly O +
related O +
to O +
a O +
BRCA1 O +
defect O +
and O +
family O +
members O +
showed O +
a O +
high O +
concordance O +
of O +
cancer U-Disease +
incidence O +
with O +
the O +
presence O +
of O +
R841W O -
. O -

The O +
age O +
of O +
cancer U-Disease +
onset O +
was O +
not O +
always O +
distinct O +
from O +
typical O +
sporadic O +
cases O -
. O -

Testing O +
of O +
a O +
sample O +
of O +
413 O +
unrelated O +
individuals O +
to O +
examine O +
the O +
hypothesis O +
that O +
R841W O +
might O +
be O +
a O +
rare O +
polymorphism O +
detected O +
one O +
additional O +
instance O +
in O +
a O +
woman O +
with O +
breast B-Disease +
cancer L-Disease +
diagnosed O +
at O +
age O +
77 O +
years O -
, O +
and O +
cancer U-Disease +
in O +
one O +
parent O -
. O -

R841W O +
is O +
likely O +
to O +
be O +
an O +
etiologically O +
significant O +
lesion O +
with O +
involvement O +
in O +
close O +
to O +
1 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O +
of O +
0 O -
- O -
1 O -
. O +
7 O -
% O -
) O +
of O +
all O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancers L-Disease +
in O +
this O +
population O -
. O -

Ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
: O +
founder O +
effect O +
among O +
north O +
African O +
Jews O -
. O -

The O +
ATM O +
gene O +
is O +
responsible O +
for O +
the O +
autosomal B-Disease +
recessive I-Disease +
disorder L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O -
, O +
characterized O +
by O +
cerebellar B-Disease +
degeneration L-Disease -
, O +
immunodeficiency U-Disease +
and O +
cancer B-Disease +
predisposition L-Disease -
. O -

A B-Disease -
- I-Disease -
T L-Disease +
carriers O +
were O +
reported O +
to O +
be O +
moderately O +
cancer B-Disease -
- I-Disease -
prone L-Disease -
. O -

A O +
wide O +
variety O +
of O +
A B-Disease -
- I-Disease -
T L-Disease +
mutations O -
, O +
most O +
of O +
which O +
are O +
unique O +
to O +
single O +
families O -
, O +
were O +
identified O +
in O +
various O +
ethnic O +
groups O -
, O +
precluding O +
carrier O +
screening O +
with O +
mutation O -
- O -
specific O +
assays O -
. O -

However O -
, O +
a O +
single O +
mutation O +
was O +
observed O +
in O +
32 O -
/ O -
33 O +
defective O +
ATM O +
alleles O +
in O +
Jewish O +
A B-Disease -
- I-Disease -
T L-Disease +
families O +
of O +
North O +
African O +
origin O -
, O +
coming O +
from O +
various O +
regions O +
of O +
Morocco O +
and O +
Tunisia O -
. O -

This O +
mutation O -
, O +
103C-- O +
> O +
T O -
, O +
results O +
in O +
a O +
stop O +
codon O +
at O +
position O +
35 O +
of O +
the O +
ATM O +
protein O -
. O -

In O +
keeping O +
with O +
the O +
nature O +
of O +
this O +
mutation O -
, O +
various O +
antibodies O +
directed O +
against O +
the O +
ATM O +
protein O +
failed O +
to O +
defect O +
this O +
protein O +
in O +
patient O +
cells O -
. O -

A O +
rapid O +
carrier O +
detection O +
assay O +
detected O +
this O +
mutation O +
in O +
three O +
out O +
of O +
488 O +
ATM O +
alleles O +
of O +
Jewish O +
Moroccan O +
or O +
Tunisian O +
origin O -
. O -

This O +
founder O +
effect O +
provides O +
a O +
unique O +
opportunity O +
for O +
population O -
- O -
based O +
screening O +
for O +
A B-Disease -
- I-Disease -
T L-Disease +
carriers O +
in O +
a O +
large O +
Jewish O +
community O -
.. O -

Mutation O +
analysis O +
of O +
BRCA1 O +
and O +
BRCA2 O +
in O +
a O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
population O -
. O -

A O +
population O -
- O -
based O +
series O +
of O +
54 O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
cases O +
from O +
Southern O +
California O +
were O +
analyzed O +
for O +
germ O -
- O -
line O +
mutations O +
in O +
the O +
inherited B-Disease +
breast I-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
genes O -
, O +
BRCA1 O +
and O +
BRCA2 O -
. O -

Nine O +
( O -
17 O -
% O -
) O +
of O +
the O +
patients O +
had O +
a O +
family O +
history O +
of O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease +
in O +
at O +
least O +
one O +
first O -
- O -
degree O +
relative O -
. O -

A O +
further O +
seven O +
( O -
13 O -
% O -
) O +
of O +
the O +
patients O +
reported O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
in O +
at O +
least O +
one O +
second O -
- O -
degree O +
relative O +
and O +
in O +
no O +
first O -
- O -
degree O +
relatives O -
. O -

No O +
germ O -
- O -
line O +
BRCA1 O +
mutations O +
were O +
found O -
. O -

Two O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
patients O +
( O -
4 O -
% O +
of O +
the O +
total O -
) O +
were O +
found O +
to O +
carry O +
novel O +
truncating O +
mutations O +
in O +
the O +
BRCA2 O +
gene O -
. O -

Only O +
one O +
of O +
the O +
two O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
patients O +
carrying O +
a O +
BRCA2 O +
mutation O +
had O +
a O +
family O +
history O +
of O +
cancer U-Disease -
, O +
with O +
one O +
case O +
of O +
ovarian B-Disease +
cancer L-Disease +
in O +
a O +
first O -
- O -
degree O +
relative O -
. O -

The O +
remaining O +
eight O +
cases O +
( O -
89 O -
% O -
) O +
of O +
male B-Disease +
breast I-Disease +
cancer L-Disease +
with O +
a O +
family O +
history O +
of O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
in O +
first O -
- O -
degree O +
relatives O +
remain O +
unaccounted O +
for O +
by O +
mutations O +
in O +
either O +
the O +
BRCA1 O +
gene O +
or O +
the O +
BRCA2 O +
gene O -
.. O -

Molecular O +
basis O +
for O +
Duarte B-Disease +
and I-Disease +
Los I-Disease +
Angeles I-Disease +
variant I-Disease +
galactosemia L-Disease -
. O -

Human O +
orythrocytes O +
that O +
are O +
homozygous O +
for O +
the O +
Duarte B-Disease +
enzyme I-Disease +
variant I-Disease +
of I-Disease +
galactosemia L-Disease +
( O -
D O -
/ O -
D O -
) O +
have O +
a O +
characteristic O +
isoform O +
on O +
isoelectric O +
focusing O +
and O +
50 O -
% O +
reduction O +
in O +
galactose-1-phosphate O +
uridyltransferase O +
( O -
GALT O -
) O +
enzyme O +
activity O -
. O -

The O +
Duarte O +
biochemical O +
phenotype O +
has O +
a O +
molecular O +
genotype O +
of O +
N314D O -
/ O -
N314D O -
. O -

The O +
characteristic O +
Duarte O +
isoform O +
is O +
also O +
associated O +
with O +
a O +
variant O +
called O +
the O +
" O +
Los O +
Angeles O +
( O -
LA O -
) O +
phenotype O -
, O +
" O +
which O +
has O +
increased O +
GALT O +
enzyme O +
activity O -
. O -

We O +
evaluated O +
GALT O +
enzyme O +
activity O +
and O +
screened O +
the O +
GALT O +
genes O +
of O +
145 O +
patients O +
with O +
one O +
or O +
more O +
N314D O -
- O -
containing O +
alleles O -
. O -

We O +
found O +
seven O +
with O +
the O +
LA O +
biochemical O +
phenotype O -
, O +
and O +
all O +
had O +
a O +
1721C-- O +
> O +
T O +
transition O +
in O +
exon O +
7 O +
in O +
cis O +
with O +
the O +
N314D O +
missense O +
mutation O -
. O -

The O +
1721C-- O +
> O +
T O +
transition O +
is O +
a O +
neutral O +
polymorphism O +
for O +
leucine O +
at O +
amino O +
acid O +
218 O +
( O -
L218L O -
) O -
. O -

In O +
pedigree O +
analyses O -
, O +
this O +
1721C-- O +
> O +
T O +
transition O +
segregated O +
with O +
the O +
LA O +
phenotype O +
of O +
increased O +
GALT O +
activity O +
in O +
three O +
different O +
biochemical O +
phenotypes O +
( O -
LA O -
/ O -
N O -
, O +
LA O -
/ O -
G O -
, O +
and O +
LA O -
/ O -
D O -
) O -
. O -

To O +
determine O +
the O +
mechanism O +
for O +
increased O +
activity O +
of O +
the O +
LA O +
variant O -
, O +
we O +
compared O +
GALT O +
mRNA O -
, O +
protein O +
abundance O -
, O +
and O +
enzyme O +
thermal O +
stability O +
in O +
lymphoblast O +
cell O +
lines O +
of O +
D O +
and O +
LA O +
phenotypes O +
with O +
comparable O +
genotypes O -
. O -

GALT O +
protein O +
abundance O +
was O +
increased O +
in O +
LA O +
compared O +
to O +
D O +
alleles O -
, O +
but O +
mRNA O +
was O +
similar O +
among O +
all O +
genotypes O -
. O -

When O +
LA O -
/ O -
D O +
and O +
D O -
/ O -
D O +
GALT O +
biochemical O +
phenotypes O +
were O +
compared O +
to O +
N O -
/ O -
N O +
GALT O +
phenotypes O -
, O +
both O +
had O +
50 O -
% O -
, O +
as O +
compared O +
to O +
21 O -
% O -
, O +
reduction O +
in O +
GALT O +
activity O +
in O +
the O +
wild O +
type O +
( O -
N O -
/ O -
N O -
) O +
after O +
exposure O +
at O +
identical O +
initial O +
enzyme O +
activity O +
to O +
50 O +
degrees O +
C O +
for O +
15 O +
min O -
. O -

We O +
conclude O +
that O +
the O +
codon O +
change O +
N314D O +
in O +
cis O +
with O +
the O +
base O -
- O -
pair O +
transition O +
1721C-- O +
> O +
T O +
produces O +
the O +
LA B-Disease +
variant I-Disease +
of I-Disease +
galactosemia L-Disease +
and O +
that O +
this O +
nucleotide O +
change O +
increases O +
GALT O +
activity O +
by O +
increasing O +
GALT O +
protein O +
abundance O +
without O +
increasing O +
transcription O +
or O +
decreasing O +
thermal O +
lability O -
. O -

A O +
favorable O +
codon O +
bias O +
for O +
the O +
mutated O +
codon O +
with O +
consequently O +
increased O +
translation O +
rates O +
is O +
postulated O +
as O +
the O +
mechanism O -
.. O -

The O +
TSG101 O +
tumor U-Disease +
susceptibility O +
gene O +
is O +
located O +
in O +
chromosome O +
11 O +
band O +
p15 O +
and O +
is O +
mutated O +
in O +
human O +
breast B-Disease +
cancer L-Disease -
. O -

Recent O +
work O +
has O +
identified O +
a O +
mouse O +
gene O +
( O -
tsg101 O -
) O +
whose O +
inactivation O +
in O +
fibroblasts O +
results O +
in O +
cellular O +
transformation O +
and O +
the O +
ability O +
to O +
produce O +
metastatic B-Disease +
tumors L-Disease +
in O +
nude O +
mice O -
. O -

Here O -
, O +
we O +
report O +
that O +
the O +
human O +
homolog O -
, O +
TSG101 O -
, O +
which O +
we O +
isolated O +
and O +
mapped O +
to O +
chromosome O +
11 O -
, O +
bands O +
15 O -
. O +
1 O -
- O -
15 O +
1 O -
- O -
15 O -
. O +
2 O -
, O +
a O +
region O +
proposed O +
to O +
contain O +
tumor U-Disease +
suppressor O +
gene O +
( O -
s O -
) O -
, O +
is O +
mutated O +
at O +
high O +
frequency O +
in O +
human O +
breast B-Disease +
cancer L-Disease -
. O -

In O +
7 O +
of O +
15 O +
uncultured O +
primary O +
human O +
breast B-Disease +
carcinomas L-Disease -
, O +
intragenic O +
deletions O +
were O +
shown O +
in O +
TSG101 O +
genomic O +
DNA O +
and O +
transcripts O +
by O +
gel O +
and O +
sequence O +
analysis O -
, O +
and O +
mutations O +
affecting O +
two O +
TSG101 O +
alleles O +
were O +
identified O +
in O +
four O +
of O +
these O +
cancers U-Disease -
. O -

No O +
TSG101 O +
defects O +
were O +
found O +
in O +
matched O +
normal O +
breast O +
tissue O +
from O +
the O +
breast B-Disease +
cancer L-Disease +
patients O -
. O -

These O +
findings O +
strongly O +
implicate O +
TSG101 O +
mutations O +
in O +
human O +
breast B-Disease +
cancer L-Disease -

Moderate O +
intergenerational O +
and O +
somatic O +
instability O +
of O +
a O +
55-CTG O +
repeat O +
in O +
transgenic O +
mice O -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
associated O +
with O +
the O +
expansion O +
of O +
a O +
( O -
CTG O -
) O +
n O +
trinucleotide O +
repeat O +
in O +
the O +
3 O +
untranslated O +
region O +
( O -
UTR O -
) O +
of O +
the O +
DM U-Disease +
protein O +
kinase O +
gene O +
( O -
DMPK O -
) O -
. O -

The O +
( O -
CTG O -
) O +
n O +
repeat O +
is O +
polymorphic O +
and O +
varies O +
in O +
size O +
between O +
5 O +
and O +
37 O +
repeats O +
in O +
unaffected O +
individuals O +
whereas O +
in O +
affected O +
patients O +
there O +
are O +
between O +
50 O +
and O +
4 O -
, O +
000 O +
CTGs O -
. O -

The O +
size O +
of O +
the O +
( O -
CTG O -
) O +
n O +
repeat O -
, O +
which O +
increases O +
through O +
generations O -
, O +
generally O +
correlates O +
with O +
clinical O +
severity O +
and O +
age O +
of O +
onset O -
. O -

The O +
instability O +
of O +
the O +
CTG O +
repeat O +
appears O +
to O +
depend O +
on O +
its O +
size O +
as O +
well O +
as O +
on O +
the O +
sex O +
of O +
the O +
transmitting O +
parent O -
. O -

Moreover O -
, O +
mitotic O +
instability O +
analysis O +
of O +
different O +
human O +
DM U-Disease +
tissues O +
shows O +
length O +
mosaicism O +
between O +
different O +
cell O +
lineages O -
. O -

The O +
molecular O +
mechanisms O +
of O +
triplet O +
instability O +
remain O +
elusive O -
. O -

To O +
investigate O +
the O +
role O +
of O +
genomic O +
sequences O +
in O +
instability O -
, O +
we O +
produced O +
transgenic O +
mice O +
containing O +
a O +
45-kb O +
genomic O +
segment O +
with O +
a O +
55-CTG O +
repeat O +
cloned O +
from O +
a O +
mildly O +
affected O +
patient O -
. O -

In O +
contrast O +
to O +
other O +
mouse O +
models O +
containing O +
CAG O +
repeats O +
within O +
cDNAs O -
, O +
these O +
mice O +
showed O +
both O +
intergenerational O +
and O +
somatic O +
repeat O +
instability O -
.. O -

Missense O +
mutations O +
in O +
the O +
Fas O +
gene O +
resulting O +
in O +
autoimmune B-Disease +
lymphoproliferative I-Disease +
syndrome L-Disease -
: O +
a O +
molecular O +
and O +
immunological O +
analysis O -
. O -

Programmed O +
cell O +
death O +
( O -
or O +
apoptosis O -
) O +
is O +
a O +
physiological O +
process O +
essential O +
to O +
the O +
normal O +
development O +
and O +
homeostatic O +
maintenance O +
of O +
the O +
immune O +
system O -
. O -

The O +
Fas O -
/ O -
Apo-1 O +
receptor O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
apoptosis O -
, O +
as O +
demonstrated O +
by O +
lymphoproliferation O +
in O +
MRL O -
- O -
lpr O -
/ O -
lpr O +
mice O +
and O +
by O +
the O +
recently O +
described O +
autoimmune B-Disease +
lymphoproliferative I-Disease +
syndrome L-Disease +
( O -
ALPS U-Disease -
) O +
in O +
humans O -
, O +
both O +
of O +
which O +
are O +
due O +
to O +
mutations O +
in O +
the O +
Fas O +
gene O -
. O -

We O +
describe O +
a O +
novel O +
family O +
with O +
ALPS U-Disease +
in O +
which O +
three O +
affected O +
siblings O +
carry O +
two O +
distinct O +
missense O +
mutations O +
on O +
both O +
the O +
Fas O +
gene O +
alleles O +
and O +
show O +
lack O +
of O +
Fas O -
- O -
induced O +
apoptosis O -
. O -

The O +
children O +
share O +
common O +
clinical O +
features O +
including O +
splenomegaly U-Disease +
and O +
lymphadenopathy U-Disease -
, O +
but O +
only O +
one O +
developed O +
severe O +
autoimmune B-Disease +
manifestations L-Disease -
. O -

In O +
all O +
three O +
siblings O -
, O +
we O +
demonstrated O +
the O +
presence O +
of O +
anergic O +
CD3 O +
+ O +
CD4-CD8- O +
( O -
double O +
negative O -
, O +
[ O -
DN O -
] O -
) O +
T O +
cells O -
; O +
moreover O -
, O +
a O +
chronic O +
lymphocyte O +
activation O +
was O +
found O -
, O +
as O +
demonstrated O +
by O +
the O +
presence O +
of O +
high O +
levels O +
of O +
HLA O -
- O -
DR O +
expression O +
on O +
peripheral O +
CD3 O +
+ O +
cells O +
and O +
by O +
the O +
presence O +
of O +
high O +
levels O +
of O +
serum O +
activation O +
markers O +
such O +
as O +
soluble O +
interleukin-2 O +
receptor O +
( O -
slL-2R O -
) O +
and O +
soluble O +
CD30 O +
( O -
sCD30 O -
) O -
.. O -

The O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
gene O +
product O -
, O +
a O +
constitutively O +
expressed O +
nuclear O +
protein O +
that O +
is O +
not O +
up O -
- O -
regulated O +
following O +
genome O +
damage O -
. O -

The O +
product O +
of O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
gene O +
( O -
ATM O -
) O +
was O +
identified O +
by O +
using O +
an O +
antiserum O +
developed O +
to O +
a O +
peptide O +
corresponding O +
to O +
the O +
deduced O +
amino O +
acid O +
sequence O -
. O -

The O +
ATM O +
protein O +
is O +
a O +
single O -
, O +
high O -
- O -
molecular O +
weight O +
protein O +
predominantly O +
confined O +
to O +
the O +
nucleus O +
of O +
human O +
fibroblasts O -
, O +
but O +
is O +
present O +
in O +
both O +
nuclear O +
and O +
microsomal O +
fractions O +
from O +
human O +
lymphoblast O +
cells O +
and O +
peripheral O +
blood O +
lymphocytes O -
. O -

ATM O +
protein O +
levels O +
and O +
localization O +
remain O +
constant O +
throughout O +
all O +
stages O +
of O +
the O +
cell O +
cycle O -
. O -

Truncated O +
ATM O +
protein O +
was O +
not O +
detected O +
in O +
lymphoblasts O +
from O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
patients O +
homozygous O +
for O +
mutations O +
leading O +
to O +
premature O +
protein O +
termination O -
. O -

Exposure O +
of O +
normal O +
human O +
cells O +
to O +
gamma O -
- O -
irradiation O +
and O +
the O +
radiomimetic O +
drug O +
neocarzinostatin O +
had O +
no O +
effect O +
on O +
ATM O +
protein O +
levels O -
, O +
in O +
contrast O +
to O +
a O +
noted O +
rise O +
in O +
p53 O +
levels O +
over O +
the O +
same O +
time O +
interval O -
. O -

These O +
findings O +
are O +
consistent O +
with O +
a O +
role O +
for O +
the O +
ATM O +
protein O +
in O +
ensuring O +
the O +
fidelity O +
of O +
DNA O +
repair O +
and O +
cell O +
cycle O +
regulation O +
following O +
genome O +
damage O -
.. O -

Type O +
III O +
collagen O +
is O +
crucial O +
for O +
collagen O +
I O +
fibrillogenesis O +
and O +
for O +
normal O +
cardiovascular O +
development O -
. O -

Type O +
III O +
collagen O +
is O +
a O +
fibrillar O +
forming O +
collagen O +
comprising O +
three O +
alpha1 O +
( O -
III O -
) O +
chains O +
and O +
is O +
expressed O +
in O +
early O +
embryos O +
and O +
throughout O +
embryogenesis O -
. O -

In O +
the O +
adult O -
, O +
type O +
III O +
collagen O +
is O +
a O +
major O +
component O +
of O +
the O +
extracellular O +
matrix O +
in O +
a O +
variety O +
of O +
internal O +
organs O +
and O +
skin O -
. O -

Mutations O +
in O +
the O +
COL3A1 O +
gene O +
have O +
been O +
implicated O +
as O +
a O +
cause O +
of O +
type B-Disease +
IV I-Disease +
Ehlers I-Disease -
- I-Disease -
Danlos I-Disease +
syndrome L-Disease -
, O +
a O +
disease O +
leading O +
to O +
aortic B-Disease +
rupture L-Disease +
in O +
early O +
adult O +
life O -
. O -

To O +
directly O +
study O +
the O +
role O +
of O +
Col3a1 O +
in O +
development O +
and O +
disease O -
, O +
we O +
have O +
inactivated O +
the O +
Col3a1 O +
gene O +
in O +
embryonic O +
stem O +
cells O +
by O +
homologous O +
recombination O -
. O -

The O +
mutated O +
allele O +
was O +
transmitted O +
through O +
the O +
mouse O +
germ O +
line O +
and O +
homozygous O +
mutant O +
animals O +
were O +
derived O +
from O +
heterozygous O +
intercrosses O -
. O -

About O +
10 O -
% O +
of O +
the O +
homozygous O +
mutant O +
animals O +
survived O +
to O +
adulthood O +
but O +
have O +
a O +
much O +
shorter O +
life O +
span O +
compared O +
with O +
wild O -
- O -
type O +
mice O -
. O -

The O +
major O +
cause O +
of O +
death O +
of O +
mutant O +
mice O +
was O +
rupture O +
of O +
the O +
major O +
blood O +
vessels O -
, O +
similar O +
to O +
patients O +
with O +
type B-Disease +
IV I-Disease +
Ehlers I-Disease -
- I-Disease -
Danlos I-Disease +
syndrome L-Disease -
. O -

Ultrastructural O +
analysis O +
of O +
tissues O +
from O +
mutant O +
mice O +
revealed O +
that O +
type O +
III O +
collagen O +
is O +
essential O +
for O +
normal O +
collagen O +
I O +
fibrillogenesis O +
in O +
the O +
cardiovascular O +
system O +
and O +
other O +
organs O -
.. O -

Nonsense O +
mutation O +
in O +
exon O +
3 O +
of O +
the O +
proteolipid O +
protein O +
gene O +
( O -
PLP O -
) O +
in O +
a O +
family O +
with O +
an O +
unusual O +
form O +
of O +
Pelizaeus B-Disease -
- I-Disease -
Merzbacher I-Disease +
disease L-Disease -
. O -

We O +
report O +
a O +
G-- O +
> O +
A O +
transition O +
at O +
nucleotide O +
431 O +
of O +
the O +
proteolipid O +
protein O +
gene O +
( O -
PLP O -
) O +
results O +
in O +
a O +
nonsense O +
codon O +
in O +
a O +
family O +
with O +
an O +
unusual O +
form O +
of O +
Pelizaeus B-Disease -
- I-Disease -
Merzbacher I-Disease +
disease L-Disease +
( O -
PMD U-Disease -
) O -
. O -

The O +
mutation O -
, O +
which O +
creates O +
a O +
second O +
AluI O +
restriction O +
site O -
, O +
results O +
in O +
a O +
nonsense O +
mutation O +
in O +
PLP O -
. O -

The O +
clinical O +
picture O +
resembles O +
somewhat O +
that O +
of O +
X B-Disease -
- I-Disease -
linked I-Disease +
spastic I-Disease +
paraplegia L-Disease +
( O -
SPG U-Disease -
) O -
. O -

It O +
differs O +
from O +
this O +
and O +
both O +
the O +
classical O +
and O +
connatal O +
forms O +
of O +
PMD U-Disease +
in O +
that O +
it O +
is O +
relatively O +
mild O +
in O +
form O -
, O +
onset O +
is O +
delayed O +
beyond O +
age O +
2 O +
years O -
, O +
nystagmus U-Disease +
is O +
absent O -
, O +
tremors U-Disease +
are O +
prominent O -
, O +
mental B-Disease +
retardation L-Disease +
is O +
not O +
severe O -
, O +
some O +
patients O +
show O +
dementia U-Disease +
or O +
personality B-Disease +
disorders L-Disease -
, O +
the O +
disease O +
is O +
progressive O +
rather O +
than O +
static O +
in O +
some O -
, O +
and O +
several O +
females O +
show O +
signs O +
of O +
disease O -
. O -

The O +
nonsense O +
mutation O -
, O +
which O +
is O +
in O +
exon O +
3B O -
, O +
should O +
block O +
the O +
synthesis O +
of O +
normal O +
PLP O +
but O +
spare O +
DM20 O -
, O +
the O +
isoform O +
whose O +
persistence O +
has O +
been O +
associated O +
with O +
mild O +
forms O +
of O +
PLP B-Disease -
- I-Disease -
associated I-Disease +
disease L-Disease +
in O +
both O +
humans O +
and O +
mice O -
.. O -

Common O +
BRCA1 O +
variants O +
and O +
susceptibility O +
to O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
in O +
the O +
general O +
population O -
. O -

Most O +
multiple O +
case O +
families O +
of O +
young O +
onset O +
breast B-Disease +
cancer L-Disease +
and O +
ovarian B-Disease +
cancer L-Disease +
are O +
thought O +
to O +
be O +
due O +
to O +
highly O +
penetrant O +
mutations O +
in O +
the O +
predisposing O +
genes O +
BRCA1 O +
and O +
BRCA2 O -
. O -

However O -
, O +
these O +
mutations O +
are O +
uncommon O +
in O +
the O +
population O +
and O +
they O +
probably O +
account O +
for O +
only O +
a O +
few O +
percent O +
of O +
all O +
breast B-Disease +
cancer L-Disease +
incidence O -
. O -

A O +
much O +
larger O +
fraction O +
of O +
breast B-Disease +
cancer L-Disease +
might O -
, O +
in O +
principle O -
, O +
be O +
due O +
to O +
common O +
variants O +
which O +
confer O +
more O +
modest O +
individual O +
risks O -
. O -

There O +
are O +
several O +
common O +
polymorphisms O +
in O +
the O +
BRCA1 O +
gene O +
which O +
generate O +
amino O +
acid O +
substitutions O -
. O -

We O +
have O +
examined O +
the O +
frequency O +
of O +
four O +
of O +
these O +
polymorphisms O -
Gln356Arg O -
, O +
Pro871Leu O -
, O +
Glu1038Gly O +
and O +
Ser1613Gly O +
in O +
large O +
series O +
of O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
cases O +
and O +
matched O +
controls O -
. O -

Due O +
to O +
strong O +
linkage O +
disequilibrium O -
, O +
these O +
four O +
sites O +
generate O +
only O +
three O +
haplotypes O +
with O +
a O +
frequency O +
> O +
1 O -
. O +
3 O -
% O -
. O -

The O +
most O +
common O +
haplotypes O -
, O +
defined O +
by O +
the O +
alleles O +
Gln356Pro871Glu1038Ser1613 O +
and O +
Gln356Leu871Gly1038Gly1613 O -
, O +
have O +
frequencies O +
of O +
0 O -
. O +
57 O +
and O +
0 O -
. O +
32 O +
respectively O -
, O +
and O +
these O +
frequencies O +
do O +
not O +
differ O +
significantly O +
between O +
patient O +
and O +
control O +
groups O -
. O -

Thus O +
the O +
most O +
common O +
polymorphisms O +
of O +
the O +
BRCA1 O +
gene O +
do O +
not O +
make O +
a O +
significant O +
contribution O +
to O +
breast B-Disease +
or I-Disease +
ovarian I-Disease +
cancer L-Disease +
risk O -
. O -

However O -
, O +
our O +
data O +
suggest O +
that O +
the O +
Arg356 O +
allele O +
may O +
have O +
a O +
different O +
genotype O +
distribution O +
in O +
breast B-Disease +
cancer L-Disease +
patients O +
from O +
that O +
in O +
controls O +
( O -
Arg356 O +
homozygotes O +
are O +
more O +
frequent O +
in O +
the O +
control O +
groups O -
, O +
P O +
= O +
0 O -
. O +
01 O -
) O -
, O +
indicating O +
that O +
it O +
may O +
be O +
protective O +
against O +
breast B-Disease +
cancer L-Disease -
. O -

If O +
this O +
finding O +
can O +
be O +
confirmed O -
, O +
it O +
may O +
provide O +
an O +
insight O +
into O +
the O +
structural O +
features O +
of O +
the O +
BRCA1 O +
protein O +
that O +
are O +
important O +
for O +
its O +
function O -
. O -

Kniest B-Disease +
dysplasia L-Disease -
: O +
Dr. O +
W. O +
Kniest O -
, O +
his O +
patient O -
, O +
the O +
molecular O +
defect O -
. O -

Kniest B-Disease +
dysplasia L-Disease +
is O +
a O +
severe O +
chondrodysplasia U-Disease +
caused O +
by O +
the O +
defective B-Disease +
formation I-Disease +
of I-Disease +
type I-Disease +
II I-Disease +
collagen L-Disease -
. O -

We O +
report O +
about O +
Dr. O +
Kniest O -
, O +
who O +
first O +
described O +
the O +
condition O +
in O +
1952 O -
, O +
and O +
his O +
patient O -
, O +
who O -
, O +
at O +
the O +
age O +
of O +
50 O +
years O +
is O +
severely B-Disease +
handicapped L-Disease +
with O +
short B-Disease +
stature L-Disease -
, O +
restricted B-Disease +
joint I-Disease +
mobility L-Disease -
, O +
and O +
blindness U-Disease +
but O +
is O +
mentally O +
alert O +
and O +
leads O +
an O +
active O +
life O -
. O -

Molecular O +
analysis O +
of O +
the O +
patients O +
DNA O +
showed O +
a O +
single O +
base O +
( O -
G O -
) O +
deletion O +
involving O +
the O +
GT O +
dinucleotide O +
at O +
the O +
start O +
of O +
intron O +
18 O +
destroying O +
a O +
splice O +
site O +
of O +
the O +
COL2A1 O +
gene O -
. O -

This O +
is O +
in O +
accordance O +
with O +
molecular O +
findings O +
in O +
other O +
patients O +
with O +
Kniest B-Disease +
dysplasia L-Disease +
and O +
confirms O -
, O +
in O +
the O +
original O +
patient O -
, O +
that O +
the O +
disorder O +
is O +
caused O +
by O +
small O +
inframe O +
deletions O +
often O +
due O +
to O +
exon O +
skipping O +
as O +
a O +
result O +
of O +
COL2A1 O +
splice O +
site O +
mutations O -
.. O -

Cloning O +
of O +
the O +
homogentisate O +
1,2-dioxygenase O +
gene O -
, O +
the O +
key O +
enzyme O +
of O +
alkaptonuria U-Disease +
in O +
mouse O -
. O -

We O +
determined O +
48 O +
amino O +
acid O +
residues O +
from O +
five O +
peptides O +
from O +
the O +
homogeneous O +
monomer O +
of O +
homogentisate O +
1 O -
, O +
2-dioxygenase O +
( O -
HGO O -
; O +
E. O +
C. O +
1 O -
. O +
13 O -
. O +
11 O -
. O +
15 O -
) O +
of O +
mouse O +
liver O -
. O -

After O +
digestion O +
with O +
trypsin O -
, O +
peptides O +
were O +
separated O +
by O +
reversed O +
phase O +
chromatography O +
and O +
amino O +
acid O +
sequenced O -
. O -

The O +
deduced O +
codon O +
sequence O +
of O +
three O +
peptides O +
was O +
used O +
to O +
derive O +
degenerated O +
oligomeres O -
. O -

By O +
combining O +
these O +
oligos O -
, O +
we O +
were O +
able O +
to O +
amplify O +
fragments O +
from O +
100 O +
to O +
300 O +
bases O +
( O -
b O -
) O +
from O +
mouse O +
liver O +
cDNA O +
by O +
polymerase O +
chain O +
reaction O +
after O +
reverse O +
transcription O +
( O -
RT O -
- O -
PCR O -
) O -
. O -

A O +
fragment O +
of O +
200 O +
b O +
was O +
cloned O +
and O +
used O +
as O +
a O +
probe O +
to O +
screen O +
a O +
mouse O +
liver O +
cDNA O +
library O -
. O -

One O +
clone O +
from O +
this O +
library O +
contained O +
the O +
complete O +
cDNA O -
- O -
insert O +
for O +
HGO O +
as O +
determined O +
by O +
sequencing O -
. O -

The O +
cDNA O +
encodes O +
for O +
a O +
protein O +
of O +
50 O +
kDa O -
, O +
as O +
predicted O -
. O -

The O +
cDNA O +
of O +
mouse O +
HGO O +
has O +
an O +
overall O +
identity O +
of O +
41 O -
% O +
to O +
the O +
corresponding O +
gene O +
hmgA O +
from O +
Aspergillus O -
. O -

Sequence O +
similarities O +
to O +
human O +
expressed O +
sequence O +
tags O +
( O -
EST O -
) O +
clones O +
ranged O +
from O +
70 O -
% O +
to O +
20 O -
% O -
. O -

The O +
positions O +
of O +
122 O +
conserved O +
amino O +
acids O +
could O +
be O +
determined O +
by O +
multiple O +
sequence O +
alignment O -
. O -

We O +
identified O +
one O +
first O +
intron O +
of O +
928 O +
b O +
in O +
the O +
mouse O +
gene O -
. O -

The O +
gene O +
for O +
HGO O +
seems O +
to O +
be O +
expressed O +
in O +
various O +
tissues O -
, O +
as O +
shown O +
by O +
RT O -
- O -
PCR O +
on O +
different O +
cDNAs O -
. O -

FISH O +
experiments O +
with O +
the O +
whole O +
murine O +
cDNA O +
as O +
probe O +
clearly O +
revealed O +
signals O +
at O +
the O +
human O +
chromosomal O +
band O +
3q13 O -
. O -

3-q21 O -
. O -

This O +
corresponds O +
well O +
to O +
the O +
previous O +
assignment O +
of O +
the O +
locus O +
for O +
the O +
human O +
alkaptonuria U-Disease +
gene O +
( O -
AKU O -
) O +
to O +
the O +
same O +
chromosomal O +
region O +
by O +
multipoint O +
linkage O +
analysis O -
. O -

We O +
therefore O +
conclude O +
that O +
the O +
HGO O +
cDNA O +
encodes O +
the O +
gene O +
responsible O +
for O +
alkaptonuria U-Disease -
. O -

PTEN O -
, O +
a O +
putative O +
protein O +
tyrosine O +
phosphatase O +
gene O +
mutated O +
in O +
human O +
brain B-Disease -
, I-Disease +
breast I-Disease -
, I-Disease +
and I-Disease +
prostate I-Disease +
cancer L-Disease -
. O -

Mapping O +
of O +
homozygous O +
deletions O +
on O +
human O +
chromosome O +
10q23 O +
has O +
led O +
to O +
the O +
isolation O +
of O +
a O +
candidate O +
tumor U-Disease +
suppressor O +
gene O -
, O +
PTEN O -
, O +
that O +
appears O +
to O +
be O +
mutated O +
at O +
considerable O +
frequency O +
in O +
human O +
cancers U-Disease -
. O -

In O +
preliminary O +
screens O -
, O +
mutations O +
of O +
PTEN O +
were O +
detected O +
in O +
31 O -
% O +
( O -
13 O -
/ O -
42 O -
) O +
of O +
glioblastoma U-Disease +
cell O +
lines O +
and O +
xenografts O -
, O +
100 O -
% O +
( O -
4 O -
/ O -
4 O -
) O +
of O +
prostate B-Disease +
cancer L-Disease +
cell O +
lines O -
, O +
6 O -
% O +
( O -
4 O -
/ O -
65 O -
) O +
of O +
breast B-Disease +
cancer L-Disease +
cell O +
lines O +
and O +
xenografts O -
, O +
and O +
17 O -
% O +
( O -
3 O -
/ O -
18 O -
) O +
of O +
primary B-Disease +
glioblastomas L-Disease -
. O -

The O +
predicted O +
PTEN O +
product O +
has O +
a O +
protein O +
tyrosine O +
phosphatase O +
domain O +
and O +
extensive O +
homology O +
to O +
tensin O -
, O +
a O +
protein O +
that O +
interacts O +
with O +
actin O +
filaments O +
at O +
focal O +
adhesions O -
. O -

These O +
homologies O +
suggest O +
that O +
PTEN O +
may O +
suppress O +
tumor U-Disease +
cell O +
growth O +
by O +
antagonizing O +
protein O +
tyrosine O +
kinases O +
and O +
may O +
regulate O +
tumor U-Disease +
cell O +
invasion O +
and O +
metastasis U-Disease +
through O +
interactions O +
at O +
focal O +
adhesions O -
.. O -

Heterogeneity O +
in O +
Schwartz B-Disease -
- I-Disease -
Jampel I-Disease +
chondrodystrophic I-Disease +
myotonia L-Disease -
. O -

The O +
Schwartz B-Disease -
- I-Disease -
Jampel I-Disease +
syndrome L-Disease +
( O -
SJS U-Disease -
; O +
chondrodystrophic B-Disease +
myotonia L-Disease -
; O +
McK O +
255 O -
, O +
800 O -
) O +
is O +
a O +
recessively B-Disease +
inherited I-Disease +
condition L-Disease +
defined O +
by O +
myotonia U-Disease -
, O +
short B-Disease +
stature L-Disease -
, O +
and O +
bone B-Disease +
dysplasia L-Disease -
. O -

Genetic O +
linkage O +
between O +
SJS U-Disease +
and O +
chromosomal O +
region O +
1q36 O -
- O -
34 O +
has O +
been O +
observed O +
in O +
several O +
families O -
, O +
but O +
the O +
gene O +
has O +
not O +
yet O +
been O +
identified O -
. O -

We O +
studied O +
the O +
clinical O +
and O +
radiological O +
features O +
in O +
81 O +
patients O +
from O +
the O +
literature O +
and O +
5 O +
own O +
patients O +
trying O +
to O +
identify O +
distinct O +
subgroups O -
. O -

In O +
addition O -
, O +
we O +
tested O +
genetic O +
linkage O +
to O +
the O +
SJS U-Disease +
locus O +
on O +
chromosome O +
1 O +
in O +
one O +
family O +
with O +
two O +
affected O +
sibs O -
. O -

We O +
found O +
that O +
a O +
group O +
of O +
patients O +
have O +
mild O +
skeletal O +
changes O +
which O +
may O +
be O +
secondary O +
consequences O +
of O +
myotonia U-Disease -
, O +
while O +
another O +
group O +
of O +
patients O +
appear O +
to O +
have O +
primary O +
bone B-Disease +
dysplasia L-Disease +
with O +
myotonia U-Disease -
. O -

Within O +
this O +
latter O +
group O -
, O +
there O +
are O +
differences O +
in O +
age O +
of O +
manifestation O -
, O +
clinical O +
course O +
and O +
pattern O +
of O +
bone O +
changes O -
. O -

We O +
tentatively O +
isolate O +
three O +
different O +
types O +
of O +
SJS B-Disease -
type I-Disease +
1A L-Disease -
, O +
usually O +
recognized O +
in O +
childhood O -
, O +
with O +
moderate O +
bone B-Disease +
dysplasia L-Disease -
, O +
corresponding O +
to O +
the O +
original O +
descriptions O +
of O +
Schwartz O -
, O +
Jampel O +
and O +
Aberfeld O -
; O +
type O +
1B O -
, O +
similar O +
to O +
type O +
1A O +
but O +
recognizable O +
at O +
birth O -
, O +
with O +
more O +
pronounced O +
bone B-Disease +
dysplasia L-Disease +
resembling O +
Kniest B-Disease +
dysplasia L-Disease -
; O +
and O +
type O +
2 O -
, O +
manifest O +
at O +
birth O -
, O +
with O +
increased O +
mortality O +
and O +
bone B-Disease +
dysplasia L-Disease +
resembling O +
Pyle B-Disease +
disease L-Disease -
. O -

Genetic O +
analysis O +
of O +
the O +
family O +
with O +
two O +
sibs O +
affected O +
by O +
SJS B-Disease +
type I-Disease +
2 L-Disease +
showed O +
evidence O +
against O +
linkage O +
to O +
chromosome O +
1p36 O -
- O -
34 O -
. O -

CONCLUSIONS O -
SJS U-Disease +
is O +
clinically O +
and O +
radiologically O +
heterogeneous O -
. O -

The O +
causes O +
of O +
heterogeneity O +
are O +
not O +
known O +
yet O +
but O +
are O +
likely O +
to O +
include O +
both O +
different O +
mutations O +
at O +
the O +
SJS U-Disease +
locus O +
on O +
chromosome O +
1 O +
and O +
the O +
presence O +
of O +
a O +
second O +
SJS U-Disease +
locus O -
. O -

A O +
tentative O +
clinico O -
- O -
radiological O +
classification O +
can O +
be O +
useful O +
for O +
the O +
characterization O +
of O +
patients O +
and O +
the O +
development O +
of O +
genotype O -
- O -
phenotype O +
correlations O -
.. O -

A O +
clinical O +
overview O +
of O +
WT1 O +
gene O +
mutations O -
. O -

Mutations O +
in O +
the O +
WT1 O +
gene O +
were O +
anticipated O +
to O +
explain O +
the O +
genetic O +
basis O +
of O +
the O +
childhood O +
kidney B-Disease +
cancer L-Disease -
, O +
Wilms B-Disease +
tumour L-Disease +
( O -
WT U-Disease -
) O -
. O -

Six O +
years O +
on O -
, O +
we O +
review O +
100 O +
reports O +
of O +
intragenic O +
WT1 O +
mutations O +
and O +
examine O +
the O +
accompanying O +
clinical O +
phenotypes O -
. O -

While O +
only O +
5 O -
% O +
of O +
sporadic B-Disease +
Wilms I-Disease +
tumours L-Disease +
have O +
intragenic O +
WT1 O +
mutations O -
, O +
> O +
90 O -
% O +
of O +
patients O +
with O +
the O +
Denys B-Disease -
- I-Disease -
Drash I-Disease +
syndrome L-Disease +
( O -
renal B-Disease +
nephropathy L-Disease -
, O +
gonadal B-Disease +
anomaly L-Disease -
, O +
predisposition B-Disease +
to I-Disease +
WT L-Disease -
) O +
carry O +
constitutional O +
intragenic O +
WT1 O +
mutations O -
. O -

WT1 O +
mutations O +
have O +
also O +
been O +
reported O +
in O +
juvenile B-Disease +
granulosa I-Disease +
cell I-Disease +
tumour L-Disease -
, O +
non B-Disease -
- I-Disease -
asbestos I-Disease +
related I-Disease +
mesothelioma L-Disease -
, O +
desmoplastic B-Disease +
small I-Disease +
round I-Disease +
cell I-Disease +
tumour L-Disease +
and O -
, O +
most O +
recently O -
, O +
acute B-Disease +
myeloid I-Disease +
leukemia L-Disease -
.. O -

A O +
mutation O +
in O +
autosomal B-Disease +
dominant I-Disease +
myotonia I-Disease +
congenita L-Disease +
affects O +
pore O +
properties O +
of O +
the O +
muscle O +
chloride O +
channel O -
. O -

Autosomal B-Disease +
dominant I-Disease +
myotonia I-Disease +
congenita L-Disease +
is O +
an O +
inherited B-Disease +
disorder I-Disease +
of I-Disease +
skeletal I-Disease +
muscle L-Disease +
caused O +
by O +
mutations O +
in O +
a O +
voltage O -
- O -
gated O +
Cl- O +
channel O +
gene O +
( O -
CLCN1 O -
, O +
7q35 O -
) O -
. O -

Here O -
, O +
we O +
report O +
that O +
a O +
mutation O +
predicting O +
the O +
substitution O +
of O +
Gly O +
230 O +
by O +
glutamic O +
acid O +
( O -
G230E O -
) O +
between O +
segments O +
D3 O +
and O +
D4 O +
dramatically O +
alters O +
the O +
pore O +
properties O +
of O +
a O +
recombinant O +
human O +
muscle O +
Cl- O +
channel O +
( O -
hCIC-1 O -
) O +
expressed O +
in O +
a O +
mammalian O +
cell O +
line O +
( O -
tsA201 O -
) O -
. O -

The O +
G230E O +
mutation O +
causes O +
substantial O +
changes O +
in O +
anion O +
and O +
cation O +
selectivity O +
as O +
well O +
as O +
a O +
fundamental O +
change O +
in O +
rectification O +
of O +
the O +
current O -
- O -
voltage O +
relationship O -
. O -

Whereas O +
wild O -
- O -
type O +
channels O +
are O +
characterized O +
by O +
pronounced O +
inward O +
rectification O +
and O +
a O +
Cl O +
> O +
thiocyanate O +
> O +
Br O +
> O +
NO O +
( O -
3 O -
) O +
> O +
I O +
> O +
CH O +
( O -
3 O -
) O +
SO O +
( O -
3 O -
) O +
selectivity O -
, O +
G230E O +
exhibits O +
outward O +
rectification O +
at O +
positive O +
potentials O +
and O +
a O +
thiocyanate O +
> O +
NO O +
( O -
3 O -
) O +
> O -

I O +
> O +
Br O +
> O +
Cl O +
> O +
CH O +
( O -
3 O -
) O +
SO O +
( O -
3 O -
) O +
selectivity O -
. O -

Furthermore O -
, O +
the O +
cation O -
- O -
to O -
- O -
anion O +
permeability O +
ratio O +
of O +
the O +
mutant O +
is O +
much O +
greater O +
than O +
that O +
of O +
the O +
wild O -
- O -
type O +
channel O -
. O -

Voltage O -
- O -
dependent O +
blocks O +
by O +
intracellular O +
and O +
extracellular O +
iodide O +
help O +
to O +
distinguish O +
two O +
distinct O +
ion O +
binding O +
sites O +
within O +
the O +
hClC-1 O +
conduction O +
pathway O -
. O -

Both O +
binding O +
sites O +
are O +
preserved O +
in O +
the O +
mutant O +
but O +
have O +
decreased O +
affinities O +
for O +
iodide O -
. O -

These O +
findings O +
suggest O +
that O +
Gly O +
230 O +
is O +
critical O +
for O +
normal O +
ion O +
conductance O +
in O +
hClC-1 O +
and O +
that O +
this O +
residue O +
resides O +
within O +
the O +
channel O +
pore O -
.. O -

The O +
incidence O +
of O +
PAX6 O +
mutation O +
in O +
patients O +
with O +
simple O +
aniridia U-Disease -
: O +
an O +
evaluation O +
of O +
mutation O +
detection O +
in O +
12 O +
cases O -
. O -

Twelve O +
aniridia U-Disease +
patients O -
, O +
five O +
with O +
a O +
family O +
history O +
and O +
seven O +
presumed O +
to O +
be O +
sporadic O -
, O +
were O +
exhaustively O +
screened O +
in O +
order O +
to O +
test O +
what O +
proportion O +
of O +
people O +
with O +
aniridia U-Disease -
, O +
uncomplicated O +
by O +
associated O +
anomalies O -
, O +
carry O +
mutations O +
in O +
the O +
human O +
PAX6 O +
gene O -
. O -

Mutations O +
were O +
detected O +
in O +
90 O -
% O +
of O +
the O +
cases O -
. O -

Three O +
mutation O +
detection O +
techniques O +
were O +
used O +
to O +
determine O +
if O +
one O +
method O +
was O +
superior O +
for O +
this O +
gene O -
. O -

The O +
protein O +
truncation O +
test O +
( O -
PTT O -
) O +
was O +
used O +
on O +
RT O -
- O -
PCR O +
products O -
, O +
SSCP O +
on O +
genomic O +
PCR O +
amplifications O -
, O +
and O +
chemical O +
cleavage O +
of O +
mismatch O +
on O +
both O +
RT O -
- O -
PCR O +
and O +
genomic O +
amplifications O -
. O -

For O +
RT O -
- O -
PCR O +
products O -
, O +
only O +
the O +
translated O +
portion O +
of O +
the O +
gene O +
was O +
screened O -
. O -

On O +
genomic O +
products O +
exons O +
1 O +
to O +
13 O +
( O -
including O +
740 O +
bp O +
of O +
the O +
3 O +
untranslated O +
sequence O +
and O +
all O +
intron O -
/ O -
exon O +
boundaries O -
) O +
were O +
screened O -
, O +
as O +
was O +
a O +
neuroretina O +
specific O +
enhancer O +
in O +
intron O +
4 O -
. O -

Ten O +
of O +
the O +
possible O +
12 O +
mutations O +
in O +
the O +
five O +
familial O +
cases O +
and O +
five O +
of O +
the O +
sporadic O +
patients O +
were O +
found O -
, O +
all O +
of O +
which O +
conformed O +
to O +
a O +
functional O +
outcome O +
of O +
haploinsufficiency O -
. O -

Five O +
were O +
splice O +
site O +
mutations O +
( O -
one O +
in O +
the O +
donor O +
site O +
of O +
intron O +
4 O -
, O +
two O +
in O +
the O +
donor O +
site O +
of O +
intron O +
6 O -
, O +
one O +
in O +
each O +
of O +
the O +
acceptor O +
sites O +
of O +
introns O +
8 O +
and O +
9 O -
) O +
and O +
five O +
were O +
nonsense O +
mutations O +
in O +
exons O +
8 O -
, O +
9 O -
, O +
10 O -
, O +
11 O -
, O +
and O +
12 O -
. O -

SSCP O +
analysis O +
of O +
individually O +
amplified O +
exons O -
, O +
with O +
which O +
nine O +
of O +
the O +
10 O +
mutations O +
were O +
seen O -
, O +
was O +
the O +
most O +
useful O +
detection O +
method O +
for O +
PAX6 O -
.. O -

Insulin O +
gene O +
region O +
contributes O +
to O +
genetic O +
susceptibility O +
to O -
, O +
but O +
may O +
not O +
to O +
low O +
incidence O +
of O -
, O +
insulin B-Disease -
- I-Disease -
dependent I-Disease +
diabetes I-Disease +
mellitus L-Disease +
in O +
Japanese O -
. O -

In O +
the O +
Caucasian O +
population O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
the O +
insulin O +
gene O +
( O -
INS O -
) O +
region O +
contains O +
the O +
insulin B-Disease -
- I-Disease -
dependent I-Disease +
diabetes I-Disease +
mellitus L-Disease +
locus O +
( O -
IDDM2 O -
) O -
. O -

In O +
the O +
Japanese O +
population O -
, O +
however O -
, O +
there O +
has O +
been O +
no O +
report O +
demonstrating O +
the O +
contribution O +
of O +
IDDM2 O +
to O +
the O +
pathogenesis O +
of O +
IDDM U-Disease -
. O -

We O +
conducted O +
an O +
association O +
study O +
of O +
IDDM U-Disease +
in O +
a O +
large O +
number O +
of O +
Japanese O +
subjects O +
with O +
multiple O +
polymorphisms O +
in O +
INS O +
region O -
. O -

We O +
found O +
a O +
significant O +
association O +
of O +
the O +
INS O +
region O +
with O +
IDDM U-Disease -
. O -

Alleles O +
positively O +
associated O +
with O +
IDDM U-Disease +
in O +
INS O +
region O +
were O +
the O +
same O +
as O +
those O +
positively O -
- O -
associated O +
with O +
IDDM U-Disease +
in O +
Caucasian O +
population O -
, O +
although O +
positively O -
- O -
associated O +
alleles O +
are O +
very O +
common O +
( O -
allele O +
frequencies O +
> O +
0 O -
. O +
9 O -
) O +
in O +
the O +
Japanese O +
general O +
population O -
. O -

These O +
data O +
suggest O +
that O +
IDDM2 O +
is O +
involved O +
in O +
the O +
genetic O +
susceptibility O +
to O +
IDDM U-Disease +
in O +
Japanese O -
. O -

The O +
high O +
frequencies O +
of O +
disease O -
- O -
associated O +
alleles O +
in O +
the O +
general O +
population O +
suggest O +
that O +
IDDM2 O +
locus O +
is O +
not O +
responsible O +
for O +
the O +
low O +
incidence O +
of O +
IDDM U-Disease +
in O +
Japanese O -
. O -

The O +
human O +
complement O +
C9 O +
gene O -
: O +
identification O +
of O +
two O +
mutations O +
causing O +
deficiency O +
and O +
revision O +
of O +
the O +
gene O +
structure O -
. O -

The O +
ninth O +
component O +
of O +
human O +
complement O +
( O -
C9 O -
) O +
is O +
the O +
last O +
of O +
the O +
terminal O +
complement O +
components O +
creating O +
the O +
membrane O +
attack O +
complex O -
. O -

C9 O +
is O +
a O +
single O -
- O -
chain O +
serum O +
protein O +
that O +
is O +
encoded O +
by O +
a O +
gene O +
located O +
on O +
chromosome O +
5p O -
. O -

Deficiency B-Disease +
of I-Disease +
terminal I-Disease +
complement I-Disease +
components L-Disease +
is O +
generally O +
associated O +
with O +
recurrent O +
neisseria B-Disease +
infections L-Disease -
. O -

We O +
studied O +
a O +
previously O +
described O +
Swiss O +
family O +
with O +
inherited B-Disease +
C9 I-Disease +
deficiency L-Disease -
. O -

To O +
identify O +
the O +
genetic O +
basis O +
of O +
C9 B-Disease +
deficiency L-Disease -
, O +
we O +
developed O +
an O +
approach O +
using O +
exon O -
- O -
specific O +
PCR O +
and O +
direct O +
DNA O +
sequencing O -
. O -

As O +
a O +
cause O +
of O +
C9 B-Disease +
deficiency L-Disease +
, O +
we O +
found O +
two O +
different O +
point O +
mutations O -
, O +
both O +
generating O +
TGA O +
stop O +
codons O +
in O +
the O +
coding O +
sequence O -
. O -

One O +
mutation O -
, O +
a O +
C O +
to O +
A O +
exchange O -
, O +
was O +
detected O +
in O +
exon O +
2 O +
at O +
cDNA O +
position O +
166 O -
, O +
the O +
other O -
, O +
a O +
C O +
to O +
T O +
exchange O -
, O +
was O +
located O +
in O +
exon O +
4 O +
( O -
cDNA O +
position O +
464 O -
) O -
. O -

In O +
family O +
studies O +
of O +
three O +
first O -
- O -
degree O +
relatives O +
with O +
heterozygous O +
C9 B-Disease +
deficiency L-Disease -
, O +
we O +
demonstrated O +
that O +
the O +
two O +
mutations O +
are O +
segregating O +
independently O -
. O -

Therefore O -
, O +
these O +
mutations O +
are O +
sufficient O +
to O +
explain O +
the O +
complete O +
deficiency O +
of O +
both O +
the O +
probands O +
studied O -
. O -

DNA O +
sequencing O +
of O +
the O +
exon O -
- O -
intron O +
junctions O +
revealed O +
a O +
number O +
of O +
revisions O +
regarding O +
the O +
boundaries O +
between O +
exons O +
4 O -
, O +
5 O -
, O +
and O +
6 O +
as O +
well O +
as O +
between O +
exons O +
10 O +
and O +
11 O -
. O -

No O +
additional O +
introns O +
were O +
detected O +
in O +
exons O +
6 O +
and O +
10 O -
. O -

Furthermore O -
, O +
DNA O +
marker O +
studies O +
were O +
conducted O +
using O +
known O +
polymorphisms O +
of O +
the O +
C6 O -
, O +
C7 O -
, O +
and O +
C9 O +
genes O -
, O +
confirming O +
the O +
linkage O +
of O +
the O +
observed O +
C9 O +
mutations O +
with O +
defined O +
haplotypes O -
.. O -

BRCA1 O +
mutations O +
in O +
women O +
attending O +
clinics O +
that O +
evaluate O +
the O +
risk O +
of O +
breast B-Disease +
cancer L-Disease -
. O -

BACKGROUND O -
To O +
define O +
the O +
incidence O +
of O +
BRCA1 O +
mutations O +
among O +
patients O +
seen O +
in O +
clinics O +
that O +
evaluate O +
the O +
risk O +
of O +
breast B-Disease +
cancer L-Disease -
, O +
we O +
analyzed O +
DNA O +
samples O +
from O +
women O +
seen O +
in O +
this O +
setting O +
and O +
constructed O +
probability O +
tables O +
to O +
provide O +
estimates O +
of O +
the O +
likelihood O +
of O +
finding O +
a O +
BRCA1 O +
mutation O +
in O +
individual O +
families O -
. O -

METHODS O -
Clinical O +
information O -
, O +
family O +
histories O -
, O +
and O +
blood O +
for O +
DNA O +
analysis O +
were O +
obtained O +
from O +
263 O +
women O +
with O +
breast B-Disease +
cancer L-Disease -
. O -

Conformation O -
- O -
sensitive O +
gel O +
electrophoresis O +
and O +
DNA O +
sequencing O +
were O +
used O +
to O +
identify O +
BRCA1 O +
mutations O -
. O -

RESULTS O -
BRCA1 O +
mutations O +
were O +
identified O +
in O +
16 O +
percent O +
of O +
women O +
with O +
a O +
family O +
history O +
of O +
breast B-Disease +
cancer L-Disease -
. O -

Only O +
7 O +
percent O +
of O +
women O +
from O +
families O +
with O +
a O +
history O +
of O +
breast B-Disease +
cancer L-Disease +
but O +
not O +
ovarian B-Disease +
cancer L-Disease +
had O +
BRCA1 O +
mutations O -
. O -

The O +
rates O +
were O +
higher O +
among O +
women O +
from O +
families O +
with O +
a O +
history O +
of O +
both O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

Among O +
family O +
members O -
, O +
an O +
average O +
age O +
of O +
less O +
than O +
55 O +
years O +
at O +
the O +
diagnosis O +
of O +
breast B-Disease +
cancer L-Disease -
, O +
the O +
presence O +
of O +
ovarian B-Disease +
cancer L-Disease -
, O +
the O +
presence O +
of O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
in O +
the O +
same O +
woman O -
, O +
and O +
Ashkenazi O +
Jewish O +
ancestry O +
were O +
all O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
detecting O +
a O +
BRCA1 O +
mutation O -
. O -

No O +
association O +
was O +
found O +
between O +
the O +
presence O +
of O +
bilateral O +
breast B-Disease +
cancer L-Disease +
or O +
the O +
number O +
of O +
breast B-Disease +
cancers L-Disease +
in O +
a O +
family O +
and O +
the O +
detection O +
of O +
a O +
BRCA1 O +
mutation O -
, O +
or O +
between O +
the O +
position O +
of O +
the O +
mutation O +
in O +
the O +
BRCA1 O +
gene O +
and O +
the O +
presence O +
of O +
ovarian B-Disease +
cancer L-Disease +
in O +
a O +
family O -
. O -

CONCLUSIONS O -
Among O +
women O +
with O +
breast B-Disease +
cancer L-Disease +
and O +
a O +
family O +
history O +
of O +
the O +
disease O -
, O +
the O +
percentage O +
with O +
BRCA1 O +
coding O -
- O -
region O +
mutations O +
is O +
less O +
than O +
the O +
45 O +
percent O +
predicted O +
by O +
genetic O -
- O -
linkage O +
analysis O -
. O -

These O +
results O +
suggest O +
that O +
even O +
in O +
a O +
referral O +
clinic O +
specializing O +
in O +
screening O +
women O +
from O +
high O -
- O -
risk O +
families O -
, O +
the O +
majority O +
of O +
tests O +
for O +
BRCA1 O +
mutations O +
will O +
be O +
negative O +
and O +
therefore O +
uninformative O -
.. O -

Mutations O +
in O +
the O +
arginine O -
- O -
rich O +
protein O +
gene O +
( O -
ARP O -
) O +
in O +
pancreatic B-Disease +
cancer L-Disease -
. O -

The O +
ARP O +
gene O +
encodes O +
a O +
highly O +
conserved O +
arginine O -
- O -
rich O +
protein O +
from O +
chromosomal O +
band O +
3p21 O -
. O -

1 O +
1 O -
. O -

At O +
the O +
cytogenetic O +
level O +
this O +
region O +
is O +
frequently O +
deleted O +
in O +
a O +
variety O +
of O +
different O +
solid B-Disease +
tumors L-Disease -
, O +
although O +
not O +
in O +
pancreatic B-Disease +
cancer L-Disease -
. O -

We O +
have O +
reported O +
the O +
presence O +
of O +
a O +
specific O +
mutation O +
( O -
ATG50 O -
- O -
- O +
> O +
AGG O -
) O +
or O +
deletion O +
of O +
codon O +
50 O +
of O +
the O +
ARP O +
gene O +
in O +
different O +
tumor B-Disease +
types L-Disease +
( O -
Shridhar O +
et O +
al. O -
, O +
1996 O -
, O +
1996a O -
) O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
have O +
observed O +
mutations O +
involving O +
codon O +
50 O +
in O +
11 O +
of O +
37 O +
pancreatic B-Disease +
tumors L-Disease -
. O -

The O +
frequency O +
of O +
codon O +
50 O +
mutation O +
is O +
roughly O +
the O +
same O +
in O +
pancreatic B-Disease +
tumors L-Disease +
as O +
in O +
the O +
other O +
types O +
of O +
tumors U-Disease +
previously O +
examined O -
. O -

In O +
addition O -
, O +
we O +
have O +
detected O +
mutations O +
at O +
codon O +
51 O +
in O +
multiple O +
PCR O +
subclones O +
in O +
two O +
other O +
pancreatic B-Disease +
tumors L-Disease -
. O -

Mutations O +
in O +
the O +
ARP O +
gene O +
are O +
thus O +
commonly O +
observed O +
in O +
pancreatic B-Disease +
cancer L-Disease -
, O +
as O +
well O +
as O +
many O +
other O +
cancers U-Disease -
. O -

Difficulties O +
in O +
the O +
ascertainment O +
of O +
C9 B-Disease +
deficiency L-Disease -
: O +
lessons O +
to O +
be O +
drawn O +
from O +
a O +
compound O +
heterozygote O +
C9-deficient U-Disease +
subject O -
. O -

A O +
group O +
of O +
patients O +
with O +
long O -
- O -
surviving O +
mismatched O +
kidney O +
allografts O +
were O +
investigated O +
for O +
complement O +
function O +
using O +
haemolytic O +
assays O +
in O +
agarose O +
gels O -
. O -

One O +
patient O +
was O +
found O +
to O +
have O +
no O +
alternative O +
pathway O +
activity O +
but O +
a O +
low O +
normal O +
classical O +
pathway O -
. O -

Surprisingly O -
, O +
investigation O +
revealed O +
that O +
the O +
patients O +
complement O +
was O +
normal O +
for O +
all O +
components O +
except O +
C9 O -
, O +
which O +
was O +
functionally O +
absent O -
. O -

The O +
patient O +
was O +
shown O +
to O +
be O +
heterozygous O +
for O +
DNA O +
markers O +
in O +
the O +
C6 O -
, O +
C7 O +
and O +
C9 O +
region O +
of O +
chromosome O +
5 O +
and O +
therefore O +
appears O +
to O +
be O +
a O +
compound O +
heterozygote O +
for O +
two O +
uncharacterized O +
C9 B-Disease +
deficiency L-Disease +
genes O -
. O -

Serological O +
analysis O +
by O +
ELISA O +
revealed O +
that O +
he O +
has O +
trace O +
concentrations O +
of O +
a O +
non O -
- O -
functional O +
C9 O +
molecule O -
. O -

Western O +
blot O +
analysis O +
was O +
not O +
sufficiently O +
sensitive O +
to O +
permit O +
detection O +
of O +
this O +
molecule O -
. O -

We O +
hypothesize O +
that O +
the O +
patient O +
is O +
heterozygous O +
for O +
a O +
complete B-Disease +
deficiency I-Disease +
of I-Disease +
C9 L-Disease +
and O +
for O +
a O +
gene O +
directing O +
hyposynthesis O +
of O +
a O +
defective O +
C9 O -
. O -

We O +
also O +
suggest O +
that O +
C9 B-Disease +
deficiency L-Disease +
may O +
be O +
more O +
common O +
among O +
Caucasians O +
than O +
has O +
been O +
reported O -
.. O -

Screening O +
for O +
ESR O +
mutations O +
in O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
patients O -
. O -

In O +
the O +
present O +
study O -
, O +
leukocyte O +
DNA O +
from O +
143 O +
patients O +
with O +
familial O +
clustering O +
of O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease +
and O +
tumour U-Disease +
DNA O +
from O +
96 O +
breast B-Disease +
carcinomas L-Disease +
were O +
screened O +
for O +
base O +
mutations O +
in O +
the O +
estrogen O +
receptor O +
gene O +
( O -
ESR O -
) O -
. O -

Three O +
patients O +
with O +
a O +
family O +
history O +
of O +
cancer U-Disease +
were O +
carrying O +
a O +
Gly160Cys O +
germline O +
substitution O -
. O -

This O +
alteration O +
was O +
also O +
detected O +
in O +
eight O +
( O -
four O +
females O +
and O +
four O +
males O -
) O +
of O +
729 O +
controls O +
( O -
366 O +
female O -
, O +
363 O +
males O -
) O -
, O +
indicating O +
that O +
the O +
substitution O +
probably O +
represents O +
a O +
polymorphism O -
. O -

However O -
, O +
in O +
the O +
229 O +
female O +
controls O +
in O +
whom O +
family O +
history O +
of O +
cancer U-Disease +
was O +
known O -
, O +
one O +
of O +
two O +
who O +
had O +
a O +
sister O +
with O +
breast B-Disease +
cancer L-Disease +
was O +
carrying O +
the O +
variant O +
allele O -
. O -

Hence O -
, O +
a O +
possible O +
clinical O +
significance O +
of O +
the O +
glycine O +
into O +
cysteine O +
can O -
not O +
be O +
completely O +
ruled O +
out O +
and O +
should O +
be O +
further O +
investigated O -
. O -

Somatic O +
mutations O +
were O +
not O +
detected O +
in O +
any O +
of O +
the O +
tumours U-Disease +
studied O -
, O +
and O +
the O +
present O +
data O +
do O +
not O +
provide O +
support O +
for O +
somatic O +
ESR O +
base O +
mutations O +
as O +
an O +
important O +
mechanism O +
for O +
hormonal O +
therapy O +
resistance O +
in O +
estrogen B-Disease +
receptor I-Disease -
- I-Disease -
positive I-Disease +
breast I-Disease +
carcinomas L-Disease -
.. O -

Molecular O +
bases O +
of O +
C7 B-Disease +
deficiency L-Disease -
: O +
three O +
different O +
defects O -
. O -

The O +
molecular O +
basis O +
of O +
C7 B-Disease +
deficiency L-Disease +
has O +
been O +
investigated O +
in O +
two O +
Irish O +
families O +
and O +
a O +
number O +
of O +
Israeli O +
families O +
of O +
Moroccan O +
Sephardic O +
Jewish O +
origin O -
. O -

Exon O +
PCR O +
and O +
sequencing O +
revealed O +
a O +
heterozygous O +
point O +
mutation O +
at O +
the O +
3 O +
splice O +
acceptor O +
site O +
of O +
intron O +
1 O +
in O +
one O +
Irish O +
family O -
. O -

In O +
the O +
other O +
Irish O +
family O -
, O +
exons O +
7 O +
and O +
8 O +
failed O +
to O +
amplify O +
and O +
they O +
were O +
shown O +
to O +
be O +
deleted O -
. O -

Marker O +
haplotype O +
studies O +
of O +
the O +
C6 O +
and O +
C7 O +
gene O +
region O +
and O +
Southern O +
blots O +
show O +
that O +
the O +
Irish O +
family O +
with O +
the O +
splice O +
defect O +
also O +
segregate O +
for O +
the O +
deletion O -
, O +
which O +
is O +
not O +
easily O +
detected O +
in O +
heterozygotes O -
. O -

The O +
Israeli O +
C7-deficient U-Disease +
cases O +
all O +
share O +
a O +
C7 O +
haplotype O +
and O +
are O +
homozygous O +
for O +
a O +
mis O -
- O -
sense O +
mutation O +
in O +
exon O +
9 O -
. O -

However O -
, O +
one O +
individual O +
is O +
heterozygous O +
for O +
markers O +
at O +
adjacent O +
C6 O +
loci O -
, O +
showing O +
that O +
there O +
has O +
been O +
an O +
intergenic O +
recombination O +
and O +
suggesting O +
that O +
the O +
deficiency O +
mutation O +
is O +
of O +
appreciable O +
antiquity O -
.. O -

Molecular O +
heterogeneity O +
of O +
classical B-Disease +
and I-Disease +
Duarte I-Disease +
galactosemia L-Disease -
: O +
mutation O +
analysis O +
by O +
denaturing O +
gradient O +
gel O +
electrophoresis O -
. O -

Classical B-Disease +
galactosemia L-Disease +
is O +
caused O +
by O +
one O +
common O +
missense O +
mutation O +
( O -
Q188R O -
) O +
and O +
by O +
several O +
rare O +
mutations O +
in O +
the O +
galactose-1-phosphate O +
uridyltransferase O +
( O -
GALT O -
) O +
gene O -
. O -

The O +
most O +
common O +
variant O +
of O +
GALT O -
, O +
the O +
Duarte O +
variant O -
, O +
occurs O +
as O +
two O +
types O -
, O +
Duarte-1 O +
( O -
D-1 O -
) O +
and O +
Duarte-2 O +
( O -
D-2 O -
) O -
, O +
both O +
of O +
which O +
carry O +
the O +
sequence O +
change O +
N314D O -
. O -

D-1 O +
increases O -
, O +
whereas O +
D-2 O +
decreases O +
GALT O +
activity O -
. O -

To O +
study O +
the O +
molecular O +
genetics O +
of O +
classical B-Disease +
and I-Disease +
Duarte I-Disease +
galactosemia L-Disease -
, O +
we O +
analyzed O +
the O +
GALT O +
mutations O +
in O +
30 O +
families O +
with O +
classical B-Disease +
galactosemia L-Disease -
, O +
in O +
10 O +
families O +
with O +
the O +
D-2 O +
variant O +
and O +
in O +
3 O +
individuals O +
carrying O +
the O +
D-1 O +
allele O +
by O +
denaturing O +
gradient O +
gel O +
electrophoresis O +
( O -
DGGE O -
) O -
. O -

DGGE O +
detected O +
59 O +
of O +
the O +
60 O +
classical O +
galactosemia U-Disease +
alleles O -
. O -

Q188R O +
accounted O +
for O +
60 O -
% O -
, O +
K285N O +
accounted O +
for O +
28 O -
% O +
of O +
these O +
alleles O -
. O -

Eight O +
novel O +
candidate O +
galactosemia U-Disease +
mutations O +
were O +
found O -
. O -

On O +
all O +
D-2 O +
alleles O +
N314D O +
occurred O +
in O +
cis O +
with O +
two O +
intronic O +
sequence O +
changes O -
, O +
on O +
the O +
D-1 O +
alleles O +
in O +
cis O +
with O +
a O +
neutral O +
mutation O +
in O +
exon O +
7 O -
. O -

We O +
conclude O +
that O +
the O +
mutations O +
causing O +
galactosemia U-Disease +
are O +
highly O +
heterogeneous O +
and O +
that O +
K285N O +
is O +
a O +
second O +
common O +
galactosemia U-Disease +
mutation O +
in O +
our O +
population O -
.. O -

Isolation O +
of O +
full O -
- O -
length O +
ATM O +
cDNA O +
and O +
correction O +
of O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
cellular O +
phenotype O -
. O -

A O +
gene O +
mutated O +
in O +
the O +
human O +
genetic B-Disease +
disorder L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O -
, O +
ATM O -
, O +
was O +
recently O +
identified O +
by O +
positional O +
cloning O -
. O -

ATM O +
is O +
a O +
member O +
of O +
the O +
phosphatidylinositol-3-kinase O +
superfamily O -
, O +
some O +
of O +
which O +
are O +
protein O +
kinases O +
and O +
appear O +
to O +
have O +
important O +
roles O +
in O +
cell O +
cycle O +
control O +
and O +
radiation O +
signal O +
transduction O -
. O -

We O +
describe O +
herein O -
, O +
to O +
our O +
knowledge O -
, O +
for O +
the O +
first O +
time O -
, O +
the O +
cloning O +
of O +
a O +
full O -
- O -
length O +
cDNA O +
for O +
ATM O +
and O +
correction O +
of O +
multiple O +
aspects O +
of O +
the O +
radio O -
- O -
sensitive O +
phenotype O +
of O +
A B-Disease -
- I-Disease -
T L-Disease +
cells O +
by O +
transfection O +
with O +
this O +
cDNA O -
. O -

Overexpression O +
of O +
ATM O +
cDNA O +
in O +
A B-Disease -
- I-Disease -
T L-Disease +
cells O +
enhanced O +
the O +
survival O +
of O +
these O +
cells O +
in O +
response O +
to O +
radiation O +
exposure O -
, O +
decreased O +
radiation O -
- O -
induced O +
chromosome O +
aberrations O -
, O +
reduced O +
radio O -
- O -
resistant O +
DNA O +
synthesis O -
, O +
and O +
partially O +
corrected O +
defective O +
cell O +
cycle O +
checkpoints O +
and O +
induction O +
of O +
stress O -
- O -
activated O +
protein O +
kinase O -
. O -

This O +
correction O +
of O +
the O +
defects O +
in O +
A B-Disease -
- I-Disease -
T L-Disease +
cells O +
provides O +
further O +
evidence O +
of O +
the O +
multiplicity O +
of O +
effector O +
functions O +
of O +
the O +
ATM O +
protein O +
and O +
suggests O +
possible O +
approaches O +
to O +
gene O +
therapy O -
.. O -

Fusion O +
genes O +
resulting O +
from O +
alternative O +
chromosomal O +
translocations O +
are O +
overexpressed O +
by O +
gene O -
- O -
specific O +
mechanisms O +
in O +
alveolar B-Disease +
rhabdomyosarcoma L-Disease -
. O -

Chromosomal O +
translocations O +
identified O +
in O +
hematopoietic B-Disease +
and I-Disease +
solid I-Disease +
tumors L-Disease +
result O +
in O +
deregulated O +
expression O +
of O +
protooncogenes O +
or O +
creation O +
of O +
chimeric O +
proteins O +
with O +
tumorigenic O +
potential O -
. O -

In O +
the O +
pediatric O +
solid B-Disease +
tumor L-Disease +
alveolar B-Disease +
rhabdomyosarcoma L-Disease -
, O +
a O +
consistent O +
t O +
( O -
2 O -
; O +
13 O -
) O +
( O -
q35 O -
; O +
q14 O -
) O +
or O +
variant O +
t O +
( O -
1 O -
; O +
13 O -
) O +
( O -
p36 O -
; O +
q14 O -
) O +
translocation O +
generates O +
PAX3-FKHR O +
or O +
PAX7-FKHR O +
fusion O +
proteins O -
, O +
respectively O -
. O -

In O +
this O +
report O -
, O +
we O +
demonstrate O +
that O +
in O +
addition O +
to O +
functional O +
alterations O +
these O +
translocations O +
are O +
associated O +
with O +
fusion O +
product O +
overexpression O -
. O -

Furthermore O -
, O +
PAX3-FKHR O +
and O +
PAX7-FKHR O +
overexpression O +
occurs O +
by O +
distinct O +
mechanisms O -
. O -

Transcription O +
of O +
PAX3-FKHR O +
is O +
increased O +
relative O +
to O +
wild O -
- O -
type O +
PAX3 O +
by O +
a O +
copy O +
number O -
- O -
independent O +
process O -
. O -

In O +
contrast O -
, O +
PAX7-FKHR O +
overexpression O +
results O +
from O +
fusion O +
gene O +
amplification O -
. O -

Thus O -
, O +
gene O -
- O -
specific O +
mechanisms O +
were O +
selected O +
to O +
overexpress O +
PAX3-FKHR O +
and O +
PAX7-FKHR O +
in O +
alveolar B-Disease +
rhabdomyosarcoma L-Disease -
, O +
presumably O +
due O +
to O +
differences O +
in O +
regulation O +
between O +
the O +
wild O -
- O -
type O +
loci O -
. O -

We O +
postulate O +
that O +
these O +
overexpression O +
mechanisms O +
ensure O +
a O +
critical O +
level O +
of O +
gene O +
product O +
for O +
the O +
oncogenic O +
effects O +
of O +
these O +
fusions O -
.. O -

atm O +
and O +
p53 O +
cooperate O +
in O +
apoptosis O +
and O +
suppression O +
of O +
tumorigenesis O -
, O +
but O +
not O +
in O +
resistance O +
to O +
acute B-Disease +
radiation I-Disease +
toxicity L-Disease -
. O -

Mutations O +
in O +
atm O +
and O +
p53 O +
cause O +
the O +
human O +
cancer B-Disease -
- I-Disease -
associated I-Disease +
diseases L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
and O +
Li B-Disease -
- I-Disease -
Fraumeni I-Disease +
syndrome L-Disease -
, O +
respectively O -
. O -

The O +
two O +
genes O +
are O +
believed O +
to O +
interact O +
in O +
a O +
number O +
of O +
pathways O -
, O +
including O +
regulation O +
of O +
DNA O +
damage O -
- O -
induced O +
cell O -
- O -
cycle O +
checkpoints O -
, O +
apoptosis O +
and O +
radiation O +
sensitivity O -
, O +
and O +
cellular O +
proliferation O -
. O -

Atm O -
- O -
null O +
mice O -
, O +
as O +
well O +
as O +
those O +
null O +
for O +
p53 O -
, O +
develop O +
mainly O +
T B-Disease -
- I-Disease -
cell I-Disease +
lymphomas L-Disease -
, O +
supporting O +
the O +
view O +
that O +
these O +
genes O +
have O +
similar O +
roles O +
in O +
thymocyte O +
development O -
. O -

To O +
study O +
the O +
interactions O +
of O +
these O +
two O +
genes O +
on O +
an O +
organismal O +
level O -
, O +
we O +
bred O +
mice O +
heterozygous O +
for O +
null O +
alleles O +
of O +
both O +
atm O +
and O +
p53 O +
to O +
produce O +
all O +
genotypic O +
combinations O -
. O -

Mice O +
doubly O +
null O +
for O +
atm O +
and O +
p53 O +
exhibited O +
a O +
dramatic O +
acceleration O +
of O +
tumour U-Disease +
formation O +
relative O +
to O +
singly O +
null O +
mice O -
, O +
indicating O +
that O +
both O +
genes O +
collaborate O +
in O +
a O +
significant O +
manner O +
to O +
prevent O +
tumorigenesis O -
. O -

With O +
respect O +
to O +
their O +
roles O +
in O +
apoptosis O -
, O +
loss O +
of O +
atm O +
rendered O +
thymocytes O +
only O +
partly O +
resistant O +
to O +
irradiation O -
- O -
induced O +
apoptosis O -
, O +
whereas O +
additional O +
loss O +
of O +
p53 O +
engendered O +
complete O +
resistance O -
. O -

This O +
implies O +
that O +
the O +
irradiation O -
- O -
induced O +
atm O +
and O +
p53 O +
apoptotic O +
pathways O +
are O +
not O +
completely O +
congruent O -
. O -

Finally O -
- O -
and O +
in O +
contrast O +
to O +
prior O +
predictions O -
- O -
atm O +
and O +
p53 O +
do O +
not O +
appear O +
to O +
interact O +
in O +
acute B-Disease +
radiation I-Disease +
toxicity L-Disease -
, O +
suggesting O +
a O +
separate O +
atm O +
effector O +
pathway O +
for O +
this O +
DNA O +
damage O +
response O +
and O +
having O +
implications O +
for O +
the O +
prognosis O +
and O +
treatment O +
of O +
human O +
tumours U-Disease -
.. O -

Trinucleotide O +
repeat O +
expansion O +
at O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
locus O +
reduces O +
expression O +
of O +
DMAHP O -
. O -

Myotonic B-Disease +
dystrophy L-Disease -
, O +
or O +
dystrophia B-Disease +
myotonica L-Disease +
( O -
DM U-Disease -
) O -
, O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
multisystem I-Disease +
disorder L-Disease +
caused O +
by O +
the O +
expansion O +
of O +
a O +
CTG O +
trinucleotide O +
repeat O +
in O +
the O +
3 O +
untranslated O +
region O +
of O +
the O +
DMPK O +
protein O +
kinase O +
gene O +
on O +
chromosome O +
19q13 O -
. O -

3 O +
( O -
refs O +
1 O -
- O -
3 O -
) O -
. O -

Although O +
the O +
DM U-Disease +
mutation O +
was O +
identified O +
more O +
than O +
five O +
years O +
ago O -
, O +
the O +
pathogenic O +
mechanisms O +
underlying O +
this O +
most O +
prevalent O +
form O +
of O +
hereditary O +
adult O +
neuromuscular B-Disease +
disease L-Disease +
remain O +
elusive O -
. O -

Previous O +
work O +
from O +
our O +
laboratory O +
demonstrated O +
that O +
a O +
DNase O +
l O -
- O -
hypersensitive O +
site O +
located O +
adjacent O +
to O +
the O +
repeats O +
on O +
the O +
wild O -
- O -
type O +
allele O +
is O +
eliminated O +
by O +
repeat O +
expansion O -
, O +
indicating O +
that O +
large O +
CTG O -
- O -
repeat O +
arrays O +
may O +
be O +
associated O +
with O +
a O +
local O +
chromatin O +
environment O +
that O +
represses O +
gene O +
expression O -
. O -

Here O +
we O +
report O +
that O +
the O +
hypersensitive O +
site O +
contains O +
an O +
enhancer O +
element O +
that O +
regulates O +
transcription O +
of O +
the O +
adjacent O +
DMAHP O +
homeobox O +
gene O -
. O -

Analysis O +
of O +
DMAHP O +
expression O +
in O +
the O +
cells O +
of O +
DM U-Disease +
patients O +
with O +
loss O +
of O +
the O +
hypersensitive O +
site O +
revealed O +
a O +
two- O +
to O +
fourfold O +
reduction O +
in O +
steady O -
- O -
state O +
DMAHP O +
transcript O +
levels O +
relative O +
to O +
wild O -
- O -
type O +
controls O -
. O -

Allele O -
- O -
specific O +
analysis O +
of O +
DMAHP O +
expression O +
showed O +
that O +
steady O -
- O -
state O +
transcript O +
levels O +
from O +
the O +
expanded O +
allele O +
were O +
greatly O +
reduced O +
in O +
comparison O +
to O +
those O +
from O +
the O +
wild O -
- O -
type O +
allele O -
. O -

Together O -
, O +
these O +
results O +
demonstrate O +
that O +
CTG O -
- O -
repeat O +
expansions O +
can O +
suppress O +
local O +
gene O +
expression O +
and O +
implicate O +
DMAHP O +
in O +
DM U-Disease +
pathogenesis O -
. O -

Constitutively O +
methylated O +
CpG O +
dinucleotides O +
as O +
mutation O +
hot O +
spots O +
in O +
the O +
retinoblastoma U-Disease +
gene O +
( O -
RB1 O -
) O -
. O -

A O +
wide O +
spectrum O +
of O +
mutations O -
, O +
ranging O +
from O +
point O +
mutations O +
to O +
large O +
deletions O -
, O +
have O +
been O +
described O +
in O +
the O +
retinoblastoma U-Disease +
gene O +
( O -
RB1 O -
) O -
. O -

Mutations O +
have O +
been O +
found O +
throughout O +
the O +
gene O -
; O +
however O -
, O +
these O +
genetic O +
alterations O +
do O +
not O +
appear O +
to O +
be O +
homogeneously O +
distributed O -
. O -

In O +
particular O -
, O +
a O +
significant O +
proportion O +
of O +
disease O -
- O -
causing O +
mutations O +
results O +
in O +
the O +
premature O +
termination O +
of O +
protein O +
synthesis O -
, O +
and O +
the O +
majority O +
of O +
these O +
mutations O +
occur O +
as O +
C-- O +
> O +
T O +
transitions O +
at O +
CpG O +
dinucleotides O +
( O -
CpGs O -
) O -
. O -

Such O +
recurrent O +
CpG O +
mutations O -
, O +
including O +
those O +
found O +
in O +
RB1 O -
, O +
are O +
likely O +
the O +
result O +
of O +
the O +
deamination O +
of O +
5-methylcytosine O +
within O +
these O +
CpGs O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
used O +
the O +
sodiumbisulfite O +
conversion O +
method O +
to O +
detect O +
cytosine O +
methylation O +
in O +
representative O +
exons O +
of O +
RB1 O -
. O -

We O +
analyzed O +
DNA O +
from O +
a O +
variety O +
of O +
tissues O +
and O +
specifically O +
targeted O +
CGA O +
codons O +
in O +
RB1 O -
, O +
where O +
recurrent O +
premature O +
termination O +
mutations O +
have O +
been O +
reported O -
. O -

We O +
found O +
that O +
DNA O +
methylation O +
within O +
RB1 O +
exons O +
8 O -
, O +
14 O -
, O +
25 O -
, O +
and O +
27 O +
appeared O +
to O +
be O +
restricted O +
to O +
CpGs O -
, O +
including O +
six O +
CGA O +
codons O -
. O -

Other O +
codons O +
containing O +
methylated O +
cytosines O +
have O +
not O +
been O +
reported O +
to O +
be O +
mutated O -
. O -

Therefore O -
, O +
disease O -
- O -
causing O +
mutations O +
at O +
CpGs O +
in O +
RB1 O +
appear O +
to O +
be O +
determined O +
by O +
several O +
factors O -
, O +
including O +
the O +
constitutive O +
presence O +
of O +
DNA O +
methylation O +
at O +
cytosines O +
within O +
CpGs O -
, O +
the O +
specific O +
codon O +
within O +
which O +
the O +
methylated O +
cytosine O +
is O +
located O -
, O +
and O +
the O +
particular O +
region O +
of O +
the O +
gene O +
within O +
which O +
that O +
codon O +
resides O -
.. O -

The O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
tumor L-Disease +
suppressor O +
gene O +
product O +
interacts O +
with O +
Sp1 O +
to O +
repress O +
vascular O +
endothelial O +
growth O +
factor O +
promoter O +
activity O -
. O -

The O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
tumor L-Disease +
suppressor O +
gene O +
( O -
VHL O -
) O +
has O +
a O +
critical O +
role O +
in O +
the O +
pathogenesis O +
of O +
clear B-Disease -
- I-Disease -
cell I-Disease +
renal I-Disease +
cell I-Disease +
carcinoma L-Disease +
( O -
RCC U-Disease -
) O -
, O +
as O +
VHL O +
mutations O +
have O +
been O +
found O +
in O +
both O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
disease I-Disease -
- I-Disease -
associated I-Disease +
and I-Disease +
sporadic I-Disease +
RCCs L-Disease -
. O -

Recent O +
studies O +
suggest O +
that O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
mRNA O +
is O +
upregulated O +
in O +
RCC- B-Disease +
and I-Disease +
von I-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
disease I-Disease -
- I-Disease -
associated I-Disease +
tumors L-Disease -
. O -

We O +
have O +
therefore O +
assessed O +
the O +
effect O +
of O +
the O +
VHL O +
gene O +
product O +
on O +
VEGF O +
expression O -
. O -

VEGF O +
promoter O -
- O -
luciferase O +
constructs O +
were O +
transiently O +
cotransfected O +
with O +
a O +
wild O -
- O -
type O +
VHL O +
( O -
wt O -
- O -
VHL O -
) O +
vector O +
in O +
several O +
cell O +
lines O -
, O +
including O +
293 O +
embryonic O +
kidney O +
and O +
RCC U-Disease +
cell O +
lines O -
. O -

wt O -
- O -
VHL O +
protein O +
inhibited O +
VEGF O +
promoter O +
activity O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
up O +
to O +
5- O +
to O +
10-fold O -
. O -

Deletion O +
analysis O +
defined O +
a O +
144-bp O +
region O +
of O +
the O +
VEGF O +
promoter O +
necessary O +
for O +
VHL O +
repression O -
. O -

This O +
VHL O -
- O -
responsive O +
element O +
is O +
GC O +
rich O +
and O +
specifically O +
binds O +
the O +
transcription O +
factor O +
Sp1 O +
in O +
crude O +
nuclear O +
extracts O -
. O -

In O +
Drosophila O +
cells O -
, O +
cotransfected O +
VHL O +
represses O +
Sp1-mediated O +
activation O +
but O +
not O +
basal O +
activity O +
of O +
the O +
VEGF O +
promoter O -
. O -

We O +
next O +
demonstrated O +
in O +
coimmunoprecipitates O +
that O +
VHL O +
and O +
Sp1 O +
were O +
part O +
of O +
the O +
same O +
complex O +
and O -
, O +
by O +
using O +
a O +
glutathione O -
- O -
S O -
- O -
transferase O -
- O -
VHL O +
fusion O +
protein O +
and O +
purified O +
Sp1 O -
, O +
that O +
VHL O +
and O +
Sp1 O +
directly O +
interact O -
. O -

Furthermore O -
, O +
endogenous O +
VEGF O +
mRNA O +
levels O +
were O +
suppressed O +
in O +
permanent O +
RCC U-Disease +
cell O +
lines O +
expressing O +
wt O -
- O -
VHL O -
, O +
and O +
nuclear O +
run O -
- O -
on O +
studies O +
indicated O +
that O +
VHL O +
regulation O +
of O +
VEGF O +
occurs O +
at O +
least O +
partly O +
at O +
the O +
transcriptional O +
level O -
. O -

These O +
observations O +
support O +
a O +
new O +
mechanism O +
for O +
VHL O -
- O -
mediated O +
transcriptional O +
repression O +
via O +
a O +
direct O +
inhibitory O +
action O +
on O +
Sp1 O +
and O +
suggest O +
that O +
loss O +
of O +
Sp1 O +
inhibition O +
may O +
be O +
important O +
in O +
the O +
pathogenesis O +
of O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
disease L-Disease +
and O +
RCC U-Disease -
.. O -

Adult B-Disease +
onset I-Disease +
globoid I-Disease +
cell I-Disease +
leukodystrophy L-Disease +
( O -
Krabbe B-Disease +
disease L-Disease -
) O -
: O +
analysis O +
of O +
galactosylceramidase O +
cDNA O +
from O +
four O +
Japanese O +
patients O -
. O -

We O +
examined O +
galactosylceramidase O +
( O -
GALC O -
) O +
cDNA O +
in O +
four O +
Japanese O +
patients O +
with O +
adult B-Disease +
onset I-Disease +
globoid I-Disease +
cell I-Disease +
leukodystrophy L-Disease +
( O -
Krabbe B-Disease +
disease L-Disease -
; O +
AO B-Disease -
- I-Disease -
GLD L-Disease -
) O +
by O +
polymerase O +
chain O +
reaction O -
/ O -
single O -
- O -
strand O +
conformation O +
polymorphism O +
( O -
PCR O -
- O -
SSCP O -
) O +
analysis O -
, O +
subsequent O +
sequence O +
determination O -
, O +
and O +
restriction O +
enzyme O +
digestion O +
of O +
PCR O +
products O -
, O +
initial O +
symptoms O +
were O +
the O +
onset O +
of O +
slowly O +
progressive O +
spastic B-Disease +
paraplegia L-Disease +
from O +
the O +
middle O +
of O +
the O +
second O +
decade O -
, O +
and O +
all O +
patients O +
had O +
diminished B-Disease +
GALC I-Disease +
activity L-Disease +
in O +
their O +
leukocytes O -
. O -

We O +
identified O +
three O +
missense O +
mutations O +
( O -
I66 O -
M O -
, O +
G270D O -
, O +
L618S O -
) O +
and O +
one O +
exon-6 O +
skipping O +
( O -
535 O -
- O -
573del O -
) O -
. O -

Two O +
of O +
the O +
patients O +
had O +
only O +
the O +
I66 O -
M O +
mutant O +
mRNA O -
, O +
and O +
one O +
only O +
the O +
G27OD O +
mutant O +
mRNA O -
. O -

The O +
fourth O +
patient O +
carried O +
a O +
compound O +
heterozygous O +
mutation O +
of O +
535 O -
- O -
573del O +
and O +
L618S O -
. O -

To O +
determine O +
the O +
enzymatic O +
activities O +
produced O +
by O +
these O +
mutations O -
, O +
we O +
constructed O +
mutated O +
GALC O +
cDNAs O +
and O +
expressed O +
them O +
in O +
COS-1 O +
cells O -
. O -

Three O +
mutations O -
, O +
viz O -
. O -
, O +
G270D O -
, O +
L618S O -
, O +
and O +
exon-6 O +
skipping O +
( O -
535 O -
- O -
573del O -
) O -
, O +
produced O +
diminished B-Disease +
GALC I-Disease +
activity L-Disease +
as O +
expected O -
. O -

The O +
I66 O -
M O +
mutation O +
in O +
the O +
wild O -
- O -
type O +
GALC O +
cDNA O +
( O -
I289 O -
) O +
had O +
normal O +
activity O -
, O +
but O +
when O +
this O +
mutation O +
and O +
the O +
V289 O +
polymorphism O +
were O +
introduced O +
into O +
the O +
same O +
allele O -
, O +
it O +
had O +
decreased O +
activity O -
. O -

Thus O -
, O +
the O +
combination O +
of O +
a O +
unique O +
mutation O +
and O +
polymorphism O +
causes O +
conformational O +
change O +
in O +
the O +
GALC O +
enzyme O -
, O +
resulting O +
in O +
low O +
enzymatic O +
activity O -
. O -

AO B-Disease -
- I-Disease -
GLD L-Disease +
mutations O -
, O +
including O +
those O +
found O +
here O -
, O +
are O +
located O +
in O +
the O +
N O -
- O -
terminus O +
( O -
I66 O -
M O -
, O +
G270D O -
, O +
535 O -
- O -
573del O -
) O +
or O +
C O -
- O -
terminus O +
( O -
L618S O -
) O +
of O +
the O +
GALC O +
enzyme O -
, O +
whereas O +
the O +
reported O +
mutations O +
in O +
the O +
infantile O +
form O +
( O -
IF B-Disease -
- I-Disease -
GLD L-Disease -
) O +
are O +
in O +
the O +
central O +
domain O -
. O -

This O +
difference O +
in O +
mutation O +
sites O +
may O +
affect O +
the O +
clinical O +
features O +
of O +
GLD U-Disease -
. O -

Clustering O +
of O +
missense O +
mutations O +
in O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
gene O +
in O +
a O +
sporadic B-Disease +
T I-Disease -
- I-Disease -
cell I-Disease +
leukaemia L-Disease -
. O -

Ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
is O +
a O +
recessive B-Disease +
multi I-Disease -
- I-Disease -
system I-Disease +
disorder L-Disease +
caused O +
by O +
mutations O +
in O +
the O +
ATM O +
gene O +
at O +
11q22-q23 O +
( O -
ref O -
. O -

3 O -
) O -
. O -

The O +
risk O +
of O +
cancer U-Disease -
, O +
especially O +
lymphoid B-Disease +
neoplasias L-Disease -
, O +
is O +
substantially O +
elevated O +
in O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O +
and O +
has O +
long O +
been O +
associated O +
with O +
chromosomal O +
instability O -
. O -

By O +
analysing O +
tumour U-Disease +
DNA O +
from O +
patients O +
with O +
sporadic B-Disease +
T I-Disease -
- I-Disease -
cell I-Disease +
prolymphocytic I-Disease +
leukaemia L-Disease +
( O -
T B-Disease -
- I-Disease -
PLL L-Disease -
) O -
, O +
a O +
rare O +
clonal B-Disease +
malignancy L-Disease +
with O +
similarities O +
to O +
a O +
mature B-Disease +
T I-Disease -
- I-Disease -
cell I-Disease +
leukaemia L-Disease +
seen O +
in O +
A B-Disease -
- I-Disease -
T L-Disease -
, O +
we O +
demonstrate O +
a O +
high O +
frequency O +
of O +
ATM O +
mutations O +
in O +
T B-Disease -
- I-Disease -
PLL L-Disease -
. O -

In O +
marked O +
contrast O +
to O +
the O +
ATM O +
mutation O +
pattern O +
in O +
A B-Disease -
- I-Disease -
T L-Disease -
, O +
the O +
most O +
frequent O +
nucleotide O +
changes O +
in O +
this O +
leukaemia U-Disease +
were O +
missense O +
mutations O -
. O -

These O +
clustered O +
in O +
the O +
region O +
corresponding O +
to O +
the O +
kinase O +
domain O -
, O +
which O +
is O +
highly O +
conserved O +
in O +
ATM O -
- O -
related O +
proteins O +
in O +
mouse O -
, O +
yeast O +
and O +
Drosophila O -
. O -

The O +
resulting O +
amino O -
- O -
acid O +
substitutions O +
are O +
predicted O +
to O +
interfere O +
with O +
ATP O +
binding O +
or O +
substrate O +
recognition O -
. O -

Two O +
of O +
seventeen O +
mutated O +
T B-Disease -
- I-Disease -
PLL L-Disease +
samples O +
had O +
a O +
previously O +
reported O +
A B-Disease -
- I-Disease -
T L-Disease +
allele O -
. O -

In O +
contrast O -
, O +
no O +
mutations O +
were O +
detected O +
in O +
the O +
p53 O +
gene O -
, O +
suggesting O +
that O +
this O +
tumour U-Disease +
suppressor O +
is O +
not O +
frequently O +
altered O +
in O +
this O +
leukaemia U-Disease -
. O -

Occasional O +
missense O +
mutations O +
in O +
ATM O +
were O +
also O +
found O +
in O +
tumour U-Disease +
DNA O +
from O +
patients O +
with O +
B B-Disease -
- I-Disease -
cell I-Disease +
non I-Disease -
- I-Disease -
Hodgkins I-Disease +
lymphomas L-Disease +
( O -
B B-Disease -
- I-Disease -
NHL L-Disease -
) O +
and O +
a O +
B B-Disease -
- I-Disease -
NHL L-Disease +
cell O +
line O -
. O -

The O +
evidence O +
of O +
a O +
significant O +
proportion O +
of O +
loss O -
- O -
of O -
- O -
function O +
mutations O +
and O +
a O +
complete O +
absence O +
of O +
the O +
normal O +
copy O +
of O +
ATM O +
in O +
the O +
majority O +
of O +
mutated O +
tumours U-Disease +
establishes O +
somatic O +
inactivation O +
of O +
this O +
gene O +
in O +
the O +
pathogenesis O +
of O +
sporadic B-Disease +
T I-Disease -
- I-Disease -
PLL L-Disease +
and O +
suggests O +
that O +
ATM O +
acts O +
as O +
a O +
tumour U-Disease +
suppressor O -
. O -

As O +
constitutional O +
DNA O +
was O +
not O +
available O -
, O +
a O +
putative O +
hereditary O +
predisposition O +
to O +
T B-Disease -
- I-Disease -
PLL L-Disease +
will O +
require O +
further O +
investigation O -
.. O -

Myotonic B-Disease +
dystrophy L-Disease +
protein O +
kinase O +
is O +
involved O +
in O +
the O +
modulation O +
of O +
the O +
Ca2 O -
+ O +
homeostasis O +
in O +
skeletal O +
muscle O +
cells O -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O -
, O +
the O +
most O +
prevalent O +
muscular B-Disease +
disorder L-Disease +
in O +
adults O -
, O +
is O +
caused O +
by O +
( O -
CTG O -
) O +
n O -
- O -
repeat O +
expansion O +
in O +
a O +
gene O +
encoding O +
a O +
protein O +
kinase O +
( O -
DM U-Disease +
protein O +
kinase O -
; O +
DMPK O -
) O +
and O +
involves O +
changes O +
in O +
cytoarchitecture O +
and O +
ion O +
homeostasis O -
. O -

To O +
obtain O +
clues O +
to O +
the O +
normal O +
biological O +
role O +
of O +
DMPK O +
in O +
cellular O +
ion O +
homeostasis O -
, O +
we O +
have O +
compared O +
the O +
resting O +
[ O -
Ca2 O +
+ O -
] O +
i O -
, O +
the O +
amplitude O +
and O +
shape O +
of O +
depolarization O -
- O -
induced O +
Ca2 O +
+ O +
transients O -
, O +
and O +
the O +
content O +
of O +
ATP O -
- O -
driven O +
ion O +
pumps O +
in O +
cultured O +
skeletal O +
muscle O +
cells O +
of O +
wild O -
- O -
type O +
and O +
DMPK O +
[ O -
- O -
/ O -
- O -
] O +
knockout O +
mice O -
. O -

In O +
vitro O -
- O -
differentiated O +
DMPK O +
[ O -
- O -
/ O -
- O -
] O +
myotubes O +
exhibit O +
a O +
higher O +
resting O +
[ O -
Ca2 O +
+ O -
] O +
i O +
than O +
do O +
wild O -
- O -
type O +
myotubes O +
because O +
of O +
an O +
altered O +
open O +
probability O +
of O +
voltage O -
- O -
dependent O +
l O -
- O -
type O +
Ca2 O +
+ O +
and O +
Na O +
+ O +
channels O -
. O -

The O +
mutant O +
myotubes O +
exhibit O +
smaller O +
and O +
slower O +
Ca2 O +
+ O +
responses O +
upon O +
triggering O +
by O +
acetylcholine O +
or O +
high O +
external O +
K O +
+ O -
. O -

In O +
addition O -
, O +
we O +
observed O +
that O +
these O +
Ca2 O +
+ O +
transients O +
partially O +
result O +
from O +
an O +
influx O +
of O +
extracellular O +
Ca2 O +
+ O +
through O +
the O +
l O -
- O -
type O +
Ca2 O +
+ O +
channel O -
. O -

Neither O +
the O +
content O +
nor O +
the O +
activity O +
of O +
Na O +
+ O -
/K O +
+ O +
ATPase O +
and O +
sarcoplasmic O +
reticulum O +
Ca2 O +
+ O +
-ATPase O +
are O +
affected O +
by O +
DMPK O +
absence O -
. O -

In O +
conclusion O -
, O +
our O +
data O +
suggest O +
that O +
DMPK O +
is O +
involved O +
in O +
modulating O +
the O +
initial O +
events O +
of O +
excitation O -
- O -
contraction O +
coupling O +
in O +
skeletal O +
muscle O -
.. O -

Constitutional O +
RB1-gene O +
mutations O +
in O +
patients O +
with O +
isolated O +
unilateral B-Disease +
retinoblastoma L-Disease -
. O -

In O +
most O +
patients O +
with O +
isolated O +
unilateral B-Disease +
retinoblastoma L-Disease -
, O +
tumor U-Disease +
development O +
is O +
initiated O +
by O +
somatic O +
inactivation O +
of O +
both O +
alleles O +
of O +
the O +
RB1 O +
gene O -
. O -

However O -
, O +
some O +
of O +
these O +
patients O +
can O +
transmit O +
retinoblastoma U-Disease +
predisposition O +
to O +
their O +
offspring O -
. O -

To O +
determine O +
the O +
frequency O +
and O +
nature O +
of O +
constitutional O +
RB1-gene O +
mutations O +
in O +
patients O +
with O +
isolated O +
unilateral B-Disease +
retinoblastoma L-Disease -
, O +
we O +
analyzed O +
DNA O +
from O +
peripheral O +
blood O +
and O +
from O +
tumor U-Disease +
tissue O -
. O -

The O +
analysis O +
of O +
tumors U-Disease +
from O +
54 O +
( O -
71 O -
% O -
) O +
of O +
76 O +
informative O +
patients O +
showed O +
loss O +
of O +
constitutional O +
heterozygosity O +
( O -
LOH O -
) O +
at O +
intragenic O +
loci O -
. O -

Three O +
of O +
13 O +
uninformative O +
patients O +
had O +
constitutional O +
deletions O -
. O -

For O +
39 O +
randomly O +
selected O +
tumors U-Disease -
, O +
SSCP O -
, O +
hetero O -
- O -
duplex O +
analysis O -
, O +
sequencing O -
, O +
and O +
Southern O +
blot O +
analysis O +
were O +
used O +
to O +
identify O +
mutations O -
. O -

Mutations O +
were O +
detected O +
in O +
21 O +
( O -
91 O -
% O -
) O +
of O +
23 O +
tumors U-Disease +
with O +
LOH O -
. O -

In O +
6 O +
( O -
38 O -
% O -
) O +
of O +
16 O +
tumors U-Disease +
without O +
LOH O -
, O +
one O +
mutation O +
was O +
detected O -
, O +
and O +
in O +
9 O +
( O -
56 O -
% O -
) O +
of O +
the O +
tumors U-Disease +
without O +
LOH O -
, O +
both O +
mutations O +
were O +
found O -
. O -

Thus O -
, O +
a O +
total O +
of O +
45 O +
mutations O +
were O +
identified O +
in O +
tumors U-Disease +
of O +
36 O +
patients O -
. O -

Thirty O -
- O -
nine O +
of O +
the O +
mutations O -
- O -
including O +
34 O +
small O +
mutations O -
, O +
2 O +
large O +
structural O +
alterations O -
, O +
and O +
hypermethylation O +
in O +
3 O +
tumors O -
- O -
were O +
not O +
detected O +
in O +
the O +
corresponding O +
peripheral O +
blood O +
DNA O -
. O -

In O +
6 O +
( O -
17 O -
% O -
) O +
of O +
the O +
36 O +
patients O -
, O +
a O +
mutation O +
was O +
detected O +
in O +
constitutional O +
DNA O -
, O +
and O +
1 O +
of O +
these O +
mutations O +
is O +
known O +
to O +
be O +
associated O +
with O +
reduced O +
expressivity O -
. O -

The O +
presence O +
of O +
a O +
constitutional O +
mutation O +
was O +
not O +
associated O +
with O +
an O +
early O +
age O +
at O +
treatment O -
. O -

In O +
1 O +
patient O -
, O +
somatic O +
mosaicism O +
was O +
demonstrated O +
by O +
molecular O +
analysis O +
of O +
DNA O +
and O +
RNA O +
from O +
peripheral O +
blood O -
. O -

In O +
2 O +
patients O +
without O +
a O +
detectable O +
mutation O +
in O +
peripheral O +
blood O -
, O +
mosaicism O +
was O +
suggested O +
because O +
1 O +
of O +
the O +
patients O +
showed O +
multifocal O +
tumors U-Disease +
and O +
the O +
other O +
later O +
developed O +
bilateral B-Disease +
retinoblastoma L-Disease -
. O -

In O +
conclusion O -
, O +
our O +
results O +
emphasize O +
that O +
the O +
manifestation O +
and O +
transmissibility O +
of O +
retinoblastoma U-Disease +
depend O +
on O +
the O +
nature O +
of O +
the O +
first O +
mutation O -
, O +
its O +
time O +
in O +
development O -
, O +
and O +
the O +
number O +
and O +
types O +
of O +
cells O +
that O +
are O +
affected O -
.. O -

Hereditary B-Disease +
deficiency I-Disease +
of I-Disease +
the I-Disease +
fifth I-Disease +
component I-Disease +
of I-Disease +
complement L-Disease +
in O +
man O -
. O -

I. O +
Clinical O -
, O +
immunochemical O -
, O +
and O +
family O +
studies O -
. O -

The O +
first O +
recognized O +
human O +
kindred O +
with O +
hereditary B-Disease +
deficiency I-Disease +
of I-Disease +
the I-Disease +
fifth I-Disease +
component I-Disease +
of I-Disease +
complement L-Disease +
( O -
C5 O -
) O +
is O +
described O -
. O -

The O +
proband O -
, O +
a O +
20-year O -
- O -
old O +
black O +
female O +
with O +
systemic B-Disease +
lupus I-Disease +
erythematosus L-Disease +
since O +
age O +
11 O -
, O +
lacked O +
serum O +
hemolytic O +
complement O +
activity O -
, O +
even O +
during O +
remission O -
. O -

C5 O +
was O +
undetectable O +
in O +
her O +
serum O +
by O +
both O +
immunodiffusion O +
and O +
hemolytic O +
assays O -
. O -

Other O +
complement O +
components O +
were O +
normal O +
during O +
remission O +
of O +
lupus O -
, O +
but O +
C1 O -
, O +
C4 O -
, O +
C2 O -
, O +
and O +
C3 O +
levels O +
fell O +
during O +
exacerbations O -
. O -

A O +
younger O +
half O -
- O -
sister O -
, O +
who O +
had O +
no O +
underlying O +
disease O -
, O +
was O +
also O +
found O +
to O +
lack O +
immunochemically O +
detectable O +
C5 O -
. O -

By O +
hemolytic O +
assay O -
, O +
she O +
exhibited O +
1 O -
- O -
2 O -
% O +
of O +
the O +
normal O +
serum O +
C5 O +
level O +
and O +
normal O +
concentrations O +
of O +
other O +
complement O +
components O -
. O -

C5 O +
levels O +
of O +
other O +
family O +
members O +
were O +
either O +
normal O +
or O +
approximately O +
half O -
- O -
normal O -
, O +
consistent O +
with O +
autosomal O +
codominant O +
inheritance O +
of O +
the O +
gene O +
determining O +
C5 B-Disease +
deficiency L-Disease -
. O -

Normal O +
hemolytic O +
titers O +
were O +
restored O +
to O +
both O +
homozygous O +
C5-deficient U-Disease +
( O -
C5D U-Disease -
) O +
sera O +
by O +
addition O +
of O +
highly O +
purified O +
human O +
C5 O -
. O -

In O +
specific O +
C5 O +
titrations O -
, O +
however O -
, O +
it O +
was O +
noted O +
that O +
when O +
limited O +
amounts O +
of O +
C5 O +
were O +
assayed O +
in O +
the O +
presence O +
of O +
low O +
dilutions O +
of O +
either O +
C5D U-Disease +
serum O -
, O +
curving O +
rather O +
than O +
linear O +
dose O -
- O -
response O +
plots O +
were O +
consistently O +
obtained O -
, O +
suggesting O +
some O +
inhibitory O +
effect O -
. O -

Further O +
studies O +
suggested O +
that O +
low O +
dilutions O +
of O +
C5D U-Disease +
serum O +
contain O +
a O +
factor O +
( O -
or O +
factors O -
) O +
interfering O +
at O +
some O +
step O +
in O +
the O +
hemolytic O +
assay O +
of O +
C5 O -
, O +
rather O +
than O +
a O +
true O +
C5 O +
inhibitor O +
or O +
inactivator O -
. O -

Of O +
clinical O +
interest O +
are O +
( O -
a O -
) O +
the O +
documentation O +
of O +
membranous O +
glomerulonephritis U-Disease -
, O +
vasculitis U-Disease -
, O +
and O +
arthritis U-Disease +
in O +
an O +
individual O +
lacking O +
C5 O +
( O -
and O +
its O +
biologic O +
functions O -
) O -
, O +
and O +
( O -
b O -
) O +
a O +
remarkable O +
propensity O +
to O +
bacterial B-Disease +
infections L-Disease +
in O +
the O +
proband O -
, O +
even O +
during O +
periods O +
of O +
low O -
- O -
dose O +
or O +
alternate O -
- O -
day O +
corticosteroid O +
therapy O -
. O -

Other O +
observations O +
indicate O +
that O +
the O +
C5D U-Disease +
state O +
is O +
compatible O +
with O +
normal O +
coagulation O +
function O +
and O +
the O +
capacity O +
to O +
mount O +
a O +
neutrophilic O +
leukocytosis O +
during O +
pyogenic B-Disease +
infection L-Disease -
.. O -

Susceptibility O +
to O +
ankylosing B-Disease +
spondylitis L-Disease +
in O +
twins O -
: O +
the O +
role O +
of O +
genes O -
, O +
HLA O -
, O +
and O +
the O +
environment O -
. O -

OBJECTIVE O -
To O +
determine O +
the O +
relative O +
effects O +
of O +
genetic O +
and O +
environmental O +
factors O +
in O +
susceptibility O +
to O +
ankylosing B-Disease +
spondylitis L-Disease +
( O -
AS U-Disease -
) O -
. O -

METHODS O -
Twins O +
with O +
AS U-Disease +
were O +
identified O +
from O +
the O +
Royal O +
National O +
Hospital O +
for O +
Rheumatic B-Disease +
Diseases L-Disease +
database O -
. O -

Clinical O +
and O +
radiographic O +
examinations O +
were O +
performed O +
to O +
establish O +
diagnoses O -
, O +
and O +
disease O +
severity O +
was O +
assessed O +
using O +
a O +
combination O +
of O +
validated O +
scoring O +
systems O -
. O -

HLA O +
typing O +
for O +
HLA O -
- O -
B27 O -
, O +
HLA O -
- O -
B60 O -
, O +
and O +
HLA O -
- O -
DR1 O +
was O +
performed O +
by O +
polymerase O +
chain O +
reaction O +
with O +
sequence O -
- O -
specific O +
primers O -
, O +
and O +
zygosity O +
was O +
assessed O +
using O +
microsatellite O +
markers O -
. O -

Genetic O +
and O +
environmental O +
variance O +
components O +
were O +
assessed O +
with O +
the O +
program O +
Mx O -
, O +
using O +
data O +
from O +
this O +
and O +
previous O +
studies O +
of O +
twins O +
with O +
AS U-Disease -
. O -

RESULTS O -
Six O +
of O +
8 O +
monozygotic O +
( O -
MZ O -
) O +
twin O +
pairs O +
were O +
disease O +
concordant O -
, O +
compared O +
with O +
4 O +
of O +
15 O +
B27-positive O +
dizygotic O +
( O -
DZ O -
) O +
twin O +
pairs O +
( O -
27 O -
% O -
) O +
and O +
4 O +
of O +
32 O +
DZ O +
twin O +
pairs O +
overall O +
( O -
12 O -
. O +
5 O -
% O -
) O -
. O -

Nonsignificant O +
increases O +
in O +
similarity O +
with O +
regard O +
to O +
age O +
at O +
disease O +
onset O +
and O +
all O +
of O +
the O +
disease O +
severity O +
scores O +
assessed O +
were O +
noted O +
in O +
disease O -
- O -
concordant O +
MZ O +
twins O +
compared O +
with O +
concordant O +
DZ O +
twins O -
. O -

HLA O -
- O -
B27 O +
and O +
B60 O +
were O +
associated O +
with O +
the O +
disease O +
in O +
probands O -
, O +
and O +
the O +
rate O +
of O +
disease O +
concordance O +
was O +
significantly O +
increased O +
among O +
DZ O +
twin O +
pairs O +
in O +
which O +
the O +
co O -
- O -
twin O +
was O +
positive O +
for O +
both O +
B27 O +
and O +
DR1 O -
. O -

Additive O +
genetic O +
effects O +
were O +
estimated O +
to O +
contribute O +
97 O -
% O +
of O +
the O +
population O +
variance O -
. O -

CONCLUSION O -
Susceptibility O +
to O +
AS U-Disease +
is O +
largely O +
genetically O +
determined O -
, O +
and O +
the O +
environmental O +
trigger O +
for O +
the O +
disease O +
is O +
probably O +
ubiquitous O -
. O -

HLA O -
- O -
B27 O +
accounts O +
for O +
a O +
minority O +
of O +
the O +
overall O +
genetic O +
susceptibility O +
to O +
AS U-Disease -
. O -

Cell O +
cycle O -
- O -
dependent O +
colocalization O +
of O +
BARD1 O +
and O +
BRCA1 O +
proteins O +
in O +
discrete O +
nuclear O +
domains O -
. O -

Germ O -
- O -
line O +
mutations O +
of O +
the O +
BRCA1 O +
gene O +
predispose O +
women O +
to O +
early O -
- O -
onset O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
by O +
compromising O +
the O +
genes O +
presumptive O +
function O +
as O +
a O +
tumor U-Disease +
suppressor O -
. O -

Although O +
the O +
biochemical O +
properties O +
of O +
BRCA1 O +
polypeptides O +
are O +
not O +
understood O -
, O +
their O +
expression O +
pattern O +
and O +
subcellular O +
localization O +
suggest O +
a O +
role O +
in O +
cell O -
- O -
cycle O +
regulation O -
. O -

When O +
resting O +
cells O +
are O +
induced O +
to O +
proliferate O -
, O +
the O +
steady O -
- O -
state O +
levels O +
of O +
BRCA1 O +
increase O +
in O +
late O +
G1 O +
and O +
reach O +
a O +
maximum O +
during O +
S O +
phase O -
. O -

Moreover O -
, O +
in O +
S O +
phase O +
cells O -
, O +
BRCA1 O +
polypeptides O +
are O +
hyperphosphorylated O +
and O +
accumulate O +
into O +
discrete O +
subnuclear O +
foci O +
termed O +
" O +
BRCA1 O +
nuclear O +
dots O -
. O +
" O +
BRCA1 O +
associates O +
in O +
vivo O +
with O +
a O +
structurally O +
related O +
protein O +
termed O +
BARD1 O -
. O -

Here O +
we O +
show O +
that O +
the O +
steady O -
- O -
state O +
levels O +
of O +
BARD1 O -
, O +
unlike O +
those O +
of O +
BRCA1 O -
, O +
remain O +
relatively O +
constant O +
during O +
cell O +
cycle O +
progression O -
. O -

However O -
, O +
immunostaining O +
revealed O +
that O +
BARD1 O +
resides O +
within O +
BRCA1 O +
nuclear O +
dots O +
during O +
S O +
phase O +
of O +
the O +
cell O +
cycle O -
, O +
but O +
not O +
during O +
the O +
G1 O +
phase O -
. O -

Nevertheless O -
, O +
BARD1 O +
polypeptides O +
are O +
found O +
exclusively O +
in O +
the O +
nuclear O +
fractions O +
of O +
both O +
G1- O +
and O +
S O -
- O -
phase O +
cells O -
. O -

Therefore O -
, O +
progression O +
to O +
S O +
phase O +
is O +
accompanied O +
by O +
the O +
aggregation O +
of O +
nuclear O +
BARD1 O +
polypeptides O +
into O +
BRCA1 O +
nuclear O +
dots O -
. O -

This O +
cell O +
cycle O -
- O -
dependent O +
colocalization O +
of O +
BARD1 O +
and O +
BRCA1 O +
indicates O +
a O +
role O +
for O +
BARD1 O +
in O +
BRCA1-mediated O +
tumor U-Disease +
suppression O -
. O -

Ethnic O +
differences O +
in O +
the O +
HFE O +
codon O +
282 O +
( O -
Cys O -
/ O -
Tyr O -
) O +
polymorphism O -
. O -

Recent O +
studies O +
have O +
shown O +
that O +
hereditary B-Disease +
hemochromatosis L-Disease +
( O -
HH U-Disease -
) O +
is O +
likely O +
to O +
be O +
caused O +
by O +
homozygosity O +
for O +
a O +
Cys282Tyr O +
mutation O +
in O +
the O +
HFE O +
gene O +
located O +
4 O -
. O -

5 O +
Mb O +
telomeric O +
to O +
HLA O -
- O -
A. O +
Population O +
studies O +
of O +
this O +
polymorphism O +
are O +
facilitated O +
by O +
the O +
fact O +
that O +
the O +
Cys282Tyr O +
mutation O +
creates O +
a O +
Rsal O +
restriction O +
site O -
. O -

We O +
have O +
studied O +
the O +
codon O +
282 O +
( O -
Cys O -
/ O -
Tyr O -
) O +
polymorphism O +
in O +
different O +
ethnic O +
groups O -
. O -

In O +
agreement O +
with O +
previous O +
observations O +
the O +
Tyr O +
allele O +
appeared O +
to O +
be O +
rare O +
or O +
absent O +
in O +
Asiatic O +
( O -
Indian O -
, O +
Chinese O -
) O +
populations O -
. O -

The O +
highest O +
allele O +
frequency O +
( O -
7 O -
. O +
5 O -
% O -
) O +
was O +
found O +
in O +
Swedes O -
. O -

Saamis O +
( O -
2 O -
% O -
) O +
and O +
Mordvinians O +
( O -
1 O -
. O +
8 O -
% O -
) O +
had O +
significantly O +
lower O +
frequencies O +
of O +
the O +
Tyr O +
allele O -
. O -

Comparisons O +
with O +
allele O +
frequencies O +
based O +
on O +
prevalence O +
estimates O +
of O +
HH U-Disease +
showed O +
some O +
disagreements O +
with O +
the O +
RFLP O +
data O -
, O +
particularly O +
in O +
Finns O -
. O -

The O +
newly O +
described O +
HFE O +
marker O +
provides O +
a O +
new O +
approach O +
to O +
the O +
screening O +
of O +
HH U-Disease +
as O +
well O +
as O +
studies O +
of O +
the O +
relationship O +
between O +
the O +
HFE O +
Tyr O +
allele O +
and O +
different O +
disorders O +
including O +
cancer U-Disease -

Autosomal B-Disease +
dominant I-Disease +
neurohypophyseal I-Disease +
diabetes I-Disease +
insipidus L-Disease +
associated O +
with O +
a O +
missense O +
mutation O +
encoding O +
Gly23 O -
- O -
->Val O +
in O +
neurophysin O +
II O -
. O -

Autosomal B-Disease +
dominant I-Disease +
neurohypophyseal I-Disease +
diabetes I-Disease +
insipidus L-Disease +
( O -
ADNDI U-Disease -
) O +
is O +
an O +
inherited B-Disease +
disease L-Disease +
caused O +
by O +
progressive O +
degeneration O +
of O +
the O +
magnocellular O +
neurons O +
of O +
the O +
hypothalamus O +
leading O +
to O +
decreased O +
ability O +
to O +
produce O +
the O +
hormone O +
arginine O +
vasopressin O +
( O -
AVP O -
) O -
. O -

Affected O +
individuals O +
are O +
not O +
symptomatic O +
at O +
birth O -
, O +
but O +
usually O +
develop O +
diabetes B-Disease +
insipidus L-Disease +
at O +
1 O -
- O -
6 O +
yr O +
of O +
age O -
. O -

The O +
genetic O +
locus O +
of O +
the O +
disease O +
is O +
the O +
AVP O -
- O -
neurophysin O +
II O +
( O -
NPII O -
) O +
gene O -
, O +
and O +
mutations O +
that O +
cause O +
ADNDI U-Disease +
have O +
been O +
found O +
in O +
both O +
the O +
signal O +
peptide O +
of O +
the O +
prepro O -
- O -
AVP O -
- O -
NPII O +
precursor O +
and O +
within O +
NPII O +
itself O -
. O -

An O +
affected O +
girl O +
who O +
presented O +
at O +
9 O +
months O +
of O +
age O +
and O +
her O +
similarly O +
affected O +
younger O +
brother O +
and O +
father O +
were O +
all O +
found O +
to O +
have O +
a O +
novel O +
missense O +
mutation O +
( O -
G1758 O -
- O -
- O +
> O +
T O -
) O +
encoding O +
the O +
amino O +
acid O +
substitution O +
Gly23 O -
- O -
- O +
> O +
Val O +
within O +
NPII O -
. O -

The O +
mutation O +
was O +
confirmed O +
by O +
restriction O +
endonuclease O +
analysis O -
. O -

A O +
T1-weighted O +
magnetic O +
resonance O +
imaging O +
of O +
the O +
fathers O +
pituitary O +
gland O +
demonstrates O +
an O +
attenuated O +
posterior O +
pituitary O +
bright O +
spot O -
. O -

This O +
mutation O +
may O +
be O +
valuable O +
for O +
developing O +
models O +
of O +
dominantly B-Disease +
inherited I-Disease +
neurodegeneration L-Disease -
, O +
as O +
the O +
early O +
age O +
of O +
onset O +
of O +
symptoms O +
suggests O +
that O +
this O +
mutation O +
may O +
be O +
particularly O +
deleterious O +
to O +
the O +
magnocellular O +
neuron O -
.. O -

Frequent O +
inactivation O +
of O +
PTEN O -
/ O -
MMAC1 O +
in O +
primary O +
prostate B-Disease +
cancer L-Disease -
. O -

Sporadic B-Disease +
prostate I-Disease +
carcinoma L-Disease +
is O +
the O +
most O +
common O +
male B-Disease +
cancer L-Disease +
in O +
the O +
Western O +
world O -
, O +
yet O +
many O +
of O +
the O +
major O +
genetic O +
events O +
involved O +
in O +
the O +
progression O +
of O +
this O +
often O +
fatal O +
cancer U-Disease +
remain O +
to O +
be O +
elucidated O -
. O -

Numerous O +
cytogenetic O +
and O +
allelotype O +
studies O +
have O +
reported O +
frequent O +
loss O +
of O +
heterozygosity O +
on O +
chromosomal O +
arm O +
10q O +
in O +
sporadic B-Disease +
prostate I-Disease +
cancer L-Disease -
. O -

Deletion O +
mapping O +
studies O +
have O +
unambiguously O +
identified O +
a O +
region O +
of O +
chromosome O +
10q23 O +
to O +
be O +
the O +
minimal O +
area O +
of O +
loss O -
. O -

A O +
new O +
tumor U-Disease +
suppressor O +
gene O -
, O +
PTEN O -
/ O -
MMAC1 O -
, O +
was O +
isolated O +
recently O +
at O +
this O +
region O +
of O +
chromosome O +
10q23 O +
and O +
found O +
to O +
be O +
inactivated O +
by O +
mutation O +
in O +
three O +
prostate B-Disease +
cancer L-Disease +
cell O +
lines O -
. O -

We O +
screened O +
80 O +
prostate B-Disease +
tumors L-Disease +
by O +
microsatellite O +
analysis O +
and O +
found O +
chromosome O +
10q23 O +
to O +
be O +
deleted O +
in O +
23 O +
cases O -
. O -

We O +
then O +
proceeded O +
with O +
sequence O +
analysis O +
of O +
the O +
entire O +
PTEN O -
/ O -
MMAC1 O +
coding O +
region O +
and O +
tested O +
for O +
homozygous O +
deletion O +
with O +
new O +
intragenic O +
markers O +
in O +
these O +
23 O +
cases O +
with O +
10q23 O +
loss O +
of O +
heterozygosity O -
. O -

The O +
identification O +
of O +
the O +
second O +
mutational O +
event O +
in O +
10 O +
( O -
43 O -
% O -
) O +
tumors U-Disease +
establishes O +
PTEN O -
/ O -
MMAC1 O +
as O +
a O +
main O +
inactivation O +
target O +
of O +
10q O +
loss O +
in O +
sporadic B-Disease +
prostate I-Disease +
cancer L-Disease -
.. O -

Risk O +
reversals O +
in O +
predictive O +
testing O +
for O +
Huntington B-Disease +
disease L-Disease -
. O -

The O +
first O +
predictive O +
testing O +
for O +
Huntington B-Disease +
disease L-Disease +
( O -
HD U-Disease -
) O +
was O +
based O +
on O +
analysis O +
of O +
linked O +
polymorphic O +
DNA O +
markers O +
to O +
estimate O +
the O +
likelihood O +
of O +
inheriting O +
the O +
mutation O +
for O +
HD U-Disease -
. O -

Limits O +
to O +
accuracy O +
included O +
recombination O +
between O +
the O +
DNA O +
markers O +
and O +
the O +
mutation O -
, O +
pedigree O +
structure O -
, O +
and O +
whether O +
DNA O +
samples O +
were O +
available O +
from O +
family O +
members O -
. O -

With O +
direct O +
tests O +
for O +
the O +
HD U-Disease +
mutation O -
, O +
we O +
have O +
assessed O +
the O +
accuracy O +
of O +
results O +
obtained O +
by O +
linkage O +
approaches O +
when O +
requested O +
to O +
do O +
so O +
by O +
the O +
test O +
individuals O -
. O -

For O +
six O +
such O +
individuals O -
, O +
there O +
was O +
significant O +
disparity O +
between O +
the O +
tests O -
. O -

Three O +
went O +
from O +
a O +
decreased O +
risk O +
to O +
an O +
increased O +
risk O -
, O +
while O +
in O +
another O +
three O +
the O +
risk O +
was O +
decreased O -
. O -

Knowledge O +
of O +
the O +
potential O +
reasons O +
for O +
these O +
changes O +
in O +
results O +
and O +
impact O +
of O +
these O +
risk O +
reversals O +
on O +
both O +
patients O +
and O +
the O +
counseling O +
team O +
can O +
assist O +
in O +
the O +
development O +
of O +
strategies O +
for O +
the O +
prevention O +
and O -
, O +
where O +
necessary O -
, O +
management O +
of O +
a O +
risk O +
reversal O +
in O +
any O +
predictive O +
testing O +
program O -
.. O -

A O +
novel O +
common O +
missense O +
mutation O +
G301C O +
in O +
the O +
N O -
- O -
acetylgalactosamine-6-sulfate O +
sulfatase O +
gene O +
in O +
mucopolysaccharidosis B-Disease +
IVA L-Disease -
. O -

Mucopolysaccharidosis B-Disease +
IVA L-Disease +
( O -
MPS B-Disease +
IVA L-Disease -
) O +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
lysosomal I-Disease +
storage I-Disease +
disorder L-Disease +
caused O +
by O +
a O +
genetic B-Disease +
defect L-Disease +
in O +
N O -
- O -
acetylgalactosamine-6-sulfate O +
sulfatase O +
( O -
GALNS O -
) O -
. O -

In O +
previous O +
studies O -
, O +
we O +
have O +
found O +
two O +
common O +
mutations O +
in O +
Caucasians O +
and O +
Japanese O -
, O +
respectively O -
. O -

To O +
characterize O +
the O +
mutational O +
spectrum O +
in O +
various O +
ethnic O +
groups O -
, O +
mutations O +
in O +
the O +
GALNS O +
gene O +
in O +
Colombian O +
MPS B-Disease +
IVA L-Disease +
patients O +
were O +
investigated O -
, O +
and O +
genetic O +
backgrounds O +
were O +
extensively O +
analyzed O +
to O +
identify O +
racial O +
origin O -
, O +
based O +
on O +
mitochondrial O +
DNA O +
( O -
mtDNA O -
) O +
lineages O -
. O -

Three O +
novel O +
missense O +
mutations O +
never O +
identified O +
previously O +
in O +
other O +
populations O +
and O +
found O +
in O +
16 O +
out O +
of O +
19 O +
Colombian O +
MPS B-Disease +
IVA L-Disease +
unrelated O +
alleles O +
account O +
for O +
84 O -
. O -

2 O -
% O +
of O +
the O +
alleles O +
in O +
this O +
study O -
. O -

The O +
G301C O +
and O +
S162F O +
mutations O +
account O +
for O +
68 O -
. O +
4 O -
% O +
and O +
10 O -
. O +
5 O -
% O +
of O +
mutations O -
, O +
respectively O -
, O +
whereas O +
the O +
remaining O +
F69V O +
is O +
limited O +
to O +
a O +
single O +
allele O -
. O -

The O +
skewed O +
prevalence O +
of O +
G301C O +
in O +
only O +
Colombian O +
patients O +
and O +
haplotype O +
analysis O +
by O +
restriction O +
fragment O +
length O +
polymorphisms O +
in O +
the O +
GALNS O +
gene O +
suggest O +
that O +
G301C O +
originated O +
from O +
a O +
common O +
ancestor O -
. O -

Investigation O +
of O +
the O +
genetic O +
background O +
by O +
means O +
of O +
mtDNA O +
lineages O +
indicate O +
that O +
all O +
our O +
patients O +
are O +
probably O +
of O +
native O +
American O +
descent O -

Low O +
frequency O +
of O +
BRCA1 O +
germline O +
mutations O +
in O +
45 O +
German O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O -
. O -

In O +
this O +
study O +
we O +
investigated O +
45 O +
German O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O +
for O +
germline O +
mutations O +
in O +
the O +
BRCA1 O +
gene O -
. O -

We O +
identified O +
four O +
germline O +
mutations O +
in O +
three O +
breast B-Disease +
cancer L-Disease +
families O +
and O +
in O +
one O +
breast B-Disease -
- I-Disease -
ovarian I-Disease +
cancer L-Disease +
family O -
. O -

among O +
these O +
were O +
one O +
frameshift O +
mutation O -
, O +
one O +
nonsense O +
mutation O -
, O +
one O +
novel O +
splice O +
site O +
mutation O -
, O +
and O +
one O +
missense O +
mutation O -
. O -

The O +
missense O +
mutation O +
was O +
also O +
found O +
in O +
2 O -
. O +
8 O -
% O +
of O +
the O +
general O +
population O -
, O +
suggesting O +
that O +
it O +
is O +
not O +
disease O +
associated O -
. O -

The O +
average O +
age O +
of O +
disease O +
onset O +
in O +
those O +
families O +
harbouring O +
causative O +
mutations O +
was O +
between O +
32 O -
. O -

3 O +
and O +
37 O -
. O +
4 O +
years O -
, O +
whereas O +
the O +
family O +
harbouring O +
the O +
missense O +
mutation O +
had O +
an O +
average O +
age O +
of O +
onset O +
of O +
51 O -
. O -

2 O +
years O -
. O -

These O +
findings O +
show O +
that O +
BRCA1 O +
is O +
implicated O +
in O +
a O +
small O +
fraction O +
of O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O +
suggesting O +
the O +
involvement O +
of O +
another O +
susceptibility O +
gene O +
( O -
s O -
) O -

Paternal O +
transmission O +
of O +
congenital B-Disease +
myotonic I-Disease +
dystrophy L-Disease -
. O -

We O +
report O +
a O +
rare O +
case O +
of O +
paternally O +
transmitted O +
congenital B-Disease +
myotonic I-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O -
. O -

The O +
proband O +
is O +
a O +
23 O +
year O +
old O -
, O +
mentally B-Disease +
retarded L-Disease +
male O +
who O +
suffers O +
severe O +
muscular B-Disease +
weakness L-Disease -
. O -

He O +
presented O +
with O +
respiratory O +
and O +
feeding O +
difficulties O +
at O +
birth O -
. O -

His O +
two O +
sibs O +
suffer O +
from O +
childhood O +
onset O +
DM U-Disease -
. O -

Their O +
late O +
father O +
had O +
the O +
adult O +
type O +
of O +
DM U-Disease -
, O +
with O +
onset O +
around O +
30 O +
years O -
. O -

Only O +
six O +
other O +
cases O +
of O +
paternal O +
transmission O +
of O +
congenital B-Disease +
DM L-Disease +
have O +
been O +
reported O +
recently O -
. O -

We O +
review O +
the O +
sex O +
related O +
effects O +
on O +
transmission O +
of O +
congenital B-Disease +
DM L-Disease -
. O -

Decreased O +
fertility O +
of O +
males O +
with O +
adult O +
onset O +
DM U-Disease +
and O +
contraction O +
of O +
the O +
repeat O +
upon O +
male O +
transmission O +
contribute O +
to O +
the O +
almost O +
absent O +
occurrence O +
of O +
paternal O +
transmission O +
of O +
congenital B-Disease +
DM L-Disease -
. O -

Also O +
the O +
fathers O +
of O +
the O +
reported O +
congenitally O +
affected O +
children O +
showed O -
, O +
on O +
average O -
, O +
shorter O +
CTG O +
repeat O +
lengths O +
and O +
hence O +
less O +
severe O +
clinical O +
symptoms O +
than O +
the O +
mothers O +
of O +
children O +
with O +
congenital B-Disease +
DM L-Disease -
. O -

We O +
conclude O +
that O +
paternal O +
transmission O +
of O +
congenital B-Disease +
DM L-Disease +
is O +
rare O +
and O +
preferentially O +
occurs O +
with O +
onset O +
of O +
DM U-Disease +
past O +
30 O +
years O +
in O +
the O +
father O -
.. O -

The O +
RB1 O +
gene O +
mutation O +
in O +
a O +
child O +
with O +
ectopic B-Disease +
intracranial I-Disease +
retinoblastoma L-Disease -
. O -

The O +
RB1 O +
gene O +
mutation O +
was O +
investigated O +
in O +
a O +
child O +
with O +
ectopic B-Disease +
intracranial I-Disease +
retinoblastoma L-Disease +
using O +
DNA O +
obtained O +
from O +
both O +
the O +
pineal B-Disease +
and I-Disease +
retinal I-Disease +
tumours L-Disease +
of O +
the O +
patient O -
. O -

A O +
nonsense O +
mutation O +
in O +
exon O +
17 O +
( O -
codon O +
556 O -
) O +
of O +
the O +
RB1 O +
gene O +
was O +
found O +
to O +
be O +
present O +
homozygously O +
in O +
both O +
the O +
retinal B-Disease +
and I-Disease +
the I-Disease +
pineal I-Disease +
tumours L-Disease -
. O -

The O +
same O +
mutation O +
was O +
present O +
heterozygously O +
in O +
the O +
DNA O +
from O +
the O +
constitutional O +
cells O +
of O +
the O +
patient O -
, O +
proving O +
it O +
to O +
be O +
of O +
germline O +
origin O -
. O -

The O +
initial O +
mutation O +
was O +
shown O +
to O +
have O +
occurred O +
in O +
the O +
paternally O +
derived O +
RB1 O +
allele O -
. O -

The O +
mutation O +
is O +
in O +
an O +
area O +
of O +
the O +
gene O +
that O +
encodes O +
the O +
protein O -
- O -
binding O +
region O +
known O +
as O +
the O +
pocket O +
region O +
and O +
has O +
been O +
detected O +
in O +
other O +
cases O +
of O +
retinoblastoma U-Disease -
.. O -

Low O +
levels O +
of O +
beta O +
hexosaminidase O +
A O +
in O +
healthy O +
individuals O +
with O +
apparent O +
deficiency O +
of O +
this O +
enzyme O -
. O -

Appreciable O +
beta O +
hexosaminidase O +
A O +
( O -
hex O +
A O -
) O +
activity O +
has O +
been O +
detected O +
in O +
cultured O +
skin O +
fibroblasts O +
and O +
melanoma U-Disease +
tissue O +
from O +
healthy O +
individuals O +
previously O +
reported O +
as O +
having O +
deficiency B-Disease +
of I-Disease +
hex I-Disease +
A L-Disease +
activity O +
indistinguishable O +
from O +
that O +
of O +
patients O +
with O +
Tay B-Disease -
- I-Disease -
Sachs I-Disease +
disease L-Disease +
( O -
TSD U-Disease -
) O -
. O -

Identification O +
and O +
quantitation O +
of O +
hex O +
A O -
, O +
amounting O +
to O +
3 O -
. O +
5 O -
% O +
-6 O -
. O -

9 O -
% O +
of O +
total O +
beta O +
hexosaminidase O +
activity O -
, O +
has O +
been O +
obtained O +
by O +
cellulose O +
acetate O +
gel O +
electrophoresis O -
, O +
DEAE O -
- O -
cellulose O +
ion O -
- O -
exchange O +
chromatography O -
, O +
radial O +
immunodiffusion O -
, O +
and O +
radioimmunoassay O -
. O -

Previous O +
family O +
studies O +
suggested O +
that O +
these O +
individuals O +
may O +
be O +
compound O +
heterozygotes O +
for O +
the O +
common O +
mutant O +
TSD U-Disease +
gene O +
and O +
a O +
rare O +
( O -
allelic O -
) O +
mutant O +
gene O -
. O -

Thus O -
, O +
the O +
postulated O +
rate O +
mutant O +
gene O +
appears O +
to O +
code O +
for O +
the O +
expression O +
of O +
low O +
amounts O +
of O +
hex O +
A. O +
Heterozygotes O +
for O +
the O +
rare O +
mutant O +
may O +
be O +
indistinguishable O +
from O +
heterozygotes O +
for O +
the O +
common O +
TSD U-Disease +
mutant O -
. O -

However O -
, O +
direct O +
visualization O +
and O +
quantitation O +
of O +
hex O +
A O +
by O +
the O +
methods O +
described O +
may O +
prevent O +
false O -
- O -
positive O +
prenatal O +
diagnosis O +
of O +
TSD U-Disease +
in O +
fetuses O +
having O +
the O +
incomplete O +
hex B-Disease +
A I-Disease +
deficiency L-Disease +
of O +
the O +
type O +
described O +
in O +
the O +
four O +
healthy O +
individuals O -

The O +
tumor U-Disease +
suppressor O +
gene O +
Smad4 O -
/ O -
Dpc4 O +
is O +
required O +
for O +
gastrulation O +
and O +
later O +
for O +
anterior O +
development O +
of O +
the O +
mouse O +
embryo O -
. O -

Mutations O +
in O +
the O +
SMAD4 O -
/ O -
DPC4 O +
tumor U-Disease +
suppressor O +
gene O -
, O +
a O +
key O +
signal O +
transducer O +
in O +
most O +
TGFbeta O -
- O -
related O +
pathways O -
, O +
are O +
involved O +
in O +
50 O -
% O +
of O +
pancreatic B-Disease +
cancers L-Disease -
. O -

Homozygous O +
Smad4 O +
mutant O +
mice O +
die O +
before O +
day O +
7 O -
. O -

5 O +
of O +
embryogenesis O -
. O -

Mutant O +
embryos O +
have O +
reduced O +
size O -
, O +
fail O +
to O +
gastrulate O +
or O +
express O +
a O +
mesodermal O +
marker O -
, O +
and O +
show O +
abnormal O +
visceral O +
endoderm O +
development O -
. O -

Growth B-Disease +
retardation L-Disease +
of O +
the O +
Smad4-deficient O +
embryos O +
results O +
from O +
reduced O +
cell O +
proliferation O +
rather O +
than O +
increased O +
apoptosis O -
. O -

Aggregation O +
of O +
mutant O +
Smad4 O +
ES O +
cells O +
with O +
wild O -
- O -
type O +
tetraploid O +
morulae O +
rescues O +
the O +
gastrulation B-Disease +
defect L-Disease -
. O -

These O +
results O +
indicate O +
that O +
Smad4 O +
is O +
initially O +
required O +
for O +
the O +
differentiation O +
of O +
the O +
visceral O +
endoderm O +
and O +
that O +
the O +
gastrulation B-Disease +
defect L-Disease +
in O +
the O +
epiblast O +
is O +
secondary O +
and O +
non O -
- O -
cell O +
autonomous O -
. O -

Rescued O +
embryos O +
show O +
severe O +
anterior O +
truncations O -
, O +
indicating O +
a O +
second O +
important O +
role O +
for O +
Smad4 O +
in O +
anterior O +
patterning O +
during O +
embryogenesis O -
. O -

Prevalence O +
of O +
p16 O +
and O +
CDK4 O +
germline O +
mutations O +
in O +
48 O +
melanoma U-Disease -
- O -
prone O +
families O +
in O +
France O -
. O -

The O +
French O +
Familial B-Disease +
Melanoma L-Disease +
Study O +
Group O -
. O -

Germline O +
mutations O +
in O +
the O +
p16 O +
and O +
CDK4 O +
genes O +
have O +
been O +
reported O +
in O +
a O +
subset O +
of O +
melanoma U-Disease +
pedigrees O -
, O +
but O +
their O +
prevalence O +
is O +
not O +
well O +
known O -
. O -

We O +
searched O +
for O +
such O +
germline O +
mutations O +
in O +
48 O +
French O +
melanoma U-Disease -
- O -
prone O +
families O +
selected O +
according O +
to O +
two O +
major O +
criteria O -
families O +
with O +
at O +
least O +
three O +
affected O +
members O +
( O -
n O +
= O +
20 O -
) O +
or O +
families O +
with O +
two O +
affected O +
members O -
, O +
one O +
of O +
them O +
affected O +
before O +
the O +
age O +
of O +
50 O +
( O -
n O +
= O +
28 O -
) O -
, O +
and O +
one O +
additional O +
minor O +
criterion O -
. O -

Sixteen O +
different O +
p16 O +
germline O +
mutations O +
were O +
found O +
in O +
21 O +
families O -
, O +
while O +
one O +
germline O +
mutation O -
, O +
Arg24His O -
, O +
was O +
detected O +
in O +
the O +
CDK4 O +
gene O -
. O -

The O +
frequency O +
of O +
p16 O +
gene O +
mutation O +
in O +
our O +
sample O +
( O -
44 O -
% O -
) O +
is O +
among O +
the O +
highest O +
rates O +
yet O +
reported O +
and O +
the O +
CDK4 O +
mutation O +
is O +
the O +
second O +
mutation O +
detected O +
in O +
this O +
gene O +
worldwide O -
. O -

In O +
summary O -
, O +
our O +
results O +
show O +
frequent O +
involvement O +
of O +
the O +
p16 O +
gene O +
in O +
familial B-Disease +
melanoma L-Disease +
and O +
confirm O +
the O +
role O +
of O +
the O +
CDK4 O +
gene O +
as O +
a O +
melanoma U-Disease -
- O -
predisposing O +
gene O -
.. O -

Progression O +
of O +
somatic O +
CTG O +
repeat O +
length O +
heterogeneity O +
in O +
the O +
blood O +
cells O +
of O +
myotonic B-Disease +
dystrophy L-Disease +
patients O -
. O -

The O +
genetic O +
basis O +
of O +
myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
the O +
expansion O +
of O +
an O +
unstable O +
CTG O +
repeat O +
in O +
the O +
34 O +
UTR O +
of O +
the O +
DM U-Disease +
protein O +
kinase O +
gene O +
on O +
chromosome O +
19 O -
. O -

One O +
of O +
the O +
principal O +
features O +
of O +
the O +
DM U-Disease +
mutation O +
is O +
an O +
extraordinarily O +
high O +
level O +
of O +
somatic O +
mosaicism O -
, O +
due O +
to O +
an O +
extremely O +
high O +
degree O +
of O +
somatic O +
instability O +
both O +
within O +
and O +
between O +
different O +
tissues O -
. O -

This O +
instability O +
appears O +
to O +
be O +
biased O +
towards O +
further O +
expansion O +
and O +
continuous O +
throughout O +
the O +
life O +
of O +
an O +
individual O -
, O +
features O +
that O +
could O +
be O +
associated O +
with O +
the O +
progressive O +
nature O +
of O +
the O +
disease O -
. O -

Although O +
increasing O +
measured O +
allele O +
size O +
between O +
patients O +
clearly O +
correlates O +
with O +
an O +
increased O +
severity O +
of O +
symptoms O +
and O +
an O +
earlier O +
age O +
of O +
onset O -
, O +
this O +
correlation O +
is O +
not O +
precise O +
and O +
measured O +
allele O +
length O +
can O -
not O +
be O +
used O +
as O +
an O +
accurate O +
predictor O +
of O +
age O +
of O +
onset O -
. O -

In O +
order O +
to O +
further O +
characterize O +
the O +
dynamics O +
of O +
DM U-Disease +
CTG O +
repeat O +
somatic O +
instability O -
, O +
we O +
have O +
studied O +
repeat O +
length O +
changes O +
over O +
time O +
in O +
111 O +
myotonic B-Disease +
dystrophy L-Disease +
patients O +
with O +
varying O +
clinical O +
severity O +
and O +
CTG O +
repeat O +
size O +
over O +
time O +
intervals O +
of O +
1 O -
- O -
7 O +
years O -
. O -

We O +
have O +
found O +
a O +
direct O +
progression O +
of O +
the O +
size O +
heterogeneity O +
over O +
time O +
related O +
to O +
initial O +
CTG O +
repeat O +
size O +
and O +
the O +
time O +
interval O +
and O +
always O +
biased O +
towards O +
further O +
expansion O -
. O -

Attempts O +
to O +
mathematically O +
model O +
the O +
dynamics O +
have O +
proved O +
only O +
partially O +
successful O +
suggesting O +
that O +
individual O +
specific O +
genetic O +
and/or O +
environmental O +
factors O +
also O +
play O +
a O +
role O +
in O +
somatic O +
mosaicism O -
.. O -

Aspartylglucosaminuria U-Disease +
among O +
Palestinian O +
Arabs O -
. O -

Aspartylglucosaminuria U-Disease +
( O -
AGU U-Disease -
) O +
is O +
a O +
rare O +
disorder B-Disease +
of I-Disease +
glycoprotein I-Disease +
metabolism L-Disease +
caused O +
by O +
the O +
deficiency B-Disease +
of I-Disease +
the I-Disease +
lysosomal I-Disease +
enzyme I-Disease +
aspartylglucosaminidase L-Disease +
( O -
AGA O -
) O -
. O -

AGU U-Disease +
is O +
inherited O +
as O +
an O +
autosomal O +
recessive O +
trait O +
and O +
occurs O +
with O +
a O +
high O +
frequency O +
in O +
Finland O +
because O +
of O +
a O +
founder O +
effect O -
. O -

While O +
very O +
few O +
patients O +
with O +
AGU U-Disease +
have O +
been O +
reported O +
from O +
non O -
- O -
Finnish O +
origin O -
, O +
we O +
diagnosed O +
the O +
disorder O +
in O +
8 O +
patients O +
originating O +
from O +
3 O +
unrelated O +
families O -
, O +
all O +
Palestinian O +
Arabs O +
from O +
the O +
region O +
of O +
Jerusalem O -
. O -

The O +
clinical O +
diagnosis O +
of O +
AGU U-Disease +
is O +
often O +
difficult O -
, O +
in O +
particular O +
early O +
in O +
the O +
course O +
of O +
the O +
disease O -
, O +
and O +
most O +
of O +
the O +
patients O +
are O +
diagnosed O +
after O +
the O +
age O +
of O +
5 O +
years O -
. O -

However O -
, O +
since O +
these O +
patients O +
excrete O +
early O +
large O +
amounts O +
of O +
aspartylglucosamine O +
in O +
urine O -
, O +
biochemical O +
screening O +
is O +
easy O +
by O +
urine O +
chromatography O -
.. O -

Detection O +
of O +
heterozygous O +
carriers O +
of O +
the O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
ATM O -
) O +
gene O +
by O +
G2 O +
phase O +
chromosomal O +
radiosensitivity O +
of O +
peripheral O +
blood O +
lymphocytes O -
. O -

In O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
patients O -
, O +
mutations O +
in O +
a O +
single O +
gene O -
, O +
ATM O -
, O +
result O +
in O +
an O +
autosomal B-Disease +
recessive I-Disease +
syndrome L-Disease +
that O +
embraces O +
a O +
variety O +
of O +
clinical O +
features O +
and O +
manifests O +
extreme O +
radiosensitivity O +
and O +
a O +
strong O +
pre O -
- O -
disposition O +
to O +
malignancy U-Disease -
. O -

Heterozygotes O +
for O +
the O +
ATM O +
gene O +
have O +
no O +
clinical O +
expression O +
of O +
A B-Disease -
- I-Disease -
T L-Disease +
but O +
may O +
be O +
cancer U-Disease +
prone O +
with O +
a O +
moderate O +
increase O +
in O +
in O +
vitro O +
radiosensitivity O -
. O -

We O +
performed O +
a O +
blind O +
chromosomal O +
analysis O +
on O +
G2-phase O +
lymphocytes O +
from O +
7 O +
unrelated O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O -
, O +
13 O +
obligate O +
A B-Disease -
- I-Disease -
T L-Disease +
heterozygotes O +
( O -
parents O +
of O +
the O +
patients O -
) O -
, O +
and O +
14 O +
normal O +
controls O +
following O +
X O -
- O -
irradiation O +
with O +
1 O +
Gy O +
in O +
order O +
to O +
evaluate O +
this O +
cytogenetic O +
method O +
as O +
a O +
tool O +
for O +
detection O +
of O +
ATM O +
carriers O -
. O -

Both O +
A B-Disease -
- I-Disease -
T L-Disease +
homozygotes O +
and O +
heterozygotes O +
showed O +
significantly O +
increased O +
levels O +
of O +
radiation O -
- O -
induced O +
chromatid O +
damage O +
relative O +
to O +
that O +
of O +
normal O +
controls O -
. O -

These O +
results O +
show O +
that O +
the O +
G2-phase O +
chromosomal O +
radiosensitivity O +
assay O +
can O +
be O +
used O +
for O +
the O +
detection O +
of O +
A B-Disease -
- I-Disease -
T L-Disease +
heterozygotes O -
. O -

In O +
combination O +
with O +
molecular O +
genetic O +
analyses O -
, O +
this O +
test O +
may O +
be O +
of O +
value O +
in O +
studies O +
of O +
familial B-Disease +
and I-Disease +
sporadic I-Disease +
cancers L-Disease +
aimed O +
at O +
determination O +
of O +
the O +
potential O +
involvement O +
of O +
ATM O +
mutations O +
in O +
tumor U-Disease +
risk O +
or O +
development O -
.. O -

Ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease -
: O +
identification O +
and O +
detection O +
of O +
founder O -
- O -
effect O +
mutations O +
in O +
the O +
ATM O +
gene O +
in O +
ethnic O +
populations O -
. O -

To O +
facilitate O +
the O +
evaluation O +
of O +
ATM O +
heterozygotes O +
for O +
susceptibility O +
to O +
other O +
diseases O -
, O +
such O +
as O +
breast B-Disease +
cancer L-Disease -
, O +
we O +
have O +
attempted O +
to O +
define O +
the O +
most O +
common O +
mutations O +
and O +
their O +
frequencies O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
homozygotes O +
from O +
10 O +
ethnic O +
populations O -
. O -

Both O +
genomic O +
mutations O +
and O +
their O +
effects O +
on O +
cDNA O +
were O +
characterized O -
. O -

Protein O -
- O -
truncation O +
testing O +
of O +
the O +
entire O +
ATM O +
cDNA O +
detected O +
92 O +
( O -
66 O -
% O -
) O +
truncating O +
mutations O +
in O +
140 O +
mutant O +
alleles O +
screened O -
. O -

The O +
haplotyping O +
of O +
patients O +
with O +
identical O +
mutations O +
indicates O +
that O +
almost O +
all O +
of O +
these O +
represent O +
common O +
ancestry O +
and O +
that O +
very O +
few O +
spontaneously O +
recurring O +
ATM O +
mutations O +
exist O -
. O -

Assays O +
requiring O +
minimal O +
amounts O +
of O +
genomic O +
DNA O +
were O +
designed O +
to O +
allow O +
rapid O +
screening O +
for O +
common O +
ethnic O +
mutations O -
. O -

These O +
rapid O +
assays O +
detected O +
mutations O +
in O +
76 O -
% O +
of O +
Costa O +
Rican O +
patients O +
( O -
3 O -
) O -
, O +
50 O -
% O +
of O +
Norwegian O +
patients O +
( O -
1 O -
) O -
, O +
25 O -
% O +
of O +
Polish O +
patients O +
( O -
4 O -
) O -
, O +
and O +
14 O -
% O +
of O +
Italian O +
patients O +
( O -
1 O -
) O -
, O +
as O +
well O +
as O +
in O +
patients O +
of O +
Amish O -
/ O -
Mennonite O +
and O +
Irish O +
English O +
backgrounds O -
. O -

Additional O +
mutations O +
were O +
observed O +
in O +
Japanese O -
, O +
Utah O +
Mormon O -
, O +
and O +
African O +
American O +
patients O -
. O -

These O +
assays O +
should O +
facilitate O +
screening O +
for O +
A B-Disease -
- I-Disease -
T L-Disease +
heterozygotes O +
in O +
the O +
populations O +
studied O -
.. O -

The O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
tumor L-Disease +
suppressor O +
gene O +
is O +
required O +
for O +
cell O +
cycle O +
exit O +
upon O +
serum O +
withdrawal O -
. O -

The O +
inactivation O +
of O +
the O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau I-Disease +
( I-Disease -
VHL I-Disease -
) I-Disease +
tumor L-Disease +
suppressor O +
gene O +
predisposes O +
affected O +
individuals O +
to O +
the O +
human O +
VHL B-Disease +
cancer I-Disease +
syndrome L-Disease +
and O +
is O +
associated O +
with O +
sporadic B-Disease +
renal I-Disease +
cell I-Disease +
carcinomas L-Disease +
( O -
RCC U-Disease -
) O +
and O +
brain B-Disease +
hemangioblastomas L-Disease -
. O -

VHL O -
- O -
negative O +
786 O -
- O -
0 O +
RCC U-Disease +
cells O +
are O +
tumorigenic O +
in O +
nude O +
mice O +
which O +
is O +
suppressed O +
by O +
the O +
reintroduction O +
of O +
VHL U-Disease -
. O -

Remarkably O -
, O +
this O +
occurs O +
without O +
affecting O +
the O +
growth O +
rate O +
and O +
cell O +
cycle O +
profile O +
of O +
these O +
cells O +
in O +
culture O -
. O -

The O +
786 O -
- O -
0 O +
cell O +
line O -
, O +
like O +
many O +
cancer U-Disease +
cells O -
, O +
fails O +
to O +
exit O +
the O +
cell O +
cycle O +
upon O +
serum O +
withdrawal O -
. O -

Here O -
, O +
it O +
is O +
shown O +
that O +
reintroduction O +
of O +
the O +
wild O -
- O -
type O +
VHL U-Disease +
gene O +
restores O +
the O +
ability O +
of O +
VHL O -
- O -
negative O +
RCC B-Disease +
cancer L-Disease +
cells O +
to O +
exit O +
the O +
cell O +
cycle O +
and O +
enter O +
G0 O -
/ O -
quiescence O +
in O +
low O +
serum O -
. O -

Both O +
VHL O -
- O -
positive O +
and O +
VHL O -
- O -
negative O +
RCC U-Disease +
cells O +
exit O +
the O +
cell O +
cycle O +
by O +
contact O +
inhibition O -
. O -

The O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O -
, O +
p27 O -
, O +
accumulates O +
upon O +
serum O +
withdrawal O -
, O +
only O +
in O +
the O +
presence O +
of O +
VHL U-Disease -
, O +
as O +
a O +
result O +
of O +
the O +
stabilization O +
of O +
the O +
protein O -
. O -

We O +
propose O +
that O +
the O +
loss O +
of O +
wild O -
- O -
type O +
VHL U-Disease +
gene O +
results O +
in O +
a O +
specific O +
cellular O +
defect O +
in O +
serum O -
- O -
dependent O +
growth O +
control O -
, O +
which O +
may O +
initiate O +
tumor U-Disease +
formation O -
. O -

This O +
is O +
corrected O +
by O +
the O +
reintroduction O +
of O +
wild O -
- O -
type O +
VHL U-Disease -
, O +
implicating O +
VHL U-Disease +
as O +
the O +
first O +
tumor U-Disease +
suppressor O +
involved O +
in O +
the O +
regulation O +
of O +
cell O +
cycle O +
exit O -
, O +
which O +
is O +
consistent O +
with O +
its O +
gatekeeper O +
function O +
in O +
the O +
kidney O -
.. O -

Piebaldism U-Disease +
with O +
deafness U-Disease -
: O +
molecular O +
evidence O +
for O +
an O +
expanded O +
syndrome O -
. O -

In O +
a O +
South O +
African O +
girl O +
of O +
Xhosa O +
stock O +
with O +
severe O +
piebaldism U-Disease +
and O +
profound O +
congenital O +
sensorineural B-Disease +
deafness L-Disease +
we O +
identified O +
a O +
novel O +
missense O +
substitution O +
at O +
a O +
highly O +
conserved O +
residue O +
in O +
the O +
intracellular O +
kinase O +
domain O +
of O +
the O +
KIT O +
proto O -
- O -
oncogene O -
, O +
R796 O -
G O -
. O -

Though O +
auditory B-Disease +
anomalies L-Disease +
have O +
been O +
observed O +
in O +
mice O +
with O +
dominant O +
white O +
spotting O +
( O -
W O -
) O +
due O +
to O +
KIT O +
mutations O -
, O +
deafness U-Disease +
is O +
not O +
typical O +
in O +
human O +
piebaldism U-Disease -
. O -

Thus O -
, O +
the O +
occurrence O +
of O +
sensorineural B-Disease +
deafness L-Disease +
in O +
this O +
patient O +
extends O +
considerably O +
the O +
phenotypic O +
range O +
of O +
piebaldism U-Disease +
due O +
to O +
KIT O +
gene O +
mutation O +
in O +
humans O +
and O +
tightens O +
the O +
clinical O +
similarity O +
between O +
piebaldism U-Disease +
and O +
the O +
various O +
forms O +
of O +
Waardenburg B-Disease +
syndrome L-Disease -
.. O -

Cycloheximide O +
facilitates O +
the O +
identification O +
of O +
aberrant O +
transcripts O +
resulting O +
from O +
a O +
novel O +
splice O -
- O -
site O +
mutation O +
in O +
COL17A1 O +
in O +
a O +
patient O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease -
. O -

Patients O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease +
often O +
show O +
decreased O +
expression O +
of O +
type O +
XVII O +
collagen O -
, O +
a O +
transmembrane O +
hemidesmosomal O +
protein O +
encoded O +
by O +
COL17A1 O -
. O -

This O +
report O +
documents O +
a O +
novel O +
splice O -
- O -
site O +
mutation O +
in O +
COL17A1 O +
in O +
a O +
patient O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease -
, O +
and O +
applies O +
a O +
new O +
methodology O +
to O +
define O +
and O +
characterize O +
the O +
resulting O +
mRNA O +
splice O +
variants O -
. O -

Mutational O +
analysis O +
of O +
COL17A1 O +
identified O +
a O +
maternally O +
inherited O +
G O -
- O -
to O -
- O -
T O +
transversion O +
at O +
the O +
-1 O +
position O +
of O +
exon O +
32 O -
. O -

This O +
acceptor O +
splice O -
- O -
site O +
mutation O +
led O +
to O +
the O +
formation O +
of O +
aberrant O +
transcripts O +
present O +
at O +
extremely O +
low O +
levels O -
. O -

Based O +
on O +
our O +
recent O +
finding O +
that O +
cycloheximide O +
stabilized O +
mutant O +
COL17A1 O +
transcripts O +
in O +
keratinocytes O +
homozygous O +
for O +
a O +
frameshift O +
mutation O -
, O +
the O +
effects O +
of O +
the O +
splice O -
- O -
site O +
mutation O +
on O +
splicing O +
of O +
COL17A1 O +
transcripts O +
were O +
determined O +
using O +
reverse O +
transcriptase O +
polymerase O +
chain O +
reaction O +
of O +
total O +
RNA O +
from O +
keratinocytes O +
incubated O +
for O +
2 O -
. O +
5 O +
h O +
in O +
the O +
presence O +
or O +
absence O +
of O +
10 O +
microg O +
cycloheximide O +
per O +
ml O -
. O -

Using O +
this O +
approach O -
, O +
an O +
abnormally O +
spliced O +
transcript O +
was O +
identified O +
that O +
contains O +
an O +
extra O +
264 O +
bases O +
upstream O +
from O +
exon O +
32 O -
, O +
resulting O +
in O +
a O +
premature O +
termination O +
codon O +
27 O +
bp O +
downstream O +
from O +
the O +
cryptic O +
splice O +
site O -
. O -

Three O +
other O +
splice O +
variants O -
, O +
including O +
one O +
derived O +
from O +
the O +
skipping O +
of O +
exon O +
32 O -
, O +
were O +
also O +
identified O -
. O -

These O +
results O +
indicate O +
the O +
usefulness O +
of O +
cycloheximide O +
treatment O +
in O +
evaluating O +
the O +
abnormal O +
processing O +
of O +
mRNA O +
due O +
to O +
splice O -
- O -
site O +
mutations O -
, O +
because O -
( O -
i O -
) O +
aberrant O +
splicing O +
often O +
generates O +
a O +
premature O +
termination O +
codon O -
, O +
( O -
ii O -
) O +
transcripts O +
with O +
premature O +
termination O +
codons O +
can O +
occur O +
at O +
low O +
or O +
undetectable O +
levels O +
due O +
to O +
nonsense O -
- O -
mediated O +
mRNA O +
decay O -
, O +
and O +
( O -
iii O -
) O +
the O +
levels O +
of O +
these O +
transcripts O +
can O +
be O +
increased O +
by O +
cycloheximide O -
. O -

A O +
deletion O +
mutation O +
in O +
COL17A1 O +
in O +
five O +
Austrian O +
families O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease +
represents O +
propagation O +
of O +
an O +
ancestral O +
allele O -
. O -

Patients O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease -
, O +
a O +
usually O +
nonlethal O +
form O +
of O +
junctional B-Disease +
epidermolysis I-Disease +
bullosa L-Disease -
, O +
have O +
generalized O +
blistering U-Disease -
, O +
nail B-Disease +
dystrophy L-Disease -
, O +
patchy B-Disease +
alopecia L-Disease -
, O +
and O +
dental B-Disease +
abnormalities L-Disease -
. O -

Skin B-Disease +
fragility L-Disease +
in O +
most O +
cases O +
is O +
due O +
to O +
mutations O +
in O +
the O +
gene O +
encoding O +
type O +
XVII O +
collagen O +
( O -
COL17A1 O -
) O -
. O -

Recently O -
, O +
we O +
reported O +
five O +
Austrian O +
families O +
with O +
generalized O +
atrophic B-Disease +
benign I-Disease +
epidermolysis I-Disease +
bullosa L-Disease +
who O +
share O +
the O +
same O +
COL17A1 O +
mutation O -
. O -

Affected O +
individuals O +
in O +
three O +
families O +
are O +
homozygous O +
for O +
4003delTC O -
, O +
whereas O +
those O +
in O +
two O +
others O +
are O +
compound O +
heterozygotes O -
. O -

To O +
determine O +
if O +
the O +
occurrence O +
of O +
4003delTC O +
in O +
these O +
unrelated O +
families O +
signifies O +
propagation O +
of O +
an O +
ancestral O +
allele O +
or O +
a O +
mutational O +
hot O +
spot O -
, O +
haplotypes O +
were O +
determined O +
for O +
polymorphisms O +
both O +
within O +
and O +
flanking O +
COL17A1 O -
. O -

Five O +
intragenic O +
polymorphisms O +
were O +
chosen O +
based O +
on O +
their O +
informativeness O -
. O -

One O +
of O +
these O -
, O +
not O +
previously O +
reported O -
, O +
was O +
2988 O +
A O +
or O +
C O +
that O +
introduces O +
a O +
new O +
restriction O +
site O +
for O +
Eco0109 O +
I. O +
All O +
the O +
4003delTC O +
alleles O +
showed O +
the O +
same O +
haplotype O +
for O +
these O +
five O +
polymorphic O +
markers O -
. O -

Fourteen O +
microsatellite O +
polymorphisms O +
were O +
selected O +
based O +
on O +
their O +
high O +
heterozygosity O +
and O +
their O +
location O +
within O +
10q23-q25 O +
near O +
COL17A1 O -
. O -

Three O +
families O +
shared O +
microsatellite O +
polymorphisms O +
covering O +
at O +
most O +
19 O +
cM O -
, O +
whereas O +
the O +
others O +
shared O +
smaller O +
regions O +
consistent O +
with O +
cross O -
- O -
over O +
events O +
during O +
passage O +
of O +
this O +
mutation O +
through O +
several O +
generations O -
. O -

These O +
results O +
indicate O +
that O +
4003delTC O +
occurs O +
on O +
a O +
single O +
ancestral O +
allele O -
.. O -

The O +
haptoglobin O -
- O -
gene O +
deletion O +
responsible O +
for O +
anhaptoglobinemia U-Disease -
. O -

We O +
have O +
found O +
an O +
allelic O +
deletion O +
of O +
the O +
haptoglobin O +
( O -
Hp O -
) O +
gene O +
from O +
an O +
individual O +
with O +
anhaptoglobinemia U-Disease -
. O -

The O +
Hp O +
gene O +
cluster O +
consists O +
of O +
coding O +
regions O +
of O +
the O +
alpha O +
chain O +
and O +
beta O +
chain O +
of O +
the O +
haptoglobin O +
gene O +
( O -
Hp O -
) O +
and O +
of O +
the O +
alpha O +
chain O +
and O +
beta O +
chain O +
of O +
the O +
haptoglobin O -
- O -
related O +
gene O +
( O -
Hpr O -
) O -
, O +
in O +
tandem O +
from O +
the O +
5 O +
side O -
. O -

Southern O +
blot O +
and O +
PCR O +
analyses O +
have O +
indicated O +
that O +
the O +
individual O +
with O +
anhaptoglobinemia U-Disease +
was O +
homozygous O +
for O +
the O +
gene O +
deletion O +
and O +
that O +
the O +
gene O +
deletion O +
was O +
included O +
at O +
least O +
from O +
the O +
promoter O +
region O +
of O +
Hp O +
to O +
Hpr O +
alpha O +
but O +
not O +
to O +
Hpr O +
beta O +
( O -
Hpdel O -
) O -
. O -

In O +
addition O -
, O +
we O +
found O +
seven O +
individuals O +
with O +
hypohaptoglobinemia U-Disease +
in O +
three O +
families O -
, O +
and O +
the O +
genotypes O +
of O +
six O +
of O +
the O +
seven O +
individuals O +
were O +
found O +
to O +
be O +
Hp2 O -
/ O -
Hpdel O -
. O -

The O +
phenotypes O +
and O +
genotypes O +
in O +
one O +
of O +
these O +
three O +
families O +
showed O +
the O +
father O +
to O +
be O +
hypohaptoglobinemic U-Disease +
( O -
Hp2 O -
) O +
and O +
Hp2 O -
/ O -
Hpdel O -
, O +
the O +
mother O +
to O +
be O +
Hp2 O -
- O -
1 O +
and O +
Hp1 O -
/ O -
Hp2 O -
, O +
one O +
of O +
the O +
two O +
children O +
to O +
be O +
hypohaptoglobinemic U-Disease +
( O -
Hp2 O -
) O +
and O +
Hp2 O -
/ O -
Hpdel O -
, O +
and O +
the O +
other O +
child O +
to O +
be O +
Hp1 O +
and O +
Hp1 O -
/ O -
Hpdel O -
, O +
showing O +
an O +
anomalous O +
inheritance O +
of O +
Hp O +
phenotypes O +
in O +
the O +
child O +
with O +
Hp1 O -
. O -

The O +
Hp2 O -
/ O -
Hpdel O +
individuals O +
had O +
an O +
extremely O +
low O +
level O +
of O +
Hp O +
( O -
mean O +
+ O -
/-SD O +
= O +
0 O -
. O +
049 O +
+ O -
/-0 O -
. O -

043 O +
mg O -
/ O -
ml O -
; O +
n O +
= O +
6 O -
) O -
, O +
compared O +
with O +
the O +
level O +
( O -
1 O -
. O +
64 O +
+ O -
/-1 O -
. O -

07 O +
mg O -
/ O -
ml O -
) O +
obtained O +
from O +
52 O +
healthy O +
volunteers O +
having O +
phenotype O +
Hp2 O -
, O +
whereas O +
the O +
serum O +
Hp O +
level O +
of O +
an O +
individual O +
with O +
Hp1 O -
/ O -
Hpdel O +
was O +
0 O -
. O +
50 O +
mg O -
/ O -
ml O -
, O +
which O +
was O +
approximately O +
half O +
the O +
level O +
of O +
Hp O +
in O +
control O +
sera O +
from O +
the O +
Hp1 O +
phenotype O +
( O -
1 O -
. O +
26 O +
+ O -
/-0 O -
. O -

33 O +
mg O -
/ O -
ml O -
; O +
n O +
= O +
9 O -
) O -
, O +
showing O +
a O +
gene O -
- O -
dosage O +
effect O -
. O -

The O +
other O +
allele O +
( O -
Hp2 O -
) O +
of O +
individuals O +
with O +
Hp2 O -
/ O -
Hpdel O +
was O +
found O +
to O +
have O -
, O +
in O +
all O +
exons O -
, O +
no O +
mutation O -
, O +
by O +
DNA O +
sequencing O -
. O -

On O +
the O +
basis O +
of O +
the O +
present O +
study O -
, O +
the O +
mechanism O +
of O +
anhaptoglobinemia U-Disease +
and O +
the O +
mechanism O +
of O +
anomalous O +
inheritance O +
of O +
Hp O +
phenotypes O +
were O +
well O +
explained O -
. O -

However O -
, O +
the O +
mechanism O +
of O +
hypohaptoglobinemia U-Disease +
remains O +
unknown O -

ATM O +
mutations O +
and O +
phenotypes O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
families O +
in O +
the O +
British O +
Isles O -
: O +
expression O +
of O +
mutant O +
ATM O +
and O +
the O +
risk O +
of O +
leukemia U-Disease -
, O +
lymphoma U-Disease -
, O +
and O +
breast B-Disease +
cancer L-Disease -
. O -

We O +
report O +
the O +
spectrum O +
of O +
59 O +
ATM O +
mutations O +
observed O +
in O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O +
patients O +
in O +
the O +
British O +
Isles O -
. O -

Of O +
51 O +
ATM O +
mutations O +
identified O +
in O +
families O +
native O +
to O +
the O +
British O +
Isles O -
, O +
11 O +
were O +
founder O +
mutations O -
, O +
and O +
2 O +
of O +
these O +
11 O +
conferred O +
a O +
milder O +
clinical O +
phenotype O +
with O +
respect O +
to O +
both O +
cerebellar B-Disease +
degeneration L-Disease +
and O +
cellular O +
features O -
. O -

We O +
report O -
, O +
in O +
two O +
A B-Disease -
- I-Disease -
T L-Disease +
families O -
, O +
an O +
ATM O +
mutation O +
( O -
7271T-- O +
> O +
G O -
) O +
that O +
may O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
breast B-Disease +
cancer L-Disease +
in O +
both O +
homozygotes O +
and O +
heterozygotes O +
( O -
relative O +
risk O +
12 O -
. O +
7 O -
; O +
P O +
= O -
. O +
0025 O -
) O -
, O +
although O +
there O +
is O +
a O +
less O +
severe O +
A B-Disease -
- I-Disease -
T L-Disease +
phenotype O +
in O +
terms O +
of O +
the O +
degree O +
of O +
cerebellar B-Disease +
degeneration L-Disease -
. O -

This O +
mutation O +
( O -
7271T-- O +
> O +
G O -
) O +
also O +
allows O +
expression O +
of O +
full O -
- O -
length O +
ATM O +
protein O +
at O +
a O +
level O +
comparable O +
with O +
that O +
in O +
unaffected O +
individuals O -
. O -

In O +
addition O -
, O +
we O +
have O +
studied O +
18 O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O -
, O +
in O +
15 O +
families O -
, O +
who O +
developed O +
leukemia U-Disease -
, O +
lymphoma U-Disease -
, O +
preleukemic O +
T O -
- O -
cell O +
proliferation O -
, O +
or O +
Hodgkin B-Disease +
lymphoma L-Disease -
, O +
mostly O +
in O +
childhood O -
. O -

A O +
wide O +
variety O +
of O +
ATM O +
mutation O +
types O -
, O +
including O +
missense O +
mutations O +
and O +
in O -
- O -
frame O +
deletions O -
, O +
were O +
seen O +
in O +
these O +
patients O -
. O -

We O +
also O +
show O +
that O +
25 O -
% O +
of O +
all O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O +
carried O +
in O -
- O -
frame O +
deletions O +
or O +
missense O +
mutations O -
, O +
many O +
of O +
which O +
were O +
also O +
associated O +
with O +
expression O +
of O +
mutant O +
ATM O +
protein O -
. O -

The O +
DMPK O +
gene O +
of O +
severely O +
affected O +
myotonic B-Disease +
dystrophy L-Disease +
patients O +
is O +
hypermethylated O +
proximal O +
to O +
the O +
largely O +
expanded O +
CTG O +
repeat O -
. O -

Using O +
methylation O -
- O -
sensitive O +
restriction O +
enzymes O -
, O +
we O +
characterized O +
the O +
methylation O +
pattern O +
on O +
the O +
5 O +
side O +
of O +
the O +
CTG O +
repeat O +
in O +
the O +
DMPK O +
gene O +
of O +
normal O +
individuals O +
and O +
of O +
patients O +
affected O +
with O +
myotonic B-Disease +
dystrophy L-Disease -
, O +
showing O +
expansions O +
of O +
the O +
repetitive O +
sequence O -
. O -

The O +
gene O +
segment O +
analyzed O +
corresponds O +
to O +
the O +
genomic O +
SacI O -
- O -
HindIII O +
fragment O +
carrying O +
exons O +
11 O -
- O -
15 O -
. O -

There O +
is O +
constitutive O +
methylation O +
in O +
intron O +
12 O +
at O +
restriction O +
sites O +
of O +
SacII O +
and O +
HhaI O -
, O +
localized O +
1 O -
, O +
159 O -
- O -
1 O -
, O +
232 O +
bp O +
upstream O +
of O +
the O +
CTG O +
repeat O -
, O +
whereas O +
most O -
, O +
if O +
not O +
all O -
, O +
of O +
the O +
other O +
sites O +
of O +
SacII O -
, O +
HhaI O -
, O +
and O +
HpaII O +
in O +
this O +
region O +
are O +
unmethylated O -
, O +
in O +
normal O +
individuals O +
and O +
most O +
of O +
the O +
patients O -
. O -

In O +
a O +
number O +
of O +
young O +
and O +
severely O +
affected O +
patients O -
, O +
however O -
, O +
complete O +
methylation O +
of O +
these O +
restriction O +
sites O +
was O +
found O +
in O +
the O +
mutated O +
allele O -
. O -

In O +
most O +
of O +
these O +
patients O -
, O +
the O +
onset O +
of O +
the O +
disease O +
was O +
congenital O -
. O -

Preliminary O +
in O +
vivo O +
footprinting O +
data O +
gave O +
evidence O +
for O +
protein O -
- O -
DNA O +
contact O +
in O +
normal O +
genes O +
at O +
an O +
Sp1 O +
consensus O +
binding O +
site O +
upstream O +
of O +
the O +
CTG O +
repeat O +
and O +
for O +
a O +
significant O +
reduction O +
of O +
this O +
interaction O +
in O +
cells O +
with O +
a O +
hypermethylated O +
DMPK O +
gene O -
.. O -

The O +
hemochromatosis U-Disease +
gene O +
product O +
complexes O +
with O +
the O +
transferrin O +
receptor O +
and O +
lowers O +
its O +
affinity O +
for O +
ligand O +
binding O -
. O -

We O +
recently O +
reported O +
the O +
positional O +
cloning O +
of O +
a O +
candidate O +
gene O +
for O +
hereditary B-Disease +
hemochromatosis L-Disease +
called O +
HFE O -
. O -

The O +
gene O +
product O -
, O +
a O +
member O +
of O +
the O +
major O +
histocompatibility O +
complex O +
class O +
I O -
- O -
like O +
family O -
, O +
was O +
found O +
to O +
have O +
a O +
mutation O -
, O +
Cys-282 O +
-- O +
> O +
Tyr O +
( O -
C282Y O -
) O -
, O +
in O +
85 O -
% O +
of O +
patient O +
chromosomes O -
. O -

This O +
mutation O +
eliminates O +
the O +
ability O +
of O +
HFE O +
to O +
associate O +
with O +
beta2-microglobulin O +
( O -
beta2 O -
m O -
) O +
and O +
prevents O +
cell O -
- O -
surface O +
expression O -
. O -

A O +
second O +
mutation O +
that O +
has O +
no O +
effect O +
on O +
beta2 O -
m O +
association O -
, O +
H63D O -
, O +
was O +
found O +
in O +
eight O +
out O +
of O +
nine O +
patients O +
heterozygous O +
for O +
the O +
C282Y O +
mutant O -
. O -

In O +
this O +
report O -
, O +
we O +
demonstrate O +
in O +
cultured O +
293 O +
cells O +
overexpressing O +
wild O -
- O -
type O +
or O +
mutant O +
HFE O +
proteins O +
that O +
both O +
the O +
wild O -
- O -
type O +
and O +
H63D O +
HFE O +
proteins O +
form O +
stable O +
complexes O +
with O +
the O +
transferrin O +
receptor O +
( O -
TfR O -
) O -
. O -

The O +
C282Y O +
mutation O +
nearly O +
completely O +
prevents O +
the O +
association O +
of O +
the O +
mutant O +
HFE O +
protein O +
with O +
the O +
TfR. O +
Studies O +
on O +
cell O -
- O -
associated O +
transferrin O +
at O +
37 O +
degrees O +
C O +
suggest O +
that O +
the O +
overexpressed O +
wild O -
- O -
type O +
HFE O +
protein O +
decreases O +
the O +
affinity O +
of O +
the O +
TfR O +
for O +
transferrin O -
. O -

The O +
overexpressed O +
H63D O +
protein O +
does O +
not O +
have O +
this O +
effect O -
, O +
providing O +
the O +
first O +
direct O +
evidence O +
for O +
a O +
functional O +
consequence O +
of O +
the O +
H63D O +
mutation O -
. O -

Addition O +
of O +
soluble O +
wild O -
- O -
type O +
HFE O -
/ O -
beta2 O -
m O +
heterodimers O +
to O +
cultured O +
cells O +
also O +
decreased O +
the O +
apparent O +
affinity O +
of O +
the O +
TfR O +
for O +
its O +
ligand O +
under O +
steady O -
- O -
state O +
conditions O -
, O +
both O +
in O +
293 O +
cells O +
and O +
in O +
HeLa O +
cells O -
. O -

Furthermore O -
, O +
at O +
4 O +
degrees O +
C O -
, O +
the O +
added O +
soluble O +
complex O +
of O +
HFE O -
/ O -
beta2 O -
m O +
inhibited O +
binding O +
of O +
transferrin O +
to O +
HeLa O +
cell O +
TfR O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O -
. O -

Scatchard O +
plots O +
of O +
these O +
data O +
indicate O +
that O +
the O +
added O +
heterodimer O +
substantially O +
reduced O +
the O +
affinity O +
of O +
TfR O +
for O +
transferrin O -
. O -

These O +
results O +
establish O +
a O +
molecular O +
link O +
between O +
HFE O +
and O +
a O +
key O +
protein O +
involved O +
in O +
iron O +
transport O -
, O +
the O +
TfR O -
, O +
and O +
raise O +
the O +
possibility O +
that O +
alterations O +
in O +
this O +
regulatory O +
mechanism O +
may O +
play O +
a O +
role O +
in O +
the O +
pathogenesis O +
of O +
hereditary B-Disease +
hemochromatosis L-Disease -
.. O -

Genomic O +
organization O +
of O +
the O +
UBE3A O -
/ O -
E6-AP O +
gene O +
and O +
related O +
pseudogenes O -
. O -

The O +
UBE3A O +
gene O +
encodes O +
the O +
E6-AP O +
ubiquitin O -
- O -
protein O +
ligase O +
and O +
has O +
recently O +
been O +
shown O +
to O +
be O +
mutated O +
in O +
Angelman B-Disease +
syndrome L-Disease +
patients O +
who O +
lack O +
15q11-q13 O +
deletions O +
or O +
chromosome O +
15 O +
paternal O +
uniparental B-Disease +
disomy L-Disease -
. O -

Previous O +
UBE3A O +
cDNA O +
analysis O +
has O +
shown O +
a O +
coding O +
region O +
of O +
approximately O +
2 O -
. O +
6 O +
kb O +
and O +
a O +
3-untranslated O +
region O +
( O -
UTR O -
) O +
of O +
< O +
50 O +
bp O -
, O +
whereas O +
Northern O +
analysis O +
has O +
indicated O +
mRNA O +
sizes O +
of O +
5 O -
- O -
8 O +
kb O -
. O -

We O +
have O +
analyzed O +
additional O +
cDNA O +
clones O +
and O +
provide O +
evidence O +
for O +
an O +
additional O +
0 O -
. O +
5 O +
kb O +
of O +
5-UTR O +
and O +
> O +
2 O +
kb O +
of O +
3-UTR O -
. O -

We O +
have O +
established O +
the O +
genomic O +
organization O +
of O +
UBE3A O +
and O +
the O +
sequence O +
of O +
intron O -
- O -
exon O +
borders O -
. O -

We O +
have O +
also O +
mapped O +
two O +
highly O +
homologous O +
processed O +
pseudogenes O -
, O +
UBE3AP1 O +
and O +
UBE3AP2 O -
, O +
to O +
chromosomes O +
2 O +
and O +
21 O -
, O +
respectively O -
, O +
and O +
determined O +
their O +
genomic O +
organization O -
. O -

These O +
results O +
will O +
form O +
the O +
basis O +
for O +
studies O +
of O +
mutation O +
and O +
imprinting O +
of O +
UBE3A O -
. O -

Mutation O +
spectrum O +
and O +
genotype O -
- O -
phenotype O +
analyses O +
in O +
Cowden B-Disease +
disease L-Disease +
and O +
Bannayan B-Disease -
- I-Disease -
Zonana I-Disease +
syndrome L-Disease -
, O +
two O +
hamartoma B-Disease +
syndromes L-Disease +
with O +
germline O +
PTEN O +
mutation O -
. O -

The O +
tumour U-Disease +
suppressor O +
gene O +
PTEN O -
, O +
which O +
maps O +
to O +
10q23 O -
. O -

3 O +
and O +
encodes O +
a O +
403 O +
amino O +
acid O +
dual O +
specificity O +
phosphatase O +
( O -
protein O +
tyrosine O +
phosphatase O -
; O +
PTPase O -
) O -
, O +
was O +
shown O +
recently O +
to O +
play O +
a O +
broad O +
role O +
in O +
human O +
malignancy U-Disease -
. O -

Somatic O +
PTEN O +
deletions O +
and O +
mutations O +
were O +
observed O +
in O +
sporadic B-Disease +
breast I-Disease -
, I-Disease +
brain I-Disease -
, I-Disease +
prostate I-Disease +
and I-Disease +
kidney I-Disease +
cancer L-Disease +
cell O +
lines O +
and O +
in O +
several O +
primary O +
tumours U-Disease +
such O +
as O +
endometrial B-Disease +
carcinomas L-Disease -
, O +
malignant B-Disease +
melanoma L-Disease +
and O +
thyroid B-Disease +
tumours L-Disease -
. O -

In O +
addition O -
, O +
PTEN O +
was O +
identified O +
as O +
the O +
susceptibility O +
gene O +
for O +
two O +
hamartoma B-Disease +
syndromes L-Disease -
Cowden B-Disease +
disease L-Disease +
( O -
CD U-Disease -
; O +
MIM O +
158350 O -
) O +
and O +
Bannayan B-Disease -
- I-Disease -
Zonana I-Disease +
( I-Disease -
BZS I-Disease -
) I-Disease +
or I-Disease +
Ruvalcaba I-Disease -
- I-Disease -
Riley I-Disease -
- I-Disease -
Smith I-Disease +
syndrome L-Disease +
( O -
MIM O +
153480 O -
) O -
. O -

Constitutive O +
DNA O +
from O +
37 O +
CD U-Disease +
families O +
and O +
seven O +
BZS U-Disease +
families O +
was O +
screened O +
for O +
germline O +
PTEN O +
mutations O -
. O -

PTEN O +
mutations O +
were O +
identified O +
in O +
30 O +
of O +
37 O +
( O -
81 O -
% O -
) O +
CD U-Disease +
families O -
, O +
including O +
missense O +
and O +
nonsense O +
point O +
mutations O -
, O +
deletions O -
, O +
insertions O -
, O +
a O +
deletion O -
/ O -
insertion O +
and O +
splice O +
site O +
mutations O -
. O -

These O +
mutations O +
were O +
scattered O +
over O +
the O +
entire O +
length O +
of O +
PTEN O -
, O +
with O +
the O +
exception O +
of O +
the O +
first O -
, O +
fourth O +
and O +
last O +
exons O -
. O -

A O +
hot O +
spot O +
for O +
PTEN O +
mutation O +
in O +
CD U-Disease +
was O +
identified O +
in O +
exon O +
5 O +
that O +
contains O +
the O +
PTPase O +
core O +
motif O -
, O +
with O +
13 O +
of O +
30 O +
( O -
43 O -
% O -
) O +
CD U-Disease +
mutations O +
identified O +
in O +
this O +
exon O -
. O -

Seven O +
of O +
30 O +
( O -
23 O -
% O -
) O +
were O +
within O +
the O +
core O +
motif O -
, O +
the O +
majority O +
( O -
five O +
of O +
seven O -
) O +
of O +
which O +
were O +
missense O +
mutations O -
, O +
possibly O +
pointing O +
to O +
the O +
functional O +
significance O +
of O +
this O +
region O -
. O -

Germline O +
PTEN O +
mutations O +
were O +
identified O +
in O +
four O +
of O +
seven O +
( O -
57 O -
% O -
) O +
BZS U-Disease +
families O +
studied O -
. O -

Interestingly O -
, O +
none O +
of O +
these O +
mutations O +
was O +
observed O +
in O +
the O +
PTPase O +
core O +
motif O -
. O -

It O +
is O +
also O +
worthy O +
of O +
note O +
that O +
a O +
single O +
nonsense O +
point O +
mutation O -
, O +
R233X O -
, O +
was O +
observed O +
in O +
the O +
germline O +
DNA O +
from O +
two O +
unrelated O +
CD U-Disease +
families O +
and O +
one O +
BZS U-Disease +
family O -
. O -

Genotype O -
- O -
phenotype O +
studies O +
were O +
not O +
performed O +
on O +
this O +
small O +
group O +
of O +
BZS U-Disease +
families O -
. O -

However O -
, O +
genotype O -
- O -
phenotype O +
analysis O +
inthe O +
group O +
of O +
CD U-Disease +
families O +
revealed O +
two O +
possible O +
associations O +
worthy O +
of O +
follow O -
- O -
up O +
in O +
independent O +
analyses O -
. O -

The O +
first O +
was O +
an O +
association O +
noted O +
in O +
the O +
group O +
of O +
CD U-Disease +
families O +
with O +
breast B-Disease +
disease L-Disease -
. O -

A O +
correlation O +
was O +
observed O +
between O +
the O +
presence O -
/ O -
absence O +
of O +
a O +
PTEN O +
mutation O +
and O +
the O +
type O +
of O +
breast O +
involvement O +
( O -
unaffected O +
versus O +
benign O +
versus O +
malignant O -
) O -
. O -

Specifically O +
and O +
more O +
directly O -
, O +
an O +
association O +
was O +
also O +
observed O +
between O +
the O +
presence O +
of O +
a O +
PTEN O +
mutation O +
and O +
malignant B-Disease +
breast I-Disease +
disease L-Disease -
. O -

Secondly O -
, O +
there O +
appeared O +
to O +
be O +
an O +
interdependent O +
association O +
between O +
mutations O +
upstream O +
and O +
within O +
the O +
PTPase O +
core O +
motif O -
, O +
the O +
core O +
motif O +
containing O +
the O +
majority O +
of O +
missense O +
mutations O -
, O +
and O +
the O +
involvement O +
of O +
all O +
major O +
organ O +
systems O +
( O -
central O +
nervous O +
system O -
, O +
thyroid O -
, O +
breast O -
, O +
skin O +
and O +
gastrointestinal O +
tract O -
) O -
. O -

However O -
, O +
these O +
observations O +
would O +
need O +
to O +
be O +
confirmed O +
by O +
studying O +
a O +
larger O +
number O +
of O +
CD U-Disease +
families O -
. O -

Molecular O +
defects O +
leading O +
to O +
human O +
complement B-Disease +
component I-Disease +
C6 I-Disease +
deficiency L-Disease +
in O +
an O +
African O -
- O -
American O +
family O -
. O -

Complement B-Disease +
component I-Disease +
C6 I-Disease +
deficiency L-Disease +
( O -
C6D U-Disease -
) O +
was O +
diagnosed O +
in O +
a O +
16-year O -
- O -
old O +
African O -
- O -
American O +
male O +
with O +
meningococcal B-Disease +
meningitis L-Disease -
. O -

The O +
patients O +
father O +
and O +
two O +
brothers O +
also O +
had O +
C6D U-Disease -
, O +
but O +
gave O +
no O +
history O +
of O +
meningitis U-Disease +
or O +
other O +
neisserial B-Disease +
infection L-Disease -
. O -

By O +
using O +
exon O -
- O -
specific O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O -
/ O -
single O -
- O -
strand O +
conformation O +
polymorphism O +
as O +
a O +
screening O +
step O +
and O +
nucleotide O +
sequencing O +
of O +
target O +
exons O -
, O +
we O +
determined O +
that O +
the O +
proband O +
was O +
a O +
compound O +
heterozygote O +
for O +
two O +
C6 O +
gene O +
mutations O -
. O -

The O +
first O -
, O +
1195delC O +
located O +
in O +
exon O +
7 O -
, O +
is O +
a O +
novel O +
mutation O -
, O +
while O +
the O +
second O -
, O +
1936delG O +
in O +
exon O +
12 O -
, O +
has O +
been O +
described O +
before O +
to O +
cause O +
C6D U-Disease +
in O +
an O +
unrelated O +
African O -
- O -
American O +
individual O -
. O -

Both O +
mutations O +
result O +
in O +
premature O +
termination O +
codons O +
and O +
C6 O +
null O +
alleles O -
. O -

Allele O -
- O -
specific O +
PCR O +
indicated O +
that O +
the O +
probands O +
two O +
brothers O +
also O +
inherited O +
the O +
1195delC O +
mutation O +
from O +
their O +
heterozygous O +
mother O +
and O +
the O +
1936delG O +
mutation O +
from O +
their O +
homozygous O +
father O -
.. O -

PAX6 O +
mutations O +
reviewed O -
. O -

Mutations O +
in O +
PAX6 O +
are O +
responsible O +
for O +
human O +
aniridia U-Disease +
and O +
have O +
also O +
been O +
found O +
in O +
patients O +
with O +
Peters B-Disease +
anomaly L-Disease -
, O +
with O +
congenital B-Disease +
cataracts L-Disease -
, O +
with O +
autosomal B-Disease +
dominant I-Disease +
keratitis L-Disease -
, O +
and O +
with O +
isolated B-Disease +
foveal I-Disease +
hypoplasia L-Disease -
. O -

No O +
locus O +
other O +
than O +
chromosome O +
11p13 O +
has O +
been O +
implicated O +
in O +
aniridia U-Disease -
, O +
and O +
PAX6 O +
is O +
clearly O +
the O +
major O -
, O +
if O +
not O +
only O -
, O +
gene O +
responsible O -
. O -

Twenty O -
- O -
eight O +
percent O +
of O +
identified O +
PAX6 O +
mutations O +
are O +
C O -
- O -
T O +
changes O +
at O +
CpG O +
dinucleotides O -
, O +
20 O -
% O +
are O +
splicing O +
errors O -
, O +
and O +
more O +
than O +
30 O -
% O +
are O +
deletion O +
or O +
insertion O +
events O -
. O -

There O +
is O +
a O +
noticeably O +
elevated O +
level O +
of O +
mutation O +
in O +
the O +
paired O +
domain O +
compared O +
with O +
the O +
rest O +
of O +
the O +
gene O -
. O -

Increased O +
mutation O +
in O +
the O +
homeodomain O +
is O +
accounted O +
for O +
by O +
the O +
hypermutable O +
CpG O +
dinucleotide O +
in O +
codon O +
240 O -
. O -

Very O +
nearly O +
all O +
mutations O +
appear O +
to O +
cause O +
loss O +
of O +
function O +
of O +
the O +
mutant O +
allele O -
, O +
and O +
more O +
than O +
80 O -
% O +
of O +
exonic O +
substitutions O +
result O +
in O +
nonsense O +
codons O -
. O -

In O +
a O +
gene O +
with O +
such O +
extraordinarily O +
high O +
sequence O +
conservation O +
throughout O +
evolution O -
, O +
there O +
are O +
presumed O +
undiscovered O +
missense O +
mutations O -
, O +
these O +
are O +
hypothesized O +
to O +
exist O +
in O +
as O -
- O -
yet O +
unidentified O +
phenotypes O -
.. O -

Genetic O +
heterogeneity O +
and O +
penetrance O +
analysis O +
of O +
the O +
BRCA1 O +
and O +
BRCA2 O +
genes O +
in O +
breast B-Disease +
cancer L-Disease +
families O -
. O -

The O +
Breast B-Disease +
Cancer L-Disease +
Linkage O +
Consortium O -
. O -

The O +
contribution O +
of O +
BRCA1 O +
and O +
BRCA2 O +
to O +
inherited B-Disease +
breast I-Disease +
cancer L-Disease +
was O +
assessed O +
by O +
linkage O +
and O +
mutation O +
analysis O +
in O +
237 O +
families O -
, O +
each O +
with O +
at O +
least O +
four O +
cases O +
of O +
breast B-Disease +
cancer L-Disease -
, O +
collected O +
by O +
the O +
Breast B-Disease +
Cancer L-Disease +
Linkage O +
Consortium O -
. O -

Families O +
were O +
included O +
without O +
regard O +
to O +
the O +
occurrence O +
of O +
ovarian B-Disease +
or I-Disease +
other I-Disease +
cancers L-Disease -
. O -

Overall O -
, O +
disease O +
was O +
linked O +
to O +
BRCA1 O +
in O +
an O +
estimated O +
52 O -
% O +
of O +
families O -
, O +
to O +
BRCA2 O +
in O +
32 O -
% O +
of O +
families O -
, O +
and O +
to O +
neither O +
gene O +
in O +
16 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O +
6 O -
% O +
-28 O -
% O -
) O -
, O +
suggesting O +
other O +
predisposition O +
genes O -
. O -

The O +
majority O +
( O -
81 O -
% O -
) O +
of O +
the O +
breast B-Disease -
- I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O +
were O +
due O +
to O +
BRCA1 O -
, O +
with O +
most O +
others O +
( O -
14 O -
% O -
) O +
due O +
to O +
BRCA2 O -
. O -

Conversely O -
, O +
the O +
majority O +
of O +
families O +
with O +
male B-Disease +
and I-Disease +
female I-Disease +
breast I-Disease +
cancer L-Disease +
were O +
due O +
to O +
BRCA2 O +
( O -
76 O -
% O -
) O -
. O -

The O +
largest O +
proportion O +
( O -
67 O -
% O -
) O +
of O +
families O +
due O +
to O +
other O +
genes O +
was O +
found O +
in O +
families O +
with O +
four O +
or O +
five O +
cases O +
of O +
female O +
breast B-Disease +
cancer L-Disease +
only O -
. O -

These O +
estimates O +
were O +
not O +
substantially O +
affected O +
either O +
by O +
changing O +
the O +
assumed O +
penetrance O +
model O +
for O +
BRCA1 O +
or O +
by O +
including O +
or O +
excluding O +
BRCA1 O +
mutation O +
data O -
. O -

Among O +
those O +
families O +
with O +
disease O +
due O +
to O +
BRCA1 O +
that O +
were O +
tested O +
by O +
one O +
of O +
the O +
standard O +
screening O +
methods O -
, O +
mutations O +
were O +
detected O +
in O +
the O +
coding O +
sequence O +
or O +
splice O +
sites O +
in O +
an O +
estimated O +
63 O -
% O +
( O -
95 O -
% O +
CI O +
51 O -
% O +
-77 O -
% O -
) O -
. O -

The O +
estimated O +
sensitivity O +
was O +
identical O +
for O +
direct O +
sequencing O +
and O +
other O +
techniques O -
. O -

The O +
penetrance O +
of O +
BRCA2 O +
was O +
estimated O +
by O +
maximizing O +
the O +
LOD O +
score O +
in O +
BRCA2-mutation O +
families O -
, O +
over O +
all O +
possible O +
penetrance O +
functions O -
. O -

The O +
estimated O +
cumulative O +
risk O +
of O +
breast B-Disease +
cancer L-Disease +
reached O +
28 O -
% O +
( O -
95 O -
% O +
CI O +
9 O -
% O +
-44 O -
% O -
) O +
by O +
age O +
50 O +
years O +
and O +
84 O -
% O +
( O -
95 O -
% O +
CI O +
43 O -
% O +
-95 O -
% O -
) O +
by O +
age O +
70 O +
years O -
. O -

The O +
corresponding O +
ovarian B-Disease +
cancer L-Disease +
risks O +
were O +
0 O -
. O +
4 O -
% O +
( O -
95 O -
% O +
CI O +
0 O -
% O +
-1 O -
% O -
) O +
by O +
age O +
50 O +
years O +
and O +
27 O -
% O +
( O -
95 O -
% O +
CI O +
0 O -
% O +
-47 O -
% O -
) O +
by O +
age O +
70 O +
years O -
. O -

The O +
lifetime O +
risk O +
of O +
breast B-Disease +
cancer L-Disease +
appears O +
similar O +
to O +
the O +
risk O +
in O +
BRCA1 O +
carriers O -
, O +
but O +
there O +
was O +
some O +
suggestion O +
of O +
a O +
lower O +
risk O +
in O +
BRCA2 O +
carriers O +
< O +
50 O +
years O +
of O +
age O -
. O -

Eye B-Disease +
movement I-Disease +
abnormalities L-Disease +
correlate O +
with O +
genotype O +
in O +
autosomal O +
dominant O +
cerebellar B-Disease +
ataxia I-Disease +
type I-Disease +
I. L-Disease +
We O +
compared O +
horizontal O +
eye O +
movements O +
( O -
visually O +
guided O +
saccades O -
, O +
antisaccades O -
, O +
and O +
smooth O +
pursuit O -
) O +
in O +
control O +
subjects O +
( O -
n O +
= O +
14 O -
) O +
and O +
patients O +
with O +
three O +
forms O +
of O +
autosomal O +
dominant O +
cerebellar B-Disease +
ataxias I-Disease +
type I-Disease +
I L-Disease +
spinocerebellar B-Disease +
ataxias I-Disease +
1 I-Disease +
and I-Disease +
2 L-Disease +
( O -
SCA1 U-Disease -
, O +
n O +
= O +
11 O -
; O +
SCA2 U-Disease -
, O +
n O +
= O +
10 O -
) O +
and O +
SCA3 U-Disease -
/ O -
Machado B-Disease -
- I-Disease -
Joseph I-Disease +
disease L-Disease +
( O -
MJD U-Disease -
) O +
( O -
n O +
= O +
16 O -
) O -
. O -

In O +
SCA1 U-Disease -
, O +
saccade O +
amplitude O +
was O +
significantly O +
increased O -
, O +
resulting O +
in O +
hypermetria U-Disease -
. O -

The O +
smooth O +
pursuit O +
gain O +
was O +
decreased O -
. O -

In O +
SCA2 U-Disease -
, O +
saccade O +
velocity O +
was O +
markedly O +
decreased O -
. O -

The O +
percentage O +
of O +
errors O +
in O +
antisaccades O +
was O +
greatly O +
increased O +
and O +
was O +
significantly O +
correlated O +
with O +
age O +
at O +
disease O +
onset O -
. O -

In O +
addition O -
, O +
a O +
correlation O +
between O +
smooth O +
pursuit O +
gain O +
and O +
the O +
number O +
of O +
trinucleotide O +
repeats O +
was O +
found O -
. O -

In O +
SCA3 U-Disease -
, O +
gaze B-Disease -
- I-Disease -
evoked I-Disease +
nystagmus L-Disease +
was O +
often O +
present O +
as O +
was O +
saccade O +
hypometria O +
and O +
smooth O +
pursuit O +
gain O +
was O +
markedly O +
decreased O -
. O -

Three O +
major O +
criteria O -
, O +
saccade O +
amplitude O -
, O +
saccade O +
velocity O -
, O +
and O +
presence O +
of O +
gaze B-Disease -
- I-Disease -
evoked I-Disease +
nystagmus L-Disease -
, O +
permitted O +
the O +
correct O +
assignment O +
of O +
90 O -
% O +
of O +
the O +
SCA1 U-Disease -
, O +
90 O -
% O +
of O +
the O +
SCA2 U-Disease -
, O +
and O +
93 O -
% O +
of O +
the O +
patients O +
with O +
SCA3 U-Disease +
to O +
their O +
genetically O +
confirmed O +
patient O +
group O +
and O -
, O +
therefore O -
, O +
may O +
help O +
orient O +
diagnoses O +
of O +
SCA1 U-Disease -
, O +
SCA2 U-Disease -
, O +
and O +
SCA3 U-Disease +
at O +
early O +
clinical O +
stages O +
of O +
the O +
diseases O -
.. O -

Genetic O +
basis O +
and O +
molecular O +
mechanism O +
for O +
idiopathic B-Disease +
ventricular I-Disease +
fibrillation L-Disease -
. O -

Ventricular B-Disease +
fibrillation L-Disease +
causes O +
more O +
than O +
300 O -
, O +
000 O +
sudden O +
deaths O +
each O +
year O +
in O +
the O +
USA O +
alone O -
. O -

In O +
approximately O +
5 O -
- O -
12 O -
% O +
of O +
these O +
cases O -
, O +
there O +
are O +
no O +
demonstrable O +
cardiac O +
or O +
non O -
- O -
cardiac O +
causes O +
to O +
account O +
for O +
the O +
episode O -
, O +
which O +
is O +
therefore O +
classified O +
as O +
idiopathic B-Disease +
ventricular I-Disease +
fibrillation L-Disease +
( O -
IVF U-Disease -
) O -
. O -

A O +
distinct O +
group O +
of O +
IVF U-Disease +
patients O +
has O +
been O +
found O +
to O +
present O +
with O +
a O +
characteristic O +
electrocardiographic O +
pattern O -
. O -

Because O +
of O +
the O +
small O +
size O +
of O +
most O +
pedigrees O +
and O +
the O +
high O +
incidence O +
of O +
sudden B-Disease +
death L-Disease -
, O +
however O -
, O +
molecular O +
genetic O +
studies O +
of O +
IVF U-Disease +
have O +
not O +
yet O +
been O +
done O -
. O -

Because O +
IVF U-Disease +
causes O +
cardiac O +
rhythm O +
disturbance O -
, O +
we O +
investigated O +
whether O +
malfunction O +
of O +
ion O +
channels O +
could O +
cause O +
the O +
disorder O +
by O +
studying O +
mutations O +
in O +
the O +
cardiac O +
sodium O +
channel O +
gene O +
SCN5A O -
. O -

We O +
have O +
now O +
identified O +
a O +
missense O +
mutation O -
, O +
a O +
splice O -
- O -
donor O +
mutation O -
, O +
and O +
a O +
frameshift O +
mutation O +
in O +
the O +
coding O +
region O +
of O +
SCN5A O +
in O +
three O +
IVF U-Disease +
families O -
. O -

We O +
show O +
that O +
sodium O +
channels O +
with O +
the O +
missense O +
mutation O +
recover O +
from O +
inactivation O +
more O +
rapidly O +
than O +
normal O +
and O +
that O +
the O +
frameshift O +
mutation O +
causes O +
the O +
sodium O +
channel O +
to O +
be O +
non O -
- O -
functional O -
. O -

Our O +
results O +
indicate O +
that O +
mutations O +
in O +
cardiac O +
ion O -
- O -
channel O +
genes O +
contribute O +
to O +
the O +
risk O +
of O +
developing O +
IVF U-Disease -
.. O -

Molecular O +
heterogeneity O +
in O +
mucopolysaccharidosis B-Disease +
IVA L-Disease +
in O +
Australia O +
and O +
Northern O +
Ireland O -
: O +
nine O +
novel O +
mutations O +
including O +
T312S O -
, O +
a O +
common O +
allele O +
that O +
confers O +
a O +
mild O +
phenotype O -
. O -

Mucopolysaccharidosis B-Disease +
IVA L-Disease +
( O -
MPS B-Disease +
IVA L-Disease -
) O +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
lysosomal I-Disease +
storage I-Disease +
disorder L-Disease +
caused O +
by O +
a O +
genetic B-Disease +
defect L-Disease +
in O +
N O -
- O -
acetylgalactosamine-6-sulfate O +
sulfatase O +
( O -
GALNS O -
) O -
. O -

Previous O +
studies O +
of O +
patients O +
from O +
a O +
British O -
- O -
Irish O +
population O +
showed O +
that O +
the O +
I113F O +
mutation O +
is O +
the O +
most O +
common O +
single O +
mutation O +
among O +
MPS B-Disease +
IVA L-Disease +
patients O +
and O +
produces O +
a O +
severe O +
clinical O +
phenotype O -
. O -

We O +
studied O +
mutations O +
in O +
the O +
GALNS O +
gene O +
from O +
23 O +
additional O +
MPS B-Disease +
IVA L-Disease +
patients O +
( O -
15 O +
from O +
Australia O -
, O +
8 O +
from O +
Northern O +
Ireland O -
) O -
, O +
with O +
various O +
clinical O +
phenotypes O +
( O -
severe O -
, O +
16 O +
cases O -
; O +
intermediate O -
, O +
4 O +
cases O -
; O +
mild O -
, O +
3 O +
cases O -
) O -
. O -

We O +
found O +
two O +
common O +
mutations O +
that O +
together O +
accounted O +
for O +
32 O -
% O +
of O +
the O +
44 O +
unrelated O +
alleles O +
in O +
these O +
patients O -
. O -

One O +
is O +
the O +
T312S O +
mutation O -
, O +
a O +
novel O +
mutation O +
found O +
exclusively O +
in O +
milder O +
patients O -
. O -

The O +
other O +
is O +
the O +
previously O +
described O +
I113F O +
that O +
produces O +
a O +
severe O +
phenotype O -
. O -

The O +
I113F O +
and O +
T312S O +
mutations O +
accounted O +
for O +
8 O +
( O -
18 O -
% O -
) O +
and O +
6 O +
( O -
14 O -
% O -
) O +
of O +
44 O +
unrelated O +
alleles O -
, O +
respectively O -
. O -

The O +
relatively O +
high O +
residual O +
GALNS O +
activity O +
seen O +
when O +
the O +
T312S O +
mutant O +
cDNA O +
is O +
overexpressed O +
in O +
mutant O +
cells O +
provides O +
an O +
explanation O +
for O +
the O +
mild O +
phenotype O +
in O +
patients O +
with O +
this O +
mutation O -
. O -

The O +
distribution O +
and O +
relative O +
frequencies O +
of O +
the O +
I113F O +
and O +
T312S O +
mutations O +
in O +
Australia O +
corresponded O +
to O +
those O +
observed O +
in O +
Northern O +
Ireland O +
and O +
are O +
unique O +
to O +
these O +
two O +
populations O -
, O +
suggesting O +
that O +
both O +
mutations O +
were O +
probably O +
introduced O +
to O +
Australia O +
by O +
Irish O +
migrants O +
during O +
the O +
19th O +
century O -
. O -

Haplotype O +
analysis O +
using O +
6 O +
RFLPs O +
provides O +
additional O +
data O +
that O +
the O +
I113F O +
mutation O +
originated O +
from O +
a O +
common O +
ancestor O -
. O -

The O +
other O +
9 O +
novel O +
mutations O +
identified O +
in O +
these O +
23 O +
patients O +
were O +
each O +
limited O +
to O +
a O +
single O +
family O -
. O -

These O +
data O +
provide O +
further O +
evidence O +
for O +
extensive O +
allelic O +
heterogeneity O +
in O +
MPS B-Disease +
IVA L-Disease +
in O +
British O -
- O -
Irish O +
patients O +
and O +
provide O +
evidence O +
for O +
their O +
transmission O +
to O +
Australia O +
by O +
British O -
- O -
Irish O +
migrants O -
.. O -

Identification O +
of O +
constitutional O +
WT1 O +
mutations O -
, O +
in O +
patients O +
with O +
isolated O +
diffuse B-Disease +
mesangial I-Disease +
sclerosis L-Disease -
, O +
and O +
analysis O +
of O +
genotype O -
/ O -
phenotype O +
correlations O +
by O +
use O +
of O +
a O +
computerized O +
mutation O +
database O -
. O -

Constitutional O +
mutations O +
of O +
the O +
WT1 O +
gene O -
, O +
encoding O +
a O +
zinc O -
- O -
finger O +
transcription O +
factor O +
involved O +
in O +
renal O +
and O +
gonadal O +
development O -
, O +
are O +
found O +
in O +
most O +
patients O +
with O +
Denys B-Disease -
- I-Disease -
Drash I-Disease +
syndrome L-Disease +
( O -
DDS U-Disease -
) O -
, O +
or O +
diffuse B-Disease +
mesangial I-Disease +
sclerosis L-Disease +
( O -
DMS U-Disease -
) O +
associated O +
with O +
pseudohermaphroditism U-Disease +
and/or O +
Wilms B-Disease +
tumor L-Disease +
( O -
WT U-Disease -
) O -
. O -

Most O +
mutations O +
in O +
DDS U-Disease +
patients O +
lie O +
in O +
exon O +
8 O +
or O +
exon O +
9 O -
, O +
encoding O +
zinc O +
finger O +
2 O +
or O +
zinc O +
finger O +
3 O -
, O +
respectively O -
, O +
with O +
a O +
hot O +
spot O +
( O -
R394W O -
) O +
in O +
exon O +
9 O -
. O -

We O +
analyzed O +
a O +
series O +
of O +
24 O +
patients O -
, O +
10 O +
with O +
isolated B-Disease +
DMS L-Disease +
( O -
IDMS U-Disease -
) O -
, O +
10 O +
with O +
DDS U-Disease -
, O +
and O +
4 O +
with O +
urogenital B-Disease +
abnormalities L-Disease +
and/or O +
WT U-Disease -
. O -

We O +
report O +
WT1 O +
heterozygous O +
mutations O +
in O +
16 O +
patients O -
, O +
4 O +
of O +
whom O +
presented O +
with O +
IDMS U-Disease -
. O -

One O +
male O +
and O +
two O +
female O +
IDMS U-Disease +
patients O +
with O +
WT1 O +
mutations O +
underwent O +
normal O +
puberty O -
. O -

Two O +
mutations O +
associated O +
with O +
IDMS U-Disease +
are O +
different O +
from O +
those O +
described O +
in O +
DDS U-Disease +
patients O -
. O -

No O +
WT1 O +
mutations O +
were O +
detected O +
in O +
the O +
six O +
other O +
IDMS U-Disease +
patients O -
, O +
suggesting O +
genetic O +
heterogeneity O +
of O +
this O +
disease O -
. O -

We O +
analyzed O +
genotype O -
/ O -
phenotype O +
correlations O -
, O +
on O +
the O +
basis O +
of O +
the O +
constitution O +
of O +
a O +
WT1 O +
mutation O +
database O +
of O +
84 O +
germ O -
- O -
line O +
mutations O -
, O +
to O +
compare O +
the O +
distribution O +
and O +
type O +
of O +
mutations O -
, O +
according O +
to O +
the O +
different O +
symptoms O -
. O -

This O +
demonstrated O +
( O -
1 O -
) O +
the O +
association O +
between O +
mutations O +
in O +
exons O +
8 O +
and O +
9 O +
and O +
DMS U-Disease -
; O +
( O -
2 O -
) O +
among O +
patients O +
with O +
DMS U-Disease -
, O +
a O +
higher O +
frequency O +
of O +
exon O +
8 O +
mutations O +
among O +
46 O -
, O +
XY O +
patients O +
with O +
female O +
phenotype O +
than O +
among O +
46 O -
, O +
XY O +
patients O +
with O +
sexual O +
ambiguity O +
or O +
male O +
phenotype O -
; O +
and O +
( O -
3 O -
) O +
statistically O +
significant O +
evidence O +
that O +
mutations O +
in O +
exons O +
8 O +
and O +
9 O +
preferentially O +
affect O +
amino O +
acids O +
with O +
different O +
functions O -
.. O -

The O +
185delAG O +
BRCA1 O +
mutation O +
originated O +
before O +
the O +
dispersion O +
of O +
Jews O +
in O +
the O +
diaspora O +
and O +
is O +
not O +
limited O +
to O +
Ashkenazim O -
. O -

The O +
185delAG O +
mutation O +
in O +
BRCA1 O +
is O +
detected O +
in O +
Ashkenazi O +
Jews O +
both O +
in O +
familial B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
and O +
in O +
the O +
general O +
population O -
. O -

All O +
tested O +
Ashkenazi O +
mutation O +
carriers O +
share O +
the O +
same O +
allelic O +
pattern O +
at O +
the O +
BRCA1 O +
locus O -
. O -

Our O +
previous O +
study O +
showed O +
that O +
this O +
Ashkenazi O +
mutation O +
also O +
occurs O +
in O +
Iraqi O +
Jews O +
with O +
a O +
similar O +
allelic O +
pattern O -
. O -

We O +
extended O +
our O +
analysis O +
to O +
other O +
non O -
- O -
Ashkenazi O +
subsets O -
354 O +
of O +
Moroccan O +
origin O -
, O +
200 O +
Yemenites O +
and O +
150 O +
Iranian O +
Jews O -
. O -

Heteroduplex O +
analysis O +
complemented O +
by O +
direct O +
DNA O +
sequencing O +
of O +
abnormally O +
migrating O +
bands O +
were O +
employed O -
. O -

Four O +
of O +
Moroccan O +
origin O +
( O -
1 O -
. O +
1 O -
% O -
) O +
and O +
none O +
of O +
the O +
Yemenites O +
or O +
Iranians O +
was O +
a O +
carrier O +
of O +
the O +
185delAG O +
mutation O -
. O -

BRCA1 O +
allelic O +
patterns O +
were O +
determined O +
for O +
four O +
of O +
these O +
individuals O +
and O +
for O +
12 O +
additional O +
non O -
- O -
Ashkenazi O +
185delAG O +
mutation O +
carriers O +
who O +
had O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease -
. O -

Six O +
non O -
- O -
Ashkenazi O +
individuals O +
shared O +
the O +
common O +
Ashkenazi O +
haplotype O -
, O +
four O +
had O +
a O +
closely O +
related O +
pattern O -
, O +
and O +
the O +
rest O +
( O -
n O +
= O +
6 O -
) O +
displayed O +
a O +
distinct O +
BRCA1 O +
allelic O +
pattern O -
. O -

We O +
conclude O +
that O +
the O +
185delAG O +
BRCA1 O +
mutation O +
occurs O +
in O +
some O +
non O -
- O -
Ashkenazi O +
populations O +
at O +
rates O +
comparable O +
with O +
that O +
of O +
Ashkenazim O -
. O -

The O +
majority O +
of O +
Jewish O +
185delAG O +
mutation O +
carriers O +
have O +
a O +
common O +
allelic O +
pattern O -
, O +
supporting O +
the O +
founder O +
effect O +
notion O -
, O +
but O +
dating O +
the O +
mutations O +
origin O +
to O +
an O +
earlier O +
date O +
than O +
currently O +
estimated O -
. O -

However O -
, O +
the O +
different O +
allelic O +
pattern O +
at O +
the O +
BRCA1 O +
locus O +
even O +
in O +
some O +
Jewish O +
mutation O +
carriers O -
, O +
might O +
suggest O +
that O +
the O +
mutation O +
arose O +
independently O -
.. O -

Crystal O +
structure O +
of O +
the O +
hemochromatosis U-Disease +
protein O +
HFE O +
and O +
characterization O +
of O +
its O +
interaction O +
with O +
transferrin O +
receptor O -
. O -

HFE O +
is O +
an O +
MHC O -
- O -
related O +
protein O +
that O +
is O +
mutated O +
in O +
the O +
iron B-Disease -
- I-Disease -
overload I-Disease +
disease L-Disease +
hereditary B-Disease +
hemochromatosis L-Disease -
. O -

HFE O +
binds O +
to O +
transferrin O +
receptor O +
( O -
TfR O -
) O +
and O +
reduces O +
its O +
affinity O +
for O +
iron O -
- O -
loaded O +
transferrin O -
, O +
implicating O +
HFE O +
in O +
iron O +
metabolism O -
. O -

The O +
2 O -
. O +
6 O +
A O +
crystal O +
structure O +
of O +
HFE O +
reveals O +
the O +
locations O +
of O +
hemochromatosis U-Disease +
mutations O +
and O +
a O +
patch O +
of O +
histidines O +
that O +
could O +
be O +
involved O +
in O +
pH O -
- O -
dependent O +
interactions O -
. O -

We O +
also O +
demonstrate O +
that O +
soluble O +
TfR O +
and O +
HFE O +
bind O +
tightly O +
at O +
the O +
basic O +
pH O +
of O +
the O +
cell O +
surface O -
, O +
but O +
not O +
at O +
the O +
acidic O +
pH O +
of O +
intracellular O +
vesicles O -
. O -

TfR O -
HFE O +
stoichiometry O +
( O -
2 O -
1 O -
) O +
differs O +
from O +
TfR O -
transferrin O +
stoichiometry O +
( O -
2 O -
2 O -
) O -
, O +
implying O +
a O +
different O +
mode O +
of O +
binding O +
for O +
HFE O +
and O +
transferrin O +
to O +
TfR O -
, O +
consistent O +
with O +
our O +
demonstration O +
that O +
HFE O -
, O +
transferrin O -
, O +
and O +
TfR O +
form O +
a O +
ternary O +
complex O -
. O -

Identification O +
of O +
three O +
novel O +
mutations O +
and O +
a O +
high O +
frequency O +
of O +
the O +
Arg778Leu O +
mutation O +
in O +
Korean O +
patients O +
with O +
Wilson B-Disease +
disease L-Disease -
. O -

Four O +
mutations O -
-- O -
R778L O -
, O +
A874V O -
, O +
L1083F O -
, O +
and O +
2304delC O -
-- O -
in O +
the O +
copper O -
- O -
transporting O +
enzyme O -
, O +
P O -
- O -
type O +
ATPase O +
( O -
ATP7B O -
) O -
, O +
were O +
identified O +
in O +
Korean O +
Patients O +
with O +
Wilson B-Disease +
disease L-Disease -
. O -

Arg778Leu O -
, O +
the O +
most O +
frequently O +
reported O +
mutation O +
of O +
this O +
enzyme O -
, O +
was O +
found O +
in O +
six O +
of O +
eight O +
unrelated O +
patients O +
studied O -
, O +
an O +
allele O +
frequency O +
of O +
37 O -
. O +
5 O -
% O -
, O +
which O +
is O +
considerably O +
higher O +
than O +
those O +
in O +
other O +
Asian O +
populations O -
. O -

The O +
novel O +
single O +
nucleotide O +
deletion O -
, O +
2304delC O -
, O +
was O +
found O +
in O +
one O +
patient O -
. O -

Since O +
a O +
mutation O +
at O +
cDNA O +
nucleotide O +
2302 O +
( O -
2302insC O -
) O +
had O +
been O +
previously O +
described O -
, O +
this O +
region O +
of O +
the O +
ATP7B O +
gene O +
may O +
be O +
susceptible O +
to O +
gene O +
rearrangements O +
causing O +
Wilson B-Disease +
disease L-Disease -
. O -

Disruption O +
of O +
splicing O +
regulated O +
by O +
a O +
CUG O -
- O -
binding O +
protein O +
in O +
myotonic B-Disease +
dystrophy L-Disease -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
caused O +
by O +
a O +
CTG O +
expansion O +
in O +
the O +
3 O +
untranslated O +
region O +
of O +
the O +
DM U-Disease +
gene O -
. O -

One O +
model O +
of O +
DM U-Disease +
pathogenesis O +
suggests O +
that O +
RNAs O +
from O +
the O +
expanded O +
allele O +
create O +
a O +
gain O -
- O -
of O -
- O -
function O +
mutation O +
by O +
the O +
inappropriate O +
binding O +
of O +
proteins O +
to O +
the O +
CUG O +
repeats O -
. O -

Data O +
presented O +
here O +
indicate O +
that O +
the O +
conserved O +
heterogeneous O +
nuclear O +
ribonucleoprotein O -
, O +
CUG O -
- O -
binding O +
protein O +
( O -
CUG O -
- O -
BP O -
) O -
, O +
may O +
mediate O +
the O +
trans O -
- O -
dominant O +
effect O +
of O +
the O +
RNA O -
. O -

CUG O -
- O -
BP O +
was O +
found O +
to O +
bind O +
to O +
the O +
human O +
cardiac O +
troponin O +
T O +
( O -
cTNT O -
) O +
pre O -
- O -
messenger O +
RNA O +
and O +
regulate O +
its O +
alternative O +
splicing O -
. O -

Splicing O +
of O +
cTNT O +
was O +
disrupted O +
in O +
DM U-Disease +
striated O +
muscle O +
and O +
in O +
normal O +
cells O +
expressing O +
transcripts O +
that O +
contain O +
CUG O +
repeats O -
. O -

Altered O +
expression O +
of O +
genes O +
regulated O +
posttranscriptionally O +
by O +
CUG O -
- O -
BP O +
therefore O +
may O +
contribute O +
to O +
DM U-Disease +
pathogenesis O -
.. O -

Identification O +
of O +
a O +
novel O +
nonsense O +
mutation O +
and O +
a O +
missense O +
substitution O +
in O +
the O +
vasopressin O -
- O -
neurophysin O +
II O +
gene O +
in O +
two O +
Spanish O +
kindreds O +
with O +
familial B-Disease +
neurohypophyseal I-Disease +
diabetes I-Disease +
insipidus L-Disease -
. O -

Familial B-Disease +
neurohypophyseal I-Disease +
diabetes I-Disease +
insipidus L-Disease +
( O -
FNDI U-Disease -
) O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
disease L-Disease +
caused O +
by O +
deficiency O +
in O +
the O +
antidiuretic O +
hormone O +
arginine O +
vasopressin O +
( O -
AVP O -
) O +
encoded O +
by O +
the O +
AVP O -
- O -
neurophysin O +
II O +
( O -
AVP O -
- O -
NPII O -
) O +
gene O +
on O +
chromosome O +
20p13 O -
. O -

In O +
this O +
study O -
, O +
we O +
analyzed O +
two O +
families O +
with O +
FNDI U-Disease +
using O +
direct O +
automated O +
fluorescent O -
, O +
solid O +
phase O -
, O +
single O -
- O -
stranded O +
DNA O +
sequencing O +
of O +
PCR O -
- O -
amplified O +
AVP O -
- O -
NPII O +
DNA O -
. O -

In O +
one O +
of O +
the O +
families O -
, O +
affected O +
individuals O +
presented O +
a O +
novel O +
nonsense O +
mutation O +
in O +
exon O +
3 O +
of O +
the O +
gene O -
, O +
consisting O +
in O +
a O +
G O +
to O +
T O +
transition O +
at O +
nucleotide O +
2101 O -
, O +
which O +
produces O +
a O +
stop O +
signal O +
in O +
codon O +
82 O +
( O -
Glu O -
) O +
of O +
NPII O -
. O -

The O +
premature O +
termination O +
eliminates O +
part O +
of O +
the O +
C O -
- O -
terminal O +
domain O +
of O +
NPII O -
, O +
including O +
a O +
cysteine O +
residue O +
in O +
position O +
85 O -
, O +
which O +
could O +
be O +
involved O +
in O +
the O +
correct O +
folding O +
of O +
the O +
prohormone O -
. O -

In O +
the O +
second O +
family O -
, O +
a O +
G279A O +
substitution O +
at O +
position O +
-1 O +
of O +
the O +
signal O +
peptide O +
was O +
observed O +
in O +
all O +
affected O +
individuals O -
. O -

This O +
missense O +
mutation O -
, O +
which O +
replaces O +
Ala O +
with O +
Thr O -
, O +
is O +
frequent O +
among O +
FNDI U-Disease +
patients O +
and O +
is O +
thought O +
to O +
reduce O +
the O +
efficiency O +
of O +
cleavage O +
by O +
signal O +
peptidases O -
.. O -

Genetic O +
heterogeneity O +
of O +
Saethre B-Disease -
- I-Disease -
Chotzen I-Disease +
syndrome L-Disease -
, O +
due O +
to O +
TWIST O +
and O +
FGFR O +
mutations O -
. O -

Thirty O -
- O -
two O +
unrelated O +
patients O +
with O +
features O +
of O +
Saethre B-Disease -
- I-Disease -
Chotzen I-Disease +
syndrome L-Disease -
, O +
a O +
common O +
autosomal B-Disease +
dominant I-Disease +
condition L-Disease +
of O +
craniosynostosis U-Disease +
and O +
limb B-Disease +
anomalies L-Disease -
, O +
were O +
screened O +
for O +
mutations O +
in O +
TWIST O -
, O +
FGFR2 O -
, O +
and O +
FGFR3 O -
. O -

Nine O +
novel O +
and O +
three O +
recurrent O +
TWIST O +
mutations O +
were O +
found O +
in O +
12 O +
families O -
. O -

Seven O +
families O +
were O +
found O +
to O +
have O +
the O +
FGFR3 O +
P250R O +
mutation O -
, O +
and O +
one O +
individual O +
was O +
found O +
to O +
have O +
an O +
FGFR2 O +
VV269 O -
- O -
270 O +
deletion O -
. O -

To O +
date O -
, O +
our O +
detection O +
rate O +
for O +
TWIST O +
or O +
FGFR O +
mutations O +
is O +
68 O -
% O +
in O +
our O +
Saethre B-Disease -
- I-Disease -
Chotzen I-Disease +
syndrome L-Disease +
patients O -
, O +
including O +
our O +
five O +
patients O +
elsewhere O +
reported O +
with O +
TWIST O +
mutations O -
. O -

More O +
than O +
35 O +
different O +
TWIST O +
mutations O +
are O +
now O +
known O +
in O +
the O +
literature O -
. O -

The O +
most O +
common O +
phenotypic O +
features O -
, O +
present O +
in O +
more O +
than O +
a O +
third O +
of O +
our O +
patients O +
with O +
TWIST O +
mutations O -
, O +
are O +
coronal B-Disease +
synostosis L-Disease -
, O +
brachycephaly U-Disease -
, O +
low B-Disease +
frontal I-Disease +
hairline L-Disease -
, O +
facial B-Disease +
asymmetry L-Disease -
, O +
ptosis U-Disease -
, O +
hypertelorism U-Disease -
, O +
broad B-Disease +
great I-Disease +
toes L-Disease -
, O +
and O +
clinodactyly U-Disease -
. O -

Significant O +
intra- O +
and O +
interfamilial O +
phenotypic O +
variability O +
is O +
present O +
for O +
either O +
TWIST O +
mutations O +
or O +
FGFR O +
mutations O -
. O -

The O +
overlap O +
in O +
clinical O +
features O +
and O +
the O +
presence O -
, O +
in O +
the O +
same O +
genes O -
, O +
of O +
mutations O +
for O +
more O +
than O +
one O +
craniosynostotic B-Disease +
condition L-Disease -
- O -
such O +
as O +
Saethre B-Disease -
- I-Disease -
Chotzen I-Disease -
, I-Disease +
Crouzon I-Disease -
, I-Disease +
and I-Disease +
Pfeiffer I-Disease +
syndromes L-Disease -
- O -
support O +
the O +
hypothesis O +
that O +
TWIST O +
and O +
FGFRs O +
are O +
components O +
of O +
the O +
same O +
molecular O +
pathway O +
involved O +
in O +
the O +
modulation O +
of O +
craniofacial O +
and O +
limb O +
development O +
in O +
humans O -
.. O -

Mutation O +
analysis O +
of O +
UBE3A O +
in O +
Angelman B-Disease +
syndrome L-Disease +
patients O -
. O -

Angelman B-Disease +
syndrome L-Disease +
( O -
AS U-Disease -
) O +
is O +
caused O +
by O +
chromosome O +
15q11-q13 O +
deletions O +
of O +
maternal O +
origin O -
, O +
by O +
paternal O +
uniparental B-Disease +
disomy L-Disease +
( O -
UPD U-Disease -
) O +
15 O -
, O +
by O +
imprinting O +
defects O -
, O +
and O +
by O +
mutations O +
in O +
the O +
UBE3A O +
gene O -
. O -

UBE3A O +
encodes O +
a O +
ubiquitin O -
- O -
protein O +
ligase O +
and O +
shows O +
brain O -
- O -
specific O +
imprinting O -
. O -

Here O +
we O +
describe O +
UBE3A O +
coding O -
- O -
region O +
mutations O +
detected O +
by O +
SSCP O +
analysis O +
in O +
13 O +
AS U-Disease +
individuals O +
or O +
families O -
. O -

Two O +
identical O +
de O +
novo O +
5-bp O +
duplications O +
in O +
exon O +
16 O +
were O +
found O -
. O -

Among O +
the O +
other O +
11 O +
unique O +
mutations O -
, O +
8 O +
were O +
small O +
deletions O +
or O +
insertions O +
predicted O +
to O +
cause O +
frameshifts O -
, O +
1 O +
was O +
a O +
mutation O +
to O +
a O +
stop O +
codon O -
, O +
1 O +
was O +
a O +
missense O +
mutation O -
, O +
and O +
1 O +
was O +
predicted O +
to O +
cause O +
insertion O +
of O +
an O +
isoleucine O +
in O +
the O +
hect O +
domain O +
of O +
the O +
UBE3A O +
protein O -
, O +
which O +
functions O +
in O +
E2 O +
binding O +
and O +
ubiquitin O +
transfer O -
. O -

Eight O +
of O +
the O +
cases O +
were O +
familial O -
, O +
and O +
five O +
were O +
sporadic O -
. O -

In O +
two O +
familial O +
cases O +
and O +
one O +
sporadic O +
case O -
, O +
mosaicism O +
for O +
UBE3A O +
mutations O +
was O +
detected O -
in O +
the O +
mother O +
of O +
three O +
AS U-Disease +
sons O -
, O +
in O +
the O +
maternal O +
grandfather O +
of O +
two O +
AS U-Disease +
first O +
cousins O -
, O +
and O +
in O +
the O +
mother O +
of O +
an O +
AS U-Disease +
daughter O -
. O -

The O +
frequencies O +
with O +
which O +
we O +
detected O +
mutations O +
were O +
5 O +
( O -
14 O -
% O -
) O +
of O +
35 O +
in O +
sporadic O +
cases O +
and O +
8 O +
( O -
80 O -
% O -
) O +
of O +
10 O +
in O +
familial O +
cases O -
.. O -

The O +
hemochromatosis U-Disease +
845 O +
G-->A O +
and O +
187 O +
C-->G O +
mutations O -
: O +
prevalence O +
in O +
non O -
- O -
Caucasian O +
populations O -
. O -

Hemochromatosis U-Disease -
, O +
the O +
inherited B-Disease +
disorder I-Disease +
of I-Disease +
iron I-Disease +
metabolism L-Disease -
, O +
leads O -
, O +
if O +
untreated O -
, O +
to O +
progressive O +
iron B-Disease +
overload L-Disease +
and O +
premature B-Disease +
death L-Disease -
. O -

The O +
hemochromatosis U-Disease +
gene O -
, O +
HFE O -
, O +
recently O +
has O +
been O +
identified O -
, O +
and O +
characterization O +
of O +
this O +
gene O +
has O +
shown O +
that O +
it O +
contains O +
two O +
mutations O +
that O +
result O +
in O +
amino O +
acid O +
substitutions O -
- O -
cDNA O +
nucleotides O +
845 O +
G-- O +
> O +
A O +
( O -
C282Y O -
) O +
and O +
187 O +
C-- O +
> O +
G O +
( O -
H63D O -
) O -
. O -

Although O +
hemochromatosis U-Disease +
is O +
common O +
in O +
Caucasians O -
, O +
affecting O +
> O +
= O +
1 O -
/ O -
300 O +
individuals O +
of O +
northern O +
European O +
origin O -
, O +
it O +
has O +
not O +
been O +
recognized O +
in O +
other O +
populations O -
. O -

The O +
present O +
study O +
used O +
PCR O +
and O +
restriction O -
- O -
enzyme O +
digestion O +
to O +
analyze O +
the O +
frequency O +
of O +
the O +
845 O +
G-- O +
> O +
A O +
and O +
187 O +
C-- O +
> O +
G O +
mutations O +
in O +
HLA O -
- O -
typed O +
samples O +
from O +
non O -
- O -
Caucasian O +
populations O -
, O +
comprising O +
Australian O +
Aboriginal O -
, O +
Chinese O -
, O +
and O +
Pacific O +
Islanders O -
. O -

Results O +
showed O +
that O +
the O +
845 O +
G-- O +
> O +
A O +
mutation O +
was O +
present O +
in O +
these O +
populations O +
( O -
allele O +
frequency O +
0 O -
. O +
32 O -
% O -
) O -
, O +
and O -
, O +
furthermore O -
, O +
it O +
was O +
always O +
seen O +
in O +
conjunction O +
with O +
HLA O +
haplotypes O +
common O +
in O +
Caucasians O -
, O +
suggesting O +
that O +
845 O +
G-- O +
> O +
A O +
may O +
have O +
been O +
introduced O +
into O +
these O +
populations O +
by O +
Caucasian O +
admixture O -
. O -

187 O +
C-- O +
> O +
G O +
was O +
present O +
at O +
an O +
allele O +
frequency O +
of O +
2 O -
. O +
68 O -
% O +
in O +
the O +
two O +
populations O +
analyzed O +
( O -
Australian O +
Aboriginal O +
and O +
Chinese O -
) O -
. O -

In O +
the O +
Australian O +
Aboriginal O +
samples O -
, O +
187 O +
C-- O +
> O +
G O +
was O +
found O +
to O +
be O +
associated O +
with O +
HLA O +
haplotypes O +
common O +
in O +
Caucasians O -
, O +
suggesting O +
that O +
it O +
was O +
introduced O +
by O +
recent O +
admixture O -
. O -

In O +
the O +
Chinese O +
samples O +
analyzed O -
, O +
187 O +
C-- O +
> O +
G O +
was O +
present O +
in O +
association O +
with O +
a O +
wide O +
variety O +
of O +
HLA O +
haplotypes O -
, O +
showing O +
this O +
mutation O +
to O +
be O +
widespread O +
and O +
likely O +
to O +
predate O +
the O +
more O +
genetically O +
restricted O +
845 O +
G-- O +
> O +
A O +
mutation O -
. O -

Genotype O -
- O -
phenotype O +
correlations O +
in O +
attenuated B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
coli L-Disease -
. O -

Germ O -
- O -
line O +
mutations O +
of O +
the O +
tumor U-Disease +
suppressor O +
APC O +
are O +
implicated O +
in O +
attenuated B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
coli L-Disease +
( O -
AAPC U-Disease -
) O -
, O +
a O +
variant O +
of O +
familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease +
( O -
FAP U-Disease -
) O -
. O -

AAPC U-Disease +
is O +
recognized O +
by O +
the O +
occurrence O +
of O +
< O +
100 O +
colonic B-Disease +
adenomas L-Disease +
and O +
a O +
later O +
onset O +
of O +
colorectal B-Disease +
cancer L-Disease +
( O -
age O +
> O +
40 O +
years O -
) O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
assess O +
genotype O -
- O -
phenotype O +
correlations O +
in O +
AAPC U-Disease +
families O -
. O -

By O +
protein O -
- O -
truncation O +
test O +
( O -
PTT O -
) O +
assay O -
, O +
the O +
entire O +
coding O +
region O +
of O +
the O +
APC U-Disease +
gene O +
was O +
screened O +
in O +
affected O +
individuals O +
from O +
11 O +
AAPC U-Disease +
kindreds O -
, O +
and O +
their O +
phenotypic O +
differences O +
were O +
examined O -
. O -

Five O +
novel O +
germ O -
- O -
line O +
APC U-Disease +
mutations O +
were O +
identified O +
in O +
seven O +
kindreds O -
. O -

Mutations O +
were O +
located O +
in O +
three O +
different O +
regions O +
of O +
the O +
APC U-Disease +
gene O -
( O -
1 O -
) O +
at O +
the O +
5 O +
end O +
spanning O +
exons O +
4 O +
and O +
5 O -
, O +
( O -
2 O -
) O +
within O +
exon O +
9 O -
, O +
and O +
( O -
3 O -
) O +
at O +
the O +
3 O +
distal O +
end O +
of O +
the O +
gene O -
. O -

Variability O +
in O +
the O +
number O +
of O +
colorectal B-Disease +
adenomas L-Disease +
was O +
most O +
apparent O +
in O +
individuals O +
with O +
mutations O +
in O +
region O +
1 O -
, O +
and O +
upper O -
- O -
gastrointestinal O +
manifestations O +
were O +
more O +
severe O +
in O +
them O -
. O -

In O +
individuals O +
with O +
mutations O +
in O +
either O +
region O +
2 O +
or O +
region O +
3 O -
, O +
the O +
average O +
number O +
of O +
adenomas U-Disease +
tended O +
to O +
be O +
lower O +
than O +
those O +
in O +
individuals O +
with O +
mutations O +
in O +
region O +
1 O -
, O +
although O +
age O +
at O +
diagnosis O +
was O +
similar O -
. O -

In O +
all O +
AAPC U-Disease +
kindreds O -
, O +
a O +
predominance O +
of O +
right O -
- O -
sided O +
colorectal B-Disease +
adenomas L-Disease +
and O +
rectal B-Disease +
polyp L-Disease +
sparing O +
was O +
observed O -
. O -

No O +
desmoid B-Disease +
tumors L-Disease +
were O +
found O +
in O +
these O +
kindreds O -
. O -

Our O +
data O +
suggest O +
that O -
, O +
in O +
AAPC U-Disease +
families O -
, O +
the O +
location O +
of O +
the O +
APC U-Disease +
mutation O +
may O +
partially O +
predict O +
specific O +
phenotypic O +
expression O -
. O -

This O +
should O +
help O +
in O +
the O +
design O +
of O +
tailored O +
clinical O -
- O -
management O +
protocols O +
in O +
this O +
subset O +
of O +
FAP U-Disease +
patients O -
.. O -

Wilms B-Disease -
' I-Disease +
tumor L-Disease +
1 O +
and O +
Dax-1 O +
modulate O +
the O +
orphan O +
nuclear O +
receptor O +
SF-1 O +
in O +
sex O -
- O -
specific O +
gene O +
expression O -
. O -

Products O +
of O +
steroidogenic O +
factor O +
1 O +
( O -
SF-1 O -
) O +
and O +
Wilms B-Disease +
tumor L-Disease +
1 O +
( O -
WT1 O -
) O +
genes O +
are O +
essential O +
for O +
mammalian O +
gonadogenesis O +
prior O +
to O +
sexual O +
differentiation O -
. O -

In O +
males O -
, O +
SF-1 O +
participates O +
in O +
sexual O +
development O +
by O +
regulating O +
expression O +
of O +
the O +
polypeptide O +
hormone O +
Mullerian O +
inhibiting O +
substance O +
( O -
MIS O -
) O -
. O -

Here O -
, O +
we O +
show O +
that O +
WT1 O +
-KTS O +
isoforms O +
associate O +
and O +
synergize O +
with O +
SF-1 O +
to O +
promote O +
MIS O +
expression O -
. O -

In O +
contrast O -
, O +
WT1 O +
missense O +
mutations O -
, O +
associated O +
with O +
male B-Disease +
pseudohermaphroditism L-Disease +
in O +
Denys B-Disease -
- I-Disease -
Drash I-Disease +
syndrome L-Disease -
, O +
fail O +
to O +
synergize O +
with O +
SF-1 O -
. O -

Additionally O -
, O +
the O +
X O -
- O -
linked O -
, O +
candidate O +
dosage O -
- O -
sensitive O +
sex O -
- O -
reversal O +
gene O -
, O +
Dax-1 O -
, O +
antagonizes O +
synergy O +
between O +
SF-1 O +
and O +
WT1 O -
, O +
most O +
likely O +
through O +
a O +
direct O +
interaction O +
with O +
SF-1 O -
. O -

We O +
propose O +
that O +
WT1 O +
and O +
Dax-1 O +
functionally O +
oppose O +
each O +
other O +
in O +
testis O +
development O +
by O +
modulating O +
SF-1-mediated O +
transactivation O -
.. O -

A O +
mouse O +
model O +
for O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
imprinting O -
- O -
centre O +
mutations O -
. O -

Imprinting O +
in O +
the O +
15q11-q13 O +
region O +
involves O +
an O +
imprinting O +
centre O +
( O -
IC O -
) O -
, O +
mapping O +
in O +
part O +
to O +
the O +
promoter O +
and O +
first O +
exon O +
of O +
SNRPN O -
. O -

Deletion O +
of O +
this O +
IC O +
abolishes O +
local O +
paternally O +
derived O +
gene O +
expression O +
and O +
results O +
in O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
( O -
PWS U-Disease -
) O -
. O -

We O +
have O +
created O +
two O +
deletion O +
mutations O +
in O +
mice O +
to O +
understand O +
PWS U-Disease +
and O +
the O +
mechanism O +
of O +
this O +
IC O -
. O -

Mice O +
harbouring O +
an O +
intragenic O +
deletion O +
in O +
Snrpn O +
are O +
phenotypically O +
normal O -
, O +
suggesting O +
that O +
mutations O +
of O +
SNRPN O +
are O +
not O +
sufficient O +
to O +
induce O +
PWS U-Disease -
. O -

Mice O +
with O +
a O +
larger O +
deletion O +
involving O +
both O +
Snrpn O +
and O +
the O +
putative O +
PWS O -
- O -
IC O +
lack O +
expression O +
of O +
the O +
imprinted O +
genes O +
Zfp127 O +
( O -
mouse O +
homologue O +
of O +
ZNF127 O -
) O -
, O +
Ndn O +
and O +
Ipw O -
, O +
and O +
manifest O +
several O +
phenotypes O +
common O +
to O +
PWS U-Disease +
infants O -
. O -

These O +
data O +
demonstrate O +
that O +
both O +
the O +
position O +
of O +
the O +
IC O +
and O +
its O +
role O +
in O +
the O +
coordinate O +
expression O +
of O +
genes O +
is O +
conserved O +
between O +
mouse O +
and O +
human O -
, O +
and O +
indicate O +
that O +
the O +
mouse O +
is O +
a O +
suitable O +
model O +
system O +
in O +
which O +
to O +
investigate O +
the O +
molecular O +
mechanisms O +
of O +
imprinting O +
in O +
this O +
region O +
of O +
the O +
genome O -
.. O -

Mutations O +
of O +
the O +
ATM O +
gene O +
detected O +
in O +
Japanese O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
patients O -
: O +
possible O +
preponderance O +
of O +
the O +
two O +
founder O +
mutations O +
4612del165 O +
and O +
7883del5 O -
. O -

The O +
ATM O +
( O -
A O -
- O -
T O -
, O +
mutated O -
) O +
gene O +
on O +
human O +
chromosome O +
11q22 O -
. O -

3 O +
has O +
recently O +
been O +
identified O +
as O +
the O +
gene O +
responsible O +
for O +
the O +
human O +
recessive B-Disease +
disease L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O -
. O -

In O +
order O +
to O +
define O +
the O +
types O +
of O +
disease O -
- O -
causing O +
ATM O +
mutations O +
in O +
Japanese O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O +
as O +
well O +
as O +
to O +
look O +
for O +
possible O +
mutational O +
hotspots O -
, O +
reverse O -
- O -
transcribed O +
RNA O +
derived O +
from O +
ten O +
patients O +
belonging O +
to O +
eight O +
unrelated O +
Japanese O +
A B-Disease -
- I-Disease -
T L-Disease +
families O +
was O +
analyzed O +
for O +
mutations O +
by O +
the O +
restriction O +
endonuclease O +
fingerprinting O +
method O -
. O -

As O +
has O +
been O +
reported O +
by O +
others O -
, O +
mutations O +
that O +
lead O +
to O +
exon O +
skipping O +
or O +
premature O +
protein O +
truncation O +
were O +
also O +
predominant O +
in O +
our O +
mutants O -
. O -

Six O +
different O +
mutations O +
were O +
identified O +
on O +
12 O +
of O +
the O +
16 O +
alleles O +
examined O -
. O -

Four O +
were O +
deletions O +
involving O +
a O +
loss O +
of O +
a O +
single O +
exon O -
exon O +
7 O -
, O +
exon O +
16 O -
, O +
exon O +
33 O +
or O +
exon O +
35 O -
. O -

The O +
others O +
were O +
minute O +
deletions O -
, O +
4649delA O +
in O +
exon O +
33 O +
and O +
7883del5 O +
in O +
exon O +
55 O -
. O -

The O +
mutations O +
4612del165 O +
and O +
7883del5 O +
were O +
found O +
in O +
more O +
than O +
two O +
unrelated O +
families O -
; O +
44 O -
% O +
( O -
7 O +
of O +
16 O -
) O +
of O +
the O +
mutant O +
alleles O +
had O +
one O +
of O +
the O +
two O +
mutations O -
. O -

The O +
4612del165 O +
mutations O +
in O +
three O +
different O +
families O +
were O +
all O +
ascribed O +
to O +
the O +
same O +
T-- O +
> O +
A O +
substitution O +
at O +
the O +
splice O +
donor O +
site O +
in O +
intron O +
33 O -
. O -

Microsatellite O +
genotyping O +
around O +
the O +
ATM O +
locus O +
also O +
indicated O +
that O +
a O +
common O +
haplotype O +
was O +
shared O +
by O +
the O +
mutant O +
alleles O +
in O +
both O +
mutations O -
. O -

This O +
suggests O +
that O +
these O +
two O +
founder O +
mutations O +
may O +
be O +
predominant O +
among O +
Japanese O +
ATM O +
mutant O +
alleles O -
. O -

W474C O +
amino O +
acid O +
substitution O +
affects O +
early O +
processing O +
of O +
the O +
alpha O -
- O -
subunit O +
of O +
beta O -
- O -
hexosaminidase O +
A O +
and O +
is O +
associated O +
with O +
subacute O +
G B-Disease -
( I-Disease -
M2 I-Disease -
) I-Disease +
gangliosidosis L-Disease -
. O -

Mutations O +
in O +
the O +
HEXA O +
gene O -
, O +
encoding O +
the O +
alpha O -
- O -
subunit O +
of O +
beta O -
- O -
hexosaminidase O +
A O +
( O -
Hex O +
A O -
) O -
, O +
that O +
abolish O +
Hex O +
A O +
enzyme O +
activity O +
cause O +
Tay B-Disease -
- I-Disease -
Sachs I-Disease +
disease L-Disease +
( O -
TSD U-Disease -
) O -
, O +
the O +
fatal O +
infantile B-Disease +
form I-Disease +
of I-Disease +
G I-Disease +
( I-Disease -
M2 I-Disease -
) I-Disease +
gangliosidosis I-Disease -
, I-Disease +
Type I-Disease +
1 L-Disease -
. O -

Less O +
severe O -
, O +
subacute O +
( O -
juvenile O -
- O -
onset O -
) O +
and O +
chronic O +
( O -
adult O -
- O -
onset O -
) O +
variants O +
are O +
characterized O +
by O +
a O +
broad O +
spectrum O +
of O +
clinical O +
manifestations O +
and O +
are O +
associated O +
with O +
residual O +
levels O +
of O +
Hex O +
A O +
enzyme O +
activity O -
. O -

We O +
identified O +
a O +
1422 O +
G-- O +
> O +
C O +
( O -
amino O +
acid O +
W474C O -
) O +
substitution O +
in O +
the O +
first O +
position O +
of O +
exon O +
13 O +
of O +
HEXA O +
of O +
a O +
non O -
- O -
Jewish O +
proband O +
who O +
manifested O +
a O +
subacute O +
variant O +
of O +
G B-Disease +
( I-Disease -
M2 I-Disease -
) I-Disease +
gangliosidosis L-Disease -
. O -

On O +
the O +
second O +
maternally O +
inherited O +
allele O -
, O +
we O +
identified O +
the O +
common O +
infantile O +
disease O -
- O -
causing O +
4-bp O +
insertion O -
, O +
+ O +
TATC O +
1278 O -
, O +
in O +
exon O +
11 O -
. O -

Pulse O -
- O -
chase O +
analysis O +
using O +
proband O +
fibroblasts O +
revealed O +
that O +
the O +
W474C O -
- O -
containing O +
alpha O -
- O -
subunit O +
precursor O +
was O +
normally O +
synthesized O -
, O +
but O +
not O +
phosphorylated O +
or O +
secreted O -
, O +
and O +
the O +
mature O +
lysosomal O +
alpha O -
- O -
subunit O +
was O +
not O +
detected O -
. O -

When O +
the O +
W474C O -
- O -
containing O +
alpha O -
- O -
subunit O +
was O +
transiently O +
co O -
- O -
expressed O +
with O +
the O +
beta O -
- O -
subunit O +
to O +
produce O +
Hex O +
A O +
( O -
alphabeta O -
) O +
in O +
COS-7 O +
cells O -
, O +
the O +
mature O +
alpha O -
- O -
subunit O +
was O +
present O -
, O +
but O +
its O +
level O +
was O +
much O +
lower O +
than O +
that O +
from O +
normal O +
alpha O -
- O -
subunit O +
transfections O -
, O +
although O +
higher O +
than O +
in O +
those O +
cells O +
transfected O +
with O +
an O +
alpha O -
- O -
subunit O +
associated O +
with O +
infantile O +
TSD U-Disease -
. O -

Furthermore O -
, O +
the O +
precursor O +
level O +
of O +
the O +
W474C O +
alpha O -
- O -
subunit O +
was O +
found O +
to O +
accumulate O +
in O +
comparison O +
to O +
the O +
normal O +
alpha O -
- O -
subunit O +
precursor O +
levels O -
. O -

We O +
conclude O +
that O +
the O +
1422 O +
G-- O +
> O +
C O +
mutation O +
is O +
the O +
cause O +
of O +
Hex B-Disease +
A I-Disease +
enzyme I-Disease +
deficiency L-Disease +
in O +
the O +
proband O -
. O -

The O +
resulting O +
W474C O +
substitution O +
clearly O +
interferes O +
with O +
alpha O -
- O -
subunit O +
processing O -
, O +
but O +
because O +
the O +
base O +
substitution O +
falls O +
at O +
the O +
first O +
position O +
of O +
exon O +
13 O -
, O +
aberrant O +
splicing O +
may O +
also O +
contribute O +
to O +
Hex B-Disease +
A I-Disease +
deficiency L-Disease +
in O +
this O +
proband O -
.. O -

Two O +
frequent O +
missense O +
mutations O +
in O +
Pendred B-Disease +
syndrome L-Disease -
. O -

Pendred B-Disease +
syndrome L-Disease +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
disorder L-Disease +
characterized O +
by O +
early O +
childhood O +
deafness U-Disease +
and O +
goiter U-Disease -
. O -

A O +
century O +
after O +
its O +
recognition O +
as O +
a O +
syndrome O +
by O +
Vaughan O +
Pendred O -
, O +
the O +
disease O +
gene O +
( O -
PDS O -
) O +
was O +
mapped O +
to O +
chromosome O +
7q22-q31 O -
. O -

1 O +
and O -
, O +
recently O -
, O +
found O +
to O +
encode O +
a O +
putative O +
sulfate O +
transporter O -
. O -

We O +
performed O +
mutation O +
analysis O +
of O +
the O +
PDS U-Disease +
gene O +
in O +
patients O +
from O +
14 O +
Pendred U-Disease +
families O +
originating O +
from O +
seven O +
countries O +
and O +
identified O +
all O +
mutations O -
. O -

The O +
mutations O +
include O +
three O +
single O +
base O +
deletions O -
, O +
one O +
splice O +
site O +
mutation O +
and O +
10 O +
missense O +
mutations O -
. O -

One O +
missense O +
mutation O +
( O -
L236P O -
) O +
was O +
found O +
in O +
a O +
homozygous O +
state O +
in O +
two O +
consanguineous O +
families O +
and O +
in O +
a O +
heterozygous O +
state O +
in O +
five O +
additional O +
non O -
- O -
consanguineous O +
families O -
. O -

Another O +
missense O +
mutation O +
( O -
T416P O -
) O +
was O +
found O +
in O +
a O +
homozygous O +
state O +
in O +
one O +
family O +
and O +
in O +
a O +
heterozygous O +
state O +
in O +
four O +
families O -
. O -

Pendred U-Disease +
patients O +
in O +
three O +
non O -
- O -
consanguineous O +
families O +
were O +
shown O +
to O +
be O +
compound O +
heterozygotes O +
for O +
L236P O +
and O +
T416P O -
. O -

In O +
total O -
, O +
one O +
or O +
both O +
of O +
these O +
mutations O +
were O +
found O +
in O +
nine O +
of O +
the O +
14 O +
families O +
analyzed O -
. O -

The O +
identification O +
of O +
two O +
frequent O +
PDS U-Disease +
mutations O +
will O +
facilitate O +
the O +
molecular O +
diagnosis O +
of O +
Pendred B-Disease +
syndrome L-Disease -
. O -

Insertional O +
mutation O +
by O +
transposable O +
element O -
, O +
L1 O -
, O +
in O +
the O +
DMD U-Disease +
gene O +
results O +
in O +
X B-Disease -
- I-Disease -
linked I-Disease +
dilated I-Disease +
cardiomyopathy L-Disease -
. O -

X B-Disease -
- I-Disease -
linked I-Disease +
dilated I-Disease +
cardiomyopathy L-Disease +
( O -
XLDCM U-Disease -
) O +
is O +
a O +
clinical O +
phenotype O +
of O +
dystrophinopathy U-Disease +
which O +
is O +
characterized O +
by O +
preferential O +
myocardial B-Disease +
involvement L-Disease +
without O +
any O +
overt O +
clinical O +
signs O +
of O +
skeletal B-Disease +
myopathy L-Disease -
. O -

To O +
date O -
, O +
several O +
mutations O +
in O +
the O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease +
gene O -
, O +
DMD O -
, O +
have O +
been O +
identified O +
in O +
patients O +
with O +
XLDCM U-Disease -
, O +
but O +
a O +
pathogenic O +
correlation O +
of O +
these O +
cardiospecific O +
mutations O +
in O +
DMD O +
with O +
the O +
XLDCM U-Disease +
phenotype O +
has O +
remained O +
to O +
be O +
elucidated O -
. O -

We O +
report O +
here O +
the O +
identification O +
of O +
a O +
unique O +
de O +
novo O +
L1 O +
insertion O +
in O +
the O +
muscle O +
exon O +
1 O +
in O +
DMD O +
in O +
three O +
XLDCM U-Disease +
patients O +
from O +
two O +
unrelated O +
Japanese O +
families O -
. O -

The O +
insertion O +
was O +
a O +
5-truncated O +
form O +
of O +
human O +
L1 O +
inversely O +
integrated O +
in O +
the O +
5-untranslated O +
region O +
in O +
the O +
muscle O +
exon O +
1 O -
, O +
which O +
affected O +
the O +
transcription O +
or O +
the O +
stability O +
of O +
the O +
muscle O +
form O +
of O +
dystrophin O +
transcripts O +
but O +
not O +
that O +
of O +
the O +
brain O +
or O +
Purkinje O +
cell O +
form O -
, O +
probably O +
due O +
to O +
its O +
unique O +
site O +
of O +
integration O -
. O -

We O +
speculate O +
that O +
this O +
insertion O +
of O +
an O +
L1 O +
sequence O +
in O +
DMD O +
is O +
responsible O +
for O +
some O +
of O +
the O +
population O +
of O +
Japanese O +
patients O +
with O +
XLDCM U-Disease -
.. O -

Severe O +
early O -
- O -
onset O +
obesity U-Disease -
, O +
adrenal B-Disease +
insufficiency L-Disease +
and O +
red O +
hair O +
pigmentation O +
caused O +
by O +
POMC O +
mutations O +
in O +
humans O -
. O -

Sequential O +
cleavage O +
of O +
the O +
precursor O +
protein O +
pre O -
- O -
pro O -
- O -
opiomelanocortin O +
( O -
POMC O -
) O +
generates O +
the O +
melanocortin O +
peptides O +
adrenocorticotrophin O +
( O -
ACTH O -
) O -
, O +
melanocyte O -
- O -
stimulating O +
hormones O +
( O -
MSH O -
) O +
alpha O -
, O +
beta O +
and O +
gamma O +
as O +
well O +
as O +
the O +
opioid O -
- O -
receptor O +
ligand O +
beta O -
- O -
endorphin O -
. O -

While O +
a O +
few O +
cases O +
of O +
isolated O +
ACTH B-Disease +
deficiency L-Disease +
have O +
been O +
reported O +
( O -
OMIM O +
201400 O -
) O -
, O +
an O +
inherited O +
POMC O +
defect O +
has O +
not O +
been O +
described O +
so O +
far O -
. O -

Recent O +
studies O +
in O +
animal O +
models O +
elucidated O +
a O +
central O +
role O +
of O +
alpha O -
- O -
MSH O +
in O +
the O +
regulation O +
of O +
food O +
intake O +
by O +
activation O +
of O +
the O +
brain O +
melanocortin-4-receptor O +
( O -
MC4-R O -
; O +
refs O +
3 O -
- O -
5 O -
) O +
and O +
the O +
linkage O +
of O +
human O +
obesity U-Disease +
to O +
chromosome O +
2 O +
in O +
close O +
proximity O +
to O +
the O +
POMC O +
locus O -
, O +
led O +
to O +
the O +
proposal O +
of O +
an O +
association O +
of O +
POMC O +
with O +
human O +
obesity U-Disease -
. O -

The O +
dual O +
role O +
of O +
alpha O -
- O -
MSH O +
in O +
regulating O +
food O +
intake O +
and O +
influencing O +
hair O +
pigmentation O +
predicts O +
that O +
the O +
phenotype O +
associated O +
with O +
a O +
defect O +
in O +
POMC O +
function O +
would O +
include O +
obesity U-Disease -
, O +
alteration O +
in O +
pigmentation O +
and O +
ACTH B-Disease +
deficiency L-Disease -
. O -

The O +
observation O +
of O +
these O +
symptoms O +
in O +
two O +
probands O +
prompted O +
us O +
to O +
search O +
for O +
mutations O +
within O +
their O +
POMC O +
genes O -
. O -

Patient O +
1 O +
was O +
found O +
to O +
be O +
a O +
compound O +
heterozygote O +
for O +
two O +
mutations O +
in O +
exon O +
3 O +
( O -
G7013 O -
T O -
, O +
C7133delta O -
) O +
which O +
interfere O +
with O +
appropriate O +
synthesis O +
of O +
ACTH O +
and O +
alpha O -
- O -
MSH O -
. O -

Patient O +
2 O +
was O +
homozygous O +
for O +
a O +
mutation O +
in O +
exon O +
2 O +
( O -
C3804A O -
) O +
which O +
abolishes O +
POMC O +
translation O -
. O -

These O +
findings O +
represent O +
the O +
first O +
examples O +
of O +
a O +
genetic B-Disease +
defect L-Disease +
within O +
the O +
POMC O +
gene O +
and O +
define O +
a O +
new O +
monogenic B-Disease +
endocrine I-Disease +
disorder L-Disease +
resulting O +
in O +
early O -
- O -
onset O +
obesity U-Disease -
, O +
adrenal B-Disease +
insufficiency L-Disease +
and O +
red O +
hair O +
pigmentation O -
.. O -

A O +
European O +
multicenter O +
study O +
of O +
phenylalanine B-Disease +
hydroxylase I-Disease +
deficiency L-Disease -
: O +
classification O +
of O +
105 O +
mutations O +
and O +
a O +
general O +
system O +
for O +
genotype O -
- O -
based O +
prediction O +
of O +
metabolic O +
phenotype O -
. O -

Phenylketonuria U-Disease +
( O -
PKU U-Disease -
) O +
and O +
mild B-Disease +
hyperphenylalaninemia L-Disease +
( O -
MHP U-Disease -
) O +
are O +
allelic B-Disease +
disorders L-Disease +
caused O +
by O +
mutations O +
in O +
the O +
gene O +
encoding O +
phenylalanine O +
hydroxylase O +
( O -
PAH O -
) O -
. O -

Previous O +
studies O +
have O +
suggested O +
that O +
the O +
highly O +
variable O +
metabolic O +
phenotypes O +
of O +
PAH B-Disease +
deficiency L-Disease +
correlate O +
with O +
PAH O +
genotypes O -
. O -

We O +
identified O +
both O +
causative O +
mutations O +
in O +
686 O +
patients O +
from O +
seven O +
European O +
centers O -
. O -

On O +
the O +
basis O +
of O +
the O +
phenotypic O +
characteristics O +
of O +
297 O +
functionally O +
hemizygous O +
patients O -
, O +
105 O +
of O +
the O +
mutations O +
were O +
assigned O +
to O +
one O +
of O +
four O +
arbitrary O +
phenotype O +
categories O -
. O -

We O +
proposed O +
and O +
tested O +
a O +
simple O +
model O +
for O +
correlation O +
between O +
genotype O +
and O +
phenotypic O +
outcome O -
. O -

The O +
observed O +
phenotype O +
matched O +
the O +
predicted O +
phenotype O +
in O +
79 O -
% O +
of O +
the O +
cases O -
, O +
and O +
in O +
only O +
5 O +
of O +
184 O +
patients O +
was O +
the O +
observed O +
phenotype O +
more O +
than O +
one O +
category O +
away O +
from O +
that O +
expected O -
. O -

Among O +
the O +
seven O +
contributing O +
centers O -
, O +
the O +
proportion O +
of O +
patients O +
for O +
whom O +
the O +
observed O +
phenotype O +
did O +
not O +
match O +
the O +
predicted O +
phenotype O +
was O +
4 O -
% O +
-23 O -
% O +
( O -
P O +
< O -
. O +
0001 O -
) O -
, O +
suggesting O +
that O +
differences O +
in O +
methods O +
used O +
for O +
mutation O +
detection O +
or O +
phenotype O +
classification O +
may O +
account O +
for O +
a O +
considerable O +
proportion O +
of O +
genotype O -
- O -
phenotype O +
inconsistencies O -
. O -

Our O +
data O +
indicate O +
that O +
the O +
PAH O -
- O -
mutation O +
genotype O +
is O +
the O +
main O +
determinant O +
of O +
metabolic O +
phenotype O +
in O +
most O +
patients O +
with O +
PAH B-Disease +
deficiency L-Disease -
. O -

In O +
the O +
present O +
study O -
, O +
the O +
classification O +
of O +
105 O +
PAH O +
mutations O +
may O +
allow O +
the O +
prediction O +
of O +
the O +
biochemical O +
phenotype O +
in O +
> O +
10 O -
, O +
000 O +
genotypes O -
, O +
which O +
may O +
be O +
useful O +
for O +
the O +
management O +
of O +
hyperphenylalaninemia U-Disease +
in O +
newborns O -
. O -

Somatic O +
instability O +
of O +
the O +
CTG O +
repeat O +
in O +
mice O +
transgenic O +
for O +
the O +
myotonic B-Disease +
dystrophy L-Disease +
region O +
is O +
age O +
dependent O +
but O +
not O +
correlated O +
to O +
the O +
relative O +
intertissue O +
transcription O +
levels O +
and O +
proliferative O +
capacities O -
. O -

A O +
( O -
CTG O -
) O +
nexpansion O +
in O +
the O +
3-untranslated O +
region O +
( O -
UTR O -
) O +
of O +
the O +
DM O +
protein O +
kinase O +
gene O +
( O -
DMPK O -
) O +
is O +
responsible O +
for O +
causing O +
myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O -
. O -

Major O +
instability O -
, O +
with O +
very O +
large O +
expansions O +
between O +
generations O +
and O +
high O +
levels O +
of O +
somatic O +
mosaicism O -
, O +
is O +
observed O +
in O +
patients O -
. O -

There O +
is O +
a O +
good O +
correlation O +
between O +
repeat O +
size O +
( O -
at O +
least O +
in O +
leucocytes O -
) O -
, O +
clinical O +
severity O +
and O +
age O +
of O +
onset O -
. O -

The O +
trinucleotide O +
repeat O +
instability O +
mechanisms O +
involved O +
in O +
DM U-Disease +
and O +
other O +
human O +
genetic B-Disease +
diseases L-Disease +
are O +
unknown O -
. O -

We O +
studied O +
somatic O +
instability O +
by O +
measuring O +
the O +
CTG O +
repeat O +
length O +
at O +
several O +
ages O +
in O +
various O +
tissues O +
of O +
transgenic O +
mice O +
carrying O +
a O +
( O -
CTG O -
) O +
55expansion O +
surrounded O +
by O +
45 O +
kb O +
of O +
the O +
human O +
DM U-Disease +
region O -
, O +
using O +
small O -
- O -
pool O +
PCR O -
. O -

These O +
mice O +
have O +
been O +
shown O +
to O +
reproduce O +
the O +
intergenerational O +
and O +
somatic O +
instability O +
of O +
the O +
55 O +
CTG O +
repeat O +
suggesting O +
that O +
surrounding O +
sequences O +
and O +
the O +
chromatin O +
environment O +
are O +
involved O +
in O +
instability O +
mechanisms O -
. O -

As O +
observed O +
in O +
some O +
of O +
the O +
tissues O +
of O +
DM U-Disease +
patients O -
, O +
there O +
is O +
a O +
tendency O +
for O +
repeat O +
length O +
and O +
somatic O +
mosaicism O +
to O +
increase O +
with O +
the O +
age O +
of O +
the O +
mouse O -
. O -

Furthermore O -
, O +
we O +
observed O +
no O +
correlation O +
between O +
the O +
somatic O +
mutation O +
rate O +
and O +
tissue O +
proliferation O +
capacity O -
. O -

The O +
somatic O +
mutation O +
rates O +
in O +
different O +
tissues O +
were O +
also O +
not O +
correlated O +
to O +
the O +
relative O +
inter O -
- O -
tissue O +
difference O +
in O +
transcriptional O +
levels O +
of O +
the O +
three O +
genes O +
( O -
DMAHP O -
, O +
DMPK O +
and O +
59 O -
) O +
surrounding O +
the O +
repeat O -
.. O -

A O +
novel O +
missense O +
mutation O +
in O +
patients O +
from O +
a O +
retinoblastoma U-Disease +
pedigree O +
showing O +
only O +
mild O +
expression O +
of O +
the O +
tumor U-Disease +
phenotype O -
. O -

We O +
have O +
used O +
single O +
strand O +
conformation O +
polymorphism O +
analysis O +
to O +
study O +
the O +
27 O +
exons O +
of O +
the O +
RB1 O +
gene O +
in O +
individuals O +
from O +
a O +
family O +
showing O +
mild O +
expression O +
of O +
the O +
retinoblastoma U-Disease +
phenotype O -
. O -

In O +
this O +
family O +
affected O +
individuals O +
developed O +
unilateral B-Disease +
tumors L-Disease +
and O -
, O +
as O +
a O +
result O +
of O +
linkage O +
analysis O -
, O +
unaffected O +
mutation O +
carriers O +
were O +
also O +
identified O +
within O +
the O +
pedigree O -
. O -

A O +
single O +
band O +
shift O +
using O +
SSCP O +
was O +
identified O +
in O +
exon O +
21 O +
which O +
resulted O +
in O +
a O +
missense O +
mutation O +
converting O +
a O +
cys-- O +
> O +
arg O +
at O +
nucleotide O +
position O +
28 O +
in O +
the O +
exon O -
. O -

The O +
mutation O +
destroyed O +
an O +
NdeI O +
restriction O +
enzyme O +
site O -
. O -

Analysis O +
of O +
all O +
family O +
members O +
demonstrated O +
that O +
the O +
missense O +
mutation O +
co O -
- O -
segregated O +
with O +
patients O +
with O +
tumors U-Disease +
or O +
who O -
, O +
as O +
a O +
result O +
of O +
linkage O +
analysis O +
had O +
been O +
predicted O +
to O +
carry O +
the O +
predisposing O +
mutation O -
. O -

These O +
observations O +
point O +
to O +
another O +
region O +
of O +
the O +
RB1 O +
gene O +
where O +
mutations O +
only O +
modify O +
the O +
function O +
of O +
the O +
gene O +
and O +
raise O +
important O +
questions O +
for O +
genetic O +
counseling O +
in O +
families O +
with O +
these O +
distinctive O +
phenotypes O -
.. O -

Maternal B-Disease +
disomy L-Disease +
and O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
consistent O +
with O +
gamete O +
complementation O +
in O +
a O +
case O +
of O +
familial O +
translocation O +
( O -
3;15 O -
) O +
( O -
p25;q11.2 O -
) O -
. O -

Maternal B-Disease +
uniparental I-Disease +
disomy I-Disease +
( I-Disease -
UPD I-Disease -
) I-Disease +
for I-Disease +
chromosome I-Disease +
15 L-Disease +
is O +
responsible O +
for O +
an O +
estimated O +
30 O -
% O +
of O +
cases O +
of O +
Prader B-Disease -
- I-Disease -
Willi I-Disease +
syndrome L-Disease +
( O -
PWS U-Disease -
) O -
. O -

We O +
report O +
on O +
an O +
unusual O +
case O +
of O +
maternal B-Disease +
disomy I-Disease +
15 L-Disease +
in O +
PWS U-Disease +
that O +
is O +
most O +
consistent O +
with O +
adjacent-1 O +
segregation O +
of O +
a O +
paternal O +
t O +
( O -
3 O -
; O +
15 O -
) O +
( O -
p25 O -
; O +
q11 O -
. O -

2 O -
) O +
with O +
simultaneous O +
maternal O +
meiotic O +
nondisjunction O +
for O +
chromosome O +
15 O -
. O -

The O +
patient O +
( O -
J. O +
B. O -
) O -
, O +
a O +
17-year O -
- O -
old O +
white O +
male O +
with O +
PWS U-Disease -
, O +
was O +
found O +
to O +
have O +
47 O +
chromosomes O +
with O +
a O +
supernumerary O -
, O +
paternal O +
der O +
( O -
15 O -
) O +
consisting O +
of O +
the O +
short O +
arm O +
and O +
the O +
proximal O +
long O +
arm O +
of O +
chromosome O +
15 O -
, O +
and O +
distal O +
chromosome O +
arm O +
3p O -
. O -

The O +
t O +
( O -
3 O -
; O +
15 O -
) O +
was O +
present O +
in O +
the O +
balanced O +
state O +
in O +
the O +
patients O +
father O +
and O +
a O +
sister O -
. O -

Fluorescent O +
in O +
situ O +
hybridization O +
analysis O +
demonstrated O +
that O +
the O +
PWS U-Disease +
critical O +
region O +
resided O +
on O +
the O +
derivative O +
chromosome O +
3 O +
and O +
that O +
there O +
was O +
no O +
deletion O +
of O +
the O +
PWS U-Disease +
region O +
on O +
the O +
normal O +
pair O +
of O +
15s O +
present O +
in O +
J. O +
B. O +
Methylation O +
analysis O +
at O +
exon O +
alpha O +
of O +
the O +
small O +
nuclear O +
ribonucleoprotein O -
- O -
associated O +
polypeptide O +
N O +
( O -
SNRPN O -
) O +
gene O +
showed O +
a O +
pattern O +
characteristic O +
of O +
only O +
the O +
maternal O +
chromosome O +
15 O +
in O +
J. O +
B. O +
Maternal B-Disease +
disomy L-Disease +
was O +
confirmed O +
by O +
polymerase O +
chain O +
reaction O +
analysis O +
of O +
microsatellite O +
repeats O +
at O +
the O +
gamma O -
- O -
aminobutyric O +
acid O +
receptor O +
beta3 O +
subunit O +
( O -
GABRB3 O -
) O +
locus O -
. O -

A O +
niece O +
( O -
B. O +
B. O -
) O +
with O +
45 O +
chromosomes O +
and O +
the O +
derivative O +
3 O +
but O +
without O +
the O +
der O +
( O -
15 O -
) O +
demonstrated O +
a O +
phenotype O +
consistent O +
with O +
that O +
reported O +
for O +
haploinsufficiency O +
of O +
distal O +
3 O +
p. O +
Uniparental B-Disease +
disomy L-Disease +
associated O +
with O +
unbalanced O +
segregation O +
of O +
non O -
- O -
Robertsonian O +
translocations O +
has O +
been O +
reported O +
previously O +
but O +
has O +
not O -
, O +
to O +
our O +
knowledge O -
, O +
been O +
observed O +
in O +
a O +
case O +
of O +
PWS U-Disease -
. O -

Furthermore O -
, O +
our O +
findings O +
are O +
best O +
interpreted O +
as O +
true O +
gamete O +
complementation O +
resulting O +
in O +
maternal B-Disease +
UPD I-Disease +
15 L-Disease +
and O +
PWS U-Disease -

Schwartz B-Disease -
- I-Disease -
Jampel I-Disease +
syndrome I-Disease +
type I-Disease +
2 L-Disease +
and O +
Stuve B-Disease -
- I-Disease -
Wiedemann I-Disease +
syndrome L-Disease -
: O +
a O +
case O +
for O +
" O -
lumping O -
" O -
. O -

Recent O +
studies O +
demonstrated O +
the O +
existence O +
of O +
a O +
genetically O +
distinct O -
, O +
usually O +
lethal O +
form O +
of O +
the O +
Schwartz B-Disease -
- I-Disease -
Jampel I-Disease +
syndrome L-Disease +
( O -
SJS U-Disease -
) O +
of O +
myotonia U-Disease +
and O +
skeletal B-Disease +
dysplasia L-Disease -
, O +
which O +
we O +
called O +
SJS B-Disease +
type I-Disease +
2 L-Disease -
. O -

This O +
disorder O +
is O +
reminiscent O +
of O +
another O +
rare O +
condition O -
, O +
the O +
Stuve B-Disease -
- I-Disease -
Wiedemann I-Disease +
syndrome L-Disease +
( O -
SWS U-Disease -
) O -
, O +
which O +
comprises O +
campomelia U-Disease +
at O +
birth O +
with O +
skeletal B-Disease +
dysplasia L-Disease -
, O +
contractures U-Disease -
, O +
and O +
early B-Disease +
death L-Disease -
. O -

To O +
test O +
for O +
possible O +
nosologic O +
identity O +
between O +
these O +
disorders O -
, O +
we O +
reviewed O +
the O +
literature O +
and O +
obtained O +
a O +
follow O -
- O -
up O +
of O +
the O +
only O +
two O +
surviving O +
patients O -
, O +
one O +
with O +
SJS B-Disease +
type I-Disease +
2 L-Disease +
at O +
age O +
10 O +
years O +
and O +
another O +
with O +
SWS U-Disease +
at O +
age O +
7 O +
years O -
. O -

Patients O +
reported O +
as O +
having O +
either O +
neonatal O +
SJS U-Disease +
or O +
SWS U-Disease +
presented O +
a O +
combination O +
of O +
a O +
severe O -
, O +
prenatal O -
- O -
onset O +
neuromuscular B-Disease +
disorder L-Disease +
( O -
with O +
congenital B-Disease +
joint I-Disease +
contractures L-Disease -
, O +
respiratory O +
and O +
feeding O +
difficulties O -
, O +
tendency O +
to O +
hyperthermia U-Disease -
, O +
and O +
frequent O +
death O +
in O +
infancy O -
) O +
with O +
a O +
distinct O +
campomelic B-Disease -
- I-Disease -
metaphyseal I-Disease +
skeletal I-Disease +
dysplasia L-Disease -
. O -

The O +
similarity O +
of O +
the O +
clinical O +
and O +
radiographic O +
findings O +
is O +
so O +
extensive O +
that O +
these O +
disorders O +
appear O +
to O +
be O +
a O +
single O +
entity O -
. O -

The O +
follow O -
- O -
up O +
observation O +
of O +
an O +
identical O +
and O +
unique O +
pattern O +
of O +
progressive O +
bone B-Disease +
dysplasia L-Disease +
in O +
the O +
two O +
patients O +
( O -
one O +
with O +
SJS B-Disease +
type I-Disease +
2 L-Disease -
, O +
one O +
with O +
SWS U-Disease -
) O +
surviving O +
beyond O +
infancy O +
adds O +
to O +
the O +
evidence O +
in O +
favor O +
of O +
identity O -
. O -

The O +
hypothesis O +
that O +
SWS U-Disease +
and O +
SJS B-Disease +
type I-Disease +
2 L-Disease +
are O +
the O +
same O +
disorder O +
should O +
be O +
testable O +
by O +
molecular O +
methods O -
.. O -

A O +
mouse O +
model O +
of O +
severe O +
von B-Disease +
Willebrand I-Disease +
disease L-Disease -
: O +
defects O +
in O +
hemostasis O +
and O +
thrombosis U-Disease -
. O -

von B-Disease +
Willebrand I-Disease +
factor I-Disease +
( I-Disease -
vWf I-Disease -
) I-Disease +
deficiency L-Disease +
causes O +
severe O +
von B-Disease +
Willebrand I-Disease +
disease L-Disease +
in O +
humans O -
. O -

We O +
generated O +
a O +
mouse O +
model O +
for O +
this O +
disease O +
by O +
using O +
gene O +
targeting O -
. O -

vWf B-Disease -
- I-Disease -
deficient L-Disease +
mice O +
appeared O +
normal O +
at O +
birth O -
; O +
they O +
were O +
viable O +
and O +
fertile O -
. O -

Neither O +
vWf O +
nor O +
vWf O +
propolypeptide O +
( O -
von B-Disease +
Willebrand L-Disease +
antigen O +
II O -
) O +
were O +
detectable O +
in O +
plasma O -
, O +
platelets O -
, O +
or O +
endothelial O +
cells O +
of O +
the O +
homozygous O +
mutant O +
mice O -
. O -

The O +
mutant O +
mice O +
exhibited O +
defects O +
in O +
hemostasis O +
with O +
a O +
highly O +
prolonged O +
bleeding O +
time O +
and O +
spontaneous O +
bleeding O +
events O +
in O +
approximately O +
10 O -
% O +
of O +
neonates O -
. O -

As O +
in O +
the O +
human O +
disease O -
, O +
the O +
factor O +
VIII O +
level O +
in O +
these O +
mice O +
was O +
reduced O +
strongly O +
as O +
a O +
result O +
of O +
the O +
lack O +
of O +
protection O +
provided O +
by O +
vWf O -
. O -

Defective O +
thrombosis U-Disease +
in O +
mutant O +
mice O +
was O +
also O +
evident O +
in O +
an O +
in O +
vivo O +
model O +
of O +
vascular B-Disease +
injury L-Disease -
. O -

In O +
this O +
model O -
, O +
the O +
exteriorized O +
mesentery O +
was O +
superfused O +
with O +
ferric O +
chloride O +
and O +
the O +
accumulation O +
of O +
fluorescently O +
labeled O +
platelets O +
was O +
observed O +
by O +
intravital O +
microscopy O -
. O -

We O +
conclude O +
that O +
these O +
mice O +
very O +
closely O +
mimic O +
severe O +
human O +
von B-Disease +
Willebrand I-Disease +
disease L-Disease +
and O +
will O +
be O +
very O +
useful O +
for O +
investigating O +
the O +
role O +
of O +
vWf O +
in O +
normal O +
physiology O +
and O +
in O +
disease O +
models O -
.. O -

Oral O +
contraceptives O +
and O +
the O +
risk O +
of O +
hereditary B-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

Hereditary B-Disease +
Ovarian I-Disease +
Cancer L-Disease +
Clinical O +
Study O +
Group O -
. O -

BACKGROUND O -
Women O +
with O +
mutations O +
in O +
either O +
the O +
BRCA1 O +
or O +
the O +
BRCA2 O +
gene O +
have O +
a O +
high O +
lifetime O +
risk O +
of O +
ovarian B-Disease +
cancer L-Disease -
. O -

Oral O +
contraceptives O +
protect O +
against O +
ovarian B-Disease +
cancer L-Disease +
in O +
general O -
, O +
but O +
it O +
is O +
not O +
known O +
whether O +
they O +
also O +
protect O +
against O +
hereditary B-Disease +
forms I-Disease +
of I-Disease +
ovarian I-Disease +
cancer L-Disease -
. O -

METHODS O -
We O +
enrolled O +
207 O +
women O +
with O +
hereditary B-Disease +
ovarian I-Disease +
cancer L-Disease +
and O +
161 O +
of O +
their O +
sisters O +
as O +
controls O +
in O +
a O +
case O -
- O -
control O +
study O -
. O -

All O +
the O +
patients O +
carried O +
a O +
pathogenic O +
mutation O +
in O +
either O +
BRCA1 O +
( O -
179 O +
women O -
) O +
or O +
BRCA2 O +
( O -
28 O +
women O -
) O -
. O -

The O +
control O +
women O +
were O +
enrolled O +
regardless O +
of O +
whether O +
or O +
not O +
they O +
had O +
either O +
mutation O -
. O -

Lifetime O +
histories O +
of O +
oral O -
- O -
contraceptive O +
use O +
were O +
obtained O +
by O +
interview O +
or O +
by O +
written O +
questionnaire O +
and O +
were O +
compared O +
between O +
patients O +
and O +
control O +
women O -
, O +
after O +
adjustment O +
for O +
year O +
of O +
birth O +
and O +
parity O -
. O -

RESULTS O -
The O +
adjusted O +
odds O +
ratio O +
for O +
ovarian B-Disease +
cancer L-Disease +
associated O +
with O +
any O +
past O +
use O +
of O +
oral O +
contraceptives O +
was O +
0 O -
. O +
5 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
0 O -
. O +
3 O +
to O +
0 O -
. O -

8) O -
. O -

The O +
risk O +
decreased O +
with O +
increasing O +
duration O +
of O +
use O +
( O -
P O +
for O +
trend O -
, O +
< O +
0 O -
. O +
001 O -
) O -
; O +
use O +
for O +
six O +
or O +
more O +
years O +
was O +
associated O +
with O +
a O +
60 O +
percent O +
reduction O +
in O +
risk O -
. O -

Oral O -
- O -
contraceptive O +
use O +
protected O +
against O +
ovarian B-Disease +
cancer L-Disease +
both O +
for O +
carriers O +
of O +
the O +
BRCA1 O +
mutation O +
( O -
odds O +
ratio O -
, O +
0 O -
. O +
5 O -
; O +
95 O +
percent O +
confidence O +
interval O -
, O +
0 O -
. O +
3 O +
to O +
0 O -
. O +
9 O -
) O +
and O +
for O +
carriers O +
of O +
the O +
BRCA2 O +
mutation O +
( O -
odds O +
ratio O -
, O +
0 O -
. O +
4 O -
; O +
95 O +
percent O +
confidence O +
interval O -
, O +
0 O -
. O +
2 O +
to O +
1 O -
. O +
1 O -
) O -
. O -

CONCLUSIONS O -
Oral O -
- O -
contraceptive O +
use O +
may O +
reduce O +
the O +
risk O +
of O +
ovarian B-Disease +
cancer L-Disease +
in O +
women O +
with O +
pathogenic O +
mutations O +
in O +
the O +
BRCA1 O +
or O +
BRCA2 O +
gene O -

A O +
Japanese O +
family O +
with O +
adrenoleukodystrophy U-Disease +
with O +
a O +
codon O +
291 O +
deletion O -
: O +
a O +
clinical O -
, O +
biochemical O -
, O +
pathological O -
, O +
and O +
genetic O +
report O -
. O -

We O +
report O +
a O +
Japanese O +
family O +
with O +
adrenoleukodystrophy U-Disease +
( O -
ALD U-Disease -
) O +
with O +
a O +
three O +
base O +
pair O +
deletion O +
( O -
delGAG O +
291 O -
) O +
in O +
the O +
ALD U-Disease +
gene O -
. O -

A O +
variety O +
of O +
phenotypes O +
were O +
observed O +
within O +
this O +
family O -
. O -

While O +
the O +
proband O +
( O -
patient O +
1 O -
) O +
was O +
classified O +
as O +
having O +
a O +
rare O +
intermediate O +
type O +
of O +
adult O +
cerebral O +
and O +
cerebello O -
- O -
brain O +
stem O +
forms O -
, O +
his O +
younger O +
brother O +
( O -
patient O +
2 O -
) O +
and O +
nephew O +
( O -
patient O +
3 O -
) O +
had O +
a O +
childhood O +
ALD U-Disease +
type O -
. O -

Another O +
nephew O +
( O -
patient O +
4 O -
) O +
of O +
patient O +
1 O +
was O +
classified O +
as O +
having O +
an O +
adolescent O +
form O -
. O -

The O +
tau O +
level O +
in O +
the O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
in O +
patient O +
1 O +
was O +
as O +
high O +
as O +
that O +
of O +
patients O +
with O +
Alzheimers B-Disease +
disease L-Disease +
( O -
AD U-Disease -
) O -
. O -

His O +
brain O +
magnetic O +
resonance O +
image O +
( O -
MRI O -
) O +
showed O +
abnormalities B-Disease +
in I-Disease +
the I-Disease +
bilateral I-Disease +
cerebellar I-Disease +
hemispheres L-Disease +
and O +
brain O +
stem O -
, O +
but O +
not O +
in O +
the O +
cerebral O +
white O +
matter O -
, O +
where O +
marked O +
reductions O +
of O +
the O +
cerebral O +
blood O +
flow O +
and O +
oxygen O +
metabolism O +
were O +
clearly O +
demonstrated O +
by O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O -
. O -

In O +
patients O +
2 O +
and O +
3 O -
, O +
the O +
autopsy O +
findings O +
showed O +
massive O +
demyelination B-Disease +
of I-Disease +
the I-Disease +
cerebral I-Disease +
white I-Disease +
matter L-Disease +
with O +
sparing O +
of O +
the O +
U O -
- O -
fibers O -
, O +
compatible O +
with O +
the O +
findings O +
of O +
childhood O +
ALD U-Disease -
. O -

Oleic O +
and O +
erucic O +
acids O +
( O -
Lorenzos O +
Oil O -
) O +
were O +
administered O +
to O +
patients O +
1 O +
and O +
4 O -
, O +
but O +
sufficient O +
effectiveness O +
was O +
not O +
obtained O -
. O -

The O +
findings O +
in O +
this O +
family O +
suggest O +
that O +
delGAG291 O +
is O +
part O +
of O +
the O +
cause O +
of O +
Japanese O +
ALD U-Disease +
with O +
phenotypic O +
variations O -
. O -

Moreover O -
, O +
although O +
the O +
scale O +
of O +
the O +
study O +
is O +
limited O -
, O +
there O +
is O +
a O +
possibility O +
that O +
PET O +
can O +
detect O +
an O +
insidious B-Disease +
lesion L-Disease +
which O +
is O +
undetectable O +
by O +
computed O +
tomogram O +
( O -
CT O -
) O +
or O +
MRI O +
analysis O -
, O +
and O +
that O +
the O +
higher O +
level O +
of O +
tau O +
reflects O +
the O +
process O +
of O +
neuronal B-Disease +
degeneration L-Disease +
in O +
ALD U-Disease -
. O -

Lorenzos O +
Oil O +
should O +
be O +
given O +
in O +
the O +
early O +
stage O -
.. O -

Nonsense O +
mutation O +
in O +
exon O +
4 O +
of O +
human O +
complement O +
C9 O +
gene O +
is O +
the O +
major O +
cause O +
of O +
Japanese O +
complement B-Disease +
C9 I-Disease +
deficiency L-Disease -
. O -

Deficiency B-Disease +
of I-Disease +
the I-Disease +
ninth I-Disease +
component I-Disease +
of I-Disease +
human I-Disease +
complement L-Disease +
( O -
C9 O -
) O +
is O +
the O +
most O +
common O +
complement B-Disease +
deficiency L-Disease +
in O +
Japan O +
but O +
is O +
rare O +
in O +
other O +
countries O -
. O -

We O +
studied O +
the O +
molecular O +
basis O +
of O +
C9 B-Disease +
deficiency L-Disease +
in O +
four O +
Japanese O +
C9-deficient U-Disease +
patients O +
who O +
had O +
suffered O +
from O +
meningococcal B-Disease +
meningitis L-Disease -
. O -

Direct O +
sequencing O +
of O +
amplified O +
C9 O +
cDNA O +
and O +
DNA O +
revealed O +
a O +
nonsense O +
substitution O +
( O -
CGA-- O +
> O +
TGA O -
) O +
at O +
codon O +
95 O +
in O +
exon O +
4 O +
in O +
the O +
four O +
C9-deficient U-Disease +
individuals O -
. O -

An O +
allele O -
- O -
specific O +
polymerase O +
chain O +
reaction O +
system O +
designed O +
to O +
detect O +
exclusively O +
only O +
one O +
of O +
the O +
normal O +
and O +
mutant O +
alleles O +
indicated O +
that O +
all O +
the O +
four O +
patients O +
were O +
homozygous O +
for O +
the O +
mutation O +
in O +
exon O +
4 O +
and O +
that O +
the O +
parents O +
of O +
patient O +
2 O +
were O +
heterozygous O -
. O -

The O +
common O +
mutation O +
at O +
codon O +
95 O +
in O +
exon O +
4 O +
might O +
be O +
responsible O +
for O +
most O +
Japanese O +
C9 B-Disease +
deficiency L-Disease -
.. O -

BRCA1 O +
required O +
for O +
transcription O -
- O -
coupled O +
repair O +
of O +
oxidative O +
DNA O +
damage O -
. O -

The O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
susceptibility O +
gene O +
BRCA1 O +
encodes O +
a O +
zinc O +
finger O +
protein O +
of O +
unknown O +
function O -
. O -

Association O +
of O +
the O +
BRCA1 O +
protein O +
with O +
the O +
DNA O +
repair O +
protein O +
Rad51 O +
and O +
changes O +
in O +
the O +
phosphorylation O +
and O +
cellular O +
localization O +
of O +
the O +
protein O +
after O +
exposure O +
to O +
DNA O -
- O -
damaging O +
agents O +
are O +
consistent O +
with O +
a O +
role O +
for O +
BRCA1 O +
in O +
DNA O +
repair O -
. O -

Here O -
, O +
it O +
is O +
shown O +
that O +
mouse O +
embryonic O +
stem O +
cells O +
deficient B-Disease +
in I-Disease +
BRCA1 L-Disease +
are O +
defective O +
in O +
the O +
ability O +
to O +
carry O +
out O +
transcription O -
- O -
coupled O +
repair O +
of O +
oxidative O +
DNA O +
damage O -
, O +
and O +
are O +
hypersensitive O +
to O +
ionizing O +
radiation O +
and O +
hydrogen O +
peroxide O -
. O -

These O +
results O +
suggest O +
that O +
BRCA1 O +
participates O -
, O +
directly O +
or O +
indirectly O -
, O +
in O +
transcription O -
- O -
coupled O +
repair O +
of O +
oxidative O +
DNA O +
damage O -
.. O -

Truncation O +
mutations O +
in O +
the O +
transactivation O +
region O +
of O +
PAX6 O +
result O +
in O +
dominant O -
- O -
negative O +
mutants O -
. O -

PAX6 O +
is O +
a O +
transcription O +
factor O +
with O +
two O +
DNA O -
- O -
binding O +
domains O +
( O -
paired O +
box O +
and O +
homeobox O -
) O +
and O +
a O +
proline O -
- O -
serine O -
- O -
threonine O +
( O -
PST O -
) O +
-rich O +
transactivation O +
domain O -
. O -

PAX6 O +
regulates O +
eye O +
development O +
in O +
animals O +
ranging O +
from O +
jellyfish O +
to O +
Drosophila O +
to O +
humans O -
. O -

Heterozygous O +
mutations O +
in O +
the O +
human O +
PAX6 O +
gene O +
result O +
in O +
various O +
phenotypes O -
, O +
including O +
aniridia U-Disease -
, O +
Peters B-Disease +
anomaly L-Disease -
, O +
autosomal B-Disease +
dominant I-Disease +
keratitis L-Disease -
, O +
and O +
familial B-Disease +
foveal I-Disease +
dysplasia L-Disease -
. O -

It O +
is O +
believed O +
that O +
the O +
mutated O +
allele O +
of O +
PAX6 O +
produces O +
an O +
inactive O +
protein O +
and O +
aniridia U-Disease +
is O +
caused O +
due O +
to O +
genetic O +
haploinsufficiency O -
. O -

However O -
, O +
several O +
truncation O +
mutations O +
have O +
been O +
found O +
to O +
occur O +
in O +
the O +
C O -
- O -
terminal O +
half O +
of O +
PAX6 O +
in O +
patients O +
with O +
Aniridia U-Disease +
resulting O +
in O +
mutant O +
proteins O +
that O +
retain O +
the O +
DNA O -
- O -
binding O +
domains O +
but O +
have O +
lost O +
most O +
of O +
the O +
transactivation O +
domain O -
. O -

It O +
is O +
not O +
clear O +
whether O +
such O +
mutants O +
really O +
behave O +
as O +
loss O -
- O -
of O -
- O -
function O +
mutants O +
as O +
predicted O +
by O +
haploinsufficiency O -
. O -

Contrary O +
to O +
this O +
theory O -
, O +
our O +
data O +
showed O +
that O +
these O +
mutants O +
are O +
dominant O -
- O -
negative O +
in O +
transient O +
transfection O +
assays O +
when O +
they O +
are O +
coexpressed O +
with O +
wild O -
- O -
type O +
PAX6 O -
. O -

We O +
found O +
that O +
the O +
dominant O -
- O -
negative O +
effects O +
result O +
from O +
the O +
enhanced O +
DNA O +
binding O +
ability O +
of O +
these O +
mutants O -
. O -

Kinetic O +
studies O +
of O +
binding O +
and O +
dissociation O +
revealed O +
that O +
various O +
truncation O +
mutants O +
have O +
3 O -
- O -
5-fold O +
higher O +
affinity O +
to O +
various O +
DNA O -
- O -
binding O +
sites O +
when O +
compared O +
with O +
the O +
wild O -
- O -
type O +
PAX6 O -
. O -

These O +
results O +
provide O +
a O +
new O +
insight O +
into O +
the O +
role O +
of O +
mutant O +
PAX6 O +
in O +
causing O +
aniridia U-Disease -
.. O -

Reversal O +
of O +
severe O +
hypertrophic B-Disease +
cardiomyopathy L-Disease +
and O +
excellent O +
neuropsychologic O +
outcome O +
in O +
very B-Disease -
- I-Disease -
long I-Disease -
- I-Disease -
chain I-Disease +
acyl I-Disease -
- I-Disease -
coenzyme I-Disease +
A I-Disease +
dehydrogenase I-Disease +
deficiency L-Disease -
. O -

Very B-Disease -
- I-Disease -
long I-Disease -
- I-Disease -
chain I-Disease +
acyl I-Disease -
- I-Disease -
coenzyme I-Disease +
A I-Disease +
dehydrogenase I-Disease +
( I-Disease -
VLCAD I-Disease -
) I-Disease +
deficiency L-Disease +
is O +
a O +
disorder O +
of O +
fatty O +
acid O +
beta O +
oxidation O +
that O +
reportedly O +
has O +
high O +
rates O +
of O +
morbidity O +
and O +
mortality O -
. O -

We O +
describe O +
the O +
outcome O +
of O +
a O +
5-year O -
- O -
old O +
girl O +
with O +
VLCAD B-Disease +
deficiency L-Disease +
who O +
was O +
first O +
seen O +
at O +
5 O +
months O +
of O +
age O +
with O +
severe O +
hypertrophic B-Disease +
cardiomyopathy L-Disease -
, O +
hepatomegaly U-Disease -
, O +
encephalopathy U-Disease -
, O +
and O +
hypotonia U-Disease -
. O -

Biochemical O +
studies O +
indicated O +
VLCAD B-Disease +
deficiency L-Disease +
caused O +
by O +
a O +
stable O +
yet O +
inactive O +
enzyme O -
. O -

Molecular O +
genetic O +
analysis O +
of O +
her O +
VLCAD O +
gene O +
revealed O +
a O +
T1372C O +
( O -
F458L O -
) O +
missense O +
mutation O +
and O +
a O +
1668 O +
ACAG O +
1669 O +
splice O +
site O +
mutation O -
. O -

After O +
initial O +
treatment O +
with O +
intravenous O +
glucose O +
and O +
carnitine O -
, O +
the O +
patient O +
has O +
thrived O +
on O +
a O +
low O -
- O -
fat O +
diet O +
supplemented O +
with O +
medium O -
- O -
chain O +
triglyceride O +
oil O +
and O +
carnitine O +
and O +
avoidance O +
of O +
fasting O -
. O -

Her O +
ventricular O +
hypertrophy O +
resolved O +
significantly O +
over O +
1 O +
year O -
, O +
and O +
cognitively O -
, O +
she O +
is O +
in O +
the O +
superior O +
range O +
for O +
age O -
. O -

Clinical O +
recognition O +
of O +
VLCAD B-Disease +
deficiency L-Disease +
is O +
important O +
because O +
it O +
is O +
one O +
of O +
the O +
few O +
directly O +
treatable O +
causes O +
of O +
cardiomyopathy U-Disease +
in O +
children O -
.. O -

Cloning O +
of O +
a O +
novel O +
member O +
of O +
the O +
low O -
- O -
density O +
lipoprotein O +
receptor O +
family O -
. O -

A O +
gene O +
encoding O +
a O +
novel O +
transmembrane O +
protein O +
was O +
identified O +
by O +
DNA O +
sequence O +
analysis O +
within O +
the O +
insulin B-Disease -
- I-Disease -
dependent I-Disease +
diabetes I-Disease +
mellitus L-Disease +
( O -
IDDM U-Disease -
) O +
locus O +
IDDM4 O +
on O +
chromosome O +
11q13 O -
. O -

Based O +
on O +
its O +
chromosomal O +
position O -
, O +
this O +
gene O +
is O +
a O +
candidate O +
for O +
conferring O +
susceptibility O +
to O +
diabetes U-Disease -
. O -

The O +
gene O -
, O +
termed O +
low O -
- O -
density O +
lipoprotein O +
receptor O +
related O +
protein O +
5 O +
( O -
LRP5 O -
) O -
, O +
encodes O +
a O +
protein O +
of O +
1615 O +
amino O +
acids O +
that O +
contains O +
conserved O +
modules O +
which O +
are O +
characteristic O +
of O +
the O +
low O -
- O -
density O +
lipoprotein O +
( O -
LDL O -
) O +
receptor O +
family O -
. O -

These O +
modules O +
include O +
a O +
putative O +
signal O +
peptide O +
for O +
protein O +
export O -
, O +
four O +
epidermal O +
growth O +
factor O +
( O -
EGF O -
) O +
repeats O +
with O +
associated O +
spacer O +
domains O -
, O +
three O +
LDL O -
- O -
receptor O +
( O -
LDLR O -
) O +
repeats O -
, O +
a O +
single O +
transmembrane O +
spanning O +
domain O -
, O +
and O +
a O +
cytoplasmic O +
domain O -
. O -

The O +
encoded O +
protein O +
has O +
a O +
unique O +
organization O +
of O +
EGF O +
and O +
LDLR O +
repeats O -
; O +
therefore O -
, O +
LRP5 O +
likely O +
represents O +
a O +
new O +
category O +
of O +
the O +
LDLR O +
family O -
. O -

Both O +
human O +
and O +
mouse O +
LRP5 O +
cDNAs O +
have O +
been O +
isolated O +
and O +
the O +
encoded O +
mature O +
proteins O +
are O +
95 O -
% O +
identical O -
, O +
indicating O +
a O +
high O +
degree O +
of O +
evolutionary O +
conservation O -
.. O -

The O +
APC U-Disease +
variants O +
I1307 O -
K O +
and O +
E1317Q O +
are O +
associated O +
with O +
colorectal B-Disease +
tumors L-Disease -
, O +
but O +
not O +
always O +
with O +
a O +
family O +
history O -
. O -

Classical O +
familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease +
( O -
FAP U-Disease -
) O +
is O +
a O +
high O -
- O -
penetrance O +
autosomal B-Disease +
dominant I-Disease +
disease L-Disease +
that O +
predisposes O +
to O +
hundreds O +
or O +
thousands O +
of O +
colorectal B-Disease +
adenomas I-Disease +
and I-Disease +
carcinoma L-Disease +
and O +
that O +
results O +
from O +
truncating O +
mutations O +
in O +
the O +
APC U-Disease +
gene O -
. O -

A O +
variant O +
of O +
FAP U-Disease +
is O +
attenuated B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
coli L-Disease -
, O +
which O +
results O +
from O +
germ O -
- O -
line O +
mutations O +
in O +
the O +
5 O +
and O +
3 O +
regions O +
of O +
the O +
APC U-Disease +
gene O -
. O -

Attenuated B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
coli L-Disease +
patients O +
have O +
" O +
multiple O +
" O +
colorectal B-Disease +
adenomas L-Disease +
( O -
typically O +
fewer O +
than O +
100 O -
) O +
without O +
the O +
florid O +
phenotype O +
of O +
classical O +
FAP U-Disease -
. O -

Another O +
group O +
of O +
patients O +
with O +
multiple O +
adenomas U-Disease +
has O +
no O +
mutations O +
in O +
the O +
APC U-Disease +
gene O -
, O +
and O +
their O +
phenotype O +
probably O +
results O +
from O +
variation O +
at O +
a O +
locus O -
, O +
or O +
loci O -
, O +
elsewhere O +
in O +
the O +
genome O -
. O -

Recently O -
, O +
however O -
, O +
a O +
missense O +
variant O +
of O +
APC U-Disease +
( O -
I1307 O -
K O -
) O +
was O +
described O +
that O +
confers O +
an O +
increased O +
risk O +
of O +
colorectal B-Disease +
tumors L-Disease -
, O +
including O +
multiple O +
adenomas U-Disease -
, O +
in O +
Ashkenazim O -
. O -

We O +
have O +
studied O +
a O +
set O +
of O +
164 O +
patients O +
with O +
multiple O +
colorectal B-Disease +
adenomas I-Disease +
and/or I-Disease +
carcinoma L-Disease +
and O +
analyzed O +
codons O +
1263 O -
- O -
1377 O +
( O -
exon O +
15 O -
G O -
) O +
of O +
the O +
APC U-Disease +
gene O +
for O +
germ O -
- O -
line O +
variants O -
. O -

Three O +
patients O +
with O +
the O +
I1307 O -
K O +
allele O +
were O +
detected O -
, O +
each O +
of O +
Ashkenazi O +
descent O -
. O -

Four O +
patients O +
had O +
a O +
germ O -
- O -
line O +
E1317Q O +
missense O +
variant O +
of O +
APC O +
that O +
was O +
not O +
present O +
in O +
controls O -
; O +
one O +
of O +
these O +
individuals O +
had O +
an O +
unusually O +
large O +
number O +
of O +
metaplastic B-Disease +
polyps I-Disease +
of I-Disease +
the I-Disease +
colorectum L-Disease -
. O -

There O +
is O +
increasing O +
evidence O +
that O +
there O +
exist O +
germ O -
- O -
line O +
variants O +
of O +
the O +
APC U-Disease +
gene O +
that O +
predispose O +
to O +
the O +
development O +
of O +
multiple O +
colorectal B-Disease +
adenomas I-Disease +
and I-Disease +
carcinoma L-Disease -
, O +
but O +
without O +
the O +
florid O +
phenotype O +
of O +
classical O +
FAP U-Disease -
, O +
and O +
possibly O +
with O +
importance O +
for O +
colorectal B-Disease +
cancer L-Disease +
risk O +
in O +
the O +
general O +
population O -
.. O -

Genomic O +
structure O +
of O +
the O +
human O +
congenital B-Disease +
chloride I-Disease +
diarrhea L-Disease +
( O -
CLD U-Disease -
) O +
gene O -
. O -

Congenital B-Disease +
chloride I-Disease +
diarrhea L-Disease +
( O -
CLD U-Disease -
) O +
is O +
caused O +
by O +
mutations O +
in O +
a O +
gene O +
which O +
encodes O +
an O +
intestinal O +
anion O +
transporter O -
. O -

We O +
report O +
here O +
the O +
complete O +
genomic O +
organization O +
of O +
the O +
human O +
CLD U-Disease +
gene O +
which O +
spans O +
approximately O +
39 O -
kb O -
, O +
and O +
comprises O +
21 O +
exons O -
. O -

All O +
exon O -
/ O -
intron O +
boundaries O +
conform O +
to O +
the O +
GT O -
/ O -
AG O +
rule O -
. O -

An O +
analysis O +
of O +
the O +
putative O +
promoter O +
region O +
sequence O +
shows O +
a O +
putative O +
TATA O +
box O +
and O +
predicts O +
multiple O +
transcription O +
factor O +
binding O +
sites O -
. O -

The O +
genomic O +
structure O +
was O +
determined O +
using O +
DNA O +
from O +
several O +
sources O +
including O +
multiple O +
large O -
- O -
insert O +
libaries O +
and O +
genomic O +
DNA O +
from O +
Finnish O +
CLD U-Disease +
patients O +
and O +
controls O -
. O -

Exon O -
- O -
specific O +
primers O +
developed O +
in O +
this O +
study O +
will O +
facilitate O +
mutation O +
screening O +
studies O +
of O +
patients O +
with O +
the O +
disease O -
. O -

Genomic O +
sequencing O +
of O +
a O +
BAC O +
clone O +
H_RG364P16 O +
revealed O +
the O +
presence O +
of O +
another O -
, O +
highly O +
homologous O +
gene O +
3 O +
of O +
the O +
CLD U-Disease +
gene O -
, O +
with O +
a O +
similar O +
genomic O +
structure O -
, O +
recently O +
identified O +
as O +
the O +
Pendred B-Disease +
syndrome L-Disease +
gene O +
( O -
PDS U-Disease -
) O -
.. O -

The O +
APCI1307 O -
K O +
allele O +
and O +
cancer U-Disease +
risk O +
in O +
a O +
community O -
- O -
based O +
study O +
of O +
Ashkenazi O +
Jews O -
. O -

Mutations O +
in O +
APC O +
are O +
classically O +
associated O +
with O +
familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease +
( O -
FAP U-Disease -
) O -
, O +
a O +
highly O +
penetrant O +
autosomal B-Disease +
dominant I-Disease +
disorder L-Disease +
characterized O +
by O +
multiple O +
intestinal O +
polyps U-Disease +
and O -
, O +
without O +
surgical O +
intervention O -
, O +
the O +
development O +
of O +
colorectal B-Disease +
cancer L-Disease +
( O -
CRC U-Disease -
) O -
. O -

APC U-Disease +
is O +
a O +
tumour O -
- O -
suppressor O +
gene O -
, O +
and O +
somatic O +
loss O +
occurs O +
in O +
tumours U-Disease -
. O -

The O +
germline O +
T O -
- O -
to O -
- O -
A O +
transversion O +
responsible O +
for O +
the O +
APC O +
I1307 O -
K O +
allele O +
converts O +
the O +
wild O -
- O -
type O +
sequence O +
to O +
a O +
homopolymer O +
tract O +
( O -
A8 O -
) O +
that O +
is O +
genetically O +
unstable O +
and O +
prone O +
to O +
somatic O +
mutation O -
. O -

The O +
I1307 O -
K O +
allele O +
was O +
found O +
in O +
6 O -
. O +
1 O -
% O +
of O +
unselected O +
Ashkenazi O +
Jews O +
and O +
higher O +
proportions O +
of O +
Ashkenazim O +
with O +
family O +
or O +
personal O +
histories O +
of O +
CRC U-Disease +
( O -
ref O -
. O -

2 O -
) O -
. O -

To O +
evaluate O +
the O +
role O +
of O +
I1307 O -
K O +
in O +
cancer U-Disease -
, O +
we O +
genotyped O +
5 O -
, O +
081 O +
Ashkenazi O +
volunteers O +
in O +
a O +
community O +
survey O -
. O -

Risk O +
of O +
developing O +
colorectal B-Disease -
, I-Disease +
breast I-Disease +
and I-Disease +
other I-Disease +
cancers L-Disease +
were O +
compared O +
between O +
genotyped O +
I1307 O -
K O +
carriers O +
and O +
non O -
- O -
carriers O +
and O +
their O +
first O -
- O -
degree O +
relatives O -
. O -

Sperm O +
DNA O +
analysis O +
in O +
a O +
Friedreich B-Disease +
ataxia L-Disease +
premutation O +
carrier O +
suggests O +
both O +
meiotic O +
and O +
mitotic O +
expansion O +
in O +
the O +
FRDA U-Disease +
gene O -
. O -

Friedreich B-Disease +
ataxia L-Disease +
is O +
usually O +
caused O +
by O +
an O +
expansion O +
of O +
a O +
GAA O +
trinucleotide O +
repeat O +
in O +
intron O +
1 O +
of O +
the O +
FRDA U-Disease +
gene O -
. O -

Occasionally O -
, O +
a O +
fully O +
expanded O +
allele O +
has O +
been O +
found O +
to O +
arise O +
from O +
a O +
premutation O +
of O +
100 O +
or O +
less O +
triplet O +
repeats O -
. O -

We O +
have O +
examined O +
the O +
sperm O +
DNA O +
of O +
a O +
premutation O +
carrier O -
. O -

This O +
mans O +
leucocyte O +
DNA O +
showed O +
one O +
normal O +
allele O +
and O +
one O +
allele O +
of O +
approximately O +
100 O +
repeats O -
. O -

His O +
sperm O +
showed O +
an O +
expanded O +
allele O +
in O +
a O +
tight O +
range O +
centering O +
on O +
a O +
size O +
of O +
approximately O +
320 O +
trinucleotide O +
repeats O -
. O -

His O +
affected O +
son O +
has O +
repeat O +
sizes O +
of O +
1040 O +
and O +
540 O -
. O -

These O +
data O +
suggest O +
that O +
expansion O +
occurs O +
in O +
two O +
stages O -
, O +
the O +
first O +
during O +
meiosis O +
followed O +
by O +
a O +
second O +
mitotic O +
expansion O -
. O -

We O +
also O +
show O +
that O +
in O +
all O +
informative O +
carrier O +
father O +
to O +
affected O +
child O +
transmissions O -
, O +
with O +
the O +
notable O +
exception O +
of O +
the O +
premutation O +
carrier O -
, O +
the O +
expansion O +
size O +
decreases O -
.. O -

The O +
R496H O +
mutation O +
of O +
arylsulfatase O +
A O +
does O +
not O +
cause O +
metachromatic B-Disease +
leukodystrophy L-Disease -
. O -

Deficiency B-Disease +
of I-Disease +
arylsulfatase I-Disease +
A L-Disease +
( O -
ARSA O -
) O +
enzyme O +
activity O +
causes O +
metachromatic B-Disease +
leukodystrophy L-Disease +
( O -
MLD U-Disease -
) O -
. O -

A O +
number O +
of O +
ARSA O +
gene O +
mutations O +
responsible O +
for O +
MLD U-Disease +
have O +
been O +
identified O -
. O -

Recently O -
, O +
the O +
R496H O +
mutation O +
of O +
ARSA O +
was O +
proposed O +
to O +
be O +
a O +
cause O +
of O +
MLD U-Disease +
( O -
Draghia O +
et O +
al. O -
, O +
1997 O -
) O -
. O -

We O +
have O +
investigated O +
the O +
R496H O +
mutation O +
and O +
found O +
this O +
mutation O +
at O +
a O +
relatively O +
high O +
frequency O +
in O +
an O +
African O +
American O +
population O +
( O -
f O +
= O +
0 O -
. O +
09 O -
, O +
n O +
= O +
61 O +
subjects O -
) O -
. O -

The O +
ARSA O +
enzyme O +
activity O +
in O +
subjects O +
with O +
and O +
without O +
the O +
R496H O +
mutation O +
was O +
determined O +
and O +
found O +
to O +
be O +
normal O -
. O -

It O +
is O +
therefore O +
concluded O +
that O +
the O +
R496H O +
mutation O +
of O +
ARSA O +
does O +
not O +
negatively O +
influence O +
the O +
activity O +
of O +
ARSA O +
and O +
is O +
not O +
a O +
cause O +
of O +
MLD U-Disease -

Down O -
- O -
regulation O +
of O +
transmembrane O +
carbonic O +
anhydrases O +
in O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
cell O +
lines O +
by O +
wild O -
- O -
type O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau L-Disease +
transgenes O -
. O -

To O +
discover O +
genes O +
involved O +
in O +
von B-Disease +
Hippel I-Disease -
- I-Disease -
Lindau L-Disease +
( O -
VHL U-Disease -
) O +
-mediated O +
carcinogenesis O -
, O +
we O +
used O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
cell O +
lines O +
stably O +
transfected O +
with O +
wild O -
- O -
type O +
VHL O -
- O -
expressing O +
transgenes O -
. O -

Large O -
- O -
scale O +
RNA O +
differential O +
display O +
technology O +
applied O +
to O +
these O +
cell O +
lines O +
identified O +
several O +
differentially O +
expressed O +
genes O -
, O +
including O +
an O +
alpha O +
carbonic O +
anhydrase O +
gene O -
, O +
termed O +
CA12 O -
. O -

The O +
deduced O +
protein O +
sequence O +
was O +
classified O +
as O +
a O +
one O -
- O -
pass O +
transmembrane O +
CA O +
possessing O +
an O +
apparently O +
intact O +
catalytic O +
domain O +
in O +
the O +
extracellular O +
CA O +
module O -
. O -

Reintroduced O +
wild O -
- O -
type O +
VHL U-Disease +
strongly O +
inhibited O +
the O +
overexpression O +
of O +
the O +
CA12 O +
gene O +
in O +
the O +
parental O +
renal B-Disease +
cell I-Disease +
carcinoma L-Disease +
cell O +
lines O -
. O -

Similar O +
results O +
were O +
obtained O +
with O +
CA9 O -
, O +
encoding O +
another O +
transmembrane O +
CA O +
with O +
an O +
intact O +
catalytic O +
domain O -
. O -

Although O +
both O +
domains O +
of O +
the O +
VHL U-Disease +
protein O +
contribute O +
to O +
regulation O +
of O +
CA12 O +
expression O -
, O +
the O +
elongin O +
binding O +
domain O +
alone O +
could O +
effectively O +
regulate O +
CA9 O +
expression O -
. O -

We O +
mapped O +
CA12 O +
and O +
CA9 O +
loci O +
to O +
chromosome O +
bands O +
15q22 O +
and O +
17q21 O -
. O -

2 O +
respectively O -
, O +
regions O +
prone O +
to O +
amplification O +
in O +
some O +
human O +
cancers U-Disease -
. O -

Additional O +
experiments O +
are O +
needed O +
to O +
define O +
the O +
role O +
of O +
CA O +
IX O +
and O +
CA O +
XII O +
enzymes O +
in O +
the O +
regulation O +
of O +
pH O +
in O +
the O +
extracellular O +
microenvironment O +
and O +
its O +
potential O +
impact O +
on O +
cancer U-Disease +
cell O +
growth O -
. O -

A O +
gene O +
encoding O +
a O +
transmembrane O +
protein O +
is O +
mutated O +
in O +
patients O +
with O +
diabetes B-Disease +
mellitus L-Disease +
and O +
optic B-Disease +
atrophy L-Disease +
( O -
Wolfram B-Disease +
syndrome L-Disease -
) O -
. O -

Wolfram B-Disease +
syndrome L-Disease +
( O -
WFS U-Disease -
; O +
OMIM O +
222300 O -
) O +
is O +
an O +
autosomal B-Disease +
recessive I-Disease +
neurodegenerative I-Disease +
disorder L-Disease +
defined O +
by O +
young O -
- O -
onset O +
non O -
- O -
immune O +
insulin B-Disease -
- I-Disease -
dependent I-Disease +
diabetes I-Disease +
mellitus L-Disease +
and O +
progressive O +
optic B-Disease +
atrophy L-Disease -
. O -

Linkage O +
to O +
markers O +
on O +
chromosome O +
4p O +
was O +
confirmed O +
in O +
five O +
families O -
. O -

On O +
the O +
basis O +
of O +
meiotic O +
recombinants O +
and O +
disease O -
- O -
associated O +
haplotypes O -
, O +
the O +
WFS U-Disease +
gene O +
was O +
localized O +
to O +
a O +
BAC O -
/ O -
P1 O +
contig O +
of O +
less O +
than O +
250 O +
kb O -
. O -

Mutations O +
in O +
a O +
novel O +
gene O +
( O -
WFS1 O -
) O +
encoding O +
a O +
putative O +
transmembrane O +
protein O +
were O +
found O +
in O +
all O +
affected O +
individuals O +
in O +
six O +
WFS U-Disease +
families O -
, O +
and O +
these O +
mutations O +
were O +
associated O +
with O +
the O +
disease O +
phenotype O -
. O -

WFS1 O +
appears O +
to O +
function O +
in O +
survival O +
of O +
islet O +
beta O -
- O -
cells O +
and O +
neurons O -
.. O -

Stable O +
interaction O +
between O +
the O +
products O +
of O +
the O +
BRCA1 O +
and O +
BRCA2 O +
tumor U-Disease +
suppressor O +
genes O +
in O +
mitotic O +
and O +
meiotic O +
cells O -
. O -

BRCA1 O +
and O +
BRCA2 O +
account O +
for O +
most O +
cases O +
of O +
familial O -
, O +
early O +
onset O +
breast B-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease +
and O +
encode O +
products O +
that O +
each O +
interact O +
with O +
hRAD51 O -
. O -

Results O +
presented O +
here O +
show O +
that O +
BRCA1 O +
and O +
BRCA2 O +
coexist O +
in O +
a O +
biochemical O +
complex O +
and O +
colocalize O +
in O +
subnuclear O +
foci O +
in O +
somatic O +
cells O +
and O +
on O +
the O +
axial O +
elements O +
of O +
developing O +
synaptonemal O +
complexes O -
. O -

Like O +
BRCA1 O +
and O +
RAD51 O -
, O +
BRCA2 O +
relocates O +
to O +
PCNA O +
+ O +
replication O +
sites O +
following O +
exposure O +
of O +
S O +
phase O +
cells O +
to O +
hydroxyurea O +
or O +
UV O +
irradiation O -
. O -

Thus O -
, O +
BRCA1 O +
and O +
BRCA2 O +
participate O -
, O +
together O -
, O +
in O +
a O +
pathway O +
( O -
s O -
) O +
associated O +
with O +
the O +
activation O +
of O +
double O -
- O -
strand O +
break O +
repair O +
and/or O +
homologous O +
recombination O -
. O -

Dysfunction O +
of O +
this O +
pathway O +
may O +
be O +
a O +
general O +
phenomenon O +
in O +
the O +
majority O +
of O +
cases O +
of O +
hereditary B-Disease +
breast I-Disease +
and/or I-Disease +
ovarian I-Disease +
cancer L-Disease -
.. O -

A O +
novel O +
Arg362Ser O +
mutation O +
in O +
the O +
sterol O +
27-hydroxylase O +
gene O +
( O -
CYP27 O -
) O -
: O +
its O +
effects O +
on O +
pre O -
- O -
mRNA O +
splicing O +
and O +
enzyme O +
activity O -
. O -

A O +
novel O +
C O +
to O +
A O +
mutation O +
in O +
the O +
sterol O +
27-hydroxylase O +
gene O +
( O -
CYP27 O -
) O +
was O +
identified O +
by O +
sequencing O +
amplified O +
CYP27 O +
gene O +
products O +
from O +
a O +
patient O +
with O +
cerebrotendinous B-Disease +
xanthomatosis L-Disease +
( O -
CTX U-Disease -
) O -
. O -

The O +
mutation O +
changed O +
the O +
adrenodoxin O +
cofactor O +
binding O +
residue O +
362Arg O +
to O +
362Ser O +
( O -
CGT O +
362Arg O +
to O +
AGT O +
362Ser O -
) O -
, O +
and O +
was O +
responsible O +
for O +
deficiency O +
in O +
the O +
sterol O +
27-hydroxylase O +
activity O -
, O +
as O +
confirmed O +
by O +
expression O +
of O +
mutant O +
cDNA O +
into O +
COS-1 O +
cells O -
. O -

Quantitative O +
analysis O +
showed O +
that O +
the O +
expression O +
of O +
CYP27 O +
gene O +
mRNA O +
in O +
the O +
patient O +
represented O +
52 O -
. O +
5 O -
% O +
of O +
the O +
normal O +
level O -
. O -

As O +
the O +
mutation O +
occurred O +
at O +
the O +
penultimate O +
nucleotide O +
of O +
exon O +
6 O +
( O -
-2 O +
position O +
of O +
exon O +
6-intron O +
6 O +
splice O +
site O -
) O +
of O +
the O +
gene O -
, O +
we O +
hypothesized O +
that O +
the O +
mutation O +
may O +
partially O +
affect O +
the O +
normal O +
splicing O +
efficiency O +
in O +
exon O +
6 O +
and O +
cause O +
alternative O +
splicing O +
elsewhere O -
, O +
which O +
resulted O +
in O +
decreased O +
transcript O +
in O +
the O +
patient O -
. O -

Transfection O +
of O +
constructed O +
minigenes O -
, O +
with O +
or O +
without O +
the O +
mutation O -
, O +
into O +
COS-1 O +
cells O +
confirmed O +
that O +
the O +
mutant O +
minigene O +
was O +
responsible O +
for O +
a O +
mRNA O +
species O +
alternatively O +
spliced O +
at O +
an O +
activated O +
cryptic O +
5 O +
splice O +
site O +
88 O +
bp O +
upstream O +
from O +
the O +
3 O +
end O +
of O +
exon O +
6 O -
. O -

Our O +
data O +
suggest O +
that O +
the O +
C O +
to O +
A O +
mutation O +
at O +
the O +
penultimate O +
nucleotide O +
of O +
exon O +
6 O +
of O +
the O +
CYP27 O +
gene O +
not O +
only O +
causes O +
the O +
deficiency B-Disease +
in I-Disease +
the I-Disease +
sterol I-Disease +
27-hydroxylase I-Disease +
activity L-Disease -
, O +
but O +
also O +
partially O +
leads O +
to O +
alternative O +
pre O -
- O -
mRNA O +
splicing O +
of O +
the O +
gene O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
regarding O +
effects O +
on O +
pre O -
- O -
mRNA O +
splicing O +
of O +
a O +
mutation O +
at O +
the O +
-2 O +
position O +
of O +
a O +
5 O +
splice O +
site O -
. O -

ATM O +
germline O +
mutations O +
in O +
classical O +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
patients O +
in O +
the O +
Dutch O +
population O -
. O -

Germline O +
mutations O +
in O +
the O +
ATM O +
gene O +
are O +
responsible O +
for O +
the O +
autosomal B-Disease +
recessive I-Disease +
disorder L-Disease +
ataxia B-Disease -
- I-Disease -
telangiectasia L-Disease +
( O -
A B-Disease -
- I-Disease -
T L-Disease -
) O -
. O -

In O +
our O +
study O -
, O +
we O +
have O +
determined O +
the O +
ATM O +
mutation O +
spectrum O +
in O +
19 O +
classical O +
A B-Disease -
- I-Disease -
T L-Disease +
patients O -
, O +
including O +
some O +
immigrant O +
populations O -
, O +
as O +
well O +
as O +
12 O +
of O +
Dutch O +
ethnic O +
origin O -
. O -

Both O +
the O +
protein O +
truncation O +
test O +
( O -
PTT O -
) O +
and O +
the O +
restriction O +
endonuclease O +
fingerprinting O +
( O -
REF O -
) O +
method O +
were O +
used O +
and O +
compared O +
for O +
their O +
detection O +
efficiency O -
, O +
identifying O +
76 O -
% O +
and O +
60 O -
% O +
of O +
the O +
mutations O -
, O +
respectively O -
. O -

Most O +
patients O +
were O +
found O +
to O +
be O +
compound O +
heterozygote O -
. O -

Seventeen O +
mutations O +
were O +
distinct O -
, O +
of O +
which O +
10 O +
were O +
not O +
reported O +
previously O -
. O -

Mutations O +
are O +
small O +
deletions O +
or O +
point O +
mutations O +
frequently O +
affecting O +
splice O +
sites O -
. O -

Moreover O -
, O +
a O +
16 O -
. O -

7-kb O +
genomic O +
deletion O +
of O +
the O +
3 O +
end O +
of O +
the O +
gene O -
, O +
most O +
likely O +
a O +
result O +
of O +
recombination O +
between O +
two O +
LINE O +
elements O -
, O +
was O +
identified O -
. O -

The O +
most O +
frequently O +
found O +
mutation O -
, O +
identified O +
in O +
three O +
unrelated O +
Turkish O +
A B-Disease -
- I-Disease -
T L-Disease +
individuals O -
, O +
was O +
previously O +
described O +
to O +
be O +
a O +
Turkish O +
A B-Disease -
- I-Disease -
T L-Disease +
founder O +
mutation O -
. O -

The O +
presence O +
of O +
a O +
founder O +
mutation O +
among O +
relatively O +
small O +
ethnic O +
population O +
groups O +
in O +
Western O +
Europe O +
could O +
indicate O +
a O +
high O +
carrier O +
frequency O +
in O +
such O +
communities O -
. O -

In O +
patients O +
of O +
Dutch O +
ethnic O +
origin O -
, O +
however O -
, O +
no O +
significant O +
founder O +
effect O +
could O +
be O +
identified O -
. O -

The O +
observed O +
genetic O +
heterogeneity O +
including O +
the O +
relative O +
high O +
percentage O +
of O +
splice O -
- O -
site O +
mutations O +
had O +
no O +
reflection O +
on O +
the O +
phenotype O -
. O -

All O +
patients O +
manifested O +
classical O +
A B-Disease -
- I-Disease -
T L-Disease +
and O +
increased O +
cellular O +
radioresistant O +
DNA O +
synthesis O -
. O -

Determination O +
of O +
the O +
genomic O +
structure O +
of O +
the O +
COL4A4 O +
gene O +
and O +
of O +
novel O +
mutations O +
causing O +
autosomal B-Disease +
recessive I-Disease +
Alport I-Disease +
syndrome L-Disease -
. O -

Autosomal B-Disease +
recessive I-Disease +
Alport I-Disease +
syndrome L-Disease +
is O +
a O +
progressive O +
hematuric B-Disease +
glomerulonephritis L-Disease +
characterized O +
by O +
glomerular B-Disease +
basement I-Disease +
membrane I-Disease +
abnormalities L-Disease +
and O +
associated O +
with O +
mutations O +
in O +
either O +
the O +
COL4A3 O +
or O +
the O +
COL4A4 O +
gene O -
, O +
which O +
encode O +
the O +
alpha3 O +
and O +
alpha4 O +
type O +
IV O +
collagen O +
chains O -
, O +
respectively O -
. O -

To O +
date O -
, O +
mutation O +
screening O +
in O +
the O +
two O +
genes O +
has O +
been O +
hampered O +
by O +
the O +
lack O +
of O +
genomic O +
structure O +
information O -
. O -

We O +
report O +
here O +
the O +
complete O +
characterization O +
of O +
the O +
48 O +
exons O +
of O +
the O +
COL4A4 O +
gene O -
, O +
a O +
comprehensive O +
gene O +
screen O -
, O +
and O +
the O +
subsequent O +
detection O +
of O +
10 O +
novel O +
mutations O +
in O +
eight O +
patients O +
diagnosed O +
with O +
autosomal B-Disease +
recessive I-Disease +
Alport I-Disease +
syndrome L-Disease -
. O -

Furthermore O -
, O +
we O +
identified O +
a O +
glycine O +
to O +
alanine O +
substitution O +
in O +
the O +
collagenous O +
domain O +
that O +
is O +
apparently O +
silent O +
in O +
the O +
heterozygous O +
carriers O -
, O +
in O +
11 O -
. O +
5 O -
% O +
of O +
all O +
control O +
individuals O -
, O +
and O +
in O +
one O +
control O +
individual O +
homozygous O +
for O +
this O +
glycine O +
substitution O -
. O -

There O +
has O +
been O +
no O +
previous O +
finding O +
of O +
a O +
glycine O +
substitution O +
that O +
is O +
not O +
associated O +
with O +
any O +
obvious O +
phenotype O +
in O +
homozygous O +
individuals O -
. O -

Founder O +
BRCA1 O +
and O +
BRCA2 O +
mutations O +
in O +
French O +
Canadian O +
breast B-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
families O -
. O -

We O +
have O +
identified O +
four O +
mutations O +
in O +
each O +
of O +
the O +
breast B-Disease +
cancer L-Disease -
- O -
susceptibility O +
genes O -
, O +
BRCA1 O +
and O +
BRCA2 O -
, O +
in O +
French O +
Canadian O +
breast B-Disease +
cancer L-Disease +
and O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O +
from O +
Quebec O -
. O -

To O +
identify O +
founder O +
effects O -
, O +
we O +
examined O +
independently O +
ascertained O +
French O +
Canadian O +
cancer U-Disease +
families O +
for O +
the O +
distribution O +
of O +
these O +
eight O +
mutations O -
. O -

Mutations O +
were O +
found O +
in O +
41 O +
of O +
97 O +
families O -
. O -

Six O +
of O +
eight O +
mutations O +
were O +
observed O +
at O +
least O +
twice O -
. O -

The O +
BRCA1 O +
C4446 O -
T O +
mutation O +
was O +
the O +
most O +
common O +
mutation O +
found O -
, O +
followed O +
by O +
the O +
BRCA2 O +
8765delAG O +
mutation O -
. O -

Together O -
, O +
these O +
mutations O +
were O +
found O +
in O +
28 O +
of O +
41 O +
families O +
identified O +
to O +
have O +
a O +
mutation O -
. O -

The O +
odds O +
of O +
detection O +
of O +
any O +
of O +
the O +
four O +
BRCA1 O +
mutations O +
was O +
18 O -
. O -

7x O +
greater O +
if O +
one O +
or O +
more O +
cases O +
of O +
ovarian B-Disease +
cancer L-Disease +
were O +
also O +
present O +
in O +
the O +
family O -
. O -

The O +
odds O +
of O +
detection O +
of O +
any O +
of O +
the O +
four O +
BRCA2 O +
mutations O +
was O +
5 O -
. O -

3x O +
greater O +
if O +
there O +
were O +
at O +
least O +
five O +
cases O +
of O +
breast B-Disease +
cancer L-Disease +
in O +
the O +
family O -
. O -

Interestingly O -
, O +
the O +
presence O +
of O +
a O +
breast B-Disease +
cancer L-Disease +
case O +
< O +
36 O +
years O +
of O +
age O +
was O +
strongly O +
predictive O +
of O +
the O +
presence O +
of O +
any O +
of O +
the O +
eight O +
mutations O +
screened O -
. O -

Carriers O +
of O +
the O +
same O +
mutation O -
, O +
from O +
different O +
families O -
, O +
shared O +
similar O +
haplotypes O -
, O +
indicating O +
that O +
the O +
mutant O +
alleles O +
were O +
likely O +
to O +
be O +
identical O +
by O +
descent O +
for O +
a O +
mutation O +
in O +
the O +
founder O +
population O -
. O -

The O +
identification O +
of O +
common O +
BRCA1 O +
and O +
BRCA2 O +
mutations O +
will O +
facilitate O +
carrier O +
detection O +
in O +
French O +
Canadian O +
breast B-Disease +
cancer L-Disease +
and O +
breast B-Disease -
/ I-Disease -
ovarian I-Disease +
cancer L-Disease +
families O -
. O -

Are O +
Dp71 O +
and O +
Dp140 O +
brain O +
dystrophin O +
isoforms O +
related O +
to O +
cognitive B-Disease +
impairment L-Disease +
in O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease -
? O -

Molecular O +
study O +
and O +
neuropsychological O +
analysis O +
were O +
performed O +
concurrently O +
on O +
49 O +
patients O +
with O +
Duchenne B-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
DMD U-Disease -
) O +
in O +
order O +
to O +
find O +
a O +
molecular O +
explanation O +
for O +
the O +
cognitive B-Disease +
impairment L-Disease +
observed O +
in O +
most O +
DMD U-Disease +
patients O -
. O -

Complete O +
analysis O +
of O +
the O +
dystrophin O +
gene O +
was O +
performed O +
to O +
define O +
the O +
localization O +
of O +
deletions O +
and O +
duplications O +
in O +
relation O +
to O +
the O +
different O +
DMD U-Disease +
promoters O -
. O -

Qualitative O +
analysis O +
of O +
the O +
Dp71 O +
transcript O +
and O +
testing O +
for O +
the O +
specific O +
first O +
exon O +
of O +
Dp140 O +
were O +
also O +
carried O +
out O -
. O -

Neuropsychological O +
analysis O +
assessed O +
verbal O +
and O +
visuospatial O +
intelligence O -
, O +
verbal O +
memory O -
, O +
and O +
reading O +
skills O -
. O -

Comparison O +
of O +
molecular O +
and O +
psychometric O +
findings O +
demonstrated O +
that O +
deletions O +
and O +
duplications O +
that O +
were O +
localized O +
in O +
the O +
distal O +
part O +
of O +
the O +
gene O +
seemed O +
to O +
be O +
preferentially O +
associated O +
with O +
cognitive B-Disease +
impairment L-Disease -
. O -

Two O +
altered O +
Dp71 O +
transcripts O +
and O +
two O +
deleted O +
Dp140 O +
DNA O +
sequences O +
were O +
found O +
in O +
four O +
patients O +
with O +
severe O +
cerebral B-Disease +
dysfunction L-Disease -
. O -

These O +
findings O +
suggest O +
that O +
some O +
sequences O +
located O +
in O +
the O +
distal O +
part O +
of O +
the O +
gene O +
and O -
, O +
in O +
particular O -
, O +
some O +
DMD U-Disease +
isoforms O +
expressed O +
in O +
the O +
brain O +
may O +
be O +
related O +
to O +
the O +
cognitive B-Disease +
impairment L-Disease +
associated O +
with O +
DMD U-Disease -
.. O -

I1307 O -
K O +
APC O +
and O +
hMLH1 O +
mutations O +
in O +
a O +
non O -
- O -
Jewish O +
family O +
with O +
hereditary B-Disease +
non I-Disease -
- I-Disease -
polyposis I-Disease +
colorectal I-Disease +
cancer L-Disease -
. O -

We O +
describe O +
a O +
French O +
Canadian O +
hereditary B-Disease +
non I-Disease -
- I-Disease -
polyposis I-Disease +
colorectal I-Disease +
cancer L-Disease +
( O -
HNPCC U-Disease -
) O +
kindred O +
which O +
carries O +
a O +
novel O +
truncating O +
mutation O +
in O +
hMLH1 O -
. O -

Interestingly O -
, O +
the O +
I1307 O -
K O +
APC O +
polymorphism O -
, O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
colorectal B-Disease +
cancer L-Disease -
, O +
is O +
also O +
present O +
in O +
this O +
family O -
. O -

The O +
I1307 O -
K O +
polymorphism O +
has O +
previously O +
only O +
been O +
identified O +
in O +
individuals O +
of O +
self O -
- O -
reported O +
Ashkenazi O +
Jewish O +
origins O -
. O -

In O +
addition O -
, O +
in O +
this O +
family O -
, O +
there O +
appears O +
to O +
be O +
no O +
relationship O +
between O +
the O +
I1307 O -
K O +
polymorphism O +
and O +
the O +
presence O +
or O +
absence O +
of O +
cancer U-Disease -
.. O -

Identification O +
of O +
a O +
novel O +
mutation O +
of O +
the O +
CPO O +
gene O +
in O +
a O +
Japanese O +
hereditary B-Disease +
coproporphyria L-Disease +
family O -
. O -

Hereditary B-Disease +
coproporphyria L-Disease +
( O -
HCP U-Disease -
) O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
disease L-Disease +
characterized O +
by O +
a O +
deficiency B-Disease +
of I-Disease +
coproporphyrinogen I-Disease +
oxidase L-Disease +
( O -
CPO O -
) O +
caused O +
by O +
a O +
mutation O +
in O +
the O +
CPO O +
gene O -
. O -

Only O +
11 O +
mutations O +
of O +
the O +
gene O +
have O +
been O +
reported O +
in O +
HCP U-Disease +
patients O -
. O -

We O +
report O +
another O +
mutation O +
in O +
a O +
Japanese O +
family O -
. O -

Polymerase O +
chain O +
reaction O -
- O -
single O +
strand O +
conformational O +
polymorphism O +
and O +
direct O +
sequence O +
analyses O +
demonstrated O +
a O +
C O +
to O +
T O +
substitution O +
in O +
exon O +
1 O +
of O +
the O +
CPO O +
gene O +
at O +
nucleotide O +
position O +
85 O -
, O +
which O +
lies O +
in O +
the O +
putative O +
presequence O +
for O +
targeting O +
to O +
mitochondria O -
. O -

This O +
mutation O +
changes O +
the O +
codon O +
for O +
glutamine O +
to O +
a O +
termination O +
codon O +
at O +
amino O +
acid O +
position O +
29 O -
. O -

MaeI O +
restriction O +
analysis O +
showed O +
two O +
other O +
carriers O +
in O +
the O +
family O -
. O -

The O +
C O -
- O -
T O +
mutation O +
is O +
located O +
within O +
a O +
recently O +
proposed O +
putative O +
alternative O +
translation O +
initiation O +
codon O +
( O -
TIC-1 O -
) O -
, O +
supporting O +
that O +
TIC-1 O +
is O +
the O +
real O +
TIC O +
rather O +
than O +
TIC-2 O -
.. O -

Human B-Disease +
complement I-Disease +
factor I-Disease +
H I-Disease +
deficiency L-Disease +
associated O +
with O +
hemolytic B-Disease +
uremic I-Disease +
syndrome L-Disease -
. O -

This O +
study O +
reports O +
on O +
six O +
cases O +
of O +
deficiency B-Disease +
in I-Disease +
the I-Disease +
human I-Disease +
complement I-Disease +
regulatory I-Disease +
protein I-Disease +
Factor I-Disease +
H L-Disease +
( O -
FH O -
) O +
in O +
the O +
context O +
of O +
an O +
acute B-Disease +
renal I-Disease +
disease L-Disease -
. O -

Five O +
of O +
the O +
cases O +
were O +
observed O +
in O +
children O +
presenting O +
with O +
idiopathic O +
hemolytic B-Disease +
uremic I-Disease +
syndrome L-Disease +
( O -
HUS U-Disease -
) O -
. O -

Two O +
of O +
the O +
children O +
exhibited O +
a O +
homozygous O +
deficiency O +
characterized O +
by O +
the O +
absence O +
of O +
the O +
150-kD O +
form O +
of O +
Factor O +
H O +
and O +
the O +
presence O -
, O +
upon O +
immunoblotting O -
, O +
of O +
the O +
42-kD O +
Factor O +
H O -
- O -
like O +
protein O +
1 O +
( O -
FHL-1 O -
) O +
and O +
other O +
FH O -
- O -
related O +
protein O +
( O -
FHR O -
) O +
bands O -
. O -

Southern O +
blot O +
and O +
PCR O +
analysis O +
of O +
DNA O +
of O +
one O +
patient O +
with O +
homozygous O +
deficiency O +
ruled O +
out O +
the O +
presence O +
of O +
a O +
large O +
deletion O +
of O +
the O +
FH O +
gene O +
as O +
the O +
underlying O +
defect O +
for O +
the O +
deficiency O -
. O -

The O +
other O +
four O +
children O +
presented O +
with O +
heterozygous O +
deficiency O +
and O +
exhibited O +
a O +
normal O +
immunoblotting O +
pattern O +
of O +
proteins O +
of O +
the O +
FH O +
family O -
. O -

Factor B-Disease +
H I-Disease +
deficiency L-Disease +
is O +
the O +
only O +
complement B-Disease +
deficiency L-Disease +
associated O +
with O +
HUS U-Disease -
. O -

These O +
observations O +
suggest O +
a O +
role O +
for O +
FH O +
and/or O +
FH O +
receptors O +
in O +
the O +
pathogenesis O +
of O +
idiopathic O +
HUS U-Disease -
.. O -

Further O +
evidence O +
for O +
a O +
major O +
ancient O +
mutation O +
underlying O +
myotonic B-Disease +
dystrophy L-Disease +
from O +
linkage O +
disequilibrium O +
studies O +
in O +
the O +
Japanese O +
population O -
. O -

The O +
myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
mutation O +
is O +
an O +
unstable O +
( O -
CTG O -
) O +
n O +
repeat O -
, O +
present O +
at O +
a O +
copy O +
number O +
of O +
5 O -
- O -
37 O +
repeats O +
on O +
normal O +
chromosomes O +
but O +
amplified O +
to O +
50 O -
- O -
3000 O +
copies O +
on O +
DM U-Disease +
chromosomes O -
. O -

Previous O +
findings O +
in O +
Caucasian O +
populations O +
of O +
a O +
DM U-Disease +
founder O +
chromosome O +
raise O +
a O +
question O +
about O +
the O +
molecular O +
events O +
involved O +
in O +
the O +
expansion O +
mutation O -
. O -

To O +
investigate O +
whether O +
a O +
founder O +
chromosome O +
for O +
the O +
DM U-Disease +
mutation O +
exists O +
in O +
the O +
Japanese O +
population O -
, O +
we O +
genotyped O +
families O +
using O +
polymorphic O +
markers O +
near O +
the O +
( O -
CTG O -
) O +
n O +
repeat O +
region O +
and O +
constructed O +
haplotypes O -
. O -

Six O +
different O +
haplotypes O +
were O +
found O +
and O +
DM U-Disease +
alleles O +
were O +
always O +
haplotype O +
A. O +
To O +
find O +
an O +
origin O +
of O +
the O +
( O -
CTG O -
) O +
n O +
repeat O +
mutation O +
and O +
to O +
investigate O +
the O +
mechanism O +
of O +
the O +
expansion O +
mutation O +
in O +
the O +
Japanese O +
population O +
we O +
have O +
studied O +
90 O +
Japanese O +
DM U-Disease +
families O +
comprising O +
190 O +
affected O +
and O +
130 O +
unaffected O +
members O -
. O -

The O +
results O +
suggest O +
that O +
a O +
few O +
common O +
ancestral O +
mutations O +
in O +
both O +
Caucasian O +
and O +
Japanese O +
populations O +
have O +
originated O +
by O +
expansion O +
of O +
an O +
ancestral O +
n O +
= O +
5 O +
repeat O +
to O +
n O +
= O +
19 O -
- O -
37 O +
copies O -
. O -

These O +
data O +
support O +
multistep O +
models O +
of O +
triplet O +
repeat O +
expansion O +
that O +
have O +
been O +
proposed O +
for O +
both O +
DM U-Disease +
and O +
Friedreichs B-Disease +
ataxia L-Disease -
.. O -

The O +
molecular O +
basis O +
of O +
C6 B-Disease +
deficiency L-Disease +
in O +
the O +
western O +
Cape O -
, O +
South O +
Africa O -
. O -

Deficiency B-Disease +
of I-Disease +
the I-Disease +
sixth I-Disease +
component I-Disease +
of I-Disease +
human I-Disease +
complement L-Disease +
( O -
C6 O -
) O +
has O +
been O +
reported O +
in O +
a O +
number O +
of O +
families O +
from O +
the O +
western O +
Cape O -
, O +
South O +
Africa O -
. O -

Meningococcal B-Disease +
disease L-Disease +
is O +
endemic O +
in O +
the O +
Cape O +
and O +
almost O +
all O +
pedigrees O +
of O +
total O +
C6 B-Disease +
deficiency L-Disease +
( O -
C6Q0 O -
) O +
have O +
been O +
ascertained O +
because O +
of O +
recurrent O +
disease O -
. O -

We O +
have O +
sequenced O +
the O +
expressed O +
exons O +
of O +
the O +
C6 O +
gene O +
from O +
selected O +
cases O +
and O +
have O +
found O +
three O +
molecular O +
defects O +
leading O +
to O +
total O +
deficiency O -
879delG O -
, O +
which O +
is O +
the O +
common O +
defect O +
in O +
the O +
Cape O +
and O +
hitherto O +
unreported O -
, O +
and O +
1195delC O +
and O +
1936delG O -
, O +
which O +
have O +
been O +
previously O +
reported O +
in O +
African O -
- O -
Americans O -
. O -

We O +
also O +
show O +
that O +
the O +
879delG O +
and O +
1195delC O +
defects O +
are O +
associated O +
with O +
characteristic O +
C6 O -
/ O -
C7 O +
region O +
DNA O +
marker O +
haplotypes O -
, O +
although O +
small O +
variations O +
were O +
observed O -
. O -

The O +
1936delG O +
defect O +
was O +
observed O +
only O +
once O +
in O +
the O +
Cape O -
, O +
but O +
its O +
associated O +
haplotype O +
could O +
be O +
deduced O -
. O -

The O +
data O +
from O +
the O +
haplotypes O +
indicate O +
that O +
these O +
three O +
molecular O +
defects O +
account O +
for O +
the O +
defects O +
in O +
all O +
the O +
38 O +
unrelated O +
C6Q0 O +
individuals O +
we O +
have O +
studied O +
from O +
the O +
Cape O -
. O -

We O +
have O +
also O +
observed O +
the O +
879delG O +
defect O +
in O +
two O +
Dutch O +
C6-deficient U-Disease +
kindreds O -
, O +
but O +
the O +
879delG O +
defect O +
in O +
the O +
Cape O +
probably O +
did O +
not O +
come O +
from O +
The O +
Netherlands O -
.. O -

Complement B-Disease +
C7 I-Disease +
deficiency L-Disease -
: O +
seven O +
further O +
molecular O +
defects O +
and O +
their O +
associated O +
marker O +
haplotypes O -
. O -

Seven O +
further O +
molecular O +
bases O +
of O +
C7 B-Disease +
deficiency L-Disease +
are O +
described O -
. O -

All O +
these O +
new O +
molecular O +
defects O +
involve O +
single O -
- O -
nucleotide O +
events O -
, O +
deletions O +
and O +
substitutions O -
, O +
some O +
of O +
which O +
alter O +
splice O +
sites O -
, O +
and O +
others O +
codons O -
. O -

They O +
are O +
distributed O +
along O +
the O +
C7 O +
gene O -
, O +
but O +
predominantly O +
towards O +
the O +
3 O +
end O -
. O -

All O +
were O +
found O +
in O +
compound O +
heterozygous O +
individuals O -
. O -

The O +
C6 O -
/ O -
C7 O +
marker O +
haplotypes O +
associated O +
with O +
most O +
C7 B-Disease +
defects L-Disease +
are O +
tabulated O -
.. O -

A O +
genome O -
- O -
wide O +
search O +
for O +
chromosomal O +
loci O +
linked O +
to O +
mental O +
health O +
wellness O +
in O +
relatives O +
at O +
high O +
risk O +
for O +
bipolar B-Disease +
affective I-Disease +
disorder L-Disease +
among O +
the O +
Old O +
Order O +
Amish O -
. O -

Bipolar B-Disease +
affective I-Disease +
disorder L-Disease +
( O -
BPAD U-Disease -
; O +
manic B-Disease -
- I-Disease -
depressive I-Disease +
illness L-Disease -
) O +
is O +
characterized O +
by O +
episodes O +
of O +
mania U-Disease +
and/or O +
hypomania U-Disease +
interspersed O +
with O +
periods O +
of O +
depression U-Disease -
. O -

Compelling O +
evidence O +
supports O +
a O +
significant O +
genetic O +
component O +
in O +
the O +
susceptibility O +
to O +
develop O +
BPAD U-Disease -
. O -

To O +
date O -
, O +
however O -
, O +
linkage O +
studies O +
have O +
attempted O +
only O +
to O +
identify O +
chromosomal O +
loci O +
that O +
cause O +
or O +
increase O +
the O +
risk O +
of O +
developing O +
BPAD U-Disease -
. O -

To O +
determine O +
whether O +
there O +
could O +
be O +
protective O +
alleles O +
that O +
prevent O +
or O +
reduce O +
the O +
risk O +
of O +
developing O +
BPAD U-Disease -
, O +
similar O +
to O +
what O +
is O +
observed O +
in O +
other O +
genetic B-Disease +
disorders L-Disease -
, O +
we O +
used O +
mental O +
health O +
wellness O +
( O -
absence O +
of O +
any O +
psychiatric B-Disease +
disorder L-Disease -
) O +
as O +
the O +
phenotype O +
in O +
our O +
genome O -
- O -
wide O +
linkage O +
scan O +
of O +
several O +
large O +
multigeneration O +
Old O +
Order O +
Amish O +
pedigrees O +
exhibiting O +
an O +
extremely O +
high O +
incidence O +
of O +
BPAD U-Disease -
. O -

We O +
have O +
found O +
strong O +
evidence O +
for O +
a O +
locus O +
on O +
chromosome O +
4p O +
at O +
D4S2949 O +
( O -
maximum O +
GENEHUNTER O -
- O -
PLUS O +
nonparametric O +
linkage O +
score O +
= O +
4 O -
. O +
05 O -
, O +
P O +
= O +
5 O -
. O +
22 O +
x O +
10 O +
( O -
-4 O -
) O -
; O +
SIBPAL O +
Pempirical O +
value O +
< O +
3 O +
x O +
10 O +
( O -
-5 O -
) O -
) O +
and O +
suggestive O +
evidence O +
for O +
a O +
locus O +
on O +
chromosome O +
4q O +
at O +
D4S397 O +
( O -
maximum O +
GENEHUNTER O -
- O -
PLUS O +
nonparametric O +
linkage O +
score O +
= O +
3 O -
. O +
29 O -
, O +
P O +
= O +
2 O -
. O +
57 O +
x O +
10 O +
( O -
-3 O -
) O -
; O +
SIBPAL O +
Pempirical O +
value O +
< O +
1 O +
x O +
10 O +
( O -
-3 O -
) O -
) O +
that O +
are O +
linked O +
to O +
mental O +
health O +
wellness O -
. O -

These O +
findings O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
certain O +
alleles O +
could O +
prevent O +
or O +
modify O +
the O +
clinical O +
manifestations O +
of O +
BPAD U-Disease +
and O +
perhaps O +
other O +
related O +
affective B-Disease +
disorders L-Disease -
. O -

Segregation O +
distortion O +
in O +
myotonic B-Disease +
dystrophy L-Disease -
. O -

Myotonic B-Disease +
dystrophy L-Disease +
( O -
DM U-Disease -
) O +
is O +
an O +
autosomal B-Disease +
dominant I-Disease +
disease L-Disease +
which O -
, O +
in O +
the O +
typical O +
pedigree O -
, O +
shows O +
a O +
three O +
generation O +
anticipation O +
cascade O -
. O -

This O +
results O +
in O +
infertility U-Disease +
and O +
congenital B-Disease +
myotonic I-Disease +
dystrophy L-Disease +
( O -
CDM U-Disease -
) O +
with O +
the O +
disappearance O +
of O +
DM U-Disease +
in O +
that O +
pedigree O -
. O -

The O +
concept O +
of O +
segregation O +
distortion O -
, O +
where O +
there O +
is O +
preferential O +
transmission O +
of O +
the O +
larger O +
allele O +
at O +
the O +
DM U-Disease +
locus O -
, O +
has O +
been O +
put O +
forward O +
to O +
explain O +
partially O +
the O +
maintenance O +
of O +
DM U-Disease +
in O +
the O +
population O -
. O -

In O +
a O +
survey O +
of O +
DM U-Disease +
in O +
Northern O +
Ireland O -
, O +
59 O +
pedigrees O +
were O +
ascertained O -
. O -

Sibships O +
where O +
the O +
status O +
of O +
all O +
the O +
members O +
had O +
been O +
identified O +
were O +
examined O +
to O +
determine O +
the O +
transmission O +
of O +
the O +
DM U-Disease +
expansion O +
from O +
affected O +
parents O +
to O +
their O +
offspring O -
. O -

Where O +
the O +
transmitting O +
parent O +
was O +
male O -
, O +
58 O -
. O +
3 O -
% O +
of O +
the O +
offspring O +
were O +
affected O -
, O +
and O +
in O +
the O +
case O +
of O +
a O +
female O +
transmitting O +
parent O -
, O +
68 O -
. O +
7 O -
% O +
were O +
affected O -
. O -

Studies O +
on O +
meiotic O +
drive O +
in O +
DM U-Disease +
have O +
shown O +
increased O +
transmission O +
of O +
the O +
larger O +
allele O +
at O +
the O +
DM U-Disease +
locus O +
in O +
non O -
- O -
DM O +
heterozygotes O +
for O +
CTGn O -
. O -

This O +
study O +
provides O +
further O +
evidence O +
that O +
the O +
DM U-Disease +
expansion O +
tends O +
to O +
be O +
transmitted O +
preferentially O -
. O -

Diagnosis O +
of O +
hemochromatosis U-Disease -
. O -

If O +
untreated O -
, O +
hemochromatosis U-Disease +
can O +
cause O +
serious O +
illness O +
and O +
early B-Disease +
death L-Disease -
, O +
but O +
the O +
disease O +
is O +
still O +
substantially O +
under O -
- O -
diagnosed O -
. O -

The O +
cornerstone O +
of O +
screening O +
and O +
case O +
detection O +
is O +
the O +
measurement O +
of O +
serum O +
transferrin O +
saturation O +
and O +
the O +
serum O +
ferritin O +
level O -
. O -

Once O +
the O +
diagnosis O +
is O +
suspected O -
, O +
physicians O +
must O +
use O +
serum O +
ferritin O +
levels O +
and O +
hepatic O +
iron O +
stores O +
on O +
liver O +
biopsy O +
specimens O +
to O +
assess O +
patients O +
for O +
the O +
presence O +
of O +
iron B-Disease +
overload L-Disease -
. O -

Liver O +
biopsy O +
is O +
also O +
used O +
to O +
establish O +
the O +
presence O +
or O +
absence O +
of O +
cirrhosis U-Disease -
, O +
which O +
can O +
affect O +
prognosis O +
and O +
management O -
. O -

A O +
DNA O -
- O -
based O +
test O +
for O +
the O +
HFE O +
gene O +
is O +
commercially O +
available O -
, O +
but O +
its O +
place O +
in O +
the O +
diagnosis O +
of O +
hemochromatosis U-Disease +
is O +
still O +
being O +
evaluated O -
. O -

Currently O -
, O +
the O +
most O +
useful O +
role O +
for O +
this O +
test O +
is O +
in O +
the O +
detection O +
of O +
hemochromatosis U-Disease +
in O +
the O +
family O +
members O +
of O +
patients O +
with O +
a O +
proven O +
case O +
of O +
the O +
disease O -
. O -

It O +
is O +
crucial O +
to O +
diagnose O +
hemochromatosis U-Disease +
before O +
hepatic B-Disease +
cirrhosis L-Disease +
develops O +
because O +
phlebotomy O +
therapy O +
can O +
avert O +
serious O +
chronic O +
disease O +
and O +
can O +
even O +
lead O +
to O +
normal O +
life O +
expectancy O -
.. O -

Prevalence O +
of O +
the O +
I1307 O -
K O +
APC U-Disease +
gene O +
variant O +
in O +
Israeli O +
Jews O +
of O +
differing O +
ethnic O +
origin O +
and O +
risk O +
for O +
colorectal B-Disease +
cancer L-Disease -
. O -

BACKGROUND O +
& O +
AIMS O -
Israeli O +
Jews O +
of O +
European O +
birth O -
, O +
i. O +
e. O -
, O +
Ashkenazim O -
, O +
have O +
the O +
highest O +
colorectal B-Disease +
cancer L-Disease +
incidence O +
of O +
any O +
Israeli O +
ethnic O +
group O -
. O -

The O +
I1307 O -
K O +
APC U-Disease +
gene O +
variant O +
was O +
found O +
in O +
6 O -
. O +
1 O -
% O +
of O +
American O +
Jews O -
, O +
28 O -
% O +
of O +
their O +
familial O +
colorectal B-Disease +
cancer L-Disease +
cases O -
, O +
but O +
not O +
in O +
non O -
- O -
Jews O -
. O -

We O +
assessed O +
the O +
I1307 O -
K O +
prevalence O +
in O +
Israeli O +
Jews O +
of O +
differing O +
ethnic O +
origin O +
and O +
risk O +
for O +
colorectal B-Disease +
cancer L-Disease -
. O -

METHODS O -
DNA O +
samples O +
from O +
500 O +
unrelated O +
Jews O +
of O +
European O +
or O +
non O -
- O -
European O +
origin O -
, O +
with O +
or O +
without O +
a O +
personal O +
and/or O +
family O +
history O +
of O +
neoplasia U-Disease -
, O +
were O +
examined O +
for O +
the O +
I1307 O -
K O +
variant O +
by O +
the O +
allele O -
- O -
specific O +
oligonucleotide O +
( O -
ASO O -
) O +
method O -
. O -

RESULTS O -
In O +
persons O +
at O +
average O +
risk O +
for O +
colorectal B-Disease +
cancer L-Disease -
, O +
I1307 O -
K O +
was O +
found O +
in O +
5 O -
. O +
0 O -
% O +
of O +
120 O +
European O +
and O +
1 O -
. O +
6 O -
% O +
of O +
188 O +
non O -
- O -
European O +
Jews O +
( O -
P O +
= O +
0 O -
. O +
08 O -
) O -
. O -

It O +
occurred O +
in O +
15 O -
. O +
4 O -
% O +
of O +
52 O +
Ashkenazi O +
Israelis O +
with O +
familial O +
cancer U-Disease +
( O -
P O +
= O +
0 O -
. O +
02 O -
) O +
and O +
was O +
not O +
detected O +
in O +
51 O +
non O -
- O -
European O +
Jews O +
at O +
increased O +
cancer U-Disease +
risk O -
. O -

Colorectal B-Disease +
neoplasia L-Disease +
occurred O +
personally O +
or O +
in O +
the O +
families O +
of O +
13 O +
of O +
20 O +
Ashkenazi O +
I1307 O -
K O +
carriers O -
, O +
8 O +
of O +
whom O +
also O +
had O +
a O +
personal O +
or O +
family O +
history O +
of O +
noncolonic O +
neoplasia U-Disease -
. O -

CONCLUSIONS O -
The O +
I1307 O -
K O +
APC O +
variant O +
may O +
represent O +
a O +
susceptibility O +
gene O +
for O +
colorectal B-Disease -
, I-Disease +
or I-Disease +
other I-Disease -
, I-Disease +
cancers L-Disease +
in O +
Ashkenazi O +
Jews O -
, O +
and O +
partially O +
explains O +
the O +
higher O +
incidence O +
of O +
colorectal B-Disease +
cancer L-Disease +
in O +
European O +
Israelis O -
. O -

Systematic O +
analysis O +
of O +
coproporphyrinogen O +
oxidase O +
gene O +
defects O +
in O +
hereditary B-Disease +
coproporphyria L-Disease +
and O +
mutation O +
update O -
. O -

Hereditary B-Disease +
coproporphyria L-Disease +
( O -
HC U-Disease -
) O +
is O +
an O +
acute O +
hepatic B-Disease +
porphyria L-Disease +
with O +
autosomal O +
dominant O +
inheritance O +
caused O +
by O +
deficient B-Disease +
activity I-Disease +
of I-Disease +
coproporphyrinogen I-Disease +
III I-Disease +
oxidase L-Disease +
( O -
CPO O -
) O -
. O -

Clinical O +
manifestations O +
of O +
the O +
disease O +
are O +
characterized O +
by O +
acute O +
attacks O +
of O +
neurological B-Disease +
dysfunction L-Disease +
often O +
precipitated O +
by O +
drugs O -
, O +
fasting O -
, O +
cyclical O +
hormonal O +
changes O -
, O +
or O +
infectious B-Disease +
diseases L-Disease -
. O -

Skin O +
photosensitivity O +
may O +
also O +
be O +
present O -
. O -

The O +
seven O +
exons O -
, O +
the O +
exon O -
/ O -
intron O +
boundaries O +
and O +
part O +
of O +
3 O +
noncoding O +
sequence O +
of O +
the O +
CPO O +
gene O +
were O +
systematically O +
analyzed O +
by O +
an O +
exon O -
- O -
by O -
- O -
exon O +
denaturing O +
gradient O +
gel O +
electrophoresis O +
( O -
DGGE O -
) O +
strategy O +
followed O +
by O +
direct O +
sequencing O +
in O +
seven O +
unrelated O +
heterozygous O +
HC U-Disease +
patients O +
from O +
France O -
, O +
Holland O -
, O +
and O +
Czech O +
Republic O -
. O -

Seven O +
novel O +
mutations O +
and O +
two O +
new O +
polymorphisms O +
were O +
detected O -
. O -

Among O +
these O +
mutations O -
two O +
are O +
missense O +
( O -
G197W O -
, O +
W427R O -
) O -
, O +
two O +
are O +
nonsense O +
( O -
Q306X O -
, O +
Q385X O -
) O -
, O +
two O +
are O +
small O +
deletions O +
( O -
662de14bp O -
; O +
1168del3bp O +
removing O +
a O +
glycine O +
at O +
position O +
390 O -
) O -
, O +
and O +
one O +
is O +
a O +
splicing O +
mutation O +
( O -
IVS1 O -
- O -
15c-- O +
> O +
g O -
) O +
which O +
creates O +
a O +
new O +
acceptor O +
splice O +
site O -
. O -

The O +
pathological O +
significance O +
of O +
the O +
point O +
mutations O +
G197W O -
, O +
W427R O -
, O +
and O +
the O +
in O -
- O -
frame O +
deletion O +
390delGly O +
were O +
assessed O +
by O +
their O +
respective O +
expression O +
in O +
a O +
prokaryotic O +
system O +
using O +
site O -
- O -
directed O +
mutagenesis O -
. O -

These O +
mutations O +
resulted O +
in O +
the O +
absence O +
or O +
a O +
dramatic O +
decrease O +
of O +
CPO O +
activity O -
. O -

The O +
two O +
polymorphisms O +
were O +
localized O +
in O +
noncoding O +
part O +
of O +
the O +
gene O -
1 O -
) O +
a O +
C O -
/ O -
G O +
polymorphism O +
in O +
the O +
promotor O +
region O -
, O +
142 O +
bp O +
upstream O +
from O +
the O +
transcriptional O +
initiation O +
site O +
( O -
-142C O -
/ O -
G O -
) O -
, O +
and O +
2 O -
) O +
a O +
6 O +
bp O +
deletion O +
polymorphism O +
in O +
the O +
3 O +
noncoding O +
part O +
of O +
the O +
CPO O +
gene O -
, O +
574 O +
bp O +
downstream O +
of O +
the O +
last O +
base O +
of O +
the O +
normal O +
termination O +
codon O +
( O -
+ O +
574 O +
delATTCTT O -
) O -
. O -

Five O +
intragenic O +
dimorphisms O +
are O +
now O +
well O +
characterized O +
and O +
the O +
high O +
degree O +
of O +
allelic O +
heterogeneity O +
in O +
HC U-Disease +
is O +
demonstrated O +
with O +
seven O +
new O +
different O +
mutations O +
making O +
a O +
total O +
of O +
nineteen O +
CPO O +
gene B-Disease +
defects L-Disease +
reported O +
so O +
far O -
.. O -

Coincidence O +
of O +
two O +
novel O +
arylsulfatase O +
A O +
alleles O +
and O +
mutation O +
459 O -
+ O -
1G O -
> O -
A O +
within O +
a O +
family O +
with O +
metachromatic B-Disease +
leukodystrophy L-Disease -
: O +
molecular O +
basis O +
of O +
phenotypic O +
heterogeneity O -
. O -

In O +
a O +
family O +
with O +
three O +
siblings O -
, O +
one O +
developed O +
classical O +
late O +
infantile O +
metachromatic B-Disease +
leukodystrophy L-Disease +
( O -
MLD U-Disease -
) O -
, O +
fatal O +
at O +
age O +
5 O +
years O -
, O +
with O +
deficient O +
arylsulfatase O +
A O +
( O -
ARSA O -
) O +
activity O +
and O +
increased O +
galactosylsulfatide O +
( O -
GS O -
) O +
excretion O -
. O -

The O +
two O +
other O +
siblings O -
, O +
apparently O +
healthy O +
at O +
12 O +
( O -
1 O -
/ O -
2 O -
) O +
and O +
15 O +
years O -
, O +
respectively O -
, O +
and O +
their O +
father O -
, O +
apparently O +
healthy O +
as O +
well O -
, O +
presented O +
ARSA O +
and O +
GS O +
values O +
within O +
the O +
range O +
of O +
MLD U-Disease +
patients O -
. O -

Mutation O +
screening O +
and O +
sequence O +
analysis O +
disclosed O +
the O +
involvement O +
of O +
three O +
different O +
ARSA O +
mutations O +
being O +
the O +
molecular O +
basis O +
of O +
intrafamilial O +
phenotypic O +
heterogeneity O -
. O -

The O +
late O +
infantile O +
patient O +
inherited O +
from O +
his O +
mother O +
the O +
frequent O +
0-type O +
mutation O +
459 O +
+ O +
1 O -
G O +
> O +
A O -
, O +
and O +
from O +
his O +
father O +
a O +
novel O -
, O +
single O +
basepair O +
microdeletion O +
of O +
guanine O +
at O +
nucleotide O +
7 O +
in O +
exon O +
1 O +
( O -
7delG O -
) O -
. O -

The O +
two O +
clinically O +
unaffected O +
siblings O +
carried O +
the O +
maternal O +
mutation O +
459 O +
+ O +
1 O -
G O +
> O +
A O +
and O -
, O +
on O +
their O +
paternal O +
allele O -
, O +
a O +
novel O +
cytosine O +
to O +
thymidine O +
transition O +
at O +
nucleotide O +
2435 O +
in O +
exon O +
8 O -
, O +
resulting O +
in O +
substitution O +
of O +
alanine O +
464 O +
by O +
valine O +
( O -
A464V O -
) O -
. O -

The O +
fathers O +
genotype O +
thus O +
was O +
7delG O -
/ O -
A464V O -
. O -

Mutation O +
A464V O +
was O +
not O +
found O +
in O +
18 O +
unrelated O +
MLD U-Disease +
patients O +
and O +
50 O +
controls O -
. O -

A464V O -
, O +
although O +
clearly O +
modifying O +
ARSA O +
and O +
GS O +
levels O -
, O +
apparently O +
bears O +
little O +
significance O +
for O +
clinical O +
manifestation O +
of O +
MLD U-Disease -
, O +
mimicking O +
the O +
frequent O +
ARSA O +
pseudodeficiency O +
allele O -
. O -

Our O +
results O +
demonstrate O +
that O +
in O +
certain O +
genetic O +
conditions O +
MLD U-Disease -
- O -
like O +
ARSA O +
and O +
GS O +
values O +
need O +
not O +
be O +
paralleled O +
by O +
clinical O +
disease O -
, O +
a O +
finding O +
with O +
serious O +
diagnostic O +
and O +
prognostic O +
implications O -
. O -

Moreover O -
, O +
further O +
ARSA O +
alleles O +
functionally O +
similar O +
to O +
A464V O +
might O +
exist O +
which O -
, O +
together O +
with O +
0-type O +
mutations O -
, O +
may O +
cause O +
pathological O +
ARSA O +
and O +
GS O +
levels O -
, O +
but O +
not O +
clinical O +
outbreak O +
of O +
the O +
disease O -
.. O -

Human O +
MLH1 O +
deficiency O +
predisposes O +
to O +
hematological B-Disease +
malignancy L-Disease +
and O +
neurofibromatosis B-Disease +
type I-Disease +
1 L-Disease -
. O -

Heterozygous O +
germ O -
- O -
line O +
mutations O +
in O +
the O +
DNA O +
mismatch O +
repair O +
genes O +
lead O +
to O +
hereditary B-Disease +
nonpolyposis I-Disease +
colorectal I-Disease +
cancer L-Disease -
. O -

The O +
disease O +
susceptibility O +
of O +
individuals O +
who O +
constitutionally O +
lack O +
both O +
wild O -
- O -
type O +
alleles O +
is O +
unknown O -
. O -

We O +
have O +
identified O +
three O +
offspring O +
in O +
a O +
hereditary B-Disease +
nonpolyposis I-Disease +
colorectal I-Disease +
cancer L-Disease +
family O +
who O +
developed O +
hematological B-Disease +
malignancy L-Disease +
at O +
a O +
very O +
early O +
age O -
, O +
and O +
at O +
least O +
two O +
of O +
them O +
displayed O +
signs O +
of O +
neurofibromatosis B-Disease +
type I-Disease +
1 L-Disease +
( O -
NF1 U-Disease -
) O -
. O -

DNA O +
sequence O +
analysis O +
and O +
allele O -
- O -
specific O +
amplification O +
in O +
two O +
siblings O +
revealed O +
a O +
homozygous O +
MLH1 O +
mutation O +
( O -
C676T-- O +
> O +
Arg226Stop O -
) O -
. O -

Thus O -
, O +
a O +
homozygous O +
germ O -
- O -
line O +
MLH1 O +
mutation O +
and O +
consequent O +
mismatch O +
repair O +
deficiency O +
results O +
in O +
a O +
mutator O +
phenotype O +
characterized O +
by O +
leukemia U-Disease +
and/or O +
lymphoma U-Disease +
associated O +
with O +
neurofibromatosis B-Disease +
type I-Disease +
1 L-Disease -
.. O -

Missense O +
mutations O +
in O +
the O +
most O +
ancient O +
residues O +
of O +
the O +
PAX6 O +
paired O +
domain O +
underlie O +
a O +
spectrum O +
of O +
human O +
congenital B-Disease +
eye I-Disease +
malformations L-Disease -
. O -

Mutations O +
of O +
the O +
human O +
PAX6 O +
gene O +
underlie O +
aniridia U-Disease +
( O -
congenital B-Disease +
absence I-Disease +
of I-Disease +
the I-Disease +
iris L-Disease -
) O -
, O +
a O +
rare O +
dominant O +
malformation B-Disease +
of I-Disease +
the I-Disease +
eye L-Disease -
. O -

The O +
spectrum O +
of O +
PAX6 O +
mutations O +
in O +
aniridia U-Disease +
patients O +
is O +
highly O +
biased O -
, O +
with O +
92 O -
% O +
of O +
all O +
reported O +
mutations O +
leading O +
to O +
premature O +
truncation O +
of O +
the O +
protein O +
( O -
nonsense O -
, O +
splicing O -
, O +
insertions O +
and O +
deletions O -
) O +
and O +
just O +
2 O -
% O +
leading O +
to O +
substitution O +
of O +
one O +
amino O +
acid O +
by O +
another O +
( O -
missense O -
) O -
. O -

The O +
extraordinary O +
conservation O +
of O +
the O +
PAX6 O +
protein O +
at O +
the O +
amino O +
acid O +
level O +
amongst O +
vertebrates O +
predicts O +
that O +
pathological O +
missense O +
mutations O +
should O +
in O +
fact O +
be O +
common O +
even O +
though O +
they O +
are O +
hardly O +
ever O +
seen O +
in O +
aniridia U-Disease +
patients O -
. O -

This O +
indicates O +
that O +
there O +
is O +
a O +
heavy O +
ascertainment O +
bias O +
in O +
the O +
selection O +
of O +
patients O +
for O +
PAX6 O +
mutation O +
analysis O +
and O +
that O +
the O +
missing O +
PAX6 O +
missense O +
mutations O +
frequently O +
may O +
underlie O +
phenotypes O +
distinct O +
from O +
textbook O +
aniridia U-Disease -
. O -

Here O +
we O +
present O +
four O +
novel O +
PAX6 O +
missense O +
mutations O -
, O +
two O +
in O +
association O +
with O +
atypical O +
phenotypes O -
ectopia B-Disease +
pupillae L-Disease +
( O -
displaced B-Disease +
pupils L-Disease -
) O +
and O +
congenital B-Disease +
nystagmus L-Disease +
( O -
searching B-Disease +
gaze L-Disease -
) O -
, O +
and O +
two O +
in O +
association O +
with O +
more O +
recognizable O +
aniridia U-Disease +
phenotypes O -
. O -

Strikingly O -
, O +
all O +
four O +
mutations O +
are O +
located O +
within O +
the O +
PAX6 O +
paired O +
domain O +
and O +
affect O +
amino O +
acids O +
which O +
are O +
highly O +
conserved O +
in O +
all O +
known O +
paired O +
domain O +
proteins O -
. O -

Our O +
results O +
support O +
the O +
hypothesis O +
that O +
the O +
under O -
- O -
representation O +
of O +
missense O +
mutations O +
is O +
caused O +
by O +
ascertainment O +
bias O +
and O +
suggest O +
that O +
a O +
substantial O +
burden O +
of O +
PAX6 B-Disease +
-related I-Disease +
disease L-Disease +
remains O +
to O +
be O +
uncovered O -
.. O -

The O +
chromosomal O +
order O +
of O +
genes O +
controlling O +
the O +
major O +
histocompatibility O +
complex O -
, O +
properdin O +
factor O +
B O -
, O +
and O +
deficiency B-Disease +
of I-Disease +
the I-Disease +
second I-Disease +
component I-Disease +
of I-Disease +
complement L-Disease -
. O -

The O +
relationship O +
of O +
the O +
genes O +
coding O +
for O +
HLA O +
to O +
those O +
coding O +
for O +
properdin O +
Factor O +
B O +
allotypes O +
and O +
for O +
deficiency B-Disease +
of I-Disease +
the I-Disease +
second I-Disease +
component I-Disease +
of I-Disease +
complement L-Disease +
( O -
C2 O -
) O +
was O +
studied O +
in O +
families O +
of O +
patients O +
with O +
connective O +
tissue O +
disorders O -
. O -

Patients O +
were O +
selected O +
because O +
they O +
were O +
heterozygous O +
or O +
homozygous O +
for O +
C2 B-Disease +
deficiency L-Disease -
. O -

12 O +
families O +
with O +
15 O +
matings O +
informative O +
for O +
C2 B-Disease +
deficiency L-Disease +
were O +
found O -
. O -

Of O +
57 O +
informative O +
meioses O -
, O +
two O +
crossovers O +
were O +
noted O +
between O +
the O +
C2 B-Disease +
deficiency L-Disease +
gene O +
and O +
the O +
HLA O -
- O -
B O +
gene O -
, O +
with O +
a O +
recombinant O +
fraction O +
of O +
0 O -
. O +
035 O -
. O -

A O +
lod O +
score O +
of O +
13 O +
was O +
calculated O +
for O +
linkage O +
between O +
C2 B-Disease +
deficiency L-Disease +
and O +
HLA O -
- O -
B O +
at O +
a O +
maximum O +
likelihood O +
value O +
of O +
the O +
recombinant O +
fraction O +
of O +
0 O -
. O +
04 O -
. O +
18 O +
families O +
with O +
21 O +
informative O +
matings O +
for O +
both O +
properdin O +
Factor O +
B O +
allotype O +
and O +
HLA O -
- O -
B O +
were O +
found O -
. O -

Of O +
72 O +
informative O +
meioses O -
, O +
three O +
recombinants O +
were O +
found O -
, O +
giving O +
a O +
recombinant O +
fraction O +
of O +
0 O -
. O +
042 O -
. O -

A O +
lod O +
score O +
of O +
16 O +
between O +
HLA O -
- O -
B O +
and O +
Factor O +
B O +
allotypes O +
was O +
calculated O +
at O +
a O +
maximum O +
likelihood O +
value O +
of O +
the O +
recombinant O +
fraction O +
of O +
0 O -
. O +
04 O -
. O -

A O +
crossover O +
was O +
shown O +
to O +
have O +
occurred O +
between O +
genes O +
for O +
Factor O +
B O +
and O +
HLA O -
- O -
D O -
, O +
in O +
which O +
HLA O -
- O -
D O +
segregared O +
with O +
HLA O -
- O -
A O +
and O +
B. O +
These O +
studies O +
suggest O +
that O +
the O +
genes O +
for O +
Factor O +
B O +
and O +
C2 B-Disease +
deficiency L-Disease +
are O +
located O +
outside O +
those O +
for O +
HLA O -
, O +
that O +
the O +
order O +
of O +
genese O +
is O +
HLA O -
- O -
A O -
, O +
-B O -
, O +
-D O -
, O +
Factor O +
B O +
allotype O -
, O +
C2 B-Disease +
deficiency L-Disease -
, O +
that O +
the O +
genes O +
coding O +
for O +
C2 B-Disease +
deficiency L-Disease +
and O +
Factor O +
B O +
allotypes O +
are O +
approximately O +
3 O -
- O -
-5 O +
centimorgans O +
from O +
the O +
HLA O -
- O -
A O +
and O +
HLA O -
- O -
B O +
loci O -
, O +
and O +
that O +
the O +
apparent O +
lack O +
of O +
recombinants O +
between O +
the O +
Factor O +
B O +
gene O +
and O +
C2 B-Disease +
deficiency L-Disease +
gene O +
suggests O +
that O +
these O +
two O +
genes O +
lie O +
in O +
close O +
proximity O +
to O +
one O +
another O -
. O -

Distribution O +
of O +
emerin O +
and O +
lamins O +
in O +
the O +
heart O +
and O +
implications O +
for O +
Emery B-Disease -
- I-Disease -
Dreifuss I-Disease +
muscular I-Disease +
dystrophy L-Disease -
. O -

Emerin O +
is O +
a O +
nuclear O +
membrane O +
protein O +
which O +
is O +
missing O +
or O +
defective O +
in O +
Emery B-Disease -
- I-Disease -
Dreifuss I-Disease +
muscular I-Disease +
dystrophy L-Disease +
( O -
EDMD U-Disease -
) O -
. O -

It O +
is O +
one O +
member O +
of O +
a O +
family O +
of O +
lamina O -
- O -
associated O +
proteins O +
which O +
includes O +
LAP1 O -
, O +
LAP2 O +
and O +
lamin O +
B O +
receptor O +
( O -
LBR O -
) O -
. O -

A O +
panel O +
of O +
16 O +
monoclonal O +
antibodies O +
( O -
mAbs O -
) O +
has O +
been O +
mapped O +
to O +
six O +
specific O +
sites O +
throughout O +
the O +
emerin O +
molecule O +
using O +
phage O -
- O -
displayed O +
peptide O +
libraries O +
and O +
has O +
been O +
used O +
to O +
localize O +
emerin O +
in O +
human O +
and O +
rabbit O +
heart O -
. O -

Several O +
mAbs O +
against O +
different O +
emerin O +
epitopes O +
did O +
not O +
recognize O +
intercalated O +
discs O +
in O +
the O +
heart O -
, O +
though O +
they O +
recognized O +
cardiomyocyte O +
nuclei O +
strongly O -
, O +
both O +
at O +
the O +
rim O +
and O +
in O +
intranuclear O +
spots O +
or O +
channels O -
. O -

A O +
polyclonal O +
rabbit O +
antiserum O +
against O +
emerin O +
did O +
recognize O +
both O +
nuclear O +
membrane O +
and O +
intercalated O +
discs O +
but O -
, O +
after O +
affinity O +
purification O +
against O +
a O +
pure O -
- O -
emerin O +
band O +
on O +
a O +
western O +
blot O -
, O +
it O +
stained O +
only O +
the O +
nuclear O +
membrane O -
. O -

These O +
results O +
would O +
not O +
be O +
expected O +
if O +
immunostaining O +
at O +
intercalated O +
discs O +
were O +
due O +
to O +
a O +
product O +
of O +
the O +
emerin O +
gene O +
and O -
, O +
therefore O -
, O +
cast O +
some O +
doubt O +
upon O +
the O +
hypothesis O +
that O +
cardiac B-Disease +
defects L-Disease +
in O +
EDMD U-Disease +
are O +
caused O +
by O +
absence O +
of O +
emerin O +
from O +
intercalated O +
discs O -
. O -

Although O +
emerin O +
was O +
abundant O +
in O +
the O +
membranes O +
of O +
cardiomyocyte O +
nuclei O -
, O +
it O +
was O +
absent O +
from O +
many O +
non O -
- O -
myocyte O +
cells O +
in O +
the O +
heart O -
. O -

This O +
distribution O +
of O +
emerin O +
was O +
similar O +
to O +
that O +
of O +
lamin O +
A O -
, O +
a O +
candidate O +
gene O +
for O +
an O +
autosomal O +
form O +
of O +
EDMD U-Disease -
. O -

In O +
contrast O -
, O +
lamin O +
B1 O +
was O +
absent O +
from O +
cardiomyocyte O +
nuclei O -
, O +
showing O +
that O +
lamin O +
B1 O +
is O +
not O +
essential O +
for O +
localization O +
of O +
emerin O +
to O +
the O +
nuclear O +
lamina O -
. O -

Lamin O +
B1 O +
is O +
also O +
almost O +
completely O +
absent O +
from O +
skeletal O +
muscle O +
nuclei O -
. O -

In O +
EDMD U-Disease -
, O +
the O +
additional O +
absence O +
of O +
lamin O +
B1 O +
from O +
heart O +
and O +
skeletal O +
muscle O +
nuclei O +
which O +
already O +
lack O +
emerin O +
may O +
offer O +
an O +
alternative O +
explanation O +
of O +
why O +
these O +
tissues O +
are O +
particularly O +
affected O -
.. O -

Genetic O +
mapping O +
of O +
the O +
copper B-Disease +
toxicosis L-Disease +
locus O +
in O +
Bedlington O +
terriers O +
to O +
dog O +
chromosome O +
10 O -
, O +
in O +
a O +
region O +
syntenic O +
to O +
human O +
chromosome O +
region O +
2p13-p16 O -
. O -

Abnormal O +
hepatic B-Disease +
copper I-Disease +
accumulation L-Disease +
is O +
recognized O +
as O +
an O +
inherited B-Disease +
disorder L-Disease +
in O +
man O -
, O +
mouse O -
, O +
rat O +
and O +
dog O -
. O -

The O +
major O +
cause O +
of O +
hepatic B-Disease +
copper I-Disease +
accumulation L-Disease +
in O +
man O +
is O +
a O +
dysfunctional O +
ATP7B O +
gene O -
, O +
causing O +
Wilson B-Disease +
disease L-Disease +
( O -
WD U-Disease -
) O -
. O -

Mutations O +
in O +
the O +
ATP7B O +
genes O +
have O +
also O +
been O +
demonstrated O +
in O +
mouse O +
and O +
rat O -
. O -

The O +
ATP7B O +
gene O +
has O +
been O +
excluded O +
in O +
the O +
much O +
rarer O +
human O +
copper B-Disease +
overload L-Disease +
disease O +
non B-Disease -
- I-Disease -
Indian I-Disease +
childhood I-Disease +
cirrhosis L-Disease -
, O +
indicating O +
genetic O +
heterogeneity O -
. O -

By O +
investigating O +
the O +
common O +
autosomal O +
recessive O +
copper B-Disease +
toxicosis L-Disease +
( O -
CT U-Disease -
) O +
in O +
Bedlington O +
terriers O -
, O +
we O +
have O +
identified O +
a O +
new O +
locus O +
involved O +
in O +
progressive O +
liver B-Disease +
disease L-Disease -
. O -

We O +
examined O +
whether O +
the O +
WD U-Disease +
gene O +
ATP7B O +
was O +
also O +
causative O +
for O +
CT U-Disease +
by O +
investigating O +
the O +
chromosomal O +
co O -
- O -
localization O +
of O +
ATP7B O +
and O +
C04107 O -
, O +
using O +
fluorescence O +
in O +
situ O +
hybridization O +
( O -
FISH O -
) O -
. O -

C04107 O +
is O +
an O +
anonymous O +
microsatellite O +
marker O +
closely O +
linked O +
to O +
CT U-Disease -
. O -

However O -
, O +
BAC O +
clones O +
containing O +
ATP7B O +
and O +
C04107 O +
mapped O +
to O +
the O +
canine O +
chromosome O +
regions O +
CFA22q11 O +
and O +
CFA10q26 O -
, O +
respectively O -
, O +
demonstrating O +
that O +
WD U-Disease +
can O -
not O +
be O +
homologous O +
to O +
CT U-Disease -
. O -

The O +
copper O +
transport O +
genes O +
CTR1 O +
and O +
CTR2 O +
were O +
also O +
excluded O +
as O +
candidate O +
genes O +
for O +
CT U-Disease +
since O +
they O +
both O +
mapped O +
to O +
canine O +
chromosome O +
region O +
CFA11q22 O -
. O -

2 O -
- O -
22 O -
. O +
5 O -
. O -

A O +
transcribed O +
sequence O +
identified O +
from O +
the O +
C04107-containing O +
BAC O +
was O +
found O +
to O +
be O +
homologous O +
to O +
a O +
gene O +
expressed O +
from O +
human O +
chromosome O +
2p13-p16 O -
, O +
a O +
region O +
devoid O +
of O +
any O +
positional O +
candidate O +
genes O -
. O -

Molecular O +
analysis O +
of O +
the O +
APC U-Disease +
gene O +
in O +
205 O +
families O -
: O +
extended O +
genotype O -
- O -
phenotype O +
correlations O +
in O +
FAP U-Disease +
and O +
evidence O +
for O +
the O +
role O +
of O +
APC U-Disease +
amino O +
acid O +
changes O +
in O +
colorectal B-Disease +
cancer L-Disease +
predisposition O -
. O -

BACKGROUND O -
/ O -
AIMS O -
The O +
development O +
of O +
colorectal B-Disease +
cancer L-Disease +
and O +
a O +
variable O +
range O +
of O +
extracolonic O +
manifestations O +
in O +
familial B-Disease +
adenomatous I-Disease +
polyposis L-Disease +
( O -
FAP U-Disease -
) O +
is O +
the O +
result O +
of O +
the O +
dominant O +
inheritance O +
of O +
adenomatous B-Disease +
polyposis I-Disease +
coli L-Disease +
( O -
APC U-Disease -
) O +
gene O +
mutations O -
. O -

In O +
this O +
study O -
, O +
direct O +
mutation O +
analysis O +
of O +
the O +
APC U-Disease +
gene O +
was O +
performed O +
to O +
determine O +
genotype O -
- O -
phenotype O +
correlations O +
for O +
nine O +
extracolonic O +
manifestations O +
and O +
to O +
investigate O +
the O +
incidence O +
of O +
APC U-Disease +
mutations O +
in O +
non O -
- O -
FAP O +
colorectal B-Disease +
cancer L-Disease -
. O -

METHODS O -
The O +
APC U-Disease +
gene O +
was O +
analysed O +
in O +
190 O +
unrelated O +
FAP U-Disease +
and O +
15 O +
non O -
- O -
FAP O +
colorectal B-Disease +
cancer L-Disease +
patients O +
using O +
denaturing O +
gradient O +
gel O +
electrophoresis O -
, O +
the O +
protein O +
truncation O +
test O -
, O +
and O +
direct O +
sequencing O -
. O -

RESULTS O -
Chain O +
terminating O +
signals O +
were O +
only O +
identified O +
in O +
patients O +
belonging O +
to O +
the O +
FAP U-Disease +
group O +
( O -
105 O +
patients O -
) O -
. O -

Amino O +
acid O +
changes O +
were O +
identified O +
in O +
four O +
patients O -
, O +
three O +
of O +
whom O +
belonged O +
to O +
the O +
non O -
- O -
FAP O +
group O +
of O +
colorectal B-Disease +
cancer L-Disease +
patients O -
. O -

Genotype O -
- O -
phenotype O +
correlations O +
identified O +
significant O +
differences O +
in O +
the O +
nature O +
of O +
certain O +
extracolonic O +
manifestations O +
in O +
FAP U-Disease +
patients O +
belonging O +
to O +
three O +
mutation O +
subgroups O -
. O -

CONCLUSIONS O -
Extended O +
genotype O -
- O -
phenotype O +
correlations O +
made O +
in O +
this O +
study O +
may O +
have O +
the O +
potential O +
to O +
determine O +
the O +
most O +
appropriate O +
surveillance O +
and O +
prophylactic O +
treatment O +
regimens O +
for O +
those O +
patients O +
with O +
mutations O +
associated O +
with O +
life O +
threatening O +
conditions O -
. O -

This O +
study O +
also O +
provided O +
evidence O +
for O +
the O +
pathological O +
nature O +
of O +
amino O +
acid O +
changes O +
in O +
APC O +
associated O +
with O +
both O +
FAP U-Disease +
and O +
non O -
- O -
FAP O +
colorectal B-Disease +
cancer L-Disease +
patients O -
.. O -

Inherited B-Disease +
colorectal I-Disease +
polyposis L-Disease +
and O +
cancer U-Disease +
risk O +
of O +
the O +
APC O +
I1307 O -
K O +
polymorphism O -
. O -

Germ O -
- O -
line O +
and O +
somatic O +
truncating O +
mutations O +
of O +
the O +
APC U-Disease +
gene O +
are O +
thought O +
to O +
initiate O +
colorectal B-Disease +
tumor L-Disease +
formation O +
in O +
familial B-Disease +
adenomatous I-Disease +
polyposis I-Disease +
syndrome L-Disease +
and O +
sporadic O +
colorectal O +
carcinogenesis O -
, O +
respectively O -
. O -

Recently O -
, O +
an O +
isoleucine-- O +
> O +
lysine O +
polymorphism O +
at O +
codon O +
1307 O +
( O -
I1307 O -
K O -
) O +
of O +
the O +
APC U-Disease +
gene O +
has O +
been O +
identified O +
in O +
6 O -
% O +
-7 O -
% O +
of O +
the O +
Ashkenazi O +
Jewish O +
population O -
. O -

To O +
assess O +
the O +
risk O +
of O +
this O +
common O +
APC U-Disease +
allelic O +
variant O +
in O +
colorectal O +
carcinogenesis O -
, O +
we O +
have O +
analyzed O +
a O +
large O +
cohort O +
of O +
unselected O +
Ashkenazi O +
Jewish O +
subjects O +
with O +
adenomatous B-Disease +
polyps L-Disease +
and O -
. O +
or O +
colorectal B-Disease +
cancer I-Disease -
, L-Disease +
for O +
the O +
APC O +
I1307 O -
K O +
polymorphism O -
. O -

The O +
APC O +
I1307 O -
K O +
allele O +
was O +
identified O +
in O +
48 O +
( O -
10 O -
. O +
1 O -
% O -
) O +
of O +
476 O +
patients O -
. O -

Compared O +
with O +
the O +
frequency O +
in O +
two O +
separate O +
population O +
control O +
groups O -
, O +
the O +
APC O +
I1307 O -
K O +
allele O +
is O +
associated O +
with O +
an O +
estimated O +
relative O +
risk O +
of O +
1 O -
. O -

5 O -
- O -
1 O -
. O +
7 O +
for O +
colorectal B-Disease +
neoplasia L-Disease +
( O -
both O +
P O +
= O -
. O -

01 O -
) O -
. O -

Furthermore O -
, O +
compared O +
with O +
noncarriers O -
, O +
APC O +
I1307 O -
K O +
carriers O +
had O +
increased O +
numbers O +
of O +
adenomas U-Disease +
and O +
colorectal B-Disease +
cancers L-Disease +
per O +
patient O +
( O -
P O +
= O -
. O +
03 O -
) O -
, O +
as O +
well O +
as O +
a O +
younger O +
age O +
at O +
diagnosis O -
. O -

We O +
conclude O +
that O +
the O +
APC O +
I1307 O -
K O +
variant O +
leads O +
to O +
increased O +
adenoma U-Disease +
formation O +
and O +
directly O +
contributes O +
to O +
3 O -
% O +
-4 O -
% O +
of O +
all O +
Ashkenazi O +
Jewish O +
colorectal B-Disease +
cancer L-Disease -
. O -

The O +
estimated O +
relative O +
risk O +
for O +
carriers O +
may O +
justify O +
specific O +
clinical O +
screening O +
for O +
the O +
360 O -
, O +
000 O +
Americans O +
expected O +
to O +
harbor O +
this O +
allele O -
, O +
and O +
genetic O +
testing O +
in O +
the O +
setting O +
of O +
long O -
- O -
term O -
- O -
outcome O +
studies O +
may O +
impact O +
significantly O +
on O +
colorectal B-Disease +
cancer L-Disease +
prevention O +
in O +
this O +
population O -
. O -

Localization O +
of O +
human O +
BRCA1 O +
and O +
its O +
loss O +
in O +
high O -
- O -
grade O -
, O +
non B-Disease -
- I-Disease -
inherited I-Disease +
breast I-Disease +
carcinomas L-Disease -
. O -

Although O +
the O +
link O +
between O +
the O +
BRCA1 O +
tumour U-Disease -
- O -
suppressor O +
gene O +
and O +
hereditary B-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancer L-Disease +
is O +
established O -
, O +
the O +
role O -
, O +
if O +
any O -
, O +
of O +
BRCA1 O +
in O +
non B-Disease -
- I-Disease -
familial I-Disease +
cancers L-Disease +
is O +
unclear O -
. O -

BRCA1 O +
mutations O +
are O +
rare O +
in O +
sporadic B-Disease +
cancers L-Disease -
, O +
but O +
loss O +
of O +
BRCA1 O +
resulting O +
from O +
reduced O +
expression O +
or O +
incorrect O +
subcellular O +
localization O +
is O +
postulated O +
to O +
be O +
important O +
in O +
non B-Disease -
- I-Disease -
familial I-Disease +
breast I-Disease +
and I-Disease +
ovarian I-Disease +
cancers L-Disease -
. O -

Epigenetic O +
loss O -
, O +
however O -
, O +
has O +
not O +
received O +
general O +
acceptance O +
due O +
to O +
controversy O +
regarding O +
the O +
subcellular O +
localization O +
of O +
BRCA1 O +
proteins O -
, O +
reports O +
of O +
which O +
have O +
ranged O +
from O +
exclusively O +
nuclear O -
, O +
to O +
conditionally O +
nuclear O -
, O +
to O +
the O +
ER O -
/ O -
golgi O -
, O +
to O +
cytoplasmic O +
invaginations O +
into O +
the O +
nucleus O -
. O -

In O +
an O +
attempt O +
to O +
resolve O +
this O +
issue O -
, O +
we O +
have O +
comprehensively O +
characterized O +
19 O +
anti O -
- O -
BRCA1 O +
antibodies O -
. O -

These O +
reagents O +
detect O +
a O +
220-kD O +
protein O +
localized O +
in O +
discrete O +
nuclear O +
foci O +
in O +
all O +
epithelial O +
cell O +
lines O -
, O +
including O +
those O +
derived O +
from O +
breast B-Disease +
malignancies L-Disease -
. O -

Immunohistochemical O +
staining O +
of O +
human O +
breast O +
specimens O +
also O +
revealed O +
BRCA1 O +
nuclear O +
foci O +
in O +
benign O +
breast O -
, O +
invasive B-Disease +
lobular I-Disease +
cancers L-Disease +
and O +
low B-Disease -
- I-Disease -
grade I-Disease +
ductal I-Disease +
carcinomas L-Disease -
. O -

Conversely O -
, O +
BRCA1 O +
expression O +
was O +
reduced O +
or O +
undetectable O +
in O +
the O +
majority O +
of O +
high O -
- O -
grade O -
, O +
ductal B-Disease +
carcinomas L-Disease -
, O +
suggesting O +
that O +
absence O +
of O +
BRCA1 O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
a O +
significant O +
percentage O +
of O +
sporadic B-Disease +
breast I-Disease +
cancers L-Disease -
.. O -

